Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2024-03-16
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| A1BG | 0.4761042 | 0.5023610 | 0.6725879 | 0.4548369 | 0.3926562 |
| A1BG-AS1 | 0.3490028 | 0.3915416 | 0.4236675 | 0.4061310 | 0.4024031 |
| A1CF | -0.7064668 | -0.6915596 | -1.1636794 | -0.2063165 | 0.0141885 |
| A2M | -0.4002831 | -0.3348964 | -0.6528852 | -0.1703941 | -0.0666336 |
| A2M-AS1 | 0.9937766 | 1.2903242 | 0.7665097 | 0.8453142 | 0.1012299 |
| A2ML1 | 0.2250478 | 0.3095958 | -0.2631657 | 0.5328646 | -0.0957386 |
Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genes_in_profile | 22286 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 16322 |
| num_profile_genes_not_in_sets | 5964 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used:
GMT file of genesets:| Gene sets metrics | |
|---|---|
| num_genesets | 7647 |
| num_genesets_excluded | 2159 |
| num_genesets_included | 5488 |
| ADOS | diagnosis | iIQ | iLang | motor | Count |
|---|---|---|---|---|---|
| -1 | -1 | -1 | -1 | -1 | 1808 |
| 1 | -1 | -1 | -1 | -1 | 3 |
| -1 | 1 | -1 | -1 | -1 | 102 |
| 1 | 1 | -1 | -1 | -1 | 47 |
| -1 | -1 | 1 | -1 | -1 | 82 |
| 1 | -1 | 1 | -1 | -1 | 33 |
| 1 | 0 | 1 | -1 | -1 | 1 |
| -1 | 1 | 1 | -1 | -1 | 5 |
| 1 | 1 | 1 | -1 | -1 | 220 |
| -1 | 1 | -1 | 0 | -1 | 1 |
| -1 | -1 | -1 | 1 | -1 | 751 |
| 1 | -1 | -1 | 1 | -1 | 50 |
| -1 | 1 | -1 | 1 | -1 | 230 |
| 1 | 1 | -1 | 1 | -1 | 1686 |
| -1 | -1 | 1 | 1 | -1 | 9 |
| 1 | -1 | 1 | 1 | -1 | 33 |
| 1 | 1 | 1 | 1 | -1 | 4692 |
| -1 | -1 | -1 | -1 | 0 | 1 |
| -1 | -1 | -1 | -1 | 1 | 1592 |
| -1 | 1 | -1 | -1 | 1 | 15 |
| 1 | 1 | -1 | -1 | 1 | 4 |
| -1 | -1 | 1 | -1 | 1 | 449 |
| 1 | -1 | 1 | -1 | 1 | 102 |
| -1 | 1 | 1 | -1 | 1 | 24 |
| 1 | 1 | 1 | -1 | 1 | 200 |
| -1 | -1 | -1 | 1 | 1 | 834 |
| 1 | -1 | -1 | 1 | 1 | 62 |
| -1 | 1 | -1 | 1 | 1 | 115 |
| 1 | 1 | -1 | 1 | 1 | 645 |
| -1 | 1 | 0 | 1 | 1 | 1 |
| -1 | -1 | 1 | 1 | 1 | 120 |
| 0 | -1 | 1 | 1 | 1 | 1 |
| 1 | -1 | 1 | 1 | 1 | 259 |
| -1 | 1 | 1 | 1 | 1 | 10 |
| 1 | 1 | 1 | 1 | 1 | 8099 |
Gene sets by sector
| s.ADOS | s.diagnosis | s.iIQ | s.iLang | s.motor | Count |
|---|---|---|---|---|---|
| -1 | -1 | -1 | -1 | -1 | 22 |
| -1 | -1 | 1 | -1 | -1 | 1 |
| 1 | -1 | 1 | -1 | -1 | 2 |
| 1 | 1 | 1 | -1 | -1 | 16 |
| -1 | -1 | -1 | 1 | -1 | 1 |
| -1 | 1 | -1 | 1 | -1 | 1 |
| 1 | 1 | -1 | 1 | -1 | 9 |
| 1 | 1 | 1 | 1 | -1 | 30 |
| -1 | -1 | -1 | -1 | 1 | 101 |
| -1 | -1 | 1 | -1 | 1 | 66 |
| 1 | -1 | 1 | -1 | 1 | 12 |
| 1 | 1 | 1 | -1 | 1 | 57 |
| -1 | -1 | -1 | 1 | 1 | 3 |
| -1 | 1 | -1 | 1 | 1 | 1 |
| 1 | 1 | -1 | 1 | 1 | 1 |
| -1 | -1 | 1 | 1 | 1 | 2 |
| 1 | 1 | 1 | 1 | 1 | 97 |
Interactive enrichment scatterplot
All sets with FDR<0.05. Try hovering over the points.
Top N sets irrespective of FDR. Try hovering over the points.
A heatmap of S values for top results
A plot of effect size versus significance
Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.
Results table
Top N= 50 gene sets
## Warning in kable_styling(., "hover", full_width = FALSE): Please specify format
## in kable. kableExtra can customize either HTML or LaTeX outputs. See
## https://haozhu233.github.io/kableExtra/ for details.| set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.ADOS | s.diagnosis | s.iIQ | s.iLang | s.motor | p.ADOS | p.diagnosis | p.iIQ | p.iLang | p.motor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS INVOLVED IN CHOLESTEROL TRANSPORT | 6 | 3.70e-02 | 3.06e-01 | 1.43 | 0.767 | 0.783 | 0.6030 | 0.654 | -0.21100 | 1.14e-03 | 8.92e-04 | 1.05e-02 | 5.55e-03 | 0.37000 |
| POSITIVE REGULATION OF NATURAL KILLER CELL CHEMOTAXIS | 5 | 9.24e-02 | 5.02e-01 | 1.39 | -0.725 | -0.762 | -0.5820 | -0.702 | -0.00696 | 5.00e-03 | 3.17e-03 | 2.41e-02 | 6.59e-03 | 0.97900 |
| POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION OF STAT PROTEIN | 17 | 8.57e-07 | 5.69e-05 | 1.38 | -0.714 | -0.664 | -0.7160 | -0.661 | -0.00460 | 3.45e-07 | 2.11e-06 | 3.13e-07 | 2.38e-06 | 0.97400 |
| T FOLLICULAR HELPER CELL DIFFERENTIATION | 7 | 7.85e-03 | 1.05e-01 | 1.38 | -0.673 | -0.697 | -0.5340 | -0.719 | -0.39500 | 2.04e-03 | 1.41e-03 | 1.43e-02 | 9.78e-04 | 0.07000 |
| POSITIVE REGULATION OF FC RECEPTOR MEDIATED STIMULATORY SIGNALING PATHWAY | 5 | 1.04e-01 | 5.36e-01 | 1.36 | -0.702 | -0.725 | -0.6110 | -0.670 | -0.04160 | 6.54e-03 | 4.98e-03 | 1.80e-02 | 9.47e-03 | 0.87200 |
| FATTY ACYL COA CATABOLIC PROCESS | 5 | 1.04e-01 | 5.36e-01 | 1.29 | 0.661 | 0.637 | 0.6410 | 0.646 | 0.06930 | 1.05e-02 | 1.36e-02 | 1.30e-02 | 1.23e-02 | 0.78800 |
| MEDIUM CHAIN FATTY ACYL COA METABOLIC PROCESS | 6 | 6.80e-02 | 4.27e-01 | 1.26 | 0.663 | 0.617 | 0.4960 | 0.716 | -0.01290 | 4.92e-03 | 8.83e-03 | 3.53e-02 | 2.38e-03 | 0.95600 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 5 | 1.24e-01 | 5.87e-01 | 1.25 | -0.641 | -0.681 | -0.4570 | -0.639 | 0.26500 | 1.30e-02 | 8.40e-03 | 7.66e-02 | 1.34e-02 | 0.30400 |
| REGULATION OF NATURAL KILLER CELL CHEMOTAXIS | 8 | 5.26e-02 | 3.76e-01 | 1.25 | -0.646 | -0.633 | -0.5970 | -0.591 | -0.17200 | 1.56e-03 | 1.94e-03 | 3.47e-03 | 3.77e-03 | 0.39800 |
| EMBRYONIC PROCESS INVOLVED IN FEMALE PREGNANCY | 6 | 1.29e-01 | 5.97e-01 | 1.21 | 0.646 | 0.639 | 0.6030 | 0.506 | 0.17100 | 6.11e-03 | 6.70e-03 | 1.05e-02 | 3.19e-02 | 0.46900 |
| POSITIVE REGULATION OF PHOSPHOLIPID TRANSLOCATION | 5 | 1.85e-01 | 6.94e-01 | 1.20 | -0.591 | -0.587 | -0.6130 | -0.504 | -0.32500 | 2.21e-02 | 2.31e-02 | 1.76e-02 | 5.09e-02 | 0.20800 |
| HEAT ACCLIMATION | 5 | 2.83e-01 | 8.10e-01 | 1.19 | 0.617 | 0.593 | 0.5850 | 0.561 | 0.17600 | 1.68e-02 | 2.16e-02 | 2.35e-02 | 2.97e-02 | 0.49600 |
| POSITIVE REGULATION OF RAC PROTEIN SIGNAL TRANSDUCTION | 5 | 2.43e-01 | 7.69e-01 | 1.19 | -0.604 | -0.590 | -0.5070 | -0.634 | -0.20700 | 1.94e-02 | 2.23e-02 | 4.94e-02 | 1.41e-02 | 0.42300 |
| NEGATIVE REGULATION OF VASOCONSTRICTION | 8 | 5.31e-02 | 3.77e-01 | 1.19 | -0.614 | -0.631 | -0.5600 | -0.538 | -0.16300 | 2.63e-03 | 1.99e-03 | 6.07e-03 | 8.35e-03 | 0.42400 |
| SERINE PHOSPHORYLATION OF STAT PROTEIN | 21 | 7.82e-06 | 3.84e-04 | 1.18 | -0.608 | -0.579 | -0.5900 | -0.588 | -0.04330 | 1.41e-06 | 4.40e-06 | 2.90e-06 | 3.10e-06 | 0.73100 |
| NEGATIVE REGULATION OF SEQUESTERING OF TRIGLYCERIDE | 6 | 9.31e-02 | 5.03e-01 | 1.18 | -0.607 | -0.637 | -0.4560 | -0.580 | 0.27600 | 9.99e-03 | 6.87e-03 | 5.33e-02 | 1.38e-02 | 0.24300 |
| REGULATION OF MYELOID DENDRITIC CELL ACTIVATION | 5 | 2.40e-02 | 2.33e-01 | 1.18 | -0.578 | -0.685 | -0.1610 | -0.612 | 0.42300 | 2.53e-02 | 7.95e-03 | 5.34e-01 | 1.79e-02 | 0.10100 |
| INTERLEUKIN 5 MEDIATED SIGNALING PATHWAY | 6 | 1.27e-01 | 5.93e-01 | 1.17 | -0.609 | -0.637 | -0.3990 | -0.660 | -0.04690 | 9.76e-03 | 6.86e-03 | 9.08e-02 | 5.08e-03 | 0.84200 |
| LOBAR BRONCHUS EPITHELIUM DEVELOPMENT | 5 | 1.97e-02 | 2.06e-01 | 1.16 | 0.614 | 0.631 | 0.2540 | 0.579 | -0.42100 | 1.74e-02 | 1.45e-02 | 3.25e-01 | 2.49e-02 | 0.10300 |
| LOBAR BRONCHUS DEVELOPMENT | 6 | 2.51e-02 | 2.38e-01 | 1.16 | 0.630 | 0.622 | 0.3290 | 0.621 | -0.24500 | 7.52e-03 | 8.28e-03 | 1.63e-01 | 8.39e-03 | 0.29800 |
| FOREBRAIN NEURON FATE COMMITMENT | 7 | 1.44e-02 | 1.63e-01 | 1.16 | 0.610 | 0.584 | 0.6290 | 0.367 | -0.30300 | 5.19e-03 | 7.42e-03 | 3.93e-03 | 9.24e-02 | 0.16500 |
| POSITIVE REGULATION OF PLATELET ACTIVATION | 9 | 3.85e-03 | 6.39e-02 | 1.15 | -0.585 | -0.652 | -0.2360 | -0.695 | 0.15600 | 2.37e-03 | 7.07e-04 | 2.20e-01 | 3.05e-04 | 0.41800 |
| RECEPTOR MEDIATED ENDOCYTOSIS INVOLVED IN CHOLESTEROL TRANSPORT | 8 | 6.47e-02 | 4.13e-01 | 1.15 | 0.611 | 0.633 | 0.4500 | 0.561 | -0.19300 | 2.74e-03 | 1.92e-03 | 2.76e-02 | 5.99e-03 | 0.34500 |
| POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS IN THE VACUOLE | 5 | 2.16e-01 | 7.38e-01 | 1.15 | 0.576 | 0.583 | 0.5790 | 0.515 | 0.22600 | 2.57e-02 | 2.40e-02 | 2.50e-02 | 4.63e-02 | 0.38000 |
| NATURAL KILLER CELL CHEMOTAXIS | 10 | 3.33e-02 | 2.89e-01 | 1.15 | -0.593 | -0.595 | -0.5400 | -0.545 | -0.16100 | 1.17e-03 | 1.11e-03 | 3.09e-03 | 2.85e-03 | 0.37700 |
| REGULATION OF CHRONIC INFLAMMATORY RESPONSE | 9 | 7.73e-03 | 1.04e-01 | 1.15 | -0.578 | -0.620 | -0.3810 | -0.494 | 0.45900 | 2.67e-03 | 1.27e-03 | 4.79e-02 | 1.03e-02 | 0.01700 |
| PH REDUCTION | 6 | 1.96e-01 | 7.10e-01 | 1.14 | 0.587 | 0.572 | 0.5770 | 0.525 | 0.12000 | 1.28e-02 | 1.52e-02 | 1.44e-02 | 2.58e-02 | 0.61200 |
| ZYMOGEN INHIBITION | 7 | 4.03e-03 | 6.52e-02 | 1.12 | -0.504 | -0.519 | -0.1460 | -0.592 | 0.59900 | 2.10e-02 | 1.75e-02 | 5.03e-01 | 6.71e-03 | 0.00604 |
| CEREBRAL CORTEX GABAERGIC INTERNEURON DEVELOPMENT | 6 | 1.36e-01 | 6.17e-01 | 1.11 | 0.582 | 0.584 | 0.4840 | 0.471 | -0.29200 | 1.35e-02 | 1.32e-02 | 4.01e-02 | 4.58e-02 | 0.21500 |
| LEUCINE IMPORT ACROSS PLASMA MEMBRANE | 5 | 1.70e-01 | 6.75e-01 | 1.10 | 0.533 | 0.561 | 0.4670 | 0.511 | 0.36500 | 3.92e-02 | 2.97e-02 | 7.05e-02 | 4.76e-02 | 0.15700 |
| LEUKOTRIENE D4 BIOSYNTHETIC PROCESS | 6 | 1.22e-02 | 1.44e-01 | 1.10 | 0.453 | 0.475 | 0.3800 | 0.642 | 0.47500 | 5.47e-02 | 4.40e-02 | 1.07e-01 | 6.49e-03 | 0.04390 |
| SUBSTRATE DEPENDENT CELL MIGRATION CELL EXTENSION | 8 | 5.20e-02 | 3.73e-01 | 1.10 | -0.532 | -0.545 | -0.4790 | -0.532 | -0.34000 | 9.14e-03 | 7.62e-03 | 1.91e-02 | 9.21e-03 | 0.09630 |
| PROTEIN RETENTION IN GOLGI APPARATUS | 5 | 3.68e-01 | 8.79e-01 | 1.09 | -0.580 | -0.592 | -0.5010 | -0.505 | -0.03590 | 2.48e-02 | 2.18e-02 | 5.24e-02 | 5.07e-02 | 0.89000 |
| RRNA PSEUDOURIDINE SYNTHESIS | 7 | 1.38e-02 | 1.57e-01 | 1.09 | 0.429 | 0.306 | 0.6520 | 0.276 | 0.63500 | 4.95e-02 | 1.61e-01 | 2.81e-03 | 2.06e-01 | 0.00364 |
| MICROGLIAL CELL MEDIATED CYTOTOXICITY | 5 | 7.63e-02 | 4.53e-01 | 1.08 | -0.558 | -0.647 | -0.2270 | -0.534 | 0.32500 | 3.08e-02 | 1.22e-02 | 3.80e-01 | 3.86e-02 | 0.20800 |
| T HELPER 2 CELL CYTOKINE PRODUCTION | 13 | 1.12e-03 | 2.51e-02 | 1.08 | -0.529 | -0.589 | -0.3040 | -0.591 | 0.30400 | 9.47e-04 | 2.35e-04 | 5.73e-02 | 2.24e-04 | 0.05770 |
| REGULATION OF PHOSPHOLIPID TRANSLOCATION | 6 | 2.11e-01 | 7.33e-01 | 1.07 | -0.541 | -0.558 | -0.4680 | -0.528 | -0.22800 | 2.18e-02 | 1.79e-02 | 4.69e-02 | 2.50e-02 | 0.33400 |
| REGULATION OF NODAL SIGNALING PATHWAY INVOLVED IN DETERMINATION OF LEFT RIGHT ASYMMETRY | 5 | 1.60e-01 | 6.59e-01 | 1.05 | 0.557 | 0.639 | 0.3930 | 0.453 | -0.17400 | 3.11e-02 | 1.33e-02 | 1.28e-01 | 7.96e-02 | 0.50100 |
| NEGATIVE REGULATION OF TOLL LIKE RECEPTOR 2 SIGNALING PATHWAY | 7 | 1.92e-01 | 7.03e-01 | 1.05 | -0.557 | -0.586 | -0.4230 | -0.511 | -0.00566 | 1.07e-02 | 7.20e-03 | 5.28e-02 | 1.93e-02 | 0.97900 |
| PROTEIN POLYUFMYLATION | 5 | 1.87e-01 | 6.95e-01 | 1.05 | 0.550 | 0.497 | 0.6090 | 0.402 | -0.10700 | 3.33e-02 | 5.45e-02 | 1.84e-02 | 1.19e-01 | 0.67900 |
| CD4 POSITIVE ALPHA BETA T CELL CYTOKINE PRODUCTION | 19 | 5.06e-05 | 1.92e-03 | 1.04 | -0.510 | -0.573 | -0.2600 | -0.583 | 0.28400 | 1.19e-04 | 1.54e-05 | 4.99e-02 | 1.07e-05 | 0.03230 |
| NEGATIVE REGULATION OF MONOCYTE CHEMOTACTIC PROTEIN 1 PRODUCTION | 6 | 9.07e-02 | 4.98e-01 | 1.04 | -0.428 | -0.409 | -0.5070 | -0.415 | -0.54200 | 6.92e-02 | 8.28e-02 | 3.15e-02 | 7.81e-02 | 0.02140 |
| REGULATION OF CALCIUM ION EXPORT ACROSS PLASMA MEMBRANE | 5 | 1.68e-01 | 6.71e-01 | 1.03 | 0.438 | 0.394 | 0.6020 | 0.296 | 0.52400 | 9.01e-02 | 1.28e-01 | 1.98e-02 | 2.52e-01 | 0.04260 |
| POSITIVE REGULATION OF CARDIAC MUSCLE ADAPTATION | 9 | 7.67e-02 | 4.54e-01 | 1.03 | 0.564 | 0.556 | 0.3960 | 0.532 | -0.05090 | 3.40e-03 | 3.85e-03 | 3.97e-02 | 5.72e-03 | 0.79100 |
| DISRUPTION OF PLASMA MEMBRANE INTEGRITY IN ANOTHER ORGANISM | 6 | 1.24e-15 | 6.65e-13 | 1.03 | -0.508 | -0.489 | -0.2550 | 0.106 | 0.69700 | 3.11e-02 | 3.79e-02 | 2.79e-01 | 6.54e-01 | 0.00312 |
| ISOCITRATE METABOLIC PROCESS | 5 | 3.29e-01 | 8.53e-01 | 1.03 | 0.488 | 0.429 | 0.5500 | 0.426 | 0.38900 | 5.88e-02 | 9.68e-02 | 3.31e-02 | 9.92e-02 | 0.13200 |
| ISOLEUCINE TRANSPORT | 5 | 2.49e-01 | 7.75e-01 | 1.03 | 0.506 | 0.529 | 0.5120 | 0.410 | 0.29800 | 5.02e-02 | 4.07e-02 | 4.72e-02 | 1.13e-01 | 0.24800 |
| MYELOID DENDRITIC CELL CHEMOTAXIS | 5 | 1.89e-03 | 3.78e-02 | 1.03 | -0.448 | -0.438 | 0.0327 | -0.677 | 0.44900 | 8.29e-02 | 8.99e-02 | 8.99e-01 | 8.76e-03 | 0.08240 |
| MAST CELL PROLIFERATION | 7 | 2.09e-01 | 7.30e-01 | 1.03 | -0.549 | -0.564 | -0.3770 | -0.537 | 0.03340 | 1.19e-02 | 9.70e-03 | 8.42e-02 | 1.38e-02 | 0.87900 |
| REGULATION OF PHENOTYPIC SWITCHING | 6 | 1.79e-08 | 1.88e-06 | 1.02 | -0.467 | -0.518 | 0.1750 | -0.556 | 0.46400 | 4.76e-02 | 2.80e-02 | 4.59e-01 | 1.84e-02 | 0.04910 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.ADOS | s.diagnosis | s.iIQ | s.iLang | s.motor | p.ADOS | p.diagnosis | p.iIQ | p.iLang | p.motor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS INVOLVED IN CHOLESTEROL TRANSPORT | 6 | 3.70e-02 | 3.06e-01 | 1.43000 | 7.67e-01 | 7.83e-01 | 6.03e-01 | 6.54e-01 | -2.11e-01 | 1.14e-03 | 8.92e-04 | 1.05e-02 | 5.55e-03 | 3.70e-01 |
| POSITIVE REGULATION OF NATURAL KILLER CELL CHEMOTAXIS | 5 | 9.24e-02 | 5.02e-01 | 1.39000 | -7.25e-01 | -7.62e-01 | -5.82e-01 | -7.02e-01 | -6.96e-03 | 5.00e-03 | 3.17e-03 | 2.41e-02 | 6.59e-03 | 9.79e-01 |
| POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION OF STAT PROTEIN | 17 | 8.57e-07 | 5.69e-05 | 1.38000 | -7.14e-01 | -6.64e-01 | -7.16e-01 | -6.61e-01 | -4.60e-03 | 3.45e-07 | 2.11e-06 | 3.13e-07 | 2.38e-06 | 9.74e-01 |
| T FOLLICULAR HELPER CELL DIFFERENTIATION | 7 | 7.85e-03 | 1.05e-01 | 1.38000 | -6.73e-01 | -6.97e-01 | -5.34e-01 | -7.19e-01 | -3.95e-01 | 2.04e-03 | 1.41e-03 | 1.43e-02 | 9.78e-04 | 7.00e-02 |
| POSITIVE REGULATION OF FC RECEPTOR MEDIATED STIMULATORY SIGNALING PATHWAY | 5 | 1.04e-01 | 5.36e-01 | 1.36000 | -7.02e-01 | -7.25e-01 | -6.11e-01 | -6.70e-01 | -4.16e-02 | 6.54e-03 | 4.98e-03 | 1.80e-02 | 9.47e-03 | 8.72e-01 |
| FATTY ACYL COA CATABOLIC PROCESS | 5 | 1.04e-01 | 5.36e-01 | 1.29000 | 6.61e-01 | 6.37e-01 | 6.41e-01 | 6.46e-01 | 6.93e-02 | 1.05e-02 | 1.36e-02 | 1.30e-02 | 1.23e-02 | 7.88e-01 |
| MEDIUM CHAIN FATTY ACYL COA METABOLIC PROCESS | 6 | 6.80e-02 | 4.27e-01 | 1.26000 | 6.63e-01 | 6.17e-01 | 4.96e-01 | 7.16e-01 | -1.29e-02 | 4.92e-03 | 8.83e-03 | 3.53e-02 | 2.38e-03 | 9.56e-01 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 5 | 1.24e-01 | 5.87e-01 | 1.25000 | -6.41e-01 | -6.81e-01 | -4.57e-01 | -6.39e-01 | 2.65e-01 | 1.30e-02 | 8.40e-03 | 7.66e-02 | 1.34e-02 | 3.04e-01 |
| REGULATION OF NATURAL KILLER CELL CHEMOTAXIS | 8 | 5.26e-02 | 3.76e-01 | 1.25000 | -6.46e-01 | -6.33e-01 | -5.97e-01 | -5.91e-01 | -1.72e-01 | 1.56e-03 | 1.94e-03 | 3.47e-03 | 3.77e-03 | 3.98e-01 |
| EMBRYONIC PROCESS INVOLVED IN FEMALE PREGNANCY | 6 | 1.29e-01 | 5.97e-01 | 1.21000 | 6.46e-01 | 6.39e-01 | 6.03e-01 | 5.06e-01 | 1.71e-01 | 6.11e-03 | 6.70e-03 | 1.05e-02 | 3.19e-02 | 4.69e-01 |
| POSITIVE REGULATION OF PHOSPHOLIPID TRANSLOCATION | 5 | 1.85e-01 | 6.94e-01 | 1.20000 | -5.91e-01 | -5.87e-01 | -6.13e-01 | -5.04e-01 | -3.25e-01 | 2.21e-02 | 2.31e-02 | 1.76e-02 | 5.09e-02 | 2.08e-01 |
| HEAT ACCLIMATION | 5 | 2.83e-01 | 8.10e-01 | 1.19000 | 6.17e-01 | 5.93e-01 | 5.85e-01 | 5.61e-01 | 1.76e-01 | 1.68e-02 | 2.16e-02 | 2.35e-02 | 2.97e-02 | 4.96e-01 |
| POSITIVE REGULATION OF RAC PROTEIN SIGNAL TRANSDUCTION | 5 | 2.43e-01 | 7.69e-01 | 1.19000 | -6.04e-01 | -5.90e-01 | -5.07e-01 | -6.34e-01 | -2.07e-01 | 1.94e-02 | 2.23e-02 | 4.94e-02 | 1.41e-02 | 4.23e-01 |
| NEGATIVE REGULATION OF VASOCONSTRICTION | 8 | 5.31e-02 | 3.77e-01 | 1.19000 | -6.14e-01 | -6.31e-01 | -5.60e-01 | -5.38e-01 | -1.63e-01 | 2.63e-03 | 1.99e-03 | 6.07e-03 | 8.35e-03 | 4.24e-01 |
| SERINE PHOSPHORYLATION OF STAT PROTEIN | 21 | 7.82e-06 | 3.84e-04 | 1.18000 | -6.08e-01 | -5.79e-01 | -5.90e-01 | -5.88e-01 | -4.33e-02 | 1.41e-06 | 4.40e-06 | 2.90e-06 | 3.10e-06 | 7.31e-01 |
| NEGATIVE REGULATION OF SEQUESTERING OF TRIGLYCERIDE | 6 | 9.31e-02 | 5.03e-01 | 1.18000 | -6.07e-01 | -6.37e-01 | -4.56e-01 | -5.80e-01 | 2.76e-01 | 9.99e-03 | 6.87e-03 | 5.33e-02 | 1.38e-02 | 2.43e-01 |
| REGULATION OF MYELOID DENDRITIC CELL ACTIVATION | 5 | 2.40e-02 | 2.33e-01 | 1.18000 | -5.78e-01 | -6.85e-01 | -1.61e-01 | -6.12e-01 | 4.23e-01 | 2.53e-02 | 7.95e-03 | 5.34e-01 | 1.79e-02 | 1.01e-01 |
| INTERLEUKIN 5 MEDIATED SIGNALING PATHWAY | 6 | 1.27e-01 | 5.93e-01 | 1.17000 | -6.09e-01 | -6.37e-01 | -3.99e-01 | -6.60e-01 | -4.69e-02 | 9.76e-03 | 6.86e-03 | 9.08e-02 | 5.08e-03 | 8.42e-01 |
| LOBAR BRONCHUS EPITHELIUM DEVELOPMENT | 5 | 1.97e-02 | 2.06e-01 | 1.16000 | 6.14e-01 | 6.31e-01 | 2.54e-01 | 5.79e-01 | -4.21e-01 | 1.74e-02 | 1.45e-02 | 3.25e-01 | 2.49e-02 | 1.03e-01 |
| LOBAR BRONCHUS DEVELOPMENT | 6 | 2.51e-02 | 2.38e-01 | 1.16000 | 6.30e-01 | 6.22e-01 | 3.29e-01 | 6.21e-01 | -2.45e-01 | 7.52e-03 | 8.28e-03 | 1.63e-01 | 8.39e-03 | 2.98e-01 |
| FOREBRAIN NEURON FATE COMMITMENT | 7 | 1.44e-02 | 1.63e-01 | 1.16000 | 6.10e-01 | 5.84e-01 | 6.29e-01 | 3.67e-01 | -3.03e-01 | 5.19e-03 | 7.42e-03 | 3.93e-03 | 9.24e-02 | 1.65e-01 |
| POSITIVE REGULATION OF PLATELET ACTIVATION | 9 | 3.85e-03 | 6.39e-02 | 1.15000 | -5.85e-01 | -6.52e-01 | -2.36e-01 | -6.95e-01 | 1.56e-01 | 2.37e-03 | 7.07e-04 | 2.20e-01 | 3.05e-04 | 4.18e-01 |
| RECEPTOR MEDIATED ENDOCYTOSIS INVOLVED IN CHOLESTEROL TRANSPORT | 8 | 6.47e-02 | 4.13e-01 | 1.15000 | 6.11e-01 | 6.33e-01 | 4.50e-01 | 5.61e-01 | -1.93e-01 | 2.74e-03 | 1.92e-03 | 2.76e-02 | 5.99e-03 | 3.45e-01 |
| POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS IN THE VACUOLE | 5 | 2.16e-01 | 7.38e-01 | 1.15000 | 5.76e-01 | 5.83e-01 | 5.79e-01 | 5.15e-01 | 2.26e-01 | 2.57e-02 | 2.40e-02 | 2.50e-02 | 4.63e-02 | 3.80e-01 |
| NATURAL KILLER CELL CHEMOTAXIS | 10 | 3.33e-02 | 2.89e-01 | 1.15000 | -5.93e-01 | -5.95e-01 | -5.40e-01 | -5.45e-01 | -1.61e-01 | 1.17e-03 | 1.11e-03 | 3.09e-03 | 2.85e-03 | 3.77e-01 |
| REGULATION OF CHRONIC INFLAMMATORY RESPONSE | 9 | 7.73e-03 | 1.04e-01 | 1.15000 | -5.78e-01 | -6.20e-01 | -3.81e-01 | -4.94e-01 | 4.59e-01 | 2.67e-03 | 1.27e-03 | 4.79e-02 | 1.03e-02 | 1.70e-02 |
| PH REDUCTION | 6 | 1.96e-01 | 7.10e-01 | 1.14000 | 5.87e-01 | 5.72e-01 | 5.77e-01 | 5.25e-01 | 1.20e-01 | 1.28e-02 | 1.52e-02 | 1.44e-02 | 2.58e-02 | 6.12e-01 |
| ZYMOGEN INHIBITION | 7 | 4.03e-03 | 6.52e-02 | 1.12000 | -5.04e-01 | -5.19e-01 | -1.46e-01 | -5.92e-01 | 5.99e-01 | 2.10e-02 | 1.75e-02 | 5.03e-01 | 6.71e-03 | 6.04e-03 |
| CEREBRAL CORTEX GABAERGIC INTERNEURON DEVELOPMENT | 6 | 1.36e-01 | 6.17e-01 | 1.11000 | 5.82e-01 | 5.84e-01 | 4.84e-01 | 4.71e-01 | -2.92e-01 | 1.35e-02 | 1.32e-02 | 4.01e-02 | 4.58e-02 | 2.15e-01 |
| LEUCINE IMPORT ACROSS PLASMA MEMBRANE | 5 | 1.70e-01 | 6.75e-01 | 1.10000 | 5.33e-01 | 5.61e-01 | 4.67e-01 | 5.11e-01 | 3.65e-01 | 3.92e-02 | 2.97e-02 | 7.05e-02 | 4.76e-02 | 1.57e-01 |
| LEUKOTRIENE D4 BIOSYNTHETIC PROCESS | 6 | 1.22e-02 | 1.44e-01 | 1.10000 | 4.53e-01 | 4.75e-01 | 3.80e-01 | 6.42e-01 | 4.75e-01 | 5.47e-02 | 4.40e-02 | 1.07e-01 | 6.49e-03 | 4.39e-02 |
| SUBSTRATE DEPENDENT CELL MIGRATION CELL EXTENSION | 8 | 5.20e-02 | 3.73e-01 | 1.10000 | -5.32e-01 | -5.45e-01 | -4.79e-01 | -5.32e-01 | -3.40e-01 | 9.14e-03 | 7.62e-03 | 1.91e-02 | 9.21e-03 | 9.63e-02 |
| PROTEIN RETENTION IN GOLGI APPARATUS | 5 | 3.68e-01 | 8.79e-01 | 1.09000 | -5.80e-01 | -5.92e-01 | -5.01e-01 | -5.05e-01 | -3.59e-02 | 2.48e-02 | 2.18e-02 | 5.24e-02 | 5.07e-02 | 8.90e-01 |
| RRNA PSEUDOURIDINE SYNTHESIS | 7 | 1.38e-02 | 1.57e-01 | 1.09000 | 4.29e-01 | 3.06e-01 | 6.52e-01 | 2.76e-01 | 6.35e-01 | 4.95e-02 | 1.61e-01 | 2.81e-03 | 2.06e-01 | 3.64e-03 |
| MICROGLIAL CELL MEDIATED CYTOTOXICITY | 5 | 7.63e-02 | 4.53e-01 | 1.08000 | -5.58e-01 | -6.47e-01 | -2.27e-01 | -5.34e-01 | 3.25e-01 | 3.08e-02 | 1.22e-02 | 3.80e-01 | 3.86e-02 | 2.08e-01 |
| T HELPER 2 CELL CYTOKINE PRODUCTION | 13 | 1.12e-03 | 2.51e-02 | 1.08000 | -5.29e-01 | -5.89e-01 | -3.04e-01 | -5.91e-01 | 3.04e-01 | 9.47e-04 | 2.35e-04 | 5.73e-02 | 2.24e-04 | 5.77e-02 |
| REGULATION OF PHOSPHOLIPID TRANSLOCATION | 6 | 2.11e-01 | 7.33e-01 | 1.07000 | -5.41e-01 | -5.58e-01 | -4.68e-01 | -5.28e-01 | -2.28e-01 | 2.18e-02 | 1.79e-02 | 4.69e-02 | 2.50e-02 | 3.34e-01 |
| REGULATION OF NODAL SIGNALING PATHWAY INVOLVED IN DETERMINATION OF LEFT RIGHT ASYMMETRY | 5 | 1.60e-01 | 6.59e-01 | 1.05000 | 5.57e-01 | 6.39e-01 | 3.93e-01 | 4.53e-01 | -1.74e-01 | 3.11e-02 | 1.33e-02 | 1.28e-01 | 7.96e-02 | 5.01e-01 |
| NEGATIVE REGULATION OF TOLL LIKE RECEPTOR 2 SIGNALING PATHWAY | 7 | 1.92e-01 | 7.03e-01 | 1.05000 | -5.57e-01 | -5.86e-01 | -4.23e-01 | -5.11e-01 | -5.66e-03 | 1.07e-02 | 7.20e-03 | 5.28e-02 | 1.93e-02 | 9.79e-01 |
| PROTEIN POLYUFMYLATION | 5 | 1.87e-01 | 6.95e-01 | 1.05000 | 5.50e-01 | 4.97e-01 | 6.09e-01 | 4.02e-01 | -1.07e-01 | 3.33e-02 | 5.45e-02 | 1.84e-02 | 1.19e-01 | 6.79e-01 |
| CD4 POSITIVE ALPHA BETA T CELL CYTOKINE PRODUCTION | 19 | 5.06e-05 | 1.92e-03 | 1.04000 | -5.10e-01 | -5.73e-01 | -2.60e-01 | -5.83e-01 | 2.84e-01 | 1.19e-04 | 1.54e-05 | 4.99e-02 | 1.07e-05 | 3.23e-02 |
| NEGATIVE REGULATION OF MONOCYTE CHEMOTACTIC PROTEIN 1 PRODUCTION | 6 | 9.07e-02 | 4.98e-01 | 1.04000 | -4.28e-01 | -4.09e-01 | -5.07e-01 | -4.15e-01 | -5.42e-01 | 6.92e-02 | 8.28e-02 | 3.15e-02 | 7.81e-02 | 2.14e-02 |
| REGULATION OF CALCIUM ION EXPORT ACROSS PLASMA MEMBRANE | 5 | 1.68e-01 | 6.71e-01 | 1.03000 | 4.38e-01 | 3.94e-01 | 6.02e-01 | 2.96e-01 | 5.24e-01 | 9.01e-02 | 1.28e-01 | 1.98e-02 | 2.52e-01 | 4.26e-02 |
| POSITIVE REGULATION OF CARDIAC MUSCLE ADAPTATION | 9 | 7.67e-02 | 4.54e-01 | 1.03000 | 5.64e-01 | 5.56e-01 | 3.96e-01 | 5.32e-01 | -5.09e-02 | 3.40e-03 | 3.85e-03 | 3.97e-02 | 5.72e-03 | 7.91e-01 |
| DISRUPTION OF PLASMA MEMBRANE INTEGRITY IN ANOTHER ORGANISM | 6 | 1.24e-15 | 6.65e-13 | 1.03000 | -5.08e-01 | -4.89e-01 | -2.55e-01 | 1.06e-01 | 6.97e-01 | 3.11e-02 | 3.79e-02 | 2.79e-01 | 6.54e-01 | 3.12e-03 |
| ISOCITRATE METABOLIC PROCESS | 5 | 3.29e-01 | 8.53e-01 | 1.03000 | 4.88e-01 | 4.29e-01 | 5.50e-01 | 4.26e-01 | 3.89e-01 | 5.88e-02 | 9.68e-02 | 3.31e-02 | 9.92e-02 | 1.32e-01 |
| ISOLEUCINE TRANSPORT | 5 | 2.49e-01 | 7.75e-01 | 1.03000 | 5.06e-01 | 5.29e-01 | 5.12e-01 | 4.10e-01 | 2.98e-01 | 5.02e-02 | 4.07e-02 | 4.72e-02 | 1.13e-01 | 2.48e-01 |
| MYELOID DENDRITIC CELL CHEMOTAXIS | 5 | 1.89e-03 | 3.78e-02 | 1.03000 | -4.48e-01 | -4.38e-01 | 3.27e-02 | -6.77e-01 | 4.49e-01 | 8.29e-02 | 8.99e-02 | 8.99e-01 | 8.76e-03 | 8.24e-02 |
| MAST CELL PROLIFERATION | 7 | 2.09e-01 | 7.30e-01 | 1.03000 | -5.49e-01 | -5.64e-01 | -3.77e-01 | -5.37e-01 | 3.34e-02 | 1.19e-02 | 9.70e-03 | 8.42e-02 | 1.38e-02 | 8.79e-01 |
| REGULATION OF PHENOTYPIC SWITCHING | 6 | 1.79e-08 | 1.88e-06 | 1.02000 | -4.67e-01 | -5.18e-01 | 1.75e-01 | -5.56e-01 | 4.64e-01 | 4.76e-02 | 2.80e-02 | 4.59e-01 | 1.84e-02 | 4.91e-02 |
| SUCCINATE METABOLIC PROCESS | 5 | 4.28e-01 | 9.17e-01 | 1.01000 | -5.16e-01 | -5.24e-01 | -4.73e-01 | -4.80e-01 | -1.57e-01 | 4.57e-02 | 4.25e-02 | 6.67e-02 | 6.31e-02 | 5.44e-01 |
| NEGATIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO OSMOTIC STRESS | 5 | 3.87e-01 | 8.92e-01 | 1.01000 | 5.06e-01 | 4.70e-01 | 5.13e-01 | 4.96e-01 | 1.66e-01 | 4.98e-02 | 6.86e-02 | 4.72e-02 | 5.50e-02 | 5.19e-01 |
| POSITIVE REGULATION OF COA TRANSFERASE ACTIVITY | 8 | 1.56e-01 | 6.53e-01 | 1.00000 | 5.09e-01 | 5.18e-01 | 4.89e-01 | 4.42e-01 | 1.95e-01 | 1.26e-02 | 1.12e-02 | 1.66e-02 | 3.04e-02 | 3.40e-01 |
| ADENOSINE TRANSPORT | 5 | 1.16e-01 | 5.66e-01 | 1.00000 | 3.57e-01 | 3.19e-01 | 5.25e-01 | 2.56e-01 | 6.55e-01 | 1.66e-01 | 2.16e-01 | 4.20e-02 | 3.22e-01 | 1.12e-02 |
| T HELPER 1 CELL CYTOKINE PRODUCTION | 8 | 5.99e-02 | 4.02e-01 | 0.99900 | -5.03e-01 | -5.58e-01 | -2.40e-01 | -6.08e-01 | 8.10e-02 | 1.37e-02 | 6.29e-03 | 2.40e-01 | 2.88e-03 | 6.92e-01 |
| ALKALOID METABOLIC PROCESS | 7 | 2.96e-03 | 5.18e-02 | 0.99900 | 4.55e-01 | 5.00e-01 | 2.11e-02 | 7.17e-01 | -1.59e-01 | 3.72e-02 | 2.19e-02 | 9.23e-01 | 1.02e-03 | 4.67e-01 |
| POLE PLASM ASSEMBLY | 6 | 1.34e-01 | 6.08e-01 | 0.99800 | -4.81e-01 | -4.99e-01 | -4.93e-01 | -3.67e-01 | -3.73e-01 | 4.12e-02 | 3.42e-02 | 3.66e-02 | 1.20e-01 | 1.14e-01 |
| POSITIVE REGULATION OF MUSCLE ADAPTATION | 13 | 7.68e-03 | 1.04e-01 | 0.99800 | 5.40e-01 | 5.14e-01 | 3.76e-01 | 5.01e-01 | -2.16e-01 | 7.49e-04 | 1.32e-03 | 1.89e-02 | 1.74e-03 | 1.77e-01 |
| REGULATION OF VERY LOW DENSITY LIPOPROTEIN PARTICLE REMODELING | 6 | 3.42e-01 | 8.60e-01 | 0.99700 | 5.28e-01 | 5.35e-01 | 4.64e-01 | 4.58e-01 | -6.73e-02 | 2.50e-02 | 2.32e-02 | 4.93e-02 | 5.21e-02 | 7.75e-01 |
| STRAND INVASION | 6 | 8.88e-02 | 4.92e-01 | 0.99100 | 4.51e-01 | 4.40e-01 | 6.10e-01 | 2.78e-01 | 3.68e-01 | 5.58e-02 | 6.20e-02 | 9.72e-03 | 2.38e-01 | 1.18e-01 |
| REGULATION OF T CELL COSTIMULATION | 5 | 9.89e-02 | 5.20e-01 | 0.98800 | -4.11e-01 | -4.60e-01 | -9.11e-02 | -4.95e-01 | 5.84e-01 | 1.11e-01 | 7.48e-02 | 7.24e-01 | 5.51e-02 | 2.37e-02 |
| REGULATION OF NATURAL KILLER CELL PROLIFERATION | 12 | 2.41e-02 | 2.33e-01 | 0.97600 | -4.93e-01 | -4.57e-01 | -3.86e-01 | -5.67e-01 | -1.71e-01 | 3.08e-03 | 6.12e-03 | 2.06e-02 | 6.69e-04 | 3.04e-01 |
| POSITIVE REGULATION OF MITOTIC SISTER CHROMATID SEGREGATION | 6 | 3.93e-01 | 8.92e-01 | 0.97600 | 5.25e-01 | 5.18e-01 | 4.71e-01 | 4.31e-01 | -4.14e-02 | 2.61e-02 | 2.80e-02 | 4.59e-02 | 6.77e-02 | 8.61e-01 |
| PROTEIN UNFOLDING | 5 | 3.42e-01 | 8.61e-01 | 0.97600 | 5.19e-01 | 4.45e-01 | 4.86e-01 | 4.97e-01 | 4.94e-02 | 4.46e-02 | 8.51e-02 | 5.98e-02 | 5.45e-02 | 8.48e-01 |
| VITAMIN B6 METABOLIC PROCESS | 5 | 1.78e-01 | 6.85e-01 | 0.97500 | 4.94e-01 | 3.74e-01 | 5.55e-01 | 4.07e-01 | 3.04e-01 | 5.57e-02 | 1.47e-01 | 3.16e-02 | 1.15e-01 | 2.40e-01 |
| NITRIC OXIDE TRANSPORT | 5 | 2.94e-01 | 8.22e-01 | 0.97400 | 5.12e-01 | 5.74e-01 | 4.11e-01 | 4.32e-01 | -3.94e-02 | 4.74e-02 | 2.62e-02 | 1.11e-01 | 9.45e-02 | 8.79e-01 |
| RESPONSE TO ACTINOMYCIN D | 5 | 4.43e-01 | 9.28e-01 | 0.96300 | 4.93e-01 | 4.34e-01 | 5.39e-01 | 4.21e-01 | 1.69e-01 | 5.63e-02 | 9.30e-02 | 3.70e-02 | 1.03e-01 | 5.13e-01 |
| ERBB4 ERBB4 SIGNALING PATHWAY | 6 | 2.47e-01 | 7.75e-01 | 0.95500 | -5.13e-01 | -5.25e-01 | -4.21e-01 | -3.67e-01 | 2.47e-01 | 2.95e-02 | 2.58e-02 | 7.41e-02 | 1.20e-01 | 2.95e-01 |
| REGULATION OF CELLULAR RESPONSE TO MACROPHAGE COLONY STIMULATING FACTOR STIMULUS | 6 | 3.96e-01 | 8.96e-01 | 0.95500 | -4.82e-01 | -4.76e-01 | -4.28e-01 | -4.84e-01 | -1.83e-01 | 4.09e-02 | 4.33e-02 | 6.92e-02 | 3.99e-02 | 4.37e-01 |
| REGULATION OF POTASSIUM ION IMPORT | 5 | 3.68e-01 | 8.79e-01 | 0.95100 | -4.72e-01 | -4.27e-01 | -3.90e-01 | -5.48e-01 | -2.17e-01 | 6.77e-02 | 9.82e-02 | 1.31e-01 | 3.37e-02 | 4.00e-01 |
| METAPHASE ANAPHASE TRANSITION OF MEIOTIC CELL CYCLE | 5 | 4.13e-01 | 9.10e-01 | 0.95000 | 4.78e-01 | 4.85e-01 | 3.34e-01 | 5.46e-01 | 1.69e-01 | 6.41e-02 | 6.01e-02 | 1.96e-01 | 3.45e-02 | 5.13e-01 |
| C X C CHEMOKINE RECEPTOR CXCR4 SIGNALING PATHWAY | 5 | 2.54e-01 | 7.81e-01 | 0.94800 | -4.65e-01 | -4.43e-01 | -2.93e-01 | -6.23e-01 | -1.14e-01 | 7.19e-02 | 8.61e-02 | 2.56e-01 | 1.59e-02 | 6.58e-01 |
| REGULATION OF ATRIAL CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 6 | 3.91e-01 | 8.92e-01 | 0.94700 | 4.75e-01 | 4.71e-01 | 4.25e-01 | 4.81e-01 | 1.96e-01 | 4.39e-02 | 4.59e-02 | 7.15e-02 | 4.13e-02 | 4.05e-01 |
| NEGATIVE REGULATION OF SYNCYTIUM FORMATION BY PLASMA MEMBRANE FUSION | 5 | 1.62e-01 | 6.62e-01 | 0.94300 | -4.67e-01 | -4.31e-01 | -3.86e-01 | -4.37e-01 | 3.82e-01 | 7.05e-02 | 9.51e-02 | 1.35e-01 | 9.09e-02 | 1.39e-01 |
| GRANULOCYTE COLONY STIMULATING FACTOR PRODUCTION | 5 | 4.30e-03 | 6.84e-02 | 0.94000 | -3.36e-01 | -5.28e-01 | 1.64e-01 | -5.17e-01 | 4.43e-01 | 1.93e-01 | 4.08e-02 | 5.25e-01 | 4.53e-02 | 8.60e-02 |
| VOLUNTARY SKELETAL MUSCLE CONTRACTION | 5 | 4.07e-01 | 9.08e-01 | 0.93800 | 4.81e-01 | 4.99e-01 | 3.69e-01 | 4.61e-01 | -2.24e-01 | 6.24e-02 | 5.31e-02 | 1.53e-01 | 7.42e-02 | 3.85e-01 |
| POSITIVE REGULATION OF ISOTYPE SWITCHING TO IGG ISOTYPES | 11 | 3.66e-02 | 3.05e-01 | 0.93700 | -4.69e-01 | -4.92e-01 | -2.67e-01 | -5.16e-01 | 2.79e-01 | 7.11e-03 | 4.68e-03 | 1.26e-01 | 3.04e-03 | 1.09e-01 |
| ENDOCANNABINOID SIGNALING PATHWAY | 5 | 3.67e-01 | 8.79e-01 | 0.93600 | 4.63e-01 | 4.06e-01 | 5.34e-01 | 4.22e-01 | 1.83e-01 | 7.30e-02 | 1.15e-01 | 3.87e-02 | 1.02e-01 | 4.78e-01 |
| CELLULAR RESPONSE TO HYDROPEROXIDE | 8 | 1.75e-01 | 6.81e-01 | 0.93500 | -4.81e-01 | -4.88e-01 | -4.66e-01 | -4.34e-01 | -2.24e-02 | 1.84e-02 | 1.69e-02 | 2.26e-02 | 3.36e-02 | 9.12e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 18 PRODUCTION | 5 | 2.70e-01 | 7.97e-01 | 0.93500 | -4.45e-01 | -4.79e-01 | -2.57e-01 | -4.38e-01 | 4.34e-01 | 8.50e-02 | 6.34e-02 | 3.19e-01 | 9.00e-02 | 9.29e-02 |
| DIACYLGLYCEROL CATABOLIC PROCESS | 5 | 5.26e-01 | 9.54e-01 | 0.93400 | 4.67e-01 | 4.31e-01 | 4.60e-01 | 4.44e-01 | 2.44e-01 | 7.03e-02 | 9.51e-02 | 7.52e-02 | 8.55e-02 | 3.45e-01 |
| LIPOXIN METABOLIC PROCESS | 5 | 1.54e-01 | 6.50e-01 | 0.93200 | 4.30e-01 | 4.43e-01 | 1.32e-01 | 5.57e-01 | -4.01e-01 | 9.60e-02 | 8.65e-02 | 6.09e-01 | 3.11e-02 | 1.21e-01 |
| LYMPHATIC ENDOTHELIAL CELL DIFFERENTIATION | 8 | 1.68e-01 | 6.71e-01 | 0.93000 | 4.95e-01 | 4.51e-01 | 5.46e-01 | 3.42e-01 | 1.19e-02 | 1.53e-02 | 2.72e-02 | 7.44e-03 | 9.41e-02 | 9.54e-01 |
| RIBOFLAVIN TRANSPORT | 6 | 8.22e-02 | 4.71e-01 | 0.92800 | 4.10e-01 | 4.80e-01 | 1.04e-01 | 5.85e-01 | -3.33e-01 | 8.19e-02 | 4.19e-02 | 6.59e-01 | 1.31e-02 | 1.58e-01 |
| NEGATIVE REGULATION OF MEIOTIC CELL CYCLE PHASE TRANSITION | 5 | 2.83e-01 | 8.10e-01 | 0.92800 | 4.55e-01 | 4.62e-01 | 2.56e-01 | 5.86e-01 | -1.78e-01 | 7.83e-02 | 7.34e-02 | 3.21e-01 | 2.33e-02 | 4.90e-01 |
| ACTIN POLYMERIZATION DEPENDENT CELL MOTILITY | 7 | 3.55e-01 | 8.74e-01 | 0.92700 | -4.80e-01 | -4.55e-01 | -4.19e-01 | -4.86e-01 | -9.87e-02 | 2.78e-02 | 3.70e-02 | 5.50e-02 | 2.58e-02 | 6.51e-01 |
| UDP N ACETYLGLUCOSAMINE BIOSYNTHETIC PROCESS | 9 | 1.46e-01 | 6.32e-01 | 0.92400 | 5.05e-01 | 4.82e-01 | 4.25e-01 | 4.05e-01 | -1.44e-01 | 8.64e-03 | 1.23e-02 | 2.72e-02 | 3.54e-02 | 4.55e-01 |
| BLOOD COAGULATION INTRINSIC PATHWAY | 6 | 2.57e-02 | 2.42e-01 | 0.92300 | -4.12e-01 | -4.62e-01 | 5.83e-04 | -6.30e-01 | 2.69e-01 | 8.07e-02 | 4.98e-02 | 9.98e-01 | 7.54e-03 | 2.54e-01 |
| GLUTATHIONE CATABOLIC PROCESS | 7 | 2.21e-01 | 7.44e-01 | 0.92200 | 4.44e-01 | 4.46e-01 | 4.79e-01 | 3.71e-01 | 2.94e-01 | 4.17e-02 | 4.09e-02 | 2.82e-02 | 8.89e-02 | 1.79e-01 |
| RESPONSE TO PROSTAGLANDIN D | 5 | 4.42e-01 | 9.28e-01 | 0.92200 | -4.89e-01 | -4.30e-01 | -4.85e-01 | -3.87e-01 | -2.01e-01 | 5.83e-02 | 9.60e-02 | 6.01e-02 | 1.34e-01 | 4.36e-01 |
| POSITIVE REGULATION OF T CELL TOLERANCE INDUCTION | 8 | 2.65e-01 | 7.94e-01 | 0.91900 | -4.89e-01 | -5.02e-01 | -3.71e-01 | -4.43e-01 | 1.35e-01 | 1.66e-02 | 1.39e-02 | 6.90e-02 | 2.99e-02 | 5.08e-01 |
| HYDROGEN SULFIDE METABOLIC PROCESS | 6 | 2.14e-01 | 7.37e-01 | 0.91700 | 4.61e-01 | 4.81e-01 | 2.07e-01 | 5.08e-01 | -3.09e-01 | 5.05e-02 | 4.12e-02 | 3.80e-01 | 3.13e-02 | 1.90e-01 |
| RESPONSE TO YEAST | 7 | 1.79e-03 | 3.63e-02 | 0.91600 | -3.76e-01 | -4.89e-01 | -2.25e-01 | -5.34e-01 | -3.50e-01 | 8.48e-02 | 2.50e-02 | 3.03e-01 | 1.43e-02 | 1.09e-01 |
| NEGATIVE REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY | 8 | 1.13e-01 | 5.59e-01 | 0.91500 | 4.47e-01 | 4.19e-01 | 4.33e-01 | 3.68e-01 | 3.72e-01 | 2.86e-02 | 3.99e-02 | 3.37e-02 | 7.13e-02 | 6.85e-02 |
| MESANGIAL CELL DEVELOPMENT | 6 | 1.70e-01 | 6.75e-01 | 0.91300 | 4.64e-01 | 4.16e-01 | 6.05e-01 | 2.74e-01 | 6.53e-02 | 4.92e-02 | 7.74e-02 | 1.03e-02 | 2.44e-01 | 7.82e-01 |
| PROTEIN LOCALIZATION TO CENP A CONTAINING CHROMATIN | 16 | 1.84e-03 | 3.69e-02 | 0.90900 | 5.06e-01 | 4.33e-01 | 4.77e-01 | 3.84e-01 | -9.53e-02 | 4.61e-04 | 2.74e-03 | 9.50e-04 | 7.90e-03 | 5.09e-01 |
| AIM2 INFLAMMASOME COMPLEX ASSEMBLY | 5 | 1.04e-01 | 5.36e-01 | 0.90300 | -5.09e-01 | -4.80e-01 | -5.29e-01 | -1.91e-01 | 1.01e-01 | 4.87e-02 | 6.29e-02 | 4.06e-02 | 4.60e-01 | 6.95e-01 |
| NEGATIVE REGULATION OF T CELL MIGRATION | 6 | 2.87e-01 | 8.13e-01 | 0.90300 | -4.31e-01 | -4.31e-01 | -3.98e-01 | -4.90e-01 | -2.12e-01 | 6.73e-02 | 6.74e-02 | 9.16e-02 | 3.77e-02 | 3.68e-01 |
| GLOSSOPHARYNGEAL NERVE DEVELOPMENT | 5 | 2.46e-03 | 4.52e-02 | 0.90300 | 3.60e-01 | 4.38e-01 | -1.72e-01 | 5.11e-01 | -4.50e-01 | 1.63e-01 | 9.01e-02 | 5.06e-01 | 4.78e-02 | 8.13e-02 |
| REGULATION OF DNA LIGATION | 6 | 1.39e-01 | 6.23e-01 | 0.90000 | 3.79e-01 | 3.10e-01 | 5.88e-01 | 1.71e-01 | 4.42e-01 | 1.08e-01 | 1.88e-01 | 1.26e-02 | 4.68e-01 | 6.09e-02 |
| MATURE CONVENTIONAL DENDRITIC CELL DIFFERENTIATION | 5 | 3.37e-02 | 2.92e-01 | 0.90000 | -3.07e-01 | -4.32e-01 | 1.51e-01 | -4.92e-01 | 5.12e-01 | 2.34e-01 | 9.41e-02 | 5.58e-01 | 5.66e-02 | 4.72e-02 |
| REGULATION OF FC GAMMA RECEPTOR SIGNALING PATHWAY INVOLVED IN PHAGOCYTOSIS | 5 | 1.84e-01 | 6.93e-01 | 0.89800 | -4.35e-01 | -5.19e-01 | -2.83e-01 | -3.27e-01 | 4.00e-01 | 9.18e-02 | 4.43e-02 | 2.74e-01 | 2.05e-01 | 1.21e-01 |
| AXON MIDLINE CHOICE POINT RECOGNITION | 5 | 2.82e-01 | 8.09e-01 | 0.89300 | -3.81e-01 | -3.92e-01 | -3.54e-01 | -4.38e-01 | -4.28e-01 | 1.40e-01 | 1.29e-01 | 1.71e-01 | 9.00e-02 | 9.74e-02 |
| CELLULAR RESPONSE TO SODIUM ARSENITE | 5 | 3.86e-01 | 8.92e-01 | 0.89300 | 4.43e-01 | 4.43e-01 | 5.18e-01 | 3.25e-01 | 1.77e-01 | 8.61e-02 | 8.61e-02 | 4.50e-02 | 2.08e-01 | 4.92e-01 |
| DIADENOSINE POLYPHOSPHATE METABOLIC PROCESS | 6 | 1.27e-01 | 5.93e-01 | 0.89200 | -4.54e-01 | -3.89e-01 | -3.54e-01 | -5.56e-01 | 6.68e-02 | 5.43e-02 | 9.93e-02 | 1.33e-01 | 1.83e-02 | 7.77e-01 |
| POSITIVE REGULATION OF DNA DEMETHYLATION | 8 | 8.37e-02 | 4.77e-01 | 0.88900 | -4.04e-01 | -3.00e-01 | -5.40e-01 | -3.21e-01 | -3.79e-01 | 4.79e-02 | 1.42e-01 | 8.18e-03 | 1.16e-01 | 6.32e-02 |
| REGULATION OF SOMITOGENESIS | 6 | 2.49e-01 | 7.75e-01 | 0.88800 | 4.89e-01 | 4.17e-01 | 4.45e-01 | 4.14e-01 | -8.20e-02 | 3.79e-02 | 7.70e-02 | 5.91e-02 | 7.93e-02 | 7.28e-01 |
| POSITIVE REGULATION OF NATURAL KILLER CELL PROLIFERATION | 10 | 7.52e-02 | 4.50e-01 | 0.88700 | -4.51e-01 | -4.15e-01 | -3.24e-01 | -5.44e-01 | -1.05e-01 | 1.34e-02 | 2.30e-02 | 7.60e-02 | 2.91e-03 | 5.67e-01 |
| POSITIVE REGULATION OF MELANOCYTE DIFFERENTIATION | 5 | 4.19e-01 | 9.11e-01 | 0.88700 | -4.43e-01 | -4.80e-01 | -2.79e-01 | -5.16e-01 | -1.28e-01 | 8.61e-02 | 6.32e-02 | 2.81e-01 | 4.58e-02 | 6.21e-01 |
| THYMOCYTE MIGRATION | 7 | 2.27e-01 | 7.48e-01 | 0.88600 | -4.17e-01 | -3.77e-01 | -4.34e-01 | -3.56e-01 | -3.94e-01 | 5.61e-02 | 8.44e-02 | 4.70e-02 | 1.02e-01 | 7.14e-02 |
| NEGATIVE REGULATION OF IRE1 MEDIATED UNFOLDED PROTEIN RESPONSE | 5 | 3.83e-01 | 8.92e-01 | 0.88600 | 4.32e-01 | 3.87e-01 | 5.72e-01 | 2.57e-01 | 2.35e-01 | 9.43e-02 | 1.34e-01 | 2.67e-02 | 3.19e-01 | 3.62e-01 |
| POSITIVE REGULATION OF DNA LIGATION | 5 | 1.31e-01 | 5.99e-01 | 0.88400 | 3.42e-01 | 2.77e-01 | 6.06e-01 | 8.26e-02 | 4.63e-01 | 1.86e-01 | 2.83e-01 | 1.89e-02 | 7.49e-01 | 7.31e-02 |
| PHOTORECEPTOR CELL MORPHOGENESIS | 5 | 3.68e-01 | 8.79e-01 | 0.88400 | 4.48e-01 | 3.87e-01 | 5.82e-01 | 2.72e-01 | 1.35e-01 | 8.30e-02 | 1.34e-01 | 2.42e-02 | 2.92e-01 | 6.00e-01 |
| FLAVIN CONTAINING COMPOUND METABOLIC PROCESS | 6 | 1.47e-01 | 6.34e-01 | 0.88300 | 4.48e-01 | 4.27e-01 | 2.63e-01 | 4.07e-01 | -4.02e-01 | 5.76e-02 | 6.98e-02 | 2.64e-01 | 8.39e-02 | 8.83e-02 |
| MEMBRANE DEPOLARIZATION DURING AV NODE CELL ACTION POTENTIAL | 6 | 2.99e-01 | 8.27e-01 | 0.88300 | 4.35e-01 | 4.78e-01 | 3.25e-01 | 4.86e-01 | 1.43e-01 | 6.48e-02 | 4.27e-02 | 1.68e-01 | 3.93e-02 | 5.45e-01 |
| BUD ELONGATION INVOLVED IN LUNG BRANCHING | 7 | 3.38e-01 | 8.59e-01 | 0.88100 | 4.58e-01 | 4.58e-01 | 3.55e-01 | 4.58e-01 | -1.44e-01 | 3.59e-02 | 3.58e-02 | 1.04e-01 | 3.57e-02 | 5.09e-01 |
| LEUKOTRIENE D4 METABOLIC PROCESS | 8 | 7.11e-02 | 4.38e-01 | 0.88000 | 3.86e-01 | 3.89e-01 | 3.59e-01 | 4.87e-01 | 3.30e-01 | 5.89e-02 | 5.67e-02 | 7.88e-02 | 1.70e-02 | 1.06e-01 |
| REGULATION OF PLASMA CELL DIFFERENTIATION | 5 | 2.35e-02 | 2.30e-01 | 0.88000 | -1.83e-01 | -2.80e-01 | 2.79e-01 | -3.64e-01 | 6.73e-01 | 4.78e-01 | 2.78e-01 | 2.80e-01 | 1.59e-01 | 9.20e-03 |
| LOW DENSITY LIPOPROTEIN RECEPTOR PARTICLE METABOLIC PROCESS | 6 | 1.62e-01 | 6.61e-01 | 0.88000 | 4.53e-01 | 5.32e-01 | 2.97e-01 | 4.33e-01 | 9.61e-02 | 5.47e-02 | 2.39e-02 | 2.07e-01 | 6.61e-02 | 6.83e-01 |
| CORTICOSTERONE SECRETION | 5 | 4.72e-01 | 9.40e-01 | 0.87900 | 4.11e-01 | 3.63e-01 | 5.14e-01 | 3.14e-01 | 3.32e-01 | 1.12e-01 | 1.60e-01 | 4.66e-02 | 2.24e-01 | 1.99e-01 |
| POSITIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL PROLIFERATION | 10 | 1.80e-01 | 6.88e-01 | 0.87900 | -4.63e-01 | -4.85e-01 | -3.52e-01 | -4.29e-01 | 1.24e-01 | 1.13e-02 | 7.97e-03 | 5.41e-02 | 1.89e-02 | 4.96e-01 |
| NATURAL KILLER CELL PROLIFERATION | 14 | 3.87e-02 | 3.15e-01 | 0.87600 | -4.54e-01 | -4.41e-01 | -3.11e-01 | -5.13e-01 | -7.95e-02 | 3.26e-03 | 4.23e-03 | 4.42e-02 | 8.78e-04 | 6.06e-01 |
| RIBOFLAVIN METABOLIC PROCESS | 5 | 3.11e-01 | 8.38e-01 | 0.87400 | 4.38e-01 | 4.50e-01 | 1.84e-01 | 4.84e-01 | -3.19e-01 | 8.95e-02 | 8.11e-02 | 4.76e-01 | 6.12e-02 | 2.16e-01 |
| RESPONSE TO INTERLEUKIN 2 | 9 | 8.28e-03 | 1.10e-01 | 0.87400 | -3.87e-01 | -4.81e-01 | -6.20e-02 | -3.76e-01 | 4.87e-01 | 4.43e-02 | 1.25e-02 | 7.48e-01 | 5.08e-02 | 1.13e-02 |
| PHOSPHATIDYLETHANOLAMINE BIOSYNTHETIC PROCESS | 10 | 2.20e-01 | 7.43e-01 | 0.87400 | 4.50e-01 | 4.34e-01 | 3.89e-01 | 4.60e-01 | 9.89e-02 | 1.38e-02 | 1.74e-02 | 3.33e-02 | 1.17e-02 | 5.88e-01 |
| GLYCERALDEHYDE 3 PHOSPHATE METABOLIC PROCESS | 6 | 1.17e-01 | 5.69e-01 | 0.87400 | 3.92e-01 | 3.38e-01 | 3.27e-01 | 5.62e-01 | 2.71e-01 | 9.66e-02 | 1.52e-01 | 1.66e-01 | 1.71e-02 | 2.51e-01 |
| AXON CHOICE POINT RECOGNITION | 7 | 2.15e-01 | 7.37e-01 | 0.87100 | -4.10e-01 | -4.30e-01 | -3.23e-01 | -4.64e-01 | -2.93e-01 | 6.02e-02 | 4.88e-02 | 1.39e-01 | 3.36e-02 | 1.79e-01 |
| POSITIVE REGULATION OF LYMPHOCYTE CHEMOTAXIS | 20 | 1.31e-02 | 1.51e-01 | 0.86600 | -4.65e-01 | -4.53e-01 | -4.58e-01 | -3.46e-01 | -1.18e-02 | 3.20e-04 | 4.54e-04 | 3.95e-04 | 7.36e-03 | 9.27e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL MATRIX ADHESION VIA FIBRONECTIN | 5 | 3.06e-01 | 8.35e-01 | 0.86500 | 3.36e-01 | 3.12e-01 | 3.84e-01 | 3.28e-01 | 5.33e-01 | 1.94e-01 | 2.27e-01 | 1.37e-01 | 2.05e-01 | 3.91e-02 |
| STABILIZATION OF MEMBRANE POTENTIAL | 17 | 2.70e-03 | 4.87e-02 | 0.86400 | 4.24e-01 | 4.46e-01 | 2.68e-01 | 3.67e-01 | -4.00e-01 | 2.45e-03 | 1.44e-03 | 5.59e-02 | 8.85e-03 | 4.25e-03 |
| REGULATION OF INTESTINAL LIPID ABSORPTION | 10 | 1.75e-01 | 6.80e-01 | 0.86200 | 4.45e-01 | 4.45e-01 | 3.43e-01 | 4.47e-01 | 1.69e-01 | 1.47e-02 | 1.47e-02 | 6.02e-02 | 1.45e-02 | 3.54e-01 |
| T CELL TOLERANCE INDUCTION | 14 | 6.62e-02 | 4.18e-01 | 0.86200 | -4.65e-01 | -4.60e-01 | -4.14e-01 | -3.63e-01 | 1.09e-01 | 2.58e-03 | 2.89e-03 | 7.37e-03 | 1.87e-02 | 4.79e-01 |
| POSITIVE REGULATION OF T HELPER 2 CELL CYTOKINE PRODUCTION | 9 | 4.94e-02 | 3.61e-01 | 0.86000 | -4.26e-01 | -5.09e-01 | -1.50e-01 | -4.88e-01 | 1.93e-01 | 2.68e-02 | 8.19e-03 | 4.35e-01 | 1.12e-02 | 3.16e-01 |
| CHOLESTEROL IMPORT | 9 | 1.06e-01 | 5.40e-01 | 0.85900 | 3.70e-01 | 3.50e-01 | 3.78e-01 | 3.79e-01 | 4.37e-01 | 5.49e-02 | 6.88e-02 | 4.96e-02 | 4.88e-02 | 2.31e-02 |
| NEGATIVE REGULATION OF SERINE TYPE PEPTIDASE ACTIVITY | 5 | 7.29e-02 | 4.45e-01 | 0.85800 | 4.18e-01 | 4.00e-01 | 1.38e-01 | 4.09e-01 | -4.63e-01 | 1.05e-01 | 1.21e-01 | 5.93e-01 | 1.13e-01 | 7.33e-02 |
| REGULATION OF CHAPERONE MEDIATED AUTOPHAGY | 8 | 2.21e-01 | 7.44e-01 | 0.85700 | 4.30e-01 | 3.73e-01 | 5.12e-01 | 3.50e-01 | 1.62e-01 | 3.52e-02 | 6.80e-02 | 1.21e-02 | 8.67e-02 | 4.29e-01 |
| POSITIVE REGULATION OF STRIATED MUSCLE CONTRACTION | 13 | 1.20e-01 | 5.78e-01 | 0.85700 | 4.57e-01 | 4.72e-01 | 3.58e-01 | 4.17e-01 | 4.36e-03 | 4.30e-03 | 3.22e-03 | 2.54e-02 | 9.21e-03 | 9.78e-01 |
| ASCENDING AORTA DEVELOPMENT | 5 | 3.32e-03 | 5.64e-02 | 0.85600 | 4.22e-01 | 3.85e-01 | 6.09e-01 | -9.70e-02 | -1.63e-01 | 1.02e-01 | 1.36e-01 | 1.83e-02 | 7.07e-01 | 5.28e-01 |
| POSITIVE REGULATION OF MICROGLIAL CELL ACTIVATION | 10 | 2.44e-02 | 2.34e-01 | 0.85500 | -4.50e-01 | -5.12e-01 | -3.82e-01 | -3.23e-01 | -1.24e-01 | 1.36e-02 | 5.06e-03 | 3.65e-02 | 7.72e-02 | 4.98e-01 |
| INHIBITION OF NEUROEPITHELIAL CELL DIFFERENTIATION | 5 | 1.71e-01 | 6.75e-01 | 0.85400 | 4.46e-01 | 4.78e-01 | 4.59e-01 | 1.84e-01 | -2.42e-01 | 8.41e-02 | 6.44e-02 | 7.56e-02 | 4.75e-01 | 3.50e-01 |
| NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION INVOLVED IN PROSTATE GLAND DEVELOPMENT | 6 | 3.52e-01 | 8.71e-01 | 0.85300 | 4.57e-01 | 4.18e-01 | 5.14e-01 | 2.60e-01 | 1.13e-01 | 5.25e-02 | 7.61e-02 | 2.92e-02 | 2.70e-01 | 6.32e-01 |
| NEGATIVE REGULATION OF MATRIX METALLOPEPTIDASE SECRETION | 6 | 6.36e-03 | 9.06e-02 | 0.85300 | 2.63e-01 | 2.48e-01 | 4.05e-02 | 1.60e-01 | -7.55e-01 | 2.65e-01 | 2.93e-01 | 8.63e-01 | 4.96e-01 | 1.35e-03 |
| HYPOXIA INDUCIBLE FACTOR 1ALPHA SIGNALING PATHWAY | 5 | 6.19e-01 | 9.90e-01 | 0.85200 | -4.39e-01 | -4.37e-01 | -4.43e-01 | -3.53e-01 | -1.43e-01 | 8.88e-02 | 9.07e-02 | 8.62e-02 | 1.72e-01 | 5.79e-01 |
| NEGATIVE REGULATION OF LENS FIBER CELL DIFFERENTIATION | 6 | 4.86e-01 | 9.43e-01 | 0.85000 | 4.19e-01 | 3.74e-01 | 4.38e-01 | 4.02e-01 | 2.30e-01 | 7.55e-02 | 1.12e-01 | 6.33e-02 | 8.79e-02 | 3.29e-01 |
| POSITIVE REGULATION OF CELL GROWTH INVOLVED IN CARDIAC MUSCLE CELL DEVELOPMENT | 8 | 1.96e-01 | 7.10e-01 | 0.84700 | 4.40e-01 | 4.11e-01 | 4.11e-01 | 4.10e-01 | -1.36e-01 | 3.11e-02 | 4.43e-02 | 4.43e-02 | 4.48e-02 | 5.04e-01 |
| FUSED ANTRUM STAGE | 6 | 2.66e-01 | 7.95e-01 | 0.84600 | -4.13e-01 | -4.52e-01 | -4.11e-01 | -3.46e-01 | -2.26e-01 | 7.97e-02 | 5.52e-02 | 8.09e-02 | 1.42e-01 | 3.38e-01 |
| REGULATION OF FAS SIGNALING PATHWAY | 6 | 1.57e-01 | 6.54e-01 | 0.84500 | -3.93e-01 | -3.85e-01 | -2.71e-01 | -3.31e-01 | 4.79e-01 | 9.57e-02 | 1.02e-01 | 2.50e-01 | 1.60e-01 | 4.23e-02 |
| RESPONSE TO CORTICOTROPIN RELEASING HORMONE | 5 | 1.46e-01 | 6.30e-01 | 0.84500 | 3.32e-01 | 2.40e-01 | 6.11e-01 | 1.55e-01 | 3.87e-01 | 1.99e-01 | 3.52e-01 | 1.81e-02 | 5.47e-01 | 1.34e-01 |
| URETERIC BUD FORMATION | 7 | 2.16e-02 | 2.19e-01 | 0.84400 | -3.08e-01 | -3.57e-01 | 1.87e-02 | -5.40e-01 | 4.45e-01 | 1.58e-01 | 1.02e-01 | 9.32e-01 | 1.33e-02 | 4.17e-02 |
| POSITIVE REGULATION OF EPIDERMAL GROWTH FACTOR ACTIVATED RECEPTOR ACTIVITY | 5 | 4.65e-02 | 3.49e-01 | 0.84000 | 3.42e-01 | 4.00e-01 | -7.65e-02 | 4.45e-01 | -4.74e-01 | 1.86e-01 | 1.22e-01 | 7.67e-01 | 8.47e-02 | 6.65e-02 |
| CEREBRAL CORTEX GABAERGIC INTERNEURON DIFFERENTIATION | 10 | 2.62e-02 | 2.45e-01 | 0.83700 | 4.29e-01 | 3.97e-01 | 5.30e-01 | 2.59e-01 | -1.04e-01 | 1.89e-02 | 2.97e-02 | 3.67e-03 | 1.56e-01 | 5.70e-01 |
| RESPONSE TO INTERLEUKIN 9 | 5 | 3.91e-01 | 8.92e-01 | 0.83600 | -4.34e-01 | -4.91e-01 | -2.01e-01 | -4.13e-01 | 2.43e-01 | 9.32e-02 | 5.75e-02 | 4.37e-01 | 1.10e-01 | 3.46e-01 |
| RIBOSOMAL SMALL SUBUNIT ASSEMBLY | 18 | 7.99e-03 | 1.07e-01 | 0.83400 | 4.28e-01 | 4.11e-01 | 4.94e-01 | 2.53e-01 | 1.89e-01 | 1.65e-03 | 2.53e-03 | 2.88e-04 | 6.26e-02 | 1.66e-01 |
| RRNA TRANSPORT | 5 | 1.79e-01 | 6.86e-01 | 0.83300 | 2.59e-01 | 2.31e-01 | 4.48e-01 | 1.21e-01 | 5.99e-01 | 3.15e-01 | 3.70e-01 | 8.29e-02 | 6.40e-01 | 2.04e-02 |
| OOCYTE CONSTRUCTION | 8 | 3.05e-01 | 8.33e-01 | 0.83300 | -4.28e-01 | -4.42e-01 | -3.91e-01 | -3.58e-01 | -1.84e-01 | 3.58e-02 | 3.04e-02 | 5.58e-02 | 7.92e-02 | 3.68e-01 |
| POSITIVE REGULATION OF DENDRITIC CELL CHEMOTAXIS | 9 | 1.74e-03 | 3.55e-02 | 0.83300 | -3.86e-01 | -4.90e-01 | 1.07e-02 | -5.40e-01 | 1.16e-01 | 4.49e-02 | 1.10e-02 | 9.56e-01 | 5.05e-03 | 5.46e-01 |
| REGULATION OF ANTIBACTERIAL PEPTIDE PRODUCTION | 7 | 7.85e-03 | 1.05e-01 | 0.83200 | 3.79e-01 | 4.70e-01 | -4.09e-02 | 5.49e-01 | -1.57e-01 | 8.25e-02 | 3.12e-02 | 8.51e-01 | 1.19e-02 | 4.73e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY ENDOTHELIN | 6 | 3.38e-01 | 8.59e-01 | 0.83100 | 4.09e-01 | 4.41e-01 | 1.85e-01 | 4.43e-01 | -3.13e-01 | 8.28e-02 | 6.15e-02 | 4.32e-01 | 6.01e-02 | 1.84e-01 |
| REGULATION OF LYMPHOCYTE CHEMOTAXIS | 26 | 6.54e-03 | 9.27e-02 | 0.83000 | -4.47e-01 | -4.35e-01 | -4.09e-01 | -3.64e-01 | 1.16e-02 | 7.94e-05 | 1.21e-04 | 3.06e-04 | 1.30e-03 | 9.19e-01 |
| NEGATIVE REGULATION OF BROWN FAT CELL DIFFERENTIATION | 5 | 4.56e-01 | 9.31e-01 | 0.82800 | 4.32e-01 | 4.08e-01 | 3.30e-01 | 3.83e-01 | -2.79e-01 | 9.45e-02 | 1.14e-01 | 2.02e-01 | 1.38e-01 | 2.80e-01 |
| SENSORY PERCEPTION OF SMELL | 382 | 7.44e-74 | 2.80e-70 | 0.82700 | -3.95e-01 | -3.56e-01 | -5.16e-01 | -2.90e-01 | -2.27e-01 | 2.78e-40 | 5.66e-33 | 1.11e-67 | 2.04e-22 | 2.76e-14 |
| NATURAL KILLER CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 31 | 1.10e-04 | 3.77e-03 | 0.82700 | -4.33e-01 | -3.98e-01 | -3.32e-01 | -4.71e-01 | 7.86e-02 | 3.04e-05 | 1.23e-04 | 1.37e-03 | 5.59e-06 | 4.49e-01 |
| MESENCHYME MIGRATION | 5 | 1.42e-01 | 6.27e-01 | 0.82700 | 4.26e-01 | 4.76e-01 | 4.52e-01 | 1.72e-01 | -2.05e-01 | 9.92e-02 | 6.53e-02 | 8.02e-02 | 5.05e-01 | 4.28e-01 |
| REGULATION OF STEM CELL DIVISION | 11 | 4.56e-03 | 7.18e-02 | 0.82700 | -4.10e-01 | -4.09e-01 | -1.06e-01 | -5.14e-01 | 2.68e-01 | 1.84e-02 | 1.88e-02 | 5.42e-01 | 3.14e-03 | 1.24e-01 |
| REGULATION OF COA TRANSFERASE ACTIVITY | 10 | 2.68e-01 | 7.95e-01 | 0.82600 | 4.27e-01 | 4.31e-01 | 4.01e-01 | 3.71e-01 | 1.27e-01 | 1.92e-02 | 1.82e-02 | 2.81e-02 | 4.23e-02 | 4.87e-01 |
| NEGATIVE REGULATION OF METALLOENDOPEPTIDASE ACTIVITY | 8 | 3.35e-01 | 8.59e-01 | 0.82400 | -4.27e-01 | -4.40e-01 | -2.82e-01 | -4.47e-01 | 1.59e-01 | 3.66e-02 | 3.13e-02 | 1.68e-01 | 2.87e-02 | 4.35e-01 |
| REGULATION OF SNRNA TRANSCRIPTION BY RNA POLYMERASE II | 5 | 6.57e-01 | 1.00e+00 | 0.82200 | 4.17e-01 | 3.94e-01 | 4.50e-01 | 3.29e-01 | 1.89e-01 | 1.06e-01 | 1.27e-01 | 8.13e-02 | 2.03e-01 | 4.65e-01 |
| NEGATIVE REGULATION OF MEGAKARYOCYTE DIFFERENTIATION | 18 | 1.34e-02 | 1.53e-01 | 0.82200 | 4.33e-01 | 3.71e-01 | 4.18e-01 | 4.16e-01 | 4.57e-02 | 1.48e-03 | 6.36e-03 | 2.15e-03 | 2.24e-03 | 7.37e-01 |
| FARNESYL DIPHOSPHATE METABOLIC PROCESS | 6 | 2.06e-01 | 7.27e-01 | 0.82000 | 3.81e-01 | 3.48e-01 | 3.41e-01 | 5.11e-01 | 1.66e-01 | 1.06e-01 | 1.39e-01 | 1.48e-01 | 3.01e-02 | 4.82e-01 |
| INDUCTION OF BACTERIAL AGGLUTINATION | 6 | 2.12e-01 | 7.34e-01 | 0.81900 | -4.68e-01 | -4.56e-01 | -3.27e-01 | -3.40e-01 | 1.43e-01 | 4.69e-02 | 5.29e-02 | 1.65e-01 | 1.49e-01 | 5.45e-01 |
| TRANSLATIONAL TERMINATION | 15 | 2.70e-02 | 2.51e-01 | 0.81900 | 4.01e-01 | 3.99e-01 | 4.48e-01 | 3.45e-01 | 1.75e-01 | 7.15e-03 | 7.52e-03 | 2.65e-03 | 2.06e-02 | 2.41e-01 |
| POSITIVE REGULATION OF GASTRO INTESTINAL SYSTEM SMOOTH MUSCLE CONTRACTION | 5 | 4.37e-02 | 3.35e-01 | 0.81600 | -4.09e-01 | -4.64e-01 | -1.38e-01 | -2.53e-01 | 4.47e-01 | 1.13e-01 | 7.21e-02 | 5.94e-01 | 3.26e-01 | 8.37e-02 |
| LUNG SACCULE DEVELOPMENT | 10 | 1.37e-01 | 6.18e-01 | 0.81500 | 4.43e-01 | 3.81e-01 | 4.67e-01 | 3.22e-01 | -1.78e-02 | 1.52e-02 | 3.70e-02 | 1.06e-02 | 7.75e-02 | 9.22e-01 |
| INTERLEUKIN 2 MEDIATED SIGNALING PATHWAY | 8 | 2.45e-02 | 2.34e-01 | 0.81400 | -3.53e-01 | -4.45e-01 | -4.39e-02 | -3.32e-01 | 4.78e-01 | 8.39e-02 | 2.93e-02 | 8.30e-01 | 1.04e-01 | 1.92e-02 |
| REGULATION OF CALCIDIOL 1 MONOOXYGENASE ACTIVITY | 7 | 1.06e-01 | 5.39e-01 | 0.81300 | -3.99e-01 | -4.69e-01 | -9.31e-02 | -4.40e-01 | 2.81e-01 | 6.76e-02 | 3.16e-02 | 6.70e-01 | 4.36e-02 | 1.98e-01 |
| KERATINOCYTE APOPTOTIC PROCESS | 7 | 4.17e-01 | 9.11e-01 | 0.81200 | 3.91e-01 | 3.68e-01 | 4.03e-01 | 3.93e-01 | 2.33e-01 | 7.31e-02 | 9.20e-02 | 6.47e-02 | 7.16e-02 | 2.86e-01 |
| REGULATION OF DEFENSE RESPONSE TO FUNGUS | 5 | 4.39e-01 | 9.25e-01 | 0.81200 | -3.90e-01 | -4.12e-01 | -2.23e-01 | -4.56e-01 | 2.82e-01 | 1.31e-01 | 1.10e-01 | 3.88e-01 | 7.76e-02 | 2.74e-01 |
| REGULATION BY VIRUS OF VIRAL PROTEIN LEVELS IN HOST CELL | 7 | 3.57e-01 | 8.74e-01 | 0.81100 | 3.75e-01 | 3.26e-01 | 4.34e-01 | 3.06e-01 | 3.57e-01 | 8.54e-02 | 1.35e-01 | 4.67e-02 | 1.61e-01 | 1.02e-01 |
| POSITIVE REGULATION OF UTERINE SMOOTH MUSCLE CONTRACTION | 7 | 1.33e-01 | 6.06e-01 | 0.81000 | 3.61e-01 | 4.12e-01 | 8.75e-02 | 3.90e-01 | -4.43e-01 | 9.77e-02 | 5.89e-02 | 6.89e-01 | 7.41e-02 | 4.23e-02 |
| REGULATION OF ASYMMETRIC CELL DIVISION | 5 | 4.54e-01 | 9.31e-01 | 0.80800 | 4.53e-01 | 4.29e-01 | 4.31e-01 | 2.64e-01 | -9.26e-02 | 7.94e-02 | 9.70e-02 | 9.54e-02 | 3.07e-01 | 7.20e-01 |
| OLFACTORY NERVE DEVELOPMENT | 6 | 4.38e-01 | 9.23e-01 | 0.80600 | 4.19e-01 | 4.24e-01 | 2.81e-01 | 3.70e-01 | -2.79e-01 | 7.55e-02 | 7.22e-02 | 2.34e-01 | 1.16e-01 | 2.36e-01 |
| CHEMOKINE C X C MOTIF LIGAND 12 SIGNALING PATHWAY | 7 | 3.68e-01 | 8.79e-01 | 0.80600 | -4.08e-01 | -4.17e-01 | -2.45e-01 | -4.96e-01 | -4.85e-02 | 6.13e-02 | 5.62e-02 | 2.63e-01 | 2.30e-02 | 8.24e-01 |
| REGULATION OF T CELL CHEMOTAXIS | 16 | 4.93e-02 | 3.61e-01 | 0.80500 | -4.37e-01 | -4.20e-01 | -4.35e-01 | -2.99e-01 | 4.42e-02 | 2.45e-03 | 3.64e-03 | 2.57e-03 | 3.87e-02 | 7.59e-01 |
| REGULATION OF MACROPHAGE FUSION | 5 | 2.12e-01 | 7.34e-01 | 0.80500 | -4.20e-01 | -5.02e-01 | -1.79e-01 | -4.32e-01 | -2.74e-02 | 1.04e-01 | 5.18e-02 | 4.88e-01 | 9.47e-02 | 9.16e-01 |
| REGULATION OF CD40 SIGNALING PATHWAY | 6 | 9.30e-02 | 5.03e-01 | 0.80500 | -3.70e-01 | -4.80e-01 | -1.38e-01 | -4.91e-01 | 1.41e-01 | 1.17e-01 | 4.17e-02 | 5.59e-01 | 3.72e-02 | 5.49e-01 |
| MEIOTIC ATTACHMENT OF TELOMERE TO NUCLEAR ENVELOPE | 5 | 2.34e-01 | 7.56e-01 | 0.80400 | -3.52e-01 | -3.01e-01 | -5.78e-01 | -1.02e-01 | -2.97e-01 | 1.73e-01 | 2.44e-01 | 2.52e-02 | 6.93e-01 | 2.50e-01 |
| POSITIVE REGULATION OF NUCLEAR CELL CYCLE DNA REPLICATION | 5 | 3.94e-01 | 8.93e-01 | 0.80400 | 4.33e-01 | 4.12e-01 | 4.95e-01 | 2.00e-01 | -5.88e-02 | 9.34e-02 | 1.11e-01 | 5.50e-02 | 4.39e-01 | 8.20e-01 |
| MELANOCYTE DIFFERENTIATION | 24 | 1.11e-02 | 1.36e-01 | 0.80200 | -4.14e-01 | -4.30e-01 | -3.16e-01 | -4.29e-01 | -3.97e-02 | 4.41e-04 | 2.62e-04 | 7.35e-03 | 2.71e-04 | 7.37e-01 |
| RESPONSE TO LECTIN | 22 | 2.11e-03 | 4.04e-02 | 0.80200 | -3.85e-01 | -4.04e-01 | -3.66e-01 | -3.38e-01 | -2.88e-01 | 1.75e-03 | 1.03e-03 | 2.99e-03 | 6.09e-03 | 1.95e-02 |
| DISRUPTION OF CELLULAR ANATOMICAL STRUCTURE IN ANOTHER ORGANISM | 10 | 3.73e-11 | 7.80e-09 | 0.80100 | -4.34e-01 | -4.10e-01 | -3.86e-01 | 8.13e-02 | 3.60e-01 | 1.74e-02 | 2.46e-02 | 3.47e-02 | 6.56e-01 | 4.84e-02 |
| POSITIVE REGULATION OF CELL PROLIFERATION INVOLVED IN HEART MORPHOGENESIS | 5 | 3.86e-01 | 8.92e-01 | 0.80000 | -3.74e-01 | -4.00e-01 | -2.03e-01 | -5.25e-01 | -1.53e-01 | 1.48e-01 | 1.21e-01 | 4.31e-01 | 4.21e-02 | 5.53e-01 |
| CAMP CATABOLIC PROCESS | 9 | 2.34e-01 | 7.56e-01 | 0.79900 | -3.76e-01 | -3.40e-01 | -3.83e-01 | -3.46e-01 | -3.40e-01 | 5.07e-02 | 7.75e-02 | 4.69e-02 | 7.20e-02 | 7.71e-02 |
| NEGATIVE REGULATION OF LAMELLIPODIUM ASSEMBLY | 5 | 1.37e-02 | 1.56e-01 | 0.79800 | 1.36e-01 | 2.13e-01 | -3.45e-01 | 3.43e-01 | -5.80e-01 | 5.97e-01 | 4.10e-01 | 1.82e-01 | 1.84e-01 | 2.46e-02 |
| POSITIVE REGULATION OF LEUKOCYTE TETHERING OR ROLLING | 13 | 4.90e-03 | 7.58e-02 | 0.79800 | -4.35e-01 | -4.80e-01 | -2.24e-01 | -3.29e-01 | 2.43e-01 | 6.61e-03 | 2.73e-03 | 1.62e-01 | 3.99e-02 | 1.29e-01 |
| TYPE III INTERFERON PRODUCTION | 5 | 2.23e-01 | 7.45e-01 | 0.79700 | -3.71e-01 | -3.72e-01 | -2.57e-01 | -3.81e-01 | -3.85e-01 | 1.51e-01 | 1.50e-01 | 3.20e-01 | 1.40e-01 | 1.36e-01 |
| LUNG SECRETORY CELL DIFFERENTIATION | 11 | 9.93e-02 | 5.21e-01 | 0.79500 | 4.26e-01 | 4.35e-01 | 2.54e-01 | 3.78e-01 | -2.32e-01 | 1.44e-02 | 1.25e-02 | 1.45e-01 | 2.98e-02 | 1.82e-01 |
| TRNA THIO MODIFICATION | 5 | 3.45e-01 | 8.64e-01 | 0.79500 | 3.27e-01 | 2.94e-01 | 4.63e-01 | 2.90e-01 | 3.74e-01 | 2.06e-01 | 2.54e-01 | 7.32e-02 | 2.61e-01 | 1.47e-01 |
| NEGATIVE REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 5 | 5.10e-01 | 9.50e-01 | 0.79400 | -4.14e-01 | -4.66e-01 | -2.04e-01 | -4.39e-01 | 9.15e-02 | 1.09e-01 | 7.14e-02 | 4.30e-01 | 8.94e-02 | 7.23e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO HYPOXIA | 9 | 2.31e-01 | 7.53e-01 | 0.79400 | 3.92e-01 | 3.44e-01 | 4.48e-01 | 2.75e-01 | 2.86e-01 | 4.16e-02 | 7.35e-02 | 2.00e-02 | 1.53e-01 | 1.37e-01 |
| ANDROGEN CATABOLIC PROCESS | 5 | 6.63e-01 | 1.00e+00 | 0.79400 | -4.18e-01 | -4.05e-01 | -4.41e-01 | -3.09e-01 | -3.42e-02 | 1.05e-01 | 1.17e-01 | 8.76e-02 | 2.31e-01 | 8.95e-01 |
| REGULATION OF RESPIRATORY BURST INVOLVED IN INFLAMMATORY RESPONSE | 7 | 2.85e-01 | 8.12e-01 | 0.79300 | 4.14e-01 | 3.40e-01 | 5.10e-01 | 2.49e-01 | 1.41e-01 | 5.76e-02 | 1.20e-01 | 1.94e-02 | 2.54e-01 | 5.18e-01 |
| REGULATION OF TRANSLATIONAL TERMINATION | 8 | 4.43e-01 | 9.28e-01 | 0.79300 | 4.02e-01 | 3.84e-01 | 4.01e-01 | 3.75e-01 | 1.36e-01 | 4.90e-02 | 6.01e-02 | 4.97e-02 | 6.63e-02 | 5.05e-01 |
| TETRAHYDROFOLATE INTERCONVERSION | 9 | 2.22e-01 | 7.45e-01 | 0.79200 | -4.12e-01 | -3.84e-01 | -2.80e-01 | -4.81e-01 | -4.18e-03 | 3.22e-02 | 4.62e-02 | 1.46e-01 | 1.25e-02 | 9.83e-01 |
| PLUS END DIRECTED ORGANELLE TRANSPORT ALONG MICROTUBULE | 7 | 4.08e-01 | 9.08e-01 | 0.79100 | -4.03e-01 | -3.92e-01 | -3.00e-01 | -4.67e-01 | 3.65e-02 | 6.46e-02 | 7.28e-02 | 1.69e-01 | 3.23e-02 | 8.67e-01 |
| CHAPERONE MEDIATED AUTOPHAGY | 14 | 6.40e-02 | 4.13e-01 | 0.79100 | 3.87e-01 | 3.43e-01 | 4.75e-01 | 3.06e-01 | 1.99e-01 | 1.23e-02 | 2.64e-02 | 2.10e-03 | 4.76e-02 | 1.98e-01 |
| REGULATION OF PRIMARY MIRNA PROCESSING | 5 | 7.01e-02 | 4.35e-01 | 0.78900 | -3.39e-01 | -3.66e-01 | 5.22e-02 | -5.51e-01 | 2.59e-01 | 1.89e-01 | 1.56e-01 | 8.40e-01 | 3.29e-02 | 3.16e-01 |
| PROLINE METABOLIC PROCESS | 10 | 8.40e-02 | 4.77e-01 | 0.78800 | 4.23e-01 | 4.72e-01 | 3.15e-01 | 2.84e-01 | -2.00e-01 | 2.07e-02 | 9.71e-03 | 8.43e-02 | 1.20e-01 | 2.74e-01 |
| GLYCINE IMPORT ACROSS PLASMA MEMBRANE | 5 | 8.66e-02 | 4.86e-01 | 0.78800 | 3.97e-01 | 4.73e-01 | 4.54e-01 | 1.79e-01 | -2.55e-02 | 1.24e-01 | 6.71e-02 | 7.84e-02 | 4.87e-01 | 9.21e-01 |
| POSITIVE REGULATION OF HAIR FOLLICLE DEVELOPMENT | 12 | 4.91e-02 | 3.61e-01 | 0.78800 | 4.26e-01 | 3.45e-01 | 4.80e-01 | 2.98e-01 | 2.99e-02 | 1.05e-02 | 3.85e-02 | 3.99e-03 | 7.42e-02 | 8.58e-01 |
| MITOCHONDRIAL ATP TRANSMEMBRANE TRANSPORT | 6 | 2.73e-01 | 7.99e-01 | 0.78800 | -3.70e-01 | -3.80e-01 | -1.97e-01 | -3.34e-01 | 4.35e-01 | 1.17e-01 | 1.07e-01 | 4.04e-01 | 1.57e-01 | 6.47e-02 |
| MESENCHYMAL STEM CELL PROLIFERATION | 10 | 7.85e-02 | 4.60e-01 | 0.78600 | -3.56e-01 | -3.54e-01 | -2.38e-01 | -4.79e-01 | -2.84e-01 | 5.13e-02 | 5.25e-02 | 1.92e-01 | 8.78e-03 | 1.19e-01 |
| REGULATION OF LIPID TRANSPORTER ACTIVITY | 6 | 3.33e-01 | 8.57e-01 | 0.78600 | -3.76e-01 | -3.99e-01 | -2.42e-01 | -4.18e-01 | 2.90e-01 | 1.10e-01 | 9.03e-02 | 3.04e-01 | 7.61e-02 | 2.19e-01 |
| RHOMBOMERE DEVELOPMENT | 8 | 5.82e-03 | 8.52e-02 | 0.78500 | 4.43e-01 | 4.45e-01 | 1.59e-01 | 3.97e-01 | -1.97e-01 | 3.01e-02 | 2.93e-02 | 4.36e-01 | 5.17e-02 | 3.35e-01 |
| OLIGOPEPTIDE IMPORT ACROSS PLASMA MEMBRANE | 5 | 4.19e-01 | 9.11e-01 | 0.78300 | -4.24e-01 | -4.10e-01 | -4.75e-01 | -1.93e-01 | 5.29e-02 | 1.01e-01 | 1.12e-01 | 6.59e-02 | 4.56e-01 | 8.38e-01 |
| SENSORY PERCEPTION OF BITTER TASTE | 44 | 5.59e-06 | 2.80e-04 | 0.78300 | -4.10e-01 | -3.62e-01 | -4.86e-01 | -2.54e-01 | -1.17e-01 | 2.58e-06 | 3.23e-05 | 2.48e-08 | 3.57e-03 | 1.79e-01 |
| NEGATIVE REGULATION OF INTERFERON ALPHA PRODUCTION | 6 | 1.67e-01 | 6.71e-01 | 0.78300 | -3.17e-01 | -3.93e-01 | -1.19e-02 | -3.78e-01 | 4.63e-01 | 1.78e-01 | 9.59e-02 | 9.60e-01 | 1.09e-01 | 4.93e-02 |
| POSITIVE REGULATION OF DENDRITIC CELL ANTIGEN PROCESSING AND PRESENTATION | 7 | 1.45e-01 | 6.29e-01 | 0.78200 | -3.93e-01 | -4.24e-01 | -1.04e-01 | -4.84e-01 | 1.81e-01 | 7.16e-02 | 5.22e-02 | 6.35e-01 | 2.66e-02 | 4.08e-01 |
| REGULATION OF GLUTAMATE RECEPTOR SIGNALING PATHWAY | 6 | 4.52e-01 | 9.30e-01 | 0.78200 | 3.97e-01 | 4.08e-01 | 2.05e-01 | 4.93e-01 | -4.81e-02 | 9.23e-02 | 8.38e-02 | 3.84e-01 | 3.63e-02 | 8.38e-01 |
| IMMUNE COMPLEX CLEARANCE | 5 | 7.80e-02 | 4.59e-01 | 0.78200 | -3.63e-01 | -4.61e-01 | 1.79e-02 | -5.04e-01 | 1.09e-01 | 1.60e-01 | 7.40e-02 | 9.45e-01 | 5.08e-02 | 6.72e-01 |
| AMINOPHOSPHOLIPID TRANSPORT | 8 | 1.57e-01 | 6.54e-01 | 0.78200 | -3.54e-01 | -3.31e-01 | -4.79e-01 | -2.76e-01 | -2.65e-01 | 8.29e-02 | 1.05e-01 | 1.89e-02 | 1.76e-01 | 1.95e-01 |
| POSITIVE REGULATION OF CARDIAC MUSCLE CONTRACTION | 8 | 3.90e-01 | 8.92e-01 | 0.78200 | 4.14e-01 | 4.22e-01 | 2.78e-01 | 4.25e-01 | 5.67e-02 | 4.24e-02 | 3.87e-02 | 1.74e-01 | 3.71e-02 | 7.81e-01 |
| PROLACTIN SECRETION | 5 | 7.52e-02 | 4.50e-01 | 0.78100 | 3.09e-01 | 4.63e-01 | -8.50e-03 | 3.71e-01 | -4.04e-01 | 2.32e-01 | 7.31e-02 | 9.74e-01 | 1.51e-01 | 1.18e-01 |
| REGULATION OF AMACRINE CELL DIFFERENTIATION | 6 | 3.60e-03 | 6.07e-02 | 0.78100 | 2.26e-01 | 1.42e-01 | 6.23e-01 | -2.18e-01 | 3.20e-01 | 3.37e-01 | 5.48e-01 | 8.21e-03 | 3.54e-01 | 1.75e-01 |
| CELLULAR RESPONSE TO TEMPERATURE STIMULUS | 5 | 6.09e-01 | 9.90e-01 | 0.78000 | 4.23e-01 | 4.14e-01 | 3.46e-01 | 3.20e-01 | -1.93e-01 | 1.02e-01 | 1.09e-01 | 1.81e-01 | 2.16e-01 | 4.55e-01 |
| REGULATION OF FC RECEPTOR MEDIATED STIMULATORY SIGNALING PATHWAY | 10 | 2.16e-01 | 7.38e-01 | 0.77900 | -4.14e-01 | -4.46e-01 | -3.42e-01 | -3.24e-01 | 1.19e-01 | 2.35e-02 | 1.45e-02 | 6.11e-02 | 7.59e-02 | 5.14e-01 |
| NEGATIVE REGULATION OF RESPIRATORY BURST INVOLVED IN INFLAMMATORY RESPONSE | 5 | 3.66e-01 | 8.79e-01 | 0.77800 | 3.70e-01 | 2.86e-01 | 5.49e-01 | 1.66e-01 | 2.40e-01 | 1.52e-01 | 2.69e-01 | 3.34e-02 | 5.21e-01 | 3.53e-01 |
| POSITIVE REGULATION OF ANTIBACTERIAL PEPTIDE PRODUCTION | 5 | 1.39e-01 | 6.22e-01 | 0.77800 | 3.64e-01 | 4.46e-01 | 3.26e-03 | 5.04e-01 | -1.43e-01 | 1.59e-01 | 8.42e-02 | 9.90e-01 | 5.11e-02 | 5.81e-01 |
| POSITIVE REGULATION OF GLOMERULAR MESANGIAL CELL PROLIFERATION | 7 | 4.96e-01 | 9.47e-01 | 0.77800 | -4.08e-01 | -4.01e-01 | -4.17e-01 | -3.22e-01 | -1.58e-02 | 6.18e-02 | 6.61e-02 | 5.60e-02 | 1.40e-01 | 9.42e-01 |
| MITOTIC NUCLEAR MEMBRANE DISASSEMBLY | 7 | 5.37e-01 | 9.57e-01 | 0.77800 | -4.12e-01 | -3.93e-01 | -3.27e-01 | -4.17e-01 | 3.49e-02 | 5.92e-02 | 7.21e-02 | 1.35e-01 | 5.63e-02 | 8.73e-01 |
| INTERKINETIC NUCLEAR MIGRATION | 5 | 6.94e-01 | 1.00e+00 | 0.77600 | -4.09e-01 | -4.25e-01 | -3.23e-01 | -3.63e-01 | 1.35e-01 | 1.13e-01 | 1.00e-01 | 2.12e-01 | 1.60e-01 | 6.02e-01 |
| MEMBRANE DEPOLARIZATION DURING SA NODE CELL ACTION POTENTIAL | 5 | 5.36e-01 | 9.56e-01 | 0.77400 | 3.81e-01 | 4.31e-01 | 2.04e-01 | 4.46e-01 | -1.66e-01 | 1.40e-01 | 9.49e-02 | 4.30e-01 | 8.42e-02 | 5.21e-01 |
| INOSITOL METABOLIC PROCESS | 8 | 1.24e-01 | 5.88e-01 | 0.77400 | 3.06e-01 | 2.69e-01 | 2.81e-01 | 4.16e-01 | 4.25e-01 | 1.34e-01 | 1.87e-01 | 1.69e-01 | 4.15e-02 | 3.72e-02 |
| SENSORY PERCEPTION OF CHEMICAL STIMULUS | 457 | 7.12e-75 | 5.36e-71 | 0.77300 | -3.73e-01 | -3.34e-01 | -4.86e-01 | -2.63e-01 | -2.03e-01 | 1.07e-42 | 1.73e-34 | 1.57e-71 | 4.23e-22 | 8.78e-14 |
| POSITIVE REGULATION OF INTERLEUKIN 23 PRODUCTION | 7 | 9.08e-02 | 4.98e-01 | 0.77200 | -3.70e-01 | -4.68e-01 | -1.69e-01 | -4.58e-01 | -3.97e-02 | 8.98e-02 | 3.20e-02 | 4.39e-01 | 3.57e-02 | 8.56e-01 |
| NEGATIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 12 | 6.07e-02 | 4.04e-01 | 0.77100 | 3.63e-01 | 3.42e-01 | 2.78e-01 | 4.86e-01 | 1.82e-01 | 2.97e-02 | 4.00e-02 | 9.55e-02 | 3.57e-03 | 2.76e-01 |
| WATER SOLUBLE VITAMIN BIOSYNTHETIC PROCESS | 11 | 1.38e-01 | 6.20e-01 | 0.77100 | 4.09e-01 | 3.36e-01 | 4.13e-01 | 3.65e-01 | 1.05e-01 | 1.89e-02 | 5.35e-02 | 1.77e-02 | 3.62e-02 | 5.48e-01 |
| TRANSITION BETWEEN FAST AND SLOW FIBER | 9 | 1.42e-01 | 6.28e-01 | 0.77100 | 3.81e-01 | 4.50e-01 | 1.56e-01 | 4.43e-01 | -1.59e-01 | 4.80e-02 | 1.93e-02 | 4.18e-01 | 2.13e-02 | 4.10e-01 |
| T CELL CHEMOTAXIS | 27 | 1.35e-03 | 2.90e-02 | 0.77000 | -4.23e-01 | -4.12e-01 | -3.56e-01 | -2.98e-01 | 1.68e-01 | 1.42e-04 | 2.09e-04 | 1.35e-03 | 7.45e-03 | 1.30e-01 |
| NEURAL PLATE ANTERIOR POSTERIOR REGIONALIZATION | 5 | 4.55e-01 | 9.31e-01 | 0.76900 | 3.83e-01 | 3.90e-01 | 3.40e-01 | 3.37e-01 | -2.53e-01 | 1.38e-01 | 1.31e-01 | 1.88e-01 | 1.92e-01 | 3.28e-01 |
| POSITIVE REGULATION OF NATURAL KILLER CELL MEDIATED IMMUNITY | 33 | 8.03e-04 | 1.90e-02 | 0.76900 | -3.93e-01 | -4.09e-01 | -3.38e-01 | -3.57e-01 | -1.71e-01 | 9.31e-05 | 4.86e-05 | 7.88e-04 | 3.91e-04 | 8.91e-02 |
| METANEPHRIC PROXIMAL TUBULE DEVELOPMENT | 5 | 6.19e-01 | 9.90e-01 | 0.76800 | 4.15e-01 | 4.26e-01 | 3.87e-01 | 2.76e-01 | -1.05e-01 | 1.08e-01 | 9.92e-02 | 1.34e-01 | 2.86e-01 | 6.84e-01 |
| SPERMIDINE METABOLIC PROCESS | 6 | 2.93e-01 | 8.20e-01 | 0.76800 | 4.18e-01 | 3.51e-01 | 4.62e-01 | 2.35e-01 | 1.51e-01 | 7.60e-02 | 1.37e-01 | 4.99e-02 | 3.20e-01 | 5.21e-01 |
| MYELOID DENDRITIC CELL CYTOKINE PRODUCTION | 8 | 1.68e-01 | 6.71e-01 | 0.76600 | -3.83e-01 | -3.69e-01 | -1.81e-01 | -4.77e-01 | 2.10e-01 | 6.10e-02 | 7.08e-02 | 3.75e-01 | 1.95e-02 | 3.03e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION INVOLVED IN WOUND HEALING | 10 | 3.09e-02 | 2.74e-01 | 0.76500 | -3.37e-01 | -4.24e-01 | -1.64e-01 | -3.20e-01 | 4.03e-01 | 6.51e-02 | 2.04e-02 | 3.69e-01 | 8.01e-02 | 2.72e-02 |
| MAINTENANCE OF PROTEIN LOCATION IN MITOCHONDRION | 5 | 6.26e-01 | 9.94e-01 | 0.76400 | 3.94e-01 | 4.30e-01 | 2.22e-01 | 4.40e-01 | -1.37e-02 | 1.27e-01 | 9.57e-02 | 3.91e-01 | 8.86e-02 | 9.58e-01 |
| POSITIVE REGULATION OF RIG I SIGNALING PATHWAY | 10 | 4.07e-01 | 9.08e-01 | 0.76400 | -3.98e-01 | -3.80e-01 | -3.74e-01 | -3.62e-01 | -9.91e-02 | 2.93e-02 | 3.75e-02 | 4.07e-02 | 4.76e-02 | 5.88e-01 |
| REGULATION OF SUPEROXIDE DISMUTASE ACTIVITY | 7 | 1.73e-01 | 6.77e-01 | 0.76300 | 3.81e-01 | 4.32e-01 | 1.78e-01 | 4.46e-01 | 1.42e-01 | 8.09e-02 | 4.78e-02 | 4.14e-01 | 4.11e-02 | 5.14e-01 |
| POSITIVE REGULATION OF NATURAL KILLER CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 7 | 5.96e-01 | 9.88e-01 | 0.76100 | -3.93e-01 | -3.67e-01 | -3.61e-01 | -3.72e-01 | -1.43e-01 | 7.15e-02 | 9.24e-02 | 9.85e-02 | 8.83e-02 | 5.12e-01 |
| NEGATIVE REGULATION OF PINOCYTOSIS | 5 | 5.86e-01 | 9.85e-01 | 0.76000 | 3.94e-01 | 4.19e-01 | 3.61e-01 | 3.26e-01 | -1.05e-01 | 1.27e-01 | 1.05e-01 | 1.62e-01 | 2.07e-01 | 6.85e-01 |
| GLOMERULAR MESANGIAL CELL DEVELOPMENT | 5 | 2.18e-01 | 7.40e-01 | 0.76000 | 3.68e-01 | 3.54e-01 | 5.44e-01 | 1.39e-01 | 5.07e-02 | 1.54e-01 | 1.70e-01 | 3.53e-02 | 5.91e-01 | 8.44e-01 |
| RESPIRATORY CHAIN COMPLEX III ASSEMBLY | 12 | 1.71e-01 | 6.75e-01 | 0.76000 | 4.15e-01 | 3.77e-01 | 4.13e-01 | 3.02e-01 | -4.75e-02 | 1.27e-02 | 2.39e-02 | 1.33e-02 | 6.98e-02 | 7.76e-01 |
| UDP N ACETYLGLUCOSAMINE METABOLIC PROCESS | 14 | 1.48e-01 | 6.36e-01 | 0.76000 | 4.12e-01 | 3.70e-01 | 3.89e-01 | 3.45e-01 | 2.16e-02 | 7.55e-03 | 1.65e-02 | 1.17e-02 | 2.54e-02 | 8.89e-01 |
| ANTRAL OVARIAN FOLLICLE GROWTH | 11 | 5.07e-02 | 3.68e-01 | 0.76000 | -3.45e-01 | -3.65e-01 | -4.12e-01 | -2.54e-01 | -3.02e-01 | 4.76e-02 | 3.58e-02 | 1.80e-02 | 1.44e-01 | 8.32e-02 |
| REGULATION OF SKELETAL MUSCLE CONTRACTION | 15 | 5.62e-02 | 3.86e-01 | 0.76000 | 3.93e-01 | 4.39e-01 | 2.96e-01 | 3.73e-01 | 5.49e-02 | 8.38e-03 | 3.24e-03 | 4.72e-02 | 1.23e-02 | 7.13e-01 |
| POSITIVE REGULATION OF LYMPHOCYTE MIGRATION | 40 | 7.02e-04 | 1.69e-02 | 0.76000 | -4.09e-01 | -4.09e-01 | -3.07e-01 | -3.85e-01 | -7.96e-03 | 7.65e-06 | 7.47e-06 | 7.79e-04 | 2.53e-05 | 9.31e-01 |
| POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR RESULTING IN TRANSCRIPTION OF P21 CLASS MEDIATOR | 5 | 3.78e-01 | 8.85e-01 | 0.76000 | 4.16e-01 | 4.30e-01 | 4.08e-01 | 1.88e-01 | -1.28e-01 | 1.07e-01 | 9.55e-02 | 1.14e-01 | 4.67e-01 | 6.21e-01 |
| ACTIVATION OF JANUS KINASE ACTIVITY | 13 | 9.44e-02 | 5.07e-01 | 0.75900 | -3.77e-01 | -3.44e-01 | -2.92e-01 | -4.49e-01 | -1.71e-01 | 1.84e-02 | 3.16e-02 | 6.85e-02 | 5.10e-03 | 2.86e-01 |
| POSITIVE REGULATION OF AXON EXTENSION INVOLVED IN AXON GUIDANCE | 7 | 4.61e-01 | 9.32e-01 | 0.75900 | -3.99e-01 | -3.79e-01 | -2.70e-01 | -4.41e-01 | 7.36e-02 | 6.76e-02 | 8.24e-02 | 2.15e-01 | 4.31e-02 | 7.36e-01 |
| POSITIVE REGULATION OF APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT | 6 | 6.83e-01 | 1.00e+00 | 0.75600 | 3.91e-01 | 3.88e-01 | 3.59e-01 | 3.48e-01 | 1.34e-01 | 9.68e-02 | 1.00e-01 | 1.28e-01 | 1.40e-01 | 5.70e-01 |
| NEGATIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT | 13 | 2.08e-01 | 7.29e-01 | 0.75300 | 4.10e-01 | 4.12e-01 | 3.27e-01 | 3.48e-01 | 2.57e-02 | 1.05e-02 | 1.01e-02 | 4.11e-02 | 2.96e-02 | 8.73e-01 |
| DETECTION OF STIMULUS INVOLVED IN SENSORY PERCEPTION | 471 | 1.30e-71 | 3.27e-68 | 0.75200 | -3.62e-01 | -3.23e-01 | -4.73e-01 | -2.52e-01 | -2.06e-01 | 1.45e-41 | 2.03e-33 | 1.26e-69 | 6.63e-21 | 1.73e-14 |
| UTERINE SMOOTH MUSCLE CONTRACTION | 9 | 9.84e-02 | 5.19e-01 | 0.75100 | 3.50e-01 | 3.71e-01 | 1.35e-01 | 3.34e-01 | -4.18e-01 | 6.92e-02 | 5.40e-02 | 4.83e-01 | 8.24e-02 | 3.00e-02 |
| NEGATIVE REGULATION OF LAMELLIPODIUM ORGANIZATION | 7 | 7.38e-03 | 1.01e-01 | 0.75100 | 1.98e-01 | 3.13e-01 | -2.44e-01 | 3.43e-01 | -4.99e-01 | 3.65e-01 | 1.51e-01 | 2.63e-01 | 1.16e-01 | 2.22e-02 |
| INTRACELLULAR NITROGEN HOMEOSTASIS | 5 | 1.16e-01 | 5.66e-01 | 0.75000 | 1.11e-01 | 2.18e-01 | -9.79e-02 | 8.82e-02 | -6.97e-01 | 6.68e-01 | 3.99e-01 | 7.05e-01 | 7.33e-01 | 6.97e-03 |
| PLATELET DEGRANULATION | 7 | 1.06e-01 | 5.39e-01 | 0.74900 | -3.68e-01 | -4.67e-01 | -1.96e-01 | -4.09e-01 | -3.55e-02 | 9.20e-02 | 3.23e-02 | 3.69e-01 | 6.06e-02 | 8.71e-01 |
| RNA GUANINE N7 METHYLATION | 6 | 1.55e-01 | 6.52e-01 | 0.74900 | 3.27e-01 | 2.61e-01 | 5.16e-01 | 6.07e-02 | 3.39e-01 | 1.65e-01 | 2.68e-01 | 2.85e-02 | 7.97e-01 | 1.50e-01 |
| POSITIVE REGULATION OF DNA TEMPLATED DNA REPLICATION | 12 | 1.80e-01 | 6.88e-01 | 0.74800 | 3.87e-01 | 3.71e-01 | 4.24e-01 | 3.01e-01 | 3.60e-02 | 2.03e-02 | 2.61e-02 | 1.10e-02 | 7.05e-02 | 8.29e-01 |
| CELLULAR RESPONSE TO L GLUTAMATE | 5 | 7.26e-01 | 1.00e+00 | 0.74600 | 3.99e-01 | 4.26e-01 | 2.97e-01 | 3.50e-01 | -7.49e-02 | 1.22e-01 | 9.92e-02 | 2.50e-01 | 1.76e-01 | 7.72e-01 |
| NEGATIVE REGULATION OF RESPIRATORY BURST | 6 | 2.39e-01 | 7.63e-01 | 0.74600 | 3.33e-01 | 2.34e-01 | 5.26e-01 | 1.41e-01 | 3.07e-01 | 1.58e-01 | 3.21e-01 | 2.58e-02 | 5.50e-01 | 1.93e-01 |
| REGULATION OF ENAMEL MINERALIZATION | 7 | 1.30e-01 | 5.98e-01 | 0.74400 | -3.43e-01 | -2.85e-01 | -5.51e-01 | -1.53e-01 | -1.65e-01 | 1.16e-01 | 1.92e-01 | 1.15e-02 | 4.84e-01 | 4.50e-01 |
| FLOOR PLATE DEVELOPMENT | 11 | 7.38e-02 | 4.47e-01 | 0.74300 | 3.93e-01 | 4.23e-01 | 3.67e-01 | 2.20e-01 | -1.88e-01 | 2.38e-02 | 1.51e-02 | 3.50e-02 | 2.06e-01 | 2.80e-01 |
| NEGATIVE REGULATION OF NEUTROPHIL MIGRATION | 5 | 9.91e-02 | 5.21e-01 | 0.74300 | -3.96e-01 | -5.02e-01 | -3.03e-01 | -2.02e-01 | 1.06e-01 | 1.26e-01 | 5.19e-02 | 2.41e-01 | 4.34e-01 | 6.80e-01 |
| GLUCOSE IMPORT ACROSS PLASMA MEMBRANE | 5 | 4.43e-01 | 9.28e-01 | 0.74300 | 3.32e-01 | 2.68e-01 | 3.52e-01 | 4.11e-01 | 2.78e-01 | 1.99e-01 | 3.00e-01 | 1.73e-01 | 1.11e-01 | 2.82e-01 |
| TRIGLYCERIDE RICH LIPOPROTEIN PARTICLE REMODELING | 12 | 2.15e-01 | 7.38e-01 | 0.74200 | 3.84e-01 | 4.01e-01 | 3.65e-01 | 3.21e-01 | 7.55e-02 | 2.13e-02 | 1.61e-02 | 2.85e-02 | 5.41e-02 | 6.51e-01 |
| HYPOTHALAMUS CELL MIGRATION | 6 | 6.26e-01 | 9.94e-01 | 0.74200 | -3.71e-01 | -3.65e-01 | -2.92e-01 | -4.04e-01 | -1.75e-01 | 1.15e-01 | 1.22e-01 | 2.15e-01 | 8.62e-02 | 4.58e-01 |
| POSITIVE REGULATION OF CYTOPLASMIC MRNA PROCESSING BODY ASSEMBLY | 6 | 5.17e-01 | 9.52e-01 | 0.74100 | -3.54e-01 | -3.38e-01 | -2.70e-01 | -4.41e-01 | -2.05e-01 | 1.33e-01 | 1.52e-01 | 2.52e-01 | 6.16e-02 | 3.85e-01 |
| DOLICHYL DIPHOSPHATE METABOLIC PROCESS | 5 | 3.68e-01 | 8.79e-01 | 0.74000 | 3.83e-01 | 3.71e-01 | 4.94e-01 | 1.31e-01 | 3.40e-02 | 1.38e-01 | 1.51e-01 | 5.56e-02 | 6.13e-01 | 8.95e-01 |
| PROTEIN IMPORT INTO PEROXISOME MEMBRANE | 6 | 4.09e-01 | 9.08e-01 | 0.73900 | 2.87e-01 | 2.53e-01 | 3.92e-01 | 2.27e-01 | 4.41e-01 | 2.24e-01 | 2.82e-01 | 9.61e-02 | 3.36e-01 | 6.15e-02 |
| CELLULAR RESPONSE TO BRAIN DERIVED NEUROTROPHIC FACTOR STIMULUS | 8 | 3.33e-01 | 8.57e-01 | 0.73800 | -3.78e-01 | -4.06e-01 | -3.78e-01 | -2.96e-01 | -8.09e-02 | 6.38e-02 | 4.67e-02 | 6.41e-02 | 1.48e-01 | 6.92e-01 |
| NAD TRANSPORT | 5 | 6.07e-01 | 9.90e-01 | 0.73700 | -3.53e-01 | -3.48e-01 | -2.75e-01 | -4.48e-01 | -1.44e-01 | 1.72e-01 | 1.78e-01 | 2.87e-01 | 8.24e-02 | 5.76e-01 |
| NEGATIVE REGULATION OF ATP BIOSYNTHETIC PROCESS | 5 | 2.62e-01 | 7.90e-01 | 0.73600 | 2.75e-01 | 2.98e-01 | 1.75e-01 | 4.17e-01 | 4.16e-01 | 2.87e-01 | 2.49e-01 | 4.98e-01 | 1.06e-01 | 1.07e-01 |
| CEREBRAL CORTEX TANGENTIAL MIGRATION | 5 | 4.83e-01 | 9.43e-01 | 0.73600 | -3.12e-01 | -2.49e-01 | -4.10e-01 | -2.03e-01 | -4.16e-01 | 2.27e-01 | 3.36e-01 | 1.12e-01 | 4.33e-01 | 1.07e-01 |
| PROTEIN MATURATION BY IRON SULFUR CLUSTER TRANSFER | 15 | 3.42e-02 | 2.95e-01 | 0.73500 | 3.91e-01 | 3.55e-01 | 4.66e-01 | 2.08e-01 | -3.32e-02 | 8.72e-03 | 1.72e-02 | 1.76e-03 | 1.64e-01 | 8.24e-01 |
| PARKIN MEDIATED STIMULATION OF MITOPHAGY IN RESPONSE TO MITOCHONDRIAL DEPOLARIZATION | 5 | 2.78e-01 | 8.05e-01 | 0.73500 | -3.54e-01 | -2.58e-01 | -3.16e-01 | -4.43e-01 | -2.28e-01 | 1.70e-01 | 3.18e-01 | 2.20e-01 | 8.64e-02 | 3.78e-01 |
| ISOLEUCINE METABOLIC PROCESS | 6 | 6.06e-01 | 9.90e-01 | 0.73400 | 3.75e-01 | 3.87e-01 | 3.09e-01 | 3.49e-01 | 1.78e-01 | 1.12e-01 | 1.00e-01 | 1.90e-01 | 1.39e-01 | 4.49e-01 |
| PROTEIN UFMYLATION | 6 | 3.54e-01 | 8.73e-01 | 0.73400 | 3.77e-01 | 3.28e-01 | 4.78e-01 | 2.46e-01 | -2.69e-02 | 1.10e-01 | 1.65e-01 | 4.28e-02 | 2.97e-01 | 9.09e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION BY GLUCOSE | 6 | 2.58e-01 | 7.86e-01 | 0.73400 | 3.71e-01 | 3.11e-01 | 5.25e-01 | 1.17e-01 | 1.22e-01 | 1.15e-01 | 1.87e-01 | 2.60e-02 | 6.19e-01 | 6.06e-01 |
| DNA TOPOLOGICAL CHANGE | 9 | 6.93e-02 | 4.32e-01 | 0.73400 | 2.75e-01 | 1.70e-01 | 4.35e-01 | 1.77e-01 | 4.61e-01 | 1.53e-01 | 3.78e-01 | 2.37e-02 | 3.59e-01 | 1.65e-02 |
| UBIQUITIN DEPENDENT ENDOCYTOSIS | 7 | 4.34e-01 | 9.22e-01 | 0.73300 | 4.07e-01 | 4.17e-01 | 3.06e-01 | 2.95e-01 | -1.35e-01 | 6.25e-02 | 5.61e-02 | 1.61e-01 | 1.77e-01 | 5.37e-01 |
| ARTICULAR CARTILAGE DEVELOPMENT | 5 | 4.24e-01 | 9.14e-01 | 0.73300 | -2.72e-01 | -2.22e-01 | -3.72e-01 | -1.83e-01 | -4.92e-01 | 2.92e-01 | 3.90e-01 | 1.50e-01 | 4.78e-01 | 5.67e-02 |
| MEIOTIC CHROMOSOME SEPARATION | 8 | 4.83e-01 | 9.43e-01 | 0.73200 | 3.58e-01 | 3.56e-01 | 3.19e-01 | 3.75e-01 | 1.97e-01 | 7.91e-02 | 8.12e-02 | 1.19e-01 | 6.60e-02 | 3.36e-01 |
| PYRIMIDINE RIBONUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 7 | 6.38e-01 | 9.98e-01 | 0.73100 | 3.89e-01 | 3.62e-01 | 3.42e-01 | 3.65e-01 | 3.39e-02 | 7.44e-02 | 9.67e-02 | 1.17e-01 | 9.48e-02 | 8.76e-01 |
| HIGH DENSITY LIPOPROTEIN PARTICLE ASSEMBLY | 13 | 8.40e-02 | 4.77e-01 | 0.73100 | 3.22e-01 | 3.21e-01 | 2.93e-01 | 3.71e-01 | 3.23e-01 | 4.43e-02 | 4.52e-02 | 6.77e-02 | 2.07e-02 | 4.36e-02 |
| REGULATION OF MESONEPHROS DEVELOPMENT | 5 | 2.26e-02 | 2.25e-01 | 0.73000 | -2.96e-04 | -1.19e-01 | 4.26e-01 | -3.68e-01 | 4.48e-01 | 9.99e-01 | 6.46e-01 | 9.89e-02 | 1.54e-01 | 8.26e-02 |
| DE NOVO PYRIMIDINE NUCLEOBASE BIOSYNTHETIC PROCESS | 6 | 5.92e-01 | 9.86e-01 | 0.73000 | 3.83e-01 | 4.18e-01 | 3.14e-01 | 3.25e-01 | -8.29e-02 | 1.04e-01 | 7.64e-02 | 1.83e-01 | 1.68e-01 | 7.25e-01 |
| REGULATION OF RELAXATION OF CARDIAC MUSCLE | 6 | 3.88e-01 | 8.92e-01 | 0.73000 | -2.92e-01 | -2.88e-01 | -3.04e-01 | -3.29e-01 | -4.04e-01 | 2.16e-01 | 2.21e-01 | 1.97e-01 | 1.63e-01 | 8.65e-02 |
| POSITIVE REGULATION OF TYPE 2 IMMUNE RESPONSE | 18 | 2.47e-02 | 2.34e-01 | 0.72800 | -3.67e-01 | -4.08e-01 | -1.85e-01 | -3.52e-01 | 2.63e-01 | 6.98e-03 | 2.71e-03 | 1.74e-01 | 9.63e-03 | 5.31e-02 |
| NEGATIVE REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 15 | 1.26e-01 | 5.91e-01 | 0.72700 | 3.59e-01 | 3.22e-01 | 4.29e-01 | 2.64e-01 | 2.05e-01 | 1.59e-02 | 3.06e-02 | 4.02e-03 | 7.65e-02 | 1.70e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION INDEPENDENT DECAY | 7 | 4.77e-01 | 9.40e-01 | 0.72700 | 3.47e-01 | 2.88e-01 | 4.38e-01 | 2.58e-01 | 2.58e-01 | 1.12e-01 | 1.87e-01 | 4.48e-02 | 2.38e-01 | 2.36e-01 |
| INTERLEUKIN 23 PRODUCTION | 9 | 6.17e-02 | 4.07e-01 | 0.72600 | -3.47e-01 | -4.25e-01 | -2.13e-01 | -3.87e-01 | -1.75e-01 | 7.14e-02 | 2.71e-02 | 2.69e-01 | 4.45e-02 | 3.63e-01 |
| MICROGLIAL CELL MIGRATION | 8 | 3.75e-01 | 8.83e-01 | 0.72600 | -3.93e-01 | -4.11e-01 | -3.69e-01 | -2.52e-01 | 6.00e-02 | 5.40e-02 | 4.41e-02 | 7.08e-02 | 2.18e-01 | 7.69e-01 |
| REGULATION OF SKELETAL MUSCLE ADAPTATION | 14 | 1.09e-01 | 5.47e-01 | 0.72600 | 3.65e-01 | 4.02e-01 | 2.04e-01 | 4.25e-01 | -9.96e-02 | 1.81e-02 | 9.26e-03 | 1.86e-01 | 5.93e-03 | 5.19e-01 |
| GEPHYRIN CLUSTERING INVOLVED IN POSTSYNAPTIC DENSITY ASSEMBLY | 5 | 6.48e-01 | 1.00e+00 | 0.72500 | 3.62e-01 | 3.83e-01 | 3.18e-01 | 3.78e-01 | 5.58e-02 | 1.61e-01 | 1.38e-01 | 2.19e-01 | 1.43e-01 | 8.29e-01 |
| LIPID DROPLET DISASSEMBLY | 6 | 4.10e-01 | 9.08e-01 | 0.72400 | 3.21e-01 | 2.58e-01 | 4.79e-01 | 2.11e-01 | 2.82e-01 | 1.73e-01 | 2.73e-01 | 4.20e-02 | 3.70e-01 | 2.32e-01 |
| REGULATION OF MICROVILLUS LENGTH | 7 | 4.33e-01 | 9.19e-01 | 0.72200 | 3.72e-01 | 4.09e-01 | 1.87e-01 | 4.25e-01 | -9.84e-03 | 8.84e-02 | 6.08e-02 | 3.93e-01 | 5.18e-02 | 9.64e-01 |
| REGULATION OF PLASMA MEMBRANE REPAIR | 6 | 2.19e-01 | 7.43e-01 | 0.72200 | 3.32e-01 | 3.71e-01 | 1.26e-01 | 4.62e-01 | 2.08e-01 | 1.59e-01 | 1.16e-01 | 5.92e-01 | 4.99e-02 | 3.77e-01 |
| DETECTION OF CHEMICAL STIMULUS INVOLVED IN SENSORY PERCEPTION OF TASTE | 46 | 3.39e-06 | 1.81e-04 | 0.72200 | -3.74e-01 | -3.17e-01 | -4.71e-01 | -2.07e-01 | -1.29e-01 | 1.16e-05 | 2.02e-04 | 3.30e-08 | 1.52e-02 | 1.31e-01 |
| REGULATION OF KIDNEY SIZE | 5 | 1.25e-01 | 5.91e-01 | 0.72200 | 3.03e-01 | 2.54e-01 | 2.71e-01 | 2.73e-01 | -4.65e-01 | 2.40e-01 | 3.26e-01 | 2.94e-01 | 2.91e-01 | 7.15e-02 |
| POSITIVE REGULATION OF APOPTOTIC PROCESS INVOLVED IN MORPHOGENESIS | 5 | 5.91e-01 | 9.86e-01 | 0.72100 | 3.22e-01 | 3.25e-01 | 3.62e-01 | 2.68e-01 | 3.30e-01 | 2.13e-01 | 2.08e-01 | 1.61e-01 | 3.00e-01 | 2.01e-01 |
| REGULATION OF DENDRITIC CELL CHEMOTAXIS | 11 | 6.63e-03 | 9.31e-02 | 0.72100 | -3.41e-01 | -4.22e-01 | -4.89e-03 | -4.47e-01 | 1.60e-01 | 5.04e-02 | 1.54e-02 | 9.78e-01 | 1.02e-02 | 3.58e-01 |
| MONOACYLGLYCEROL CATABOLIC PROCESS | 7 | 3.72e-01 | 8.82e-01 | 0.72000 | 3.89e-01 | 3.39e-01 | 3.94e-01 | 2.78e-01 | -1.37e-01 | 7.44e-02 | 1.20e-01 | 7.07e-02 | 2.03e-01 | 5.30e-01 |
| DETECTION OF LIPOPOLYSACCHARIDE | 5 | 4.63e-01 | 9.33e-01 | 0.71900 | -3.48e-01 | -3.85e-01 | -2.64e-01 | -3.77e-01 | 1.88e-01 | 1.78e-01 | 1.36e-01 | 3.06e-01 | 1.44e-01 | 4.67e-01 |
| INTERLEUKIN 18 PRODUCTION | 14 | 1.72e-01 | 6.75e-01 | 0.71800 | -3.83e-01 | -4.04e-01 | -2.72e-01 | -3.28e-01 | 1.53e-01 | 1.30e-02 | 8.82e-03 | 7.79e-02 | 3.34e-02 | 3.21e-01 |
| ISOTYPE SWITCHING TO IGG ISOTYPES | 15 | 2.98e-02 | 2.68e-01 | 0.71700 | -3.33e-01 | -3.63e-01 | -1.37e-01 | -4.31e-01 | 2.60e-01 | 2.57e-02 | 1.51e-02 | 3.60e-01 | 3.88e-03 | 8.08e-02 |
| MATURATION OF LSU RRNA FROM TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 16 | 9.54e-02 | 5.10e-01 | 0.71700 | 3.50e-01 | 2.93e-01 | 3.98e-01 | 3.06e-01 | 2.32e-01 | 1.54e-02 | 4.22e-02 | 5.90e-03 | 3.39e-02 | 1.09e-01 |
| TELOMERE TETHERING AT NUCLEAR PERIPHERY | 6 | 3.25e-01 | 8.49e-01 | 0.71600 | -2.97e-01 | -2.34e-01 | -4.93e-01 | -1.14e-01 | -3.38e-01 | 2.07e-01 | 3.22e-01 | 3.66e-02 | 6.28e-01 | 1.52e-01 |
| SOMATOSTATIN RECEPTOR SIGNALING PATHWAY | 5 | 2.13e-01 | 7.34e-01 | 0.71600 | 1.98e-01 | 2.55e-01 | -1.81e-02 | 2.99e-01 | -5.64e-01 | 4.43e-01 | 3.24e-01 | 9.44e-01 | 2.46e-01 | 2.89e-02 |
| ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 14 | 1.67e-01 | 6.71e-01 | 0.71400 | -3.68e-01 | -3.60e-01 | -3.07e-01 | -3.85e-01 | 5.65e-02 | 1.71e-02 | 1.96e-02 | 4.69e-02 | 1.27e-02 | 7.15e-01 |
| NK T CELL ACTIVATION | 12 | 2.91e-01 | 8.18e-01 | 0.71400 | -3.66e-01 | -3.55e-01 | -2.91e-01 | -3.79e-01 | -1.47e-01 | 2.81e-02 | 3.32e-02 | 8.08e-02 | 2.30e-02 | 3.79e-01 |
| COMPLEMENT RECEPTOR MEDIATED SIGNALING PATHWAY | 12 | 1.91e-02 | 2.01e-01 | 0.71400 | -3.69e-01 | -4.55e-01 | -2.57e-01 | -2.61e-01 | 1.79e-01 | 2.69e-02 | 6.32e-03 | 1.24e-01 | 1.17e-01 | 2.84e-01 |
| POSITIVE REGULATION OF LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 10 | 3.99e-01 | 8.98e-01 | 0.71300 | -3.79e-01 | -3.62e-01 | -3.21e-01 | -3.50e-01 | 9.39e-02 | 3.80e-02 | 4.75e-02 | 7.87e-02 | 5.56e-02 | 6.07e-01 |
| VERY LONG CHAIN FATTY ACID CATABOLIC PROCESS | 6 | 2.24e-01 | 7.46e-01 | 0.71300 | 3.24e-01 | 3.52e-01 | 1.84e-01 | 4.91e-01 | -6.94e-02 | 1.69e-01 | 1.35e-01 | 4.35e-01 | 3.74e-02 | 7.68e-01 |
| NEGATIVE T CELL SELECTION | 13 | 6.56e-02 | 4.17e-01 | 0.71300 | -3.85e-01 | -4.03e-01 | -1.86e-01 | -4.00e-01 | 4.95e-02 | 1.62e-02 | 1.18e-02 | 2.45e-01 | 1.24e-02 | 7.57e-01 |
| GLYCOLIPID TRANSPORT | 8 | 3.15e-02 | 2.79e-01 | 0.71300 | 3.75e-01 | 4.02e-01 | 3.19e-01 | 1.09e-01 | -3.03e-01 | 6.61e-02 | 4.87e-02 | 1.18e-01 | 5.94e-01 | 1.38e-01 |
| REGULATION OF PROTEIN ADP RIBOSYLATION | 8 | 4.28e-01 | 9.17e-01 | 0.71200 | 3.26e-01 | 2.82e-01 | 3.56e-01 | 3.31e-01 | 2.92e-01 | 1.11e-01 | 1.67e-01 | 8.10e-02 | 1.05e-01 | 1.53e-01 |
| NEGATIVE REGULATION OF T CELL CYTOKINE PRODUCTION | 10 | 6.45e-02 | 4.13e-01 | 0.71200 | -3.29e-01 | -3.65e-01 | -2.05e-01 | -4.25e-01 | 2.09e-01 | 7.14e-02 | 4.59e-02 | 2.61e-01 | 2.00e-02 | 2.53e-01 |
| POSITIVE REGULATION OF VASCULAR WOUND HEALING | 5 | 2.70e-01 | 7.97e-01 | 0.71200 | 3.48e-01 | 3.05e-01 | 5.33e-01 | 9.23e-02 | 1.81e-02 | 1.78e-01 | 2.38e-01 | 3.90e-02 | 7.21e-01 | 9.44e-01 |
| REGULATION OF NAD P H OXIDASE ACTIVITY | 7 | 2.24e-01 | 7.45e-01 | 0.71200 | 3.60e-01 | 4.07e-01 | 2.90e-01 | 2.00e-01 | -2.95e-01 | 9.92e-02 | 6.21e-02 | 1.84e-01 | 3.59e-01 | 1.76e-01 |
| XENOBIOTIC TRANSPORT ACROSS BLOOD BRAIN BARRIER | 6 | 5.66e-01 | 9.72e-01 | 0.71000 | -3.54e-01 | -3.40e-01 | -2.79e-01 | -3.60e-01 | -2.34e-01 | 1.33e-01 | 1.49e-01 | 2.36e-01 | 1.26e-01 | 3.20e-01 |
| SA NODE CELL TO ATRIAL CARDIAC MUSCLE CELL SIGNALING | 9 | 3.10e-01 | 8.37e-01 | 0.71000 | 3.49e-01 | 3.72e-01 | 2.14e-01 | 3.50e-01 | -2.74e-01 | 6.96e-02 | 5.36e-02 | 2.65e-01 | 6.93e-02 | 1.54e-01 |
| POSITIVE REGULATION OF MITOPHAGY | 7 | 2.30e-01 | 7.52e-01 | 0.70900 | -3.86e-01 | -3.33e-01 | -3.94e-01 | -2.17e-01 | 2.03e-01 | 7.71e-02 | 1.28e-01 | 7.08e-02 | 3.20e-01 | 3.53e-01 |
| POSITIVE REGULATION OF T CELL MIGRATION | 33 | 5.44e-03 | 8.18e-02 | 0.70900 | -3.87e-01 | -3.87e-01 | -2.80e-01 | -3.53e-01 | 2.06e-02 | 1.21e-04 | 1.18e-04 | 5.44e-03 | 4.44e-04 | 8.38e-01 |
| NEUROTRANSMITTER LOADING INTO SYNAPTIC VESICLE | 7 | 5.76e-02 | 3.93e-01 | 0.70900 | 1.13e-01 | 1.44e-01 | -1.43e-01 | 2.21e-01 | -6.32e-01 | 6.06e-01 | 5.11e-01 | 5.13e-01 | 3.12e-01 | 3.76e-03 |
| EPITHELIAL CELL PROLIFERATION INVOLVED IN SALIVARY GLAND MORPHOGENESIS | 5 | 1.71e-01 | 6.75e-01 | 0.70800 | 3.66e-01 | 2.74e-01 | 2.78e-01 | 4.25e-01 | -1.85e-01 | 1.56e-01 | 2.89e-01 | 2.81e-01 | 9.96e-02 | 4.74e-01 |
| CHONDROCYTE DEVELOPMENT INVOLVED IN ENDOCHONDRAL BONE MORPHOGENESIS | 8 | 3.63e-01 | 8.78e-01 | 0.70800 | 3.53e-01 | 3.83e-01 | 3.43e-01 | 3.08e-01 | 1.32e-01 | 8.39e-02 | 6.10e-02 | 9.32e-02 | 1.31e-01 | 5.18e-01 |
| BRONCHUS DEVELOPMENT | 11 | 3.10e-01 | 8.37e-01 | 0.70800 | 3.85e-01 | 3.81e-01 | 2.55e-01 | 3.71e-01 | -6.89e-02 | 2.72e-02 | 2.86e-02 | 1.43e-01 | 3.31e-02 | 6.93e-01 |
| TRANSLOCATION OF MOLECULES INTO HOST | 7 | 3.82e-01 | 8.92e-01 | 0.70800 | 3.61e-01 | 3.35e-01 | 4.35e-01 | 1.77e-01 | 1.94e-01 | 9.85e-02 | 1.25e-01 | 4.60e-02 | 4.17e-01 | 3.74e-01 |
| POSITIVE REGULATION OF DENDRITIC CELL CYTOKINE PRODUCTION | 13 | 1.50e-01 | 6.41e-01 | 0.70700 | -3.60e-01 | -3.80e-01 | -1.76e-01 | -4.09e-01 | 1.66e-01 | 2.46e-02 | 1.78e-02 | 2.71e-01 | 1.07e-02 | 3.01e-01 |
| RESPONSE TO STIMULUS INVOLVED IN REGULATION OF MUSCLE ADAPTATION | 13 | 1.76e-01 | 6.81e-01 | 0.70600 | 3.75e-01 | 4.01e-01 | 3.10e-01 | 2.88e-01 | -1.37e-01 | 1.93e-02 | 1.22e-02 | 5.33e-02 | 7.22e-02 | 3.93e-01 |
| PHOSPHOLIPID EFFLUX | 14 | 1.27e-01 | 5.93e-01 | 0.70600 | 3.52e-01 | 3.72e-01 | 3.06e-01 | 3.70e-01 | 7.53e-02 | 2.27e-02 | 1.58e-02 | 4.77e-02 | 1.65e-02 | 6.26e-01 |
| REGULATION OF CAVEOLIN MEDIATED ENDOCYTOSIS | 6 | 4.85e-01 | 9.43e-01 | 0.70600 | 3.54e-01 | 3.97e-01 | 1.42e-01 | 4.38e-01 | -5.98e-02 | 1.33e-01 | 9.21e-02 | 5.47e-01 | 6.34e-02 | 8.00e-01 |
| POSITIVE REGULATION OF BLOOD BRAIN BARRIER PERMEABILITY | 5 | 4.95e-01 | 9.47e-01 | 0.70600 | -3.94e-01 | -3.55e-01 | -4.17e-01 | -1.90e-01 | 8.09e-02 | 1.27e-01 | 1.69e-01 | 1.06e-01 | 4.61e-01 | 7.54e-01 |
| CELLULAR GLUCURONIDATION | 21 | 6.95e-03 | 9.63e-02 | 0.70600 | -3.04e-01 | -2.85e-01 | -4.08e-01 | -2.39e-01 | -3.16e-01 | 1.59e-02 | 2.38e-02 | 1.19e-03 | 5.76e-02 | 1.20e-02 |
| PYRIMIDINE NUCLEOSIDE DIPHOSPHATE BIOSYNTHETIC PROCESS | 6 | 4.98e-01 | 9.47e-01 | 0.70600 | 3.84e-01 | 3.37e-01 | 4.27e-01 | 2.13e-01 | 9.93e-02 | 1.04e-01 | 1.53e-01 | 7.03e-02 | 3.67e-01 | 6.74e-01 |
| G1 TO G0 TRANSITION | 19 | 5.33e-02 | 3.78e-01 | 0.70500 | 3.43e-01 | 3.01e-01 | 4.27e-01 | 2.47e-01 | 2.11e-01 | 9.62e-03 | 2.32e-02 | 1.27e-03 | 6.19e-02 | 1.11e-01 |
| LIPOXYGENASE PATHWAY | 11 | 3.77e-02 | 3.09e-01 | 0.70400 | 2.89e-01 | 3.00e-01 | 6.54e-02 | 3.74e-01 | -4.22e-01 | 9.71e-02 | 8.45e-02 | 7.07e-01 | 3.19e-02 | 1.53e-02 |
| TETRAHYDROFOLATE METABOLIC PROCESS | 15 | 1.47e-01 | 6.32e-01 | 0.70400 | -3.59e-01 | -3.81e-01 | -2.36e-01 | -3.98e-01 | 8.42e-02 | 1.61e-02 | 1.05e-02 | 1.13e-01 | 7.59e-03 | 5.72e-01 |
| POSITIVE REGULATION OF SYNAPTIC VESICLE FUSION TO PRESYNAPTIC ACTIVE ZONE MEMBRANE | 6 | 5.12e-01 | 9.51e-01 | 0.70300 | -3.61e-01 | -3.76e-01 | -1.55e-01 | -4.15e-01 | 1.59e-01 | 1.25e-01 | 1.11e-01 | 5.11e-01 | 7.84e-02 | 5.00e-01 |
| MELANOCYTE PROLIFERATION | 5 | 1.25e-01 | 5.89e-01 | 0.70200 | -2.41e-01 | -3.03e-01 | -1.81e-01 | -2.68e-01 | -4.88e-01 | 3.50e-01 | 2.41e-01 | 4.84e-01 | 3.00e-01 | 5.86e-02 |
| REGULATION OF NODAL SIGNALING PATHWAY | 9 | 5.02e-01 | 9.48e-01 | 0.70200 | 3.75e-01 | 3.95e-01 | 2.85e-01 | 3.31e-01 | -7.35e-02 | 5.16e-02 | 4.02e-02 | 1.39e-01 | 8.56e-02 | 7.03e-01 |
| L PROLINE BIOSYNTHETIC PROCESS | 6 | 1.02e-01 | 5.29e-01 | 0.70100 | 3.25e-01 | 3.60e-01 | 2.97e-01 | 6.79e-02 | -4.05e-01 | 1.67e-01 | 1.27e-01 | 2.08e-01 | 7.73e-01 | 8.61e-02 |
| ACTIVATION OF TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE ACTIVITY | 6 | 7.30e-01 | 1.00e+00 | 0.70100 | -3.70e-01 | -3.75e-01 | -2.65e-01 | -3.77e-01 | -3.56e-02 | 1.17e-01 | 1.12e-01 | 2.61e-01 | 1.10e-01 | 8.80e-01 |
| PARACRINE SIGNALING | 7 | 1.62e-01 | 6.62e-01 | 0.69900 | -3.78e-01 | -4.16e-01 | -2.78e-01 | -1.86e-01 | 2.47e-01 | 8.35e-02 | 5.64e-02 | 2.03e-01 | 3.93e-01 | 2.57e-01 |
| NATURAL KILLER CELL CYTOKINE PRODUCTION | 9 | 3.85e-01 | 8.92e-01 | 0.69900 | -3.78e-01 | -4.10e-01 | -3.03e-01 | -2.91e-01 | 3.33e-02 | 4.93e-02 | 3.31e-02 | 1.16e-01 | 1.31e-01 | 8.63e-01 |
| APOPTOTIC CHROMOSOME CONDENSATION | 6 | 4.31e-01 | 9.18e-01 | 0.69900 | 3.39e-01 | 3.93e-01 | 2.28e-01 | 3.27e-01 | -2.46e-01 | 1.51e-01 | 9.57e-02 | 3.33e-01 | 1.65e-01 | 2.96e-01 |
| APOLIPOPROTEIN A I MEDIATED SIGNALING PATHWAY | 7 | 3.35e-01 | 8.59e-01 | 0.69900 | 3.13e-01 | 3.40e-01 | 1.53e-01 | 3.18e-01 | -3.89e-01 | 1.52e-01 | 1.20e-01 | 4.85e-01 | 1.45e-01 | 7.51e-02 |
| REGULATION OF ACTIVATION OF JANUS KINASE ACTIVITY | 8 | 4.14e-02 | 3.26e-01 | 0.69800 | -3.07e-01 | -2.65e-01 | -1.29e-01 | -5.14e-01 | -2.06e-01 | 1.33e-01 | 1.94e-01 | 5.28e-01 | 1.19e-02 | 3.14e-01 |
| GASTRIC MOTILITY | 5 | 2.73e-01 | 7.99e-01 | 0.69700 | -3.03e-01 | -3.98e-01 | -2.40e-02 | -2.97e-01 | 3.84e-01 | 2.41e-01 | 1.23e-01 | 9.26e-01 | 2.49e-01 | 1.37e-01 |
| EMBRYONIC HEART TUBE LEFT RIGHT PATTERN FORMATION | 5 | 6.16e-01 | 9.90e-01 | 0.69700 | 3.52e-01 | 3.11e-01 | 4.66e-01 | 1.83e-01 | 1.18e-01 | 1.73e-01 | 2.28e-01 | 7.11e-02 | 4.79e-01 | 6.47e-01 |
| RENAL RESPONSE TO BLOOD FLOW INVOLVED IN CIRCULATORY RENIN ANGIOTENSIN REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 6 | 4.47e-01 | 9.30e-01 | 0.69500 | -3.17e-01 | -3.71e-01 | -1.38e-01 | -3.28e-01 | 3.44e-01 | 1.79e-01 | 1.15e-01 | 5.59e-01 | 1.64e-01 | 1.44e-01 |
| NORADRENERGIC NEURON DIFFERENTIATION | 10 | 6.33e-03 | 9.04e-02 | 0.69400 | 3.66e-01 | 2.84e-01 | 4.88e-01 | 7.39e-02 | -1.56e-01 | 4.53e-02 | 1.20e-01 | 7.55e-03 | 6.86e-01 | 3.92e-01 |
| REGULATION OF SYNAPTIC TRANSMISSION DOPAMINERGIC | 9 | 2.72e-01 | 7.99e-01 | 0.69400 | 3.11e-01 | 2.92e-01 | 3.96e-01 | 2.72e-01 | 2.62e-01 | 1.06e-01 | 1.29e-01 | 3.94e-02 | 1.58e-01 | 1.74e-01 |
| REGULATION OF NEUTROPHIL DEGRANULATION | 8 | 1.14e-02 | 1.38e-01 | 0.69400 | -2.24e-01 | -3.45e-01 | 1.11e-01 | -2.19e-01 | 5.02e-01 | 2.72e-01 | 9.15e-02 | 5.86e-01 | 2.82e-01 | 1.40e-02 |
| CELLULAR RESPONSE TO CGMP | 7 | 3.71e-01 | 8.81e-01 | 0.69300 | 3.18e-01 | 3.58e-01 | 1.07e-01 | 3.97e-01 | -2.85e-01 | 1.45e-01 | 1.01e-01 | 6.24e-01 | 6.86e-02 | 1.91e-01 |
| ISOPRENOID CATABOLIC PROCESS | 10 | 3.45e-02 | 2.96e-01 | 0.69300 | 2.56e-01 | 3.46e-01 | -1.80e-02 | 2.75e-01 | -4.67e-01 | 1.60e-01 | 5.78e-02 | 9.21e-01 | 1.32e-01 | 1.05e-02 |
| PROTEIN MATURATION BY 4FE 4S CLUSTER TRANSFER | 7 | 4.58e-01 | 9.32e-01 | 0.69300 | 3.24e-01 | 2.96e-01 | 4.17e-01 | 1.87e-01 | 2.80e-01 | 1.38e-01 | 1.75e-01 | 5.61e-02 | 3.92e-01 | 2.00e-01 |
| MATERNAL PROCESS INVOLVED IN PARTURITION | 5 | 7.44e-01 | 1.00e+00 | 0.69200 | 3.53e-01 | 3.52e-01 | 3.55e-01 | 3.22e-01 | 4.52e-02 | 1.72e-01 | 1.73e-01 | 1.70e-01 | 2.12e-01 | 8.61e-01 |
| REGULATION OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ACTIVITY | 8 | 2.77e-01 | 8.04e-01 | 0.69200 | 2.85e-01 | 2.19e-01 | 3.47e-01 | 2.54e-01 | 4.06e-01 | 1.62e-01 | 2.83e-01 | 8.92e-02 | 2.13e-01 | 4.69e-02 |
| REGULATION OF ATPASE COUPLED CALCIUM TRANSMEMBRANE TRANSPORTER ACTIVITY | 6 | 7.34e-01 | 1.00e+00 | 0.69200 | -3.64e-01 | -3.62e-01 | -3.45e-01 | -3.10e-01 | 7.87e-03 | 1.23e-01 | 1.25e-01 | 1.43e-01 | 1.89e-01 | 9.73e-01 |
| NEGATIVE REGULATION OF MEMBRANE DEPOLARIZATION | 7 | 6.32e-01 | 9.96e-01 | 0.69000 | 3.54e-01 | 3.48e-01 | 3.79e-01 | 2.71e-01 | 1.16e-01 | 1.05e-01 | 1.11e-01 | 8.25e-02 | 2.15e-01 | 5.95e-01 |
| DETERMINATION OF LEFT RIGHT ASYMMETRY IN LATERAL MESODERM | 8 | 3.24e-01 | 8.48e-01 | 0.69000 | 3.65e-01 | 4.00e-01 | 3.46e-01 | 2.36e-01 | -9.08e-02 | 7.41e-02 | 5.03e-02 | 9.02e-02 | 2.47e-01 | 6.56e-01 |
| REGULATION OF RETINAL GANGLION CELL AXON GUIDANCE | 6 | 7.07e-01 | 1.00e+00 | 0.69000 | -3.52e-01 | -3.41e-01 | -3.17e-01 | -3.66e-01 | -3.93e-02 | 1.35e-01 | 1.48e-01 | 1.79e-01 | 1.20e-01 | 8.68e-01 |
| CARDIAC SEPTUM CELL DIFFERENTIATION | 5 | 9.61e-02 | 5.12e-01 | 0.68900 | -2.18e-01 | -2.40e-01 | -1.04e-02 | -5.04e-01 | -3.38e-01 | 3.98e-01 | 3.52e-01 | 9.68e-01 | 5.08e-02 | 1.90e-01 |
| COBALT ION TRANSPORT | 6 | 3.09e-01 | 8.35e-01 | 0.68900 | -3.47e-01 | -4.19e-01 | -2.87e-01 | -3.10e-01 | 6.58e-03 | 1.41e-01 | 7.53e-02 | 2.24e-01 | 1.88e-01 | 9.78e-01 |
| POSITIVE REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 6 | 2.78e-01 | 8.05e-01 | 0.68900 | 3.54e-01 | 3.99e-01 | 3.73e-01 | 1.88e-01 | -1.25e-01 | 1.34e-01 | 9.07e-02 | 1.13e-01 | 4.25e-01 | 5.97e-01 |
| CHRONIC INFLAMMATORY RESPONSE | 18 | 9.92e-02 | 5.21e-01 | 0.68800 | -3.73e-01 | -3.67e-01 | -3.02e-01 | -2.95e-01 | 1.47e-01 | 6.18e-03 | 6.95e-03 | 2.66e-02 | 3.00e-02 | 2.81e-01 |
| NEGATIVE REGULATION OF B CELL PROLIFERATION | 16 | 2.38e-04 | 7.19e-03 | 0.68800 | -3.30e-01 | -4.38e-01 | -4.71e-02 | -4.11e-01 | 4.02e-02 | 2.22e-02 | 2.39e-03 | 7.44e-01 | 4.46e-03 | 7.81e-01 |
| NEGATIVE REGULATION OF NOREPINEPHRINE SECRETION | 5 | 4.44e-01 | 9.28e-01 | 0.68800 | 3.43e-01 | 3.12e-01 | 3.49e-01 | 2.28e-01 | -2.89e-01 | 1.84e-01 | 2.26e-01 | 1.76e-01 | 3.77e-01 | 2.62e-01 |
| ENDOCARDIAL CUSHION TO MESENCHYMAL TRANSITION | 6 | 4.40e-01 | 9.26e-01 | 0.68700 | 3.56e-01 | 3.44e-01 | 4.49e-01 | 1.56e-01 | 3.51e-02 | 1.31e-01 | 1.45e-01 | 5.67e-02 | 5.08e-01 | 8.81e-01 |
| CELLULAR RESPONSE TO MINERALOCORTICOID STIMULUS | 11 | 4.48e-01 | 9.30e-01 | 0.68700 | 3.58e-01 | 3.32e-01 | 3.35e-01 | 3.23e-01 | 1.32e-01 | 3.99e-02 | 5.64e-02 | 5.44e-02 | 6.33e-02 | 4.49e-01 |
| POSITIVE REGULATION OF DEVELOPMENTAL PIGMENTATION | 9 | 3.31e-01 | 8.56e-01 | 0.68700 | -3.29e-01 | -3.37e-01 | -2.16e-01 | -4.26e-01 | -1.46e-01 | 8.72e-02 | 7.99e-02 | 2.61e-01 | 2.69e-02 | 4.48e-01 |
| PURINE NUCLEOSIDE DIPHOSPHATE CATABOLIC PROCESS | 5 | 2.46e-01 | 7.74e-01 | 0.68700 | 2.10e-01 | 2.34e-01 | 1.16e-01 | 1.33e-01 | -5.84e-01 | 4.16e-01 | 3.66e-01 | 6.54e-01 | 6.05e-01 | 2.36e-02 |
| REGULATION OF SEROTONIN SECRETION | 6 | 1.93e-01 | 7.05e-01 | 0.68700 | 3.31e-01 | 2.97e-01 | 3.88e-01 | 1.57e-01 | -3.14e-01 | 1.60e-01 | 2.08e-01 | 1.00e-01 | 5.04e-01 | 1.82e-01 |
| POSITIVE REGULATION OF ANTIGEN PROCESSING AND PRESENTATION | 9 | 3.49e-01 | 8.68e-01 | 0.68600 | -3.64e-01 | -3.80e-01 | -1.86e-01 | -3.96e-01 | 5.17e-02 | 5.84e-02 | 4.84e-02 | 3.33e-01 | 3.99e-02 | 7.88e-01 |
| TRNA TRANSCRIPTION | 11 | 2.84e-01 | 8.12e-01 | 0.68600 | 3.47e-01 | 3.43e-01 | 3.97e-01 | 2.49e-01 | 1.15e-01 | 4.64e-02 | 4.91e-02 | 2.26e-02 | 1.53e-01 | 5.11e-01 |
| B 1 B CELL DIFFERENTIATION | 5 | 1.67e-01 | 6.71e-01 | 0.68400 | -1.79e-01 | -2.97e-01 | 7.18e-02 | -1.43e-01 | 5.68e-01 | 4.88e-01 | 2.50e-01 | 7.81e-01 | 5.79e-01 | 2.79e-02 |
| POSITIVE REGULATION OF NECROPTOTIC PROCESS | 7 | 5.07e-01 | 9.48e-01 | 0.68200 | -3.41e-01 | -3.50e-01 | -2.54e-01 | -3.96e-01 | 7.74e-02 | 1.19e-01 | 1.09e-01 | 2.45e-01 | 6.96e-02 | 7.23e-01 |
| FOREBRAIN VENTRICULAR ZONE PROGENITOR CELL DIVISION | 5 | 3.32e-01 | 8.56e-01 | 0.68200 | 2.59e-01 | 3.54e-01 | 1.59e-02 | 3.47e-01 | -3.90e-01 | 3.15e-01 | 1.71e-01 | 9.51e-01 | 1.79e-01 | 1.31e-01 |
| NEGATIVE REGULATION OF NUCLEOTIDE BIOSYNTHETIC PROCESS | 6 | 4.68e-01 | 9.36e-01 | 0.68200 | 3.02e-01 | 3.20e-01 | 2.15e-01 | 3.91e-01 | 2.67e-01 | 1.99e-01 | 1.75e-01 | 3.61e-01 | 9.68e-02 | 2.57e-01 |
| INTERLEUKIN 3 MEDIATED SIGNALING PATHWAY | 6 | 3.94e-02 | 3.19e-01 | 0.68200 | -2.14e-01 | -3.35e-01 | 1.97e-01 | -3.74e-01 | 3.58e-01 | 3.63e-01 | 1.56e-01 | 4.04e-01 | 1.13e-01 | 1.29e-01 |
| POSITIVE REGULATION OF MYELOID LEUKOCYTE MEDIATED IMMUNITY | 21 | 4.24e-03 | 6.76e-02 | 0.68100 | -3.27e-01 | -3.83e-01 | -9.09e-02 | -3.53e-01 | 2.77e-01 | 9.48e-03 | 2.35e-03 | 4.71e-01 | 5.04e-03 | 2.79e-02 |
| POSITIVE REGULATION OF NEUROINFLAMMATORY RESPONSE | 18 | 1.25e-02 | 1.47e-01 | 0.68100 | -3.68e-01 | -3.87e-01 | -3.68e-01 | -1.93e-01 | -7.71e-02 | 6.88e-03 | 4.42e-03 | 6.92e-03 | 1.57e-01 | 5.71e-01 |
| REGULATION OF NK T CELL ACTIVATION | 11 | 3.44e-01 | 8.63e-01 | 0.68100 | -3.47e-01 | -3.34e-01 | -2.59e-01 | -3.81e-01 | -1.39e-01 | 4.61e-02 | 5.53e-02 | 1.38e-01 | 2.86e-02 | 4.24e-01 |
| NEGATIVE REGULATION OF AUTOPHAGOSOME MATURATION | 5 | 2.85e-01 | 8.12e-01 | 0.68100 | 1.99e-01 | 1.54e-01 | 3.04e-01 | 8.94e-02 | 5.47e-01 | 4.42e-01 | 5.52e-01 | 2.39e-01 | 7.29e-01 | 3.40e-02 |
| REVERSE CHOLESTEROL TRANSPORT | 20 | 1.15e-01 | 5.64e-01 | 0.68000 | 3.50e-01 | 3.54e-01 | 3.05e-01 | 3.45e-01 | 5.23e-02 | 6.80e-03 | 6.09e-03 | 1.82e-02 | 7.54e-03 | 6.86e-01 |
| REACTIVE GLIOSIS | 6 | 2.08e-01 | 7.29e-01 | 0.67900 | 2.97e-01 | 3.68e-01 | 1.10e-01 | 1.86e-01 | -4.36e-01 | 2.08e-01 | 1.18e-01 | 6.40e-01 | 4.29e-01 | 6.43e-02 |
| LEFT RIGHT AXIS SPECIFICATION | 13 | 2.37e-01 | 7.60e-01 | 0.67900 | 3.45e-01 | 3.24e-01 | 2.69e-01 | 4.02e-01 | 4.70e-02 | 3.10e-02 | 4.31e-02 | 9.26e-02 | 1.21e-02 | 7.69e-01 |
| REGULATION OF INOSITOL 1 4 5 TRISPHOSPHATE SENSITIVE CALCIUM RELEASE CHANNEL ACTIVITY | 5 | 7.28e-01 | 1.00e+00 | 0.67800 | -3.65e-01 | -3.19e-01 | -3.07e-01 | -3.52e-01 | -8.52e-02 | 1.58e-01 | 2.17e-01 | 2.35e-01 | 1.73e-01 | 7.41e-01 |
| REGULATION OF PROTEIN FOLDING | 8 | 1.99e-01 | 7.14e-01 | 0.67800 | 3.46e-01 | 3.43e-01 | 4.47e-01 | 1.22e-01 | 8.85e-02 | 9.06e-02 | 9.31e-02 | 2.86e-02 | 5.49e-01 | 6.65e-01 |
| G1 TO G0 TRANSITION INVOLVED IN CELL DIFFERENTIATION | 6 | 7.40e-01 | 1.00e+00 | 0.67800 | 3.41e-01 | 3.44e-01 | 3.07e-01 | 3.42e-01 | 1.16e-01 | 1.48e-01 | 1.45e-01 | 1.92e-01 | 1.47e-01 | 6.22e-01 |
| POSITIVE REGULATION OF MAMMARY GLAND EPITHELIAL CELL PROLIFERATION | 6 | 5.94e-01 | 9.87e-01 | 0.67700 | 3.14e-01 | 2.72e-01 | 3.99e-01 | 1.98e-01 | 2.97e-01 | 1.83e-01 | 2.49e-01 | 9.04e-02 | 4.00e-01 | 2.08e-01 |
| POSITIVE REGULATION OF NK T CELL ACTIVATION | 9 | 4.54e-01 | 9.31e-01 | 0.67700 | -3.32e-01 | -2.97e-01 | -2.99e-01 | -3.60e-01 | -2.03e-01 | 8.48e-02 | 1.23e-01 | 1.20e-01 | 6.14e-02 | 2.91e-01 |
| ANTIFUNGAL INNATE IMMUNE RESPONSE | 19 | 1.14e-01 | 5.61e-01 | 0.67700 | -3.37e-01 | -3.37e-01 | -3.25e-01 | -3.21e-01 | -1.49e-01 | 1.10e-02 | 1.09e-02 | 1.42e-02 | 1.53e-02 | 2.61e-01 |
| DENDRITIC CELL CHEMOTAXIS | 25 | 1.36e-04 | 4.53e-03 | 0.67700 | -2.86e-01 | -3.52e-01 | 6.56e-04 | -3.80e-01 | 3.29e-01 | 1.33e-02 | 2.33e-03 | 9.95e-01 | 1.01e-03 | 4.44e-03 |
| NUCLEOSIDE DIPHOSPHATE BIOSYNTHETIC PROCESS | 13 | 2.42e-01 | 7.67e-01 | 0.67700 | 3.65e-01 | 3.84e-01 | 3.01e-01 | 2.90e-01 | 5.35e-02 | 2.28e-02 | 1.64e-02 | 6.05e-02 | 7.05e-02 | 7.38e-01 |
| CARBOHYDRATE IMPORT ACROSS PLASMA MEMBRANE | 6 | 5.18e-01 | 9.52e-01 | 0.67600 | 2.97e-01 | 2.64e-01 | 2.88e-01 | 3.78e-01 | 2.72e-01 | 2.08e-01 | 2.63e-01 | 2.22e-01 | 1.09e-01 | 2.49e-01 |
| MAINTENANCE OF POSTSYNAPTIC SPECIALIZATION STRUCTURE | 7 | 5.14e-01 | 9.52e-01 | 0.67600 | 3.65e-01 | 3.92e-01 | 3.21e-01 | 2.55e-01 | 4.33e-02 | 9.47e-02 | 7.26e-02 | 1.41e-01 | 2.43e-01 | 8.43e-01 |
| POLYOL TRANSMEMBRANE TRANSPORT | 10 | 3.59e-01 | 8.76e-01 | 0.67500 | 3.46e-01 | 3.44e-01 | 3.45e-01 | 3.14e-01 | -1.40e-02 | 5.80e-02 | 6.00e-02 | 5.91e-02 | 8.60e-02 | 9.39e-01 |
| PROTEIN TO MEMBRANE DOCKING | 5 | 2.09e-01 | 7.30e-01 | 0.67400 | 1.93e-03 | -9.49e-02 | 2.44e-01 | -1.16e-01 | 6.10e-01 | 9.94e-01 | 7.13e-01 | 3.44e-01 | 6.55e-01 | 1.82e-02 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO CHROMATIN | 6 | 1.85e-01 | 6.93e-01 | 0.67300 | 3.24e-01 | 2.50e-01 | 5.23e-01 | 4.63e-02 | 9.87e-02 | 1.69e-01 | 2.89e-01 | 2.64e-02 | 8.44e-01 | 6.75e-01 |
| REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 5 | 5.39e-01 | 9.58e-01 | 0.67300 | -3.49e-01 | -3.75e-01 | -2.81e-01 | -2.69e-01 | -1.97e-01 | 1.77e-01 | 1.46e-01 | 2.77e-01 | 2.97e-01 | 4.45e-01 |
| AMINOPHOSPHOLIPID TRANSLOCATION | 6 | 2.24e-01 | 7.46e-01 | 0.67200 | -2.52e-01 | -2.11e-01 | -4.57e-01 | -1.60e-01 | -3.32e-01 | 2.86e-01 | 3.71e-01 | 5.27e-02 | 4.98e-01 | 1.59e-01 |
| RIBONUCLEOSIDE DIPHOSPHATE BIOSYNTHETIC PROCESS | 9 | 3.22e-01 | 8.47e-01 | 0.67200 | 3.65e-01 | 3.91e-01 | 3.32e-01 | 2.34e-01 | 2.96e-02 | 5.80e-02 | 4.21e-02 | 8.50e-02 | 2.25e-01 | 8.78e-01 |
| REGULATION OF LENS FIBER CELL DIFFERENTIATION | 9 | 5.06e-01 | 9.48e-01 | 0.67100 | 3.46e-01 | 2.98e-01 | 3.80e-01 | 2.73e-01 | 1.47e-01 | 7.19e-02 | 1.21e-01 | 4.82e-02 | 1.55e-01 | 4.45e-01 |
| PROTEIN DEUBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 5 | 6.21e-01 | 9.90e-01 | 0.67000 | -3.59e-01 | -2.84e-01 | -4.18e-01 | -2.34e-01 | -9.96e-02 | 1.65e-01 | 2.72e-01 | 1.06e-01 | 3.64e-01 | 7.00e-01 |
| MESENCHYMAL CELL PROLIFERATION INVOLVED IN LUNG DEVELOPMENT | 6 | 2.84e-01 | 8.12e-01 | 0.66900 | 3.09e-01 | 2.86e-01 | 1.32e-01 | 4.28e-01 | -2.63e-01 | 1.89e-01 | 2.24e-01 | 5.74e-01 | 6.95e-02 | 2.64e-01 |
| CELLULAR RESPONSE TO ARSENIC CONTAINING SUBSTANCE | 17 | 9.47e-02 | 5.08e-01 | 0.66900 | 3.18e-01 | 2.82e-01 | 4.10e-01 | 2.25e-01 | 2.20e-01 | 2.34e-02 | 4.39e-02 | 3.46e-03 | 1.07e-01 | 1.17e-01 |
| CANONICAL WNT SIGNALING PATHWAY INVOLVED IN OSTEOBLAST DIFFERENTIATION | 7 | 2.50e-01 | 7.76e-01 | 0.66800 | -2.45e-01 | -2.20e-01 | -2.79e-01 | -2.00e-01 | -4.69e-01 | 2.62e-01 | 3.13e-01 | 2.01e-01 | 3.60e-01 | 3.16e-02 |
| NEGATIVE REGULATION OF LYMPHOCYTE MIGRATION | 15 | 2.78e-01 | 8.05e-01 | 0.66800 | -3.44e-01 | -3.30e-01 | -3.06e-01 | -3.49e-01 | -6.04e-02 | 2.12e-02 | 2.68e-02 | 4.04e-02 | 1.91e-02 | 6.85e-01 |
| NEGATIVE REGULATION OF INTERFERON BETA PRODUCTION | 15 | 1.73e-01 | 6.77e-01 | 0.66700 | 3.50e-01 | 3.10e-01 | 3.14e-01 | 3.58e-01 | 1.11e-02 | 1.90e-02 | 3.78e-02 | 3.55e-02 | 1.63e-02 | 9.41e-01 |
| POSITIVE REGULATION OF SPINDLE ASSEMBLY | 8 | 5.06e-01 | 9.48e-01 | 0.66700 | 3.32e-01 | 3.49e-01 | 3.27e-01 | 2.96e-01 | 1.33e-01 | 1.04e-01 | 8.71e-02 | 1.09e-01 | 1.47e-01 | 5.16e-01 |
| NEGATIVE REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS NONSENSE MEDIATED DECAY | 8 | 5.92e-01 | 9.86e-01 | 0.66600 | -3.52e-01 | -3.13e-01 | -3.21e-01 | -3.22e-01 | -1.19e-01 | 8.46e-02 | 1.25e-01 | 1.15e-01 | 1.15e-01 | 5.59e-01 |
| MESANGIAL CELL DIFFERENTIATION | 7 | 1.09e-01 | 5.47e-01 | 0.66500 | 2.91e-01 | 2.37e-01 | 5.19e-01 | 1.07e-01 | 1.43e-01 | 1.82e-01 | 2.77e-01 | 1.74e-02 | 6.25e-01 | 5.13e-01 |
| ENUCLEATE ERYTHROCYTE DIFFERENTIATION | 10 | 2.41e-01 | 7.67e-01 | 0.66500 | 3.16e-01 | 2.78e-01 | 3.39e-01 | 2.33e-01 | 3.09e-01 | 8.38e-02 | 1.28e-01 | 6.35e-02 | 2.02e-01 | 9.05e-02 |
| NEGATIVE REGULATION OF T HELPER 2 CELL DIFFERENTIATION | 5 | 1.93e-01 | 7.04e-01 | 0.66400 | 3.25e-01 | 3.11e-01 | 4.16e-01 | 2.41e-02 | -2.54e-01 | 2.08e-01 | 2.28e-01 | 1.07e-01 | 9.26e-01 | 3.26e-01 |
| NEGATIVE REGULATION OF DELAYED RECTIFIER POTASSIUM CHANNEL ACTIVITY | 10 | 1.70e-01 | 6.75e-01 | 0.66400 | -3.36e-01 | -2.88e-01 | -4.31e-01 | -1.41e-01 | -1.96e-01 | 6.58e-02 | 1.14e-01 | 1.82e-02 | 4.39e-01 | 2.82e-01 |
| REGULATION OF CELL CHEMOTAXIS TO FIBROBLAST GROWTH FACTOR | 9 | 4.33e-01 | 9.20e-01 | 0.66300 | -3.10e-01 | -2.72e-01 | -3.19e-01 | -2.90e-01 | -2.90e-01 | 1.07e-01 | 1.57e-01 | 9.78e-02 | 1.31e-01 | 1.33e-01 |
| REGULATION OF TOLL LIKE RECEPTOR 7 SIGNALING PATHWAY | 5 | 3.59e-01 | 8.75e-01 | 0.66300 | -3.18e-01 | -4.15e-01 | -1.56e-01 | -3.67e-01 | 8.38e-02 | 2.19e-01 | 1.08e-01 | 5.46e-01 | 1.55e-01 | 7.45e-01 |
| SMOOTH MUSCLE ADAPTATION | 5 | 2.79e-01 | 8.05e-01 | 0.66200 | 3.14e-01 | 2.71e-01 | 5.10e-01 | 2.70e-02 | 7.52e-02 | 2.24e-01 | 2.94e-01 | 4.83e-02 | 9.17e-01 | 7.71e-01 |
| PROXIMAL DISTAL PATTERN FORMATION INVOLVED IN NEPHRON DEVELOPMENT | 5 | 2.08e-01 | 7.29e-01 | 0.66100 | 3.02e-01 | 1.70e-01 | 4.25e-01 | 1.72e-01 | 3.27e-01 | 2.42e-01 | 5.11e-01 | 9.95e-02 | 5.05e-01 | 2.06e-01 |
| NEGATIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 6 | 2.17e-02 | 2.19e-01 | 0.66100 | -3.11e-01 | -3.58e-01 | 5.64e-02 | -4.58e-01 | 6.21e-03 | 1.87e-01 | 1.29e-01 | 8.11e-01 | 5.23e-02 | 9.79e-01 |
| REGULATION OF GLUCAGON SECRETION | 8 | 9.82e-02 | 5.18e-01 | 0.66100 | -3.23e-01 | -2.81e-01 | -1.52e-01 | -4.56e-01 | -1.49e-01 | 1.14e-01 | 1.68e-01 | 4.58e-01 | 2.54e-02 | 4.65e-01 |
| REGULATION OF CORE PROMOTER BINDING | 5 | 8.05e-01 | 1.00e+00 | 0.66000 | -3.30e-01 | -3.05e-01 | -3.02e-01 | -3.58e-01 | -1.21e-01 | 2.01e-01 | 2.37e-01 | 2.42e-01 | 1.66e-01 | 6.40e-01 |
| NATURAL KILLER CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 11 | 8.50e-02 | 4.79e-01 | 0.66000 | -3.44e-01 | -3.58e-01 | -1.11e-01 | -4.09e-01 | 9.44e-02 | 4.80e-02 | 3.96e-02 | 5.25e-01 | 1.89e-02 | 5.88e-01 |
| NEGATIVE REGULATION OF DENDRITIC SPINE MORPHOGENESIS | 6 | 6.55e-01 | 1.00e+00 | 0.65900 | -3.27e-01 | -2.70e-01 | -3.62e-01 | -3.13e-01 | -1.60e-01 | 1.65e-01 | 2.53e-01 | 1.24e-01 | 1.84e-01 | 4.97e-01 |
| FATTY ACID DERIVATIVE CATABOLIC PROCESS | 17 | 9.12e-03 | 1.18e-01 | 0.65800 | 3.21e-01 | 2.89e-01 | 2.79e-01 | 4.06e-01 | -6.07e-02 | 2.20e-02 | 3.92e-02 | 4.68e-02 | 3.72e-03 | 6.65e-01 |
| LEUCINE CATABOLIC PROCESS | 6 | 6.48e-01 | 1.00e+00 | 0.65800 | -3.24e-01 | -2.61e-01 | -4.05e-01 | -2.36e-01 | -2.00e-01 | 1.69e-01 | 2.68e-01 | 8.59e-02 | 3.17e-01 | 3.97e-01 |
| POSITIVE REGULATION OF DNA DAMAGE CHECKPOINT | 5 | 6.93e-01 | 1.00e+00 | 0.65800 | 3.03e-01 | 3.21e-01 | 2.54e-01 | 3.44e-01 | 2.33e-01 | 2.40e-01 | 2.14e-01 | 3.24e-01 | 1.83e-01 | 3.67e-01 |
| MALONYL COA METABOLIC PROCESS | 6 | 6.38e-01 | 9.98e-01 | 0.65700 | 3.30e-01 | 3.40e-01 | 2.52e-01 | 3.35e-01 | -1.77e-01 | 1.62e-01 | 1.49e-01 | 2.85e-01 | 1.56e-01 | 4.52e-01 |
| LYMPHOCYTE CHEMOTAXIS | 62 | 1.82e-07 | 1.45e-05 | 0.65700 | -3.65e-01 | -3.46e-01 | -3.28e-01 | -2.23e-01 | 1.47e-01 | 6.82e-07 | 2.43e-06 | 8.01e-06 | 2.39e-03 | 4.58e-02 |
| PYRUVATE FAMILY AMINO ACID METABOLIC PROCESS | 5 | 2.55e-01 | 7.83e-01 | 0.65700 | 3.12e-01 | 3.54e-01 | -5.47e-03 | 4.07e-01 | -2.08e-01 | 2.27e-01 | 1.70e-01 | 9.83e-01 | 1.15e-01 | 4.21e-01 |
| TRAIL ACTIVATED APOPTOTIC SIGNALING PATHWAY | 11 | 1.51e-01 | 6.42e-01 | 0.65600 | -3.17e-01 | -3.46e-01 | -1.01e-01 | -4.42e-01 | 6.65e-02 | 6.86e-02 | 4.66e-02 | 5.61e-01 | 1.12e-02 | 7.03e-01 |
| REGULATION OF MUCUS SECRETION | 8 | 6.66e-01 | 1.00e+00 | 0.65600 | 3.44e-01 | 3.48e-01 | 2.89e-01 | 3.13e-01 | 9.45e-02 | 9.16e-02 | 8.80e-02 | 1.57e-01 | 1.25e-01 | 6.44e-01 |
| PULMONARY ARTERY MORPHOGENESIS | 6 | 7.07e-01 | 1.00e+00 | 0.65500 | 3.49e-01 | 3.58e-01 | 3.25e-01 | 2.55e-01 | -9.68e-02 | 1.39e-01 | 1.29e-01 | 1.68e-01 | 2.79e-01 | 6.81e-01 |
| POSITIVE REGULATION OF MACROPHAGE ACTIVATION | 30 | 2.53e-04 | 7.59e-03 | 0.65500 | -3.54e-01 | -4.01e-01 | -1.62e-01 | -3.31e-01 | 8.54e-02 | 7.89e-04 | 1.44e-04 | 1.24e-01 | 1.73e-03 | 4.18e-01 |
| NEGATIVE REGULATION OF DNA TEMPLATED DNA REPLICATION | 9 | 6.46e-02 | 4.13e-01 | 0.65500 | 3.20e-01 | 3.11e-01 | 4.73e-01 | 7.38e-02 | 1.02e-02 | 9.63e-02 | 1.06e-01 | 1.39e-02 | 7.02e-01 | 9.58e-01 |
| HYDROCARBON METABOLIC PROCESS | 7 | 2.15e-01 | 7.38e-01 | 0.65400 | 2.82e-01 | 3.68e-01 | 5.14e-02 | 4.03e-01 | -2.19e-01 | 1.96e-01 | 9.18e-02 | 8.14e-01 | 6.48e-02 | 3.15e-01 |
| REGULATION OF COMPLEMENT ACTIVATION CLASSICAL PATHWAY | 9 | 3.61e-01 | 8.77e-01 | 0.65400 | -3.18e-01 | -2.59e-01 | -4.31e-01 | -2.08e-01 | -1.74e-01 | 9.82e-02 | 1.79e-01 | 2.53e-02 | 2.80e-01 | 3.67e-01 |
| TRANSCRIPTION ELONGATION COUPLED CHROMATIN REMODELING | 7 | 4.54e-01 | 9.31e-01 | 0.65200 | 3.15e-01 | 2.53e-01 | 3.76e-01 | 2.11e-01 | 2.77e-01 | 1.48e-01 | 2.47e-01 | 8.53e-02 | 3.33e-01 | 2.04e-01 |
| POSITIVE REGULATION OF T HELPER 1 TYPE IMMUNE RESPONSE | 18 | 5.57e-02 | 3.84e-01 | 0.65200 | -3.24e-01 | -3.40e-01 | -1.45e-01 | -4.21e-01 | 7.28e-02 | 1.72e-02 | 1.24e-02 | 2.87e-01 | 1.98e-03 | 5.93e-01 |
| EYE PIGMENTATION | 5 | 8.14e-01 | 1.00e+00 | 0.65100 | -3.22e-01 | -3.11e-01 | -2.67e-01 | -3.61e-01 | -1.51e-01 | 2.13e-01 | 2.28e-01 | 3.01e-01 | 1.62e-01 | 5.58e-01 |
| EARLY ENDOSOME TO RECYCLING ENDOSOME TRANSPORT | 6 | 7.09e-01 | 1.00e+00 | 0.65100 | -3.33e-01 | -3.67e-01 | -1.96e-01 | -3.71e-01 | 5.11e-02 | 1.57e-01 | 1.20e-01 | 4.05e-01 | 1.16e-01 | 8.28e-01 |
| REGULATION OF LYSOSOME SIZE | 8 | 5.30e-01 | 9.54e-01 | 0.65100 | 3.36e-01 | 3.38e-01 | 3.50e-01 | 2.72e-01 | -7.68e-03 | 9.97e-02 | 9.81e-02 | 8.66e-02 | 1.83e-01 | 9.70e-01 |
| INTESTINAL EPITHELIAL CELL MATURATION | 6 | 5.40e-02 | 3.80e-01 | 0.65100 | 3.09e-01 | 3.25e-01 | -2.55e-02 | 3.75e-01 | -2.84e-01 | 1.91e-01 | 1.68e-01 | 9.14e-01 | 1.11e-01 | 2.28e-01 |
| POSITIVE REGULATION OF INOSITOL TRISPHOSPHATE BIOSYNTHETIC PROCESS | 5 | 1.07e-01 | 5.41e-01 | 0.65000 | 9.30e-02 | 1.74e-01 | -1.05e-01 | 2.53e-01 | -5.56e-01 | 7.19e-01 | 5.01e-01 | 6.84e-01 | 3.27e-01 | 3.14e-02 |
| FOREGUT MORPHOGENESIS | 10 | 3.03e-01 | 8.31e-01 | 0.65000 | 3.33e-01 | 3.27e-01 | 2.29e-01 | 2.84e-01 | -2.68e-01 | 6.84e-02 | 7.33e-02 | 2.09e-01 | 1.20e-01 | 1.42e-01 |
| CENTRAL NERVOUS SYSTEM MYELIN MAINTENANCE | 5 | 2.18e-01 | 7.40e-01 | 0.64900 | -4.66e-02 | -7.30e-02 | 2.12e-01 | -1.76e-01 | 5.82e-01 | 8.57e-01 | 7.77e-01 | 4.11e-01 | 4.96e-01 | 2.43e-02 |
| FOLLICLE STIMULATING HORMONE SECRETION | 8 | 2.79e-01 | 8.05e-01 | 0.64900 | -3.08e-01 | -2.65e-01 | -2.82e-01 | -2.77e-01 | -3.15e-01 | 1.32e-01 | 1.94e-01 | 1.67e-01 | 1.75e-01 | 1.22e-01 |
| NEGATIVE REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 7 | 3.85e-01 | 8.92e-01 | 0.64800 | -2.95e-01 | -3.11e-01 | -9.79e-02 | -3.32e-01 | 3.42e-01 | 1.77e-01 | 1.55e-01 | 6.54e-01 | 1.28e-01 | 1.18e-01 |
| PROTEIN OXIDATION | 13 | 2.45e-01 | 7.72e-01 | 0.64800 | 2.99e-01 | 2.72e-01 | 3.37e-01 | 2.98e-01 | 2.35e-01 | 6.24e-02 | 9.00e-02 | 3.56e-02 | 6.27e-02 | 1.43e-01 |
| REGULATION OF POLYAMINE TRANSMEMBRANE TRANSPORT | 5 | 6.32e-01 | 9.96e-01 | 0.64700 | 2.99e-01 | 2.99e-01 | 3.68e-01 | 2.55e-01 | 1.99e-01 | 2.48e-01 | 2.47e-01 | 1.54e-01 | 3.23e-01 | 4.42e-01 |
| CYTOPLASMIC TRANSLATIONAL ELONGATION | 5 | 7.06e-01 | 1.00e+00 | 0.64600 | 3.30e-01 | 3.29e-01 | 3.94e-01 | 2.05e-01 | 6.19e-02 | 2.01e-01 | 2.03e-01 | 1.27e-01 | 4.28e-01 | 8.11e-01 |
| NEGATIVE REGULATION OF MAST CELL ACTIVATION | 12 | 1.30e-01 | 5.97e-01 | 0.64600 | -3.26e-01 | -3.65e-01 | -1.19e-01 | -4.04e-01 | 1.18e-02 | 5.06e-02 | 2.87e-02 | 4.74e-01 | 1.54e-02 | 9.44e-01 |
| REGULATION OF SMOOTH MUSCLE CELL CHEMOTAXIS | 7 | 4.30e-01 | 9.18e-01 | 0.64500 | -3.06e-01 | -3.67e-01 | -1.37e-01 | -2.89e-01 | 2.92e-01 | 1.61e-01 | 9.25e-02 | 5.29e-01 | 1.85e-01 | 1.82e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 6 MEDIATED SIGNALING PATHWAY | 8 | 2.36e-06 | 1.31e-04 | 0.64500 | 1.37e-01 | 3.36e-01 | -3.45e-01 | 2.00e-01 | -3.53e-01 | 5.01e-01 | 9.96e-02 | 9.07e-02 | 3.28e-01 | 8.37e-02 |
| NEGATIVE REGULATION OF CIRCADIAN RHYTHM | 11 | 2.86e-01 | 8.12e-01 | 0.64400 | 3.25e-01 | 2.58e-01 | 4.03e-01 | 2.32e-01 | 1.62e-01 | 6.19e-02 | 1.38e-01 | 2.05e-02 | 1.82e-01 | 3.52e-01 |
| RESPONSE TO SODIUM ARSENITE | 6 | 4.55e-01 | 9.31e-01 | 0.64200 | 3.22e-01 | 3.37e-01 | 4.01e-01 | 1.62e-01 | 8.89e-02 | 1.71e-01 | 1.53e-01 | 8.88e-02 | 4.93e-01 | 7.06e-01 |
| GANGLIOSIDE BIOSYNTHETIC PROCESS VIA LACTOSYLCERAMIDE | 6 | 5.00e-01 | 9.47e-01 | 0.64200 | -2.90e-01 | -3.34e-01 | -6.56e-02 | -3.45e-01 | 3.05e-01 | 2.18e-01 | 1.57e-01 | 7.81e-01 | 1.43e-01 | 1.96e-01 |
| TELOMERASE HOLOENZYME COMPLEX ASSEMBLY | 6 | 4.46e-01 | 9.30e-01 | 0.64200 | 2.71e-01 | 2.08e-01 | 4.52e-01 | 1.08e-01 | 2.81e-01 | 2.50e-01 | 3.78e-01 | 5.50e-02 | 6.48e-01 | 2.33e-01 |
| MATURATION OF LSU RRNA | 27 | 4.67e-02 | 3.50e-01 | 0.64200 | 3.27e-01 | 2.90e-01 | 3.67e-01 | 2.59e-01 | 1.38e-01 | 3.30e-03 | 9.04e-03 | 9.77e-04 | 1.96e-02 | 2.15e-01 |
| PROTEIN REFOLDING | 27 | 1.48e-02 | 1.67e-01 | 0.64100 | 3.31e-01 | 3.53e-01 | 3.28e-01 | 2.46e-01 | 9.12e-02 | 2.90e-03 | 1.49e-03 | 3.18e-03 | 2.67e-02 | 4.12e-01 |
| NEGATIVE REGULATION OF BONE MINERALIZATION | 18 | 1.44e-01 | 6.29e-01 | 0.64100 | -3.45e-01 | -3.15e-01 | -3.17e-01 | -2.92e-01 | 8.07e-02 | 1.12e-02 | 2.07e-02 | 1.99e-02 | 3.19e-02 | 5.53e-01 |
| FAS SIGNALING PATHWAY | 8 | 2.15e-01 | 7.38e-01 | 0.64100 | -2.57e-01 | -2.65e-01 | -1.04e-01 | -2.85e-01 | 4.27e-01 | 2.09e-01 | 1.94e-01 | 6.12e-01 | 1.63e-01 | 3.63e-02 |
| CYTIDINE METABOLIC PROCESS | 12 | 2.93e-02 | 2.65e-01 | 0.64000 | -3.42e-01 | -2.74e-01 | -2.28e-01 | -3.79e-01 | 1.50e-01 | 4.05e-02 | 9.98e-02 | 1.71e-01 | 2.31e-02 | 3.67e-01 |
| NEGATIVE REGULATION OF MYELOID LEUKOCYTE MEDIATED IMMUNITY | 10 | 4.13e-03 | 6.63e-02 | 0.64000 | -2.62e-01 | -3.91e-01 | 8.31e-02 | -3.82e-01 | 1.89e-01 | 1.51e-01 | 3.22e-02 | 6.49e-01 | 3.65e-02 | 3.02e-01 |
| MALE MATING BEHAVIOR | 6 | 1.26e-01 | 5.91e-01 | 0.64000 | -3.60e-01 | -2.48e-01 | -3.14e-01 | -3.44e-01 | 4.35e-02 | 1.27e-01 | 2.92e-01 | 1.83e-01 | 1.45e-01 | 8.54e-01 |
| FAT PAD DEVELOPMENT | 8 | 6.89e-01 | 1.00e+00 | 0.64000 | 3.33e-01 | 3.09e-01 | 3.12e-01 | 2.98e-01 | 1.33e-01 | 1.02e-01 | 1.31e-01 | 1.27e-01 | 1.45e-01 | 5.16e-01 |
| DETECTION OF STIMULUS | 591 | 7.41e-64 | 1.40e-60 | 0.64000 | -3.11e-01 | -2.77e-01 | -4.04e-01 | -2.11e-01 | -1.68e-01 | 2.67e-38 | 1.23e-30 | 1.11e-63 | 1.50e-18 | 2.63e-12 |
| INTERLEUKIN 12 MEDIATED SIGNALING PATHWAY | 9 | 4.28e-01 | 9.17e-01 | 0.64000 | -3.26e-01 | -3.03e-01 | -2.22e-01 | -3.86e-01 | -1.11e-01 | 8.99e-02 | 1.15e-01 | 2.49e-01 | 4.47e-02 | 5.65e-01 |
| NECROPTOTIC SIGNALING PATHWAY | 8 | 3.58e-01 | 8.74e-01 | 0.64000 | -3.13e-01 | -3.29e-01 | -2.36e-01 | -2.97e-01 | -2.43e-01 | 1.25e-01 | 1.07e-01 | 2.47e-01 | 1.46e-01 | 2.34e-01 |
| MONOACYLGLYCEROL METABOLIC PROCESS | 12 | 4.10e-01 | 9.08e-01 | 0.64000 | 3.45e-01 | 3.15e-01 | 3.22e-01 | 2.91e-01 | -4.06e-02 | 3.83e-02 | 5.85e-02 | 5.34e-02 | 8.05e-02 | 8.08e-01 |
| MACROPHAGE FUSION | 6 | 3.72e-01 | 8.82e-01 | 0.63900 | -3.34e-01 | -3.91e-01 | -1.13e-01 | -3.61e-01 | 3.12e-02 | 1.57e-01 | 9.72e-02 | 6.32e-01 | 1.25e-01 | 8.95e-01 |
| POSITIVE REGULATION OF GASTRULATION | 6 | 2.71e-01 | 7.99e-01 | 0.63900 | 3.17e-01 | 2.52e-01 | 4.76e-01 | 5.52e-02 | 1.19e-01 | 1.78e-01 | 2.85e-01 | 4.35e-02 | 8.15e-01 | 6.13e-01 |
| REGULATION OF MESODERMAL CELL FATE SPECIFICATION | 5 | 6.47e-01 | 1.00e+00 | 0.63900 | -3.26e-01 | -3.39e-01 | -1.27e-01 | -4.11e-01 | 4.01e-02 | 2.07e-01 | 1.89e-01 | 6.23e-01 | 1.12e-01 | 8.77e-01 |
| REGULATION OF PIGMENT CELL DIFFERENTIATION | 8 | 5.83e-01 | 9.85e-01 | 0.63800 | -3.25e-01 | -3.26e-01 | -2.03e-01 | -3.93e-01 | -6.83e-03 | 1.11e-01 | 1.11e-01 | 3.21e-01 | 5.41e-02 | 9.73e-01 |
| TOLL LIKE RECEPTOR 7 SIGNALING PATHWAY | 9 | 1.74e-01 | 6.80e-01 | 0.63800 | -2.95e-01 | -3.75e-01 | -9.79e-02 | -3.83e-01 | 1.51e-01 | 1.25e-01 | 5.15e-02 | 6.11e-01 | 4.66e-02 | 4.31e-01 |
| RENAL WATER TRANSPORT | 9 | 5.82e-01 | 9.85e-01 | 0.63700 | 3.25e-01 | 3.10e-01 | 2.87e-01 | 3.03e-01 | 1.75e-01 | 9.14e-02 | 1.08e-01 | 1.36e-01 | 1.16e-01 | 3.63e-01 |
| NEGATIVE REGULATION OF AMINE METABOLIC PROCESS | 6 | 2.95e-01 | 8.22e-01 | 0.63700 | 3.46e-01 | 3.83e-01 | 1.13e-01 | 3.48e-01 | -8.15e-02 | 1.43e-01 | 1.04e-01 | 6.33e-01 | 1.40e-01 | 7.29e-01 |
| REGULATION OF CILIUM BEAT FREQUENCY INVOLVED IN CILIARY MOTILITY | 9 | 4.84e-01 | 9.43e-01 | 0.63700 | 3.32e-01 | 2.92e-01 | 3.56e-01 | 2.31e-01 | 1.72e-01 | 8.42e-02 | 1.29e-01 | 6.45e-02 | 2.31e-01 | 3.73e-01 |
| REGULATION OF CD4 POSITIVE CD25 POSITIVE ALPHA BETA REGULATORY T CELL DIFFERENTIATION | 5 | 5.30e-01 | 9.54e-01 | 0.63600 | -3.22e-01 | -3.19e-01 | -2.20e-01 | -3.08e-01 | -2.37e-01 | 2.13e-01 | 2.16e-01 | 3.94e-01 | 2.33e-01 | 3.59e-01 |
| POSITIVE REGULATION OF ANOIKIS | 6 | 4.02e-01 | 9.01e-01 | 0.63600 | 2.70e-01 | 3.09e-01 | 2.36e-01 | 3.19e-01 | 2.80e-01 | 2.52e-01 | 1.90e-01 | 3.18e-01 | 1.76e-01 | 2.34e-01 |
| NEGATIVE REGULATION OF RIG I SIGNALING PATHWAY | 8 | 3.70e-01 | 8.80e-01 | 0.63500 | 3.16e-01 | 2.70e-01 | 4.40e-01 | 1.71e-01 | 8.69e-02 | 1.22e-01 | 1.86e-01 | 3.12e-02 | 4.01e-01 | 6.70e-01 |
| REGULATION OF PHOSPHATIDYLINOSITOL DEPHOSPHORYLATION | 5 | 5.18e-01 | 9.52e-01 | 0.63500 | -1.87e-01 | -1.21e-01 | -3.48e-01 | -9.18e-02 | -4.73e-01 | 4.70e-01 | 6.40e-01 | 1.77e-01 | 7.22e-01 | 6.71e-02 |
| NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 5 | 1.98e-01 | 7.13e-01 | 0.63400 | 2.71e-01 | 1.93e-01 | 4.94e-01 | -4.27e-02 | 2.13e-01 | 2.93e-01 | 4.55e-01 | 5.59e-02 | 8.69e-01 | 4.10e-01 |
| NEGATIVE REGULATION OF ADIPOSE TISSUE DEVELOPMENT | 5 | 1.94e-01 | 7.06e-01 | 0.63400 | -1.99e-01 | -3.22e-01 | 1.21e-01 | -3.65e-01 | 3.32e-01 | 4.41e-01 | 2.13e-01 | 6.39e-01 | 1.57e-01 | 1.98e-01 |
| GLUCOCORTICOID BIOSYNTHETIC PROCESS | 16 | 2.55e-01 | 7.82e-01 | 0.63400 | 3.22e-01 | 3.36e-01 | 2.49e-01 | 3.40e-01 | 8.53e-02 | 2.57e-02 | 1.98e-02 | 8.50e-02 | 1.87e-02 | 5.54e-01 |
| TRACHEA CARTILAGE DEVELOPMENT | 7 | 7.42e-01 | 1.00e+00 | 0.63300 | 3.30e-01 | 3.16e-01 | 3.08e-01 | 2.76e-01 | 1.43e-01 | 1.31e-01 | 1.47e-01 | 1.58e-01 | 2.06e-01 | 5.13e-01 |
| NEURONAL SIGNAL TRANSDUCTION | 7 | 3.57e-01 | 8.74e-01 | 0.63200 | 3.27e-01 | 2.50e-01 | 4.47e-01 | 1.52e-01 | 8.91e-02 | 1.34e-01 | 2.52e-01 | 4.06e-02 | 4.87e-01 | 6.83e-01 |
| POSITIVE REGULATION OF ODONTOGENESIS | 7 | 1.75e-01 | 6.81e-01 | 0.63200 | -2.07e-01 | -2.32e-01 | 3.71e-03 | -1.89e-01 | 5.17e-01 | 3.43e-01 | 2.88e-01 | 9.86e-01 | 3.86e-01 | 1.79e-02 |
| STOMACH DEVELOPMENT | 5 | 3.13e-01 | 8.40e-01 | 0.63100 | 2.85e-01 | 3.27e-01 | 2.87e-01 | 9.91e-02 | -3.44e-01 | 2.70e-01 | 2.05e-01 | 2.67e-01 | 7.01e-01 | 1.82e-01 |
| POSITIVE REGULATION OF BLOOD VESSEL REMODELING | 6 | 4.91e-01 | 9.45e-01 | 0.63100 | 3.18e-01 | 2.96e-01 | 3.47e-01 | 2.74e-01 | -1.19e-01 | 1.77e-01 | 2.09e-01 | 1.41e-01 | 2.45e-01 | 6.14e-01 |
| REGULATION OF CIRCADIAN SLEEP WAKE CYCLE NON REM SLEEP | 5 | 2.88e-01 | 8.15e-01 | 0.63100 | -2.53e-01 | -3.31e-01 | 9.38e-03 | -2.17e-01 | 4.22e-01 | 3.27e-01 | 2.00e-01 | 9.71e-01 | 4.01e-01 | 1.02e-01 |
| REGULATION OF DENDRITIC CELL ANTIGEN PROCESSING AND PRESENTATION | 11 | 1.56e-02 | 1.75e-01 | 0.63000 | -2.95e-01 | -3.65e-01 | 1.97e-02 | -3.78e-01 | 1.84e-01 | 9.03e-02 | 3.61e-02 | 9.10e-01 | 2.99e-02 | 2.89e-01 |
| PYRIMIDINE NUCLEOBASE BIOSYNTHETIC PROCESS | 7 | 5.76e-01 | 9.80e-01 | 0.63000 | 3.22e-01 | 3.69e-01 | 2.24e-01 | 3.05e-01 | -1.19e-01 | 1.40e-01 | 9.10e-02 | 3.04e-01 | 1.63e-01 | 5.86e-01 |
| POSITIVE REGULATION OF GAMMA DELTA T CELL DIFFERENTIATION | 7 | 1.90e-01 | 6.99e-01 | 0.63000 | -2.24e-01 | -3.02e-01 | 3.15e-03 | -3.50e-01 | 3.65e-01 | 3.05e-01 | 1.66e-01 | 9.88e-01 | 1.09e-01 | 9.46e-02 |
| RESPONSE TO CGMP | 8 | 4.92e-01 | 9.45e-01 | 0.63000 | 3.10e-01 | 3.21e-01 | 1.53e-01 | 3.90e-01 | -1.49e-01 | 1.29e-01 | 1.16e-01 | 4.55e-01 | 5.63e-02 | 4.66e-01 |
| T CELL PROLIFERATION INVOLVED IN IMMUNE RESPONSE | 5 | 7.22e-01 | 1.00e+00 | 0.63000 | 3.04e-01 | 3.18e-01 | 2.83e-01 | 2.54e-01 | 2.41e-01 | 2.39e-01 | 2.18e-01 | 2.73e-01 | 3.24e-01 | 3.51e-01 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO OXIDATIVE STRESS | 8 | 4.54e-02 | 3.45e-01 | 0.62900 | 3.17e-01 | 3.34e-01 | 9.75e-02 | 3.76e-01 | 1.83e-01 | 1.21e-01 | 1.02e-01 | 6.33e-01 | 6.56e-02 | 3.69e-01 |
| SNRNA MODIFICATION | 6 | 4.89e-01 | 9.44e-01 | 0.62800 | 2.17e-01 | 1.85e-01 | 3.58e-01 | 1.46e-01 | 4.05e-01 | 3.57e-01 | 4.33e-01 | 1.29e-01 | 5.36e-01 | 8.60e-02 |
| AMMONIUM HOMEOSTASIS | 5 | 4.53e-01 | 9.30e-01 | 0.62800 | -2.12e-01 | -1.10e-01 | -3.90e-01 | -1.25e-01 | -4.12e-01 | 4.11e-01 | 6.70e-01 | 1.31e-01 | 6.28e-01 | 1.10e-01 |
| NEGATIVE REGULATION OF TRIGLYCERIDE CATABOLIC PROCESS | 5 | 8.29e-01 | 1.00e+00 | 0.62800 | -3.24e-01 | -3.32e-01 | -2.77e-01 | -3.15e-01 | 5.43e-02 | 2.09e-01 | 1.99e-01 | 2.83e-01 | 2.22e-01 | 8.33e-01 |
| REGULATION OF INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 10 | 3.41e-01 | 8.60e-01 | 0.62800 | -3.08e-01 | -2.47e-01 | -3.07e-01 | -3.29e-01 | -1.89e-01 | 9.20e-02 | 1.76e-01 | 9.26e-02 | 7.14e-02 | 3.00e-01 |
| NEGATIVE REGULATION OF MESENCHYMAL CELL PROLIFERATION | 7 | 6.77e-01 | 1.00e+00 | 0.62800 | 3.26e-01 | 2.96e-01 | 2.78e-01 | 3.51e-01 | 9.09e-03 | 1.35e-01 | 1.76e-01 | 2.03e-01 | 1.08e-01 | 9.67e-01 |
| REGULATION OF I KAPPAB PHOSPHORYLATION | 8 | 3.65e-01 | 8.79e-01 | 0.62700 | 3.04e-01 | 2.99e-01 | 1.39e-01 | 4.18e-01 | -1.31e-01 | 1.36e-01 | 1.43e-01 | 4.95e-01 | 4.06e-02 | 5.20e-01 |
| PURINE NUCLEOSIDE DIPHOSPHATE BIOSYNTHETIC PROCESS | 6 | 6.18e-01 | 9.90e-01 | 0.62700 | 3.26e-01 | 3.75e-01 | 2.56e-01 | 2.81e-01 | 4.68e-02 | 1.66e-01 | 1.12e-01 | 2.78e-01 | 2.34e-01 | 8.43e-01 |
| EPITHELIAL MESENCHYMAL CELL SIGNALING | 6 | 3.87e-01 | 8.92e-01 | 0.62700 | 3.43e-01 | 2.99e-01 | 4.14e-01 | 1.15e-01 | -3.74e-02 | 1.45e-01 | 2.04e-01 | 7.92e-02 | 6.26e-01 | 8.74e-01 |
| ENDONUCLEOLYTIC CLEAVAGE OF TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 17 | 7.23e-03 | 9.94e-02 | 0.62700 | 2.89e-01 | 2.34e-01 | 4.18e-01 | 7.30e-02 | 2.73e-01 | 3.92e-02 | 9.48e-02 | 2.82e-03 | 6.02e-01 | 5.14e-02 |
| L ASCORBIC ACID METABOLIC PROCESS | 9 | 5.96e-02 | 4.01e-01 | 0.62700 | 2.74e-01 | 2.04e-01 | 2.46e-01 | 4.30e-01 | 1.77e-01 | 1.54e-01 | 2.90e-01 | 2.01e-01 | 2.57e-02 | 3.59e-01 |
| LATERAL MESODERM DEVELOPMENT | 15 | 1.62e-02 | 1.79e-01 | 0.62700 | 3.10e-01 | 3.65e-01 | 2.63e-01 | 1.57e-01 | -2.62e-01 | 3.74e-02 | 1.43e-02 | 7.73e-02 | 2.92e-01 | 7.84e-02 |
| DENDRITIC CELL ANTIGEN PROCESSING AND PRESENTATION | 14 | 8.99e-03 | 1.16e-01 | 0.62700 | -3.14e-01 | -3.69e-01 | -3.43e-02 | -3.70e-01 | 1.39e-01 | 4.22e-02 | 1.67e-02 | 8.24e-01 | 1.64e-02 | 3.68e-01 |
| SEQUESTERING OF IRON ION | 6 | 3.46e-01 | 8.64e-01 | 0.62600 | 2.64e-01 | 1.60e-01 | 3.73e-01 | 2.56e-01 | 3.04e-01 | 2.63e-01 | 4.99e-01 | 1.13e-01 | 2.78e-01 | 1.97e-01 |
| REGULATION OF SYNAPTIC VESICLE PRIMING | 7 | 7.01e-01 | 1.00e+00 | 0.62600 | 3.18e-01 | 2.77e-01 | 3.01e-01 | 3.19e-01 | 1.50e-01 | 1.46e-01 | 2.05e-01 | 1.68e-01 | 1.44e-01 | 4.92e-01 |
| POSITIVE REGULATION OF NUCLEASE ACTIVITY | 7 | 4.95e-01 | 9.47e-01 | 0.62600 | 2.45e-01 | 1.85e-01 | 3.62e-01 | 1.95e-01 | 3.59e-01 | 2.61e-01 | 3.97e-01 | 9.76e-02 | 3.72e-01 | 9.97e-02 |
| POSITIVE REGULATION OF DEFENSE RESPONSE TO BACTERIUM | 14 | 3.91e-02 | 3.17e-01 | 0.62600 | 2.67e-01 | 2.92e-01 | 1.96e-01 | 2.95e-01 | 3.31e-01 | 8.42e-02 | 5.83e-02 | 2.04e-01 | 5.63e-02 | 3.20e-02 |
| CHIASMA ASSEMBLY | 6 | 5.44e-01 | 9.61e-01 | 0.62400 | 3.14e-01 | 2.73e-01 | 2.87e-01 | 3.66e-01 | -2.14e-02 | 1.83e-01 | 2.46e-01 | 2.23e-01 | 1.21e-01 | 9.28e-01 |
| NUCLEOBASE CONTAINING SMALL MOLECULE INTERCONVERSION | 8 | 4.96e-01 | 9.47e-01 | 0.62300 | 3.12e-01 | 3.21e-01 | 3.58e-01 | 2.03e-01 | 1.37e-01 | 1.27e-01 | 1.16e-01 | 7.98e-02 | 3.19e-01 | 5.01e-01 |
| THREONINE METABOLIC PROCESS | 5 | 8.42e-01 | 1.00e+00 | 0.62300 | 3.37e-01 | 3.42e-01 | 2.21e-01 | 3.27e-01 | -3.76e-02 | 1.92e-01 | 1.86e-01 | 3.92e-01 | 2.05e-01 | 8.84e-01 |
| MUCOCILIARY CLEARANCE | 8 | 1.68e-01 | 6.71e-01 | 0.62000 | -3.14e-01 | -3.35e-01 | -4.02e-01 | -9.44e-02 | -6.34e-02 | 1.24e-01 | 1.01e-01 | 4.89e-02 | 6.44e-01 | 7.56e-01 |
| REGULATION OF APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT | 13 | 3.93e-01 | 8.92e-01 | 0.61900 | 3.24e-01 | 3.19e-01 | 3.10e-01 | 2.81e-01 | -3.51e-02 | 4.29e-02 | 4.65e-02 | 5.29e-02 | 7.89e-02 | 8.26e-01 |
| SYNAPTIC SIGNALING VIA NEUROPEPTIDE | 6 | 1.88e-01 | 6.95e-01 | 0.61900 | -2.15e-01 | -1.96e-01 | -1.75e-01 | -4.17e-01 | -3.07e-01 | 3.62e-01 | 4.06e-01 | 4.58e-01 | 7.71e-02 | 1.93e-01 |
| GLUTATHIONE TRANSPORT | 9 | 3.71e-01 | 8.81e-01 | 0.61900 | -3.45e-01 | -3.02e-01 | -3.11e-01 | -2.47e-01 | 1.22e-01 | 7.32e-02 | 1.17e-01 | 1.06e-01 | 2.00e-01 | 5.27e-01 |
| NEGATIVE REGULATION OF CD8 POSITIVE ALPHA BETA T CELL ACTIVATION | 8 | 4.13e-01 | 9.10e-01 | 0.61800 | 3.17e-01 | 3.53e-01 | 2.39e-01 | 2.76e-01 | 1.54e-01 | 1.20e-01 | 8.39e-02 | 2.42e-01 | 1.76e-01 | 4.52e-01 |
| REGULATION OF INTRACELLULAR LIPID TRANSPORT | 10 | 2.21e-01 | 7.44e-01 | 0.61800 | 2.86e-01 | 3.18e-01 | 2.02e-01 | 2.07e-01 | -3.41e-01 | 1.17e-01 | 8.20e-02 | 2.70e-01 | 2.58e-01 | 6.22e-02 |
| REGULATION OF MICROVILLUS ORGANIZATION | 13 | 1.52e-01 | 6.46e-01 | 0.61700 | 2.99e-01 | 3.52e-01 | 1.10e-01 | 3.83e-01 | -9.40e-02 | 6.16e-02 | 2.79e-02 | 4.92e-01 | 1.68e-02 | 5.57e-01 |
| POSITIVE REGULATION OF ALPHA BETA T CELL PROLIFERATION | 25 | 1.00e-01 | 5.23e-01 | 0.61700 | -3.19e-01 | -3.27e-01 | -2.45e-01 | -3.35e-01 | 6.80e-03 | 5.77e-03 | 4.68e-03 | 3.40e-02 | 3.70e-03 | 9.53e-01 |
| REGULATION OF TRANSCRIPTION BY GLUCOSE | 8 | 2.31e-01 | 7.53e-01 | 0.61700 | 3.25e-01 | 2.68e-01 | 4.38e-01 | 1.05e-01 | -1.33e-02 | 1.12e-01 | 1.90e-01 | 3.19e-02 | 6.07e-01 | 9.48e-01 |
| NEUTROPHIL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 20 | 4.61e-05 | 1.81e-03 | 0.61600 | -3.20e-02 | -1.18e-01 | 2.88e-01 | -1.33e-01 | 5.14e-01 | 8.04e-01 | 3.63e-01 | 2.58e-02 | 3.04e-01 | 6.86e-05 |
| MATURATION OF SSU RRNA | 51 | 7.14e-07 | 5.07e-05 | 0.61600 | 3.11e-01 | 2.84e-01 | 4.17e-01 | 1.04e-01 | 1.31e-01 | 1.22e-04 | 4.53e-04 | 2.49e-07 | 2.01e-01 | 1.05e-01 |
| POSITIVE REGULATION OF IMMATURE T CELL PROLIFERATION | 5 | 2.47e-01 | 7.74e-01 | 0.61500 | -2.98e-01 | -3.18e-01 | -5.34e-02 | -2.49e-01 | 3.51e-01 | 2.48e-01 | 2.17e-01 | 8.36e-01 | 3.34e-01 | 1.74e-01 |
| CONSTITUTIVE SECRETORY PATHWAY | 7 | 1.43e-01 | 6.29e-01 | 0.61500 | 2.64e-01 | 2.05e-01 | 4.92e-01 | -4.03e-03 | 1.56e-01 | 2.26e-01 | 3.48e-01 | 2.42e-02 | 9.85e-01 | 4.76e-01 |
| REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 8 | 5.45e-01 | 9.61e-01 | 0.61500 | 3.31e-01 | 3.34e-01 | 3.00e-01 | 2.30e-01 | 1.17e-01 | 1.05e-01 | 1.02e-01 | 1.41e-01 | 2.59e-01 | 5.66e-01 |
| POLYAMINE METABOLIC PROCESS | 15 | 2.35e-01 | 7.58e-01 | 0.61500 | 3.11e-01 | 2.69e-01 | 3.68e-01 | 2.04e-01 | 1.79e-01 | 3.70e-02 | 7.15e-02 | 1.37e-02 | 1.72e-01 | 2.29e-01 |
| UBIQUITIN DEPENDENT GLYCOPROTEIN ERAD PATHWAY | 7 | 3.87e-01 | 8.92e-01 | 0.61400 | -2.79e-01 | -3.30e-01 | -4.64e-02 | -3.12e-01 | 3.02e-01 | 2.01e-01 | 1.31e-01 | 8.32e-01 | 1.53e-01 | 1.66e-01 |
| GLUCOCORTICOID METABOLIC PROCESS | 24 | 1.30e-01 | 5.97e-01 | 0.61300 | 3.14e-01 | 3.09e-01 | 2.77e-01 | 3.17e-01 | 6.45e-02 | 7.81e-03 | 8.68e-03 | 1.86e-02 | 7.09e-03 | 5.84e-01 |
| NADH OXIDATION | 6 | 3.68e-01 | 8.79e-01 | 0.61300 | 2.71e-01 | 3.12e-01 | 1.52e-01 | 4.21e-01 | 6.82e-02 | 2.50e-01 | 1.86e-01 | 5.19e-01 | 7.42e-02 | 7.72e-01 |
| CILIARY BASAL BODY ORGANIZATION | 5 | 7.03e-01 | 1.00e+00 | 0.61300 | 3.05e-01 | 2.77e-01 | 3.68e-01 | 2.61e-01 | 4.53e-02 | 2.37e-01 | 2.83e-01 | 1.54e-01 | 3.12e-01 | 8.61e-01 |
| NEGATIVE REGULATION OF CALCIUM ION DEPENDENT EXOCYTOSIS | 8 | 1.44e-01 | 6.29e-01 | 0.61300 | 3.27e-01 | 2.81e-01 | 4.27e-01 | 6.50e-02 | 4.98e-02 | 1.09e-01 | 1.68e-01 | 3.64e-02 | 7.50e-01 | 8.07e-01 |
| 10 FORMYLTETRAHYDROFOLATE METABOLIC PROCESS | 6 | 7.12e-01 | 1.00e+00 | 0.61300 | -3.07e-01 | -2.52e-01 | -3.06e-01 | -3.14e-01 | -1.60e-01 | 1.93e-01 | 2.85e-01 | 1.94e-01 | 1.84e-01 | 4.98e-01 |
| POSITIVE REGULATION OF T CELL CYTOKINE PRODUCTION | 25 | 8.38e-04 | 1.96e-02 | 0.61300 | -2.78e-01 | -3.42e-01 | -1.58e-02 | -3.61e-01 | 2.25e-01 | 1.62e-02 | 3.07e-03 | 8.91e-01 | 1.77e-03 | 5.20e-02 |
| FATTY ACID OMEGA OXIDATION | 5 | 2.52e-01 | 7.78e-01 | 0.61100 | -1.50e-01 | -8.73e-02 | -2.56e-01 | -2.76e-01 | -4.49e-01 | 5.62e-01 | 7.35e-01 | 3.22e-01 | 2.85e-01 | 8.20e-02 |
| NEGATIVE REGULATION OF EPINEPHRINE SECRETION | 5 | 5.17e-01 | 9.52e-01 | 0.61000 | 3.20e-01 | 2.89e-01 | 2.27e-01 | 2.24e-01 | -2.91e-01 | 2.15e-01 | 2.62e-01 | 3.79e-01 | 3.86e-01 | 2.60e-01 |
| POSITIVE REGULATION OF METALLOENDOPEPTIDASE ACTIVITY | 7 | 5.80e-04 | 1.46e-02 | 0.61000 | 1.52e-01 | 1.57e-01 | -2.13e-01 | 1.77e-01 | -4.98e-01 | 4.87e-01 | 4.73e-01 | 3.29e-01 | 4.17e-01 | 2.25e-02 |
| POSITIVE REGULATION OF B CELL DIFFERENTIATION | 14 | 2.21e-03 | 4.18e-02 | 0.61000 | -1.45e-01 | -2.59e-01 | 1.79e-01 | -2.74e-01 | 4.21e-01 | 3.46e-01 | 9.39e-02 | 2.46e-01 | 7.54e-02 | 6.44e-03 |
| GABAERGIC NEURON DIFFERENTIATION | 19 | 3.22e-03 | 5.54e-02 | 0.61000 | 2.97e-01 | 2.86e-01 | 3.63e-01 | 1.68e-01 | -2.04e-01 | 2.50e-02 | 3.08e-02 | 6.13e-03 | 2.06e-01 | 1.23e-01 |
| GLUTATHIONE TRANSMEMBRANE TRANSPORT | 7 | 5.06e-01 | 9.48e-01 | 0.60900 | -3.45e-01 | -2.98e-01 | -3.00e-01 | -2.58e-01 | 8.34e-02 | 1.14e-01 | 1.73e-01 | 1.69e-01 | 2.36e-01 | 7.02e-01 |
| RENAL WATER ABSORPTION | 6 | 6.20e-01 | 9.90e-01 | 0.60900 | 2.94e-01 | 3.27e-01 | 1.89e-01 | 3.35e-01 | 1.72e-01 | 2.12e-01 | 1.65e-01 | 4.22e-01 | 1.55e-01 | 4.66e-01 |
| SNRNA CATABOLIC PROCESS | 5 | 6.95e-01 | 1.00e+00 | 0.60900 | -2.82e-01 | -3.15e-01 | -9.13e-02 | -3.10e-01 | 2.97e-01 | 2.75e-01 | 2.22e-01 | 7.24e-01 | 2.30e-01 | 2.51e-01 |
| CORNIFICATION | 9 | 3.28e-02 | 2.87e-01 | 0.60900 | 2.29e-01 | 2.73e-01 | -1.47e-02 | 4.72e-01 | 1.43e-01 | 2.34e-01 | 1.56e-01 | 9.39e-01 | 1.42e-02 | 4.59e-01 |
| SMOOTH MUSCLE CELL CHEMOTAXIS | 9 | 1.84e-01 | 6.93e-01 | 0.60800 | -2.50e-01 | -3.25e-01 | -6.61e-02 | -2.25e-01 | 3.84e-01 | 1.94e-01 | 9.10e-02 | 7.31e-01 | 2.43e-01 | 4.63e-02 |
| POLYAMINE BIOSYNTHETIC PROCESS | 12 | 3.32e-01 | 8.57e-01 | 0.60800 | 3.07e-01 | 2.58e-01 | 3.80e-01 | 1.90e-01 | 1.69e-01 | 6.53e-02 | 1.22e-01 | 2.28e-02 | 2.55e-01 | 3.10e-01 |
| NEGATIVE REGULATION OF INCLUSION BODY ASSEMBLY | 12 | 1.47e-01 | 6.32e-01 | 0.60800 | 2.36e-01 | 2.22e-01 | 2.20e-01 | 2.68e-01 | 3.80e-01 | 1.57e-01 | 1.83e-01 | 1.87e-01 | 1.08e-01 | 2.26e-02 |
| POSITIVE REGULATION OF INTERLEUKIN 18 PRODUCTION | 8 | 6.50e-01 | 1.00e+00 | 0.60700 | -3.35e-01 | -3.45e-01 | -2.58e-01 | -2.57e-01 | 7.13e-02 | 1.01e-01 | 9.09e-02 | 2.06e-01 | 2.09e-01 | 7.27e-01 |
| NK T CELL PROLIFERATION | 8 | 6.45e-01 | 1.00e+00 | 0.60700 | -2.89e-01 | -2.56e-01 | -2.87e-01 | -2.99e-01 | -2.20e-01 | 1.57e-01 | 2.10e-01 | 1.60e-01 | 1.43e-01 | 2.81e-01 |
| THROMBOPOIETIN MEDIATED SIGNALING PATHWAY | 5 | 4.10e-01 | 9.08e-01 | 0.60700 | 2.78e-01 | 2.02e-01 | 3.31e-01 | 3.47e-01 | 1.43e-01 | 2.81e-01 | 4.35e-01 | 2.00e-01 | 1.78e-01 | 5.79e-01 |
| MANCHETTE ASSEMBLY | 6 | 5.83e-01 | 9.85e-01 | 0.60700 | -3.17e-01 | -3.10e-01 | -1.50e-01 | -3.85e-01 | -2.09e-02 | 1.79e-01 | 1.88e-01 | 5.23e-01 | 1.02e-01 | 9.29e-01 |
| PYRIMIDINE NUCLEOSIDE CATABOLIC PROCESS | 16 | 5.57e-02 | 3.84e-01 | 0.60600 | -3.29e-01 | -2.74e-01 | -2.53e-01 | -3.29e-01 | 1.08e-01 | 2.28e-02 | 5.74e-02 | 7.94e-02 | 2.26e-02 | 4.55e-01 |
| OMEGA HYDROXYLASE P450 PATHWAY | 11 | 7.47e-02 | 4.49e-01 | 0.60600 | -3.27e-01 | -3.90e-01 | -2.68e-01 | -1.89e-01 | -8.94e-04 | 6.01e-02 | 2.52e-02 | 1.24e-01 | 2.77e-01 | 9.96e-01 |
| RESPONSE TO PHORBOL 13 ACETATE 12 MYRISTATE | 10 | 2.55e-03 | 4.65e-02 | 0.60500 | 2.84e-01 | 1.30e-01 | 3.53e-01 | 3.22e-01 | 2.01e-01 | 1.20e-01 | 4.75e-01 | 5.34e-02 | 7.77e-02 | 2.70e-01 |
| POSITIVE REGULATION OF SYNAPTIC PLASTICITY | 10 | 4.84e-01 | 9.43e-01 | 0.60500 | 3.15e-01 | 3.15e-01 | 2.97e-01 | 2.57e-01 | -1.13e-01 | 8.42e-02 | 8.42e-02 | 1.04e-01 | 1.59e-01 | 5.34e-01 |
| HIGH DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 17 | 1.76e-01 | 6.81e-01 | 0.60500 | 3.25e-01 | 3.58e-01 | 2.04e-01 | 2.97e-01 | -4.73e-02 | 2.04e-02 | 1.05e-02 | 1.45e-01 | 3.39e-02 | 7.36e-01 |
| POSITIVE REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS | 6 | 4.99e-01 | 9.47e-01 | 0.60500 | 2.62e-01 | 2.11e-01 | 4.34e-01 | 1.01e-01 | 2.32e-01 | 2.67e-01 | 3.71e-01 | 6.53e-02 | 6.69e-01 | 3.24e-01 |
| RETINA LAYER FORMATION | 23 | 1.55e-01 | 6.52e-01 | 0.60500 | -3.18e-01 | -3.06e-01 | -2.56e-01 | -3.12e-01 | -8.77e-02 | 8.22e-03 | 1.11e-02 | 3.38e-02 | 9.57e-03 | 4.67e-01 |
| CRANIAL GANGLION DEVELOPMENT | 5 | 7.23e-01 | 1.00e+00 | 0.60400 | -2.90e-01 | -3.09e-01 | -1.52e-01 | -3.93e-01 | 9.16e-02 | 2.62e-01 | 2.31e-01 | 5.56e-01 | 1.28e-01 | 7.23e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 13 PRODUCTION | 14 | 2.57e-02 | 2.42e-01 | 0.60400 | -2.04e-01 | -2.76e-01 | -3.67e-02 | -1.83e-01 | 4.61e-01 | 1.86e-01 | 7.41e-02 | 8.12e-01 | 2.36e-01 | 2.79e-03 |
| NEGATIVE REGULATION OF MAST CELL DEGRANULATION | 5 | 3.43e-01 | 8.61e-01 | 0.60400 | -2.73e-01 | -3.45e-01 | -1.16e-02 | -4.12e-01 | -3.14e-02 | 2.90e-01 | 1.81e-01 | 9.64e-01 | 1.10e-01 | 9.03e-01 |
| PROTEIN K27 LINKED UBIQUITINATION | 7 | 3.09e-01 | 8.35e-01 | 0.60400 | 2.88e-01 | 2.70e-01 | 2.54e-01 | 1.54e-01 | -3.48e-01 | 1.86e-01 | 2.17e-01 | 2.45e-01 | 4.82e-01 | 1.11e-01 |
| DIAPHRAGM DEVELOPMENT | 8 | 7.08e-01 | 1.00e+00 | 0.60400 | 3.20e-01 | 3.10e-01 | 2.44e-01 | 3.16e-01 | -8.53e-02 | 1.17e-01 | 1.29e-01 | 2.32e-01 | 1.21e-01 | 6.76e-01 |
| IRON ION IMPORT ACROSS PLASMA MEMBRANE | 5 | 1.87e-01 | 6.95e-01 | 0.60400 | -1.51e-01 | -2.08e-01 | -1.59e-01 | -1.94e-01 | -4.86e-01 | 5.60e-01 | 4.21e-01 | 5.37e-01 | 4.54e-01 | 5.99e-02 |
| NEGATIVE REGULATION OF MACROPHAGE CHEMOTAXIS | 7 | 7.43e-01 | 1.00e+00 | 0.60400 | -3.20e-01 | -3.36e-01 | -2.00e-01 | -3.09e-01 | 1.17e-01 | 1.42e-01 | 1.24e-01 | 3.59e-01 | 1.57e-01 | 5.93e-01 |
| REGULATION OF MELANOCYTE DIFFERENTIATION | 6 | 8.23e-01 | 1.00e+00 | 0.60400 | -3.11e-01 | -3.18e-01 | -2.19e-01 | -3.44e-01 | -3.30e-02 | 1.88e-01 | 1.77e-01 | 3.54e-01 | 1.45e-01 | 8.89e-01 |
| B CELL HOMEOSTASIS | 31 | 6.59e-03 | 9.29e-02 | 0.60400 | -2.96e-01 | -3.26e-01 | -1.82e-01 | -3.49e-01 | -1.23e-01 | 4.27e-03 | 1.68e-03 | 7.88e-02 | 7.79e-04 | 2.34e-01 |
| DNA CYTOSINE DEAMINATION | 9 | 1.73e-01 | 6.77e-01 | 0.60300 | -2.98e-01 | -2.69e-01 | -1.27e-01 | -3.61e-01 | 2.37e-01 | 1.21e-01 | 1.63e-01 | 5.08e-01 | 6.08e-02 | 2.17e-01 |
| NEUROTRANSMITTER RECEPTOR TRANSPORT POSTSYNAPTIC ENDOSOME TO LYSOSOME | 7 | 2.37e-01 | 7.60e-01 | 0.60300 | 3.17e-01 | 3.55e-01 | 3.47e-01 | 1.14e-01 | 6.46e-02 | 1.46e-01 | 1.04e-01 | 1.12e-01 | 6.00e-01 | 7.67e-01 |
| XYLULOSE 5 PHOSPHATE METABOLIC PROCESS | 6 | 7.75e-01 | 1.00e+00 | 0.60300 | 2.99e-01 | 2.73e-01 | 3.55e-01 | 2.38e-01 | 1.32e-01 | 2.05e-01 | 2.47e-01 | 1.32e-01 | 3.12e-01 | 5.75e-01 |
| POSITIVE REGULATION OF MIRNA PROCESSING | 5 | 3.48e-01 | 8.67e-01 | 0.60300 | -2.44e-01 | -2.64e-01 | -9.41e-02 | -3.47e-01 | -3.24e-01 | 3.46e-01 | 3.07e-01 | 7.16e-01 | 1.79e-01 | 2.10e-01 |
| NEGATIVE REGULATION OF EXECUTION PHASE OF APOPTOSIS | 9 | 3.49e-01 | 8.69e-01 | 0.60300 | -3.36e-01 | -3.22e-01 | -3.47e-01 | -1.56e-01 | 4.59e-02 | 8.12e-02 | 9.47e-02 | 7.14e-02 | 4.18e-01 | 8.12e-01 |
| DNA UNWINDING INVOLVED IN DNA REPLICATION | 21 | 1.38e-02 | 1.57e-01 | 0.60300 | 2.53e-01 | 2.19e-01 | 3.90e-01 | 9.31e-02 | 3.01e-01 | 4.51e-02 | 8.25e-02 | 1.96e-03 | 4.60e-01 | 1.71e-02 |
| POSITIVE REGULATION OF EXTRACELLULAR MATRIX DISASSEMBLY | 8 | 1.56e-01 | 6.53e-01 | 0.60200 | 2.25e-01 | 2.49e-01 | 1.24e-01 | 2.61e-01 | -4.09e-01 | 2.71e-01 | 2.23e-01 | 5.42e-01 | 2.01e-01 | 4.53e-02 |
| MUCOSA ASSOCIATED LYMPHOID TISSUE DEVELOPMENT | 8 | 5.68e-01 | 9.73e-01 | 0.60200 | 3.03e-01 | 2.90e-01 | 2.69e-01 | 3.38e-01 | -1.31e-02 | 1.38e-01 | 1.55e-01 | 1.88e-01 | 9.77e-02 | 9.49e-01 |
| CORONARY ARTERY MORPHOGENESIS | 9 | 1.18e-01 | 5.71e-01 | 0.60200 | -2.22e-01 | -2.34e-01 | -9.28e-03 | -3.62e-01 | 3.57e-01 | 2.49e-01 | 2.25e-01 | 9.62e-01 | 6.02e-02 | 6.35e-02 |
| CD4 POSITIVE ALPHA BETA T CELL PROLIFERATION | 20 | 1.01e-01 | 5.25e-01 | 0.60200 | -3.08e-01 | -3.23e-01 | -1.63e-01 | -3.10e-01 | 2.02e-01 | 1.73e-02 | 1.24e-02 | 2.07e-01 | 1.65e-02 | 1.18e-01 |
| CARBON DIOXIDE TRANSPORT | 15 | 2.26e-02 | 2.25e-01 | 0.60100 | 1.83e-01 | 2.48e-01 | -2.47e-02 | 2.30e-01 | -4.61e-01 | 2.19e-01 | 9.66e-02 | 8.69e-01 | 1.23e-01 | 1.98e-03 |
| CD4 POSITIVE CD25 POSITIVE ALPHA BETA REGULATORY T CELL DIFFERENTIATION | 8 | 2.26e-01 | 7.48e-01 | 0.60100 | -3.00e-01 | -3.62e-01 | -7.76e-02 | -3.66e-01 | -3.47e-03 | 1.42e-01 | 7.63e-02 | 7.04e-01 | 7.27e-02 | 9.86e-01 |
| NEGATIVE REGULATION OF PROTEIN K63 LINKED UBIQUITINATION | 5 | 2.56e-01 | 7.83e-01 | 0.60000 | -2.59e-01 | -2.09e-01 | -1.01e-01 | -3.66e-01 | 3.25e-01 | 3.16e-01 | 4.18e-01 | 6.94e-01 | 1.56e-01 | 2.09e-01 |
| AORTA SMOOTH MUSCLE TISSUE MORPHOGENESIS | 6 | 5.54e-04 | 1.40e-02 | 0.60000 | -2.51e-01 | -2.94e-01 | 1.93e-01 | -3.37e-01 | 2.45e-01 | 2.86e-01 | 2.13e-01 | 4.14e-01 | 1.53e-01 | 2.99e-01 |
| FORMATE METABOLIC PROCESS | 6 | 5.09e-01 | 9.49e-01 | 0.60000 | -2.98e-01 | -2.64e-01 | -2.57e-01 | -3.40e-01 | 1.39e-01 | 2.06e-01 | 2.62e-01 | 2.76e-01 | 1.49e-01 | 5.55e-01 |
| NEGATIVE REGULATION OF CHEMOKINE MEDIATED SIGNALING PATHWAY | 6 | 4.28e-01 | 9.17e-01 | 0.59900 | -2.92e-01 | -3.72e-01 | -1.08e-01 | -2.53e-01 | 2.46e-01 | 2.16e-01 | 1.15e-01 | 6.48e-01 | 2.83e-01 | 2.98e-01 |
| ENDONUCLEOLYTIC CLEAVAGE IN 5 ETS OF TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 8 | 1.90e-01 | 6.99e-01 | 0.59900 | 2.40e-01 | 1.95e-01 | 4.26e-01 | 1.34e-02 | 2.85e-01 | 2.39e-01 | 3.39e-01 | 3.70e-02 | 9.48e-01 | 1.63e-01 |
| PROPIONATE METABOLIC PROCESS | 5 | 3.61e-01 | 8.77e-01 | 0.59800 | 2.63e-01 | 2.75e-01 | 3.72e-01 | 2.23e-01 | 1.59e-01 | 3.08e-01 | 2.87e-01 | 1.50e-01 | 3.88e-01 | 5.38e-01 |
| REGULATION OF L GLUTAMATE IMPORT ACROSS PLASMA MEMBRANE | 8 | 4.90e-01 | 9.45e-01 | 0.59800 | 2.85e-01 | 3.30e-01 | 1.41e-01 | 3.43e-01 | -1.73e-01 | 1.62e-01 | 1.07e-01 | 4.91e-01 | 9.28e-02 | 3.96e-01 |
| RESPONSE TO MUSCLE INACTIVITY | 9 | 4.83e-01 | 9.43e-01 | 0.59800 | 3.10e-01 | 3.56e-01 | 2.16e-01 | 2.65e-01 | -1.33e-01 | 1.07e-01 | 6.46e-02 | 2.61e-01 | 1.68e-01 | 4.89e-01 |
| POSITIVE REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 7 | 4.78e-01 | 9.40e-01 | 0.59800 | -2.90e-01 | -2.24e-01 | -2.78e-01 | -3.42e-01 | -1.71e-01 | 1.84e-01 | 3.06e-01 | 2.03e-01 | 1.17e-01 | 4.35e-01 |
| BOX C D SNORNP ASSEMBLY | 10 | 2.68e-01 | 7.95e-01 | 0.59800 | 2.91e-01 | 2.80e-01 | 3.80e-01 | 2.09e-01 | 8.05e-02 | 1.11e-01 | 1.26e-01 | 3.74e-02 | 2.53e-01 | 6.59e-01 |
| RESPONSE TO INSECTICIDE | 6 | 5.73e-01 | 9.78e-01 | 0.59700 | 3.24e-01 | 3.12e-01 | 3.45e-01 | 1.43e-01 | -1.21e-01 | 1.69e-01 | 1.86e-01 | 1.43e-01 | 5.45e-01 | 6.07e-01 |
| REGULATION OF MYOFIBROBLAST DIFFERENTIATION | 9 | 5.56e-01 | 9.68e-01 | 0.59700 | 3.07e-01 | 3.13e-01 | 1.64e-01 | 3.40e-01 | -1.48e-01 | 1.11e-01 | 1.04e-01 | 3.95e-01 | 7.74e-02 | 4.42e-01 |
| REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CONTRACTION | 10 | 1.45e-01 | 6.29e-01 | 0.59600 | -2.68e-01 | -3.10e-01 | -2.96e-01 | -2.13e-01 | -2.33e-01 | 1.42e-01 | 8.92e-02 | 1.05e-01 | 2.43e-01 | 2.03e-01 |
| BLOOD COAGULATION FIBRIN CLOT FORMATION | 14 | 2.04e-01 | 7.24e-01 | 0.59600 | -3.03e-01 | -3.01e-01 | -2.00e-01 | -3.28e-01 | -1.60e-01 | 4.97e-02 | 5.15e-02 | 1.94e-01 | 3.34e-02 | 3.00e-01 |
| N ACETYLNEURAMINATE CATABOLIC PROCESS | 6 | 5.47e-01 | 9.61e-01 | 0.59600 | 2.90e-01 | 3.34e-01 | 1.10e-01 | 2.51e-01 | -2.92e-01 | 2.19e-01 | 1.57e-01 | 6.42e-01 | 2.87e-01 | 2.15e-01 |
| POSITIVE REGULATION OF INFLAMMASOME MEDIATED SIGNALING PATHWAY | 18 | 2.31e-01 | 7.53e-01 | 0.59600 | -3.12e-01 | -3.23e-01 | -1.85e-01 | -3.41e-01 | 5.25e-02 | 2.19e-02 | 1.78e-02 | 1.73e-01 | 1.22e-02 | 7.00e-01 |
| NEUTROPHIL DEGRANULATION | 13 | 1.10e-02 | 1.35e-01 | 0.59600 | -8.15e-03 | -9.32e-02 | 2.75e-01 | -1.14e-01 | 5.07e-01 | 9.59e-01 | 5.60e-01 | 8.56e-02 | 4.77e-01 | 1.54e-03 |
| CHAPERONE MEDIATED PROTEIN COMPLEX ASSEMBLY | 21 | 4.91e-03 | 7.58e-02 | 0.59600 | 2.20e-01 | 1.89e-01 | 3.16e-01 | 9.41e-02 | 4.02e-01 | 8.10e-02 | 1.34e-01 | 1.21e-02 | 4.55e-01 | 1.41e-03 |
| SEQUESTERING OF BMP IN EXTRACELLULAR MATRIX | 5 | 1.86e-02 | 1.97e-01 | 0.59600 | 2.10e-01 | 3.93e-01 | -1.59e-01 | 3.25e-01 | -1.59e-01 | 4.16e-01 | 1.28e-01 | 5.39e-01 | 2.09e-01 | 5.37e-01 |
| REGULATION OF PHOSPHOLIPASE A2 ACTIVITY | 9 | 3.25e-01 | 8.49e-01 | 0.59500 | 2.90e-01 | 3.16e-01 | 1.81e-01 | 1.94e-01 | -3.16e-01 | 1.32e-01 | 1.01e-01 | 3.48e-01 | 3.12e-01 | 1.01e-01 |
| REGULATION OF VENTRICULAR CARDIAC MUSCLE CELL MEMBRANE DEPOLARIZATION | 7 | 6.63e-01 | 1.00e+00 | 0.59500 | 2.80e-01 | 2.83e-01 | 2.17e-01 | 3.47e-01 | 1.66e-01 | 1.99e-01 | 1.94e-01 | 3.19e-01 | 1.11e-01 | 4.47e-01 |
| RNA IMPORT INTO MITOCHONDRION | 5 | 5.25e-01 | 9.54e-01 | 0.59500 | 1.20e-01 | 5.52e-02 | 2.74e-01 | 9.75e-02 | 5.02e-01 | 6.43e-01 | 8.31e-01 | 2.88e-01 | 7.06e-01 | 5.19e-02 |
| NEGATIVE REGULATION OF MACROPHAGE APOPTOTIC PROCESS | 7 | 5.87e-01 | 9.85e-01 | 0.59500 | -3.04e-01 | -2.91e-01 | -1.64e-01 | -3.58e-01 | 1.47e-01 | 1.63e-01 | 1.83e-01 | 4.52e-01 | 1.01e-01 | 5.01e-01 |
| RESPONSE TO PHEROMONE | 7 | 1.08e-01 | 5.46e-01 | 0.59400 | -2.33e-01 | -2.37e-01 | -3.76e-01 | 1.21e-02 | -3.17e-01 | 2.86e-01 | 2.77e-01 | 8.49e-02 | 9.56e-01 | 1.46e-01 |
| REGULATION OF NATURAL KILLER CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 10 | 5.38e-01 | 9.57e-01 | 0.59400 | -3.09e-01 | -3.09e-01 | -1.83e-01 | -3.58e-01 | 1.03e-02 | 9.10e-02 | 9.04e-02 | 3.17e-01 | 4.97e-02 | 9.55e-01 |
| ESTABLISHMENT OF SISTER CHROMATID COHESION | 9 | 5.34e-01 | 9.56e-01 | 0.59400 | -2.87e-01 | -3.02e-01 | -2.86e-01 | -2.55e-01 | -1.80e-01 | 1.37e-01 | 1.17e-01 | 1.37e-01 | 1.85e-01 | 3.51e-01 |
| CELL MIGRATION INVOLVED IN GASTRULATION | 13 | 3.26e-01 | 8.51e-01 | 0.59400 | 3.24e-01 | 3.22e-01 | 2.34e-01 | 2.55e-01 | -1.53e-01 | 4.29e-02 | 4.42e-02 | 1.44e-01 | 1.11e-01 | 3.40e-01 |
| CADMIUM ION TRANSMEMBRANE TRANSPORT | 6 | 6.58e-01 | 1.00e+00 | 0.59300 | 2.98e-01 | 3.10e-01 | 1.18e-01 | 3.40e-01 | -1.95e-01 | 2.06e-01 | 1.89e-01 | 6.17e-01 | 1.49e-01 | 4.09e-01 |
| POSITIVE REGULATION OF ISOTYPE SWITCHING TO IGA ISOTYPES | 6 | 3.45e-01 | 8.64e-01 | 0.59300 | -2.22e-01 | -2.22e-01 | -4.04e-02 | -3.24e-01 | 3.82e-01 | 3.47e-01 | 3.45e-01 | 8.64e-01 | 1.69e-01 | 1.05e-01 |
| BASE EXCISION REPAIR GAP FILLING | 14 | 5.73e-02 | 3.91e-01 | 0.59200 | 2.99e-01 | 2.20e-01 | 4.02e-01 | 1.33e-01 | 1.84e-01 | 5.26e-02 | 1.53e-01 | 9.22e-03 | 3.89e-01 | 2.34e-01 |
| PROTEIN K29 LINKED UBIQUITINATION | 7 | 1.14e-01 | 5.61e-01 | 0.59200 | 1.70e-01 | 1.58e-01 | 3.76e-02 | 9.13e-02 | -5.36e-01 | 4.36e-01 | 4.69e-01 | 8.63e-01 | 6.76e-01 | 1.41e-02 |
| POSITIVE REGULATION OF SKELETAL MUSCLE TISSUE REGENERATION | 5 | 1.15e-01 | 5.65e-01 | 0.59200 | 2.72e-01 | 3.31e-01 | -5.78e-02 | 4.04e-01 | 1.50e-02 | 2.92e-01 | 2.00e-01 | 8.23e-01 | 1.17e-01 | 9.54e-01 |
| REGULATION OF NUCLEAR CELL CYCLE DNA REPLICATION | 12 | 1.42e-01 | 6.27e-01 | 0.59200 | 2.98e-01 | 2.43e-01 | 4.18e-01 | 1.64e-01 | 2.49e-02 | 7.34e-02 | 1.45e-01 | 1.22e-02 | 3.25e-01 | 8.81e-01 |
| REGULATION OF OSTEOCLAST PROLIFERATION | 6 | 3.94e-01 | 8.93e-01 | 0.59200 | -2.10e-01 | -2.76e-01 | -4.75e-02 | -1.62e-01 | 4.49e-01 | 3.72e-01 | 2.42e-01 | 8.40e-01 | 4.91e-01 | 5.70e-02 |
| REGULATION OF LEUKOCYTE TETHERING OR ROLLING | 18 | 2.13e-02 | 2.17e-01 | 0.59200 | -3.26e-01 | -3.59e-01 | -1.95e-01 | -2.15e-01 | 1.74e-01 | 1.66e-02 | 8.27e-03 | 1.51e-01 | 1.14e-01 | 2.02e-01 |
| CALCIUM ACTIVATED PHOSPHOLIPID SCRAMBLING | 5 | 3.15e-01 | 8.42e-01 | 0.59200 | 1.48e-01 | 2.31e-01 | -1.66e-01 | 3.29e-01 | -3.73e-01 | 5.66e-01 | 3.70e-01 | 5.20e-01 | 2.03e-01 | 1.49e-01 |
| MATURATION OF SSU RRNA FROM TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 34 | 1.11e-04 | 3.77e-03 | 0.59100 | 2.50e-01 | 2.22e-01 | 3.77e-01 | 7.07e-02 | 3.01e-01 | 1.18e-02 | 2.49e-02 | 1.41e-04 | 4.76e-01 | 2.37e-03 |
| CORPUS CALLOSUM MORPHOGENESIS | 6 | 6.76e-01 | 1.00e+00 | 0.59100 | 2.79e-01 | 2.99e-01 | 1.80e-01 | 3.45e-01 | 1.75e-01 | 2.37e-01 | 2.04e-01 | 4.44e-01 | 1.43e-01 | 4.59e-01 |
| CELLULAR RESPONSE TO GAMMA RADIATION | 26 | 8.29e-02 | 4.74e-01 | 0.59100 | 3.12e-01 | 3.36e-01 | 1.97e-01 | 3.00e-01 | -1.00e-01 | 5.82e-03 | 3.01e-03 | 8.22e-02 | 8.07e-03 | 3.75e-01 |
| NATURAL KILLER CELL ACTIVATION | 93 | 1.57e-07 | 1.29e-05 | 0.59100 | -2.99e-01 | -3.26e-01 | -1.50e-01 | -3.48e-01 | 1.01e-01 | 6.46e-07 | 5.30e-08 | 1.23e-02 | 6.62e-09 | 9.29e-02 |
| POSITIVE REGULATION OF TOLERANCE INDUCTION | 11 | 5.20e-01 | 9.53e-01 | 0.59100 | -3.14e-01 | -3.13e-01 | -1.98e-01 | -3.20e-01 | 1.02e-01 | 7.11e-02 | 7.20e-02 | 2.55e-01 | 6.57e-02 | 5.59e-01 |
| EOSINOPHIL DIFFERENTIATION | 6 | 3.32e-01 | 8.56e-01 | 0.59000 | -3.05e-01 | -3.95e-01 | -1.36e-01 | -2.79e-01 | 5.28e-02 | 1.96e-01 | 9.38e-02 | 5.64e-01 | 2.36e-01 | 8.23e-01 |
| REGULATION OF SKELETAL MUSCLE CONTRACTION BY CALCIUM ION SIGNALING | 6 | 2.04e-01 | 7.24e-01 | 0.59000 | 1.64e-01 | 2.07e-01 | 1.72e-01 | 1.90e-01 | 4.61e-01 | 4.86e-01 | 3.80e-01 | 4.66e-01 | 4.21e-01 | 5.03e-02 |
| CALCIUM ION IMPORT INTO SARCOPLASMIC RETICULUM | 5 | 1.04e-01 | 5.36e-01 | 0.59000 | -3.08e-01 | -1.54e-01 | -3.62e-01 | -2.95e-01 | -1.04e-01 | 2.33e-01 | 5.50e-01 | 1.61e-01 | 2.54e-01 | 6.86e-01 |
| NEGATIVE REGULATION OF COMPLEMENT ACTIVATION | 12 | 4.17e-01 | 9.11e-01 | 0.59000 | -3.06e-01 | -2.59e-01 | -3.60e-01 | -2.24e-01 | -8.27e-02 | 6.63e-02 | 1.20e-01 | 3.10e-02 | 1.78e-01 | 6.20e-01 |
| POSITIVE REGULATION OF RECEPTOR CLUSTERING | 6 | 5.32e-01 | 9.54e-01 | 0.58900 | -2.62e-01 | -2.63e-01 | -9.48e-02 | -3.14e-01 | 3.19e-01 | 2.66e-01 | 2.64e-01 | 6.88e-01 | 1.83e-01 | 1.75e-01 |
| PROTEIN INSERTION INTO MITOCHONDRIAL INNER MEMBRANE | 12 | 2.34e-01 | 7.56e-01 | 0.58900 | 3.33e-01 | 2.93e-01 | 3.27e-01 | 2.03e-01 | 4.68e-02 | 4.59e-02 | 7.84e-02 | 4.99e-02 | 2.23e-01 | 7.79e-01 |
| OSTEOBLAST DEVELOPMENT | 17 | 2.09e-01 | 7.30e-01 | 0.58900 | 3.20e-01 | 2.78e-01 | 3.43e-01 | 2.23e-01 | 4.44e-03 | 2.24e-02 | 4.73e-02 | 1.43e-02 | 1.12e-01 | 9.75e-01 |
| NEGATIVE REGULATION OF HYPOXIA INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 6 | 4.57e-01 | 9.32e-01 | 0.58900 | 2.75e-01 | 2.36e-01 | 3.87e-01 | 7.56e-02 | 2.45e-01 | 2.43e-01 | 3.17e-01 | 1.01e-01 | 7.48e-01 | 2.98e-01 |
| HEPOXILIN METABOLIC PROCESS | 9 | 2.53e-01 | 7.80e-01 | 0.58800 | 2.29e-01 | 2.52e-01 | 6.24e-02 | 2.85e-01 | -3.81e-01 | 2.35e-01 | 1.91e-01 | 7.46e-01 | 1.38e-01 | 4.76e-02 |
| TERPENOID CATABOLIC PROCESS | 8 | 2.78e-01 | 8.05e-01 | 0.58800 | 2.51e-01 | 2.96e-01 | 6.82e-02 | 2.00e-01 | -3.88e-01 | 2.19e-01 | 1.47e-01 | 7.38e-01 | 3.28e-01 | 5.71e-02 |
| GENERAL ADAPTATION SYNDROME | 6 | 4.84e-01 | 9.43e-01 | 0.58800 | -2.93e-01 | -2.91e-01 | -8.63e-02 | -4.05e-01 | 5.74e-02 | 2.15e-01 | 2.16e-01 | 7.14e-01 | 8.55e-02 | 8.08e-01 |
| POSITIVE REGULATION OF NITRIC OXIDE MEDIATED SIGNAL TRANSDUCTION | 5 | 3.28e-01 | 8.53e-01 | 0.58800 | 2.39e-01 | 3.04e-01 | 5.99e-02 | 4.37e-01 | -2.56e-02 | 3.54e-01 | 2.39e-01 | 8.16e-01 | 9.03e-02 | 9.21e-01 |
| CHOLINE METABOLIC PROCESS | 6 | 1.64e-01 | 6.64e-01 | 0.58800 | -1.43e-01 | -1.47e-02 | -3.75e-01 | 7.78e-03 | -4.29e-01 | 5.43e-01 | 9.50e-01 | 1.11e-01 | 9.74e-01 | 6.91e-02 |
| RESPONSE TO ZINC ION STARVATION | 9 | 2.98e-01 | 8.24e-01 | 0.58700 | 2.16e-01 | 1.57e-01 | 2.99e-01 | 2.50e-01 | 3.49e-01 | 2.62e-01 | 4.13e-01 | 1.20e-01 | 1.95e-01 | 6.97e-02 |
| RESPONSE TO FRUCTOSE | 8 | 5.92e-01 | 9.86e-01 | 0.58600 | 2.74e-01 | 2.56e-01 | 3.56e-01 | 1.90e-01 | 2.01e-01 | 1.80e-01 | 2.10e-01 | 8.12e-02 | 3.53e-01 | 3.25e-01 |
| ATRIAL CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 9 | 5.45e-01 | 9.61e-01 | 0.58600 | 2.79e-01 | 2.61e-01 | 3.08e-01 | 2.84e-01 | 1.50e-01 | 1.47e-01 | 1.75e-01 | 1.10e-01 | 1.41e-01 | 4.37e-01 |
| PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 21 | 1.24e-01 | 5.88e-01 | 0.58600 | -3.15e-01 | -3.42e-01 | -2.61e-01 | -2.37e-01 | 5.48e-02 | 1.24e-02 | 6.71e-03 | 3.84e-02 | 5.97e-02 | 6.64e-01 |
| MODULATION OF MICROTUBULE CYTOSKELETON INVOLVED IN CEREBRAL CORTEX RADIAL GLIA GUIDED MIGRATION | 5 | 6.88e-01 | 1.00e+00 | 0.58600 | -3.08e-01 | -2.59e-01 | -3.79e-01 | -1.82e-01 | 6.30e-02 | 2.33e-01 | 3.16e-01 | 1.42e-01 | 4.80e-01 | 8.07e-01 |
| MAST CELL CYTOKINE PRODUCTION | 6 | 3.57e-01 | 8.74e-01 | 0.58500 | -2.33e-01 | -3.21e-01 | 2.02e-02 | -3.46e-01 | 2.55e-01 | 3.24e-01 | 1.73e-01 | 9.32e-01 | 1.42e-01 | 2.79e-01 |
| POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO TELOMERE | 9 | 4.74e-01 | 9.40e-01 | 0.58500 | -2.96e-01 | -3.15e-01 | -1.15e-01 | -3.60e-01 | 1.13e-01 | 1.24e-01 | 1.02e-01 | 5.49e-01 | 6.17e-02 | 5.56e-01 |
| REGULATION OF NOREPINEPHRINE SECRETION | 13 | 1.41e-01 | 6.26e-01 | 0.58500 | 3.09e-01 | 2.66e-01 | 3.13e-01 | 2.09e-01 | -1.86e-01 | 5.40e-02 | 9.73e-02 | 5.08e-02 | 1.91e-01 | 2.45e-01 |
| FOLIC ACID CONTAINING COMPOUND METABOLIC PROCESS | 26 | 5.41e-02 | 3.80e-01 | 0.58500 | -3.00e-01 | -2.83e-01 | -2.13e-01 | -3.55e-01 | 1.99e-02 | 8.02e-03 | 1.26e-02 | 5.96e-02 | 1.72e-03 | 8.61e-01 |
| PROTEIN LOCALIZATION TO PHOTORECEPTOR OUTER SEGMENT | 7 | 6.81e-01 | 1.00e+00 | 0.58500 | 3.22e-01 | 3.01e-01 | 2.18e-01 | 3.12e-01 | -5.22e-02 | 1.40e-01 | 1.67e-01 | 3.19e-01 | 1.53e-01 | 8.11e-01 |
| DORSAL ROOT GANGLION DEVELOPMENT | 7 | 5.23e-01 | 9.53e-01 | 0.58500 | -2.20e-01 | -2.07e-01 | -2.48e-01 | -2.64e-01 | -3.46e-01 | 3.13e-01 | 3.42e-01 | 2.57e-01 | 2.27e-01 | 1.13e-01 |
| REGULATION OF MEMBRANE TUBULATION | 5 | 6.18e-01 | 9.90e-01 | 0.58500 | -2.70e-01 | -3.11e-01 | -1.75e-01 | -3.19e-01 | 1.99e-01 | 2.95e-01 | 2.29e-01 | 4.98e-01 | 2.17e-01 | 4.41e-01 |
| RESPONSE TO SYMBIONT | 6 | 1.45e-01 | 6.29e-01 | 0.58400 | -1.89e-01 | -5.21e-02 | -4.08e-01 | -3.01e-02 | -3.69e-01 | 4.23e-01 | 8.25e-01 | 8.38e-02 | 8.98e-01 | 1.18e-01 |
| REGULATION OF PHOSPHOLIPID CATABOLIC PROCESS | 7 | 6.92e-01 | 1.00e+00 | 0.58400 | 2.91e-01 | 2.50e-01 | 3.75e-01 | 1.81e-01 | 1.42e-01 | 1.83e-01 | 2.51e-01 | 8.54e-02 | 4.07e-01 | 5.16e-01 |
| METANEPHRIC TUBULE FORMATION | 6 | 6.15e-01 | 9.90e-01 | 0.58400 | 2.98e-01 | 2.89e-01 | 3.53e-01 | 1.99e-01 | -6.58e-02 | 2.06e-01 | 2.20e-01 | 1.34e-01 | 4.00e-01 | 7.80e-01 |
| REGULATION OF ENDOSOME ORGANIZATION | 5 | 8.18e-01 | 1.00e+00 | 0.58400 | -2.89e-01 | -3.08e-01 | -1.83e-01 | -2.81e-01 | 2.23e-01 | 2.63e-01 | 2.32e-01 | 4.78e-01 | 2.76e-01 | 3.88e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO TELOMERE | 17 | 2.63e-01 | 7.90e-01 | 0.58400 | -3.05e-01 | -3.13e-01 | -1.77e-01 | -3.43e-01 | 3.43e-02 | 2.96e-02 | 2.57e-02 | 2.07e-01 | 1.42e-02 | 8.07e-01 |
| T CELL ACTIVATION VIA T CELL RECEPTOR CONTACT WITH ANTIGEN BOUND TO MHC MOLECULE ON ANTIGEN PRESENTING CELL | 10 | 5.77e-02 | 3.93e-01 | 0.58300 | -2.48e-01 | -3.51e-01 | 1.69e-02 | -2.90e-01 | 2.67e-01 | 1.74e-01 | 5.47e-02 | 9.26e-01 | 1.13e-01 | 1.44e-01 |
| REGULATION OF MEGAKARYOCYTE DIFFERENTIATION | 35 | 1.04e-02 | 1.29e-01 | 0.58300 | 3.10e-01 | 2.62e-01 | 3.23e-01 | 2.66e-01 | 8.62e-03 | 1.49e-03 | 7.20e-03 | 9.43e-04 | 6.44e-03 | 9.30e-01 |
| ALDEHYDE BIOSYNTHETIC PROCESS | 16 | 3.21e-01 | 8.47e-01 | 0.58300 | 2.91e-01 | 2.93e-01 | 2.74e-01 | 2.94e-01 | 8.88e-02 | 4.36e-02 | 4.27e-02 | 5.81e-02 | 4.15e-02 | 5.39e-01 |
| NEGATIVE REGULATION OF T HELPER 1 TYPE IMMUNE RESPONSE | 8 | 6.66e-01 | 1.00e+00 | 0.58200 | -3.08e-01 | -3.30e-01 | -2.70e-01 | -2.34e-01 | 7.83e-02 | 1.31e-01 | 1.06e-01 | 1.86e-01 | 2.51e-01 | 7.01e-01 |
| MITOCHONDRIAL ELECTRON TRANSPORT SUCCINATE TO UBIQUINONE | 5 | 2.91e-01 | 8.18e-01 | 0.58100 | 2.51e-01 | 2.11e-01 | 3.51e-01 | 2.72e-02 | 3.26e-01 | 3.30e-01 | 4.15e-01 | 1.74e-01 | 9.16e-01 | 2.06e-01 |
| REGULATION OF RESPIRATORY GASEOUS EXCHANGE BY NERVOUS SYSTEM PROCESS | 10 | 1.22e-01 | 5.83e-01 | 0.58100 | 2.71e-01 | 2.81e-01 | 2.61e-01 | 9.34e-02 | -3.29e-01 | 1.37e-01 | 1.25e-01 | 1.52e-01 | 6.09e-01 | 7.15e-02 |
| PHOSPHATIDYLSERINE EXPOSURE ON APOPTOTIC CELL SURFACE | 8 | 2.88e-01 | 8.15e-01 | 0.58100 | -1.96e-01 | -1.48e-01 | -2.63e-01 | -1.38e-01 | -4.35e-01 | 3.37e-01 | 4.68e-01 | 1.98e-01 | 5.00e-01 | 3.31e-02 |
| NEGATIVE REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 9 | 6.95e-01 | 1.00e+00 | 0.58100 | -3.06e-01 | -2.80e-01 | -2.99e-01 | -2.47e-01 | -1.24e-01 | 1.12e-01 | 1.46e-01 | 1.21e-01 | 2.00e-01 | 5.20e-01 |
| NEGATIVE REGULATION OF T CELL MEDIATED CYTOTOXICITY | 10 | 2.77e-02 | 2.56e-01 | 0.58000 | -2.98e-01 | -3.85e-01 | -1.80e-01 | -2.28e-01 | -1.24e-01 | 1.02e-01 | 3.50e-02 | 3.25e-01 | 2.12e-01 | 4.99e-01 |
| REGULATION OF PRE MIRNA PROCESSING | 6 | 1.62e-02 | 1.79e-01 | 0.58000 | -2.60e-01 | -1.47e-01 | -1.67e-01 | -3.23e-01 | -3.40e-01 | 2.70e-01 | 5.34e-01 | 4.79e-01 | 1.71e-01 | 1.49e-01 |
| PYRIMIDINE NUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 9 | 6.11e-01 | 9.90e-01 | 0.57900 | 3.11e-01 | 2.65e-01 | 2.93e-01 | 2.79e-01 | 7.12e-02 | 1.06e-01 | 1.69e-01 | 1.28e-01 | 1.47e-01 | 7.12e-01 |
| NEGATIVE REGULATION OF PEPTIDYL CYSTEINE S NITROSYLATION | 7 | 3.02e-01 | 8.30e-01 | 0.57900 | 2.23e-01 | 1.85e-01 | 2.93e-01 | 1.04e-01 | 3.93e-01 | 3.06e-01 | 3.96e-01 | 1.80e-01 | 6.35e-01 | 7.17e-02 |
| DESMOSOME ORGANIZATION | 10 | 2.43e-02 | 2.34e-01 | 0.57900 | 2.50e-01 | 3.63e-01 | -3.66e-02 | 3.48e-01 | -1.36e-01 | 1.71e-01 | 4.69e-02 | 8.41e-01 | 5.68e-02 | 4.57e-01 |
| REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS | 13 | 4.71e-02 | 3.52e-01 | 0.57800 | 2.41e-01 | 2.18e-01 | 4.20e-01 | 3.82e-02 | 2.27e-01 | 1.33e-01 | 1.74e-01 | 8.79e-03 | 8.11e-01 | 1.56e-01 |
| REGULATION OF GLUCOCORTICOID METABOLIC PROCESS | 11 | 5.07e-01 | 9.48e-01 | 0.57800 | 2.96e-01 | 3.05e-01 | 3.08e-01 | 2.31e-01 | 7.58e-02 | 8.92e-02 | 7.96e-02 | 7.74e-02 | 1.84e-01 | 6.63e-01 |
| REGULATION OF SYNAPTIC ASSEMBLY AT NEUROMUSCULAR JUNCTION | 6 | 2.49e-01 | 7.75e-01 | 0.57800 | -1.90e-01 | -1.87e-01 | 3.60e-02 | -3.22e-01 | 3.98e-01 | 4.19e-01 | 4.27e-01 | 8.79e-01 | 1.72e-01 | 9.14e-02 |
| REGULATION OF LYMPHOCYTE MIGRATION | 66 | 8.89e-04 | 2.05e-02 | 0.57800 | -3.12e-01 | -2.95e-01 | -2.64e-01 | -2.78e-01 | -5.42e-02 | 1.17e-05 | 3.38e-05 | 2.10e-04 | 9.15e-05 | 4.46e-01 |
| AMACRINE CELL DIFFERENTIATION | 12 | 1.04e-03 | 2.35e-02 | 0.57800 | 2.63e-01 | 2.34e-01 | 4.44e-01 | -1.03e-01 | -5.14e-02 | 1.15e-01 | 1.61e-01 | 7.76e-03 | 5.36e-01 | 7.58e-01 |
| REGULATION OF POTASSIUM ION EXPORT ACROSS PLASMA MEMBRANE | 8 | 4.27e-01 | 9.16e-01 | 0.57700 | 3.18e-01 | 2.71e-01 | 2.23e-01 | 3.23e-01 | -7.30e-02 | 1.20e-01 | 1.85e-01 | 2.76e-01 | 1.14e-01 | 7.21e-01 |
| PERICYTE CELL DIFFERENTIATION | 11 | 1.10e-01 | 5.50e-01 | 0.57700 | 2.55e-01 | 2.29e-01 | 4.21e-01 | 1.13e-01 | 1.62e-01 | 1.44e-01 | 1.88e-01 | 1.57e-02 | 5.17e-01 | 3.52e-01 |
| NEGATIVE REGULATION OF TRANSCRIPTION REGULATORY REGION DNA BINDING | 11 | 4.28e-02 | 3.31e-01 | 0.57700 | 2.86e-01 | 2.40e-01 | 4.39e-01 | 2.00e-02 | -2.89e-02 | 1.01e-01 | 1.68e-01 | 1.17e-02 | 9.08e-01 | 8.68e-01 |
| REGULATION OF KILLING OF CELLS OF ANOTHER ORGANISM | 11 | 4.09e-01 | 9.08e-01 | 0.57700 | -2.97e-01 | -3.40e-01 | -1.82e-01 | -3.08e-01 | -2.06e-02 | 8.77e-02 | 5.09e-02 | 2.96e-01 | 7.65e-02 | 9.06e-01 |
| MUCUS SECRETION | 18 | 2.79e-01 | 8.05e-01 | 0.57700 | 3.05e-01 | 2.96e-01 | 2.44e-01 | 2.85e-01 | 1.06e-01 | 2.50e-02 | 2.99e-02 | 7.31e-02 | 3.61e-02 | 4.38e-01 |
| ENDONUCLEOLYTIC CLEAVAGE IN ITS1 TO SEPARATE SSU RRNA FROM 5 8S RRNA AND LSU RRNA FROM TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 10 | 1.05e-01 | 5.38e-01 | 0.57600 | 1.78e-01 | 1.19e-01 | 3.72e-01 | -1.35e-02 | 3.84e-01 | 3.29e-01 | 5.13e-01 | 4.14e-02 | 9.41e-01 | 3.55e-02 |
| TOLERANCE INDUCTION | 29 | 6.39e-02 | 4.13e-01 | 0.57600 | -3.06e-01 | -3.34e-01 | -2.12e-01 | -2.84e-01 | 3.50e-02 | 4.36e-03 | 1.86e-03 | 4.80e-02 | 8.01e-03 | 7.45e-01 |
| NEGATIVE REGULATION OF CELL CYCLE CHECKPOINT | 6 | 8.26e-01 | 1.00e+00 | 0.57600 | 3.10e-01 | 2.97e-01 | 2.33e-01 | 2.85e-01 | -1.08e-01 | 1.88e-01 | 2.08e-01 | 3.23e-01 | 2.26e-01 | 6.48e-01 |
| REGULATION OF ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE OR POLYSACCHARIDE ANTIGEN VIA MHC CLASS II | 5 | 4.49e-01 | 9.30e-01 | 0.57600 | -1.51e-01 | -7.70e-02 | -3.63e-01 | 2.86e-02 | -4.12e-01 | 5.59e-01 | 7.66e-01 | 1.59e-01 | 9.12e-01 | 1.11e-01 |
| NEGATIVE REGULATION OF MYELINATION | 9 | 4.28e-01 | 9.17e-01 | 0.57600 | -2.77e-01 | -3.28e-01 | -9.10e-02 | -3.49e-01 | 1.30e-01 | 1.50e-01 | 8.89e-02 | 6.36e-01 | 6.95e-02 | 4.99e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 4 PRODUCTION | 7 | 6.62e-01 | 1.00e+00 | 0.57500 | 2.72e-01 | 2.42e-01 | 3.46e-01 | 1.55e-01 | 2.35e-01 | 2.13e-01 | 2.68e-01 | 1.13e-01 | 4.77e-01 | 2.82e-01 |
| NEGATIVE REGULATION OF MONOOXYGENASE ACTIVITY | 14 | 2.66e-01 | 7.95e-01 | 0.57500 | 2.82e-01 | 2.79e-01 | 2.35e-01 | 2.65e-01 | 2.18e-01 | 6.73e-02 | 7.07e-02 | 1.28e-01 | 8.63e-02 | 1.57e-01 |
| REGULATION OF INTESTINAL ABSORPTION | 12 | 4.36e-01 | 9.22e-01 | 0.57500 | 2.81e-01 | 2.72e-01 | 2.37e-01 | 2.81e-01 | 2.07e-01 | 9.24e-02 | 1.02e-01 | 1.56e-01 | 9.25e-02 | 2.15e-01 |
| POSITIVE REGULATION OF ENAMEL MINERALIZATION | 5 | 8.14e-02 | 4.70e-01 | 0.57500 | -2.30e-01 | -1.45e-01 | -5.04e-01 | -4.69e-02 | 7.82e-03 | 3.73e-01 | 5.73e-01 | 5.10e-02 | 8.56e-01 | 9.76e-01 |
| NEGATIVE REGULATION OF ATP METABOLIC PROCESS | 7 | 5.01e-01 | 9.48e-01 | 0.57400 | 2.38e-01 | 2.57e-01 | 1.95e-01 | 2.85e-01 | 2.97e-01 | 2.76e-01 | 2.39e-01 | 3.71e-01 | 1.92e-01 | 1.74e-01 |
| RESPONSE TO LIPOTEICHOIC ACID | 10 | 4.77e-01 | 9.40e-01 | 0.57400 | -2.86e-01 | -2.66e-01 | -2.68e-01 | -3.22e-01 | -3.33e-02 | 1.17e-01 | 1.45e-01 | 1.42e-01 | 7.75e-02 | 8.55e-01 |
| CELLULAR RESPONSE TO HISTAMINE | 7 | 3.11e-01 | 8.38e-01 | 0.57400 | 2.98e-01 | 3.30e-01 | 3.47e-01 | 1.01e-01 | 2.56e-02 | 1.71e-01 | 1.31e-01 | 1.11e-01 | 6.43e-01 | 9.06e-01 |
| ANTIGEN PROCESSING AND PRESENTATION ENDOGENOUS LIPID ANTIGEN VIA MHC CLASS IB | 5 | 7.67e-01 | 1.00e+00 | 0.57400 | -2.98e-01 | -2.65e-01 | -3.11e-01 | -2.53e-01 | 9.81e-02 | 2.49e-01 | 3.05e-01 | 2.29e-01 | 3.27e-01 | 7.04e-01 |
| POSITIVE REGULATION OF PROTEIN SUMOYLATION | 12 | 4.32e-02 | 3.33e-01 | 0.57300 | 1.18e-01 | 1.16e-01 | 2.50e-01 | 4.94e-02 | 4.86e-01 | 4.79e-01 | 4.85e-01 | 1.33e-01 | 7.67e-01 | 3.54e-03 |
| NEGATIVE REGULATION OF RNA SPLICING | 25 | 9.33e-02 | 5.04e-01 | 0.57300 | 2.91e-01 | 2.80e-01 | 3.28e-01 | 1.93e-01 | 1.46e-01 | 1.19e-02 | 1.53e-02 | 4.55e-03 | 9.54e-02 | 2.06e-01 |
| REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR RESULTING IN TRANSCRIPTION OF P21 CLASS MEDIATOR | 6 | 4.57e-01 | 9.32e-01 | 0.57300 | 3.14e-01 | 3.10e-01 | 3.43e-01 | 9.47e-02 | -8.29e-02 | 1.83e-01 | 1.89e-01 | 1.45e-01 | 6.88e-01 | 7.25e-01 |
| ANAGEN | 5 | 1.63e-01 | 6.64e-01 | 0.57300 | -2.11e-01 | -2.82e-01 | -2.92e-01 | -1.19e-01 | -3.24e-01 | 4.14e-01 | 2.76e-01 | 2.59e-01 | 6.46e-01 | 2.09e-01 |
| SMOOTHENED SIGNALING PATHWAY INVOLVED IN DORSAL VENTRAL NEURAL TUBE PATTERNING | 13 | 1.94e-01 | 7.06e-01 | 0.57300 | -2.66e-01 | -2.85e-01 | -1.80e-01 | -2.06e-01 | 3.18e-01 | 9.68e-02 | 7.51e-02 | 2.61e-01 | 1.99e-01 | 4.70e-02 |
| PODOCYTE CELL MIGRATION | 7 | 8.01e-01 | 1.00e+00 | 0.57200 | 3.12e-01 | 3.01e-01 | 3.01e-01 | 2.20e-01 | 3.08e-02 | 1.53e-01 | 1.68e-01 | 1.68e-01 | 3.13e-01 | 8.88e-01 |
| PYRIMIDINE CONTAINING COMPOUND SALVAGE | 7 | 5.23e-01 | 9.53e-01 | 0.57200 | -2.76e-01 | -2.82e-01 | -2.47e-01 | -2.05e-01 | 2.62e-01 | 2.06e-01 | 1.96e-01 | 2.57e-01 | 3.48e-01 | 2.30e-01 |
| TAIL ANCHORED MEMBRANE PROTEIN INSERTION INTO ER MEMBRANE | 15 | 6.65e-02 | 4.20e-01 | 0.57200 | 2.09e-01 | 1.77e-01 | 3.33e-01 | 1.90e-01 | 3.24e-01 | 1.61e-01 | 2.36e-01 | 2.54e-02 | 2.02e-01 | 2.98e-02 |
| NEGATIVE REGULATION OF IMMATURE T CELL PROLIFERATION | 5 | 4.22e-01 | 9.12e-01 | 0.57200 | 1.83e-01 | 2.83e-01 | -2.29e-02 | 2.00e-01 | -4.16e-01 | 4.78e-01 | 2.74e-01 | 9.29e-01 | 4.38e-01 | 1.07e-01 |
| CARDIAC NEURAL CREST CELL DIFFERENTIATION INVOLVED IN HEART DEVELOPMENT | 16 | 3.37e-01 | 8.59e-01 | 0.57200 | 2.96e-01 | 2.93e-01 | 2.58e-01 | 2.88e-01 | -6.12e-02 | 4.02e-02 | 4.24e-02 | 7.41e-02 | 4.60e-02 | 6.72e-01 |
| REGULATION OF POSTSYNAPTIC NEUROTRANSMITTER RECEPTOR ACTIVITY | 5 | 4.64e-01 | 9.33e-01 | 0.57100 | 9.56e-02 | 1.64e-01 | -1.43e-01 | 1.61e-01 | -4.94e-01 | 7.11e-01 | 5.26e-01 | 5.80e-01 | 5.32e-01 | 5.59e-02 |
| VACUOLE FUSION | 12 | 2.20e-02 | 2.21e-01 | 0.57100 | 1.18e-01 | 1.20e-01 | 2.87e-01 | -9.18e-03 | 4.64e-01 | 4.79e-01 | 4.70e-01 | 8.53e-02 | 9.56e-01 | 5.38e-03 |
| POSITIVE REGULATION OF GRANULOCYTE DIFFERENTIATION | 9 | 4.99e-01 | 9.47e-01 | 0.57100 | -2.84e-01 | -3.30e-01 | -1.76e-01 | -3.03e-01 | 1.15e-01 | 1.40e-01 | 8.63e-02 | 3.59e-01 | 1.15e-01 | 5.50e-01 |
| DORSAL AORTA MORPHOGENESIS | 8 | 2.05e-01 | 7.25e-01 | 0.57100 | 2.85e-01 | 2.06e-01 | 4.37e-01 | 6.69e-02 | 7.92e-02 | 1.63e-01 | 3.13e-01 | 3.21e-02 | 7.43e-01 | 6.98e-01 |
| REGULATION OF SYNAPSE STRUCTURAL PLASTICITY | 7 | 6.19e-01 | 9.90e-01 | 0.57100 | 2.74e-01 | 2.95e-01 | 1.60e-01 | 3.72e-01 | -7.68e-03 | 2.09e-01 | 1.77e-01 | 4.62e-01 | 8.86e-02 | 9.72e-01 |
| REGULATION OF NATURAL KILLER CELL MEDIATED IMMUNITY | 52 | 5.04e-04 | 1.30e-02 | 0.57000 | -2.94e-01 | -3.26e-01 | -2.09e-01 | -2.86e-01 | -8.60e-02 | 2.39e-04 | 4.85e-05 | 9.18e-03 | 3.65e-04 | 2.83e-01 |
| NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING 1 SIGNALING PATHWAY | 7 | 6.71e-01 | 1.00e+00 | 0.57000 | -2.80e-01 | -3.00e-01 | -1.39e-01 | -3.69e-01 | 2.87e-02 | 2.00e-01 | 1.69e-01 | 5.23e-01 | 9.05e-02 | 8.95e-01 |
| NEGATIVE REGULATION OF DENDRITIC SPINE DEVELOPMENT | 12 | 4.37e-01 | 9.23e-01 | 0.57000 | -2.87e-01 | -2.41e-01 | -3.22e-01 | -2.63e-01 | -1.04e-01 | 8.52e-02 | 1.48e-01 | 5.31e-02 | 1.14e-01 | 5.34e-01 |
| POSITIVE REGULATION OF SEQUESTERING OF TRIGLYCERIDE | 9 | 6.95e-01 | 1.00e+00 | 0.57000 | 2.98e-01 | 3.07e-01 | 2.88e-01 | 2.40e-01 | 2.65e-02 | 1.21e-01 | 1.10e-01 | 1.35e-01 | 2.13e-01 | 8.91e-01 |
| NEGATIVE REGULATION OF AUTOPHAGY OF MITOCHONDRION | 7 | 2.48e-01 | 7.75e-01 | 0.57000 | 2.20e-01 | 2.32e-01 | 2.40e-01 | 1.29e-01 | 3.85e-01 | 3.14e-01 | 2.88e-01 | 2.71e-01 | 5.56e-01 | 7.80e-02 |
| PROTEIN HEXAMERIZATION | 9 | 1.41e-02 | 1.60e-01 | 0.56900 | 2.48e-01 | 2.20e-01 | 3.92e-01 | -7.65e-02 | -2.33e-01 | 1.98e-01 | 2.52e-01 | 4.18e-02 | 6.91e-01 | 2.25e-01 |
| DETERMINATION OF DIGESTIVE TRACT LEFT RIGHT ASYMMETRY | 6 | 6.88e-01 | 1.00e+00 | 0.56900 | 2.97e-01 | 2.58e-01 | 3.75e-01 | 1.68e-01 | -6.67e-03 | 2.07e-01 | 2.74e-01 | 1.12e-01 | 4.75e-01 | 9.77e-01 |
| B CELL PROLIFERATION INVOLVED IN IMMUNE RESPONSE | 6 | 5.66e-01 | 9.72e-01 | 0.56900 | -2.80e-01 | -3.44e-01 | -1.36e-01 | -3.28e-01 | -3.48e-02 | 2.35e-01 | 1.45e-01 | 5.63e-01 | 1.64e-01 | 8.83e-01 |
| POSITIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DIFFERENTIATION | 12 | 1.56e-01 | 6.54e-01 | 0.56900 | 3.12e-01 | 2.34e-01 | 3.59e-01 | 2.05e-01 | 2.29e-02 | 6.12e-02 | 1.61e-01 | 3.12e-02 | 2.18e-01 | 8.91e-01 |
| ADENYLATE CYCLASE ACTIVATING ADRENERGIC RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART PROCESS | 9 | 3.61e-01 | 8.77e-01 | 0.56800 | -2.51e-01 | -2.23e-01 | -3.17e-01 | -1.29e-01 | -3.04e-01 | 1.92e-01 | 2.46e-01 | 9.93e-02 | 5.01e-01 | 1.14e-01 |
| DNA LIGATION | 16 | 2.02e-01 | 7.18e-01 | 0.56800 | 2.77e-01 | 2.54e-01 | 3.67e-01 | 1.51e-01 | 1.56e-01 | 5.52e-02 | 7.87e-02 | 1.11e-02 | 2.96e-01 | 2.80e-01 |
| ORNITHINE METABOLIC PROCESS | 9 | 6.01e-01 | 9.90e-01 | 0.56800 | 3.01e-01 | 2.60e-01 | 3.17e-01 | 2.51e-01 | -1.62e-02 | 1.17e-01 | 1.76e-01 | 9.96e-02 | 1.93e-01 | 9.33e-01 |
| OLFACTORY BEHAVIOR | 10 | 6.77e-01 | 1.00e+00 | 0.56800 | 2.93e-01 | 2.88e-01 | 2.86e-01 | 2.36e-01 | 1.25e-01 | 1.09e-01 | 1.14e-01 | 1.17e-01 | 1.96e-01 | 4.95e-01 |
| RETINAL CELL PROGRAMMED CELL DEATH | 6 | 2.64e-01 | 7.91e-01 | 0.56800 | -2.80e-02 | 2.22e-02 | -2.04e-01 | -7.33e-02 | -5.23e-01 | 9.05e-01 | 9.25e-01 | 3.86e-01 | 7.56e-01 | 2.64e-02 |
| ESTABLISHMENT OF MITOTIC SISTER CHROMATID COHESION | 5 | 8.86e-01 | 1.00e+00 | 0.56800 | -2.93e-01 | -3.02e-01 | -1.81e-01 | -3.26e-01 | 7.72e-02 | 2.56e-01 | 2.43e-01 | 4.84e-01 | 2.06e-01 | 7.65e-01 |
| RECOGNITION OF APOPTOTIC CELL | 7 | 3.35e-01 | 8.59e-01 | 0.56800 | 1.33e-01 | 4.77e-02 | 3.13e-01 | 7.54e-02 | 4.45e-01 | 5.41e-01 | 8.27e-01 | 1.51e-01 | 7.30e-01 | 4.13e-02 |
| MONOCYTE AGGREGATION | 5 | 4.11e-01 | 9.08e-01 | 0.56700 | -2.15e-01 | -2.50e-01 | 6.34e-02 | -2.98e-01 | 3.47e-01 | 4.04e-01 | 3.33e-01 | 8.06e-01 | 2.49e-01 | 1.79e-01 |
| B CELL CHEMOTAXIS | 7 | 8.05e-01 | 1.00e+00 | 0.56700 | -2.95e-01 | -2.81e-01 | -2.74e-01 | -2.46e-01 | -1.41e-01 | 1.77e-01 | 1.99e-01 | 2.09e-01 | 2.59e-01 | 5.18e-01 |
| DORSAL AORTA DEVELOPMENT | 10 | 2.16e-01 | 7.38e-01 | 0.56700 | 3.02e-01 | 2.29e-01 | 3.98e-01 | 1.36e-01 | 3.09e-02 | 9.84e-02 | 2.10e-01 | 2.92e-02 | 4.56e-01 | 8.66e-01 |
| GERMINAL CENTER B CELL DIFFERENTIATION | 9 | 1.18e-01 | 5.71e-01 | 0.56700 | -2.18e-01 | -2.99e-01 | 6.78e-02 | -2.96e-01 | 3.05e-01 | 2.58e-01 | 1.21e-01 | 7.25e-01 | 1.25e-01 | 1.14e-01 |
| PROTEIN LOCALIZATION TO CYTOPLASMIC STRESS GRANULE | 7 | 5.76e-01 | 9.80e-01 | 0.56700 | -2.96e-01 | -2.46e-01 | -2.58e-01 | -2.80e-01 | -1.69e-01 | 1.75e-01 | 2.60e-01 | 2.38e-01 | 2.00e-01 | 4.39e-01 |
| REGULATION OF MITOCHONDRIAL RNA CATABOLIC PROCESS | 5 | 3.56e-02 | 3.01e-01 | 0.56700 | 5.76e-02 | -1.30e-01 | 3.65e-01 | 8.12e-03 | 4.09e-01 | 8.23e-01 | 6.15e-01 | 1.57e-01 | 9.75e-01 | 1.13e-01 |
| INTERNEURON MIGRATION FROM THE SUBPALLIUM TO THE CORTEX | 7 | 8.11e-01 | 1.00e+00 | 0.56700 | 2.97e-01 | 3.08e-01 | 1.99e-01 | 2.96e-01 | -1.02e-01 | 1.73e-01 | 1.58e-01 | 3.62e-01 | 1.75e-01 | 6.41e-01 |
| CIRCADIAN SLEEP WAKE CYCLE NON REM SLEEP | 6 | 5.08e-01 | 9.48e-01 | 0.56700 | -2.84e-01 | -3.27e-01 | -9.84e-02 | -2.35e-01 | 2.61e-01 | 2.28e-01 | 1.65e-01 | 6.76e-01 | 3.19e-01 | 2.68e-01 |
| B CELL PROLIFERATION | 98 | 1.42e-06 | 8.52e-05 | 0.56600 | -2.89e-01 | -3.10e-01 | -1.69e-01 | -3.31e-01 | 4.46e-02 | 7.52e-07 | 1.13e-07 | 3.91e-03 | 1.44e-08 | 4.45e-01 |
| POSITIVE REGULATION OF RNA BINDING | 5 | 3.75e-01 | 8.83e-01 | 0.56500 | 2.64e-01 | 3.54e-01 | 7.75e-02 | 1.78e-01 | -2.94e-01 | 3.06e-01 | 1.70e-01 | 7.64e-01 | 4.92e-01 | 2.55e-01 |
| NEUTROPHIL MEDIATED KILLING OF SYMBIONT CELL | 12 | 6.18e-02 | 4.07e-01 | 0.56500 | -1.83e-01 | -2.34e-01 | 8.51e-02 | -2.98e-01 | 3.68e-01 | 2.74e-01 | 1.61e-01 | 6.10e-01 | 7.40e-02 | 2.72e-02 |
| REGULATION OF GENE EXPRESSION BY GENOMIC IMPRINTING | 10 | 1.71e-01 | 6.75e-01 | 0.56500 | 2.85e-01 | 2.25e-01 | 4.04e-01 | 1.50e-01 | -4.00e-02 | 1.19e-01 | 2.18e-01 | 2.71e-02 | 4.10e-01 | 8.27e-01 |
| POSITIVE REGULATION OF MICROTUBULE NUCLEATION | 7 | 6.91e-01 | 1.00e+00 | 0.56400 | 2.80e-01 | 2.86e-01 | 2.01e-01 | 3.39e-01 | -5.18e-02 | 2.00e-01 | 1.90e-01 | 3.56e-01 | 1.20e-01 | 8.13e-01 |
| NEGATIVE REGULATION OF VOLTAGE GATED CALCIUM CHANNEL ACTIVITY | 14 | 1.93e-01 | 7.04e-01 | 0.56400 | 2.56e-01 | 2.73e-01 | 1.86e-01 | 2.96e-01 | 2.38e-01 | 9.78e-02 | 7.74e-02 | 2.28e-01 | 5.53e-02 | 1.23e-01 |
| AMINO SUGAR BIOSYNTHETIC PROCESS | 11 | 3.92e-01 | 8.92e-01 | 0.56400 | 2.92e-01 | 2.88e-01 | 2.29e-01 | 2.12e-01 | -2.29e-01 | 9.30e-02 | 9.84e-02 | 1.88e-01 | 2.23e-01 | 1.88e-01 |
| PROTECTION FROM NATURAL KILLER CELL MEDIATED CYTOTOXICITY | 6 | 7.23e-01 | 1.00e+00 | 0.56400 | -2.65e-01 | -2.78e-01 | -2.75e-01 | -2.64e-01 | -1.59e-01 | 2.61e-01 | 2.39e-01 | 2.43e-01 | 2.63e-01 | 4.99e-01 |
| GLIAL CELL FATE SPECIFICATION | 7 | 2.86e-01 | 8.12e-01 | 0.56400 | 2.64e-01 | 2.77e-01 | 2.76e-01 | 7.12e-02 | -3.01e-01 | 2.26e-01 | 2.05e-01 | 2.07e-01 | 7.44e-01 | 1.68e-01 |
| EMBRYONIC SKELETAL JOINT DEVELOPMENT | 15 | 1.46e-01 | 6.30e-01 | 0.56400 | 2.64e-01 | 2.80e-01 | 1.87e-01 | 2.03e-01 | -3.06e-01 | 7.63e-02 | 6.05e-02 | 2.10e-01 | 1.74e-01 | 4.00e-02 |
| CHAPERONE COFACTOR DEPENDENT PROTEIN REFOLDING | 32 | 5.85e-03 | 8.55e-02 | 0.56300 | 2.81e-01 | 2.38e-01 | 3.91e-01 | 1.38e-01 | 1.01e-01 | 5.91e-03 | 1.98e-02 | 1.31e-04 | 1.76e-01 | 3.25e-01 |
| FLAVONOID GLUCURONIDATION | 5 | 6.57e-01 | 1.00e+00 | 0.56300 | 2.58e-01 | 3.17e-01 | 8.26e-02 | 2.24e-01 | -3.05e-01 | 3.18e-01 | 2.19e-01 | 7.49e-01 | 3.86e-01 | 2.37e-01 |
| METANEPHRIC COLLECTING DUCT DEVELOPMENT | 10 | 2.18e-01 | 7.41e-01 | 0.56300 | 2.85e-01 | 1.99e-01 | 3.43e-01 | 2.64e-01 | 9.34e-02 | 1.19e-01 | 2.76e-01 | 6.03e-02 | 1.48e-01 | 6.09e-01 |
| LYMPHOCYTE ANERGY | 7 | 6.96e-01 | 1.00e+00 | 0.56200 | -3.06e-01 | -3.04e-01 | -3.13e-01 | -1.71e-01 | 5.95e-02 | 1.61e-01 | 1.64e-01 | 1.51e-01 | 4.34e-01 | 7.85e-01 |
| REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO CHROMOSOME | 11 | 5.20e-01 | 9.53e-01 | 0.56200 | -3.02e-01 | -2.97e-01 | -1.86e-01 | -3.20e-01 | -2.14e-03 | 8.30e-02 | 8.85e-02 | 2.85e-01 | 6.61e-02 | 9.90e-01 |
| NEGATIVE REGULATION OF PERK MEDIATED UNFOLDED PROTEIN RESPONSE | 6 | 8.08e-01 | 1.00e+00 | 0.56200 | 2.71e-01 | 2.42e-01 | 2.55e-01 | 2.68e-01 | 2.16e-01 | 2.50e-01 | 3.05e-01 | 2.79e-01 | 2.55e-01 | 3.59e-01 |
| ADRENAL GLAND DEVELOPMENT | 27 | 1.22e-01 | 5.83e-01 | 0.56200 | 3.08e-01 | 3.01e-01 | 2.52e-01 | 2.47e-01 | -7.23e-02 | 5.55e-03 | 6.74e-03 | 2.35e-02 | 2.62e-02 | 5.16e-01 |
| NEGATIVE REGULATION OF DENDRITE DEVELOPMENT | 8 | 7.94e-01 | 1.00e+00 | 0.56100 | 3.01e-01 | 3.05e-01 | 2.31e-01 | 2.77e-01 | 3.16e-02 | 1.40e-01 | 1.35e-01 | 2.58e-01 | 1.74e-01 | 8.77e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 5 PRODUCTION | 10 | 4.77e-01 | 9.40e-01 | 0.56100 | -2.87e-01 | -3.33e-01 | -1.84e-01 | -2.51e-01 | 1.57e-01 | 1.16e-01 | 6.86e-02 | 3.13e-01 | 1.69e-01 | 3.89e-01 |
| NEGATIVE REGULATION OF TRIGLYCERIDE BIOSYNTHETIC PROCESS | 5 | 4.45e-01 | 9.29e-01 | 0.56100 | -2.63e-01 | -1.99e-01 | -4.46e-01 | -2.03e-02 | -8.20e-02 | 3.08e-01 | 4.42e-01 | 8.40e-02 | 9.37e-01 | 7.51e-01 |
| REGULATION OF T CELL MIGRATION | 47 | 6.57e-03 | 9.29e-02 | 0.56100 | -3.03e-01 | -2.76e-01 | -2.75e-01 | -2.50e-01 | -9.42e-02 | 3.27e-04 | 1.04e-03 | 1.12e-03 | 3.03e-03 | 2.64e-01 |
| PROTEIN DNA COVALENT CROSS LINKING REPAIR | 6 | 4.56e-01 | 9.31e-01 | 0.56100 | 2.84e-01 | 2.04e-01 | 3.89e-01 | 2.02e-01 | 1.40e-02 | 2.28e-01 | 3.86e-01 | 9.93e-02 | 3.90e-01 | 9.53e-01 |
| SPERM EJACULATION | 5 | 5.52e-01 | 9.65e-01 | 0.56000 | 1.85e-01 | 2.29e-01 | -9.02e-03 | 1.69e-01 | -4.46e-01 | 4.75e-01 | 3.76e-01 | 9.72e-01 | 5.13e-01 | 8.41e-02 |
| RIBOSOMAL SMALL SUBUNIT BIOGENESIS | 101 | 1.06e-10 | 1.85e-08 | 0.56000 | 2.78e-01 | 2.55e-01 | 3.65e-01 | 1.08e-01 | 1.62e-01 | 1.32e-06 | 9.57e-06 | 2.17e-10 | 6.02e-02 | 5.01e-03 |
| MONOACYLGLYCEROL BIOSYNTHETIC PROCESS | 5 | 9.05e-01 | 1.00e+00 | 0.56000 | 2.83e-01 | 2.82e-01 | 2.21e-01 | 3.10e-01 | 9.44e-02 | 2.73e-01 | 2.75e-01 | 3.93e-01 | 2.30e-01 | 7.15e-01 |
| RESPONSE TO INTERLEUKIN 18 | 11 | 5.25e-01 | 9.54e-01 | 0.56000 | -2.74e-01 | -2.70e-01 | -3.14e-01 | -2.22e-01 | -1.32e-01 | 1.15e-01 | 1.21e-01 | 7.17e-02 | 2.01e-01 | 4.47e-01 |
| GANGLIOSIDE CATABOLIC PROCESS | 7 | 3.88e-01 | 8.92e-01 | 0.55900 | 1.12e-01 | 6.84e-02 | 2.46e-01 | 1.09e-01 | 4.72e-01 | 6.09e-01 | 7.54e-01 | 2.59e-01 | 6.16e-01 | 3.05e-02 |
| LEUCINE TRANSPORT | 10 | 4.99e-01 | 9.47e-01 | 0.55900 | 2.63e-01 | 2.46e-01 | 2.75e-01 | 2.04e-01 | 2.56e-01 | 1.50e-01 | 1.77e-01 | 1.32e-01 | 2.65e-01 | 1.61e-01 |
| REGULATION OF CYTOPLASMIC MRNA PROCESSING BODY ASSEMBLY | 7 | 7.74e-01 | 1.00e+00 | 0.55900 | -2.66e-01 | -2.36e-01 | -2.71e-01 | -2.81e-01 | -1.83e-01 | 2.23e-01 | 2.80e-01 | 2.14e-01 | 1.97e-01 | 4.01e-01 |
| NODAL SIGNALING PATHWAY | 16 | 2.70e-01 | 7.97e-01 | 0.55900 | 2.96e-01 | 3.33e-01 | 2.18e-01 | 2.45e-01 | -7.86e-02 | 4.03e-02 | 2.12e-02 | 1.31e-01 | 8.97e-02 | 5.86e-01 |
| EYELID DEVELOPMENT IN CAMERA TYPE EYE | 13 | 4.81e-01 | 9.43e-01 | 0.55900 | 2.81e-01 | 2.74e-01 | 2.89e-01 | 2.64e-01 | 6.88e-02 | 7.90e-02 | 8.75e-02 | 7.15e-02 | 9.88e-02 | 6.68e-01 |
| RESPONSE TO STILBENOID | 8 | 1.04e-01 | 5.36e-01 | 0.55800 | 2.63e-01 | 3.42e-01 | -2.10e-02 | 3.25e-01 | -1.41e-01 | 1.97e-01 | 9.39e-02 | 9.18e-01 | 1.12e-01 | 4.91e-01 |
| EMBRYONIC SKELETAL JOINT MORPHOGENESIS | 11 | 1.58e-01 | 6.57e-01 | 0.55800 | 2.31e-01 | 2.23e-01 | 1.22e-01 | 2.14e-01 | -3.85e-01 | 1.85e-01 | 2.01e-01 | 4.84e-01 | 2.20e-01 | 2.71e-02 |
| BONE MINERALIZATION INVOLVED IN BONE MATURATION | 13 | 1.51e-01 | 6.42e-01 | 0.55800 | -2.98e-01 | -2.39e-01 | -2.63e-01 | -2.93e-01 | 9.89e-02 | 6.29e-02 | 1.36e-01 | 1.00e-01 | 6.70e-02 | 5.37e-01 |
| DE NOVO NAD BIOSYNTHETIC PROCESS | 8 | 8.06e-01 | 1.00e+00 | 0.55700 | -3.00e-01 | -2.91e-01 | -2.39e-01 | -2.77e-01 | 4.66e-02 | 1.42e-01 | 1.55e-01 | 2.42e-01 | 1.75e-01 | 8.20e-01 |
| REGULATION OF HYPERSENSITIVITY | 9 | 5.28e-04 | 1.35e-02 | 0.55700 | -9.52e-02 | -2.68e-01 | 2.58e-01 | -1.26e-01 | 3.84e-01 | 6.21e-01 | 1.64e-01 | 1.80e-01 | 5.14e-01 | 4.63e-02 |
| LIPID DROPLET FORMATION | 13 | 3.07e-01 | 8.35e-01 | 0.55600 | 2.47e-01 | 2.50e-01 | 2.59e-01 | 2.67e-01 | 2.17e-01 | 1.22e-01 | 1.18e-01 | 1.06e-01 | 9.52e-02 | 1.75e-01 |
| POSITIVE REGULATION OF TRIGLYCERIDE CATABOLIC PROCESS | 8 | 7.31e-01 | 1.00e+00 | 0.55600 | 2.66e-01 | 2.52e-01 | 2.37e-01 | 3.00e-01 | 1.70e-01 | 1.92e-01 | 2.17e-01 | 2.46e-01 | 1.41e-01 | 4.05e-01 |
| HEPARAN SULFATE PROTEOGLYCAN CATABOLIC PROCESS | 8 | 6.27e-01 | 9.94e-01 | 0.55600 | 2.43e-01 | 2.12e-01 | 2.74e-01 | 2.68e-01 | 2.41e-01 | 2.34e-01 | 3.00e-01 | 1.79e-01 | 1.89e-01 | 2.38e-01 |
| POSITIVE REGULATION OF CHEMOKINE C C MOTIF LIGAND 5 PRODUCTION | 5 | 4.63e-01 | 9.33e-01 | 0.55600 | 2.57e-01 | 2.67e-01 | 3.94e-01 | 8.45e-02 | 9.87e-02 | 3.21e-01 | 3.01e-01 | 1.27e-01 | 7.43e-01 | 7.02e-01 |
| POSITIVE REGULATION OF CELLULAR RESPIRATION | 13 | 4.82e-01 | 9.43e-01 | 0.55600 | 2.94e-01 | 3.12e-01 | 1.74e-01 | 3.07e-01 | -2.19e-02 | 6.65e-02 | 5.14e-02 | 2.76e-01 | 5.53e-02 | 8.91e-01 |
| POSITIVE REGULATION OF DENDRITIC CELL DIFFERENTIATION | 6 | 8.43e-01 | 1.00e+00 | 0.55500 | 2.90e-01 | 2.65e-01 | 3.11e-01 | 2.38e-01 | 1.40e-02 | 2.19e-01 | 2.60e-01 | 1.87e-01 | 3.12e-01 | 9.53e-01 |
| SUCCINATE TRANSMEMBRANE TRANSPORT | 6 | 7.75e-01 | 1.00e+00 | 0.55500 | 2.75e-01 | 2.61e-01 | 2.94e-01 | 2.72e-01 | 6.05e-02 | 2.43e-01 | 2.68e-01 | 2.12e-01 | 2.49e-01 | 7.97e-01 |
| LIPID TRANSPORT ACROSS BLOOD BRAIN BARRIER | 6 | 6.62e-01 | 1.00e+00 | 0.55500 | 2.74e-01 | 3.15e-01 | 2.25e-01 | 2.46e-01 | 1.51e-01 | 2.46e-01 | 1.82e-01 | 3.39e-01 | 2.97e-01 | 5.22e-01 |
| POSITIVE REGULATION OF SKELETAL MUSCLE CELL DIFFERENTIATION | 7 | 3.92e-01 | 8.92e-01 | 0.55500 | 1.78e-01 | 1.52e-01 | 3.53e-01 | 5.39e-02 | 3.54e-01 | 4.14e-01 | 4.87e-01 | 1.06e-01 | 8.05e-01 | 1.05e-01 |
| NOREPINEPHRINE TRANSPORT | 22 | 3.47e-02 | 2.96e-01 | 0.55500 | 2.95e-01 | 2.60e-01 | 3.27e-01 | 1.67e-01 | -1.36e-01 | 1.67e-02 | 3.49e-02 | 7.96e-03 | 1.76e-01 | 2.69e-01 |
| REGULATION OF CATECHOLAMINE UPTAKE INVOLVED IN SYNAPTIC TRANSMISSION | 8 | 5.56e-02 | 3.84e-01 | 0.55400 | 1.97e-01 | 6.08e-02 | 3.90e-01 | 1.62e-01 | 2.95e-01 | 3.35e-01 | 7.66e-01 | 5.63e-02 | 4.29e-01 | 1.48e-01 |
| REGULATION OF MACROPHAGE PROLIFERATION | 7 | 1.67e-01 | 6.71e-01 | 0.55400 | 1.50e-01 | 2.52e-01 | -1.43e-01 | 3.05e-01 | -3.29e-01 | 4.91e-01 | 2.49e-01 | 5.13e-01 | 1.62e-01 | 1.32e-01 |
| REGULATION OF HOMOPHILIC CELL ADHESION | 5 | 6.11e-01 | 9.90e-01 | 0.55400 | -2.81e-01 | -1.90e-01 | -3.67e-01 | -1.73e-01 | -1.64e-01 | 2.76e-01 | 4.62e-01 | 1.55e-01 | 5.03e-01 | 5.24e-01 |
| NEGATIVE REGULATION OF MITOCHONDRIAL FUSION | 7 | 5.21e-01 | 9.53e-01 | 0.55300 | -2.45e-01 | -2.83e-01 | -4.27e-02 | -2.72e-01 | 3.00e-01 | 2.61e-01 | 1.94e-01 | 8.45e-01 | 2.12e-01 | 1.70e-01 |
| PROTON TRANSPORTING V TYPE ATPASE COMPLEX ASSEMBLY | 7 | 3.38e-01 | 8.59e-01 | 0.55300 | 2.43e-01 | 2.36e-01 | 3.06e-01 | 2.74e-01 | 1.48e-01 | 2.65e-01 | 2.79e-01 | 1.60e-01 | 2.09e-01 | 4.96e-01 |
| DENDRITIC CELL MIGRATION | 32 | 1.92e-03 | 3.79e-02 | 0.55300 | -2.57e-01 | -3.03e-01 | -4.04e-02 | -3.14e-01 | 2.20e-01 | 1.20e-02 | 3.01e-03 | 6.93e-01 | 2.11e-03 | 3.12e-02 |
| POSITIVE REGULATION OF CD8 POSITIVE ALPHA BETA T CELL ACTIVATION | 9 | 5.21e-01 | 9.53e-01 | 0.55300 | -2.65e-01 | -2.92e-01 | -2.37e-01 | -2.47e-01 | -1.82e-01 | 1.69e-01 | 1.29e-01 | 2.19e-01 | 2.00e-01 | 3.44e-01 |
| MAINTENANCE OF LENS TRANSPARENCY | 7 | 3.87e-01 | 8.92e-01 | 0.55300 | -2.92e-01 | -3.63e-01 | -2.10e-01 | -2.04e-01 | 5.83e-02 | 1.81e-01 | 9.65e-02 | 3.36e-01 | 3.51e-01 | 7.89e-01 |
| RESPONSE TO INTERLEUKIN 7 | 12 | 3.15e-01 | 8.42e-01 | 0.55300 | 2.24e-01 | 1.69e-01 | 3.07e-01 | 2.13e-01 | 2.95e-01 | 1.79e-01 | 3.10e-01 | 6.55e-02 | 2.01e-01 | 7.67e-02 |
| REGULATION OF ISOTYPE SWITCHING TO IGE ISOTYPES | 6 | 4.76e-01 | 9.40e-01 | 0.55200 | -1.77e-01 | -2.15e-01 | 2.12e-02 | -2.72e-01 | 3.91e-01 | 4.53e-01 | 3.62e-01 | 9.28e-01 | 2.48e-01 | 9.75e-02 |
| REGULATION PROTEIN CATABOLIC PROCESS AT SYNAPSE | 6 | 6.99e-01 | 1.00e+00 | 0.55100 | -2.79e-01 | -2.56e-01 | -1.95e-01 | -2.85e-01 | 2.04e-01 | 2.36e-01 | 2.77e-01 | 4.09e-01 | 2.27e-01 | 3.87e-01 |
| DNA REPAIR DEPENDENT CHROMATIN REMODELING | 19 | 2.25e-01 | 7.48e-01 | 0.55100 | 2.68e-01 | 2.43e-01 | 3.37e-01 | 1.84e-01 | 1.61e-01 | 4.35e-02 | 6.72e-02 | 1.10e-02 | 1.64e-01 | 2.24e-01 |
| REDUCTION OF FOOD INTAKE IN RESPONSE TO DIETARY EXCESS | 5 | 5.42e-01 | 9.59e-01 | 0.55100 | -1.37e-01 | -1.21e-01 | -2.93e-01 | -2.66e-02 | -4.29e-01 | 5.96e-01 | 6.39e-01 | 2.57e-01 | 9.18e-01 | 9.69e-02 |
| NEGATIVE REGULATION OF MUSCLE ADAPTATION | 10 | 8.40e-02 | 4.77e-01 | 0.55100 | 2.44e-01 | 2.83e-01 | -3.62e-02 | 3.41e-01 | -2.15e-01 | 1.81e-01 | 1.22e-01 | 8.43e-01 | 6.19e-02 | 2.38e-01 |
| FOLIC ACID METABOLIC PROCESS | 15 | 1.31e-01 | 5.99e-01 | 0.55000 | -2.72e-01 | -2.53e-01 | -1.37e-01 | -3.44e-01 | 1.67e-01 | 6.81e-02 | 9.00e-02 | 3.59e-01 | 2.10e-02 | 2.64e-01 |
| ANTIBACTERIAL PEPTIDE PRODUCTION | 9 | 1.77e-01 | 6.84e-01 | 0.55000 | 2.67e-01 | 3.18e-01 | 3.78e-02 | 3.59e-01 | 1.99e-02 | 1.66e-01 | 9.90e-02 | 8.44e-01 | 6.21e-02 | 9.18e-01 |
| PROTEIN ACTIVATION CASCADE | 17 | 1.69e-01 | 6.74e-01 | 0.55000 | -2.84e-01 | -2.66e-01 | -2.30e-01 | -2.56e-01 | -1.81e-01 | 4.28e-02 | 5.77e-02 | 1.00e-01 | 6.72e-02 | 1.98e-01 |
| CARDIAC VASCULAR SMOOTH MUSCLE CELL DIFFERENTIATION | 10 | 4.85e-02 | 3.59e-01 | 0.55000 | 2.32e-01 | 2.30e-01 | 4.16e-01 | 7.19e-02 | 1.34e-01 | 2.03e-01 | 2.09e-01 | 2.28e-02 | 6.94e-01 | 4.65e-01 |
| BRANCHED CHAIN AMINO ACID TRANSPORT | 13 | 4.58e-01 | 9.32e-01 | 0.54900 | 2.83e-01 | 2.56e-01 | 2.56e-01 | 2.53e-01 | 1.62e-01 | 7.71e-02 | 1.10e-01 | 1.10e-01 | 1.14e-01 | 3.12e-01 |
| ABSCISSION | 6 | 4.22e-01 | 9.12e-01 | 0.54900 | -2.09e-01 | -2.11e-01 | -2.15e-02 | -2.33e-01 | 3.98e-01 | 3.76e-01 | 3.72e-01 | 9.27e-01 | 3.22e-01 | 9.10e-02 |
| EPOXIDE METABOLIC PROCESS | 5 | 6.53e-01 | 1.00e+00 | 0.54900 | 2.70e-01 | 2.98e-01 | 5.03e-02 | 3.62e-01 | -8.03e-02 | 2.96e-01 | 2.48e-01 | 8.46e-01 | 1.62e-01 | 7.56e-01 |
| REGULATION OF AMINO ACID TRANSMEMBRANE TRANSPORT | 14 | 2.55e-01 | 7.83e-01 | 0.54900 | 2.78e-01 | 3.25e-01 | 2.03e-01 | 2.64e-01 | -8.68e-02 | 7.12e-02 | 3.54e-02 | 1.89e-01 | 8.73e-02 | 5.74e-01 |
| CALCIUM ION EXPORT ACROSS PLASMA MEMBRANE | 9 | 2.58e-01 | 7.86e-01 | 0.54800 | 2.63e-01 | 2.84e-01 | 3.24e-01 | 1.04e-01 | 1.86e-01 | 1.72e-01 | 1.40e-01 | 9.21e-02 | 5.88e-01 | 3.35e-01 |
| PUTRESCINE METABOLIC PROCESS | 7 | 2.06e-01 | 7.27e-01 | 0.54800 | 1.51e-01 | 7.09e-02 | 3.42e-01 | -4.21e-02 | 3.92e-01 | 4.88e-01 | 7.45e-01 | 1.17e-01 | 8.47e-01 | 7.26e-02 |
| CARDIAC FIBROBLAST CELL DIFFERENTIATION | 5 | 4.58e-01 | 9.32e-01 | 0.54800 | 3.07e-01 | 3.20e-01 | 1.21e-01 | 2.97e-01 | 2.17e-02 | 2.34e-01 | 2.15e-01 | 6.39e-01 | 2.50e-01 | 9.33e-01 |
| KETONE BODY METABOLIC PROCESS | 10 | 1.17e-01 | 5.69e-01 | 0.54800 | -2.02e-01 | -1.77e-01 | -3.78e-01 | 1.01e-02 | -2.91e-01 | 2.70e-01 | 3.31e-01 | 3.82e-02 | 9.56e-01 | 1.11e-01 |
| POSITIVE REGULATION OF INTRACELLULAR STEROID HORMONE RECEPTOR SIGNALING PATHWAY | 11 | 4.92e-01 | 9.45e-01 | 0.54700 | 2.63e-01 | 2.08e-01 | 3.11e-01 | 2.17e-01 | 2.07e-01 | 1.31e-01 | 2.33e-01 | 7.37e-02 | 2.13e-01 | 2.35e-01 |
| POLYPRENOL METABOLIC PROCESS | 23 | 2.29e-02 | 2.26e-01 | 0.54700 | 2.77e-01 | 3.06e-01 | 2.55e-01 | 1.57e-01 | -1.98e-01 | 2.14e-02 | 1.11e-02 | 3.44e-02 | 1.93e-01 | 1.01e-01 |
| CELLULAR RESPONSE TO ANTIBIOTIC | 11 | 5.45e-01 | 9.61e-01 | 0.54700 | 2.69e-01 | 2.24e-01 | 3.35e-01 | 1.86e-01 | 1.71e-01 | 1.22e-01 | 1.99e-01 | 5.40e-02 | 2.85e-01 | 3.27e-01 |
| POSITIVE REGULATION OF MAST CELL CHEMOTAXIS | 5 | 7.51e-01 | 1.00e+00 | 0.54600 | 2.71e-01 | 3.15e-01 | 2.11e-01 | 2.34e-01 | -1.65e-01 | 2.94e-01 | 2.23e-01 | 4.15e-01 | 3.66e-01 | 5.22e-01 |
| REGULATION OF GAMMA DELTA T CELL DIFFERENTIATION | 9 | 8.43e-02 | 4.78e-01 | 0.54600 | -7.58e-02 | -1.62e-01 | 1.57e-01 | -2.24e-01 | 4.37e-01 | 6.94e-01 | 4.00e-01 | 4.16e-01 | 2.46e-01 | 2.31e-02 |
| REGULATION OF BARBED END ACTIN FILAMENT CAPPING | 5 | 4.09e-01 | 9.08e-01 | 0.54500 | -2.26e-02 | 3.14e-02 | -2.89e-01 | 1.15e-01 | -4.46e-01 | 9.30e-01 | 9.03e-01 | 2.63e-01 | 6.56e-01 | 8.40e-02 |
| REGULATION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA SIGNALING PATHWAY | 8 | 4.36e-01 | 9.22e-01 | 0.54500 | 1.75e-01 | 1.64e-01 | 2.60e-01 | 1.44e-01 | 3.89e-01 | 3.92e-01 | 4.21e-01 | 2.02e-01 | 4.82e-01 | 5.66e-02 |
| POSITIVE REGULATION OF TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 6 | 6.36e-02 | 4.12e-01 | 0.54500 | -2.12e-01 | -3.68e-01 | 1.80e-02 | -2.45e-01 | 2.38e-01 | 3.68e-01 | 1.19e-01 | 9.39e-01 | 2.98e-01 | 3.13e-01 |
| PROTEIN DEPALMITOYLATION | 8 | 5.33e-01 | 9.55e-01 | 0.54500 | -2.29e-01 | -1.92e-01 | -2.18e-01 | -3.04e-01 | -2.61e-01 | 2.62e-01 | 3.46e-01 | 2.85e-01 | 1.37e-01 | 2.02e-01 |
| CLEARANCE OF FOREIGN INTRACELLULAR NUCLEIC ACIDS | 6 | 6.27e-02 | 4.11e-01 | 0.54500 | -2.38e-01 | -1.60e-01 | -6.23e-02 | -3.79e-01 | 2.60e-01 | 3.13e-01 | 4.96e-01 | 7.92e-01 | 1.08e-01 | 2.70e-01 |
| SERTOLI CELL PROLIFERATION | 5 | 3.77e-01 | 8.85e-01 | 0.54500 | 1.70e-01 | 1.86e-01 | 1.08e-01 | 1.87e-01 | -4.32e-01 | 5.09e-01 | 4.71e-01 | 6.76e-01 | 4.68e-01 | 9.47e-02 |
| TRYPTOPHAN CATABOLIC PROCESS TO KYNURENINE | 5 | 7.62e-01 | 1.00e+00 | 0.54300 | -1.82e-01 | -1.43e-01 | -2.74e-01 | -1.53e-01 | -3.78e-01 | 4.81e-01 | 5.79e-01 | 2.89e-01 | 5.53e-01 | 1.44e-01 |
| PROTEIN LOCALIZATION TO GOLGI MEMBRANE | 5 | 6.76e-02 | 4.25e-01 | 0.54300 | 1.88e-01 | 2.53e-02 | 4.81e-01 | -4.97e-02 | 1.58e-01 | 4.67e-01 | 9.22e-01 | 6.26e-02 | 8.47e-01 | 5.40e-01 |
| NEGATIVE REGULATION OF COLLAGEN METABOLIC PROCESS | 12 | 4.05e-01 | 9.06e-01 | 0.54200 | -2.73e-01 | -3.18e-01 | -1.69e-01 | -2.93e-01 | 6.50e-02 | 1.02e-01 | 5.64e-02 | 3.11e-01 | 7.93e-02 | 6.97e-01 |
| MICROGLIAL CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 5 | 1.87e-01 | 6.95e-01 | 0.54200 | -2.24e-01 | -2.22e-01 | -1.88e-01 | 3.01e-02 | 3.98e-01 | 3.86e-01 | 3.90e-01 | 4.66e-01 | 9.07e-01 | 1.23e-01 |
| PARTURITION | 14 | 3.94e-01 | 8.93e-01 | 0.54200 | 2.77e-01 | 2.75e-01 | 1.59e-01 | 3.20e-01 | -1.17e-01 | 7.26e-02 | 7.44e-02 | 3.04e-01 | 3.82e-02 | 4.47e-01 |
| PROTEIN LOCALIZATION TO NUCLEOLUS | 18 | 4.20e-02 | 3.28e-01 | 0.54200 | 2.19e-01 | 1.92e-01 | 3.23e-01 | 7.22e-02 | 3.15e-01 | 1.07e-01 | 1.59e-01 | 1.75e-02 | 5.96e-01 | 2.09e-02 |
| PURINE DEOXYRIBONUCLEOTIDE BIOSYNTHETIC PROCESS | 5 | 5.17e-01 | 9.52e-01 | 0.54100 | 1.37e-01 | 1.83e-01 | -6.35e-02 | 2.55e-01 | -4.15e-01 | 5.95e-01 | 4.79e-01 | 8.06e-01 | 3.24e-01 | 1.08e-01 |
| RRNA TRANSCRIPTION | 37 | 3.29e-02 | 2.87e-01 | 0.54100 | 2.80e-01 | 2.82e-01 | 2.91e-01 | 2.22e-01 | 3.50e-02 | 3.25e-03 | 2.97e-03 | 2.20e-03 | 1.93e-02 | 7.13e-01 |
| REGULATION OF NK T CELL PROLIFERATION | 7 | 7.02e-01 | 1.00e+00 | 0.54100 | -2.48e-01 | -2.08e-01 | -2.35e-01 | -2.91e-01 | -2.19e-01 | 2.55e-01 | 3.40e-01 | 2.82e-01 | 1.82e-01 | 3.16e-01 |
| REGULATION OF TYPE B PANCREATIC CELL PROLIFERATION | 13 | 4.91e-01 | 9.45e-01 | 0.54100 | 2.84e-01 | 2.49e-01 | 2.82e-01 | 2.65e-01 | 6.62e-03 | 7.59e-02 | 1.20e-01 | 7.82e-02 | 9.85e-02 | 9.67e-01 |
| NEGATIVE REGULATION OF B CELL RECEPTOR SIGNALING PATHWAY | 8 | 3.96e-01 | 8.96e-01 | 0.54100 | -2.43e-01 | -2.80e-01 | -8.09e-02 | -3.74e-01 | -9.47e-02 | 2.34e-01 | 1.70e-01 | 6.92e-01 | 6.72e-02 | 6.43e-01 |
| NUCLEOLAR LARGE RRNA TRANSCRIPTION BY RNA POLYMERASE I | 21 | 2.31e-01 | 7.53e-01 | 0.54000 | 2.79e-01 | 2.98e-01 | 2.51e-01 | 2.48e-01 | 3.25e-02 | 2.68e-02 | 1.80e-02 | 4.68e-02 | 4.94e-02 | 7.97e-01 |
| DENTINOGENESIS | 6 | 8.27e-01 | 1.00e+00 | 0.54000 | 2.80e-01 | 2.92e-01 | 1.43e-01 | 3.20e-01 | -7.14e-02 | 2.34e-01 | 2.15e-01 | 5.45e-01 | 1.75e-01 | 7.62e-01 |
| RESPONSE TO INTERLEUKIN 15 | 11 | 1.42e-01 | 6.28e-01 | 0.54000 | -2.28e-01 | -2.96e-01 | -1.96e-02 | -2.12e-01 | 3.27e-01 | 1.90e-01 | 8.92e-02 | 9.11e-01 | 2.23e-01 | 6.07e-02 |
| PYRIMIDINE NUCLEOSIDE BIOSYNTHETIC PROCESS | 5 | 5.07e-01 | 9.48e-01 | 0.54000 | 2.33e-01 | 1.68e-01 | 2.00e-01 | 2.62e-01 | 3.17e-01 | 3.68e-01 | 5.15e-01 | 4.39e-01 | 3.10e-01 | 2.20e-01 |
| NEUROTRANSMITTER BIOSYNTHETIC PROCESS | 14 | 4.87e-01 | 9.43e-01 | 0.54000 | 2.91e-01 | 2.53e-01 | 3.01e-01 | 2.21e-01 | 5.00e-02 | 5.96e-02 | 1.01e-01 | 5.09e-02 | 1.51e-01 | 7.46e-01 |
| REGULATION OF CORTICOTROPIN SECRETION | 5 | 3.86e-01 | 8.92e-01 | 0.53900 | -2.52e-01 | -2.82e-01 | -3.15e-01 | -1.28e-01 | 1.78e-01 | 3.30e-01 | 2.75e-01 | 2.22e-01 | 6.19e-01 | 4.91e-01 |
| MONOCYTE ACTIVATION | 12 | 5.00e-01 | 9.47e-01 | 0.53900 | -2.73e-01 | -2.84e-01 | -1.91e-01 | -2.47e-01 | 1.94e-01 | 1.02e-01 | 8.83e-02 | 2.52e-01 | 1.39e-01 | 2.43e-01 |
| DEFENSE RESPONSE TO FUNGUS | 52 | 3.91e-03 | 6.42e-02 | 0.53800 | -2.99e-01 | -3.05e-01 | -2.29e-01 | -2.30e-01 | 4.19e-02 | 1.93e-04 | 1.39e-04 | 4.22e-03 | 4.05e-03 | 6.02e-01 |
| SPHINGOLIPID TRANSLOCATION | 5 | 8.66e-01 | 1.00e+00 | 0.53800 | -2.96e-01 | -2.85e-01 | -3.03e-01 | -1.70e-01 | 1.84e-02 | 2.52e-01 | 2.69e-01 | 2.41e-01 | 5.11e-01 | 9.43e-01 |
| GLUTAMINE FAMILY AMINO ACID BIOSYNTHETIC PROCESS | 15 | 3.01e-03 | 5.26e-02 | 0.53800 | 1.93e-01 | 2.20e-01 | 2.28e-01 | -1.14e-02 | -3.89e-01 | 1.96e-01 | 1.41e-01 | 1.26e-01 | 9.39e-01 | 9.02e-03 |
| REGULATION OF BONE MINERALIZATION INVOLVED IN BONE MATURATION | 7 | 6.05e-01 | 9.90e-01 | 0.53700 | -2.93e-01 | -2.44e-01 | -2.97e-01 | -2.02e-01 | 1.17e-01 | 1.79e-01 | 2.63e-01 | 1.74e-01 | 3.56e-01 | 5.93e-01 |
| LEUKOCYTE AGGREGATION | 12 | 1.20e-01 | 5.78e-01 | 0.53600 | -1.96e-01 | -2.43e-01 | 4.50e-02 | -2.69e-01 | 3.40e-01 | 2.40e-01 | 1.44e-01 | 7.87e-01 | 1.07e-01 | 4.12e-02 |
| EGG ACTIVATION | 11 | 1.66e-01 | 6.70e-01 | 0.53600 | -2.07e-01 | -1.34e-01 | -3.60e-01 | -5.08e-02 | -3.07e-01 | 2.34e-01 | 4.43e-01 | 3.87e-02 | 7.70e-01 | 7.75e-02 |
| REGULATION OF MIRNA CATABOLIC PROCESS | 9 | 1.08e-01 | 5.46e-01 | 0.53600 | 2.31e-01 | 1.87e-01 | 4.17e-01 | 1.18e-01 | 1.06e-01 | 2.31e-01 | 3.33e-01 | 3.02e-02 | 5.39e-01 | 5.83e-01 |
| POSITIVE REGULATION OF METAPHASE ANAPHASE TRANSITION OF CELL CYCLE | 15 | 2.25e-01 | 7.47e-01 | 0.53600 | 2.95e-01 | 3.23e-01 | 2.44e-01 | 1.91e-01 | -1.12e-03 | 4.81e-02 | 3.04e-02 | 1.02e-01 | 2.01e-01 | 9.94e-01 |
| PLATELET ACTIVATING FACTOR METABOLIC PROCESS | 8 | 4.76e-01 | 9.40e-01 | 0.53500 | -2.76e-01 | -2.44e-01 | -3.62e-01 | -1.28e-01 | 5.72e-02 | 1.76e-01 | 2.33e-01 | 7.60e-02 | 5.29e-01 | 7.79e-01 |
| INTERLEUKIN 4 MEDIATED SIGNALING PATHWAY | 9 | 2.97e-01 | 8.24e-01 | 0.53500 | -2.25e-01 | -2.69e-01 | -4.63e-02 | -1.87e-01 | 3.55e-01 | 2.42e-01 | 1.62e-01 | 8.10e-01 | 3.31e-01 | 6.50e-02 |
| NEGATIVE REGULATION OF SKELETAL MUSCLE CELL DIFFERENTIATION | 5 | 3.63e-02 | 3.03e-01 | 0.53500 | -1.31e-02 | -1.42e-02 | 2.41e-01 | -3.89e-01 | 2.77e-01 | 9.59e-01 | 9.56e-01 | 3.52e-01 | 1.32e-01 | 2.83e-01 |
| NEGATIVE REGULATION OF FATTY ACID BETA OXIDATION | 6 | 7.77e-01 | 1.00e+00 | 0.53500 | 2.76e-01 | 3.24e-01 | 1.70e-01 | 2.72e-01 | -4.15e-02 | 2.41e-01 | 1.70e-01 | 4.70e-01 | 2.49e-01 | 8.60e-01 |
| POSITIVE REGULATION OF MEGAKARYOCYTE DIFFERENTIATION | 10 | 7.40e-01 | 1.00e+00 | 0.53400 | 2.85e-01 | 2.77e-01 | 2.78e-01 | 2.24e-01 | -8.16e-03 | 1.19e-01 | 1.29e-01 | 1.28e-01 | 2.19e-01 | 9.64e-01 |
| PROTEIN LOCALIZATION TO CILIARY MEMBRANE | 11 | 8.83e-02 | 4.91e-01 | 0.53400 | 6.95e-02 | -1.17e-03 | 2.16e-01 | 1.11e-01 | 4.71e-01 | 6.90e-01 | 9.95e-01 | 2.15e-01 | 5.23e-01 | 6.88e-03 |
| CELLULAR RESPONSE TO LEUCINE | 12 | 6.75e-01 | 1.00e+00 | 0.53400 | -2.83e-01 | -2.90e-01 | -2.15e-01 | -2.69e-01 | 5.02e-02 | 9.00e-02 | 8.16e-02 | 1.98e-01 | 1.07e-01 | 7.63e-01 |
| RESPONSE TO LEUCINE | 15 | 4.71e-01 | 9.40e-01 | 0.53400 | -2.75e-01 | -2.71e-01 | -2.07e-01 | -3.01e-01 | 4.49e-02 | 6.52e-02 | 6.93e-02 | 1.65e-01 | 4.32e-02 | 7.64e-01 |
| METANEPHRIC MESENCHYMAL CELL DIFFERENTIATION | 5 | 8.26e-01 | 1.00e+00 | 0.53300 | 2.85e-01 | 2.27e-01 | 2.88e-01 | 2.60e-01 | 3.60e-02 | 2.70e-01 | 3.80e-01 | 2.65e-01 | 3.13e-01 | 8.89e-01 |
| PYRIDINE CONTAINING COMPOUND CATABOLIC PROCESS | 8 | 1.17e-01 | 5.68e-01 | 0.53300 | -1.95e-01 | -2.19e-01 | 8.72e-02 | -4.05e-01 | 1.64e-01 | 3.40e-01 | 2.84e-01 | 6.69e-01 | 4.71e-02 | 4.23e-01 |
| KETONE BODY BIOSYNTHETIC PROCESS | 6 | 4.35e-01 | 9.22e-01 | 0.53300 | -2.43e-01 | -1.82e-01 | -3.93e-01 | -2.18e-02 | -1.93e-01 | 3.03e-01 | 4.39e-01 | 9.56e-02 | 9.26e-01 | 4.14e-01 |
| NEGATIVE REGULATION OF MUSCLE ORGAN DEVELOPMENT | 9 | 4.74e-01 | 9.40e-01 | 0.53300 | 2.95e-01 | 2.87e-01 | 1.60e-01 | 2.78e-01 | -1.08e-01 | 1.25e-01 | 1.36e-01 | 4.06e-01 | 1.49e-01 | 5.76e-01 |
| REGULATION OF GLIAL CELL MIGRATION | 19 | 4.20e-01 | 9.11e-01 | 0.53300 | -2.81e-01 | -2.89e-01 | -2.31e-01 | -2.59e-01 | 2.59e-02 | 3.39e-02 | 2.94e-02 | 8.12e-02 | 5.04e-02 | 8.45e-01 |
| RESPONSE TO FUNGUS | 62 | 3.91e-04 | 1.07e-02 | 0.53200 | -2.93e-01 | -3.14e-01 | -2.00e-01 | -2.38e-01 | 4.74e-02 | 6.40e-05 | 1.92e-05 | 6.36e-03 | 1.21e-03 | 5.18e-01 |
| NEGATIVE REGULATION OF VITAMIN METABOLIC PROCESS | 7 | 7.30e-01 | 1.00e+00 | 0.53200 | -2.53e-01 | -2.36e-01 | -1.91e-01 | -3.31e-01 | -1.33e-01 | 2.47e-01 | 2.80e-01 | 3.81e-01 | 1.30e-01 | 5.41e-01 |
| NEGATIVE REGULATION OF UBIQUITIN PROTEIN LIGASE ACTIVITY | 9 | 9.26e-02 | 5.02e-01 | 0.53200 | 1.92e-01 | 1.70e-01 | 4.05e-01 | -5.10e-02 | 2.25e-01 | 3.18e-01 | 3.78e-01 | 3.52e-02 | 7.91e-01 | 2.44e-01 |
| PROTEIN DENEDDYLATION | 11 | 1.46e-01 | 6.32e-01 | 0.53100 | 2.88e-01 | 2.15e-01 | 3.68e-01 | 1.24e-01 | -4.81e-02 | 9.86e-02 | 2.18e-01 | 3.45e-02 | 4.76e-01 | 7.82e-01 |
| DENDRITIC CELL CYTOKINE PRODUCTION | 19 | 1.89e-01 | 6.99e-01 | 0.53100 | -2.69e-01 | -3.00e-01 | -1.24e-01 | -2.67e-01 | 1.82e-01 | 4.24e-02 | 2.37e-02 | 3.48e-01 | 4.43e-02 | 1.70e-01 |
| NEGATIVE REGULATION OF LIPOPROTEIN LIPASE ACTIVITY | 8 | 7.13e-01 | 1.00e+00 | 0.53100 | -2.77e-01 | -3.01e-01 | -2.59e-01 | -2.12e-01 | -4.41e-02 | 1.75e-01 | 1.40e-01 | 2.04e-01 | 2.99e-01 | 8.29e-01 |
| CYCLIC NUCLEOTIDE CATABOLIC PROCESS | 14 | 2.66e-01 | 7.95e-01 | 0.53100 | -2.30e-01 | -1.85e-01 | -2.47e-01 | -2.22e-01 | -2.90e-01 | 1.35e-01 | 2.31e-01 | 1.09e-01 | 1.51e-01 | 6.04e-02 |
| POSITIVE REGULATION OF HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 6 | 8.95e-01 | 1.00e+00 | 0.53000 | -2.76e-01 | -2.73e-01 | -2.06e-01 | -2.87e-01 | -6.86e-02 | 2.41e-01 | 2.47e-01 | 3.81e-01 | 2.23e-01 | 7.71e-01 |
| FACIAL NERVE STRUCTURAL ORGANIZATION | 7 | 1.86e-01 | 6.94e-01 | 0.53000 | 2.68e-01 | 2.86e-01 | 1.13e-02 | 3.20e-01 | -1.57e-01 | 2.19e-01 | 1.91e-01 | 9.59e-01 | 1.43e-01 | 4.73e-01 |
| CORTICOSPINAL TRACT MORPHOGENESIS | 8 | 7.64e-01 | 1.00e+00 | 0.52900 | -2.72e-01 | -2.95e-01 | -2.26e-01 | -2.59e-01 | -1.83e-02 | 1.83e-01 | 1.48e-01 | 2.67e-01 | 2.04e-01 | 9.29e-01 |
| SIALYLATION | 8 | 7.25e-01 | 1.00e+00 | 0.52900 | -2.77e-01 | -2.90e-01 | -1.50e-01 | -2.67e-01 | 1.58e-01 | 1.76e-01 | 1.55e-01 | 4.63e-01 | 1.91e-01 | 4.39e-01 |
| RESPONSE TO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR | 9 | 4.15e-01 | 9.11e-01 | 0.52800 | 1.75e-01 | 1.33e-01 | 2.52e-01 | 2.06e-01 | 3.54e-01 | 3.63e-01 | 4.89e-01 | 1.90e-01 | 2.85e-01 | 6.63e-02 |
| MACROPHAGE COLONY STIMULATING FACTOR PRODUCTION | 7 | 4.39e-02 | 3.36e-01 | 0.52800 | -1.77e-01 | -3.23e-01 | 1.25e-01 | -2.91e-01 | 2.07e-01 | 4.18e-01 | 1.39e-01 | 5.67e-01 | 1.82e-01 | 3.43e-01 |
| PIGMENT CELL DIFFERENTIATION | 35 | 2.99e-02 | 2.69e-01 | 0.52800 | -2.62e-01 | -2.82e-01 | -1.55e-01 | -3.26e-01 | 6.89e-03 | 7.27e-03 | 3.86e-03 | 1.13e-01 | 8.36e-04 | 9.44e-01 |
| RESPONSE TO INTERLEUKIN 12 | 12 | 6.50e-01 | 1.00e+00 | 0.52800 | -2.89e-01 | -2.77e-01 | -2.23e-01 | -2.61e-01 | 4.00e-03 | 8.33e-02 | 9.62e-02 | 1.81e-01 | 1.17e-01 | 9.81e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION ELONGATION BY RNA POLYMERASE II | 48 | 2.16e-03 | 4.10e-02 | 0.52700 | 2.38e-01 | 1.92e-01 | 3.13e-01 | 2.06e-01 | 2.09e-01 | 4.39e-03 | 2.12e-02 | 1.72e-04 | 1.35e-02 | 1.20e-02 |
| REGULATION OF ODONTOBLAST DIFFERENTIATION | 5 | 8.36e-01 | 1.00e+00 | 0.52700 | -2.59e-01 | -2.92e-01 | -1.70e-01 | -3.04e-01 | 6.25e-02 | 3.16e-01 | 2.58e-01 | 5.10e-01 | 2.39e-01 | 8.09e-01 |
| MIDBODY ABSCISSION | 17 | 3.57e-02 | 3.01e-01 | 0.52700 | 1.40e-01 | 1.23e-01 | 2.85e-01 | 3.56e-02 | 4.01e-01 | 3.16e-01 | 3.80e-01 | 4.21e-02 | 8.00e-01 | 4.24e-03 |
| REGULATION OF ANTIMICROBIAL HUMORAL RESPONSE | 12 | 2.45e-02 | 2.34e-01 | 0.52600 | 1.43e-01 | 1.90e-01 | -1.58e-01 | 2.74e-01 | -3.47e-01 | 3.91e-01 | 2.55e-01 | 3.43e-01 | 1.01e-01 | 3.75e-02 |
| REGULATION OF MICROVILLUS ASSEMBLY | 6 | 4.98e-01 | 9.47e-01 | 0.52600 | 2.15e-01 | 2.85e-01 | 2.06e-02 | 3.34e-01 | -1.92e-01 | 3.63e-01 | 2.26e-01 | 9.30e-01 | 1.56e-01 | 4.15e-01 |
| IRE1 MEDIATED UNFOLDED PROTEIN RESPONSE | 20 | 2.04e-01 | 7.23e-01 | 0.52600 | 2.81e-01 | 2.46e-01 | 3.17e-01 | 1.68e-01 | 9.13e-02 | 2.95e-02 | 5.66e-02 | 1.42e-02 | 1.94e-01 | 4.79e-01 |
| NEURON NEURON SYNAPTIC TRANSMISSION | 6 | 8.27e-01 | 1.00e+00 | 0.52600 | -2.69e-01 | -2.82e-01 | -1.73e-01 | -2.90e-01 | -1.04e-01 | 2.54e-01 | 2.32e-01 | 4.63e-01 | 2.18e-01 | 6.59e-01 |
| REGULATION OF MITOTIC RECOMBINATION | 7 | 6.98e-01 | 1.00e+00 | 0.52600 | -2.58e-01 | -2.70e-01 | -2.03e-01 | -2.00e-01 | 2.36e-01 | 2.37e-01 | 2.15e-01 | 3.53e-01 | 3.60e-01 | 2.79e-01 |
| POSITIVE REGULATION OF TOLL LIKE RECEPTOR 4 SIGNALING PATHWAY | 13 | 4.91e-01 | 9.45e-01 | 0.52600 | -2.71e-01 | -2.61e-01 | -1.76e-01 | -3.12e-01 | 8.07e-02 | 9.07e-02 | 1.03e-01 | 2.72e-01 | 5.15e-02 | 6.14e-01 |
| INSULIN PROCESSING | 8 | 3.27e-01 | 8.51e-01 | 0.52500 | -2.32e-01 | -2.89e-01 | -1.26e-01 | -2.93e-01 | -1.91e-01 | 2.55e-01 | 1.57e-01 | 5.36e-01 | 1.51e-01 | 3.50e-01 |
| REGULATION OF MATRIX METALLOPEPTIDASE SECRETION | 10 | 2.26e-02 | 2.25e-01 | 0.52500 | 3.96e-02 | 2.41e-02 | -1.93e-03 | -1.19e-01 | -5.09e-01 | 8.28e-01 | 8.95e-01 | 9.92e-01 | 5.15e-01 | 5.30e-03 |
| ATF6 MEDIATED UNFOLDED PROTEIN RESPONSE | 8 | 1.73e-01 | 6.78e-01 | 0.52500 | 1.04e-01 | 9.61e-02 | 2.71e-01 | -5.21e-02 | 4.23e-01 | 6.10e-01 | 6.38e-01 | 1.84e-01 | 7.98e-01 | 3.81e-02 |
| ACETATE ESTER METABOLIC PROCESS | 6 | 4.76e-01 | 9.40e-01 | 0.52500 | 2.50e-01 | 3.12e-01 | 1.88e-01 | 2.23e-01 | 1.75e-01 | 2.88e-01 | 1.86e-01 | 4.26e-01 | 3.45e-01 | 4.57e-01 |
| NON LYTIC VIRAL RELEASE | 14 | 7.76e-02 | 4.57e-01 | 0.52500 | 1.67e-01 | 1.68e-01 | 2.87e-01 | 7.62e-02 | 3.62e-01 | 2.80e-01 | 2.77e-01 | 6.27e-02 | 6.22e-01 | 1.91e-02 |
| NEUTROPHIL EXTRAVASATION | 11 | 1.02e-01 | 5.29e-01 | 0.52500 | -2.31e-01 | -3.25e-01 | -7.70e-03 | -2.86e-01 | 1.86e-01 | 1.85e-01 | 6.19e-02 | 9.65e-01 | 1.01e-01 | 2.86e-01 |
| NEGATIVE REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 16 | 1.16e-01 | 5.66e-01 | 0.52400 | 2.63e-01 | 2.75e-01 | 2.77e-01 | 1.46e-01 | -1.79e-01 | 6.90e-02 | 5.66e-02 | 5.54e-02 | 3.11e-01 | 2.15e-01 |
| MEIOTIC CELL CYCLE PHASE TRANSITION | 13 | 5.96e-01 | 9.88e-01 | 0.52400 | 2.68e-01 | 2.54e-01 | 2.11e-01 | 3.00e-01 | 6.26e-02 | 9.46e-02 | 1.13e-01 | 1.88e-01 | 6.12e-02 | 6.96e-01 |
| DETECTION OF MUSCLE STRETCH | 7 | 3.85e-01 | 8.92e-01 | 0.52300 | -2.55e-01 | -2.09e-01 | -4.03e-01 | -4.68e-02 | -1.70e-02 | 2.42e-01 | 3.38e-01 | 6.47e-02 | 8.30e-01 | 9.38e-01 |
| MEIOTIC DNA DOUBLE STRAND BREAK FORMATION | 6 | 3.48e-01 | 8.67e-01 | 0.52300 | -1.24e-01 | -8.74e-02 | -2.70e-01 | 4.10e-02 | -4.19e-01 | 5.98e-01 | 7.11e-01 | 2.52e-01 | 8.62e-01 | 7.53e-02 |
| POSITIVE REGULATION OF KILLING OF CELLS OF ANOTHER ORGANISM | 8 | 4.36e-01 | 9.22e-01 | 0.52300 | -2.43e-01 | -2.95e-01 | -1.80e-01 | -2.81e-01 | -1.28e-01 | 2.33e-01 | 1.49e-01 | 3.78e-01 | 1.69e-01 | 5.32e-01 |
| REGULATION OF CELLULAR AMINO ACID METABOLIC PROCESS | 13 | 2.19e-01 | 7.43e-01 | 0.52300 | 2.46e-01 | 2.96e-01 | 1.25e-01 | 1.83e-01 | -2.77e-01 | 1.25e-01 | 6.49e-02 | 4.36e-01 | 2.54e-01 | 8.36e-02 |
| NEGATIVE REGULATION OF NEUTROPHIL ACTIVATION | 6 | 8.16e-02 | 4.71e-01 | 0.52300 | -1.28e-01 | -1.70e-01 | 2.29e-01 | -3.12e-01 | 2.79e-01 | 5.86e-01 | 4.70e-01 | 3.31e-01 | 1.86e-01 | 2.36e-01 |
| NEURON PROJECTION MAINTENANCE | 11 | 1.16e-01 | 5.66e-01 | 0.52300 | 2.12e-01 | 2.08e-01 | 1.85e-01 | 1.83e-01 | -3.42e-01 | 2.24e-01 | 2.31e-01 | 2.87e-01 | 2.92e-01 | 4.96e-02 |
| PURINE DEOXYRIBONUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 6 | 5.00e-01 | 9.47e-01 | 0.52200 | 2.46e-01 | 2.12e-01 | 1.62e-01 | 3.25e-01 | -1.90e-01 | 2.97e-01 | 3.69e-01 | 4.91e-01 | 1.68e-01 | 4.21e-01 |
| CILIUM DISASSEMBLY | 5 | 4.71e-01 | 9.40e-01 | 0.52200 | 2.11e-01 | 2.00e-01 | 2.39e-01 | 5.45e-02 | -3.58e-01 | 4.13e-01 | 4.38e-01 | 3.55e-01 | 8.33e-01 | 1.65e-01 |
| REGULATION OF CELL PROJECTION SIZE | 12 | 5.56e-01 | 9.68e-01 | 0.52200 | 2.68e-01 | 2.96e-01 | 1.40e-01 | 2.98e-01 | -7.23e-02 | 1.08e-01 | 7.62e-02 | 4.00e-01 | 7.35e-02 | 6.65e-01 |
| POSITIVE REGULATION OF T HELPER 2 CELL DIFFERENTIATION | 7 | 4.61e-01 | 9.32e-01 | 0.52200 | -1.79e-01 | -2.42e-01 | 2.37e-02 | -2.05e-01 | 3.74e-01 | 4.12e-01 | 2.67e-01 | 9.13e-01 | 3.47e-01 | 8.70e-02 |
| PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA SIGNALING PATHWAY | 14 | 2.07e-01 | 7.27e-01 | 0.52200 | 1.74e-01 | 1.60e-01 | 2.34e-01 | 1.78e-01 | 3.61e-01 | 2.59e-01 | 3.01e-01 | 1.30e-01 | 2.48e-01 | 1.93e-02 |
| SEROTONIN SECRETION | 9 | 1.85e-02 | 1.97e-01 | 0.52200 | 2.56e-01 | 1.34e-01 | 4.11e-01 | 1.05e-01 | -9.69e-02 | 1.83e-01 | 4.86e-01 | 3.28e-02 | 5.84e-01 | 6.15e-01 |
| NEUTROPHIL MEDIATED KILLING OF GRAM NEGATIVE BACTERIUM | 6 | 4.71e-01 | 9.40e-01 | 0.52200 | -1.81e-01 | -2.26e-01 | 7.06e-02 | -2.74e-01 | 3.31e-01 | 4.43e-01 | 3.38e-01 | 7.65e-01 | 2.46e-01 | 1.61e-01 |
| SKELETAL MUSCLE CONTRACTION | 43 | 1.47e-02 | 1.65e-01 | 0.52200 | 2.63e-01 | 2.88e-01 | 1.80e-01 | 2.96e-01 | 1.13e-02 | 2.85e-03 | 1.06e-03 | 4.12e-02 | 7.69e-04 | 8.98e-01 |
| POSITIVE REGULATION OF CELL KILLING | 75 | 1.22e-04 | 4.12e-03 | 0.52200 | -2.67e-01 | -2.96e-01 | -1.66e-01 | -2.91e-01 | -3.34e-02 | 6.40e-05 | 9.17e-06 | 1.27e-02 | 1.36e-05 | 6.17e-01 |
| POSITIVE REGULATION OF CENTRIOLE REPLICATION | 9 | 2.36e-01 | 7.59e-01 | 0.52200 | 1.51e-01 | 7.54e-02 | 3.55e-01 | 6.33e-02 | 3.37e-01 | 4.34e-01 | 6.95e-01 | 6.51e-02 | 7.42e-01 | 8.00e-02 |
| NEGATIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE I | 11 | 7.01e-01 | 1.00e+00 | 0.52100 | 2.59e-01 | 2.31e-01 | 2.84e-01 | 2.21e-01 | 1.48e-01 | 1.37e-01 | 1.84e-01 | 1.03e-01 | 2.05e-01 | 3.94e-01 |
| POSITIVE REGULATION OF CELL PROLIFERATION INVOLVED IN KIDNEY DEVELOPMENT | 9 | 6.41e-01 | 1.00e+00 | 0.52100 | -2.53e-01 | -2.39e-01 | -2.42e-01 | -2.93e-01 | -7.97e-02 | 1.89e-01 | 2.14e-01 | 2.09e-01 | 1.28e-01 | 6.79e-01 |
| SODIUM INDEPENDENT ORGANIC ANION TRANSPORT | 15 | 2.28e-01 | 7.50e-01 | 0.52000 | -2.62e-01 | -2.36e-01 | -2.39e-01 | -2.94e-01 | 5.62e-02 | 7.93e-02 | 1.14e-01 | 1.09e-01 | 4.86e-02 | 7.06e-01 |
| LACTATE TRANSMEMBRANE TRANSPORT | 7 | 6.97e-01 | 1.00e+00 | 0.52000 | -2.91e-01 | -3.07e-01 | -1.78e-01 | -2.37e-01 | 6.24e-02 | 1.82e-01 | 1.60e-01 | 4.15e-01 | 2.78e-01 | 7.75e-01 |
| GOLGI DISASSEMBLY | 6 | 6.92e-01 | 1.00e+00 | 0.52000 | 2.98e-01 | 2.77e-01 | 2.85e-01 | 1.52e-01 | -2.12e-02 | 2.07e-01 | 2.39e-01 | 2.26e-01 | 5.18e-01 | 9.28e-01 |
| REGULATION OF NEUTROPHIL CHEMOTAXIS | 31 | 3.15e-03 | 5.47e-02 | 0.52000 | -2.72e-01 | -3.37e-01 | -1.36e-01 | -2.36e-01 | 9.65e-02 | 8.76e-03 | 1.18e-03 | 1.89e-01 | 2.32e-02 | 3.52e-01 |
| POSITIVE REGULATION OF GROWTH HORMONE SECRETION | 9 | 2.23e-01 | 7.45e-01 | 0.52000 | 2.15e-01 | 1.60e-01 | 3.04e-01 | 2.59e-01 | 1.97e-01 | 2.65e-01 | 4.06e-01 | 1.15e-01 | 1.78e-01 | 3.07e-01 |
| CELLULAR RESPONSE TO UV B | 12 | 3.20e-01 | 8.47e-01 | 0.51900 | 2.72e-01 | 3.28e-01 | 1.48e-01 | 2.53e-01 | -4.49e-02 | 1.03e-01 | 4.94e-02 | 3.76e-01 | 1.30e-01 | 7.88e-01 |
| RETINAL CELL APOPTOTIC PROCESS | 7 | 6.77e-01 | 1.00e+00 | 0.51800 | 2.76e-01 | 2.74e-01 | 1.26e-01 | 3.17e-01 | -3.37e-02 | 2.07e-01 | 2.09e-01 | 5.63e-01 | 1.46e-01 | 8.77e-01 |
| NEGATIVE REGULATION OF CGMP MEDIATED SIGNALING | 6 | 4.04e-01 | 9.05e-01 | 0.51800 | -4.08e-03 | 6.16e-02 | -2.47e-01 | 9.23e-02 | -4.42e-01 | 9.86e-01 | 7.94e-01 | 2.95e-01 | 6.95e-01 | 6.10e-02 |
| REGULATION OF RENAL SODIUM EXCRETION | 8 | 5.06e-01 | 9.48e-01 | 0.51800 | 2.43e-01 | 2.55e-01 | 2.17e-01 | 1.80e-01 | -2.53e-01 | 2.33e-01 | 2.11e-01 | 2.88e-01 | 3.77e-01 | 2.15e-01 |
| REGULATION OF PHOSPHATIDYLCHOLINE BIOSYNTHETIC PROCESS | 5 | 6.09e-01 | 9.90e-01 | 0.51700 | -3.02e-01 | -2.60e-01 | -1.99e-01 | -2.63e-01 | 8.12e-03 | 2.43e-01 | 3.14e-01 | 4.42e-01 | 3.08e-01 | 9.75e-01 |
| PROSTHETIC GROUP METABOLIC PROCESS | 6 | 8.30e-01 | 1.00e+00 | 0.51700 | 2.21e-01 | 2.00e-01 | 2.73e-01 | 1.87e-01 | 2.64e-01 | 3.49e-01 | 3.96e-01 | 2.47e-01 | 4.29e-01 | 2.63e-01 |
| NETRIN ACTIVATED SIGNALING PATHWAY | 9 | 3.86e-01 | 8.92e-01 | 0.51700 | -2.01e-01 | -1.49e-01 | -2.34e-01 | -1.75e-01 | -3.46e-01 | 2.97e-01 | 4.39e-01 | 2.25e-01 | 3.64e-01 | 7.21e-02 |
| NEGATIVE REGULATION BY HOST OF VIRAL PROCESS | 14 | 4.61e-01 | 9.32e-01 | 0.51700 | -2.62e-01 | -2.53e-01 | -1.79e-01 | -3.01e-01 | -1.10e-01 | 9.01e-02 | 1.01e-01 | 2.47e-01 | 5.13e-02 | 4.76e-01 |
| ESTABLISHMENT OF LEFT RIGHT ASYMMETRY | 6 | 7.07e-01 | 1.00e+00 | 0.51700 | 2.72e-01 | 2.80e-01 | 3.16e-01 | 1.16e-01 | 4.40e-02 | 2.49e-01 | 2.35e-01 | 1.81e-01 | 6.23e-01 | 8.52e-01 |
| NEGATIVE REGULATION OF PHOSPHOLIPASE ACTIVITY | 7 | 3.67e-01 | 8.79e-01 | 0.51600 | 4.85e-02 | 8.70e-02 | -1.22e-01 | 5.34e-02 | -4.89e-01 | 8.24e-01 | 6.90e-01 | 5.77e-01 | 8.07e-01 | 2.51e-02 |
| RESPIRATORY BURST INVOLVED IN INFLAMMATORY RESPONSE | 9 | 5.23e-01 | 9.53e-01 | 0.51600 | 2.77e-01 | 2.59e-01 | 3.29e-01 | 1.11e-01 | 4.50e-02 | 1.51e-01 | 1.78e-01 | 8.74e-02 | 5.65e-01 | 8.15e-01 |
| GENERAL ADAPTATION SYNDROME BEHAVIORAL PROCESS | 5 | 7.65e-01 | 1.00e+00 | 0.51600 | -2.55e-01 | -2.01e-01 | -2.18e-01 | -3.19e-01 | -1.04e-01 | 3.23e-01 | 4.36e-01 | 3.99e-01 | 2.16e-01 | 6.86e-01 |
| CRANIAL NERVE FORMATION | 10 | 1.59e-01 | 6.58e-01 | 0.51600 | 2.62e-01 | 1.65e-01 | 3.16e-01 | 2.51e-01 | 8.50e-02 | 1.52e-01 | 3.66e-01 | 8.35e-02 | 1.69e-01 | 6.42e-01 |
| POSITIVE REGULATION OF MUSCLE CONTRACTION | 46 | 4.88e-02 | 3.59e-01 | 0.51600 | 2.69e-01 | 2.67e-01 | 2.18e-01 | 2.73e-01 | 1.03e-02 | 1.61e-03 | 1.73e-03 | 1.04e-02 | 1.34e-03 | 9.04e-01 |
| OVIDUCT DEVELOPMENT | 5 | 8.12e-01 | 1.00e+00 | 0.51600 | -2.77e-01 | -2.94e-01 | -2.82e-01 | -1.45e-01 | -4.22e-02 | 2.83e-01 | 2.55e-01 | 2.75e-01 | 5.74e-01 | 8.70e-01 |
| CORTISOL BIOSYNTHETIC PROCESS | 10 | 7.65e-01 | 1.00e+00 | 0.51500 | 2.63e-01 | 2.66e-01 | 2.45e-01 | 2.44e-01 | 7.45e-02 | 1.50e-01 | 1.45e-01 | 1.79e-01 | 1.81e-01 | 6.83e-01 |
| REGULATION OF LUNG BLOOD PRESSURE | 5 | 6.41e-01 | 1.00e+00 | 0.51500 | 1.54e-01 | 2.03e-01 | -3.10e-02 | 2.38e-01 | -3.78e-01 | 5.51e-01 | 4.32e-01 | 9.04e-01 | 3.57e-01 | 1.43e-01 |
| RESPONSE TO L GLUTAMATE | 14 | 3.45e-01 | 8.64e-01 | 0.51500 | 2.26e-01 | 2.11e-01 | 2.97e-01 | 1.90e-01 | 2.12e-01 | 1.43e-01 | 1.72e-01 | 5.40e-02 | 2.17e-01 | 1.70e-01 |
| NEGATIVE REGULATION OF TOLL LIKE RECEPTOR 4 SIGNALING PATHWAY | 14 | 1.32e-01 | 6.03e-01 | 0.51500 | -2.47e-01 | -2.83e-01 | -2.22e-01 | -2.73e-01 | -5.14e-03 | 1.09e-01 | 6.69e-02 | 1.51e-01 | 7.65e-02 | 9.73e-01 |
| RNA POLYMERASE II PREINITIATION COMPLEX ASSEMBLY | 53 | 2.22e-04 | 6.76e-03 | 0.51500 | 2.10e-01 | 1.53e-01 | 3.30e-01 | 1.34e-01 | 2.66e-01 | 8.22e-03 | 5.45e-02 | 3.21e-05 | 9.15e-02 | 8.23e-04 |
| POSITIVE REGULATION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 6 | 7.34e-01 | 1.00e+00 | 0.51500 | 2.65e-01 | 3.18e-01 | 1.15e-01 | 2.69e-01 | -8.77e-02 | 2.60e-01 | 1.77e-01 | 6.25e-01 | 2.55e-01 | 7.10e-01 |
| NEGATIVE REGULATION OF T HELPER 17 TYPE IMMUNE RESPONSE | 12 | 3.51e-01 | 8.70e-01 | 0.51400 | -2.67e-01 | -2.68e-01 | -1.14e-01 | -3.29e-01 | 2.21e-03 | 1.09e-01 | 1.08e-01 | 4.96e-01 | 4.81e-02 | 9.89e-01 |
| ALPHA KETOGLUTARATE TRANSPORT | 7 | 6.83e-01 | 1.00e+00 | 0.51400 | 2.63e-01 | 3.14e-01 | 1.86e-01 | 2.46e-01 | -3.88e-02 | 2.28e-01 | 1.50e-01 | 3.95e-01 | 2.60e-01 | 8.59e-01 |
| POSITIVE REGULATION OF LIPOPROTEIN PARTICLE CLEARANCE | 11 | 1.73e-01 | 6.77e-01 | 0.51400 | 2.59e-01 | 3.26e-01 | 8.57e-02 | 2.10e-01 | -1.99e-01 | 1.37e-01 | 6.12e-02 | 6.23e-01 | 2.28e-01 | 2.53e-01 |
| INTERLEUKIN 13 PRODUCTION | 21 | 2.21e-02 | 2.22e-01 | 0.51400 | -1.89e-01 | -2.38e-01 | -7.73e-02 | -1.54e-01 | 3.77e-01 | 1.33e-01 | 5.88e-02 | 5.40e-01 | 2.21e-01 | 2.80e-03 |
| CORTISOL METABOLIC PROCESS | 12 | 6.43e-01 | 1.00e+00 | 0.51400 | 2.69e-01 | 2.90e-01 | 2.18e-01 | 2.43e-01 | -2.18e-02 | 1.06e-01 | 8.16e-02 | 1.90e-01 | 1.45e-01 | 8.96e-01 |
| ADENYLATE CYCLASE INHIBITING SEROTONIN RECEPTOR SIGNALING PATHWAY | 7 | 1.29e-01 | 5.97e-01 | 0.51300 | -8.09e-02 | -7.72e-02 | -4.99e-02 | -1.15e-01 | -4.85e-01 | 7.11e-01 | 7.24e-01 | 8.19e-01 | 6.00e-01 | 2.62e-02 |
| SOMATOTROPIN SECRETING CELL DIFFERENTIATION | 5 | 3.08e-01 | 8.35e-01 | 0.51300 | 1.35e-01 | 1.95e-01 | 1.37e-01 | 1.64e-01 | 4.01e-01 | 6.02e-01 | 4.51e-01 | 5.95e-01 | 5.25e-01 | 1.20e-01 |
| PEPTIDE MODIFICATION | 5 | 4.41e-01 | 9.26e-01 | 0.51200 | 2.28e-01 | 1.83e-01 | 1.27e-01 | 3.39e-01 | -2.15e-01 | 3.78e-01 | 4.79e-01 | 6.22e-01 | 1.89e-01 | 4.05e-01 |
| GLUTAMATE REUPTAKE | 6 | 4.77e-01 | 9.40e-01 | 0.51200 | 2.30e-01 | 2.91e-01 | 1.22e-01 | 3.30e-01 | -2.90e-02 | 3.28e-01 | 2.17e-01 | 6.05e-01 | 1.61e-01 | 9.02e-01 |
| PIRNA PROCESSING | 24 | 4.46e-03 | 7.06e-02 | 0.51200 | -1.95e-01 | -1.97e-01 | -3.20e-01 | -1.24e-01 | -2.61e-01 | 9.87e-02 | 9.56e-02 | 6.72e-03 | 2.91e-01 | 2.67e-02 |
| REGULATION OF NATURAL KILLER CELL ACTIVATION | 42 | 8.64e-03 | 1.14e-01 | 0.51200 | -2.57e-01 | -2.77e-01 | -1.31e-01 | -3.17e-01 | -4.49e-02 | 3.99e-03 | 1.91e-03 | 1.42e-01 | 3.73e-04 | 6.15e-01 |
| POSITIVE REGULATION OF NATURAL KILLER CELL ACTIVATION | 25 | 8.66e-02 | 4.86e-01 | 0.51200 | -2.64e-01 | -2.78e-01 | -1.15e-01 | -3.18e-01 | 2.66e-02 | 2.25e-02 | 1.61e-02 | 3.19e-01 | 5.85e-03 | 8.18e-01 |
| IRON SULFUR CLUSTER ASSEMBLY | 27 | 3.39e-02 | 2.93e-01 | 0.51200 | 2.69e-01 | 2.64e-01 | 3.24e-01 | 1.21e-01 | -1.90e-02 | 1.55e-02 | 1.74e-02 | 3.59e-03 | 2.76e-01 | 8.65e-01 |
| POSITIVE REGULATION OF PHOSPHOLIPID BIOSYNTHETIC PROCESS | 9 | 4.48e-01 | 9.30e-01 | 0.51200 | -1.89e-01 | -1.21e-01 | -3.25e-01 | -9.91e-02 | -3.10e-01 | 3.26e-01 | 5.28e-01 | 9.16e-02 | 6.07e-01 | 1.07e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE CHEMOTAXIS | 21 | 3.88e-01 | 8.92e-01 | 0.51100 | -2.74e-01 | -2.73e-01 | -2.60e-01 | -2.11e-01 | 4.08e-04 | 2.98e-02 | 3.05e-02 | 3.89e-02 | 9.45e-02 | 9.97e-01 |
| POSITIVE REGULATION OF MONONUCLEAR CELL MIGRATION | 69 | 2.23e-03 | 4.20e-02 | 0.51100 | -2.75e-01 | -2.91e-01 | -1.89e-01 | -2.49e-01 | 5.74e-02 | 7.70e-05 | 2.82e-05 | 6.72e-03 | 3.47e-04 | 4.09e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE DEGRANULATION | 12 | 4.04e-03 | 6.53e-02 | 0.51100 | -1.77e-01 | -2.90e-01 | 1.40e-01 | -3.39e-01 | 1.04e-01 | 2.90e-01 | 8.23e-02 | 4.01e-01 | 4.17e-02 | 5.33e-01 |
| MACROPHAGE COLONY STIMULATING FACTOR SIGNALING PATHWAY | 7 | 6.88e-01 | 1.00e+00 | 0.51100 | -2.73e-01 | -2.98e-01 | -2.45e-01 | -1.53e-01 | 1.19e-01 | 2.11e-01 | 1.72e-01 | 2.62e-01 | 4.84e-01 | 5.85e-01 |
| REGULATION OF TOLERANCE INDUCTION | 19 | 2.98e-01 | 8.24e-01 | 0.51000 | -2.64e-01 | -2.94e-01 | -1.61e-01 | -2.44e-01 | 1.38e-01 | 4.67e-02 | 2.64e-02 | 2.26e-01 | 6.54e-02 | 2.96e-01 |
| LIPOPHAGY | 7 | 4.59e-01 | 9.32e-01 | 0.51000 | -2.40e-01 | -2.76e-01 | -2.53e-02 | -3.55e-01 | 1.24e-02 | 2.72e-01 | 2.06e-01 | 9.08e-01 | 1.04e-01 | 9.55e-01 |
| HINDGUT DEVELOPMENT | 8 | 2.47e-01 | 7.74e-01 | 0.51000 | 2.57e-01 | 1.78e-01 | 3.98e-01 | 5.20e-02 | 3.75e-02 | 2.08e-01 | 3.83e-01 | 5.11e-02 | 7.99e-01 | 8.54e-01 |
| VASCULOGENESIS INVOLVED IN CORONARY VASCULAR MORPHOGENESIS | 5 | 9.02e-01 | 1.00e+00 | 0.51000 | 2.33e-01 | 2.05e-01 | 2.95e-01 | 1.90e-01 | 2.02e-01 | 3.66e-01 | 4.27e-01 | 2.54e-01 | 4.62e-01 | 4.33e-01 |
| NEGATIVE REGULATION OF NOTCH SIGNALING PATHWAY | 38 | 2.90e-02 | 2.64e-01 | 0.51000 | 2.64e-01 | 2.78e-01 | 2.48e-01 | 2.20e-01 | -5.34e-02 | 4.80e-03 | 2.99e-03 | 8.11e-03 | 1.88e-02 | 5.69e-01 |
| NUCLEOTIDE SUGAR BIOSYNTHETIC PROCESS | 19 | 4.77e-02 | 3.54e-01 | 0.51000 | 2.79e-01 | 2.81e-01 | 3.03e-01 | 9.05e-02 | -6.22e-02 | 3.52e-02 | 3.42e-02 | 2.24e-02 | 4.95e-01 | 6.39e-01 |
| RESPONSE TO HYDROSTATIC PRESSURE | 7 | 4.04e-01 | 9.05e-01 | 0.51000 | 2.47e-01 | 2.94e-01 | 1.11e-02 | 3.14e-01 | -1.18e-01 | 2.58e-01 | 1.78e-01 | 9.59e-01 | 1.50e-01 | 5.88e-01 |
| NEGATIVE REGULATION OF DENDRITIC CELL DIFFERENTIATION | 6 | 6.55e-02 | 4.17e-01 | 0.51000 | 3.17e-02 | 3.45e-02 | 1.76e-01 | -2.19e-01 | -4.23e-01 | 8.93e-01 | 8.84e-01 | 4.55e-01 | 3.53e-01 | 7.30e-02 |
| NADPH OXIDATION | 5 | 5.75e-01 | 9.79e-01 | 0.51000 | 2.04e-01 | 2.78e-01 | 4.78e-02 | 2.95e-01 | -2.27e-01 | 4.29e-01 | 2.82e-01 | 8.53e-01 | 2.53e-01 | 3.80e-01 |
| OLIGOSACCHARIDE LIPID INTERMEDIATE BIOSYNTHETIC PROCESS | 20 | 3.41e-02 | 2.94e-01 | 0.50900 | 2.58e-01 | 2.68e-01 | 3.06e-01 | 1.06e-01 | -1.27e-01 | 4.60e-02 | 3.78e-02 | 1.78e-02 | 4.13e-01 | 3.25e-01 |
| GOLGI TO ENDOSOME TRANSPORT | 17 | 1.70e-01 | 6.75e-01 | 0.50900 | -2.64e-01 | -2.88e-01 | -1.05e-01 | -2.51e-01 | 1.80e-01 | 5.92e-02 | 3.98e-02 | 4.52e-01 | 7.30e-02 | 1.98e-01 |
| REGULATION OF DEFENSE RESPONSE TO BACTERIUM | 20 | 7.31e-02 | 4.45e-01 | 0.50900 | 2.56e-01 | 2.89e-01 | 1.56e-01 | 2.56e-01 | 1.41e-01 | 4.75e-02 | 2.52e-02 | 2.26e-01 | 4.74e-02 | 2.76e-01 |
| POSITIVE REGULATION OF DIGESTIVE SYSTEM PROCESS | 12 | 4.50e-01 | 9.30e-01 | 0.50900 | 2.39e-01 | 2.20e-01 | 1.73e-01 | 3.00e-01 | 1.82e-01 | 1.52e-01 | 1.87e-01 | 2.98e-01 | 7.18e-02 | 2.75e-01 |
| T CELL CYTOKINE PRODUCTION | 36 | 3.87e-03 | 6.42e-02 | 0.50800 | -2.18e-01 | -2.62e-01 | -3.70e-02 | -2.75e-01 | 2.56e-01 | 2.36e-02 | 6.54e-03 | 7.01e-01 | 4.35e-03 | 7.79e-03 |
| PROTEIN LOCALIZATION TO CHROMOSOME TELOMERIC REGION | 28 | 1.45e-01 | 6.29e-01 | 0.50800 | -2.71e-01 | -2.84e-01 | -1.62e-01 | -2.58e-01 | 1.08e-01 | 1.32e-02 | 9.27e-03 | 1.39e-01 | 1.83e-02 | 3.21e-01 |
| CYTOPLASMIC TRANSLATION | 141 | 1.08e-08 | 1.23e-06 | 0.50800 | 2.62e-01 | 2.45e-01 | 3.14e-01 | 1.49e-01 | 9.10e-02 | 7.64e-08 | 4.80e-07 | 1.19e-10 | 2.23e-03 | 6.21e-02 |
| OXYGEN METABOLIC PROCESS | 5 | 4.51e-01 | 9.30e-01 | 0.50800 | -2.77e-01 | -2.38e-01 | -1.14e-01 | -3.32e-01 | -4.05e-02 | 2.84e-01 | 3.56e-01 | 6.58e-01 | 1.99e-01 | 8.75e-01 |
| REGULATION OF T HELPER 17 CELL LINEAGE COMMITMENT | 7 | 2.93e-01 | 8.22e-01 | 0.50800 | -2.59e-01 | -1.78e-01 | -1.99e-01 | -3.30e-01 | -1.03e-01 | 2.36e-01 | 4.16e-01 | 3.62e-01 | 1.30e-01 | 6.36e-01 |
| EPITHELIAL CELL FATE COMMITMENT | 14 | 8.67e-02 | 4.86e-01 | 0.50800 | 2.84e-01 | 2.45e-01 | 3.12e-01 | 9.55e-02 | -1.05e-01 | 6.62e-02 | 1.13e-01 | 4.34e-02 | 5.36e-01 | 4.98e-01 |
| REGULATION OF GASTRULATION | 16 | 1.89e-01 | 6.99e-01 | 0.50700 | 2.71e-01 | 3.12e-01 | 2.23e-01 | 1.72e-01 | -8.39e-02 | 6.06e-02 | 3.06e-02 | 1.22e-01 | 2.34e-01 | 5.61e-01 |
| TYPE II PNEUMOCYTE DIFFERENTIATION | 6 | 9.01e-01 | 1.00e+00 | 0.50700 | 2.64e-01 | 2.63e-01 | 2.35e-01 | 2.50e-01 | -3.18e-02 | 2.64e-01 | 2.65e-01 | 3.19e-01 | 2.88e-01 | 8.93e-01 |
| REGULATION OF EOSINOPHIL MIGRATION | 6 | 4.91e-01 | 9.45e-01 | 0.50700 | -2.57e-01 | -3.01e-01 | -3.40e-02 | -3.08e-01 | 6.93e-02 | 2.76e-01 | 2.02e-01 | 8.85e-01 | 1.92e-01 | 7.69e-01 |
| MATURATION OF 5 8S RRNA FROM TRICISTRONIC RRNA TRANSCRIPT SSU RRNA 5 8S RRNA LSU RRNA | 25 | 4.52e-02 | 3.44e-01 | 0.50700 | 2.02e-01 | 1.69e-01 | 2.84e-01 | 1.11e-01 | 3.07e-01 | 8.05e-02 | 1.45e-01 | 1.38e-02 | 3.35e-01 | 7.83e-03 |
| RIBOSOMAL SMALL SUBUNIT EXPORT FROM NUCLEUS | 8 | 2.17e-04 | 6.68e-03 | 0.50600 | 2.07e-01 | 2.13e-01 | 2.88e-01 | -1.64e-01 | 2.41e-01 | 3.11e-01 | 2.97e-01 | 1.58e-01 | 4.21e-01 | 2.39e-01 |
| RESPONSE TO IMMOBILIZATION STRESS | 21 | 3.83e-01 | 8.92e-01 | 0.50600 | 2.78e-01 | 2.71e-01 | 2.47e-01 | 2.11e-01 | -6.40e-03 | 2.75e-02 | 3.17e-02 | 4.98e-02 | 9.41e-02 | 9.59e-01 |
| REGULATION OF BLOOD VOLUME BY RENIN ANGIOTENSIN | 6 | 9.13e-01 | 1.00e+00 | 0.50600 | 2.65e-01 | 2.60e-01 | 2.37e-01 | 2.48e-01 | -2.88e-02 | 2.60e-01 | 2.71e-01 | 3.15e-01 | 2.93e-01 | 9.03e-01 |
| NEGATIVE REGULATION OF METALLOPEPTIDASE ACTIVITY | 12 | 6.65e-01 | 1.00e+00 | 0.50600 | -2.64e-01 | -2.73e-01 | -1.61e-01 | -2.90e-01 | 4.56e-02 | 1.14e-01 | 1.01e-01 | 3.35e-01 | 8.24e-02 | 7.85e-01 |
| PROTEIN IMPORT | 7 | 1.93e-02 | 2.03e-01 | 0.50600 | 1.40e-01 | 2.11e-01 | 2.96e-01 | -1.50e-02 | 3.23e-01 | 5.20e-01 | 3.34e-01 | 1.76e-01 | 9.45e-01 | 1.39e-01 |
| NEGATIVE REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS | 6 | 3.28e-01 | 8.53e-01 | 0.50600 | 2.22e-01 | 2.31e-01 | 3.68e-01 | -9.75e-03 | 1.32e-01 | 3.46e-01 | 3.28e-01 | 1.18e-01 | 9.67e-01 | 5.74e-01 |
| NEGATIVE REGULATION OF PROTEIN POLYUBIQUITINATION | 8 | 3.45e-01 | 8.64e-01 | 0.50500 | -2.60e-01 | -2.08e-01 | -1.58e-01 | -3.35e-01 | 8.38e-02 | 2.02e-01 | 3.09e-01 | 4.39e-01 | 1.01e-01 | 6.82e-01 |
| URINARY BLADDER SMOOTH MUSCLE CONTRACTION | 7 | 7.69e-01 | 1.00e+00 | 0.50500 | 2.57e-01 | 2.60e-01 | 1.54e-01 | 2.28e-01 | -2.12e-01 | 2.39e-01 | 2.33e-01 | 4.81e-01 | 2.95e-01 | 3.32e-01 |
| FOLIC ACID CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 7 | 2.11e-01 | 7.33e-01 | 0.50400 | -2.08e-01 | -2.94e-01 | -7.83e-02 | -3.06e-01 | 1.57e-01 | 3.40e-01 | 1.78e-01 | 7.20e-01 | 1.60e-01 | 4.72e-01 |
| SEBACEOUS GLAND DEVELOPMENT | 10 | 5.00e-01 | 9.47e-01 | 0.50400 | -1.87e-01 | -1.46e-01 | -2.76e-01 | -1.24e-01 | -3.26e-01 | 3.05e-01 | 4.24e-01 | 1.30e-01 | 4.99e-01 | 7.42e-02 |
| REGULATION OF TOLL LIKE RECEPTOR 2 SIGNALING PATHWAY | 12 | 3.86e-01 | 8.92e-01 | 0.50400 | -2.36e-01 | -2.68e-01 | -8.36e-02 | -3.34e-01 | 9.23e-02 | 1.58e-01 | 1.08e-01 | 6.16e-01 | 4.53e-02 | 5.80e-01 |
| REGULATION OF FOREBRAIN NEURON DIFFERENTIATION | 5 | 2.30e-01 | 7.52e-01 | 0.50400 | 1.98e-01 | 1.56e-01 | 4.22e-01 | -1.11e-01 | -2.30e-02 | 4.44e-01 | 5.46e-01 | 1.03e-01 | 6.66e-01 | 9.29e-01 |
| REGULATION OF ANTIGEN PROCESSING AND PRESENTATION | 19 | 9.41e-02 | 5.06e-01 | 0.50400 | -2.64e-01 | -3.10e-01 | -9.94e-02 | -2.62e-01 | 9.64e-02 | 4.60e-02 | 1.92e-02 | 4.53e-01 | 4.82e-02 | 4.67e-01 |
| GOLGI VESICLE FUSION TO TARGET MEMBRANE | 5 | 6.43e-01 | 1.00e+00 | 0.50400 | 2.42e-01 | 2.54e-01 | 1.65e-01 | 1.04e-01 | -3.04e-01 | 3.49e-01 | 3.25e-01 | 5.23e-01 | 6.86e-01 | 2.38e-01 |
| DENDRITIC CELL APOPTOTIC PROCESS | 11 | 2.49e-01 | 7.75e-01 | 0.50400 | -2.50e-01 | -3.08e-01 | -5.54e-02 | -3.01e-01 | 5.01e-02 | 1.51e-01 | 7.70e-02 | 7.50e-01 | 8.34e-02 | 7.73e-01 |
| POSITIVE REGULATION OF EPITHELIAL TUBE FORMATION | 8 | 2.86e-01 | 8.12e-01 | 0.50400 | -1.32e-01 | -1.88e-01 | 1.16e-01 | -2.73e-01 | 3.36e-01 | 5.17e-01 | 3.57e-01 | 5.71e-01 | 1.81e-01 | 9.96e-02 |
| CARBON CATABOLITE REGULATION OF TRANSCRIPTION | 7 | 6.56e-01 | 1.00e+00 | 0.50400 | 2.54e-01 | 2.38e-01 | 3.46e-01 | 1.00e-01 | 4.92e-02 | 2.44e-01 | 2.76e-01 | 1.12e-01 | 6.47e-01 | 8.22e-01 |
| ESCRT COMPLEX DISASSEMBLY | 10 | 4.60e-01 | 9.32e-01 | 0.50300 | 2.11e-01 | 1.83e-01 | 3.18e-01 | 8.36e-02 | 2.59e-01 | 2.48e-01 | 3.16e-01 | 8.13e-02 | 6.47e-01 | 1.57e-01 |
| URONIC ACID METABOLIC PROCESS | 26 | 6.93e-02 | 4.32e-01 | 0.50300 | -2.07e-01 | -1.92e-01 | -2.82e-01 | -1.68e-01 | -2.56e-01 | 6.73e-02 | 8.93e-02 | 1.30e-02 | 1.39e-01 | 2.38e-02 |
| NEGATIVE REGULATION OF MHC CLASS II BIOSYNTHETIC PROCESS | 6 | 3.53e-01 | 8.71e-01 | 0.50300 | -4.07e-02 | -8.61e-02 | 2.23e-01 | -1.77e-01 | 4.04e-01 | 8.63e-01 | 7.15e-01 | 3.43e-01 | 4.54e-01 | 8.69e-02 |
| NEGATIVE REGULATION OF VIRAL TRANSCRIPTION | 14 | 2.29e-01 | 7.51e-01 | 0.50300 | 1.83e-01 | 1.65e-01 | 2.78e-01 | 9.28e-02 | 3.26e-01 | 2.35e-01 | 2.86e-01 | 7.19e-02 | 5.48e-01 | 3.45e-02 |
| NEURAL PLATE REGIONALIZATION | 6 | 5.81e-01 | 9.85e-01 | 0.50200 | 2.08e-01 | 2.30e-01 | 1.50e-01 | 1.98e-01 | -3.07e-01 | 3.78e-01 | 3.30e-01 | 5.23e-01 | 4.01e-01 | 1.92e-01 |
| POSITIVE REGULATION OF HIGH DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 7 | 2.68e-01 | 7.95e-01 | 0.50200 | 2.18e-01 | 2.81e-01 | -2.51e-02 | 2.13e-01 | -2.83e-01 | 3.19e-01 | 1.97e-01 | 9.08e-01 | 3.30e-01 | 1.95e-01 |
| CELLULAR RESPONSE TO OXYGEN GLUCOSE DEPRIVATION | 5 | 3.85e-01 | 8.92e-01 | 0.50200 | 2.22e-01 | 2.97e-01 | 1.15e-01 | 6.23e-02 | -3.12e-01 | 3.89e-01 | 2.51e-01 | 6.56e-01 | 8.10e-01 | 2.28e-01 |
| POSITIVE REGULATION OF PROTEIN KINASE A SIGNALING | 12 | 4.12e-02 | 3.26e-01 | 0.50100 | 3.96e-02 | 5.07e-02 | -3.74e-03 | -9.24e-02 | -4.89e-01 | 8.12e-01 | 7.61e-01 | 9.82e-01 | 5.80e-01 | 3.37e-03 |
| ANTEROGRADE DENDRITIC TRANSPORT OF NEUROTRANSMITTER RECEPTOR COMPLEX | 5 | 7.81e-01 | 1.00e+00 | 0.50100 | -2.61e-01 | -2.31e-01 | -1.44e-01 | -3.17e-01 | 9.29e-02 | 3.12e-01 | 3.71e-01 | 5.78e-01 | 2.19e-01 | 7.19e-01 |
| REGULATION OF LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 28 | 1.04e-01 | 5.36e-01 | 0.50100 | -2.52e-01 | -2.54e-01 | -1.78e-01 | -2.64e-01 | 1.50e-01 | 2.12e-02 | 2.01e-02 | 1.03e-01 | 1.57e-02 | 1.69e-01 |
| REGULATION OF SKELETAL MUSCLE TISSUE REGENERATION | 8 | 9.11e-02 | 4.98e-01 | 0.50100 | 2.25e-01 | 2.83e-01 | -6.89e-02 | 2.89e-01 | -1.80e-01 | 2.72e-01 | 1.66e-01 | 7.36e-01 | 1.57e-01 | 3.77e-01 |
| INTESTINAL CHOLESTEROL ABSORPTION | 18 | 6.04e-02 | 4.03e-01 | 0.50100 | 2.08e-01 | 2.36e-01 | 1.04e-01 | 3.16e-01 | 2.04e-01 | 1.27e-01 | 8.31e-02 | 4.44e-01 | 2.03e-02 | 1.33e-01 |
| REGULATION OF ANTIMICROBIAL PEPTIDE PRODUCTION | 9 | 3.08e-02 | 2.74e-01 | 0.50100 | 1.47e-01 | 2.15e-01 | -1.95e-01 | 3.08e-01 | -2.24e-01 | 4.45e-01 | 2.64e-01 | 3.11e-01 | 1.09e-01 | 2.44e-01 |
| NEGATIVE REGULATION OF PROTEIN IMPORT INTO NUCLEUS | 15 | 4.01e-01 | 9.01e-01 | 0.50100 | -2.66e-01 | -2.30e-01 | -2.80e-01 | -2.18e-01 | 4.03e-02 | 7.48e-02 | 1.24e-01 | 6.01e-02 | 1.43e-01 | 7.87e-01 |
| POSITIVE REGULATION OF UBIQUITIN PROTEIN LIGASE ACTIVITY | 9 | 7.08e-01 | 1.00e+00 | 0.50100 | 2.57e-01 | 2.79e-01 | 1.72e-01 | 2.10e-01 | -1.82e-01 | 1.82e-01 | 1.48e-01 | 3.71e-01 | 2.75e-01 | 3.45e-01 |
| HIGH DENSITY LIPOPROTEIN PARTICLE REMODELING | 16 | 2.94e-01 | 8.22e-01 | 0.50100 | 2.38e-01 | 2.57e-01 | 1.53e-01 | 2.86e-01 | 1.52e-01 | 9.99e-02 | 7.53e-02 | 2.89e-01 | 4.76e-02 | 2.94e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY CIRCULATORY RENIN ANGIOTENSIN | 14 | 1.90e-01 | 6.99e-01 | 0.50000 | -2.50e-01 | -2.95e-01 | -5.84e-02 | -2.67e-01 | 1.60e-01 | 1.05e-01 | 5.59e-02 | 7.05e-01 | 8.32e-02 | 2.99e-01 |
| POSITIVE REGULATION OF MRNA 3 END PROCESSING | 6 | 7.16e-01 | 1.00e+00 | 0.50000 | -2.40e-01 | -2.53e-01 | -1.17e-01 | -3.04e-01 | -1.47e-01 | 3.08e-01 | 2.82e-01 | 6.18e-01 | 1.97e-01 | 5.33e-01 |
| CHORIONIC TROPHOBLAST CELL PROLIFERATION | 5 | 3.19e-01 | 8.47e-01 | 0.50000 | 2.23e-01 | 3.35e-01 | 6.77e-02 | 2.88e-01 | 3.01e-03 | 3.87e-01 | 1.94e-01 | 7.93e-01 | 2.65e-01 | 9.91e-01 |
| REGULATION OF MITOCHONDRIAL FUSION | 11 | 4.05e-01 | 9.06e-01 | 0.50000 | -2.14e-01 | -2.37e-01 | -6.18e-02 | -2.27e-01 | 3.04e-01 | 2.20e-01 | 1.73e-01 | 7.23e-01 | 1.92e-01 | 8.11e-02 |
| NEGATIVE REGULATION OF PEPTIDYL LYSINE ACETYLATION | 6 | 7.14e-02 | 4.39e-01 | 0.50000 | -6.03e-02 | -2.14e-03 | 9.78e-02 | -1.66e-01 | 4.57e-01 | 7.98e-01 | 9.93e-01 | 6.78e-01 | 4.81e-01 | 5.26e-02 |
| POSITIVE REGULATION OF INTERLEUKIN 4 PRODUCTION | 24 | 5.59e-02 | 3.85e-01 | 0.49900 | -2.20e-01 | -2.54e-01 | -9.82e-02 | -1.91e-01 | 3.00e-01 | 6.24e-02 | 3.11e-02 | 4.05e-01 | 1.05e-01 | 1.10e-02 |
| REGULATION OF GUANYLATE CYCLASE ACTIVITY | 6 | 1.95e-01 | 7.07e-01 | 0.49900 | 1.94e-01 | 2.25e-01 | 1.11e-01 | 3.85e-01 | 1.21e-02 | 4.11e-01 | 3.40e-01 | 6.37e-01 | 1.03e-01 | 9.59e-01 |
| PARENTAL BEHAVIOR | 10 | 5.71e-01 | 9.76e-01 | 0.49900 | 2.66e-01 | 2.26e-01 | 2.31e-01 | 2.63e-01 | -6.93e-02 | 1.45e-01 | 2.17e-01 | 2.06e-01 | 1.50e-01 | 7.04e-01 |
| RESPONSE TO THYROXINE | 5 | 6.71e-01 | 1.00e+00 | 0.49900 | -1.47e-01 | -1.07e-01 | -1.54e-01 | -2.07e-01 | -3.87e-01 | 5.68e-01 | 6.79e-01 | 5.52e-01 | 4.23e-01 | 1.34e-01 |
| OSTEOCLAST PROLIFERATION | 11 | 1.65e-01 | 6.68e-01 | 0.49900 | -4.10e-02 | -1.02e-01 | 1.15e-01 | -5.64e-02 | 4.69e-01 | 8.14e-01 | 5.59e-01 | 5.10e-01 | 7.46e-01 | 7.04e-03 |
| POSITIVE REGULATION OF MEMORY T CELL DIFFERENTIATION | 9 | 4.58e-01 | 9.32e-01 | 0.49900 | -2.73e-01 | -2.23e-01 | -2.39e-01 | -2.29e-01 | -1.22e-01 | 1.56e-01 | 2.47e-01 | 2.15e-01 | 2.35e-01 | 5.25e-01 |
| NOREPINEPHRINE UPTAKE | 8 | 5.51e-01 | 9.65e-01 | 0.49800 | 2.55e-01 | 2.35e-01 | 2.97e-01 | 1.32e-01 | -1.49e-01 | 2.11e-01 | 2.50e-01 | 1.46e-01 | 5.17e-01 | 4.66e-01 |
| SUCCINYL COA METABOLIC PROCESS | 10 | 3.62e-01 | 8.77e-01 | 0.49800 | 2.47e-01 | 2.85e-01 | 2.34e-01 | 1.90e-01 | -1.23e-01 | 1.76e-01 | 1.18e-01 | 2.01e-01 | 2.99e-01 | 5.01e-01 |
| MITOCHONDRIAL ELECTRON TRANSPORT UBIQUINOL TO CYTOCHROME C | 12 | 1.97e-01 | 7.12e-01 | 0.49800 | 2.22e-01 | 1.40e-01 | 3.42e-01 | 1.73e-01 | 1.79e-01 | 1.83e-01 | 4.02e-01 | 4.00e-02 | 2.99e-01 | 2.83e-01 |
| NUCLEOSOME ORGANIZATION | 119 | 2.10e-07 | 1.66e-05 | 0.49800 | 2.35e-01 | 1.96e-01 | 3.18e-01 | 1.50e-01 | 1.75e-01 | 9.18e-06 | 2.22e-04 | 2.02e-09 | 4.72e-03 | 9.77e-04 |
| REGULATION OF IRON ION TRANSPORT | 7 | 2.76e-01 | 8.03e-01 | 0.49800 | -1.90e-01 | -2.84e-01 | 6.94e-02 | -2.59e-01 | 2.43e-01 | 3.84e-01 | 1.93e-01 | 7.50e-01 | 2.35e-01 | 2.65e-01 |
| REGULATION OF APOPTOTIC PROCESS IN BONE MARROW CELL | 5 | 1.71e-01 | 6.75e-01 | 0.49700 | 8.92e-02 | 1.70e-01 | -2.70e-01 | 2.49e-01 | -2.75e-01 | 7.30e-01 | 5.12e-01 | 2.96e-01 | 3.35e-01 | 2.86e-01 |
| MYCOTOXIN METABOLIC PROCESS | 6 | 2.42e-02 | 2.33e-01 | 0.49700 | 1.25e-01 | 1.61e-01 | -2.22e-01 | 3.89e-01 | 7.44e-02 | 5.97e-01 | 4.95e-01 | 3.46e-01 | 9.93e-02 | 7.52e-01 |
| TROPHECTODERMAL CELL DIFFERENTIATION | 19 | 3.24e-01 | 8.48e-01 | 0.49700 | 2.51e-01 | 2.23e-01 | 2.96e-01 | 1.54e-01 | 1.49e-01 | 5.82e-02 | 9.25e-02 | 2.53e-02 | 2.44e-01 | 2.61e-01 |
| NEGATIVE REGULATION OF CHEMOKINE C X C MOTIF LIGAND 2 PRODUCTION | 5 | 9.23e-02 | 5.02e-01 | 0.49600 | 1.58e-01 | 3.00e-01 | -1.06e-01 | 9.76e-02 | -3.33e-01 | 5.40e-01 | 2.46e-01 | 6.81e-01 | 7.05e-01 | 1.97e-01 |
| CELL MOTILITY INVOLVED IN CEREBRAL CORTEX RADIAL GLIA GUIDED MIGRATION | 8 | 5.65e-01 | 9.72e-01 | 0.49600 | -2.44e-01 | -1.83e-01 | -3.58e-01 | -1.31e-01 | -9.20e-02 | 2.33e-01 | 3.71e-01 | 7.99e-02 | 5.20e-01 | 6.52e-01 |
| NEGATIVE REGULATION OF CALCIUM ION IMPORT | 10 | 6.06e-01 | 9.90e-01 | 0.49600 | -2.07e-01 | -1.87e-01 | -2.21e-01 | -2.40e-01 | -2.49e-01 | 2.58e-01 | 3.07e-01 | 2.25e-01 | 1.90e-01 | 1.72e-01 |
| REGULATION OF MACROPHAGE APOPTOTIC PROCESS | 11 | 3.26e-01 | 8.50e-01 | 0.49600 | -2.30e-01 | -2.35e-01 | -5.84e-02 | -3.55e-01 | 9.23e-02 | 1.87e-01 | 1.77e-01 | 7.37e-01 | 4.14e-02 | 5.96e-01 |
| POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA1 PRODUCTION | 6 | 2.01e-01 | 7.17e-01 | 0.49600 | 2.09e-01 | 2.81e-01 | -9.17e-02 | 3.28e-01 | -8.57e-02 | 3.76e-01 | 2.33e-01 | 6.97e-01 | 1.64e-01 | 7.16e-01 |
| EOSINOPHIL MIGRATION | 31 | 1.93e-02 | 2.02e-01 | 0.49600 | -2.74e-01 | -2.68e-01 | -2.54e-01 | -1.38e-01 | 1.25e-01 | 8.28e-03 | 9.85e-03 | 1.44e-02 | 1.84e-01 | 2.28e-01 |
| FUNGIFORM PAPILLA DEVELOPMENT | 6 | 6.96e-01 | 1.00e+00 | 0.49600 | -2.28e-01 | -2.34e-01 | -6.22e-02 | -3.43e-01 | 1.30e-01 | 3.33e-01 | 3.20e-01 | 7.92e-01 | 1.45e-01 | 5.82e-01 |
| LYMPHANGIOGENESIS | 18 | 9.63e-02 | 5.12e-01 | 0.49500 | 2.42e-01 | 2.53e-01 | 2.41e-01 | 2.14e-01 | -1.37e-01 | 7.55e-02 | 6.29e-02 | 7.64e-02 | 1.16e-01 | 3.14e-01 |
| COMMON BILE DUCT DEVELOPMENT | 5 | 3.99e-01 | 8.98e-01 | 0.49500 | -1.57e-01 | -1.08e-01 | -1.33e-01 | -3.45e-01 | -2.69e-01 | 5.44e-01 | 6.75e-01 | 6.08e-01 | 1.81e-01 | 2.98e-01 |
| RESPONSE TO PROTOZOAN | 31 | 2.73e-11 | 5.88e-09 | 0.49500 | -2.44e-01 | -2.99e-01 | 1.26e-02 | -1.42e-01 | 2.76e-01 | 1.89e-02 | 3.97e-03 | 9.03e-01 | 1.70e-01 | 7.84e-03 |
| NEGATIVE REGULATION OF TROPHOBLAST CELL MIGRATION | 7 | 4.92e-01 | 9.45e-01 | 0.49500 | -2.56e-01 | -2.67e-01 | -6.43e-02 | -3.21e-01 | 2.21e-02 | 2.40e-01 | 2.20e-01 | 7.68e-01 | 1.41e-01 | 9.19e-01 |
| EMBRYONIC CAMERA TYPE EYE MORPHOGENESIS | 26 | 6.46e-02 | 4.13e-01 | 0.49500 | 2.62e-01 | 2.04e-01 | 3.19e-01 | 1.75e-01 | 4.58e-02 | 2.06e-02 | 7.11e-02 | 4.90e-03 | 1.23e-01 | 6.86e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO MICROTUBULE | 5 | 5.92e-01 | 9.86e-01 | 0.49500 | -2.03e-01 | -1.96e-01 | -5.87e-02 | -3.54e-01 | -1.90e-01 | 4.33e-01 | 4.47e-01 | 8.20e-01 | 1.71e-01 | 4.61e-01 |
| VIRAL TRANSLATION | 20 | 2.17e-01 | 7.39e-01 | 0.49400 | 2.50e-01 | 2.14e-01 | 3.09e-01 | 1.95e-01 | 5.00e-02 | 5.29e-02 | 9.69e-02 | 1.66e-02 | 1.32e-01 | 6.99e-01 |
| POSITIVE REGULATION OF HYPERSENSITIVITY | 5 | 8.98e-02 | 4.95e-01 | 0.49400 | -5.30e-02 | -2.00e-01 | 8.95e-02 | 7.44e-02 | 4.34e-01 | 8.37e-01 | 4.39e-01 | 7.29e-01 | 7.73e-01 | 9.30e-02 |
| ENDOPLASMIC RETICULUM TUBULAR NETWORK FORMATION | 5 | 7.14e-01 | 1.00e+00 | 0.49400 | 2.35e-01 | 2.40e-01 | 2.28e-01 | 9.45e-02 | -2.65e-01 | 3.62e-01 | 3.53e-01 | 3.77e-01 | 7.14e-01 | 3.04e-01 |
| INTERLEUKIN 18 MEDIATED SIGNALING PATHWAY | 9 | 6.63e-01 | 1.00e+00 | 0.49400 | -2.27e-01 | -2.25e-01 | -2.77e-01 | -1.87e-01 | -1.75e-01 | 2.39e-01 | 2.43e-01 | 1.49e-01 | 3.32e-01 | 3.63e-01 |
| PROXIMAL TUBULE DEVELOPMENT | 10 | 3.84e-01 | 8.92e-01 | 0.49400 | 2.40e-01 | 2.87e-01 | 1.92e-01 | 1.87e-01 | -1.79e-01 | 1.89e-01 | 1.15e-01 | 2.94e-01 | 3.05e-01 | 3.28e-01 |
| POSITIVE REGULATION OF OSTEOCLAST DIFFERENTIATION | 27 | 2.11e-01 | 7.33e-01 | 0.49400 | -2.68e-01 | -2.80e-01 | -1.79e-01 | -2.47e-01 | 2.24e-02 | 1.60e-02 | 1.18e-02 | 1.08e-01 | 2.61e-02 | 8.41e-01 |
| REGULATION OF IRE1 MEDIATED UNFOLDED PROTEIN RESPONSE | 14 | 6.04e-01 | 9.90e-01 | 0.49400 | 2.65e-01 | 2.47e-01 | 2.53e-01 | 2.01e-01 | 8.96e-02 | 8.61e-02 | 1.10e-01 | 1.01e-01 | 1.92e-01 | 5.62e-01 |
| POSITIVE REGULATION OF SMAD PROTEIN SIGNAL TRANSDUCTION | 26 | 2.91e-01 | 8.18e-01 | 0.49400 | -2.61e-01 | -2.48e-01 | -2.22e-01 | -2.39e-01 | -8.89e-02 | 2.15e-02 | 2.86e-02 | 5.01e-02 | 3.50e-02 | 4.33e-01 |
| RESPONSE TO CHEMOKINE | 96 | 4.79e-05 | 1.86e-03 | 0.49300 | -2.61e-01 | -2.84e-01 | -1.91e-01 | -2.15e-01 | 1.09e-01 | 1.02e-05 | 1.45e-06 | 1.23e-03 | 2.63e-04 | 6.59e-02 |
| IMMUNOLOGICAL MEMORY FORMATION PROCESS | 14 | 2.18e-01 | 7.41e-01 | 0.49300 | -2.78e-01 | -2.35e-01 | -2.06e-01 | -2.58e-01 | -4.56e-02 | 7.20e-02 | 1.28e-01 | 1.81e-01 | 9.48e-02 | 7.68e-01 |
| VIRION ASSEMBLY | 34 | 3.99e-03 | 6.49e-02 | 0.49300 | 1.81e-01 | 1.58e-01 | 3.06e-01 | 6.10e-02 | 2.96e-01 | 6.70e-02 | 1.10e-01 | 1.99e-03 | 5.38e-01 | 2.78e-03 |
| SULFATION | 20 | 1.60e-02 | 1.78e-01 | 0.49300 | -1.93e-01 | -1.50e-01 | -2.93e-01 | -3.80e-02 | -3.11e-01 | 1.36e-01 | 2.47e-01 | 2.33e-02 | 7.68e-01 | 1.61e-02 |
| REGULATION OF ACUTE INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 15 | 1.64e-02 | 1.81e-01 | 0.49300 | -1.95e-01 | -2.78e-01 | 7.70e-02 | -2.69e-01 | 2.23e-01 | 1.90e-01 | 6.27e-02 | 6.06e-01 | 7.15e-02 | 1.34e-01 |
| PROTEIN LOCALIZATION TO CHROMOSOME CENTROMERIC REGION | 38 | 4.78e-03 | 7.45e-02 | 0.49300 | 2.60e-01 | 2.13e-01 | 3.40e-01 | 1.10e-01 | 5.18e-02 | 5.63e-03 | 2.29e-02 | 2.90e-04 | 2.39e-01 | 5.80e-01 |
| DNA REPLICATION SYNTHESIS OF RNA PRIMER | 6 | 4.03e-01 | 9.04e-01 | 0.49300 | -1.60e-01 | -2.40e-01 | -2.09e-02 | -7.85e-02 | 3.91e-01 | 4.98e-01 | 3.09e-01 | 9.29e-01 | 7.39e-01 | 9.69e-02 |
| CYTIDINE TO URIDINE EDITING | 12 | 3.96e-02 | 3.20e-01 | 0.49200 | -2.72e-01 | -1.89e-01 | -2.13e-01 | -2.68e-01 | 1.23e-01 | 1.03e-01 | 2.58e-01 | 2.02e-01 | 1.07e-01 | 4.59e-01 |
| SULFUR AMINO ACID CATABOLIC PROCESS | 10 | 4.62e-01 | 9.33e-01 | 0.49200 | 2.32e-01 | 2.72e-01 | 9.20e-02 | 3.22e-01 | 4.21e-02 | 2.04e-01 | 1.36e-01 | 6.14e-01 | 7.77e-02 | 8.18e-01 |
| DNA DEAMINATION | 13 | 2.33e-01 | 7.54e-01 | 0.49200 | -2.09e-01 | -2.19e-01 | -3.33e-02 | -2.83e-01 | 2.62e-01 | 1.91e-01 | 1.71e-01 | 8.35e-01 | 7.68e-02 | 1.02e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CHROMOSOME TELOMERIC REGION | 12 | 4.52e-01 | 9.30e-01 | 0.49200 | -2.53e-01 | -2.65e-01 | -9.94e-02 | -2.74e-01 | 1.48e-01 | 1.28e-01 | 1.11e-01 | 5.51e-01 | 9.97e-02 | 3.75e-01 |
| REGULATION OF BINDING OF SPERM TO ZONA PELLUCIDA | 5 | 3.93e-01 | 8.92e-01 | 0.49100 | -2.14e-01 | -1.77e-01 | -3.63e-01 | 5.66e-02 | -1.72e-01 | 4.07e-01 | 4.92e-01 | 1.60e-01 | 8.26e-01 | 5.06e-01 |
| NEGATIVE REGULATION OF APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT | 6 | 6.32e-01 | 9.96e-01 | 0.49100 | 2.32e-01 | 2.26e-01 | 2.37e-01 | 1.84e-01 | -2.16e-01 | 3.25e-01 | 3.38e-01 | 3.14e-01 | 4.36e-01 | 3.60e-01 |
| DRINKING BEHAVIOR | 8 | 4.73e-01 | 9.40e-01 | 0.49100 | 2.55e-01 | 2.33e-01 | 1.75e-01 | 1.73e-01 | -2.48e-01 | 2.12e-01 | 2.54e-01 | 3.90e-01 | 3.96e-01 | 2.25e-01 |
| NEGATIVE REGULATION OF TISSUE REMODELING | 21 | 5.05e-02 | 3.67e-01 | 0.49100 | -2.05e-01 | -2.41e-01 | 9.60e-04 | -2.94e-01 | 2.34e-01 | 1.05e-01 | 5.57e-02 | 9.94e-01 | 1.98e-02 | 6.29e-02 |
| TRANSFORMING GROWTH FACTOR BETA2 PRODUCTION | 9 | 7.35e-01 | 1.00e+00 | 0.49100 | 2.46e-01 | 2.52e-01 | 1.50e-01 | 2.53e-01 | -1.75e-01 | 2.01e-01 | 1.91e-01 | 4.35e-01 | 1.89e-01 | 3.63e-01 |
| NUCLEOSIDE DIPHOSPHATE CATABOLIC PROCESS | 12 | 4.82e-01 | 9.43e-01 | 0.49100 | 2.28e-01 | 2.45e-01 | 1.01e-01 | 2.59e-01 | -2.29e-01 | 1.72e-01 | 1.42e-01 | 5.45e-01 | 1.21e-01 | 1.70e-01 |
| FOLATE TRANSMEMBRANE TRANSPORT | 5 | 2.80e-01 | 8.06e-01 | 0.49100 | -1.28e-01 | -1.07e-01 | 1.06e-01 | -2.76e-01 | 3.55e-01 | 6.21e-01 | 6.79e-01 | 6.83e-01 | 2.85e-01 | 1.69e-01 |
| REGULATION OF NEUROTRANSMITTER RECEPTOR LOCALIZATION TO POSTSYNAPTIC SPECIALIZATION MEMBRANE | 8 | 4.75e-01 | 9.40e-01 | 0.49100 | -2.43e-01 | -2.36e-01 | -1.79e-01 | -1.30e-01 | 2.78e-01 | 2.34e-01 | 2.48e-01 | 3.80e-01 | 5.23e-01 | 1.73e-01 |
| NEGATIVE REGULATION OF DOUBLE STRAND BREAK REPAIR VIA NONHOMOLOGOUS END JOINING | 7 | 5.20e-01 | 9.53e-01 | 0.49100 | -1.31e-01 | -1.71e-01 | 3.27e-02 | -1.55e-01 | 4.12e-01 | 5.50e-01 | 4.34e-01 | 8.81e-01 | 4.76e-01 | 5.92e-02 |
| RENAL SODIUM EXCRETION | 11 | 6.68e-01 | 1.00e+00 | 0.49100 | 2.56e-01 | 2.75e-01 | 2.08e-01 | 2.08e-01 | -1.14e-01 | 1.41e-01 | 1.14e-01 | 2.32e-01 | 2.33e-01 | 5.13e-01 |
| POSITIVE REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 11 | 1.14e-01 | 5.61e-01 | 0.49100 | 2.44e-01 | 1.75e-01 | 3.67e-01 | 9.62e-02 | -8.26e-02 | 1.62e-01 | 3.16e-01 | 3.49e-02 | 5.81e-01 | 6.35e-01 |
| REGULATION OF AMPA RECEPTOR ACTIVITY | 23 | 1.45e-01 | 6.29e-01 | 0.49100 | 2.57e-01 | 2.82e-01 | 2.50e-01 | 1.76e-01 | 4.81e-02 | 3.30e-02 | 1.94e-02 | 3.82e-02 | 1.44e-01 | 6.90e-01 |
| NEGATIVE REGULATION OF B CELL ACTIVATION | 31 | 4.78e-05 | 1.86e-03 | 0.49000 | -1.92e-01 | -2.87e-01 | 6.02e-02 | -2.87e-01 | 1.87e-01 | 6.39e-02 | 5.64e-03 | 5.62e-01 | 5.64e-03 | 7.14e-02 |
| TOXIN METABOLIC PROCESS | 14 | 6.38e-02 | 4.13e-01 | 0.49000 | 2.41e-01 | 2.67e-01 | 1.14e-02 | 3.24e-01 | -7.97e-02 | 1.18e-01 | 8.39e-02 | 9.41e-01 | 3.60e-02 | 6.05e-01 |
| EPITHELIAL CELL PROLIFERATION INVOLVED IN PROSTATE GLAND DEVELOPMENT | 10 | 3.41e-01 | 8.59e-01 | 0.49000 | 2.49e-01 | 1.77e-01 | 3.61e-01 | 1.09e-01 | 6.79e-02 | 1.74e-01 | 3.32e-01 | 4.78e-02 | 5.50e-01 | 7.10e-01 |
| MEMBRANE DISASSEMBLY | 11 | 7.14e-01 | 1.00e+00 | 0.49000 | -2.65e-01 | -2.50e-01 | -1.96e-01 | -2.53e-01 | 7.11e-02 | 1.28e-01 | 1.52e-01 | 2.60e-01 | 1.46e-01 | 6.83e-01 |
| RETINAL METABOLIC PROCESS | 18 | 4.86e-02 | 3.59e-01 | 0.49000 | -2.58e-01 | -2.31e-01 | -3.16e-01 | -7.26e-02 | -1.23e-01 | 5.80e-02 | 8.98e-02 | 2.04e-02 | 5.94e-01 | 3.66e-01 |
| NEGATIVE REGULATION OF CALCIUM ION IMPORT ACROSS PLASMA MEMBRANE | 8 | 3.36e-01 | 8.59e-01 | 0.49000 | 1.92e-01 | 2.60e-01 | -5.26e-02 | 3.14e-01 | -1.85e-01 | 3.47e-01 | 2.02e-01 | 7.97e-01 | 1.24e-01 | 3.66e-01 |
| INTRACELLULAR SPHINGOLIPID HOMEOSTASIS | 5 | 7.33e-01 | 1.00e+00 | 0.49000 | 2.13e-01 | 1.84e-01 | 3.33e-01 | 4.06e-02 | 2.19e-01 | 4.08e-01 | 4.77e-01 | 1.97e-01 | 8.75e-01 | 3.97e-01 |
| REGULATION OF PRESYNAPSE ORGANIZATION | 28 | 1.28e-01 | 5.96e-01 | 0.49000 | 2.72e-01 | 2.61e-01 | 2.66e-01 | 1.63e-01 | -8.03e-03 | 1.28e-02 | 1.67e-02 | 1.47e-02 | 1.35e-01 | 9.41e-01 |
| LIMB JOINT MORPHOGENESIS | 5 | 7.13e-02 | 4.39e-01 | 0.48900 | 8.93e-02 | 5.91e-02 | -1.20e-02 | 3.06e-01 | -3.67e-01 | 7.30e-01 | 8.19e-01 | 9.63e-01 | 2.36e-01 | 1.56e-01 |
| REGULATION OF SMOOTHENED SIGNALING PATHWAY INVOLVED IN DORSAL VENTRAL NEURAL TUBE PATTERNING | 11 | 5.42e-01 | 9.59e-01 | 0.48900 | -2.34e-01 | -2.40e-01 | -1.42e-01 | -2.18e-01 | 2.43e-01 | 1.78e-01 | 1.67e-01 | 4.14e-01 | 2.10e-01 | 1.63e-01 |
| VIRAL BUDDING | 25 | 1.70e-02 | 1.85e-01 | 0.48900 | 1.52e-01 | 1.25e-01 | 2.95e-01 | 3.95e-02 | 3.35e-01 | 1.90e-01 | 2.80e-01 | 1.07e-02 | 7.33e-01 | 3.73e-03 |
| RECEPTOR TRANSACTIVATION | 5 | 4.77e-01 | 9.40e-01 | 0.48900 | 1.69e-01 | 1.42e-01 | 3.05e-02 | 1.80e-01 | -3.96e-01 | 5.12e-01 | 5.82e-01 | 9.06e-01 | 4.86e-01 | 1.25e-01 |
| TRIF DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 11 | 5.82e-02 | 3.95e-01 | 0.48900 | -2.20e-01 | -2.76e-01 | 5.21e-02 | -3.17e-01 | 1.05e-01 | 2.06e-01 | 1.13e-01 | 7.65e-01 | 6.82e-02 | 5.47e-01 |
| RESPONSE TO VASOPRESSIN | 8 | 7.46e-01 | 1.00e+00 | 0.48900 | 2.30e-01 | 2.46e-01 | 1.96e-01 | 2.37e-01 | 1.78e-01 | 2.61e-01 | 2.29e-01 | 3.38e-01 | 2.46e-01 | 3.84e-01 |
| CDP CHOLINE PATHWAY | 6 | 5.60e-01 | 9.69e-01 | 0.48900 | 1.65e-01 | 1.22e-01 | 1.50e-01 | 2.18e-01 | 3.56e-01 | 4.84e-01 | 6.05e-01 | 5.26e-01 | 3.54e-01 | 1.31e-01 |
| KERATINOCYTE DEVELOPMENT | 13 | 2.13e-02 | 2.16e-01 | 0.48900 | 1.85e-01 | 2.25e-01 | -8.89e-02 | 3.79e-01 | -5.05e-02 | 2.49e-01 | 1.60e-01 | 5.79e-01 | 1.79e-02 | 7.53e-01 |
| 4FE 4S CLUSTER ASSEMBLY | 5 | 5.24e-01 | 9.54e-01 | 0.48900 | 1.93e-01 | 1.86e-01 | 2.96e-01 | 1.16e-03 | 2.82e-01 | 4.56e-01 | 4.72e-01 | 2.52e-01 | 9.96e-01 | 2.74e-01 |
| HYPOTHALAMUS GONADOTROPHIN RELEASING HORMONE NEURON DIFFERENTIATION | 7 | 7.12e-01 | 1.00e+00 | 0.48800 | -2.44e-01 | -2.81e-01 | -2.01e-01 | -2.37e-01 | 6.03e-02 | 2.63e-01 | 1.98e-01 | 3.57e-01 | 2.78e-01 | 7.82e-01 |
| HYALOID VASCULAR PLEXUS REGRESSION | 7 | 4.35e-01 | 9.22e-01 | 0.48800 | 2.93e-02 | 6.31e-02 | -1.27e-01 | 3.80e-02 | -4.65e-01 | 8.93e-01 | 7.72e-01 | 5.60e-01 | 8.62e-01 | 3.32e-02 |
| REGULATION OF CARDIAC MUSCLE ADAPTATION | 17 | 2.86e-01 | 8.12e-01 | 0.48800 | 2.55e-01 | 2.67e-01 | 1.07e-01 | 2.83e-01 | -1.01e-01 | 6.84e-02 | 5.63e-02 | 4.47e-01 | 4.33e-02 | 4.70e-01 |
| VENTRAL SPINAL CORD INTERNEURON DIFFERENTIATION | 13 | 3.87e-01 | 8.92e-01 | 0.48800 | 2.50e-01 | 2.35e-01 | 3.26e-01 | 1.06e-01 | 5.29e-02 | 1.18e-01 | 1.42e-01 | 4.17e-02 | 5.10e-01 | 7.41e-01 |
| DNA STRAND RESECTION INVOLVED IN REPLICATION FORK PROCESSING | 8 | 5.20e-01 | 9.53e-01 | 0.48800 | -2.50e-01 | -2.98e-01 | -7.64e-02 | -2.83e-01 | 2.79e-02 | 2.21e-01 | 1.44e-01 | 7.08e-01 | 1.66e-01 | 8.91e-01 |
| FATTY ACID HOMEOSTASIS | 16 | 3.58e-01 | 8.74e-01 | 0.48800 | 2.68e-01 | 2.46e-01 | 2.94e-01 | 1.39e-01 | 1.99e-02 | 6.38e-02 | 8.91e-02 | 4.18e-02 | 3.35e-01 | 8.90e-01 |
| PROTEIN DNA COMPLEX DISASSEMBLY | 21 | 1.21e-01 | 5.80e-01 | 0.48700 | 2.34e-01 | 2.43e-01 | 2.94e-01 | 1.52e-01 | 1.19e-01 | 6.33e-02 | 5.44e-02 | 1.96e-02 | 2.29e-01 | 3.45e-01 |
| POSITIVE REGULATION OF AXON GUIDANCE | 5 | 6.21e-01 | 9.91e-01 | 0.48600 | -2.07e-01 | -1.56e-01 | -1.93e-01 | -3.28e-01 | -1.56e-01 | 4.23e-01 | 5.47e-01 | 4.54e-01 | 2.04e-01 | 5.45e-01 |
| FOREBRAIN DORSAL VENTRAL PATTERN FORMATION | 7 | 6.45e-01 | 1.00e+00 | 0.48600 | 2.29e-01 | 1.86e-01 | 3.38e-01 | 6.94e-02 | 1.74e-01 | 2.94e-01 | 3.94e-01 | 1.21e-01 | 7.50e-01 | 4.26e-01 |
| PROTECTION FROM NON HOMOLOGOUS END JOINING AT TELOMERE | 8 | 4.14e-01 | 9.11e-01 | 0.48600 | 2.00e-01 | 1.60e-01 | 3.72e-01 | 5.83e-02 | 1.69e-01 | 3.27e-01 | 4.34e-01 | 6.83e-02 | 7.75e-01 | 4.07e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 7 | 7.20e-01 | 1.00e+00 | 0.48600 | -2.34e-01 | -1.68e-01 | -2.97e-01 | -2.00e-01 | -1.57e-01 | 2.84e-01 | 4.41e-01 | 1.74e-01 | 3.59e-01 | 4.72e-01 |
| ASYMMETRIC NEUROBLAST DIVISION | 5 | 8.01e-01 | 1.00e+00 | 0.48600 | -2.21e-01 | -2.47e-01 | -1.52e-01 | -2.26e-01 | 2.29e-01 | 3.93e-01 | 3.39e-01 | 5.57e-01 | 3.82e-01 | 3.75e-01 |
| REGULATION OF TYPE B PANCREATIC CELL DEVELOPMENT | 9 | 5.20e-01 | 9.53e-01 | 0.48600 | -2.21e-01 | -2.21e-01 | -1.03e-01 | -3.40e-01 | -1.10e-01 | 2.51e-01 | 2.50e-01 | 5.91e-01 | 7.76e-02 | 5.69e-01 |
| REGULATION OF PERK MEDIATED UNFOLDED PROTEIN RESPONSE | 11 | 6.10e-01 | 9.90e-01 | 0.48600 | 2.52e-01 | 2.49e-01 | 2.10e-01 | 2.13e-01 | 1.44e-01 | 1.47e-01 | 1.52e-01 | 2.28e-01 | 2.21e-01 | 4.07e-01 |
| REPLICATIVE SENESCENCE | 17 | 2.48e-01 | 7.75e-01 | 0.48600 | 2.78e-01 | 2.75e-01 | 2.23e-01 | 1.81e-01 | -1.71e-02 | 4.72e-02 | 4.95e-02 | 1.12e-01 | 1.95e-01 | 9.03e-01 |
| MEGAKARYOCYTE DEVELOPMENT | 22 | 1.17e-02 | 1.41e-01 | 0.48500 | 4.89e-02 | -1.03e-03 | 2.36e-01 | -5.60e-02 | 4.17e-01 | 6.92e-01 | 9.93e-01 | 5.52e-02 | 6.49e-01 | 7.07e-04 |
| REGULATION OF PROTEIN K63 LINKED UBIQUITINATION | 13 | 4.33e-01 | 9.19e-01 | 0.48500 | -2.36e-01 | -2.33e-01 | -1.35e-01 | -2.32e-01 | 2.30e-01 | 1.41e-01 | 1.45e-01 | 3.98e-01 | 1.48e-01 | 1.52e-01 |
| POSITIVE REGULATION OF MAINTENANCE OF SISTER CHROMATID COHESION | 6 | 8.49e-02 | 4.79e-01 | 0.48400 | 2.54e-01 | 1.11e-01 | 3.82e-01 | 1.03e-01 | -6.04e-03 | 2.81e-01 | 6.37e-01 | 1.05e-01 | 6.61e-01 | 9.80e-01 |
| NEGATIVE REGULATION OF B CELL DIFFERENTIATION | 6 | 7.89e-01 | 1.00e+00 | 0.48300 | 2.01e-01 | 1.58e-01 | 2.87e-01 | 1.09e-01 | 2.72e-01 | 3.93e-01 | 5.03e-01 | 2.24e-01 | 6.43e-01 | 2.49e-01 |
| REGULATION OF DNA DEMETHYLATION | 11 | 3.98e-01 | 8.98e-01 | 0.48300 | -2.49e-01 | -1.76e-01 | -2.87e-01 | -2.17e-01 | -1.04e-01 | 1.53e-01 | 3.12e-01 | 9.90e-02 | 2.13e-01 | 5.50e-01 |
| UBIQUITIN INDEPENDENT PROTEIN CATABOLIC PROCESS VIA THE MULTIVESICULAR BODY SORTING PATHWAY | 5 | 7.94e-01 | 1.00e+00 | 0.48300 | 1.77e-01 | 1.79e-01 | 2.00e-01 | 1.57e-01 | 3.25e-01 | 4.94e-01 | 4.89e-01 | 4.40e-01 | 5.44e-01 | 2.08e-01 |
| 5S CLASS RRNA TRANSCRIPTION BY RNA POLYMERASE III | 6 | 7.17e-01 | 1.00e+00 | 0.48300 | 2.43e-01 | 2.40e-01 | 2.88e-01 | 1.39e-01 | -1.18e-01 | 3.02e-01 | 3.09e-01 | 2.21e-01 | 5.56e-01 | 6.18e-01 |
| SUBTELOMERIC HETEROCHROMATIN FORMATION | 8 | 4.20e-01 | 9.11e-01 | 0.48200 | 1.47e-01 | 1.20e-01 | 3.14e-01 | 3.33e-03 | 3.13e-01 | 4.71e-01 | 5.58e-01 | 1.24e-01 | 9.87e-01 | 1.25e-01 |
| INTERFERON ALPHA PRODUCTION | 27 | 1.65e-02 | 1.81e-01 | 0.48200 | -2.08e-01 | -2.54e-01 | -5.89e-03 | -2.54e-01 | 2.45e-01 | 6.17e-02 | 2.22e-02 | 9.58e-01 | 2.21e-02 | 2.74e-02 |
| POSITIVE REGULATION OF NEUTROPHIL MIGRATION | 30 | 1.60e-03 | 3.33e-02 | 0.48200 | -2.41e-01 | -3.11e-01 | -5.25e-02 | -2.59e-01 | 8.95e-02 | 2.23e-02 | 3.16e-03 | 6.19e-01 | 1.42e-02 | 3.96e-01 |
| MEDIUM CHAIN FATTY ACID CATABOLIC PROCESS | 5 | 6.11e-01 | 9.90e-01 | 0.48200 | -2.21e-01 | -2.12e-01 | -1.97e-01 | -3.10e-01 | 6.07e-02 | 3.91e-01 | 4.11e-01 | 4.46e-01 | 2.31e-01 | 8.14e-01 |
| PHOSPHATIDYLINOSITOL MEDIATED SIGNALING | 26 | 2.92e-01 | 8.20e-01 | 0.48200 | -2.59e-01 | -2.50e-01 | -2.56e-01 | -1.83e-01 | -5.93e-02 | 2.25e-02 | 2.71e-02 | 2.36e-02 | 1.06e-01 | 6.01e-01 |
| REGULATION OF HAIR FOLLICLE DEVELOPMENT | 19 | 2.10e-01 | 7.33e-01 | 0.48200 | 2.58e-01 | 2.09e-01 | 2.97e-01 | 1.83e-01 | -1.93e-02 | 5.14e-02 | 1.15e-01 | 2.52e-02 | 1.66e-01 | 8.84e-01 |
| LONG CHAIN FATTY ACID IMPORT ACROSS PLASMA MEMBRANE | 10 | 5.67e-01 | 9.72e-01 | 0.48200 | 2.33e-01 | 2.65e-01 | 1.08e-01 | 3.06e-01 | 4.93e-02 | 2.03e-01 | 1.46e-01 | 5.56e-01 | 9.36e-02 | 7.87e-01 |
| QUINOLINATE METABOLIC PROCESS | 5 | 4.20e-01 | 9.11e-01 | 0.48200 | -2.46e-01 | -3.08e-01 | -4.70e-02 | -2.65e-01 | -6.79e-02 | 3.41e-01 | 2.33e-01 | 8.56e-01 | 3.06e-01 | 7.93e-01 |
| URETER DEVELOPMENT | 18 | 2.13e-02 | 2.17e-01 | 0.48200 | 2.31e-01 | 2.21e-01 | 3.23e-01 | 4.39e-02 | -1.54e-01 | 8.96e-02 | 1.05e-01 | 1.77e-02 | 7.47e-01 | 2.59e-01 |
| REGULATION OF WNT PROTEIN SECRETION | 5 | 4.99e-01 | 9.47e-01 | 0.48100 | -1.96e-01 | -8.49e-02 | -3.31e-01 | -9.22e-02 | -2.60e-01 | 4.48e-01 | 7.42e-01 | 1.99e-01 | 7.21e-01 | 3.14e-01 |
| WNT PROTEIN SECRETION | 5 | 4.99e-01 | 9.47e-01 | 0.48100 | -1.96e-01 | -8.49e-02 | -3.31e-01 | -9.22e-02 | -2.60e-01 | 4.48e-01 | 7.42e-01 | 1.99e-01 | 7.21e-01 | 3.14e-01 |
| REGULATION OF SKELETAL MUSCLE TISSUE GROWTH | 6 | 2.75e-01 | 8.02e-01 | 0.48100 | 7.64e-02 | 1.38e-01 | 3.64e-02 | -8.21e-02 | -4.45e-01 | 7.46e-01 | 5.58e-01 | 8.77e-01 | 7.28e-01 | 5.88e-02 |
| MITOTIC CYTOKINETIC PROCESS | 26 | 5.45e-02 | 3.82e-01 | 0.48100 | 1.74e-01 | 1.40e-01 | 2.92e-01 | 9.60e-02 | 2.94e-01 | 1.24e-01 | 2.16e-01 | 9.92e-03 | 3.97e-01 | 9.38e-03 |
| NEGATIVE REGULATION OF VASCULAR WOUND HEALING | 7 | 6.75e-01 | 1.00e+00 | 0.48100 | 2.73e-01 | 2.38e-01 | 2.09e-01 | 2.32e-01 | 4.95e-02 | 2.11e-01 | 2.75e-01 | 3.38e-01 | 2.89e-01 | 8.21e-01 |
| POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 10 | 7.43e-01 | 1.00e+00 | 0.48100 | -2.53e-01 | -2.23e-01 | -2.48e-01 | -2.36e-01 | 8.04e-03 | 1.66e-01 | 2.21e-01 | 1.74e-01 | 1.96e-01 | 9.65e-01 |
| REGULATION OF COMPLEMENT ACTIVATION ALTERNATIVE PATHWAY | 5 | 5.75e-01 | 9.79e-01 | 0.48100 | 1.55e-01 | 1.32e-01 | 7.81e-02 | 3.15e-01 | 2.91e-01 | 5.49e-01 | 6.10e-01 | 7.62e-01 | 2.23e-01 | 2.60e-01 |
| FUNGIFORM PAPILLA MORPHOGENESIS | 5 | 6.20e-01 | 9.90e-01 | 0.48100 | -1.72e-01 | -1.72e-01 | 8.00e-03 | -2.87e-01 | 2.99e-01 | 5.05e-01 | 5.06e-01 | 9.75e-01 | 2.67e-01 | 2.46e-01 |
| NEGATIVE REGULATION OF NEURON MIGRATION | 9 | 6.53e-01 | 1.00e+00 | 0.48100 | -2.39e-01 | -2.21e-01 | -3.10e-01 | -1.06e-01 | -1.34e-01 | 2.15e-01 | 2.51e-01 | 1.07e-01 | 5.83e-01 | 4.86e-01 |
| ANAPHASE PROMOTING COMPLEX DEPENDENT CATABOLIC PROCESS | 24 | 4.86e-02 | 3.59e-01 | 0.48100 | 2.52e-01 | 2.48e-01 | 3.00e-01 | 9.16e-02 | 9.07e-02 | 3.29e-02 | 3.57e-02 | 1.11e-02 | 4.37e-01 | 4.42e-01 |
| NEGATIVE REGULATION OF TYPE B PANCREATIC CELL APOPTOTIC PROCESS | 6 | 5.32e-01 | 9.54e-01 | 0.48100 | 5.89e-02 | -7.63e-04 | 2.68e-01 | -2.83e-02 | 3.93e-01 | 8.03e-01 | 9.97e-01 | 2.55e-01 | 9.04e-01 | 9.51e-02 |
| MITOCHONDRIAL RESPIRASOME ASSEMBLY | 10 | 2.14e-01 | 7.37e-01 | 0.48000 | 2.58e-01 | 1.71e-01 | 3.09e-01 | 1.55e-01 | 1.25e-01 | 1.58e-01 | 3.50e-01 | 9.07e-02 | 3.95e-01 | 4.94e-01 |
| TRICARBOXYLIC ACID METABOLIC PROCESS | 14 | 4.99e-01 | 9.47e-01 | 0.48000 | 2.55e-01 | 2.36e-01 | 2.75e-01 | 1.72e-01 | -7.16e-02 | 9.87e-02 | 1.27e-01 | 7.51e-02 | 2.65e-01 | 6.43e-01 |
| VENTRAL MIDLINE DEVELOPMENT | 6 | 2.68e-01 | 7.95e-01 | 0.48000 | 2.37e-01 | 2.69e-01 | 2.97e-01 | -1.79e-02 | -1.19e-01 | 3.16e-01 | 2.54e-01 | 2.08e-01 | 9.39e-01 | 6.15e-01 |
| N TERMINAL PROTEIN LIPIDATION | 6 | 5.64e-01 | 9.71e-01 | 0.48000 | 1.03e-01 | 2.44e-02 | 2.29e-01 | 1.00e-01 | 3.96e-01 | 6.61e-01 | 9.17e-01 | 3.31e-01 | 6.71e-01 | 9.29e-02 |
| RIBOSOMAL LARGE SUBUNIT BIOGENESIS | 70 | 4.87e-05 | 1.87e-03 | 0.48000 | 2.35e-01 | 2.19e-01 | 3.22e-01 | 9.73e-02 | 1.20e-01 | 6.65e-04 | 1.55e-03 | 3.27e-06 | 1.59e-01 | 8.16e-02 |
| REGULATION OF URINE VOLUME | 20 | 1.61e-01 | 6.59e-01 | 0.48000 | 1.86e-01 | 1.81e-01 | 2.39e-01 | 1.64e-01 | 2.81e-01 | 1.51e-01 | 1.61e-01 | 6.43e-02 | 2.05e-01 | 2.94e-02 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS BY VEGF ACTIVATED VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 5 | 1.76e-01 | 6.82e-01 | 0.48000 | 1.28e-01 | 1.55e-01 | 2.75e-01 | -1.26e-01 | 3.13e-01 | 6.21e-01 | 5.47e-01 | 2.87e-01 | 6.26e-01 | 2.25e-01 |
| NEGATIVE REGULATION OF ACTION POTENTIAL | 6 | 6.42e-01 | 1.00e+00 | 0.48000 | 1.15e-01 | 5.06e-02 | 2.75e-01 | 3.27e-02 | 3.72e-01 | 6.27e-01 | 8.30e-01 | 2.44e-01 | 8.90e-01 | 1.15e-01 |
| EMBRYONIC RETINA MORPHOGENESIS IN CAMERA TYPE EYE | 6 | 5.51e-01 | 9.64e-01 | 0.48000 | -2.03e-01 | -2.01e-01 | -5.00e-02 | -3.72e-01 | -8.64e-02 | 3.88e-01 | 3.93e-01 | 8.32e-01 | 1.15e-01 | 7.14e-01 |
| POSITIVE REGULATION OF SYNAPTIC TRANSMISSION CHOLINERGIC | 6 | 8.03e-01 | 1.00e+00 | 0.48000 | -1.71e-01 | -1.31e-01 | -2.52e-01 | -1.48e-01 | -3.14e-01 | 4.69e-01 | 5.77e-01 | 2.85e-01 | 5.31e-01 | 1.83e-01 |
| REGULATION OF FEVER GENERATION | 9 | 5.30e-01 | 9.54e-01 | 0.47900 | -2.16e-01 | -2.56e-01 | -4.12e-02 | -2.26e-01 | 2.55e-01 | 2.63e-01 | 1.83e-01 | 8.31e-01 | 2.41e-01 | 1.85e-01 |
| RESPONSE TO DSRNA | 53 | 5.46e-03 | 8.18e-02 | 0.47900 | -2.47e-01 | -2.31e-01 | -1.72e-01 | -2.68e-01 | 1.16e-01 | 1.83e-03 | 3.57e-03 | 3.06e-02 | 7.37e-04 | 1.45e-01 |
| POSITIVE REGULATION OF I KAPPAB PHOSPHORYLATION | 6 | 6.86e-01 | 1.00e+00 | 0.47900 | 2.25e-01 | 2.21e-01 | 7.44e-02 | 3.52e-01 | 1.54e-02 | 3.40e-01 | 3.50e-01 | 7.52e-01 | 1.35e-01 | 9.48e-01 |
| PHAGOSOME ACIDIFICATION | 7 | 5.25e-01 | 9.54e-01 | 0.47900 | -1.96e-01 | -2.40e-01 | -1.35e-01 | -1.13e-01 | 3.20e-01 | 3.69e-01 | 2.72e-01 | 5.35e-01 | 6.06e-01 | 1.43e-01 |
| REGULATION OF T HELPER 1 TYPE IMMUNE RESPONSE | 31 | 3.13e-02 | 2.77e-01 | 0.47800 | -2.30e-01 | -2.53e-01 | -6.60e-02 | -3.18e-01 | 7.69e-02 | 2.68e-02 | 1.46e-02 | 5.25e-01 | 2.15e-03 | 4.59e-01 |
| POSITIVE REGULATION OF ENDOCYTIC RECYCLING | 8 | 7.74e-01 | 1.00e+00 | 0.47800 | -2.56e-01 | -2.58e-01 | -2.56e-01 | -1.54e-01 | 8.95e-02 | 2.11e-01 | 2.07e-01 | 2.10e-01 | 4.52e-01 | 6.61e-01 |
| VENTRICULAR COMPACT MYOCARDIUM MORPHOGENESIS | 8 | 7.12e-01 | 1.00e+00 | 0.47800 | -2.42e-01 | -2.13e-01 | -2.91e-01 | -1.99e-01 | -1.10e-02 | 2.36e-01 | 2.97e-01 | 1.54e-01 | 3.29e-01 | 9.57e-01 |
| AUTOPHAGY OF PEROXISOME | 10 | 4.99e-01 | 9.47e-01 | 0.47800 | -2.23e-01 | -2.39e-01 | -1.14e-01 | -2.89e-01 | -1.58e-01 | 2.22e-01 | 1.91e-01 | 5.31e-01 | 1.13e-01 | 3.87e-01 |
| COP9 SIGNALOSOME ASSEMBLY | 5 | 8.00e-01 | 1.00e+00 | 0.47800 | 2.45e-01 | 2.17e-01 | 2.23e-01 | 1.61e-01 | -2.13e-01 | 3.42e-01 | 4.01e-01 | 3.88e-01 | 5.32e-01 | 4.09e-01 |
| NEGATIVE REGULATION OF OLIGODENDROCYTE DIFFERENTIATION | 14 | 8.84e-03 | 1.15e-01 | 0.47800 | -1.22e-01 | -1.66e-01 | 1.48e-01 | -3.73e-01 | 1.58e-01 | 4.29e-01 | 2.83e-01 | 3.37e-01 | 1.57e-02 | 3.07e-01 |
| POSITIVE REGULATION OF SODIUM PROTON ANTIPORTER ACTIVITY | 5 | 7.72e-01 | 1.00e+00 | 0.47800 | 1.99e-01 | 1.71e-01 | 1.38e-01 | 2.87e-01 | 2.40e-01 | 4.41e-01 | 5.08e-01 | 5.93e-01 | 2.66e-01 | 3.53e-01 |
| REGULATION OF GLUTAMINE FAMILY AMINO ACID METABOLIC PROCESS | 8 | 2.12e-01 | 7.34e-01 | 0.47700 | 1.73e-01 | 1.84e-01 | 1.28e-02 | 1.01e-01 | -3.92e-01 | 3.97e-01 | 3.67e-01 | 9.50e-01 | 6.19e-01 | 5.49e-02 |
| CERAMIDE 1 PHOSPHATE TRANSPORT | 7 | 7.68e-01 | 1.00e+00 | 0.47700 | 2.65e-01 | 2.87e-01 | 1.89e-01 | 1.81e-01 | -7.85e-02 | 2.25e-01 | 1.88e-01 | 3.86e-01 | 4.07e-01 | 7.19e-01 |
| FRUCTOSE 6 PHOSPHATE METABOLIC PROCESS | 11 | 2.49e-01 | 7.75e-01 | 0.47700 | 2.28e-01 | 1.76e-01 | 1.87e-01 | 3.26e-01 | 5.64e-02 | 1.91e-01 | 3.13e-01 | 2.83e-01 | 6.10e-02 | 7.46e-01 |
| TETRAHYDROFOLATE BIOSYNTHETIC PROCESS | 5 | 2.68e-01 | 7.95e-01 | 0.47700 | -2.08e-01 | -3.18e-01 | -1.13e-01 | -2.29e-01 | 1.35e-01 | 4.22e-01 | 2.18e-01 | 6.63e-01 | 3.76e-01 | 6.02e-01 |
| REGULATION OF ENDOSOME SIZE | 13 | 2.21e-01 | 7.45e-01 | 0.47600 | 2.04e-01 | 1.81e-01 | 3.42e-01 | 9.70e-02 | 1.61e-01 | 2.03e-01 | 2.58e-01 | 3.28e-02 | 5.45e-01 | 3.14e-01 |
| PHOSPHATIDYLGLYCEROL ACYL CHAIN REMODELING | 9 | 5.85e-01 | 9.85e-01 | 0.47600 | 2.42e-01 | 2.79e-01 | 1.14e-01 | 2.72e-01 | 5.81e-02 | 2.09e-01 | 1.47e-01 | 5.55e-01 | 1.57e-01 | 7.63e-01 |
| DOUBLE STRAND BREAK REPAIR VIA SYNTHESIS DEPENDENT STRAND ANNEALING | 8 | 3.42e-01 | 8.60e-01 | 0.47600 | 1.09e-02 | -3.20e-02 | 1.84e-01 | 4.76e-03 | 4.38e-01 | 9.57e-01 | 8.75e-01 | 3.69e-01 | 9.81e-01 | 3.20e-02 |
| REGULATION OF MICROTUBULE NUCLEATION | 17 | 4.29e-01 | 9.17e-01 | 0.47600 | 2.46e-01 | 2.13e-01 | 2.83e-01 | 1.98e-01 | 2.87e-02 | 7.85e-02 | 1.28e-01 | 4.31e-02 | 1.58e-01 | 8.37e-01 |
| REGULATION OF CILIUM BEAT FREQUENCY | 17 | 4.57e-01 | 9.32e-01 | 0.47600 | 2.62e-01 | 2.32e-01 | 2.29e-01 | 2.24e-01 | -3.57e-02 | 6.10e-02 | 9.75e-02 | 1.02e-01 | 1.10e-01 | 7.99e-01 |
| GLYCOSYLCERAMIDE CATABOLIC PROCESS | 6 | 3.87e-01 | 8.92e-01 | 0.47500 | -1.39e-01 | -1.92e-01 | 1.11e-01 | -3.43e-01 | 1.99e-01 | 5.56e-01 | 4.15e-01 | 6.39e-01 | 1.45e-01 | 3.98e-01 |
| NEGATIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 6 | 9.35e-01 | 1.00e+00 | 0.47500 | -2.57e-01 | -2.35e-01 | -2.42e-01 | -2.11e-01 | -3.68e-02 | 2.75e-01 | 3.19e-01 | 3.05e-01 | 3.70e-01 | 8.76e-01 |
| REGULATION OF HIGH DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 10 | 4.22e-01 | 9.12e-01 | 0.47500 | 2.54e-01 | 2.75e-01 | 1.01e-01 | 2.21e-01 | -1.60e-01 | 1.64e-01 | 1.31e-01 | 5.80e-01 | 2.25e-01 | 3.80e-01 |
| SENSORY PERCEPTION OF TASTE | 66 | 1.61e-04 | 5.13e-03 | 0.47500 | -2.45e-01 | -1.97e-01 | -3.22e-01 | -1.22e-01 | -9.09e-02 | 5.75e-04 | 5.71e-03 | 5.99e-06 | 8.78e-02 | 2.02e-01 |
| CAVEOLA ASSEMBLY | 5 | 4.67e-01 | 9.36e-01 | 0.47500 | 1.84e-01 | 2.54e-01 | 1.29e-01 | 2.32e-01 | 2.38e-01 | 4.76e-01 | 3.26e-01 | 6.18e-01 | 3.69e-01 | 3.57e-01 |
| TRANSCYTOSIS | 20 | 2.60e-01 | 7.89e-01 | 0.47400 | 2.05e-01 | 1.99e-01 | 2.47e-01 | 1.59e-01 | 2.39e-01 | 1.12e-01 | 1.23e-01 | 5.57e-02 | 2.20e-01 | 6.44e-02 |
| CELLULAR MODIFIED AMINO ACID CATABOLIC PROCESS | 22 | 4.26e-01 | 9.15e-01 | 0.47400 | 2.48e-01 | 2.42e-01 | 1.91e-01 | 2.59e-01 | -3.72e-02 | 4.42e-02 | 4.95e-02 | 1.21e-01 | 3.54e-02 | 7.62e-01 |
| POSITIVE REGULATION OF HEMOGLOBIN BIOSYNTHETIC PROCESS | 6 | 2.12e-01 | 7.34e-01 | 0.47400 | 2.84e-02 | 4.46e-02 | 2.10e-01 | -1.48e-01 | 3.95e-01 | 9.04e-01 | 8.50e-01 | 3.74e-01 | 5.29e-01 | 9.42e-02 |
| NEGATIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL MIGRATION | 21 | 7.03e-02 | 4.35e-01 | 0.47400 | -2.27e-01 | -2.43e-01 | -2.27e-01 | -2.48e-01 | -1.75e-02 | 7.14e-02 | 5.35e-02 | 7.19e-02 | 4.88e-02 | 8.90e-01 |
| REGULATION OF GLUCOCORTICOID RECEPTOR SIGNALING PATHWAY | 7 | 1.87e-01 | 6.95e-01 | 0.47300 | 1.90e-01 | 1.02e-01 | 3.29e-01 | -1.30e-02 | 2.63e-01 | 3.83e-01 | 6.39e-01 | 1.32e-01 | 9.52e-01 | 2.28e-01 |
| POSITIVE REGULATION OF GLIAL CELL MIGRATION | 11 | 5.32e-01 | 9.54e-01 | 0.47300 | -2.60e-01 | -2.87e-01 | -2.11e-01 | -1.60e-01 | 6.03e-02 | 1.35e-01 | 9.90e-02 | 2.25e-01 | 3.59e-01 | 7.29e-01 |
| NEGATIVE REGULATION OF MEIOTIC NUCLEAR DIVISION | 9 | 7.52e-02 | 4.50e-01 | 0.47300 | -1.34e-01 | -1.64e-01 | 2.63e-02 | -3.81e-01 | -1.82e-01 | 4.87e-01 | 3.96e-01 | 8.92e-01 | 4.76e-02 | 3.44e-01 |
| GROWTH HORMONE RECEPTOR SIGNALING PATHWAY VIA JAK STAT | 10 | 4.63e-01 | 9.33e-01 | 0.47300 | -2.24e-01 | -2.61e-01 | -3.35e-02 | -2.67e-01 | 1.83e-01 | 2.20e-01 | 1.54e-01 | 8.54e-01 | 1.44e-01 | 3.16e-01 |
| HISTONE H3 K9 METHYLATION | 5 | 6.49e-01 | 1.00e+00 | 0.47300 | 1.07e-01 | 4.42e-02 | 2.37e-01 | 8.37e-03 | 3.92e-01 | 6.77e-01 | 8.64e-01 | 3.59e-01 | 9.74e-01 | 1.29e-01 |
| REGULATION OF SYNAPSE PRUNING | 6 | 5.42e-01 | 9.59e-01 | 0.47300 | -1.96e-01 | -2.34e-01 | -1.78e-01 | -2.64e-01 | -1.71e-01 | 4.06e-01 | 3.21e-01 | 4.51e-01 | 2.63e-01 | 4.68e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEOLUS | 6 | 5.64e-01 | 9.71e-01 | 0.47300 | 1.91e-01 | 2.08e-01 | 1.66e-01 | 1.55e-01 | 3.04e-01 | 4.17e-01 | 3.79e-01 | 4.83e-01 | 5.12e-01 | 1.97e-01 |
| ERBB3 SIGNALING PATHWAY | 5 | 5.83e-01 | 9.85e-01 | 0.47200 | 1.20e-01 | 1.64e-01 | -1.27e-01 | 2.73e-01 | -3.02e-01 | 6.44e-01 | 5.24e-01 | 6.24e-01 | 2.90e-01 | 2.42e-01 |
| POSITIVE REGULATION OF HEPATIC STELLATE CELL ACTIVATION | 5 | 2.67e-01 | 7.95e-01 | 0.47200 | -2.73e-01 | -2.67e-01 | -5.83e-02 | -2.59e-01 | 8.36e-02 | 2.91e-01 | 3.01e-01 | 8.21e-01 | 3.17e-01 | 7.46e-01 |
| DETECTION OF TEMPERATURE STIMULUS INVOLVED IN THERMOCEPTION | 5 | 8.92e-01 | 1.00e+00 | 0.47200 | 2.38e-01 | 2.68e-01 | 1.99e-01 | 2.10e-01 | 1.04e-01 | 3.57e-01 | 3.00e-01 | 4.41e-01 | 4.16e-01 | 6.87e-01 |
| MONOTERPENOID METABOLIC PROCESS | 6 | 2.19e-01 | 7.43e-01 | 0.47200 | 2.05e-01 | 1.97e-01 | -5.39e-02 | 3.24e-01 | -1.84e-01 | 3.84e-01 | 4.03e-01 | 8.19e-01 | 1.69e-01 | 4.36e-01 |
| REGULATION OF MEMBRANE INVAGINATION | 15 | 3.66e-01 | 8.79e-01 | 0.47200 | -2.22e-01 | -2.37e-01 | -2.46e-01 | -1.61e-01 | -1.75e-01 | 1.36e-01 | 1.12e-01 | 9.90e-02 | 2.80e-01 | 2.40e-01 |
| HEPATOCYTE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 12 | 2.92e-03 | 5.15e-02 | 0.47200 | -6.90e-02 | 6.48e-02 | -3.08e-01 | 1.40e-01 | -3.15e-01 | 6.79e-01 | 6.97e-01 | 6.45e-02 | 4.01e-01 | 5.91e-02 |
| POSITIVE REGULATION OF METALLOPEPTIDASE ACTIVITY | 10 | 2.85e-02 | 2.61e-01 | 0.47200 | 1.07e-01 | 1.56e-01 | -1.84e-01 | 1.59e-01 | -3.57e-01 | 5.60e-01 | 3.93e-01 | 3.14e-01 | 3.83e-01 | 5.07e-02 |
| CITRULLINE METABOLIC PROCESS | 7 | 8.36e-01 | 1.00e+00 | 0.47100 | 2.34e-01 | 2.51e-01 | 1.98e-01 | 2.54e-01 | 3.09e-02 | 2.84e-01 | 2.51e-01 | 3.65e-01 | 2.45e-01 | 8.88e-01 |
| MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 16 | 1.79e-01 | 6.85e-01 | 0.47100 | -2.44e-01 | -2.70e-01 | -7.28e-02 | -2.89e-01 | 2.60e-02 | 9.05e-02 | 6.18e-02 | 6.14e-01 | 4.53e-02 | 8.57e-01 |
| UV PROTECTION | 12 | 6.16e-01 | 9.90e-01 | 0.47100 | 2.31e-01 | 2.03e-01 | 3.03e-01 | 1.55e-01 | 1.08e-01 | 1.66e-01 | 2.23e-01 | 6.95e-02 | 3.53e-01 | 5.15e-01 |
| LYMPHOCYTE MIGRATION | 117 | 3.36e-06 | 1.80e-04 | 0.47100 | -2.60e-01 | -2.59e-01 | -1.82e-01 | -2.07e-01 | 1.06e-01 | 1.22e-06 | 1.24e-06 | 6.87e-04 | 1.12e-04 | 4.82e-02 |
| MULTI CILIATED EPITHELIAL CELL DIFFERENTIATION | 9 | 5.08e-01 | 9.48e-01 | 0.47100 | -2.25e-01 | -2.10e-01 | -1.02e-01 | -3.28e-01 | -9.23e-02 | 2.43e-01 | 2.74e-01 | 5.97e-01 | 8.80e-02 | 6.32e-01 |
| POSITIVE REGULATION OF HORMONE BIOSYNTHETIC PROCESS | 9 | 7.38e-01 | 1.00e+00 | 0.47100 | -2.58e-01 | -2.19e-01 | -2.82e-01 | -1.64e-01 | -3.01e-02 | 1.80e-01 | 2.56e-01 | 1.44e-01 | 3.94e-01 | 8.76e-01 |
| NEGATIVE REGULATION OF CELL KILLING | 29 | 7.65e-03 | 1.04e-01 | 0.47000 | -2.33e-01 | -3.03e-01 | -7.10e-02 | -2.42e-01 | 1.10e-01 | 2.98e-02 | 4.80e-03 | 5.08e-01 | 2.43e-02 | 3.05e-01 |
| ARTERIAL ENDOTHELIAL CELL DIFFERENTIATION | 6 | 1.30e-01 | 5.98e-01 | 0.47000 | 2.28e-01 | 1.90e-01 | 3.36e-01 | -9.22e-02 | -1.09e-01 | 3.34e-01 | 4.20e-01 | 1.54e-01 | 6.96e-01 | 6.43e-01 |
| TRNA AMINOACYLATION FOR MITOCHONDRIAL PROTEIN TRANSLATION | 8 | 7.85e-01 | 1.00e+00 | 0.47000 | 2.57e-01 | 2.45e-01 | 2.73e-01 | 1.40e-01 | -3.76e-02 | 2.08e-01 | 2.31e-01 | 1.81e-01 | 4.94e-01 | 8.54e-01 |
| ARGININE CATABOLIC PROCESS | 11 | 5.64e-01 | 9.71e-01 | 0.47000 | 2.53e-01 | 2.66e-01 | 1.25e-01 | 2.66e-01 | 4.86e-04 | 1.46e-01 | 1.26e-01 | 4.73e-01 | 1.27e-01 | 9.98e-01 |
| RETINAL BLOOD VESSEL MORPHOGENESIS | 5 | 7.10e-01 | 1.00e+00 | 0.47000 | 2.08e-01 | 1.25e-01 | 3.22e-01 | 1.68e-01 | 1.73e-01 | 4.20e-01 | 6.28e-01 | 2.12e-01 | 5.16e-01 | 5.02e-01 |
| G PROTEIN COUPLED PURINERGIC RECEPTOR SIGNALING PATHWAY | 12 | 5.96e-01 | 9.88e-01 | 0.47000 | 2.23e-01 | 2.19e-01 | 2.26e-01 | 2.44e-01 | 1.09e-01 | 1.81e-01 | 1.88e-01 | 1.75e-01 | 1.43e-01 | 5.12e-01 |
| NEGATIVE REGULATION OF KERATINOCYTE PROLIFERATION | 23 | 1.17e-01 | 5.69e-01 | 0.47000 | 2.55e-01 | 2.60e-01 | 1.29e-01 | 2.28e-01 | -1.38e-01 | 3.41e-02 | 3.06e-02 | 2.83e-01 | 5.82e-02 | 2.53e-01 |
| SCHWANN CELL MIGRATION | 5 | 6.82e-01 | 1.00e+00 | 0.47000 | -1.61e-01 | -2.05e-01 | -5.86e-02 | -1.92e-01 | 3.35e-01 | 5.32e-01 | 4.28e-01 | 8.21e-01 | 4.56e-01 | 1.95e-01 |
| GRANZYME MEDIATED PROGRAMMED CELL DEATH SIGNALING PATHWAY | 8 | 1.40e-01 | 6.24e-01 | 0.47000 | -2.67e-01 | -3.09e-01 | -8.05e-02 | -2.16e-01 | 2.30e-02 | 1.91e-01 | 1.30e-01 | 6.93e-01 | 2.90e-01 | 9.10e-01 |
| RIBONUCLEOSIDE CATABOLIC PROCESS | 20 | 1.37e-01 | 6.18e-01 | 0.46900 | -2.57e-01 | -2.15e-01 | -1.86e-01 | -2.63e-01 | 5.81e-02 | 4.64e-02 | 9.54e-02 | 1.50e-01 | 4.17e-02 | 6.53e-01 |
| ER OVERLOAD RESPONSE | 11 | 1.54e-01 | 6.50e-01 | 0.46900 | 1.83e-01 | 1.67e-01 | 3.49e-01 | -2.00e-02 | 1.90e-01 | 2.93e-01 | 3.37e-01 | 4.52e-02 | 9.09e-01 | 2.75e-01 |
| MAINTENANCE OF ANIMAL ORGAN IDENTITY | 5 | 8.03e-01 | 1.00e+00 | 0.46800 | -2.03e-01 | -1.84e-01 | -1.63e-01 | -3.10e-01 | -1.47e-01 | 4.32e-01 | 4.76e-01 | 5.28e-01 | 2.30e-01 | 5.70e-01 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO OSMOTIC STRESS | 8 | 8.67e-01 | 1.00e+00 | 0.46800 | 2.31e-01 | 2.04e-01 | 2.70e-01 | 1.85e-01 | 1.29e-01 | 2.58e-01 | 3.17e-01 | 1.86e-01 | 3.65e-01 | 5.27e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 10 | 2.08e-01 | 7.30e-01 | 0.46800 | 1.63e-01 | 1.84e-01 | 2.67e-01 | 6.30e-02 | 2.88e-01 | 3.72e-01 | 3.13e-01 | 1.44e-01 | 7.30e-01 | 1.15e-01 |
| CEREBRAL CORTEX NEURON DIFFERENTIATION | 24 | 1.54e-02 | 1.72e-01 | 0.46800 | 2.37e-01 | 2.03e-01 | 3.21e-01 | 6.99e-02 | -1.15e-01 | 4.48e-02 | 8.45e-02 | 6.40e-03 | 5.53e-01 | 3.31e-01 |
| SHORT TERM MEMORY | 10 | 1.90e-01 | 6.99e-01 | 0.46700 | 1.54e-01 | 2.16e-01 | 5.06e-02 | 1.86e-01 | -3.33e-01 | 3.98e-01 | 2.38e-01 | 7.82e-01 | 3.09e-01 | 6.82e-02 |
| REGULATION OF SYNAPTIC VESICLE TRANSPORT | 5 | 7.00e-01 | 1.00e+00 | 0.46700 | -2.26e-01 | -2.51e-01 | -2.76e-01 | -8.01e-02 | -1.47e-01 | 3.82e-01 | 3.32e-01 | 2.85e-01 | 7.56e-01 | 5.70e-01 |
| PROTEIN DE ADP RIBOSYLATION | 5 | 6.63e-01 | 1.00e+00 | 0.46700 | -1.86e-01 | -2.57e-01 | 2.09e-03 | -3.04e-01 | 1.56e-01 | 4.72e-01 | 3.19e-01 | 9.94e-01 | 2.38e-01 | 5.46e-01 |
| POSITIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION | 65 | 1.54e-04 | 4.96e-03 | 0.46700 | 2.01e-01 | 1.44e-01 | 3.09e-01 | 1.29e-01 | 2.11e-01 | 5.10e-03 | 4.51e-02 | 1.61e-05 | 7.19e-02 | 3.28e-03 |
| POSITIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION ELONGATION | 61 | 1.44e-03 | 3.03e-02 | 0.46700 | 2.11e-01 | 1.65e-01 | 2.86e-01 | 1.76e-01 | 1.82e-01 | 4.35e-03 | 2.55e-02 | 1.10e-04 | 1.75e-02 | 1.42e-02 |
| MYELOID DENDRITIC CELL ACTIVATION | 29 | 2.23e-02 | 2.24e-01 | 0.46600 | -2.36e-01 | -2.66e-01 | -1.28e-01 | -1.55e-01 | 2.25e-01 | 2.76e-02 | 1.33e-02 | 2.32e-01 | 1.47e-01 | 3.60e-02 |
| NEUROENDOCRINE CELL DIFFERENTIATION | 16 | 6.88e-02 | 4.30e-01 | 0.46600 | 2.34e-01 | 2.35e-01 | 3.12e-01 | 3.94e-02 | -9.31e-02 | 1.05e-01 | 1.03e-01 | 3.09e-02 | 7.85e-01 | 5.19e-01 |
| POSITIVE REGULATION OF ADIPOSE TISSUE DEVELOPMENT | 10 | 7.58e-01 | 1.00e+00 | 0.46600 | -2.56e-01 | -2.64e-01 | -2.00e-01 | -2.02e-01 | -2.94e-02 | 1.61e-01 | 1.48e-01 | 2.73e-01 | 2.68e-01 | 8.72e-01 |
| SEQUESTERING OF ACTIN MONOMERS | 6 | 4.30e-01 | 9.17e-01 | 0.46600 | 1.23e-01 | 6.62e-02 | 3.60e-01 | -4.92e-02 | 2.57e-01 | 6.02e-01 | 7.79e-01 | 1.27e-01 | 8.35e-01 | 2.77e-01 |
| INNER DYNEIN ARM ASSEMBLY | 16 | 4.17e-01 | 9.11e-01 | 0.46600 | 2.39e-01 | 2.25e-01 | 2.37e-01 | 2.19e-01 | -7.18e-02 | 9.77e-02 | 1.20e-01 | 1.01e-01 | 1.29e-01 | 6.19e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF LIPID ANTIGEN VIA MHC CLASS IB | 7 | 8.65e-01 | 1.00e+00 | 0.46600 | -2.39e-01 | -2.28e-01 | -2.50e-01 | -2.12e-01 | 6.97e-03 | 2.73e-01 | 2.95e-01 | 2.53e-01 | 3.31e-01 | 9.75e-01 |
| RETROGRADE TRANSPORT VESICLE RECYCLING WITHIN GOLGI | 9 | 7.50e-01 | 1.00e+00 | 0.46600 | -2.32e-01 | -2.29e-01 | -1.81e-01 | -2.29e-01 | -1.60e-01 | 2.28e-01 | 2.35e-01 | 3.47e-01 | 2.34e-01 | 4.07e-01 |
| SKELETAL MUSCLE ADAPTATION | 25 | 9.68e-02 | 5.12e-01 | 0.46600 | 2.21e-01 | 2.59e-01 | 5.94e-02 | 2.49e-01 | -1.88e-01 | 5.53e-02 | 2.52e-02 | 6.07e-01 | 3.11e-02 | 1.04e-01 |
| REGULATION OF CARDIAC MUSCLE CELL MEMBRANE POTENTIAL | 7 | 5.98e-01 | 9.89e-01 | 0.46600 | -1.96e-01 | -1.47e-01 | -1.66e-01 | -2.85e-01 | -2.20e-01 | 3.70e-01 | 5.01e-01 | 4.47e-01 | 1.92e-01 | 3.14e-01 |
| REGULATION OF B CELL PROLIFERATION | 63 | 5.51e-05 | 2.08e-03 | 0.46500 | -2.22e-01 | -2.72e-01 | -4.91e-02 | -2.86e-01 | 9.45e-02 | 2.29e-03 | 1.89e-04 | 5.01e-01 | 8.67e-05 | 1.94e-01 |
| ENTERIC NERVOUS SYSTEM DEVELOPMENT | 12 | 7.22e-01 | 1.00e+00 | 0.46500 | 2.57e-01 | 2.47e-01 | 2.38e-01 | 1.79e-01 | 1.64e-02 | 1.23e-01 | 1.38e-01 | 1.54e-01 | 2.83e-01 | 9.21e-01 |
| AUTOPHAGOSOME MEMBRANE DOCKING | 7 | 5.78e-01 | 9.81e-01 | 0.46500 | -2.13e-01 | -1.91e-01 | -8.96e-02 | -2.59e-01 | 2.43e-01 | 3.30e-01 | 3.81e-01 | 6.81e-01 | 2.36e-01 | 2.66e-01 |
| SKELETAL MUSCLE FIBER DIFFERENTIATION | 8 | 2.44e-01 | 7.69e-01 | 0.46400 | 1.26e-01 | 8.34e-02 | 3.44e-01 | -9.25e-02 | 2.57e-01 | 5.36e-01 | 6.83e-01 | 9.22e-02 | 6.51e-01 | 2.08e-01 |
| PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 6 | 4.60e-01 | 9.32e-01 | 0.46400 | 8.71e-02 | 1.70e-01 | -5.26e-02 | 5.19e-02 | -4.16e-01 | 7.12e-01 | 4.70e-01 | 8.24e-01 | 8.26e-01 | 7.73e-02 |
| BRUSH BORDER ASSEMBLY | 7 | 3.79e-01 | 8.86e-01 | 0.46400 | 2.21e-01 | 2.55e-01 | -1.54e-02 | 2.87e-01 | -1.37e-01 | 3.10e-01 | 2.43e-01 | 9.44e-01 | 1.89e-01 | 5.30e-01 |
| PRIMITIVE STREAK FORMATION | 10 | 1.55e-01 | 6.53e-01 | 0.46400 | 2.18e-01 | 2.08e-01 | 3.31e-01 | 2.86e-03 | -1.23e-01 | 2.33e-01 | 2.55e-01 | 7.02e-02 | 9.88e-01 | 5.01e-01 |
| SA NODE CELL TO ATRIAL CARDIAC MUSCLE CELL COMMUNICATION | 11 | 4.67e-01 | 9.36e-01 | 0.46300 | 1.94e-01 | 2.07e-01 | 6.64e-02 | 2.32e-01 | -2.77e-01 | 2.66e-01 | 2.35e-01 | 7.03e-01 | 1.83e-01 | 1.12e-01 |
| REGULATION OF TRANSCRIPTION OF NUCLEOLAR LARGE RRNA BY RNA POLYMERASE I | 15 | 6.62e-01 | 1.00e+00 | 0.46300 | 2.40e-01 | 2.36e-01 | 2.31e-01 | 2.19e-01 | 1.44e-02 | 1.08e-01 | 1.13e-01 | 1.22e-01 | 1.43e-01 | 9.23e-01 |
| REGULATION OF LEUKOCYTE MEDIATED CYTOTOXICITY | 95 | 1.64e-05 | 7.20e-04 | 0.46300 | -2.38e-01 | -2.76e-01 | -1.17e-01 | -2.58e-01 | 3.53e-02 | 5.93e-05 | 3.30e-06 | 4.78e-02 | 1.39e-05 | 5.52e-01 |
| CARDIAC NEURAL CREST CELL DEVELOPMENT INVOLVED IN OUTFLOW TRACT MORPHOGENESIS | 13 | 6.21e-01 | 9.91e-01 | 0.46300 | 2.37e-01 | 2.44e-01 | 2.14e-01 | 2.23e-01 | -5.72e-02 | 1.39e-01 | 1.28e-01 | 1.81e-01 | 1.64e-01 | 7.21e-01 |
| HOST MEDIATED REGULATION OF INTESTINAL MICROBIOTA COMPOSITION | 9 | 3.65e-02 | 3.04e-01 | 0.46300 | 1.12e-01 | 1.56e-01 | -1.56e-01 | 3.89e-01 | 4.01e-02 | 5.60e-01 | 4.18e-01 | 4.17e-01 | 4.35e-02 | 8.35e-01 |
| INTESTINAL EPITHELIAL CELL DIFFERENTIATION | 27 | 1.21e-02 | 1.44e-01 | 0.46200 | 1.90e-01 | 2.07e-01 | 3.05e-02 | 1.75e-01 | -3.21e-01 | 8.75e-02 | 6.27e-02 | 7.84e-01 | 1.15e-01 | 3.86e-03 |
| REGULATION OF BLOOD BRAIN BARRIER PERMEABILITY | 9 | 5.31e-01 | 9.54e-01 | 0.46200 | -2.45e-01 | -2.11e-01 | -2.01e-01 | -1.81e-01 | 1.89e-01 | 2.02e-01 | 2.74e-01 | 2.96e-01 | 3.46e-01 | 3.26e-01 |
| MESENCHYMAL EPITHELIAL CELL SIGNALING | 7 | 1.41e-01 | 6.26e-01 | 0.46200 | -3.06e-02 | -6.29e-02 | -1.21e-01 | 7.63e-02 | -4.34e-01 | 8.89e-01 | 7.73e-01 | 5.79e-01 | 7.27e-01 | 4.68e-02 |
| POSITIVE REGULATION OF DOUBLE STRAND BREAK REPAIR VIA NONHOMOLOGOUS END JOINING | 14 | 5.58e-01 | 9.69e-01 | 0.46200 | 2.20e-01 | 1.95e-01 | 2.82e-01 | 1.30e-01 | 1.74e-01 | 1.54e-01 | 2.06e-01 | 6.81e-02 | 3.99e-01 | 2.60e-01 |
| RESPONSE TO GONADOTROPIN RELEASING HORMONE | 7 | 5.36e-01 | 9.57e-01 | 0.46100 | -2.05e-01 | -2.53e-01 | -1.57e-01 | -2.60e-01 | -1.20e-01 | 3.47e-01 | 2.46e-01 | 4.71e-01 | 2.33e-01 | 5.84e-01 |
| PEPTIDE ANTIGEN ASSEMBLY WITH MHC CLASS II PROTEIN COMPLEX | 14 | 2.39e-01 | 7.63e-01 | 0.46100 | -2.66e-01 | -2.74e-01 | -1.71e-01 | -1.95e-01 | -3.68e-03 | 8.49e-02 | 7.62e-02 | 2.68e-01 | 2.07e-01 | 9.81e-01 |
| MONOUBIQUITINATED PROTEIN DEUBIQUITINATION | 7 | 8.40e-01 | 1.00e+00 | 0.46100 | -1.98e-01 | -1.80e-01 | -2.61e-01 | -1.46e-01 | -2.28e-01 | 3.65e-01 | 4.11e-01 | 2.33e-01 | 5.03e-01 | 2.96e-01 |
| NEGATIVE REGULATION OF CYTOKINESIS | 7 | 2.94e-01 | 8.22e-01 | 0.46100 | -6.06e-02 | -4.90e-02 | 7.52e-02 | -5.66e-02 | 4.44e-01 | 7.81e-01 | 8.22e-01 | 7.31e-01 | 7.95e-01 | 4.17e-02 |
| CELLULAR RESPONSE TO UV A | 10 | 5.45e-01 | 9.61e-01 | 0.46100 | -2.27e-01 | -2.56e-01 | -2.34e-01 | -1.60e-01 | -1.22e-01 | 2.15e-01 | 1.61e-01 | 1.99e-01 | 3.81e-01 | 5.04e-01 |
| DEVELOPMENTAL PIGMENTATION | 47 | 5.20e-02 | 3.73e-01 | 0.46100 | -2.32e-01 | -2.42e-01 | -1.61e-01 | -2.71e-01 | -1.86e-02 | 5.84e-03 | 4.07e-03 | 5.62e-02 | 1.32e-03 | 8.25e-01 |
| SPINAL CORD OLIGODENDROCYTE CELL DIFFERENTIATION | 5 | 5.06e-01 | 9.48e-01 | 0.46100 | 1.90e-01 | 2.23e-01 | 1.92e-01 | -7.32e-03 | -3.00e-01 | 4.63e-01 | 3.89e-01 | 4.58e-01 | 9.77e-01 | 2.46e-01 |
| PROLINE TRANSPORT | 11 | 4.70e-01 | 9.38e-01 | 0.46000 | 2.46e-01 | 2.90e-01 | 1.89e-01 | 1.62e-01 | -7.12e-02 | 1.58e-01 | 9.54e-02 | 2.77e-01 | 3.52e-01 | 6.82e-01 |
| GOLGI TO LYSOSOME TRANSPORT | 12 | 6.95e-01 | 1.00e+00 | 0.46000 | -2.39e-01 | -2.46e-01 | -1.45e-01 | -2.66e-01 | -4.41e-02 | 1.51e-01 | 1.40e-01 | 3.83e-01 | 1.10e-01 | 7.91e-01 |
| COLUMNAR CUBOIDAL EPITHELIAL CELL MATURATION | 13 | 5.38e-01 | 9.57e-01 | 0.45900 | 2.53e-01 | 2.50e-01 | 1.44e-01 | 2.50e-01 | -3.34e-02 | 1.14e-01 | 1.18e-01 | 3.69e-01 | 1.18e-01 | 8.35e-01 |
| SMOOTH MUSCLE CELL MATRIX ADHESION | 6 | 2.48e-01 | 7.75e-01 | 0.45800 | 2.58e-01 | 2.33e-01 | 2.99e-01 | 1.72e-03 | 2.24e-03 | 2.74e-01 | 3.23e-01 | 2.05e-01 | 9.94e-01 | 9.92e-01 |
| LUNG EPITHELIUM DEVELOPMENT | 44 | 2.82e-02 | 2.59e-01 | 0.45800 | 2.34e-01 | 2.27e-01 | 1.89e-01 | 2.07e-01 | -1.58e-01 | 7.23e-03 | 9.19e-03 | 3.03e-02 | 1.75e-02 | 6.97e-02 |
| POINTED END ACTIN FILAMENT CAPPING | 7 | 6.95e-01 | 1.00e+00 | 0.45800 | -1.80e-01 | -1.55e-01 | -2.66e-01 | -6.96e-02 | -2.78e-01 | 4.10e-01 | 4.77e-01 | 2.23e-01 | 7.50e-01 | 2.02e-01 |
| DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR RESULTING IN CELL CYCLE ARREST | 18 | 5.70e-02 | 3.90e-01 | 0.45800 | 2.41e-01 | 2.57e-01 | 2.80e-01 | 5.30e-02 | -6.56e-02 | 7.70e-02 | 5.88e-02 | 3.98e-02 | 6.97e-01 | 6.30e-01 |
| RIBOSOME ASSEMBLY | 58 | 1.62e-04 | 5.15e-03 | 0.45800 | 2.28e-01 | 2.17e-01 | 3.12e-01 | 7.04e-02 | 8.96e-02 | 2.66e-03 | 4.25e-03 | 3.90e-05 | 3.54e-01 | 2.38e-01 |
| POSITIVE REGULATION OF GRANULOCYTE CHEMOTAXIS | 27 | 1.13e-01 | 5.59e-01 | 0.45800 | -2.41e-01 | -2.81e-01 | -1.37e-01 | -2.04e-01 | 1.10e-01 | 3.01e-02 | 1.16e-02 | 2.20e-01 | 6.59e-02 | 3.22e-01 |
| REGULATION OF ADIPONECTIN SECRETION | 7 | 7.16e-01 | 1.00e+00 | 0.45800 | -2.17e-01 | -2.72e-01 | -5.97e-02 | -2.69e-01 | 1.12e-01 | 3.21e-01 | 2.13e-01 | 7.84e-01 | 2.17e-01 | 6.09e-01 |
| NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS IN THE VACUOLE | 5 | 8.59e-01 | 1.00e+00 | 0.45800 | -2.02e-01 | -1.46e-01 | -2.82e-01 | -1.17e-01 | -2.34e-01 | 4.35e-01 | 5.72e-01 | 2.75e-01 | 6.51e-01 | 3.66e-01 |
| POSITIVE REGULATION OF HUMORAL IMMUNE RESPONSE MEDIATED BY CIRCULATING IMMUNOGLOBULIN | 7 | 7.32e-01 | 1.00e+00 | 0.45700 | -2.21e-01 | -2.45e-01 | -1.89e-01 | -1.48e-01 | 2.07e-01 | 3.11e-01 | 2.61e-01 | 3.88e-01 | 4.96e-01 | 3.43e-01 |
| POSITIVE REGULATION OF ACROSOME REACTION | 11 | 4.91e-01 | 9.45e-01 | 0.45700 | 2.22e-01 | 2.21e-01 | 9.01e-02 | 3.18e-01 | 4.77e-02 | 2.03e-01 | 2.05e-01 | 6.05e-01 | 6.82e-02 | 7.84e-01 |
| HISTIDINE METABOLIC PROCESS | 10 | 4.97e-01 | 9.47e-01 | 0.45700 | -2.09e-01 | -2.07e-01 | -1.17e-01 | -2.81e-01 | 1.74e-01 | 2.52e-01 | 2.58e-01 | 5.23e-01 | 1.24e-01 | 3.40e-01 |
| CELL MIGRATION INVOLVED IN HEART DEVELOPMENT | 21 | 4.81e-01 | 9.43e-01 | 0.45700 | 2.38e-01 | 2.43e-01 | 2.34e-01 | 1.93e-01 | 3.20e-02 | 5.86e-02 | 5.40e-02 | 6.30e-02 | 1.26e-01 | 8.00e-01 |
| ISOTYPE SWITCHING TO IGA ISOTYPES | 8 | 6.13e-01 | 9.90e-01 | 0.45700 | -1.77e-01 | -1.94e-01 | -3.48e-02 | -1.97e-01 | 3.16e-01 | 3.85e-01 | 3.42e-01 | 8.65e-01 | 3.34e-01 | 1.22e-01 |
| PROTEOGLYCAN CATABOLIC PROCESS | 9 | 7.84e-01 | 1.00e+00 | 0.45700 | 2.15e-01 | 1.93e-01 | 2.12e-01 | 2.50e-01 | 1.35e-01 | 2.64e-01 | 3.16e-01 | 2.71e-01 | 1.95e-01 | 4.84e-01 |
| POSITIVE REGULATION OF FEVER GENERATION | 7 | 3.57e-01 | 8.74e-01 | 0.45700 | -1.71e-01 | -2.35e-01 | 8.18e-02 | -2.26e-01 | 2.58e-01 | 4.34e-01 | 2.82e-01 | 7.08e-01 | 3.01e-01 | 2.37e-01 |
| REGULATION OF PROTEIN DEUBIQUITINATION | 10 | 1.87e-01 | 6.95e-01 | 0.45700 | -5.27e-02 | -1.24e-02 | -6.93e-02 | -1.69e-01 | -4.15e-01 | 7.73e-01 | 9.46e-01 | 7.04e-01 | 3.55e-01 | 2.30e-02 |
| OPTIC NERVE MORPHOGENESIS | 6 | 4.97e-01 | 9.47e-01 | 0.45700 | 1.67e-01 | 1.48e-01 | 3.50e-01 | 1.36e-02 | 1.90e-01 | 4.79e-01 | 5.31e-01 | 1.37e-01 | 9.54e-01 | 4.21e-01 |
| ANGIOGENESIS INVOLVED IN CORONARY VASCULAR MORPHOGENESIS | 5 | 8.67e-01 | 1.00e+00 | 0.45700 | -2.26e-01 | -2.69e-01 | -1.60e-01 | -2.17e-01 | 1.12e-01 | 3.81e-01 | 2.98e-01 | 5.36e-01 | 4.01e-01 | 6.64e-01 |
| CRANIAL SUTURE MORPHOGENESIS | 8 | 2.15e-01 | 7.38e-01 | 0.45700 | 2.43e-01 | 1.45e-01 | 3.47e-01 | 8.51e-02 | 3.00e-02 | 2.34e-01 | 4.78e-01 | 8.95e-02 | 6.77e-01 | 8.83e-01 |
| POST EMBRYONIC CAMERA TYPE EYE DEVELOPMENT | 8 | 5.87e-01 | 9.85e-01 | 0.45600 | 2.21e-01 | 2.51e-01 | 2.54e-01 | 1.45e-01 | 1.06e-01 | 2.80e-01 | 2.20e-01 | 2.13e-01 | 4.78e-01 | 6.04e-01 |
| POSITIVE REGULATION OF SYNAPSE MATURATION | 9 | 8.23e-01 | 1.00e+00 | 0.45600 | 2.27e-01 | 2.31e-01 | 1.63e-01 | 2.55e-01 | 1.09e-01 | 2.39e-01 | 2.31e-01 | 3.96e-01 | 1.85e-01 | 5.71e-01 |
| NEURONAL ACTION POTENTIAL PROPAGATION | 9 | 5.18e-01 | 9.52e-01 | 0.45600 | 1.74e-01 | 1.86e-01 | 2.67e-02 | 2.17e-01 | -3.09e-01 | 3.66e-01 | 3.34e-01 | 8.89e-01 | 2.60e-01 | 1.08e-01 |
| PROTEIN INSERTION INTO ER MEMBRANE BY STOP TRANSFER MEMBRANE ANCHOR SEQUENCE | 10 | 4.14e-01 | 9.11e-01 | 0.45600 | 1.72e-01 | 1.46e-01 | 2.63e-01 | 1.82e-01 | 2.33e-01 | 3.46e-01 | 4.23e-01 | 1.50e-01 | 3.18e-01 | 2.02e-01 |
| RESPONSE TO INTERLEUKIN 3 | 6 | 3.74e-01 | 8.82e-01 | 0.45500 | -1.58e-01 | -2.05e-01 | 6.32e-02 | -3.67e-01 | -3.85e-02 | 5.02e-01 | 3.84e-01 | 7.89e-01 | 1.19e-01 | 8.70e-01 |
| NEGATIVE REGULATION OF T CELL MEDIATED IMMUNITY | 28 | 1.13e-01 | 5.59e-01 | 0.45500 | -2.33e-01 | -2.76e-01 | -1.38e-01 | -2.39e-01 | 2.66e-02 | 3.29e-02 | 1.15e-02 | 2.06e-01 | 2.87e-02 | 8.08e-01 |
| POSITIVE REGULATION OF ANTIMICROBIAL HUMORAL RESPONSE | 8 | 1.88e-01 | 6.95e-01 | 0.45500 | -1.92e-02 | 3.27e-02 | -2.89e-01 | 1.22e-01 | -3.28e-01 | 9.25e-01 | 8.73e-01 | 1.57e-01 | 5.51e-01 | 1.08e-01 |
| CARDIAC MUSCLE CELL CARDIAC MUSCLE CELL ADHESION | 7 | 5.82e-02 | 3.95e-01 | 0.45500 | 1.76e-02 | 1.71e-01 | -2.31e-01 | 1.25e-01 | -3.30e-01 | 9.36e-01 | 4.33e-01 | 2.91e-01 | 5.68e-01 | 1.31e-01 |
| DOPAMINE BIOSYNTHETIC PROCESS | 12 | 6.21e-01 | 9.90e-01 | 0.45500 | 2.34e-01 | 2.21e-01 | 1.84e-01 | 2.07e-01 | -1.63e-01 | 1.61e-01 | 1.84e-01 | 2.71e-01 | 2.13e-01 | 3.29e-01 |
| POSITIVE REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 14 | 4.16e-01 | 9.11e-01 | 0.45500 | -1.95e-01 | -2.05e-01 | -2.18e-01 | -1.61e-01 | -2.31e-01 | 2.06e-01 | 1.83e-01 | 1.58e-01 | 2.97e-01 | 1.35e-01 |
| OTOLITH DEVELOPMENT | 10 | 3.65e-01 | 8.79e-01 | 0.45500 | -2.31e-01 | -1.57e-01 | -2.99e-01 | -1.22e-01 | -1.56e-01 | 2.05e-01 | 3.89e-01 | 1.02e-01 | 5.06e-01 | 3.93e-01 |
| LEUCINE METABOLIC PROCESS | 8 | 8.22e-01 | 1.00e+00 | 0.45500 | -2.36e-01 | -1.98e-01 | -2.74e-01 | -1.88e-01 | -3.63e-02 | 2.48e-01 | 3.33e-01 | 1.79e-01 | 3.57e-01 | 8.59e-01 |
| ATRIOVENTRICULAR VALVE FORMATION | 8 | 2.17e-01 | 7.40e-01 | 0.45400 | 2.37e-01 | 1.70e-01 | 3.48e-01 | 7.84e-03 | -1.05e-03 | 2.45e-01 | 4.06e-01 | 8.83e-02 | 9.69e-01 | 9.96e-01 |
| EMBRYONIC CAMERA TYPE EYE DEVELOPMENT | 37 | 5.13e-02 | 3.71e-01 | 0.45400 | 2.29e-01 | 1.80e-01 | 2.94e-01 | 1.51e-01 | 1.11e-01 | 1.61e-02 | 5.80e-02 | 1.98e-03 | 1.13e-01 | 2.44e-01 |
| REGULATION OF CHEMOKINE MEDIATED SIGNALING PATHWAY | 9 | 3.50e-01 | 8.69e-01 | 0.45400 | -2.31e-01 | -3.07e-01 | -9.80e-02 | -1.92e-01 | 1.08e-01 | 2.30e-01 | 1.11e-01 | 6.11e-01 | 3.18e-01 | 5.74e-01 |
| ESTROGEN METABOLIC PROCESS | 39 | 2.61e-02 | 2.45e-01 | 0.45400 | -2.10e-01 | -1.92e-01 | -2.98e-01 | -1.10e-01 | -1.57e-01 | 2.34e-02 | 3.81e-02 | 1.30e-03 | 2.35e-01 | 9.07e-02 |
| PLASMA CELL DIFFERENTIATION | 8 | 8.60e-02 | 4.84e-01 | 0.45400 | 3.30e-02 | -9.02e-03 | 3.23e-01 | -1.18e-01 | 2.94e-01 | 8.72e-01 | 9.65e-01 | 1.14e-01 | 5.63e-01 | 1.50e-01 |
| POSITIVE REGULATION OF RECEPTOR BINDING | 6 | 7.94e-01 | 1.00e+00 | 0.45400 | 1.73e-01 | 1.14e-01 | 2.58e-01 | 1.22e-01 | 2.85e-01 | 4.64e-01 | 6.28e-01 | 2.73e-01 | 6.06e-01 | 2.26e-01 |
| REGULATION OF NEUROMUSCULAR JUNCTION DEVELOPMENT | 8 | 5.41e-01 | 9.59e-01 | 0.45400 | -2.03e-01 | -1.95e-01 | -4.82e-02 | -2.73e-01 | 2.23e-01 | 3.20e-01 | 3.39e-01 | 8.13e-01 | 1.81e-01 | 2.75e-01 |
| REGULATION OF GLUCOCORTICOID BIOSYNTHETIC PROCESS | 9 | 7.76e-01 | 1.00e+00 | 0.45400 | 2.19e-01 | 2.30e-01 | 2.17e-01 | 2.17e-01 | 1.04e-01 | 2.55e-01 | 2.33e-01 | 2.60e-01 | 2.60e-01 | 5.89e-01 |
| PARANODAL JUNCTION ASSEMBLY | 6 | 5.01e-01 | 9.47e-01 | 0.45400 | 1.76e-01 | 1.97e-01 | -5.71e-02 | 3.38e-01 | -1.36e-01 | 4.56e-01 | 4.03e-01 | 8.09e-01 | 1.52e-01 | 5.65e-01 |
| GLUTAMINE FAMILY AMINO ACID CATABOLIC PROCESS | 26 | 3.56e-01 | 8.74e-01 | 0.45300 | 2.44e-01 | 2.60e-01 | 1.90e-01 | 2.06e-01 | -1.64e-02 | 3.12e-02 | 2.20e-02 | 9.37e-02 | 6.95e-02 | 8.85e-01 |
| POSITIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 79 | 2.93e-06 | 1.61e-04 | 0.45300 | -2.07e-01 | -2.52e-01 | -2.20e-02 | -2.75e-01 | 1.52e-01 | 1.46e-03 | 1.09e-04 | 7.35e-01 | 2.39e-05 | 1.92e-02 |
| SATELLITE CELL ACTIVATION INVOLVED IN SKELETAL MUSCLE REGENERATION | 5 | 4.61e-02 | 3.48e-01 | 0.45300 | 1.45e-01 | 2.33e-01 | -2.27e-01 | 2.45e-01 | -1.37e-01 | 5.74e-01 | 3.66e-01 | 3.79e-01 | 3.43e-01 | 5.97e-01 |
| T CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 118 | 1.16e-05 | 5.30e-04 | 0.45300 | -2.37e-01 | -2.53e-01 | -1.16e-01 | -2.58e-01 | 7.18e-02 | 8.86e-06 | 2.01e-06 | 2.92e-02 | 1.28e-06 | 1.78e-01 |
| CORTICOSTEROID RECEPTOR SIGNALING PATHWAY | 14 | 1.51e-01 | 6.44e-01 | 0.45300 | 1.98e-01 | 1.23e-01 | 3.14e-01 | 6.12e-02 | 2.20e-01 | 2.00e-01 | 4.24e-01 | 4.18e-02 | 6.92e-01 | 1.54e-01 |
| PROTEIN HISTIDYL MODIFICATION TO DIPHTHAMIDE | 6 | 6.33e-01 | 9.96e-01 | 0.45300 | -1.64e-01 | -2.36e-01 | 2.23e-03 | -1.62e-01 | 3.11e-01 | 4.88e-01 | 3.17e-01 | 9.92e-01 | 4.93e-01 | 1.87e-01 |
| PROTEIN LOCALIZATION TO MEMBRANE RAFT | 9 | 7.45e-02 | 4.49e-01 | 0.45300 | -1.39e-01 | -1.38e-01 | 5.15e-02 | -3.98e-01 | -7.48e-02 | 4.69e-01 | 4.74e-01 | 7.89e-01 | 3.87e-02 | 6.97e-01 |
| REGULATION OF MACROPHAGE ACTIVATION | 61 | 8.43e-06 | 4.09e-04 | 0.45300 | -2.36e-01 | -2.70e-01 | -6.83e-02 | -2.68e-01 | -3.60e-03 | 1.44e-03 | 2.68e-04 | 3.56e-01 | 2.93e-04 | 9.61e-01 |
| POSITIVE REGULATION OF MYELOID LEUKOCYTE CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 35 | 1.62e-02 | 1.79e-01 | 0.45200 | -2.08e-01 | -2.52e-01 | -3.42e-02 | -2.78e-01 | 1.40e-01 | 3.32e-02 | 9.87e-03 | 7.26e-01 | 4.42e-03 | 1.52e-01 |
| REGULATION OF ADIPOSE TISSUE DEVELOPMENT | 16 | 3.20e-01 | 8.47e-01 | 0.45200 | -2.25e-01 | -2.70e-01 | -7.22e-02 | -2.60e-01 | 8.93e-02 | 1.18e-01 | 6.15e-02 | 6.17e-01 | 7.18e-02 | 5.36e-01 |
| MESODERMAL CELL MIGRATION | 5 | 8.90e-01 | 1.00e+00 | 0.45200 | 2.18e-01 | 2.18e-01 | 1.09e-01 | 2.98e-01 | -9.35e-02 | 3.99e-01 | 3.99e-01 | 6.74e-01 | 2.49e-01 | 7.17e-01 |
| LYSOSOMAL LUMEN ACIDIFICATION | 20 | 1.47e-01 | 6.32e-01 | 0.45200 | 1.88e-01 | 1.45e-01 | 3.22e-01 | 7.83e-02 | 1.95e-01 | 1.45e-01 | 2.63e-01 | 1.27e-02 | 5.44e-01 | 1.31e-01 |
| REGULATION OF INFLAMMASOME MEDIATED SIGNALING PATHWAY | 34 | 1.37e-01 | 6.17e-01 | 0.45200 | -2.33e-01 | -2.30e-01 | -1.37e-01 | -2.72e-01 | 6.13e-02 | 1.87e-02 | 2.00e-02 | 1.68e-01 | 6.00e-03 | 5.36e-01 |
| REGULATION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA SIGNALING PATHWAY | 5 | 6.59e-01 | 1.00e+00 | 0.45200 | -1.53e-01 | -1.34e-01 | -8.37e-02 | -3.09e-01 | -2.45e-01 | 5.55e-01 | 6.04e-01 | 7.46e-01 | 2.31e-01 | 3.42e-01 |
| PHOSPHAGEN METABOLIC PROCESS | 5 | 5.24e-03 | 7.94e-02 | 0.45200 | -4.80e-03 | -4.68e-02 | -1.51e-02 | 2.37e-01 | -3.81e-01 | 9.85e-01 | 8.56e-01 | 9.53e-01 | 3.59e-01 | 1.40e-01 |
| NEGATIVE REGULATION OF MAST CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 8 | 2.93e-01 | 8.21e-01 | 0.45100 | -1.86e-01 | -2.29e-01 | -1.07e-02 | -3.02e-01 | -1.60e-01 | 3.62e-01 | 2.62e-01 | 9.58e-01 | 1.40e-01 | 4.34e-01 |
| NEURON FATE DETERMINATION | 10 | 3.61e-01 | 8.77e-01 | 0.45100 | -1.90e-01 | -2.05e-01 | -4.55e-02 | -3.34e-01 | -1.11e-01 | 2.98e-01 | 2.62e-01 | 8.03e-01 | 6.76e-02 | 5.45e-01 |
| ADULT FEEDING BEHAVIOR | 9 | 5.94e-01 | 9.87e-01 | 0.45100 | -2.05e-01 | -2.16e-01 | -1.03e-01 | -1.55e-01 | 2.83e-01 | 2.87e-01 | 2.62e-01 | 5.92e-01 | 4.21e-01 | 1.42e-01 |
| TYPE B PANCREATIC CELL PROLIFERATION | 27 | 1.48e-01 | 6.35e-01 | 0.45000 | 2.36e-01 | 1.98e-01 | 2.85e-01 | 1.63e-01 | 7.40e-04 | 3.39e-02 | 7.44e-02 | 1.05e-02 | 1.42e-01 | 9.95e-01 |
| SNORNA LOCALIZATION | 6 | 6.84e-01 | 1.00e+00 | 0.45000 | 1.13e-01 | 1.05e-01 | 2.15e-01 | 9.11e-02 | 3.53e-01 | 6.32e-01 | 6.57e-01 | 3.62e-01 | 6.99e-01 | 1.35e-01 |
| SIRNA MEDIATED RETROTRANSPOSON SILENCING BY HETEROCHROMATIN FORMATION | 11 | 6.58e-02 | 4.17e-01 | 0.45000 | -1.10e-01 | -1.11e-01 | -3.09e-01 | 4.14e-02 | -2.85e-01 | 5.29e-01 | 5.26e-01 | 7.60e-02 | 8.12e-01 | 1.02e-01 |
| NEURAL CREST CELL MIGRATION INVOLVED IN AUTONOMIC NERVOUS SYSTEM DEVELOPMENT | 6 | 8.11e-01 | 1.00e+00 | 0.45000 | -1.51e-01 | -1.18e-01 | -2.41e-01 | -1.37e-01 | -2.98e-01 | 5.22e-01 | 6.16e-01 | 3.06e-01 | 5.60e-01 | 2.07e-01 |
| POSITIVE REGULATION OF ACTIVIN RECEPTOR SIGNALING PATHWAY | 8 | 7.50e-01 | 1.00e+00 | 0.45000 | 2.27e-01 | 2.69e-01 | 1.62e-01 | 2.01e-01 | -1.08e-01 | 2.65e-01 | 1.88e-01 | 4.28e-01 | 3.24e-01 | 5.99e-01 |
| APOPTOTIC PROCESS IN BONE MARROW CELL | 6 | 2.20e-01 | 7.43e-01 | 0.45000 | 6.02e-02 | 1.41e-01 | -2.58e-01 | 2.38e-01 | -2.36e-01 | 7.98e-01 | 5.50e-01 | 2.74e-01 | 3.14e-01 | 3.17e-01 |
| GOLGI RIBBON FORMATION | 10 | 6.25e-01 | 9.93e-01 | 0.45000 | -2.37e-01 | -2.55e-01 | -1.06e-01 | -2.16e-01 | 1.51e-01 | 1.94e-01 | 1.63e-01 | 5.62e-01 | 2.36e-01 | 4.07e-01 |
| REGULATION OF TOLL LIKE RECEPTOR 4 SIGNALING PATHWAY | 31 | 1.26e-01 | 5.91e-01 | 0.44900 | -2.24e-01 | -2.49e-01 | -1.54e-01 | -2.51e-01 | 5.68e-02 | 3.10e-02 | 1.65e-02 | 1.38e-01 | 1.55e-02 | 5.84e-01 |
| DIET INDUCED THERMOGENESIS | 13 | 7.33e-01 | 1.00e+00 | 0.44900 | 2.46e-01 | 2.23e-01 | 2.18e-01 | 2.09e-01 | 2.10e-02 | 1.24e-01 | 1.65e-01 | 1.74e-01 | 1.91e-01 | 8.96e-01 |
| NEGATIVE REGULATION OF RESPONSE TO OXIDATIVE STRESS | 11 | 1.92e-01 | 7.03e-01 | 0.44900 | 2.18e-01 | 2.43e-01 | 6.25e-02 | 2.69e-01 | 1.39e-01 | 2.11e-01 | 1.63e-01 | 7.20e-01 | 1.23e-01 | 4.24e-01 |
| NEGATIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR PRODUCTION | 22 | 3.26e-03 | 5.56e-02 | 0.44900 | -1.84e-01 | -1.41e-01 | -3.20e-01 | -1.70e-01 | -1.32e-01 | 1.36e-01 | 2.54e-01 | 9.37e-03 | 1.69e-01 | 2.86e-01 |
| POST CHAPERONIN TUBULIN FOLDING PATHWAY | 6 | 7.54e-01 | 1.00e+00 | 0.44900 | -2.38e-01 | -1.80e-01 | -2.07e-01 | -2.53e-01 | -7.43e-02 | 3.12e-01 | 4.46e-01 | 3.79e-01 | 2.83e-01 | 7.53e-01 |
| POSITIVE REGULATION OF SUPEROXIDE ANION GENERATION | 16 | 7.90e-02 | 4.63e-01 | 0.44900 | -2.11e-01 | -2.69e-01 | 5.00e-04 | -2.81e-01 | 7.46e-02 | 1.44e-01 | 6.23e-02 | 9.97e-01 | 5.18e-02 | 6.06e-01 |
| GOLGI LUMEN ACIDIFICATION | 10 | 6.24e-01 | 9.93e-01 | 0.44900 | 1.96e-01 | 1.44e-01 | 2.66e-01 | 1.26e-01 | 2.35e-01 | 2.83e-01 | 4.29e-01 | 1.45e-01 | 4.91e-01 | 1.98e-01 |
| VITAMIN A METABOLIC PROCESS | 8 | 6.91e-01 | 1.00e+00 | 0.44800 | -1.63e-01 | -1.26e-01 | -2.79e-01 | -6.92e-02 | -2.75e-01 | 4.26e-01 | 5.36e-01 | 1.72e-01 | 7.35e-01 | 1.77e-01 |
| ASTROCYTE CELL MIGRATION | 9 | 8.99e-01 | 1.00e+00 | 0.44800 | -2.39e-01 | -2.31e-01 | -1.97e-01 | -2.26e-01 | 1.75e-02 | 2.14e-01 | 2.29e-01 | 3.06e-01 | 2.41e-01 | 9.28e-01 |
| GTP BIOSYNTHETIC PROCESS | 11 | 5.35e-01 | 9.56e-01 | 0.44800 | 2.44e-01 | 2.04e-01 | 2.36e-01 | 1.76e-01 | -1.13e-01 | 1.60e-01 | 2.42e-01 | 1.76e-01 | 3.11e-01 | 5.15e-01 |
| DE NOVO PROTEIN FOLDING | 41 | 1.35e-02 | 1.54e-01 | 0.44800 | 2.16e-01 | 1.76e-01 | 3.18e-01 | 9.55e-02 | 1.14e-01 | 1.67e-02 | 5.11e-02 | 4.27e-04 | 2.90e-01 | 2.06e-01 |
| NEUTROPHIL DIFFERENTIATION | 11 | 6.13e-02 | 4.06e-01 | 0.44800 | -7.27e-02 | -1.86e-01 | 1.69e-01 | -1.59e-01 | 3.27e-01 | 6.76e-01 | 2.85e-01 | 3.32e-01 | 3.60e-01 | 6.04e-02 |
| NEGATIVE REGULATION OF RESPONSE TO FOOD | 10 | 4.70e-01 | 9.38e-01 | 0.44800 | -2.09e-01 | -1.52e-01 | -2.29e-01 | -2.57e-01 | -1.25e-01 | 2.53e-01 | 4.06e-01 | 2.09e-01 | 1.60e-01 | 4.93e-01 |
| REGULATION OF SPINDLE ORGANIZATION | 46 | 3.03e-02 | 2.72e-01 | 0.44800 | 2.07e-01 | 1.89e-01 | 2.72e-01 | 1.28e-01 | 1.78e-01 | 1.49e-02 | 2.64e-02 | 1.44e-03 | 1.33e-01 | 3.71e-02 |
| STRIATED MUSCLE ATROPHY | 7 | 5.68e-01 | 9.73e-01 | 0.44800 | 1.59e-01 | 1.73e-01 | 3.15e-02 | 1.16e-01 | -3.62e-01 | 4.66e-01 | 4.28e-01 | 8.85e-01 | 5.96e-01 | 9.76e-02 |
| MITOCHONDRIAL RNA 3 END PROCESSING | 5 | 3.80e-01 | 8.87e-01 | 0.44700 | 2.18e-01 | 1.23e-01 | 3.70e-01 | -6.40e-03 | 4.80e-03 | 3.99e-01 | 6.35e-01 | 1.51e-01 | 9.80e-01 | 9.85e-01 |
| CRANIAL NERVE MORPHOGENESIS | 29 | 1.04e-01 | 5.36e-01 | 0.44700 | 2.50e-01 | 2.17e-01 | 1.94e-01 | 2.28e-01 | 3.66e-03 | 1.96e-02 | 4.27e-02 | 7.09e-02 | 3.33e-02 | 9.73e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 12 PRODUCTION | 42 | 2.58e-03 | 4.67e-02 | 0.44700 | -1.97e-01 | -2.31e-01 | -1.86e-02 | -3.08e-01 | 1.10e-01 | 2.72e-02 | 9.44e-03 | 8.35e-01 | 5.53e-04 | 2.18e-01 |
| NEGATIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 23 | 3.58e-01 | 8.74e-01 | 0.44700 | -2.37e-01 | -2.16e-01 | -1.97e-01 | -2.31e-01 | 6.80e-02 | 4.96e-02 | 7.31e-02 | 1.01e-01 | 5.50e-02 | 5.72e-01 |
| SYNAPTIC VESICLE COATING | 5 | 5.75e-01 | 9.79e-01 | 0.44700 | -1.68e-01 | -2.00e-01 | -3.60e-03 | -3.08e-01 | -1.91e-01 | 5.16e-01 | 4.39e-01 | 9.89e-01 | 2.33e-01 | 4.59e-01 |
| AMYLOID BETA CLEARANCE BY TRANSCYTOSIS | 7 | 4.50e-01 | 9.30e-01 | 0.44600 | 1.33e-02 | -2.65e-02 | 2.12e-01 | -1.26e-01 | 3.71e-01 | 9.51e-01 | 9.03e-01 | 3.31e-01 | 5.64e-01 | 8.92e-02 |
| LYMPHOCYTE COSTIMULATION | 46 | 3.63e-02 | 3.03e-01 | 0.44600 | -2.32e-01 | -2.48e-01 | -1.13e-01 | -2.41e-01 | 1.16e-01 | 6.46e-03 | 3.67e-03 | 1.85e-01 | 4.73e-03 | 1.73e-01 |
| REGULATION OF T CIRCLE FORMATION | 5 | 8.43e-01 | 1.00e+00 | 0.44600 | 1.51e-01 | 1.09e-01 | 2.21e-01 | 1.77e-01 | 2.91e-01 | 5.59e-01 | 6.73e-01 | 3.92e-01 | 4.94e-01 | 2.60e-01 |
| UREA TRANSMEMBRANE TRANSPORT | 9 | 2.40e-01 | 7.66e-01 | 0.44600 | 1.05e-01 | 1.88e-01 | -1.10e-01 | 2.36e-01 | -2.91e-01 | 5.84e-01 | 3.30e-01 | 5.69e-01 | 2.20e-01 | 1.31e-01 |
| NEGATIVE REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 21 | 2.37e-01 | 7.61e-01 | 0.44600 | 2.39e-01 | 2.03e-01 | 2.26e-01 | 1.97e-01 | -9.99e-02 | 5.75e-02 | 1.07e-01 | 7.30e-02 | 1.17e-01 | 4.28e-01 |
| INTRACILIARY ANTEROGRADE TRANSPORT | 17 | 9.70e-02 | 5.13e-01 | 0.44600 | 1.67e-01 | 1.07e-01 | 3.37e-01 | 9.89e-03 | 2.14e-01 | 2.32e-01 | 4.43e-01 | 1.62e-02 | 9.44e-01 | 1.27e-01 |
| NEGATIVE REGULATION OF ENDOPLASMIC RETICULUM CALCIUM ION CONCENTRATION | 7 | 6.10e-01 | 9.90e-01 | 0.44600 | -6.18e-02 | -3.11e-02 | -1.50e-01 | -7.94e-02 | -4.06e-01 | 7.77e-01 | 8.87e-01 | 4.91e-01 | 7.16e-01 | 6.28e-02 |
| NEGATIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION ELONGATION | 22 | 3.88e-01 | 8.92e-01 | 0.44500 | 2.24e-01 | 1.89e-01 | 2.76e-01 | 1.56e-01 | 1.07e-01 | 6.86e-02 | 1.25e-01 | 2.49e-02 | 2.05e-01 | 3.84e-01 |
| NEGATIVE REGULATION OF LOW DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 15 | 4.73e-01 | 9.40e-01 | 0.44500 | 2.38e-01 | 2.16e-01 | 2.31e-01 | 1.59e-01 | -1.26e-01 | 1.10e-01 | 1.47e-01 | 1.21e-01 | 2.88e-01 | 3.96e-01 |
| OLIGOSACCHARIDE CATABOLIC PROCESS | 17 | 3.05e-01 | 8.34e-01 | 0.44500 | 1.78e-01 | 1.86e-01 | 1.85e-01 | 1.98e-01 | 2.41e-01 | 2.03e-01 | 1.85e-01 | 1.88e-01 | 1.57e-01 | 8.54e-02 |
| POSITIVE REGULATION OF RNA SPLICING | 37 | 9.55e-03 | 1.22e-01 | 0.44500 | 1.73e-01 | 1.10e-01 | 2.97e-01 | 1.02e-01 | 2.39e-01 | 6.83e-02 | 2.48e-01 | 1.78e-03 | 2.83e-01 | 1.18e-02 |
| DNA PROTECTION | 6 | 2.79e-01 | 8.05e-01 | 0.44500 | 1.85e-01 | 1.24e-01 | 2.09e-01 | 3.29e-02 | -3.22e-01 | 4.32e-01 | 6.00e-01 | 3.76e-01 | 8.89e-01 | 1.73e-01 |
| CARDIAC NEURAL CREST CELL MIGRATION INVOLVED IN OUTFLOW TRACT MORPHOGENESIS | 11 | 6.46e-01 | 1.00e+00 | 0.44500 | 2.20e-01 | 2.15e-01 | 1.89e-01 | 2.59e-01 | -1.93e-02 | 2.07e-01 | 2.17e-01 | 2.77e-01 | 1.38e-01 | 9.12e-01 |
| DIGESTIVE TRACT MORPHOGENESIS | 48 | 3.58e-02 | 3.02e-01 | 0.44500 | 2.42e-01 | 2.20e-01 | 2.44e-01 | 1.64e-01 | -6.09e-02 | 3.66e-03 | 8.25e-03 | 3.44e-03 | 4.88e-02 | 4.65e-01 |
| LIPID DROPLET ORGANIZATION | 34 | 7.39e-02 | 4.47e-01 | 0.44500 | 1.83e-01 | 1.72e-01 | 2.22e-01 | 1.80e-01 | 2.30e-01 | 6.54e-02 | 8.35e-02 | 2.48e-02 | 7.00e-02 | 2.00e-02 |
| REGULATION OF VOLTAGE GATED CALCIUM CHANNEL ACTIVITY | 33 | 1.94e-01 | 7.05e-01 | 0.44400 | 2.30e-01 | 2.46e-01 | 1.57e-01 | 2.38e-01 | 5.22e-02 | 2.25e-02 | 1.43e-02 | 1.19e-01 | 1.79e-02 | 6.04e-01 |
| MINERALOCORTICOID SECRETION | 7 | 7.85e-01 | 1.00e+00 | 0.44400 | 2.16e-01 | 2.31e-01 | 2.11e-01 | 2.28e-01 | 3.07e-02 | 3.22e-01 | 2.90e-01 | 3.34e-01 | 2.97e-01 | 8.88e-01 |
| POSITIVE REGULATION OF ENDOPLASMIC RETICULUM STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 10 | 5.41e-01 | 9.59e-01 | 0.44400 | -2.39e-01 | -2.08e-01 | -2.89e-01 | -8.77e-02 | -7.38e-02 | 1.92e-01 | 2.54e-01 | 1.13e-01 | 6.31e-01 | 6.86e-01 |
| POSITIVE REGULATION OF VITAMIN D RECEPTOR SIGNALING PATHWAY | 6 | 7.35e-01 | 1.00e+00 | 0.44400 | 2.02e-01 | 2.42e-01 | 1.80e-01 | 1.87e-01 | 1.74e-01 | 3.91e-01 | 3.05e-01 | 4.46e-01 | 4.27e-01 | 4.61e-01 |
| REGULATION OF VOLTAGE GATED SODIUM CHANNEL ACTIVITY | 8 | 5.39e-01 | 9.58e-01 | 0.44300 | 1.86e-01 | 2.26e-01 | -7.14e-03 | 3.18e-01 | -9.84e-02 | 3.61e-01 | 2.69e-01 | 9.72e-01 | 1.19e-01 | 6.30e-01 |
| PROGESTERONE METABOLIC PROCESS | 16 | 2.51e-01 | 7.77e-01 | 0.44300 | -2.53e-01 | -2.48e-01 | -2.08e-01 | -1.58e-01 | -5.64e-02 | 8.01e-02 | 8.61e-02 | 1.50e-01 | 2.75e-01 | 6.96e-01 |
| GLYCEROL TRANSMEMBRANE TRANSPORT | 7 | 5.47e-01 | 9.61e-01 | 0.44300 | 1.98e-01 | 2.05e-01 | 1.90e-01 | 1.85e-01 | -2.12e-01 | 3.65e-01 | 3.47e-01 | 3.84e-01 | 3.97e-01 | 3.32e-01 |
| POSITIVE REGULATION OF MYELOID CELL APOPTOTIC PROCESS | 10 | 2.83e-01 | 8.10e-01 | 0.44300 | -1.62e-01 | -1.87e-01 | -7.76e-02 | -3.06e-01 | -1.88e-01 | 3.76e-01 | 3.06e-01 | 6.71e-01 | 9.37e-02 | 3.02e-01 |
| REGULATION OF CELL KILLING | 113 | 1.19e-05 | 5.39e-04 | 0.44300 | -2.29e-01 | -2.61e-01 | -1.13e-01 | -2.46e-01 | 4.63e-02 | 2.54e-05 | 1.64e-06 | 3.82e-02 | 6.13e-06 | 3.95e-01 |
| CYTOPLASM ORGANIZATION | 15 | 6.05e-01 | 9.90e-01 | 0.44300 | -2.27e-01 | -2.33e-01 | -1.80e-01 | -2.10e-01 | -1.18e-01 | 1.29e-01 | 1.18e-01 | 2.27e-01 | 1.60e-01 | 4.28e-01 |
| SMALL NUCLEOLAR RIBONUCLEOPROTEIN COMPLEX ASSEMBLY | 12 | 4.24e-01 | 9.14e-01 | 0.44200 | 2.07e-01 | 1.82e-01 | 3.08e-01 | 1.31e-01 | 8.88e-02 | 2.15e-01 | 2.76e-01 | 6.47e-02 | 4.33e-01 | 5.94e-01 |
| POSITIVE REGULATION OF MITOCHONDRIAL TRANSLATION | 16 | 1.85e-01 | 6.93e-01 | 0.44200 | 2.24e-01 | 2.10e-01 | 2.89e-01 | 7.51e-02 | -1.09e-01 | 1.21e-01 | 1.46e-01 | 4.51e-02 | 6.03e-01 | 4.51e-01 |
| RESPONSE TO AMMONIUM ION | 6 | 5.88e-01 | 9.85e-01 | 0.44200 | -2.03e-01 | -2.15e-01 | -2.32e-01 | -6.92e-02 | -2.22e-01 | 3.90e-01 | 3.63e-01 | 3.25e-01 | 7.69e-01 | 3.46e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO LYSOSOME | 5 | 9.44e-01 | 1.00e+00 | 0.44200 | 2.13e-01 | 2.15e-01 | 1.79e-01 | 2.14e-01 | 1.60e-01 | 4.10e-01 | 4.05e-01 | 4.87e-01 | 4.08e-01 | 5.37e-01 |
| FIBROBLAST ACTIVATION | 15 | 1.56e-01 | 6.54e-01 | 0.44100 | -2.13e-01 | -2.64e-01 | -1.88e-02 | -2.75e-01 | 6.15e-02 | 1.53e-01 | 7.64e-02 | 9.00e-01 | 6.56e-02 | 6.80e-01 |
| PROTEIN DEGLUTAMYLATION | 6 | 6.68e-01 | 1.00e+00 | 0.44100 | -6.27e-02 | -7.39e-03 | -1.57e-01 | -7.63e-02 | -4.00e-01 | 7.90e-01 | 9.75e-01 | 5.06e-01 | 7.46e-01 | 8.94e-02 |
| POSITIVE REGULATION OF DOPAMINE SECRETION | 6 | 5.42e-01 | 9.59e-01 | 0.44100 | 1.09e-01 | 1.70e-02 | 2.95e-01 | 1.65e-03 | 3.09e-01 | 6.45e-01 | 9.43e-01 | 2.11e-01 | 9.94e-01 | 1.90e-01 |
| REGULATION OF FOCAL ADHESION DISASSEMBLY | 6 | 7.96e-01 | 1.00e+00 | 0.44100 | 2.13e-01 | 1.75e-01 | 3.13e-01 | 6.30e-02 | 1.30e-01 | 3.67e-01 | 4.58e-01 | 1.84e-01 | 7.89e-01 | 5.80e-01 |
| POSITIVE REGULATION OF LEUKOCYTE MEDIATED IMMUNITY | 146 | 3.80e-08 | 3.62e-06 | 0.44100 | -2.21e-01 | -2.54e-01 | -8.22e-02 | -2.57e-01 | 9.17e-02 | 4.10e-06 | 1.16e-07 | 8.63e-02 | 8.00e-08 | 5.59e-02 |
| POSITIVE REGULATION OF TYPE II INTERFERON PRODUCTION | 74 | 8.71e-04 | 2.02e-02 | 0.44100 | -2.29e-01 | -2.63e-01 | -1.10e-01 | -2.42e-01 | 4.55e-02 | 6.49e-04 | 9.28e-05 | 1.00e-01 | 3.13e-04 | 4.99e-01 |
| REGULATION OF RETROGRADE TRANSPORT ENDOSOME TO GOLGI | 7 | 4.15e-01 | 9.11e-01 | 0.44100 | -2.37e-01 | -2.72e-01 | -2.00e-01 | -5.80e-02 | 1.43e-01 | 2.77e-01 | 2.12e-01 | 3.59e-01 | 7.90e-01 | 5.13e-01 |
| T CELL MIGRATION | 68 | 5.54e-03 | 8.23e-02 | 0.44100 | -2.47e-01 | -2.34e-01 | -1.87e-01 | -2.04e-01 | 3.61e-02 | 4.18e-04 | 8.32e-04 | 7.52e-03 | 3.56e-03 | 6.07e-01 |
| NAD BIOSYNTHESIS VIA NICOTINAMIDE RIBOSIDE SALVAGE PATHWAY | 10 | 6.11e-01 | 9.90e-01 | 0.44100 | 2.07e-01 | 2.41e-01 | 1.48e-01 | 2.33e-01 | 1.32e-01 | 2.57e-01 | 1.87e-01 | 4.17e-01 | 2.03e-01 | 4.71e-01 |
| POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 7 | 3.29e-01 | 8.53e-01 | 0.44000 | 1.41e-01 | 9.92e-02 | 3.58e-01 | -7.95e-02 | 1.73e-01 | 5.19e-01 | 6.49e-01 | 1.01e-01 | 7.16e-01 | 4.28e-01 |
| MEIOTIC TELOMERE CLUSTERING | 10 | 7.38e-01 | 1.00e+00 | 0.44000 | -2.12e-01 | -1.97e-01 | -2.71e-01 | -1.14e-01 | -1.54e-01 | 2.45e-01 | 2.82e-01 | 1.38e-01 | 5.33e-01 | 4.00e-01 |
| POSITIVE REGULATION OF TRANSLATION IN RESPONSE TO STRESS | 6 | 5.44e-01 | 9.60e-01 | 0.44000 | -3.40e-02 | -1.78e-03 | -2.40e-01 | 8.76e-02 | -3.56e-01 | 8.85e-01 | 9.94e-01 | 3.08e-01 | 7.10e-01 | 1.31e-01 |
| REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 30 | 2.27e-01 | 7.48e-01 | 0.44000 | 2.10e-01 | 1.78e-01 | 2.60e-01 | 1.52e-01 | 1.64e-01 | 4.63e-02 | 9.11e-02 | 1.37e-02 | 1.49e-01 | 1.20e-01 |
| NEGATIVE REGULATION OF PROTEIN AUTOPHOSPHORYLATION | 11 | 5.46e-01 | 9.61e-01 | 0.44000 | -2.21e-01 | -1.95e-01 | -1.30e-01 | -2.99e-01 | -2.65e-03 | 2.05e-01 | 2.62e-01 | 4.55e-01 | 8.59e-02 | 9.88e-01 |
| NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO STRESS | 8 | 7.80e-01 | 1.00e+00 | 0.44000 | 2.32e-01 | 2.07e-01 | 1.89e-01 | 2.00e-01 | -1.45e-01 | 2.56e-01 | 3.11e-01 | 3.54e-01 | 3.28e-01 | 4.79e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 17 PRODUCTION | 26 | 1.57e-02 | 1.75e-01 | 0.43900 | -2.01e-01 | -2.34e-01 | 1.04e-02 | -2.77e-01 | 1.47e-01 | 7.66e-02 | 3.90e-02 | 9.27e-01 | 1.46e-02 | 1.95e-01 |
| GLUCOCORTICOID SECRETION | 12 | 6.04e-01 | 9.90e-01 | 0.43900 | 1.87e-01 | 1.54e-01 | 2.76e-01 | 1.00e-01 | 2.18e-01 | 2.62e-01 | 3.55e-01 | 9.74e-02 | 5.47e-01 | 1.90e-01 |
| RRNA 5 END PROCESSING | 5 | 4.76e-01 | 9.40e-01 | 0.43900 | 1.69e-01 | 1.18e-01 | 3.32e-01 | -8.03e-02 | 1.83e-01 | 5.13e-01 | 6.49e-01 | 1.99e-01 | 7.56e-01 | 4.78e-01 |
| ENDOTHELIAL CELL ACTIVATION | 11 | 2.09e-01 | 7.30e-01 | 0.43900 | -2.19e-01 | -2.93e-01 | -1.12e-01 | -2.10e-01 | -5.01e-02 | 2.09e-01 | 9.26e-02 | 5.22e-01 | 2.29e-01 | 7.73e-01 |
| MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA PRODUCTION | 6 | 9.44e-01 | 1.00e+00 | 0.43900 | 2.29e-01 | 2.14e-01 | 2.10e-01 | 2.24e-01 | -6.94e-03 | 3.32e-01 | 3.63e-01 | 3.73e-01 | 3.42e-01 | 9.77e-01 |
| POSITIVE REGULATION OF CHEMOKINE C X C MOTIF LIGAND 2 PRODUCTION | 11 | 1.44e-01 | 6.29e-01 | 0.43900 | -1.68e-01 | -1.74e-01 | 3.65e-03 | -3.40e-01 | -1.36e-01 | 3.35e-01 | 3.17e-01 | 9.83e-01 | 5.10e-02 | 4.36e-01 |
| NEGATIVE REGULATION OF MRNA PROCESSING | 22 | 2.89e-01 | 8.17e-01 | 0.43900 | 1.91e-01 | 1.58e-01 | 2.65e-01 | 1.16e-01 | 2.17e-01 | 1.21e-01 | 2.00e-01 | 3.13e-02 | 3.45e-01 | 7.77e-02 |
| STEM CELL FATE SPECIFICATION | 6 | 1.16e-01 | 5.66e-01 | 0.43900 | 1.65e-04 | -8.69e-02 | 3.13e-01 | -2.81e-01 | 8.67e-02 | 9.99e-01 | 7.12e-01 | 1.84e-01 | 2.33e-01 | 7.13e-01 |
| SEGMENT SPECIFICATION | 16 | 5.37e-01 | 9.57e-01 | 0.43900 | 2.32e-01 | 2.15e-01 | 2.27e-01 | 1.77e-01 | -9.79e-02 | 1.08e-01 | 1.37e-01 | 1.16e-01 | 2.21e-01 | 4.98e-01 |
| REGULATION OF GASTRIC ACID SECRETION | 6 | 5.14e-01 | 9.52e-01 | 0.43900 | 1.66e-01 | 1.93e-01 | 6.96e-02 | 2.15e-01 | 2.77e-01 | 4.82e-01 | 4.13e-01 | 7.68e-01 | 3.63e-01 | 2.40e-01 |
| HYPERSENSITIVITY | 12 | 4.36e-02 | 3.35e-01 | 0.43900 | -1.39e-01 | -2.26e-01 | 1.30e-01 | -1.98e-01 | 2.57e-01 | 4.05e-01 | 1.75e-01 | 4.35e-01 | 2.36e-01 | 1.23e-01 |
| FRUCTOSE METABOLIC PROCESS | 13 | 3.64e-01 | 8.78e-01 | 0.43800 | 1.41e-01 | 1.03e-01 | 2.62e-01 | 3.97e-02 | 3.02e-01 | 3.79e-01 | 5.19e-01 | 1.02e-01 | 8.04e-01 | 5.90e-02 |
| AMINO ACID SALVAGE | 7 | 2.20e-01 | 7.43e-01 | 0.43800 | 9.97e-02 | 1.56e-01 | 1.03e-01 | -3.04e-02 | -3.83e-01 | 6.48e-01 | 4.75e-01 | 6.36e-01 | 8.89e-01 | 7.96e-02 |
| CELLULAR RESPONSE TO ALDOSTERONE | 7 | 8.42e-01 | 1.00e+00 | 0.43800 | 1.97e-01 | 1.94e-01 | 1.55e-01 | 2.64e-01 | 1.48e-01 | 3.66e-01 | 3.75e-01 | 4.77e-01 | 2.26e-01 | 4.97e-01 |
| PEPTIDYL LYSINE OXIDATION | 5 | 9.41e-01 | 1.00e+00 | 0.43800 | 2.00e-01 | 1.67e-01 | 2.35e-01 | 1.97e-01 | 1.74e-01 | 4.39e-01 | 5.18e-01 | 3.62e-01 | 4.46e-01 | 5.01e-01 |
| REGULATION OF RESPONSE TO DRUG | 15 | 1.81e-01 | 6.88e-01 | 0.43800 | 1.60e-01 | 1.03e-01 | 2.12e-01 | 2.20e-01 | 2.49e-01 | 2.83e-01 | 4.90e-01 | 1.55e-01 | 1.40e-01 | 9.49e-02 |
| POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 13 | 4.71e-01 | 9.40e-01 | 0.43800 | -2.20e-01 | -2.42e-01 | -1.28e-01 | -1.52e-01 | 2.12e-01 | 1.69e-01 | 1.30e-01 | 4.24e-01 | 3.42e-01 | 1.86e-01 |
| GLUTAMINE METABOLIC PROCESS | 25 | 3.96e-02 | 3.20e-01 | 0.43800 | 2.08e-01 | 2.14e-01 | 2.26e-01 | 1.08e-01 | -2.01e-01 | 7.24e-02 | 6.45e-02 | 5.06e-02 | 3.52e-01 | 8.25e-02 |
| REGULATION OF CELLULAR RESPIRATION | 46 | 1.54e-01 | 6.50e-01 | 0.43800 | 2.31e-01 | 2.22e-01 | 1.99e-01 | 2.21e-01 | -1.07e-02 | 6.61e-03 | 9.05e-03 | 1.98e-02 | 9.44e-03 | 9.00e-01 |
| REGULATION OF TELOMERE MAINTENANCE IN RESPONSE TO DNA DAMAGE | 19 | 1.39e-01 | 6.22e-01 | 0.43700 | 1.49e-01 | 1.29e-01 | 2.66e-01 | 1.04e-01 | 2.67e-01 | 2.61e-01 | 3.30e-01 | 4.50e-02 | 4.31e-01 | 4.43e-02 |
| SKELETAL MUSCLE THIN FILAMENT ASSEMBLY | 7 | 9.71e-02 | 5.13e-01 | 0.43700 | 4.44e-02 | 1.26e-01 | 1.70e-03 | -1.60e-01 | -3.85e-01 | 8.39e-01 | 5.64e-01 | 9.94e-01 | 4.65e-01 | 7.81e-02 |
| REGULATION OF UBIQUITIN PROTEIN LIGASE ACTIVITY | 18 | 2.20e-01 | 7.43e-01 | 0.43700 | 2.25e-01 | 2.24e-01 | 2.89e-01 | 7.97e-02 | 2.13e-02 | 9.89e-02 | 9.94e-02 | 3.38e-02 | 5.58e-01 | 8.76e-01 |
| MEGAKARYOCYTE DIFFERENTIATION | 61 | 3.18e-03 | 5.49e-02 | 0.43700 | 2.04e-01 | 1.59e-01 | 2.90e-01 | 1.21e-01 | 1.60e-01 | 5.90e-03 | 3.22e-02 | 8.89e-05 | 1.03e-01 | 3.05e-02 |
| NEPHRIC DUCT FORMATION | 5 | 5.79e-01 | 9.82e-01 | 0.43700 | 2.04e-01 | 1.55e-01 | 3.32e-01 | 2.35e-02 | -1.20e-01 | 4.30e-01 | 5.48e-01 | 1.99e-01 | 9.28e-01 | 6.43e-01 |
| NEGATIVE REGULATION OF SYNAPTIC TRANSMISSION GABAERGIC | 6 | 3.86e-01 | 8.92e-01 | 0.43700 | -5.59e-02 | -1.38e-01 | 2.02e-01 | -1.20e-01 | 3.37e-01 | 8.13e-01 | 5.57e-01 | 3.92e-01 | 6.10e-01 | 1.53e-01 |
| RECEPTOR DIFFUSION TRAPPING | 10 | 4.44e-01 | 9.28e-01 | 0.43700 | 2.03e-01 | 2.25e-01 | 2.39e-01 | 9.58e-02 | 1.80e-01 | 2.66e-01 | 2.17e-01 | 1.91e-01 | 6.00e-01 | 3.24e-01 |
| ICOSANOID CATABOLIC PROCESS | 9 | 2.00e-01 | 7.14e-01 | 0.43700 | 1.94e-01 | 1.59e-01 | 2.23e-01 | 2.79e-01 | 1.44e-02 | 3.13e-01 | 4.09e-01 | 2.47e-01 | 1.48e-01 | 9.40e-01 |
| SEMICIRCULAR CANAL MORPHOGENESIS | 7 | 1.26e-01 | 5.92e-01 | 0.43600 | -1.61e-01 | -2.90e-01 | 5.75e-02 | -1.69e-01 | 2.20e-01 | 4.61e-01 | 1.84e-01 | 7.92e-01 | 4.39e-01 | 3.13e-01 |
| NEGATIVE REGULATION OF MONONUCLEAR CELL MIGRATION | 24 | 2.37e-01 | 7.60e-01 | 0.43600 | -2.09e-01 | -1.87e-01 | -2.65e-01 | -1.79e-01 | -9.82e-02 | 7.63e-02 | 1.14e-01 | 2.48e-02 | 1.29e-01 | 4.05e-01 |
| LEUKOCYTE CHEMOTAXIS INVOLVED IN INFLAMMATORY RESPONSE | 8 | 5.94e-02 | 4.01e-01 | 0.43600 | 2.04e-01 | 6.82e-02 | 2.75e-01 | 2.11e-01 | 1.54e-01 | 3.17e-01 | 7.38e-01 | 1.78e-01 | 3.01e-01 | 4.52e-01 |
| INTRACILIARY RETROGRADE TRANSPORT | 14 | 3.09e-01 | 8.35e-01 | 0.43600 | 1.12e-01 | 8.83e-02 | 2.16e-01 | 8.95e-02 | 3.39e-01 | 4.69e-01 | 5.67e-01 | 1.62e-01 | 5.62e-01 | 2.79e-02 |
| MESONEPHRIC TUBULE FORMATION | 10 | 1.39e-01 | 6.23e-01 | 0.43600 | -6.46e-02 | -1.35e-01 | 1.65e-01 | -2.52e-01 | 2.77e-01 | 7.24e-01 | 4.60e-01 | 3.66e-01 | 1.68e-01 | 1.29e-01 |
| DNA REPLICATION DEPENDENT CHROMATIN ASSEMBLY | 6 | 3.17e-01 | 8.45e-01 | 0.43600 | 1.94e-01 | 1.89e-01 | 3.26e-01 | -7.65e-02 | 6.80e-02 | 4.10e-01 | 4.24e-01 | 1.67e-01 | 7.46e-01 | 7.73e-01 |
| POST TRANSLATIONAL PROTEIN TARGETING TO ENDOPLASMIC RETICULUM MEMBRANE | 15 | 1.62e-02 | 1.79e-01 | 0.43500 | 1.57e-01 | 1.75e-01 | 3.02e-01 | -4.87e-02 | 2.02e-01 | 2.94e-01 | 2.41e-01 | 4.26e-02 | 7.44e-01 | 1.76e-01 |
| ENDOSOME TO LYSOSOME TRANSPORT VIA MULTIVESICULAR BODY SORTING PATHWAY | 17 | 1.68e-01 | 6.71e-01 | 0.43500 | 1.55e-01 | 1.36e-01 | 2.85e-01 | 3.05e-02 | 2.54e-01 | 2.69e-01 | 3.30e-01 | 4.17e-02 | 8.27e-01 | 6.98e-02 |
| TOLL LIKE RECEPTOR 2 SIGNALING PATHWAY | 17 | 3.18e-01 | 8.46e-01 | 0.43500 | -1.99e-01 | -2.35e-01 | -5.38e-02 | -2.80e-01 | 1.15e-01 | 1.55e-01 | 9.35e-02 | 7.01e-01 | 4.57e-02 | 4.11e-01 |
| SPINDLE ASSEMBLY INVOLVED IN FEMALE MEIOSIS | 9 | 1.84e-02 | 1.97e-01 | 0.43500 | 1.40e-01 | 4.96e-02 | 3.63e-01 | -1.77e-01 | 6.45e-02 | 4.67e-01 | 7.96e-01 | 5.94e-02 | 3.58e-01 | 7.38e-01 |
| PREVENTION OF POLYSPERMY | 7 | 6.18e-01 | 9.90e-01 | 0.43500 | -1.97e-01 | -1.32e-01 | -2.93e-01 | -6.60e-02 | -2.06e-01 | 3.67e-01 | 5.44e-01 | 1.79e-01 | 7.62e-01 | 3.45e-01 |
| LEUKOCYTE TETHERING OR ROLLING | 34 | 1.04e-02 | 1.29e-01 | 0.43500 | -2.40e-01 | -2.66e-01 | -1.25e-01 | -1.70e-01 | 1.27e-01 | 1.53e-02 | 7.28e-03 | 2.08e-01 | 8.67e-02 | 2.00e-01 |
| LUTEOLYSIS | 6 | 5.53e-01 | 9.66e-01 | 0.43400 | -2.09e-01 | -2.90e-01 | -3.73e-02 | -1.95e-01 | 1.47e-01 | 3.76e-01 | 2.19e-01 | 8.74e-01 | 4.07e-01 | 5.34e-01 |
| REGULATION OF GAMMA DELTA T CELL ACTIVATION | 11 | 1.54e-01 | 6.50e-01 | 0.43400 | 8.86e-04 | -8.37e-02 | 1.84e-01 | -1.05e-01 | 3.69e-01 | 9.96e-01 | 6.31e-01 | 2.90e-01 | 5.45e-01 | 3.39e-02 |
| TYPE 2 IMMUNE RESPONSE | 42 | 3.62e-02 | 3.03e-01 | 0.43400 | -2.09e-01 | -2.30e-01 | -7.57e-02 | -2.40e-01 | 1.68e-01 | 1.89e-02 | 1.00e-02 | 3.96e-01 | 7.02e-03 | 5.91e-02 |
| REGULATION OF MITOTIC CYTOKINESIS | 11 | 3.72e-01 | 8.82e-01 | 0.43400 | 1.91e-01 | 1.64e-01 | 2.98e-01 | 1.49e-01 | 1.18e-01 | 2.73e-01 | 3.45e-01 | 8.75e-02 | 3.92e-01 | 4.97e-01 |
| POSITIVE REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 31 | 7.51e-02 | 4.50e-01 | 0.43400 | 2.30e-01 | 2.23e-01 | 2.73e-01 | 9.48e-02 | 4.32e-02 | 2.67e-02 | 3.18e-02 | 8.45e-03 | 3.61e-01 | 6.77e-01 |
| MRNA ALTERNATIVE POLYADENYLATION | 5 | 5.35e-01 | 9.56e-01 | 0.43300 | 2.08e-01 | 1.32e-01 | 2.95e-01 | 1.98e-01 | -2.26e-02 | 4.20e-01 | 6.09e-01 | 2.54e-01 | 4.42e-01 | 9.30e-01 |
| NEGATIVE REGULATION OF UBIQUITIN PROTEIN TRANSFERASE ACTIVITY | 15 | 2.84e-02 | 2.60e-01 | 0.43300 | 1.50e-01 | 1.54e-01 | 3.11e-01 | -5.58e-02 | 2.04e-01 | 3.13e-01 | 3.01e-01 | 3.73e-02 | 7.08e-01 | 1.72e-01 |
| REGULATION OF HISTAMINE SECRETION BY MAST CELL | 6 | 4.54e-01 | 9.31e-01 | 0.43300 | 2.08e-01 | 2.06e-01 | 5.71e-02 | 1.42e-01 | -2.80e-01 | 3.78e-01 | 3.82e-01 | 8.09e-01 | 5.48e-01 | 2.35e-01 |
| PROTEIN DNA COMPLEX ASSEMBLY | 203 | 1.72e-11 | 4.06e-09 | 0.43300 | 1.98e-01 | 1.55e-01 | 2.89e-01 | 1.10e-01 | 1.68e-01 | 1.15e-06 | 1.43e-04 | 1.14e-12 | 6.69e-03 | 3.65e-05 |
| REGULATION OF ANAPHASE PROMOTING COMPLEX DEPENDENT CATABOLIC PROCESS | 5 | 9.08e-01 | 1.00e+00 | 0.43300 | 2.17e-01 | 2.55e-01 | 1.58e-01 | 2.24e-01 | 2.01e-02 | 4.01e-01 | 3.24e-01 | 5.41e-01 | 3.86e-01 | 9.38e-01 |
| OUTER EAR MORPHOGENESIS | 7 | 1.78e-01 | 6.85e-01 | 0.43300 | 1.45e-01 | 1.59e-02 | 3.27e-01 | 8.09e-02 | 2.28e-01 | 5.05e-01 | 9.42e-01 | 1.34e-01 | 7.11e-01 | 2.95e-01 |
| POSITIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND TRANSPORT | 6 | 5.63e-01 | 9.71e-01 | 0.43300 | 1.75e-01 | 1.14e-01 | 2.49e-01 | 2.31e-01 | 1.67e-01 | 4.57e-01 | 6.28e-01 | 2.91e-01 | 3.27e-01 | 4.78e-01 |
| NEGATIVE REGULATION OF CELL PROLIFERATION INVOLVED IN KIDNEY DEVELOPMENT | 6 | 4.74e-01 | 9.40e-01 | 0.43300 | 2.03e-01 | 2.75e-01 | 1.71e-01 | 1.86e-01 | 7.82e-02 | 3.89e-01 | 2.43e-01 | 4.67e-01 | 4.30e-01 | 7.40e-01 |
| REGULATION OF VASCULAR WOUND HEALING | 13 | 4.86e-01 | 9.43e-01 | 0.43300 | 2.32e-01 | 1.95e-01 | 2.90e-01 | 9.84e-02 | 4.15e-02 | 1.47e-01 | 2.24e-01 | 7.06e-02 | 5.39e-01 | 7.96e-01 |
| SYNAPTIC ASSEMBLY AT NEUROMUSCULAR JUNCTION | 10 | 2.80e-01 | 8.06e-01 | 0.43300 | -1.76e-01 | -1.70e-01 | 4.70e-03 | -3.14e-01 | 1.68e-01 | 3.36e-01 | 3.52e-01 | 9.79e-01 | 8.51e-02 | 3.57e-01 |
| POSITIVE REGULATION OF GONADOTROPIN SECRETION | 7 | 4.44e-01 | 9.28e-01 | 0.43200 | -6.81e-02 | -7.09e-02 | -4.85e-02 | -1.87e-01 | -3.74e-01 | 7.55e-01 | 7.45e-01 | 8.24e-01 | 3.92e-01 | 8.63e-02 |
| PSEUDOURIDINE SYNTHESIS | 17 | 1.27e-01 | 5.93e-01 | 0.43200 | 1.80e-01 | 1.24e-01 | 3.30e-01 | 1.82e-02 | 1.72e-01 | 1.98e-01 | 3.75e-01 | 1.85e-02 | 8.96e-01 | 2.19e-01 |
| MULTI PASS TRANSMEMBRANE PROTEIN INSERTION INTO ER MEMBRANE | 8 | 4.86e-01 | 9.43e-01 | 0.43200 | -8.44e-02 | -1.35e-01 | 1.10e-01 | -1.84e-01 | 3.39e-01 | 6.79e-01 | 5.08e-01 | 5.89e-01 | 3.66e-01 | 9.67e-02 |
| DOUBLE STRAND BREAK REPAIR VIA SINGLE STRAND ANNEALING | 6 | 5.17e-01 | 9.52e-01 | 0.43200 | -2.11e-01 | -3.00e-01 | -8.00e-02 | -2.01e-01 | 7.13e-02 | 3.70e-01 | 2.04e-01 | 7.34e-01 | 3.94e-01 | 7.62e-01 |
| MOTOR NEURON MIGRATION | 13 | 1.91e-01 | 7.01e-01 | 0.43100 | -1.60e-01 | -1.12e-01 | -1.34e-01 | -2.74e-01 | -2.35e-01 | 3.18e-01 | 4.85e-01 | 4.04e-01 | 8.71e-02 | 1.43e-01 |
| REGULATION OF PROTEIN MONOUBIQUITINATION | 6 | 4.85e-01 | 9.43e-01 | 0.43100 | -3.72e-02 | -1.20e-01 | 1.47e-01 | -1.48e-01 | 3.56e-01 | 8.74e-01 | 6.12e-01 | 5.34e-01 | 5.31e-01 | 1.31e-01 |
| UREA TRANSPORT | 11 | 3.01e-01 | 8.29e-01 | 0.43100 | 1.08e-01 | 1.59e-01 | -5.70e-02 | 1.99e-01 | -3.26e-01 | 5.35e-01 | 3.61e-01 | 7.43e-01 | 2.53e-01 | 6.15e-02 |
| REGULATION OF SERINE TYPE PEPTIDASE ACTIVITY | 7 | 7.32e-02 | 4.45e-01 | 0.43100 | 1.08e-01 | 1.02e-01 | -1.19e-01 | 1.06e-01 | -3.71e-01 | 6.20e-01 | 6.41e-01 | 5.84e-01 | 6.27e-01 | 8.88e-02 |
| POSITIVE REGULATION OF INTEGRIN ACTIVATION | 11 | 7.78e-01 | 1.00e+00 | 0.43000 | -2.26e-01 | -2.20e-01 | -2.56e-01 | -1.36e-01 | -4.52e-02 | 1.95e-01 | 2.06e-01 | 1.42e-01 | 4.35e-01 | 7.95e-01 |
| CHROMOSOME ATTACHMENT TO THE NUCLEAR ENVELOPE | 7 | 4.50e-01 | 9.30e-01 | 0.43000 | -1.69e-01 | -1.36e-01 | -3.43e-01 | 4.11e-02 | -1.35e-01 | 4.39e-01 | 5.34e-01 | 1.16e-01 | 8.51e-01 | 5.35e-01 |
| RESPONSE TO LITHIUM ION | 15 | 3.51e-01 | 8.69e-01 | 0.43000 | 2.15e-01 | 1.71e-01 | 2.95e-01 | 1.46e-01 | 2.40e-02 | 1.49e-01 | 2.51e-01 | 4.77e-02 | 3.27e-01 | 8.72e-01 |
| NEUTROPHIL MEDIATED CYTOTOXICITY | 14 | 1.67e-01 | 6.70e-01 | 0.43000 | -9.86e-02 | -1.28e-01 | 9.28e-02 | -1.58e-01 | 3.53e-01 | 5.23e-01 | 4.07e-01 | 5.48e-01 | 3.06e-01 | 2.20e-02 |
| REGULATION OF INOSITOL TRISPHOSPHATE BIOSYNTHETIC PROCESS | 6 | 3.79e-01 | 8.86e-01 | 0.42900 | -2.21e-02 | 3.67e-02 | -1.40e-01 | 9.39e-02 | -3.92e-01 | 9.25e-01 | 8.76e-01 | 5.52e-01 | 6.90e-01 | 9.60e-02 |
| REGULATION OF ODONTOGENESIS | 18 | 4.11e-02 | 3.25e-01 | 0.42900 | 4.05e-02 | -1.63e-02 | 2.55e-01 | -4.80e-02 | 3.39e-01 | 7.66e-01 | 9.05e-01 | 6.12e-02 | 7.24e-01 | 1.27e-02 |
| POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 14 | 5.29e-01 | 9.54e-01 | 0.42900 | -2.39e-01 | -2.60e-01 | -1.54e-01 | -1.88e-01 | 2.16e-02 | 1.22e-01 | 9.21e-02 | 3.17e-01 | 2.23e-01 | 8.89e-01 |
| SYMPATHETIC GANGLION DEVELOPMENT | 9 | 4.21e-01 | 9.12e-01 | 0.42900 | -9.95e-02 | -1.10e-01 | -1.15e-01 | -1.37e-01 | -3.61e-01 | 6.05e-01 | 5.67e-01 | 5.49e-01 | 4.77e-01 | 6.09e-02 |
| NEGATIVE REGULATION OF LIPOPROTEIN PARTICLE CLEARANCE | 20 | 3.56e-01 | 8.74e-01 | 0.42900 | 2.29e-01 | 2.08e-01 | 2.14e-01 | 1.64e-01 | -1.26e-01 | 7.64e-02 | 1.08e-01 | 9.70e-02 | 2.04e-01 | 3.29e-01 |
| REGULATION OF MITOCHONDRIAL TRANSCRIPTION | 5 | 1.14e-01 | 5.61e-01 | 0.42900 | 5.20e-02 | 8.53e-02 | 1.98e-01 | -2.80e-01 | -2.38e-01 | 8.40e-01 | 7.41e-01 | 4.44e-01 | 2.79e-01 | 3.56e-01 |
| MITOCHONDRIAL CYTOCHROME C OXIDASE ASSEMBLY | 25 | 1.27e-02 | 1.48e-01 | 0.42900 | 1.39e-01 | 1.09e-01 | 3.17e-01 | 1.41e-02 | 2.29e-01 | 2.29e-01 | 3.47e-01 | 6.07e-03 | 9.03e-01 | 4.79e-02 |
| HEMATOPOIETIC STEM CELL MIGRATION | 8 | 7.02e-01 | 1.00e+00 | 0.42900 | -2.24e-01 | -2.63e-01 | -2.05e-01 | -1.48e-01 | 2.93e-02 | 2.73e-01 | 1.98e-01 | 3.15e-01 | 4.70e-01 | 8.86e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 6 | 8.09e-01 | 1.00e+00 | 0.42800 | 1.33e-01 | 1.25e-01 | 1.96e-01 | 1.21e-01 | 3.12e-01 | 5.73e-01 | 5.97e-01 | 4.06e-01 | 6.08e-01 | 1.86e-01 |
| TRANSCRIPTION PREINITIATION COMPLEX ASSEMBLY | 66 | 1.64e-03 | 3.40e-02 | 0.42800 | 1.81e-01 | 1.39e-01 | 2.76e-01 | 1.09e-01 | 2.07e-01 | 1.08e-02 | 5.09e-02 | 1.03e-04 | 1.26e-01 | 3.67e-03 |
| POSITIVE REGULATION OF AUTOPHAGY OF MITOCHONDRION | 14 | 4.63e-01 | 9.33e-01 | 0.42800 | -2.40e-01 | -1.94e-01 | -2.43e-01 | -1.67e-01 | 3.03e-02 | 1.20e-01 | 2.09e-01 | 1.15e-01 | 2.79e-01 | 8.44e-01 |
| NEGATIVE REGULATION OF SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 14 | 2.59e-01 | 7.87e-01 | 0.42800 | 1.79e-01 | 2.10e-01 | 1.15e-02 | 1.76e-01 | -2.75e-01 | 2.45e-01 | 1.74e-01 | 9.41e-01 | 2.54e-01 | 7.51e-02 |
| CGMP CATABOLIC PROCESS | 5 | 7.23e-01 | 1.00e+00 | 0.42700 | -3.67e-02 | -8.97e-03 | -9.21e-02 | -4.72e-02 | -4.13e-01 | 8.87e-01 | 9.72e-01 | 7.21e-01 | 8.55e-01 | 1.10e-01 |
| NEGATIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 16 | 3.05e-01 | 8.34e-01 | 0.42700 | -1.23e-01 | -1.02e-01 | -1.94e-01 | -9.48e-02 | -3.32e-01 | 3.93e-01 | 4.78e-01 | 1.78e-01 | 5.12e-01 | 2.15e-02 |
| NEGATIVE REGULATION OF LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 14 | 2.96e-01 | 8.24e-01 | 0.42700 | -1.59e-01 | -1.81e-01 | -1.86e-02 | -2.42e-01 | 2.56e-01 | 3.04e-01 | 2.40e-01 | 9.04e-01 | 1.17e-01 | 9.71e-02 |
| REGULATION OF T CELL ACTIVATION VIA T CELL RECEPTOR CONTACT WITH ANTIGEN BOUND TO MHC MOLECULE ON ANTIGEN PRESENTING CELL | 6 | 2.77e-01 | 8.04e-01 | 0.42700 | -7.42e-02 | -1.67e-01 | 1.92e-01 | -1.14e-01 | 3.15e-01 | 7.53e-01 | 4.80e-01 | 4.14e-01 | 6.30e-01 | 1.81e-01 |
| NEGATIVE REGULATION OF RESPONSE TO TYPE II INTERFERON | 7 | 7.05e-01 | 1.00e+00 | 0.42700 | -1.88e-01 | -1.88e-01 | -6.70e-02 | -2.89e-01 | 1.54e-01 | 3.89e-01 | 3.88e-01 | 7.59e-01 | 1.86e-01 | 4.80e-01 |
| POSITIVE REGULATION OF HAIR FOLLICLE MATURATION | 5 | 1.25e-01 | 5.90e-01 | 0.42700 | 1.97e-01 | 6.54e-02 | 3.56e-01 | -2.17e-02 | -1.11e-01 | 4.46e-01 | 8.00e-01 | 1.68e-01 | 9.33e-01 | 6.66e-01 |
| EPOXYGENASE P450 PATHWAY | 18 | 2.01e-01 | 7.17e-01 | 0.42700 | -2.47e-01 | -2.54e-01 | -1.87e-01 | -1.44e-01 | 3.06e-02 | 6.96e-02 | 6.19e-02 | 1.70e-01 | 2.89e-01 | 8.22e-01 |
| EPIGENETIC PROGRAMMING IN THE ZYGOTIC PRONUCLEI | 8 | 3.49e-01 | 8.68e-01 | 0.42700 | -2.49e-02 | -1.65e-02 | 6.40e-02 | 7.10e-03 | 4.21e-01 | 9.03e-01 | 9.36e-01 | 7.54e-01 | 9.72e-01 | 3.93e-02 |
| NEGATIVE REGULATION OF STEROL TRANSPORT | 31 | 3.61e-01 | 8.77e-01 | 0.42700 | 2.28e-01 | 2.18e-01 | 2.17e-01 | 1.86e-01 | -2.67e-02 | 2.78e-02 | 3.55e-02 | 3.65e-02 | 7.33e-02 | 7.97e-01 |
| HEME TRANSPORT | 9 | 4.15e-01 | 9.11e-01 | 0.42700 | -2.09e-01 | -1.65e-01 | -1.22e-01 | -3.09e-01 | 2.24e-02 | 2.77e-01 | 3.92e-01 | 5.25e-01 | 1.08e-01 | 9.07e-01 |
| TELENCEPHALON REGIONALIZATION | 13 | 2.12e-02 | 2.16e-01 | 0.42700 | 2.10e-01 | 1.08e-01 | 3.50e-01 | 4.15e-02 | -4.36e-02 | 1.90e-01 | 5.01e-01 | 2.88e-02 | 7.96e-01 | 7.86e-01 |
| SIGNAL TRANSDUCTION INVOLVED IN REGULATION OF GENE EXPRESSION | 22 | 2.10e-01 | 7.33e-01 | 0.42700 | 2.24e-01 | 2.54e-01 | 1.91e-01 | 1.36e-01 | -1.09e-01 | 6.88e-02 | 3.88e-02 | 1.20e-01 | 2.70e-01 | 3.78e-01 |
| POSITIVE REGULATION OF UNSATURATED FATTY ACID BIOSYNTHETIC PROCESS | 8 | 2.73e-01 | 7.99e-01 | 0.42600 | 1.87e-01 | 1.47e-01 | 2.87e-01 | 6.23e-02 | -1.97e-01 | 3.59e-01 | 4.72e-01 | 1.60e-01 | 7.60e-01 | 3.34e-01 |
| NEGATIVE REGULATION OF SKELETAL MUSCLE CELL PROLIFERATION | 5 | 8.06e-02 | 4.68e-01 | 0.42600 | 1.54e-01 | 1.86e-01 | 2.75e-01 | -2.10e-01 | -5.88e-02 | 5.50e-01 | 4.72e-01 | 2.87e-01 | 4.15e-01 | 8.20e-01 |
| CARNITINE TRANSPORT | 8 | 5.67e-01 | 9.73e-01 | 0.42600 | -1.85e-01 | -2.01e-01 | -2.32e-02 | -3.26e-01 | -1.21e-02 | 3.65e-01 | 3.24e-01 | 9.09e-01 | 1.11e-01 | 9.53e-01 |
| POSITIVE REGULATION OF PROTEIN NEDDYLATION | 5 | 5.85e-01 | 9.85e-01 | 0.42600 | 4.67e-02 | 2.77e-02 | 2.50e-01 | -5.06e-02 | 3.37e-01 | 8.56e-01 | 9.15e-01 | 3.32e-01 | 8.45e-01 | 1.93e-01 |
| SYNAPTIC VESICLE BUDDING | 10 | 1.00e-01 | 5.24e-01 | 0.42600 | -1.03e-01 | -1.29e-01 | 4.38e-02 | -2.81e-01 | -2.70e-01 | 5.72e-01 | 4.78e-01 | 8.11e-01 | 1.24e-01 | 1.39e-01 |
| RIBOSOMAL LARGE SUBUNIT ASSEMBLY | 24 | 2.30e-02 | 2.27e-01 | 0.42500 | 1.63e-01 | 1.46e-01 | 3.03e-01 | -6.78e-03 | 2.02e-01 | 1.68e-01 | 2.15e-01 | 1.01e-02 | 9.54e-01 | 8.61e-02 |
| NEGATIVE REGULATION OF RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 43 | 5.60e-03 | 8.28e-02 | 0.42500 | 2.11e-01 | 2.00e-01 | 2.99e-01 | 7.25e-02 | 4.32e-02 | 1.69e-02 | 2.29e-02 | 6.98e-04 | 4.11e-01 | 6.24e-01 |
| PONS DEVELOPMENT | 11 | 2.74e-01 | 8.01e-01 | 0.42500 | 2.49e-01 | 2.21e-01 | 1.42e-01 | 2.23e-01 | -8.71e-03 | 1.53e-01 | 2.05e-01 | 4.15e-01 | 2.01e-01 | 9.60e-01 |
| CELL FATE DETERMINATION | 42 | 2.69e-03 | 4.85e-02 | 0.42500 | 2.07e-01 | 2.06e-01 | 2.34e-01 | 8.78e-02 | -1.80e-01 | 2.04e-02 | 2.06e-02 | 8.58e-03 | 3.25e-01 | 4.32e-02 |
| RNA 3 URIDYLATION | 5 | 9.34e-01 | 1.00e+00 | 0.42500 | -2.39e-01 | -2.22e-01 | -2.09e-01 | -1.69e-01 | -3.90e-02 | 3.54e-01 | 3.89e-01 | 4.18e-01 | 5.14e-01 | 8.80e-01 |
| SPLICEOSOMAL CONFORMATIONAL CHANGES TO GENERATE CATALYTIC CONFORMATION | 5 | 6.93e-01 | 1.00e+00 | 0.42500 | 1.77e-01 | 1.02e-01 | 2.78e-01 | 5.15e-02 | 2.42e-01 | 4.93e-01 | 6.93e-01 | 2.82e-01 | 8.42e-01 | 3.48e-01 |
| CORTICOSTEROID HORMONE SECRETION | 19 | 5.00e-01 | 9.47e-01 | 0.42400 | 1.98e-01 | 1.83e-01 | 2.52e-01 | 1.47e-01 | 1.49e-01 | 1.35e-01 | 1.68e-01 | 5.69e-02 | 2.66e-01 | 2.60e-01 |
| DETECTION OF OTHER ORGANISM | 19 | 4.53e-01 | 9.31e-01 | 0.42400 | -2.12e-01 | -2.44e-01 | -1.08e-01 | -2.42e-01 | 7.55e-02 | 1.10e-01 | 6.57e-02 | 4.15e-01 | 6.81e-02 | 5.69e-01 |
| POSITIVE REGULATION OF SYNAPTIC VESICLE RECYCLING | 8 | 8.60e-01 | 1.00e+00 | 0.42400 | -2.14e-01 | -2.28e-01 | -2.00e-01 | -1.70e-01 | -1.16e-01 | 2.95e-01 | 2.65e-01 | 3.27e-01 | 4.04e-01 | 5.70e-01 |
| ADP METABOLIC PROCESS | 8 | 7.14e-01 | 1.00e+00 | 0.42400 | 1.95e-01 | 2.19e-01 | 1.27e-01 | 1.20e-01 | -2.52e-01 | 3.40e-01 | 2.84e-01 | 5.35e-01 | 5.57e-01 | 2.17e-01 |
| RADIAL GLIA GUIDED PYRAMIDAL NEURON MIGRATION | 6 | 8.76e-01 | 1.00e+00 | 0.42400 | -2.12e-01 | -2.22e-01 | -1.78e-01 | -1.73e-01 | -1.55e-01 | 3.69e-01 | 3.46e-01 | 4.50e-01 | 4.62e-01 | 5.12e-01 |
| BASOLATERAL PROTEIN SECRETION | 5 | 7.37e-01 | 1.00e+00 | 0.42400 | 1.37e-01 | 1.27e-01 | 2.73e-01 | 7.40e-02 | 2.54e-01 | 5.96e-01 | 6.23e-01 | 2.90e-01 | 7.75e-01 | 3.24e-01 |
| CYTOCHROME COMPLEX ASSEMBLY | 38 | 6.33e-03 | 9.04e-02 | 0.42400 | 1.77e-01 | 1.39e-01 | 3.19e-01 | 4.27e-02 | 1.60e-01 | 5.84e-02 | 1.39e-01 | 6.70e-04 | 6.48e-01 | 8.84e-02 |
| REGULATION OF PROSTAGLANDIN SECRETION | 13 | 5.48e-01 | 9.61e-01 | 0.42400 | -2.30e-01 | -2.25e-01 | -1.42e-01 | -1.84e-01 | 1.48e-01 | 1.51e-01 | 1.59e-01 | 3.75e-01 | 2.51e-01 | 3.55e-01 |
| POSITIVE REGULATION OF RECEPTOR CATABOLIC PROCESS | 7 | 7.14e-01 | 1.00e+00 | 0.42400 | 2.05e-01 | 2.28e-01 | 2.48e-01 | 1.39e-01 | 6.53e-02 | 3.47e-01 | 2.96e-01 | 2.55e-01 | 5.26e-01 | 7.65e-01 |
| EPIDERMAL CELL FATE SPECIFICATION | 5 | 3.75e-01 | 8.83e-01 | 0.42300 | 1.66e-01 | 1.11e-01 | 3.48e-01 | -4.10e-02 | -1.30e-01 | 5.21e-01 | 6.68e-01 | 1.78e-01 | 8.74e-01 | 6.16e-01 |
| VESICLE TARGETING ROUGH ER TO CIS GOLGI | 25 | 6.15e-02 | 4.07e-01 | 0.42300 | 1.38e-01 | 1.19e-01 | 1.98e-01 | 7.41e-02 | 3.18e-01 | 2.32e-01 | 3.03e-01 | 8.73e-02 | 5.21e-01 | 5.86e-03 |
| REGULATION OF SYNCYTIUM FORMATION BY PLASMA MEMBRANE FUSION | 30 | 3.73e-01 | 8.82e-01 | 0.42300 | -2.23e-01 | -2.25e-01 | -2.18e-01 | -1.76e-01 | -1.39e-02 | 3.48e-02 | 3.33e-02 | 3.84e-02 | 9.50e-02 | 8.95e-01 |
| RESPONSE TO MUSCLE ACTIVITY | 28 | 1.58e-01 | 6.58e-01 | 0.42300 | 2.16e-01 | 2.55e-01 | 1.55e-01 | 1.96e-01 | -6.74e-02 | 4.75e-02 | 1.96e-02 | 1.55e-01 | 7.23e-02 | 5.37e-01 |
| CELLULAR RESPONSE TO ATP | 16 | 8.43e-02 | 4.78e-01 | 0.42300 | 1.91e-01 | 1.49e-01 | 3.22e-01 | 1.18e-01 | 4.75e-02 | 1.86e-01 | 3.02e-01 | 2.57e-02 | 4.13e-01 | 7.42e-01 |
| LENS FIBER CELL DEVELOPMENT | 14 | 8.03e-01 | 1.00e+00 | 0.42300 | 2.18e-01 | 2.17e-01 | 2.00e-01 | 2.05e-01 | 4.48e-02 | 1.58e-01 | 1.59e-01 | 1.96e-01 | 1.83e-01 | 7.72e-01 |
| GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 6 | 5.19e-01 | 9.53e-01 | 0.42300 | 2.03e-01 | 2.32e-01 | 2.83e-01 | 4.64e-02 | -3.92e-02 | 3.90e-01 | 3.25e-01 | 2.31e-01 | 8.44e-01 | 8.68e-01 |
| CELLULAR RESPONSE TO UV C | 5 | 4.92e-01 | 9.45e-01 | 0.42300 | 1.98e-01 | 1.45e-01 | 3.19e-01 | -4.07e-02 | 1.22e-01 | 4.43e-01 | 5.76e-01 | 2.17e-01 | 8.75e-01 | 6.38e-01 |
| POSITIVE REGULATION OF MITOTIC NUCLEAR DIVISION | 44 | 1.37e-01 | 6.18e-01 | 0.42200 | 2.18e-01 | 2.08e-01 | 2.43e-01 | 1.61e-01 | 4.89e-02 | 1.23e-02 | 1.71e-02 | 5.24e-03 | 6.40e-02 | 5.74e-01 |
| NEGATIVE REGULATION OF BONE REMODELING | 18 | 2.09e-01 | 7.30e-01 | 0.42200 | -1.85e-01 | -2.12e-01 | -5.06e-03 | -2.63e-01 | 1.72e-01 | 1.73e-01 | 1.20e-01 | 9.70e-01 | 5.30e-02 | 2.06e-01 |
| TRANSEPITHELIAL CHLORIDE TRANSPORT | 8 | 8.32e-01 | 1.00e+00 | 0.42200 | 2.13e-01 | 2.13e-01 | 2.28e-01 | 1.88e-01 | -7.08e-03 | 2.96e-01 | 2.96e-01 | 2.65e-01 | 3.56e-01 | 9.72e-01 |
| SENSORY PERCEPTION OF SOUR TASTE | 9 | 7.83e-01 | 1.00e+00 | 0.42200 | 2.06e-01 | 2.30e-01 | 1.04e-01 | 2.64e-01 | 4.51e-02 | 2.85e-01 | 2.32e-01 | 5.89e-01 | 1.70e-01 | 8.15e-01 |
| PURINE NUCLEOSIDE TRIPHOSPHATE CATABOLIC PROCESS | 5 | 9.02e-01 | 1.00e+00 | 0.42200 | 1.95e-01 | 1.55e-01 | 2.66e-01 | 1.74e-01 | 1.21e-01 | 4.50e-01 | 5.48e-01 | 3.03e-01 | 5.02e-01 | 6.40e-01 |
| CHAPERONE MEDIATED PROTEIN FOLDING | 74 | 6.65e-05 | 2.46e-03 | 0.42200 | 1.96e-01 | 1.60e-01 | 3.07e-01 | 5.97e-02 | 1.25e-01 | 3.53e-03 | 1.72e-02 | 4.84e-06 | 3.74e-01 | 6.36e-02 |
| PEPTIDYL HISTIDINE MODIFICATION | 8 | 4.36e-01 | 9.22e-01 | 0.42100 | -6.66e-02 | -1.41e-01 | 1.02e-01 | -6.98e-02 | 3.71e-01 | 7.44e-01 | 4.88e-01 | 6.16e-01 | 7.33e-01 | 6.91e-02 |
| NEGATIVE REGULATION OF SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 14 | 3.86e-01 | 8.92e-01 | 0.42100 | 1.92e-01 | 2.05e-01 | 1.87e-01 | 2.34e-01 | 9.40e-02 | 2.13e-01 | 1.83e-01 | 2.25e-01 | 1.30e-01 | 5.42e-01 |
| HINDBRAIN TANGENTIAL CELL MIGRATION | 5 | 8.25e-01 | 1.00e+00 | 0.42100 | 2.13e-01 | 2.06e-01 | 2.93e-01 | 4.57e-02 | 3.53e-02 | 4.10e-01 | 4.24e-01 | 2.56e-01 | 8.59e-01 | 8.91e-01 |
| PROTEIN LOCALIZATION TO CONDENSED CHROMOSOME | 15 | 3.63e-02 | 3.03e-01 | 0.42100 | 1.05e-01 | 5.90e-02 | 3.27e-01 | -1.11e-01 | 2.09e-01 | 4.81e-01 | 6.92e-01 | 2.84e-02 | 4.55e-01 | 1.62e-01 |
| UTP METABOLIC PROCESS | 12 | 7.53e-01 | 1.00e+00 | 0.42100 | 2.34e-01 | 2.10e-01 | 2.05e-01 | 1.83e-01 | -5.02e-02 | 1.60e-01 | 2.07e-01 | 2.18e-01 | 2.72e-01 | 7.63e-01 |
| REGULATION OF MITOCHONDRIAL MRNA STABILITY | 7 | 4.84e-02 | 3.59e-01 | 0.42100 | -2.96e-02 | -2.18e-02 | 1.83e-01 | -3.04e-01 | -2.24e-01 | 8.92e-01 | 9.20e-01 | 4.03e-01 | 1.64e-01 | 3.05e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 6 | 2.86e-01 | 8.12e-01 | 0.42100 | 8.65e-03 | -1.10e-01 | 2.58e-01 | -1.36e-01 | 2.83e-01 | 9.71e-01 | 6.42e-01 | 2.74e-01 | 5.64e-01 | 2.30e-01 |
| METANEPHRIC TUBULE MORPHOGENESIS | 11 | 8.01e-01 | 1.00e+00 | 0.42100 | 2.18e-01 | 2.16e-01 | 2.45e-01 | 1.41e-01 | 5.75e-02 | 2.11e-01 | 2.15e-01 | 1.60e-01 | 4.17e-01 | 7.41e-01 |
| REGULATION OF GLUTAMATE RECEPTOR CLUSTERING | 6 | 7.22e-01 | 1.00e+00 | 0.42100 | -1.09e-01 | -1.58e-01 | 1.67e-02 | -9.19e-02 | 3.63e-01 | 6.42e-01 | 5.04e-01 | 9.43e-01 | 6.97e-01 | 1.24e-01 |
| REGULATION OF MDA 5 SIGNALING PATHWAY | 7 | 2.73e-01 | 7.99e-01 | 0.42000 | 6.35e-02 | 5.96e-02 | 1.19e-01 | -1.10e-01 | -3.78e-01 | 7.71e-01 | 7.85e-01 | 5.86e-01 | 6.16e-01 | 8.32e-02 |
| POSITIVE REGULATION OF PROTEIN DEUBIQUITINATION | 5 | 3.63e-01 | 8.78e-01 | 0.42000 | -6.05e-02 | -6.59e-02 | 8.76e-02 | -2.87e-01 | -2.80e-01 | 8.15e-01 | 7.99e-01 | 7.34e-01 | 2.66e-01 | 2.78e-01 |
| SYNAPTIC TRANSMISSION DOPAMINERGIC | 28 | 2.90e-01 | 8.18e-01 | 0.42000 | 2.01e-01 | 1.83e-01 | 2.55e-01 | 1.48e-01 | 1.27e-01 | 6.61e-02 | 9.44e-02 | 1.95e-02 | 1.76e-01 | 2.45e-01 |
| PHARYNGEAL ARCH ARTERY MORPHOGENESIS | 10 | 5.18e-01 | 9.52e-01 | 0.42000 | -1.09e-01 | -6.01e-02 | -1.88e-01 | -8.35e-02 | -3.45e-01 | 5.51e-01 | 7.42e-01 | 3.05e-01 | 6.47e-01 | 5.91e-02 |
| REGULATION OF FEMALE GONAD DEVELOPMENT | 7 | 6.55e-01 | 1.00e+00 | 0.42000 | -1.69e-01 | -1.16e-01 | -2.85e-01 | -2.70e-02 | -2.29e-01 | 4.39e-01 | 5.95e-01 | 1.92e-01 | 9.02e-01 | 2.93e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 1 BETA PRODUCTION | 61 | 9.65e-03 | 1.22e-01 | 0.42000 | -2.14e-01 | -2.47e-01 | -1.07e-01 | -2.09e-01 | 1.20e-01 | 3.90e-03 | 8.35e-04 | 1.49e-01 | 4.77e-03 | 1.04e-01 |
| RESPONSE TO GRAM POSITIVE BACTERIUM | 5 | 5.03e-01 | 9.48e-01 | 0.42000 | 5.21e-02 | 1.00e-02 | 2.99e-01 | -7.81e-02 | 2.79e-01 | 8.40e-01 | 9.69e-01 | 2.47e-01 | 7.62e-01 | 2.80e-01 |
| RENAL TUBULAR SECRETION | 19 | 3.95e-01 | 8.95e-01 | 0.42000 | 2.15e-01 | 2.53e-01 | 1.34e-01 | 1.87e-01 | -1.14e-01 | 1.05e-01 | 5.62e-02 | 3.10e-01 | 1.59e-01 | 3.88e-01 |
| NEGATIVE REGULATION OF SECONDARY METABOLITE BIOSYNTHETIC PROCESS | 5 | 2.91e-01 | 8.18e-01 | 0.41900 | -1.96e-01 | -2.88e-01 | -1.60e-01 | -9.13e-02 | -1.43e-01 | 4.47e-01 | 2.66e-01 | 5.36e-01 | 7.24e-01 | 5.79e-01 |
| POSITIVE REGULATION OF CHOLESTEROL METABOLIC PROCESS | 15 | 2.82e-01 | 8.08e-01 | 0.41900 | 1.75e-01 | 2.03e-01 | 1.78e-01 | 1.90e-01 | 1.89e-01 | 2.39e-01 | 1.73e-01 | 2.34e-01 | 2.04e-01 | 2.05e-01 |
| INTERLEUKIN 5 PRODUCTION | 19 | 4.40e-01 | 9.26e-01 | 0.41900 | -2.16e-01 | -2.43e-01 | -1.53e-01 | -1.65e-01 | 1.38e-01 | 1.04e-01 | 6.69e-02 | 2.48e-01 | 2.12e-01 | 2.98e-01 |
| NEGATIVE REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 9 | 5.78e-01 | 9.82e-01 | 0.41900 | 1.18e-01 | 9.16e-02 | 2.44e-01 | 7.29e-02 | 2.97e-01 | 5.40e-01 | 6.34e-01 | 2.05e-01 | 7.05e-01 | 1.23e-01 |
| MRNA 3 END PROCESSING BY STEM LOOP BINDING AND CLEAVAGE | 6 | 5.66e-01 | 9.72e-01 | 0.41800 | 1.11e-01 | 3.06e-02 | 3.16e-01 | -1.80e-02 | 2.48e-01 | 6.37e-01 | 8.97e-01 | 1.80e-01 | 9.39e-01 | 2.94e-01 |
| ESTABLISHMENT OF LYMPHOCYTE POLARITY | 16 | 5.30e-01 | 9.54e-01 | 0.41800 | -2.19e-01 | -2.17e-01 | -1.15e-01 | -2.22e-01 | 1.30e-01 | 1.29e-01 | 1.33e-01 | 4.25e-01 | 1.24e-01 | 3.67e-01 |
| NEUTROPHIL CHEMOTAXIS | 102 | 1.28e-04 | 4.28e-03 | 0.41800 | -2.25e-01 | -2.49e-01 | -1.65e-01 | -1.61e-01 | 9.44e-02 | 8.50e-05 | 1.42e-05 | 4.01e-03 | 4.99e-03 | 9.93e-02 |
| PROTEIN LOCALIZATION TO EARLY ENDOSOME | 11 | 8.59e-01 | 1.00e+00 | 0.41800 | -2.27e-01 | -2.08e-01 | -2.26e-01 | -1.69e-01 | -1.03e-02 | 1.93e-01 | 2.33e-01 | 1.94e-01 | 3.31e-01 | 9.53e-01 |
| PROTEIN DESUMOYLATION | 8 | 5.57e-01 | 9.68e-01 | 0.41800 | -8.68e-02 | -8.72e-02 | -1.39e-01 | -1.18e-01 | -3.55e-01 | 6.71e-01 | 6.69e-01 | 4.97e-01 | 5.64e-01 | 8.19e-02 |
| ADENINE TRANSPORT | 5 | 7.56e-01 | 1.00e+00 | 0.41700 | -1.16e-01 | -1.40e-01 | 6.90e-02 | -1.65e-01 | 3.30e-01 | 6.54e-01 | 5.88e-01 | 7.89e-01 | 5.23e-01 | 2.01e-01 |
| PRE MIRNA PROCESSING | 17 | 7.93e-02 | 4.63e-01 | 0.41700 | -1.90e-01 | -1.43e-01 | -1.31e-01 | -2.36e-01 | -2.12e-01 | 1.75e-01 | 3.09e-01 | 3.50e-01 | 9.20e-02 | 1.30e-01 |
| REGULATION OF WOUND HEALING SPREADING OF EPIDERMAL CELLS | 8 | 6.93e-01 | 1.00e+00 | 0.41700 | -2.08e-01 | -1.60e-01 | -2.76e-01 | -8.43e-02 | -1.50e-01 | 3.09e-01 | 4.34e-01 | 1.77e-01 | 6.80e-01 | 4.63e-01 |
| REGULATION OF NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING 2 SIGNALING PATHWAY | 10 | 6.46e-01 | 1.00e+00 | 0.41700 | -1.98e-01 | -2.34e-01 | -1.25e-01 | -2.30e-01 | -1.08e-01 | 2.78e-01 | 1.99e-01 | 4.94e-01 | 2.08e-01 | 5.55e-01 |
| NEGATIVE REGULATION OF MACROPHAGE CYTOKINE PRODUCTION | 12 | 3.55e-01 | 8.73e-01 | 0.41600 | 1.80e-01 | 1.49e-01 | 3.11e-01 | 9.14e-02 | 1.18e-01 | 2.80e-01 | 3.73e-01 | 6.20e-02 | 5.84e-01 | 4.80e-01 |
| REGULATION OF NEUTROPHIL MIGRATION | 40 | 7.24e-04 | 1.74e-02 | 0.41600 | -2.09e-01 | -2.78e-01 | -5.75e-02 | -1.99e-01 | 9.58e-02 | 2.19e-02 | 2.33e-03 | 5.29e-01 | 2.92e-02 | 2.95e-01 |
| BRAINSTEM DEVELOPMENT | 7 | 6.55e-01 | 1.00e+00 | 0.41600 | 2.35e-01 | 1.82e-01 | 2.59e-01 | 1.15e-01 | -6.51e-02 | 2.81e-01 | 4.03e-01 | 2.35e-01 | 5.99e-01 | 7.66e-01 |
| DISTAL CONVOLUTED TUBULE DEVELOPMENT | 5 | 9.74e-01 | 1.00e+00 | 0.41600 | -2.17e-01 | -2.07e-01 | -2.29e-01 | -1.61e-01 | -7.16e-02 | 4.02e-01 | 4.22e-01 | 3.75e-01 | 5.34e-01 | 7.81e-01 |
| CENP A CONTAINING CHROMATIN ASSEMBLY | 9 | 3.84e-01 | 8.92e-01 | 0.41600 | 1.15e-01 | 6.79e-02 | 3.07e-01 | -5.06e-02 | 2.42e-01 | 5.49e-01 | 7.24e-01 | 1.10e-01 | 7.93e-01 | 2.09e-01 |
| POSITIVE REGULATION OF LONG TERM NEURONAL SYNAPTIC PLASTICITY | 6 | 4.91e-01 | 9.45e-01 | 0.41600 | 4.47e-02 | 1.85e-02 | 1.83e-02 | 1.91e-01 | 3.66e-01 | 8.50e-01 | 9.37e-01 | 9.38e-01 | 4.17e-01 | 1.21e-01 |
| NEGATIVE REGULATION OF FATTY ACID OXIDATION | 14 | 6.20e-01 | 9.90e-01 | 0.41600 | 2.02e-01 | 2.29e-01 | 9.85e-02 | 1.94e-01 | -1.80e-01 | 1.91e-01 | 1.38e-01 | 5.23e-01 | 2.09e-01 | 2.43e-01 |
| BILE ACID SIGNALING PATHWAY | 11 | 3.75e-01 | 8.83e-01 | 0.41600 | -2.17e-01 | -1.66e-01 | -1.76e-01 | -2.26e-01 | 1.28e-01 | 2.12e-01 | 3.40e-01 | 3.13e-01 | 1.94e-01 | 4.63e-01 |
| NEGATIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORT | 29 | 3.53e-01 | 8.72e-01 | 0.41600 | -2.10e-01 | -1.93e-01 | -2.36e-01 | -1.44e-01 | -1.22e-01 | 5.05e-02 | 7.18e-02 | 2.77e-02 | 1.79e-01 | 2.56e-01 |
| ANDROGEN METABOLIC PROCESS | 29 | 1.91e-01 | 7.01e-01 | 0.41600 | -2.11e-01 | -1.80e-01 | -2.75e-01 | -1.34e-01 | -4.46e-02 | 4.88e-02 | 9.34e-02 | 1.03e-02 | 2.12e-01 | 6.78e-01 |
| PROTEIN FOLDING IN ENDOPLASMIC RETICULUM | 12 | 5.31e-02 | 3.77e-01 | 0.41500 | -9.15e-02 | -1.35e-01 | 1.85e-01 | -2.69e-01 | 1.98e-01 | 5.83e-01 | 4.19e-01 | 2.66e-01 | 1.06e-01 | 2.34e-01 |
| L METHIONINE SALVAGE FROM METHYLTHIOADENOSINE | 5 | 1.78e-01 | 6.85e-01 | 0.41500 | 1.34e-01 | 1.89e-01 | 2.46e-01 | -1.29e-01 | -2.04e-01 | 6.04e-01 | 4.64e-01 | 3.41e-01 | 6.18e-01 | 4.29e-01 |
| REGULATION OF NITRIC OXIDE MEDIATED SIGNAL TRANSDUCTION | 11 | 2.12e-01 | 7.34e-01 | 0.41500 | 1.69e-01 | 2.21e-01 | 5.81e-02 | 2.87e-01 | -9.67e-02 | 3.33e-01 | 2.04e-01 | 7.39e-01 | 9.95e-02 | 5.79e-01 |
| TRICUSPID VALVE MORPHOGENESIS | 5 | 9.49e-01 | 1.00e+00 | 0.41500 | -2.00e-01 | -2.08e-01 | -1.30e-01 | -2.57e-01 | -7.92e-02 | 4.40e-01 | 4.22e-01 | 6.13e-01 | 3.20e-01 | 7.59e-01 |
| REGULATION OF INCLUSION BODY ASSEMBLY | 17 | 3.58e-01 | 8.74e-01 | 0.41500 | 1.53e-01 | 1.31e-01 | 1.86e-01 | 1.25e-01 | 2.84e-01 | 2.75e-01 | 3.49e-01 | 1.83e-01 | 3.70e-01 | 4.23e-02 |
| NEGATIVE REGULATION OF CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 52 | 8.82e-02 | 4.91e-01 | 0.41500 | -2.12e-01 | -2.19e-01 | -1.36e-01 | -2.45e-01 | 1.60e-02 | 8.15e-03 | 6.21e-03 | 8.97e-02 | 2.24e-03 | 8.42e-01 |
| REGULATION OF RESTING MEMBRANE POTENTIAL | 10 | 2.26e-01 | 7.48e-01 | 0.41400 | 4.87e-02 | 1.14e-01 | -7.59e-02 | -2.65e-02 | -3.87e-01 | 7.90e-01 | 5.32e-01 | 6.78e-01 | 8.85e-01 | 3.40e-02 |
| ORGANELLE INHERITANCE | 15 | 6.46e-01 | 1.00e+00 | 0.41400 | 2.16e-01 | 1.85e-01 | 2.38e-01 | 1.46e-01 | 1.14e-01 | 1.47e-01 | 2.14e-01 | 1.11e-01 | 3.29e-01 | 4.44e-01 |
| NEGATIVE REGULATION OF CERAMIDE BIOSYNTHETIC PROCESS | 5 | 2.98e-01 | 8.24e-01 | 0.41400 | 1.46e-01 | 1.66e-01 | 3.19e-01 | -1.23e-01 | 7.75e-02 | 5.72e-01 | 5.21e-01 | 2.17e-01 | 6.33e-01 | 7.64e-01 |
| NEUTRAL LIPID CATABOLIC PROCESS | 37 | 3.15e-01 | 8.42e-01 | 0.41400 | 2.25e-01 | 2.23e-01 | 1.83e-01 | 1.91e-01 | -3.17e-02 | 1.76e-02 | 1.88e-02 | 5.44e-02 | 4.48e-02 | 7.39e-01 |
| REGULATION OF NEUTROPHIL EXTRAVASATION | 5 | 2.29e-01 | 7.51e-01 | 0.41400 | -7.04e-02 | -2.15e-01 | 1.50e-01 | -1.60e-01 | 2.68e-01 | 7.85e-01 | 4.05e-01 | 5.61e-01 | 5.35e-01 | 2.99e-01 |
| SOMATIC STEM CELL DIVISION | 11 | 3.62e-02 | 3.03e-01 | 0.41400 | 3.22e-02 | -6.78e-02 | 3.16e-01 | -1.18e-01 | 2.27e-01 | 8.53e-01 | 6.97e-01 | 6.92e-02 | 4.97e-01 | 1.92e-01 |
| NEGATIVE REGULATION OF GLIAL CELL MIGRATION | 6 | 7.02e-01 | 1.00e+00 | 0.41400 | -1.80e-01 | -1.63e-01 | -1.23e-01 | -3.07e-01 | -5.15e-02 | 4.45e-01 | 4.88e-01 | 6.03e-01 | 1.93e-01 | 8.27e-01 |
| CLATHRIN COATED VESICLE CARGO LOADING | 7 | 4.15e-01 | 9.11e-01 | 0.41400 | -1.18e-01 | -1.48e-01 | -1.18e-02 | -2.40e-01 | -2.78e-01 | 5.88e-01 | 4.97e-01 | 9.57e-01 | 2.71e-01 | 2.02e-01 |
| REGULATION OF SUPEROXIDE ANION GENERATION | 19 | 2.28e-02 | 2.25e-01 | 0.41400 | -1.81e-01 | -2.31e-01 | 4.79e-02 | -2.81e-01 | 5.94e-02 | 1.72e-01 | 8.13e-02 | 7.18e-01 | 3.37e-02 | 6.54e-01 |
| OXYGEN TRANSPORT | 15 | 2.24e-01 | 7.45e-01 | 0.41400 | 1.28e-01 | 1.84e-01 | 5.43e-03 | 1.29e-01 | -3.23e-01 | 3.92e-01 | 2.17e-01 | 9.71e-01 | 3.88e-01 | 3.04e-02 |
| NEGATIVE REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 5 | 5.17e-01 | 9.52e-01 | 0.41300 | -1.61e-01 | -2.45e-01 | -5.47e-02 | -4.68e-02 | 2.82e-01 | 5.32e-01 | 3.44e-01 | 8.32e-01 | 8.56e-01 | 2.75e-01 |
| GLYCOLYTIC PROCESS THROUGH FRUCTOSE 6 PHOSPHATE | 22 | 4.57e-01 | 9.32e-01 | 0.41300 | 2.15e-01 | 1.86e-01 | 2.36e-01 | 1.83e-01 | 1.82e-02 | 8.15e-02 | 1.31e-01 | 5.48e-02 | 1.37e-01 | 8.82e-01 |
| GAS TRANSPORT | 22 | 7.63e-02 | 4.53e-01 | 0.41300 | 1.17e-01 | 1.71e-01 | -1.32e-02 | 1.20e-01 | -3.36e-01 | 3.40e-01 | 1.65e-01 | 9.15e-01 | 3.31e-01 | 6.36e-03 |
| CARDIAC MUSCLE CELL MYOBLAST DIFFERENTIATION | 12 | 6.32e-01 | 9.96e-01 | 0.41300 | 2.09e-01 | 1.88e-01 | 2.82e-01 | 8.60e-02 | 6.53e-02 | 2.10e-01 | 2.59e-01 | 9.07e-02 | 6.06e-01 | 6.95e-01 |
| CAVEOLIN MEDIATED ENDOCYTOSIS | 11 | 8.20e-01 | 1.00e+00 | 0.41300 | 2.09e-01 | 2.22e-01 | 1.27e-01 | 2.46e-01 | 3.21e-02 | 2.30e-01 | 2.03e-01 | 4.67e-01 | 1.59e-01 | 8.54e-01 |
| U4 SNRNA 3 END PROCESSING | 8 | 6.49e-01 | 1.00e+00 | 0.41200 | 1.87e-01 | 1.27e-01 | 3.05e-01 | 5.40e-02 | 1.52e-01 | 3.60e-01 | 5.34e-01 | 1.35e-01 | 7.91e-01 | 4.56e-01 |
| PHAGOSOME LYSOSOME FUSION | 13 | 5.92e-01 | 9.86e-01 | 0.41200 | -2.05e-01 | -1.90e-01 | -1.50e-01 | -2.27e-01 | 1.34e-01 | 2.01e-01 | 2.35e-01 | 3.51e-01 | 1.57e-01 | 4.04e-01 |
| MAST CELL MIGRATION | 13 | 6.54e-01 | 1.00e+00 | 0.41200 | -2.14e-01 | -2.40e-01 | -9.37e-02 | -2.36e-01 | 3.75e-02 | 1.82e-01 | 1.33e-01 | 5.58e-01 | 1.40e-01 | 8.15e-01 |
| POSITIVE REGULATION OF LIPID CATABOLIC PROCESS | 26 | 4.37e-01 | 9.22e-01 | 0.41200 | 2.00e-01 | 1.81e-01 | 2.39e-01 | 1.49e-01 | 1.31e-01 | 7.68e-02 | 1.10e-01 | 3.45e-02 | 1.90e-01 | 2.48e-01 |
| PLASMA MEMBRANE REPAIR | 27 | 7.73e-02 | 4.56e-01 | 0.41100 | 1.59e-01 | 1.76e-01 | 1.61e-01 | 1.75e-01 | 2.37e-01 | 1.53e-01 | 1.13e-01 | 1.47e-01 | 1.15e-01 | 3.31e-02 |
| REGULATION OF DEVELOPMENT HETEROCHRONIC | 12 | 1.45e-01 | 6.29e-01 | 0.41100 | 1.74e-01 | 1.64e-01 | 2.51e-01 | 7.91e-03 | -2.22e-01 | 2.98e-01 | 3.26e-01 | 1.32e-01 | 9.62e-01 | 1.83e-01 |
| REGULATION OF CHROMOSOME CONDENSATION | 13 | 2.15e-01 | 7.37e-01 | 0.41100 | 4.99e-02 | 9.76e-03 | 2.40e-01 | -6.44e-02 | 3.24e-01 | 7.56e-01 | 9.51e-01 | 1.34e-01 | 6.88e-01 | 4.31e-02 |
| NEGATIVE REGULATION OF OSTEOCLAST DEVELOPMENT | 5 | 7.91e-01 | 1.00e+00 | 0.41100 | -2.08e-01 | -1.91e-01 | -2.72e-01 | -3.83e-02 | -1.17e-01 | 4.20e-01 | 4.59e-01 | 2.93e-01 | 8.82e-01 | 6.50e-01 |
| T HELPER 17 CELL LINEAGE COMMITMENT | 16 | 4.47e-01 | 9.30e-01 | 0.41100 | -2.28e-01 | -2.19e-01 | -1.22e-01 | -2.27e-01 | 5.32e-02 | 1.15e-01 | 1.30e-01 | 3.97e-01 | 1.16e-01 | 7.12e-01 |
| ERROR FREE TRANSLESION SYNTHESIS | 5 | 3.66e-01 | 8.79e-01 | 0.41100 | 1.66e-01 | 6.45e-02 | 2.85e-01 | -4.76e-04 | 2.37e-01 | 5.19e-01 | 8.03e-01 | 2.70e-01 | 9.99e-01 | 3.60e-01 |
| NEURON GLIAL CELL SIGNALING | 5 | 8.71e-01 | 1.00e+00 | 0.41100 | 1.56e-01 | 1.98e-01 | 2.56e-02 | 1.52e-01 | -2.86e-01 | 5.46e-01 | 4.43e-01 | 9.21e-01 | 5.57e-01 | 2.68e-01 |
| REGULATION OF PEPTIDYL CYSTEINE S NITROSYLATION | 10 | 7.52e-01 | 1.00e+00 | 0.41100 | 1.96e-01 | 1.74e-01 | 1.93e-01 | 1.62e-01 | 1.91e-01 | 2.83e-01 | 3.40e-01 | 2.90e-01 | 3.76e-01 | 2.95e-01 |
| RNA SPLICING VIA ENDONUCLEOLYTIC CLEAVAGE AND LIGATION | 14 | 3.24e-01 | 8.48e-01 | 0.41100 | 1.60e-01 | 1.39e-01 | 2.93e-01 | 4.40e-02 | 1.91e-01 | 3.01e-01 | 3.67e-01 | 5.80e-02 | 7.76e-01 | 2.17e-01 |
| REGULATION OF CORTISOL BIOSYNTHETIC PROCESS | 7 | 8.39e-01 | 1.00e+00 | 0.41100 | 1.84e-01 | 1.89e-01 | 2.35e-01 | 1.37e-01 | 1.59e-01 | 3.99e-01 | 3.87e-01 | 2.81e-01 | 5.31e-01 | 4.68e-01 |
| ADENYLATE CYCLASE INHIBITING DOPAMINE RECEPTOR SIGNALING PATHWAY | 5 | 1.45e-01 | 6.29e-01 | 0.41100 | -6.24e-02 | -1.99e-01 | 1.88e-01 | -3.29e-02 | 2.98e-01 | 8.09e-01 | 4.42e-01 | 4.66e-01 | 8.99e-01 | 2.49e-01 |
| NEGATIVE REGULATION OF MYOFIBROBLAST DIFFERENTIATION | 6 | 7.23e-01 | 1.00e+00 | 0.41000 | 1.77e-01 | 1.87e-01 | 1.16e-01 | 2.40e-01 | -1.76e-01 | 4.53e-01 | 4.27e-01 | 6.23e-01 | 3.10e-01 | 4.54e-01 |
| GASTRO INTESTINAL SYSTEM SMOOTH MUSCLE CONTRACTION | 12 | 2.07e-01 | 7.27e-01 | 0.41000 | -2.32e-01 | -2.51e-01 | -2.13e-01 | -6.03e-02 | 5.25e-02 | 1.65e-01 | 1.33e-01 | 2.02e-01 | 7.18e-01 | 7.53e-01 |
| REGULATION OF MITOCHONDRIAL ATP SYNTHESIS COUPLED ELECTRON TRANSPORT | 7 | 2.20e-01 | 7.43e-01 | 0.41000 | 2.19e-01 | 1.72e-01 | 1.33e-01 | 1.13e-01 | -2.46e-01 | 3.17e-01 | 4.31e-01 | 5.41e-01 | 6.06e-01 | 2.60e-01 |
| PROTEIN LIPID COMPLEX ASSEMBLY | 30 | 4.03e-01 | 9.04e-01 | 0.41000 | 2.03e-01 | 1.97e-01 | 2.05e-01 | 1.90e-01 | 1.00e-01 | 5.48e-02 | 6.18e-02 | 5.15e-02 | 7.17e-02 | 3.43e-01 |
| PROTEASOME ASSEMBLY | 11 | 6.99e-01 | 1.00e+00 | 0.41000 | 2.15e-01 | 1.92e-01 | 2.19e-01 | 1.53e-01 | -1.16e-01 | 2.16e-01 | 2.70e-01 | 2.09e-01 | 3.80e-01 | 5.04e-01 |
| PSEUDOPODIUM ORGANIZATION | 16 | 4.85e-01 | 9.43e-01 | 0.41000 | -2.09e-01 | -1.99e-01 | -2.14e-01 | -1.61e-01 | 1.16e-01 | 1.49e-01 | 1.69e-01 | 1.39e-01 | 2.65e-01 | 4.22e-01 |
| TELOMERE MAINTENANCE IN RESPONSE TO DNA DAMAGE | 29 | 3.28e-02 | 2.86e-01 | 0.41000 | 1.51e-01 | 1.25e-01 | 2.92e-01 | 4.03e-02 | 2.07e-01 | 1.60e-01 | 2.46e-01 | 6.54e-03 | 7.07e-01 | 5.36e-02 |
| REGULATION OF TYPE 2 IMMUNE RESPONSE | 34 | 1.20e-01 | 5.78e-01 | 0.41000 | -1.92e-01 | -2.07e-01 | -8.17e-02 | -2.31e-01 | 1.68e-01 | 5.31e-02 | 3.70e-02 | 4.10e-01 | 1.95e-02 | 9.04e-02 |
| ACTIN FILAMENT SEVERING | 16 | 3.59e-01 | 8.75e-01 | 0.41000 | 1.62e-01 | 1.72e-01 | 1.63e-01 | 2.03e-01 | 2.10e-01 | 2.62e-01 | 2.34e-01 | 2.58e-01 | 1.60e-01 | 1.45e-01 |
| REGULATION OF MITOTIC SPINDLE ASSEMBLY | 22 | 6.48e-02 | 4.13e-01 | 0.41000 | 1.01e-01 | 7.28e-02 | 2.56e-01 | -1.61e-02 | 2.94e-01 | 4.12e-01 | 5.54e-01 | 3.78e-02 | 8.96e-01 | 1.69e-02 |
| CARDIAC MUSCLE TISSUE REGENERATION | 8 | 6.94e-01 | 1.00e+00 | 0.41000 | 1.53e-01 | 1.73e-01 | 6.76e-02 | 1.15e-01 | -3.11e-01 | 4.53e-01 | 3.96e-01 | 7.41e-01 | 5.74e-01 | 1.28e-01 |
| RESPONSE TO ARSENIC CONTAINING SUBSTANCE | 31 | 2.92e-01 | 8.19e-01 | 0.40900 | 2.09e-01 | 2.03e-01 | 2.40e-01 | 1.50e-01 | 5.06e-02 | 4.39e-02 | 5.06e-02 | 2.05e-02 | 1.49e-01 | 6.26e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION INVOLVED IN LUNG MORPHOGENESIS | 5 | 7.88e-01 | 1.00e+00 | 0.40900 | 1.46e-01 | 1.59e-01 | -6.63e-03 | 2.62e-01 | -2.29e-01 | 5.72e-01 | 5.39e-01 | 9.80e-01 | 3.10e-01 | 3.76e-01 |
| POSITIVE REGULATION OF FATTY ACID BETA OXIDATION | 10 | 7.70e-01 | 1.00e+00 | 0.40900 | 2.16e-01 | 2.07e-01 | 2.35e-01 | 1.27e-01 | -8.14e-02 | 2.38e-01 | 2.56e-01 | 1.98e-01 | 4.87e-01 | 6.56e-01 |
| NUCLEAR PORE COMPLEX ASSEMBLY | 11 | 7.48e-01 | 1.00e+00 | 0.40900 | -2.16e-01 | -2.04e-01 | -1.73e-01 | -1.90e-01 | -1.14e-01 | 2.15e-01 | 2.40e-01 | 3.20e-01 | 2.76e-01 | 5.13e-01 |
| HEPARAN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS POLYSACCHARIDE CHAIN BIOSYNTHETIC PROCESS | 8 | 2.34e-01 | 7.56e-01 | 0.40900 | 9.96e-02 | 1.77e-01 | -1.67e-01 | 1.88e-01 | -2.51e-01 | 6.26e-01 | 3.87e-01 | 4.13e-01 | 3.57e-01 | 2.19e-01 |
| NEGATIVE REGULATION OF GLUCOSE TRANSMEMBRANE TRANSPORT | 21 | 2.04e-01 | 7.24e-01 | 0.40900 | -2.10e-01 | -2.00e-01 | -8.11e-02 | -2.53e-01 | 1.11e-01 | 9.56e-02 | 1.12e-01 | 5.20e-01 | 4.44e-02 | 3.80e-01 |
| NERVOUS SYSTEM PROCESS INVOLVED IN REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 11 | 7.76e-01 | 1.00e+00 | 0.40900 | 2.04e-01 | 2.02e-01 | 1.35e-01 | 2.37e-01 | -1.00e-01 | 2.41e-01 | 2.45e-01 | 4.39e-01 | 1.73e-01 | 5.65e-01 |
| REGULATION OF PROTEIN LIPIDATION | 11 | 1.44e-01 | 6.29e-01 | 0.40800 | -2.17e-02 | -7.78e-02 | 2.25e-01 | -2.01e-01 | 2.63e-01 | 9.01e-01 | 6.55e-01 | 1.97e-01 | 2.47e-01 | 1.31e-01 |
| RRNA METABOLIC PROCESS | 254 | 2.53e-13 | 9.06e-11 | 0.40800 | 2.07e-01 | 1.81e-01 | 2.78e-01 | 8.88e-02 | 7.54e-02 | 1.32e-08 | 6.59e-07 | 2.24e-14 | 1.48e-02 | 3.86e-02 |
| POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 28 | 3.03e-01 | 8.32e-01 | 0.40800 | -2.03e-01 | -2.17e-01 | -1.35e-01 | -2.41e-01 | 4.04e-02 | 6.31e-02 | 4.64e-02 | 2.15e-01 | 2.72e-02 | 7.11e-01 |
| GLYCOSPHINGOLIPID CATABOLIC PROCESS | 13 | 2.39e-01 | 7.63e-01 | 0.40800 | -4.02e-03 | -5.19e-02 | 1.84e-01 | -9.96e-02 | 3.46e-01 | 9.80e-01 | 7.46e-01 | 2.51e-01 | 5.34e-01 | 3.06e-02 |
| REGULATION OF LYSOSOMAL PROTEIN CATABOLIC PROCESS | 11 | 7.78e-01 | 1.00e+00 | 0.40800 | 2.00e-01 | 2.09e-01 | 2.17e-01 | 1.59e-01 | 9.96e-02 | 2.51e-01 | 2.29e-01 | 2.12e-01 | 3.61e-01 | 5.67e-01 |
| SPHINGOMYELIN BIOSYNTHETIC PROCESS | 11 | 4.44e-01 | 9.28e-01 | 0.40800 | -2.26e-01 | -1.95e-01 | -1.19e-01 | -2.39e-01 | 7.91e-02 | 1.95e-01 | 2.62e-01 | 4.96e-01 | 1.71e-01 | 6.49e-01 |
| PROTEIN LOCALIZATION TO ENDOPLASMIC RETICULUM EXIT SITE | 6 | 7.23e-01 | 1.00e+00 | 0.40800 | -2.13e-01 | -2.19e-01 | -2.55e-01 | -4.84e-02 | -7.38e-02 | 3.66e-01 | 3.53e-01 | 2.79e-01 | 8.37e-01 | 7.54e-01 |
| NEGATIVE REGULATION OF RIBOSOME BIOGENESIS | 7 | 6.27e-01 | 9.94e-01 | 0.40700 | 8.09e-02 | 1.02e-01 | -6.52e-02 | 1.55e-01 | -3.47e-01 | 7.11e-01 | 6.40e-01 | 7.65e-01 | 4.76e-01 | 1.12e-01 |
| REGULATION OF MIDBRAIN DOPAMINERGIC NEURON DIFFERENTIATION | 5 | 4.28e-01 | 9.17e-01 | 0.40700 | -1.49e-01 | -1.21e-01 | 2.81e-02 | -1.74e-01 | 3.13e-01 | 5.64e-01 | 6.39e-01 | 9.13e-01 | 5.01e-01 | 2.26e-01 |
| MITOCHONDRIAL RIBOSOME ASSEMBLY | 10 | 1.99e-01 | 7.14e-01 | 0.40700 | 1.62e-01 | 1.88e-01 | 1.94e-01 | -2.19e-02 | -2.57e-01 | 3.74e-01 | 3.04e-01 | 2.87e-01 | 9.04e-01 | 1.60e-01 |
| TORC2 SIGNALING | 12 | 3.39e-01 | 8.59e-01 | 0.40700 | -1.23e-01 | -1.59e-01 | 2.39e-02 | -2.18e-01 | 2.78e-01 | 4.61e-01 | 3.41e-01 | 8.86e-01 | 1.91e-01 | 9.54e-02 |
| NEGATIVE REGULATION OF OXIDATIVE PHOSPHORYLATION | 8 | 2.01e-01 | 7.17e-01 | 0.40700 | 5.79e-02 | 2.48e-02 | 7.14e-02 | 1.25e-02 | -3.95e-01 | 7.77e-01 | 9.03e-01 | 7.27e-01 | 9.51e-01 | 5.27e-02 |
| MAST CELL DIFFERENTIATION | 6 | 7.96e-01 | 1.00e+00 | 0.40700 | 1.98e-01 | 1.45e-01 | 1.80e-01 | 2.11e-01 | 1.69e-01 | 4.01e-01 | 5.39e-01 | 4.46e-01 | 3.71e-01 | 4.73e-01 |
| AUTOPHAGIC CELL DEATH | 9 | 3.13e-01 | 8.40e-01 | 0.40700 | -1.59e-01 | -2.34e-01 | 6.80e-02 | -2.45e-01 | 1.45e-01 | 4.10e-01 | 2.24e-01 | 7.24e-01 | 2.04e-01 | 4.51e-01 |
| POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 9 | 6.02e-01 | 9.90e-01 | 0.40700 | -1.83e-01 | -1.47e-01 | -2.39e-01 | -2.05e-01 | -1.03e-01 | 3.40e-01 | 4.44e-01 | 2.14e-01 | 2.86e-01 | 5.93e-01 |
| POSITIVE REGULATION OF GAMMA DELTA T CELL ACTIVATION | 9 | 3.57e-01 | 8.74e-01 | 0.40700 | -9.72e-02 | -1.75e-01 | 7.10e-02 | -1.77e-01 | 2.98e-01 | 6.14e-01 | 3.62e-01 | 7.12e-01 | 3.57e-01 | 1.22e-01 |
| REGULATION OF EXCRETION | 11 | 6.96e-01 | 1.00e+00 | 0.40700 | 2.01e-01 | 2.13e-01 | 1.70e-01 | 2.04e-01 | -9.56e-02 | 2.49e-01 | 2.21e-01 | 3.30e-01 | 2.41e-01 | 5.83e-01 |
| INTESTINAL HEXOSE ABSORPTION | 5 | 4.15e-01 | 9.11e-01 | 0.40600 | 1.08e-01 | 1.59e-01 | -1.07e-01 | 3.15e-01 | 1.33e-01 | 6.76e-01 | 5.38e-01 | 6.80e-01 | 2.23e-01 | 6.07e-01 |
| NEGATIVE REGULATION OF NERVOUS SYSTEM PROCESS | 15 | 3.84e-01 | 8.92e-01 | 0.40600 | -1.77e-01 | -2.22e-01 | -3.04e-02 | -2.53e-01 | 1.40e-01 | 2.36e-01 | 1.36e-01 | 8.39e-01 | 9.04e-02 | 3.47e-01 |
| NEGATIVE REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 20 | 5.65e-01 | 9.71e-01 | 0.40600 | 2.00e-01 | 1.65e-01 | 2.22e-01 | 1.83e-01 | 1.22e-01 | 1.22e-01 | 2.00e-01 | 8.51e-02 | 1.57e-01 | 3.46e-01 |
| CARDIAC PACEMAKER CELL DIFFERENTIATION | 11 | 9.11e-02 | 4.98e-01 | 0.40600 | -1.34e-01 | -1.55e-01 | 7.76e-02 | -3.33e-01 | -7.72e-02 | 4.42e-01 | 3.73e-01 | 6.56e-01 | 5.57e-02 | 6.58e-01 |
| ACYLGLYCEROL TRANSPORT | 8 | 6.88e-01 | 1.00e+00 | 0.40600 | -1.44e-01 | -1.38e-01 | -2.45e-01 | -5.95e-02 | -2.48e-01 | 4.82e-01 | 5.01e-01 | 2.30e-01 | 7.71e-01 | 2.24e-01 |
| REGULATION OF NK T CELL DIFFERENTIATION | 6 | 5.35e-01 | 9.56e-01 | 0.40600 | -1.17e-01 | -1.47e-01 | -1.21e-02 | -2.73e-01 | -2.34e-01 | 6.19e-01 | 5.32e-01 | 9.59e-01 | 2.47e-01 | 3.21e-01 |
| RESPONSE TO TYPE III INTERFERON | 12 | 5.25e-02 | 3.76e-01 | 0.40600 | 1.43e-01 | 1.44e-01 | 1.65e-01 | 1.40e-01 | -2.78e-01 | 3.92e-01 | 3.89e-01 | 3.24e-01 | 4.02e-01 | 9.60e-02 |
| MRNA SPLICE SITE RECOGNITION | 35 | 8.19e-02 | 4.71e-01 | 0.40600 | 2.12e-01 | 1.61e-01 | 2.63e-01 | 1.48e-01 | 5.12e-02 | 3.00e-02 | 9.88e-02 | 7.07e-03 | 1.31e-01 | 6.00e-01 |
| REGULATION OF MITOPHAGY | 15 | 3.96e-01 | 8.96e-01 | 0.40600 | -2.05e-01 | -1.81e-01 | -2.09e-01 | -1.31e-01 | 1.70e-01 | 1.69e-01 | 2.26e-01 | 1.61e-01 | 3.79e-01 | 2.56e-01 |
| MUSCULAR SEPTUM MORPHOGENESIS | 5 | 4.92e-01 | 9.45e-01 | 0.40500 | 1.79e-01 | 1.74e-01 | 2.74e-01 | -7.33e-02 | -1.46e-01 | 4.87e-01 | 5.01e-01 | 2.88e-01 | 7.77e-01 | 5.72e-01 |
| ELASTIN METABOLIC PROCESS | 8 | 4.07e-01 | 9.08e-01 | 0.40500 | -8.12e-02 | -3.85e-02 | -7.54e-02 | -2.07e-01 | -3.28e-01 | 6.91e-01 | 8.50e-01 | 7.12e-01 | 3.11e-01 | 1.08e-01 |
| TRNA WOBBLE BASE MODIFICATION | 20 | 9.41e-02 | 5.06e-01 | 0.40500 | -1.42e-01 | -1.53e-01 | 2.42e-02 | -1.87e-01 | 2.92e-01 | 2.73e-01 | 2.37e-01 | 8.51e-01 | 1.49e-01 | 2.36e-02 |
| TRANSCRIPTION INITIATION COUPLED CHROMATIN REMODELING | 38 | 1.21e-01 | 5.81e-01 | 0.40500 | 1.75e-01 | 1.53e-01 | 2.32e-01 | 1.17e-01 | 2.06e-01 | 6.16e-02 | 1.02e-01 | 1.35e-02 | 2.11e-01 | 2.82e-02 |
| RRNA BASE METHYLATION | 9 | 4.45e-01 | 9.29e-01 | 0.40500 | 1.92e-01 | 1.84e-01 | 3.04e-01 | 2.53e-02 | -1.76e-02 | 3.18e-01 | 3.40e-01 | 1.15e-01 | 8.95e-01 | 9.27e-01 |
| NATURAL KILLER CELL MEDIATED IMMUNITY | 78 | 1.99e-03 | 3.89e-02 | 0.40500 | -2.09e-01 | -2.37e-01 | -1.03e-01 | -2.31e-01 | -2.20e-03 | 1.43e-03 | 2.94e-04 | 1.15e-01 | 4.28e-04 | 9.73e-01 |
| REGULATION OF ATRIAL CARDIAC MUSCLE CELL MEMBRANE DEPOLARIZATION | 9 | 5.71e-01 | 9.76e-01 | 0.40400 | 2.02e-01 | 2.22e-01 | 2.08e-01 | 6.51e-02 | -1.61e-01 | 2.94e-01 | 2.48e-01 | 2.81e-01 | 7.35e-01 | 4.03e-01 |
| DTMP METABOLIC PROCESS | 6 | 7.19e-01 | 1.00e+00 | 0.40400 | -1.32e-01 | -1.91e-01 | 5.75e-02 | -1.69e-01 | 2.78e-01 | 5.75e-01 | 4.17e-01 | 8.07e-01 | 4.72e-01 | 2.38e-01 |
| LYSOSOMAL MEMBRANE ORGANIZATION | 14 | 8.72e-02 | 4.87e-01 | 0.40400 | -6.96e-02 | -6.26e-02 | 9.30e-02 | -1.42e-01 | 3.55e-01 | 6.52e-01 | 6.85e-01 | 5.47e-01 | 3.57e-01 | 2.16e-02 |
| RESPONSE TO PEPTIDOGLYCAN | 13 | 2.53e-01 | 7.80e-01 | 0.40400 | 5.07e-02 | 4.12e-03 | 2.31e-01 | -2.27e-02 | 3.27e-01 | 7.52e-01 | 9.79e-01 | 1.49e-01 | 8.87e-01 | 4.15e-02 |
| REGULATION OF PROTEIN KINASE A SIGNALING | 20 | 3.60e-02 | 3.03e-01 | 0.40400 | -1.67e-02 | -1.63e-02 | -3.04e-02 | -8.51e-02 | -3.93e-01 | 8.97e-01 | 9.00e-01 | 8.14e-01 | 5.10e-01 | 2.34e-03 |
| RIBOSOME BIOGENESIS | 304 | 1.79e-19 | 1.50e-16 | 0.40400 | 2.02e-01 | 1.80e-01 | 2.81e-01 | 6.07e-02 | 8.30e-02 | 1.32e-09 | 6.20e-08 | 3.19e-17 | 6.85e-02 | 1.28e-02 |
| NEGATIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 7 | 3.23e-01 | 8.48e-01 | 0.40400 | 1.48e-01 | 2.39e-01 | -4.35e-02 | 1.13e-01 | -2.63e-01 | 4.98e-01 | 2.74e-01 | 8.42e-01 | 6.04e-01 | 2.28e-01 |
| PROTEIN REPAIR | 7 | 6.35e-01 | 9.97e-01 | 0.40400 | -1.94e-01 | -1.56e-01 | -2.14e-01 | -2.34e-01 | 2.07e-02 | 3.74e-01 | 4.75e-01 | 3.26e-01 | 2.84e-01 | 9.24e-01 |
| POSITIVE REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 5 | 7.31e-01 | 1.00e+00 | 0.40300 | -1.17e-01 | -1.43e-01 | -1.65e-01 | -8.21e-02 | -3.07e-01 | 6.50e-01 | 5.79e-01 | 5.22e-01 | 7.51e-01 | 2.34e-01 |
| REGULATION OF OXIDATIVE PHOSPHORYLATION | 21 | 4.55e-01 | 9.31e-01 | 0.40300 | 2.10e-01 | 1.92e-01 | 1.90e-01 | 1.97e-01 | -8.40e-02 | 9.63e-02 | 1.28e-01 | 1.33e-01 | 1.18e-01 | 5.05e-01 |
| REGULATION OF AEROBIC RESPIRATION | 30 | 3.89e-01 | 8.92e-01 | 0.40300 | 2.10e-01 | 2.06e-01 | 1.96e-01 | 1.92e-01 | -2.72e-02 | 4.66e-02 | 5.09e-02 | 6.27e-02 | 6.89e-02 | 7.97e-01 |
| POSITIVE REGULATION OF MITOTIC SISTER CHROMATID SEPARATION | 18 | 3.50e-01 | 8.69e-01 | 0.40300 | 2.07e-01 | 2.27e-01 | 2.33e-01 | 1.11e-01 | 3.97e-02 | 1.28e-01 | 9.61e-02 | 8.69e-02 | 4.14e-01 | 7.71e-01 |
| DENDRITE SELF AVOIDANCE | 14 | 2.51e-01 | 7.77e-01 | 0.40300 | 5.42e-02 | 7.78e-02 | -8.63e-02 | 1.03e-01 | -3.68e-01 | 7.26e-01 | 6.14e-01 | 5.76e-01 | 5.03e-01 | 1.71e-02 |
| NEGATIVE REGULATION OF NUCLEOTIDE METABOLIC PROCESS | 11 | 4.93e-01 | 9.46e-01 | 0.40300 | 1.58e-01 | 1.84e-01 | 1.09e-01 | 2.17e-01 | 2.12e-01 | 3.65e-01 | 2.91e-01 | 5.31e-01 | 2.13e-01 | 2.23e-01 |
| METHIONINE BIOSYNTHETIC PROCESS | 12 | 4.18e-01 | 9.11e-01 | 0.40300 | -1.70e-01 | -1.26e-01 | -1.37e-01 | -2.44e-01 | -1.98e-01 | 3.09e-01 | 4.51e-01 | 4.10e-01 | 1.43e-01 | 2.35e-01 |
| POSITIVE REGULATION OF INOSITOL PHOSPHATE BIOSYNTHETIC PROCESS | 14 | 6.85e-02 | 4.29e-01 | 0.40300 | 1.65e-01 | 1.96e-01 | 1.17e-01 | 2.44e-01 | -1.53e-01 | 2.86e-01 | 2.03e-01 | 4.48e-01 | 1.14e-01 | 3.23e-01 |
| REGULATION OF SARCOMERE ORGANIZATION | 9 | 8.94e-01 | 1.00e+00 | 0.40300 | 2.07e-01 | 2.05e-01 | 1.36e-01 | 2.33e-01 | -6.57e-02 | 2.81e-01 | 2.86e-01 | 4.79e-01 | 2.27e-01 | 7.33e-01 |
| REGULATION OF ENDOTHELIAL TUBE MORPHOGENESIS | 6 | 5.07e-01 | 9.48e-01 | 0.40300 | 9.43e-04 | 6.13e-02 | -2.45e-01 | 1.31e-01 | -2.85e-01 | 9.97e-01 | 7.95e-01 | 2.99e-01 | 5.79e-01 | 2.26e-01 |
| NEGATIVE REGULATION OF EPIDERMAL GROWTH FACTOR ACTIVATED RECEPTOR ACTIVITY | 13 | 5.29e-01 | 9.54e-01 | 0.40300 | 2.09e-01 | 2.48e-01 | 1.78e-01 | 1.59e-01 | 3.09e-03 | 1.93e-01 | 1.21e-01 | 2.66e-01 | 3.22e-01 | 9.85e-01 |
| STRIATED MUSCLE ADAPTATION | 55 | 1.89e-02 | 1.99e-01 | 0.40300 | 2.12e-01 | 2.32e-01 | 1.01e-01 | 1.97e-01 | -1.19e-01 | 6.48e-03 | 2.91e-03 | 1.97e-01 | 1.14e-02 | 1.26e-01 |
| REGULATION OF BRANCHING INVOLVED IN SALIVARY GLAND MORPHOGENESIS | 8 | 5.91e-01 | 9.86e-01 | 0.40200 | -2.36e-02 | 1.03e-02 | -1.16e-01 | -9.65e-04 | -3.84e-01 | 9.08e-01 | 9.60e-01 | 5.71e-01 | 9.96e-01 | 5.98e-02 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO CHROMOSOME | 27 | 3.32e-01 | 8.56e-01 | 0.40200 | -2.07e-01 | -2.30e-01 | -1.06e-01 | -2.33e-01 | 1.24e-02 | 6.30e-02 | 3.82e-02 | 3.40e-01 | 3.57e-02 | 9.11e-01 |
| REGULATION OF EPIDERMAL GROWTH FACTOR ACTIVATED RECEPTOR ACTIVITY | 19 | 3.38e-01 | 8.59e-01 | 0.40200 | 1.99e-01 | 2.41e-01 | 7.16e-02 | 1.93e-01 | -1.47e-01 | 1.33e-01 | 6.86e-02 | 5.89e-01 | 1.46e-01 | 2.68e-01 |
| POSITIVE REGULATION OF MHC CLASS II BIOSYNTHETIC PROCESS | 14 | 5.13e-01 | 9.52e-01 | 0.40200 | -1.82e-01 | -2.08e-01 | -1.06e-01 | -2.04e-01 | 1.80e-01 | 2.38e-01 | 1.78e-01 | 4.92e-01 | 1.86e-01 | 2.44e-01 |
| POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 7 | 5.62e-01 | 9.71e-01 | 0.40200 | -1.26e-01 | -1.88e-01 | -3.24e-02 | -5.47e-02 | 3.26e-01 | 5.64e-01 | 3.89e-01 | 8.82e-01 | 8.02e-01 | 1.35e-01 |
| CARDIAC VENTRICLE FORMATION | 8 | 1.56e-01 | 6.54e-01 | 0.40200 | -9.24e-02 | -1.20e-01 | 9.90e-02 | -3.44e-01 | -1.01e-01 | 6.51e-01 | 5.57e-01 | 6.28e-01 | 9.16e-02 | 6.22e-01 |
| POSITIVE REGULATION OF AMYLOID FIBRIL FORMATION | 5 | 7.56e-01 | 1.00e+00 | 0.40200 | -1.64e-01 | -1.44e-01 | -6.07e-02 | -2.82e-01 | -1.76e-01 | 5.26e-01 | 5.78e-01 | 8.14e-01 | 2.75e-01 | 4.96e-01 |
| REGULATION OF PROTEIN CATABOLIC PROCESS IN THE VACUOLE | 12 | 6.67e-01 | 1.00e+00 | 0.40200 | 1.92e-01 | 2.06e-01 | 2.17e-01 | 1.45e-01 | 1.18e-01 | 2.50e-01 | 2.17e-01 | 1.92e-01 | 3.84e-01 | 4.78e-01 |
| RESPIRATORY CHAIN COMPLEX IV ASSEMBLY | 29 | 9.94e-03 | 1.25e-01 | 0.40200 | 1.08e-01 | 7.12e-02 | 2.88e-01 | -9.50e-03 | 2.48e-01 | 3.15e-01 | 5.07e-01 | 7.27e-03 | 9.29e-01 | 2.07e-02 |
| REGULATION OF MYELOID LEUKOCYTE MEDIATED IMMUNITY | 55 | 6.70e-05 | 2.47e-03 | 0.40200 | -1.56e-01 | -2.19e-01 | 4.02e-02 | -2.08e-01 | 2.10e-01 | 4.52e-02 | 4.96e-03 | 6.06e-01 | 7.69e-03 | 7.00e-03 |
| RESPONSE TO CORTICOSTERONE | 12 | 2.31e-01 | 7.53e-01 | 0.40100 | 1.41e-01 | 2.07e-01 | 6.07e-02 | 7.92e-02 | -2.98e-01 | 3.98e-01 | 2.15e-01 | 7.16e-01 | 6.35e-01 | 7.41e-02 |
| REGULATION OF APOPTOTIC CELL CLEARANCE | 10 | 8.36e-01 | 1.00e+00 | 0.40100 | 1.82e-01 | 1.80e-01 | 1.69e-01 | 1.89e-01 | 1.77e-01 | 3.18e-01 | 3.25e-01 | 3.55e-01 | 3.02e-01 | 3.32e-01 |
| CLUSTERING OF VOLTAGE GATED SODIUM CHANNELS | 6 | 7.17e-01 | 1.00e+00 | 0.40100 | -1.27e-01 | -1.03e-01 | -2.30e-01 | -1.38e-01 | -2.49e-01 | 5.89e-01 | 6.61e-01 | 3.29e-01 | 5.58e-01 | 2.90e-01 |
| REGULATION OF VITAMIN D BIOSYNTHETIC PROCESS | 7 | 9.45e-01 | 1.00e+00 | 0.40100 | -2.13e-01 | -2.32e-01 | -1.54e-01 | -1.92e-01 | 3.88e-02 | 3.29e-01 | 2.89e-01 | 4.80e-01 | 3.80e-01 | 8.59e-01 |
| REGULATION OF ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY | 27 | 3.09e-01 | 8.35e-01 | 0.40100 | -2.06e-01 | -2.31e-01 | -1.45e-01 | -1.65e-01 | 1.30e-01 | 6.36e-02 | 3.79e-02 | 1.92e-01 | 1.38e-01 | 2.42e-01 |
| SENSORY PERCEPTION | 883 | 1.07e-39 | 1.61e-36 | 0.40100 | -1.92e-01 | -1.66e-01 | -2.62e-01 | -1.25e-01 | -1.11e-01 | 3.15e-22 | 4.91e-17 | 5.99e-40 | 3.05e-10 | 2.47e-08 |
| NEGATIVE REGULATION OF CARDIAC MUSCLE ADAPTATION | 8 | 1.12e-01 | 5.59e-01 | 0.40100 | 1.45e-01 | 1.86e-01 | -1.38e-01 | 2.48e-01 | -1.57e-01 | 4.77e-01 | 3.63e-01 | 4.98e-01 | 2.24e-01 | 4.43e-01 |
| REGULATION OF MEIOTIC CELL CYCLE PHASE TRANSITION | 10 | 7.70e-01 | 1.00e+00 | 0.40100 | 1.93e-01 | 1.99e-01 | 9.60e-02 | 2.73e-01 | 1.47e-02 | 2.91e-01 | 2.77e-01 | 5.99e-01 | 1.34e-01 | 9.36e-01 |
| CAMKK AMPK SIGNALING CASCADE | 9 | 6.94e-01 | 1.00e+00 | 0.40100 | -1.91e-01 | -1.99e-01 | -6.76e-02 | -2.74e-01 | -7.11e-02 | 3.22e-01 | 3.01e-01 | 7.26e-01 | 1.55e-01 | 7.12e-01 |
| CELLULAR RESPONSE TO IRON ION | 8 | 2.94e-01 | 8.22e-01 | 0.40000 | 9.49e-02 | 4.93e-02 | 3.15e-01 | -1.80e-02 | 2.22e-01 | 6.42e-01 | 8.09e-01 | 1.23e-01 | 9.30e-01 | 2.77e-01 |
| RESPONSE TO ISOQUINOLINE ALKALOID | 11 | 8.24e-01 | 1.00e+00 | 0.40000 | -2.12e-01 | -1.94e-01 | -1.73e-01 | -1.98e-01 | -9.09e-02 | 2.24e-01 | 2.65e-01 | 3.20e-01 | 2.55e-01 | 6.02e-01 |
| RESPONSE TO LUTEINIZING HORMONE | 7 | 8.90e-01 | 1.00e+00 | 0.40000 | 2.22e-01 | 2.01e-01 | 1.70e-01 | 1.83e-01 | -8.72e-02 | 3.08e-01 | 3.57e-01 | 4.36e-01 | 4.01e-01 | 6.90e-01 |
| POSITIVE REGULATION OF WNT SIGNALING PATHWAY PLANAR CELL POLARITY PATHWAY | 8 | 8.86e-01 | 1.00e+00 | 0.40000 | -2.02e-01 | -2.07e-01 | -1.66e-01 | -1.83e-01 | 1.23e-01 | 3.22e-01 | 3.10e-01 | 4.16e-01 | 3.69e-01 | 5.48e-01 |
| OVULATION FROM OVARIAN FOLLICLE | 8 | 6.25e-01 | 9.93e-01 | 0.40000 | -1.55e-01 | -1.69e-01 | -2.01e-01 | -7.38e-02 | -2.48e-01 | 4.47e-01 | 4.08e-01 | 3.25e-01 | 7.18e-01 | 2.25e-01 |
| POSITIVE REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 21 | 6.01e-01 | 9.90e-01 | 0.40000 | -2.10e-01 | -2.26e-01 | -1.35e-01 | -2.15e-01 | -4.37e-03 | 9.53e-02 | 7.32e-02 | 2.84e-01 | 8.76e-02 | 9.72e-01 |
| L KYNURENINE METABOLIC PROCESS | 7 | 5.35e-01 | 9.56e-01 | 0.40000 | -1.79e-01 | -1.67e-01 | -2.40e-01 | -1.84e-02 | -2.05e-01 | 4.13e-01 | 4.44e-01 | 2.72e-01 | 9.33e-01 | 3.47e-01 |
| ADP BIOSYNTHETIC PROCESS | 5 | 7.92e-01 | 1.00e+00 | 0.39900 | 2.11e-01 | 2.69e-01 | 1.34e-01 | 1.58e-01 | 1.48e-02 | 4.15e-01 | 2.98e-01 | 6.05e-01 | 5.42e-01 | 9.54e-01 |
| FC RECEPTOR MEDIATED STIMULATORY SIGNALING PATHWAY | 32 | 5.66e-02 | 3.88e-01 | 0.39900 | -2.02e-01 | -2.46e-01 | -5.92e-02 | -2.18e-01 | 8.15e-02 | 4.76e-02 | 1.58e-02 | 5.62e-01 | 3.29e-02 | 4.25e-01 |
| CELLULAR RESPONSE TO CAFFEINE | 11 | 7.40e-01 | 1.00e+00 | 0.39900 | -1.87e-01 | -2.01e-01 | -9.50e-02 | -1.76e-01 | 2.09e-01 | 2.83e-01 | 2.48e-01 | 5.85e-01 | 3.11e-01 | 2.30e-01 |
| CELLULAR RESPONSE TO MURAMYL DIPEPTIDE | 8 | 1.99e-01 | 7.14e-01 | 0.39900 | 2.20e-02 | -5.39e-02 | 2.24e-01 | -1.87e-01 | 2.66e-01 | 9.14e-01 | 7.92e-01 | 2.72e-01 | 3.60e-01 | 1.93e-01 |
| NEGATIVE REGULATION OF RESPONSE TO TUMOR CELL | 5 | 7.77e-01 | 1.00e+00 | 0.39900 | -1.38e-01 | -1.84e-01 | 6.40e-02 | -2.69e-01 | 1.72e-01 | 5.93e-01 | 4.77e-01 | 8.04e-01 | 2.97e-01 | 5.05e-01 |
| REGULATION OF METALLOENDOPEPTIDASE ACTIVITY | 15 | 7.00e-02 | 4.35e-01 | 0.39900 | -1.57e-01 | -1.61e-01 | -2.50e-01 | -1.56e-01 | -1.47e-01 | 2.93e-01 | 2.79e-01 | 9.41e-02 | 2.96e-01 | 3.23e-01 |
| PYRUVATE TRANSPORT | 7 | 4.18e-01 | 9.11e-01 | 0.39900 | -1.57e-01 | -1.44e-01 | 1.90e-03 | -3.23e-01 | -9.70e-02 | 4.71e-01 | 5.10e-01 | 9.93e-01 | 1.39e-01 | 6.57e-01 |
| TRYPTOPHAN TRANSPORT | 5 | 4.39e-01 | 9.25e-01 | 0.39900 | 1.97e-01 | 2.76e-01 | 1.76e-01 | 8.19e-02 | 7.84e-02 | 4.46e-01 | 2.84e-01 | 4.97e-01 | 7.51e-01 | 7.61e-01 |
| PYRIMIDINE NUCLEOSIDE TRANSPORT | 6 | 5.26e-01 | 9.54e-01 | 0.39800 | 1.63e-01 | 2.28e-01 | 1.26e-01 | 1.79e-01 | 1.79e-01 | 4.88e-01 | 3.33e-01 | 5.94e-01 | 4.48e-01 | 4.47e-01 |
| GLUCURONATE CATABOLIC PROCESS TO XYLULOSE 5 PHOSPHATE | 5 | 9.02e-01 | 1.00e+00 | 0.39800 | 1.98e-01 | 1.96e-01 | 2.52e-01 | 1.33e-01 | -2.07e-03 | 4.43e-01 | 4.48e-01 | 3.29e-01 | 6.07e-01 | 9.94e-01 |
| POSITIVE REGULATION OF T CELL PROLIFERATION | 100 | 1.52e-03 | 3.18e-02 | 0.39800 | -2.14e-01 | -2.27e-01 | -1.21e-01 | -2.04e-01 | 6.79e-02 | 2.12e-04 | 8.50e-05 | 3.58e-02 | 4.22e-04 | 2.41e-01 |
| SINOATRIAL NODE CELL DEVELOPMENT | 5 | 5.13e-01 | 9.52e-01 | 0.39800 | -2.89e-02 | -9.68e-02 | 2.39e-01 | -1.49e-01 | 2.63e-01 | 9.11e-01 | 7.08e-01 | 3.55e-01 | 5.63e-01 | 3.09e-01 |
| POSITIVE REGULATION OF INTERFERON ALPHA PRODUCTION | 21 | 1.78e-01 | 6.85e-01 | 0.39800 | -1.76e-01 | -2.15e-01 | -4.18e-03 | -2.19e-01 | 1.83e-01 | 1.62e-01 | 8.85e-02 | 9.74e-01 | 8.22e-02 | 1.47e-01 |
| LUNG LOBE DEVELOPMENT | 7 | 8.12e-01 | 1.00e+00 | 0.39800 | 1.99e-01 | 2.45e-01 | 1.33e-01 | 1.61e-01 | -1.24e-01 | 3.63e-01 | 2.62e-01 | 5.41e-01 | 4.60e-01 | 5.71e-01 |
| NEGATIVE REGULATION OF OXIDOREDUCTASE ACTIVITY | 27 | 2.73e-01 | 7.99e-01 | 0.39800 | 2.17e-01 | 2.19e-01 | 1.60e-01 | 1.82e-01 | 7.11e-02 | 5.14e-02 | 4.92e-02 | 1.51e-01 | 1.01e-01 | 5.23e-01 |
| POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 8 | 5.38e-02 | 3.79e-01 | 0.39800 | 1.66e-01 | 1.25e-01 | 2.99e-01 | -1.42e-01 | 7.31e-02 | 4.16e-01 | 5.41e-01 | 1.43e-01 | 4.86e-01 | 7.20e-01 |
| MITOCHONDRIAL RNA CATABOLIC PROCESS | 6 | 2.17e-01 | 7.40e-01 | 0.39800 | 7.63e-02 | -5.21e-02 | 3.24e-01 | -5.79e-02 | 2.04e-01 | 7.46e-01 | 8.25e-01 | 1.70e-01 | 8.06e-01 | 3.87e-01 |
| L SERINE TRANSPORT | 7 | 6.11e-01 | 9.90e-01 | 0.39700 | 6.77e-02 | 7.35e-02 | -1.08e-02 | 2.64e-02 | -3.83e-01 | 7.56e-01 | 7.36e-01 | 9.60e-01 | 9.04e-01 | 7.90e-02 |
| ALPHA BETA T CELL PROLIFERATION | 43 | 1.91e-01 | 7.01e-01 | 0.39700 | -2.11e-01 | -2.00e-01 | -1.49e-01 | -2.22e-01 | 4.02e-02 | 1.68e-02 | 2.32e-02 | 9.10e-02 | 1.16e-02 | 6.48e-01 |
| ERK5 CASCADE | 5 | 8.48e-01 | 1.00e+00 | 0.39700 | -1.84e-01 | -2.12e-01 | -1.41e-01 | -2.13e-01 | 1.17e-01 | 4.77e-01 | 4.11e-01 | 5.86e-01 | 4.10e-01 | 6.50e-01 |
| ELASTIN CATABOLIC PROCESS | 5 | 3.87e-01 | 8.92e-01 | 0.39700 | -1.20e-01 | -9.10e-02 | 6.22e-03 | -3.60e-01 | -7.38e-02 | 6.42e-01 | 7.25e-01 | 9.81e-01 | 1.64e-01 | 7.75e-01 |
| SEROTONIN TRANSPORT | 20 | 4.12e-02 | 3.25e-01 | 0.39700 | 2.00e-01 | 1.37e-01 | 2.77e-01 | 9.90e-02 | -1.10e-01 | 1.21e-01 | 2.87e-01 | 3.22e-02 | 4.43e-01 | 3.95e-01 |
| DNA LIGATION INVOLVED IN DNA REPAIR | 5 | 9.54e-01 | 1.00e+00 | 0.39600 | 2.00e-01 | 1.84e-01 | 2.49e-01 | 1.41e-01 | 3.95e-02 | 4.39e-01 | 4.77e-01 | 3.35e-01 | 5.85e-01 | 8.79e-01 |
| POSITIVE REGULATION OF T CELL MEDIATED IMMUNITY | 66 | 1.37e-03 | 2.93e-02 | 0.39600 | -1.84e-01 | -2.19e-01 | -3.06e-02 | -2.40e-01 | 1.28e-01 | 9.58e-03 | 2.09e-03 | 6.67e-01 | 7.46e-04 | 7.12e-02 |
| POSITIVE REGULATION OF LONG TERM SYNAPTIC DEPRESSION | 6 | 8.70e-01 | 1.00e+00 | 0.39600 | -1.93e-01 | -1.75e-01 | -1.23e-01 | -2.09e-01 | 1.74e-01 | 4.13e-01 | 4.58e-01 | 6.03e-01 | 3.75e-01 | 4.60e-01 |
| MEMBRANE RAFT ASSEMBLY | 11 | 6.12e-01 | 9.90e-01 | 0.39600 | 1.73e-01 | 1.93e-01 | 1.09e-01 | 2.13e-01 | 1.79e-01 | 3.20e-01 | 2.67e-01 | 5.30e-01 | 2.21e-01 | 3.03e-01 |
| MEIOTIC CHROMOSOME CONDENSATION | 6 | 1.80e-01 | 6.87e-01 | 0.39600 | -3.16e-02 | -2.47e-02 | 2.25e-01 | -1.86e-01 | 2.65e-01 | 8.93e-01 | 9.16e-01 | 3.40e-01 | 4.30e-01 | 2.62e-01 |
| L PHENYLALANINE METABOLIC PROCESS | 8 | 7.76e-01 | 1.00e+00 | 0.39600 | 1.95e-01 | 1.92e-01 | 2.67e-01 | 7.29e-02 | 7.28e-02 | 3.39e-01 | 3.46e-01 | 1.92e-01 | 7.21e-01 | 7.21e-01 |
| DIAPEDESIS | 6 | 4.50e-01 | 9.30e-01 | 0.39600 | 1.72e-03 | 6.17e-02 | -1.03e-01 | 9.41e-02 | -3.65e-01 | 9.94e-01 | 7.94e-01 | 6.62e-01 | 6.90e-01 | 1.21e-01 |
| REGULATION OF INTERLEUKIN 6 MEDIATED SIGNALING PATHWAY | 11 | 6.48e-04 | 1.59e-02 | 0.39600 | 5.39e-02 | 1.85e-01 | -2.55e-01 | 7.90e-02 | -2.20e-01 | 7.57e-01 | 2.88e-01 | 1.44e-01 | 6.50e-01 | 2.06e-01 |
| REGULATION OF HISTONE ACETYLATION | 18 | 6.42e-01 | 1.00e+00 | 0.39600 | 1.86e-01 | 1.77e-01 | 2.20e-01 | 1.52e-01 | 1.37e-01 | 1.72e-01 | 1.93e-01 | 1.06e-01 | 2.64e-01 | 3.13e-01 |
| LENS FIBER CELL DIFFERENTIATION | 37 | 1.19e-01 | 5.74e-01 | 0.39600 | 2.07e-01 | 1.61e-01 | 2.46e-01 | 1.52e-01 | 6.19e-02 | 2.91e-02 | 8.95e-02 | 9.67e-03 | 1.09e-01 | 5.14e-01 |
| PARASYMPATHETIC NERVOUS SYSTEM DEVELOPMENT | 17 | 2.87e-01 | 8.15e-01 | 0.39500 | 2.31e-01 | 2.06e-01 | 2.01e-01 | 1.28e-01 | -6.25e-02 | 9.96e-02 | 1.41e-01 | 1.51e-01 | 3.62e-01 | 6.56e-01 |
| FEMALE MEIOSIS CHROMOSOME SEGREGATION | 6 | 6.94e-01 | 1.00e+00 | 0.39500 | 1.19e-01 | 8.69e-02 | 2.89e-01 | 1.42e-02 | 2.25e-01 | 6.13e-01 | 7.12e-01 | 2.20e-01 | 9.52e-01 | 3.40e-01 |
| PROTEIN LOCALIZATION TO PLASMA MEMBRANE RAFT | 5 | 5.90e-01 | 9.86e-01 | 0.39500 | -1.21e-01 | -1.01e-01 | -7.60e-03 | -3.04e-01 | -1.96e-01 | 6.38e-01 | 6.96e-01 | 9.77e-01 | 2.38e-01 | 4.48e-01 |
| POST FERTILIZATION EPIGENETIC REGULATION OF GENE EXPRESSION | 13 | 1.45e-01 | 6.29e-01 | 0.39500 | 1.80e-02 | 2.52e-02 | 1.51e-01 | -4.49e-02 | 3.61e-01 | 9.11e-01 | 8.75e-01 | 3.45e-01 | 7.79e-01 | 2.42e-02 |
| LYMPH VESSEL MORPHOGENESIS | 23 | 9.07e-02 | 4.98e-01 | 0.39500 | 1.82e-01 | 2.14e-01 | 1.53e-01 | 1.68e-01 | -1.61e-01 | 1.31e-01 | 7.62e-02 | 2.03e-01 | 1.64e-01 | 1.82e-01 |
| NEGATIVE REGULATION OF PROTEIN TARGETING TO MEMBRANE | 5 | 7.80e-01 | 1.00e+00 | 0.39500 | -9.72e-02 | -1.06e-01 | 2.31e-02 | -7.72e-02 | 3.59e-01 | 7.07e-01 | 6.81e-01 | 9.29e-01 | 7.65e-01 | 1.65e-01 |
| REGULATION OF FATTY ACID BETA OXIDATION | 19 | 5.89e-01 | 9.86e-01 | 0.39500 | 1.97e-01 | 2.14e-01 | 1.15e-01 | 1.98e-01 | -1.38e-01 | 1.38e-01 | 1.06e-01 | 3.86e-01 | 1.35e-01 | 2.97e-01 |
| GAMMA DELTA T CELL DIFFERENTIATION | 13 | 3.09e-01 | 8.35e-01 | 0.39500 | -1.42e-01 | -2.10e-01 | 1.90e-02 | -2.05e-01 | 2.21e-01 | 3.74e-01 | 1.90e-01 | 9.06e-01 | 2.00e-01 | 1.67e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DEVELOPMENT | 12 | 5.50e-02 | 3.84e-01 | 0.39500 | 1.14e-01 | 1.09e-01 | 2.87e-01 | -1.27e-01 | 1.80e-01 | 4.93e-01 | 5.15e-01 | 8.51e-02 | 4.46e-01 | 2.80e-01 |
| DUCTUS ARTERIOSUS CLOSURE | 5 | 8.84e-01 | 1.00e+00 | 0.39500 | 1.78e-01 | 1.78e-01 | 2.02e-01 | 2.04e-01 | 1.00e-01 | 4.92e-01 | 4.90e-01 | 4.35e-01 | 4.29e-01 | 6.98e-01 |
| POSITIVE REGULATION OF MYELINATION | 17 | 2.12e-01 | 7.34e-01 | 0.39500 | 7.27e-02 | 5.84e-02 | 1.47e-01 | 9.66e-02 | 3.41e-01 | 6.04e-01 | 6.77e-01 | 2.94e-01 | 4.91e-01 | 1.50e-02 |
| REGULATION OF CHONDROCYTE DEVELOPMENT | 6 | 6.83e-01 | 1.00e+00 | 0.39400 | -1.47e-01 | -1.25e-01 | -7.86e-02 | -2.92e-01 | -1.64e-01 | 5.32e-01 | 5.97e-01 | 7.39e-01 | 2.16e-01 | 4.86e-01 |
| POSITIVE REGULATION OF ISOTYPE SWITCHING | 28 | 6.05e-02 | 4.03e-01 | 0.39400 | -1.52e-01 | -1.68e-01 | 1.46e-03 | -2.40e-01 | 2.16e-01 | 1.64e-01 | 1.25e-01 | 9.89e-01 | 2.81e-02 | 4.76e-02 |
| URATE TRANSPORT | 11 | 1.43e-01 | 6.29e-01 | 0.39400 | -1.60e-01 | -1.02e-01 | -3.44e-01 | -7.31e-03 | -2.62e-02 | 3.58e-01 | 5.56e-01 | 4.79e-02 | 9.67e-01 | 8.80e-01 |
| REGULATION OF TRANSCRIPTION ELONGATION BY RNA POLYMERASE II | 85 | 4.67e-04 | 1.23e-02 | 0.39400 | 1.63e-01 | 1.17e-01 | 2.47e-01 | 1.17e-01 | 2.02e-01 | 9.51e-03 | 6.31e-02 | 8.47e-05 | 6.24e-02 | 1.27e-03 |
| NEGATIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 26 | 5.35e-01 | 9.56e-01 | 0.39400 | -2.06e-01 | -2.12e-01 | -1.50e-01 | -1.96e-01 | 8.12e-02 | 6.85e-02 | 6.15e-02 | 1.85e-01 | 8.33e-02 | 4.74e-01 |
| POSITIVE REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 8 | 6.40e-01 | 1.00e+00 | 0.39400 | 1.59e-01 | 1.83e-01 | 1.29e-02 | 2.89e-01 | -1.13e-01 | 4.37e-01 | 3.71e-01 | 9.50e-01 | 1.57e-01 | 5.81e-01 |
| NUCLEOSIDE BISPHOSPHATE CATABOLIC PROCESS | 11 | 6.41e-01 | 1.00e+00 | 0.39400 | 1.84e-01 | 2.08e-01 | 1.32e-01 | 2.44e-01 | 3.00e-02 | 2.90e-01 | 2.32e-01 | 4.48e-01 | 1.62e-01 | 8.63e-01 |
| GPI ANCHOR METABOLIC PROCESS | 31 | 1.27e-01 | 5.93e-01 | 0.39400 | 2.15e-01 | 1.89e-01 | 2.53e-01 | 9.40e-02 | -1.56e-02 | 3.81e-02 | 6.90e-02 | 1.47e-02 | 3.65e-01 | 8.80e-01 |
| PANCREATIC A CELL DIFFERENTIATION | 11 | 3.81e-02 | 3.12e-01 | 0.39400 | 1.64e-01 | 1.25e-01 | 2.92e-01 | -1.17e-01 | -1.17e-01 | 3.46e-01 | 4.74e-01 | 9.36e-02 | 5.03e-01 | 5.00e-01 |
| LEUKOCYTE MEDIATED CYTOTOXICITY | 135 | 5.28e-07 | 3.90e-05 | 0.39400 | -1.97e-01 | -2.33e-01 | -6.00e-02 | -2.23e-01 | 9.30e-02 | 7.65e-05 | 2.95e-06 | 2.29e-01 | 7.69e-06 | 6.21e-02 |
| VESICLE TETHERING TO GOLGI | 5 | 7.64e-01 | 1.00e+00 | 0.39400 | -1.94e-01 | -2.66e-01 | -5.93e-02 | -2.05e-01 | 3.81e-02 | 4.54e-01 | 3.03e-01 | 8.18e-01 | 4.28e-01 | 8.83e-01 |
| PUTRESCINE BIOSYNTHETIC PROCESS | 5 | 5.81e-01 | 9.85e-01 | 0.39300 | -6.10e-02 | -1.50e-01 | 1.36e-01 | -1.94e-01 | 2.69e-01 | 8.13e-01 | 5.60e-01 | 6.00e-01 | 4.52e-01 | 2.98e-01 |
| APOPTOTIC PROCESS INVOLVED IN HEART MORPHOGENESIS | 7 | 4.73e-01 | 9.40e-01 | 0.39300 | 1.74e-01 | 1.71e-01 | 2.68e-01 | 2.82e-02 | -1.50e-01 | 4.26e-01 | 4.34e-01 | 2.19e-01 | 8.97e-01 | 4.92e-01 |
| ENDOTHELIAL CELL FATE COMMITMENT | 8 | 1.68e-01 | 6.71e-01 | 0.39300 | 1.49e-01 | 1.04e-01 | 2.28e-01 | -7.37e-02 | -2.53e-01 | 4.66e-01 | 6.12e-01 | 2.64e-01 | 7.18e-01 | 2.14e-01 |
| LUTEINIZING HORMONE SECRETION | 10 | 2.52e-01 | 7.78e-01 | 0.39300 | -1.37e-01 | -9.56e-02 | -1.75e-01 | -4.89e-02 | -3.06e-01 | 4.55e-01 | 6.01e-01 | 3.37e-01 | 7.89e-01 | 9.37e-02 |
| PATTERN SPECIFICATION INVOLVED IN KIDNEY DEVELOPMENT | 8 | 4.37e-01 | 9.22e-01 | 0.39300 | 1.95e-01 | 1.08e-01 | 2.92e-01 | 7.87e-02 | 1.15e-01 | 3.39e-01 | 5.98e-01 | 1.52e-01 | 7.00e-01 | 5.74e-01 |
| REGULATION OF SKELETAL MUSCLE FIBER DEVELOPMENT | 11 | 3.40e-01 | 8.59e-01 | 0.39300 | -1.32e-01 | -1.49e-01 | -1.15e-01 | -1.19e-01 | -2.95e-01 | 4.47e-01 | 3.91e-01 | 5.08e-01 | 4.93e-01 | 9.00e-02 |
| AMINO ACID IMPORT ACROSS PLASMA MEMBRANE | 44 | 8.76e-02 | 4.89e-01 | 0.39300 | 2.04e-01 | 2.36e-01 | 1.42e-01 | 1.91e-01 | -2.35e-02 | 1.92e-02 | 6.66e-03 | 1.04e-01 | 2.88e-02 | 7.87e-01 |
| MESENCHYMAL STEM CELL DIFFERENTIATION | 12 | 2.71e-01 | 7.97e-01 | 0.39300 | -1.44e-01 | -1.24e-01 | -1.26e-01 | -1.28e-01 | -2.94e-01 | 3.88e-01 | 4.57e-01 | 4.51e-01 | 4.42e-01 | 7.83e-02 |
| RETINAL CONE CELL DIFFERENTIATION | 13 | 3.23e-01 | 8.47e-01 | 0.39300 | 1.78e-01 | 2.33e-01 | 1.85e-03 | 2.56e-01 | -5.16e-02 | 2.67e-01 | 1.46e-01 | 9.91e-01 | 1.09e-01 | 7.47e-01 |
| SUCCINYL COA CATABOLIC PROCESS | 6 | 9.28e-01 | 1.00e+00 | 0.39300 | 1.98e-01 | 2.01e-01 | 1.93e-01 | 1.90e-01 | -3.30e-02 | 4.00e-01 | 3.94e-01 | 4.12e-01 | 4.21e-01 | 8.89e-01 |
| VIRAL TRANSLATIONAL TERMINATION REINITIATION | 5 | 8.35e-01 | 1.00e+00 | 0.39300 | 1.98e-01 | 1.38e-01 | 2.78e-01 | 1.35e-01 | 5.34e-03 | 4.42e-01 | 5.92e-01 | 2.81e-01 | 6.02e-01 | 9.83e-01 |
| CELLULAR RESPONSE TO LAMINAR FLUID SHEAR STRESS | 8 | 5.64e-01 | 9.71e-01 | 0.39200 | 1.97e-01 | 2.36e-01 | 2.24e-01 | 9.42e-02 | -2.46e-02 | 3.35e-01 | 2.48e-01 | 2.73e-01 | 6.44e-01 | 9.04e-01 |
| CARDIAC PACEMAKER CELL DEVELOPMENT | 9 | 2.61e-01 | 7.89e-01 | 0.39200 | -1.46e-01 | -2.00e-01 | 8.56e-02 | -2.90e-01 | 3.34e-02 | 4.47e-01 | 2.98e-01 | 6.57e-01 | 1.32e-01 | 8.62e-01 |
| MINERALOCORTICOID BIOSYNTHETIC PROCESS | 12 | 7.22e-01 | 1.00e+00 | 0.39200 | 1.97e-01 | 2.22e-01 | 1.70e-01 | 1.92e-01 | 1.21e-02 | 2.38e-01 | 1.83e-01 | 3.08e-01 | 2.51e-01 | 9.42e-01 |
| LONG CHAIN FATTY ACID CATABOLIC PROCESS | 8 | 6.87e-01 | 1.00e+00 | 0.39200 | -2.15e-01 | -2.37e-01 | -1.67e-01 | -9.55e-02 | 1.20e-01 | 2.92e-01 | 2.46e-01 | 4.14e-01 | 6.40e-01 | 5.56e-01 |
| BLOOD VESSEL ENDOTHELIAL CELL DIFFERENTIATION | 14 | 1.24e-01 | 5.87e-01 | 0.39200 | 1.98e-01 | 1.83e-01 | 2.73e-01 | -8.68e-03 | 7.74e-02 | 2.00e-01 | 2.35e-01 | 7.66e-02 | 9.55e-01 | 6.16e-01 |
| CHONDROBLAST DIFFERENTIATION | 5 | 8.11e-01 | 1.00e+00 | 0.39100 | 1.93e-01 | 2.10e-01 | 2.61e-01 | 4.98e-02 | 2.98e-02 | 4.54e-01 | 4.15e-01 | 3.12e-01 | 8.47e-01 | 9.08e-01 |
| DETECTION OF CALCIUM ION | 13 | 8.51e-01 | 1.00e+00 | 0.39100 | -2.08e-01 | -2.15e-01 | -1.48e-01 | -2.02e-01 | -1.97e-02 | 1.93e-01 | 1.79e-01 | 3.56e-01 | 2.07e-01 | 9.02e-01 |
| POSITIVE REGULATION OF INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 12 | 5.61e-01 | 9.70e-01 | 0.39100 | -1.86e-01 | -2.27e-01 | -7.18e-02 | -1.47e-01 | 2.00e-01 | 2.66e-01 | 1.73e-01 | 6.67e-01 | 3.78e-01 | 2.31e-01 |
| GALACTOLIPID METABOLIC PROCESS | 9 | 6.82e-01 | 1.00e+00 | 0.39100 | -1.07e-01 | -6.30e-02 | -1.85e-01 | -7.48e-02 | -3.12e-01 | 5.78e-01 | 7.43e-01 | 3.36e-01 | 6.98e-01 | 1.05e-01 |
| RESPONSE TO SELENIUM ION | 8 | 7.85e-01 | 1.00e+00 | 0.39100 | 1.90e-01 | 1.77e-01 | 2.75e-01 | 7.96e-02 | 5.62e-02 | 3.52e-01 | 3.87e-01 | 1.77e-01 | 6.97e-01 | 7.83e-01 |
| PROTEIN LOCALIZATION TO NON MOTILE CILIUM | 12 | 7.54e-01 | 1.00e+00 | 0.39100 | 2.05e-01 | 1.75e-01 | 1.78e-01 | 1.95e-01 | 1.02e-01 | 2.19e-01 | 2.95e-01 | 2.85e-01 | 2.43e-01 | 5.40e-01 |
| SYNAPTIC VESICLE DOCKING | 10 | 7.52e-01 | 1.00e+00 | 0.39100 | 1.87e-01 | 1.72e-01 | 2.60e-01 | 1.21e-01 | 7.56e-02 | 3.05e-01 | 3.48e-01 | 1.54e-01 | 5.09e-01 | 6.79e-01 |
| DICARBOXYLIC ACID BIOSYNTHETIC PROCESS | 12 | 3.13e-01 | 8.40e-01 | 0.39100 | -1.80e-01 | -1.42e-01 | -1.26e-01 | -2.04e-01 | -2.05e-01 | 2.80e-01 | 3.93e-01 | 4.48e-01 | 2.20e-01 | 2.19e-01 |
| SPINAL CORD PATTERNING | 21 | 2.30e-01 | 7.52e-01 | 0.39100 | 1.96e-01 | 1.86e-01 | 2.70e-01 | 5.47e-02 | 5.88e-02 | 1.20e-01 | 1.39e-01 | 3.21e-02 | 6.64e-01 | 6.41e-01 |
| ONCOGENE INDUCED CELL SENESCENCE | 6 | 8.71e-01 | 1.00e+00 | 0.39000 | 1.19e-01 | 8.73e-02 | 1.68e-01 | 1.38e-01 | 2.88e-01 | 6.14e-01 | 7.11e-01 | 4.75e-01 | 5.57e-01 | 2.21e-01 |
| GRANULOCYTE ACTIVATION | 49 | 1.73e-06 | 9.86e-05 | 0.39000 | -1.14e-01 | -1.80e-01 | 1.28e-01 | -1.82e-01 | 2.40e-01 | 1.69e-01 | 2.96e-02 | 1.20e-01 | 2.78e-02 | 3.61e-03 |
| POSITIVE REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY | 123 | 2.44e-05 | 1.02e-03 | 0.39000 | -1.95e-01 | -2.27e-01 | -7.37e-02 | -2.28e-01 | 7.34e-02 | 1.87e-04 | 1.35e-05 | 1.58e-01 | 1.30e-05 | 1.60e-01 |
| PLASMA MEMBRANE RAFT ASSEMBLY | 7 | 4.32e-01 | 9.19e-01 | 0.39000 | 6.23e-02 | 9.80e-02 | 8.30e-02 | 1.00e-01 | 3.49e-01 | 7.75e-01 | 6.53e-01 | 7.04e-01 | 6.47e-01 | 1.10e-01 |
| POSITIVE REGULATION OF SARCOMERE ORGANIZATION | 6 | 9.47e-01 | 1.00e+00 | 0.39000 | 2.11e-01 | 1.80e-01 | 2.22e-01 | 1.60e-01 | -1.36e-02 | 3.71e-01 | 4.45e-01 | 3.45e-01 | 4.98e-01 | 9.54e-01 |
| MRNA CIS SPLICING VIA SPLICEOSOME | 26 | 1.48e-01 | 6.36e-01 | 0.39000 | 2.14e-01 | 1.74e-01 | 2.40e-01 | 1.19e-01 | -6.54e-02 | 5.84e-02 | 1.25e-01 | 3.45e-02 | 2.94e-01 | 5.64e-01 |
| POSITIVE REGULATION OF MRNA PROCESSING | 28 | 2.62e-02 | 2.45e-01 | 0.39000 | 1.32e-01 | 5.96e-02 | 2.79e-01 | 6.13e-02 | 2.22e-01 | 2.25e-01 | 5.85e-01 | 1.07e-02 | 5.75e-01 | 4.19e-02 |
| POSITIVE REGULATION OF TRIGLYCERIDE METABOLIC PROCESS | 21 | 6.18e-01 | 9.90e-01 | 0.38900 | 1.83e-01 | 1.68e-01 | 2.08e-01 | 1.54e-01 | 1.52e-01 | 1.48e-01 | 1.82e-01 | 9.89e-02 | 2.22e-01 | 2.27e-01 |
| REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 35 | 2.52e-01 | 7.78e-01 | 0.38900 | 1.99e-01 | 1.87e-01 | 1.84e-01 | 2.05e-01 | -2.20e-02 | 4.12e-02 | 5.49e-02 | 5.89e-02 | 3.61e-02 | 8.22e-01 |
| POSITIVE REGULATION OF OXIDATIVE STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 7 | 4.63e-01 | 9.33e-01 | 0.38900 | 1.58e-01 | 2.29e-01 | 6.84e-02 | 2.14e-01 | -1.53e-01 | 4.68e-01 | 2.95e-01 | 7.54e-01 | 3.27e-01 | 4.83e-01 |
| GLUCOSYLCERAMIDE METABOLIC PROCESS | 7 | 6.09e-01 | 9.90e-01 | 0.38900 | -1.32e-01 | -1.41e-01 | 3.27e-02 | -2.68e-01 | 2.03e-01 | 5.46e-01 | 5.19e-01 | 8.81e-01 | 2.20e-01 | 3.52e-01 |
| LUTEINIZATION | 12 | 3.24e-01 | 8.49e-01 | 0.38900 | -1.94e-01 | -2.57e-01 | -4.96e-02 | -1.68e-01 | 1.28e-01 | 2.44e-01 | 1.23e-01 | 7.66e-01 | 3.14e-01 | 4.44e-01 |
| SEROTONIN UPTAKE | 12 | 4.81e-01 | 9.43e-01 | 0.38800 | 1.82e-01 | 1.60e-01 | 1.51e-01 | 1.91e-01 | -1.81e-01 | 2.75e-01 | 3.38e-01 | 3.66e-01 | 2.51e-01 | 2.79e-01 |
| EMBRYONIC BODY MORPHOGENESIS | 11 | 4.48e-01 | 9.30e-01 | 0.38800 | 1.47e-01 | 2.10e-01 | 2.89e-02 | 1.70e-01 | -2.35e-01 | 3.98e-01 | 2.29e-01 | 8.68e-01 | 3.30e-01 | 1.77e-01 |
| PROTEIN K63 LINKED DEUBIQUITINATION | 27 | 4.55e-01 | 9.31e-01 | 0.38800 | -2.02e-01 | -1.99e-01 | -1.26e-01 | -2.33e-01 | -1.07e-02 | 6.93e-02 | 7.39e-02 | 2.58e-01 | 3.61e-02 | 9.23e-01 |
| MONOCYTE CHEMOTAXIS | 69 | 3.27e-03 | 5.56e-02 | 0.38800 | -2.00e-01 | -2.17e-01 | -1.48e-01 | -1.23e-01 | 1.62e-01 | 4.11e-03 | 1.81e-03 | 3.30e-02 | 7.81e-02 | 1.97e-02 |
| ENDOCARDIUM MORPHOGENESIS | 6 | 6.55e-01 | 1.00e+00 | 0.38800 | 1.97e-01 | 1.84e-01 | 2.79e-01 | -7.23e-03 | -2.99e-03 | 4.04e-01 | 4.35e-01 | 2.37e-01 | 9.76e-01 | 9.90e-01 |
| NEGATIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL PROLIFERATION | 10 | 6.92e-01 | 1.00e+00 | 0.38700 | -1.92e-01 | -1.93e-01 | -5.50e-02 | -2.45e-01 | 1.13e-01 | 2.93e-01 | 2.89e-01 | 7.63e-01 | 1.80e-01 | 5.37e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION OF NUCLEOLAR LARGE RRNA BY RNA POLYMERASE I | 10 | 7.48e-01 | 1.00e+00 | 0.38700 | 1.81e-01 | 1.99e-01 | 1.10e-01 | 2.23e-01 | -1.24e-01 | 3.20e-01 | 2.75e-01 | 5.46e-01 | 2.21e-01 | 4.97e-01 |
| POSITIVE REGULATION OF POST TRANSCRIPTIONAL GENE SILENCING | 14 | 2.89e-01 | 8.17e-01 | 0.38700 | -1.37e-01 | -1.06e-01 | -1.57e-01 | -9.98e-02 | -2.92e-01 | 3.74e-01 | 4.94e-01 | 3.10e-01 | 5.18e-01 | 5.82e-02 |
| RESPONSE TO MERCURY ION | 10 | 6.82e-01 | 1.00e+00 | 0.38700 | 1.69e-01 | 2.05e-01 | 9.28e-02 | 1.26e-01 | -2.34e-01 | 3.54e-01 | 2.62e-01 | 6.11e-01 | 4.91e-01 | 1.99e-01 |
| POSITIVE REGULATION OF MYOBLAST PROLIFERATION | 14 | 3.62e-01 | 8.77e-01 | 0.38700 | 1.58e-01 | 2.10e-01 | 1.57e-02 | 2.43e-01 | -1.47e-01 | 3.06e-01 | 1.73e-01 | 9.19e-01 | 1.16e-01 | 3.41e-01 |
| CELL FATE COMMITMENT INVOLVED IN PATTERN SPECIFICATION | 11 | 4.67e-01 | 9.36e-01 | 0.38700 | 1.65e-01 | 1.48e-01 | 2.75e-01 | 6.84e-03 | 1.58e-01 | 3.44e-01 | 3.95e-01 | 1.14e-01 | 9.69e-01 | 3.64e-01 |
| PROTEIN LIPOYLATION | 5 | 5.98e-01 | 9.89e-01 | 0.38700 | 1.67e-01 | 1.69e-01 | 2.80e-01 | 1.12e-01 | 4.54e-02 | 5.18e-01 | 5.12e-01 | 2.78e-01 | 6.65e-01 | 8.61e-01 |
| CYTOLYSIS BY HOST OF SYMBIONT CELLS | 7 | 8.27e-01 | 1.00e+00 | 0.38700 | -1.63e-01 | -1.81e-01 | -1.79e-01 | -1.46e-01 | -1.92e-01 | 4.56e-01 | 4.07e-01 | 4.11e-01 | 5.03e-01 | 3.80e-01 |
| CARDIAC LEFT VENTRICLE MORPHOGENESIS | 16 | 1.66e-01 | 6.70e-01 | 0.38700 | -1.57e-01 | -1.97e-01 | -6.53e-03 | -2.84e-01 | -7.35e-02 | 2.78e-01 | 1.73e-01 | 9.64e-01 | 4.89e-02 | 6.11e-01 |
| NEGATIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL PROLIFERATION INVOLVED IN SPROUTING ANGIOGENESIS | 22 | 1.46e-01 | 6.32e-01 | 0.38600 | -1.41e-01 | -1.42e-01 | -5.47e-02 | -1.42e-01 | 2.94e-01 | 2.52e-01 | 2.50e-01 | 6.57e-01 | 2.49e-01 | 1.71e-02 |
| COLLATERAL SPROUTING IN ABSENCE OF INJURY | 5 | 5.32e-01 | 9.54e-01 | 0.38600 | -1.55e-01 | -2.37e-01 | -8.54e-03 | -2.33e-01 | -1.21e-01 | 5.49e-01 | 3.58e-01 | 9.74e-01 | 3.67e-01 | 6.38e-01 |
| PROTEIN K6 LINKED UBIQUITINATION | 11 | 2.17e-01 | 7.39e-01 | 0.38600 | 1.71e-01 | 1.27e-01 | 2.37e-01 | 3.47e-02 | -2.15e-01 | 3.25e-01 | 4.67e-01 | 1.73e-01 | 8.42e-01 | 2.17e-01 |
| REGULATION OF ISOTYPE SWITCHING | 37 | 2.88e-03 | 5.12e-02 | 0.38600 | -7.69e-02 | -1.09e-01 | 1.02e-01 | -1.93e-01 | 2.90e-01 | 4.18e-01 | 2.53e-01 | 2.84e-01 | 4.24e-02 | 2.29e-03 |
| GLYCEROL 3 PHOSPHATE METABOLIC PROCESS | 7 | 2.34e-01 | 7.56e-01 | 0.38600 | -2.74e-02 | 1.29e-02 | -2.92e-01 | 1.86e-01 | -1.68e-01 | 9.00e-01 | 9.53e-01 | 1.81e-01 | 3.94e-01 | 4.41e-01 |
| REGULATION OF NEUTROPHIL MEDIATED CYTOTOXICITY | 5 | 7.78e-01 | 1.00e+00 | 0.38600 | -1.40e-01 | -1.23e-01 | -8.66e-02 | -7.98e-02 | 3.17e-01 | 5.87e-01 | 6.34e-01 | 7.37e-01 | 7.57e-01 | 2.20e-01 |
| NEGATIVE REGULATION OF HAIR FOLLICLE DEVELOPMENT | 5 | 9.23e-01 | 1.00e+00 | 0.38600 | 1.89e-01 | 2.02e-01 | 2.08e-01 | 1.66e-01 | 3.75e-02 | 4.65e-01 | 4.34e-01 | 4.20e-01 | 5.21e-01 | 8.85e-01 |
| PRIMARY ALCOHOL BIOSYNTHETIC PROCESS | 14 | 4.84e-01 | 9.43e-01 | 0.38600 | 1.94e-01 | 2.33e-01 | 1.76e-01 | 1.57e-01 | 2.88e-02 | 2.08e-01 | 1.32e-01 | 2.53e-01 | 3.08e-01 | 8.52e-01 |
| AGGRESSIVE BEHAVIOR | 7 | 4.71e-01 | 9.40e-01 | 0.38500 | -1.09e-01 | -1.20e-01 | 1.15e-02 | -2.67e-01 | -2.25e-01 | 6.18e-01 | 5.81e-01 | 9.58e-01 | 2.21e-01 | 3.03e-01 |
| POSITIVE REGULATION OF ASTROCYTE DIFFERENTIATION | 13 | 1.17e-01 | 5.69e-01 | 0.38500 | 1.73e-01 | 8.27e-02 | 3.15e-01 | 2.18e-02 | 1.09e-01 | 2.80e-01 | 6.06e-01 | 4.91e-02 | 8.92e-01 | 4.95e-01 |
| NEGATIVE REGULATION OF MYOTUBE DIFFERENTIATION | 17 | 5.66e-01 | 9.72e-01 | 0.38500 | 1.82e-01 | 1.79e-01 | 1.28e-01 | 2.12e-01 | 1.49e-01 | 1.94e-01 | 2.01e-01 | 3.60e-01 | 1.31e-01 | 2.89e-01 |
| PROTEIN POLY ADP RIBOSYLATION | 10 | 7.49e-01 | 1.00e+00 | 0.38500 | -1.75e-01 | -1.86e-01 | -1.02e-01 | -1.38e-01 | 2.32e-01 | 3.39e-01 | 3.09e-01 | 5.75e-01 | 4.49e-01 | 2.04e-01 |
| DEPYRIMIDINATION | 8 | 1.97e-01 | 7.11e-01 | 0.38500 | 1.60e-01 | 1.57e-01 | 2.83e-01 | -9.66e-02 | 9.41e-02 | 4.32e-01 | 4.41e-01 | 1.66e-01 | 6.36e-01 | 6.45e-01 |
| PHOSPHATIDYLETHANOLAMINE METABOLIC PROCESS | 28 | 5.84e-01 | 9.85e-01 | 0.38500 | 2.00e-01 | 2.03e-01 | 1.70e-01 | 1.95e-01 | 2.55e-02 | 6.68e-02 | 6.36e-02 | 1.20e-01 | 7.48e-02 | 8.15e-01 |
| CELL FATE SPECIFICATION INVOLVED IN PATTERN SPECIFICATION | 7 | 6.75e-01 | 1.00e+00 | 0.38500 | -2.53e-02 | -5.29e-02 | 1.32e-01 | -9.53e-02 | 3.44e-01 | 9.08e-01 | 8.08e-01 | 5.47e-01 | 6.62e-01 | 1.15e-01 |
| NEGATIVE REGULATION OF CELL ADHESION MOLECULE PRODUCTION | 10 | 3.48e-01 | 8.67e-01 | 0.38500 | 2.05e-01 | 1.51e-01 | 1.36e-01 | 2.12e-01 | -1.39e-01 | 2.61e-01 | 4.07e-01 | 4.56e-01 | 2.46e-01 | 4.46e-01 |
| NEGATIVE REGULATION OF GLUCOSE IMPORT | 16 | 4.88e-01 | 9.44e-01 | 0.38500 | -2.00e-01 | -2.00e-01 | -7.39e-02 | -2.32e-01 | 9.29e-02 | 1.67e-01 | 1.66e-01 | 6.09e-01 | 1.08e-01 | 5.20e-01 |
| FOREBRAIN NEUROBLAST DIVISION | 5 | 8.23e-01 | 1.00e+00 | 0.38400 | 2.01e-01 | 1.60e-01 | 1.12e-01 | 2.62e-01 | 1.09e-02 | 4.37e-01 | 5.36e-01 | 6.65e-01 | 3.10e-01 | 9.66e-01 |
| NEGATIVE REGULATION OF DENDRITE MORPHOGENESIS | 7 | 6.88e-01 | 1.00e+00 | 0.38400 | 1.85e-01 | 1.32e-01 | 1.63e-01 | 2.56e-01 | 5.79e-02 | 3.97e-01 | 5.46e-01 | 4.54e-01 | 2.40e-01 | 7.91e-01 |
| MYOBLAST FATE COMMITMENT | 6 | 5.24e-01 | 9.54e-01 | 0.38400 | 8.03e-02 | 7.48e-02 | -1.02e-01 | 2.09e-01 | -2.85e-01 | 7.33e-01 | 7.51e-01 | 6.66e-01 | 3.75e-01 | 2.27e-01 |
| MITOCHONDRIAL TRANSLATION | 130 | 2.81e-09 | 3.91e-07 | 0.38400 | 1.89e-01 | 1.67e-01 | 2.86e-01 | 4.02e-02 | 1.28e-02 | 2.02e-04 | 1.01e-03 | 1.71e-08 | 4.29e-01 | 8.01e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO CELL PERIPHERY | 29 | 1.55e-01 | 6.53e-01 | 0.38400 | -2.01e-01 | -2.32e-01 | -1.14e-01 | -1.43e-01 | 1.39e-01 | 6.15e-02 | 3.05e-02 | 2.87e-01 | 1.82e-01 | 1.94e-01 |
| ENGULFMENT OF APOPTOTIC CELL | 15 | 1.08e-01 | 5.46e-01 | 0.38400 | 8.88e-02 | 8.92e-02 | -5.29e-02 | 2.11e-01 | -2.90e-01 | 5.52e-01 | 5.50e-01 | 7.23e-01 | 1.58e-01 | 5.18e-02 |
| ECTODERMAL CELL DIFFERENTIATION | 6 | 4.06e-01 | 9.07e-01 | 0.38300 | -1.25e-01 | -1.71e-01 | 9.28e-02 | -1.14e-01 | 2.84e-01 | 5.96e-01 | 4.68e-01 | 6.94e-01 | 6.28e-01 | 2.29e-01 |
| SALIVARY GLAND DEVELOPMENT | 33 | 9.61e-02 | 5.12e-01 | 0.38300 | 1.73e-01 | 2.10e-01 | 7.10e-02 | 2.18e-01 | -1.43e-01 | 8.55e-02 | 3.64e-02 | 4.80e-01 | 3.05e-02 | 1.56e-01 |
| PTERIDINE CONTAINING COMPOUND METABOLIC PROCESS | 32 | 1.24e-01 | 5.88e-01 | 0.38300 | -1.83e-01 | -1.79e-01 | -1.12e-01 | -2.58e-01 | 4.80e-02 | 7.29e-02 | 7.91e-02 | 2.73e-01 | 1.16e-02 | 6.38e-01 |
| INTESTINAL LIPID ABSORPTION | 22 | 4.34e-02 | 3.34e-01 | 0.38300 | 1.44e-01 | 1.77e-01 | 2.12e-02 | 2.54e-01 | 1.73e-01 | 2.42e-01 | 1.50e-01 | 8.64e-01 | 3.91e-02 | 1.61e-01 |
| REGULATION OF ODONTOGENESIS OF DENTIN CONTAINING TOOTH | 12 | 2.65e-01 | 7.94e-01 | 0.38300 | 7.76e-02 | 6.54e-02 | 2.06e-01 | 6.45e-02 | 3.00e-01 | 6.42e-01 | 6.95e-01 | 2.16e-01 | 6.99e-01 | 7.23e-02 |
| DE NOVO CENTRIOLE ASSEMBLY INVOLVED IN MULTI CILIATED EPITHELIAL CELL DIFFERENTIATION | 5 | 8.91e-01 | 1.00e+00 | 0.38300 | -1.84e-01 | -2.08e-01 | -2.25e-02 | -2.52e-01 | 7.40e-02 | 4.76e-01 | 4.21e-01 | 9.31e-01 | 3.29e-01 | 7.74e-01 |
| ANTERIOR HEAD DEVELOPMENT | 7 | 7.11e-01 | 1.00e+00 | 0.38300 | -1.64e-01 | -1.59e-01 | -3.29e-02 | -2.82e-01 | 1.18e-01 | 4.52e-01 | 4.66e-01 | 8.80e-01 | 1.97e-01 | 5.89e-01 |
| WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 5 | 4.17e-01 | 9.11e-01 | 0.38300 | -6.98e-02 | -1.89e-01 | 1.11e-01 | -1.49e-01 | 2.68e-01 | 7.87e-01 | 4.65e-01 | 6.69e-01 | 5.65e-01 | 2.99e-01 |
| REGULATION OF SYNAPSE MATURATION | 20 | 7.58e-01 | 1.00e+00 | 0.38300 | 2.05e-01 | 2.08e-01 | 1.59e-01 | 1.89e-01 | -1.38e-02 | 1.12e-01 | 1.08e-01 | 2.19e-01 | 1.43e-01 | 9.15e-01 |
| INTESTINAL EPITHELIAL CELL DEVELOPMENT | 17 | 1.57e-01 | 6.54e-01 | 0.38300 | 1.34e-01 | 1.53e-01 | -3.07e-02 | 1.44e-01 | -2.88e-01 | 3.38e-01 | 2.74e-01 | 8.26e-01 | 3.03e-01 | 3.97e-02 |
| STEM CELL DIVISION | 30 | 4.36e-02 | 3.35e-01 | 0.38300 | -1.52e-01 | -1.92e-01 | 2.74e-02 | -2.01e-01 | 2.13e-01 | 1.51e-01 | 6.80e-02 | 7.95e-01 | 5.66e-02 | 4.39e-02 |
| NEGATIVE REGULATION OF LEUKOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELL | 11 | 1.44e-04 | 4.72e-03 | 0.38200 | -4.15e-02 | 9.46e-02 | -3.44e-01 | 5.05e-03 | -1.31e-01 | 8.11e-01 | 5.87e-01 | 4.81e-02 | 9.77e-01 | 4.51e-01 |
| NEGATIVE REGULATION OF PROTEIN ACETYLATION | 8 | 3.07e-02 | 2.74e-01 | 0.38200 | -1.34e-01 | -4.65e-02 | -2.34e-02 | -2.37e-01 | 2.64e-01 | 5.11e-01 | 8.20e-01 | 9.09e-01 | 2.46e-01 | 1.97e-01 |
| NEGATIVE REGULATION OF ARP2 3 COMPLEX MEDIATED ACTIN NUCLEATION | 7 | 2.89e-01 | 8.17e-01 | 0.38200 | 1.08e-01 | 9.81e-02 | 3.14e-01 | -9.94e-02 | 1.29e-01 | 6.21e-01 | 6.53e-01 | 1.51e-01 | 6.49e-01 | 5.54e-01 |
| TRANSLATIONAL READTHROUGH | 9 | 8.51e-01 | 1.00e+00 | 0.38200 | -1.94e-01 | -2.28e-01 | -1.02e-01 | -1.79e-01 | 1.19e-01 | 3.15e-01 | 2.37e-01 | 5.97e-01 | 3.51e-01 | 5.36e-01 |
| REGULATION OF ANGIOTENSIN LEVELS IN BLOOD | 8 | 2.77e-01 | 8.04e-01 | 0.38200 | -2.00e-01 | -2.38e-01 | 1.01e-03 | -2.22e-01 | 2.20e-02 | 3.28e-01 | 2.44e-01 | 9.96e-01 | 2.78e-01 | 9.14e-01 |
| POSITIVE REGULATION OF UBIQUITIN PROTEIN TRANSFERASE ACTIVITY | 19 | 6.07e-01 | 9.90e-01 | 0.38200 | 2.04e-01 | 2.15e-01 | 2.00e-01 | 1.32e-01 | 1.92e-02 | 1.24e-01 | 1.05e-01 | 1.31e-01 | 3.19e-01 | 8.85e-01 |
| NEGATIVE REGULATION OF ADAPTIVE IMMUNE RESPONSE | 62 | 7.15e-02 | 4.39e-01 | 0.38200 | -1.98e-01 | -2.19e-01 | -1.28e-01 | -1.97e-01 | 5.83e-02 | 7.00e-03 | 2.87e-03 | 8.15e-02 | 7.36e-03 | 4.27e-01 |
| REGULATION OF SPINDLE ASSEMBLY | 32 | 9.66e-02 | 5.12e-01 | 0.38100 | 1.44e-01 | 1.27e-01 | 2.43e-01 | 6.07e-02 | 2.14e-01 | 1.58e-01 | 2.15e-01 | 1.73e-02 | 5.52e-01 | 3.62e-02 |
| PYRIMIDINE DEOXYRIBONUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 6 | 5.26e-01 | 9.54e-01 | 0.38100 | 9.81e-02 | 1.54e-03 | 2.92e-01 | -2.08e-02 | 2.23e-01 | 6.77e-01 | 9.95e-01 | 2.15e-01 | 9.30e-01 | 3.44e-01 |
| SERTOLI CELL DEVELOPMENT | 12 | 1.23e-01 | 5.86e-01 | 0.38100 | 1.28e-01 | 1.12e-01 | 1.18e-01 | 1.52e-01 | -2.81e-01 | 4.42e-01 | 5.01e-01 | 4.77e-01 | 3.63e-01 | 9.13e-02 |
| REGULATION OF B CELL DIFFERENTIATION | 31 | 5.15e-03 | 7.88e-02 | 0.38100 | 8.98e-02 | 8.39e-03 | 2.61e-01 | -1.52e-02 | 2.62e-01 | 3.87e-01 | 9.36e-01 | 1.18e-02 | 8.84e-01 | 1.16e-02 |
| ERBB4 SIGNALING PATHWAY | 10 | 7.74e-01 | 1.00e+00 | 0.38100 | -1.87e-01 | -1.70e-01 | -2.63e-01 | -8.77e-02 | -6.80e-02 | 3.07e-01 | 3.52e-01 | 1.50e-01 | 6.31e-01 | 7.09e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 1 ALPHA PRODUCTION | 5 | 9.13e-01 | 1.00e+00 | 0.38100 | -1.98e-01 | -1.45e-01 | -2.02e-01 | -1.78e-01 | -1.11e-01 | 4.43e-01 | 5.74e-01 | 4.35e-01 | 4.90e-01 | 6.67e-01 |
| NEGATIVE REGULATION OF MYOBLAST PROLIFERATION | 9 | 6.20e-01 | 9.90e-01 | 0.38100 | -1.58e-01 | -1.25e-01 | -2.88e-01 | -7.01e-02 | -1.27e-01 | 4.11e-01 | 5.16e-01 | 1.34e-01 | 7.16e-01 | 5.09e-01 |
| REGULATION OF GLUCOCORTICOID SECRETION | 10 | 7.81e-01 | 1.00e+00 | 0.38100 | 1.52e-01 | 1.35e-01 | 2.23e-01 | 8.25e-02 | 2.17e-01 | 4.06e-01 | 4.58e-01 | 2.23e-01 | 6.51e-01 | 2.35e-01 |
| RETROTRANSPOSON SILENCING BY HETEROCHROMATIN FORMATION | 15 | 4.97e-02 | 3.63e-01 | 0.38100 | -3.14e-02 | -4.24e-02 | -1.94e-01 | 6.48e-02 | -3.16e-01 | 8.33e-01 | 7.76e-01 | 1.93e-01 | 6.64e-01 | 3.39e-02 |
| NEGATIVE REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 6 | 8.05e-01 | 1.00e+00 | 0.38000 | -1.97e-01 | -2.14e-01 | -5.55e-02 | -1.80e-01 | 1.56e-01 | 4.02e-01 | 3.63e-01 | 8.14e-01 | 4.45e-01 | 5.09e-01 |
| POSITIVE REGULATION OF TELOMERASE RNA LOCALIZATION TO CAJAL BODY | 14 | 4.01e-01 | 9.01e-01 | 0.38000 | -1.67e-01 | -1.85e-01 | 1.80e-03 | -2.28e-01 | 1.72e-01 | 2.78e-01 | 2.30e-01 | 9.91e-01 | 1.39e-01 | 2.64e-01 |
| I KAPPAB PHOSPHORYLATION | 15 | 4.26e-01 | 9.15e-01 | 0.37900 | 1.58e-01 | 1.53e-01 | 7.82e-02 | 1.62e-01 | -2.52e-01 | 2.90e-01 | 3.05e-01 | 6.00e-01 | 2.77e-01 | 9.17e-02 |
| VENTRICULAR TRABECULA MYOCARDIUM MORPHOGENESIS | 14 | 4.89e-01 | 9.44e-01 | 0.37900 | -1.68e-01 | -2.01e-01 | -2.72e-02 | -2.65e-01 | 6.96e-02 | 2.78e-01 | 1.94e-01 | 8.60e-01 | 8.64e-02 | 6.52e-01 |
| MEIOTIC SPINDLE ASSEMBLY | 12 | 7.06e-03 | 9.75e-02 | 0.37900 | 1.23e-01 | 2.66e-02 | 3.20e-01 | -1.53e-01 | 4.70e-02 | 4.59e-01 | 8.73e-01 | 5.53e-02 | 3.60e-01 | 7.78e-01 |
| ANTEROGRADE NEURONAL DENSE CORE VESICLE TRANSPORT | 6 | 8.31e-01 | 1.00e+00 | 0.37900 | 1.36e-01 | 1.11e-01 | 2.24e-01 | 2.70e-02 | 2.49e-01 | 5.65e-01 | 6.38e-01 | 3.42e-01 | 9.09e-01 | 2.92e-01 |
| ORNITHINE TRANSPORT | 6 | 7.35e-01 | 1.00e+00 | 0.37900 | -1.81e-01 | -1.39e-01 | -1.04e-01 | -2.78e-01 | -5.64e-02 | 4.42e-01 | 5.56e-01 | 6.59e-01 | 2.39e-01 | 8.11e-01 |
| URINARY TRACT SMOOTH MUSCLE CONTRACTION | 9 | 8.53e-01 | 1.00e+00 | 0.37900 | 1.98e-01 | 1.85e-01 | 1.79e-01 | 1.41e-01 | -1.34e-01 | 3.04e-01 | 3.37e-01 | 3.53e-01 | 4.63e-01 | 4.86e-01 |
| PEPTIDYL TYROSINE AUTOPHOSPHORYLATION | 18 | 6.45e-01 | 1.00e+00 | 0.37900 | 1.88e-01 | 2.02e-01 | 1.44e-01 | 1.90e-01 | 1.03e-01 | 1.68e-01 | 1.39e-01 | 2.91e-01 | 1.62e-01 | 4.49e-01 |
| LIVER REGENERATION | 28 | 8.13e-03 | 1.08e-01 | 0.37800 | 4.73e-02 | -1.92e-02 | 2.54e-01 | -6.86e-02 | 2.67e-01 | 6.65e-01 | 8.60e-01 | 2.01e-02 | 5.30e-01 | 1.43e-02 |
| MATURATION OF 5 8S RRNA | 35 | 1.13e-01 | 5.59e-01 | 0.37800 | 1.70e-01 | 1.45e-01 | 2.46e-01 | 6.70e-02 | 1.69e-01 | 8.19e-02 | 1.37e-01 | 1.19e-02 | 4.93e-01 | 8.41e-02 |
| SULFUR COMPOUND CATABOLIC PROCESS | 35 | 1.86e-01 | 6.94e-01 | 0.37800 | 1.77e-01 | 1.91e-01 | 1.33e-01 | 2.22e-01 | 9.15e-02 | 6.97e-02 | 5.05e-02 | 1.73e-01 | 2.33e-02 | 3.49e-01 |
| POSITIVE REGULATION OF FATTY ACID OXIDATION | 14 | 7.61e-01 | 1.00e+00 | 0.37800 | 1.96e-01 | 1.92e-01 | 2.24e-01 | 1.32e-01 | 1.34e-02 | 2.05e-01 | 2.13e-01 | 1.47e-01 | 3.92e-01 | 9.31e-01 |
| POLAR BODY EXTRUSION AFTER MEIOTIC DIVISIONS | 5 | 8.99e-01 | 1.00e+00 | 0.37800 | -1.00e-01 | -9.12e-02 | -1.65e-01 | -8.36e-02 | -3.00e-01 | 6.97e-01 | 7.24e-01 | 5.22e-01 | 7.46e-01 | 2.45e-01 |
| CELLULAR RESPONSE TO COPPER ION | 25 | 1.52e-01 | 6.46e-01 | 0.37800 | 1.72e-01 | 1.18e-01 | 2.81e-01 | 6.76e-02 | 1.27e-01 | 1.37e-01 | 3.09e-01 | 1.51e-02 | 5.58e-01 | 2.70e-01 |
| HISTIDINE CATABOLIC PROCESS | 8 | 5.38e-01 | 9.57e-01 | 0.37800 | -6.90e-02 | -8.52e-02 | 5.49e-02 | -1.62e-01 | 3.18e-01 | 7.35e-01 | 6.76e-01 | 7.88e-01 | 4.27e-01 | 1.19e-01 |
| REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION | 77 | 6.66e-04 | 1.63e-02 | 0.37700 | 1.62e-01 | 1.11e-01 | 2.61e-01 | 9.40e-02 | 1.64e-01 | 1.38e-02 | 9.17e-02 | 7.48e-05 | 1.54e-01 | 1.29e-02 |
| REGULATION OF RESPONSE TO FOOD | 14 | 3.93e-01 | 8.92e-01 | 0.37700 | -1.79e-01 | -1.34e-01 | -1.65e-01 | -2.46e-01 | -6.66e-02 | 2.46e-01 | 3.85e-01 | 2.85e-01 | 1.10e-01 | 6.66e-01 |
| POSITIVE REGULATION OF SMOOTH MUSCLE CONTRACTION | 30 | 4.11e-01 | 9.08e-01 | 0.37700 | 1.92e-01 | 1.91e-01 | 1.47e-01 | 2.11e-01 | -5.11e-02 | 6.85e-02 | 6.98e-02 | 1.63e-01 | 4.54e-02 | 6.28e-01 |
| CANONICAL WNT SIGNALING PATHWAY INVOLVED IN CARDIAC MUSCLE CELL FATE COMMITMENT | 5 | 3.84e-01 | 8.92e-01 | 0.37700 | 4.95e-02 | -4.64e-03 | 1.27e-01 | -1.35e-01 | -3.24e-01 | 8.48e-01 | 9.86e-01 | 6.22e-01 | 6.01e-01 | 2.09e-01 |
| POSITIVE REGULATION OF VASOCONSTRICTION | 30 | 1.04e-01 | 5.36e-01 | 0.37700 | 1.47e-01 | 1.56e-01 | 5.48e-02 | 1.54e-01 | -2.64e-01 | 1.65e-01 | 1.40e-01 | 6.04e-01 | 1.44e-01 | 1.24e-02 |
| GLYCOSIDE CATABOLIC PROCESS | 8 | 8.66e-01 | 1.00e+00 | 0.37700 | 1.73e-01 | 1.39e-01 | 2.46e-01 | 8.26e-02 | 1.59e-01 | 3.96e-01 | 4.96e-01 | 2.28e-01 | 6.86e-01 | 4.35e-01 |
| DCMP CATABOLIC PROCESS | 6 | 9.07e-01 | 1.00e+00 | 0.37700 | -2.04e-01 | -1.57e-01 | -2.22e-01 | -1.63e-01 | 4.62e-03 | 3.87e-01 | 5.05e-01 | 3.46e-01 | 4.91e-01 | 9.84e-01 |
| REGULATION OF CYTOPLASMIC TRANSLATIONAL INITIATION | 7 | 6.45e-01 | 1.00e+00 | 0.37700 | 3.81e-02 | 9.58e-02 | -6.13e-02 | 3.55e-02 | -3.56e-01 | 8.61e-01 | 6.61e-01 | 7.79e-01 | 8.71e-01 | 1.03e-01 |
| NEGATIVE REGULATION OF VIRAL LIFE CYCLE | 26 | 3.63e-01 | 8.78e-01 | 0.37700 | -1.84e-01 | -1.89e-01 | -1.33e-01 | -1.84e-01 | 1.44e-01 | 1.04e-01 | 9.50e-02 | 2.40e-01 | 1.05e-01 | 2.03e-01 |
| REVERSIBLE DIFFERENTIATION | 11 | 6.04e-01 | 9.90e-01 | 0.37700 | 1.80e-01 | 1.27e-01 | 2.84e-01 | 7.62e-02 | 8.45e-02 | 3.01e-01 | 4.66e-01 | 1.03e-01 | 6.62e-01 | 6.28e-01 |
| PROTEIN LOCALIZATION TO ADHERENS JUNCTION | 6 | 9.68e-01 | 1.00e+00 | 0.37700 | -1.95e-01 | -1.98e-01 | -1.89e-01 | -1.71e-01 | -7.59e-03 | 4.09e-01 | 4.02e-01 | 4.23e-01 | 4.68e-01 | 9.74e-01 |
| FERMENTATION | 5 | 5.43e-01 | 9.60e-01 | 0.37700 | -4.74e-02 | 3.26e-02 | -8.75e-02 | -1.62e-01 | -3.23e-01 | 8.54e-01 | 9.00e-01 | 7.35e-01 | 5.30e-01 | 2.11e-01 |
| REGULATION OF PROTEIN AUTOUBIQUITINATION | 5 | 6.75e-01 | 1.00e+00 | 0.37700 | -1.87e-01 | -2.20e-01 | -1.69e-01 | -7.30e-02 | -1.57e-01 | 4.69e-01 | 3.95e-01 | 5.13e-01 | 7.77e-01 | 5.42e-01 |
| HEPATIC STELLATE CELL ACTIVATION | 9 | 5.17e-01 | 9.52e-01 | 0.37600 | -1.94e-01 | -2.14e-01 | -2.94e-02 | -2.40e-01 | 4.31e-03 | 3.13e-01 | 2.67e-01 | 8.79e-01 | 2.13e-01 | 9.82e-01 |
| RIBOSOMAL LARGE SUBUNIT EXPORT FROM NUCLEUS | 7 | 2.67e-02 | 2.49e-01 | 0.37600 | 8.44e-02 | 7.16e-02 | 2.33e-01 | -2.69e-01 | 5.25e-02 | 6.99e-01 | 7.43e-01 | 2.85e-01 | 2.18e-01 | 8.10e-01 |
| POSITIVE REGULATION OF AUTOPHAGOSOME MATURATION | 7 | 8.72e-01 | 1.00e+00 | 0.37600 | -1.82e-01 | -1.59e-01 | -1.42e-01 | -2.48e-01 | -3.76e-02 | 4.05e-01 | 4.66e-01 | 5.16e-01 | 2.55e-01 | 8.63e-01 |
| NEGATIVE REGULATION OF VOLTAGE GATED POTASSIUM CHANNEL ACTIVITY | 18 | 7.56e-01 | 1.00e+00 | 0.37600 | -1.93e-01 | -1.88e-01 | -1.71e-01 | -1.73e-01 | -9.87e-02 | 1.56e-01 | 1.66e-01 | 2.10e-01 | 2.04e-01 | 4.68e-01 |
| REGULATION OF VIRAL TRANSCRIPTION | 18 | 2.85e-01 | 8.12e-01 | 0.37600 | 8.39e-02 | 6.50e-02 | 1.77e-01 | 2.96e-02 | 3.13e-01 | 5.38e-01 | 6.33e-01 | 1.93e-01 | 8.28e-01 | 2.16e-02 |
| REGULATION OF HYALURONAN BIOSYNTHETIC PROCESS | 8 | 3.84e-01 | 8.92e-01 | 0.37600 | -1.57e-01 | -1.23e-01 | -2.86e-02 | -1.85e-01 | 2.58e-01 | 4.43e-01 | 5.46e-01 | 8.88e-01 | 3.64e-01 | 2.07e-01 |
| TYPE II HYPERSENSITIVITY | 5 | 2.94e-01 | 8.22e-01 | 0.37600 | -9.14e-02 | -2.02e-01 | 1.90e-01 | -1.90e-01 | 1.41e-01 | 7.23e-01 | 4.34e-01 | 4.62e-01 | 4.62e-01 | 5.86e-01 |
| MEMBRANE DEPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 22 | 2.06e-01 | 7.27e-01 | 0.37600 | 1.76e-01 | 2.32e-01 | 5.81e-02 | 2.02e-01 | -1.10e-01 | 1.53e-01 | 5.95e-02 | 6.37e-01 | 1.01e-01 | 3.74e-01 |
| RESPONSE TO HISTAMINE | 11 | 6.24e-01 | 9.93e-01 | 0.37600 | 1.59e-01 | 1.29e-01 | 2.77e-01 | 6.03e-02 | 1.38e-01 | 3.61e-01 | 4.59e-01 | 1.12e-01 | 7.29e-01 | 4.29e-01 |
| MYELOID DENDRITIC CELL DIFFERENTIATION | 20 | 1.42e-01 | 6.28e-01 | 0.37500 | -1.88e-01 | -1.89e-01 | -1.67e-01 | -5.35e-02 | 1.98e-01 | 1.45e-01 | 1.44e-01 | 1.97e-01 | 6.79e-01 | 1.25e-01 |
| LUNG CELL DIFFERENTIATION | 28 | 1.30e-01 | 5.98e-01 | 0.37500 | 1.67e-01 | 1.64e-01 | 1.31e-01 | 1.36e-01 | -2.24e-01 | 1.27e-01 | 1.33e-01 | 2.29e-01 | 2.13e-01 | 3.98e-02 |
| GAMMA AMINOBUTYRIC ACID BIOSYNTHETIC PROCESS | 6 | 7.59e-01 | 1.00e+00 | 0.37500 | 5.34e-02 | -3.99e-03 | 2.17e-01 | -3.61e-03 | 3.01e-01 | 8.21e-01 | 9.86e-01 | 3.56e-01 | 9.88e-01 | 2.02e-01 |
| POSITIVE REGULATION BY HOST OF VIRAL TRANSCRIPTION | 17 | 6.43e-01 | 1.00e+00 | 0.37500 | 1.73e-01 | 1.40e-01 | 2.28e-01 | 1.11e-01 | 1.64e-01 | 2.16e-01 | 3.18e-01 | 1.03e-01 | 4.29e-01 | 2.42e-01 |
| POSITIVE REGULATION OF CHROMATIN BINDING | 9 | 7.38e-01 | 1.00e+00 | 0.37500 | 1.92e-01 | 1.89e-01 | 2.51e-01 | 6.56e-02 | -2.24e-02 | 3.17e-01 | 3.25e-01 | 1.92e-01 | 7.33e-01 | 9.07e-01 |
| SUBSTRATE DEPENDENT CELL MIGRATION | 25 | 4.80e-01 | 9.42e-01 | 0.37500 | -1.64e-01 | -1.51e-01 | -2.00e-01 | -1.43e-01 | -1.74e-01 | 1.55e-01 | 1.92e-01 | 8.35e-02 | 2.15e-01 | 1.33e-01 |
| NEUTROPHIL MIGRATION | 121 | 2.08e-04 | 6.41e-03 | 0.37500 | -2.01e-01 | -2.26e-01 | -1.30e-01 | -1.60e-01 | 8.09e-02 | 1.31e-04 | 1.76e-05 | 1.36e-02 | 2.43e-03 | 1.24e-01 |
| EMBRYONIC CAMERA TYPE EYE FORMATION | 11 | 7.22e-01 | 1.00e+00 | 0.37500 | 1.90e-01 | 1.41e-01 | 2.45e-01 | 1.45e-01 | 5.53e-02 | 2.75e-01 | 4.18e-01 | 1.59e-01 | 4.03e-01 | 7.51e-01 |
| VITAMIN BIOSYNTHETIC PROCESS | 24 | 6.34e-01 | 9.97e-01 | 0.37500 | 1.99e-01 | 1.80e-01 | 1.78e-01 | 1.92e-01 | 6.62e-03 | 9.15e-02 | 1.28e-01 | 1.32e-01 | 1.04e-01 | 9.55e-01 |
| CELLULAR RESPONSE TO TESTOSTERONE STIMULUS | 9 | 8.24e-01 | 1.00e+00 | 0.37400 | -1.79e-01 | -1.97e-01 | -1.27e-01 | -2.30e-01 | 3.84e-04 | 3.52e-01 | 3.07e-01 | 5.08e-01 | 2.32e-01 | 9.98e-01 |
| RIBONUCLEOSIDE DIPHOSPHATE CATABOLIC PROCESS | 8 | 7.13e-01 | 1.00e+00 | 0.37400 | 1.39e-01 | 1.37e-01 | 7.67e-02 | 1.29e-01 | -2.82e-01 | 4.97e-01 | 5.03e-01 | 7.07e-01 | 5.28e-01 | 1.67e-01 |
| SKELETAL MUSCLE ATROPHY | 5 | 7.81e-01 | 1.00e+00 | 0.37400 | 2.18e-03 | 2.75e-02 | -1.04e-01 | -4.37e-02 | -3.56e-01 | 9.93e-01 | 9.15e-01 | 6.89e-01 | 8.66e-01 | 1.68e-01 |
| NEGATIVE REGULATION OF SINGLE STRANDED VIRAL RNA REPLICATION VIA DOUBLE STRANDED DNA INTERMEDIATE | 16 | 2.22e-01 | 7.45e-01 | 0.37400 | -1.66e-01 | -1.50e-01 | -3.33e-02 | -2.25e-01 | 1.95e-01 | 2.50e-01 | 3.00e-01 | 8.18e-01 | 1.19e-01 | 1.76e-01 |
| POSITIVE REGULATION OF RESPONSE TO TYPE II INTERFERON | 6 | 7.86e-01 | 1.00e+00 | 0.37400 | 1.29e-01 | 1.13e-01 | 2.32e-01 | -8.23e-04 | 2.38e-01 | 5.84e-01 | 6.31e-01 | 3.26e-01 | 9.97e-01 | 3.12e-01 |
| MATURE B CELL DIFFERENTIATION | 35 | 3.17e-03 | 5.49e-02 | 0.37400 | -1.28e-01 | -1.80e-01 | 8.32e-02 | -1.97e-01 | 2.13e-01 | 1.89e-01 | 6.54e-02 | 3.94e-01 | 4.36e-02 | 2.93e-02 |
| POSITIVE REGULATION BY HOST OF VIRAL GENOME REPLICATION | 10 | 2.97e-01 | 8.24e-01 | 0.37400 | -5.69e-02 | -1.39e-01 | 1.59e-01 | -1.57e-01 | 2.59e-01 | 7.55e-01 | 4.47e-01 | 3.84e-01 | 3.90e-01 | 1.55e-01 |
| REGULATION OF MITOTIC NUCLEAR DIVISION | 118 | 1.80e-04 | 5.63e-03 | 0.37400 | 1.84e-01 | 1.60e-01 | 2.50e-01 | 1.14e-01 | 7.05e-02 | 5.44e-04 | 2.76e-03 | 2.79e-06 | 3.25e-02 | 1.86e-01 |
| REGULATION OF AXON GUIDANCE | 13 | 4.54e-01 | 9.31e-01 | 0.37400 | -1.58e-01 | -1.38e-01 | -1.24e-01 | -2.61e-01 | -1.10e-01 | 3.23e-01 | 3.88e-01 | 4.38e-01 | 1.04e-01 | 4.93e-01 |
| POSITIVE REGULATION OF PROTEIN K63 LINKED UBIQUITINATION | 7 | 8.71e-01 | 1.00e+00 | 0.37400 | -1.82e-01 | -2.14e-01 | -1.04e-01 | -1.30e-01 | 1.81e-01 | 4.05e-01 | 3.27e-01 | 6.33e-01 | 5.52e-01 | 4.06e-01 |
| FORMATION OF TRANSLATION PREINITIATION COMPLEX | 7 | 6.58e-01 | 1.00e+00 | 0.37300 | 1.41e-01 | 8.48e-02 | 2.57e-01 | 1.32e-01 | 1.70e-01 | 5.18e-01 | 6.98e-01 | 2.40e-01 | 5.44e-01 | 4.36e-01 |
| CANONICAL WNT SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 6 | 3.64e-01 | 8.79e-01 | 0.37300 | -5.61e-02 | -1.17e-01 | 9.28e-03 | -1.51e-01 | -3.16e-01 | 8.12e-01 | 6.21e-01 | 9.69e-01 | 5.23e-01 | 1.80e-01 |
| REGULATION OF LIPOPROTEIN PARTICLE CLEARANCE | 35 | 1.85e-01 | 6.93e-01 | 0.37300 | 1.97e-01 | 2.14e-01 | 1.40e-01 | 1.33e-01 | -1.32e-01 | 4.41e-02 | 2.83e-02 | 1.51e-01 | 1.74e-01 | 1.76e-01 |
| NUCLEAR PORE LOCALIZATION | 5 | 9.29e-01 | 1.00e+00 | 0.37300 | 1.50e-01 | 1.24e-01 | 1.47e-01 | 2.11e-01 | 1.89e-01 | 5.63e-01 | 6.32e-01 | 5.70e-01 | 4.14e-01 | 4.65e-01 |
| REGULATION OF RECEPTOR CATABOLIC PROCESS | 11 | 5.96e-01 | 9.88e-01 | 0.37300 | 1.80e-01 | 2.23e-01 | 1.40e-01 | 1.78e-01 | 7.75e-02 | 3.02e-01 | 2.01e-01 | 4.21e-01 | 3.07e-01 | 6.56e-01 |
| ADENYLATE CYCLASE INHIBITING G PROTEIN COUPLED ACETYLCHOLINE RECEPTOR SIGNALING PATHWAY | 8 | 8.33e-01 | 1.00e+00 | 0.37300 | -1.32e-01 | -1.00e-01 | -2.30e-01 | -8.54e-02 | -2.27e-01 | 5.18e-01 | 6.24e-01 | 2.60e-01 | 6.76e-01 | 2.67e-01 |
| INTRACELLULAR MONOATOMIC ANION HOMEOSTASIS | 10 | 7.91e-01 | 1.00e+00 | 0.37300 | -1.82e-01 | -1.73e-01 | -1.42e-01 | -1.77e-01 | -1.56e-01 | 3.19e-01 | 3.43e-01 | 4.38e-01 | 3.31e-01 | 3.92e-01 |
| MITOTIC DNA REPLICATION | 15 | 1.16e-01 | 5.67e-01 | 0.37300 | 9.16e-02 | 6.40e-02 | 2.52e-01 | -9.31e-02 | 2.33e-01 | 5.39e-01 | 6.68e-01 | 9.07e-02 | 5.32e-01 | 1.18e-01 |
| REGULATION OF NEUTROPHIL ACTIVATION | 15 | 2.46e-02 | 2.34e-01 | 0.37300 | -4.36e-02 | -1.12e-01 | 1.89e-01 | -6.80e-02 | 2.90e-01 | 7.70e-01 | 4.54e-01 | 2.05e-01 | 6.48e-01 | 5.16e-02 |
| IRON IMPORT INTO CELL | 10 | 6.73e-01 | 1.00e+00 | 0.37200 | -1.77e-01 | -1.86e-01 | -1.90e-01 | -9.29e-02 | -1.67e-01 | 3.33e-01 | 3.09e-01 | 2.97e-01 | 6.11e-01 | 3.59e-01 |
| MYELIN MAINTENANCE | 17 | 2.37e-01 | 7.60e-01 | 0.37200 | 1.26e-01 | 1.28e-01 | 2.27e-01 | 5.33e-02 | 2.28e-01 | 3.70e-01 | 3.61e-01 | 1.04e-01 | 7.04e-01 | 1.04e-01 |
| INNATE IMMUNE RESPONSE IN MUCOSA | 26 | 6.52e-06 | 3.23e-04 | 0.37200 | -1.68e-02 | -3.67e-02 | 1.24e-01 | 9.68e-02 | 3.35e-01 | 8.82e-01 | 7.46e-01 | 2.76e-01 | 3.93e-01 | 3.12e-03 |
| POSITIVE REGULATION OF B CELL PROLIFERATION | 43 | 1.22e-01 | 5.82e-01 | 0.37200 | -1.82e-01 | -2.00e-01 | -6.66e-02 | -2.18e-01 | 1.15e-01 | 3.91e-02 | 2.30e-02 | 4.50e-01 | 1.35e-02 | 1.90e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO OSMOTIC STRESS | 10 | 8.66e-01 | 1.00e+00 | 0.37200 | 1.89e-01 | 1.51e-01 | 2.34e-01 | 1.32e-01 | 8.98e-02 | 3.02e-01 | 4.10e-01 | 2.01e-01 | 4.71e-01 | 6.23e-01 |
| NEGATIVE REGULATION OF MIRNA METABOLIC PROCESS | 26 | 2.20e-01 | 7.43e-01 | 0.37200 | 1.82e-01 | 1.93e-01 | 2.27e-01 | 1.10e-01 | 6.36e-02 | 1.08e-01 | 8.87e-02 | 4.48e-02 | 3.30e-01 | 5.74e-01 |
| REGULATION OF ENTRY OF BACTERIUM INTO HOST CELL | 7 | 7.33e-01 | 1.00e+00 | 0.37200 | -1.43e-01 | -1.11e-01 | -1.51e-01 | -1.15e-01 | -2.64e-01 | 5.13e-01 | 6.12e-01 | 4.90e-01 | 5.99e-01 | 2.26e-01 |
| PURINE DEOXYRIBONUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 6 | 6.58e-01 | 1.00e+00 | 0.37200 | 2.20e-02 | -3.07e-02 | 2.27e-01 | -1.22e-01 | 2.65e-01 | 9.26e-01 | 8.96e-01 | 3.36e-01 | 6.05e-01 | 2.60e-01 |
| BASE CONVERSION OR SUBSTITUTION EDITING | 19 | 1.12e-01 | 5.56e-01 | 0.37100 | -1.99e-01 | -1.47e-01 | -1.58e-01 | -1.80e-01 | 1.38e-01 | 1.32e-01 | 2.67e-01 | 2.33e-01 | 1.74e-01 | 2.98e-01 |
| RESPONSE TO THYROGLOBULIN TRIIODOTHYRONINE | 5 | 8.33e-01 | 1.00e+00 | 0.37100 | -6.12e-02 | -6.27e-02 | -9.44e-02 | -7.79e-02 | -3.39e-01 | 8.13e-01 | 8.08e-01 | 7.15e-01 | 7.63e-01 | 1.89e-01 |
| GALACTOSE CATABOLIC PROCESS | 5 | 3.98e-01 | 8.97e-01 | 0.37100 | 1.61e-01 | 2.69e-01 | 7.45e-02 | 1.40e-01 | -1.20e-01 | 5.34e-01 | 2.97e-01 | 7.73e-01 | 5.88e-01 | 6.42e-01 |
| TAURINE TRANSPORT | 8 | 6.84e-01 | 1.00e+00 | 0.37100 | 1.33e-01 | 1.59e-01 | 8.15e-02 | 1.14e-01 | -2.74e-01 | 5.16e-01 | 4.36e-01 | 6.90e-01 | 5.76e-01 | 1.79e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO CELL SURFACE | 11 | 8.28e-01 | 1.00e+00 | 0.37100 | 2.00e-01 | 2.25e-01 | 1.19e-01 | 1.80e-01 | -2.69e-02 | 2.52e-01 | 1.97e-01 | 4.94e-01 | 3.01e-01 | 8.77e-01 |
| POSITIVE REGULATION OF ORGAN GROWTH | 47 | 1.21e-03 | 2.67e-02 | 0.37100 | 1.56e-01 | 1.51e-01 | 1.52e-01 | 3.91e-02 | -2.56e-01 | 6.35e-02 | 7.24e-02 | 7.14e-02 | 6.43e-01 | 2.38e-03 |
| PERIPHERAL NERVOUS SYSTEM MYELIN MAINTENANCE | 9 | 3.48e-01 | 8.67e-01 | 0.37100 | 8.21e-02 | 1.18e-01 | 9.10e-02 | 1.37e-01 | 3.00e-01 | 6.70e-01 | 5.40e-01 | 6.36e-01 | 4.76e-01 | 1.20e-01 |
| REGULATION OF GLYCOGEN CATABOLIC PROCESS | 7 | 2.67e-01 | 7.95e-01 | 0.37100 | 1.42e-01 | 8.93e-02 | 3.19e-01 | -8.37e-03 | -8.60e-02 | 5.15e-01 | 6.83e-01 | 1.44e-01 | 9.69e-01 | 6.94e-01 |
| ERBB2 EGFR SIGNALING PATHWAY | 8 | 2.34e-01 | 7.56e-01 | 0.37100 | 1.15e-01 | 1.46e-01 | 2.66e-02 | 2.63e-01 | -1.82e-01 | 5.73e-01 | 4.74e-01 | 8.96e-01 | 1.98e-01 | 3.73e-01 |
| REGULATION OF GROWTH RATE | 5 | 9.58e-01 | 1.00e+00 | 0.37100 | 1.62e-01 | 1.41e-01 | 1.47e-01 | 1.90e-01 | 1.83e-01 | 5.31e-01 | 5.84e-01 | 5.70e-01 | 4.61e-01 | 4.79e-01 |
| ENDODERMAL CELL FATE COMMITMENT | 15 | 1.26e-01 | 5.91e-01 | 0.37000 | -1.02e-02 | 1.50e-02 | -1.03e-02 | -1.35e-01 | -3.44e-01 | 9.45e-01 | 9.20e-01 | 9.45e-01 | 3.66e-01 | 2.10e-02 |
| NEUROEPITHELIAL CELL DIFFERENTIATION | 38 | 2.11e-02 | 2.16e-01 | 0.37000 | 1.91e-01 | 1.76e-01 | 2.45e-01 | 4.72e-02 | -8.47e-02 | 4.11e-02 | 6.08e-02 | 8.98e-03 | 6.15e-01 | 3.66e-01 |
| PURINE NUCLEOBASE TRANSMEMBRANE TRANSPORT | 8 | 6.22e-01 | 9.91e-01 | 0.37000 | 1.58e-01 | 2.07e-01 | 7.70e-02 | 2.34e-01 | 8.97e-02 | 4.39e-01 | 3.10e-01 | 7.06e-01 | 2.51e-01 | 6.60e-01 |
| RECEPTOR GUANYLYL CYCLASE SIGNALING PATHWAY | 10 | 7.21e-01 | 1.00e+00 | 0.37000 | 1.70e-01 | 1.82e-01 | 9.48e-02 | 2.48e-01 | -6.60e-02 | 3.52e-01 | 3.18e-01 | 6.04e-01 | 1.75e-01 | 7.18e-01 |
| POSITIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL PROLIFERATION | 49 | 8.61e-02 | 4.84e-01 | 0.37000 | 2.02e-01 | 2.16e-01 | 1.16e-01 | 1.74e-01 | -7.25e-02 | 1.43e-02 | 8.76e-03 | 1.60e-01 | 3.50e-02 | 3.80e-01 |
| CARNITINE METABOLIC PROCESS | 11 | 7.38e-01 | 1.00e+00 | 0.37000 | 1.54e-01 | 1.40e-01 | 1.19e-01 | 2.16e-01 | 1.80e-01 | 3.76e-01 | 4.20e-01 | 4.94e-01 | 2.14e-01 | 3.02e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 2 PRODUCTION | 33 | 8.99e-02 | 4.95e-01 | 0.37000 | -1.98e-01 | -2.22e-01 | -7.69e-02 | -2.05e-01 | 1.42e-02 | 4.87e-02 | 2.75e-02 | 4.44e-01 | 4.14e-02 | 8.88e-01 |
| OLFACTORY BULB INTERNEURON DEVELOPMENT | 7 | 5.02e-01 | 9.48e-01 | 0.37000 | -1.81e-01 | -2.21e-01 | -1.82e-01 | -5.73e-02 | -1.38e-01 | 4.07e-01 | 3.12e-01 | 4.06e-01 | 7.93e-01 | 5.27e-01 |
| TNFSF11 MEDIATED SIGNALING PATHWAY | 5 | 6.60e-01 | 1.00e+00 | 0.37000 | 2.02e-02 | 1.54e-02 | 1.34e-01 | 6.15e-02 | 3.38e-01 | 9.38e-01 | 9.52e-01 | 6.03e-01 | 8.12e-01 | 1.91e-01 |
| REGULATION OF MESENCHYMAL STEM CELL DIFFERENTIATION | 8 | 5.47e-01 | 9.61e-01 | 0.36900 | -1.36e-01 | -1.28e-01 | -7.41e-02 | -1.72e-01 | -2.58e-01 | 5.05e-01 | 5.32e-01 | 7.17e-01 | 4.01e-01 | 2.06e-01 |
| REGULATION OF TERMINATION OF DNA TEMPLATED TRANSCRIPTION | 5 | 9.26e-01 | 1.00e+00 | 0.36900 | -1.96e-01 | -2.35e-01 | -9.69e-02 | -1.81e-01 | 2.08e-02 | 4.47e-01 | 3.63e-01 | 7.07e-01 | 4.84e-01 | 9.36e-01 |
| BRANCHING INVOLVED IN PROSTATE GLAND MORPHOGENESIS | 12 | 5.23e-01 | 9.53e-01 | 0.36900 | 1.58e-01 | 1.50e-01 | 1.30e-01 | 9.22e-02 | -2.52e-01 | 3.42e-01 | 3.70e-01 | 4.34e-01 | 5.80e-01 | 1.31e-01 |
| TESTOSTERONE BIOSYNTHETIC PROCESS | 11 | 4.88e-01 | 9.44e-01 | 0.36900 | -1.65e-01 | -9.32e-02 | -2.72e-01 | -1.04e-01 | -1.26e-01 | 3.45e-01 | 5.92e-01 | 1.18e-01 | 5.52e-01 | 4.69e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE OR POLYSACCHARIDE ANTIGEN VIA MHC CLASS II | 35 | 7.22e-02 | 4.42e-01 | 0.36900 | -1.93e-01 | -2.25e-01 | -6.71e-02 | -2.09e-01 | 1.64e-02 | 4.86e-02 | 2.15e-02 | 4.92e-01 | 3.21e-02 | 8.67e-01 |
| NEGATIVE REGULATION OF MYOSIN LIGHT CHAIN PHOSPHATASE ACTIVITY | 5 | 3.69e-01 | 8.79e-01 | 0.36900 | -1.30e-01 | -2.22e-01 | -1.04e-01 | 9.88e-03 | 2.43e-01 | 6.16e-01 | 3.90e-01 | 6.88e-01 | 9.69e-01 | 3.46e-01 |
| TYPE I PNEUMOCYTE DIFFERENTIATION | 8 | 2.55e-01 | 7.82e-01 | 0.36900 | -5.90e-02 | -7.80e-02 | 2.85e-02 | -1.37e-01 | -3.27e-01 | 7.73e-01 | 7.02e-01 | 8.89e-01 | 5.04e-01 | 1.09e-01 |
| TONGUE MORPHOGENESIS | 10 | 1.84e-01 | 6.93e-01 | 0.36900 | -7.21e-02 | -1.08e-01 | 1.74e-01 | -1.86e-01 | 2.33e-01 | 6.93e-01 | 5.56e-01 | 3.41e-01 | 3.08e-01 | 2.02e-01 |
| LNCRNA MEDIATED POST TRANSCRIPTIONAL GENE SILENCING | 9 | 8.24e-01 | 1.00e+00 | 0.36900 | 1.52e-01 | 1.27e-01 | 2.44e-01 | 8.83e-02 | 1.72e-01 | 4.30e-01 | 5.10e-01 | 2.06e-01 | 6.46e-01 | 3.71e-01 |
| BILE ACID AND BILE SALT TRANSPORT | 28 | 5.64e-02 | 3.87e-01 | 0.36900 | -1.43e-01 | -1.09e-01 | -2.77e-01 | 4.20e-03 | -1.64e-01 | 1.92e-01 | 3.17e-01 | 1.11e-02 | 9.69e-01 | 1.33e-01 |
| PORE COMPLEX ASSEMBLY | 19 | 6.06e-01 | 9.90e-01 | 0.36900 | -1.97e-01 | -1.81e-01 | -1.58e-01 | -1.78e-01 | -8.93e-02 | 1.38e-01 | 1.72e-01 | 2.32e-01 | 1.80e-01 | 5.01e-01 |
| POSITIVE REGULATION OF VIRAL LIFE CYCLE | 23 | 6.55e-01 | 1.00e+00 | 0.36900 | 1.86e-01 | 1.79e-01 | 2.08e-01 | 1.40e-01 | 7.99e-02 | 1.22e-01 | 1.37e-01 | 8.44e-02 | 2.46e-01 | 5.07e-01 |
| NEGATIVE REGULATION OF CHOLESTEROL METABOLIC PROCESS | 10 | 9.12e-01 | 1.00e+00 | 0.36900 | 1.97e-01 | 1.77e-01 | 2.16e-01 | 1.38e-01 | 1.01e-02 | 2.82e-01 | 3.32e-01 | 2.37e-01 | 4.49e-01 | 9.56e-01 |
| MDA 5 SIGNALING PATHWAY | 11 | 1.80e-01 | 6.87e-01 | 0.36800 | 1.10e-01 | 9.71e-02 | 1.75e-01 | -5.17e-02 | -2.85e-01 | 5.28e-01 | 5.77e-01 | 3.15e-01 | 7.67e-01 | 1.02e-01 |
| DNA REPLICATION CHECKPOINT SIGNALING | 18 | 3.57e-01 | 8.74e-01 | 0.36800 | 1.85e-01 | 1.63e-01 | 2.62e-01 | 7.82e-02 | -2.09e-02 | 1.75e-01 | 2.32e-01 | 5.42e-02 | 5.66e-01 | 8.78e-01 |
| NEGATIVE REGULATION OF CYTOPLASMIC TRANSLATION | 8 | 8.03e-01 | 1.00e+00 | 0.36800 | 1.80e-01 | 2.13e-01 | 1.62e-01 | 1.73e-01 | 4.12e-02 | 3.79e-01 | 2.97e-01 | 4.27e-01 | 3.96e-01 | 8.40e-01 |
| MITOTIC G1 S TRANSITION CHECKPOINT SIGNALING | 29 | 1.27e-01 | 5.93e-01 | 0.36800 | 1.95e-01 | 1.84e-01 | 2.43e-01 | 5.66e-02 | 4.02e-02 | 6.90e-02 | 8.67e-02 | 2.36e-02 | 5.98e-01 | 7.08e-01 |
| SKELETAL MUSCLE SATELLITE CELL ACTIVATION | 8 | 1.98e-01 | 7.13e-01 | 0.36800 | 1.50e-01 | 1.92e-01 | -1.03e-01 | 2.26e-01 | -1.21e-01 | 4.64e-01 | 3.46e-01 | 6.15e-01 | 2.68e-01 | 5.55e-01 |
| AMINO ACID NEUROTRANSMITTER REUPTAKE | 10 | 4.96e-01 | 9.47e-01 | 0.36800 | 1.47e-01 | 2.07e-01 | 1.76e-02 | 2.29e-01 | -1.34e-01 | 4.21e-01 | 2.57e-01 | 9.23e-01 | 2.09e-01 | 4.62e-01 |
| HEPARAN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS ENZYMATIC MODIFICATION | 11 | 2.47e-01 | 7.75e-01 | 0.36800 | -7.52e-02 | -3.88e-02 | -2.10e-01 | 9.01e-02 | -2.76e-01 | 6.66e-01 | 8.24e-01 | 2.29e-01 | 6.05e-01 | 1.13e-01 |
| REGULATION OF EXTRACELLULAR MATRIX DISASSEMBLY | 15 | 5.04e-01 | 9.48e-01 | 0.36800 | 1.73e-01 | 1.87e-01 | 1.49e-01 | 1.64e-01 | -1.46e-01 | 2.45e-01 | 2.11e-01 | 3.16e-01 | 2.71e-01 | 3.29e-01 |
| LIPID PHOSPHORYLATION | 10 | 7.25e-01 | 1.00e+00 | 0.36800 | -1.84e-01 | -1.53e-01 | -2.42e-01 | -6.52e-02 | -1.24e-01 | 3.15e-01 | 4.03e-01 | 1.85e-01 | 7.21e-01 | 4.98e-01 |
| PHAGOLYSOSOME ASSEMBLY | 17 | 6.14e-01 | 9.90e-01 | 0.36800 | -1.78e-01 | -1.83e-01 | -7.46e-02 | -2.24e-01 | 1.20e-01 | 2.03e-01 | 1.91e-01 | 5.94e-01 | 1.10e-01 | 3.93e-01 |
| PEPTIDYL LYSINE HYDROXYLATION | 8 | 3.92e-01 | 8.92e-01 | 0.36800 | -7.24e-02 | -9.83e-02 | 1.53e-01 | -1.84e-01 | 2.51e-01 | 7.23e-01 | 6.30e-01 | 4.55e-01 | 3.67e-01 | 2.18e-01 |
| CARTILAGE MORPHOGENESIS | 10 | 3.18e-01 | 8.45e-01 | 0.36800 | 1.86e-01 | 1.80e-01 | 1.55e-01 | 9.73e-02 | 1.86e-01 | 3.10e-01 | 3.24e-01 | 3.95e-01 | 5.94e-01 | 3.08e-01 |
| INHIBITORY SYNAPSE ASSEMBLY | 19 | 2.84e-01 | 8.12e-01 | 0.36800 | 1.95e-01 | 2.12e-01 | 1.88e-01 | 6.91e-02 | -1.09e-01 | 1.41e-01 | 1.09e-01 | 1.56e-01 | 6.02e-01 | 4.13e-01 |
| BLASTOCYST FORMATION | 45 | 2.15e-01 | 7.38e-01 | 0.36700 | 2.01e-01 | 1.76e-01 | 2.09e-01 | 1.41e-01 | 2.48e-02 | 1.99e-02 | 4.13e-02 | 1.55e-02 | 1.03e-01 | 7.73e-01 |
| RESPONSE TO SALT STRESS | 24 | 5.07e-01 | 9.48e-01 | 0.36700 | 1.59e-01 | 1.31e-01 | 2.02e-01 | 1.38e-01 | 1.80e-01 | 1.77e-01 | 2.68e-01 | 8.64e-02 | 2.41e-01 | 1.26e-01 |
| INTRACELLULAR PH ELEVATION | 7 | 7.21e-01 | 1.00e+00 | 0.36700 | -2.00e-01 | -2.26e-01 | -1.73e-01 | -6.59e-02 | 9.75e-02 | 3.60e-01 | 3.00e-01 | 4.29e-01 | 7.63e-01 | 6.55e-01 |
| NEGATIVE REGULATION OF SMOOTH MUSCLE CONTRACTION | 13 | 1.83e-01 | 6.93e-01 | 0.36700 | 1.14e-01 | 8.84e-02 | 1.23e-01 | 2.70e-02 | -3.13e-01 | 4.75e-01 | 5.81e-01 | 4.42e-01 | 8.66e-01 | 5.07e-02 |
| REGULATION OF EXECUTION PHASE OF APOPTOSIS | 17 | 3.90e-01 | 8.92e-01 | 0.36700 | -2.11e-01 | -2.06e-01 | -1.81e-01 | -1.02e-01 | 6.69e-02 | 1.31e-01 | 1.42e-01 | 1.97e-01 | 4.65e-01 | 6.33e-01 |
| VALINE METABOLIC PROCESS | 7 | 4.27e-01 | 9.16e-01 | 0.36700 | 8.22e-02 | -1.37e-02 | 1.85e-01 | 4.32e-02 | 3.03e-01 | 7.07e-01 | 9.50e-01 | 3.97e-01 | 8.43e-01 | 1.65e-01 |
| INTRACILIARY TRANSPORT | 45 | 1.06e-01 | 5.39e-01 | 0.36700 | 1.57e-01 | 1.33e-01 | 2.29e-01 | 1.00e-01 | 1.73e-01 | 6.92e-02 | 1.23e-01 | 7.76e-03 | 2.45e-01 | 4.50e-02 |
| POSITIVE REGULATION OF URINE VOLUME | 13 | 4.23e-01 | 9.13e-01 | 0.36700 | 1.15e-01 | 1.05e-01 | 2.20e-01 | 8.21e-02 | 2.35e-01 | 4.74e-01 | 5.13e-01 | 1.70e-01 | 6.08e-01 | 1.42e-01 |
| DIGESTIVE SYSTEM DEVELOPMENT | 142 | 6.44e-04 | 1.59e-02 | 0.36700 | 2.01e-01 | 1.84e-01 | 1.72e-01 | 1.66e-01 | -5.43e-02 | 3.67e-05 | 1.47e-04 | 4.01e-04 | 6.31e-04 | 2.64e-01 |
| REGULATION OF UBIQUITIN PROTEIN TRANSFERASE ACTIVITY | 36 | 4.24e-02 | 3.30e-01 | 0.36600 | 1.74e-01 | 1.78e-01 | 2.44e-01 | 5.13e-02 | 1.00e-01 | 7.00e-02 | 6.45e-02 | 1.13e-02 | 5.95e-01 | 2.99e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE MEDIATED IMMUNITY | 67 | 2.94e-03 | 5.17e-02 | 0.36600 | -1.73e-01 | -2.20e-01 | -4.90e-02 | -2.03e-01 | 1.11e-01 | 1.43e-02 | 1.87e-03 | 4.88e-01 | 4.00e-03 | 1.16e-01 |
| POSITIVE REGULATION OF MUSCLE HYPERTROPHY | 36 | 9.64e-02 | 5.12e-01 | 0.36600 | 1.94e-01 | 1.66e-01 | 1.26e-01 | 2.24e-01 | -5.43e-02 | 4.39e-02 | 8.56e-02 | 1.91e-01 | 2.00e-02 | 5.73e-01 |
| CIRCADIAN SLEEP WAKE CYCLE SLEEP | 16 | 2.29e-01 | 7.51e-01 | 0.36600 | 5.08e-02 | 7.86e-04 | 2.10e-01 | 7.34e-03 | 2.95e-01 | 7.25e-01 | 9.96e-01 | 1.45e-01 | 9.59e-01 | 4.10e-02 |
| RESPONSE TO DISACCHARIDE | 7 | 9.43e-01 | 1.00e+00 | 0.36600 | 1.73e-01 | 1.53e-01 | 1.90e-01 | 1.83e-01 | 1.04e-01 | 4.27e-01 | 4.82e-01 | 3.84e-01 | 4.01e-01 | 6.34e-01 |
| PYRIMIDINE RIBONUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 17 | 8.04e-01 | 1.00e+00 | 0.36600 | 1.94e-01 | 1.88e-01 | 1.38e-01 | 2.01e-01 | -4.04e-02 | 1.67e-01 | 1.79e-01 | 3.23e-01 | 1.52e-01 | 7.73e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF EXOGENOUS PEPTIDE ANTIGEN VIA MHC CLASS II | 29 | 3.90e-02 | 3.17e-01 | 0.36600 | -1.77e-01 | -2.17e-01 | -6.57e-03 | -2.31e-01 | 4.95e-02 | 9.97e-02 | 4.32e-02 | 9.51e-01 | 3.16e-02 | 6.44e-01 |
| RESPONSE TO CELL CYCLE CHECKPOINT SIGNALING | 7 | 6.59e-01 | 1.00e+00 | 0.36600 | -2.84e-02 | -3.88e-02 | 9.68e-02 | -3.33e-02 | 3.48e-01 | 8.96e-01 | 8.59e-01 | 6.57e-01 | 8.79e-01 | 1.11e-01 |
| LIPID DIGESTION | 21 | 2.33e-01 | 7.54e-01 | 0.36600 | 1.64e-01 | 1.90e-01 | 6.44e-02 | 2.26e-01 | 1.24e-01 | 1.93e-01 | 1.31e-01 | 6.09e-01 | 7.27e-02 | 3.24e-01 |
| TRANSCRIPTION BY RNA POLYMERASE I | 68 | 7.60e-02 | 4.52e-01 | 0.36600 | 1.89e-01 | 1.75e-01 | 2.19e-01 | 1.28e-01 | 5.61e-02 | 7.12e-03 | 1.28e-02 | 1.76e-03 | 6.73e-02 | 4.23e-01 |
| MAINTENANCE OF ORGANELLE LOCATION | 13 | 5.50e-01 | 9.64e-01 | 0.36600 | -1.13e-01 | -9.82e-02 | -1.28e-01 | -1.19e-01 | -2.84e-01 | 4.80e-01 | 5.40e-01 | 4.25e-01 | 4.56e-01 | 7.63e-02 |
| DECIDUALIZATION | 24 | 1.15e-01 | 5.64e-01 | 0.36600 | 8.15e-02 | 3.45e-02 | 2.33e-01 | -5.54e-03 | 2.68e-01 | 4.90e-01 | 7.70e-01 | 4.85e-02 | 9.63e-01 | 2.32e-02 |
| LUNG ALVEOLUS DEVELOPMENT | 47 | 2.87e-01 | 8.13e-01 | 0.36500 | 1.91e-01 | 1.90e-01 | 1.34e-01 | 2.05e-01 | -2.75e-02 | 2.35e-02 | 2.40e-02 | 1.12e-01 | 1.49e-02 | 7.44e-01 |
| POSITIVE REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 28 | 1.70e-03 | 3.47e-02 | 0.36500 | 3.57e-02 | 1.94e-02 | 5.14e-02 | -1.07e-01 | -3.43e-01 | 7.43e-01 | 8.59e-01 | 6.37e-01 | 3.27e-01 | 1.67e-03 |
| REGULATION OF LIPOPHAGY | 5 | 7.90e-01 | 1.00e+00 | 0.36500 | -1.64e-01 | -2.04e-01 | 3.10e-02 | -2.43e-01 | 7.06e-02 | 5.26e-01 | 4.30e-01 | 9.04e-01 | 3.46e-01 | 7.85e-01 |
| PROTON MOTIVE FORCE DRIVEN ATP SYNTHESIS | 65 | 7.55e-04 | 1.80e-02 | 0.36500 | 1.71e-01 | 1.44e-01 | 2.73e-01 | 2.70e-02 | 8.99e-02 | 1.70e-02 | 4.50e-02 | 1.43e-04 | 7.06e-01 | 2.10e-01 |
| GLYCOSIDE TRANSPORT | 5 | 8.53e-01 | 1.00e+00 | 0.36500 | 8.77e-02 | 8.77e-02 | 8.11e-02 | 1.65e-01 | 2.90e-01 | 7.34e-01 | 7.34e-01 | 7.54e-01 | 5.23e-01 | 2.62e-01 |
| CELL DIFFERENTIATION INVOLVED IN PHENOTYPIC SWITCHING | 5 | 2.68e-01 | 7.95e-01 | 0.36400 | 1.39e-01 | 3.55e-02 | 3.10e-01 | -8.88e-02 | -9.21e-02 | 5.90e-01 | 8.91e-01 | 2.31e-01 | 7.31e-01 | 7.21e-01 |
| RETINAL CONE CELL DEVELOPMENT | 11 | 4.22e-01 | 9.12e-01 | 0.36400 | 1.37e-01 | 2.07e-01 | -3.65e-02 | 2.11e-01 | -1.60e-01 | 4.31e-01 | 2.36e-01 | 8.34e-01 | 2.26e-01 | 3.59e-01 |
| ANTIBACTERIAL INNATE IMMUNE RESPONSE | 6 | 9.21e-01 | 1.00e+00 | 0.36400 | -1.71e-01 | -1.90e-01 | -1.43e-01 | -2.05e-01 | -7.15e-02 | 4.69e-01 | 4.20e-01 | 5.45e-01 | 3.85e-01 | 7.62e-01 |
| NEGATIVE REGULATION OF NATURAL KILLER CELL ACTIVATION | 10 | 5.31e-01 | 9.54e-01 | 0.36400 | -1.30e-01 | -1.92e-01 | 3.66e-02 | -2.17e-01 | 1.74e-01 | 4.75e-01 | 2.94e-01 | 8.41e-01 | 2.35e-01 | 3.40e-01 |
| REGULATION OF LONG CHAIN FATTY ACID IMPORT ACROSS PLASMA MEMBRANE | 6 | 8.60e-01 | 1.00e+00 | 0.36400 | 1.60e-01 | 2.00e-01 | 3.78e-02 | 2.49e-01 | -5.74e-02 | 4.98e-01 | 3.96e-01 | 8.72e-01 | 2.90e-01 | 8.08e-01 |
| CELLULAR RESPONSE TO SALT STRESS | 14 | 6.31e-01 | 9.96e-01 | 0.36400 | 1.31e-01 | 9.52e-02 | 2.28e-01 | 7.13e-02 | 2.22e-01 | 3.97e-01 | 5.38e-01 | 1.40e-01 | 6.44e-01 | 1.50e-01 |
| MACROPHAGE APOPTOTIC PROCESS | 14 | 1.84e-01 | 6.93e-01 | 0.36400 | -1.23e-01 | -1.44e-01 | 6.81e-02 | -2.86e-01 | 9.74e-02 | 4.24e-01 | 3.50e-01 | 6.59e-01 | 6.35e-02 | 5.28e-01 |
| MRNA 3 SPLICE SITE RECOGNITION | 6 | 7.17e-01 | 1.00e+00 | 0.36300 | 1.49e-01 | 7.23e-02 | 2.87e-01 | 6.67e-02 | 1.33e-01 | 5.27e-01 | 7.59e-01 | 2.23e-01 | 7.77e-01 | 5.74e-01 |
| POSITIVE REGULATION OF T CELL APOPTOTIC PROCESS | 13 | 4.08e-01 | 9.08e-01 | 0.36300 | -1.12e-01 | -1.20e-01 | -6.37e-02 | -9.04e-02 | 3.04e-01 | 4.85e-01 | 4.53e-01 | 6.91e-01 | 5.72e-01 | 5.74e-02 |
| PHOSPHATIDYLINOSITOL ACYL CHAIN REMODELING | 6 | 8.26e-01 | 1.00e+00 | 0.36300 | -7.65e-02 | -5.31e-02 | -1.91e-01 | 1.17e-02 | -2.94e-01 | 7.46e-01 | 8.22e-01 | 4.18e-01 | 9.60e-01 | 2.13e-01 |
| SMOOTHENED SIGNALING PATHWAY INVOLVED IN VENTRAL SPINAL CORD PATTERNING | 8 | 7.06e-01 | 1.00e+00 | 0.36300 | 3.23e-02 | 7.95e-03 | 1.53e-01 | -2.81e-02 | 3.26e-01 | 8.74e-01 | 9.69e-01 | 4.53e-01 | 8.91e-01 | 1.11e-01 |
| NEGATIVE REGULATION OF PLATELET ACTIVATION | 17 | 6.86e-01 | 1.00e+00 | 0.36200 | 1.94e-01 | 2.03e-01 | 1.23e-01 | 1.55e-01 | -1.15e-01 | 1.65e-01 | 1.47e-01 | 3.79e-01 | 2.70e-01 | 4.12e-01 |
| PEPTIDYL SERINE DEPHOSPHORYLATION | 14 | 7.87e-01 | 1.00e+00 | 0.36200 | 1.75e-01 | 1.52e-01 | 2.29e-01 | 1.27e-01 | 9.67e-02 | 2.58e-01 | 3.26e-01 | 1.38e-01 | 4.12e-01 | 5.31e-01 |
| INOSITOL TRISPHOSPHATE BIOSYNTHETIC PROCESS | 8 | 1.63e-01 | 6.63e-01 | 0.36200 | -7.68e-02 | -1.90e-02 | -1.86e-01 | 1.04e-01 | -2.82e-01 | 7.07e-01 | 9.26e-01 | 3.62e-01 | 6.11e-01 | 1.67e-01 |
| THYROID STIMULATING HORMONE SECRETING CELL DIFFERENTIATION | 6 | 6.75e-01 | 1.00e+00 | 0.36200 | 1.35e-01 | 1.77e-01 | 1.63e-01 | 1.11e-01 | 2.07e-01 | 5.66e-01 | 4.54e-01 | 4.88e-01 | 6.39e-01 | 3.80e-01 |
| DETERMINATION OF DORSAL VENTRAL ASYMMETRY | 11 | 1.80e-01 | 6.87e-01 | 0.36200 | 9.68e-02 | 1.88e-01 | -1.24e-01 | 1.73e-01 | -2.02e-01 | 5.78e-01 | 2.81e-01 | 4.78e-01 | 3.19e-01 | 2.46e-01 |
| RETINAL BIPOLAR NEURON DIFFERENTIATION | 7 | 7.37e-01 | 1.00e+00 | 0.36200 | 1.81e-01 | 2.41e-01 | 5.92e-02 | 1.89e-01 | -2.77e-02 | 4.06e-01 | 2.70e-01 | 7.86e-01 | 3.88e-01 | 8.99e-01 |
| REGULATION OF DEOXYRIBONUCLEASE ACTIVITY | 10 | 3.47e-01 | 8.65e-01 | 0.36200 | -5.19e-02 | -1.21e-01 | 1.64e-01 | -1.77e-01 | 2.35e-01 | 7.76e-01 | 5.09e-01 | 3.69e-01 | 3.33e-01 | 1.98e-01 |
| CELLULAR RESPONSE TO ESTROGEN STIMULUS | 18 | 1.94e-01 | 7.05e-01 | 0.36200 | -1.03e-01 | -1.58e-01 | 5.08e-02 | -1.90e-01 | 2.38e-01 | 4.49e-01 | 2.45e-01 | 7.09e-01 | 1.63e-01 | 8.09e-02 |
| TAURINE METABOLIC PROCESS | 9 | 6.14e-01 | 9.90e-01 | 0.36100 | -1.92e-01 | -2.06e-01 | -1.19e-01 | -8.96e-02 | 1.71e-01 | 3.18e-01 | 2.85e-01 | 5.38e-01 | 6.42e-01 | 3.75e-01 |
| PROSTATIC BUD FORMATION | 8 | 1.66e-01 | 6.70e-01 | 0.36100 | -1.17e-01 | -1.71e-01 | -8.73e-02 | -4.78e-02 | -2.79e-01 | 5.65e-01 | 4.03e-01 | 6.69e-01 | 8.15e-01 | 1.72e-01 |
| REGULATION OF HEMOGLOBIN BIOSYNTHETIC PROCESS | 8 | 2.46e-01 | 7.72e-01 | 0.36100 | 3.79e-03 | 2.34e-02 | 1.66e-01 | -1.51e-01 | 2.82e-01 | 9.85e-01 | 9.09e-01 | 4.16e-01 | 4.60e-01 | 1.67e-01 |
| ESTABLISHMENT OF CENTROSOME LOCALIZATION | 10 | 7.46e-01 | 1.00e+00 | 0.36100 | -2.03e-01 | -1.73e-01 | -1.71e-01 | -1.60e-01 | -6.64e-02 | 2.66e-01 | 3.43e-01 | 3.50e-01 | 3.80e-01 | 7.16e-01 |
| MESENCHYMAL CELL DEVELOPMENT | 6 | 3.74e-01 | 8.82e-01 | 0.36100 | 1.29e-01 | 8.00e-02 | 2.30e-01 | -8.69e-02 | -2.17e-01 | 5.84e-01 | 7.34e-01 | 3.30e-01 | 7.12e-01 | 3.58e-01 |
| ATRIOVENTRICULAR NODE DEVELOPMENT | 9 | 3.41e-01 | 8.59e-01 | 0.36100 | -6.61e-02 | -6.92e-02 | 2.09e-02 | -2.24e-01 | -2.66e-01 | 7.32e-01 | 7.19e-01 | 9.14e-01 | 2.44e-01 | 1.68e-01 |
| SYNAPTIC VESICLE ENDOSOMAL PROCESSING | 8 | 7.86e-01 | 1.00e+00 | 0.36100 | -1.43e-01 | -1.85e-01 | -1.00e-02 | -1.42e-01 | 2.34e-01 | 4.83e-01 | 3.64e-01 | 9.61e-01 | 4.87e-01 | 2.51e-01 |
| POSITIVE REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 10 | 1.64e-01 | 6.64e-01 | 0.36100 | 1.38e-01 | 1.30e-01 | 2.84e-01 | -7.39e-02 | -9.10e-02 | 4.50e-01 | 4.78e-01 | 1.20e-01 | 6.86e-01 | 6.18e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 2 PRODUCTION | 26 | 1.23e-01 | 5.85e-01 | 0.36000 | -1.01e-01 | -1.39e-01 | 1.68e-02 | -9.45e-02 | 3.02e-01 | 3.74e-01 | 2.18e-01 | 8.82e-01 | 4.04e-01 | 7.72e-03 |
| REGULATION OF TRANSMISSION OF NERVE IMPULSE | 15 | 3.16e-01 | 8.43e-01 | 0.36000 | -1.01e-01 | -1.39e-01 | 5.58e-02 | -1.11e-01 | 2.91e-01 | 4.96e-01 | 3.51e-01 | 7.08e-01 | 4.58e-01 | 5.08e-02 |
| POSITIVE REGULATION OF PHOSPHOLIPASE A2 ACTIVITY | 5 | 7.42e-01 | 1.00e+00 | 0.36000 | 1.50e-01 | 1.63e-01 | 2.00e-01 | -4.58e-04 | -2.02e-01 | 5.63e-01 | 5.29e-01 | 4.38e-01 | 9.99e-01 | 4.34e-01 |
| POSITIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL MIGRATION | 22 | 3.91e-01 | 8.92e-01 | 0.36000 | 2.02e-01 | 2.16e-01 | 1.19e-01 | 1.53e-01 | -6.92e-02 | 1.02e-01 | 7.92e-02 | 3.36e-01 | 2.13e-01 | 5.74e-01 |
| REGULATION OF METANEPHROS DEVELOPMENT | 5 | 8.92e-01 | 1.00e+00 | 0.36000 | 1.88e-01 | 1.84e-01 | 1.82e-01 | 6.08e-02 | -1.54e-01 | 4.67e-01 | 4.75e-01 | 4.82e-01 | 8.14e-01 | 5.52e-01 |
| NUCLEOSIDE TRANSMEMBRANE TRANSPORT | 8 | 5.93e-01 | 9.86e-01 | 0.36000 | 1.34e-01 | 1.75e-01 | 1.15e-01 | 1.63e-01 | 2.02e-01 | 5.11e-01 | 3.90e-01 | 5.72e-01 | 4.24e-01 | 3.22e-01 |
| POSITIVE REGULATION OF RETINOIC ACID RECEPTOR SIGNALING PATHWAY | 5 | 8.94e-01 | 1.00e+00 | 0.36000 | -1.88e-01 | -1.50e-01 | -1.58e-01 | -1.69e-01 | -1.35e-01 | 4.66e-01 | 5.60e-01 | 5.42e-01 | 5.13e-01 | 6.02e-01 |
| CELL CELL JUNCTION DISASSEMBLY | 5 | 8.30e-01 | 1.00e+00 | 0.36000 | 1.44e-01 | 2.10e-01 | 7.66e-03 | 1.26e-01 | -2.21e-01 | 5.77e-01 | 4.16e-01 | 9.76e-01 | 6.26e-01 | 3.92e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE III | 17 | 3.36e-01 | 8.59e-01 | 0.36000 | -1.12e-01 | -1.23e-01 | -1.94e-02 | -1.35e-01 | 2.89e-01 | 4.26e-01 | 3.79e-01 | 8.90e-01 | 3.37e-01 | 3.93e-02 |
| NEGATIVE REGULATION OF INTERLEUKIN 13 PRODUCTION | 7 | 8.06e-01 | 1.00e+00 | 0.36000 | -1.60e-01 | -1.63e-01 | -1.58e-01 | -9.67e-02 | 2.07e-01 | 4.64e-01 | 4.55e-01 | 4.68e-01 | 6.58e-01 | 3.43e-01 |
| REGULATION OF EPITHELIAL CELL PROLIFERATION INVOLVED IN LUNG MORPHOGENESIS | 7 | 7.48e-01 | 1.00e+00 | 0.36000 | 1.16e-01 | 1.25e-01 | 1.02e-02 | 1.86e-01 | -2.56e-01 | 5.96e-01 | 5.68e-01 | 9.63e-01 | 3.93e-01 | 2.41e-01 |
| SUBSTRATE INDEPENDENT TELENCEPHALIC TANGENTIAL MIGRATION | 10 | 7.76e-01 | 1.00e+00 | 0.35900 | 1.65e-01 | 1.71e-01 | 7.24e-02 | 2.39e-01 | -1.03e-01 | 3.67e-01 | 3.49e-01 | 6.92e-01 | 1.91e-01 | 5.73e-01 |
| NEGATIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 7 | 6.79e-01 | 1.00e+00 | 0.35900 | 1.55e-01 | 1.20e-01 | 1.69e-01 | 2.36e-01 | 8.06e-02 | 4.77e-01 | 5.83e-01 | 4.38e-01 | 2.80e-01 | 7.12e-01 |
| TYPE B PANCREATIC CELL APOPTOTIC PROCESS | 10 | 4.42e-01 | 9.27e-01 | 0.35900 | -1.12e-01 | -1.57e-01 | 9.33e-02 | -1.86e-01 | 2.21e-01 | 5.38e-01 | 3.91e-01 | 6.09e-01 | 3.09e-01 | 2.27e-01 |
| CRANIAL NERVE STRUCTURAL ORGANIZATION | 9 | 7.31e-01 | 1.00e+00 | 0.35900 | 1.97e-01 | 2.07e-01 | 7.50e-02 | 1.86e-01 | -8.35e-02 | 3.05e-01 | 2.82e-01 | 6.97e-01 | 3.34e-01 | 6.64e-01 |
| PROTEIN TRIMERIZATION | 17 | 3.94e-01 | 8.93e-01 | 0.35900 | -1.54e-01 | -1.42e-01 | -1.34e-01 | -1.40e-01 | -2.18e-01 | 2.72e-01 | 3.10e-01 | 3.39e-01 | 3.18e-01 | 1.20e-01 |
| REGULATION OF MESODERMAL CELL DIFFERENTIATION | 9 | 8.55e-01 | 1.00e+00 | 0.35900 | -1.78e-01 | -1.33e-01 | -1.91e-01 | -1.70e-01 | -1.19e-01 | 3.54e-01 | 4.88e-01 | 3.21e-01 | 3.79e-01 | 5.38e-01 |
| TOLERANCE INDUCTION DEPENDENT UPON IMMUNE RESPONSE | 5 | 2.85e-01 | 8.12e-01 | 0.35900 | -1.51e-01 | -3.80e-02 | -1.82e-01 | -1.16e-01 | -2.41e-01 | 5.57e-01 | 8.83e-01 | 4.81e-01 | 6.53e-01 | 3.51e-01 |
| GLUTAMINE TRANSPORT | 9 | 8.75e-01 | 1.00e+00 | 0.35900 | 1.86e-01 | 1.72e-01 | 1.38e-01 | 1.65e-01 | -1.36e-01 | 3.33e-01 | 3.71e-01 | 4.75e-01 | 3.92e-01 | 4.80e-01 |
| INDOLE CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 5 | 8.59e-01 | 1.00e+00 | 0.35900 | 8.08e-02 | 1.33e-01 | -6.04e-02 | 8.31e-02 | -3.06e-01 | 7.54e-01 | 6.06e-01 | 8.15e-01 | 7.48e-01 | 2.35e-01 |
| REGULATION OF ER ASSOCIATED UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 7 | 6.17e-01 | 9.90e-01 | 0.35900 | 1.33e-01 | 1.25e-01 | 1.39e-01 | -3.92e-03 | -2.75e-01 | 5.42e-01 | 5.67e-01 | 5.23e-01 | 9.86e-01 | 2.07e-01 |
| CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 118 | 5.04e-06 | 2.58e-04 | 0.35800 | -1.54e-01 | -1.89e-01 | -4.32e-03 | -2.01e-01 | 1.70e-01 | 3.88e-03 | 3.93e-04 | 9.35e-01 | 1.63e-04 | 1.46e-03 |
| PROTEIN IMPORT INTO PEROXISOME MATRIX SUBSTRATE RELEASE | 5 | 9.19e-01 | 1.00e+00 | 0.35800 | -1.87e-01 | -1.30e-01 | -2.08e-01 | -1.72e-01 | -6.19e-02 | 4.70e-01 | 6.15e-01 | 4.20e-01 | 5.05e-01 | 8.11e-01 |
| CELLULAR RESPONSE TO EXOGENOUS DSRNA | 16 | 1.42e-01 | 6.27e-01 | 0.35800 | -9.87e-02 | -1.40e-01 | 1.15e-01 | -1.88e-01 | 2.24e-01 | 4.94e-01 | 3.31e-01 | 4.25e-01 | 1.93e-01 | 1.21e-01 |
| POSITIVE REGULATION OF ACTION POTENTIAL | 8 | 8.67e-01 | 1.00e+00 | 0.35800 | 1.57e-01 | 1.67e-01 | 1.52e-01 | 1.88e-01 | 1.32e-01 | 4.42e-01 | 4.12e-01 | 4.58e-01 | 3.58e-01 | 5.17e-01 |
| CALCITONIN FAMILY RECEPTOR SIGNALING PATHWAY | 8 | 6.42e-01 | 1.00e+00 | 0.35800 | -1.95e-01 | -2.10e-01 | -1.86e-01 | -7.19e-02 | -7.96e-02 | 3.39e-01 | 3.04e-01 | 3.62e-01 | 7.25e-01 | 6.97e-01 |
| REGULATION OF ATTACHMENT OF MITOTIC SPINDLE MICROTUBULES TO KINETOCHORE | 8 | 5.09e-01 | 9.49e-01 | 0.35800 | 5.68e-02 | 7.64e-03 | 1.89e-01 | 8.37e-02 | 2.87e-01 | 7.81e-01 | 9.70e-01 | 3.54e-01 | 6.82e-01 | 1.60e-01 |
| METANEPHRIC RENAL VESICLE MORPHOGENESIS | 14 | 3.57e-01 | 8.74e-01 | 0.35800 | -1.53e-01 | -2.03e-01 | 4.26e-03 | -2.51e-01 | 2.36e-02 | 3.22e-01 | 1.89e-01 | 9.78e-01 | 1.03e-01 | 8.79e-01 |
| RESPONSE TO OXYGEN RADICAL | 27 | 1.25e-01 | 5.89e-01 | 0.35800 | 1.92e-01 | 1.68e-01 | 1.73e-01 | 1.30e-01 | 1.26e-01 | 8.35e-02 | 1.31e-01 | 1.19e-01 | 2.41e-01 | 2.57e-01 |
| SPINAL CORD MOTOR NEURON CELL FATE SPECIFICATION | 10 | 1.02e-01 | 5.29e-01 | 0.35800 | -4.51e-02 | -7.29e-02 | 1.62e-01 | -2.99e-01 | 6.90e-02 | 8.05e-01 | 6.90e-01 | 3.74e-01 | 1.01e-01 | 7.06e-01 |
| POSITIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 16 | 5.60e-01 | 9.69e-01 | 0.35800 | -1.58e-01 | -1.61e-01 | -9.31e-02 | -1.60e-01 | 2.07e-01 | 2.75e-01 | 2.65e-01 | 5.19e-01 | 2.67e-01 | 1.51e-01 |
| PROTEIN TARGETING TO LYSOSOME | 31 | 2.61e-01 | 7.90e-01 | 0.35800 | -1.78e-01 | -2.13e-01 | -6.86e-02 | -1.93e-01 | 9.44e-02 | 8.60e-02 | 3.99e-02 | 5.09e-01 | 6.30e-02 | 3.63e-01 |
| REGULATION OF TRANSCRIPTION BY RNA POLYMERASE III | 28 | 9.41e-02 | 5.06e-01 | 0.35800 | -1.30e-01 | -1.37e-01 | -2.70e-02 | -1.93e-01 | 2.33e-01 | 2.33e-01 | 2.09e-01 | 8.05e-01 | 7.70e-02 | 3.31e-02 |
| 3 UTR MEDIATED MRNA STABILIZATION | 20 | 1.86e-01 | 6.94e-01 | 0.35800 | 5.61e-02 | 5.45e-02 | 1.08e-01 | 7.54e-02 | 3.23e-01 | 6.64e-01 | 6.73e-01 | 4.04e-01 | 5.59e-01 | 1.23e-02 |
| BRANCHED CHAIN AMINO ACID BIOSYNTHETIC PROCESS | 5 | 8.10e-01 | 1.00e+00 | 0.35700 | 1.61e-01 | 1.59e-01 | 1.04e-01 | 1.48e-01 | 2.10e-01 | 5.34e-01 | 5.39e-01 | 6.86e-01 | 5.68e-01 | 4.16e-01 |
| PROTEIN SIALYLATION | 5 | 8.85e-01 | 1.00e+00 | 0.35700 | -1.41e-01 | -1.86e-01 | -1.32e-02 | -1.14e-01 | 2.46e-01 | 5.85e-01 | 4.72e-01 | 9.59e-01 | 6.60e-01 | 3.41e-01 |
| POSITIVE REGULATION OF CILIUM MOVEMENT | 11 | 6.76e-01 | 1.00e+00 | 0.35700 | 1.64e-01 | 1.97e-01 | 4.98e-02 | 2.40e-01 | 4.15e-02 | 3.47e-01 | 2.58e-01 | 7.75e-01 | 1.68e-01 | 8.12e-01 |
| REGULATION OF COMPLEMENT DEPENDENT CYTOTOXICITY | 11 | 3.73e-01 | 8.82e-01 | 0.35700 | -9.89e-02 | -8.64e-02 | 1.17e-02 | -1.10e-01 | 3.13e-01 | 5.70e-01 | 6.20e-01 | 9.46e-01 | 5.28e-01 | 7.22e-02 |
| DERMATAN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS | 8 | 4.35e-01 | 9.22e-01 | 0.35700 | -1.28e-01 | -1.79e-01 | -5.09e-02 | -1.63e-01 | -2.23e-01 | 5.30e-01 | 3.81e-01 | 8.03e-01 | 4.25e-01 | 2.74e-01 |
| CHITIN METABOLIC PROCESS | 6 | 3.05e-01 | 8.33e-01 | 0.35700 | -1.80e-01 | -8.64e-02 | -2.94e-01 | 2.08e-02 | -2.40e-02 | 4.45e-01 | 7.14e-01 | 2.12e-01 | 9.30e-01 | 9.19e-01 |
| POSITIVE REGULATION OF ARP2 3 COMPLEX MEDIATED ACTIN NUCLEATION | 8 | 6.31e-01 | 9.96e-01 | 0.35700 | -1.52e-01 | -1.84e-01 | -1.46e-01 | -9.19e-02 | 2.01e-01 | 4.57e-01 | 3.67e-01 | 4.74e-01 | 6.53e-01 | 3.25e-01 |
| REGULATION OF EATING BEHAVIOR | 7 | 5.90e-01 | 9.86e-01 | 0.35700 | -1.71e-01 | -2.08e-01 | -7.89e-02 | -5.69e-02 | 2.13e-01 | 4.34e-01 | 3.40e-01 | 7.18e-01 | 7.94e-01 | 3.30e-01 |
| POSITIVE REGULATION OF PROTEOGLYCAN BIOSYNTHETIC PROCESS | 5 | 9.30e-01 | 1.00e+00 | 0.35700 | 1.75e-01 | 1.59e-01 | 2.45e-01 | 1.04e-01 | 1.86e-02 | 4.99e-01 | 5.37e-01 | 3.43e-01 | 6.86e-01 | 9.43e-01 |
| PIGMENT GRANULE MATURATION | 10 | 2.75e-01 | 8.02e-01 | 0.35700 | -7.30e-02 | -1.18e-01 | 1.31e-01 | -2.63e-01 | 1.47e-01 | 6.90e-01 | 5.19e-01 | 4.74e-01 | 1.50e-01 | 4.21e-01 |
| N GLYCAN PROCESSING | 17 | 5.17e-01 | 9.52e-01 | 0.35600 | -1.64e-01 | -1.90e-01 | -6.90e-02 | -2.39e-01 | -4.75e-02 | 2.41e-01 | 1.75e-01 | 6.23e-01 | 8.84e-02 | 7.35e-01 |
| RESPIRATORY BURST INVOLVED IN DEFENSE RESPONSE | 16 | 1.81e-02 | 1.95e-01 | 0.35600 | 1.62e-01 | 8.95e-02 | 2.84e-01 | -5.31e-02 | 9.75e-02 | 2.62e-01 | 5.35e-01 | 4.95e-02 | 7.13e-01 | 4.99e-01 |
| REGULATION OF GLOMERULUS DEVELOPMENT | 5 | 7.93e-01 | 1.00e+00 | 0.35600 | 5.46e-02 | 6.73e-02 | 3.43e-02 | 1.45e-03 | -3.44e-01 | 8.33e-01 | 7.94e-01 | 8.94e-01 | 9.96e-01 | 1.83e-01 |
| HISTONE H3 ACETYLATION | 6 | 5.16e-01 | 9.52e-01 | 0.35600 | 6.85e-02 | 7.73e-02 | 1.08e-01 | -1.15e-01 | -3.02e-01 | 7.71e-01 | 7.43e-01 | 6.47e-01 | 6.26e-01 | 2.00e-01 |
| IMMUNOLOGICAL MEMORY PROCESS | 17 | 3.22e-01 | 8.47e-01 | 0.35600 | -2.04e-01 | -1.68e-01 | -1.36e-01 | -1.94e-01 | 2.93e-02 | 1.45e-01 | 2.31e-01 | 3.33e-01 | 1.66e-01 | 8.34e-01 |
| MULTIVESICULAR BODY ORGANIZATION | 32 | 4.17e-02 | 3.27e-01 | 0.35600 | 8.90e-02 | 6.80e-02 | 2.17e-01 | -1.53e-02 | 2.58e-01 | 3.83e-01 | 5.06e-01 | 3.34e-02 | 8.81e-01 | 1.14e-02 |
| FOLIC ACID TRANSPORT | 10 | 3.13e-01 | 8.40e-01 | 0.35600 | -8.46e-02 | -8.46e-02 | 9.98e-02 | -1.88e-01 | 2.59e-01 | 6.43e-01 | 6.43e-01 | 5.85e-01 | 3.02e-01 | 1.56e-01 |
| C21 STEROID HORMONE BIOSYNTHETIC PROCESS | 20 | 6.49e-01 | 1.00e+00 | 0.35600 | 1.73e-01 | 1.81e-01 | 1.59e-01 | 1.87e-01 | 6.17e-02 | 1.80e-01 | 1.62e-01 | 2.19e-01 | 1.47e-01 | 6.33e-01 |
| VIRAL RELEASE FROM HOST CELL | 28 | 6.55e-02 | 4.17e-01 | 0.35600 | 1.05e-01 | 1.07e-01 | 1.92e-01 | 2.59e-02 | 2.58e-01 | 3.37e-01 | 3.26e-01 | 7.90e-02 | 8.12e-01 | 1.79e-02 |
| REGULATION OF PEPTIDYL LYSINE ACETYLATION | 28 | 2.58e-01 | 7.85e-01 | 0.35600 | 1.64e-01 | 1.70e-01 | 2.10e-01 | 9.63e-02 | 1.32e-01 | 1.34e-01 | 1.19e-01 | 5.40e-02 | 3.78e-01 | 2.27e-01 |
| REGULATION OF RNA POLYMERASE II TRANSCRIPTION PREINITIATION COMPLEX ASSEMBLY | 7 | 7.80e-01 | 1.00e+00 | 0.35600 | 1.37e-01 | 8.26e-02 | 2.74e-01 | 3.36e-02 | 1.56e-01 | 5.29e-01 | 7.05e-01 | 2.09e-01 | 8.78e-01 | 4.73e-01 |
| MEMBRANE REPOLARIZATION DURING ATRIAL CARDIAC MUSCLE CELL ACTION POTENTIAL | 6 | 8.09e-01 | 1.00e+00 | 0.35600 | 1.48e-01 | 1.52e-01 | 1.90e-01 | 1.73e-01 | 1.26e-01 | 5.30e-01 | 5.20e-01 | 4.21e-01 | 4.64e-01 | 5.92e-01 |
| REGULATION OF MUSCLE ADAPTATION | 92 | 3.69e-02 | 3.06e-01 | 0.35600 | 1.84e-01 | 1.81e-01 | 1.47e-01 | 1.95e-01 | -2.13e-02 | 2.25e-03 | 2.75e-03 | 1.51e-02 | 1.23e-03 | 7.24e-01 |
| REGULATION OF XENOBIOTIC DETOXIFICATION BY TRANSMEMBRANE EXPORT ACROSS THE PLASMA MEMBRANE | 12 | 4.83e-01 | 9.43e-01 | 0.35600 | 1.42e-01 | 9.52e-02 | 1.79e-01 | 1.99e-01 | 1.60e-01 | 3.96e-01 | 5.68e-01 | 2.82e-01 | 2.32e-01 | 3.38e-01 |
| PERISTALSIS | 12 | 1.57e-01 | 6.54e-01 | 0.35600 | 1.27e-01 | 4.85e-02 | 3.14e-01 | -3.57e-02 | 9.10e-02 | 4.46e-01 | 7.71e-01 | 5.99e-02 | 8.30e-01 | 5.85e-01 |
| LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 57 | 5.72e-02 | 3.91e-01 | 0.35600 | -1.67e-01 | -1.87e-01 | -7.66e-02 | -1.94e-01 | 1.42e-01 | 2.91e-02 | 1.44e-02 | 3.17e-01 | 1.15e-02 | 6.41e-02 |
| REGULATION OF NMDA RECEPTOR ACTIVITY | 17 | 8.04e-01 | 1.00e+00 | 0.35600 | -1.91e-01 | -1.78e-01 | -1.42e-01 | -1.95e-01 | -8.99e-03 | 1.73e-01 | 2.04e-01 | 3.12e-01 | 1.63e-01 | 9.49e-01 |
| NEGATIVE REGULATION OF FATTY ACID TRANSPORT | 7 | 7.13e-01 | 1.00e+00 | 0.35500 | 8.01e-02 | 1.36e-01 | -2.81e-02 | 1.01e-01 | -3.01e-01 | 7.14e-01 | 5.32e-01 | 8.98e-01 | 6.43e-01 | 1.69e-01 |
| ATP SYNTHESIS COUPLED ELECTRON TRANSPORT | 85 | 4.65e-04 | 1.23e-02 | 0.35500 | 1.78e-01 | 1.50e-01 | 2.52e-01 | 5.11e-02 | 7.68e-02 | 4.57e-03 | 1.70e-02 | 5.73e-05 | 4.15e-01 | 2.21e-01 |
| ROUNDABOUT SIGNALING PATHWAY | 5 | 7.99e-01 | 1.00e+00 | 0.35500 | -1.94e-01 | -2.00e-01 | -1.96e-01 | -5.47e-02 | -8.43e-02 | 4.52e-01 | 4.39e-01 | 4.48e-01 | 8.32e-01 | 7.44e-01 |
| BONE MARROW DEVELOPMENT | 9 | 4.57e-01 | 9.32e-01 | 0.35500 | 4.95e-02 | 3.56e-02 | 5.98e-02 | 4.97e-02 | 3.41e-01 | 7.97e-01 | 8.53e-01 | 7.56e-01 | 7.96e-01 | 7.65e-02 |
| REGULATION OF LYSOSOMAL LUMEN PH | 27 | 2.14e-01 | 7.37e-01 | 0.35500 | 1.46e-01 | 1.06e-01 | 2.49e-01 | 8.80e-02 | 1.53e-01 | 1.88e-01 | 3.39e-01 | 2.53e-02 | 4.28e-01 | 1.68e-01 |
| POSITIVE REGULATION OF PYROPTOSIS | 5 | 2.91e-01 | 8.18e-01 | 0.35500 | -1.43e-01 | -2.30e-01 | -1.18e-03 | -9.43e-04 | 2.29e-01 | 5.80e-01 | 3.72e-01 | 9.96e-01 | 9.97e-01 | 3.76e-01 |
| PROTEIN CATABOLIC PROCESS IN THE VACUOLE | 22 | 1.75e-01 | 6.80e-01 | 0.35500 | 1.65e-01 | 1.75e-01 | 2.41e-01 | 6.32e-02 | 7.82e-02 | 1.81e-01 | 1.56e-01 | 5.02e-02 | 6.08e-01 | 5.26e-01 |
| METANEPHRIC GLOMERULUS VASCULATURE DEVELOPMENT | 9 | 3.63e-01 | 8.78e-01 | 0.35500 | 1.73e-01 | 8.89e-02 | 2.67e-01 | 1.27e-01 | 1.96e-02 | 3.69e-01 | 6.44e-01 | 1.65e-01 | 5.09e-01 | 9.19e-01 |
| CYTOKINETIC PROCESS | 42 | 1.87e-01 | 6.95e-01 | 0.35500 | 1.61e-01 | 1.46e-01 | 2.18e-01 | 1.14e-01 | 1.35e-01 | 7.18e-02 | 1.02e-01 | 1.46e-02 | 2.01e-01 | 1.29e-01 |
| HEPARIN BIOSYNTHETIC PROCESS | 11 | 4.58e-01 | 9.32e-01 | 0.35400 | 6.87e-02 | 1.27e-01 | -1.12e-01 | 1.23e-01 | -2.78e-01 | 6.93e-01 | 4.66e-01 | 5.20e-01 | 4.80e-01 | 1.11e-01 |
| RESPONSE TO BILE ACID | 7 | 7.99e-01 | 1.00e+00 | 0.35400 | -2.03e-01 | -1.55e-01 | -1.71e-01 | -1.77e-01 | -7.23e-03 | 3.53e-01 | 4.79e-01 | 4.33e-01 | 4.18e-01 | 9.74e-01 |
| VIRAL TRANSCRIPTION | 50 | 1.13e-02 | 1.37e-01 | 0.35400 | 7.71e-02 | 3.97e-02 | 1.79e-01 | 2.61e-02 | 2.92e-01 | 3.46e-01 | 6.27e-01 | 2.84e-02 | 7.50e-01 | 3.57e-04 |
| FOREBRAIN RADIAL GLIAL CELL DIFFERENTIATION | 7 | 5.55e-01 | 9.67e-01 | 0.35400 | -1.18e-01 | -1.42e-01 | 4.52e-02 | -2.95e-01 | -5.03e-02 | 5.90e-01 | 5.15e-01 | 8.36e-01 | 1.77e-01 | 8.18e-01 |
| POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 27 | 1.99e-02 | 2.07e-01 | 0.35400 | -1.70e-01 | -2.34e-01 | -3.42e-02 | -1.25e-01 | 1.57e-01 | 1.26e-01 | 3.51e-02 | 7.58e-01 | 2.59e-01 | 1.58e-01 |
| EOSINOPHIL ACTIVATION | 8 | 3.72e-01 | 8.82e-01 | 0.35400 | -6.26e-02 | -1.39e-01 | 1.50e-01 | -2.27e-01 | 1.68e-01 | 7.59e-01 | 4.96e-01 | 4.62e-01 | 2.67e-01 | 4.11e-01 |
| S ADENOSYLMETHIONINE METABOLIC PROCESS | 15 | 4.29e-01 | 9.17e-01 | 0.35400 | 1.76e-01 | 1.77e-01 | 2.19e-01 | 5.64e-02 | -1.07e-01 | 2.38e-01 | 2.34e-01 | 1.41e-01 | 7.05e-01 | 4.72e-01 |
| NEGATIVE REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 12 | 3.24e-01 | 8.49e-01 | 0.35400 | 1.72e-01 | 2.07e-01 | 2.19e-01 | 5.14e-02 | 4.90e-02 | 3.04e-01 | 2.14e-01 | 1.90e-01 | 7.58e-01 | 7.69e-01 |
| REGULATION OF B CELL RECEPTOR SIGNALING PATHWAY | 23 | 3.21e-01 | 8.47e-01 | 0.35400 | -1.56e-01 | -1.83e-01 | -2.27e-02 | -2.36e-01 | 1.05e-01 | 1.94e-01 | 1.28e-01 | 8.51e-01 | 5.01e-02 | 3.85e-01 |
| CORTISOL SECRETION | 5 | 8.97e-01 | 1.00e+00 | 0.35400 | -1.37e-01 | -1.44e-01 | -4.25e-03 | -2.20e-01 | 1.93e-01 | 5.95e-01 | 5.78e-01 | 9.87e-01 | 3.95e-01 | 4.55e-01 |
| REGULATION OF SECONDARY HEART FIELD CARDIOBLAST PROLIFERATION | 9 | 1.27e-01 | 5.93e-01 | 0.35400 | -4.93e-02 | -1.19e-01 | 1.65e-01 | -2.85e-01 | 1.72e-02 | 7.98e-01 | 5.36e-01 | 3.91e-01 | 1.39e-01 | 9.29e-01 |
| G PROTEIN COUPLED PURINERGIC NUCLEOTIDE RECEPTOR SIGNALING PATHWAY | 10 | 5.11e-01 | 9.51e-01 | 0.35400 | -1.50e-01 | -1.21e-01 | -2.55e-01 | 1.60e-02 | -1.50e-01 | 4.10e-01 | 5.08e-01 | 1.62e-01 | 9.30e-01 | 4.12e-01 |
| IRES DEPENDENT VIRAL TRANSLATIONAL INITIATION | 10 | 6.36e-01 | 9.98e-01 | 0.35400 | 1.57e-01 | 1.07e-01 | 2.78e-01 | 3.06e-02 | 1.03e-01 | 3.89e-01 | 5.56e-01 | 1.29e-01 | 8.67e-01 | 5.72e-01 |
| BRANCH ELONGATION OF AN EPITHELIUM | 19 | 1.57e-01 | 6.54e-01 | 0.35400 | 1.64e-01 | 1.42e-01 | 2.16e-01 | 9.28e-02 | -1.51e-01 | 2.16e-01 | 2.85e-01 | 1.03e-01 | 4.84e-01 | 2.55e-01 |
| CELLULAR RESPONSE TO WATER STIMULUS | 6 | 7.73e-01 | 1.00e+00 | 0.35400 | -7.98e-02 | -1.41e-01 | 5.57e-02 | -1.36e-01 | 2.78e-01 | 7.35e-01 | 5.51e-01 | 8.13e-01 | 5.63e-01 | 2.39e-01 |
| NEGATIVE REGULATION OF SMOOTHENED SIGNALING PATHWAY INVOLVED IN DORSAL VENTRAL NEURAL TUBE PATTERNING | 7 | 7.16e-01 | 1.00e+00 | 0.35300 | -8.75e-02 | -9.07e-02 | -4.38e-02 | -2.09e-02 | 3.27e-01 | 6.88e-01 | 6.78e-01 | 8.41e-01 | 9.24e-01 | 1.34e-01 |
| HEMIDESMOSOME ASSEMBLY | 6 | 4.12e-01 | 9.08e-01 | 0.35300 | 1.57e-02 | 1.06e-01 | -1.82e-01 | 1.94e-01 | -2.07e-01 | 9.47e-01 | 6.54e-01 | 4.40e-01 | 4.11e-01 | 3.80e-01 |
| NEGATIVE REGULATION OF THYMOCYTE APOPTOTIC PROCESS | 10 | 8.25e-01 | 1.00e+00 | 0.35300 | 1.64e-01 | 1.81e-01 | 5.97e-02 | 2.35e-01 | -7.93e-02 | 3.69e-01 | 3.21e-01 | 7.44e-01 | 1.98e-01 | 6.64e-01 |
| PHOSPHATE ION TRANSMEMBRANE TRANSPORT | 17 | 7.28e-01 | 1.00e+00 | 0.35300 | 1.78e-01 | 1.71e-01 | 1.12e-01 | 2.22e-01 | 5.00e-02 | 2.05e-01 | 2.23e-01 | 4.24e-01 | 1.14e-01 | 7.21e-01 |
| REGULATION OF TOOTH MINERALIZATION | 10 | 3.19e-01 | 8.47e-01 | 0.35300 | -1.14e-01 | -7.03e-02 | -3.03e-01 | 5.72e-02 | -1.10e-01 | 5.33e-01 | 7.00e-01 | 9.74e-02 | 7.54e-01 | 5.48e-01 |
| DAMP METABOLIC PROCESS | 7 | 9.38e-01 | 1.00e+00 | 0.35300 | 1.78e-01 | 1.73e-01 | 1.70e-01 | 1.81e-01 | -3.25e-02 | 4.14e-01 | 4.27e-01 | 4.35e-01 | 4.06e-01 | 8.82e-01 |
| FEVER GENERATION | 11 | 4.75e-01 | 9.40e-01 | 0.35300 | -1.92e-01 | -1.93e-01 | -9.14e-02 | -1.26e-01 | 1.62e-01 | 2.69e-01 | 2.68e-01 | 6.00e-01 | 4.69e-01 | 3.53e-01 |
| REGULATION OF TRANSCRIPTION BY RNA POLYMERASE I | 45 | 3.85e-01 | 8.92e-01 | 0.35300 | 1.77e-01 | 1.67e-01 | 1.80e-01 | 1.57e-01 | 8.95e-02 | 3.98e-02 | 5.28e-02 | 3.62e-02 | 6.76e-02 | 2.99e-01 |
| DISACCHARIDE METABOLIC PROCESS | 11 | 7.67e-01 | 1.00e+00 | 0.35300 | -1.56e-01 | -1.88e-01 | -3.67e-02 | -1.65e-01 | 1.91e-01 | 3.71e-01 | 2.80e-01 | 8.33e-01 | 3.44e-01 | 2.73e-01 |
| MITOCHONDRIAL GENE EXPRESSION | 162 | 6.67e-11 | 1.29e-08 | 0.35300 | 1.72e-01 | 1.54e-01 | 2.65e-01 | 3.34e-02 | -1.59e-02 | 1.55e-04 | 7.46e-04 | 6.17e-09 | 4.64e-01 | 7.27e-01 |
| KILLING BY HOST OF SYMBIONT CELLS | 28 | 3.39e-01 | 8.59e-01 | 0.35300 | -1.93e-01 | -2.00e-01 | -9.74e-02 | -1.78e-01 | 7.91e-02 | 7.76e-02 | 6.72e-02 | 3.72e-01 | 1.03e-01 | 4.69e-01 |
| INTERLEUKIN 21 PRODUCTION | 5 | 3.26e-01 | 8.49e-01 | 0.35300 | -3.65e-02 | -4.23e-02 | -2.40e-01 | 2.39e-01 | -8.07e-02 | 8.88e-01 | 8.70e-01 | 3.52e-01 | 3.55e-01 | 7.55e-01 |
| DOUBLE STRAND BREAK REPAIR VIA BREAK INDUCED REPLICATION | 12 | 2.70e-01 | 7.97e-01 | 0.35300 | 1.19e-01 | 1.07e-01 | 2.56e-01 | -6.34e-02 | 1.70e-01 | 4.74e-01 | 5.23e-01 | 1.24e-01 | 7.04e-01 | 3.07e-01 |
| NEUTROPHIL MEDIATED IMMUNITY | 36 | 6.67e-03 | 9.31e-02 | 0.35300 | -1.87e-02 | -6.32e-02 | 1.66e-01 | -8.85e-02 | 2.91e-01 | 8.46e-01 | 5.12e-01 | 8.42e-02 | 3.58e-01 | 2.54e-03 |
| POSITIVE REGULATION OF LOW DENSITY LIPOPROTEIN RECEPTOR ACTIVITY | 5 | 3.62e-01 | 8.77e-01 | 0.35300 | -1.77e-02 | 4.52e-02 | -6.55e-04 | -5.95e-02 | 3.44e-01 | 9.45e-01 | 8.61e-01 | 9.98e-01 | 8.18e-01 | 1.83e-01 |
| CONVERGENT EXTENSION INVOLVED IN ORGANOGENESIS | 5 | 4.53e-01 | 9.30e-01 | 0.35200 | 5.64e-02 | 1.02e-01 | 8.42e-02 | -2.63e-03 | -3.22e-01 | 8.27e-01 | 6.94e-01 | 7.44e-01 | 9.92e-01 | 2.13e-01 |
| MODIFICATION OF POSTSYNAPTIC ACTIN CYTOSKELETON | 11 | 7.82e-01 | 1.00e+00 | 0.35200 | 1.88e-01 | 1.53e-01 | 1.94e-01 | 1.54e-01 | -6.23e-02 | 2.81e-01 | 3.78e-01 | 2.64e-01 | 3.76e-01 | 7.20e-01 |
| POSITIVE REGULATION OF CGMP MEDIATED SIGNALING | 5 | 9.40e-01 | 1.00e+00 | 0.35200 | 1.73e-01 | 1.38e-01 | 1.76e-01 | 2.06e-01 | 4.19e-02 | 5.03e-01 | 5.94e-01 | 4.95e-01 | 4.24e-01 | 8.71e-01 |
| CELLULAR RESPONSE TO PEPTIDOGLYCAN | 6 | 8.76e-01 | 1.00e+00 | 0.35200 | 1.27e-01 | 1.34e-01 | 1.18e-01 | 1.29e-01 | 2.44e-01 | 5.89e-01 | 5.71e-01 | 6.17e-01 | 5.83e-01 | 3.01e-01 |
| POST TRANSLATIONAL PROTEIN TARGETING TO MEMBRANE TRANSLOCATION | 8 | 8.20e-02 | 4.71e-01 | 0.35200 | 1.26e-01 | 1.73e-01 | 2.35e-01 | -1.18e-01 | 9.69e-02 | 5.39e-01 | 3.98e-01 | 2.50e-01 | 5.62e-01 | 6.35e-01 |
| SUGAR MEDIATED SIGNALING PATHWAY | 9 | 3.92e-01 | 8.92e-01 | 0.35200 | 1.48e-01 | 1.38e-01 | 2.76e-01 | -5.77e-02 | 5.94e-02 | 4.41e-01 | 4.73e-01 | 1.52e-01 | 7.65e-01 | 7.58e-01 |
| CELLULAR LIPID BIOSYNTHETIC PROCESS | 12 | 3.61e-01 | 8.77e-01 | 0.35200 | -1.57e-01 | -1.56e-01 | -2.19e-01 | -3.67e-02 | 1.61e-01 | 3.46e-01 | 3.50e-01 | 1.89e-01 | 8.26e-01 | 3.34e-01 |
| CELLULAR RESPONSE TO EPINEPHRINE STIMULUS | 11 | 6.49e-01 | 1.00e+00 | 0.35200 | 1.70e-01 | 1.50e-01 | 1.48e-01 | 2.02e-01 | -1.01e-01 | 3.29e-01 | 3.90e-01 | 3.97e-01 | 2.46e-01 | 5.62e-01 |
| METAPHASE CHROMOSOME ALIGNMENT | 97 | 4.85e-04 | 1.26e-02 | 0.35200 | 1.31e-01 | 9.85e-02 | 2.25e-01 | 7.60e-02 | 2.01e-01 | 2.55e-02 | 9.36e-02 | 1.25e-04 | 1.96e-01 | 6.06e-04 |
| PRIMARY AMINO COMPOUND BIOSYNTHETIC PROCESS | 6 | 8.46e-01 | 1.00e+00 | 0.35200 | -1.67e-01 | -1.18e-01 | -2.30e-01 | -1.60e-01 | -5.88e-02 | 4.79e-01 | 6.16e-01 | 3.28e-01 | 4.97e-01 | 8.03e-01 |
| TRANSCRIPTION INITIATION AT RNA POLYMERASE II PROMOTER | 95 | 3.72e-04 | 1.03e-02 | 0.35200 | 1.53e-01 | 1.12e-01 | 2.51e-01 | 7.03e-02 | 1.42e-01 | 9.90e-03 | 5.89e-02 | 2.35e-05 | 2.36e-01 | 1.70e-02 |
| MOTOR LEARNING | 7 | 4.43e-01 | 9.28e-01 | 0.35200 | 1.13e-01 | 7.95e-02 | 1.57e-01 | -4.25e-02 | -2.80e-01 | 6.03e-01 | 7.16e-01 | 4.72e-01 | 8.46e-01 | 2.00e-01 |
| AMYLIN RECEPTOR SIGNALING PATHWAY | 6 | 9.51e-01 | 1.00e+00 | 0.35200 | -1.73e-01 | -1.79e-01 | -6.94e-02 | -2.24e-01 | 8.21e-02 | 4.63e-01 | 4.47e-01 | 7.68e-01 | 3.41e-01 | 7.28e-01 |
| POSITIVE REGULATION OF CHROMOSOME SEPARATION | 29 | 2.53e-01 | 7.80e-01 | 0.35200 | 1.76e-01 | 1.89e-01 | 2.08e-01 | 1.02e-01 | 5.75e-02 | 1.01e-01 | 7.79e-02 | 5.23e-02 | 3.43e-01 | 5.92e-01 |
| NEGATIVE REGULATION OF CELL VOLUME | 5 | 8.01e-01 | 1.00e+00 | 0.35200 | -1.72e-01 | -1.37e-01 | -2.51e-01 | -8.81e-03 | 1.09e-01 | 5.06e-01 | 5.95e-01 | 3.30e-01 | 9.73e-01 | 6.72e-01 |
| REGULATION OF CALCIUM ION DEPENDENT EXOCYTOSIS | 39 | 2.91e-01 | 8.18e-01 | 0.35100 | 1.94e-01 | 2.03e-01 | 1.63e-01 | 1.35e-01 | -4.48e-04 | 3.57e-02 | 2.85e-02 | 7.89e-02 | 1.45e-01 | 9.96e-01 |
| EXIT FROM MITOSIS | 32 | 6.36e-02 | 4.12e-01 | 0.35100 | 1.60e-01 | 1.52e-01 | 1.61e-01 | 6.58e-02 | -2.11e-01 | 1.16e-01 | 1.37e-01 | 1.15e-01 | 5.19e-01 | 3.91e-02 |
| REGULATION OF TORC2 SIGNALING | 6 | 6.80e-01 | 1.00e+00 | 0.35100 | -9.62e-02 | -1.19e-01 | 5.33e-02 | -2.51e-01 | 1.84e-01 | 6.83e-01 | 6.13e-01 | 8.21e-01 | 2.87e-01 | 4.35e-01 |
| IMMUNOLOGICAL SYNAPSE FORMATION | 15 | 3.47e-01 | 8.66e-01 | 0.35100 | -1.58e-01 | -1.71e-01 | 9.98e-03 | -2.40e-01 | 1.06e-01 | 2.88e-01 | 2.51e-01 | 9.47e-01 | 1.08e-01 | 4.77e-01 |
| POSITIVE REGULATION OF CHEMOKINE C X C MOTIF LIGAND 1 PRODUCTION | 5 | 9.18e-01 | 1.00e+00 | 0.35100 | -1.54e-01 | -1.83e-01 | -4.66e-02 | -2.49e-01 | 3.98e-02 | 5.51e-01 | 4.78e-01 | 8.57e-01 | 3.34e-01 | 8.78e-01 |
| XENOBIOTIC GLUCURONIDATION | 7 | 7.77e-01 | 1.00e+00 | 0.35100 | -5.28e-02 | -2.22e-02 | -1.95e-01 | 9.97e-03 | -2.86e-01 | 8.09e-01 | 9.19e-01 | 3.72e-01 | 9.64e-01 | 1.90e-01 |
| RESPONSE TO HYPEROXIA | 18 | 6.52e-01 | 1.00e+00 | 0.35100 | 1.72e-01 | 1.69e-01 | 2.08e-01 | 1.32e-01 | 6.32e-02 | 2.08e-01 | 2.14e-01 | 1.26e-01 | 3.31e-01 | 6.42e-01 |
| COLLECTING DUCT DEVELOPMENT | 15 | 3.09e-01 | 8.35e-01 | 0.35100 | 1.28e-01 | 6.22e-02 | 2.27e-01 | 1.25e-01 | 1.89e-01 | 3.89e-01 | 6.77e-01 | 1.29e-01 | 4.02e-01 | 2.05e-01 |
| TRIPARTITE REGIONAL SUBDIVISION | 19 | 3.05e-01 | 8.33e-01 | 0.35100 | -1.72e-01 | -2.07e-01 | -1.12e-01 | -1.58e-01 | -1.15e-01 | 1.95e-01 | 1.18e-01 | 4.00e-01 | 2.33e-01 | 3.86e-01 |
| NEGATIVE REGULATION OF POTASSIUM ION TRANSPORT | 36 | 3.18e-01 | 8.46e-01 | 0.35000 | -1.57e-01 | -1.30e-01 | -2.05e-01 | -1.10e-01 | -1.65e-01 | 1.03e-01 | 1.76e-01 | 3.37e-02 | 2.51e-01 | 8.68e-02 |
| PROTEIN CONTAINING COMPLEX REMODELING | 36 | 4.75e-01 | 9.40e-01 | 0.35000 | 1.82e-01 | 1.81e-01 | 1.34e-01 | 1.90e-01 | 5.33e-02 | 5.82e-02 | 6.09e-02 | 1.64e-01 | 4.83e-02 | 5.80e-01 |
| RESPONSE TO INCREASED OXYGEN LEVELS | 24 | 3.94e-01 | 8.93e-01 | 0.35000 | 1.63e-01 | 1.39e-01 | 2.39e-01 | 1.06e-01 | 9.34e-02 | 1.67e-01 | 2.38e-01 | 4.30e-02 | 3.71e-01 | 4.28e-01 |
| FC EPSILON RECEPTOR SIGNALING PATHWAY | 24 | 5.15e-01 | 9.52e-01 | 0.35000 | -1.94e-01 | -2.09e-01 | -1.27e-01 | -1.53e-01 | 4.13e-02 | 1.00e-01 | 7.59e-02 | 2.82e-01 | 1.94e-01 | 7.26e-01 |
| NEGATIVE REGULATION OF CHEMOTAXIS | 65 | 6.58e-02 | 4.17e-01 | 0.35000 | -1.83e-01 | -2.06e-01 | -1.44e-01 | -1.60e-01 | -8.85e-03 | 1.06e-02 | 4.06e-03 | 4.41e-02 | 2.57e-02 | 9.02e-01 |
| MITOTIC METAPHASE CHROMOSOME ALIGNMENT | 58 | 1.31e-02 | 1.51e-01 | 0.35000 | 1.07e-01 | 8.22e-02 | 1.93e-01 | 5.05e-02 | 2.54e-01 | 1.58e-01 | 2.79e-01 | 1.11e-02 | 5.06e-01 | 8.22e-04 |
| VITAMIN D3 METABOLIC PROCESS | 6 | 9.25e-01 | 1.00e+00 | 0.35000 | 1.68e-01 | 1.56e-01 | 1.16e-01 | 1.80e-01 | -1.55e-01 | 4.75e-01 | 5.08e-01 | 6.24e-01 | 4.45e-01 | 5.12e-01 |
| POSITIVE REGULATION OF HEPATOCYTE PROLIFERATION | 10 | 2.22e-01 | 7.45e-01 | 0.35000 | -4.86e-02 | -1.47e-01 | 9.27e-02 | -4.90e-02 | 2.95e-01 | 7.90e-01 | 4.20e-01 | 6.12e-01 | 7.88e-01 | 1.06e-01 |
| SEMICIRCULAR CANAL DEVELOPMENT | 9 | 1.10e-01 | 5.51e-01 | 0.35000 | -1.15e-01 | -2.32e-01 | 8.25e-02 | -1.29e-01 | 1.78e-01 | 5.52e-01 | 2.28e-01 | 6.68e-01 | 5.02e-01 | 3.54e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS EXONUCLEOLYTIC 3 5 | 12 | 6.59e-01 | 1.00e+00 | 0.34900 | 1.17e-01 | 6.82e-02 | 2.12e-01 | 9.17e-02 | 2.25e-01 | 4.85e-01 | 6.83e-01 | 2.03e-01 | 5.82e-01 | 1.78e-01 |
| NEGATIVE REGULATION OF NEUROTRANSMITTER TRANSPORT | 8 | 4.81e-01 | 9.43e-01 | 0.34900 | 1.59e-01 | 1.13e-01 | 2.36e-01 | 8.51e-02 | -1.46e-01 | 4.37e-01 | 5.79e-01 | 2.48e-01 | 6.77e-01 | 4.74e-01 |
| SODIUM DEPENDENT PHOSPHATE TRANSPORT | 12 | 3.57e-01 | 8.74e-01 | 0.34900 | 5.58e-02 | 6.27e-02 | -5.51e-02 | 1.39e-01 | -3.04e-01 | 7.38e-01 | 7.07e-01 | 7.41e-01 | 4.05e-01 | 6.78e-02 |
| MAMMARY GLAND BRANCHING INVOLVED IN PREGNANCY | 6 | 8.40e-01 | 1.00e+00 | 0.34900 | -1.28e-01 | -1.35e-01 | -3.46e-02 | -8.93e-02 | 2.80e-01 | 5.86e-01 | 5.68e-01 | 8.83e-01 | 7.05e-01 | 2.35e-01 |
| POSITIVE REGULATION OF SYNCYTIUM FORMATION BY PLASMA MEMBRANE FUSION | 24 | 6.25e-01 | 9.94e-01 | 0.34900 | -1.82e-01 | -1.92e-01 | -1.74e-01 | -1.37e-01 | -5.34e-02 | 1.23e-01 | 1.03e-01 | 1.39e-01 | 2.45e-01 | 6.51e-01 |
| CHEMOKINE C C MOTIF LIGAND 5 PRODUCTION | 10 | 4.39e-01 | 9.25e-01 | 0.34900 | 1.34e-01 | 1.26e-01 | 2.71e-01 | 1.93e-02 | 1.19e-01 | 4.65e-01 | 4.90e-01 | 1.38e-01 | 9.16e-01 | 5.14e-01 |
| VESICLE TARGETING TO FROM OR WITHIN GOLGI | 32 | 9.38e-02 | 5.05e-01 | 0.34900 | 1.07e-01 | 8.65e-02 | 1.92e-01 | 2.48e-02 | 2.56e-01 | 2.94e-01 | 3.97e-01 | 6.01e-02 | 8.08e-01 | 1.24e-02 |
| NEGATIVE REGULATION OF INTERLEUKIN 1 PRODUCTION | 49 | 2.57e-02 | 2.42e-01 | 0.34900 | -1.79e-01 | -1.70e-01 | -8.35e-02 | -2.25e-01 | -5.91e-02 | 3.04e-02 | 3.97e-02 | 3.12e-01 | 6.52e-03 | 4.74e-01 |
| REGULATION OF NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING SIGNALING PATHWAY | 14 | 5.87e-01 | 9.85e-01 | 0.34900 | -1.71e-01 | -1.94e-01 | -1.27e-01 | -1.48e-01 | -1.29e-01 | 2.67e-01 | 2.09e-01 | 4.12e-01 | 3.39e-01 | 4.02e-01 |
| ERBB2 SIGNALING PATHWAY | 18 | 1.60e-01 | 6.59e-01 | 0.34900 | 1.04e-01 | 1.60e-01 | -4.78e-02 | 2.15e-01 | -1.92e-01 | 4.43e-01 | 2.41e-01 | 7.25e-01 | 1.15e-01 | 1.59e-01 |
| FIBROBLAST GROWTH FACTOR PRODUCTION | 9 | 5.45e-01 | 9.61e-01 | 0.34900 | -1.24e-01 | -1.23e-01 | -5.39e-02 | -1.96e-01 | 2.23e-01 | 5.20e-01 | 5.24e-01 | 7.79e-01 | 3.08e-01 | 2.47e-01 |
| NEGATIVE REGULATION OF PHOTORECEPTOR CELL DIFFERENTIATION | 6 | 4.04e-01 | 9.05e-01 | 0.34900 | -1.37e-02 | -6.16e-02 | 2.37e-01 | -1.19e-01 | 2.17e-01 | 9.54e-01 | 7.94e-01 | 3.15e-01 | 6.13e-01 | 3.57e-01 |
| POSITIVE REGULATION OF THE FORCE OF HEART CONTRACTION | 5 | 9.48e-01 | 1.00e+00 | 0.34900 | -1.57e-01 | -1.36e-01 | -2.19e-01 | -5.93e-02 | -1.64e-01 | 5.43e-01 | 5.99e-01 | 3.96e-01 | 8.18e-01 | 5.26e-01 |
| POSITIVE REGULATION OF PROTEIN MONOUBIQUITINATION | 5 | 5.99e-01 | 9.90e-01 | 0.34800 | 3.31e-02 | -6.31e-02 | 1.89e-01 | -7.73e-02 | 2.73e-01 | 8.98e-01 | 8.07e-01 | 4.65e-01 | 7.65e-01 | 2.90e-01 |
| PROTEIN LOCALIZATION TO SITE OF DOUBLE STRAND BREAK | 6 | 1.45e-01 | 6.29e-01 | 0.34800 | 1.61e-01 | 6.24e-02 | 2.89e-01 | -8.63e-02 | -1.62e-02 | 4.93e-01 | 7.91e-01 | 2.20e-01 | 7.14e-01 | 9.45e-01 |
| NEGATIVE REGULATION OF FIBROBLAST GROWTH FACTOR PRODUCTION | 5 | 3.17e-02 | 2.80e-01 | 0.34800 | 4.87e-02 | 3.32e-02 | 3.84e-02 | -1.41e-01 | 3.11e-01 | 8.50e-01 | 8.98e-01 | 8.82e-01 | 5.85e-01 | 2.29e-01 |
| NEGATIVE REGULATION OF FIBRINOLYSIS | 13 | 4.73e-01 | 9.40e-01 | 0.34800 | 1.73e-01 | 1.79e-01 | 1.65e-01 | 4.26e-02 | -1.74e-01 | 2.80e-01 | 2.63e-01 | 3.04e-01 | 7.90e-01 | 2.77e-01 |
| LEPTIN MEDIATED SIGNALING PATHWAY | 10 | 9.15e-01 | 1.00e+00 | 0.34800 | -1.82e-01 | -1.74e-01 | -1.14e-01 | -2.05e-01 | 4.93e-02 | 3.19e-01 | 3.40e-01 | 5.32e-01 | 2.61e-01 | 7.87e-01 |
| REGULATION OF LIGASE ACTIVITY | 7 | 7.35e-01 | 1.00e+00 | 0.34800 | -1.61e-01 | -1.92e-01 | 1.60e-02 | -2.26e-01 | 8.42e-02 | 4.61e-01 | 3.80e-01 | 9.41e-01 | 3.00e-01 | 7.00e-01 |
| REGULATION OF B CELL APOPTOTIC PROCESS | 20 | 6.30e-02 | 4.12e-01 | 0.34800 | -1.45e-01 | -1.71e-01 | 4.43e-02 | -2.62e-01 | 2.73e-03 | 2.61e-01 | 1.85e-01 | 7.32e-01 | 4.24e-02 | 9.83e-01 |
| OVULATION | 15 | 1.30e-01 | 5.97e-01 | 0.34800 | -1.46e-01 | -1.92e-01 | -1.84e-01 | -6.30e-02 | -1.59e-01 | 3.28e-01 | 1.99e-01 | 2.18e-01 | 6.73e-01 | 2.87e-01 |
| COMPLEMENT DEPENDENT CYTOTOXICITY | 13 | 4.19e-01 | 9.11e-01 | 0.34800 | -1.06e-01 | -1.06e-01 | 6.50e-03 | -1.12e-01 | 2.93e-01 | 5.07e-01 | 5.09e-01 | 9.68e-01 | 4.86e-01 | 6.73e-02 |
| RESPONSE TO FOLLICLE STIMULATING HORMONE | 15 | 7.34e-01 | 1.00e+00 | 0.34800 | -1.72e-01 | -1.66e-01 | -1.72e-01 | -1.21e-01 | -1.40e-01 | 2.50e-01 | 2.66e-01 | 2.49e-01 | 4.17e-01 | 3.46e-01 |
| NEGATIVE REGULATION OF VIRAL ENTRY INTO HOST CELL | 22 | 3.23e-01 | 8.48e-01 | 0.34700 | -1.55e-01 | -1.63e-01 | -1.23e-01 | -1.41e-01 | 1.88e-01 | 2.09e-01 | 1.86e-01 | 3.19e-01 | 2.52e-01 | 1.27e-01 |
| IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN PHAGOCYTOSIS | 26 | 1.51e-01 | 6.42e-01 | 0.34700 | -1.71e-01 | -2.21e-01 | -3.82e-02 | -1.92e-01 | 6.56e-02 | 1.31e-01 | 5.10e-02 | 7.36e-01 | 9.09e-02 | 5.63e-01 |
| CELLULAR DEFENSE RESPONSE | 50 | 1.46e-01 | 6.32e-01 | 0.34700 | -1.84e-01 | -2.01e-01 | -1.69e-01 | -1.29e-01 | 2.59e-02 | 2.41e-02 | 1.38e-02 | 3.84e-02 | 1.14e-01 | 7.51e-01 |
| KYNURENINE METABOLIC PROCESS | 11 | 7.55e-01 | 1.00e+00 | 0.34700 | -1.27e-01 | -1.07e-01 | -1.96e-01 | -5.59e-02 | -2.27e-01 | 4.66e-01 | 5.38e-01 | 2.61e-01 | 7.48e-01 | 1.92e-01 |
| NUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 35 | 5.13e-01 | 9.52e-01 | 0.34700 | 1.82e-01 | 1.89e-01 | 1.32e-01 | 1.73e-01 | -6.64e-02 | 6.31e-02 | 5.35e-02 | 1.77e-01 | 7.57e-02 | 4.97e-01 |
| POSITIVE REGULATION OF RRNA PROCESSING | 10 | 1.38e-01 | 6.20e-01 | 0.34700 | 5.87e-02 | 2.34e-02 | 2.34e-01 | -1.83e-01 | 1.67e-01 | 7.48e-01 | 8.98e-01 | 2.00e-01 | 3.15e-01 | 3.60e-01 |
| REGULATION OF AMINE METABOLIC PROCESS | 31 | 4.16e-01 | 9.11e-01 | 0.34700 | 1.82e-01 | 1.70e-01 | 1.67e-01 | 1.48e-01 | -9.27e-02 | 7.91e-02 | 1.02e-01 | 1.08e-01 | 1.53e-01 | 3.72e-01 |
| NEGATIVE REGULATION OF HORMONE METABOLIC PROCESS | 12 | 7.40e-01 | 1.00e+00 | 0.34700 | -1.77e-01 | -1.68e-01 | -8.75e-02 | -2.26e-01 | -4.58e-02 | 2.88e-01 | 3.15e-01 | 6.00e-01 | 1.76e-01 | 7.83e-01 |
| LONG CHAIN FATTY ACID BIOSYNTHETIC PROCESS | 26 | 2.06e-01 | 7.27e-01 | 0.34600 | 1.46e-01 | 1.45e-01 | 3.98e-02 | 1.69e-01 | -2.18e-01 | 1.98e-01 | 2.01e-01 | 7.25e-01 | 1.35e-01 | 5.45e-02 |
| PYRIMIDINE NUCLEOBASE CATABOLIC PROCESS | 8 | 8.09e-01 | 1.00e+00 | 0.34600 | 1.22e-01 | 1.51e-01 | 7.82e-03 | 1.79e-01 | -2.23e-01 | 5.49e-01 | 4.59e-01 | 9.69e-01 | 3.80e-01 | 2.75e-01 |
| MEMBRANE RAFT LOCALIZATION | 8 | 5.15e-01 | 9.52e-01 | 0.34600 | 7.99e-03 | -2.36e-04 | -1.56e-02 | 9.20e-02 | 3.33e-01 | 9.69e-01 | 9.99e-01 | 9.39e-01 | 6.52e-01 | 1.03e-01 |
| CONVERGENT EXTENSION INVOLVED IN AXIS ELONGATION | 6 | 5.56e-01 | 9.68e-01 | 0.34600 | 6.49e-03 | -8.04e-02 | 2.25e-01 | -1.24e-01 | 2.17e-01 | 9.78e-01 | 7.33e-01 | 3.40e-01 | 5.99e-01 | 3.57e-01 |
| PURINE RIBONUCLEOSIDE SALVAGE | 6 | 9.23e-01 | 1.00e+00 | 0.34600 | -1.59e-01 | -1.43e-01 | -9.75e-02 | -2.33e-01 | -9.94e-02 | 5.01e-01 | 5.44e-01 | 6.79e-01 | 3.22e-01 | 6.73e-01 |
| SYNAPTIC VESICLE PRIMING | 18 | 7.68e-01 | 1.00e+00 | 0.34500 | 1.61e-01 | 1.57e-01 | 1.65e-01 | 1.66e-01 | 1.18e-01 | 2.37e-01 | 2.49e-01 | 2.27e-01 | 2.22e-01 | 3.85e-01 |
| CRANIAL NERVE DEVELOPMENT | 61 | 5.58e-02 | 3.85e-01 | 0.34500 | 1.97e-01 | 1.88e-01 | 1.47e-01 | 1.51e-01 | -3.18e-02 | 7.88e-03 | 1.12e-02 | 4.76e-02 | 4.13e-02 | 6.67e-01 |
| FACIAL NERVE MORPHOGENESIS | 9 | 4.86e-01 | 9.43e-01 | 0.34500 | 1.72e-01 | 1.97e-01 | -3.93e-03 | 1.86e-01 | -1.28e-01 | 3.73e-01 | 3.07e-01 | 9.84e-01 | 3.34e-01 | 5.05e-01 |
| REGULATION OF DNA TEMPLATED TRANSCRIPTION ELONGATION | 102 | 9.54e-04 | 2.18e-02 | 0.34500 | 1.40e-01 | 1.02e-01 | 2.19e-01 | 9.72e-02 | 1.78e-01 | 1.42e-02 | 7.53e-02 | 1.37e-04 | 8.99e-02 | 1.84e-03 |
| INTERLEUKIN 17 PRODUCTION | 46 | 1.20e-02 | 1.43e-01 | 0.34500 | -1.31e-01 | -1.63e-01 | 3.54e-02 | -2.00e-01 | 1.84e-01 | 1.24e-01 | 5.56e-02 | 6.78e-01 | 1.89e-02 | 3.06e-02 |
| ESTABLISHMENT OR MAINTENANCE OF MONOPOLAR CELL POLARITY | 25 | 4.33e-01 | 9.19e-01 | 0.34500 | 1.55e-01 | 1.73e-01 | 6.27e-02 | 1.79e-01 | -1.71e-01 | 1.81e-01 | 1.34e-01 | 5.87e-01 | 1.22e-01 | 1.39e-01 |
| LEUKOCYTE ADHESION TO ARTERIAL ENDOTHELIAL CELL | 6 | 6.00e-01 | 9.90e-01 | 0.34500 | 1.05e-01 | 7.33e-02 | 5.18e-03 | 1.79e-01 | -2.65e-01 | 6.57e-01 | 7.56e-01 | 9.82e-01 | 4.47e-01 | 2.60e-01 |
| CELL KILLING | 220 | 1.22e-06 | 7.48e-05 | 0.34500 | -1.84e-01 | -2.04e-01 | -9.73e-02 | -1.77e-01 | 5.14e-02 | 2.57e-06 | 1.73e-07 | 1.29e-02 | 6.23e-06 | 1.89e-01 |
| CUT CATABOLIC PROCESS | 5 | 6.75e-01 | 1.00e+00 | 0.34500 | -1.41e-01 | -1.33e-01 | -2.14e-01 | -7.21e-02 | 1.75e-01 | 5.86e-01 | 6.08e-01 | 4.07e-01 | 7.80e-01 | 4.99e-01 |
| AMINE BIOSYNTHETIC PROCESS | 37 | 8.90e-02 | 4.92e-01 | 0.34500 | 1.84e-01 | 1.44e-01 | 2.36e-01 | 8.84e-02 | -2.51e-02 | 5.25e-02 | 1.29e-01 | 1.30e-02 | 3.52e-01 | 7.92e-01 |
| REGULATION OF ESTABLISHMENT OF T CELL POLARITY | 6 | 9.53e-01 | 1.00e+00 | 0.34500 | -1.71e-01 | -1.72e-01 | -8.62e-02 | -1.71e-01 | 1.54e-01 | 4.69e-01 | 4.66e-01 | 7.15e-01 | 4.69e-01 | 5.14e-01 |
| NEGATIVE REGULATION OF OXIDATIVE STRESS INDUCED NEURON INTRINSIC APOPTOTIC SIGNALING PATHWAY | 12 | 2.69e-01 | 7.95e-01 | 0.34500 | -1.52e-01 | -1.29e-01 | -1.01e-02 | -2.79e-01 | 3.01e-02 | 3.61e-01 | 4.39e-01 | 9.52e-01 | 9.38e-02 | 8.57e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY BARORECEPTOR FEEDBACK | 5 | 8.33e-01 | 1.00e+00 | 0.34500 | 1.31e-01 | 1.74e-01 | 1.48e-02 | 2.43e-01 | -1.11e-01 | 6.12e-01 | 5.01e-01 | 9.54e-01 | 3.48e-01 | 6.67e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 1 PRODUCTION | 71 | 1.72e-02 | 1.86e-01 | 0.34500 | -1.61e-01 | -1.91e-01 | -6.39e-02 | -1.61e-01 | 1.62e-01 | 1.87e-02 | 5.39e-03 | 3.52e-01 | 1.90e-02 | 1.81e-02 |
| SPINDLE MIDZONE ASSEMBLY | 13 | 1.47e-01 | 6.34e-01 | 0.34500 | -8.21e-02 | -1.22e-01 | 8.90e-02 | -5.19e-02 | 2.94e-01 | 6.08e-01 | 4.47e-01 | 5.79e-01 | 7.46e-01 | 6.61e-02 |
| N ACETYLGLUCOSAMINE METABOLIC PROCESS | 16 | 3.21e-01 | 8.47e-01 | 0.34500 | 1.19e-01 | 1.72e-01 | 3.05e-02 | 8.36e-02 | -2.59e-01 | 4.10e-01 | 2.32e-01 | 8.33e-01 | 5.63e-01 | 7.32e-02 |
| DEFENSE RESPONSE TO GRAM NEGATIVE BACTERIUM | 85 | 2.07e-03 | 3.98e-02 | 0.34500 | -1.81e-01 | -2.09e-01 | -7.66e-02 | -1.62e-01 | 9.94e-02 | 3.85e-03 | 8.47e-04 | 2.22e-01 | 9.83e-03 | 1.13e-01 |
| POSITIVE REGULATION OF RESPONSE TO TUMOR CELL | 15 | 2.67e-01 | 7.95e-01 | 0.34400 | -1.91e-01 | -1.22e-01 | -1.99e-01 | -1.59e-01 | -5.21e-02 | 2.01e-01 | 4.15e-01 | 1.83e-01 | 2.85e-01 | 7.27e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 10 PRODUCTION | 40 | 5.24e-02 | 3.75e-01 | 0.34400 | -1.85e-01 | -1.89e-01 | -8.59e-02 | -1.97e-01 | -4.86e-02 | 4.26e-02 | 3.85e-02 | 3.47e-01 | 3.11e-02 | 5.95e-01 |
| PROTEIN C LINKED GLYCOSYLATION | 6 | 5.85e-01 | 9.85e-01 | 0.34400 | 6.93e-02 | 4.90e-02 | 1.06e-01 | -7.24e-02 | -3.08e-01 | 7.69e-01 | 8.35e-01 | 6.53e-01 | 7.59e-01 | 1.91e-01 |
| RESPONSE TO INTERFERON ALPHA | 17 | 9.66e-02 | 5.12e-01 | 0.34400 | -7.45e-02 | -9.39e-02 | 1.15e-01 | -2.38e-01 | 1.85e-01 | 5.95e-01 | 5.03e-01 | 4.13e-01 | 8.87e-02 | 1.87e-01 |
| POSITIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORT | 35 | 4.71e-02 | 3.52e-01 | 0.34400 | 7.13e-02 | 9.26e-02 | -3.50e-02 | 7.77e-02 | -3.12e-01 | 4.65e-01 | 3.43e-01 | 7.20e-01 | 4.26e-01 | 1.38e-03 |
| REGULATION OF NEURON MATURATION | 8 | 8.25e-01 | 1.00e+00 | 0.34400 | 1.28e-01 | 1.47e-01 | 9.91e-03 | 1.91e-01 | -2.09e-01 | 5.30e-01 | 4.71e-01 | 9.61e-01 | 3.50e-01 | 3.05e-01 |
| TONIC SMOOTH MUSCLE CONTRACTION | 11 | 6.59e-01 | 1.00e+00 | 0.34400 | 1.43e-01 | 1.54e-01 | 4.25e-03 | 1.80e-01 | -2.05e-01 | 4.11e-01 | 3.78e-01 | 9.81e-01 | 3.01e-01 | 2.40e-01 |
| SEROTONIN RECEPTOR SIGNALING PATHWAY | 27 | 1.04e-01 | 5.37e-01 | 0.34400 | -6.83e-02 | -4.28e-02 | -1.79e-01 | 2.11e-02 | -2.82e-01 | 5.39e-01 | 7.00e-01 | 1.08e-01 | 8.50e-01 | 1.12e-02 |
| MULTICELLULAR ORGANISMAL LEVEL WATER HOMEOSTASIS | 33 | 3.60e-02 | 3.03e-01 | 0.34400 | 5.93e-02 | 1.82e-02 | 1.25e-01 | 1.10e-01 | 2.94e-01 | 5.55e-01 | 8.56e-01 | 2.12e-01 | 2.74e-01 | 3.43e-03 |
| REGULATION OF RAB PROTEIN SIGNAL TRANSDUCTION | 7 | 7.49e-01 | 1.00e+00 | 0.34400 | -9.78e-02 | -1.57e-01 | 1.09e-02 | -9.48e-02 | 2.74e-01 | 6.54e-01 | 4.71e-01 | 9.60e-01 | 6.64e-01 | 2.10e-01 |
| PROTEIN O LINKED MANNOSYLATION | 17 | 8.01e-01 | 1.00e+00 | 0.34400 | 1.63e-01 | 1.64e-01 | 1.52e-01 | 1.69e-01 | 1.14e-01 | 2.45e-01 | 2.43e-01 | 2.76e-01 | 2.27e-01 | 4.17e-01 |
| ESTABLISHMENT OR MAINTENANCE OF CYTOSKELETON POLARITY | 7 | 8.17e-01 | 1.00e+00 | 0.34400 | 1.62e-01 | 1.98e-01 | 4.99e-02 | 2.11e-01 | 7.46e-02 | 4.58e-01 | 3.63e-01 | 8.19e-01 | 3.34e-01 | 7.32e-01 |
| RESPONSE TO ERYTHROPOIETIN | 7 | 3.66e-01 | 8.79e-01 | 0.34400 | -6.79e-02 | -7.21e-02 | 1.50e-01 | -1.79e-01 | 2.32e-01 | 7.56e-01 | 7.41e-01 | 4.91e-01 | 4.12e-01 | 2.88e-01 |
| CO TRANSCRIPTIONAL MRNA 3 END PROCESSING CLEAVAGE AND POLYADENYLATION PATHWAY | 5 | 6.20e-01 | 9.90e-01 | 0.34400 | -2.42e-02 | -8.96e-02 | 1.48e-01 | -2.01e-01 | 2.17e-01 | 9.25e-01 | 7.29e-01 | 5.66e-01 | 4.37e-01 | 4.00e-01 |
| CELL SUBSTRATE JUNCTION DISASSEMBLY | 8 | 7.12e-01 | 1.00e+00 | 0.34400 | 1.54e-01 | 1.43e-01 | 2.58e-01 | -6.73e-05 | 8.69e-02 | 4.49e-01 | 4.85e-01 | 2.07e-01 | 1.00e+00 | 6.70e-01 |
| CORPUS CALLOSUM DEVELOPMENT | 26 | 5.52e-01 | 9.65e-01 | 0.34300 | 1.62e-01 | 1.69e-01 | 1.48e-01 | 1.57e-01 | 1.29e-01 | 1.52e-01 | 1.36e-01 | 1.93e-01 | 1.65e-01 | 2.56e-01 |
| TELOMERASE RNA LOCALIZATION | 18 | 3.42e-01 | 8.60e-01 | 0.34300 | -1.47e-01 | -1.62e-01 | 5.98e-03 | -1.94e-01 | 1.80e-01 | 2.81e-01 | 2.35e-01 | 9.65e-01 | 1.54e-01 | 1.85e-01 |
| NEGATIVE REGULATION OF ERAD PATHWAY | 6 | 6.16e-01 | 9.90e-01 | 0.34300 | 1.38e-01 | 1.32e-01 | 1.87e-01 | -5.10e-02 | -2.10e-01 | 5.59e-01 | 5.75e-01 | 4.28e-01 | 8.29e-01 | 3.73e-01 |
| RNA SECONDARY STRUCTURE UNWINDING | 8 | 9.55e-01 | 1.00e+00 | 0.34300 | -1.73e-01 | -1.45e-01 | -1.83e-01 | -1.63e-01 | -8.15e-02 | 3.96e-01 | 4.77e-01 | 3.70e-01 | 4.24e-01 | 6.90e-01 |
| POLY A PLUS MRNA EXPORT FROM NUCLEUS | 18 | 3.50e-01 | 8.69e-01 | 0.34300 | 1.58e-01 | 1.10e-01 | 1.55e-01 | 1.61e-01 | 1.76e-01 | 2.46e-01 | 4.20e-01 | 2.55e-01 | 2.37e-01 | 1.96e-01 |
| POSITIVE REGULATION OF FEEDING BEHAVIOR | 10 | 3.24e-01 | 8.48e-01 | 0.34300 | -8.42e-02 | -1.47e-01 | 9.75e-02 | -7.44e-02 | 2.72e-01 | 6.45e-01 | 4.20e-01 | 5.93e-01 | 6.84e-01 | 1.37e-01 |
| REGULATION OF DNA CATABOLIC PROCESS | 11 | 7.74e-01 | 1.00e+00 | 0.34300 | 1.53e-01 | 1.56e-01 | 1.83e-01 | 8.54e-02 | 1.72e-01 | 3.79e-01 | 3.72e-01 | 2.94e-01 | 6.24e-01 | 3.24e-01 |
| OVULATION CYCLE PROCESS | 50 | 5.33e-03 | 8.06e-02 | 0.34300 | -1.71e-01 | -1.90e-01 | -1.67e-01 | -8.55e-02 | -1.31e-01 | 3.61e-02 | 2.02e-02 | 4.12e-02 | 2.96e-01 | 1.10e-01 |
| G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 1159 | 2.94e-33 | 3.68e-30 | 0.34300 | -1.69e-01 | -1.57e-01 | -2.13e-01 | -1.11e-01 | -8.12e-02 | 2.23e-22 | 2.38e-19 | 1.54e-34 | 1.54e-10 | 3.13e-06 |
| NUCLEOTIDE SUGAR TRANSMEMBRANE TRANSPORT | 11 | 1.06e-02 | 1.31e-01 | 0.34300 | 1.45e-01 | 1.79e-01 | 1.35e-01 | -1.19e-01 | -1.79e-01 | 4.04e-01 | 3.05e-01 | 4.39e-01 | 4.93e-01 | 3.03e-01 |
| REGULATION OF T CELL MEDIATED IMMUNITY | 95 | 4.78e-04 | 1.26e-02 | 0.34300 | -1.57e-01 | -1.94e-01 | -2.47e-02 | -1.95e-01 | 1.28e-01 | 8.17e-03 | 1.05e-03 | 6.77e-01 | 1.02e-03 | 3.09e-02 |
| ANTERIOR COMMISSURE MORPHOGENESIS | 7 | 7.32e-01 | 1.00e+00 | 0.34300 | 1.40e-01 | 1.59e-01 | 1.29e-01 | 1.21e-01 | -2.03e-01 | 5.20e-01 | 4.65e-01 | 5.55e-01 | 5.80e-01 | 3.52e-01 |
| DEADENYLATION DEPENDENT DECAPPING OF NUCLEAR TRANSCRIBED MRNA | 11 | 8.12e-01 | 1.00e+00 | 0.34300 | -1.37e-01 | -1.05e-01 | -1.55e-01 | -1.59e-01 | -1.96e-01 | 4.32e-01 | 5.48e-01 | 3.75e-01 | 3.60e-01 | 2.60e-01 |
| PIGMENT ACCUMULATION | 11 | 4.77e-01 | 9.40e-01 | 0.34300 | -1.20e-01 | -1.55e-01 | 5.20e-02 | -2.57e-01 | 1.01e-01 | 4.91e-01 | 3.72e-01 | 7.65e-01 | 1.40e-01 | 5.63e-01 |
| REGULATION OF EXTRACELLULAR MATRIX CONSTITUENT SECRETION | 9 | 5.87e-01 | 9.85e-01 | 0.34300 | -1.18e-01 | -1.77e-01 | 5.81e-02 | -1.48e-01 | 2.17e-01 | 5.39e-01 | 3.58e-01 | 7.63e-01 | 4.43e-01 | 2.60e-01 |
| REGULATION OF MYELOID CELL APOPTOTIC PROCESS | 31 | 4.38e-01 | 9.23e-01 | 0.34300 | -1.70e-01 | -1.66e-01 | -1.14e-01 | -2.19e-01 | -1.08e-02 | 1.02e-01 | 1.09e-01 | 2.71e-01 | 3.52e-02 | 9.17e-01 |
| TRANSCRIPTION DEPENDENT TETHERING OF RNA POLYMERASE II GENE DNA AT NUCLEAR PERIPHERY | 7 | 7.36e-01 | 1.00e+00 | 0.34200 | -9.44e-02 | -1.18e-01 | -9.41e-02 | -1.31e-01 | -2.62e-01 | 6.65e-01 | 5.90e-01 | 6.67e-01 | 5.48e-01 | 2.31e-01 |
| MONOCYTE CHEMOTACTIC PROTEIN 1 PRODUCTION | 21 | 4.03e-01 | 9.04e-01 | 0.34200 | -1.47e-01 | -1.69e-01 | -1.01e-01 | -1.86e-01 | -1.49e-01 | 2.43e-01 | 1.81e-01 | 4.21e-01 | 1.40e-01 | 2.39e-01 |
| POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 60 | 5.18e-02 | 3.73e-01 | 0.34200 | -1.78e-01 | -2.05e-01 | -7.93e-02 | -1.76e-01 | 7.71e-02 | 1.69e-02 | 5.95e-03 | 2.88e-01 | 1.87e-02 | 3.01e-01 |
| RESPONSE TO L PHENYLALANINE DERIVATIVE | 6 | 8.79e-01 | 1.00e+00 | 0.34200 | -9.23e-02 | -6.43e-02 | -1.07e-01 | -1.33e-01 | -2.74e-01 | 6.95e-01 | 7.85e-01 | 6.50e-01 | 5.72e-01 | 2.45e-01 |
| POSITIVE REGULATION OF BASEMENT MEMBRANE ASSEMBLY INVOLVED IN EMBRYONIC BODY MORPHOGENESIS | 5 | 5.17e-01 | 9.52e-01 | 0.34200 | 5.55e-02 | 1.42e-01 | -1.37e-01 | 2.39e-01 | -1.32e-01 | 8.30e-01 | 5.82e-01 | 5.94e-01 | 3.54e-01 | 6.09e-01 |
| INTESTINE SMOOTH MUSCLE CONTRACTION | 8 | 4.98e-01 | 9.47e-01 | 0.34200 | -1.80e-01 | -2.05e-01 | -2.02e-01 | -2.65e-03 | 4.03e-02 | 3.78e-01 | 3.15e-01 | 3.23e-01 | 9.90e-01 | 8.43e-01 |
| REGULATION OF RESPIRATORY SYSTEM PROCESS | 13 | 2.75e-01 | 8.02e-01 | 0.34200 | 1.18e-01 | 1.26e-01 | 1.23e-01 | -2.57e-02 | -2.66e-01 | 4.60e-01 | 4.30e-01 | 4.43e-01 | 8.73e-01 | 9.62e-02 |
| MITOTIC DNA REPLICATION CHECKPOINT SIGNALING | 10 | 4.09e-01 | 9.08e-01 | 0.34200 | 1.41e-01 | 1.13e-01 | 2.04e-01 | 2.55e-02 | -2.05e-01 | 4.41e-01 | 5.37e-01 | 2.64e-01 | 8.89e-01 | 2.62e-01 |
| ENDOSOMAL LUMEN ACIDIFICATION | 12 | 7.37e-01 | 1.00e+00 | 0.34200 | 1.35e-01 | 1.10e-01 | 2.27e-01 | 7.97e-02 | 1.69e-01 | 4.20e-01 | 5.09e-01 | 1.73e-01 | 6.33e-01 | 3.12e-01 |
| REGULATION OF BLOOD VESSEL REMODELING | 12 | 4.92e-01 | 9.45e-01 | 0.34200 | 1.61e-01 | 1.29e-01 | 2.67e-01 | 5.42e-02 | -9.68e-03 | 3.33e-01 | 4.40e-01 | 1.10e-01 | 7.45e-01 | 9.54e-01 |
| CELL MIGRATION INVOLVED IN KIDNEY DEVELOPMENT | 6 | 8.54e-01 | 1.00e+00 | 0.34200 | 3.03e-02 | 1.00e-02 | 1.33e-01 | 1.72e-02 | 3.12e-01 | 8.98e-01 | 9.66e-01 | 5.73e-01 | 9.42e-01 | 1.85e-01 |
| ATRIAL CARDIAC MUSCLE TISSUE MORPHOGENESIS | 6 | 6.94e-01 | 1.00e+00 | 0.34100 | -5.15e-03 | -8.05e-03 | 1.72e-02 | -1.04e-01 | -3.24e-01 | 9.83e-01 | 9.73e-01 | 9.42e-01 | 6.58e-01 | 1.69e-01 |
| AMINOACYL TRNA METABOLISM INVOLVED IN TRANSLATIONAL FIDELITY | 13 | 5.26e-01 | 9.54e-01 | 0.34100 | 1.78e-01 | 1.22e-01 | 2.49e-01 | 8.96e-02 | 7.91e-03 | 2.67e-01 | 4.46e-01 | 1.20e-01 | 5.76e-01 | 9.61e-01 |
| REGULATION OF KERATINOCYTE PROLIFERATION | 47 | 7.84e-02 | 4.60e-01 | 0.34100 | 1.64e-01 | 1.84e-01 | 3.83e-02 | 2.20e-01 | -7.74e-02 | 5.15e-02 | 2.91e-02 | 6.49e-01 | 9.21e-03 | 3.58e-01 |
| AUDITORY RECEPTOR CELL MORPHOGENESIS | 20 | 2.59e-01 | 7.87e-01 | 0.34100 | 1.53e-01 | 2.00e-01 | -6.83e-03 | 2.01e-01 | -1.11e-01 | 2.37e-01 | 1.21e-01 | 9.58e-01 | 1.19e-01 | 3.91e-01 |
| POSITIVE REGULATION OF MONOCYTE CHEMOTAXIS | 20 | 2.78e-01 | 8.05e-01 | 0.34100 | -1.48e-01 | -1.37e-01 | -1.22e-01 | -7.73e-02 | 2.34e-01 | 2.52e-01 | 2.89e-01 | 3.44e-01 | 5.50e-01 | 7.01e-02 |
| POSITIVE REGULATION OF KIDNEY DEVELOPMENT | 9 | 4.76e-01 | 9.40e-01 | 0.34100 | 1.09e-01 | 1.28e-01 | 1.31e-01 | -1.69e-02 | -2.66e-01 | 5.70e-01 | 5.07e-01 | 4.98e-01 | 9.30e-01 | 1.67e-01 |
| REGULATION OF INTEGRIN MEDIATED SIGNALING PATHWAY | 19 | 3.64e-01 | 8.78e-01 | 0.34100 | -1.57e-01 | -1.81e-01 | -8.57e-02 | -8.38e-02 | 2.11e-01 | 2.35e-01 | 1.73e-01 | 5.18e-01 | 5.27e-01 | 1.12e-01 |
| REGULATION OF HAIR CYCLE | 28 | 6.17e-01 | 9.90e-01 | 0.34100 | 1.85e-01 | 1.62e-01 | 1.88e-01 | 1.41e-01 | 1.90e-02 | 9.04e-02 | 1.37e-01 | 8.50e-02 | 1.96e-01 | 8.62e-01 |
| SINOATRIAL NODE DEVELOPMENT | 12 | 2.68e-01 | 7.95e-01 | 0.34100 | 1.48e-01 | 1.30e-01 | 2.70e-01 | -2.71e-03 | -6.76e-02 | 3.75e-01 | 4.37e-01 | 1.05e-01 | 9.87e-01 | 6.85e-01 |
| REGULATION OF LIPID CATABOLIC PROCESS | 60 | 2.68e-01 | 7.95e-01 | 0.34100 | 1.81e-01 | 1.68e-01 | 1.59e-01 | 1.71e-01 | 2.31e-02 | 1.50e-02 | 2.46e-02 | 3.29e-02 | 2.21e-02 | 7.57e-01 |
| REGULATION OF OSTEOCLAST DEVELOPMENT | 11 | 2.32e-01 | 7.54e-01 | 0.34100 | -1.99e-01 | -2.05e-01 | -1.38e-01 | -5.43e-02 | 1.12e-01 | 2.53e-01 | 2.38e-01 | 4.29e-01 | 7.55e-01 | 5.22e-01 |
| T CELL DIFFERENTIATION INVOLVED IN IMMUNE RESPONSE | 82 | 8.88e-04 | 2.05e-02 | 0.34100 | -1.77e-01 | -1.94e-01 | -4.83e-02 | -2.05e-01 | 5.40e-02 | 5.50e-03 | 2.42e-03 | 4.50e-01 | 1.37e-03 | 3.98e-01 |
| REGULATION OF VITAMIN METABOLIC PROCESS | 12 | 9.13e-01 | 1.00e+00 | 0.34100 | -1.74e-01 | -1.85e-01 | -1.26e-01 | -1.84e-01 | -4.23e-02 | 2.97e-01 | 2.68e-01 | 4.51e-01 | 2.69e-01 | 8.00e-01 |
| CD4 POSITIVE OR CD8 POSITIVE ALPHA BETA T CELL LINEAGE COMMITMENT | 25 | 8.20e-02 | 4.71e-01 | 0.34100 | -1.78e-01 | -1.82e-01 | -3.43e-02 | -2.23e-01 | 7.49e-03 | 1.23e-01 | 1.14e-01 | 7.67e-01 | 5.35e-02 | 9.48e-01 |
| RETINOIC ACID METABOLIC PROCESS | 33 | 4.11e-02 | 3.25e-01 | 0.34000 | -3.47e-02 | -2.03e-02 | -1.51e-01 | 4.72e-03 | -3.02e-01 | 7.30e-01 | 8.40e-01 | 1.33e-01 | 9.63e-01 | 2.65e-03 |
| NEGATIVE REGULATION OF ACTIN NUCLEATION | 9 | 8.64e-02 | 4.86e-01 | 0.34000 | 8.24e-02 | 9.90e-02 | 2.67e-01 | -1.59e-01 | 4.95e-02 | 6.69e-01 | 6.07e-01 | 1.65e-01 | 4.09e-01 | 7.97e-01 |
| POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE BIOSYNTHETIC PROCESS | 16 | 6.51e-01 | 1.00e+00 | 0.34000 | -1.64e-01 | -1.34e-01 | -2.20e-01 | -7.14e-02 | -1.31e-01 | 2.56e-01 | 3.52e-01 | 1.27e-01 | 6.21e-01 | 3.65e-01 |
| REGULATION OF RESPONSE TO TUMOR CELL | 22 | 3.89e-01 | 8.92e-01 | 0.34000 | -1.82e-01 | -1.60e-01 | -1.01e-01 | -2.09e-01 | 5.23e-02 | 1.39e-01 | 1.93e-01 | 4.11e-01 | 8.90e-02 | 6.71e-01 |
| MICROGLIA DIFFERENTIATION | 11 | 3.21e-01 | 8.47e-01 | 0.34000 | 5.73e-02 | -4.43e-03 | 2.34e-01 | -1.05e-01 | 2.16e-01 | 7.42e-01 | 9.80e-01 | 1.78e-01 | 5.47e-01 | 2.16e-01 |
| POSITIVE REGULATION OF MONOCYTE EXTRAVASATION | 5 | 5.17e-01 | 9.52e-01 | 0.34000 | -1.20e-01 | -1.48e-01 | -2.13e-01 | 9.10e-02 | 1.59e-01 | 6.41e-01 | 5.65e-01 | 4.09e-01 | 7.25e-01 | 5.37e-01 |
| NEGATIVE REGULATION OF MEMBRANE PERMEABILITY | 20 | 5.98e-01 | 9.89e-01 | 0.34000 | 1.69e-01 | 1.76e-01 | 9.62e-02 | 1.40e-01 | -1.65e-01 | 1.91e-01 | 1.73e-01 | 4.57e-01 | 2.79e-01 | 2.01e-01 |
| INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 89 | 1.64e-02 | 1.81e-01 | 0.34000 | -1.68e-01 | -1.88e-01 | -1.17e-01 | -1.94e-01 | -2.80e-02 | 6.00e-03 | 2.17e-03 | 5.63e-02 | 1.60e-03 | 6.48e-01 |
| POSITIVE REGULATION OF PEPTIDYL LYSINE ACETYLATION | 16 | 6.57e-01 | 1.00e+00 | 0.34000 | 1.48e-01 | 1.44e-01 | 2.07e-01 | 7.90e-02 | 1.55e-01 | 3.06e-01 | 3.18e-01 | 1.53e-01 | 5.84e-01 | 2.82e-01 |
| CALCIUM MEDIATED SIGNALING USING INTRACELLULAR CALCIUM SOURCE | 20 | 2.53e-01 | 7.80e-01 | 0.34000 | -1.61e-01 | -1.63e-01 | -1.97e-01 | -7.66e-02 | 1.37e-01 | 2.14e-01 | 2.08e-01 | 1.28e-01 | 5.53e-01 | 2.89e-01 |
| REGULATION OF HYDROGEN PEROXIDE BIOSYNTHETIC PROCESS | 7 | 6.29e-01 | 9.96e-01 | 0.34000 | -7.07e-02 | -1.23e-02 | -8.93e-02 | -1.44e-01 | -2.86e-01 | 7.46e-01 | 9.55e-01 | 6.83e-01 | 5.10e-01 | 1.90e-01 |
| POSITIVE REGULATION OF RECEPTOR INTERNALIZATION | 26 | 3.71e-01 | 8.81e-01 | 0.34000 | -1.67e-01 | -1.90e-01 | -6.35e-02 | -2.17e-01 | -2.47e-02 | 1.41e-01 | 9.40e-02 | 5.75e-01 | 5.52e-02 | 8.27e-01 |
| DITERPENOID BIOSYNTHETIC PROCESS | 10 | 7.50e-01 | 1.00e+00 | 0.34000 | -1.38e-01 | -1.51e-01 | -1.40e-01 | -1.10e-01 | -2.05e-01 | 4.49e-01 | 4.09e-01 | 4.45e-01 | 5.47e-01 | 2.62e-01 |
| POSITIVE REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 133 | 1.39e-07 | 1.20e-05 | 0.34000 | -1.35e-01 | -1.75e-01 | 2.36e-02 | -2.19e-01 | 1.34e-01 | 7.06e-03 | 4.83e-04 | 6.39e-01 | 1.33e-05 | 7.43e-03 |
| REGULATION OF SREBP SIGNALING PATHWAY | 8 | 6.21e-01 | 9.91e-01 | 0.34000 | -1.06e-01 | -1.78e-01 | 3.80e-02 | -1.09e-01 | 2.44e-01 | 6.04e-01 | 3.84e-01 | 8.52e-01 | 5.95e-01 | 2.33e-01 |
| LIPID GLYCOSYLATION | 12 | 4.64e-01 | 9.33e-01 | 0.34000 | -1.54e-02 | -1.91e-02 | 7.48e-02 | -4.46e-02 | 3.27e-01 | 9.26e-01 | 9.09e-01 | 6.54e-01 | 7.89e-01 | 4.95e-02 |
| CELLULAR RESPONSE TO GONADOTROPIN RELEASING HORMONE | 5 | 5.47e-01 | 9.61e-01 | 0.34000 | -1.31e-01 | -2.11e-01 | -3.95e-02 | -2.28e-01 | -7.30e-03 | 6.13e-01 | 4.13e-01 | 8.78e-01 | 3.77e-01 | 9.77e-01 |
| POSITIVE REGULATION OF MACROPHAGE CYTOKINE PRODUCTION | 23 | 1.71e-01 | 6.75e-01 | 0.33900 | -1.40e-01 | -1.98e-01 | 1.17e-02 | -1.90e-01 | 1.42e-01 | 2.44e-01 | 9.97e-02 | 9.23e-01 | 1.15e-01 | 2.39e-01 |
| RETROGRADE AXONAL TRANSPORT | 21 | 1.80e-01 | 6.88e-01 | 0.33900 | -1.29e-01 | -1.09e-01 | -7.00e-02 | -1.97e-01 | -2.07e-01 | 3.07e-01 | 3.86e-01 | 5.79e-01 | 1.18e-01 | 1.01e-01 |
| ER ASSOCIATED MISFOLDED PROTEIN CATABOLIC PROCESS | 12 | 1.07e-01 | 5.43e-01 | 0.33900 | 1.60e-01 | 8.17e-02 | 2.74e-01 | -7.10e-03 | -8.84e-02 | 3.37e-01 | 6.24e-01 | 1.01e-01 | 9.66e-01 | 5.96e-01 |
| LYMPH NODE DEVELOPMENT | 18 | 4.66e-01 | 9.35e-01 | 0.33900 | -1.60e-01 | -1.85e-01 | -2.75e-02 | -2.33e-01 | 1.57e-02 | 2.40e-01 | 1.74e-01 | 8.40e-01 | 8.73e-02 | 9.08e-01 |
| NEGATIVE REGULATION OF MEMBRANE POTENTIAL | 12 | 7.65e-01 | 1.00e+00 | 0.33900 | 1.52e-01 | 1.88e-01 | 4.16e-02 | 1.93e-01 | -1.32e-01 | 3.61e-01 | 2.60e-01 | 8.03e-01 | 2.46e-01 | 4.29e-01 |
| AXO DENDRITIC PROTEIN TRANSPORT | 9 | 7.73e-01 | 1.00e+00 | 0.33900 | -1.24e-01 | -9.77e-02 | -1.04e-01 | -1.95e-01 | -2.03e-01 | 5.20e-01 | 6.12e-01 | 5.89e-01 | 3.11e-01 | 2.92e-01 |
| MACROPHAGE ACTIVATION INVOLVED IN IMMUNE RESPONSE | 19 | 3.06e-01 | 8.35e-01 | 0.33900 | -1.76e-01 | -2.01e-01 | -1.31e-01 | -7.03e-02 | 1.47e-01 | 1.85e-01 | 1.30e-01 | 3.23e-01 | 5.96e-01 | 2.68e-01 |
| METHIONINE METABOLIC PROCESS | 15 | 2.25e-01 | 7.47e-01 | 0.33900 | -4.63e-02 | 1.10e-02 | -9.42e-02 | -1.18e-01 | -2.99e-01 | 7.56e-01 | 9.41e-01 | 5.28e-01 | 4.28e-01 | 4.48e-02 |
| REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY | 181 | 1.01e-06 | 6.50e-05 | 0.33900 | -1.62e-01 | -1.96e-01 | -4.66e-02 | -1.95e-01 | 9.83e-02 | 1.65e-04 | 5.57e-06 | 2.80e-01 | 5.78e-06 | 2.25e-02 |
| EMBRYONIC DIGESTIVE TRACT DEVELOPMENT | 33 | 5.49e-02 | 3.84e-01 | 0.33900 | 1.75e-01 | 1.11e-01 | 2.40e-01 | 1.03e-01 | 5.86e-02 | 8.15e-02 | 2.68e-01 | 1.72e-02 | 3.07e-01 | 5.60e-01 |
| PARAXIAL MESODERM DEVELOPMENT | 17 | 8.47e-01 | 1.00e+00 | 0.33800 | 1.76e-01 | 1.80e-01 | 1.26e-01 | 1.76e-01 | -6.64e-02 | 2.09e-01 | 1.99e-01 | 3.69e-01 | 2.08e-01 | 6.36e-01 |
| NEGATIVE REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY | 57 | 3.54e-02 | 3.00e-01 | 0.33800 | -1.62e-01 | -2.02e-01 | -5.72e-02 | -1.87e-01 | 9.53e-02 | 3.39e-02 | 8.36e-03 | 4.55e-01 | 1.45e-02 | 2.13e-01 |
| REGULATION OF LEUKOCYTE MEDIATED IMMUNITY | 239 | 6.26e-11 | 1.24e-08 | 0.33800 | -1.55e-01 | -1.94e-01 | -2.15e-02 | -1.96e-01 | 1.17e-01 | 3.54e-05 | 2.31e-07 | 5.68e-01 | 1.75e-07 | 1.76e-03 |
| MULTICELLULAR ORGANISMAL MOVEMENT | 57 | 1.51e-01 | 6.43e-01 | 0.33800 | 1.69e-01 | 1.83e-01 | 1.22e-01 | 1.93e-01 | 1.01e-03 | 2.71e-02 | 1.68e-02 | 1.10e-01 | 1.16e-02 | 9.90e-01 |
| SERINE TRANSPORT | 9 | 5.03e-01 | 9.48e-01 | 0.33800 | 5.38e-02 | 6.27e-02 | 4.63e-02 | -6.22e-02 | -3.19e-01 | 7.80e-01 | 7.45e-01 | 8.10e-01 | 7.47e-01 | 9.77e-02 |
| MHC CLASS II BIOSYNTHETIC PROCESS | 20 | 3.34e-01 | 8.58e-01 | 0.33800 | -1.10e-01 | -1.43e-01 | -1.22e-03 | -1.57e-01 | 2.39e-01 | 3.93e-01 | 2.68e-01 | 9.92e-01 | 2.23e-01 | 6.47e-02 |
| NEGATIVE REGULATION BY HOST OF VIRAL GENOME REPLICATION | 9 | 7.21e-01 | 1.00e+00 | 0.33800 | -1.41e-01 | -1.23e-01 | -1.02e-01 | -1.59e-01 | -2.09e-01 | 4.65e-01 | 5.23e-01 | 5.95e-01 | 4.09e-01 | 2.77e-01 |
| IMMUNE RESPONSE INHIBITING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 9 | 4.10e-01 | 9.08e-01 | 0.33800 | -1.62e-01 | -2.24e-01 | -7.18e-02 | -1.47e-01 | -1.05e-01 | 3.99e-01 | 2.45e-01 | 7.09e-01 | 4.45e-01 | 5.85e-01 |
| FC RECEPTOR SIGNALING PATHWAY | 54 | 3.73e-02 | 3.07e-01 | 0.33800 | -1.76e-01 | -2.14e-01 | -7.92e-02 | -1.71e-01 | 4.71e-02 | 2.53e-02 | 6.64e-03 | 3.14e-01 | 2.97e-02 | 5.49e-01 |
| POSITIVE REGULATION OF LEUKOCYTE PROLIFERATION | 159 | 1.23e-04 | 4.12e-03 | 0.33800 | -1.79e-01 | -1.91e-01 | -8.38e-02 | -1.86e-01 | 6.56e-02 | 1.00e-04 | 3.36e-05 | 6.83e-02 | 5.29e-05 | 1.53e-01 |
| PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA SIGNALING PATHWAY | 7 | 6.42e-01 | 1.00e+00 | 0.33800 | 1.45e-02 | 3.72e-02 | 6.05e-03 | -9.97e-02 | -3.20e-01 | 9.47e-01 | 8.65e-01 | 9.78e-01 | 6.48e-01 | 1.42e-01 |
| NEGATIVE REGULATION OF MORPHOGENESIS OF AN EPITHELIUM | 9 | 5.17e-01 | 9.52e-01 | 0.33700 | 1.39e-01 | 1.23e-01 | -4.93e-03 | 2.06e-01 | -1.93e-01 | 4.71e-01 | 5.24e-01 | 9.80e-01 | 2.85e-01 | 3.16e-01 |
| GLANDULAR EPITHELIAL CELL MATURATION | 9 | 8.51e-01 | 1.00e+00 | 0.33700 | 1.45e-01 | 1.15e-01 | 2.20e-01 | 1.18e-01 | 1.32e-01 | 4.52e-01 | 5.49e-01 | 2.54e-01 | 5.40e-01 | 4.94e-01 |
| CAP DEPENDENT TRANSLATIONAL INITIATION | 7 | 4.46e-01 | 9.30e-01 | 0.33700 | 7.05e-02 | 5.66e-02 | 1.47e-01 | -1.03e-01 | -2.71e-01 | 7.47e-01 | 7.95e-01 | 5.01e-01 | 6.37e-01 | 2.14e-01 |
| POSITIVE REGULATION OF PROTEIN KINASE C SIGNALING | 9 | 7.41e-01 | 1.00e+00 | 0.33700 | 1.58e-01 | 1.77e-01 | 1.63e-01 | 8.98e-02 | -1.51e-01 | 4.12e-01 | 3.57e-01 | 3.96e-01 | 6.41e-01 | 4.34e-01 |
| INTERLEUKIN 12 PRODUCTION | 62 | 5.60e-03 | 8.28e-02 | 0.33700 | -1.54e-01 | -1.95e-01 | -1.67e-02 | -2.18e-01 | 6.37e-02 | 3.56e-02 | 7.94e-03 | 8.20e-01 | 2.98e-03 | 3.85e-01 |
| POSITIVE REGULATION OF MITOTIC CYTOKINESIS | 8 | 4.81e-01 | 9.43e-01 | 0.33700 | 1.46e-01 | 1.21e-01 | 2.41e-01 | 1.36e-01 | 3.01e-02 | 4.74e-01 | 5.53e-01 | 2.37e-01 | 5.06e-01 | 8.83e-01 |
| MEIOTIC SISTER CHROMATID COHESION | 13 | 4.08e-01 | 9.08e-01 | 0.33700 | -9.25e-02 | -1.59e-01 | 4.91e-02 | -1.19e-01 | 2.51e-01 | 5.64e-01 | 3.21e-01 | 7.59e-01 | 4.56e-01 | 1.17e-01 |
| MAMMARY GLAND DUCT MORPHOGENESIS | 28 | 4.88e-01 | 9.44e-01 | 0.33700 | 1.58e-01 | 1.44e-01 | 1.34e-01 | 2.01e-01 | 9.71e-02 | 1.47e-01 | 1.88e-01 | 2.19e-01 | 6.57e-02 | 3.74e-01 |
| SUCKLING BEHAVIOR | 12 | 2.36e-01 | 7.59e-01 | 0.33700 | 1.34e-01 | 1.22e-01 | 1.58e-01 | -3.73e-02 | -2.33e-01 | 4.20e-01 | 4.65e-01 | 3.42e-01 | 8.23e-01 | 1.63e-01 |
| POSITIVE REGULATION OF FERTILIZATION | 5 | 7.62e-01 | 1.00e+00 | 0.33700 | 1.39e-01 | 9.80e-02 | 2.69e-01 | -5.59e-02 | 9.55e-02 | 5.90e-01 | 7.04e-01 | 2.98e-01 | 8.29e-01 | 7.11e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CONTRACTION | 26 | 2.28e-01 | 7.50e-01 | 0.33700 | -1.51e-01 | -1.60e-01 | -2.02e-01 | -1.15e-01 | -1.04e-01 | 1.81e-01 | 1.57e-01 | 7.47e-02 | 3.11e-01 | 3.60e-01 |
| DNA DOUBLE STRAND BREAK PROCESSING | 19 | 4.04e-01 | 9.05e-01 | 0.33700 | -1.66e-01 | -2.05e-01 | -6.41e-02 | -1.95e-01 | -4.04e-02 | 2.10e-01 | 1.22e-01 | 6.29e-01 | 1.41e-01 | 7.60e-01 |
| GANGLIOSIDE BIOSYNTHETIC PROCESS | 17 | 5.01e-01 | 9.48e-01 | 0.33700 | -1.52e-01 | -2.00e-01 | -3.64e-02 | -1.77e-01 | 1.32e-01 | 2.79e-01 | 1.53e-01 | 7.95e-01 | 2.05e-01 | 3.46e-01 |
| MATURE B CELL DIFFERENTIATION INVOLVED IN IMMUNE RESPONSE | 30 | 1.38e-02 | 1.57e-01 | 0.33700 | -1.20e-01 | -1.60e-01 | 8.50e-02 | -2.06e-01 | 1.54e-01 | 2.57e-01 | 1.28e-01 | 4.20e-01 | 5.09e-02 | 1.45e-01 |
| INNER CELL MASS CELL DIFFERENTIATION | 8 | 5.05e-01 | 9.48e-01 | 0.33600 | -6.41e-02 | -7.29e-02 | 3.12e-03 | -2.18e-01 | -2.37e-01 | 7.54e-01 | 7.21e-01 | 9.88e-01 | 2.85e-01 | 2.46e-01 |
| T HELPER 1 CELL DIFFERENTIATION | 23 | 1.15e-02 | 1.39e-01 | 0.33600 | -1.02e-01 | -1.34e-01 | 1.26e-01 | -2.16e-01 | 1.48e-01 | 3.99e-01 | 2.68e-01 | 2.94e-01 | 7.24e-02 | 2.19e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CHROMATIN | 10 | 3.94e-01 | 8.93e-01 | 0.33600 | 1.52e-01 | 8.69e-02 | 2.84e-01 | -1.24e-02 | 4.03e-02 | 4.05e-01 | 6.34e-01 | 1.21e-01 | 9.46e-01 | 8.25e-01 |
| INFLAMMASOME MEDIATED SIGNALING PATHWAY | 39 | 2.95e-01 | 8.22e-01 | 0.33600 | -1.69e-01 | -1.66e-01 | -9.38e-02 | -2.15e-01 | 4.10e-02 | 6.77e-02 | 7.34e-02 | 3.10e-01 | 2.02e-02 | 6.58e-01 |
| PYRIMIDINE NUCLEOSIDE METABOLIC PROCESS | 24 | 3.74e-01 | 8.83e-01 | 0.33600 | -1.55e-01 | -1.49e-01 | -8.69e-02 | -1.51e-01 | 1.90e-01 | 1.87e-01 | 2.08e-01 | 4.61e-01 | 2.01e-01 | 1.07e-01 |
| NEGATIVE REGULATION OF PROTEIN EXIT FROM ENDOPLASMIC RETICULUM | 10 | 1.76e-01 | 6.81e-01 | 0.33600 | 1.60e-01 | 1.22e-01 | 1.84e-01 | -3.02e-02 | -1.93e-01 | 3.81e-01 | 5.05e-01 | 3.13e-01 | 8.68e-01 | 2.90e-01 |
| EXCRETION | 29 | 6.00e-01 | 9.90e-01 | 0.33500 | 1.71e-01 | 1.85e-01 | 1.09e-01 | 1.87e-01 | -4.80e-02 | 1.11e-01 | 8.46e-02 | 3.12e-01 | 8.16e-02 | 6.55e-01 |
| REGULATION OF EXIT FROM MITOSIS | 18 | 1.38e-01 | 6.20e-01 | 0.33500 | 1.50e-01 | 1.22e-01 | 2.17e-01 | 2.93e-03 | -1.68e-01 | 2.72e-01 | 3.68e-01 | 1.12e-01 | 9.83e-01 | 2.18e-01 |
| PLASMA MEMBRANE TO ENDOSOME TRANSPORT | 8 | 8.08e-01 | 1.00e+00 | 0.33500 | 1.19e-01 | 8.74e-02 | 1.71e-01 | 5.52e-02 | 2.41e-01 | 5.61e-01 | 6.69e-01 | 4.01e-01 | 7.87e-01 | 2.37e-01 |
| NEGATIVE REGULATION OF MYELOID CELL APOPTOTIC PROCESS | 18 | 5.78e-01 | 9.82e-01 | 0.33500 | -1.67e-01 | -1.51e-01 | -9.65e-02 | -2.21e-01 | 6.03e-02 | 2.21e-01 | 2.67e-01 | 4.79e-01 | 1.04e-01 | 6.58e-01 |
| ATTACHMENT OF SPINDLE MICROTUBULES TO KINETOCHORE | 49 | 7.37e-03 | 1.01e-01 | 0.33500 | 1.30e-01 | 7.83e-02 | 2.42e-01 | 9.04e-02 | 1.51e-01 | 1.15e-01 | 3.43e-01 | 3.41e-03 | 2.73e-01 | 6.82e-02 |
| G PROTEIN COUPLED SEROTONIN RECEPTOR SIGNALING PATHWAY | 22 | 1.93e-01 | 7.04e-01 | 0.33500 | 2.93e-02 | 4.81e-02 | -8.35e-02 | 7.62e-02 | -3.10e-01 | 8.12e-01 | 6.96e-01 | 4.98e-01 | 5.36e-01 | 1.17e-02 |
| MIDBRAIN DOPAMINERGIC NEURON DIFFERENTIATION | 17 | 1.45e-01 | 6.30e-01 | 0.33500 | -1.58e-01 | -2.17e-01 | 1.32e-03 | -2.01e-01 | 1.48e-03 | 2.59e-01 | 1.22e-01 | 9.92e-01 | 1.52e-01 | 9.92e-01 |
| DTTP METABOLIC PROCESS | 5 | 6.39e-01 | 1.00e+00 | 0.33500 | 3.69e-02 | -4.00e-02 | 2.52e-01 | -1.40e-01 | 1.61e-01 | 8.86e-01 | 8.77e-01 | 3.29e-01 | 5.88e-01 | 5.32e-01 |
| DETECTION OF EXTERNAL BIOTIC STIMULUS | 26 | 3.63e-01 | 8.78e-01 | 0.33500 | -1.53e-01 | -1.86e-01 | -7.62e-02 | -1.62e-01 | 1.50e-01 | 1.78e-01 | 1.01e-01 | 5.01e-01 | 1.54e-01 | 1.87e-01 |
| ADP TRANSPORT | 10 | 6.41e-01 | 1.00e+00 | 0.33500 | -1.14e-01 | -1.20e-01 | -1.28e-03 | -1.99e-01 | 2.12e-01 | 5.31e-01 | 5.10e-01 | 9.94e-01 | 2.75e-01 | 2.47e-01 |
| CENTRIOLE ELONGATION | 8 | 6.67e-01 | 1.00e+00 | 0.33500 | -4.28e-02 | -8.03e-02 | 1.26e-01 | -8.48e-02 | 2.84e-01 | 8.34e-01 | 6.94e-01 | 5.36e-01 | 6.78e-01 | 1.64e-01 |
| REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 15 | 7.42e-01 | 1.00e+00 | 0.33500 | -1.56e-01 | -1.53e-01 | -1.48e-01 | -1.29e-01 | -1.61e-01 | 2.96e-01 | 3.04e-01 | 3.21e-01 | 3.89e-01 | 2.80e-01 |
| B CELL RECEPTOR SIGNALING PATHWAY | 61 | 1.01e-02 | 1.26e-01 | 0.33500 | -1.52e-01 | -1.94e-01 | -3.19e-02 | -2.11e-01 | 7.31e-02 | 3.96e-02 | 8.62e-03 | 6.67e-01 | 4.29e-03 | 3.23e-01 |
| GUANINE NUCLEOTIDE TRANSPORT | 9 | 7.54e-01 | 1.00e+00 | 0.33500 | -1.41e-01 | -1.17e-01 | -9.54e-02 | -1.88e-01 | -1.84e-01 | 4.64e-01 | 5.43e-01 | 6.20e-01 | 3.29e-01 | 3.38e-01 |
| RIBOSOMAL SUBUNIT EXPORT FROM NUCLEUS | 14 | 1.65e-03 | 3.40e-02 | 0.33500 | 1.38e-01 | 1.38e-01 | 2.16e-01 | -1.50e-01 | 6.79e-02 | 3.72e-01 | 3.72e-01 | 1.61e-01 | 3.30e-01 | 6.60e-01 |
| ZINC ION IMPORT ACROSS PLASMA MEMBRANE | 9 | 8.70e-01 | 1.00e+00 | 0.33500 | 1.20e-01 | 1.03e-01 | 1.88e-01 | 9.81e-02 | 2.05e-01 | 5.33e-01 | 5.93e-01 | 3.30e-01 | 6.10e-01 | 2.86e-01 |
| OSTEOCLAST FUSION | 6 | 4.35e-01 | 9.22e-01 | 0.33500 | 1.25e-01 | 2.21e-01 | 4.50e-02 | 6.27e-02 | -2.04e-01 | 5.97e-01 | 3.49e-01 | 8.49e-01 | 7.90e-01 | 3.87e-01 |
| RESPONSE TO HEPATOCYTE GROWTH FACTOR | 17 | 6.05e-01 | 9.90e-01 | 0.33500 | -1.81e-01 | -1.64e-01 | -1.19e-01 | -1.84e-01 | -6.44e-02 | 1.96e-01 | 2.41e-01 | 3.95e-01 | 1.89e-01 | 6.46e-01 |
| SODIUM ION IMPORT ACROSS PLASMA MEMBRANE | 23 | 3.06e-01 | 8.35e-01 | 0.33500 | 1.55e-01 | 1.67e-01 | 3.48e-02 | 2.41e-01 | 2.57e-02 | 1.98e-01 | 1.66e-01 | 7.72e-01 | 4.52e-02 | 8.31e-01 |
| REGULATION OF SPONTANEOUS SYNAPTIC TRANSMISSION | 6 | 9.71e-01 | 1.00e+00 | 0.33500 | 1.71e-01 | 1.89e-01 | 9.32e-02 | 1.58e-01 | -1.15e-01 | 4.68e-01 | 4.23e-01 | 6.92e-01 | 5.03e-01 | 6.25e-01 |
| BRANCHING INVOLVED IN MAMMARY GLAND DUCT MORPHOGENESIS | 20 | 6.30e-01 | 9.96e-01 | 0.33400 | 1.38e-01 | 1.28e-01 | 1.48e-01 | 1.62e-01 | 1.68e-01 | 2.87e-01 | 3.21e-01 | 2.53e-01 | 2.09e-01 | 1.92e-01 |
| POSITIVE REGULATION OF HEART GROWTH | 38 | 2.25e-03 | 4.20e-02 | 0.33400 | 1.07e-01 | 9.02e-02 | 1.14e-01 | -1.42e-02 | -2.81e-01 | 2.55e-01 | 3.36e-01 | 2.24e-01 | 8.79e-01 | 2.71e-03 |
| SOFT PALATE DEVELOPMENT | 5 | 3.93e-01 | 8.92e-01 | 0.33400 | -2.57e-02 | -1.10e-01 | 2.17e-01 | -2.28e-01 | -1.65e-02 | 9.21e-01 | 6.71e-01 | 4.01e-01 | 3.78e-01 | 9.49e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CILIUM | 11 | 8.44e-01 | 1.00e+00 | 0.33400 | 1.42e-01 | 1.11e-01 | 2.22e-01 | 8.21e-02 | 1.53e-01 | 4.15e-01 | 5.23e-01 | 2.03e-01 | 6.37e-01 | 3.80e-01 |
| FOREBRAIN REGIONALIZATION | 24 | 5.52e-02 | 3.84e-01 | 0.33400 | 1.56e-01 | 9.40e-02 | 2.77e-01 | 7.00e-03 | 4.05e-02 | 1.87e-01 | 4.25e-01 | 1.87e-02 | 9.53e-01 | 7.31e-01 |
| LIPID IMPORT INTO CELL | 20 | 6.11e-01 | 9.90e-01 | 0.33400 | 1.60e-01 | 1.81e-01 | 7.93e-02 | 2.16e-01 | 1.80e-02 | 2.15e-01 | 1.61e-01 | 5.39e-01 | 9.47e-02 | 8.89e-01 |
| PROTOPORPHYRINOGEN IX BIOSYNTHETIC PROCESS | 8 | 3.01e-01 | 8.29e-01 | 0.33400 | 6.88e-02 | -1.72e-02 | 2.68e-01 | 1.33e-02 | 1.85e-01 | 7.36e-01 | 9.33e-01 | 1.89e-01 | 9.48e-01 | 3.64e-01 |
| REGULATION OF MYOSIN LIGHT CHAIN PHOSPHATASE ACTIVITY | 7 | 3.57e-01 | 8.74e-01 | 0.33400 | -1.68e-01 | -2.40e-01 | -1.50e-01 | -2.76e-02 | 4.59e-02 | 4.40e-01 | 2.71e-01 | 4.91e-01 | 8.99e-01 | 8.33e-01 |
| RESPONSE TO BLUE LIGHT | 6 | 6.05e-01 | 9.90e-01 | 0.33400 | 9.94e-02 | 1.14e-01 | -1.02e-01 | 2.67e-01 | -8.26e-02 | 6.73e-01 | 6.28e-01 | 6.65e-01 | 2.58e-01 | 7.26e-01 |
| URETER MORPHOGENESIS | 7 | 1.57e-01 | 6.54e-01 | 0.33400 | -1.49e-02 | -1.96e-02 | 2.36e-01 | -2.14e-01 | 9.66e-02 | 9.45e-01 | 9.28e-01 | 2.79e-01 | 3.28e-01 | 6.58e-01 |
| POTASSIUM ION EXPORT ACROSS PLASMA MEMBRANE | 19 | 5.69e-01 | 9.75e-01 | 0.33400 | 1.55e-01 | 1.68e-01 | 7.91e-02 | 2.13e-01 | -8.60e-02 | 2.43e-01 | 2.05e-01 | 5.51e-01 | 1.07e-01 | 5.16e-01 |
| FC GAMMA RECEPTOR SIGNALING PATHWAY | 33 | 3.61e-02 | 3.03e-01 | 0.33400 | -1.60e-01 | -2.16e-01 | -2.04e-02 | -1.93e-01 | 3.80e-02 | 1.11e-01 | 3.19e-02 | 8.39e-01 | 5.53e-02 | 7.06e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF EXOGENOUS ANTIGEN | 47 | 4.11e-02 | 3.25e-01 | 0.33400 | -1.71e-01 | -2.06e-01 | -4.85e-02 | -1.84e-01 | 5.68e-02 | 4.27e-02 | 1.44e-02 | 5.65e-01 | 2.89e-02 | 5.01e-01 |
| PYRIMIDINE NUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 8 | 9.08e-01 | 1.00e+00 | 0.33400 | -1.56e-01 | -1.69e-01 | -8.31e-02 | -1.24e-01 | 1.90e-01 | 4.45e-01 | 4.07e-01 | 6.84e-01 | 5.42e-01 | 3.53e-01 |
| NEGATIVE REGULATION OF CARDIAC MUSCLE TISSUE GROWTH | 27 | 2.36e-01 | 7.59e-01 | 0.33300 | 1.67e-01 | 1.83e-01 | 1.72e-01 | 7.82e-02 | -1.18e-01 | 1.33e-01 | 9.89e-02 | 1.21e-01 | 4.82e-01 | 2.90e-01 |
| ALDITOL BIOSYNTHETIC PROCESS | 5 | 7.96e-01 | 1.00e+00 | 0.33300 | -1.97e-03 | 3.81e-02 | -1.26e-01 | 1.14e-01 | -2.84e-01 | 9.94e-01 | 8.83e-01 | 6.25e-01 | 6.59e-01 | 2.71e-01 |
| POSITIVE REGULATION OF IMMUNOGLOBULIN PRODUCTION | 52 | 1.28e-03 | 2.78e-02 | 0.33300 | -9.98e-02 | -1.42e-01 | 7.64e-02 | -2.19e-01 | 1.65e-01 | 2.13e-01 | 7.71e-02 | 3.41e-01 | 6.26e-03 | 3.95e-02 |
| CENTROMERIC SISTER CHROMATID COHESION | 10 | 7.30e-01 | 1.00e+00 | 0.33300 | 1.48e-01 | 8.84e-02 | 2.40e-01 | 7.94e-02 | 1.33e-01 | 4.19e-01 | 6.28e-01 | 1.89e-01 | 6.64e-01 | 4.66e-01 |
| MEIOTIC CYTOKINESIS | 8 | 8.15e-01 | 1.00e+00 | 0.33300 | -1.23e-01 | -1.38e-01 | -1.23e-01 | -1.13e-01 | -2.21e-01 | 5.46e-01 | 5.00e-01 | 5.48e-01 | 5.79e-01 | 2.78e-01 |
| LONG TERM SYNAPTIC DEPRESSION | 30 | 5.99e-01 | 9.90e-01 | 0.33300 | 1.65e-01 | 1.69e-01 | 1.62e-01 | 1.43e-01 | 9.01e-02 | 1.18e-01 | 1.10e-01 | 1.24e-01 | 1.74e-01 | 3.93e-01 |
| RRNA MODIFICATION | 32 | 2.43e-02 | 2.34e-01 | 0.33300 | 1.29e-01 | 9.32e-02 | 2.76e-01 | -1.07e-02 | 9.57e-02 | 2.08e-01 | 3.61e-01 | 6.87e-03 | 9.17e-01 | 3.49e-01 |
| REGULATION OF BRANCHING INVOLVED IN LUNG MORPHOGENESIS | 6 | 3.31e-01 | 8.56e-01 | 0.33300 | -9.25e-02 | -1.56e-01 | -1.33e-03 | -1.03e-01 | -2.59e-01 | 6.95e-01 | 5.07e-01 | 9.95e-01 | 6.62e-01 | 2.72e-01 |
| FATTY ACID TRANSMEMBRANE TRANSPORT | 19 | 3.76e-01 | 8.84e-01 | 0.33300 | 1.48e-01 | 1.77e-01 | 4.32e-02 | 2.21e-01 | 8.30e-02 | 2.64e-01 | 1.83e-01 | 7.44e-01 | 9.55e-02 | 5.31e-01 |
| RENAL WATER HOMEOSTASIS | 24 | 1.01e-01 | 5.25e-01 | 0.33300 | 7.07e-02 | 2.64e-02 | 1.11e-01 | 1.45e-01 | 2.67e-01 | 5.49e-01 | 8.23e-01 | 3.46e-01 | 2.18e-01 | 2.33e-02 |
| CILIARY NEUROTROPHIC FACTOR MEDIATED SIGNALING PATHWAY | 5 | 8.48e-01 | 1.00e+00 | 0.33300 | 1.46e-01 | 1.50e-01 | -1.83e-02 | 2.46e-01 | -7.84e-02 | 5.73e-01 | 5.62e-01 | 9.44e-01 | 3.41e-01 | 7.61e-01 |
| TRIGLYCERIDE RICH LIPOPROTEIN PARTICLE CLEARANCE | 7 | 8.76e-01 | 1.00e+00 | 0.33200 | 1.63e-01 | 2.10e-01 | 9.64e-02 | 1.62e-01 | -6.55e-02 | 4.54e-01 | 3.37e-01 | 6.59e-01 | 4.59e-01 | 7.64e-01 |
| DETECTION OF LIGHT STIMULUS INVOLVED IN SENSORY PERCEPTION | 20 | 1.86e-01 | 6.94e-01 | 0.33200 | 8.83e-02 | 1.22e-01 | -7.37e-02 | 2.08e-01 | -1.98e-01 | 4.94e-01 | 3.44e-01 | 5.68e-01 | 1.08e-01 | 1.26e-01 |
| FLAVONE METABOLIC PROCESS | 6 | 9.10e-01 | 1.00e+00 | 0.33200 | 1.51e-01 | 1.97e-01 | 1.98e-02 | 1.80e-01 | -1.26e-01 | 5.22e-01 | 4.04e-01 | 9.33e-01 | 4.45e-01 | 5.93e-01 |
| LYSOSOMAL PROTEIN CATABOLIC PROCESS | 19 | 4.10e-01 | 9.08e-01 | 0.33200 | 1.57e-01 | 1.50e-01 | 2.39e-01 | 5.42e-02 | 5.48e-02 | 2.37e-01 | 2.56e-01 | 7.14e-02 | 6.82e-01 | 6.79e-01 |
| REGULATION OF OSTEOCLAST DIFFERENTIATION | 68 | 6.04e-02 | 4.03e-01 | 0.33200 | -1.84e-01 | -1.93e-01 | -1.14e-01 | -1.58e-01 | 2.69e-02 | 8.60e-03 | 5.82e-03 | 1.03e-01 | 2.40e-02 | 7.01e-01 |
| TRUNK SEGMENTATION | 5 | 9.35e-01 | 1.00e+00 | 0.33200 | 1.19e-01 | 1.45e-01 | 1.49e-02 | 1.71e-01 | -2.13e-01 | 6.45e-01 | 5.74e-01 | 9.54e-01 | 5.09e-01 | 4.09e-01 |
| PEPTIDYL PROLINE HYDROXYLATION TO 4 HYDROXY L PROLINE | 8 | 6.33e-01 | 9.96e-01 | 0.33200 | -9.97e-02 | -1.30e-01 | 7.93e-02 | -1.38e-01 | 2.41e-01 | 6.25e-01 | 5.25e-01 | 6.98e-01 | 4.99e-01 | 2.39e-01 |
| RIBONUCLEOPROTEIN COMPLEX BIOGENESIS | 448 | 4.36e-19 | 3.28e-16 | 0.33100 | 1.60e-01 | 1.37e-01 | 2.37e-01 | 4.88e-02 | 8.34e-02 | 5.79e-09 | 7.07e-07 | 8.20e-18 | 7.66e-02 | 2.48e-03 |
| POSITIVE REGULATION OF STEROID HORMONE SECRETION | 11 | 8.70e-01 | 1.00e+00 | 0.33100 | -1.65e-01 | -1.80e-01 | -5.79e-02 | -1.90e-01 | 1.04e-01 | 3.44e-01 | 3.01e-01 | 7.39e-01 | 2.76e-01 | 5.52e-01 |
| SENSORY PERCEPTION OF UMAMI TASTE | 7 | 1.64e-01 | 6.64e-01 | 0.33100 | 1.38e-02 | 9.78e-02 | -1.81e-01 | 2.59e-01 | -9.46e-03 | 9.50e-01 | 6.54e-01 | 4.08e-01 | 2.35e-01 | 9.65e-01 |
| SPHINGOSINE 1 PHOSPHATE RECEPTOR SIGNALING PATHWAY | 15 | 5.44e-01 | 9.61e-01 | 0.33100 | 1.62e-01 | 1.57e-01 | 2.23e-01 | 9.33e-02 | -1.43e-02 | 2.77e-01 | 2.92e-01 | 1.35e-01 | 5.32e-01 | 9.23e-01 |
| REGULATION OF LAMELLIPODIUM MORPHOGENESIS | 11 | 3.44e-01 | 8.64e-01 | 0.33100 | 1.46e-01 | 2.26e-01 | 8.25e-03 | 1.79e-01 | -7.04e-02 | 4.02e-01 | 1.95e-01 | 9.62e-01 | 3.03e-01 | 6.86e-01 |
| GLYCOLIPID CATABOLIC PROCESS | 16 | 2.87e-01 | 8.15e-01 | 0.33100 | 1.41e-02 | -2.43e-02 | 1.71e-01 | -1.02e-01 | 2.63e-01 | 9.22e-01 | 8.66e-01 | 2.36e-01 | 4.81e-01 | 6.90e-02 |
| GLYOXYLATE METABOLIC PROCESS | 8 | 8.80e-01 | 1.00e+00 | 0.33100 | 1.66e-01 | 1.77e-01 | 9.03e-02 | 1.81e-01 | 9.86e-02 | 4.16e-01 | 3.86e-01 | 6.58e-01 | 3.76e-01 | 6.29e-01 |
| MITOCHONDRIAL PROTEIN CATABOLIC PROCESS | 6 | 5.59e-01 | 9.69e-01 | 0.33100 | -1.85e-02 | -5.84e-02 | 2.65e-02 | -9.49e-02 | -3.10e-01 | 9.37e-01 | 8.04e-01 | 9.10e-01 | 6.87e-01 | 1.89e-01 |
| REGULATION OF MONONUCLEAR CELL MIGRATION | 119 | 3.72e-02 | 3.07e-01 | 0.33100 | -1.79e-01 | -1.80e-01 | -1.51e-01 | -1.48e-01 | 9.04e-03 | 7.42e-04 | 6.98e-04 | 4.34e-03 | 5.34e-03 | 8.65e-01 |
| CELL PROLIFERATION INVOLVED IN METANEPHROS DEVELOPMENT | 9 | 5.31e-01 | 9.54e-01 | 0.33000 | 1.79e-01 | 1.16e-01 | 1.75e-01 | 1.54e-01 | -9.82e-02 | 3.54e-01 | 5.46e-01 | 3.64e-01 | 4.25e-01 | 6.10e-01 |
| TUBULIN COMPLEX ASSEMBLY | 8 | 6.35e-01 | 9.97e-01 | 0.33000 | -1.76e-01 | -1.06e-01 | -1.95e-01 | -1.37e-01 | -1.01e-01 | 3.89e-01 | 6.03e-01 | 3.40e-01 | 5.03e-01 | 6.20e-01 |
| NEGATIVE REGULATION OF ANTIGEN PROCESSING AND PRESENTATION | 9 | 3.02e-01 | 8.30e-01 | 0.33000 | -1.18e-01 | -1.99e-01 | 5.43e-02 | -9.00e-02 | 2.11e-01 | 5.41e-01 | 3.00e-01 | 7.78e-01 | 6.40e-01 | 2.74e-01 |
| MEMBRANE PROTEIN INTRACELLULAR DOMAIN PROTEOLYSIS | 13 | 7.61e-01 | 1.00e+00 | 0.33000 | 1.39e-01 | 9.96e-02 | 2.12e-01 | 7.00e-02 | 1.73e-01 | 3.87e-01 | 5.34e-01 | 1.86e-01 | 6.62e-01 | 2.80e-01 |
| CO TRANSCRIPTIONAL RNA 3 END PROCESSING CLEAVAGE AND POLYADENYLATION PATHWAY | 6 | 6.16e-01 | 9.90e-01 | 0.33000 | 9.78e-02 | 2.48e-02 | 2.48e-01 | -6.80e-02 | 1.81e-01 | 6.78e-01 | 9.16e-01 | 2.93e-01 | 7.73e-01 | 4.44e-01 |
| PHOTOPERIODISM | 28 | 7.15e-01 | 1.00e+00 | 0.33000 | 1.76e-01 | 1.72e-01 | 1.66e-01 | 1.36e-01 | 4.34e-02 | 1.07e-01 | 1.14e-01 | 1.28e-01 | 2.12e-01 | 6.91e-01 |
| MITOTIC CHROMOSOME CONDENSATION | 19 | 2.00e-01 | 7.16e-01 | 0.33000 | 9.36e-02 | 9.34e-02 | 2.10e-01 | -2.42e-03 | 2.17e-01 | 4.80e-01 | 4.81e-01 | 1.13e-01 | 9.85e-01 | 1.02e-01 |
| REGULATION OF MONOCYTE EXTRAVASATION | 7 | 1.40e-01 | 6.24e-01 | 0.32900 | -3.75e-02 | -3.37e-02 | -2.79e-01 | 1.33e-01 | -1.03e-01 | 8.64e-01 | 8.77e-01 | 2.02e-01 | 5.42e-01 | 6.38e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF EXOGENOUS PEPTIDE ANTIGEN | 38 | 1.93e-02 | 2.02e-01 | 0.32900 | -1.60e-01 | -2.07e-01 | -8.06e-03 | -1.92e-01 | 5.60e-02 | 8.88e-02 | 2.69e-02 | 9.32e-01 | 4.05e-02 | 5.50e-01 |
| TRANS SYNAPTIC SIGNALING MODULATING SYNAPTIC TRANSMISSION | 10 | 7.69e-01 | 1.00e+00 | 0.32900 | -1.44e-01 | -1.72e-01 | -6.33e-02 | -2.07e-01 | 1.06e-01 | 4.29e-01 | 3.45e-01 | 7.29e-01 | 2.58e-01 | 5.61e-01 |
| POSITIVE REGULATION OF APOPTOTIC CELL CLEARANCE | 8 | 6.38e-01 | 9.98e-01 | 0.32900 | 1.24e-01 | 1.69e-01 | 6.96e-02 | 1.65e-01 | 1.80e-01 | 5.44e-01 | 4.08e-01 | 7.33e-01 | 4.19e-01 | 3.77e-01 |
| ENDOTHELIAL CELL MATRIX ADHESION | 8 | 8.01e-01 | 1.00e+00 | 0.32900 | 9.68e-02 | 7.41e-02 | 8.77e-02 | 1.52e-01 | 2.50e-01 | 6.35e-01 | 7.17e-01 | 6.68e-01 | 4.56e-01 | 2.20e-01 |
| PROTEIN LOCALIZATION TO NUCLEAR BODY | 11 | 7.01e-01 | 1.00e+00 | 0.32900 | -1.10e-01 | -1.45e-01 | 3.26e-02 | -1.48e-01 | 2.29e-01 | 5.27e-01 | 4.05e-01 | 8.51e-01 | 3.96e-01 | 1.89e-01 |
| REGULATION OF SALIVA SECRETION | 7 | 3.90e-01 | 8.92e-01 | 0.32900 | 1.38e-01 | 4.82e-02 | 2.74e-01 | 9.54e-02 | 5.00e-02 | 5.27e-01 | 8.25e-01 | 2.09e-01 | 6.62e-01 | 8.19e-01 |
| CLATHRIN COAT ASSEMBLY | 17 | 6.27e-01 | 9.94e-01 | 0.32900 | -1.58e-01 | -1.70e-01 | -3.53e-02 | -2.04e-01 | 1.07e-01 | 2.60e-01 | 2.24e-01 | 8.01e-01 | 1.45e-01 | 4.47e-01 |
| POSITIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL ACTIVATION | 40 | 3.41e-01 | 8.59e-01 | 0.32900 | -1.67e-01 | -1.69e-01 | -8.83e-02 | -2.09e-01 | 1.71e-02 | 6.68e-02 | 6.49e-02 | 3.34e-01 | 2.23e-02 | 8.52e-01 |
| NEGATIVE REGULATION OF LIPID STORAGE | 22 | 7.47e-01 | 1.00e+00 | 0.32900 | -1.71e-01 | -1.78e-01 | -1.63e-01 | -1.32e-01 | -5.82e-02 | 1.65e-01 | 1.48e-01 | 1.86e-01 | 2.85e-01 | 6.37e-01 |
| REGULATION OF MITOCHONDRIAL DNA METABOLIC PROCESS | 8 | 5.92e-01 | 9.86e-01 | 0.32900 | 1.51e-01 | 1.21e-01 | 2.14e-01 | 1.09e-01 | -1.15e-01 | 4.61e-01 | 5.53e-01 | 2.95e-01 | 5.94e-01 | 5.74e-01 |
| SNRNA TRANSCRIPTION | 19 | 4.28e-01 | 9.17e-01 | 0.32900 | 1.51e-01 | 1.23e-01 | 2.47e-01 | 2.70e-02 | 9.21e-02 | 2.55e-01 | 3.54e-01 | 6.25e-02 | 8.39e-01 | 4.87e-01 |
| NEGATIVE REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY | 19 | 3.67e-01 | 8.79e-01 | 0.32800 | 1.02e-01 | 6.33e-02 | 2.33e-01 | 1.10e-02 | 1.98e-01 | 4.41e-01 | 6.33e-01 | 7.92e-02 | 9.34e-01 | 1.35e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO MEMBRANE | 34 | 1.85e-01 | 6.94e-01 | 0.32800 | -1.65e-01 | -1.90e-01 | -8.12e-02 | -1.17e-01 | 1.56e-01 | 9.69e-02 | 5.46e-02 | 4.13e-01 | 2.39e-01 | 1.15e-01 |
| BLEB ASSEMBLY | 11 | 4.94e-01 | 9.47e-01 | 0.32800 | -1.53e-01 | -1.33e-01 | -2.55e-01 | 5.46e-03 | 3.77e-02 | 3.78e-01 | 4.46e-01 | 1.43e-01 | 9.75e-01 | 8.29e-01 |
| DOUBLE STRAND BREAK REPAIR VIA NONHOMOLOGOUS END JOINING | 65 | 1.08e-02 | 1.33e-01 | 0.32800 | 1.28e-01 | 9.33e-02 | 2.32e-01 | 5.78e-02 | 1.58e-01 | 7.36e-02 | 1.93e-01 | 1.20e-03 | 4.21e-01 | 2.73e-02 |
| B CELL APOPTOTIC PROCESS | 26 | 2.75e-02 | 2.55e-01 | 0.32800 | -1.33e-01 | -1.59e-01 | 4.21e-02 | -2.49e-01 | -2.81e-02 | 2.40e-01 | 1.61e-01 | 7.10e-01 | 2.80e-02 | 8.04e-01 |
| REGULATION OF DOSAGE COMPENSATION BY INACTIVATION OF X CHROMOSOME | 9 | 6.74e-01 | 1.00e+00 | 0.32800 | 1.44e-01 | 1.33e-01 | 1.72e-01 | 1.89e-01 | 6.18e-02 | 4.55e-01 | 4.89e-01 | 3.72e-01 | 3.26e-01 | 7.48e-01 |
| NEGATIVE REGULATION OF STRIATED MUSCLE CELL APOPTOTIC PROCESS | 33 | 3.30e-01 | 8.55e-01 | 0.32800 | 1.72e-01 | 1.81e-01 | 1.83e-01 | 9.75e-02 | -4.10e-02 | 8.68e-02 | 7.12e-02 | 6.83e-02 | 3.32e-01 | 6.84e-01 |
| VACUOLAR PROTON TRANSPORTING V TYPE ATPASE COMPLEX ASSEMBLY | 5 | 8.06e-01 | 1.00e+00 | 0.32800 | 1.43e-01 | 1.71e-01 | 1.75e-01 | 1.50e-01 | 6.65e-02 | 5.79e-01 | 5.09e-01 | 4.98e-01 | 5.61e-01 | 7.97e-01 |
| NEGATIVE REGULATION OF REGULATED SECRETORY PATHWAY | 22 | 2.25e-03 | 4.20e-02 | 0.32800 | -2.24e-02 | -1.02e-01 | 2.09e-01 | -2.20e-01 | 6.29e-02 | 8.56e-01 | 4.07e-01 | 8.94e-02 | 7.34e-02 | 6.09e-01 |
| NUCLEOBASE CATABOLIC PROCESS | 10 | 6.57e-01 | 1.00e+00 | 0.32800 | 6.72e-03 | 5.29e-02 | -1.11e-01 | 5.56e-02 | -2.98e-01 | 9.71e-01 | 7.72e-01 | 5.44e-01 | 7.61e-01 | 1.02e-01 |
| RESPONSE TO WATER DEPRIVATION | 5 | 8.12e-01 | 1.00e+00 | 0.32700 | -9.13e-02 | -1.68e-01 | 4.66e-02 | -1.25e-01 | 2.30e-01 | 7.24e-01 | 5.16e-01 | 8.57e-01 | 6.29e-01 | 3.72e-01 |
| L LYSINE TRANSPORT | 7 | 6.39e-01 | 9.99e-01 | 0.32700 | -1.28e-01 | -1.13e-01 | -2.19e-03 | -2.79e-01 | 1.17e-02 | 5.57e-01 | 6.05e-01 | 9.92e-01 | 2.01e-01 | 9.57e-01 |
| FIBRINOLYSIS | 27 | 4.61e-01 | 9.32e-01 | 0.32700 | -1.33e-01 | -1.29e-01 | -1.56e-01 | -1.10e-01 | -1.90e-01 | 2.30e-01 | 2.46e-01 | 1.61e-01 | 3.23e-01 | 8.69e-02 |
| CELL CYCLE DNA REPLICATION | 42 | 2.43e-03 | 4.49e-02 | 0.32700 | 1.14e-01 | 8.93e-02 | 2.55e-01 | -5.81e-02 | 1.33e-01 | 2.03e-01 | 3.17e-01 | 4.22e-03 | 5.14e-01 | 1.36e-01 |
| MIDGUT DEVELOPMENT | 10 | 7.43e-01 | 1.00e+00 | 0.32700 | 1.32e-01 | 1.57e-01 | 6.60e-02 | 1.63e-01 | -1.84e-01 | 4.70e-01 | 3.90e-01 | 7.18e-01 | 3.73e-01 | 3.13e-01 |
| NEGATIVE REGULATION OF AMINE TRANSPORT | 28 | 5.12e-02 | 3.71e-01 | 0.32700 | 1.20e-01 | 1.07e-01 | 1.31e-01 | 2.68e-02 | -2.52e-01 | 2.73e-01 | 3.29e-01 | 2.30e-01 | 8.06e-01 | 2.11e-02 |
| SENSORY PERCEPTION OF SWEET TASTE | 7 | 4.15e-01 | 9.11e-01 | 0.32700 | -1.88e-01 | -1.05e-01 | -1.93e-01 | -1.28e-01 | -8.22e-02 | 3.90e-01 | 6.32e-01 | 3.76e-01 | 5.56e-01 | 7.07e-01 |
| REGULATION OF SODIUM DEPENDENT PHOSPHATE TRANSPORT | 5 | 8.87e-01 | 1.00e+00 | 0.32700 | 1.56e-01 | 1.25e-01 | 1.77e-01 | 1.33e-01 | -1.33e-01 | 5.45e-01 | 6.29e-01 | 4.93e-01 | 6.06e-01 | 6.07e-01 |
| NEGATIVE REGULATION OF CELLULAR EXTRAVASATION | 9 | 4.51e-01 | 9.30e-01 | 0.32700 | 1.60e-01 | 1.43e-01 | 4.23e-02 | 1.30e-01 | -2.04e-01 | 4.05e-01 | 4.57e-01 | 8.26e-01 | 4.98e-01 | 2.88e-01 |
| CELLULAR RESPONSE TO NITROSATIVE STRESS | 6 | 7.10e-01 | 1.00e+00 | 0.32700 | 1.46e-01 | 1.55e-01 | 2.20e-01 | 4.42e-02 | -1.06e-01 | 5.37e-01 | 5.11e-01 | 3.50e-01 | 8.51e-01 | 6.54e-01 |
| POSITIVE REGULATION OF DENDRITIC SPINE MAINTENANCE | 5 | 8.46e-01 | 1.00e+00 | 0.32700 | 7.56e-02 | 1.10e-01 | -8.03e-03 | 1.31e-01 | -2.68e-01 | 7.70e-01 | 6.70e-01 | 9.75e-01 | 6.13e-01 | 3.00e-01 |
| SYNAPSE PRUNING | 14 | 4.96e-01 | 9.47e-01 | 0.32700 | -7.38e-02 | -6.29e-02 | -1.44e-01 | -9.59e-02 | -2.60e-01 | 6.33e-01 | 6.84e-01 | 3.52e-01 | 5.34e-01 | 9.24e-02 |
| NEGATIVE REGULATION OF CALCINEURIN MEDIATED SIGNALING | 15 | 6.85e-01 | 1.00e+00 | 0.32700 | 1.60e-01 | 1.99e-01 | 8.87e-02 | 1.74e-01 | -5.53e-02 | 2.82e-01 | 1.82e-01 | 5.52e-01 | 2.43e-01 | 7.11e-01 |
| DNA TEMPLATED TRANSCRIPTION ELONGATION | 132 | 4.41e-04 | 1.19e-02 | 0.32700 | 1.39e-01 | 1.06e-01 | 2.10e-01 | 8.75e-02 | 1.56e-01 | 5.83e-03 | 3.63e-02 | 3.08e-05 | 8.26e-02 | 1.91e-03 |
| REGULATION OF WNT SIGNALING PATHWAY PLANAR CELL POLARITY PATHWAY | 15 | 8.83e-01 | 1.00e+00 | 0.32600 | -1.74e-01 | -1.71e-01 | -1.15e-01 | -1.74e-01 | 5.95e-02 | 2.43e-01 | 2.50e-01 | 4.41e-01 | 2.44e-01 | 6.90e-01 |
| UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS VIA THE MULTIVESICULAR BODY SORTING PATHWAY | 35 | 1.20e-01 | 5.78e-01 | 0.32600 | 1.19e-01 | 1.06e-01 | 2.12e-01 | 2.68e-02 | 1.89e-01 | 2.23e-01 | 2.80e-01 | 3.00e-02 | 7.84e-01 | 5.32e-02 |
| CELLULAR RESPONSE TO HEPARIN | 5 | 8.66e-01 | 1.00e+00 | 0.32600 | -1.77e-01 | -2.21e-01 | -9.43e-02 | -1.29e-01 | -2.10e-02 | 4.93e-01 | 3.91e-01 | 7.15e-01 | 6.16e-01 | 9.35e-01 |
| POSITIVE REGULATION OF FATTY ACID BIOSYNTHETIC PROCESS | 21 | 1.60e-01 | 6.59e-01 | 0.32600 | 1.53e-01 | 1.31e-01 | 2.45e-01 | 4.67e-02 | -5.87e-02 | 2.26e-01 | 2.97e-01 | 5.15e-02 | 7.11e-01 | 6.42e-01 |
| REGULATION OF RIBOSOME BIOGENESIS | 9 | 7.08e-01 | 1.00e+00 | 0.32600 | 1.04e-01 | 1.04e-01 | -7.52e-03 | 1.22e-01 | -2.64e-01 | 5.89e-01 | 5.90e-01 | 9.69e-01 | 5.26e-01 | 1.70e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CILIUM | 7 | 9.47e-01 | 1.00e+00 | 0.32600 | 1.55e-01 | 1.34e-01 | 1.78e-01 | 1.65e-01 | 7.42e-02 | 4.77e-01 | 5.40e-01 | 4.14e-01 | 4.50e-01 | 7.34e-01 |
| HYPEROSMOTIC SALINITY RESPONSE | 10 | 7.75e-01 | 1.00e+00 | 0.32600 | 9.28e-02 | 5.93e-02 | 2.07e-01 | 3.10e-02 | 2.25e-01 | 6.11e-01 | 7.45e-01 | 2.57e-01 | 8.65e-01 | 2.19e-01 |
| POSITIVE REGULATION OF NUCLEAR DIVISION | 60 | 1.74e-01 | 6.79e-01 | 0.32600 | 1.58e-01 | 1.37e-01 | 2.01e-01 | 1.05e-01 | 1.07e-01 | 3.41e-02 | 6.62e-02 | 7.20e-03 | 1.61e-01 | 1.53e-01 |
| REGULATION OF DNA TEMPLATED DNA REPLICATION INITIATION | 15 | 1.48e-01 | 6.36e-01 | 0.32600 | -1.45e-01 | -1.01e-01 | -5.25e-02 | -2.62e-01 | -6.12e-02 | 3.31e-01 | 4.99e-01 | 7.25e-01 | 7.91e-02 | 6.81e-01 |
| AORTA MORPHOGENESIS | 38 | 7.98e-03 | 1.07e-01 | 0.32600 | 1.00e-01 | 5.49e-02 | 2.65e-01 | -2.59e-02 | 1.49e-01 | 2.85e-01 | 5.58e-01 | 4.66e-03 | 7.82e-01 | 1.12e-01 |
| NEUTROPHIL CLEARANCE | 6 | 6.86e-01 | 1.00e+00 | 0.32600 | 1.66e-01 | 9.37e-02 | 2.60e-01 | 4.24e-02 | -2.80e-02 | 4.83e-01 | 6.91e-01 | 2.71e-01 | 8.57e-01 | 9.06e-01 |
| POSITIVE REGULATION OF HOMOTYPIC CELL CELL ADHESION | 16 | 1.23e-01 | 5.85e-01 | 0.32600 | -1.23e-01 | -1.57e-01 | 7.53e-02 | -1.61e-01 | 1.86e-01 | 3.95e-01 | 2.77e-01 | 6.02e-01 | 2.64e-01 | 1.97e-01 |
| COMPLEMENT ACTIVATION LECTIN PATHWAY | 11 | 8.84e-01 | 1.00e+00 | 0.32600 | -1.70e-01 | -1.83e-01 | -1.74e-01 | -1.09e-01 | -3.71e-02 | 3.28e-01 | 2.92e-01 | 3.18e-01 | 5.31e-01 | 8.31e-01 |
| REPLICATION BORN DOUBLE STRAND BREAK REPAIR VIA SISTER CHROMATID EXCHANGE | 6 | 2.49e-01 | 7.75e-01 | 0.32600 | -1.34e-02 | -1.41e-02 | 2.31e-01 | -1.77e-01 | 1.45e-01 | 9.55e-01 | 9.52e-01 | 3.28e-01 | 4.53e-01 | 5.38e-01 |
| SARCOMERE ORGANIZATION | 45 | 3.49e-01 | 8.68e-01 | 0.32600 | 1.69e-01 | 1.69e-01 | 9.83e-02 | 1.98e-01 | -2.20e-02 | 5.05e-02 | 5.04e-02 | 2.54e-01 | 2.17e-02 | 7.99e-01 |
| COMPLEMENT ACTIVATION ALTERNATIVE PATHWAY | 16 | 5.40e-02 | 3.80e-01 | 0.32600 | -1.21e-01 | -1.19e-01 | -2.64e-01 | 7.47e-02 | 4.15e-02 | 4.00e-01 | 4.08e-01 | 6.75e-02 | 6.05e-01 | 7.74e-01 |
| UTP BIOSYNTHETIC PROCESS | 10 | 7.10e-01 | 1.00e+00 | 0.32600 | 1.66e-01 | 1.45e-01 | 1.75e-01 | 6.10e-02 | -1.52e-01 | 3.63e-01 | 4.27e-01 | 3.38e-01 | 7.38e-01 | 4.06e-01 |
| LIPID HYDROXYLATION | 7 | 1.64e-01 | 6.64e-01 | 0.32500 | -8.53e-02 | -1.03e-01 | -2.21e-01 | 1.96e-01 | 2.84e-02 | 6.96e-01 | 6.36e-01 | 3.11e-01 | 3.70e-01 | 8.96e-01 |
| RESPONSE TO HUMAN CHORIONIC GONADOTROPIN | 5 | 8.47e-01 | 1.00e+00 | 0.32500 | -6.89e-02 | -6.46e-02 | -2.49e-02 | -1.57e-01 | -2.68e-01 | 7.90e-01 | 8.02e-01 | 9.23e-01 | 5.44e-01 | 3.00e-01 |
| STEROL BIOSYNTHETIC PROCESS | 63 | 4.17e-02 | 3.27e-01 | 0.32500 | 1.41e-01 | 1.37e-01 | 1.69e-01 | 1.46e-01 | 1.31e-01 | 5.36e-02 | 5.92e-02 | 2.00e-02 | 4.53e-02 | 7.29e-02 |
| CARDIAC MUSCLE CELL FATE COMMITMENT | 11 | 1.42e-01 | 6.27e-01 | 0.32500 | 1.88e-02 | -2.01e-02 | 1.16e-01 | -1.17e-01 | -2.79e-01 | 9.14e-01 | 9.08e-01 | 5.04e-01 | 5.01e-01 | 1.10e-01 |
| NEURAL PLATE MORPHOGENESIS | 5 | 7.04e-01 | 1.00e+00 | 0.32500 | 1.15e-01 | 1.67e-01 | 5.02e-02 | 1.83e-01 | -1.69e-01 | 6.56e-01 | 5.17e-01 | 8.46e-01 | 4.79e-01 | 5.13e-01 |
| TOLL LIKE RECEPTOR 4 SIGNALING PATHWAY | 55 | 9.04e-02 | 4.97e-01 | 0.32500 | -1.55e-01 | -1.74e-01 | -8.87e-02 | -2.02e-01 | 4.68e-02 | 4.61e-02 | 2.55e-02 | 2.55e-01 | 9.41e-03 | 5.49e-01 |
| CATECHOLAMINE UPTAKE | 18 | 6.43e-01 | 1.00e+00 | 0.32500 | 1.48e-01 | 1.07e-01 | 2.22e-01 | 9.10e-02 | 1.20e-01 | 2.77e-01 | 4.31e-01 | 1.03e-01 | 5.04e-01 | 3.77e-01 |
| PURINE NUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 18 | 3.94e-01 | 8.93e-01 | 0.32500 | 1.28e-01 | 1.73e-01 | 5.39e-02 | 1.21e-01 | -2.05e-01 | 3.48e-01 | 2.05e-01 | 6.92e-01 | 3.75e-01 | 1.33e-01 |
| MRNA MODIFICATION | 31 | 2.34e-02 | 2.30e-01 | 0.32500 | -1.21e-01 | -1.19e-01 | -1.53e-02 | -2.23e-01 | -1.62e-01 | 2.43e-01 | 2.51e-01 | 8.83e-01 | 3.13e-02 | 1.17e-01 |
| TRICUSPID VALVE DEVELOPMENT | 6 | 8.26e-01 | 1.00e+00 | 0.32500 | -9.28e-02 | -1.06e-01 | -4.91e-02 | -1.93e-01 | -2.15e-01 | 6.94e-01 | 6.54e-01 | 8.35e-01 | 4.14e-01 | 3.63e-01 |
| INTRACELLULAR TRIGLYCERIDE HOMEOSTASIS | 7 | 7.75e-01 | 1.00e+00 | 0.32500 | -1.48e-01 | -1.98e-01 | -8.91e-02 | -1.85e-01 | 4.31e-02 | 4.96e-01 | 3.65e-01 | 6.83e-01 | 3.96e-01 | 8.43e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN VIA MHC CLASS IB | 18 | 2.33e-01 | 7.56e-01 | 0.32400 | 1.37e-01 | 7.51e-02 | 2.65e-01 | 1.04e-02 | 1.04e-01 | 3.16e-01 | 5.81e-01 | 5.18e-02 | 9.39e-01 | 4.46e-01 |
| CELLULAR RESPONSE TO STEROL DEPLETION | 16 | 5.21e-01 | 9.53e-01 | 0.32400 | 1.23e-01 | 7.22e-02 | 1.95e-01 | 1.24e-01 | 1.77e-01 | 3.93e-01 | 6.17e-01 | 1.77e-01 | 3.92e-01 | 2.19e-01 |
| REGULATION OF RECEPTOR CLUSTERING | 13 | 5.10e-01 | 9.50e-01 | 0.32400 | -4.17e-03 | -2.94e-02 | 1.32e-01 | -7.77e-02 | 2.84e-01 | 9.79e-01 | 8.54e-01 | 4.10e-01 | 6.28e-01 | 7.58e-02 |
| PEPTIDE CROSS LINKING | 27 | 1.87e-03 | 3.76e-02 | 0.32400 | -1.12e-01 | -6.08e-02 | -2.80e-01 | 8.71e-02 | 5.15e-02 | 3.13e-01 | 5.84e-01 | 1.17e-02 | 4.34e-01 | 6.43e-01 |
| POSITIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 10 | 6.90e-01 | 1.00e+00 | 0.32400 | 1.49e-01 | 9.82e-02 | 1.99e-01 | 7.32e-02 | 1.68e-01 | 4.14e-01 | 5.91e-01 | 2.76e-01 | 6.89e-01 | 3.57e-01 |
| NEGATIVE REGULATION OF GRANULOCYTE DIFFERENTIATION | 8 | 5.10e-01 | 9.50e-01 | 0.32400 | 1.62e-01 | 1.13e-01 | 2.40e-01 | -1.05e-02 | -9.31e-02 | 4.28e-01 | 5.79e-01 | 2.41e-01 | 9.59e-01 | 6.48e-01 |
| CELLULAR RESPONSE TO PARATHYROID HORMONE STIMULUS | 8 | 6.59e-01 | 1.00e+00 | 0.32400 | 3.97e-02 | 3.26e-02 | -1.05e-02 | 4.43e-02 | -3.17e-01 | 8.46e-01 | 8.73e-01 | 9.59e-01 | 8.28e-01 | 1.21e-01 |
| REGULATION OF MITOCHONDRIAL ELECTRON TRANSPORT NADH TO UBIQUINONE | 6 | 8.86e-01 | 1.00e+00 | 0.32400 | 1.59e-01 | 2.05e-01 | 1.02e-01 | 1.04e-01 | -1.28e-01 | 5.01e-01 | 3.85e-01 | 6.64e-01 | 6.58e-01 | 5.86e-01 |
| DEOXYRIBONUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 8 | 8.12e-01 | 1.00e+00 | 0.32400 | 1.62e-01 | 1.28e-01 | 1.48e-01 | 1.79e-01 | -9.18e-02 | 4.28e-01 | 5.30e-01 | 4.70e-01 | 3.80e-01 | 6.53e-01 |
| REGULATION OF GAP JUNCTION ASSEMBLY | 9 | 8.32e-02 | 4.75e-01 | 0.32400 | 1.21e-02 | -4.20e-02 | 2.76e-01 | -1.16e-01 | 1.16e-01 | 9.50e-01 | 8.27e-01 | 1.52e-01 | 5.47e-01 | 5.46e-01 |
| CELL PROLIFERATION INVOLVED IN HEART MORPHOGENESIS | 20 | 1.58e-01 | 6.56e-01 | 0.32400 | -1.19e-01 | -1.59e-01 | 3.79e-02 | -2.52e-01 | 2.38e-02 | 3.58e-01 | 2.18e-01 | 7.69e-01 | 5.12e-02 | 8.54e-01 |
| PHAGOCYTOSIS ENGULFMENT | 48 | 2.26e-02 | 2.25e-01 | 0.32400 | -1.69e-01 | -1.94e-01 | -1.61e-01 | -8.62e-02 | -7.21e-02 | 4.23e-02 | 2.02e-02 | 5.37e-02 | 3.01e-01 | 3.87e-01 |
| PHENOTYPIC SWITCHING | 16 | 3.07e-01 | 8.35e-01 | 0.32400 | 9.50e-02 | 4.91e-02 | 2.51e-01 | 3.11e-03 | 1.74e-01 | 5.11e-01 | 7.34e-01 | 8.21e-02 | 9.83e-01 | 2.28e-01 |
| POSITIVE REGULATION OF NON MOTILE CILIUM ASSEMBLY | 8 | 7.97e-01 | 1.00e+00 | 0.32400 | -7.43e-02 | -8.83e-02 | 2.73e-02 | -7.58e-02 | 2.91e-01 | 7.16e-01 | 6.65e-01 | 8.94e-01 | 7.11e-01 | 1.53e-01 |
| BRANCHING INVOLVED IN SALIVARY GLAND MORPHOGENESIS | 21 | 2.41e-01 | 7.67e-01 | 0.32400 | 1.13e-01 | 1.51e-01 | -1.08e-02 | 2.06e-01 | -1.64e-01 | 3.72e-01 | 2.32e-01 | 9.31e-01 | 1.03e-01 | 1.94e-01 |
| REGULATION OF RECEPTOR SIGNALING PATHWAY VIA STAT | 113 | 7.22e-03 | 9.94e-02 | 0.32400 | -1.65e-01 | -1.53e-01 | -1.44e-01 | -1.80e-01 | 2.67e-02 | 2.45e-03 | 4.85e-03 | 7.98e-03 | 9.56e-04 | 6.24e-01 |
| EPITHELIAL CELL DIFFERENTIATION INVOLVED IN PROSTATE GLAND DEVELOPMENT | 10 | 5.76e-01 | 9.80e-01 | 0.32300 | 1.33e-01 | 1.15e-01 | 6.49e-02 | 2.10e-01 | -1.59e-01 | 4.65e-01 | 5.30e-01 | 7.22e-01 | 2.50e-01 | 3.84e-01 |
| NEGATIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 75 | 6.57e-04 | 1.61e-02 | 0.32300 | -1.38e-01 | -1.83e-01 | 9.06e-03 | -2.10e-01 | 8.69e-02 | 3.86e-02 | 6.03e-03 | 8.92e-01 | 1.65e-03 | 1.93e-01 |
| PHOSPHATIDYLCHOLINE BIOSYNTHETIC PROCESS | 28 | 2.26e-01 | 7.48e-01 | 0.32300 | 1.27e-01 | 1.46e-01 | 1.07e-01 | 1.45e-01 | 1.86e-01 | 2.47e-01 | 1.82e-01 | 3.29e-01 | 1.83e-01 | 8.78e-02 |
| POSITIVE REGULATION OF PSEUDOPODIUM ASSEMBLY | 12 | 8.24e-01 | 1.00e+00 | 0.32300 | -1.57e-01 | -1.58e-01 | -7.95e-02 | -1.43e-01 | 1.67e-01 | 3.46e-01 | 3.42e-01 | 6.34e-01 | 3.91e-01 | 3.17e-01 |
| VACUOLAR ACIDIFICATION | 32 | 8.78e-02 | 4.90e-01 | 0.32300 | 1.02e-01 | 6.94e-02 | 2.33e-01 | 2.24e-02 | 1.85e-01 | 3.20e-01 | 4.97e-01 | 2.24e-02 | 8.27e-01 | 6.99e-02 |
| POSITIVE REGULATION OF PROTEIN GLYCOSYLATION | 8 | 9.67e-01 | 1.00e+00 | 0.32300 | 1.56e-01 | 1.36e-01 | 1.68e-01 | 1.56e-01 | 9.50e-02 | 4.44e-01 | 5.06e-01 | 4.12e-01 | 4.45e-01 | 6.42e-01 |
| TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE PHOSPHATASE SIGNALING PATHWAY | 6 | 7.25e-01 | 1.00e+00 | 0.32300 | -1.50e-01 | -9.45e-02 | -2.58e-01 | 1.90e-02 | -7.86e-02 | 5.26e-01 | 6.88e-01 | 2.74e-01 | 9.36e-01 | 7.39e-01 |
| NUCLEOTIDE EXCISION REPAIR DNA GAP FILLING | 6 | 6.12e-01 | 9.90e-01 | 0.32300 | 1.69e-01 | 1.06e-01 | 2.23e-01 | 2.70e-02 | -1.19e-01 | 4.74e-01 | 6.54e-01 | 3.44e-01 | 9.09e-01 | 6.15e-01 |
| MITOCHONDRIAL RESPIRATORY CHAIN COMPLEX ASSEMBLY | 92 | 3.65e-06 | 1.90e-04 | 0.32300 | 1.19e-01 | 8.68e-02 | 2.56e-01 | -2.76e-02 | 1.26e-01 | 4.86e-02 | 1.50e-01 | 2.12e-05 | 6.47e-01 | 3.64e-02 |
| CELLULAR RESPONSE TO INCREASED OXYGEN LEVELS | 10 | 3.93e-01 | 8.92e-01 | 0.32200 | 3.33e-02 | -4.15e-02 | 2.03e-01 | 2.60e-03 | 2.45e-01 | 8.55e-01 | 8.20e-01 | 2.67e-01 | 9.89e-01 | 1.80e-01 |
| BEHAVIORAL RESPONSE TO PAIN | 19 | 2.61e-01 | 7.89e-01 | 0.32200 | 1.34e-01 | 1.47e-01 | 6.04e-02 | 2.32e-01 | -8.56e-02 | 3.13e-01 | 2.69e-01 | 6.48e-01 | 8.05e-02 | 5.18e-01 |
| CELLULAR RESPONSE TO MACROPHAGE COLONY STIMULATING FACTOR STIMULUS | 13 | 8.56e-01 | 1.00e+00 | 0.32200 | -1.67e-01 | -1.53e-01 | -1.43e-01 | -1.47e-01 | -1.03e-01 | 2.97e-01 | 3.38e-01 | 3.73e-01 | 3.60e-01 | 5.20e-01 |
| PLATELET MORPHOGENESIS | 22 | 4.58e-01 | 9.32e-01 | 0.32200 | 1.34e-01 | 8.59e-02 | 2.02e-01 | 1.09e-01 | 1.61e-01 | 2.76e-01 | 4.86e-01 | 1.01e-01 | 3.74e-01 | 1.92e-01 |
| POSITIVE REGULATION OF MITOCHONDRIAL FISSION | 21 | 5.87e-01 | 9.85e-01 | 0.32200 | -1.52e-01 | -1.68e-01 | -1.58e-01 | -1.29e-01 | -1.03e-01 | 2.28e-01 | 1.82e-01 | 2.09e-01 | 3.06e-01 | 4.15e-01 |
| NEGATIVE REGULATION OF CATECHOLAMINE SECRETION | 13 | 3.88e-01 | 8.92e-01 | 0.32200 | 9.61e-02 | 8.93e-02 | 8.57e-02 | -2.45e-03 | -2.81e-01 | 5.49e-01 | 5.77e-01 | 5.93e-01 | 9.88e-01 | 7.92e-02 |
| DETECTION OF BACTERIUM | 16 | 5.75e-01 | 9.79e-01 | 0.32200 | -1.05e-01 | -1.35e-01 | -1.77e-03 | -1.23e-01 | 2.43e-01 | 4.69e-01 | 3.50e-01 | 9.90e-01 | 3.94e-01 | 9.19e-02 |
| PYRIMIDINE DEOXYRIBONUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 11 | 7.46e-01 | 1.00e+00 | 0.32200 | -1.15e-01 | -1.45e-01 | -1.72e-02 | -9.48e-02 | 2.45e-01 | 5.09e-01 | 4.05e-01 | 9.21e-01 | 5.86e-01 | 1.60e-01 |
| CELLULAR RESPONSE TO COCAINE | 8 | 7.31e-01 | 1.00e+00 | 0.32200 | 1.46e-01 | 7.70e-02 | 2.43e-01 | 7.66e-02 | 1.06e-01 | 4.73e-01 | 7.06e-01 | 2.34e-01 | 7.07e-01 | 6.03e-01 |
| PROTEIN DEGLYCOSYLATION | 15 | 4.96e-01 | 9.47e-01 | 0.32200 | -9.43e-02 | -1.04e-01 | 2.47e-02 | -1.51e-01 | 2.46e-01 | 5.27e-01 | 4.84e-01 | 8.68e-01 | 3.12e-01 | 9.96e-02 |
| NEPHRON TUBULE FORMATION | 20 | 2.85e-02 | 2.61e-01 | 0.32200 | 4.98e-02 | -2.54e-02 | 2.28e-01 | -1.23e-01 | 1.82e-01 | 7.00e-01 | 8.44e-01 | 7.74e-02 | 3.43e-01 | 1.58e-01 |
| T CELL MEDIATED IMMUNITY | 123 | 3.06e-04 | 8.78e-03 | 0.32200 | -1.50e-01 | -1.75e-01 | -2.83e-02 | -1.93e-01 | 1.11e-01 | 4.08e-03 | 8.20e-04 | 5.88e-01 | 2.13e-04 | 3.37e-02 |
| ESTROGEN BIOSYNTHETIC PROCESS | 11 | 1.05e-01 | 5.37e-01 | 0.32200 | -1.60e-01 | -7.11e-02 | -2.57e-01 | -8.17e-03 | 7.93e-02 | 3.57e-01 | 6.83e-01 | 1.39e-01 | 9.63e-01 | 6.49e-01 |
| POSITIVE REGULATION OF HISTONE ACETYLATION | 10 | 7.59e-01 | 1.00e+00 | 0.32200 | 4.10e-02 | 8.88e-03 | 1.35e-01 | 1.90e-02 | 2.88e-01 | 8.22e-01 | 9.61e-01 | 4.59e-01 | 9.17e-01 | 1.15e-01 |
| REGULATION OF LEUKOCYTE CHEMOTAXIS | 120 | 8.84e-03 | 1.15e-01 | 0.32100 | -1.74e-01 | -1.91e-01 | -1.21e-01 | -1.41e-01 | 4.57e-02 | 1.00e-03 | 3.01e-04 | 2.22e-02 | 7.50e-03 | 3.87e-01 |
| REGULATION OF SENSORY PERCEPTION | 17 | 5.97e-01 | 9.89e-01 | 0.32100 | -1.55e-01 | -1.38e-01 | -1.49e-01 | -1.95e-01 | -1.22e-02 | 2.70e-01 | 3.25e-01 | 2.89e-01 | 1.63e-01 | 9.31e-01 |
| CYCLIC NUCLEOTIDE TRANSPORT | 9 | 7.66e-01 | 1.00e+00 | 0.32100 | -1.55e-01 | -1.34e-01 | -8.41e-02 | -2.00e-01 | -1.19e-01 | 4.20e-01 | 4.85e-01 | 6.62e-01 | 2.99e-01 | 5.37e-01 |
| SPERMIDINE TRANSPORT | 5 | 5.03e-01 | 9.48e-01 | 0.32100 | 7.68e-02 | 2.02e-03 | 3.00e-01 | -6.42e-02 | 5.61e-02 | 7.66e-01 | 9.94e-01 | 2.45e-01 | 8.04e-01 | 8.28e-01 |
| PYRIMIDINE CONTAINING COMPOUND TRANSMEMBRANE TRANSPORT | 16 | 8.90e-01 | 1.00e+00 | 0.32100 | 1.59e-01 | 1.53e-01 | 1.57e-01 | 1.58e-01 | 7.02e-02 | 2.71e-01 | 2.88e-01 | 2.78e-01 | 2.74e-01 | 6.27e-01 |
| POSITIVE REGULATION OF LAMELLIPODIUM MORPHOGENESIS | 7 | 7.67e-01 | 1.00e+00 | 0.32100 | 1.34e-01 | 1.82e-01 | 2.27e-02 | 2.18e-01 | 6.35e-02 | 5.39e-01 | 4.04e-01 | 9.17e-01 | 3.18e-01 | 7.71e-01 |
| CELL ADHESION INVOLVED IN HEART MORPHOGENESIS | 6 | 8.96e-01 | 1.00e+00 | 0.32100 | 1.48e-01 | 1.81e-01 | 1.22e-01 | 9.72e-02 | -1.56e-01 | 5.31e-01 | 4.43e-01 | 6.05e-01 | 6.80e-01 | 5.09e-01 |
| POSITIVE REGULATION OF HEART RATE BY EPINEPHRINE NOREPINEPHRINE | 5 | 9.85e-01 | 1.00e+00 | 0.32100 | -1.59e-01 | -1.69e-01 | -8.56e-02 | -1.93e-01 | 6.93e-02 | 5.39e-01 | 5.12e-01 | 7.40e-01 | 4.56e-01 | 7.88e-01 |
| REGULATION OF MESODERM DEVELOPMENT | 6 | 7.56e-01 | 1.00e+00 | 0.32100 | 1.23e-01 | 1.94e-01 | 3.33e-02 | 1.12e-01 | -1.91e-01 | 6.01e-01 | 4.11e-01 | 8.88e-01 | 6.34e-01 | 4.17e-01 |
| UTERUS MORPHOGENESIS | 6 | 9.10e-01 | 1.00e+00 | 0.32100 | 1.86e-01 | 1.60e-01 | 1.60e-01 | 1.25e-01 | 4.05e-02 | 4.30e-01 | 4.98e-01 | 4.98e-01 | 5.95e-01 | 8.64e-01 |
| GLYCEROL ETHER METABOLIC PROCESS | 21 | 4.05e-01 | 9.06e-01 | 0.32100 | -1.64e-01 | -1.40e-01 | -2.28e-01 | -5.70e-02 | 3.78e-02 | 1.94e-01 | 2.66e-01 | 7.09e-02 | 6.51e-01 | 7.64e-01 |
| POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 97 | 3.24e-02 | 2.84e-01 | 0.32100 | -1.70e-01 | -1.62e-01 | -1.06e-01 | -1.89e-01 | 2.33e-02 | 3.81e-03 | 5.74e-03 | 7.06e-02 | 1.26e-03 | 6.92e-01 |
| VERY LOW DENSITY LIPOPROTEIN PARTICLE ASSEMBLY | 12 | 8.82e-01 | 1.00e+00 | 0.32100 | 1.63e-01 | 1.60e-01 | 1.39e-01 | 1.40e-01 | -1.09e-01 | 3.29e-01 | 3.39e-01 | 4.03e-01 | 4.01e-01 | 5.13e-01 |
| SECRETION BY TISSUE | 44 | 5.34e-01 | 9.56e-01 | 0.32100 | 1.68e-01 | 1.62e-01 | 1.36e-01 | 1.71e-01 | 2.27e-02 | 5.41e-02 | 6.37e-02 | 1.17e-01 | 4.90e-02 | 7.94e-01 |
| NUCLEAR MRNA SURVEILLANCE | 10 | 7.22e-01 | 1.00e+00 | 0.32100 | 1.03e-01 | 4.75e-02 | 2.20e-01 | 2.51e-02 | 2.02e-01 | 5.72e-01 | 7.95e-01 | 2.27e-01 | 8.90e-01 | 2.69e-01 |
| PROTEIN SIDE CHAIN DEGLUTAMYLATION | 5 | 9.08e-01 | 1.00e+00 | 0.32100 | -1.64e-02 | 1.41e-02 | -1.18e-01 | 4.15e-02 | -2.94e-01 | 9.49e-01 | 9.57e-01 | 6.49e-01 | 8.72e-01 | 2.54e-01 |
| POSITIVE REGULATION OF T CELL DIFFERENTIATION IN THYMUS | 10 | 9.52e-01 | 1.00e+00 | 0.32100 | 1.73e-01 | 1.66e-01 | 1.76e-01 | 1.14e-01 | 3.59e-02 | 3.44e-01 | 3.63e-01 | 3.36e-01 | 5.31e-01 | 8.44e-01 |
| MORPHOGENESIS OF AN EPITHELIAL BUD | 14 | 1.01e-01 | 5.25e-01 | 0.32100 | 4.14e-02 | 1.45e-02 | -1.66e-02 | 1.18e-01 | -2.94e-01 | 7.88e-01 | 9.25e-01 | 9.15e-01 | 4.43e-01 | 5.67e-02 |
| POSITIVE REGULATION OF CYTOKINESIS | 43 | 8.99e-03 | 1.16e-01 | 0.32100 | -1.89e-01 | -2.02e-01 | -1.09e-01 | -1.17e-01 | 2.55e-02 | 3.21e-02 | 2.19e-02 | 2.18e-01 | 1.82e-01 | 7.72e-01 |
| NEGATIVE REGULATION OF OSSIFICATION | 37 | 5.21e-01 | 9.53e-01 | 0.32000 | -1.66e-01 | -1.53e-01 | -1.31e-01 | -1.85e-01 | -1.99e-02 | 8.05e-02 | 1.08e-01 | 1.69e-01 | 5.12e-02 | 8.34e-01 |
| AMINOGLYCOSIDE ANTIBIOTIC METABOLIC PROCESS | 10 | 4.10e-01 | 9.08e-01 | 0.32000 | 1.21e-02 | 6.20e-02 | -1.08e-01 | 1.26e-01 | -2.66e-01 | 9.47e-01 | 7.34e-01 | 5.53e-01 | 4.89e-01 | 1.45e-01 |
| POSITIVE REGULATION OF POTASSIUM ION TRANSPORT | 41 | 6.47e-02 | 4.13e-01 | 0.32000 | 1.11e-01 | 1.20e-01 | 2.25e-02 | 1.01e-01 | -2.55e-01 | 2.19e-01 | 1.85e-01 | 8.03e-01 | 2.61e-01 | 4.67e-03 |
| RESPONSE TO LAMINAR FLUID SHEAR STRESS | 14 | 3.40e-01 | 8.59e-01 | 0.32000 | 1.46e-01 | 1.99e-01 | 1.02e-01 | 1.54e-01 | -8.66e-02 | 3.44e-01 | 1.97e-01 | 5.10e-01 | 3.19e-01 | 5.75e-01 |
| INTERLEUKIN 4 PRODUCTION | 32 | 1.75e-01 | 6.81e-01 | 0.32000 | -1.03e-01 | -1.27e-01 | -8.65e-03 | -9.87e-02 | 2.57e-01 | 3.13e-01 | 2.15e-01 | 9.33e-01 | 3.34e-01 | 1.19e-02 |
| NEGATIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL ACTIVATION | 33 | 1.82e-01 | 6.91e-01 | 0.32000 | -1.55e-01 | -1.73e-01 | -2.28e-02 | -2.10e-01 | 6.09e-02 | 1.23e-01 | 8.50e-02 | 8.21e-01 | 3.70e-02 | 5.45e-01 |
| UBIQUINONE METABOLIC PROCESS | 19 | 2.48e-01 | 7.75e-01 | 0.32000 | 1.32e-01 | 1.26e-01 | 2.38e-01 | -9.43e-03 | 1.10e-01 | 3.20e-01 | 3.41e-01 | 7.22e-02 | 9.43e-01 | 4.07e-01 |
| PROSTAGLANDIN SECRETION | 17 | 6.74e-01 | 1.00e+00 | 0.32000 | -1.85e-01 | -1.71e-01 | -1.41e-01 | -1.33e-01 | 3.24e-02 | 1.87e-01 | 2.22e-01 | 3.14e-01 | 3.42e-01 | 8.17e-01 |
| VOCALIZATION BEHAVIOR | 15 | 6.68e-01 | 1.00e+00 | 0.32000 | 1.50e-01 | 1.50e-01 | 1.05e-01 | 1.93e-01 | -9.43e-02 | 3.15e-01 | 3.16e-01 | 4.80e-01 | 1.96e-01 | 5.27e-01 |
| VESICLE UNCOATING | 8 | 8.46e-01 | 1.00e+00 | 0.31900 | 9.86e-02 | 9.53e-02 | 1.62e-01 | 4.15e-02 | 2.35e-01 | 6.29e-01 | 6.41e-01 | 4.29e-01 | 8.39e-01 | 2.49e-01 |
| PROTEIN RNA COMPLEX DISASSEMBLY | 8 | 8.43e-01 | 1.00e+00 | 0.31900 | 1.16e-01 | 6.21e-02 | 1.78e-01 | 1.15e-01 | 1.99e-01 | 5.71e-01 | 7.61e-01 | 3.82e-01 | 5.75e-01 | 3.29e-01 |
| REGULATION OF ENDOPLASMIC RETICULUM TUBULAR NETWORK ORGANIZATION | 6 | 7.63e-01 | 1.00e+00 | 0.31900 | -7.51e-02 | -8.65e-02 | -4.53e-03 | -2.00e-01 | -2.22e-01 | 7.50e-01 | 7.14e-01 | 9.85e-01 | 3.97e-01 | 3.47e-01 |
| NEGATIVE REGULATION OF STEM CELL POPULATION MAINTENANCE | 24 | 2.47e-02 | 2.34e-01 | 0.31900 | 2.23e-02 | -3.94e-02 | 2.15e-01 | -3.70e-02 | 2.28e-01 | 8.50e-01 | 7.38e-01 | 6.77e-02 | 7.54e-01 | 5.31e-02 |
| CARDIOBLAST PROLIFERATION | 11 | 1.36e-01 | 6.17e-01 | 0.31900 | 9.28e-02 | 2.35e-02 | 2.66e-01 | -1.28e-01 | 7.31e-02 | 5.94e-01 | 8.93e-01 | 1.26e-01 | 4.62e-01 | 6.75e-01 |
| POSITIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 27 | 4.60e-01 | 9.32e-01 | 0.31900 | -1.73e-01 | -1.92e-01 | -8.30e-02 | -1.64e-01 | 3.29e-02 | 1.20e-01 | 8.38e-02 | 4.55e-01 | 1.39e-01 | 7.67e-01 |
| SYNAPTIC VESICLE LUMEN ACIDIFICATION | 14 | 4.19e-01 | 9.11e-01 | 0.31900 | 1.01e-01 | 7.65e-02 | 2.44e-01 | -2.18e-02 | 1.61e-01 | 5.15e-01 | 6.20e-01 | 1.15e-01 | 8.88e-01 | 2.97e-01 |
| REGULATION OF LUTEINIZING HORMONE SECRETION | 6 | 8.86e-01 | 1.00e+00 | 0.31900 | -6.17e-02 | -4.96e-02 | -8.43e-02 | -7.74e-02 | -2.87e-01 | 7.93e-01 | 8.34e-01 | 7.21e-01 | 7.43e-01 | 2.24e-01 |
| ENDOCARDIUM DEVELOPMENT | 12 | 6.59e-01 | 1.00e+00 | 0.31900 | -1.27e-01 | -1.37e-01 | -4.54e-02 | -2.24e-01 | -1.19e-01 | 4.48e-01 | 4.10e-01 | 7.85e-01 | 1.78e-01 | 4.75e-01 |
| NEGATIVE REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 6 | 8.67e-01 | 1.00e+00 | 0.31900 | -1.79e-02 | -4.42e-02 | 1.18e-01 | -6.62e-02 | 2.85e-01 | 9.39e-01 | 8.51e-01 | 6.18e-01 | 7.79e-01 | 2.27e-01 |
| POSITIVE REGULATION OF CELL MIGRATION BY VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 8 | 5.37e-01 | 9.57e-01 | 0.31900 | 9.87e-02 | 1.00e-01 | 2.13e-01 | -6.73e-02 | 1.79e-01 | 6.29e-01 | 6.23e-01 | 2.98e-01 | 7.42e-01 | 3.82e-01 |
| TYPE II INTERFERON PRODUCTION | 113 | 1.76e-02 | 1.90e-01 | 0.31800 | -1.68e-01 | -1.81e-01 | -9.21e-02 | -1.67e-01 | 6.23e-02 | 1.97e-03 | 9.08e-04 | 9.09e-02 | 2.11e-03 | 2.53e-01 |
| HEPATOCYTE DIFFERENTIATION | 15 | 1.95e-01 | 7.07e-01 | 0.31800 | 1.21e-01 | 1.52e-01 | 1.48e-01 | 1.67e-02 | -2.04e-01 | 4.18e-01 | 3.09e-01 | 3.21e-01 | 9.11e-01 | 1.72e-01 |
| REGULATION OF APOPTOTIC DNA FRAGMENTATION | 10 | 6.66e-01 | 1.00e+00 | 0.31800 | 1.26e-01 | 1.43e-01 | 1.43e-01 | 6.43e-02 | 2.01e-01 | 4.89e-01 | 4.34e-01 | 4.33e-01 | 7.25e-01 | 2.71e-01 |
| RESPONSE TO COPPER ION | 35 | 2.78e-01 | 8.05e-01 | 0.31800 | 1.39e-01 | 1.20e-01 | 2.16e-01 | 5.83e-02 | 1.32e-01 | 1.54e-01 | 2.21e-01 | 2.68e-02 | 5.51e-01 | 1.76e-01 |
| REGULATION OF MODIFICATION OF POSTSYNAPTIC ACTIN CYTOSKELETON | 5 | 9.03e-01 | 1.00e+00 | 0.31800 | 1.20e-01 | 1.39e-01 | 3.58e-02 | 1.98e-01 | -1.65e-01 | 6.43e-01 | 5.90e-01 | 8.90e-01 | 4.43e-01 | 5.24e-01 |
| LATE ENDOSOME TO VACUOLE TRANSPORT | 36 | 8.12e-02 | 4.69e-01 | 0.31800 | 9.21e-02 | 8.76e-02 | 1.79e-01 | 2.33e-02 | 2.29e-01 | 3.39e-01 | 3.63e-01 | 6.27e-02 | 8.09e-01 | 1.75e-02 |
| NEGATIVE REGULATION OF AMYLOID PRECURSOR PROTEIN BIOSYNTHETIC PROCESS | 18 | 7.06e-01 | 1.00e+00 | 0.31800 | 1.68e-01 | 1.55e-01 | 1.40e-01 | 1.21e-01 | -1.21e-01 | 2.19e-01 | 2.56e-01 | 3.03e-01 | 3.72e-01 | 3.72e-01 |
| PYRIMIDINE NUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 23 | 7.09e-01 | 1.00e+00 | 0.31800 | 1.69e-01 | 1.39e-01 | 1.79e-01 | 1.43e-01 | 2.84e-02 | 1.61e-01 | 2.47e-01 | 1.38e-01 | 2.35e-01 | 8.14e-01 |
| VITAMIN D RECEPTOR SIGNALING PATHWAY | 12 | 3.37e-01 | 8.59e-01 | 0.31800 | 1.03e-01 | 1.22e-01 | 1.55e-01 | -1.11e-03 | 2.27e-01 | 5.36e-01 | 4.62e-01 | 3.53e-01 | 9.95e-01 | 1.74e-01 |
| CELL PROLIFERATION IN MIDBRAIN | 8 | 1.63e-01 | 6.63e-01 | 0.31800 | -1.28e-01 | -2.37e-01 | -1.54e-02 | -1.67e-01 | -1.80e-02 | 5.30e-01 | 2.46e-01 | 9.40e-01 | 4.13e-01 | 9.30e-01 |
| PLASMA MEMBRANE FUSION | 30 | 8.59e-02 | 4.84e-01 | 0.31800 | 1.39e-01 | 1.12e-01 | 8.43e-02 | 2.42e-01 | 5.86e-02 | 1.87e-01 | 2.87e-01 | 4.24e-01 | 2.19e-02 | 5.79e-01 |
| RETINAL GANGLION CELL AXON GUIDANCE | 22 | 5.96e-01 | 9.88e-01 | 0.31800 | -1.46e-01 | -1.40e-01 | -9.46e-02 | -2.06e-01 | -9.45e-02 | 2.37e-01 | 2.56e-01 | 4.42e-01 | 9.47e-02 | 4.43e-01 |
| HEPATOCYTE APOPTOTIC PROCESS | 21 | 5.88e-01 | 9.85e-01 | 0.31800 | 1.30e-01 | 1.22e-01 | 1.44e-01 | 1.05e-01 | 1.94e-01 | 3.03e-01 | 3.32e-01 | 2.54e-01 | 4.06e-01 | 1.24e-01 |
| CEREBELLAR PURKINJE CELL GRANULE CELL PRECURSOR CELL SIGNALING INVOLVED IN REGULATION OF GRANULE CELL PRECURSOR CELL PROLIFERATION | 5 | 4.86e-01 | 9.43e-01 | 0.31800 | 2.29e-02 | -3.99e-03 | 2.09e-01 | -2.38e-01 | 9.15e-03 | 9.29e-01 | 9.88e-01 | 4.18e-01 | 3.57e-01 | 9.72e-01 |
| CEREBELLAR PURKINJE CELL LAYER DEVELOPMENT | 27 | 5.30e-01 | 9.54e-01 | 0.31800 | 1.51e-01 | 1.24e-01 | 2.15e-01 | 8.78e-02 | 9.26e-02 | 1.74e-01 | 2.65e-01 | 5.30e-02 | 4.30e-01 | 4.05e-01 |
| PEPTIDYL LYSINE TRIMETHYLATION | 9 | 6.46e-01 | 1.00e+00 | 0.31700 | -5.31e-03 | -1.67e-02 | 1.19e-01 | -2.58e-02 | 2.93e-01 | 9.78e-01 | 9.31e-01 | 5.37e-01 | 8.93e-01 | 1.29e-01 |
| LEUKOTRIENE B4 METABOLIC PROCESS | 5 | 5.47e-02 | 3.83e-01 | 0.31700 | -1.39e-01 | -1.55e-01 | -1.14e-01 | 1.67e-01 | 1.29e-01 | 5.92e-01 | 5.49e-01 | 6.58e-01 | 5.19e-01 | 6.17e-01 |
| DNA DEALKYLATION INVOLVED IN DNA REPAIR | 9 | 7.82e-01 | 1.00e+00 | 0.31700 | -1.56e-01 | -1.59e-01 | -2.18e-01 | -5.56e-02 | 1.87e-02 | 4.18e-01 | 4.09e-01 | 2.57e-01 | 7.73e-01 | 9.22e-01 |
| NEGATIVE REGULATION OF STEROID METABOLIC PROCESS | 32 | 5.40e-01 | 9.58e-01 | 0.31700 | 1.64e-01 | 1.49e-01 | 1.99e-01 | 9.27e-02 | 5.73e-02 | 1.09e-01 | 1.44e-01 | 5.10e-02 | 3.64e-01 | 5.75e-01 |
| REGULATION OF STRIATED MUSCLE CONTRACTION | 92 | 6.27e-02 | 4.11e-01 | 0.31700 | 1.63e-01 | 1.76e-01 | 1.26e-01 | 1.61e-01 | -3.17e-02 | 6.80e-03 | 3.44e-03 | 3.63e-02 | 7.60e-03 | 5.99e-01 |
| DISRUPTION OF ANATOMICAL STRUCTURE IN ANOTHER ORGANISM | 98 | 3.27e-02 | 2.86e-01 | 0.31700 | -1.76e-01 | -1.81e-01 | -1.43e-01 | -1.28e-01 | 1.34e-03 | 2.56e-03 | 1.99e-03 | 1.45e-02 | 2.88e-02 | 9.82e-01 |
| G QUADRUPLEX DNA UNWINDING | 7 | 8.83e-01 | 1.00e+00 | 0.31700 | -1.34e-01 | -1.34e-01 | -8.54e-02 | -1.60e-01 | 1.77e-01 | 5.38e-01 | 5.40e-01 | 6.96e-01 | 4.62e-01 | 4.17e-01 |
| SYNAPTIC MEMBRANE ADHESION | 25 | 6.09e-01 | 9.90e-01 | 0.31700 | 1.57e-01 | 1.78e-01 | 8.62e-02 | 1.41e-01 | -1.29e-01 | 1.75e-01 | 1.23e-01 | 4.56e-01 | 2.21e-01 | 2.65e-01 |
| POSITIVE REGULATION OF EXOSOMAL SECRETION | 15 | 8.44e-01 | 1.00e+00 | 0.31700 | 1.72e-01 | 1.83e-01 | 1.53e-01 | 1.15e-01 | 1.57e-02 | 2.47e-01 | 2.20e-01 | 3.04e-01 | 4.41e-01 | 9.16e-01 |
| POSITIVE REGULATION OF ER ASSOCIATED UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 5 | 8.77e-01 | 1.00e+00 | 0.31700 | 5.87e-02 | 9.46e-02 | 8.43e-03 | 3.63e-02 | -2.94e-01 | 8.20e-01 | 7.14e-01 | 9.74e-01 | 8.88e-01 | 2.55e-01 |
| POSITIVE REGULATION OF CATECHOLAMINE SECRETION | 12 | 5.22e-01 | 9.53e-01 | 0.31600 | 7.43e-02 | 2.40e-02 | 2.31e-01 | -3.14e-02 | 1.99e-01 | 6.56e-01 | 8.86e-01 | 1.66e-01 | 8.51e-01 | 2.32e-01 |
| BIOLOGICAL PHASE | 11 | 7.59e-02 | 4.52e-01 | 0.31600 | 1.33e-01 | 7.64e-02 | 6.41e-02 | 7.01e-02 | -2.60e-01 | 4.44e-01 | 6.61e-01 | 7.13e-01 | 6.87e-01 | 1.36e-01 |
| POSITIVE REGULATION OF GLYCOLYTIC PROCESS | 22 | 2.22e-01 | 7.45e-01 | 0.31600 | -1.09e-02 | 1.43e-02 | -5.55e-02 | -2.93e-02 | -3.09e-01 | 9.30e-01 | 9.07e-01 | 6.52e-01 | 8.12e-01 | 1.20e-02 |
| GONADOTROPIN SECRETION | 17 | 6.23e-01 | 9.92e-01 | 0.31600 | -1.13e-01 | -8.88e-02 | -1.46e-01 | -8.63e-02 | -2.25e-01 | 4.19e-01 | 5.26e-01 | 2.97e-01 | 5.38e-01 | 1.09e-01 |
| REGULATION OF SECONDARY METABOLIC PROCESS | 15 | 3.45e-01 | 8.64e-01 | 0.31600 | -1.66e-01 | -2.02e-01 | -1.31e-01 | -4.92e-02 | 1.09e-01 | 2.65e-01 | 1.75e-01 | 3.81e-01 | 7.42e-01 | 4.66e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO NUCLEOLUS | 10 | 6.09e-01 | 9.90e-01 | 0.31600 | 4.76e-02 | 4.38e-02 | 1.65e-01 | -2.93e-02 | 2.60e-01 | 7.94e-01 | 8.10e-01 | 3.66e-01 | 8.73e-01 | 1.55e-01 |
| PROTEIN LOCALIZATION TO CELL CELL JUNCTION | 21 | 2.86e-01 | 8.12e-01 | 0.31600 | -1.46e-01 | -1.36e-01 | -1.58e-01 | -4.01e-02 | 1.83e-01 | 2.48e-01 | 2.81e-01 | 2.10e-01 | 7.51e-01 | 1.46e-01 |
| GMP BIOSYNTHETIC PROCESS | 13 | 5.90e-01 | 9.86e-01 | 0.31600 | 1.83e-01 | 1.44e-01 | 1.34e-01 | 1.64e-01 | -2.72e-02 | 2.54e-01 | 3.68e-01 | 4.01e-01 | 3.06e-01 | 8.65e-01 |
| ISOPENTENYL DIPHOSPHATE BIOSYNTHETIC PROCESS | 5 | 8.17e-01 | 1.00e+00 | 0.31600 | 3.63e-02 | 1.94e-02 | 1.92e-01 | -1.07e-01 | 2.23e-01 | 8.88e-01 | 9.40e-01 | 4.56e-01 | 6.78e-01 | 3.88e-01 |
| PROTEIN O LINKED GLYCOSYLATION VIA THREONINE | 10 | 6.49e-01 | 1.00e+00 | 0.31600 | -1.53e-01 | -2.06e-01 | -1.01e-01 | -1.52e-01 | -2.36e-02 | 4.02e-01 | 2.60e-01 | 5.80e-01 | 4.04e-01 | 8.97e-01 |
| NEGATIVE REGULATION OF JUN KINASE ACTIVITY | 14 | 9.04e-01 | 1.00e+00 | 0.31600 | 1.61e-01 | 1.59e-01 | 1.47e-01 | 1.35e-01 | 9.29e-02 | 2.97e-01 | 3.03e-01 | 3.41e-01 | 3.82e-01 | 5.47e-01 |
| POSITIVE REGULATION OF CHROMOSOME CONDENSATION | 8 | 5.13e-01 | 9.52e-01 | 0.31600 | 6.20e-02 | 9.56e-03 | 2.59e-01 | -5.70e-02 | 1.59e-01 | 7.61e-01 | 9.63e-01 | 2.05e-01 | 7.80e-01 | 4.35e-01 |
| T HELPER CELL LINEAGE COMMITMENT | 20 | 6.15e-02 | 4.07e-01 | 0.31600 | -1.75e-01 | -1.63e-01 | -3.23e-02 | -1.84e-01 | 8.60e-02 | 1.76e-01 | 2.07e-01 | 8.02e-01 | 1.53e-01 | 5.05e-01 |
| POSITIVE REGULATION OF G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 27 | 5.59e-01 | 9.69e-01 | 0.31500 | 1.48e-01 | 1.26e-01 | 1.31e-01 | 1.74e-01 | 1.20e-01 | 1.82e-01 | 2.57e-01 | 2.39e-01 | 1.18e-01 | 2.80e-01 |
| REGULATION OF CELL COMMUNICATION BY ELECTRICAL COUPLING | 16 | 3.43e-01 | 8.61e-01 | 0.31500 | -1.38e-01 | -1.83e-01 | -1.06e-02 | -2.10e-01 | -5.49e-02 | 3.40e-01 | 2.05e-01 | 9.42e-01 | 1.47e-01 | 7.04e-01 |
| POSITIVE REGULATION OF MACROPHAGE DIFFERENTIATION | 16 | 2.39e-01 | 7.63e-01 | 0.31500 | -7.45e-02 | -1.42e-01 | 1.02e-01 | -1.20e-01 | 2.22e-01 | 6.06e-01 | 3.27e-01 | 4.81e-01 | 4.06e-01 | 1.25e-01 |
| POSITIVE REGULATION OF TAU PROTEIN KINASE ACTIVITY | 8 | 7.82e-01 | 1.00e+00 | 0.31500 | 1.81e-01 | 1.75e-01 | 1.62e-01 | 6.21e-02 | -7.62e-02 | 3.75e-01 | 3.90e-01 | 4.27e-01 | 7.61e-01 | 7.09e-01 |
| EPITHELIAL TUBE BRANCHING INVOLVED IN LUNG MORPHOGENESIS | 30 | 2.46e-01 | 7.74e-01 | 0.31500 | 1.51e-01 | 1.40e-01 | 1.39e-01 | 1.49e-01 | -1.25e-01 | 1.53e-01 | 1.83e-01 | 1.88e-01 | 1.59e-01 | 2.38e-01 |
| POSITIVE REGULATION OF TOLL LIKE RECEPTOR 2 SIGNALING PATHWAY | 6 | 5.43e-01 | 9.60e-01 | 0.31500 | 6.36e-02 | 3.30e-02 | 2.03e-01 | -1.44e-01 | 1.79e-01 | 7.87e-01 | 8.89e-01 | 3.88e-01 | 5.41e-01 | 4.47e-01 |
| NON CANONICAL WNT SIGNALING PATHWAY VIA JNK CASCADE | 6 | 2.56e-01 | 7.83e-01 | 0.31500 | 1.24e-01 | 7.19e-02 | 7.60e-02 | -8.74e-03 | -2.70e-01 | 5.99e-01 | 7.60e-01 | 7.47e-01 | 9.70e-01 | 2.52e-01 |
| GAMMA AMINOBUTYRIC ACID SECRETION | 12 | 9.12e-01 | 1.00e+00 | 0.31500 | -1.70e-01 | -1.66e-01 | -1.68e-01 | -1.07e-01 | 5.45e-02 | 3.08e-01 | 3.20e-01 | 3.12e-01 | 5.19e-01 | 7.44e-01 |
| CAMP METABOLIC PROCESS | 23 | 7.88e-01 | 1.00e+00 | 0.31500 | -1.60e-01 | -1.62e-01 | -1.64e-01 | -1.27e-01 | -6.69e-02 | 1.84e-01 | 1.80e-01 | 1.74e-01 | 2.92e-01 | 5.79e-01 |
| ENDODERMAL CELL FATE SPECIFICATION | 8 | 1.81e-01 | 6.88e-01 | 0.31500 | 6.04e-02 | 1.28e-01 | 2.22e-02 | -1.22e-01 | -2.53e-01 | 7.67e-01 | 5.32e-01 | 9.13e-01 | 5.51e-01 | 2.16e-01 |
| MELANIN METABOLIC PROCESS | 24 | 4.32e-01 | 9.19e-01 | 0.31500 | -1.74e-01 | -1.92e-01 | -1.39e-01 | -9.17e-02 | 6.42e-02 | 1.40e-01 | 1.03e-01 | 2.38e-01 | 4.37e-01 | 5.86e-01 |
| NCRNA TRANSCRIPTION | 134 | 4.20e-04 | 1.14e-02 | 0.31500 | 1.46e-01 | 1.40e-01 | 2.03e-01 | 9.08e-02 | 9.29e-02 | 3.47e-03 | 5.21e-03 | 4.96e-05 | 6.95e-02 | 6.33e-02 |
| REGULATION OF DOPAMINE RECEPTOR SIGNALING PATHWAY | 11 | 7.69e-01 | 1.00e+00 | 0.31500 | -1.46e-01 | -1.59e-01 | -1.14e-01 | -1.26e-01 | -1.53e-01 | 4.00e-01 | 3.61e-01 | 5.14e-01 | 4.68e-01 | 3.81e-01 |
| MAMMARY GLAND INVOLUTION | 8 | 7.97e-01 | 1.00e+00 | 0.31400 | 1.56e-01 | 2.05e-01 | 1.09e-01 | 1.05e-01 | -9.80e-02 | 4.44e-01 | 3.16e-01 | 5.93e-01 | 6.06e-01 | 6.31e-01 |
| POSITIVE REGULATION OF B CELL MEDIATED IMMUNITY | 41 | 1.37e-01 | 6.18e-01 | 0.31400 | -1.25e-01 | -1.58e-01 | -1.20e-02 | -1.55e-01 | 1.85e-01 | 1.67e-01 | 8.05e-02 | 8.94e-01 | 8.51e-02 | 4.09e-02 |
| REGULATION OF CORTICOSTEROID HORMONE SECRETION | 16 | 7.53e-01 | 1.00e+00 | 0.31400 | 1.29e-01 | 1.27e-01 | 1.70e-01 | 9.40e-02 | 1.69e-01 | 3.73e-01 | 3.81e-01 | 2.40e-01 | 5.15e-01 | 2.43e-01 |
| PROTON TRANSPORTING TWO SECTOR ATPASE COMPLEX ASSEMBLY | 15 | 3.08e-01 | 8.35e-01 | 0.31400 | 1.30e-01 | 7.84e-02 | 2.38e-01 | 1.03e-01 | 9.06e-02 | 3.84e-01 | 5.99e-01 | 1.10e-01 | 4.88e-01 | 5.44e-01 |
| PROTEIN TARGETING TO VACUOLE | 46 | 3.39e-01 | 8.59e-01 | 0.31400 | -1.65e-01 | -1.82e-01 | -8.59e-02 | -1.70e-01 | 4.62e-02 | 5.34e-02 | 3.28e-02 | 3.14e-01 | 4.57e-02 | 5.88e-01 |
| PROTEIN POLYGLUTAMYLATION | 12 | 6.95e-01 | 1.00e+00 | 0.31400 | 1.36e-01 | 1.62e-01 | 4.74e-02 | 2.26e-01 | -2.17e-02 | 4.14e-01 | 3.31e-01 | 7.76e-01 | 1.75e-01 | 8.96e-01 |
| GOLGI TO VACUOLE TRANSPORT | 20 | 7.82e-01 | 1.00e+00 | 0.31400 | -1.57e-01 | -1.58e-01 | -9.60e-02 | -1.98e-01 | -2.77e-02 | 2.24e-01 | 2.22e-01 | 4.57e-01 | 1.26e-01 | 8.30e-01 |
| REGULATION OF HEART RATE BY CARDIAC CONDUCTION | 37 | 1.20e-01 | 5.78e-01 | 0.31400 | 1.34e-01 | 1.76e-01 | 5.19e-02 | 1.47e-01 | -1.60e-01 | 1.60e-01 | 6.46e-02 | 5.85e-01 | 1.21e-01 | 9.24e-02 |
| PROTEIN INSERTION INTO ER MEMBRANE | 28 | 1.38e-01 | 6.20e-01 | 0.31400 | 7.77e-02 | 5.10e-02 | 1.98e-01 | 3.99e-02 | 2.22e-01 | 4.77e-01 | 6.41e-01 | 7.04e-02 | 7.15e-01 | 4.21e-02 |
| NEURON CELL CELL ADHESION | 13 | 6.11e-01 | 9.90e-01 | 0.31400 | -5.89e-02 | -4.16e-02 | -1.42e-01 | 2.86e-03 | -2.70e-01 | 7.13e-01 | 7.95e-01 | 3.75e-01 | 9.86e-01 | 9.17e-02 |
| HYPOTHALAMUS CELL DIFFERENTIATION | 12 | 4.93e-01 | 9.46e-01 | 0.31400 | -1.18e-01 | -1.46e-01 | 2.26e-02 | -2.49e-01 | -2.94e-02 | 4.78e-01 | 3.82e-01 | 8.92e-01 | 1.36e-01 | 8.60e-01 |
| C TERMINAL PROTEIN LIPIDATION | 5 | 7.09e-01 | 1.00e+00 | 0.31400 | -1.77e-01 | -2.12e-01 | -1.21e-01 | -6.64e-02 | -5.25e-02 | 4.93e-01 | 4.11e-01 | 6.40e-01 | 7.97e-01 | 8.39e-01 |
| MULTICELLULAR ORGANISMAL LEVEL IRON ION HOMEOSTASIS | 25 | 4.60e-01 | 9.32e-01 | 0.31300 | -1.56e-01 | -1.78e-01 | -4.88e-02 | -1.54e-01 | 1.27e-01 | 1.76e-01 | 1.24e-01 | 6.73e-01 | 1.83e-01 | 2.72e-01 |
| REGULATION OF DIGESTIVE SYSTEM PROCESS | 37 | 2.73e-01 | 7.99e-01 | 0.31300 | 1.23e-01 | 9.42e-02 | 1.60e-01 | 1.38e-01 | 1.72e-01 | 1.94e-01 | 3.22e-01 | 9.27e-02 | 1.46e-01 | 7.10e-02 |
| NEGATIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 22 | 3.65e-01 | 8.79e-01 | 0.31300 | -1.32e-01 | -1.34e-01 | -5.02e-02 | -2.31e-01 | -8.30e-02 | 2.85e-01 | 2.76e-01 | 6.83e-01 | 6.06e-02 | 5.01e-01 |
| EMBRYONIC AXIS SPECIFICATION | 39 | 2.27e-01 | 7.48e-01 | 0.31300 | -1.63e-01 | -1.83e-01 | -8.95e-02 | -1.66e-01 | -5.08e-02 | 7.78e-02 | 4.80e-02 | 3.34e-01 | 7.35e-02 | 5.83e-01 |
| NEGATIVE REGULATION OF KIDNEY DEVELOPMENT | 5 | 7.33e-01 | 1.00e+00 | 0.31300 | -2.28e-02 | -6.11e-02 | -3.43e-02 | -5.31e-02 | -3.00e-01 | 9.30e-01 | 8.13e-01 | 8.94e-01 | 8.37e-01 | 2.46e-01 |
| U2 TYPE PRESPLICEOSOME ASSEMBLY | 22 | 2.14e-01 | 7.37e-01 | 0.31300 | 1.10e-01 | 6.34e-02 | 1.69e-01 | 1.52e-01 | 1.74e-01 | 3.71e-01 | 6.06e-01 | 1.71e-01 | 2.18e-01 | 1.57e-01 |
| NEGATIVE REGULATION OF CELLULAR RESPIRATION | 10 | 5.08e-01 | 9.48e-01 | 0.31300 | 1.21e-01 | 9.40e-02 | 1.45e-01 | 7.46e-02 | -2.19e-01 | 5.08e-01 | 6.07e-01 | 4.27e-01 | 6.83e-01 | 2.31e-01 |
| NEGATIVE REGULATION OF MICROGLIAL CELL ACTIVATION | 8 | 6.26e-01 | 9.94e-01 | 0.31300 | 6.59e-02 | 6.42e-02 | 1.19e-01 | 1.32e-01 | 2.41e-01 | 7.47e-01 | 7.53e-01 | 5.60e-01 | 5.19e-01 | 2.39e-01 |
| PYRIMIDINE DEOXYRIBONUCLEOSIDE METABOLIC PROCESS | 5 | 6.81e-01 | 1.00e+00 | 0.31300 | 1.58e-01 | 9.77e-02 | 8.79e-02 | 2.15e-01 | 9.66e-02 | 5.40e-01 | 7.05e-01 | 7.34e-01 | 4.05e-01 | 7.08e-01 |
| RESPONSE TO GLYCOPROTEIN | 11 | 5.82e-01 | 9.85e-01 | 0.31300 | -1.50e-01 | -2.03e-01 | -6.68e-03 | -1.71e-01 | 7.07e-02 | 3.90e-01 | 2.44e-01 | 9.69e-01 | 3.26e-01 | 6.85e-01 |
| PROTEIN LOCALIZATION TO MICROTUBULE ORGANIZING CENTER | 35 | 4.97e-01 | 9.47e-01 | 0.31300 | -1.60e-01 | -1.63e-01 | -8.33e-02 | -1.95e-01 | 1.90e-02 | 1.01e-01 | 9.46e-02 | 3.94e-01 | 4.54e-02 | 8.46e-01 |
| NEGATIVE REGULATION OF VASCULAR ENDOTHELIAL CELL PROLIFERATION | 21 | 2.10e-01 | 7.33e-01 | 0.31300 | -1.54e-01 | -1.15e-01 | -1.86e-01 | -7.00e-02 | 1.46e-01 | 2.22e-01 | 3.60e-01 | 1.40e-01 | 5.79e-01 | 2.48e-01 |
| SERTOLI CELL DIFFERENTIATION | 17 | 3.50e-01 | 8.69e-01 | 0.31300 | 1.40e-01 | 1.28e-01 | 1.36e-01 | 1.57e-01 | -1.36e-01 | 3.17e-01 | 3.59e-01 | 3.30e-01 | 2.63e-01 | 3.32e-01 |
| VESICLE FUSION WITH GOLGI APPARATUS | 9 | 5.26e-01 | 9.54e-01 | 0.31300 | -8.63e-02 | -1.11e-01 | 4.68e-02 | -2.39e-01 | 1.36e-01 | 6.54e-01 | 5.63e-01 | 8.08e-01 | 2.14e-01 | 4.79e-01 |
| METANEPHRIC DISTAL TUBULE DEVELOPMENT | 7 | 9.56e-01 | 1.00e+00 | 0.31300 | -1.62e-01 | -1.39e-01 | -1.95e-01 | -1.19e-01 | 8.71e-03 | 4.58e-01 | 5.26e-01 | 3.72e-01 | 5.85e-01 | 9.68e-01 |
| MITOTIC NUCLEAR MEMBRANE ORGANIZATION | 10 | 5.28e-01 | 9.54e-01 | 0.31200 | 1.57e-01 | 1.60e-01 | 2.01e-01 | -1.37e-02 | -8.15e-02 | 3.90e-01 | 3.80e-01 | 2.72e-01 | 9.40e-01 | 6.56e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO ENDOSOME | 12 | 8.48e-01 | 1.00e+00 | 0.31200 | -1.74e-01 | -1.39e-01 | -1.62e-01 | -1.46e-01 | -1.42e-02 | 2.98e-01 | 4.03e-01 | 3.31e-01 | 3.80e-01 | 9.32e-01 |
| LENS FIBER CELL MORPHOGENESIS | 6 | 9.44e-01 | 1.00e+00 | 0.31200 | 1.52e-01 | 1.49e-01 | 1.85e-01 | 1.34e-01 | 1.52e-02 | 5.19e-01 | 5.28e-01 | 4.33e-01 | 5.70e-01 | 9.48e-01 |
| SOMITE ROSTRAL CAUDAL AXIS SPECIFICATION | 10 | 6.16e-01 | 9.90e-01 | 0.31200 | -1.76e-01 | -1.44e-01 | -9.03e-02 | -1.94e-01 | 8.32e-03 | 3.35e-01 | 4.31e-01 | 6.21e-01 | 2.89e-01 | 9.64e-01 |
| NEGATIVE REGULATION OF MICROTUBULE POLYMERIZATION | 13 | 9.17e-01 | 1.00e+00 | 0.31200 | 1.55e-01 | 1.58e-01 | 1.17e-01 | 1.84e-01 | 2.83e-02 | 3.33e-01 | 3.25e-01 | 4.65e-01 | 2.50e-01 | 8.60e-01 |
| REGULATION OF TRANSCRIPTION REGULATORY REGION DNA BINDING | 37 | 2.16e-03 | 4.10e-02 | 0.31200 | 1.11e-01 | 1.07e-01 | 2.43e-01 | -7.09e-02 | 9.69e-02 | 2.42e-01 | 2.61e-01 | 1.05e-02 | 4.55e-01 | 3.08e-01 |
| THORAX AND ANTERIOR ABDOMEN DETERMINATION | 5 | 8.10e-01 | 1.00e+00 | 0.31200 | 1.53e-01 | 8.86e-02 | 2.42e-01 | 7.42e-02 | -4.57e-02 | 5.54e-01 | 7.32e-01 | 3.49e-01 | 7.74e-01 | 8.60e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 6 PRODUCTION | 63 | 1.35e-03 | 2.91e-02 | 0.31200 | -1.33e-01 | -1.89e-01 | -1.06e-04 | -1.99e-01 | 6.39e-02 | 6.69e-02 | 9.53e-03 | 9.99e-01 | 6.31e-03 | 3.80e-01 |
| RNA 5 END PROCESSING | 21 | 1.32e-01 | 6.02e-01 | 0.31200 | 1.31e-01 | 1.16e-01 | 2.44e-01 | -4.13e-02 | 7.23e-02 | 2.99e-01 | 3.58e-01 | 5.27e-02 | 7.43e-01 | 5.66e-01 |
| POSITIVE REGULATION OF BMP SIGNALING PATHWAY | 40 | 3.58e-01 | 8.74e-01 | 0.31200 | 1.65e-01 | 1.49e-01 | 1.99e-01 | 8.86e-02 | 3.71e-03 | 7.02e-02 | 1.02e-01 | 2.95e-02 | 3.32e-01 | 9.68e-01 |
| REGULATION OF MODIFICATION OF SYNAPTIC STRUCTURE | 12 | 6.64e-01 | 1.00e+00 | 0.31100 | -1.28e-01 | -1.42e-01 | -1.26e-01 | -8.91e-02 | -1.92e-01 | 4.44e-01 | 3.95e-01 | 4.50e-01 | 5.93e-01 | 2.50e-01 |
| REGULATION OF CD4 POSITIVE ALPHA BETA T CELL ACTIVATION | 73 | 4.58e-02 | 3.48e-01 | 0.31100 | -1.54e-01 | -1.64e-01 | -5.15e-02 | -1.95e-01 | 7.54e-02 | 2.31e-02 | 1.54e-02 | 4.46e-01 | 3.93e-03 | 2.65e-01 |
| PROTEIN LIPID COMPLEX ORGANIZATION | 54 | 4.26e-01 | 9.15e-01 | 0.31100 | 1.60e-01 | 1.52e-01 | 1.37e-01 | 1.60e-01 | 6.16e-02 | 4.18e-02 | 5.31e-02 | 8.12e-02 | 4.22e-02 | 4.34e-01 |
| REGULATION OF CHOLESTEROL BIOSYNTHETIC PROCESS | 24 | 7.01e-01 | 1.00e+00 | 0.31100 | 1.53e-01 | 1.64e-01 | 1.43e-01 | 1.47e-01 | 6.62e-02 | 1.94e-01 | 1.63e-01 | 2.26e-01 | 2.12e-01 | 5.75e-01 |
| CELLULAR RESPONSE TO LUTEINIZING HORMONE STIMULUS | 5 | 7.16e-01 | 1.00e+00 | 0.31100 | 1.60e-01 | 9.88e-02 | 2.24e-01 | 1.08e-02 | -1.07e-01 | 5.35e-01 | 7.02e-01 | 3.86e-01 | 9.67e-01 | 6.80e-01 |
| PURINE NUCLEOTIDE SALVAGE | 10 | 7.61e-01 | 1.00e+00 | 0.31100 | 1.34e-01 | 1.65e-01 | 3.93e-03 | 1.31e-01 | -1.86e-01 | 4.64e-01 | 3.65e-01 | 9.83e-01 | 4.74e-01 | 3.09e-01 |
| STEM CELL FATE COMMITMENT | 10 | 1.81e-01 | 6.88e-01 | 0.31100 | 7.50e-02 | 1.25e-02 | 2.70e-01 | -1.34e-01 | 3.03e-03 | 6.81e-01 | 9.46e-01 | 1.39e-01 | 4.62e-01 | 9.87e-01 |
| REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 89 | 4.34e-02 | 3.34e-01 | 0.31100 | 1.50e-01 | 1.48e-01 | 1.70e-01 | 1.35e-01 | 7.12e-02 | 1.42e-02 | 1.55e-02 | 5.65e-03 | 2.72e-02 | 2.46e-01 |
| REGULATION OF ALTERNATIVE MRNA SPLICING VIA SPLICEOSOME | 50 | 3.70e-01 | 8.80e-01 | 0.31100 | 1.54e-01 | 1.33e-01 | 1.72e-01 | 1.42e-01 | 7.47e-02 | 5.89e-02 | 1.03e-01 | 3.56e-02 | 8.26e-02 | 3.61e-01 |
| TELOMERE MAINTENANCE VIA RECOMBINATION | 14 | 4.06e-01 | 9.07e-01 | 0.31100 | 1.07e-01 | 1.20e-01 | 1.81e-01 | 8.01e-02 | 1.78e-01 | 4.88e-01 | 4.38e-01 | 2.41e-01 | 6.04e-01 | 2.48e-01 |
| ACUTE INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 24 | 1.52e-01 | 6.47e-01 | 0.31100 | -1.14e-01 | -1.63e-01 | 5.75e-02 | -1.83e-01 | 1.44e-01 | 3.36e-01 | 1.68e-01 | 6.26e-01 | 1.22e-01 | 2.21e-01 |
| SNRNA PROCESSING | 25 | 1.41e-01 | 6.26e-01 | 0.31100 | -2.50e-04 | -5.53e-02 | 1.40e-01 | -7.15e-02 | 2.63e-01 | 9.98e-01 | 6.32e-01 | 2.27e-01 | 5.36e-01 | 2.29e-02 |
| NEGATIVE REGULATION OF CILIUM ASSEMBLY | 18 | 6.11e-01 | 9.90e-01 | 0.31100 | -1.44e-01 | -1.33e-01 | -8.35e-02 | -2.22e-01 | -4.22e-02 | 2.90e-01 | 3.28e-01 | 5.39e-01 | 1.03e-01 | 7.57e-01 |
| RESPONSE TO CAFFEINE | 15 | 5.53e-01 | 9.66e-01 | 0.31100 | -1.34e-01 | -1.24e-01 | -3.72e-02 | -1.62e-01 | 1.89e-01 | 3.68e-01 | 4.06e-01 | 8.03e-01 | 2.77e-01 | 2.06e-01 |
| ENDOCARDIAL CUSHION FUSION | 5 | 9.35e-01 | 1.00e+00 | 0.31100 | 1.49e-01 | 1.76e-01 | 1.38e-01 | 1.37e-01 | -7.39e-02 | 5.63e-01 | 4.96e-01 | 5.92e-01 | 5.95e-01 | 7.75e-01 |
| POSITIVE REGULATION OF COLLATERAL SPROUTING | 10 | 4.51e-01 | 9.30e-01 | 0.31100 | 5.48e-02 | -1.57e-02 | 1.28e-01 | 1.09e-01 | 2.55e-01 | 7.64e-01 | 9.32e-01 | 4.82e-01 | 5.52e-01 | 1.62e-01 |
| POSITIVE REGULATION BY HOST OF VIRAL PROCESS | 20 | 3.25e-01 | 8.49e-01 | 0.31000 | 1.14e-01 | 7.73e-02 | 2.43e-01 | -2.21e-03 | 1.36e-01 | 3.78e-01 | 5.50e-01 | 6.02e-02 | 9.86e-01 | 2.93e-01 |
| CELLULAR RESPONSE TO AMMONIUM ION | 5 | 6.09e-01 | 9.90e-01 | 0.31000 | -8.70e-02 | -9.82e-02 | -1.40e-01 | 6.19e-02 | -2.36e-01 | 7.36e-01 | 7.04e-01 | 5.89e-01 | 8.11e-01 | 3.61e-01 |
| TRNA 3 END PROCESSING | 6 | 6.23e-01 | 9.92e-01 | 0.31000 | -6.24e-02 | -8.99e-02 | 1.48e-02 | -2.28e-01 | -1.79e-01 | 7.91e-01 | 7.03e-01 | 9.50e-01 | 3.34e-01 | 4.47e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 1 ALPHA PRODUCTION | 6 | 8.26e-01 | 1.00e+00 | 0.31000 | 7.24e-02 | 7.53e-03 | 1.62e-01 | 2.71e-02 | 2.53e-01 | 7.59e-01 | 9.75e-01 | 4.92e-01 | 9.08e-01 | 2.84e-01 |
| PROXIMAL DISTAL PATTERN FORMATION | 34 | 2.95e-02 | 2.67e-01 | 0.31000 | 1.42e-01 | 1.03e-01 | 2.55e-01 | -5.18e-03 | 3.54e-03 | 1.51e-01 | 2.97e-01 | 9.99e-03 | 9.58e-01 | 9.72e-01 |
| DE NOVO AMP BIOSYNTHETIC PROCESS | 8 | 8.15e-01 | 1.00e+00 | 0.31000 | -1.38e-01 | -1.81e-01 | -6.15e-02 | -1.94e-01 | -5.58e-02 | 4.98e-01 | 3.77e-01 | 7.63e-01 | 3.43e-01 | 7.85e-01 |
| SLEEP | 22 | 2.73e-01 | 7.99e-01 | 0.31000 | -3.95e-02 | -6.81e-02 | 7.56e-02 | -4.11e-02 | 2.87e-01 | 7.48e-01 | 5.80e-01 | 5.39e-01 | 7.38e-01 | 1.98e-02 |
| REGULATION OF NEUROTRANSMITTER UPTAKE | 18 | 2.49e-01 | 7.75e-01 | 0.31000 | 1.37e-01 | 9.87e-02 | 1.40e-01 | 2.13e-01 | 5.08e-02 | 3.15e-01 | 4.68e-01 | 3.05e-01 | 1.18e-01 | 7.09e-01 |
| MICROGLIAL CELL PROLIFERATION | 8 | 6.12e-01 | 9.90e-01 | 0.31000 | 1.06e-01 | 1.41e-01 | -3.73e-02 | 2.35e-01 | 9.07e-02 | 6.03e-01 | 4.89e-01 | 8.55e-01 | 2.51e-01 | 6.57e-01 |
| DNA METHYLATION ON CYTOSINE | 6 | 8.52e-01 | 1.00e+00 | 0.31000 | 1.19e-01 | 1.17e-01 | 2.11e-01 | 7.39e-02 | 1.34e-01 | 6.14e-01 | 6.20e-01 | 3.71e-01 | 7.54e-01 | 5.69e-01 |
| NADH DEHYDROGENASE COMPLEX ASSEMBLY | 52 | 1.39e-03 | 2.95e-02 | 0.31000 | 1.14e-01 | 9.19e-02 | 2.37e-01 | -4.78e-02 | 1.26e-01 | 1.54e-01 | 2.52e-01 | 3.12e-03 | 5.51e-01 | 1.15e-01 |
| MITOCHONDRIAL FRAGMENTATION INVOLVED IN APOPTOTIC PROCESS | 10 | 6.40e-01 | 1.00e+00 | 0.30900 | 5.28e-03 | 9.76e-03 | -5.47e-02 | -3.74e-02 | -3.02e-01 | 9.77e-01 | 9.57e-01 | 7.65e-01 | 8.38e-01 | 9.81e-02 |
| CARNITINE TRANSMEMBRANE TRANSPORT | 6 | 7.89e-01 | 1.00e+00 | 0.30900 | -1.11e-01 | -1.37e-01 | 3.60e-02 | -2.47e-01 | -4.59e-02 | 6.36e-01 | 5.61e-01 | 8.79e-01 | 2.94e-01 | 8.46e-01 |
| EARLY ENDOSOME TO GOLGI TRANSPORT | 13 | 3.35e-01 | 8.59e-01 | 0.30900 | 6.84e-02 | 2.17e-02 | 2.01e-01 | -8.11e-02 | 2.08e-01 | 6.69e-01 | 8.92e-01 | 2.09e-01 | 6.13e-01 | 1.93e-01 |
| POSITIVE REGULATION OF B CELL ACTIVATION | 79 | 1.22e-03 | 2.67e-02 | 0.30900 | -1.08e-01 | -1.37e-01 | 3.73e-02 | -1.80e-01 | 1.77e-01 | 9.57e-02 | 3.47e-02 | 5.67e-01 | 5.63e-03 | 6.65e-03 |
| NEGATIVE REGULATION OF DOUBLE STRAND BREAK REPAIR VIA HOMOLOGOUS RECOMBINATION | 19 | 6.84e-01 | 1.00e+00 | 0.30900 | 1.64e-01 | 1.36e-01 | 1.95e-01 | 1.07e-01 | -3.11e-02 | 2.17e-01 | 3.04e-01 | 1.42e-01 | 4.18e-01 | 8.14e-01 |
| REGULATION OF SULFUR METABOLIC PROCESS | 12 | 7.05e-01 | 1.00e+00 | 0.30900 | 1.29e-01 | 1.26e-01 | 2.27e-02 | 1.90e-01 | -1.64e-01 | 4.40e-01 | 4.50e-01 | 8.92e-01 | 2.55e-01 | 3.27e-01 |
| REGULATION OF EPINEPHRINE SECRETION | 7 | 7.84e-01 | 1.00e+00 | 0.30900 | 1.17e-01 | 1.59e-01 | 5.65e-02 | 3.21e-02 | -2.29e-01 | 5.92e-01 | 4.65e-01 | 7.96e-01 | 8.83e-01 | 2.95e-01 |
| POSITIVE REGULATION OF ACTIN NUCLEATION | 14 | 3.56e-01 | 8.74e-01 | 0.30900 | -1.26e-01 | -1.75e-01 | -9.78e-02 | -7.07e-02 | 1.86e-01 | 4.15e-01 | 2.58e-01 | 5.26e-01 | 6.47e-01 | 2.29e-01 |
| NEGATIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT VIA HIGH VOLTAGE GATED CALCIUM CHANNEL | 5 | 8.34e-01 | 1.00e+00 | 0.30900 | -1.24e-01 | -1.14e-01 | 1.51e-02 | -2.55e-01 | 4.33e-02 | 6.32e-01 | 6.59e-01 | 9.53e-01 | 3.24e-01 | 8.67e-01 |
| REGULATION OF PROTEIN KINASE C ACTIVITY | 5 | 6.58e-01 | 1.00e+00 | 0.30900 | 1.49e-01 | 9.79e-02 | 6.52e-02 | 1.45e-01 | -1.95e-01 | 5.63e-01 | 7.05e-01 | 8.01e-01 | 5.75e-01 | 4.50e-01 |
| REGULATION OF PROTEIN POLYUBIQUITINATION | 26 | 6.13e-01 | 9.90e-01 | 0.30800 | -1.50e-01 | -1.70e-01 | -5.93e-02 | -1.67e-01 | 1.11e-01 | 1.86e-01 | 1.33e-01 | 6.01e-01 | 1.41e-01 | 3.26e-01 |
| REGULATION OF B CELL ACTIVATION | 124 | 2.30e-08 | 2.25e-06 | 0.30800 | -7.93e-02 | -1.35e-01 | 9.14e-02 | -1.70e-01 | 1.82e-01 | 1.27e-01 | 9.46e-03 | 7.89e-02 | 1.06e-03 | 4.48e-04 |
| PROTEIN SULFATION | 6 | 2.47e-01 | 7.75e-01 | 0.30800 | -1.73e-01 | -1.28e-01 | -2.11e-01 | 5.78e-02 | 2.56e-02 | 4.62e-01 | 5.87e-01 | 3.70e-01 | 8.06e-01 | 9.13e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF EXOGENOUS PEPTIDE ANTIGEN VIA MHC CLASS I | 8 | 7.25e-02 | 4.43e-01 | 0.30800 | -1.02e-01 | -2.20e-01 | 1.15e-01 | -1.03e-01 | 1.11e-01 | 6.18e-01 | 2.81e-01 | 5.72e-01 | 6.13e-01 | 5.88e-01 |
| L ASPARTATE IMPORT ACROSS PLASMA MEMBRANE | 6 | 9.86e-01 | 1.00e+00 | 0.30800 | 1.59e-01 | 1.72e-01 | 1.14e-01 | 1.51e-01 | -6.56e-02 | 4.99e-01 | 4.65e-01 | 6.29e-01 | 5.23e-01 | 7.81e-01 |
| TRACHEA DEVELOPMENT | 18 | 8.32e-01 | 1.00e+00 | 0.30800 | 1.66e-01 | 1.39e-01 | 1.67e-01 | 1.39e-01 | 2.36e-02 | 2.22e-01 | 3.06e-01 | 2.19e-01 | 3.08e-01 | 8.62e-01 |
| PROTEIN LOCALIZATION TO AXON | 9 | 9.38e-01 | 1.00e+00 | 0.30800 | 1.41e-01 | 1.20e-01 | 1.29e-01 | 1.72e-01 | 1.20e-01 | 4.64e-01 | 5.34e-01 | 5.03e-01 | 3.71e-01 | 5.32e-01 |
| POSITIVE REGULATION OF CIRCADIAN RHYTHM | 18 | 7.07e-01 | 1.00e+00 | 0.30800 | -1.72e-01 | -1.70e-01 | -1.69e-01 | -8.20e-02 | 3.35e-02 | 2.06e-01 | 2.13e-01 | 2.13e-01 | 5.47e-01 | 8.06e-01 |
| NATURAL KILLER CELL DEGRANULATION | 11 | 5.29e-02 | 3.77e-01 | 0.30800 | -7.24e-02 | -5.94e-02 | 1.48e-01 | -2.41e-01 | 7.96e-02 | 6.78e-01 | 7.33e-01 | 3.96e-01 | 1.67e-01 | 6.48e-01 |
| ACTIN MYOSIN FILAMENT SLIDING | 16 | 5.92e-01 | 9.86e-01 | 0.30800 | 1.41e-01 | 1.19e-01 | 8.20e-02 | 2.11e-01 | 9.57e-02 | 3.28e-01 | 4.10e-01 | 5.70e-01 | 1.43e-01 | 5.07e-01 |
| REGULATION OF GERMINAL CENTER FORMATION | 8 | 4.00e-01 | 9.00e-01 | 0.30800 | -6.89e-02 | -1.06e-01 | 1.09e-01 | -2.43e-01 | -8.75e-02 | 7.36e-01 | 6.02e-01 | 5.95e-01 | 2.34e-01 | 6.68e-01 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR | 16 | 4.68e-02 | 3.50e-01 | 0.30800 | -6.21e-02 | -5.15e-02 | 7.49e-02 | -2.63e-01 | -1.15e-01 | 6.67e-01 | 7.21e-01 | 6.04e-01 | 6.84e-02 | 4.26e-01 |
| NEGATIVE REGULATION OF ORGANIC ACID TRANSPORT | 24 | 2.48e-01 | 7.75e-01 | 0.30700 | 1.10e-01 | 1.27e-01 | 8.49e-02 | 5.46e-02 | -2.37e-01 | 3.53e-01 | 2.80e-01 | 4.71e-01 | 6.43e-01 | 4.46e-02 |
| ATTACHMENT OF MITOTIC SPINDLE MICROTUBULES TO KINETOCHORE | 21 | 3.89e-01 | 8.92e-01 | 0.30700 | 8.56e-02 | 3.59e-02 | 1.97e-01 | 2.88e-02 | 2.15e-01 | 4.97e-01 | 7.76e-01 | 1.19e-01 | 8.19e-01 | 8.77e-02 |
| POSITIVE REGULATION OF TRANSCRIPTION REGULATORY REGION DNA BINDING | 22 | 1.09e-02 | 1.33e-01 | 0.30700 | -2.50e-02 | -1.55e-02 | 1.34e-01 | -2.04e-01 | 1.84e-01 | 8.39e-01 | 9.00e-01 | 2.75e-01 | 9.79e-02 | 1.36e-01 |
| POSITIVE REGULATION OF PROTEIN TYROSINE KINASE ACTIVITY | 29 | 2.97e-01 | 8.24e-01 | 0.30700 | 1.43e-01 | 1.57e-01 | 4.20e-02 | 2.11e-01 | 5.09e-02 | 1.81e-01 | 1.44e-01 | 6.96e-01 | 4.88e-02 | 6.35e-01 |
| NEGATIVE REGULATION OF VIRAL GENOME REPLICATION | 55 | 6.58e-03 | 9.29e-02 | 0.30700 | -1.39e-01 | -1.33e-01 | -9.95e-03 | -2.10e-01 | 1.13e-01 | 7.47e-02 | 8.70e-02 | 8.98e-01 | 6.98e-03 | 1.47e-01 |
| REGULATION OF VESICLE SIZE | 19 | 3.45e-01 | 8.64e-01 | 0.30700 | 9.29e-02 | 5.83e-02 | 2.25e-01 | 2.32e-02 | 1.76e-01 | 4.83e-01 | 6.60e-01 | 8.95e-02 | 8.61e-01 | 1.84e-01 |
| MARGINAL ZONE B CELL DIFFERENTIATION | 8 | 9.48e-01 | 1.00e+00 | 0.30700 | -1.70e-01 | -1.39e-01 | -1.64e-01 | -1.37e-01 | 2.99e-03 | 4.05e-01 | 4.95e-01 | 4.22e-01 | 5.02e-01 | 9.88e-01 |
| POSITIVE REGULATION OF RECEPTOR SIGNALING PATHWAY VIA STAT | 50 | 1.59e-01 | 6.58e-01 | 0.30700 | -1.51e-01 | -1.56e-01 | -5.03e-02 | -1.99e-01 | 6.94e-02 | 6.54e-02 | 5.57e-02 | 5.39e-01 | 1.50e-02 | 3.96e-01 |
| LYMPHOCYTE ACTIVATION INVOLVED IN IMMUNE RESPONSE | 204 | 5.13e-08 | 4.77e-06 | 0.30600 | -1.39e-01 | -1.61e-01 | -7.70e-03 | -2.00e-01 | 9.28e-02 | 6.20e-04 | 7.08e-05 | 8.50e-01 | 8.64e-07 | 2.23e-02 |
| T CELL MEDIATED CYTOTOXICITY | 59 | 6.00e-02 | 4.02e-01 | 0.30600 | -1.51e-01 | -1.80e-01 | -3.82e-02 | -1.84e-01 | 5.91e-02 | 4.47e-02 | 1.69e-02 | 6.11e-01 | 1.46e-02 | 4.33e-01 |
| CHEMOKINE C X C MOTIF LIGAND 1 PRODUCTION | 6 | 7.14e-01 | 1.00e+00 | 0.30600 | -6.22e-02 | -1.05e-01 | 9.31e-02 | -2.22e-01 | 1.45e-01 | 7.92e-01 | 6.56e-01 | 6.93e-01 | 3.47e-01 | 5.38e-01 |
| CHONDROCYTE DIFFERENTIATION INVOLVED IN ENDOCHONDRAL BONE MORPHOGENESIS | 15 | 5.75e-01 | 9.79e-01 | 0.30600 | 1.36e-01 | 1.32e-01 | 2.21e-01 | 2.97e-02 | 8.97e-02 | 3.63e-01 | 3.76e-01 | 1.38e-01 | 8.42e-01 | 5.47e-01 |
| APICAL PROTEIN LOCALIZATION | 14 | 7.70e-01 | 1.00e+00 | 0.30600 | 1.48e-01 | 1.82e-01 | 7.07e-02 | 1.82e-01 | -2.80e-02 | 3.39e-01 | 2.38e-01 | 6.47e-01 | 2.39e-01 | 8.56e-01 |
| INTRACELLULAR OXYGEN HOMEOSTASIS | 7 | 7.18e-01 | 1.00e+00 | 0.30600 | 1.38e-01 | 1.22e-01 | 1.91e-01 | 1.11e-01 | -1.04e-01 | 5.26e-01 | 5.75e-01 | 3.81e-01 | 6.12e-01 | 6.34e-01 |
| POSITIVE REGULATION OF MEMBRANE POTENTIAL | 15 | 3.22e-01 | 8.47e-01 | 0.30600 | 1.07e-01 | 1.10e-01 | 1.33e-01 | -1.58e-02 | -2.29e-01 | 4.73e-01 | 4.62e-01 | 3.73e-01 | 9.16e-01 | 1.25e-01 |
| CELLULAR RESPIRATION | 216 | 1.25e-06 | 7.59e-05 | 0.30600 | 1.56e-01 | 1.36e-01 | 2.09e-01 | 5.93e-02 | 6.08e-02 | 7.55e-05 | 5.69e-04 | 1.25e-07 | 1.33e-01 | 1.24e-01 |
| DNA DEALKYLATION | 37 | 3.19e-01 | 8.47e-01 | 0.30600 | -1.66e-01 | -1.40e-01 | -1.28e-01 | -1.69e-01 | 3.49e-02 | 7.99e-02 | 1.41e-01 | 1.77e-01 | 7.48e-02 | 7.13e-01 |
| POSITIVE REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 21 | 3.92e-01 | 8.92e-01 | 0.30600 | -5.92e-02 | -4.34e-02 | -8.70e-02 | -8.06e-02 | -2.72e-01 | 6.39e-01 | 7.31e-01 | 4.90e-01 | 5.22e-01 | 3.08e-02 |
| COCHLEA MORPHOGENESIS | 23 | 9.58e-02 | 5.12e-01 | 0.30600 | 1.41e-01 | 7.70e-02 | 2.43e-01 | 8.64e-02 | 3.40e-02 | 2.42e-01 | 5.23e-01 | 4.36e-02 | 4.73e-01 | 7.78e-01 |
| RNA POLYMERASE I PREINITIATION COMPLEX ASSEMBLY | 9 | 8.06e-01 | 1.00e+00 | 0.30600 | 1.39e-01 | 1.82e-01 | 6.34e-02 | 9.11e-02 | -1.69e-01 | 4.69e-01 | 3.43e-01 | 7.42e-01 | 6.36e-01 | 3.81e-01 |
| REGULATION OF CARDIOBLAST DIFFERENTIATION | 5 | 5.79e-01 | 9.82e-01 | 0.30600 | -4.42e-02 | -5.76e-02 | 1.40e-01 | -2.51e-01 | -7.37e-02 | 8.64e-01 | 8.23e-01 | 5.88e-01 | 3.31e-01 | 7.75e-01 |
| CHEMOSENSORY BEHAVIOR | 18 | 8.81e-01 | 1.00e+00 | 0.30600 | 1.62e-01 | 1.71e-01 | 1.03e-01 | 1.65e-01 | -1.02e-02 | 2.34e-01 | 2.08e-01 | 4.50e-01 | 2.26e-01 | 9.40e-01 |
| OXIDATIVE PHOSPHORYLATION | 126 | 7.96e-05 | 2.85e-03 | 0.30600 | 1.52e-01 | 1.29e-01 | 2.22e-01 | 3.53e-02 | 5.61e-02 | 3.28e-03 | 1.22e-02 | 1.69e-05 | 4.93e-01 | 2.77e-01 |
| POSITIVE REGULATION OF NEUTROPHIL ACTIVATION | 6 | 3.15e-01 | 8.42e-01 | 0.30500 | -6.86e-02 | -1.11e-01 | 4.26e-02 | 7.46e-02 | 2.63e-01 | 7.71e-01 | 6.39e-01 | 8.57e-01 | 7.52e-01 | 2.65e-01 |
| DETOXIFICATION OF NITROGEN COMPOUND | 5 | 6.29e-01 | 9.96e-01 | 0.30500 | -7.41e-02 | -6.95e-02 | 9.32e-02 | -2.70e-01 | -3.79e-02 | 7.74e-01 | 7.88e-01 | 7.18e-01 | 2.96e-01 | 8.83e-01 |
| NUCLEOBASE CONTAINING SMALL MOLECULE CATABOLIC PROCESS | 30 | 4.36e-01 | 9.22e-01 | 0.30500 | -1.71e-01 | -1.47e-01 | -1.26e-01 | -1.63e-01 | -6.09e-03 | 1.06e-01 | 1.63e-01 | 2.33e-01 | 1.22e-01 | 9.54e-01 |
| POSITIVE REGULATION OF HETEROTYPIC CELL CELL ADHESION | 14 | 2.71e-01 | 7.97e-01 | 0.30500 | -1.69e-01 | -1.94e-01 | -1.10e-01 | -4.39e-02 | 1.14e-01 | 2.75e-01 | 2.08e-01 | 4.76e-01 | 7.76e-01 | 4.61e-01 |
| CD4 POSITIVE ALPHA BETA T CELL ACTIVATION | 113 | 1.14e-04 | 3.87e-03 | 0.30500 | -1.48e-01 | -1.66e-01 | -1.61e-02 | -1.96e-01 | 7.01e-02 | 6.53e-03 | 2.32e-03 | 7.67e-01 | 3.14e-04 | 1.98e-01 |
| POSITIVE REGULATION OF LEUKOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELL | 25 | 9.13e-02 | 4.99e-01 | 0.30500 | -1.55e-01 | -2.06e-01 | -4.31e-02 | -1.05e-01 | 1.17e-01 | 1.80e-01 | 7.49e-02 | 7.09e-01 | 3.62e-01 | 3.10e-01 |
| GRANULOCYTE CHEMOTAXIS | 125 | 2.07e-03 | 3.98e-02 | 0.30500 | -1.64e-01 | -1.77e-01 | -1.44e-01 | -9.28e-02 | 7.42e-02 | 1.51e-03 | 6.45e-04 | 5.47e-03 | 7.33e-02 | 1.52e-01 |
| NEURONAL DENSE CORE VESICLE EXOCYTOSIS | 7 | 7.74e-01 | 1.00e+00 | 0.30500 | 1.47e-01 | 1.48e-01 | 2.04e-01 | -1.69e-03 | 8.81e-02 | 4.99e-01 | 4.98e-01 | 3.50e-01 | 9.94e-01 | 6.87e-01 |
| LYMPHOCYTE MIGRATION INTO LYMPHOID ORGANS | 9 | 3.75e-01 | 8.83e-01 | 0.30500 | -1.33e-01 | -2.01e-01 | 2.67e-02 | -1.81e-01 | -3.60e-02 | 4.89e-01 | 2.96e-01 | 8.90e-01 | 3.48e-01 | 8.52e-01 |
| PROTEIN GERANYLGERANYLATION | 6 | 4.73e-02 | 3.52e-01 | 0.30500 | -1.83e-02 | -5.50e-02 | -8.60e-02 | 2.85e-01 | -2.88e-02 | 9.38e-01 | 8.16e-01 | 7.15e-01 | 2.27e-01 | 9.03e-01 |
| DERMATAN SULFATE BIOSYNTHETIC PROCESS | 5 | 8.26e-01 | 1.00e+00 | 0.30400 | -8.08e-02 | -1.17e-01 | -6.06e-02 | -1.02e-01 | -2.41e-01 | 7.54e-01 | 6.49e-01 | 8.14e-01 | 6.93e-01 | 3.50e-01 |
| SYNAPTIC TRANSMISSION GLYCINERGIC | 5 | 5.11e-01 | 9.51e-01 | 0.30400 | -1.23e-01 | -6.22e-02 | -1.78e-02 | -2.50e-01 | 1.05e-01 | 6.34e-01 | 8.10e-01 | 9.45e-01 | 3.33e-01 | 6.85e-01 |
| REGULATION OF T HELPER 17 CELL DIFFERENTIATION | 21 | 7.34e-01 | 1.00e+00 | 0.30400 | -1.51e-01 | -1.56e-01 | -7.53e-02 | -2.00e-01 | -1.04e-02 | 2.31e-01 | 2.17e-01 | 5.50e-01 | 1.13e-01 | 9.34e-01 |
| AUTOCRINE SIGNALING | 7 | 5.55e-01 | 9.67e-01 | 0.30400 | -1.08e-01 | -7.40e-02 | -1.89e-01 | -1.58e-02 | 1.99e-01 | 6.21e-01 | 7.35e-01 | 3.86e-01 | 9.42e-01 | 3.63e-01 |
| HINDBRAIN MATURATION | 5 | 9.86e-01 | 1.00e+00 | 0.30400 | 1.63e-01 | 1.80e-01 | 9.68e-02 | 1.37e-01 | -7.53e-02 | 5.29e-01 | 4.86e-01 | 7.08e-01 | 5.96e-01 | 7.71e-01 |
| CELLULAR RESPONSE TO INTERFERON ALPHA | 7 | 2.70e-01 | 7.97e-01 | 0.30400 | 2.54e-02 | 1.52e-02 | 1.85e-01 | -2.38e-01 | -2.67e-02 | 9.07e-01 | 9.44e-01 | 3.98e-01 | 2.75e-01 | 9.03e-01 |
| POSITIVE REGULATION OF MITOPHAGY IN RESPONSE TO MITOCHONDRIAL DEPOLARIZATION | 8 | 1.48e-01 | 6.36e-01 | 0.30400 | -1.15e-01 | -3.36e-02 | -4.37e-02 | -2.61e-01 | -9.00e-02 | 5.74e-01 | 8.69e-01 | 8.31e-01 | 2.01e-01 | 6.59e-01 |
| REGULATION OF CHOLESTEROL METABOLIC PROCESS | 40 | 5.61e-01 | 9.70e-01 | 0.30400 | 1.55e-01 | 1.65e-01 | 1.32e-01 | 1.48e-01 | 4.27e-02 | 8.91e-02 | 7.14e-02 | 1.49e-01 | 1.05e-01 | 6.41e-01 |
| REGULATION OF LOCOMOTION INVOLVED IN LOCOMOTORY BEHAVIOR | 5 | 8.88e-01 | 1.00e+00 | 0.30400 | 3.76e-03 | -2.21e-02 | 1.58e-01 | -6.74e-02 | 2.50e-01 | 9.88e-01 | 9.32e-01 | 5.42e-01 | 7.94e-01 | 3.33e-01 |
| REGULATION OF MYOBLAST FUSION | 21 | 6.79e-01 | 1.00e+00 | 0.30400 | -1.51e-01 | -1.52e-01 | -1.88e-01 | -9.72e-02 | -4.38e-02 | 2.31e-01 | 2.29e-01 | 1.36e-01 | 4.41e-01 | 7.28e-01 |
| MEDIUM CHAIN FATTY ACID METABOLIC PROCESS | 15 | 3.60e-01 | 8.76e-01 | 0.30400 | 8.13e-02 | 8.60e-02 | 4.20e-02 | 2.00e-01 | 1.91e-01 | 5.86e-01 | 5.64e-01 | 7.78e-01 | 1.80e-01 | 2.00e-01 |
| MICROTUBULE NUCLEATION BY MICROTUBULE ORGANIZING CENTER | 5 | 8.42e-01 | 1.00e+00 | 0.30400 | -7.77e-02 | -7.18e-02 | -4.99e-02 | -2.08e-01 | -1.88e-01 | 7.64e-01 | 7.81e-01 | 8.47e-01 | 4.21e-01 | 4.66e-01 |
| MONONUCLEAR CELL MIGRATION | 199 | 1.05e-04 | 3.66e-03 | 0.30400 | -1.61e-01 | -1.75e-01 | -1.00e-01 | -1.27e-01 | 9.70e-02 | 8.62e-05 | 2.11e-05 | 1.48e-02 | 1.93e-03 | 1.83e-02 |
| REGULATION OF MAST CELL ACTIVATION | 38 | 3.46e-02 | 2.96e-01 | 0.30400 | -1.13e-01 | -1.68e-01 | 3.43e-02 | -1.93e-01 | 1.12e-01 | 2.26e-01 | 7.33e-02 | 7.14e-01 | 3.90e-02 | 2.33e-01 |
| CELLULAR RESPONSE TO OXYGEN RADICAL | 23 | 2.07e-01 | 7.28e-01 | 0.30400 | 1.77e-01 | 1.62e-01 | 1.28e-01 | 1.22e-01 | 5.74e-02 | 1.41e-01 | 1.78e-01 | 2.88e-01 | 3.13e-01 | 6.33e-01 |
| POSITIVE REGULATION OF DOPAMINERGIC NEURON DIFFERENTIATION | 5 | 9.87e-01 | 1.00e+00 | 0.30300 | 1.56e-01 | 1.80e-01 | 9.69e-02 | 1.51e-01 | -5.55e-02 | 5.45e-01 | 4.85e-01 | 7.08e-01 | 5.60e-01 | 8.30e-01 |
| VENOUS BLOOD VESSEL MORPHOGENESIS | 9 | 7.74e-01 | 1.00e+00 | 0.30300 | 9.05e-02 | 8.46e-02 | 1.94e-01 | 1.65e-02 | 1.97e-01 | 6.38e-01 | 6.60e-01 | 3.14e-01 | 9.32e-01 | 3.07e-01 |
| REGULATION OF BRANCHING MORPHOGENESIS OF A NERVE | 5 | 2.38e-01 | 7.63e-01 | 0.30300 | 5.35e-02 | -3.86e-04 | -2.75e-02 | 2.91e-01 | -5.81e-02 | 8.36e-01 | 9.99e-01 | 9.15e-01 | 2.60e-01 | 8.22e-01 |
| NEGATIVE REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 7 | 3.35e-01 | 8.59e-01 | 0.30300 | -4.14e-02 | -3.94e-02 | -2.28e-01 | 3.56e-02 | -1.87e-01 | 8.49e-01 | 8.57e-01 | 2.96e-01 | 8.70e-01 | 3.91e-01 |
| REGULATION OF MITOTIC SISTER CHROMATID SEGREGATION | 54 | 5.34e-02 | 3.78e-01 | 0.30300 | 1.42e-01 | 1.10e-01 | 2.26e-01 | 6.66e-02 | 6.29e-02 | 7.17e-02 | 1.63e-01 | 4.03e-03 | 3.97e-01 | 4.24e-01 |
| POSITIVE REGULATION OF RYANODINE SENSITIVE CALCIUM RELEASE CHANNEL ACTIVITY | 8 | 7.70e-01 | 1.00e+00 | 0.30300 | -9.08e-02 | -1.03e-01 | 1.96e-02 | -6.93e-02 | 2.60e-01 | 6.57e-01 | 6.13e-01 | 9.24e-01 | 7.34e-01 | 2.03e-01 |
| REGULATION OF LOW DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 22 | 7.13e-01 | 1.00e+00 | 0.30300 | 1.64e-01 | 1.68e-01 | 1.47e-01 | 9.67e-02 | -7.51e-02 | 1.84e-01 | 1.72e-01 | 2.33e-01 | 4.32e-01 | 5.42e-01 |
| ELECTRON TRANSPORT CHAIN | 156 | 3.51e-04 | 9.82e-03 | 0.30300 | 1.55e-01 | 1.34e-01 | 2.03e-01 | 6.77e-02 | 5.92e-02 | 8.13e-04 | 3.77e-03 | 1.18e-05 | 1.44e-01 | 2.02e-01 |
| CARDIAC CELL FATE COMMITMENT | 16 | 1.36e-01 | 6.14e-01 | 0.30200 | 6.52e-02 | 4.33e-02 | 1.12e-01 | -7.48e-02 | -2.59e-01 | 6.52e-01 | 7.64e-01 | 4.39e-01 | 6.04e-01 | 7.25e-02 |
| PHOSPHATIDYLSERINE METABOLIC PROCESS | 23 | 5.31e-01 | 9.54e-01 | 0.30200 | 1.72e-01 | 1.60e-01 | 1.09e-01 | 1.55e-01 | -6.88e-03 | 1.52e-01 | 1.84e-01 | 3.67e-01 | 1.97e-01 | 9.54e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION OF NOTCH RECEPTOR TARGET | 7 | 8.51e-01 | 1.00e+00 | 0.30200 | -8.16e-02 | -1.24e-01 | 7.32e-02 | -1.47e-01 | 2.05e-01 | 7.08e-01 | 5.70e-01 | 7.37e-01 | 4.99e-01 | 3.47e-01 |
| TACHYKININ RECEPTOR SIGNALING PATHWAY | 8 | 8.53e-01 | 1.00e+00 | 0.30200 | 1.10e-01 | 1.04e-01 | 1.02e-01 | 1.86e-01 | 1.53e-01 | 5.91e-01 | 6.12e-01 | 6.18e-01 | 3.62e-01 | 4.53e-01 |
| RENAL PROTEIN ABSORPTION | 7 | 9.11e-01 | 1.00e+00 | 0.30200 | -1.55e-01 | -1.26e-01 | -2.18e-01 | -5.57e-02 | 2.37e-02 | 4.77e-01 | 5.64e-01 | 3.18e-01 | 7.99e-01 | 9.14e-01 |
| MELANOSOME ASSEMBLY | 18 | 3.11e-01 | 8.38e-01 | 0.30200 | -1.07e-01 | -1.29e-01 | -1.58e-02 | -2.24e-01 | -1.13e-01 | 4.33e-01 | 3.43e-01 | 9.08e-01 | 9.98e-02 | 4.08e-01 |
| NEGATIVE REGULATION OF PROTEIN KINASE ACTIVITY BY REGULATION OF PROTEIN PHOSPHORYLATION | 6 | 4.90e-01 | 9.45e-01 | 0.30200 | 1.23e-01 | 1.71e-01 | 1.88e-01 | -3.31e-02 | 1.02e-01 | 6.03e-01 | 4.68e-01 | 4.25e-01 | 8.88e-01 | 6.66e-01 |
| RESPONSE TO CADMIUM ION | 57 | 1.66e-01 | 6.70e-01 | 0.30200 | 1.56e-01 | 1.37e-01 | 1.96e-01 | 7.44e-02 | 6.12e-02 | 4.10e-02 | 7.33e-02 | 1.03e-02 | 3.32e-01 | 4.24e-01 |
| NEGATIVE REGULATION OF PHOSPHATASE ACTIVITY | 24 | 7.20e-01 | 1.00e+00 | 0.30200 | 1.36e-01 | 1.12e-01 | 1.65e-01 | 1.29e-01 | 1.27e-01 | 2.49e-01 | 3.43e-01 | 1.61e-01 | 2.72e-01 | 2.83e-01 |
| REGULATION OF GUANYL NUCLEOTIDE EXCHANGE FACTOR ACTIVITY | 7 | 8.65e-01 | 1.00e+00 | 0.30200 | -1.78e-02 | 2.21e-02 | -1.27e-01 | 3.77e-02 | -2.70e-01 | 9.35e-01 | 9.20e-01 | 5.60e-01 | 8.63e-01 | 2.17e-01 |
| GROWTH PLATE CARTILAGE CHONDROCYTE DEVELOPMENT | 5 | 9.08e-01 | 1.00e+00 | 0.30200 | 1.35e-01 | 1.70e-01 | 1.25e-01 | 1.54e-01 | 6.80e-02 | 6.01e-01 | 5.11e-01 | 6.27e-01 | 5.51e-01 | 7.92e-01 |
| PEPTIDYL ARGININE METHYLATION | 7 | 8.17e-01 | 1.00e+00 | 0.30200 | -1.42e-01 | -1.90e-01 | -2.48e-03 | -1.46e-01 | 1.15e-01 | 5.14e-01 | 3.84e-01 | 9.91e-01 | 5.03e-01 | 5.99e-01 |
| MYELOID LEUKOCYTE CYTOKINE PRODUCTION | 50 | 1.03e-02 | 1.28e-01 | 0.30100 | -1.11e-01 | -1.48e-01 | 5.22e-02 | -2.00e-01 | 1.18e-01 | 1.75e-01 | 6.99e-02 | 5.23e-01 | 1.43e-02 | 1.50e-01 |
| HEART TRABECULA MORPHOGENESIS | 32 | 7.25e-01 | 1.00e+00 | 0.30100 | -1.58e-01 | -1.61e-01 | -1.07e-01 | -1.69e-01 | -9.52e-04 | 1.23e-01 | 1.15e-01 | 2.94e-01 | 9.82e-02 | 9.93e-01 |
| POSITIVE REGULATION OF TRIGLYCERIDE BIOSYNTHETIC PROCESS | 13 | 8.59e-01 | 1.00e+00 | 0.30100 | 1.31e-01 | 1.16e-01 | 1.90e-01 | 6.35e-02 | 1.41e-01 | 4.14e-01 | 4.68e-01 | 2.35e-01 | 6.92e-01 | 3.78e-01 |
| RESPONSE TO MURAMYL DIPEPTIDE | 20 | 2.85e-01 | 8.12e-01 | 0.30100 | 9.20e-02 | 6.57e-02 | 2.15e-01 | -3.99e-02 | 1.73e-01 | 4.76e-01 | 6.11e-01 | 9.54e-02 | 7.58e-01 | 1.80e-01 |
| PEPTIDOGLYCAN METABOLIC PROCESS | 6 | 7.72e-01 | 1.00e+00 | 0.30100 | -1.26e-01 | -1.29e-01 | -1.95e-01 | 1.79e-02 | 1.40e-01 | 5.92e-01 | 5.83e-01 | 4.08e-01 | 9.39e-01 | 5.52e-01 |
| NEGATIVE REGULATION OF NEURON DIFFERENTIATION | 72 | 1.70e-03 | 3.47e-02 | 0.30100 | 1.57e-01 | 1.33e-01 | 2.12e-01 | 2.60e-02 | -5.19e-02 | 2.15e-02 | 5.17e-02 | 1.83e-03 | 7.03e-01 | 4.46e-01 |
| GDP MANNOSE METABOLIC PROCESS | 7 | 5.12e-01 | 9.52e-01 | 0.30100 | 1.31e-01 | 1.63e-01 | 2.14e-01 | -3.75e-02 | -3.43e-03 | 5.50e-01 | 4.55e-01 | 3.28e-01 | 8.64e-01 | 9.87e-01 |
| POLYKETIDE METABOLIC PROCESS | 10 | 4.54e-01 | 9.31e-01 | 0.30100 | -1.15e-01 | -7.94e-02 | -1.34e-01 | -4.46e-02 | -2.26e-01 | 5.27e-01 | 6.64e-01 | 4.64e-01 | 8.07e-01 | 2.16e-01 |
| T HELPER 1 TYPE IMMUNE RESPONSE | 48 | 1.26e-02 | 1.47e-01 | 0.30100 | -1.29e-01 | -1.41e-01 | 2.41e-02 | -1.96e-01 | 1.22e-01 | 1.23e-01 | 9.13e-02 | 7.73e-01 | 1.88e-02 | 1.43e-01 |
| MRNA 5 SPLICE SITE RECOGNITION | 10 | 4.01e-01 | 9.01e-01 | 0.30100 | 1.31e-01 | 7.68e-02 | 1.62e-01 | 6.00e-02 | -1.94e-01 | 4.73e-01 | 6.74e-01 | 3.75e-01 | 7.42e-01 | 2.89e-01 |
| PARATHYROID GLAND DEVELOPMENT | 7 | 3.49e-01 | 8.68e-01 | 0.30100 | -5.89e-02 | -9.16e-02 | 4.34e-02 | -2.69e-01 | -6.43e-02 | 7.87e-01 | 6.75e-01 | 8.42e-01 | 2.17e-01 | 7.68e-01 |
| RESPONSE TO WATER | 13 | 7.44e-01 | 1.00e+00 | 0.30000 | 1.60e-01 | 1.63e-01 | 5.87e-02 | 1.86e-01 | 4.17e-03 | 3.18e-01 | 3.10e-01 | 7.14e-01 | 2.45e-01 | 9.79e-01 |
| MEIOTIC CELL CYCLE CHECKPOINT SIGNALING | 8 | 7.75e-01 | 1.00e+00 | 0.30000 | 1.10e-02 | 1.21e-02 | -2.87e-02 | -6.26e-03 | -2.98e-01 | 9.57e-01 | 9.53e-01 | 8.88e-01 | 9.76e-01 | 1.44e-01 |
| PRIMARY ALCOHOL CATABOLIC PROCESS | 13 | 5.85e-01 | 9.85e-01 | 0.30000 | -8.54e-02 | -5.77e-02 | -1.99e-01 | 3.29e-02 | -1.97e-01 | 5.94e-01 | 7.18e-01 | 2.15e-01 | 8.37e-01 | 2.18e-01 |
| SYMPATHETIC NEURON PROJECTION EXTENSION | 5 | 9.86e-01 | 1.00e+00 | 0.30000 | -1.39e-01 | -1.40e-01 | -1.52e-01 | -1.03e-01 | -1.33e-01 | 5.90e-01 | 5.89e-01 | 5.57e-01 | 6.91e-01 | 6.08e-01 |
| SNRNA 3 END PROCESSING | 20 | 2.13e-01 | 7.36e-01 | 0.30000 | 4.42e-02 | -1.87e-02 | 1.80e-01 | -4.63e-02 | 2.31e-01 | 7.32e-01 | 8.85e-01 | 1.63e-01 | 7.20e-01 | 7.43e-02 |
| LEUKOCYTE CHEMOTAXIS | 233 | 1.78e-06 | 1.00e-04 | 0.30000 | -1.58e-01 | -1.79e-01 | -9.15e-02 | -1.20e-01 | 9.96e-02 | 3.12e-05 | 2.37e-06 | 1.61e-02 | 1.59e-03 | 8.81e-03 |
| RESPONSE TO INTERLEUKIN 4 | 33 | 1.71e-02 | 1.86e-01 | 0.30000 | -1.24e-01 | -1.45e-01 | 5.55e-02 | -1.95e-01 | 1.12e-01 | 2.19e-01 | 1.50e-01 | 5.81e-01 | 5.28e-02 | 2.63e-01 |
| TELOMERE ORGANIZATION | 178 | 2.78e-05 | 1.14e-03 | 0.30000 | 1.15e-01 | 9.19e-02 | 1.91e-01 | 5.45e-02 | 1.69e-01 | 8.00e-03 | 3.44e-02 | 1.09e-05 | 2.10e-01 | 9.64e-05 |
| SINOATRIAL NODE CELL DIFFERENTIATION | 6 | 5.93e-01 | 9.86e-01 | 0.30000 | -6.32e-02 | -8.41e-02 | 1.51e-01 | -1.90e-01 | 1.41e-01 | 7.89e-01 | 7.21e-01 | 5.22e-01 | 4.19e-01 | 5.51e-01 |
| PROTEIN IMPORT INTO MITOCHONDRIAL MATRIX | 19 | 3.32e-01 | 8.57e-01 | 0.30000 | -3.55e-02 | -7.44e-02 | 7.74e-02 | -1.04e-01 | 2.57e-01 | 7.89e-01 | 5.75e-01 | 5.59e-01 | 4.33e-01 | 5.21e-02 |
| POSITIVE REGULATION OF BLOOD PRESSURE | 32 | 3.27e-01 | 8.53e-01 | 0.30000 | 1.60e-01 | 1.50e-01 | 1.65e-01 | 7.00e-02 | -9.93e-02 | 1.18e-01 | 1.43e-01 | 1.07e-01 | 4.93e-01 | 3.31e-01 |
| SKIN MORPHOGENESIS | 13 | 1.22e-01 | 5.84e-01 | 0.30000 | -1.09e-02 | 3.43e-02 | -1.06e-01 | 1.27e-01 | -2.47e-01 | 9.46e-01 | 8.30e-01 | 5.07e-01 | 4.29e-01 | 1.23e-01 |
| HISTONE DEACETYLATION | 19 | 5.07e-01 | 9.48e-01 | 0.30000 | 9.65e-02 | 7.82e-02 | 2.00e-01 | 2.27e-02 | 1.84e-01 | 4.67e-01 | 5.55e-01 | 1.31e-01 | 8.64e-01 | 1.66e-01 |
| POSITIVE REGULATION OF THYROID HORMONE GENERATION | 5 | 9.14e-01 | 1.00e+00 | 0.29900 | -1.09e-01 | -1.66e-01 | 2.77e-02 | -1.61e-01 | 1.54e-01 | 6.74e-01 | 5.20e-01 | 9.15e-01 | 5.34e-01 | 5.52e-01 |
| SKELETAL MUSCLE SATELLITE CELL MAINTENANCE INVOLVED IN SKELETAL MUSCLE REGENERATION | 5 | 4.31e-01 | 9.19e-01 | 0.29900 | 1.56e-01 | 8.45e-02 | 2.34e-01 | -5.40e-02 | 2.30e-02 | 5.47e-01 | 7.44e-01 | 3.64e-01 | 8.34e-01 | 9.29e-01 |
| L CYSTINE TRANSPORT | 6 | 6.64e-01 | 1.00e+00 | 0.29900 | -4.24e-02 | 3.07e-03 | -2.35e-01 | 1.35e-01 | -1.19e-01 | 8.57e-01 | 9.90e-01 | 3.18e-01 | 5.66e-01 | 6.14e-01 |
| NEGATIVE REGULATION OF MONOCYTE CHEMOTAXIS | 6 | 8.19e-01 | 1.00e+00 | 0.29900 | 1.04e-01 | 1.13e-01 | -1.30e-03 | 2.09e-01 | 1.49e-01 | 6.60e-01 | 6.33e-01 | 9.96e-01 | 3.75e-01 | 5.26e-01 |
| AUDITORY RECEPTOR CELL DEVELOPMENT | 24 | 2.02e-01 | 7.20e-01 | 0.29900 | 1.03e-01 | 1.44e-01 | -5.24e-02 | 2.06e-01 | -1.14e-01 | 3.81e-01 | 2.23e-01 | 6.57e-01 | 8.03e-02 | 3.36e-01 |
| COBALAMIN TRANSPORT | 8 | 5.02e-01 | 9.48e-01 | 0.29900 | -8.27e-02 | -1.62e-01 | 8.44e-03 | -2.97e-02 | 2.35e-01 | 6.85e-01 | 4.27e-01 | 9.67e-01 | 8.84e-01 | 2.49e-01 |
| REGULATION OF MEMBRANE DEPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 5 | 2.79e-01 | 8.05e-01 | 0.29900 | 8.94e-02 | 2.09e-01 | -3.58e-02 | 1.83e-01 | 5.37e-02 | 7.29e-01 | 4.18e-01 | 8.90e-01 | 4.78e-01 | 8.35e-01 |
| PROTEIN LOCALIZATION TO PRESYNAPSE | 11 | 7.94e-01 | 1.00e+00 | 0.29900 | -1.09e-01 | -7.75e-02 | -1.10e-01 | -1.34e-01 | -2.04e-01 | 5.33e-01 | 6.56e-01 | 5.29e-01 | 4.41e-01 | 2.42e-01 |
| PEPTIDYL LYSINE DEACETYLATION | 6 | 5.61e-01 | 9.70e-01 | 0.29900 | 1.15e-03 | -1.23e-02 | 1.15e-01 | -1.52e-01 | -2.30e-01 | 9.96e-01 | 9.58e-01 | 6.26e-01 | 5.20e-01 | 3.29e-01 |
| POSITIVE REGULATION OF SISTER CHROMATID COHESION | 9 | 1.55e-01 | 6.53e-01 | 0.29900 | 1.62e-01 | 6.00e-02 | 2.23e-01 | 7.47e-02 | -6.28e-02 | 4.00e-01 | 7.55e-01 | 2.46e-01 | 6.98e-01 | 7.44e-01 |
| REGULATION OF DNA DIRECTED DNA POLYMERASE ACTIVITY | 9 | 2.68e-01 | 7.95e-01 | 0.29900 | 1.03e-01 | 3.25e-02 | 2.60e-01 | -1.01e-01 | 3.26e-03 | 5.94e-01 | 8.66e-01 | 1.78e-01 | 5.98e-01 | 9.87e-01 |
| MATERNAL PLACENTA DEVELOPMENT | 33 | 1.57e-01 | 6.54e-01 | 0.29900 | 7.04e-02 | 3.61e-02 | 1.92e-01 | 3.36e-03 | 2.15e-01 | 4.84e-01 | 7.20e-01 | 5.67e-02 | 9.73e-01 | 3.25e-02 |
| PHOSPHATIDYLGLYCEROL METABOLIC PROCESS | 33 | 1.26e-01 | 5.93e-01 | 0.29900 | 1.51e-01 | 1.71e-01 | 9.21e-02 | 1.29e-01 | 1.10e-01 | 1.34e-01 | 8.90e-02 | 3.60e-01 | 1.98e-01 | 2.76e-01 |
| MITOCHONDRIAL DNA REPLICATION | 14 | 5.55e-02 | 3.84e-01 | 0.29900 | 1.08e-01 | 3.50e-02 | 2.05e-01 | -7.92e-03 | -1.85e-01 | 4.86e-01 | 8.21e-01 | 1.85e-01 | 9.59e-01 | 2.30e-01 |
| COPI COATED VESICLE BUDDING | 6 | 9.13e-01 | 1.00e+00 | 0.29800 | 7.06e-02 | 3.33e-02 | 1.96e-01 | -1.63e-03 | 2.11e-01 | 7.65e-01 | 8.88e-01 | 4.05e-01 | 9.94e-01 | 3.71e-01 |
| POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 8.54e-01 | 1.00e+00 | 0.29800 | -1.52e-01 | -1.74e-01 | -1.45e-02 | -1.78e-01 | 5.98e-02 | 4.87e-01 | 4.25e-01 | 9.47e-01 | 4.14e-01 | 7.84e-01 |
| FATTY ACID DERIVATIVE METABOLIC PROCESS | 69 | 1.90e-03 | 3.78e-02 | 0.29800 | 1.26e-01 | 1.25e-01 | 4.48e-02 | 2.33e-01 | -3.30e-02 | 7.09e-02 | 7.16e-02 | 5.20e-01 | 8.17e-04 | 6.36e-01 |
| NUCLEAR RNA SURVEILLANCE | 14 | 8.12e-01 | 1.00e+00 | 0.29800 | 1.06e-01 | 7.87e-02 | 1.68e-01 | 6.32e-02 | 1.98e-01 | 4.91e-01 | 6.10e-01 | 2.77e-01 | 6.82e-01 | 1.99e-01 |
| REGULATION OF TRANSLATIONAL FIDELITY | 18 | 6.87e-01 | 1.00e+00 | 0.29800 | 1.61e-01 | 1.36e-01 | 1.96e-01 | 7.24e-02 | -2.91e-02 | 2.38e-01 | 3.19e-01 | 1.49e-01 | 5.95e-01 | 8.31e-01 |
| NEGATIVE REGULATION OF DENDRITIC CELL APOPTOTIC PROCESS | 8 | 5.91e-01 | 9.86e-01 | 0.29800 | -1.09e-01 | -1.46e-01 | 8.14e-02 | -2.15e-01 | 5.33e-02 | 5.92e-01 | 4.75e-01 | 6.90e-01 | 2.93e-01 | 7.94e-01 |
| POSITIVE REGULATION OF CELL MATURATION | 7 | 5.82e-01 | 9.85e-01 | 0.29800 | 8.27e-03 | -2.82e-02 | 3.63e-02 | -6.32e-02 | -2.87e-01 | 9.70e-01 | 8.97e-01 | 8.68e-01 | 7.72e-01 | 1.88e-01 |
| NEGATIVE REGULATION OF SOMATIC STEM CELL POPULATION MAINTENANCE | 5 | 7.16e-02 | 4.39e-01 | 0.29800 | 2.20e-02 | -2.78e-02 | 2.92e-01 | -3.04e-02 | 3.91e-02 | 9.32e-01 | 9.14e-01 | 2.59e-01 | 9.06e-01 | 8.80e-01 |
| NEGATIVE REGULATION OF CELL CELL ADHESION MEDIATED BY CADHERIN | 9 | 3.95e-01 | 8.94e-01 | 0.29800 | -1.09e-01 | -7.69e-02 | 2.12e-02 | -2.16e-01 | 1.55e-01 | 5.71e-01 | 6.89e-01 | 9.12e-01 | 2.62e-01 | 4.22e-01 |
| NEGATIVE REGULATION OF LIPID CATABOLIC PROCESS | 27 | 6.92e-01 | 1.00e+00 | 0.29800 | 1.53e-01 | 1.25e-01 | 1.82e-01 | 1.17e-01 | 5.31e-02 | 1.69e-01 | 2.60e-01 | 1.02e-01 | 2.91e-01 | 6.33e-01 |
| MANNOSE METABOLIC PROCESS | 9 | 6.27e-01 | 9.94e-01 | 0.29800 | 1.47e-01 | 1.78e-01 | 1.43e-01 | 5.26e-02 | 1.10e-01 | 4.45e-01 | 3.54e-01 | 4.58e-01 | 7.85e-01 | 5.68e-01 |
| POSITIVE REGULATION OF CALCINEURIN MEDIATED SIGNALING | 21 | 3.80e-01 | 8.88e-01 | 0.29800 | 1.02e-01 | 1.42e-01 | -1.72e-02 | 1.76e-01 | -1.64e-01 | 4.16e-01 | 2.61e-01 | 8.92e-01 | 1.63e-01 | 1.94e-01 |
| PHOSPHATE ION HOMEOSTASIS | 20 | 6.02e-01 | 9.90e-01 | 0.29800 | -1.30e-01 | -1.08e-01 | -1.93e-01 | -4.07e-02 | -1.45e-01 | 3.13e-01 | 4.01e-01 | 1.35e-01 | 7.53e-01 | 2.63e-01 |
| CELLULAR RESPONSE TO GLUCAGON STIMULUS | 11 | 6.94e-01 | 1.00e+00 | 0.29800 | 1.26e-01 | 1.59e-01 | 5.17e-02 | 2.11e-01 | 9.30e-03 | 4.68e-01 | 3.62e-01 | 7.66e-01 | 2.25e-01 | 9.57e-01 |
| POSITIVE REGULATION OF BROWN FAT CELL DIFFERENTIATION | 15 | 4.74e-01 | 9.40e-01 | 0.29700 | 1.42e-01 | 1.53e-01 | 2.02e-01 | 6.36e-02 | -1.23e-02 | 3.42e-01 | 3.04e-01 | 1.76e-01 | 6.70e-01 | 9.34e-01 |
| AXONEMAL CENTRAL APPARATUS ASSEMBLY | 6 | 4.09e-01 | 9.08e-01 | 0.29700 | -1.30e-01 | -1.96e-01 | -1.68e-01 | 3.32e-02 | 6.09e-02 | 5.80e-01 | 4.07e-01 | 4.75e-01 | 8.88e-01 | 7.96e-01 |
| NEGATIVE REGULATION OF NITRIC OXIDE METABOLIC PROCESS | 14 | 6.66e-01 | 1.00e+00 | 0.29700 | 1.35e-01 | 1.19e-01 | 2.25e-01 | 4.36e-02 | 5.91e-02 | 3.83e-01 | 4.42e-01 | 1.44e-01 | 7.78e-01 | 7.02e-01 |
| RESPIRATORY ELECTRON TRANSPORT CHAIN | 107 | 2.73e-03 | 4.89e-02 | 0.29700 | 1.51e-01 | 1.29e-01 | 2.00e-01 | 5.31e-02 | 7.80e-02 | 7.04e-03 | 2.10e-02 | 3.45e-04 | 3.43e-01 | 1.63e-01 |
| PROTEIN LOCALIZATION TO BASOLATERAL PLASMA MEMBRANE | 7 | 6.81e-01 | 1.00e+00 | 0.29700 | 4.68e-04 | 8.60e-03 | 1.27e-01 | -9.28e-02 | 2.52e-01 | 9.98e-01 | 9.69e-01 | 5.59e-01 | 6.71e-01 | 2.48e-01 |
| NEGATIVE REGULATION OF RUFFLE ASSEMBLY | 7 | 9.01e-01 | 1.00e+00 | 0.29700 | 1.13e-01 | 1.37e-01 | -1.19e-02 | 1.99e-01 | -1.31e-01 | 6.05e-01 | 5.31e-01 | 9.56e-01 | 3.62e-01 | 5.48e-01 |
| PERIPHERAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 15 | 1.42e-01 | 6.27e-01 | 0.29700 | -6.79e-02 | -1.01e-01 | 8.82e-02 | -2.54e-01 | -3.44e-02 | 6.49e-01 | 5.00e-01 | 5.54e-01 | 8.83e-02 | 8.18e-01 |
| CARDIAC MUSCLE MYOBLAST PROLIFERATION | 7 | 8.14e-01 | 1.00e+00 | 0.29700 | 1.35e-01 | 1.43e-01 | 1.59e-01 | 4.35e-03 | -1.56e-01 | 5.36e-01 | 5.13e-01 | 4.67e-01 | 9.84e-01 | 4.74e-01 |
| EOSINOPHIL MEDIATED IMMUNITY | 8 | 6.17e-01 | 9.90e-01 | 0.29700 | 9.31e-04 | -6.70e-02 | 1.58e-01 | -1.16e-01 | 2.13e-01 | 9.96e-01 | 7.43e-01 | 4.38e-01 | 5.69e-01 | 2.98e-01 |
| REGULATION OF MITOCHONDRIAL TRANSLATION | 25 | 2.31e-01 | 7.54e-01 | 0.29700 | 1.44e-01 | 1.34e-01 | 2.19e-01 | 1.84e-02 | -3.14e-02 | 2.13e-01 | 2.45e-01 | 5.77e-02 | 8.74e-01 | 7.86e-01 |
| NEGATIVE REGULATION OF NATURAL KILLER CELL MEDIATED IMMUNITY | 21 | 1.16e-01 | 5.67e-01 | 0.29700 | -1.44e-01 | -2.07e-01 | -1.19e-02 | -1.52e-01 | 3.42e-02 | 2.52e-01 | 1.00e-01 | 9.25e-01 | 2.29e-01 | 7.86e-01 |
| MUSCLE ATROPHY | 10 | 7.29e-01 | 1.00e+00 | 0.29700 | 7.09e-02 | 8.07e-02 | -4.25e-02 | 8.52e-02 | -2.60e-01 | 6.98e-01 | 6.58e-01 | 8.16e-01 | 6.41e-01 | 1.55e-01 |
| REGULATION OF CGMP MEDIATED SIGNALING | 11 | 7.25e-01 | 1.00e+00 | 0.29700 | 7.65e-02 | 9.62e-02 | -5.46e-02 | 1.44e-01 | -2.22e-01 | 6.61e-01 | 5.81e-01 | 7.54e-01 | 4.08e-01 | 2.03e-01 |
| CANNABINOID SIGNALING PATHWAY | 9 | 4.18e-01 | 9.11e-01 | 0.29700 | 6.75e-02 | 1.84e-02 | 1.58e-01 | 1.37e-01 | 1.98e-01 | 7.26e-01 | 9.24e-01 | 4.11e-01 | 4.77e-01 | 3.03e-01 |
| REGULATION OF RIBONUCLEASE ACTIVITY | 9 | 7.47e-01 | 1.00e+00 | 0.29700 | 1.27e-01 | 1.62e-01 | 1.04e-01 | 1.09e-01 | 1.52e-01 | 5.09e-01 | 4.01e-01 | 5.88e-01 | 5.72e-01 | 4.31e-01 |
| COMPLEMENT ACTIVATION CLASSICAL PATHWAY | 34 | 1.99e-01 | 7.14e-01 | 0.29700 | -1.09e-01 | -6.67e-02 | -2.09e-01 | -5.80e-02 | -1.57e-01 | 2.73e-01 | 5.01e-01 | 3.47e-02 | 5.58e-01 | 1.13e-01 |
| REGULATION OF FERTILIZATION | 17 | 8.98e-01 | 1.00e+00 | 0.29600 | -1.61e-01 | -1.48e-01 | -1.27e-01 | -1.54e-01 | -2.93e-03 | 2.49e-01 | 2.92e-01 | 3.65e-01 | 2.71e-01 | 9.83e-01 |
| INTERLEUKIN 17 MEDIATED SIGNALING PATHWAY | 11 | 8.42e-01 | 1.00e+00 | 0.29600 | 9.81e-02 | 6.38e-02 | 1.74e-01 | 8.39e-02 | 1.91e-01 | 5.73e-01 | 7.14e-01 | 3.17e-01 | 6.30e-01 | 2.72e-01 |
| HYDROGEN PEROXIDE BIOSYNTHETIC PROCESS | 14 | 3.33e-01 | 8.57e-01 | 0.29600 | 1.43e-01 | 1.90e-01 | 1.36e-01 | 3.71e-02 | -1.06e-01 | 3.55e-01 | 2.18e-01 | 3.79e-01 | 8.10e-01 | 4.91e-01 |
| POSITIVE REGULATION OF HEAT GENERATION | 9 | 6.20e-01 | 9.90e-01 | 0.29600 | -4.98e-02 | -7.95e-02 | 1.20e-01 | -9.82e-02 | 2.34e-01 | 7.96e-01 | 6.80e-01 | 5.32e-01 | 6.10e-01 | 2.25e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 58 | 3.21e-01 | 8.47e-01 | 0.29600 | 1.49e-01 | 1.59e-01 | 1.16e-01 | 1.51e-01 | 6.24e-02 | 4.98e-02 | 3.64e-02 | 1.27e-01 | 4.70e-02 | 4.11e-01 |
| POSITIVE REGULATION OF IMMUNE EFFECTOR PROCESS | 259 | 1.70e-09 | 2.46e-07 | 0.29600 | -1.36e-01 | -1.70e-01 | -1.79e-02 | -1.88e-01 | 6.45e-02 | 1.60e-04 | 2.36e-06 | 6.19e-01 | 1.83e-07 | 7.38e-02 |
| INOSINE METABOLIC PROCESS | 5 | 8.29e-01 | 1.00e+00 | 0.29600 | 1.18e-01 | 1.43e-01 | 7.48e-02 | 1.94e-01 | -1.01e-01 | 6.49e-01 | 5.80e-01 | 7.72e-01 | 4.54e-01 | 6.97e-01 |
| REGULATION OF CYTOPLASMIC TRANSPORT | 29 | 6.22e-02 | 4.09e-01 | 0.29500 | -9.65e-02 | -1.46e-01 | -1.35e-02 | -2.69e-02 | 2.36e-01 | 3.68e-01 | 1.73e-01 | 9.00e-01 | 8.02e-01 | 2.78e-02 |
| REGULATION OF MITOCHONDRIAL FISSION | 30 | 6.88e-01 | 1.00e+00 | 0.29500 | -1.49e-01 | -1.50e-01 | -1.55e-01 | -1.09e-01 | -8.24e-02 | 1.59e-01 | 1.56e-01 | 1.40e-01 | 3.03e-01 | 4.35e-01 |
| MACROMOLECULE DEPALMITOYLATION | 11 | 6.66e-01 | 1.00e+00 | 0.29500 | -1.19e-01 | -8.02e-02 | -9.54e-02 | -1.57e-01 | -1.82e-01 | 4.96e-01 | 6.45e-01 | 5.84e-01 | 3.68e-01 | 2.97e-01 |
| PEPTIDYL LYSINE DIMETHYLATION | 11 | 8.07e-01 | 1.00e+00 | 0.29500 | -1.47e-01 | -1.83e-01 | -1.03e-01 | -9.12e-02 | 1.15e-01 | 3.97e-01 | 2.95e-01 | 5.56e-01 | 6.00e-01 | 5.08e-01 |
| LIMB BUD FORMATION | 9 | 8.52e-01 | 1.00e+00 | 0.29500 | 1.30e-01 | 1.27e-01 | 1.27e-01 | 7.87e-02 | -1.78e-01 | 4.98e-01 | 5.08e-01 | 5.11e-01 | 6.83e-01 | 3.55e-01 |
| IMMUNOGLOBULIN V D J RECOMBINATION | 8 | 4.46e-01 | 9.30e-01 | 0.29500 | -7.96e-02 | -1.50e-01 | 1.25e-01 | -1.97e-01 | 6.04e-02 | 6.97e-01 | 4.62e-01 | 5.39e-01 | 3.34e-01 | 7.67e-01 |
| LATERAL VENTRICLE DEVELOPMENT | 12 | 3.60e-01 | 8.76e-01 | 0.29500 | 4.81e-02 | 7.88e-02 | 6.07e-02 | -6.58e-02 | -2.66e-01 | 7.73e-01 | 6.36e-01 | 7.16e-01 | 6.93e-01 | 1.11e-01 |
| NUCLEAR MEMBRANE REASSEMBLY | 25 | 1.06e-01 | 5.41e-01 | 0.29500 | 7.27e-02 | 6.83e-02 | 1.84e-01 | -5.32e-02 | 2.01e-01 | 5.29e-01 | 5.54e-01 | 1.11e-01 | 6.45e-01 | 8.21e-02 |
| REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DIFFERENTIATION | 23 | 2.24e-01 | 7.46e-01 | 0.29500 | 1.03e-01 | 5.32e-02 | 2.33e-01 | -1.47e-02 | 1.38e-01 | 3.93e-01 | 6.58e-01 | 5.29e-02 | 9.03e-01 | 2.53e-01 |
| POSITIVE REGULATION OF NATURAL KILLER CELL DIFFERENTIATION | 7 | 9.71e-01 | 1.00e+00 | 0.29500 | -1.61e-01 | -1.79e-01 | -1.13e-01 | -1.28e-01 | 7.00e-03 | 4.60e-01 | 4.13e-01 | 6.06e-01 | 5.59e-01 | 9.74e-01 |
| NEGATIVE REGULATION OF REGULATORY T CELL DIFFERENTIATION | 7 | 4.08e-02 | 3.25e-01 | 0.29500 | 4.26e-02 | -7.57e-02 | 8.02e-03 | 1.96e-01 | 2.02e-01 | 8.45e-01 | 7.29e-01 | 9.71e-01 | 3.69e-01 | 3.55e-01 |
| DORSAL SPINAL CORD DEVELOPMENT | 20 | 1.24e-02 | 1.46e-01 | 0.29500 | 2.15e-02 | 1.95e-02 | 1.52e-01 | -1.77e-01 | -1.78e-01 | 8.68e-01 | 8.80e-01 | 2.39e-01 | 1.71e-01 | 1.69e-01 |
| REGULATION OF VITAMIN D RECEPTOR SIGNALING PATHWAY | 10 | 4.20e-01 | 9.11e-01 | 0.29400 | 1.13e-01 | 1.50e-01 | 1.39e-01 | 1.81e-02 | 1.78e-01 | 5.35e-01 | 4.11e-01 | 4.48e-01 | 9.21e-01 | 3.30e-01 |
| POSITIVE REGULATION OF CELLULAR PH REDUCTION | 5 | 6.17e-01 | 9.90e-01 | 0.29400 | 9.77e-02 | 7.05e-03 | 2.69e-01 | -5.07e-02 | 4.61e-02 | 7.05e-01 | 9.78e-01 | 2.98e-01 | 8.44e-01 | 8.58e-01 |
| REGULATION OF MRNA SPLICING VIA SPLICEOSOME | 95 | 1.32e-02 | 1.52e-01 | 0.29400 | 1.18e-01 | 9.04e-02 | 1.94e-01 | 6.15e-02 | 1.52e-01 | 4.65e-02 | 1.28e-01 | 1.10e-03 | 3.01e-01 | 1.06e-02 |
| CELLULAR RESPONSE TO PH | 26 | 3.78e-01 | 8.85e-01 | 0.29400 | 1.44e-01 | 1.85e-01 | 7.92e-02 | 1.59e-01 | -4.46e-03 | 2.03e-01 | 1.03e-01 | 4.85e-01 | 1.61e-01 | 9.69e-01 |
| POSITIVE REGULATION OF T CELL MEDIATED CYTOTOXICITY | 40 | 2.63e-01 | 7.91e-01 | 0.29400 | -1.36e-01 | -1.58e-01 | -2.71e-02 | -1.92e-01 | 7.19e-02 | 1.36e-01 | 8.38e-02 | 7.67e-01 | 3.56e-02 | 4.31e-01 |
| NEGATIVE REGULATION OF GLUTAMATE SECRETION | 6 | 4.90e-01 | 9.45e-01 | 0.29400 | 1.18e-02 | -4.69e-02 | 5.13e-02 | -8.51e-02 | -2.72e-01 | 9.60e-01 | 8.42e-01 | 8.28e-01 | 7.18e-01 | 2.48e-01 |
| MINERALOCORTICOID METABOLIC PROCESS | 14 | 8.37e-01 | 1.00e+00 | 0.29400 | 1.41e-01 | 1.57e-01 | 1.45e-01 | 1.21e-01 | 7.63e-02 | 3.60e-01 | 3.09e-01 | 3.46e-01 | 4.33e-01 | 6.21e-01 |
| ACYLGLYCEROL HOMEOSTASIS | 42 | 2.23e-01 | 7.45e-01 | 0.29400 | 1.55e-01 | 1.43e-01 | 1.84e-01 | 6.12e-02 | 6.31e-02 | 8.13e-02 | 1.08e-01 | 3.95e-02 | 4.92e-01 | 4.79e-01 |
| CELL CHEMOTAXIS | 309 | 2.86e-06 | 1.58e-04 | 0.29300 | -1.58e-01 | -1.72e-01 | -9.93e-02 | -1.33e-01 | 6.17e-02 | 1.69e-06 | 2.05e-07 | 2.69e-03 | 5.76e-05 | 6.21e-02 |
| T HELPER 2 CELL DIFFERENTIATION | 19 | 1.79e-01 | 6.86e-01 | 0.29300 | -6.74e-02 | -1.15e-01 | 1.23e-01 | -1.63e-01 | 1.62e-01 | 6.11e-01 | 3.85e-01 | 3.54e-01 | 2.18e-01 | 2.21e-01 |
| REGULATION OF GLIAL CELL APOPTOTIC PROCESS | 10 | 8.18e-01 | 1.00e+00 | 0.29300 | -1.35e-01 | -9.95e-02 | -1.42e-01 | -1.08e-01 | -1.61e-01 | 4.60e-01 | 5.86e-01 | 4.37e-01 | 5.56e-01 | 3.77e-01 |
| N ACYLPHOSPHATIDYLETHANOLAMINE METABOLIC PROCESS | 9 | 8.41e-01 | 1.00e+00 | 0.29300 | -1.60e-01 | -1.40e-01 | -1.24e-01 | -1.29e-01 | -9.34e-02 | 4.07e-01 | 4.68e-01 | 5.21e-01 | 5.02e-01 | 6.27e-01 |
| GLIAL CELL FATE COMMITMENT | 13 | 2.32e-01 | 7.54e-01 | 0.29300 | 1.23e-01 | 1.13e-01 | 1.71e-01 | -6.55e-02 | -1.56e-01 | 4.44e-01 | 4.79e-01 | 2.86e-01 | 6.83e-01 | 3.31e-01 |
| CELL PROLIFERATION IN BONE MARROW | 10 | 6.99e-01 | 1.00e+00 | 0.29300 | 1.35e-01 | 1.15e-01 | 3.92e-02 | 2.29e-01 | 6.36e-03 | 4.58e-01 | 5.29e-01 | 8.30e-01 | 2.10e-01 | 9.72e-01 |
| REGULATION OF OPSONIZATION | 10 | 9.25e-01 | 1.00e+00 | 0.29300 | -1.21e-01 | -1.14e-01 | -1.63e-01 | -1.02e-01 | -1.46e-01 | 5.09e-01 | 5.32e-01 | 3.73e-01 | 5.78e-01 | 4.24e-01 |
| MONOCYTE EXTRAVASATION | 10 | 3.22e-01 | 8.47e-01 | 0.29300 | -6.31e-02 | -4.78e-02 | -2.45e-01 | 8.53e-02 | -1.09e-01 | 7.30e-01 | 7.93e-01 | 1.79e-01 | 6.41e-01 | 5.49e-01 |
| RIBONUCLEOSIDE METABOLIC PROCESS | 34 | 3.07e-01 | 8.35e-01 | 0.29200 | -1.61e-01 | -1.23e-01 | -1.51e-01 | -1.47e-01 | 6.81e-03 | 1.04e-01 | 2.14e-01 | 1.27e-01 | 1.39e-01 | 9.45e-01 |
| CELLULAR RESPONSE TO VIRUS | 81 | 1.40e-01 | 6.24e-01 | 0.29200 | -1.52e-01 | -1.37e-01 | -1.24e-01 | -1.68e-01 | 5.32e-04 | 1.82e-02 | 3.28e-02 | 5.42e-02 | 8.84e-03 | 9.93e-01 |
| POSITIVE REGULATION OF HORMONE METABOLIC PROCESS | 15 | 8.69e-01 | 1.00e+00 | 0.29200 | -1.62e-01 | -1.62e-01 | -1.22e-01 | -1.13e-01 | 7.07e-02 | 2.76e-01 | 2.76e-01 | 4.15e-01 | 4.48e-01 | 6.35e-01 |
| GLOMERULUS VASCULATURE MORPHOGENESIS | 6 | 8.94e-01 | 1.00e+00 | 0.29200 | 1.45e-01 | 1.06e-01 | 1.27e-01 | 1.89e-01 | -3.32e-02 | 5.39e-01 | 6.51e-01 | 5.90e-01 | 4.23e-01 | 8.88e-01 |
| NEGATIVE REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION | 24 | 5.90e-01 | 9.86e-01 | 0.29200 | 1.40e-01 | 1.16e-01 | 1.93e-01 | 1.09e-01 | 5.54e-02 | 2.35e-01 | 3.27e-01 | 1.02e-01 | 3.54e-01 | 6.39e-01 |
| INTESTINAL EPITHELIAL STRUCTURE MAINTENANCE | 8 | 4.99e-01 | 9.47e-01 | 0.29200 | 8.23e-02 | 5.92e-02 | 1.69e-01 | -8.23e-02 | -1.99e-01 | 6.87e-01 | 7.72e-01 | 4.07e-01 | 6.87e-01 | 3.30e-01 |
| AEROBIC RESPIRATION | 170 | 5.57e-06 | 2.80e-04 | 0.29200 | 1.43e-01 | 1.23e-01 | 2.14e-01 | 3.35e-02 | 5.49e-02 | 1.28e-03 | 5.75e-03 | 1.55e-06 | 4.52e-01 | 2.16e-01 |
| STRESS INDUCED PREMATURE SENESCENCE | 8 | 9.30e-01 | 1.00e+00 | 0.29200 | -1.44e-01 | -1.37e-01 | -2.01e-01 | -7.07e-02 | -2.67e-02 | 4.81e-01 | 5.03e-01 | 3.26e-01 | 7.29e-01 | 8.96e-01 |
| C TERMINAL PROTEIN AMINO ACID MODIFICATION | 12 | 9.05e-01 | 1.00e+00 | 0.29200 | -1.29e-01 | -1.06e-01 | -1.43e-01 | -1.15e-01 | -1.54e-01 | 4.38e-01 | 5.26e-01 | 3.92e-01 | 4.90e-01 | 3.55e-01 |
| REGULATION OF RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 78 | 4.26e-02 | 3.31e-01 | 0.29200 | 1.44e-01 | 1.37e-01 | 1.92e-01 | 8.49e-02 | 4.00e-02 | 2.83e-02 | 3.61e-02 | 3.32e-03 | 1.95e-01 | 5.41e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS NONSENSE MEDIATED DECAY | 42 | 4.12e-01 | 9.08e-01 | 0.29200 | -1.47e-01 | -1.55e-01 | -6.43e-02 | -1.58e-01 | 1.02e-01 | 1.00e-01 | 8.12e-02 | 4.71e-01 | 7.56e-02 | 2.54e-01 |
| POSITIVE REGULATION OF HELICASE ACTIVITY | 6 | 5.04e-01 | 9.48e-01 | 0.29200 | 8.42e-03 | -2.06e-02 | 7.54e-02 | -1.84e-01 | -2.12e-01 | 9.71e-01 | 9.30e-01 | 7.49e-01 | 4.34e-01 | 3.68e-01 |
| IONOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAY | 22 | 6.94e-01 | 1.00e+00 | 0.29200 | -1.16e-01 | -1.08e-01 | -1.29e-01 | -1.08e-01 | -1.78e-01 | 3.46e-01 | 3.78e-01 | 2.96e-01 | 3.82e-01 | 1.48e-01 |
| BASE EXCISION REPAIR AP SITE FORMATION | 12 | 1.15e-01 | 5.63e-01 | 0.29200 | 1.01e-01 | 6.29e-02 | 2.14e-01 | -1.19e-01 | 1.04e-01 | 5.44e-01 | 7.06e-01 | 1.99e-01 | 4.74e-01 | 5.32e-01 |
| POSITIVE REGULATION OF FEAR RESPONSE | 6 | 7.18e-01 | 1.00e+00 | 0.29200 | -1.02e-01 | -6.25e-02 | -2.24e-01 | -9.01e-02 | -1.11e-01 | 6.65e-01 | 7.91e-01 | 3.41e-01 | 7.02e-01 | 6.38e-01 |
| POSITIVE REGULATION OF T CELL RECEPTOR SIGNALING PATHWAY | 16 | 5.30e-01 | 9.54e-01 | 0.29200 | 6.82e-02 | 4.12e-02 | 1.94e-01 | -2.37e-02 | 2.01e-01 | 6.37e-01 | 7.76e-01 | 1.79e-01 | 8.70e-01 | 1.64e-01 |
| PROSTATE GLAND GROWTH | 10 | 8.08e-01 | 1.00e+00 | 0.29200 | -7.63e-02 | -6.02e-02 | -1.29e-01 | -2.78e-02 | -2.41e-01 | 6.76e-01 | 7.42e-01 | 4.79e-01 | 8.79e-01 | 1.87e-01 |
| RESPONSE TO NEMATODE | 7 | 8.97e-01 | 1.00e+00 | 0.29200 | 6.27e-02 | 5.01e-02 | 1.57e-01 | 1.67e-03 | 2.32e-01 | 7.74e-01 | 8.18e-01 | 4.71e-01 | 9.94e-01 | 2.88e-01 |
| PYRIMIDINE DEOXYRIBONUCLEOTIDE BIOSYNTHETIC PROCESS | 6 | 7.43e-01 | 1.00e+00 | 0.29200 | -9.02e-02 | -1.69e-01 | 6.86e-02 | -1.34e-01 | 1.60e-01 | 7.02e-01 | 4.74e-01 | 7.71e-01 | 5.69e-01 | 4.97e-01 |
| CARDIAC CHAMBER FORMATION | 12 | 1.32e-01 | 6.03e-01 | 0.29100 | 2.26e-02 | -6.69e-03 | 1.55e-01 | -1.86e-01 | -1.60e-01 | 8.92e-01 | 9.68e-01 | 3.52e-01 | 2.64e-01 | 3.37e-01 |
| NEGATIVE REGULATION OF TELOMERE MAINTENANCE VIA TELOMERE LENGTHENING | 24 | 3.24e-01 | 8.48e-01 | 0.29100 | -9.78e-02 | -1.08e-01 | 6.51e-03 | -9.60e-02 | 2.33e-01 | 4.07e-01 | 3.61e-01 | 9.56e-01 | 4.15e-01 | 4.81e-02 |
| DOPAMINE METABOLIC PROCESS | 35 | 2.76e-01 | 8.04e-01 | 0.29100 | 1.43e-01 | 1.26e-01 | 1.19e-01 | 1.51e-01 | -1.08e-01 | 1.44e-01 | 1.98e-01 | 2.23e-01 | 1.23e-01 | 2.67e-01 |
| POSITIVE REGULATION OF CHEMOKINE PRODUCTION | 70 | 4.22e-02 | 3.29e-01 | 0.29100 | -1.49e-01 | -1.70e-01 | -4.82e-02 | -1.77e-01 | 1.30e-02 | 3.11e-02 | 1.41e-02 | 4.86e-01 | 1.05e-02 | 8.51e-01 |
| SHORT CHAIN FATTY ACID CATABOLIC PROCESS | 7 | 8.77e-01 | 1.00e+00 | 0.29100 | -8.85e-02 | -1.04e-01 | -8.26e-02 | -1.35e-01 | -2.03e-01 | 6.85e-01 | 6.35e-01 | 7.05e-01 | 5.36e-01 | 3.53e-01 |
| CELLULAR RESPONSE TO MANGANESE ION | 10 | 5.92e-01 | 9.86e-01 | 0.29100 | -7.46e-02 | -5.72e-02 | -5.05e-02 | -9.70e-02 | -2.53e-01 | 6.83e-01 | 7.54e-01 | 7.82e-01 | 5.95e-01 | 1.66e-01 |
| REGULATION OF PROTEIN OLIGOMERIZATION | 5 | 8.17e-01 | 1.00e+00 | 0.29100 | 1.01e-01 | 5.44e-02 | 2.09e-01 | 1.09e-01 | 1.25e-01 | 6.95e-01 | 8.33e-01 | 4.19e-01 | 6.72e-01 | 6.28e-01 |
| SOMATIC DIVERSIFICATION OF IMMUNE RECEPTORS VIA SOMATIC MUTATION | 13 | 1.93e-01 | 7.04e-01 | 0.29100 | 7.17e-02 | 4.45e-02 | 2.30e-01 | -1.37e-01 | 7.62e-02 | 6.55e-01 | 7.81e-01 | 1.51e-01 | 3.94e-01 | 6.34e-01 |
| MEIOTIC SPINDLE ORGANIZATION | 18 | 6.65e-02 | 4.20e-01 | 0.29100 | 6.77e-02 | 7.55e-03 | 2.25e-01 | -1.21e-01 | 1.21e-01 | 6.19e-01 | 9.56e-01 | 9.88e-02 | 3.75e-01 | 3.72e-01 |
| NUCLEOSIDE SALVAGE | 8 | 9.75e-01 | 1.00e+00 | 0.29100 | -1.52e-01 | -1.51e-01 | -8.87e-02 | -1.58e-01 | 7.51e-02 | 4.57e-01 | 4.59e-01 | 6.64e-01 | 4.38e-01 | 7.13e-01 |
| VESICLE TETHERING INVOLVED IN EXOCYTOSIS | 9 | 7.92e-01 | 1.00e+00 | 0.29100 | -7.71e-02 | -3.45e-02 | -1.01e-01 | -1.08e-01 | -2.35e-01 | 6.89e-01 | 8.58e-01 | 5.99e-01 | 5.73e-01 | 2.22e-01 |
| GROWTH PLATE CARTILAGE CHONDROCYTE DIFFERENTIATION | 10 | 8.62e-01 | 1.00e+00 | 0.29100 | 1.25e-01 | 8.80e-02 | 2.16e-01 | 3.98e-02 | 1.13e-01 | 4.95e-01 | 6.30e-01 | 2.36e-01 | 8.28e-01 | 5.36e-01 |
| REGULATION OF MITOCHONDRIAL GENE EXPRESSION | 30 | 3.54e-02 | 3.00e-01 | 0.29000 | 1.29e-01 | 1.26e-01 | 2.16e-01 | -3.14e-02 | -6.59e-02 | 2.22e-01 | 2.32e-01 | 4.08e-02 | 7.66e-01 | 5.32e-01 |
| ACTIN CROSSLINK FORMATION | 12 | 5.30e-01 | 9.54e-01 | 0.29000 | -1.62e-01 | -1.04e-01 | -1.97e-01 | -7.58e-02 | -5.33e-02 | 3.32e-01 | 5.33e-01 | 2.38e-01 | 6.49e-01 | 7.49e-01 |
| MAINTENANCE OF CENTROSOME LOCATION | 6 | 7.34e-01 | 1.00e+00 | 0.29000 | 9.67e-02 | 8.87e-02 | 1.70e-01 | -2.68e-02 | -1.94e-01 | 6.82e-01 | 7.07e-01 | 4.72e-01 | 9.10e-01 | 4.11e-01 |
| SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE SIGNAL SEQUENCE RECOGNITION | 6 | 9.81e-01 | 1.00e+00 | 0.29000 | 1.31e-01 | 1.35e-01 | 1.33e-01 | 1.39e-01 | 1.08e-01 | 5.78e-01 | 5.66e-01 | 5.73e-01 | 5.55e-01 | 6.46e-01 |
| SINGLE STRANDED VIRAL RNA REPLICATION VIA DOUBLE STRANDED DNA INTERMEDIATE | 20 | 2.16e-01 | 7.38e-01 | 0.29000 | -6.55e-02 | -7.14e-02 | 8.26e-02 | -1.58e-01 | 2.07e-01 | 6.12e-01 | 5.80e-01 | 5.23e-01 | 2.22e-01 | 1.08e-01 |
| NEGATIVE REGULATION OF MIRNA PROCESSING | 9 | 3.20e-02 | 2.81e-01 | 0.29000 | -1.22e-01 | -7.54e-02 | 7.55e-02 | -1.97e-01 | 1.38e-01 | 5.28e-01 | 6.95e-01 | 6.95e-01 | 3.07e-01 | 4.72e-01 |
| POSITIVE REGULATION OF MHC CLASS I BIOSYNTHETIC PROCESS | 6 | 5.71e-01 | 9.76e-01 | 0.29000 | -1.23e-01 | -6.09e-02 | -2.44e-01 | 7.46e-02 | -5.69e-03 | 6.02e-01 | 7.96e-01 | 3.01e-01 | 7.52e-01 | 9.81e-01 |
| CARDIOLIPIN BIOSYNTHETIC PROCESS | 7 | 5.20e-01 | 9.53e-01 | 0.29000 | 1.20e-01 | 1.33e-01 | 1.70e-01 | -4.62e-02 | 1.45e-01 | 5.83e-01 | 5.42e-01 | 4.37e-01 | 8.32e-01 | 5.06e-01 |
| L SERINE BIOSYNTHETIC PROCESS | 5 | 4.79e-01 | 9.41e-01 | 0.29000 | 1.44e-01 | 4.03e-02 | 2.17e-01 | 1.01e-01 | -6.71e-02 | 5.77e-01 | 8.76e-01 | 4.02e-01 | 6.97e-01 | 7.95e-01 |
| POSITIVE REGULATION OF CHROMOSOME SEGREGATION | 27 | 4.22e-01 | 9.12e-01 | 0.29000 | 1.35e-01 | 1.19e-01 | 2.02e-01 | 8.84e-02 | 5.47e-02 | 2.24e-01 | 2.85e-01 | 6.98e-02 | 4.27e-01 | 6.23e-01 |
| NEUROBLAST MIGRATION | 6 | 9.71e-01 | 1.00e+00 | 0.29000 | -1.32e-01 | -1.31e-01 | -1.07e-01 | -1.82e-01 | -6.88e-02 | 5.77e-01 | 5.79e-01 | 6.50e-01 | 4.39e-01 | 7.70e-01 |
| POSITIVE REGULATION OF CHEMOTAXIS | 140 | 8.31e-03 | 1.10e-01 | 0.29000 | -1.51e-01 | -1.69e-01 | -7.57e-02 | -1.51e-01 | 6.30e-02 | 2.01e-03 | 5.43e-04 | 1.22e-01 | 2.10e-03 | 1.98e-01 |
| REGULATION OF BILE ACID SECRETION | 6 | 9.36e-01 | 1.00e+00 | 0.29000 | 1.21e-01 | 1.36e-01 | 7.02e-02 | 5.76e-02 | -2.06e-01 | 6.07e-01 | 5.65e-01 | 7.66e-01 | 8.07e-01 | 3.82e-01 |
| REGULATION OF MALE GONAD DEVELOPMENT | 8 | 7.64e-01 | 1.00e+00 | 0.29000 | 1.48e-01 | 9.74e-02 | 1.83e-01 | 1.18e-01 | -7.17e-02 | 4.69e-01 | 6.33e-01 | 3.71e-01 | 5.62e-01 | 7.26e-01 |
| PTERIDINE CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 12 | 6.79e-02 | 4.27e-01 | 0.29000 | 1.60e-02 | -5.43e-02 | 1.11e-01 | -1.20e-01 | 2.32e-01 | 9.23e-01 | 7.45e-01 | 5.06e-01 | 4.71e-01 | 1.64e-01 |
| INFLAMMATORY CELL APOPTOTIC PROCESS | 24 | 2.63e-01 | 7.90e-01 | 0.28900 | -1.22e-01 | -1.53e-01 | 2.24e-02 | -2.09e-01 | 3.74e-02 | 3.02e-01 | 1.94e-01 | 8.50e-01 | 7.66e-02 | 7.51e-01 |
| DERMATAN SULFATE PROTEOGLYCAN METABOLIC PROCESS | 11 | 7.35e-01 | 1.00e+00 | 0.28900 | -1.39e-01 | -1.81e-01 | -5.29e-02 | -1.63e-01 | -4.88e-02 | 4.26e-01 | 2.98e-01 | 7.61e-01 | 3.49e-01 | 7.80e-01 |
| REGULATION OF LEUKOCYTE DEGRANULATION | 43 | 2.06e-03 | 3.98e-02 | 0.28900 | -7.85e-02 | -1.46e-01 | 1.06e-01 | -1.60e-01 | 1.39e-01 | 3.73e-01 | 9.79e-02 | 2.29e-01 | 6.92e-02 | 1.14e-01 |
| MITOTIC NUCLEAR DIVISION | 270 | 1.16e-07 | 1.04e-05 | 0.28900 | 1.35e-01 | 1.08e-01 | 2.07e-01 | 6.56e-02 | 8.14e-02 | 1.35e-04 | 2.20e-03 | 4.91e-09 | 6.33e-02 | 2.13e-02 |
| NEGATIVE REGULATION OF TRIGLYCERIDE METABOLIC PROCESS | 15 | 5.10e-01 | 9.50e-01 | 0.28900 | -1.25e-01 | -6.96e-02 | -2.34e-01 | -3.88e-02 | -8.32e-02 | 4.01e-01 | 6.41e-01 | 1.17e-01 | 7.95e-01 | 5.77e-01 |
| REGULATION OF REGULATORY NCRNA PROCESSING | 16 | 9.56e-03 | 1.22e-01 | 0.28900 | -1.17e-01 | -9.91e-02 | 7.67e-02 | -2.32e-01 | -2.29e-02 | 4.20e-01 | 4.92e-01 | 5.95e-01 | 1.09e-01 | 8.74e-01 |
| POSITIVE REGULATION OF ERAD PATHWAY | 13 | 8.52e-01 | 1.00e+00 | 0.28900 | 1.20e-01 | 1.10e-01 | 1.48e-01 | 1.34e-01 | 1.30e-01 | 4.55e-01 | 4.92e-01 | 3.54e-01 | 4.01e-01 | 4.17e-01 |
| SPLICEOSOMAL TRI SNRNP COMPLEX ASSEMBLY | 19 | 8.47e-01 | 1.00e+00 | 0.28900 | 1.30e-01 | 1.08e-01 | 1.66e-01 | 1.07e-01 | 1.26e-01 | 3.27e-01 | 4.17e-01 | 2.10e-01 | 4.19e-01 | 3.41e-01 |
| CD4 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 89 | 4.20e-04 | 1.14e-02 | 0.28900 | -1.34e-01 | -1.60e-01 | 7.25e-03 | -1.93e-01 | 5.01e-02 | 2.92e-02 | 9.17e-03 | 9.06e-01 | 1.60e-03 | 4.14e-01 |
| EMBRYONIC BRAIN DEVELOPMENT | 16 | 8.62e-01 | 1.00e+00 | 0.28900 | -1.30e-01 | -1.35e-01 | -1.25e-01 | -1.26e-01 | -1.28e-01 | 3.66e-01 | 3.49e-01 | 3.87e-01 | 3.81e-01 | 3.75e-01 |
| RELAXATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE | 6 | 8.50e-01 | 1.00e+00 | 0.28900 | 1.35e-01 | 1.01e-01 | 2.05e-01 | 5.62e-02 | -9.87e-02 | 5.67e-01 | 6.69e-01 | 3.85e-01 | 8.12e-01 | 6.75e-01 |
| GLYCOLYTIC PROCESS THROUGH GLUCOSE 6 PHOSPHATE | 19 | 7.99e-01 | 1.00e+00 | 0.28900 | 1.45e-01 | 1.22e-01 | 1.78e-01 | 1.21e-01 | 3.31e-02 | 2.73e-01 | 3.57e-01 | 1.80e-01 | 3.61e-01 | 8.03e-01 |
| REGULATION OF STEROL TRANSPORT | 80 | 1.81e-01 | 6.88e-01 | 0.28900 | 1.49e-01 | 1.61e-01 | 1.28e-01 | 1.37e-01 | 7.44e-03 | 2.12e-02 | 1.27e-02 | 4.82e-02 | 3.46e-02 | 9.08e-01 |
| REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT | 5 | 9.87e-01 | 1.00e+00 | 0.28800 | 1.39e-01 | 1.54e-01 | 1.10e-01 | 1.62e-01 | 4.30e-02 | 5.89e-01 | 5.51e-01 | 6.70e-01 | 5.32e-01 | 8.68e-01 |
| CELL CELL ADHESION INVOLVED IN GASTRULATION | 11 | 7.44e-01 | 1.00e+00 | 0.28800 | 1.13e-01 | 1.23e-01 | 1.80e-01 | 5.12e-02 | 1.42e-01 | 5.15e-01 | 4.81e-01 | 3.00e-01 | 7.69e-01 | 4.15e-01 |
| MUSCLE ADAPTATION | 117 | 1.27e-01 | 5.93e-01 | 0.28800 | 1.54e-01 | 1.52e-01 | 1.29e-01 | 1.40e-01 | -1.42e-02 | 4.09e-03 | 4.60e-03 | 1.61e-02 | 8.79e-03 | 7.91e-01 |
| CELLULAR RESPONSE TO LEPTIN STIMULUS | 17 | 8.25e-01 | 1.00e+00 | 0.28800 | -1.38e-01 | -1.60e-01 | -5.75e-02 | -1.77e-01 | 6.14e-02 | 3.23e-01 | 2.55e-01 | 6.82e-01 | 2.06e-01 | 6.61e-01 |
| POST EMBRYONIC ANIMAL MORPHOGENESIS | 16 | 7.88e-01 | 1.00e+00 | 0.28800 | -1.26e-01 | -9.45e-02 | -1.98e-01 | -5.44e-02 | -1.27e-01 | 3.84e-01 | 5.13e-01 | 1.71e-01 | 7.06e-01 | 3.80e-01 |
| MUSCLE CELL FATE COMMITMENT | 20 | 1.20e-02 | 1.43e-01 | 0.28800 | 4.33e-02 | -1.05e-02 | 1.45e-01 | -6.97e-02 | -2.34e-01 | 7.37e-01 | 9.35e-01 | 2.61e-01 | 5.89e-01 | 6.95e-02 |
| ANOIKIS | 33 | 7.23e-01 | 1.00e+00 | 0.28800 | 1.41e-01 | 1.34e-01 | 1.36e-01 | 1.45e-01 | 7.42e-02 | 1.62e-01 | 1.82e-01 | 1.75e-01 | 1.49e-01 | 4.61e-01 |
| VERY LOW DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 7 | 5.30e-01 | 9.54e-01 | 0.28800 | 9.68e-02 | 1.03e-01 | 2.05e-01 | -6.57e-02 | -1.28e-01 | 6.57e-01 | 6.38e-01 | 3.47e-01 | 7.63e-01 | 5.58e-01 |
| PEXOPHAGY | 6 | 6.77e-01 | 1.00e+00 | 0.28800 | -8.18e-03 | 3.79e-03 | 6.45e-02 | -1.49e-01 | -2.37e-01 | 9.72e-01 | 9.87e-01 | 7.85e-01 | 5.26e-01 | 3.15e-01 |
| NEURAL CREST CELL FATE COMMITMENT | 6 | 4.56e-01 | 9.32e-01 | 0.28800 | 5.75e-02 | -4.26e-03 | 2.18e-01 | -1.37e-01 | -1.16e-01 | 8.07e-01 | 9.86e-01 | 3.56e-01 | 5.62e-01 | 6.24e-01 |
| RIBONUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 28 | 6.66e-01 | 1.00e+00 | 0.28700 | 1.45e-01 | 1.60e-01 | 1.05e-01 | 1.21e-01 | -1.03e-01 | 1.85e-01 | 1.43e-01 | 3.37e-01 | 2.69e-01 | 3.47e-01 |
| CHROMOSOME MOVEMENT TOWARDS SPINDLE POLE | 7 | 7.90e-01 | 1.00e+00 | 0.28700 | -1.10e-01 | -1.05e-01 | 2.75e-02 | -1.69e-01 | 1.73e-01 | 6.13e-01 | 6.29e-01 | 9.00e-01 | 4.38e-01 | 4.28e-01 |
| SIRNA PROCESSING | 9 | 7.88e-01 | 1.00e+00 | 0.28700 | 1.38e-01 | 8.30e-02 | 2.26e-01 | 6.06e-02 | 4.75e-02 | 4.75e-01 | 6.66e-01 | 2.41e-01 | 7.53e-01 | 8.05e-01 |
| CELLULAR RESPONSE TO INDOLE 3 METHANOL | 5 | 3.80e-01 | 8.87e-01 | 0.28700 | -2.50e-03 | 7.54e-02 | -1.41e-01 | 2.08e-01 | -1.18e-01 | 9.92e-01 | 7.70e-01 | 5.86e-01 | 4.20e-01 | 6.49e-01 |
| IMMATURE B CELL DIFFERENTIATION | 12 | 6.18e-01 | 9.90e-01 | 0.28700 | -1.31e-01 | -1.81e-01 | 4.74e-03 | -1.76e-01 | 4.35e-02 | 4.33e-01 | 2.78e-01 | 9.77e-01 | 2.92e-01 | 7.94e-01 |
| REGULATION OF GTP BINDING | 11 | 7.98e-01 | 1.00e+00 | 0.28700 | -6.85e-02 | -4.58e-02 | -1.62e-01 | 3.59e-03 | -2.22e-01 | 6.94e-01 | 7.93e-01 | 3.51e-01 | 9.84e-01 | 2.02e-01 |
| METANEPHRIC NEPHRON TUBULE EPITHELIAL CELL DIFFERENTIATION | 6 | 9.09e-01 | 1.00e+00 | 0.28700 | 1.14e-01 | 9.78e-02 | 8.00e-02 | 1.02e-01 | -2.08e-01 | 6.28e-01 | 6.78e-01 | 7.35e-01 | 6.67e-01 | 3.78e-01 |
| SIGNAL PEPTIDE PROCESSING | 13 | 6.74e-01 | 1.00e+00 | 0.28700 | -1.31e-01 | -1.14e-01 | -8.37e-02 | -1.89e-01 | 9.70e-02 | 4.13e-01 | 4.76e-01 | 6.01e-01 | 2.37e-01 | 5.45e-01 |
| POSITIVE REGULATION OF BLOOD CIRCULATION | 38 | 5.45e-01 | 9.61e-01 | 0.28700 | 1.60e-01 | 1.41e-01 | 1.50e-01 | 1.19e-01 | -1.42e-02 | 8.71e-02 | 1.32e-01 | 1.10e-01 | 2.04e-01 | 8.79e-01 |
| MITOCHONDRIAL DNA REPAIR | 5 | 8.33e-01 | 1.00e+00 | 0.28700 | 8.26e-02 | 1.57e-03 | 1.85e-01 | 3.95e-02 | 1.99e-01 | 7.49e-01 | 9.95e-01 | 4.73e-01 | 8.79e-01 | 4.40e-01 |
| NEGATIVE REGULATION OF SCHWANN CELL PROLIFERATION | 8 | 9.28e-01 | 1.00e+00 | 0.28700 | -1.30e-01 | -1.39e-01 | -4.85e-02 | -2.06e-01 | 3.74e-02 | 5.23e-01 | 4.97e-01 | 8.12e-01 | 3.12e-01 | 8.55e-01 |
| REGULATION OF NUCLEAR DIVISION | 146 | 5.74e-04 | 1.44e-02 | 0.28700 | 1.33e-01 | 1.05e-01 | 2.04e-01 | 6.87e-02 | 8.56e-02 | 5.68e-03 | 2.86e-02 | 2.00e-05 | 1.52e-01 | 7.42e-02 |
| NEGATIVE REGULATION OF DNA REPLICATION | 24 | 1.24e-01 | 5.87e-01 | 0.28700 | 1.21e-01 | 1.35e-01 | 1.61e-01 | -5.83e-03 | -1.53e-01 | 3.07e-01 | 2.52e-01 | 1.71e-01 | 9.61e-01 | 1.94e-01 |
| NEGATIVE REGULATION OF NON CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 36 | 3.07e-01 | 8.35e-01 | 0.28700 | -1.39e-01 | -1.71e-01 | -7.84e-02 | -1.60e-01 | 4.47e-02 | 1.50e-01 | 7.50e-02 | 4.15e-01 | 9.73e-02 | 6.43e-01 |
| POSITIVE REGULATION OF OSTEOBLAST PROLIFERATION | 12 | 8.68e-01 | 1.00e+00 | 0.28700 | 1.34e-01 | 1.48e-01 | 7.82e-02 | 1.90e-01 | -1.34e-02 | 4.22e-01 | 3.76e-01 | 6.39e-01 | 2.54e-01 | 9.36e-01 |
| REGULATION OF MONOATOMIC ANION TRANSMEMBRANE TRANSPORT | 8 | 9.24e-01 | 1.00e+00 | 0.28700 | -1.03e-01 | -7.58e-02 | -1.88e-01 | -6.44e-02 | -1.63e-01 | 6.15e-01 | 7.10e-01 | 3.58e-01 | 7.53e-01 | 4.25e-01 |
| EXTRACELLULAR MATRIX CONSTITUENT SECRETION | 13 | 3.21e-01 | 8.47e-01 | 0.28600 | -2.65e-02 | -7.79e-02 | 1.55e-01 | -6.98e-02 | 2.15e-01 | 8.69e-01 | 6.27e-01 | 3.34e-01 | 6.63e-01 | 1.79e-01 |
| SKELETAL MUSCLE SATELLITE CELL DIFFERENTIATION | 9 | 3.01e-01 | 8.29e-01 | 0.28600 | 1.21e-01 | 1.23e-01 | 1.92e-01 | -8.33e-02 | 9.05e-02 | 5.29e-01 | 5.23e-01 | 3.18e-01 | 6.65e-01 | 6.38e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER INVOLVED IN CELLULAR RESPONSE TO CHEMICAL STIMULUS | 17 | 1.27e-01 | 5.93e-01 | 0.28600 | -1.63e-02 | -3.24e-02 | 1.72e-01 | -1.52e-01 | 1.67e-01 | 9.07e-01 | 8.17e-01 | 2.20e-01 | 2.78e-01 | 2.33e-01 |
| LEUKOCYTE PROLIFERATION | 334 | 1.68e-06 | 9.75e-05 | 0.28600 | -1.49e-01 | -1.59e-01 | -7.19e-02 | -1.65e-01 | 4.12e-02 | 2.72e-06 | 5.65e-07 | 2.39e-02 | 2.04e-07 | 1.96e-01 |
| ANTIMICROBIAL PEPTIDE PRODUCTION | 11 | 3.40e-01 | 8.59e-01 | 0.28600 | 9.71e-02 | 1.37e-01 | -1.03e-01 | 1.97e-01 | -6.73e-02 | 5.77e-01 | 4.33e-01 | 5.56e-01 | 2.59e-01 | 6.99e-01 |
| PIGMENT GRANULE ORGANIZATION | 37 | 3.57e-01 | 8.74e-01 | 0.28600 | -1.32e-01 | -1.50e-01 | -3.12e-02 | -1.88e-01 | 7.34e-02 | 1.66e-01 | 1.13e-01 | 7.42e-01 | 4.74e-02 | 4.40e-01 |
| REGULATION OF BIOLOGICAL PROCESS INVOLVED IN SYMBIOTIC INTERACTION | 64 | 1.33e-01 | 6.07e-01 | 0.28600 | -1.49e-01 | -1.51e-01 | -1.11e-01 | -9.80e-02 | 1.22e-01 | 3.99e-02 | 3.71e-02 | 1.23e-01 | 1.75e-01 | 9.03e-02 |
| BLOOD VESSEL REMODELING | 46 | 7.14e-02 | 4.39e-01 | 0.28600 | 1.28e-01 | 1.19e-01 | 1.32e-01 | 7.31e-02 | -1.69e-01 | 1.34e-01 | 1.64e-01 | 1.21e-01 | 3.91e-01 | 4.73e-02 |
| RESPONSE TO HYDROPEROXIDE | 18 | 8.63e-01 | 1.00e+00 | 0.28600 | -1.32e-01 | -1.27e-01 | -1.58e-01 | -9.51e-02 | -1.18e-01 | 3.31e-01 | 3.50e-01 | 2.45e-01 | 4.85e-01 | 3.87e-01 |
| NEGATIVE REGULATION BY HOST OF VIRAL TRANSCRIPTION | 14 | 6.35e-01 | 9.97e-01 | 0.28600 | -7.57e-02 | -1.11e-01 | 6.53e-02 | -1.46e-01 | 1.95e-01 | 6.24e-01 | 4.73e-01 | 6.72e-01 | 3.43e-01 | 2.07e-01 |
| NEURAL CREST FORMATION | 15 | 4.86e-01 | 9.43e-01 | 0.28600 | 1.45e-01 | 1.01e-01 | 1.97e-01 | 6.27e-02 | -8.82e-02 | 3.32e-01 | 4.98e-01 | 1.87e-01 | 6.74e-01 | 5.54e-01 |
| NEGATIVE REGULATION OF T CELL DIFFERENTIATION IN THYMUS | 10 | 8.15e-01 | 1.00e+00 | 0.28600 | 9.58e-02 | 1.35e-01 | 1.64e-02 | 7.42e-02 | -2.20e-01 | 6.00e-01 | 4.60e-01 | 9.29e-01 | 6.84e-01 | 2.29e-01 |
| PIGMENT GRANULE LOCALIZATION | 23 | 2.16e-01 | 7.38e-01 | 0.28500 | -6.40e-02 | -6.44e-02 | 4.85e-02 | -8.77e-02 | 2.51e-01 | 5.95e-01 | 5.93e-01 | 6.87e-01 | 4.66e-01 | 3.69e-02 |
| REGULATION OF TRANSFORMING GROWTH FACTOR BETA1 PRODUCTION | 12 | 7.05e-01 | 1.00e+00 | 0.28500 | 9.42e-02 | 1.37e-01 | -5.04e-02 | 1.57e-01 | -1.63e-01 | 5.72e-01 | 4.12e-01 | 7.63e-01 | 3.45e-01 | 3.29e-01 |
| RIBOSOME DISASSEMBLY | 12 | 8.16e-01 | 1.00e+00 | 0.28500 | 1.30e-01 | 8.22e-02 | 1.71e-01 | 1.01e-01 | 1.36e-01 | 4.37e-01 | 6.22e-01 | 3.05e-01 | 5.45e-01 | 4.16e-01 |
| DEDIFFERENTIATION | 11 | 6.10e-01 | 9.90e-01 | 0.28500 | 1.31e-01 | 1.34e-01 | 2.05e-01 | -1.54e-02 | 6.57e-02 | 4.54e-01 | 4.43e-01 | 2.40e-01 | 9.29e-01 | 7.06e-01 |
| MICROTUBULE ANCHORING | 23 | 6.33e-01 | 9.96e-01 | 0.28500 | -1.19e-01 | -1.02e-01 | -1.53e-01 | -6.92e-02 | -1.68e-01 | 3.22e-01 | 3.98e-01 | 2.03e-01 | 5.66e-01 | 1.62e-01 |
| POST GOLGI VESICLE MEDIATED TRANSPORT | 101 | 9.66e-02 | 5.12e-01 | 0.28500 | -1.50e-01 | -1.60e-01 | -8.47e-02 | -1.51e-01 | 5.41e-02 | 9.11e-03 | 5.44e-03 | 1.41e-01 | 8.52e-03 | 3.48e-01 |
| SOMATIC STEM CELL POPULATION MAINTENANCE | 65 | 1.52e-02 | 1.70e-01 | 0.28500 | 1.35e-01 | 1.12e-01 | 2.18e-01 | 4.91e-02 | 2.11e-02 | 6.05e-02 | 1.19e-01 | 2.32e-03 | 4.94e-01 | 7.69e-01 |
| POSITIVE REGULATION OF TELOMERE MAINTENANCE VIA TELOMERE LENGTHENING | 36 | 5.63e-01 | 9.71e-01 | 0.28500 | -1.42e-01 | -1.48e-01 | -8.23e-02 | -1.35e-01 | 1.18e-01 | 1.40e-01 | 1.23e-01 | 3.93e-01 | 1.62e-01 | 2.20e-01 |
| UREA METABOLIC PROCESS | 12 | 9.61e-01 | 1.00e+00 | 0.28500 | -1.44e-01 | -1.51e-01 | -1.17e-01 | -1.47e-01 | -4.48e-02 | 3.88e-01 | 3.64e-01 | 4.81e-01 | 3.77e-01 | 7.88e-01 |
| REGULATION OF MONOCYTE CHEMOTAXIS | 27 | 2.34e-01 | 7.56e-01 | 0.28500 | -1.16e-01 | -1.07e-01 | -1.14e-01 | -4.13e-02 | 2.04e-01 | 2.98e-01 | 3.36e-01 | 3.07e-01 | 7.10e-01 | 6.64e-02 |
| RESPONSE TO INACTIVITY | 12 | 5.08e-01 | 9.49e-01 | 0.28500 | 1.31e-01 | 1.46e-01 | 1.94e-01 | 4.44e-02 | -5.26e-02 | 4.32e-01 | 3.82e-01 | 2.44e-01 | 7.90e-01 | 7.52e-01 |
| NOTOCHORD MORPHOGENESIS | 8 | 4.70e-01 | 9.38e-01 | 0.28500 | 1.09e-01 | 1.38e-01 | 1.21e-01 | -6.90e-02 | -1.75e-01 | 5.93e-01 | 4.98e-01 | 5.55e-01 | 7.35e-01 | 3.92e-01 |
| REGULATION OF DNA STRAND ELONGATION | 17 | 4.45e-01 | 9.29e-01 | 0.28400 | -2.96e-03 | -3.73e-02 | 1.39e-01 | -5.36e-02 | 2.39e-01 | 9.83e-01 | 7.90e-01 | 3.21e-01 | 7.02e-01 | 8.74e-02 |
| CERAMIDE TRANSPORT | 17 | 5.03e-01 | 9.48e-01 | 0.28400 | 1.83e-02 | 5.27e-02 | -5.74e-02 | -1.10e-02 | -2.73e-01 | 8.96e-01 | 7.07e-01 | 6.82e-01 | 9.37e-01 | 5.16e-02 |
| ESTABLISHMENT OF GOLGI LOCALIZATION | 8 | 8.97e-01 | 1.00e+00 | 0.28400 | 8.72e-02 | 7.92e-02 | 1.28e-01 | 1.14e-01 | 1.94e-01 | 6.69e-01 | 6.98e-01 | 5.31e-01 | 5.77e-01 | 3.42e-01 |
| PROTEIN RNA COMPLEX ORGANIZATION | 205 | 1.38e-05 | 6.21e-04 | 0.28400 | 1.28e-01 | 1.01e-01 | 2.02e-01 | 5.58e-02 | 1.01e-01 | 1.59e-03 | 1.24e-02 | 5.98e-07 | 1.69e-01 | 1.25e-02 |
| MHC CLASS I BIOSYNTHETIC PROCESS | 8 | 5.46e-01 | 9.61e-01 | 0.28400 | -1.04e-01 | -6.90e-02 | -2.09e-01 | 5.39e-02 | 1.36e-01 | 6.11e-01 | 7.35e-01 | 3.05e-01 | 7.92e-01 | 5.05e-01 |
| NEGATIVE REGULATION OF PROTEIN MATURATION | 27 | 1.72e-01 | 6.75e-01 | 0.28400 | -1.30e-01 | -1.17e-01 | -2.38e-02 | -2.22e-01 | -1.54e-02 | 2.43e-01 | 2.94e-01 | 8.30e-01 | 4.54e-02 | 8.90e-01 |
| THIAMINE DIPHOSPHATE METABOLIC PROCESS | 5 | 9.77e-01 | 1.00e+00 | 0.28400 | 1.37e-01 | 1.06e-01 | 2.09e-01 | 5.59e-02 | 6.29e-02 | 5.96e-01 | 6.80e-01 | 4.19e-01 | 8.28e-01 | 8.08e-01 |
| NEUROTRANSMITTER RECEPTOR TRANSPORT | 25 | 6.58e-01 | 1.00e+00 | 0.28400 | 1.48e-01 | 1.55e-01 | 1.65e-01 | 8.03e-02 | 3.16e-02 | 2.02e-01 | 1.78e-01 | 1.53e-01 | 4.87e-01 | 7.84e-01 |
| CHROMOSOME CONDENSATION | 46 | 2.21e-01 | 7.44e-01 | 0.28400 | 1.19e-01 | 1.11e-01 | 1.81e-01 | 5.30e-02 | 1.37e-01 | 1.63e-01 | 1.92e-01 | 3.41e-02 | 5.34e-01 | 1.09e-01 |
| CERAMIDE CATABOLIC PROCESS | 20 | 4.29e-01 | 9.17e-01 | 0.28400 | -8.97e-03 | -2.24e-02 | 8.40e-02 | -2.46e-02 | 2.69e-01 | 9.45e-01 | 8.63e-01 | 5.16e-01 | 8.49e-01 | 3.73e-02 |
| TRNA TRANSPORT | 6 | 9.28e-01 | 1.00e+00 | 0.28400 | 3.30e-02 | 1.76e-02 | 1.10e-01 | 3.50e-02 | 2.57e-01 | 8.89e-01 | 9.40e-01 | 6.41e-01 | 8.82e-01 | 2.76e-01 |
| NEGATIVE REGULATION OF INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS | 9 | 3.39e-01 | 8.59e-01 | 0.28400 | 1.12e-01 | 6.06e-02 | 2.19e-01 | -8.12e-02 | 9.87e-02 | 5.59e-01 | 7.53e-01 | 2.56e-01 | 6.73e-01 | 6.08e-01 |
| POSITIVE REGULATION OF STORE OPERATED CALCIUM CHANNEL ACTIVITY | 5 | 8.74e-01 | 1.00e+00 | 0.28400 | -1.27e-01 | -1.80e-01 | 2.06e-04 | -1.76e-01 | -3.39e-02 | 6.23e-01 | 4.87e-01 | 9.99e-01 | 4.96e-01 | 8.96e-01 |
| ADHESION OF SYMBIONT TO HOST CELL | 8 | 4.24e-01 | 9.14e-01 | 0.28400 | 9.95e-02 | 9.26e-03 | 1.42e-01 | 1.25e-01 | 1.86e-01 | 6.26e-01 | 9.64e-01 | 4.86e-01 | 5.41e-01 | 3.61e-01 |
| PROTEIN HYDROXYLATION | 23 | 1.83e-01 | 6.93e-01 | 0.28400 | 1.46e-02 | -1.27e-02 | 1.66e-01 | -4.88e-02 | 2.24e-01 | 9.03e-01 | 9.16e-01 | 1.68e-01 | 6.85e-01 | 6.29e-02 |
| SYNAPSE MATURATION | 33 | 7.52e-01 | 1.00e+00 | 0.28400 | 1.54e-01 | 1.55e-01 | 1.35e-01 | 1.17e-01 | -2.90e-02 | 1.27e-01 | 1.23e-01 | 1.79e-01 | 2.46e-01 | 7.73e-01 |
| REGULATION OF SNARE COMPLEX ASSEMBLY | 14 | 7.68e-01 | 1.00e+00 | 0.28300 | -1.37e-01 | -1.48e-01 | -2.33e-02 | -1.63e-01 | 1.11e-01 | 3.73e-01 | 3.36e-01 | 8.80e-01 | 2.91e-01 | 4.73e-01 |
| MACROPHAGE ACTIVATION | 109 | 3.65e-05 | 1.47e-03 | 0.28300 | -1.42e-01 | -1.70e-01 | -1.07e-02 | -1.69e-01 | 4.79e-02 | 1.02e-02 | 2.13e-03 | 8.47e-01 | 2.27e-03 | 3.88e-01 |
| FATTY ACYL COA METABOLIC PROCESS | 37 | 2.73e-01 | 7.99e-01 | 0.28300 | 1.31e-01 | 1.25e-01 | 7.69e-02 | 2.04e-01 | 7.58e-03 | 1.67e-01 | 1.90e-01 | 4.19e-01 | 3.19e-02 | 9.36e-01 |
| AGGREPHAGY | 10 | 8.31e-01 | 1.00e+00 | 0.28300 | 9.26e-02 | 1.02e-01 | 2.12e-02 | 1.23e-01 | -2.14e-01 | 6.12e-01 | 5.75e-01 | 9.08e-01 | 5.02e-01 | 2.42e-01 |
| PEPTIDE ANTIGEN ASSEMBLY WITH MHC PROTEIN COMPLEX | 18 | 2.24e-01 | 7.45e-01 | 0.28300 | -1.46e-01 | -1.77e-01 | -2.74e-02 | -9.53e-02 | 1.32e-01 | 2.82e-01 | 1.93e-01 | 8.41e-01 | 4.84e-01 | 3.32e-01 |
| MITOCHONDRIAL ELECTRON TRANSPORT NADH TO UBIQUINONE | 43 | 4.88e-02 | 3.59e-01 | 0.28300 | 1.36e-01 | 1.38e-01 | 2.01e-01 | 7.94e-03 | 4.50e-02 | 1.22e-01 | 1.17e-01 | 2.25e-02 | 9.28e-01 | 6.09e-01 |
| POSITIVE REGULATION OF DNA REPLICATION | 37 | 4.95e-01 | 9.47e-01 | 0.28300 | 1.46e-01 | 1.55e-01 | 1.58e-01 | 9.15e-02 | 3.29e-02 | 1.23e-01 | 1.02e-01 | 9.63e-02 | 3.36e-01 | 7.29e-01 |
| RRNA 3 END PROCESSING | 10 | 9.40e-01 | 1.00e+00 | 0.28300 | 1.30e-01 | 1.14e-01 | 1.72e-01 | 6.64e-02 | 1.26e-01 | 4.77e-01 | 5.31e-01 | 3.45e-01 | 7.16e-01 | 4.89e-01 |
| RESPONSE TO INTERLEUKIN 17 | 17 | 4.83e-01 | 9.43e-01 | 0.28300 | -5.88e-02 | -8.81e-02 | 7.99e-02 | -9.34e-02 | 2.32e-01 | 6.75e-01 | 5.30e-01 | 5.68e-01 | 5.05e-01 | 9.82e-02 |
| NEGATIVE REGULATION OF ASTROCYTE ACTIVATION | 5 | 3.36e-01 | 8.59e-01 | 0.28300 | 1.06e-01 | 2.10e-01 | 3.10e-02 | -2.93e-02 | -1.51e-01 | 6.83e-01 | 4.16e-01 | 9.04e-01 | 9.10e-01 | 5.59e-01 |
| REGULATION OF RNA BINDING | 7 | 6.53e-01 | 1.00e+00 | 0.28300 | 5.02e-02 | 1.15e-01 | -7.14e-02 | 9.94e-04 | -2.43e-01 | 8.18e-01 | 5.99e-01 | 7.44e-01 | 9.96e-01 | 2.66e-01 |
| RESPONSE TO STEROL DEPLETION | 18 | 3.40e-01 | 8.59e-01 | 0.28300 | 6.89e-02 | 1.02e-02 | 1.62e-01 | 7.98e-02 | 2.06e-01 | 6.13e-01 | 9.40e-01 | 2.34e-01 | 5.58e-01 | 1.30e-01 |
| MODULATION OF PROCESS OF ANOTHER ORGANISM | 19 | 5.31e-01 | 9.54e-01 | 0.28200 | -1.37e-01 | -1.66e-01 | -1.23e-01 | -1.35e-01 | 6.03e-04 | 3.03e-01 | 2.09e-01 | 3.52e-01 | 3.09e-01 | 9.96e-01 |
| REGULATION OF CARDIAC MUSCLE CELL PROLIFERATION | 45 | 5.68e-03 | 8.35e-02 | 0.28200 | 5.86e-02 | 5.53e-02 | 5.70e-02 | -4.87e-02 | -2.60e-01 | 4.96e-01 | 5.21e-01 | 5.08e-01 | 5.72e-01 | 2.54e-03 |
| DNA STRAND ELONGATION INVOLVED IN DNA REPLICATION | 14 | 4.31e-01 | 9.18e-01 | 0.28200 | 8.46e-02 | 5.14e-02 | 2.29e-01 | -6.12e-02 | 1.18e-01 | 5.84e-01 | 7.39e-01 | 1.39e-01 | 6.92e-01 | 4.45e-01 |
| NEGATIVE REGULATION OF HIPPO SIGNALING | 12 | 3.20e-01 | 8.47e-01 | 0.28200 | 7.16e-03 | 7.15e-02 | -1.43e-01 | 1.47e-01 | -1.80e-01 | 9.66e-01 | 6.68e-01 | 3.91e-01 | 3.78e-01 | 2.80e-01 |
| INTERLEUKIN 1 PRODUCTION | 123 | 5.01e-03 | 7.72e-02 | 0.28200 | -1.40e-01 | -1.58e-01 | -4.01e-02 | -1.66e-01 | 7.66e-02 | 7.19e-03 | 2.45e-03 | 4.43e-01 | 1.50e-03 | 1.42e-01 |
| REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION INVOLVED IN ENDOCARDIAL CUSHION FORMATION | 6 | 9.02e-01 | 1.00e+00 | 0.28200 | -2.52e-02 | -3.58e-02 | 7.78e-02 | -4.09e-02 | 2.64e-01 | 9.15e-01 | 8.79e-01 | 7.41e-01 | 8.62e-01 | 2.62e-01 |
| POSITIVE REGULATION OF PROTEIN ACETYLATION | 24 | 6.03e-01 | 9.90e-01 | 0.28200 | 1.32e-01 | 1.22e-01 | 1.91e-01 | 4.55e-02 | 9.38e-02 | 2.63e-01 | 3.01e-01 | 1.06e-01 | 7.00e-01 | 4.26e-01 |
| SEMAPHORIN PLEXIN SIGNALING PATHWAY INVOLVED IN NEURON PROJECTION GUIDANCE | 14 | 5.98e-01 | 9.89e-01 | 0.28200 | 1.10e-01 | 1.40e-01 | -1.02e-03 | 2.17e-01 | -1.81e-02 | 4.75e-01 | 3.63e-01 | 9.95e-01 | 1.59e-01 | 9.07e-01 |
| RESPONSE TO OZONE | 5 | 4.43e-01 | 9.28e-01 | 0.28200 | 9.72e-02 | 9.91e-02 | 2.19e-01 | 9.84e-02 | 4.86e-02 | 7.07e-01 | 7.01e-01 | 3.95e-01 | 7.03e-01 | 8.51e-01 |
| REGULATION OF THYROID HORMONE GENERATION | 7 | 6.80e-01 | 1.00e+00 | 0.28200 | 5.75e-03 | -2.42e-02 | 1.80e-01 | -1.57e-01 | 1.47e-01 | 9.79e-01 | 9.12e-01 | 4.10e-01 | 4.71e-01 | 5.00e-01 |
| NEGATIVE REGULATION OF PROTEIN TARGETING TO MITOCHONDRION | 5 | 7.75e-01 | 1.00e+00 | 0.28200 | 1.13e-01 | 7.59e-02 | 1.46e-01 | 1.94e-01 | 4.60e-02 | 6.61e-01 | 7.69e-01 | 5.73e-01 | 4.53e-01 | 8.59e-01 |
| NEGATIVE REGULATION OF SPROUTING ANGIOGENESIS | 27 | 2.42e-01 | 7.68e-01 | 0.28200 | 1.06e-01 | 1.15e-01 | 8.13e-02 | 2.26e-02 | -2.19e-01 | 3.41e-01 | 3.03e-01 | 4.65e-01 | 8.39e-01 | 4.90e-02 |
| NUCLEOTIDE SUGAR METABOLIC PROCESS | 37 | 1.64e-01 | 6.64e-01 | 0.28200 | 1.47e-01 | 1.26e-01 | 2.00e-01 | 3.00e-02 | -3.06e-02 | 1.21e-01 | 1.85e-01 | 3.53e-02 | 7.52e-01 | 7.47e-01 |
| IMMUNE RESPONSE INHIBITING SIGNAL TRANSDUCTION | 11 | 2.72e-01 | 7.99e-01 | 0.28100 | -9.47e-02 | -1.56e-01 | -4.15e-02 | -1.02e-01 | -1.83e-01 | 5.87e-01 | 3.69e-01 | 8.12e-01 | 5.58e-01 | 2.93e-01 |
| POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL PROLIFERATION INVOLVED IN SPROUTING ANGIOGENESIS | 21 | 1.49e-01 | 6.38e-01 | 0.28100 | 1.17e-01 | 9.32e-02 | 3.75e-02 | 9.06e-02 | -2.17e-01 | 3.54e-01 | 4.60e-01 | 7.66e-01 | 4.73e-01 | 8.51e-02 |
| BLASTOCYST GROWTH | 22 | 2.21e-01 | 7.44e-01 | 0.28100 | -3.35e-02 | -4.05e-02 | -2.12e-02 | -1.16e-01 | -2.50e-01 | 7.85e-01 | 7.42e-01 | 8.63e-01 | 3.46e-01 | 4.27e-02 |
| POSITIVE REGULATION OF SMOOTH MUSCLE CELL DIFFERENTIATION | 20 | 3.85e-01 | 8.92e-01 | 0.28100 | 1.55e-01 | 1.00e-01 | 1.92e-01 | 8.98e-02 | 1.50e-02 | 2.31e-01 | 4.38e-01 | 1.38e-01 | 4.87e-01 | 9.07e-01 |
| MUSCLE HYPERTROPHY IN RESPONSE TO STRESS | 31 | 4.73e-01 | 9.40e-01 | 0.28100 | 1.57e-01 | 1.71e-01 | 8.87e-02 | 1.25e-01 | -3.87e-02 | 1.30e-01 | 9.96e-02 | 3.93e-01 | 2.27e-01 | 7.09e-01 |
| CEREBROSPINAL FLUID CIRCULATION | 15 | 3.30e-01 | 8.55e-01 | 0.28100 | -1.20e-01 | -1.11e-01 | -2.20e-01 | 5.08e-02 | -3.54e-02 | 4.20e-01 | 4.56e-01 | 1.41e-01 | 7.33e-01 | 8.13e-01 |
| NEGATIVE REGULATION OF LIPID TRANSPORT | 48 | 5.26e-01 | 9.54e-01 | 0.28100 | 1.49e-01 | 1.51e-01 | 1.28e-01 | 1.17e-01 | -6.22e-02 | 7.37e-02 | 7.11e-02 | 1.25e-01 | 1.60e-01 | 4.56e-01 |
| CYSTEINE METABOLIC PROCESS | 11 | 5.62e-01 | 9.71e-01 | 0.28100 | 3.14e-02 | 5.00e-02 | -8.13e-02 | 1.45e-01 | -2.19e-01 | 8.57e-01 | 7.74e-01 | 6.41e-01 | 4.06e-01 | 2.09e-01 |
| POSITIVE REGULATION OF CELLULAR EXTRAVASATION | 15 | 2.67e-01 | 7.95e-01 | 0.28100 | -4.35e-02 | -1.12e-01 | 3.45e-02 | 2.05e-03 | 2.52e-01 | 7.71e-01 | 4.53e-01 | 8.17e-01 | 9.89e-01 | 9.16e-02 |
| TRICARBOXYLIC ACID CYCLE | 29 | 8.43e-02 | 4.78e-01 | 0.28100 | 1.16e-01 | 9.41e-02 | 2.20e-01 | -4.26e-02 | 8.06e-02 | 2.79e-01 | 3.80e-01 | 4.06e-02 | 6.92e-01 | 4.52e-01 |
| POSITIVE REGULATION OF RNA EXPORT FROM NUCLEUS | 5 | 6.17e-01 | 9.90e-01 | 0.28100 | 6.50e-02 | 1.01e-03 | 1.57e-01 | 1.49e-01 | 1.67e-01 | 8.01e-01 | 9.97e-01 | 5.43e-01 | 5.64e-01 | 5.18e-01 |
| POSITIVE REGULATION OF CILIUM ASSEMBLY | 28 | 2.06e-01 | 7.27e-01 | 0.28100 | 6.45e-02 | 2.55e-02 | 1.79e-01 | 3.92e-02 | 2.01e-01 | 5.55e-01 | 8.15e-01 | 1.01e-01 | 7.19e-01 | 6.54e-02 |
| ISOPRENOID TRANSPORT | 5 | 9.23e-01 | 1.00e+00 | 0.28100 | -1.13e-01 | -8.20e-02 | -1.90e-01 | -1.15e-01 | -9.89e-02 | 6.61e-01 | 7.51e-01 | 4.62e-01 | 6.56e-01 | 7.02e-01 |
| PROTEIN FOLDING | 209 | 1.14e-05 | 5.27e-04 | 0.28000 | 1.38e-01 | 1.12e-01 | 2.00e-01 | 5.17e-02 | 6.67e-02 | 5.76e-04 | 5.40e-03 | 6.23e-07 | 1.97e-01 | 9.63e-02 |
| REGULATION OF SISTER CHROMATID SEGREGATION | 104 | 1.88e-02 | 1.99e-01 | 0.28000 | 1.33e-01 | 1.29e-01 | 1.81e-01 | 7.13e-02 | 7.96e-02 | 1.90e-02 | 2.31e-02 | 1.41e-03 | 2.09e-01 | 1.61e-01 |
| G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY COUPLED TO CYCLIC NUCLEOTIDE SECOND MESSENGER | 54 | 2.19e-02 | 2.21e-01 | 0.28000 | 2.10e-02 | 4.95e-02 | -8.81e-02 | 8.39e-02 | -2.47e-01 | 7.89e-01 | 5.29e-01 | 2.63e-01 | 2.86e-01 | 1.71e-03 |
| NEGATIVE REGULATION OF MACROPHAGE DIFFERENTIATION | 8 | 8.46e-01 | 1.00e+00 | 0.28000 | 4.24e-02 | 6.96e-02 | -6.20e-02 | 1.08e-01 | -2.37e-01 | 8.35e-01 | 7.33e-01 | 7.61e-01 | 5.96e-01 | 2.45e-01 |
| GLYCEROLIPID CATABOLIC PROCESS | 64 | 2.73e-01 | 7.99e-01 | 0.28000 | 1.49e-01 | 1.67e-01 | 9.41e-02 | 1.37e-01 | -2.45e-02 | 3.94e-02 | 2.05e-02 | 1.93e-01 | 5.80e-02 | 7.35e-01 |
| POSITIVE REGULATION OF LEUKOCYTE MIGRATION | 142 | 1.50e-03 | 3.15e-02 | 0.28000 | -1.53e-01 | -1.74e-01 | -8.49e-02 | -1.25e-01 | 4.38e-02 | 1.63e-03 | 3.53e-04 | 8.06e-02 | 9.98e-03 | 3.68e-01 |
| 2FE 2S CLUSTER ASSEMBLY | 9 | 5.13e-01 | 9.52e-01 | 0.28000 | 9.62e-02 | 7.64e-02 | 2.25e-01 | -9.59e-02 | 5.87e-02 | 6.17e-01 | 6.92e-01 | 2.42e-01 | 6.18e-01 | 7.60e-01 |
| INTRACELLULAR WATER HOMEOSTASIS | 6 | 9.70e-01 | 1.00e+00 | 0.28000 | 1.34e-01 | 1.26e-01 | 7.11e-02 | 1.42e-01 | -1.39e-01 | 5.69e-01 | 5.92e-01 | 7.63e-01 | 5.48e-01 | 5.56e-01 |
| CALCIUM ION IMPORT ACROSS PLASMA MEMBRANE | 52 | 4.79e-02 | 3.56e-01 | 0.28000 | 7.69e-02 | 9.51e-02 | -3.03e-02 | 1.34e-01 | -2.11e-01 | 3.37e-01 | 2.35e-01 | 7.05e-01 | 9.38e-02 | 8.58e-03 |
| HEMOGLOBIN BIOSYNTHETIC PROCESS | 13 | 5.11e-01 | 9.50e-01 | 0.28000 | 7.05e-02 | 7.45e-02 | 1.75e-01 | 8.25e-03 | 1.92e-01 | 6.60e-01 | 6.42e-01 | 2.74e-01 | 9.59e-01 | 2.30e-01 |
| PROTEIN TRANSPORT WITHIN LIPID BILAYER | 6 | 4.17e-01 | 9.11e-01 | 0.28000 | -6.88e-04 | -1.08e-02 | 4.28e-02 | -2.12e-01 | -1.77e-01 | 9.98e-01 | 9.64e-01 | 8.56e-01 | 3.69e-01 | 4.52e-01 |
| TRANSFORMING GROWTH FACTOR BETA ACTIVATION | 13 | 2.26e-01 | 7.48e-01 | 0.27900 | 9.05e-02 | 1.53e-01 | 6.84e-02 | 4.01e-02 | -2.00e-01 | 5.72e-01 | 3.39e-01 | 6.69e-01 | 8.02e-01 | 2.12e-01 |
| REGULATION OF T HELPER 1 CELL DIFFERENTIATION | 11 | 2.44e-01 | 7.70e-01 | 0.27900 | -2.76e-02 | -8.43e-02 | 1.82e-01 | -1.84e-01 | 5.29e-02 | 8.74e-01 | 6.28e-01 | 2.95e-01 | 2.91e-01 | 7.61e-01 |
| POSITIVE REGULATION OF MEIOTIC NUCLEAR DIVISION | 17 | 2.77e-01 | 8.04e-01 | 0.27900 | 1.84e-02 | -4.37e-02 | 1.17e-01 | -4.24e-02 | 2.45e-01 | 8.95e-01 | 7.55e-01 | 4.03e-01 | 7.62e-01 | 8.04e-02 |
| NEGATIVE REGULATION OF CELL SIZE | 9 | 4.47e-01 | 9.30e-01 | 0.27900 | 1.19e-01 | 1.99e-01 | -2.03e-02 | 1.50e-01 | -3.12e-02 | 5.35e-01 | 3.01e-01 | 9.16e-01 | 4.36e-01 | 8.71e-01 |
| NEGATIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 80 | 5.50e-02 | 3.84e-01 | 0.27900 | -1.54e-01 | -1.64e-01 | -7.81e-02 | -1.40e-01 | 3.55e-02 | 1.72e-02 | 1.12e-02 | 2.27e-01 | 3.02e-02 | 5.83e-01 |
| POSITIVE REGULATION OF LEUKOCYTE CHEMOTAXIS | 93 | 4.95e-02 | 3.61e-01 | 0.27900 | -1.49e-01 | -1.71e-01 | -8.35e-02 | -1.29e-01 | 5.10e-02 | 1.32e-02 | 4.36e-03 | 1.64e-01 | 3.14e-02 | 3.95e-01 |
| ATP BIOSYNTHETIC PROCESS | 89 | 2.25e-03 | 4.20e-02 | 0.27900 | 1.16e-01 | 9.01e-02 | 2.05e-01 | 3.65e-03 | 1.19e-01 | 5.93e-02 | 1.42e-01 | 8.48e-04 | 9.52e-01 | 5.20e-02 |
| POSITIVE REGULATION OF DNA RECOMBINATION | 67 | 3.27e-03 | 5.56e-02 | 0.27800 | -2.19e-02 | -4.38e-02 | 1.02e-01 | -1.06e-01 | 2.32e-01 | 7.56e-01 | 5.36e-01 | 1.50e-01 | 1.35e-01 | 1.04e-03 |
| MISMATCH REPAIR | 34 | 2.51e-01 | 7.77e-01 | 0.27800 | -1.25e-01 | -1.32e-01 | -1.05e-02 | -2.02e-01 | 5.93e-02 | 2.09e-01 | 1.83e-01 | 9.16e-01 | 4.12e-02 | 5.49e-01 |
| CHOLESTEROL EFFLUX | 73 | 1.92e-01 | 7.03e-01 | 0.27800 | 1.37e-01 | 1.49e-01 | 1.25e-01 | 1.30e-01 | 6.09e-02 | 4.24e-02 | 2.74e-02 | 6.49e-02 | 5.49e-02 | 3.68e-01 |
| NEGATIVE REGULATION OF CHOLESTEROL EFFLUX | 22 | 8.61e-01 | 1.00e+00 | 0.27800 | 1.49e-01 | 1.38e-01 | 1.44e-01 | 1.17e-01 | -3.72e-02 | 2.25e-01 | 2.62e-01 | 2.42e-01 | 3.41e-01 | 7.63e-01 |
| T HELPER 17 CELL DIFFERENTIATION | 32 | 6.55e-01 | 1.00e+00 | 0.27800 | -1.43e-01 | -1.54e-01 | -6.43e-02 | -1.61e-01 | 5.31e-02 | 1.61e-01 | 1.31e-01 | 5.29e-01 | 1.14e-01 | 6.03e-01 |
| FORMATION OF EXTRACHROMOSOMAL CIRCULAR DNA | 13 | 6.93e-01 | 1.00e+00 | 0.27800 | -1.32e-02 | -2.97e-02 | 7.41e-02 | -1.12e-02 | 2.66e-01 | 9.34e-01 | 8.53e-01 | 6.44e-01 | 9.44e-01 | 9.74e-02 |
| REGULATION OF MICROGLIAL CELL ACTIVATION | 20 | 1.61e-01 | 6.59e-01 | 0.27800 | -1.50e-01 | -1.88e-01 | -5.86e-02 | -1.15e-01 | -5.12e-02 | 2.45e-01 | 1.46e-01 | 6.50e-01 | 3.74e-01 | 6.92e-01 |
| MEMBRANE DEPOLARIZATION DURING ACTION POTENTIAL | 28 | 4.20e-01 | 9.11e-01 | 0.27700 | 1.11e-01 | 1.42e-01 | 3.60e-03 | 1.71e-01 | -1.24e-01 | 3.08e-01 | 1.95e-01 | 9.74e-01 | 1.18e-01 | 2.56e-01 |
| REGULATION OF CHEMOTAXIS | 221 | 2.07e-03 | 3.98e-02 | 0.27700 | -1.46e-01 | -1.61e-01 | -9.27e-02 | -1.44e-01 | 2.59e-02 | 1.87e-04 | 3.86e-05 | 1.75e-02 | 2.32e-04 | 5.06e-01 |
| POSITIVE REGULATION OF CENTRIOLE ELONGATION | 5 | 7.92e-01 | 1.00e+00 | 0.27700 | -1.08e-01 | -1.57e-01 | 7.00e-02 | -1.29e-01 | 1.38e-01 | 6.76e-01 | 5.44e-01 | 7.86e-01 | 6.18e-01 | 5.94e-01 |
| NEGATIVE REGULATION OF ATP DEPENDENT ACTIVITY | 17 | 5.38e-01 | 9.57e-01 | 0.27700 | 6.35e-02 | 3.95e-02 | 1.30e-01 | -2.53e-03 | 2.33e-01 | 6.50e-01 | 7.78e-01 | 3.52e-01 | 9.86e-01 | 9.69e-02 |
| NEGATIVE REGULATION OF MUSCLE CELL APOPTOTIC PROCESS | 50 | 3.04e-01 | 8.32e-01 | 0.27700 | 1.44e-01 | 1.56e-01 | 1.25e-01 | 8.99e-02 | -8.69e-02 | 7.78e-02 | 5.58e-02 | 1.25e-01 | 2.71e-01 | 2.88e-01 |
| REGULATION OF ACUTE INFLAMMATORY RESPONSE | 48 | 1.08e-02 | 1.33e-01 | 0.27700 | -1.31e-01 | -1.79e-01 | -6.57e-03 | -1.13e-01 | 1.21e-01 | 1.16e-01 | 3.21e-02 | 9.37e-01 | 1.75e-01 | 1.47e-01 |
| ATRIAL CARDIAC MUSCLE TISSUE DEVELOPMENT | 21 | 1.78e-01 | 6.85e-01 | 0.27700 | 9.96e-02 | 9.43e-02 | 1.52e-01 | -2.04e-02 | -1.85e-01 | 4.30e-01 | 4.54e-01 | 2.27e-01 | 8.71e-01 | 1.42e-01 |
| REGULATION OF DEFENSE RESPONSE TO VIRUS BY HOST | 43 | 4.59e-02 | 3.48e-01 | 0.27700 | -1.51e-01 | -1.51e-01 | -4.25e-02 | -1.70e-01 | 1.04e-02 | 8.57e-02 | 8.68e-02 | 6.30e-01 | 5.35e-02 | 9.06e-01 |
| POSITIVE REGULATION OF PROTEIN POLYUBIQUITINATION | 15 | 6.63e-01 | 1.00e+00 | 0.27700 | -1.22e-01 | -1.65e-01 | -3.69e-02 | -9.31e-02 | 1.57e-01 | 4.15e-01 | 2.69e-01 | 8.05e-01 | 5.33e-01 | 2.92e-01 |
| TRANSCRIPTION COUPLED NUCLEOTIDE EXCISION REPAIR | 10 | 7.83e-01 | 1.00e+00 | 0.27600 | 8.59e-02 | 3.90e-02 | 1.49e-01 | 1.10e-01 | 1.82e-01 | 6.38e-01 | 8.31e-01 | 4.15e-01 | 5.46e-01 | 3.18e-01 |
| MITOTIC SISTER CHROMATID SEPARATION | 62 | 4.10e-02 | 3.25e-01 | 0.27600 | 1.28e-01 | 1.14e-01 | 2.07e-01 | 3.69e-02 | 4.98e-02 | 8.04e-02 | 1.19e-01 | 4.76e-03 | 6.16e-01 | 4.98e-01 |
| REGULATION OF GLOMERULAR FILTRATION | 8 | 8.61e-01 | 1.00e+00 | 0.27600 | 3.91e-02 | 2.27e-02 | 5.64e-02 | 9.70e-02 | 2.48e-01 | 8.48e-01 | 9.12e-01 | 7.82e-01 | 6.35e-01 | 2.24e-01 |
| CHROMOSOME LOCALIZATION | 117 | 5.02e-03 | 7.73e-02 | 0.27600 | 1.06e-01 | 8.21e-02 | 1.81e-01 | 6.27e-02 | 1.47e-01 | 4.73e-02 | 1.25e-01 | 7.21e-04 | 2.41e-01 | 6.08e-03 |
| EXOCRINE SYSTEM DEVELOPMENT | 45 | 1.00e-01 | 5.23e-01 | 0.27600 | 1.26e-01 | 1.68e-01 | 5.69e-02 | 1.45e-01 | -9.09e-02 | 1.45e-01 | 5.19e-02 | 5.09e-01 | 9.33e-02 | 2.91e-01 |
| MYELOID LEUKOCYTE ACTIVATION | 236 | 1.19e-09 | 1.79e-07 | 0.27600 | -1.30e-01 | -1.63e-01 | -3.14e-03 | -1.52e-01 | 9.62e-02 | 5.71e-04 | 1.52e-05 | 9.34e-01 | 5.44e-05 | 1.09e-02 |
| POSITIVE REGULATION OF ATTACHMENT OF SPINDLE MICROTUBULES TO KINETOCHORE | 11 | 5.92e-01 | 9.86e-01 | 0.27600 | 8.99e-02 | 5.09e-02 | 1.99e-01 | 7.90e-02 | 1.40e-01 | 6.06e-01 | 7.70e-01 | 2.52e-01 | 6.50e-01 | 4.22e-01 |
| PEPTIDYL SERINE AUTOPHOSPHORYLATION | 8 | 8.40e-01 | 1.00e+00 | 0.27600 | -1.24e-01 | -1.64e-01 | -8.40e-02 | -1.33e-01 | 9.49e-02 | 5.43e-01 | 4.22e-01 | 6.81e-01 | 5.14e-01 | 6.42e-01 |
| REGULATION OF ORGANELLE TRANSPORT ALONG MICROTUBULE | 9 | 8.60e-01 | 1.00e+00 | 0.27600 | 7.62e-02 | 7.18e-02 | 1.55e-01 | 1.19e-02 | 2.02e-01 | 6.92e-01 | 7.09e-01 | 4.20e-01 | 9.51e-01 | 2.93e-01 |
| INTERLEUKIN 2 PRODUCTION | 60 | 4.08e-02 | 3.25e-01 | 0.27600 | -1.32e-01 | -1.61e-01 | -2.05e-02 | -1.31e-01 | 1.22e-01 | 7.59e-02 | 3.05e-02 | 7.84e-01 | 7.95e-02 | 1.02e-01 |
| REGULATION OF HIPPOCAMPAL NEURON APOPTOTIC PROCESS | 5 | 9.97e-01 | 1.00e+00 | 0.27600 | -1.45e-01 | -1.45e-01 | -1.20e-01 | -1.35e-01 | -3.82e-02 | 5.74e-01 | 5.75e-01 | 6.43e-01 | 6.02e-01 | 8.82e-01 |
| DEOXYRIBONUCLEOSIDE CATABOLIC PROCESS | 6 | 9.52e-01 | 1.00e+00 | 0.27600 | -1.52e-01 | -1.38e-01 | -1.10e-01 | -1.27e-01 | -7.30e-02 | 5.19e-01 | 5.59e-01 | 6.40e-01 | 5.89e-01 | 7.57e-01 |
| GANGLION DEVELOPMENT | 17 | 1.59e-01 | 6.59e-01 | 0.27500 | -1.35e-02 | -9.06e-03 | 3.29e-02 | -1.70e-01 | -2.14e-01 | 9.23e-01 | 9.48e-01 | 8.15e-01 | 2.25e-01 | 1.27e-01 |
| INTERLEUKIN 17A MEDIATED SIGNALING PATHWAY | 6 | 7.16e-01 | 1.00e+00 | 0.27500 | 1.91e-02 | -5.96e-02 | 1.23e-01 | 4.99e-02 | 2.33e-01 | 9.35e-01 | 8.00e-01 | 6.02e-01 | 8.32e-01 | 3.23e-01 |
| RESPONSE TO MISFOLDED PROTEIN | 23 | 1.63e-01 | 6.63e-01 | 0.27500 | 9.01e-02 | 3.04e-02 | 2.21e-01 | -3.14e-02 | 1.30e-01 | 4.54e-01 | 8.01e-01 | 6.66e-02 | 7.94e-01 | 2.79e-01 |
| MITOCHONDRIAL TRANSMEMBRANE TRANSPORT | 59 | 1.27e-02 | 1.48e-01 | 0.27500 | -5.58e-03 | -2.77e-02 | 1.14e-01 | -7.81e-02 | 2.36e-01 | 9.41e-01 | 7.13e-01 | 1.29e-01 | 2.99e-01 | 1.70e-03 |
| MRNA PSEUDOURIDINE SYNTHESIS | 8 | 3.80e-01 | 8.88e-01 | 0.27500 | 1.84e-02 | 7.40e-03 | 1.52e-01 | -1.93e-01 | -1.22e-01 | 9.28e-01 | 9.71e-01 | 4.56e-01 | 3.43e-01 | 5.52e-01 |
| TRYPTOPHAN METABOLIC PROCESS | 10 | 9.45e-01 | 1.00e+00 | 0.27500 | -1.32e-01 | -1.29e-01 | -1.10e-01 | -1.24e-01 | -1.19e-01 | 4.70e-01 | 4.79e-01 | 5.48e-01 | 4.98e-01 | 5.13e-01 |
| EMBRYONIC SKELETAL SYSTEM MORPHOGENESIS | 93 | 4.62e-02 | 3.48e-01 | 0.27500 | 1.49e-01 | 1.34e-01 | 1.50e-01 | 9.08e-02 | -6.82e-02 | 1.28e-02 | 2.59e-02 | 1.23e-02 | 1.30e-01 | 2.56e-01 |
| DETECTION OF TEMPERATURE STIMULUS INVOLVED IN SENSORY PERCEPTION OF PAIN | 17 | 9.11e-01 | 1.00e+00 | 0.27500 | 1.43e-01 | 1.32e-01 | 1.52e-01 | 1.21e-01 | -1.40e-03 | 3.09e-01 | 3.45e-01 | 2.78e-01 | 3.87e-01 | 9.92e-01 |
| LATE NUCLEOPHAGY | 8 | 9.74e-01 | 1.00e+00 | 0.27500 | 1.36e-01 | 1.35e-01 | 8.13e-02 | 1.78e-01 | -1.70e-02 | 5.05e-01 | 5.08e-01 | 6.90e-01 | 3.82e-01 | 9.34e-01 |
| NEGATIVE REGULATION OF ENDOPLASMIC RETICULUM STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 19 | 2.24e-01 | 7.45e-01 | 0.27500 | 1.13e-01 | 1.27e-01 | 2.05e-01 | -3.35e-03 | 6.59e-02 | 3.93e-01 | 3.38e-01 | 1.21e-01 | 9.80e-01 | 6.19e-01 |
| ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS BY CYTOCHROME C | 6 | 5.86e-01 | 9.85e-01 | 0.27500 | 1.23e-01 | 1.47e-01 | 1.68e-01 | -7.72e-02 | -6.66e-02 | 6.01e-01 | 5.34e-01 | 4.75e-01 | 7.43e-01 | 7.78e-01 |
| REGULATION OF FATTY ACID OXIDATION | 33 | 6.52e-01 | 1.00e+00 | 0.27400 | 1.36e-01 | 1.46e-01 | 9.13e-02 | 1.29e-01 | -1.03e-01 | 1.77e-01 | 1.46e-01 | 3.64e-01 | 2.01e-01 | 3.07e-01 |
| POSITIVE REGULATION OF PHAGOCYTOSIS | 68 | 3.75e-02 | 3.09e-01 | 0.27400 | -1.26e-01 | -1.62e-01 | -4.31e-02 | -1.06e-01 | 1.41e-01 | 7.29e-02 | 2.05e-02 | 5.38e-01 | 1.29e-01 | 4.45e-02 |
| GRANULOCYTE MIGRATION | 148 | 6.02e-03 | 8.76e-02 | 0.27400 | -1.49e-01 | -1.64e-01 | -1.12e-01 | -1.02e-01 | 5.73e-02 | 1.80e-03 | 5.71e-04 | 1.85e-02 | 3.24e-02 | 2.29e-01 |
| REGULATION OF HEART RATE BY CHEMICAL SIGNAL | 7 | 8.37e-01 | 1.00e+00 | 0.27400 | 9.62e-02 | 1.18e-01 | 1.64e-02 | 2.13e-01 | 8.09e-02 | 6.59e-01 | 5.89e-01 | 9.40e-01 | 3.30e-01 | 7.11e-01 |
| IMP CATABOLIC PROCESS | 5 | 8.17e-01 | 1.00e+00 | 0.27400 | -1.17e-02 | -3.47e-02 | 1.71e-01 | -1.20e-01 | 1.73e-01 | 9.64e-01 | 8.93e-01 | 5.07e-01 | 6.43e-01 | 5.02e-01 |
| POSITIVE REGULATION OF NEUROTRANSMITTER UPTAKE | 6 | 2.14e-01 | 7.37e-01 | 0.27400 | -5.18e-02 | -8.49e-02 | -1.41e-01 | 2.04e-01 | -6.26e-02 | 8.26e-01 | 7.19e-01 | 5.50e-01 | 3.88e-01 | 7.91e-01 |
| HEART VALVE FORMATION | 15 | 1.70e-01 | 6.74e-01 | 0.27400 | 1.13e-01 | 7.85e-02 | 1.95e-01 | -7.12e-02 | -1.14e-01 | 4.49e-01 | 5.99e-01 | 1.91e-01 | 6.33e-01 | 4.44e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE MIGRATION | 53 | 2.12e-01 | 7.34e-01 | 0.27400 | -1.32e-01 | -1.36e-01 | -1.59e-01 | -1.06e-01 | -5.05e-02 | 9.65e-02 | 8.57e-02 | 4.55e-02 | 1.81e-01 | 5.25e-01 |
| CELLULAR RESPONSE TO NITROGEN STARVATION | 12 | 3.39e-01 | 8.59e-01 | 0.27400 | -2.21e-02 | -7.29e-02 | 2.92e-02 | 8.54e-02 | 2.47e-01 | 8.94e-01 | 6.62e-01 | 8.61e-01 | 6.09e-01 | 1.38e-01 |
| REGULATION OF RETINOIC ACID RECEPTOR SIGNALING PATHWAY | 16 | 5.55e-01 | 9.67e-01 | 0.27400 | -7.72e-02 | -6.16e-02 | -4.87e-02 | -1.38e-01 | -2.09e-01 | 5.93e-01 | 6.70e-01 | 7.36e-01 | 3.40e-01 | 1.47e-01 |
| MITOCHONDRIAL ELECTRON TRANSPORT CYTOCHROME C TO OXYGEN | 19 | 2.86e-01 | 8.12e-01 | 0.27400 | 1.14e-01 | 7.85e-02 | 2.27e-01 | -3.83e-02 | 5.10e-02 | 3.89e-01 | 5.54e-01 | 8.62e-02 | 7.72e-01 | 7.00e-01 |
| ACETYLCHOLINE SECRETION | 5 | 9.53e-01 | 1.00e+00 | 0.27400 | 1.40e-01 | 1.78e-01 | 1.18e-01 | 9.67e-02 | 2.25e-02 | 5.87e-01 | 4.92e-01 | 6.48e-01 | 7.08e-01 | 9.30e-01 |
| AV NODE CELL TO BUNDLE OF HIS CELL SIGNALING | 11 | 6.89e-01 | 1.00e+00 | 0.27400 | 9.65e-02 | 1.24e-01 | -7.63e-03 | 2.04e-01 | -9.14e-02 | 5.79e-01 | 4.77e-01 | 9.65e-01 | 2.41e-01 | 6.00e-01 |
| NEGATIVE REGULATION OF VITAMIN D BIOSYNTHETIC PROCESS | 5 | 9.75e-01 | 1.00e+00 | 0.27300 | -1.26e-01 | -1.17e-01 | -6.66e-02 | -1.60e-01 | 1.23e-01 | 6.25e-01 | 6.51e-01 | 7.96e-01 | 5.35e-01 | 6.35e-01 |
| REGULATION OF CELL GROWTH INVOLVED IN CARDIAC MUSCLE CELL DEVELOPMENT | 19 | 3.99e-01 | 8.98e-01 | 0.27300 | 1.25e-01 | 1.10e-01 | 2.05e-01 | 6.98e-02 | 3.28e-03 | 3.45e-01 | 4.07e-01 | 1.22e-01 | 5.98e-01 | 9.80e-01 |
| MITOTIC SISTER CHROMATID SEGREGATION | 180 | 9.93e-06 | 4.75e-04 | 0.27300 | 1.03e-01 | 7.29e-02 | 1.97e-01 | 3.39e-02 | 1.37e-01 | 1.73e-02 | 9.17e-02 | 4.88e-06 | 4.33e-01 | 1.54e-03 |
| RESPONSE TO COCAINE | 47 | 3.68e-01 | 8.79e-01 | 0.27300 | 1.40e-01 | 1.12e-01 | 1.72e-01 | 1.09e-01 | 2.84e-02 | 9.59e-02 | 1.83e-01 | 4.11e-02 | 1.94e-01 | 7.36e-01 |
| MEIOTIC CELL CYCLE PROCESS INVOLVED IN OOCYTE MATURATION | 6 | 9.29e-01 | 1.00e+00 | 0.27300 | 9.56e-02 | 1.08e-01 | 4.35e-02 | 3.40e-02 | -2.26e-01 | 6.85e-01 | 6.47e-01 | 8.54e-01 | 8.85e-01 | 3.39e-01 |
| MAINTENANCE OF PROTEIN LOCATION IN EXTRACELLULAR REGION | 8 | 3.36e-01 | 8.59e-01 | 0.27300 | -4.94e-02 | 5.16e-02 | -2.28e-01 | 2.78e-02 | -1.30e-01 | 8.09e-01 | 8.00e-01 | 2.64e-01 | 8.92e-01 | 5.25e-01 |
| LYMPH VESSEL DEVELOPMENT | 31 | 3.96e-01 | 8.96e-01 | 0.27300 | 1.35e-01 | 1.34e-01 | 1.64e-01 | 1.01e-01 | -3.18e-02 | 1.92e-01 | 1.95e-01 | 1.14e-01 | 3.28e-01 | 7.60e-01 |
| CALMODULIN DEPENDENT KINASE SIGNALING PATHWAY | 11 | 5.60e-01 | 9.70e-01 | 0.27300 | -9.82e-02 | -9.67e-02 | 2.10e-02 | -2.25e-01 | -6.86e-02 | 5.73e-01 | 5.79e-01 | 9.04e-01 | 1.97e-01 | 6.94e-01 |
| BRANCHING INVOLVED IN LABYRINTHINE LAYER MORPHOGENESIS | 13 | 2.41e-01 | 7.67e-01 | 0.27300 | -8.58e-02 | -4.79e-02 | -5.45e-02 | -1.35e-02 | 2.49e-01 | 5.92e-01 | 7.65e-01 | 7.34e-01 | 9.33e-01 | 1.21e-01 |
| REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 129 | 2.10e-02 | 2.15e-01 | 0.27300 | -1.40e-01 | -1.35e-01 | -7.69e-02 | -1.75e-01 | 1.62e-02 | 6.11e-03 | 7.89e-03 | 1.31e-01 | 6.15e-04 | 7.50e-01 |
| TRANSFERRIN TRANSPORT | 10 | 6.43e-01 | 1.00e+00 | 0.27300 | -4.40e-02 | -4.29e-02 | -3.63e-02 | -2.64e-02 | 2.62e-01 | 8.09e-01 | 8.14e-01 | 8.42e-01 | 8.85e-01 | 1.51e-01 |
| MYELOID LEUKOCYTE MIGRATION | 233 | 7.93e-05 | 2.85e-03 | 0.27300 | -1.44e-01 | -1.66e-01 | -9.65e-02 | -1.10e-01 | 6.89e-02 | 1.48e-04 | 1.33e-05 | 1.11e-02 | 3.71e-03 | 7.01e-02 |
| ADENOHYPOPHYSIS DEVELOPMENT | 16 | 4.29e-01 | 9.17e-01 | 0.27300 | 1.17e-01 | 1.32e-01 | 1.75e-01 | 3.09e-03 | 1.12e-01 | 4.19e-01 | 3.60e-01 | 2.24e-01 | 9.83e-01 | 4.38e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE I | 33 | 7.98e-01 | 1.00e+00 | 0.27300 | 1.43e-01 | 1.37e-01 | 1.50e-01 | 1.07e-01 | 3.55e-02 | 1.54e-01 | 1.72e-01 | 1.37e-01 | 2.89e-01 | 7.24e-01 |
| REGULATION OF NOTCH SIGNALING PATHWAY | 94 | 2.38e-02 | 2.32e-01 | 0.27300 | 1.32e-01 | 1.56e-01 | 9.34e-02 | 1.12e-01 | -1.07e-01 | 2.72e-02 | 8.88e-03 | 1.17e-01 | 6.11e-02 | 7.39e-02 |
| P BODY ASSEMBLY | 20 | 6.76e-01 | 1.00e+00 | 0.27300 | -1.03e-01 | -8.38e-02 | -9.29e-02 | -1.50e-01 | -1.60e-01 | 4.26e-01 | 5.17e-01 | 4.72e-01 | 2.46e-01 | 2.15e-01 |
| REGULATION OF ERAD PATHWAY | 19 | 8.38e-01 | 1.00e+00 | 0.27300 | 1.40e-01 | 1.38e-01 | 1.68e-01 | 8.57e-02 | 1.35e-02 | 2.91e-01 | 2.96e-01 | 2.06e-01 | 5.18e-01 | 9.19e-01 |
| POSITIVE REGULATION OF PROGRAMMED NECROTIC CELL DEATH | 10 | 8.71e-01 | 1.00e+00 | 0.27300 | -1.25e-01 | -1.34e-01 | -9.95e-02 | -1.43e-01 | 1.03e-01 | 4.95e-01 | 4.63e-01 | 5.86e-01 | 4.35e-01 | 5.74e-01 |
| COMMA SHAPED BODY MORPHOGENESIS | 5 | 6.05e-01 | 9.90e-01 | 0.27200 | -4.94e-02 | -2.42e-02 | 4.98e-02 | -2.56e-01 | -5.48e-02 | 8.48e-01 | 9.25e-01 | 8.47e-01 | 3.21e-01 | 8.32e-01 |
| CELLULAR RESPONSE TO TYPE II INTERFERON | 115 | 5.52e-03 | 8.22e-02 | 0.27200 | -1.40e-01 | -1.56e-01 | -4.58e-02 | -1.38e-01 | 9.64e-02 | 9.64e-03 | 3.79e-03 | 3.96e-01 | 1.08e-02 | 7.43e-02 |
| PEROXISOME FISSION | 9 | 8.02e-01 | 1.00e+00 | 0.27200 | 5.12e-02 | 4.37e-02 | 1.55e-01 | -3.36e-02 | 2.11e-01 | 7.90e-01 | 8.21e-01 | 4.22e-01 | 8.62e-01 | 2.73e-01 |
| STEROL METABOLIC PROCESS | 150 | 3.91e-03 | 6.42e-02 | 0.27200 | 1.27e-01 | 1.31e-01 | 1.45e-01 | 1.17e-01 | 7.71e-02 | 7.04e-03 | 5.69e-03 | 2.11e-03 | 1.36e-02 | 1.03e-01 |
| PROTEIN PEPTIDYL PROLYL ISOMERIZATION | 19 | 7.29e-01 | 1.00e+00 | 0.27200 | 1.28e-01 | 1.06e-01 | 1.55e-01 | 6.78e-02 | 1.33e-01 | 3.34e-01 | 4.23e-01 | 2.41e-01 | 6.09e-01 | 3.17e-01 |
| DNA TEMPLATED TRANSCRIPTION INITIATION | 135 | 5.09e-04 | 1.31e-02 | 0.27200 | 1.22e-01 | 8.84e-02 | 2.04e-01 | 4.85e-02 | 8.49e-02 | 1.42e-02 | 7.61e-02 | 4.15e-05 | 3.31e-01 | 8.85e-02 |
| NEGATIVE ADAPTATION OF SIGNALING PATHWAY | 18 | 1.60e-01 | 6.59e-01 | 0.27200 | -1.07e-01 | -1.75e-01 | 5.11e-02 | -1.23e-01 | 1.19e-01 | 4.34e-01 | 1.99e-01 | 7.07e-01 | 3.65e-01 | 3.80e-01 |
| REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 25 | 7.12e-01 | 1.00e+00 | 0.27200 | -1.42e-01 | -1.55e-01 | -5.90e-02 | -1.41e-01 | 7.90e-02 | 2.20e-01 | 1.79e-01 | 6.10e-01 | 2.21e-01 | 4.94e-01 |
| OSTEOBLAST PROLIFERATION | 36 | 6.48e-01 | 1.00e+00 | 0.27200 | 1.36e-01 | 1.46e-01 | 1.05e-01 | 1.52e-01 | -3.90e-04 | 1.58e-01 | 1.29e-01 | 2.77e-01 | 1.15e-01 | 9.97e-01 |
| LEUKOCYTE DEGRANULATION | 78 | 1.14e-03 | 2.53e-02 | 0.27200 | -1.03e-01 | -1.43e-01 | 4.68e-02 | -1.75e-01 | 9.93e-02 | 1.15e-01 | 2.87e-02 | 4.75e-01 | 7.57e-03 | 1.29e-01 |
| REGULATION OF INWARD RECTIFIER POTASSIUM CHANNEL ACTIVITY | 7 | 9.31e-01 | 1.00e+00 | 0.27200 | 1.46e-01 | 1.49e-01 | 1.58e-01 | 3.83e-02 | -6.21e-02 | 5.04e-01 | 4.94e-01 | 4.69e-01 | 8.61e-01 | 7.76e-01 |
| RENAL FILTRATION | 25 | 3.31e-01 | 8.55e-01 | 0.27200 | -1.30e-01 | -1.29e-01 | -1.08e-01 | -3.70e-02 | 1.65e-01 | 2.60e-01 | 2.64e-01 | 3.52e-01 | 7.49e-01 | 1.53e-01 |
| DENDRITIC TRANSPORT OF RIBONUCLEOPROTEIN COMPLEX | 5 | 9.06e-01 | 1.00e+00 | 0.27200 | 3.81e-02 | -2.08e-02 | 1.39e-01 | -2.64e-02 | 2.28e-01 | 8.83e-01 | 9.36e-01 | 5.90e-01 | 9.19e-01 | 3.78e-01 |
| SIGNALING RECEPTOR LIGAND PRECURSOR PROCESSING | 36 | 3.17e-01 | 8.45e-01 | 0.27200 | -1.37e-01 | -1.34e-01 | -1.01e-01 | -1.20e-01 | -1.12e-01 | 1.56e-01 | 1.65e-01 | 2.95e-01 | 2.12e-01 | 2.43e-01 |
| POSITIVE REGULATION OF HEART RATE | 27 | 7.06e-01 | 1.00e+00 | 0.27200 | 1.49e-01 | 1.35e-01 | 1.54e-01 | 8.63e-02 | 4.53e-02 | 1.81e-01 | 2.24e-01 | 1.65e-01 | 4.38e-01 | 6.84e-01 |
| POSITIVE REGULATION OF PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 60 | 1.71e-01 | 6.75e-01 | 0.27100 | -1.30e-01 | -1.53e-01 | -3.38e-02 | -1.69e-01 | 6.12e-02 | 8.07e-02 | 4.05e-02 | 6.51e-01 | 2.38e-02 | 4.12e-01 |
| ROOF OF MOUTH DEVELOPMENT | 90 | 9.68e-03 | 1.22e-01 | 0.27100 | 1.29e-01 | 9.72e-02 | 2.06e-01 | 5.10e-02 | 5.06e-02 | 3.46e-02 | 1.11e-01 | 7.24e-04 | 4.03e-01 | 4.07e-01 |
| RESPONSE TO COBALT ION | 9 | 8.36e-01 | 1.00e+00 | 0.27100 | -2.67e-02 | -4.51e-02 | 7.01e-02 | -8.29e-02 | 2.43e-01 | 8.90e-01 | 8.15e-01 | 7.16e-01 | 6.67e-01 | 2.07e-01 |
| TELOMERIC D LOOP DISASSEMBLY | 7 | 9.52e-01 | 1.00e+00 | 0.27100 | -1.03e-01 | -1.24e-01 | 3.44e-03 | -1.45e-01 | 1.63e-01 | 6.37e-01 | 5.70e-01 | 9.87e-01 | 5.07e-01 | 4.55e-01 |
| PLANAR CELL POLARITY PATHWAY INVOLVED IN AXIS ELONGATION | 6 | 7.75e-01 | 1.00e+00 | 0.27100 | -4.42e-02 | -1.10e-01 | 1.37e-01 | -1.34e-01 | 1.51e-01 | 8.51e-01 | 6.40e-01 | 5.60e-01 | 5.70e-01 | 5.23e-01 |
| WYBUTOSINE METABOLIC PROCESS | 6 | 8.59e-01 | 1.00e+00 | 0.27100 | 2.06e-02 | 5.03e-02 | -5.04e-02 | -4.65e-02 | -2.57e-01 | 9.30e-01 | 8.31e-01 | 8.31e-01 | 8.44e-01 | 2.76e-01 |
| METHYLGLYOXAL METABOLIC PROCESS | 6 | 7.22e-01 | 1.00e+00 | 0.27100 | -6.70e-03 | 1.59e-02 | 9.79e-02 | -4.94e-02 | 2.47e-01 | 9.77e-01 | 9.46e-01 | 6.78e-01 | 8.34e-01 | 2.94e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 17 PRODUCTION | 21 | 5.03e-01 | 9.48e-01 | 0.27100 | -7.37e-02 | -9.65e-02 | 3.27e-02 | -1.36e-01 | 1.98e-01 | 5.59e-01 | 4.44e-01 | 7.95e-01 | 2.81e-01 | 1.17e-01 |
| REGULATION OF EARLY ENDOSOME TO LATE ENDOSOME TRANSPORT | 17 | 2.28e-01 | 7.50e-01 | 0.27100 | -4.06e-02 | -9.85e-02 | 4.72e-02 | 2.52e-02 | 2.43e-01 | 7.72e-01 | 4.82e-01 | 7.36e-01 | 8.57e-01 | 8.25e-02 |
| POSITIVE REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 35 | 3.72e-01 | 8.82e-01 | 0.27100 | 1.21e-01 | 1.34e-01 | 8.97e-02 | 1.70e-01 | 6.44e-02 | 2.17e-01 | 1.71e-01 | 3.58e-01 | 8.23e-02 | 5.10e-01 |
| DIPEPTIDE TRANSMEMBRANE TRANSPORT | 7 | 8.09e-01 | 1.00e+00 | 0.27100 | -1.41e-01 | -1.46e-01 | -1.75e-01 | 9.53e-03 | 3.53e-02 | 5.19e-01 | 5.03e-01 | 4.21e-01 | 9.65e-01 | 8.71e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CENTROSOME | 12 | 9.20e-01 | 1.00e+00 | 0.27100 | -1.25e-01 | -1.33e-01 | -4.52e-02 | -1.54e-01 | 1.18e-01 | 4.53e-01 | 4.24e-01 | 7.86e-01 | 3.54e-01 | 4.78e-01 |
| POSITIVE REGULATION OF SYNAPTIC VESICLE ENDOCYTOSIS | 6 | 8.09e-01 | 1.00e+00 | 0.27100 | -8.00e-02 | -1.06e-01 | -1.17e-01 | -7.35e-03 | -2.04e-01 | 7.34e-01 | 6.53e-01 | 6.19e-01 | 9.75e-01 | 3.86e-01 |
| REGULATION OF IMMUNOGLOBULIN PRODUCTION | 72 | 4.05e-04 | 1.11e-02 | 0.27100 | -2.50e-02 | -6.85e-02 | 1.29e-01 | -1.40e-01 | 1.78e-01 | 7.14e-01 | 3.15e-01 | 5.90e-02 | 4.06e-02 | 8.81e-03 |
| CELL MIGRATION INVOLVED IN METANEPHROS DEVELOPMENT | 5 | 9.16e-01 | 1.00e+00 | 0.27100 | -1.64e-03 | -5.77e-02 | 1.25e-01 | -7.55e-02 | 2.20e-01 | 9.95e-01 | 8.23e-01 | 6.28e-01 | 7.70e-01 | 3.94e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DIFFERENTIATION | 38 | 5.14e-02 | 3.71e-01 | 0.27100 | 8.63e-02 | 5.68e-02 | 2.14e-01 | -4.72e-02 | 1.21e-01 | 3.57e-01 | 5.45e-01 | 2.26e-02 | 6.14e-01 | 1.98e-01 |
| ALDITOL PHOSPHATE METABOLIC PROCESS | 10 | 3.51e-01 | 8.69e-01 | 0.27000 | 7.11e-02 | 6.78e-02 | -1.04e-01 | 2.17e-01 | -7.31e-02 | 6.97e-01 | 7.10e-01 | 5.67e-01 | 2.34e-01 | 6.89e-01 |
| TRIGLYCERIDE CATABOLIC PROCESS | 27 | 7.89e-01 | 1.00e+00 | 0.27000 | 1.46e-01 | 1.56e-01 | 8.66e-02 | 1.33e-01 | -4.94e-02 | 1.90e-01 | 1.61e-01 | 4.36e-01 | 2.32e-01 | 6.57e-01 |
| REGULATION OF NEURON DIFFERENTIATION | 192 | 1.76e-06 | 9.99e-05 | 0.27000 | 1.39e-01 | 1.24e-01 | 1.72e-01 | 4.41e-02 | -8.20e-02 | 8.71e-04 | 2.96e-03 | 3.96e-05 | 2.92e-01 | 4.99e-02 |
| ESTABLISHMENT OF PIGMENT GRANULE LOCALIZATION | 21 | 3.36e-01 | 8.59e-01 | 0.27000 | -7.81e-02 | -7.36e-02 | 1.44e-02 | -8.13e-02 | 2.34e-01 | 5.35e-01 | 5.59e-01 | 9.09e-01 | 5.19e-01 | 6.33e-02 |
| CRISTAE FORMATION | 15 | 2.16e-01 | 7.38e-01 | 0.27000 | 3.53e-02 | -1.54e-02 | 2.23e-01 | -1.01e-01 | 1.08e-01 | 8.13e-01 | 9.18e-01 | 1.35e-01 | 4.97e-01 | 4.69e-01 |
| HIS PURKINJE SYSTEM DEVELOPMENT | 7 | 7.78e-01 | 1.00e+00 | 0.27000 | -8.95e-02 | -1.34e-01 | 7.22e-02 | -2.01e-01 | 3.68e-02 | 6.82e-01 | 5.39e-01 | 7.41e-01 | 3.57e-01 | 8.66e-01 |
| LATERAL SPROUTING FROM AN EPITHELIUM | 10 | 3.90e-01 | 8.92e-01 | 0.27000 | -2.99e-02 | -4.70e-02 | -8.27e-02 | 7.30e-02 | -2.40e-01 | 8.70e-01 | 7.97e-01 | 6.51e-01 | 6.89e-01 | 1.88e-01 |
| MORPHOGENESIS OF AN EPITHELIAL FOLD | 23 | 8.49e-02 | 4.79e-01 | 0.27000 | 1.51e-02 | 6.52e-03 | -2.95e-02 | 7.75e-02 | -2.57e-01 | 9.00e-01 | 9.57e-01 | 8.07e-01 | 5.20e-01 | 3.31e-02 |
| PYRIMIDINE RIBONUCLEOSIDE TRIPHOSPHATE BIOSYNTHETIC PROCESS | 14 | 9.19e-01 | 1.00e+00 | 0.27000 | 1.42e-01 | 1.38e-01 | 1.14e-01 | 1.05e-01 | -9.87e-02 | 3.57e-01 | 3.72e-01 | 4.60e-01 | 4.95e-01 | 5.22e-01 |
| TELOMERIC LOOP DISASSEMBLY | 9 | 8.53e-01 | 1.00e+00 | 0.27000 | 8.92e-03 | 1.65e-04 | 5.86e-02 | 1.84e-02 | 2.63e-01 | 9.63e-01 | 9.99e-01 | 7.61e-01 | 9.24e-01 | 1.72e-01 |
| PROTEIN KINASE A SIGNALING | 37 | 1.81e-01 | 6.88e-01 | 0.27000 | -3.60e-02 | -2.96e-02 | -9.48e-02 | -2.87e-02 | -2.47e-01 | 7.05e-01 | 7.55e-01 | 3.18e-01 | 7.63e-01 | 9.36e-03 |
| EMBRYONIC DIGESTIVE TRACT MORPHOGENESIS | 17 | 1.98e-01 | 7.13e-01 | 0.27000 | 1.25e-01 | 6.04e-02 | 2.29e-01 | 1.72e-02 | -3.20e-02 | 3.73e-01 | 6.66e-01 | 1.02e-01 | 9.02e-01 | 8.19e-01 |
| ER TO GOLGI CERAMIDE TRANSPORT | 5 | 4.70e-01 | 9.38e-01 | 0.27000 | 1.13e-01 | 1.42e-01 | 1.73e-02 | -3.69e-02 | -1.96e-01 | 6.61e-01 | 5.83e-01 | 9.47e-01 | 8.86e-01 | 4.48e-01 |
| REGULATION OF HUMORAL IMMUNE RESPONSE MEDIATED BY CIRCULATING IMMUNOGLOBULIN | 18 | 9.43e-01 | 1.00e+00 | 0.27000 | -1.44e-01 | -1.49e-01 | -1.16e-01 | -1.29e-01 | -7.46e-03 | 2.91e-01 | 2.73e-01 | 3.96e-01 | 3.45e-01 | 9.56e-01 |
| CYTOPLASMIC SEQUESTERING OF TRANSCRIPTION FACTOR | 11 | 3.42e-01 | 8.60e-01 | 0.27000 | 1.12e-02 | -2.16e-02 | 1.88e-01 | -3.84e-02 | 1.88e-01 | 9.49e-01 | 9.01e-01 | 2.80e-01 | 8.26e-01 | 2.80e-01 |
| NEGATIVE REGULATION OF T HELPER CELL DIFFERENTIATION | 18 | 4.48e-01 | 9.30e-01 | 0.27000 | -1.25e-01 | -1.39e-01 | 1.17e-02 | -1.91e-01 | 3.67e-02 | 3.58e-01 | 3.09e-01 | 9.31e-01 | 1.61e-01 | 7.88e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN VIA MHC CLASS I | 37 | 9.45e-03 | 1.21e-01 | 0.27000 | 4.09e-02 | -3.23e-02 | 1.94e-01 | -1.36e-02 | 1.79e-01 | 6.67e-01 | 7.34e-01 | 4.10e-02 | 8.86e-01 | 5.91e-02 |
| LEYDIG CELL DIFFERENTIATION | 9 | 9.13e-01 | 1.00e+00 | 0.27000 | 1.33e-01 | 1.17e-01 | 8.12e-02 | 1.25e-01 | -1.39e-01 | 4.91e-01 | 5.43e-01 | 6.73e-01 | 5.16e-01 | 4.72e-01 |
| REGULATION OF TRANSFORMING GROWTH FACTOR BETA ACTIVATION | 10 | 2.44e-01 | 7.69e-01 | 0.27000 | -1.80e-03 | 9.33e-02 | -8.12e-02 | -1.84e-02 | -2.39e-01 | 9.92e-01 | 6.10e-01 | 6.57e-01 | 9.20e-01 | 1.91e-01 |
| SECONDARY HEART FIELD SPECIFICATION | 11 | 3.18e-01 | 8.45e-01 | 0.26900 | -5.23e-02 | -9.90e-02 | 1.09e-01 | -2.09e-01 | -6.69e-02 | 7.64e-01 | 5.70e-01 | 5.31e-01 | 2.30e-01 | 7.01e-01 |
| THIAMINE TRANSPORT | 8 | 9.49e-01 | 1.00e+00 | 0.26900 | 1.19e-01 | 9.91e-02 | 1.94e-01 | 4.28e-02 | 9.42e-02 | 5.59e-01 | 6.27e-01 | 3.41e-01 | 8.34e-01 | 6.44e-01 |
| NEGATIVE REGULATION OF TYPE I INTERFERON MEDIATED SIGNALING PATHWAY | 22 | 8.51e-01 | 1.00e+00 | 0.26900 | 1.43e-01 | 1.52e-01 | 1.19e-01 | 1.03e-01 | -6.46e-02 | 2.47e-01 | 2.18e-01 | 3.35e-01 | 4.02e-01 | 6.00e-01 |
| MESENCHYMAL TO EPITHELIAL TRANSITION | 18 | 2.51e-01 | 7.77e-01 | 0.26900 | 7.05e-02 | -3.49e-04 | 1.98e-01 | -2.40e-02 | 1.66e-01 | 6.05e-01 | 9.98e-01 | 1.45e-01 | 8.60e-01 | 2.24e-01 |
| CELL AGGREGATION | 23 | 2.02e-01 | 7.20e-01 | 0.26900 | -5.83e-02 | -3.18e-02 | -2.89e-02 | -1.44e-01 | -2.15e-01 | 6.29e-01 | 7.92e-01 | 8.10e-01 | 2.33e-01 | 7.37e-02 |
| POSITIVE REGULATION OF CHOLESTEROL BIOSYNTHETIC PROCESS | 10 | 3.11e-01 | 8.38e-01 | 0.26900 | 3.42e-02 | 6.98e-02 | 7.11e-02 | 9.51e-02 | 2.28e-01 | 8.51e-01 | 7.02e-01 | 6.97e-01 | 6.02e-01 | 2.11e-01 |
| SNRNA METABOLIC PROCESS | 53 | 1.88e-02 | 1.99e-01 | 0.26900 | 2.46e-02 | -1.42e-02 | 1.60e-01 | -6.73e-02 | 2.03e-01 | 7.56e-01 | 8.58e-01 | 4.37e-02 | 3.97e-01 | 1.06e-02 |
| CELLULAR RESPONSE TO DSRNA | 22 | 1.77e-01 | 6.85e-01 | 0.26900 | -7.89e-02 | -9.67e-02 | 8.70e-02 | -1.89e-01 | 1.16e-01 | 5.22e-01 | 4.32e-01 | 4.80e-01 | 1.25e-01 | 3.48e-01 |
| SEQUESTERING OF TRIGLYCERIDE | 18 | 7.79e-01 | 1.00e+00 | 0.26800 | -1.16e-01 | -1.39e-01 | -1.55e-02 | -1.43e-01 | 1.36e-01 | 3.94e-01 | 3.08e-01 | 9.10e-01 | 2.92e-01 | 3.16e-01 |
| MEMBRANE DEPOLARIZATION | 78 | 2.89e-01 | 8.17e-01 | 0.26800 | 1.38e-01 | 1.46e-01 | 1.12e-01 | 1.38e-01 | -1.04e-02 | 3.55e-02 | 2.59e-02 | 8.71e-02 | 3.47e-02 | 8.74e-01 |
| SISTER CHROMATID SEGREGATION | 221 | 1.10e-05 | 5.13e-04 | 0.26800 | 1.09e-01 | 8.89e-02 | 1.84e-01 | 4.71e-02 | 1.27e-01 | 5.33e-03 | 2.27e-02 | 2.30e-06 | 2.27e-01 | 1.19e-03 |
| EPITHELIAL CELL MATURATION | 24 | 8.12e-01 | 1.00e+00 | 0.26800 | 1.49e-01 | 1.29e-01 | 1.42e-01 | 1.12e-01 | 1.14e-02 | 2.05e-01 | 2.72e-01 | 2.29e-01 | 3.41e-01 | 9.23e-01 |
| CELLULAR HYPOTONIC RESPONSE | 11 | 9.41e-01 | 1.00e+00 | 0.26800 | -1.47e-01 | -1.48e-01 | -1.09e-01 | -9.89e-02 | 8.17e-02 | 3.97e-01 | 3.96e-01 | 5.30e-01 | 5.70e-01 | 6.39e-01 |
| MYELOID LEUKOCYTE MEDIATED IMMUNITY | 107 | 5.32e-04 | 1.36e-02 | 0.26800 | -1.03e-01 | -1.39e-01 | 3.07e-02 | -1.52e-01 | 1.33e-01 | 6.50e-02 | 1.31e-02 | 5.83e-01 | 6.44e-03 | 1.70e-02 |
| NEGATIVE REGULATION OF RETINOIC ACID RECEPTOR SIGNALING PATHWAY | 9 | 6.78e-01 | 1.00e+00 | 0.26800 | -2.55e-03 | 2.02e-02 | 1.37e-02 | -1.02e-01 | -2.47e-01 | 9.89e-01 | 9.16e-01 | 9.43e-01 | 5.95e-01 | 2.00e-01 |
| TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 183 | 4.85e-05 | 1.87e-03 | 0.26800 | -1.22e-01 | -1.45e-01 | -1.33e-02 | -1.76e-01 | 6.94e-02 | 4.57e-03 | 6.85e-04 | 7.57e-01 | 4.11e-05 | 1.05e-01 |
| NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE ACTIVITY | 24 | 2.64e-01 | 7.91e-01 | 0.26800 | -9.75e-02 | -1.07e-01 | 3.92e-03 | -2.13e-01 | 7.44e-02 | 4.08e-01 | 3.63e-01 | 9.74e-01 | 7.15e-02 | 5.28e-01 |
| GRANULOCYTE DIFFERENTIATION | 40 | 1.95e-02 | 2.04e-01 | 0.26800 | -5.66e-02 | -1.14e-01 | 1.09e-01 | -1.22e-01 | 1.69e-01 | 5.36e-01 | 2.12e-01 | 2.31e-01 | 1.82e-01 | 6.37e-02 |
| MAINTENANCE OF APICAL BASAL CELL POLARITY | 10 | 9.70e-01 | 1.00e+00 | 0.26800 | 1.44e-01 | 1.23e-01 | 1.32e-01 | 1.27e-01 | 4.82e-02 | 4.31e-01 | 5.00e-01 | 4.70e-01 | 4.87e-01 | 7.92e-01 |
| PROTEIN O LINKED GLYCOSYLATION VIA SERINE | 10 | 8.14e-01 | 1.00e+00 | 0.26800 | -9.78e-02 | -7.98e-02 | -6.04e-02 | -1.86e-01 | -1.32e-01 | 5.92e-01 | 6.62e-01 | 7.41e-01 | 3.07e-01 | 4.71e-01 |
| DIOL BIOSYNTHETIC PROCESS | 21 | 4.60e-01 | 9.32e-01 | 0.26800 | -5.38e-03 | -2.82e-02 | 9.06e-02 | -6.15e-02 | 2.43e-01 | 9.66e-01 | 8.23e-01 | 4.72e-01 | 6.26e-01 | 5.43e-02 |
| REGULATION OF MUSCLE SYSTEM PROCESS | 239 | 3.42e-03 | 5.79e-02 | 0.26800 | 1.39e-01 | 1.36e-01 | 1.26e-01 | 1.33e-01 | -1.47e-02 | 2.10e-04 | 2.96e-04 | 7.77e-04 | 3.99e-04 | 6.95e-01 |
| TELOMERE LOCALIZATION | 12 | 9.16e-01 | 1.00e+00 | 0.26800 | -1.11e-01 | -8.93e-02 | -1.63e-01 | -5.60e-02 | -1.47e-01 | 5.04e-01 | 5.92e-01 | 3.29e-01 | 7.37e-01 | 3.78e-01 |
| REGULATION OF BROWN FAT CELL DIFFERENTIATION | 24 | 4.77e-01 | 9.40e-01 | 0.26800 | 1.21e-01 | 1.30e-01 | 1.24e-01 | 6.09e-02 | -1.45e-01 | 3.05e-01 | 2.72e-01 | 2.91e-01 | 6.06e-01 | 2.19e-01 |
| SMOOTH MUSCLE TISSUE DEVELOPMENT | 27 | 2.38e-02 | 2.32e-01 | 0.26800 | 5.85e-02 | 2.17e-02 | 2.23e-01 | -5.46e-03 | 1.34e-01 | 5.99e-01 | 8.45e-01 | 4.49e-02 | 9.61e-01 | 2.28e-01 |
| METANEPHRIC GLOMERULAR MESANGIUM DEVELOPMENT | 5 | 8.87e-01 | 1.00e+00 | 0.26800 | -1.19e-01 | -1.64e-01 | 3.37e-02 | -1.40e-01 | 9.94e-02 | 6.46e-01 | 5.26e-01 | 8.96e-01 | 5.87e-01 | 7.00e-01 |
| RENAL SODIUM ION ABSORPTION | 12 | 9.60e-01 | 1.00e+00 | 0.26800 | -1.38e-01 | -1.30e-01 | -1.59e-01 | -9.99e-02 | -1.90e-02 | 4.09e-01 | 4.35e-01 | 3.40e-01 | 5.49e-01 | 9.09e-01 |
| INNER EAR RECEPTOR CELL FATE COMMITMENT | 5 | 9.66e-01 | 1.00e+00 | 0.26700 | -1.46e-01 | -1.35e-01 | -5.87e-02 | -1.68e-01 | 1.77e-02 | 5.73e-01 | 6.01e-01 | 8.20e-01 | 5.14e-01 | 9.45e-01 |
| POSITIVE REGULATION OF DEOXYRIBONUCLEASE ACTIVITY | 5 | 8.93e-01 | 1.00e+00 | 0.26700 | 1.89e-02 | -4.40e-02 | 1.38e-01 | 1.62e-02 | 2.24e-01 | 9.42e-01 | 8.65e-01 | 5.94e-01 | 9.50e-01 | 3.87e-01 |
| G PROTEIN COUPLED GLUTAMATE RECEPTOR SIGNALING PATHWAY | 14 | 8.52e-01 | 1.00e+00 | 0.26700 | 1.26e-01 | 1.53e-01 | 3.29e-02 | 1.73e-01 | -3.34e-02 | 4.15e-01 | 3.22e-01 | 8.31e-01 | 2.61e-01 | 8.29e-01 |
| NUCLEOSIDE TRIPHOSPHATE BIOSYNTHETIC PROCESS | 113 | 4.11e-03 | 6.61e-02 | 0.26700 | 1.24e-01 | 1.01e-01 | 1.92e-01 | 3.11e-02 | 8.86e-02 | 2.24e-02 | 6.25e-02 | 4.20e-04 | 5.68e-01 | 1.04e-01 |
| PEPTIDYL METHIONINE MODIFICATION | 12 | 8.75e-01 | 1.00e+00 | 0.26700 | 1.39e-01 | 1.10e-01 | 1.45e-01 | 1.34e-01 | -3.57e-02 | 4.05e-01 | 5.10e-01 | 3.85e-01 | 4.23e-01 | 8.31e-01 |
| POSITIVE REGULATION OF MONOCYTE DIFFERENTIATION | 10 | 4.74e-01 | 9.40e-01 | 0.26700 | 4.76e-02 | 5.74e-02 | 7.49e-02 | 1.39e-01 | 2.02e-01 | 7.94e-01 | 7.53e-01 | 6.82e-01 | 4.48e-01 | 2.68e-01 |
| NEGATIVE REGULATION OF CELL FATE COMMITMENT | 11 | 4.91e-01 | 9.45e-01 | 0.26700 | 1.51e-01 | 1.61e-01 | 1.50e-01 | 9.27e-03 | 4.91e-03 | 3.85e-01 | 3.56e-01 | 3.88e-01 | 9.58e-01 | 9.78e-01 |
| INTERNEURON MIGRATION | 14 | 7.24e-01 | 1.00e+00 | 0.26700 | 1.36e-01 | 1.27e-01 | 1.41e-01 | 3.68e-02 | -1.25e-01 | 3.80e-01 | 4.11e-01 | 3.63e-01 | 8.12e-01 | 4.17e-01 |
| REGULATION OF MRNA PROCESSING | 116 | 9.59e-03 | 1.22e-01 | 0.26700 | 1.03e-01 | 7.28e-02 | 1.73e-01 | 5.63e-02 | 1.49e-01 | 5.59e-02 | 1.76e-01 | 1.26e-03 | 2.95e-01 | 5.58e-03 |
| CEREBELLAR GRANULAR LAYER FORMATION | 6 | 9.89e-01 | 1.00e+00 | 0.26700 | 1.42e-01 | 1.57e-01 | 8.72e-02 | 1.18e-01 | -6.86e-02 | 5.46e-01 | 5.06e-01 | 7.11e-01 | 6.15e-01 | 7.71e-01 |
| CHOLINE TRANSPORT | 9 | 8.28e-01 | 1.00e+00 | 0.26700 | 1.16e-01 | 1.61e-01 | 2.49e-02 | 1.77e-01 | -1.36e-03 | 5.46e-01 | 4.04e-01 | 8.97e-01 | 3.59e-01 | 9.94e-01 |
| REGULATION OF DNA TEMPLATED DNA REPLICATION | 46 | 4.73e-03 | 7.40e-02 | 0.26700 | 1.09e-01 | 8.40e-02 | 2.22e-01 | -4.06e-02 | -3.47e-02 | 2.02e-01 | 3.24e-01 | 9.06e-03 | 6.34e-01 | 6.84e-01 |
| ESTABLISHMENT OR MAINTENANCE OF TRANSMEMBRANE ELECTROCHEMICAL GRADIENT | 11 | 7.14e-01 | 1.00e+00 | 0.26700 | -1.71e-02 | 1.18e-02 | -3.82e-02 | -8.20e-02 | -2.50e-01 | 9.22e-01 | 9.46e-01 | 8.26e-01 | 6.38e-01 | 1.51e-01 |
| CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 293 | 5.44e-09 | 6.82e-07 | 0.26700 | -1.22e-01 | -1.45e-01 | -4.83e-03 | -1.68e-01 | 8.36e-02 | 3.43e-04 | 1.83e-05 | 8.87e-01 | 7.46e-07 | 1.38e-02 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 18 | 5.71e-01 | 9.76e-01 | 0.26700 | 2.14e-02 | 4.42e-02 | -3.72e-02 | 1.92e-02 | -2.59e-01 | 8.75e-01 | 7.46e-01 | 7.85e-01 | 8.88e-01 | 5.73e-02 |
| TRANSFORMING GROWTH FACTOR BETA1 PRODUCTION | 15 | 6.92e-01 | 1.00e+00 | 0.26700 | 8.12e-02 | 1.03e-01 | -7.49e-03 | 1.37e-01 | -1.87e-01 | 5.86e-01 | 4.88e-01 | 9.60e-01 | 3.57e-01 | 2.10e-01 |
| REGULATION OF INNER EAR AUDITORY RECEPTOR CELL DIFFERENTIATION | 9 | 3.38e-01 | 8.59e-01 | 0.26700 | -7.18e-03 | 2.23e-03 | 7.95e-02 | -2.11e-01 | -1.42e-01 | 9.70e-01 | 9.91e-01 | 6.80e-01 | 2.73e-01 | 4.60e-01 |
| POSITIVE REGULATION OF IRE1 MEDIATED UNFOLDED PROTEIN RESPONSE | 7 | 5.88e-01 | 9.85e-01 | 0.26700 | 1.20e-01 | 1.51e-01 | -5.82e-02 | 1.47e-01 | -9.35e-02 | 5.81e-01 | 4.89e-01 | 7.90e-01 | 5.00e-01 | 6.68e-01 |
| MITOCHONDRIAL FUSION | 32 | 7.03e-01 | 1.00e+00 | 0.26700 | -1.35e-01 | -1.35e-01 | -7.48e-02 | -1.70e-01 | -3.37e-03 | 1.86e-01 | 1.86e-01 | 4.64e-01 | 9.56e-02 | 9.74e-01 |
| NEGATIVE REGULATION OF RYANODINE SENSITIVE CALCIUM RELEASE CHANNEL ACTIVITY | 11 | 8.54e-01 | 1.00e+00 | 0.26700 | -8.03e-02 | -1.04e-01 | 2.53e-02 | -1.26e-01 | 1.93e-01 | 6.45e-01 | 5.49e-01 | 8.85e-01 | 4.69e-01 | 2.68e-01 |
| REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA | 10 | 7.58e-01 | 1.00e+00 | 0.26700 | -9.27e-02 | -9.17e-02 | -1.53e-02 | -1.87e-01 | -1.38e-01 | 6.12e-01 | 6.16e-01 | 9.33e-01 | 3.07e-01 | 4.50e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 57 | 1.29e-01 | 5.97e-01 | 0.26600 | -1.24e-01 | -1.41e-01 | -1.43e-02 | -1.64e-01 | 9.31e-02 | 1.04e-01 | 6.52e-02 | 8.52e-01 | 3.27e-02 | 2.24e-01 |
| REGULATION OF ASPARTIC TYPE PEPTIDASE ACTIVITY | 10 | 7.29e-01 | 1.00e+00 | 0.26600 | -1.10e-01 | -1.03e-01 | -6.50e-02 | -1.85e-01 | 1.00e-01 | 5.49e-01 | 5.71e-01 | 7.22e-01 | 3.12e-01 | 5.83e-01 |
| REGULATION OF BASEMENT MEMBRANE ORGANIZATION | 11 | 5.77e-01 | 9.81e-01 | 0.26600 | -5.32e-02 | -1.77e-02 | -1.78e-01 | 8.97e-02 | -1.67e-01 | 7.60e-01 | 9.19e-01 | 3.06e-01 | 6.06e-01 | 3.37e-01 |
| REGULATION OF ICOSANOID SECRETION | 20 | 3.30e-01 | 8.55e-01 | 0.26600 | -1.53e-01 | -1.71e-01 | -5.57e-02 | -1.13e-01 | 5.08e-02 | 2.37e-01 | 1.87e-01 | 6.66e-01 | 3.83e-01 | 6.94e-01 |
| NEURON FATE SPECIFICATION | 34 | 7.51e-03 | 1.02e-01 | 0.26600 | 8.45e-02 | 5.83e-02 | 2.29e-01 | -8.78e-02 | -5.36e-03 | 3.94e-01 | 5.56e-01 | 2.08e-02 | 3.76e-01 | 9.57e-01 |
| HEPARAN SULFATE PROTEOGLYCAN METABOLIC PROCESS | 15 | 2.81e-01 | 8.07e-01 | 0.26600 | -4.91e-02 | -3.89e-02 | -1.44e-01 | 9.32e-02 | -1.93e-01 | 7.42e-01 | 7.94e-01 | 3.35e-01 | 5.32e-01 | 1.95e-01 |
| COMMISSURAL NEURON AXON GUIDANCE | 12 | 8.99e-01 | 1.00e+00 | 0.26600 | -1.21e-01 | -1.43e-01 | -6.70e-02 | -8.99e-02 | 1.52e-01 | 4.67e-01 | 3.93e-01 | 6.88e-01 | 5.90e-01 | 3.62e-01 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 SIGNALING PATHWAY | 6 | 4.94e-01 | 9.46e-01 | 0.26600 | -4.03e-02 | -5.27e-02 | 1.72e-01 | -1.64e-01 | 1.00e-01 | 8.64e-01 | 8.23e-01 | 4.67e-01 | 4.87e-01 | 6.71e-01 |
| RISC COMPLEX ASSEMBLY | 10 | 6.40e-01 | 1.00e+00 | 0.26600 | 1.04e-01 | 1.20e-01 | 1.44e-01 | 7.59e-03 | -1.57e-01 | 5.68e-01 | 5.11e-01 | 4.30e-01 | 9.67e-01 | 3.91e-01 |
| VESICLE MEDIATED CHOLESTEROL TRANSPORT | 9 | 9.53e-01 | 1.00e+00 | 0.26600 | -1.32e-01 | -1.11e-01 | -1.86e-01 | -7.16e-02 | -3.42e-02 | 4.93e-01 | 5.64e-01 | 3.34e-01 | 7.10e-01 | 8.59e-01 |
| METANEPHRIC MESENCHYME DEVELOPMENT | 14 | 6.38e-01 | 9.98e-01 | 0.26600 | 1.38e-01 | 1.18e-01 | 1.92e-01 | 5.95e-03 | 2.49e-02 | 3.71e-01 | 4.43e-01 | 2.14e-01 | 9.69e-01 | 8.72e-01 |
| REGULATION OF RELAXATION OF MUSCLE | 14 | 2.95e-01 | 8.22e-01 | 0.26600 | -8.81e-02 | -1.39e-01 | 2.79e-02 | -1.70e-01 | -1.18e-01 | 5.68e-01 | 3.67e-01 | 8.56e-01 | 2.71e-01 | 4.46e-01 |
| NOREPINEPHRINE BIOSYNTHETIC PROCESS | 8 | 1.64e-01 | 6.64e-01 | 0.26600 | 5.40e-02 | -3.75e-02 | 1.85e-01 | -1.12e-01 | -1.40e-01 | 7.91e-01 | 8.54e-01 | 3.65e-01 | 5.85e-01 | 4.92e-01 |
| PROTOPORPHYRINOGEN IX METABOLIC PROCESS | 10 | 3.66e-01 | 8.79e-01 | 0.26600 | 4.11e-02 | -2.18e-02 | 2.22e-01 | -2.10e-02 | 1.37e-01 | 8.22e-01 | 9.05e-01 | 2.25e-01 | 9.08e-01 | 4.53e-01 |
| NEGATIVE REGULATION OF B CELL APOPTOTIC PROCESS | 16 | 1.14e-01 | 5.62e-01 | 0.26600 | -6.57e-02 | -9.95e-02 | 1.35e-01 | -1.89e-01 | 4.76e-02 | 6.49e-01 | 4.91e-01 | 3.49e-01 | 1.90e-01 | 7.42e-01 |
| REGULATION OF DOUBLE STRAND BREAK REPAIR VIA NONHOMOLOGOUS END JOINING | 26 | 3.56e-01 | 8.74e-01 | 0.26600 | 4.14e-02 | 1.71e-02 | 1.41e-01 | -3.43e-02 | 2.18e-01 | 7.15e-01 | 8.80e-01 | 2.14e-01 | 7.62e-01 | 5.42e-02 |
| RNA SPLICING | 421 | 1.04e-10 | 1.85e-08 | 0.26600 | 1.14e-01 | 9.27e-02 | 1.86e-01 | 4.24e-02 | 1.12e-01 | 5.98e-05 | 1.10e-03 | 5.77e-11 | 1.36e-01 | 8.00e-05 |
| SKELETAL MYOFIBRIL ASSEMBLY | 10 | 3.06e-01 | 8.34e-01 | 0.26600 | 8.35e-02 | 1.49e-01 | 2.55e-02 | -3.76e-02 | -1.98e-01 | 6.48e-01 | 4.14e-01 | 8.89e-01 | 8.37e-01 | 2.78e-01 |
| DEHYDROASCORBIC ACID TRANSPORT | 9 | 8.50e-01 | 1.00e+00 | 0.26500 | 1.23e-01 | 1.14e-01 | 1.23e-01 | 1.64e-01 | -1.78e-02 | 5.23e-01 | 5.53e-01 | 5.23e-01 | 3.95e-01 | 9.26e-01 |
| REGULATION OF POSTSYNAPTIC CYTOSOLIC CALCIUM ION CONCENTRATION | 10 | 9.67e-01 | 1.00e+00 | 0.26500 | -1.18e-01 | -1.15e-01 | -1.42e-01 | -9.83e-02 | -1.16e-01 | 5.17e-01 | 5.31e-01 | 4.36e-01 | 5.90e-01 | 5.26e-01 |
| T CELL LINEAGE COMMITMENT | 31 | 1.33e-01 | 6.06e-01 | 0.26500 | -1.34e-01 | -1.34e-01 | -1.54e-02 | -1.85e-01 | -1.15e-02 | 1.98e-01 | 1.95e-01 | 8.82e-01 | 7.51e-02 | 9.12e-01 |
| REGULATION OF NON MOTILE CILIUM ASSEMBLY | 11 | 9.48e-01 | 1.00e+00 | 0.26500 | -1.38e-01 | -1.31e-01 | -8.09e-02 | -1.39e-01 | 9.11e-02 | 4.29e-01 | 4.51e-01 | 6.42e-01 | 4.24e-01 | 6.01e-01 |
| MICROTUBULE ANCHORING AT MICROTUBULE ORGANIZING CENTER | 13 | 8.33e-01 | 1.00e+00 | 0.26500 | -8.66e-02 | -7.32e-02 | -1.05e-01 | -7.29e-02 | -2.03e-01 | 5.89e-01 | 6.48e-01 | 5.12e-01 | 6.49e-01 | 2.05e-01 |
| NEGATIVE REGULATION OF HUMORAL IMMUNE RESPONSE | 16 | 9.13e-01 | 1.00e+00 | 0.26500 | -1.14e-01 | -1.06e-01 | -1.29e-01 | -1.15e-01 | -1.27e-01 | 4.30e-01 | 4.63e-01 | 3.73e-01 | 4.24e-01 | 3.78e-01 |
| POSITIVE REGULATION OF FATTY ACID TRANSPORT | 23 | 2.28e-01 | 7.50e-01 | 0.26500 | -1.53e-01 | -1.58e-01 | -5.44e-02 | -1.16e-01 | 7.49e-02 | 2.05e-01 | 1.89e-01 | 6.52e-01 | 3.37e-01 | 5.34e-01 |
| NUCLEOTIDE TRANSMEMBRANE TRANSPORT | 26 | 7.41e-01 | 1.00e+00 | 0.26500 | -1.39e-01 | -1.48e-01 | -7.08e-02 | -1.54e-01 | -1.91e-02 | 2.20e-01 | 1.91e-01 | 5.32e-01 | 1.74e-01 | 8.66e-01 |
| BEHAVIORAL RESPONSE TO NICOTINE | 9 | 8.53e-01 | 1.00e+00 | 0.26500 | 1.11e-01 | 1.06e-01 | 1.21e-01 | 1.62e-01 | 7.65e-02 | 5.65e-01 | 5.83e-01 | 5.29e-01 | 3.99e-01 | 6.91e-01 |
| VASCULAR WOUND HEALING | 22 | 5.43e-01 | 9.60e-01 | 0.26500 | 1.17e-01 | 9.23e-02 | 2.06e-01 | 1.91e-02 | 6.97e-02 | 3.40e-01 | 4.54e-01 | 9.36e-02 | 8.76e-01 | 5.72e-01 |
| REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 12 | 4.35e-01 | 9.22e-01 | 0.26500 | 2.46e-02 | -2.11e-02 | 1.97e-01 | -1.22e-01 | 1.24e-01 | 8.83e-01 | 8.99e-01 | 2.37e-01 | 4.65e-01 | 4.58e-01 |
| REGULATION OF TRANSCRIPTION INVOLVED IN G1 S TRANSITION OF MITOTIC CELL CYCLE | 21 | 4.14e-01 | 9.11e-01 | 0.26500 | 1.12e-01 | 1.20e-01 | 1.80e-01 | 1.22e-02 | 1.04e-01 | 3.76e-01 | 3.42e-01 | 1.54e-01 | 9.23e-01 | 4.07e-01 |
| INTRACELLULAR STEROL TRANSPORT | 35 | 6.37e-01 | 9.98e-01 | 0.26500 | 1.35e-01 | 1.58e-01 | 8.35e-02 | 1.35e-01 | -4.25e-02 | 1.66e-01 | 1.07e-01 | 3.93e-01 | 1.67e-01 | 6.64e-01 |
| NUCLEOLAR CHROMATIN ORGANIZATION | 9 | 7.67e-01 | 1.00e+00 | 0.26500 | 1.29e-01 | 8.66e-02 | 9.99e-02 | 1.89e-01 | 6.18e-03 | 5.02e-01 | 6.53e-01 | 6.04e-01 | 3.25e-01 | 9.74e-01 |
| PHOTOTRANSDUCTION VISIBLE LIGHT | 18 | 1.21e-01 | 5.82e-01 | 0.26500 | -8.92e-02 | -5.36e-02 | -2.12e-01 | 6.77e-02 | 9.89e-02 | 5.13e-01 | 6.94e-01 | 1.20e-01 | 6.19e-01 | 4.68e-01 |
| LATE ENDOSOME TO VACUOLE TRANSPORT VIA MULTIVESICULAR BODY SORTING PATHWAY | 26 | 2.68e-01 | 7.95e-01 | 0.26500 | 9.84e-02 | 1.04e-01 | 1.73e-01 | 1.56e-03 | 1.40e-01 | 3.85e-01 | 3.58e-01 | 1.27e-01 | 9.89e-01 | 2.17e-01 |
| ASPARAGINE METABOLIC PROCESS | 5 | 7.64e-01 | 1.00e+00 | 0.26400 | 5.77e-02 | -1.88e-02 | 9.07e-02 | 1.00e-01 | 2.19e-01 | 8.23e-01 | 9.42e-01 | 7.25e-01 | 6.98e-01 | 3.96e-01 |
| R LOOP PROCESSING | 6 | 8.78e-01 | 1.00e+00 | 0.26400 | -3.82e-02 | -7.72e-02 | 1.16e-01 | -1.50e-01 | 1.63e-01 | 8.71e-01 | 7.43e-01 | 6.24e-01 | 5.23e-01 | 4.90e-01 |
| NEGATIVE REGULATION OF IMMUNOGLOBULIN PRODUCTION | 11 | 7.52e-01 | 1.00e+00 | 0.26400 | 1.22e-01 | 9.82e-02 | 1.77e-01 | 9.11e-03 | 1.19e-01 | 4.84e-01 | 5.73e-01 | 3.10e-01 | 9.58e-01 | 4.96e-01 |
| UROGENITAL SYSTEM DEVELOPMENT | 66 | 5.80e-03 | 8.52e-02 | 0.26400 | 1.28e-01 | 9.47e-02 | 1.64e-01 | 7.22e-02 | -1.12e-01 | 7.31e-02 | 1.83e-01 | 2.14e-02 | 3.11e-01 | 1.16e-01 |
| ETHER BIOSYNTHETIC PROCESS | 12 | 5.57e-01 | 9.68e-01 | 0.26400 | -1.16e-01 | -1.23e-01 | -1.83e-01 | -5.32e-03 | 8.87e-02 | 4.88e-01 | 4.62e-01 | 2.72e-01 | 9.75e-01 | 5.95e-01 |
| HISTAMINE TRANSPORT | 15 | 4.25e-01 | 9.15e-01 | 0.26400 | 1.37e-01 | 7.28e-02 | 1.54e-01 | 1.29e-01 | 7.26e-02 | 3.58e-01 | 6.26e-01 | 3.01e-01 | 3.89e-01 | 6.27e-01 |
| MAINTENANCE OF PROTEIN LOCALIZATION IN ENDOPLASMIC RETICULUM | 12 | 1.74e-01 | 6.79e-01 | 0.26400 | 1.31e-01 | 1.50e-01 | 1.59e-01 | -5.31e-02 | 4.35e-02 | 4.32e-01 | 3.69e-01 | 3.40e-01 | 7.50e-01 | 7.94e-01 |
| RESPONSE TO ACTIVITY | 72 | 9.66e-02 | 5.12e-01 | 0.26400 | 1.34e-01 | 1.46e-01 | 1.38e-01 | 8.79e-02 | -6.04e-02 | 4.87e-02 | 3.23e-02 | 4.34e-02 | 1.97e-01 | 3.75e-01 |
| REGULATION OF METAPHASE PLATE CONGRESSION | 13 | 6.24e-01 | 9.93e-01 | 0.26400 | 1.03e-01 | 9.20e-02 | 1.73e-01 | 1.03e-01 | 1.00e-01 | 5.20e-01 | 5.66e-01 | 2.81e-01 | 5.19e-01 | 5.31e-01 |
| REGULATION OF RESPIRATORY GASEOUS EXCHANGE | 21 | 4.92e-01 | 9.45e-01 | 0.26400 | 1.20e-01 | 8.83e-02 | 2.13e-01 | 1.92e-02 | 3.91e-02 | 3.39e-01 | 4.84e-01 | 9.10e-02 | 8.79e-01 | 7.57e-01 |
| REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 18 | 6.11e-01 | 9.90e-01 | 0.26400 | -1.07e-01 | -1.26e-01 | -3.20e-02 | -6.12e-02 | 1.94e-01 | 4.32e-01 | 3.55e-01 | 8.14e-01 | 6.53e-01 | 1.55e-01 |
| HEART FIELD SPECIFICATION | 17 | 4.32e-01 | 9.19e-01 | 0.26400 | -1.03e-01 | -1.31e-01 | 2.87e-02 | -2.00e-01 | -3.17e-02 | 4.63e-01 | 3.48e-01 | 8.38e-01 | 1.54e-01 | 8.21e-01 |
| POSITIVE REGULATION OF EARLY ENDOSOME TO LATE ENDOSOME TRANSPORT | 8 | 6.43e-01 | 1.00e+00 | 0.26400 | -1.25e-01 | -1.48e-01 | -3.95e-02 | -3.07e-02 | 1.72e-01 | 5.40e-01 | 4.69e-01 | 8.47e-01 | 8.80e-01 | 4.00e-01 |
| CARDIOLIPIN METABOLIC PROCESS | 14 | 4.79e-01 | 9.41e-01 | 0.26400 | 1.41e-01 | 1.63e-01 | 1.46e-01 | 2.29e-02 | 3.67e-02 | 3.62e-01 | 2.90e-01 | 3.46e-01 | 8.82e-01 | 8.12e-01 |
| TRYPTOPHAN CATABOLIC PROCESS | 9 | 9.27e-01 | 1.00e+00 | 0.26300 | -1.02e-01 | -9.54e-02 | -9.47e-02 | -1.01e-01 | -1.75e-01 | 5.96e-01 | 6.20e-01 | 6.23e-01 | 5.99e-01 | 3.63e-01 |
| METANEPHRIC NEPHRON TUBULE MORPHOGENESIS | 8 | 7.37e-01 | 1.00e+00 | 0.26300 | 1.09e-01 | 1.30e-01 | 1.45e-01 | -1.43e-02 | -1.39e-01 | 5.94e-01 | 5.23e-01 | 4.78e-01 | 9.44e-01 | 4.97e-01 |
| REGULATION OF GRANULOCYTE DIFFERENTIATION | 16 | 6.18e-01 | 9.90e-01 | 0.26300 | -1.09e-01 | -1.42e-01 | -2.70e-02 | -1.90e-01 | 9.53e-03 | 4.49e-01 | 3.27e-01 | 8.52e-01 | 1.87e-01 | 9.47e-01 |
| INNERVATION | 26 | 5.85e-01 | 9.85e-01 | 0.26300 | -1.15e-01 | -9.45e-02 | -1.05e-01 | -1.65e-01 | -9.36e-02 | 3.12e-01 | 4.04e-01 | 3.54e-01 | 1.45e-01 | 4.09e-01 |
| LUNG MORPHOGENESIS | 54 | 2.26e-01 | 7.48e-01 | 0.26300 | 1.35e-01 | 1.16e-01 | 1.44e-01 | 1.22e-01 | -4.42e-02 | 8.71e-02 | 1.41e-01 | 6.69e-02 | 1.22e-01 | 5.74e-01 |
| NEUROTRANSMITTER CATABOLIC PROCESS | 8 | 8.89e-01 | 1.00e+00 | 0.26300 | -8.06e-02 | -8.58e-02 | -1.43e-02 | -4.73e-02 | 2.30e-01 | 6.93e-01 | 6.74e-01 | 9.44e-01 | 8.17e-01 | 2.61e-01 |
| DENDRITIC TRANSPORT | 12 | 8.73e-01 | 1.00e+00 | 0.26300 | -1.14e-01 | -1.21e-01 | -1.63e-02 | -1.70e-01 | 1.10e-01 | 4.93e-01 | 4.68e-01 | 9.22e-01 | 3.07e-01 | 5.11e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CELL PERIPHERY | 70 | 3.30e-01 | 8.55e-01 | 0.26300 | 1.34e-01 | 1.47e-01 | 1.03e-01 | 1.35e-01 | 2.52e-02 | 5.29e-02 | 3.31e-02 | 1.37e-01 | 5.07e-02 | 7.16e-01 |
| POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 18 | 6.00e-01 | 9.90e-01 | 0.26300 | 1.16e-01 | 1.13e-01 | 1.27e-01 | 7.12e-02 | -1.47e-01 | 3.95e-01 | 4.06e-01 | 3.49e-01 | 6.01e-01 | 2.81e-01 |
| NEGATIVE REGULATION OF INFLAMMASOME MEDIATED SIGNALING PATHWAY | 15 | 8.01e-01 | 1.00e+00 | 0.26300 | -1.18e-01 | -1.13e-01 | -5.30e-02 | -1.64e-01 | 1.12e-01 | 4.29e-01 | 4.49e-01 | 7.22e-01 | 2.72e-01 | 4.51e-01 |
| ENTRY OF BACTERIUM INTO HOST CELL | 9 | 8.23e-01 | 1.00e+00 | 0.26200 | -3.10e-02 | 5.06e-03 | -7.48e-02 | -2.72e-02 | -2.48e-01 | 8.72e-01 | 9.79e-01 | 6.98e-01 | 8.88e-01 | 1.97e-01 |
| RESPONSE TO GLUCAGON | 20 | 8.00e-01 | 1.00e+00 | 0.26200 | 1.24e-01 | 1.37e-01 | 6.79e-02 | 1.65e-01 | -5.22e-02 | 3.37e-01 | 2.89e-01 | 5.99e-01 | 2.00e-01 | 6.86e-01 |
| CEREBRAL CORTEX REGIONALIZATION | 7 | 3.90e-01 | 8.92e-01 | 0.26200 | 6.49e-02 | -4.12e-02 | 2.22e-01 | -4.18e-02 | 1.09e-01 | 7.66e-01 | 8.50e-01 | 3.09e-01 | 8.48e-01 | 6.18e-01 |
| PROTEIN LOCALIZATION TO ENDOSOME | 26 | 8.46e-01 | 1.00e+00 | 0.26200 | -1.41e-01 | -1.24e-01 | -1.51e-01 | -1.04e-01 | -7.70e-03 | 2.13e-01 | 2.75e-01 | 1.83e-01 | 3.61e-01 | 9.46e-01 |
| POSITIVE REGULATION OF TRIGLYCERIDE LIPASE ACTIVITY | 9 | 6.32e-01 | 9.96e-01 | 0.26200 | 1.27e-01 | 1.80e-01 | 1.09e-01 | 3.69e-02 | -8.39e-02 | 5.08e-01 | 3.50e-01 | 5.72e-01 | 8.48e-01 | 6.63e-01 |
| PEPTIDYL LYSINE MONOMETHYLATION | 9 | 9.28e-01 | 1.00e+00 | 0.26200 | -1.30e-01 | -1.67e-01 | -6.45e-02 | -1.30e-01 | 5.24e-02 | 4.98e-01 | 3.84e-01 | 7.38e-01 | 5.01e-01 | 7.85e-01 |
| CEREBELLAR CORTEX DEVELOPMENT | 49 | 2.99e-01 | 8.26e-01 | 0.26200 | 1.23e-01 | 9.95e-02 | 1.87e-01 | 5.03e-02 | 7.86e-02 | 1.35e-01 | 2.28e-01 | 2.37e-02 | 5.43e-01 | 3.41e-01 |
| NATURAL KILLER CELL DIFFERENTIATION | 24 | 5.63e-01 | 9.71e-01 | 0.26200 | -1.00e-01 | -1.28e-01 | 1.41e-02 | -1.50e-01 | 1.39e-01 | 3.96e-01 | 2.77e-01 | 9.05e-01 | 2.02e-01 | 2.38e-01 |
| PENILE ERECTION | 7 | 7.50e-01 | 1.00e+00 | 0.26200 | 9.32e-02 | 1.64e-01 | -1.04e-02 | 7.21e-02 | -1.67e-01 | 6.69e-01 | 4.54e-01 | 9.62e-01 | 7.41e-01 | 4.44e-01 |
| REGULATION OF RNA SPLICING | 163 | 2.78e-03 | 4.95e-02 | 0.26200 | 1.16e-01 | 1.01e-01 | 1.73e-01 | 6.20e-02 | 1.05e-01 | 1.08e-02 | 2.56e-02 | 1.35e-04 | 1.72e-01 | 2.06e-02 |
| MIDDLE EAR MORPHOGENESIS | 20 | 1.30e-02 | 1.51e-01 | 0.26200 | 4.80e-02 | -3.85e-02 | 2.32e-01 | -1.04e-01 | 1.67e-02 | 7.10e-01 | 7.65e-01 | 7.29e-02 | 4.21e-01 | 8.97e-01 |
| LOOP OF HENLE DEVELOPMENT | 12 | 7.89e-01 | 1.00e+00 | 0.26200 | 1.11e-01 | 8.99e-02 | 1.34e-01 | 5.31e-02 | 1.66e-01 | 5.05e-01 | 5.90e-01 | 4.23e-01 | 7.50e-01 | 3.20e-01 |
| REGULATION OF PROTEIN AUTOPHOSPHORYLATION | 39 | 1.04e-01 | 5.36e-01 | 0.26200 | -1.29e-01 | -1.18e-01 | -3.09e-02 | -1.91e-01 | -2.34e-02 | 1.63e-01 | 2.01e-01 | 7.38e-01 | 3.94e-02 | 8.01e-01 |
| AXIS ELONGATION | 28 | 2.03e-01 | 7.22e-01 | 0.26200 | 1.21e-01 | 9.56e-02 | 2.03e-01 | 4.95e-02 | -3.07e-02 | 2.66e-01 | 3.81e-01 | 6.31e-02 | 6.50e-01 | 7.78e-01 |
| NEGATIVE REGULATION OF MAP KINASE ACTIVITY | 50 | 8.08e-02 | 4.68e-01 | 0.26200 | -5.62e-03 | -3.05e-02 | 9.64e-02 | -4.42e-02 | 2.37e-01 | 9.45e-01 | 7.09e-01 | 2.38e-01 | 5.89e-01 | 3.72e-03 |
| CITRATE METABOLIC PROCESS | 5 | 9.10e-01 | 1.00e+00 | 0.26200 | 1.24e-01 | 8.74e-02 | 2.04e-01 | -4.57e-03 | -6.00e-02 | 6.31e-01 | 7.35e-01 | 4.29e-01 | 9.86e-01 | 8.16e-01 |
| TRANSDIFFERENTIATION | 7 | 7.59e-01 | 1.00e+00 | 0.26100 | -5.96e-02 | -5.28e-02 | 2.36e-02 | -1.90e-01 | -1.60e-01 | 7.85e-01 | 8.09e-01 | 9.14e-01 | 3.85e-01 | 4.64e-01 |
| INDUCTION OF POSITIVE CHEMOTAXIS | 13 | 9.06e-01 | 1.00e+00 | 0.26100 | 1.25e-01 | 1.03e-01 | 1.83e-01 | 7.28e-02 | 5.75e-02 | 4.35e-01 | 5.22e-01 | 2.53e-01 | 6.49e-01 | 7.20e-01 |
| REGULATION OF MUSCLE CONTRACTION | 163 | 1.17e-02 | 1.41e-01 | 0.26100 | 1.33e-01 | 1.33e-01 | 1.28e-01 | 1.26e-01 | -2.47e-02 | 3.32e-03 | 3.29e-03 | 4.91e-03 | 5.58e-03 | 5.86e-01 |
| POSITIVE REGULATION OF 3 UTR MEDIATED MRNA STABILIZATION | 5 | 8.97e-01 | 1.00e+00 | 0.26100 | -8.26e-02 | -6.99e-02 | -8.94e-02 | 2.53e-02 | 2.19e-01 | 7.49e-01 | 7.87e-01 | 7.29e-01 | 9.22e-01 | 3.97e-01 |
| REGULATION OF PROTEIN ACETYLATION | 38 | 2.45e-01 | 7.72e-01 | 0.26100 | 1.23e-01 | 1.32e-01 | 1.68e-01 | 4.28e-02 | 7.44e-02 | 1.90e-01 | 1.58e-01 | 7.30e-02 | 6.48e-01 | 4.28e-01 |
| REGULATION OF REMOVAL OF SUPEROXIDE RADICALS | 9 | 1.92e-01 | 7.02e-01 | 0.26100 | -2.08e-02 | 1.72e-02 | -1.86e-01 | 1.02e-01 | 1.50e-01 | 9.14e-01 | 9.29e-01 | 3.34e-01 | 5.96e-01 | 4.36e-01 |
| REGULATION OF MODIFICATION OF POSTSYNAPTIC STRUCTURE | 9 | 5.68e-01 | 9.73e-01 | 0.26100 | -6.99e-02 | -8.50e-02 | -1.03e-01 | 2.33e-02 | -2.12e-01 | 7.16e-01 | 6.59e-01 | 5.94e-01 | 9.04e-01 | 2.70e-01 |
| REGULATION OF TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 10 | 5.02e-01 | 9.48e-01 | 0.26100 | -7.45e-02 | -1.48e-01 | 9.03e-03 | -7.62e-02 | 1.86e-01 | 6.83e-01 | 4.17e-01 | 9.61e-01 | 6.76e-01 | 3.08e-01 |
| COMPARTMENT PATTERN SPECIFICATION | 5 | 9.56e-01 | 1.00e+00 | 0.26100 | 1.35e-01 | 1.36e-01 | 1.73e-01 | 1.37e-02 | -3.64e-02 | 6.01e-01 | 5.98e-01 | 5.04e-01 | 9.58e-01 | 8.88e-01 |
| VERY LONG CHAIN FATTY ACID METABOLIC PROCESS | 34 | 7.57e-02 | 4.52e-01 | 0.26100 | 9.86e-02 | 1.09e-01 | 3.16e-02 | 2.13e-01 | -3.26e-03 | 3.20e-01 | 2.73e-01 | 7.50e-01 | 3.14e-02 | 9.74e-01 |
| REGULATION OF B CELL MEDIATED IMMUNITY | 61 | 4.44e-02 | 3.39e-01 | 0.26100 | -7.77e-02 | -1.11e-01 | 4.06e-02 | -1.32e-01 | 1.75e-01 | 2.94e-01 | 1.34e-01 | 5.84e-01 | 7.37e-02 | 1.83e-02 |
| REGULATION OF TELOMERE MAINTENANCE VIA TELOMERE LENGTHENING | 57 | 1.34e-01 | 6.08e-01 | 0.26100 | -1.10e-01 | -1.17e-01 | -2.96e-02 | -1.06e-01 | 1.73e-01 | 1.51e-01 | 1.25e-01 | 6.99e-01 | 1.67e-01 | 2.37e-02 |
| NUCLEOSIDE TRANSPORT | 10 | 7.51e-01 | 1.00e+00 | 0.26100 | 8.63e-02 | 1.17e-01 | 6.80e-02 | 1.13e-01 | 1.72e-01 | 6.36e-01 | 5.22e-01 | 7.10e-01 | 5.36e-01 | 3.48e-01 |
| AXON ENSHEATHMENT IN CENTRAL NERVOUS SYSTEM | 25 | 1.82e-01 | 6.89e-01 | 0.26100 | -4.45e-02 | -5.14e-02 | 5.98e-02 | -1.46e-01 | 1.96e-01 | 7.00e-01 | 6.57e-01 | 6.05e-01 | 2.07e-01 | 8.98e-02 |
| SECRETION OF LYSOSOMAL ENZYMES | 7 | 7.42e-01 | 1.00e+00 | 0.26100 | 6.54e-02 | 3.98e-02 | 2.19e-01 | -8.35e-02 | 8.41e-02 | 7.64e-01 | 8.55e-01 | 3.16e-01 | 7.02e-01 | 7.00e-01 |
| POSITIVE REGULATION OF PINOCYTOSIS | 7 | 6.46e-01 | 1.00e+00 | 0.26000 | -8.01e-02 | -1.54e-01 | 6.07e-02 | -1.80e-01 | 4.12e-02 | 7.14e-01 | 4.80e-01 | 7.81e-01 | 4.10e-01 | 8.50e-01 |
| TAXIS | 447 | 1.50e-07 | 1.25e-05 | 0.26000 | -1.41e-01 | -1.56e-01 | -8.75e-02 | -1.21e-01 | 3.62e-02 | 3.00e-07 | 1.59e-08 | 1.52e-03 | 1.19e-05 | 1.90e-01 |
| DNA STRAND ELONGATION | 36 | 1.02e-01 | 5.30e-01 | 0.26000 | 1.84e-02 | -1.78e-02 | 1.60e-01 | -6.69e-02 | 1.92e-01 | 8.49e-01 | 8.53e-01 | 9.64e-02 | 4.87e-01 | 4.60e-02 |
| MITOTIC SPINDLE ASSEMBLY | 67 | 8.09e-03 | 1.08e-01 | 0.26000 | 6.99e-02 | 3.32e-02 | 1.93e-01 | 7.06e-03 | 1.56e-01 | 3.23e-01 | 6.39e-01 | 6.38e-03 | 9.20e-01 | 2.68e-02 |
| CELL CELL JUNCTION MAINTENANCE | 18 | 7.78e-01 | 1.00e+00 | 0.26000 | 1.15e-01 | 1.08e-01 | 1.70e-01 | 8.06e-02 | 8.42e-02 | 3.96e-01 | 4.29e-01 | 2.11e-01 | 5.54e-01 | 5.36e-01 |
| GAMMA AMINOBUTYRIC ACID IMPORT | 6 | 7.48e-01 | 1.00e+00 | 0.26000 | 7.35e-03 | 8.63e-02 | -1.06e-01 | -6.42e-03 | -2.21e-01 | 9.75e-01 | 7.14e-01 | 6.53e-01 | 9.78e-01 | 3.49e-01 |
| CELL REDOX HOMEOSTASIS | 38 | 2.54e-01 | 7.81e-01 | 0.26000 | 1.28e-01 | 1.34e-01 | 1.52e-01 | 5.30e-02 | -8.57e-02 | 1.73e-01 | 1.53e-01 | 1.05e-01 | 5.72e-01 | 3.61e-01 |
| REGULATION OF PLASMA LIPOPROTEIN PARTICLE LEVELS | 91 | 2.82e-01 | 8.09e-01 | 0.26000 | 1.40e-01 | 1.46e-01 | 1.01e-01 | 1.28e-01 | 4.49e-03 | 2.09e-02 | 1.63e-02 | 9.71e-02 | 3.42e-02 | 9.41e-01 |
| ANDROGEN BIOSYNTHETIC PROCESS | 10 | 4.48e-01 | 9.30e-01 | 0.26000 | -1.19e-01 | -3.92e-02 | -2.09e-01 | -8.31e-02 | -3.73e-02 | 5.15e-01 | 8.30e-01 | 2.53e-01 | 6.49e-01 | 8.38e-01 |
| MAMMALIAN OOGENESIS STAGE | 12 | 3.71e-01 | 8.81e-01 | 0.26000 | -2.42e-02 | -5.01e-02 | -1.02e-01 | -1.36e-02 | -2.32e-01 | 8.84e-01 | 7.64e-01 | 5.42e-01 | 9.35e-01 | 1.64e-01 |
| PLASMINOGEN ACTIVATION | 26 | 7.07e-01 | 1.00e+00 | 0.25900 | -1.13e-01 | -1.10e-01 | -1.40e-01 | -6.93e-02 | -1.34e-01 | 3.18e-01 | 3.30e-01 | 2.17e-01 | 5.41e-01 | 2.36e-01 |
| REGULATION OF GERM CELL PROLIFERATION | 7 | 8.88e-01 | 1.00e+00 | 0.25900 | 8.90e-02 | 4.47e-02 | 1.52e-01 | 1.89e-02 | 1.84e-01 | 6.84e-01 | 8.38e-01 | 4.85e-01 | 9.31e-01 | 4.00e-01 |
| NEGATIVE REGULATION OF SYNAPSE ORGANIZATION | 11 | 7.06e-01 | 1.00e+00 | 0.25900 | 1.28e-01 | 1.21e-01 | 1.62e-01 | -6.84e-03 | -9.84e-02 | 4.63e-01 | 4.86e-01 | 3.51e-01 | 9.69e-01 | 5.72e-01 |
| MIDBRAIN HINDBRAIN BOUNDARY DEVELOPMENT | 7 | 6.97e-01 | 1.00e+00 | 0.25900 | 8.26e-02 | 7.93e-02 | 1.93e-01 | -9.13e-02 | 9.18e-02 | 7.05e-01 | 7.16e-01 | 3.76e-01 | 6.76e-01 | 6.74e-01 |
| RENAL SYSTEM PROCESS INVOLVED IN REGULATION OF BLOOD VOLUME | 13 | 2.96e-01 | 8.24e-01 | 0.25900 | -2.95e-02 | -7.24e-02 | 7.25e-02 | 4.43e-02 | 2.32e-01 | 8.54e-01 | 6.51e-01 | 6.51e-01 | 7.82e-01 | 1.48e-01 |
| AMP CATABOLIC PROCESS | 5 | 9.79e-01 | 1.00e+00 | 0.25900 | 1.14e-01 | 7.80e-02 | 1.53e-01 | 1.22e-01 | 9.79e-02 | 6.58e-01 | 7.63e-01 | 5.53e-01 | 6.36e-01 | 7.05e-01 |
| GLUCOSAMINE CONTAINING COMPOUND METABOLIC PROCESS | 23 | 2.52e-01 | 7.79e-01 | 0.25900 | 6.92e-02 | 1.26e-01 | -2.27e-02 | 9.62e-02 | -1.91e-01 | 5.66e-01 | 2.96e-01 | 8.50e-01 | 4.24e-01 | 1.12e-01 |
| METANEPHRIC LOOP OF HENLE DEVELOPMENT | 6 | 8.06e-01 | 1.00e+00 | 0.25900 | 1.82e-02 | 1.87e-02 | -9.75e-03 | 4.65e-02 | 2.53e-01 | 9.38e-01 | 9.37e-01 | 9.67e-01 | 8.44e-01 | 2.83e-01 |
| REGULATION OF NCRNA TRANSCRIPTION | 91 | 3.05e-02 | 2.72e-01 | 0.25900 | 1.11e-01 | 1.05e-01 | 1.70e-01 | 6.76e-02 | 1.00e-01 | 6.64e-02 | 8.48e-02 | 4.98e-03 | 2.65e-01 | 9.88e-02 |
| REGULATION OF MICROTUBULE DEPOLYMERIZATION | 26 | 5.47e-01 | 9.61e-01 | 0.25900 | 1.28e-01 | 1.21e-01 | 1.55e-01 | 7.45e-02 | -7.86e-02 | 2.58e-01 | 2.86e-01 | 1.70e-01 | 5.11e-01 | 4.88e-01 |
| REGULATION OF HYDROGEN PEROXIDE MEDIATED PROGRAMMED CELL DEATH | 14 | 4.40e-01 | 9.26e-01 | 0.25900 | -3.15e-02 | 3.58e-02 | -1.78e-01 | 4.72e-02 | -1.75e-01 | 8.38e-01 | 8.16e-01 | 2.49e-01 | 7.60e-01 | 2.56e-01 |
| GLYCOSYL COMPOUND CATABOLIC PROCESS | 34 | 4.08e-01 | 9.08e-01 | 0.25900 | -1.38e-01 | -1.17e-01 | -7.99e-02 | -1.65e-01 | 2.87e-02 | 1.65e-01 | 2.39e-01 | 4.20e-01 | 9.68e-02 | 7.72e-01 |
| RESPONSE TO L ASCORBIC ACID | 6 | 1.37e-01 | 6.17e-01 | 0.25900 | -7.78e-02 | -3.90e-02 | -1.00e-02 | -3.00e-02 | -2.41e-01 | 7.41e-01 | 8.69e-01 | 9.66e-01 | 8.99e-01 | 3.06e-01 |
| PROTEIN PROCESSING INVOLVED IN PROTEIN TARGETING TO MITOCHONDRION | 7 | 7.45e-01 | 1.00e+00 | 0.25900 | -1.35e-02 | -2.31e-02 | -4.35e-02 | 3.85e-02 | -2.51e-01 | 9.51e-01 | 9.16e-01 | 8.42e-01 | 8.60e-01 | 2.51e-01 |
| NUCLEOSIDE MONOPHOSPHATE PHOSPHORYLATION | 11 | 9.69e-01 | 1.00e+00 | 0.25800 | 1.37e-01 | 1.22e-01 | 1.60e-01 | 8.02e-02 | 3.03e-02 | 4.31e-01 | 4.83e-01 | 3.58e-01 | 6.45e-01 | 8.62e-01 |
| RESPONSE TO TYPE II INTERFERON | 137 | 2.07e-03 | 3.98e-02 | 0.25800 | -1.33e-01 | -1.48e-01 | -4.23e-02 | -1.30e-01 | 9.18e-02 | 7.08e-03 | 2.78e-03 | 3.93e-01 | 8.68e-03 | 6.37e-02 |
| ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 15 | 2.81e-01 | 8.06e-01 | 0.25800 | 1.07e-01 | 1.41e-01 | 1.66e-01 | 4.48e-02 | 7.60e-02 | 4.74e-01 | 3.46e-01 | 2.64e-01 | 7.64e-01 | 6.10e-01 |
| HAIR FOLLICLE MATURATION | 15 | 3.76e-01 | 8.83e-01 | 0.25800 | -9.69e-02 | -1.42e-01 | -5.76e-02 | -1.53e-01 | -1.00e-01 | 5.16e-01 | 3.40e-01 | 6.99e-01 | 3.04e-01 | 5.01e-01 |
| SPHINGOLIPID MEDIATED SIGNALING PATHWAY | 18 | 3.89e-01 | 8.92e-01 | 0.25800 | 1.09e-01 | 1.15e-01 | 1.96e-01 | 2.19e-02 | 5.28e-02 | 4.25e-01 | 3.99e-01 | 1.51e-01 | 8.72e-01 | 6.98e-01 |
| CELLULAR RESPONSE TO ALDEHYDE | 16 | 8.12e-01 | 1.00e+00 | 0.25800 | 1.16e-01 | 1.26e-01 | 4.38e-02 | 1.88e-01 | 5.65e-03 | 4.23e-01 | 3.83e-01 | 7.62e-01 | 1.94e-01 | 9.69e-01 |
| DENDRITIC CELL DIFFERENTIATION | 45 | 1.53e-01 | 6.49e-01 | 0.25800 | -1.16e-01 | -1.44e-01 | 4.50e-03 | -1.45e-01 | 1.04e-01 | 1.77e-01 | 9.35e-02 | 9.58e-01 | 9.19e-02 | 2.26e-01 |
| NEGATIVE REGULATION OF VASCULAR PERMEABILITY | 18 | 9.16e-01 | 1.00e+00 | 0.25800 | -1.43e-01 | -1.33e-01 | -1.14e-01 | -1.15e-01 | 4.55e-02 | 2.95e-01 | 3.28e-01 | 4.02e-01 | 3.98e-01 | 7.38e-01 |
| REGULATION OF INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 46 | 7.96e-02 | 4.64e-01 | 0.25800 | -1.23e-01 | -1.64e-01 | -6.47e-03 | -1.47e-01 | 5.36e-02 | 1.49e-01 | 5.47e-02 | 9.39e-01 | 8.50e-02 | 5.29e-01 |
| LOCOMOTION INVOLVED IN LOCOMOTORY BEHAVIOR | 11 | 4.80e-01 | 9.42e-01 | 0.25800 | 5.92e-02 | -7.50e-03 | 2.11e-01 | -1.47e-03 | 1.35e-01 | 7.34e-01 | 9.66e-01 | 2.25e-01 | 9.93e-01 | 4.38e-01 |
| S ADENOSYLMETHIONINE CYCLE | 7 | 7.06e-01 | 1.00e+00 | 0.25800 | 4.03e-02 | 2.76e-02 | 1.98e-01 | -1.07e-01 | 1.16e-01 | 8.54e-01 | 8.99e-01 | 3.65e-01 | 6.24e-01 | 5.94e-01 |
| MESENCHYMAL TO EPITHELIAL TRANSITION INVOLVED IN METANEPHROS MORPHOGENESIS | 11 | 3.92e-01 | 8.92e-01 | 0.25800 | -5.57e-02 | -1.22e-01 | 1.20e-01 | -1.77e-01 | 5.26e-02 | 7.49e-01 | 4.84e-01 | 4.92e-01 | 3.10e-01 | 7.63e-01 |
| PROTEIN K11 LINKED UBIQUITINATION | 28 | 4.06e-02 | 3.24e-01 | 0.25800 | 1.22e-01 | 1.36e-01 | 1.71e-01 | -4.58e-02 | -3.86e-02 | 2.64e-01 | 2.12e-01 | 1.17e-01 | 6.75e-01 | 7.24e-01 |
| NEGATIVE REGULATION OF CHROMOSOME SEGREGATION | 50 | 1.27e-01 | 5.93e-01 | 0.25700 | 1.19e-01 | 9.12e-02 | 1.98e-01 | 5.29e-02 | 4.24e-02 | 1.45e-01 | 2.65e-01 | 1.54e-02 | 5.17e-01 | 6.04e-01 |
| NEGATIVE REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 34 | 7.93e-01 | 1.00e+00 | 0.25700 | 1.33e-01 | 1.31e-01 | 1.19e-01 | 1.32e-01 | -6.40e-03 | 1.81e-01 | 1.85e-01 | 2.32e-01 | 1.84e-01 | 9.49e-01 |
| MAINTENANCE OF DNA REPEAT ELEMENTS | 7 | 7.86e-01 | 1.00e+00 | 0.25700 | -7.21e-02 | -9.75e-02 | 6.13e-02 | -2.18e-01 | 8.51e-03 | 7.41e-01 | 6.55e-01 | 7.79e-01 | 3.17e-01 | 9.69e-01 |
| APOPTOTIC PROCESS INVOLVED IN BLOOD VESSEL MORPHOGENESIS | 5 | 9.57e-01 | 1.00e+00 | 0.25700 | -1.05e-01 | -1.33e-01 | -1.45e-02 | -1.83e-01 | -6.16e-02 | 6.86e-01 | 6.06e-01 | 9.55e-01 | 4.79e-01 | 8.11e-01 |
| REGULATION OF INFLAMMATORY RESPONSE TO WOUNDING | 12 | 4.27e-01 | 9.16e-01 | 0.25700 | 1.11e-01 | 1.22e-01 | -3.27e-02 | 1.88e-01 | 4.74e-02 | 5.05e-01 | 4.63e-01 | 8.44e-01 | 2.59e-01 | 7.76e-01 |
| CARDIAC RIGHT VENTRICLE MORPHOGENESIS | 21 | 2.45e-02 | 2.34e-01 | 0.25700 | 1.27e-02 | -3.28e-02 | 1.51e-01 | -1.78e-01 | -1.01e-01 | 9.20e-01 | 7.94e-01 | 2.30e-01 | 1.58e-01 | 4.22e-01 |
| THYROID HORMONE MEDIATED SIGNALING PATHWAY | 8 | 4.95e-01 | 9.47e-01 | 0.25700 | -1.30e-02 | 3.48e-02 | -8.93e-02 | 1.02e-01 | 2.15e-01 | 9.49e-01 | 8.65e-01 | 6.62e-01 | 6.17e-01 | 2.92e-01 |
| INTRACELLULAR POTASSIUM ION HOMEOSTASIS | 15 | 3.02e-01 | 8.30e-01 | 0.25700 | -2.32e-02 | 1.68e-02 | -1.60e-02 | -1.39e-01 | -2.14e-01 | 8.77e-01 | 9.10e-01 | 9.14e-01 | 3.51e-01 | 1.52e-01 |
| EXOCYST LOCALIZATION | 5 | 4.52e-01 | 9.30e-01 | 0.25700 | 4.77e-02 | 1.44e-01 | -7.24e-02 | 1.76e-01 | 8.17e-02 | 8.54e-01 | 5.76e-01 | 7.79e-01 | 4.96e-01 | 7.52e-01 |
| TRACHEA MORPHOGENESIS | 11 | 5.62e-01 | 9.71e-01 | 0.25700 | 1.45e-01 | 9.52e-02 | 9.51e-02 | 1.64e-01 | 4.18e-03 | 4.06e-01 | 5.85e-01 | 5.85e-01 | 3.46e-01 | 9.81e-01 |
| POSITIVE REGULATION OF AMINE METABOLIC PROCESS | 6 | 9.07e-01 | 1.00e+00 | 0.25700 | 2.78e-02 | 3.93e-02 | -1.45e-02 | -3.93e-02 | -2.49e-01 | 9.06e-01 | 8.68e-01 | 9.51e-01 | 8.68e-01 | 2.91e-01 |
| POSITIVE REGULATION OF NOTCH SIGNALING PATHWAY | 45 | 3.61e-01 | 8.77e-01 | 0.25700 | 1.21e-01 | 1.48e-01 | 6.01e-02 | 1.09e-01 | -1.18e-01 | 1.62e-01 | 8.57e-02 | 4.85e-01 | 2.05e-01 | 1.71e-01 |
| ETHANOL CATABOLIC PROCESS | 10 | 6.84e-01 | 1.00e+00 | 0.25700 | -3.56e-02 | -2.03e-02 | -1.38e-01 | 8.46e-02 | -1.95e-01 | 8.45e-01 | 9.11e-01 | 4.51e-01 | 6.43e-01 | 2.86e-01 |
| REGULATION OF CELLULAR RESPONSE TO OSMOTIC STRESS | 13 | 7.71e-01 | 1.00e+00 | 0.25700 | 9.08e-02 | 5.96e-02 | 1.96e-01 | -5.96e-03 | 1.25e-01 | 5.71e-01 | 7.10e-01 | 2.21e-01 | 9.70e-01 | 4.36e-01 |
| NEGATIVE CHEMOTAXIS | 46 | 7.08e-02 | 4.37e-01 | 0.25600 | -6.67e-02 | -7.00e-02 | -1.16e-01 | -1.00e-02 | -2.07e-01 | 4.34e-01 | 4.11e-01 | 1.72e-01 | 9.06e-01 | 1.52e-02 |
| MITOCHONDRIAL TRANSLATIONAL ELONGATION | 5 | 9.86e-01 | 1.00e+00 | 0.25600 | 8.17e-02 | 5.61e-02 | 1.43e-01 | 4.83e-02 | 1.82e-01 | 7.52e-01 | 8.28e-01 | 5.80e-01 | 8.52e-01 | 4.81e-01 |
| POSITIVE REGULATION OF G0 TO G1 TRANSITION | 5 | 2.96e-01 | 8.24e-01 | 0.25600 | -4.94e-02 | -5.33e-02 | -2.02e-01 | -6.80e-02 | -1.22e-01 | 8.48e-01 | 8.36e-01 | 4.34e-01 | 7.92e-01 | 6.36e-01 |
| SEROTONIN METABOLIC PROCESS | 10 | 7.78e-01 | 1.00e+00 | 0.25600 | 2.25e-02 | 6.91e-02 | -1.05e-01 | 9.98e-02 | -1.98e-01 | 9.02e-01 | 7.05e-01 | 5.65e-01 | 5.85e-01 | 2.78e-01 |
| NEGATIVE REGULATION OF OSTEOBLAST DIFFERENTIATION | 62 | 1.31e-01 | 6.00e-01 | 0.25600 | 1.36e-01 | 1.20e-01 | 9.36e-02 | 1.13e-01 | -1.05e-01 | 6.40e-02 | 1.01e-01 | 2.02e-01 | 1.23e-01 | 1.52e-01 |
| KERATINIZATION | 80 | 3.57e-07 | 2.72e-05 | 0.25600 | -6.66e-02 | -2.32e-02 | -2.29e-01 | 9.00e-02 | -1.09e-02 | 3.03e-01 | 7.19e-01 | 3.99e-04 | 1.64e-01 | 8.66e-01 |
| DIACYLGLYCEROL BIOSYNTHETIC PROCESS | 9 | 9.67e-01 | 1.00e+00 | 0.25600 | 9.76e-02 | 7.55e-02 | 1.44e-01 | 8.10e-02 | 1.52e-01 | 6.12e-01 | 6.95e-01 | 4.54e-01 | 6.74e-01 | 4.31e-01 |
| ZYGOTIC DETERMINATION OF ANTERIOR POSTERIOR AXIS EMBRYO | 6 | 8.87e-01 | 1.00e+00 | 0.25600 | 1.30e-01 | 7.73e-02 | 1.69e-01 | 1.16e-01 | -2.56e-02 | 5.80e-01 | 7.43e-01 | 4.74e-01 | 6.24e-01 | 9.14e-01 |
| VESICLE COATING | 38 | 2.66e-01 | 7.95e-01 | 0.25600 | 7.94e-02 | 5.46e-02 | 1.63e-01 | 1.09e-04 | 1.72e-01 | 3.97e-01 | 5.60e-01 | 8.22e-02 | 9.99e-01 | 6.62e-02 |
| TYPE B PANCREATIC CELL DEVELOPMENT | 24 | 1.23e-01 | 5.84e-01 | 0.25600 | -6.43e-02 | -7.12e-02 | 3.95e-02 | -2.01e-01 | -1.20e-01 | 5.86e-01 | 5.46e-01 | 7.38e-01 | 8.88e-02 | 3.08e-01 |
| REGULATION OF DNA DAMAGE CHECKPOINT | 23 | 4.83e-01 | 9.43e-01 | 0.25600 | 5.47e-02 | 2.39e-02 | 1.52e-01 | 3.36e-02 | 1.94e-01 | 6.50e-01 | 8.43e-01 | 2.06e-01 | 7.80e-01 | 1.08e-01 |
| PROTEIN TARGETING TO VACUOLE INVOLVED IN AUTOPHAGY | 5 | 8.32e-01 | 1.00e+00 | 0.25600 | -4.12e-02 | -9.95e-03 | 1.98e-02 | -8.38e-02 | 2.37e-01 | 8.73e-01 | 9.69e-01 | 9.39e-01 | 7.46e-01 | 3.59e-01 |
| NEGATIVE REGULATION OF CARDIAC MUSCLE CELL DIFFERENTIATION | 10 | 7.59e-01 | 1.00e+00 | 0.25600 | -1.06e-01 | -1.08e-01 | -7.57e-02 | -1.92e-01 | -6.72e-03 | 5.61e-01 | 5.55e-01 | 6.78e-01 | 2.94e-01 | 9.71e-01 |
| CELLULAR PIGMENTATION | 60 | 1.10e-01 | 5.51e-01 | 0.25600 | -1.03e-01 | -1.19e-01 | 5.03e-03 | -1.53e-01 | 1.31e-01 | 1.68e-01 | 1.09e-01 | 9.46e-01 | 4.09e-02 | 7.91e-02 |
| LEUKOTRIENE BIOSYNTHETIC PROCESS | 17 | 3.63e-01 | 8.78e-01 | 0.25600 | 9.40e-02 | 6.78e-02 | 1.25e-01 | 1.64e-01 | 9.83e-02 | 5.02e-01 | 6.28e-01 | 3.74e-01 | 2.43e-01 | 4.83e-01 |
| CELL VOLUME HOMEOSTASIS | 34 | 4.90e-01 | 9.45e-01 | 0.25600 | 1.18e-01 | 1.36e-01 | 1.12e-01 | 1.13e-01 | 8.69e-02 | 2.34e-01 | 1.69e-01 | 2.58e-01 | 2.55e-01 | 3.81e-01 |
| NEURAL NUCLEUS DEVELOPMENT | 61 | 5.05e-01 | 9.48e-01 | 0.25600 | 1.39e-01 | 1.28e-01 | 1.41e-01 | 9.81e-02 | -1.03e-02 | 6.02e-02 | 8.40e-02 | 5.70e-02 | 1.85e-01 | 8.90e-01 |
| DGMP METABOLIC PROCESS | 5 | 9.90e-01 | 1.00e+00 | 0.25600 | -1.40e-01 | -1.22e-01 | -9.58e-02 | -1.47e-01 | -1.43e-02 | 5.89e-01 | 6.36e-01 | 7.11e-01 | 5.70e-01 | 9.56e-01 |
| REGULATION OF PLATELET ACTIVATION | 47 | 1.34e-01 | 6.09e-01 | 0.25500 | -1.20e-01 | -1.42e-01 | 1.33e-04 | -1.67e-01 | 5.32e-02 | 1.56e-01 | 9.23e-02 | 9.99e-01 | 4.74e-02 | 5.28e-01 |
| CHORIONIC TROPHOBLAST CELL DIFFERENTIATION | 7 | 9.59e-01 | 1.00e+00 | 0.25500 | 1.23e-01 | 1.05e-01 | 1.54e-01 | 1.22e-01 | 1.71e-02 | 5.72e-01 | 6.30e-01 | 4.80e-01 | 5.75e-01 | 9.38e-01 |
| POSITIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 107 | 1.32e-02 | 1.52e-01 | 0.25500 | -1.16e-01 | -1.36e-01 | -1.32e-02 | -1.69e-01 | 6.56e-02 | 3.84e-02 | 1.50e-02 | 8.14e-01 | 2.49e-03 | 2.41e-01 |
| REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 185 | 1.11e-06 | 6.98e-05 | 0.25500 | -8.28e-02 | -1.17e-01 | 4.32e-02 | -1.53e-01 | 1.39e-01 | 5.21e-02 | 6.16e-03 | 3.11e-01 | 3.45e-04 | 1.09e-03 |
| L GLUTAMATE IMPORT ACROSS PLASMA MEMBRANE | 17 | 7.39e-01 | 1.00e+00 | 0.25500 | 1.17e-01 | 1.48e-01 | 5.28e-02 | 1.61e-01 | -2.20e-02 | 4.04e-01 | 2.89e-01 | 7.06e-01 | 2.50e-01 | 8.75e-01 |
| REGULATION OF ATTACHMENT OF SPINDLE MICROTUBULES TO KINETOCHORE | 21 | 1.45e-01 | 6.29e-01 | 0.25500 | 8.23e-02 | 2.88e-02 | 1.96e-01 | 7.62e-02 | 1.15e-01 | 5.14e-01 | 8.20e-01 | 1.21e-01 | 5.46e-01 | 3.60e-01 |
| RESPONSE TO ATP | 31 | 7.08e-02 | 4.37e-01 | 0.25500 | 1.08e-01 | 7.10e-02 | 2.10e-01 | 6.16e-02 | 2.13e-02 | 2.98e-01 | 4.94e-01 | 4.33e-02 | 5.53e-01 | 8.37e-01 |
| POSITIVE REGULATION OF DNA CATABOLIC PROCESS | 5 | 9.53e-01 | 1.00e+00 | 0.25500 | 1.21e-01 | 1.19e-01 | 1.78e-01 | 5.97e-02 | -3.44e-02 | 6.41e-01 | 6.46e-01 | 4.91e-01 | 8.17e-01 | 8.94e-01 |
| ACETYL COA METABOLIC PROCESS | 31 | 4.77e-01 | 9.40e-01 | 0.25500 | 1.30e-01 | 1.48e-01 | 1.40e-01 | 7.94e-02 | -1.87e-02 | 2.11e-01 | 1.55e-01 | 1.77e-01 | 4.44e-01 | 8.57e-01 |
| REGULATION OF PODOSOME ASSEMBLY | 13 | 6.73e-01 | 1.00e+00 | 0.25500 | 8.02e-02 | 5.80e-02 | 1.92e-01 | 2.66e-02 | 1.32e-01 | 6.17e-01 | 7.17e-01 | 2.31e-01 | 8.68e-01 | 4.09e-01 |
| REGULATION OF HIPPO SIGNALING | 25 | 9.28e-02 | 5.02e-01 | 0.25500 | 4.54e-02 | 9.77e-02 | -7.50e-02 | 1.60e-01 | -1.49e-01 | 6.95e-01 | 3.98e-01 | 5.16e-01 | 1.66e-01 | 1.99e-01 |
| NAIL DEVELOPMENT | 11 | 8.39e-01 | 1.00e+00 | 0.25500 | 5.47e-02 | 2.25e-02 | 1.65e-01 | -1.59e-02 | 1.84e-01 | 7.53e-01 | 8.97e-01 | 3.44e-01 | 9.27e-01 | 2.91e-01 |
| POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 54 | 3.83e-01 | 8.92e-01 | 0.25400 | 1.23e-01 | 1.20e-01 | 1.49e-01 | 1.03e-01 | 4.81e-02 | 1.17e-01 | 1.28e-01 | 5.81e-02 | 1.90e-01 | 5.41e-01 |
| ASTRAL MICROTUBULE ORGANIZATION | 10 | 8.51e-01 | 1.00e+00 | 0.25400 | 8.32e-02 | 9.80e-02 | 6.45e-02 | 1.38e-01 | 1.58e-01 | 6.49e-01 | 5.91e-01 | 7.24e-01 | 4.51e-01 | 3.86e-01 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 37 | 7.58e-03 | 1.03e-01 | 0.25400 | 3.47e-02 | 1.47e-02 | 1.98e-01 | -1.20e-01 | 9.79e-02 | 7.15e-01 | 8.77e-01 | 3.72e-02 | 2.07e-01 | 3.03e-01 |
| BUNDLE OF HIS CELL TO PURKINJE MYOCYTE COMMUNICATION | 15 | 1.96e-01 | 7.09e-01 | 0.25400 | 8.44e-03 | 9.57e-02 | -1.09e-01 | 2.79e-02 | -2.07e-01 | 9.55e-01 | 5.21e-01 | 4.65e-01 | 8.51e-01 | 1.66e-01 |
| TERMINATION OF RNA POLYMERASE II TRANSCRIPTION | 10 | 7.39e-01 | 1.00e+00 | 0.25400 | -1.10e-01 | -9.67e-02 | 1.28e-03 | -1.63e-01 | 1.29e-01 | 5.48e-01 | 5.97e-01 | 9.94e-01 | 3.73e-01 | 4.79e-01 |
| AMYLOID PRECURSOR PROTEIN BIOSYNTHETIC PROCESS | 25 | 7.94e-01 | 1.00e+00 | 0.25400 | 1.36e-01 | 1.22e-01 | 1.09e-01 | 1.17e-01 | -7.35e-02 | 2.39e-01 | 2.89e-01 | 3.44e-01 | 3.12e-01 | 5.25e-01 |
| REGULATION OF MEMBRANE REPOLARIZATION DURING VENTRICULAR CARDIAC MUSCLE CELL ACTION POTENTIAL | 5 | 7.23e-01 | 1.00e+00 | 0.25400 | -1.48e-01 | -1.81e-01 | -9.07e-02 | -3.37e-02 | -1.90e-02 | 5.66e-01 | 4.83e-01 | 7.25e-01 | 8.96e-01 | 9.41e-01 |
| CENTRAL NERVOUS SYSTEM MYELIN FORMATION | 8 | 8.65e-01 | 1.00e+00 | 0.25400 | -1.20e-01 | -8.87e-02 | -9.69e-02 | -1.81e-01 | 1.19e-02 | 5.58e-01 | 6.64e-01 | 6.35e-01 | 3.75e-01 | 9.54e-01 |
| GROWTH PLATE CARTILAGE DEVELOPMENT | 20 | 7.91e-01 | 1.00e+00 | 0.25400 | 1.12e-01 | 1.14e-01 | 1.38e-01 | 6.46e-02 | 1.25e-01 | 3.87e-01 | 3.76e-01 | 2.84e-01 | 6.17e-01 | 3.34e-01 |
| POSITIVE REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 52 | 3.42e-01 | 8.60e-01 | 0.25400 | -1.15e-01 | -1.32e-01 | -2.99e-02 | -1.47e-01 | 1.06e-01 | 1.50e-01 | 9.94e-02 | 7.09e-01 | 6.74e-02 | 1.85e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 17 | 6.77e-01 | 1.00e+00 | 0.25400 | 1.49e-01 | 1.56e-01 | 9.92e-02 | 8.96e-02 | -9.43e-03 | 2.89e-01 | 2.65e-01 | 4.79e-01 | 5.22e-01 | 9.46e-01 |
| PEPTIDYL L CYSTEINE S PALMITOYLATION | 20 | 8.43e-01 | 1.00e+00 | 0.25400 | 1.17e-01 | 1.26e-01 | 1.13e-01 | 1.24e-01 | 8.26e-02 | 3.66e-01 | 3.31e-01 | 3.80e-01 | 3.38e-01 | 5.23e-01 |
| REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY | 28 | 8.18e-01 | 1.00e+00 | 0.25400 | 1.28e-01 | 1.39e-01 | 7.66e-02 | 1.50e-01 | 1.66e-02 | 2.42e-01 | 2.03e-01 | 4.83e-01 | 1.69e-01 | 8.79e-01 |
| THYROID HORMONE TRANSPORT | 10 | 4.25e-01 | 9.15e-01 | 0.25400 | 1.11e-01 | 1.68e-01 | 1.16e-01 | 5.09e-02 | 8.69e-02 | 5.44e-01 | 3.56e-01 | 5.24e-01 | 7.80e-01 | 6.34e-01 |
| RECEPTOR SIGNALING PATHWAY VIA STAT | 182 | 9.73e-03 | 1.23e-01 | 0.25400 | -1.28e-01 | -1.24e-01 | -8.21e-02 | -1.60e-01 | 1.46e-02 | 2.81e-03 | 3.94e-03 | 5.62e-02 | 1.98e-04 | 7.33e-01 |
| NEGATIVE REGULATION OF TELOMERE MAINTENANCE VIA TELOMERASE | 19 | 5.18e-01 | 9.52e-01 | 0.25400 | -5.54e-02 | -6.71e-02 | 5.79e-02 | -8.23e-02 | 2.16e-01 | 6.76e-01 | 6.13e-01 | 6.62e-01 | 5.35e-01 | 1.03e-01 |
| CHONDROCYTE HYPERTROPHY | 6 | 8.31e-01 | 1.00e+00 | 0.25400 | 4.34e-03 | 1.18e-02 | 1.08e-01 | -1.74e-02 | 2.28e-01 | 9.85e-01 | 9.60e-01 | 6.47e-01 | 9.41e-01 | 3.33e-01 |
| REGULATION OF STRIATED MUSCLE TISSUE DEVELOPMENT | 18 | 6.50e-01 | 1.00e+00 | 0.25400 | 1.24e-01 | 1.39e-01 | 6.08e-03 | 1.56e-01 | -7.34e-02 | 3.64e-01 | 3.06e-01 | 9.64e-01 | 2.53e-01 | 5.90e-01 |
| LEUKOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELL | 55 | 6.15e-01 | 9.90e-01 | 0.25300 | -1.38e-01 | -1.36e-01 | -1.26e-01 | -1.02e-01 | 2.29e-02 | 7.73e-02 | 8.14e-02 | 1.05e-01 | 1.92e-01 | 7.69e-01 |
| PROSTATE GLAND DEVELOPMENT | 49 | 2.01e-02 | 2.09e-01 | 0.25300 | 1.17e-01 | 8.11e-02 | 1.43e-01 | 7.19e-02 | -1.35e-01 | 1.57e-01 | 3.26e-01 | 8.32e-02 | 3.84e-01 | 1.01e-01 |
| POSITIVE REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 65 | 9.61e-02 | 5.12e-01 | 0.25300 | -1.13e-01 | -1.37e-01 | -1.85e-02 | -1.76e-01 | 3.39e-02 | 1.15e-01 | 5.52e-02 | 7.96e-01 | 1.41e-02 | 6.37e-01 |
| HISTONE H3 K4 METHYLATION | 18 | 6.24e-01 | 9.93e-01 | 0.25300 | 8.31e-02 | 6.68e-02 | 1.22e-01 | 1.22e-01 | 1.52e-01 | 5.42e-01 | 6.24e-01 | 3.71e-01 | 3.69e-01 | 2.65e-01 |
| CORONARY VASCULATURE MORPHOGENESIS | 19 | 5.07e-01 | 9.48e-01 | 0.25300 | -5.45e-02 | -7.87e-02 | 7.77e-02 | -1.42e-01 | 1.69e-01 | 6.81e-01 | 5.52e-01 | 5.58e-01 | 2.84e-01 | 2.01e-01 |
| REGULATION OF CEREBELLAR GRANULE CELL PRECURSOR PROLIFERATION | 11 | 6.97e-01 | 1.00e+00 | 0.25300 | 1.13e-01 | 1.26e-01 | 1.55e-01 | 7.64e-03 | -1.07e-01 | 5.18e-01 | 4.68e-01 | 3.74e-01 | 9.65e-01 | 5.39e-01 |
| POSITIVE REGULATION OF TELOMERE CAPPING | 17 | 5.24e-01 | 9.54e-01 | 0.25300 | 5.97e-02 | 6.81e-02 | 1.89e-02 | 1.24e-01 | 2.00e-01 | 6.70e-01 | 6.27e-01 | 8.93e-01 | 3.75e-01 | 1.53e-01 |
| NEGATIVE REGULATION OF LONG TERM SYNAPTIC POTENTIATION | 13 | 4.12e-01 | 9.08e-01 | 0.25300 | -9.92e-02 | -1.01e-01 | -1.09e-01 | 4.88e-02 | 1.73e-01 | 5.36e-01 | 5.30e-01 | 4.97e-01 | 7.61e-01 | 2.80e-01 |
| REGULATION OF CHLORIDE TRANSPORT | 6 | 9.28e-01 | 1.00e+00 | 0.25300 | -3.99e-02 | -4.60e-02 | -1.00e-01 | -2.60e-02 | -2.23e-01 | 8.66e-01 | 8.45e-01 | 6.71e-01 | 9.12e-01 | 3.45e-01 |
| VIRAL GENE EXPRESSION | 99 | 4.33e-03 | 6.88e-02 | 0.25300 | 5.00e-02 | 1.47e-02 | 1.49e-01 | 3.02e-03 | 1.97e-01 | 3.90e-01 | 8.01e-01 | 1.02e-02 | 9.59e-01 | 6.84e-04 |
| CDP DIACYLGLYCEROL BIOSYNTHETIC PROCESS | 12 | 5.58e-01 | 9.69e-01 | 0.25300 | 1.28e-01 | 1.32e-01 | 2.97e-02 | 1.49e-01 | 8.50e-02 | 4.42e-01 | 4.30e-01 | 8.59e-01 | 3.72e-01 | 6.10e-01 |
| VIRAL PROTEIN PROCESSING | 31 | 4.14e-01 | 9.11e-01 | 0.25300 | -1.05e-01 | -1.35e-01 | 1.04e-02 | -1.35e-01 | 1.27e-01 | 3.10e-01 | 1.92e-01 | 9.20e-01 | 1.92e-01 | 2.21e-01 |
| DETECTION OF TEMPERATURE STIMULUS | 24 | 8.68e-01 | 1.00e+00 | 0.25300 | 1.32e-01 | 1.43e-01 | 1.13e-01 | 1.14e-01 | -2.08e-02 | 2.65e-01 | 2.25e-01 | 3.36e-01 | 3.36e-01 | 8.60e-01 |
| POSITIVE REGULATION OF PROSTAGLANDIN BIOSYNTHETIC PROCESS | 7 | 6.03e-01 | 9.90e-01 | 0.25300 | 7.58e-02 | 2.98e-02 | 2.01e-01 | -6.20e-02 | -1.15e-01 | 7.29e-01 | 8.92e-01 | 3.58e-01 | 7.76e-01 | 5.98e-01 |
| RESPONSE TO SODIUM PHOSPHATE | 7 | 8.86e-01 | 1.00e+00 | 0.25300 | 1.01e-01 | 1.07e-01 | 9.96e-02 | 5.04e-02 | 1.73e-01 | 6.45e-01 | 6.24e-01 | 6.48e-01 | 8.17e-01 | 4.28e-01 |
| BLASTODERM SEGMENTATION | 24 | 4.10e-01 | 9.08e-01 | 0.25300 | -1.11e-01 | -1.34e-01 | -8.52e-02 | -8.95e-02 | -1.35e-01 | 3.46e-01 | 2.57e-01 | 4.70e-01 | 4.48e-01 | 2.51e-01 |
| BONE RESORPTION | 65 | 3.51e-02 | 2.98e-01 | 0.25300 | -1.29e-01 | -1.33e-01 | -3.59e-02 | -1.16e-01 | 1.22e-01 | 7.30e-02 | 6.34e-02 | 6.17e-01 | 1.06e-01 | 8.92e-02 |
| GANGLIOSIDE METABOLIC PROCESS | 28 | 2.72e-01 | 7.99e-01 | 0.25300 | -3.50e-02 | -8.47e-02 | 8.12e-02 | -6.52e-02 | 2.11e-01 | 7.48e-01 | 4.38e-01 | 4.57e-01 | 5.50e-01 | 5.33e-02 |
| DETOXIFICATION OF COPPER ION | 15 | 1.81e-01 | 6.89e-01 | 0.25200 | 2.33e-02 | -1.04e-02 | 1.77e-01 | -1.70e-01 | 5.23e-02 | 8.76e-01 | 9.45e-01 | 2.35e-01 | 2.53e-01 | 7.26e-01 |
| INCLUSION BODY ASSEMBLY | 23 | 6.48e-01 | 1.00e+00 | 0.25200 | 8.05e-02 | 6.29e-02 | 9.09e-02 | 8.95e-02 | 1.92e-01 | 5.04e-01 | 6.01e-01 | 4.50e-01 | 4.58e-01 | 1.10e-01 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 43 | 4.97e-01 | 9.47e-01 | 0.25200 | -1.31e-01 | -1.19e-01 | -9.90e-02 | -1.21e-01 | 8.89e-02 | 1.36e-01 | 1.77e-01 | 2.61e-01 | 1.71e-01 | 3.13e-01 |
| NEGATIVE REGULATION OF MEIOTIC CELL CYCLE | 17 | 3.93e-01 | 8.92e-01 | 0.25200 | 1.08e-01 | 8.36e-02 | 1.35e-01 | -6.30e-03 | -1.63e-01 | 4.43e-01 | 5.51e-01 | 3.33e-01 | 9.64e-01 | 2.43e-01 |
| L ALANINE TRANSPORT | 10 | 3.73e-01 | 8.82e-01 | 0.25200 | 1.11e-01 | 1.41e-01 | -2.83e-02 | 6.08e-02 | -1.64e-01 | 5.44e-01 | 4.39e-01 | 8.77e-01 | 7.39e-01 | 3.69e-01 |
| ASPARTATE FAMILY AMINO ACID BIOSYNTHETIC PROCESS | 21 | 6.37e-01 | 9.98e-01 | 0.25200 | -1.33e-01 | -9.98e-02 | -1.04e-01 | -1.58e-01 | -1.34e-02 | 2.91e-01 | 4.29e-01 | 4.09e-01 | 2.10e-01 | 9.15e-01 |
| CELLULAR RESPONSE TO MAGNESIUM ION | 7 | 8.88e-01 | 1.00e+00 | 0.25200 | -8.13e-02 | -9.07e-02 | -1.71e-02 | -1.88e-01 | -1.15e-01 | 7.10e-01 | 6.78e-01 | 9.38e-01 | 3.89e-01 | 5.99e-01 |
| SULFUR AMINO ACID BIOSYNTHETIC PROCESS | 16 | 6.73e-01 | 1.00e+00 | 0.25200 | -7.01e-02 | -4.04e-02 | -7.78e-02 | -9.31e-02 | -2.06e-01 | 6.27e-01 | 7.80e-01 | 5.90e-01 | 5.19e-01 | 1.55e-01 |
| GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR PRODUCTION | 18 | 2.43e-01 | 7.69e-01 | 0.25200 | -8.20e-02 | -1.14e-01 | 5.14e-02 | -1.84e-01 | -8.52e-02 | 5.47e-01 | 4.02e-01 | 7.06e-01 | 1.77e-01 | 5.31e-01 |
| CELL FATE COMMITMENT INVOLVED IN FORMATION OF PRIMARY GERM LAYER | 32 | 6.37e-02 | 4.13e-01 | 0.25200 | 4.38e-02 | 4.52e-02 | 7.81e-02 | -5.47e-02 | -2.25e-01 | 6.68e-01 | 6.58e-01 | 4.44e-01 | 5.93e-01 | 2.79e-02 |
| C 5 METHYLATION OF CYTOSINE | 5 | 9.35e-01 | 1.00e+00 | 0.25200 | 9.44e-02 | 9.53e-02 | 1.71e-01 | 6.76e-02 | 1.08e-01 | 7.15e-01 | 7.12e-01 | 5.09e-01 | 7.94e-01 | 6.74e-01 |
| INTESTINAL ABSORPTION | 41 | 1.18e-01 | 5.71e-01 | 0.25200 | 1.01e-01 | 1.26e-01 | 3.45e-02 | 1.44e-01 | 1.24e-01 | 2.63e-01 | 1.63e-01 | 7.02e-01 | 1.11e-01 | 1.69e-01 |
| NEGATIVE REGULATION OF LOW DENSITY LIPOPROTEIN RECEPTOR ACTIVITY | 10 | 7.70e-01 | 1.00e+00 | 0.25200 | -6.80e-02 | -8.78e-02 | -2.09e-02 | -1.46e-01 | -1.71e-01 | 7.10e-01 | 6.31e-01 | 9.09e-01 | 4.23e-01 | 3.49e-01 |
| REGULATION OF XENOPHAGY | 9 | 8.54e-01 | 1.00e+00 | 0.25200 | 3.81e-03 | 2.44e-03 | 5.32e-02 | -1.20e-02 | 2.46e-01 | 9.84e-01 | 9.90e-01 | 7.82e-01 | 9.50e-01 | 2.02e-01 |
| REGULATION OF AMINO ACID TRANSPORT | 41 | 3.76e-01 | 8.84e-01 | 0.25200 | 1.25e-01 | 1.27e-01 | 1.35e-01 | 6.98e-02 | -9.32e-02 | 1.66e-01 | 1.60e-01 | 1.35e-01 | 4.39e-01 | 3.02e-01 |
| WNT SIGNALING PATHWAY INVOLVED IN MIDBRAIN DOPAMINERGIC NEURON DIFFERENTIATION | 12 | 5.83e-01 | 9.85e-01 | 0.25200 | -1.07e-01 | -1.46e-01 | -4.96e-02 | -1.05e-01 | -1.31e-01 | 5.22e-01 | 3.82e-01 | 7.66e-01 | 5.28e-01 | 4.31e-01 |
| REGULATION OF LEUKOCYTE ADHESION TO ARTERIAL ENDOTHELIAL CELL | 5 | 8.06e-01 | 1.00e+00 | 0.25200 | 4.58e-02 | 3.75e-02 | -4.56e-02 | 1.83e-01 | -1.56e-01 | 8.59e-01 | 8.84e-01 | 8.60e-01 | 4.78e-01 | 5.47e-01 |
| REGULATION OF MAINTENANCE OF SISTER CHROMATID COHESION | 7 | 1.09e-01 | 5.46e-01 | 0.25200 | 1.09e-01 | -1.74e-02 | 2.21e-01 | -1.48e-02 | -4.74e-02 | 6.18e-01 | 9.36e-01 | 3.12e-01 | 9.46e-01 | 8.28e-01 |
| REGULATION OF ACTIVIN RECEPTOR SIGNALING PATHWAY | 26 | 5.65e-01 | 9.72e-01 | 0.25200 | 1.07e-01 | 1.32e-01 | 6.50e-02 | 9.99e-02 | -1.42e-01 | 3.44e-01 | 2.45e-01 | 5.66e-01 | 3.78e-01 | 2.09e-01 |
| AMINE CATABOLIC PROCESS | 15 | 5.72e-01 | 9.76e-01 | 0.25200 | 8.94e-02 | 8.31e-02 | -2.35e-02 | 1.44e-01 | -1.65e-01 | 5.49e-01 | 5.78e-01 | 8.75e-01 | 3.35e-01 | 2.69e-01 |
| ESTABLISHMENT OF MEIOTIC SPINDLE LOCALIZATION | 6 | 6.61e-01 | 1.00e+00 | 0.25100 | 5.29e-02 | 3.73e-02 | -5.84e-02 | 2.35e-01 | 2.51e-02 | 8.23e-01 | 8.74e-01 | 8.04e-01 | 3.20e-01 | 9.15e-01 |
| RESPONSE TO FLUID SHEAR STRESS | 34 | 3.91e-01 | 8.92e-01 | 0.25100 | 1.21e-01 | 1.15e-01 | 1.32e-01 | 1.35e-01 | -5.19e-03 | 2.24e-01 | 2.46e-01 | 1.84e-01 | 1.75e-01 | 9.58e-01 |
| REGULATION OF LEUKOCYTE PROLIFERATION | 257 | 1.04e-05 | 4.92e-04 | 0.25100 | -1.30e-01 | -1.46e-01 | -3.89e-02 | -1.45e-01 | 5.00e-02 | 3.49e-04 | 5.73e-05 | 2.83e-01 | 6.02e-05 | 1.67e-01 |
| MODULATION BY VIRUS OF HOST PROCESS | 7 | 1.70e-01 | 6.75e-01 | 0.25100 | 6.52e-03 | -1.34e-02 | -1.66e-01 | 1.48e-01 | 1.16e-01 | 9.76e-01 | 9.51e-01 | 4.47e-01 | 4.99e-01 | 5.94e-01 |
| DOUBLE STRAND BREAK REPAIR INVOLVED IN MEIOTIC RECOMBINATION | 11 | 8.32e-01 | 1.00e+00 | 0.25100 | -1.02e-01 | -1.18e-01 | -4.55e-03 | -1.95e-01 | -2.39e-02 | 5.57e-01 | 4.97e-01 | 9.79e-01 | 2.63e-01 | 8.91e-01 |
| POSITIVE REGULATION OF DENDRITE DEVELOPMENT | 15 | 7.17e-01 | 1.00e+00 | 0.25100 | 5.20e-02 | 5.91e-02 | -2.22e-02 | 4.58e-02 | -2.33e-01 | 7.27e-01 | 6.92e-01 | 8.82e-01 | 7.59e-01 | 1.18e-01 |
| REGULATION OF SYNAPTIC VESICLE ENDOCYTOSIS | 18 | 1.17e-01 | 5.69e-01 | 0.25100 | 7.17e-02 | 2.66e-02 | 5.58e-02 | 9.32e-02 | -2.13e-01 | 5.98e-01 | 8.45e-01 | 6.82e-01 | 4.94e-01 | 1.18e-01 |
| POSITIVE REGULATION OF HEMATOPOIETIC STEM CELL PROLIFERATION | 9 | 7.01e-01 | 1.00e+00 | 0.25100 | -6.47e-02 | -9.34e-02 | -1.48e-02 | -9.97e-02 | -2.00e-01 | 7.37e-01 | 6.27e-01 | 9.39e-01 | 6.05e-01 | 2.99e-01 |
| PIECEMEAL MICROAUTOPHAGY OF THE NUCLEUS | 10 | 9.75e-01 | 1.00e+00 | 0.25100 | -1.16e-01 | -1.06e-01 | -1.43e-01 | -1.02e-01 | -8.58e-02 | 5.26e-01 | 5.61e-01 | 4.34e-01 | 5.76e-01 | 6.39e-01 |
| PENTOSE PHOSPHATE SHUNT NON OXIDATIVE BRANCH | 6 | 8.11e-01 | 1.00e+00 | 0.25100 | 1.08e-01 | 7.46e-02 | 1.72e-02 | 1.64e-01 | -1.36e-01 | 6.47e-01 | 7.52e-01 | 9.42e-01 | 4.86e-01 | 5.64e-01 |
| INTERLEUKIN 6 MEDIATED SIGNALING PATHWAY | 25 | 1.70e-01 | 6.75e-01 | 0.25100 | -8.26e-02 | -2.34e-02 | -1.58e-01 | -1.01e-01 | -1.42e-01 | 4.74e-01 | 8.39e-01 | 1.71e-01 | 3.81e-01 | 2.19e-01 |
| B CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 85 | 5.41e-04 | 1.38e-02 | 0.25100 | -6.19e-02 | -9.94e-02 | 8.86e-02 | -1.57e-01 | 1.29e-01 | 3.24e-01 | 1.13e-01 | 1.58e-01 | 1.25e-02 | 3.92e-02 |
| INTERSTRAND CROSS LINK REPAIR | 37 | 5.05e-01 | 9.48e-01 | 0.25100 | 1.35e-01 | 1.18e-01 | 1.59e-01 | 6.26e-02 | -4.04e-02 | 1.57e-01 | 2.15e-01 | 9.41e-02 | 5.10e-01 | 6.71e-01 |
| DETECTION OF VIRUS | 6 | 7.39e-01 | 1.00e+00 | 0.25100 | -6.11e-02 | -1.01e-01 | 1.24e-01 | -1.79e-01 | 3.85e-02 | 7.95e-01 | 6.68e-01 | 6.00e-01 | 4.48e-01 | 8.70e-01 |
| POSITIVE REGULATION OF ADAPTIVE IMMUNE RESPONSE | 125 | 6.13e-03 | 8.87e-02 | 0.25100 | -1.09e-01 | -1.33e-01 | -7.94e-03 | -1.56e-01 | 9.33e-02 | 3.45e-02 | 1.00e-02 | 8.78e-01 | 2.64e-03 | 7.16e-02 |
| REGULATION OF SKELETAL MUSCLE CELL DIFFERENTIATION | 20 | 2.23e-01 | 7.45e-01 | 0.25100 | -5.99e-02 | -6.57e-02 | 7.14e-02 | -2.00e-01 | 9.82e-02 | 6.43e-01 | 6.11e-01 | 5.80e-01 | 1.21e-01 | 4.47e-01 |
| REGULATION OF 3 UTR MEDIATED MRNA STABILIZATION | 6 | 8.96e-01 | 1.00e+00 | 0.25100 | -1.12e-01 | -8.77e-02 | -7.90e-02 | -5.74e-02 | 1.81e-01 | 6.34e-01 | 7.10e-01 | 7.38e-01 | 8.08e-01 | 4.41e-01 |
| POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 12 | 6.51e-01 | 1.00e+00 | 0.25000 | 6.63e-02 | 1.15e-01 | 3.90e-03 | 7.01e-02 | -2.00e-01 | 6.91e-01 | 4.89e-01 | 9.81e-01 | 6.74e-01 | 2.30e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO STRESS | 17 | 6.46e-02 | 4.13e-01 | 0.25000 | 7.57e-02 | 1.07e-01 | 1.89e-01 | -6.08e-02 | 7.82e-02 | 5.89e-01 | 4.43e-01 | 1.78e-01 | 6.64e-01 | 5.77e-01 |
| POSITIVE REGULATION OF MYOBLAST DIFFERENTIATION | 43 | 2.55e-01 | 7.83e-01 | 0.25000 | 1.16e-01 | 1.42e-01 | 8.88e-02 | 8.42e-02 | -1.19e-01 | 1.88e-01 | 1.07e-01 | 3.14e-01 | 3.39e-01 | 1.79e-01 |
| TETRAHYDROBIOPTERIN METABOLIC PROCESS | 8 | 2.47e-01 | 7.75e-01 | 0.25000 | 9.93e-02 | 4.34e-02 | 1.40e-01 | -3.89e-02 | 1.72e-01 | 6.27e-01 | 8.32e-01 | 4.92e-01 | 8.49e-01 | 3.98e-01 |
| BASE EXCISION REPAIR | 42 | 3.46e-02 | 2.96e-01 | 0.25000 | 7.53e-02 | 2.89e-02 | 1.81e-01 | -4.32e-02 | 1.47e-01 | 3.99e-01 | 7.46e-01 | 4.29e-02 | 6.28e-01 | 9.89e-02 |
| MAINTENANCE OF SYNAPSE STRUCTURE | 25 | 7.58e-01 | 1.00e+00 | 0.25000 | 1.23e-01 | 1.27e-01 | 1.53e-01 | 6.70e-02 | 5.88e-02 | 2.86e-01 | 2.73e-01 | 1.85e-01 | 5.62e-01 | 6.11e-01 |
| KERATINOCYTE PROLIFERATION | 59 | 9.20e-02 | 5.01e-01 | 0.25000 | 1.07e-01 | 1.24e-01 | -3.06e-03 | 1.80e-01 | -5.84e-02 | 1.55e-01 | 1.00e-01 | 9.68e-01 | 1.68e-02 | 4.38e-01 |
| FLAVONOID METABOLIC PROCESS | 11 | 8.17e-01 | 1.00e+00 | 0.25000 | -1.18e-01 | -8.37e-02 | -8.87e-02 | -1.51e-01 | -1.05e-01 | 4.97e-01 | 6.31e-01 | 6.11e-01 | 3.86e-01 | 5.48e-01 |
| GLYCOSYLCERAMIDE METABOLIC PROCESS | 16 | 8.97e-01 | 1.00e+00 | 0.25000 | -1.38e-01 | -1.28e-01 | -8.24e-02 | -1.42e-01 | 4.66e-03 | 3.40e-01 | 3.75e-01 | 5.68e-01 | 3.24e-01 | 9.74e-01 |
| REGULATION OF HEAT GENERATION | 12 | 7.76e-01 | 1.00e+00 | 0.25000 | -3.24e-02 | -5.23e-02 | 8.52e-02 | -7.09e-02 | 2.15e-01 | 8.46e-01 | 7.54e-01 | 6.09e-01 | 6.70e-01 | 1.97e-01 |
| DETOXIFICATION OF INORGANIC COMPOUND | 21 | 3.76e-02 | 3.09e-01 | 0.25000 | 3.00e-02 | -9.81e-03 | 1.77e-01 | -1.62e-01 | -6.15e-02 | 8.12e-01 | 9.38e-01 | 1.60e-01 | 1.98e-01 | 6.25e-01 |
| LUNG VASCULATURE DEVELOPMENT | 8 | 8.50e-01 | 1.00e+00 | 0.25000 | 1.14e-01 | 7.83e-02 | 2.07e-01 | -8.74e-03 | 1.26e-02 | 5.76e-01 | 7.01e-01 | 3.10e-01 | 9.66e-01 | 9.51e-01 |
| AMPA GLUTAMATE RECEPTOR CLUSTERING | 10 | 8.63e-01 | 1.00e+00 | 0.25000 | 2.15e-04 | -7.04e-03 | 5.45e-02 | 4.20e-03 | 2.43e-01 | 9.99e-01 | 9.69e-01 | 7.65e-01 | 9.82e-01 | 1.83e-01 |
| NEGATIVE REGULATION OF CARDIAC MUSCLE CONTRACTION | 7 | 8.51e-01 | 1.00e+00 | 0.24900 | -1.07e-01 | -1.18e-01 | -1.92e-02 | -1.46e-01 | -1.22e-01 | 6.23e-01 | 5.87e-01 | 9.30e-01 | 5.03e-01 | 5.75e-01 |
| NEGATIVE REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 38 | 2.16e-01 | 7.38e-01 | 0.24900 | 1.11e-01 | 1.21e-01 | 8.95e-02 | 2.86e-02 | -1.63e-01 | 2.38e-01 | 1.98e-01 | 3.40e-01 | 7.61e-01 | 8.21e-02 |
| REGULATION OF SYNAPTIC TRANSMISSION CHOLINERGIC | 8 | 9.60e-01 | 1.00e+00 | 0.24900 | -1.07e-01 | -7.35e-02 | -1.23e-01 | -1.23e-01 | -1.23e-01 | 6.01e-01 | 7.19e-01 | 5.47e-01 | 5.48e-01 | 5.46e-01 |
| REGULATION OF T CELL MEDIATED CYTOTOXICITY | 50 | 1.68e-01 | 6.71e-01 | 0.24900 | -1.20e-01 | -1.52e-01 | -1.88e-02 | -1.53e-01 | 3.22e-02 | 1.43e-01 | 6.35e-02 | 8.18e-01 | 6.20e-02 | 6.94e-01 |
| PERICARDIUM DEVELOPMENT | 19 | 5.68e-01 | 9.73e-01 | 0.24900 | 1.31e-01 | 1.01e-01 | 1.24e-01 | 7.41e-02 | -1.17e-01 | 3.25e-01 | 4.47e-01 | 3.48e-01 | 5.76e-01 | 3.75e-01 |
| REGULATION OF GRANULOCYTE CHEMOTAXIS | 50 | 2.45e-01 | 7.72e-01 | 0.24900 | -1.31e-01 | -1.52e-01 | -1.11e-01 | -6.81e-02 | 6.79e-02 | 1.08e-01 | 6.30e-02 | 1.74e-01 | 4.05e-01 | 4.07e-01 |
| INTRACILIARY TRANSPORT INVOLVED IN CILIUM ASSEMBLY | 6 | 8.85e-01 | 1.00e+00 | 0.24900 | -1.21e-01 | -1.59e-01 | 5.48e-03 | -1.13e-01 | 9.54e-02 | 6.08e-01 | 4.99e-01 | 9.81e-01 | 6.30e-01 | 6.86e-01 |
| MYELOID PROGENITOR CELL DIFFERENTIATION | 9 | 7.77e-01 | 1.00e+00 | 0.24900 | -6.45e-02 | -1.19e-01 | 2.88e-02 | -1.09e-01 | 1.76e-01 | 7.38e-01 | 5.38e-01 | 8.81e-01 | 5.72e-01 | 3.60e-01 |
| REGULATION OF PROTEIN GLYCOSYLATION | 12 | 7.17e-01 | 1.00e+00 | 0.24900 | 9.44e-02 | 6.46e-02 | 2.05e-01 | 2.39e-02 | 7.85e-02 | 5.71e-01 | 6.98e-01 | 2.18e-01 | 8.86e-01 | 6.38e-01 |
| SNRNA TRANSCRIPTION BY RNA POLYMERASE III | 8 | 6.46e-01 | 1.00e+00 | 0.24900 | -8.46e-02 | -6.84e-02 | -2.07e-02 | -2.21e-01 | 2.98e-02 | 6.79e-01 | 7.38e-01 | 9.19e-01 | 2.79e-01 | 8.84e-01 |
| POSITIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 12 | 8.37e-01 | 1.00e+00 | 0.24900 | -3.70e-02 | -3.68e-03 | -9.04e-02 | -3.93e-02 | -2.25e-01 | 8.24e-01 | 9.82e-01 | 5.88e-01 | 8.14e-01 | 1.76e-01 |
| NEGATIVE REGULATION OF RECEPTOR RECYCLING | 5 | 5.87e-01 | 9.85e-01 | 0.24900 | 8.15e-02 | 1.46e-01 | 1.13e-01 | -6.68e-02 | -1.28e-01 | 7.52e-01 | 5.71e-01 | 6.60e-01 | 7.96e-01 | 6.19e-01 |
| TELOMERE MAINTENANCE VIA TELOMERE LENGTHENING | 77 | 1.46e-02 | 1.65e-01 | 0.24900 | -4.51e-02 | -5.71e-02 | 4.86e-02 | -7.00e-02 | 2.22e-01 | 4.94e-01 | 3.86e-01 | 4.61e-01 | 2.88e-01 | 7.53e-04 |
| POSITIVE REGULATION OF PROTEIN EXIT FROM ENDOPLASMIC RETICULUM | 12 | 6.01e-01 | 9.90e-01 | 0.24900 | 2.74e-02 | -1.96e-02 | 8.98e-02 | -1.81e-02 | 2.29e-01 | 8.69e-01 | 9.07e-01 | 5.90e-01 | 9.13e-01 | 1.70e-01 |
| TRANS SYNAPTIC SIGNALING BY TRANS SYNAPTIC COMPLEX | 6 | 8.18e-01 | 1.00e+00 | 0.24900 | -1.28e-01 | -1.14e-01 | -1.30e-01 | 8.89e-03 | 1.24e-01 | 5.86e-01 | 6.30e-01 | 5.80e-01 | 9.70e-01 | 5.99e-01 |
| DEVELOPMENT OF SECONDARY FEMALE SEXUAL CHARACTERISTICS | 6 | 6.36e-01 | 9.98e-01 | 0.24900 | 8.06e-02 | 7.28e-02 | 1.25e-01 | 8.95e-02 | -1.63e-01 | 7.33e-01 | 7.58e-01 | 5.97e-01 | 7.04e-01 | 4.90e-01 |
| NUCLEOSIDE TRIPHOSPHATE CATABOLIC PROCESS | 12 | 7.49e-01 | 1.00e+00 | 0.24900 | 1.09e-01 | 9.96e-02 | 9.62e-02 | 1.38e-01 | -1.09e-01 | 5.15e-01 | 5.50e-01 | 5.64e-01 | 4.09e-01 | 5.13e-01 |
| POSITIVE REGULATION OF GLIAL CELL DIFFERENTIATION | 45 | 4.19e-01 | 9.11e-01 | 0.24800 | 1.18e-01 | 1.02e-01 | 1.68e-01 | 4.31e-02 | 8.45e-02 | 1.70e-01 | 2.36e-01 | 5.06e-02 | 6.17e-01 | 3.27e-01 |
| ATRIOVENTRICULAR CANAL DEVELOPMENT | 13 | 4.09e-01 | 9.08e-01 | 0.24800 | -3.59e-02 | -4.39e-02 | 5.68e-02 | -1.79e-01 | -1.52e-01 | 8.22e-01 | 7.84e-01 | 7.23e-01 | 2.63e-01 | 3.42e-01 |
| POSITIVE REGULATION OF CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION | 9 | 8.19e-01 | 1.00e+00 | 0.24800 | 7.53e-04 | -1.61e-02 | 5.24e-02 | 5.91e-02 | 2.35e-01 | 9.97e-01 | 9.33e-01 | 7.86e-01 | 7.59e-01 | 2.22e-01 |
| NEGATIVE REGULATION OF DEFENSE RESPONSE TO BACTERIUM | 5 | 4.22e-01 | 9.12e-01 | 0.24800 | 1.09e-01 | 1.92e-01 | -2.49e-02 | 1.12e-02 | -1.11e-01 | 6.72e-01 | 4.58e-01 | 9.23e-01 | 9.65e-01 | 6.69e-01 |
| EPITHELIAL FLUID TRANSPORT | 11 | 7.01e-01 | 1.00e+00 | 0.24800 | 3.06e-02 | -2.91e-02 | 1.09e-01 | 2.85e-02 | 2.17e-01 | 8.61e-01 | 8.67e-01 | 5.31e-01 | 8.70e-01 | 2.13e-01 |
| TANGENTIAL MIGRATION FROM THE SUBVENTRICULAR ZONE TO THE OLFACTORY BULB | 7 | 3.36e-01 | 8.59e-01 | 0.24800 | 1.58e-02 | 3.10e-03 | -6.45e-02 | 2.16e-01 | -1.03e-01 | 9.42e-01 | 9.89e-01 | 7.68e-01 | 3.23e-01 | 6.37e-01 |
| POSITIVE REGULATION OF NEURON DIFFERENTIATION | 91 | 1.61e-03 | 3.35e-02 | 0.24800 | 1.15e-01 | 1.02e-01 | 1.61e-01 | 1.81e-02 | -1.08e-01 | 5.79e-02 | 9.22e-02 | 8.05e-03 | 7.66e-01 | 7.36e-02 |
| RNA EXPORT FROM NUCLEUS | 83 | 4.65e-02 | 3.49e-01 | 0.24800 | 1.06e-01 | 7.54e-02 | 1.60e-01 | 4.21e-02 | 1.31e-01 | 9.37e-02 | 2.35e-01 | 1.18e-02 | 5.07e-01 | 3.87e-02 |
| NEGATIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DIFFERENTIATION | 12 | 6.19e-01 | 9.90e-01 | 0.24800 | -4.32e-02 | -5.05e-02 | 7.10e-02 | -1.56e-01 | 1.66e-01 | 7.95e-01 | 7.62e-01 | 6.70e-01 | 3.49e-01 | 3.18e-01 |
| POSITIVE REGULATION OF GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR PRODUCTION | 15 | 2.68e-01 | 7.95e-01 | 0.24800 | -6.89e-02 | -1.02e-01 | 1.01e-01 | -1.90e-01 | -1.52e-03 | 6.44e-01 | 4.93e-01 | 4.96e-01 | 2.03e-01 | 9.92e-01 |
| MESODERMAL CELL FATE SPECIFICATION | 12 | 4.39e-01 | 9.25e-01 | 0.24800 | -5.14e-02 | -5.32e-02 | 3.87e-02 | -1.44e-01 | -1.84e-01 | 7.58e-01 | 7.50e-01 | 8.16e-01 | 3.86e-01 | 2.71e-01 |
| HEMATOPOIETIC STEM CELL HOMEOSTASIS | 20 | 5.60e-01 | 9.69e-01 | 0.24800 | 1.12e-01 | 1.42e-01 | 1.08e-01 | 1.08e-01 | 7.34e-02 | 3.85e-01 | 2.72e-01 | 4.02e-01 | 4.03e-01 | 5.70e-01 |
| ENTRAINMENT OF CIRCADIAN CLOCK | 30 | 7.93e-01 | 1.00e+00 | 0.24800 | 1.27e-01 | 1.42e-01 | 9.43e-02 | 1.25e-01 | 2.33e-02 | 2.30e-01 | 1.77e-01 | 3.71e-01 | 2.35e-01 | 8.25e-01 |
| PHENYLPROPANOID METABOLIC PROCESS | 7 | 1.83e-01 | 6.93e-01 | 0.24800 | -2.59e-02 | -8.13e-02 | 1.44e-01 | 4.18e-02 | 1.77e-01 | 9.05e-01 | 7.09e-01 | 5.08e-01 | 8.48e-01 | 4.17e-01 |
| REGULATION OF MUSCLE TISSUE DEVELOPMENT | 45 | 3.21e-01 | 8.47e-01 | 0.24800 | 1.15e-01 | 1.06e-01 | 7.26e-02 | 1.08e-01 | -1.40e-01 | 1.81e-01 | 2.17e-01 | 3.99e-01 | 2.09e-01 | 1.03e-01 |
| SYNAPTIC VESICLE MATURATION | 23 | 5.35e-01 | 9.56e-01 | 0.24800 | 7.61e-02 | 5.44e-02 | 1.78e-01 | 1.04e-02 | 1.45e-01 | 5.27e-01 | 6.52e-01 | 1.41e-01 | 9.31e-01 | 2.30e-01 |
| NEGATIVE REGULATION OF GLYCOGEN METABOLIC PROCESS | 10 | 4.59e-01 | 9.32e-01 | 0.24800 | -1.02e-01 | -8.43e-02 | 2.31e-02 | -1.98e-01 | -6.22e-02 | 5.76e-01 | 6.45e-01 | 8.99e-01 | 2.77e-01 | 7.33e-01 |
| CELLULAR RESPONSE TO RETINOIC ACID | 67 | 2.96e-01 | 8.24e-01 | 0.24800 | 1.31e-01 | 1.10e-01 | 1.63e-01 | 7.14e-02 | 2.00e-02 | 6.35e-02 | 1.18e-01 | 2.14e-02 | 3.12e-01 | 7.77e-01 |
| HAIR CYCLE PHASE | 9 | 1.69e-01 | 6.74e-01 | 0.24700 | 1.32e-01 | 4.35e-02 | 1.35e-01 | 7.64e-02 | -1.34e-01 | 4.94e-01 | 8.21e-01 | 4.83e-01 | 6.92e-01 | 4.87e-01 |
| DEFENSE RESPONSE TO TUMOR CELL | 13 | 4.62e-01 | 9.33e-01 | 0.24700 | -1.19e-01 | -1.08e-01 | 7.15e-03 | -1.88e-01 | 5.56e-03 | 4.57e-01 | 5.00e-01 | 9.64e-01 | 2.41e-01 | 9.72e-01 |
| NEGATIVE REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 19 | 7.86e-01 | 1.00e+00 | 0.24700 | 7.88e-02 | 6.76e-02 | 1.35e-01 | 6.27e-02 | 1.68e-01 | 5.52e-01 | 6.10e-01 | 3.09e-01 | 6.36e-01 | 2.04e-01 |
| POSITIVE REGULATION OF TRANSLATION | 127 | 8.18e-02 | 4.71e-01 | 0.24700 | 1.29e-01 | 1.30e-01 | 1.24e-01 | 9.79e-02 | -5.06e-02 | 1.20e-02 | 1.14e-02 | 1.60e-02 | 5.66e-02 | 3.24e-01 |
| NEPHRIC DUCT MORPHOGENESIS | 10 | 3.78e-01 | 8.85e-01 | 0.24700 | 3.08e-02 | -1.63e-02 | 2.11e-01 | -1.23e-01 | 1.24e-02 | 8.66e-01 | 9.29e-01 | 2.48e-01 | 5.02e-01 | 9.46e-01 |
| COPPER ION TRANSMEMBRANE TRANSPORT | 7 | 7.04e-01 | 1.00e+00 | 0.24700 | -1.39e-01 | -1.66e-01 | -1.37e-02 | -1.15e-01 | 2.86e-02 | 5.25e-01 | 4.47e-01 | 9.50e-01 | 5.99e-01 | 8.96e-01 |
| CENTROSOME SEPARATION | 15 | 6.03e-01 | 9.90e-01 | 0.24700 | 1.12e-01 | 8.21e-02 | 2.03e-01 | -1.80e-02 | 2.00e-02 | 4.54e-01 | 5.82e-01 | 1.74e-01 | 9.04e-01 | 8.93e-01 |
| PROTEIN MONOUBIQUITINATION | 41 | 3.35e-01 | 8.59e-01 | 0.24700 | -9.92e-02 | -1.29e-01 | -9.24e-03 | -1.41e-01 | 1.20e-01 | 2.72e-01 | 1.52e-01 | 9.18e-01 | 1.17e-01 | 1.85e-01 |
| REGULATION OF DENDRITIC CELL DIFFERENTIATION | 14 | 1.50e-01 | 6.39e-01 | 0.24700 | 1.96e-02 | -1.81e-02 | 1.96e-01 | -1.43e-01 | -3.81e-02 | 8.99e-01 | 9.07e-01 | 2.05e-01 | 3.54e-01 | 8.05e-01 |
| MAINTENANCE OF PROTEIN LOCALIZATION IN ORGANELLE | 41 | 3.58e-01 | 8.74e-01 | 0.24700 | 1.29e-01 | 1.28e-01 | 1.49e-01 | 4.62e-02 | 5.70e-02 | 1.52e-01 | 1.55e-01 | 9.77e-02 | 6.09e-01 | 5.28e-01 |
| REGULATION OF CHOLESTEROL EFFLUX | 54 | 4.44e-01 | 9.28e-01 | 0.24700 | 1.21e-01 | 1.32e-01 | 1.13e-01 | 1.22e-01 | 3.26e-02 | 1.23e-01 | 9.40e-02 | 1.50e-01 | 1.22e-01 | 6.79e-01 |
| CHEMOKINE C X C MOTIF LIGAND 2 PRODUCTION | 19 | 1.71e-01 | 6.75e-01 | 0.24700 | -5.80e-02 | -3.41e-02 | -1.73e-04 | -2.03e-01 | -1.23e-01 | 6.62e-01 | 7.97e-01 | 9.99e-01 | 1.26e-01 | 3.52e-01 |
| REGULATION OF T HELPER 2 CELL DIFFERENTIATION | 12 | 5.24e-01 | 9.54e-01 | 0.24700 | 3.10e-02 | -1.15e-02 | 1.87e-01 | -1.10e-01 | 1.12e-01 | 8.52e-01 | 9.45e-01 | 2.61e-01 | 5.11e-01 | 5.01e-01 |
| REGULATION OF HEART GROWTH | 68 | 9.27e-03 | 1.19e-01 | 0.24700 | 9.78e-02 | 9.55e-02 | 1.02e-01 | 2.58e-03 | -1.78e-01 | 1.63e-01 | 1.73e-01 | 1.46e-01 | 9.71e-01 | 1.11e-02 |
| POSITIVE REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS | 27 | 1.99e-02 | 2.07e-01 | 0.24700 | 9.44e-02 | 1.36e-01 | 7.94e-02 | 1.63e-01 | 2.69e-02 | 3.96e-01 | 2.23e-01 | 4.75e-01 | 1.43e-01 | 8.09e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO SYNAPSE | 6 | 8.97e-01 | 1.00e+00 | 0.24600 | 1.06e-01 | 9.44e-02 | 1.26e-01 | 1.55e-01 | 2.34e-02 | 6.52e-01 | 6.89e-01 | 5.92e-01 | 5.11e-01 | 9.21e-01 |
| ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 74 | 4.81e-02 | 3.57e-01 | 0.24600 | 1.21e-01 | 1.14e-01 | 1.79e-01 | 2.64e-02 | 1.81e-02 | 7.12e-02 | 8.90e-02 | 7.87e-03 | 6.94e-01 | 7.88e-01 |
| RESPONSE TO MACROPHAGE COLONY STIMULATING FACTOR | 17 | 9.32e-01 | 1.00e+00 | 0.24600 | -1.35e-01 | -1.43e-01 | -1.06e-01 | -1.04e-01 | -1.28e-02 | 3.35e-01 | 3.08e-01 | 4.51e-01 | 4.60e-01 | 9.27e-01 |
| OTIC VESICLE FORMATION | 8 | 9.40e-01 | 1.00e+00 | 0.24600 | 8.78e-02 | 1.03e-01 | 5.04e-02 | 5.26e-02 | -1.92e-01 | 6.67e-01 | 6.12e-01 | 8.05e-01 | 7.97e-01 | 3.46e-01 |
| CELLULAR RESPONSE TO X RAY | 11 | 7.47e-01 | 1.00e+00 | 0.24600 | 4.27e-02 | -4.48e-03 | 1.68e-01 | -5.27e-02 | 1.67e-01 | 8.06e-01 | 9.79e-01 | 3.35e-01 | 7.62e-01 | 3.37e-01 |
| CELLULAR RESPONSE TO GONADOTROPIN STIMULUS | 17 | 8.68e-01 | 1.00e+00 | 0.24600 | 1.22e-01 | 1.11e-01 | 8.17e-02 | 1.38e-01 | -8.76e-02 | 3.86e-01 | 4.26e-01 | 5.60e-01 | 3.23e-01 | 5.32e-01 |
| ROSTROCAUDAL NEURAL TUBE PATTERNING | 10 | 3.38e-01 | 8.59e-01 | 0.24600 | 6.70e-02 | 6.27e-02 | 1.76e-01 | -1.40e-01 | 4.08e-02 | 7.14e-01 | 7.31e-01 | 3.35e-01 | 4.43e-01 | 8.23e-01 |
| MRNA METHYLATION | 17 | 1.86e-01 | 6.95e-01 | 0.24600 | -8.96e-02 | -1.13e-01 | 4.35e-02 | -1.63e-01 | -1.06e-01 | 5.22e-01 | 4.20e-01 | 7.56e-01 | 2.44e-01 | 4.48e-01 |
| ECTODERMAL PLACODE DEVELOPMENT | 13 | 4.72e-01 | 9.40e-01 | 0.24600 | -9.09e-02 | -8.34e-02 | 4.05e-02 | -2.07e-01 | 2.77e-02 | 5.70e-01 | 6.03e-01 | 8.00e-01 | 1.96e-01 | 8.63e-01 |
| TELENCEPHALON GLIAL CELL MIGRATION | 27 | 5.63e-01 | 9.71e-01 | 0.24600 | -1.34e-01 | -1.31e-01 | -1.55e-01 | -3.79e-02 | -1.07e-02 | 2.30e-01 | 2.40e-01 | 1.63e-01 | 7.33e-01 | 9.24e-01 |
| REGULATION OF CELL COMMUNICATION BY ELECTRICAL COUPLING INVOLVED IN CARDIAC CONDUCTION | 12 | 2.00e-01 | 7.15e-01 | 0.24600 | 2.05e-02 | -3.92e-02 | 1.92e-01 | -1.40e-01 | -4.70e-02 | 9.02e-01 | 8.14e-01 | 2.50e-01 | 4.02e-01 | 7.78e-01 |
| REGULATION OF VERY LOW DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 5 | 8.10e-01 | 1.00e+00 | 0.24600 | 8.20e-02 | 7.84e-02 | 1.83e-01 | -3.31e-02 | -1.14e-01 | 7.51e-01 | 7.61e-01 | 4.79e-01 | 8.98e-01 | 6.58e-01 |
| BIOLOGICAL PROCESS INVOLVED IN INTRASPECIES INTERACTION BETWEEN ORGANISMS | 48 | 5.70e-01 | 9.76e-01 | 0.24600 | 1.20e-01 | 1.20e-01 | 9.95e-02 | 1.45e-01 | 2.35e-02 | 1.49e-01 | 1.49e-01 | 2.33e-01 | 8.21e-02 | 7.79e-01 |
| NEGATIVE REGULATION OF AMINO ACID TRANSPORT | 16 | 5.82e-01 | 9.85e-01 | 0.24600 | 8.04e-02 | 7.69e-02 | 9.21e-02 | 2.15e-02 | -1.98e-01 | 5.78e-01 | 5.94e-01 | 5.24e-01 | 8.82e-01 | 1.71e-01 |
| NEGATIVE REGULATION OF MACROAUTOPHAGY | 31 | 4.64e-01 | 9.33e-01 | 0.24600 | 6.19e-02 | 5.66e-02 | 8.56e-02 | 6.09e-02 | 2.06e-01 | 5.51e-01 | 5.85e-01 | 4.09e-01 | 5.57e-01 | 4.74e-02 |
| REGULATION OF ADHERENS JUNCTION ORGANIZATION | 5 | 2.74e-01 | 8.01e-01 | 0.24600 | -1.63e-02 | 7.11e-02 | 4.16e-02 | -2.51e-02 | 2.30e-01 | 9.50e-01 | 7.83e-01 | 8.72e-01 | 9.23e-01 | 3.74e-01 |
| POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 21 | 2.90e-01 | 8.18e-01 | 0.24600 | 4.09e-02 | 5.70e-02 | 5.62e-02 | -5.01e-02 | -2.23e-01 | 7.46e-01 | 6.51e-01 | 6.56e-01 | 6.91e-01 | 7.68e-02 |
| REGULATION OF NUCLEOTIDE EXCISION REPAIR | 28 | 4.30e-01 | 9.18e-01 | 0.24600 | 1.16e-01 | 1.47e-01 | 9.13e-02 | 1.27e-01 | 2.27e-02 | 2.87e-01 | 1.77e-01 | 4.03e-01 | 2.44e-01 | 8.36e-01 |
| NEGATIVE REGULATION OF FILOPODIUM ASSEMBLY | 5 | 9.05e-01 | 1.00e+00 | 0.24600 | -2.36e-02 | -1.86e-02 | -4.85e-02 | -1.12e-01 | -2.11e-01 | 9.27e-01 | 9.43e-01 | 8.51e-01 | 6.64e-01 | 4.14e-01 |
| ANTERIOR POSTERIOR PATTERN SPECIFICATION | 209 | 1.61e-06 | 9.55e-05 | 0.24600 | 1.24e-01 | 1.12e-01 | 1.41e-01 | 3.43e-02 | -1.06e-01 | 1.93e-03 | 5.06e-03 | 4.47e-04 | 3.93e-01 | 8.52e-03 |
| BRADYKININ CATABOLIC PROCESS | 7 | 6.67e-01 | 1.00e+00 | 0.24500 | 9.46e-02 | 1.33e-01 | 9.40e-02 | 1.05e-01 | -1.17e-01 | 6.65e-01 | 5.43e-01 | 6.67e-01 | 6.30e-01 | 5.91e-01 |
| MYELOID CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 95 | 5.47e-03 | 8.18e-02 | 0.24500 | -1.02e-01 | -1.39e-01 | 1.38e-02 | -1.27e-01 | 1.18e-01 | 8.54e-02 | 1.90e-02 | 8.16e-01 | 3.19e-02 | 4.68e-02 |
| SNRNA TRANSCRIPTION BY RNA POLYMERASE II | 16 | 8.43e-01 | 1.00e+00 | 0.24500 | 1.18e-01 | 1.11e-01 | 1.66e-01 | 3.27e-02 | 7.10e-02 | 4.12e-01 | 4.41e-01 | 2.50e-01 | 8.21e-01 | 6.23e-01 |
| ORGANIC CATION TRANSPORT | 62 | 1.84e-01 | 6.93e-01 | 0.24500 | 1.15e-01 | 1.16e-01 | 1.03e-01 | 7.51e-02 | -1.31e-01 | 1.18e-01 | 1.13e-01 | 1.62e-01 | 3.07e-01 | 7.43e-02 |
| NLS BEARING PROTEIN IMPORT INTO NUCLEUS | 19 | 7.75e-01 | 1.00e+00 | 0.24500 | -1.12e-01 | -1.11e-01 | -6.48e-02 | -1.76e-01 | -7.78e-04 | 3.97e-01 | 4.04e-01 | 6.25e-01 | 1.83e-01 | 9.95e-01 |
| CELLULAR RESPONSE TO CORTICOSTEROID STIMULUS | 58 | 3.86e-01 | 8.92e-01 | 0.24500 | 1.33e-01 | 1.35e-01 | 1.24e-01 | 7.36e-02 | -5.69e-02 | 8.04e-02 | 7.47e-02 | 1.01e-01 | 3.32e-01 | 4.53e-01 |
| COLUMNAR CUBOIDAL EPITHELIAL CELL DIFFERENTIATION | 121 | 9.91e-03 | 1.25e-01 | 0.24500 | 1.21e-01 | 1.22e-01 | 1.08e-01 | 5.88e-02 | -1.24e-01 | 2.12e-02 | 2.05e-02 | 4.03e-02 | 2.64e-01 | 1.86e-02 |
| VASCULOGENESIS | 81 | 2.60e-01 | 7.89e-01 | 0.24500 | 1.26e-01 | 1.07e-01 | 1.59e-01 | 7.71e-02 | 3.54e-02 | 5.04e-02 | 9.48e-02 | 1.31e-02 | 2.31e-01 | 5.82e-01 |
| DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION RESULTING IN TRANSCRIPTION | 18 | 3.41e-01 | 8.60e-01 | 0.24500 | 1.11e-01 | 1.13e-01 | 1.80e-01 | -3.97e-02 | 2.80e-02 | 4.16e-01 | 4.05e-01 | 1.86e-01 | 7.71e-01 | 8.37e-01 |
| REGULATION OF PROTEIN K48 LINKED UBIQUITINATION | 6 | 8.32e-01 | 1.00e+00 | 0.24500 | 8.18e-02 | 4.57e-02 | 1.08e-01 | 2.73e-02 | -1.97e-01 | 7.29e-01 | 8.46e-01 | 6.47e-01 | 9.08e-01 | 4.04e-01 |
| REGULATION OF HEPATIC STELLATE CELL ACTIVATION | 7 | 6.76e-01 | 1.00e+00 | 0.24500 | -1.29e-01 | -1.29e-01 | 1.28e-02 | -1.61e-01 | 1.98e-02 | 5.55e-01 | 5.54e-01 | 9.53e-01 | 4.60e-01 | 9.28e-01 |
| NUCLEOBASE BIOSYNTHETIC PROCESS | 16 | 9.13e-01 | 1.00e+00 | 0.24500 | 1.30e-01 | 1.50e-01 | 9.91e-02 | 9.46e-02 | -4.09e-02 | 3.66e-01 | 3.00e-01 | 4.93e-01 | 5.12e-01 | 7.77e-01 |
| CARTILAGE CONDENSATION | 19 | 1.06e-01 | 5.39e-01 | 0.24500 | -4.85e-02 | -2.53e-02 | 3.75e-02 | -1.60e-01 | -1.73e-01 | 7.14e-01 | 8.49e-01 | 7.77e-01 | 2.27e-01 | 1.93e-01 |
| EMBRYONIC HEMOPOIESIS | 23 | 3.33e-01 | 8.57e-01 | 0.24500 | -6.49e-02 | -9.57e-02 | 8.28e-02 | -1.61e-01 | 1.17e-01 | 5.90e-01 | 4.27e-01 | 4.92e-01 | 1.81e-01 | 3.31e-01 |
| RETINAL ROD CELL DIFFERENTIATION | 14 | 2.69e-01 | 7.97e-01 | 0.24500 | 1.08e-01 | 1.32e-01 | -5.29e-02 | 1.22e-01 | -1.15e-01 | 4.84e-01 | 3.93e-01 | 7.32e-01 | 4.30e-01 | 4.57e-01 |
| CELLULAR RESPONSE TO PROSTAGLANDIN STIMULUS | 20 | 6.44e-01 | 1.00e+00 | 0.24500 | -1.25e-01 | -8.04e-02 | -1.37e-01 | -1.17e-01 | -7.38e-02 | 3.34e-01 | 5.34e-01 | 2.90e-01 | 3.66e-01 | 5.68e-01 |
| FORMATION OF ANATOMICAL BOUNDARY | 7 | 6.33e-01 | 9.96e-01 | 0.24500 | 7.47e-02 | 1.03e-01 | 1.35e-01 | -2.97e-02 | -1.57e-01 | 7.32e-01 | 6.38e-01 | 5.36e-01 | 8.92e-01 | 4.73e-01 |
| AMMONIUM ION METABOLIC PROCESS | 22 | 4.65e-01 | 9.35e-01 | 0.24500 | -4.98e-02 | -6.86e-03 | -1.50e-01 | 2.91e-02 | -1.84e-01 | 6.86e-01 | 9.56e-01 | 2.22e-01 | 8.13e-01 | 1.36e-01 |
| NEURON FATE COMMITMENT | 73 | 1.94e-05 | 8.35e-04 | 0.24400 | 8.40e-02 | 5.81e-02 | 2.00e-01 | -8.47e-02 | -4.54e-02 | 2.15e-01 | 3.90e-01 | 3.09e-03 | 2.11e-01 | 5.02e-01 |
| INTERLEUKIN 6 PRODUCTION | 165 | 8.49e-06 | 4.10e-04 | 0.24400 | -8.39e-02 | -1.28e-01 | 3.46e-02 | -1.25e-01 | 1.40e-01 | 6.29e-02 | 4.67e-03 | 4.44e-01 | 5.57e-03 | 1.92e-03 |
| PROLINE TRANSMEMBRANE TRANSPORT | 9 | 9.00e-01 | 1.00e+00 | 0.24400 | 1.20e-01 | 1.63e-01 | 4.93e-02 | 1.09e-01 | -6.63e-02 | 5.33e-01 | 3.96e-01 | 7.98e-01 | 5.72e-01 | 7.30e-01 |
| TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 17 | 6.06e-01 | 9.90e-01 | 0.24400 | -1.11e-01 | -1.46e-01 | -7.29e-02 | -1.34e-01 | 5.35e-02 | 4.29e-01 | 2.96e-01 | 6.03e-01 | 3.40e-01 | 7.03e-01 |
| RESPONSE TO PARATHYROID HORMONE | 10 | 6.54e-01 | 1.00e+00 | 0.24400 | -1.63e-02 | -2.20e-02 | -6.79e-02 | 5.72e-02 | -2.26e-01 | 9.29e-01 | 9.04e-01 | 7.10e-01 | 7.54e-01 | 2.16e-01 |
| NEGATIVE REGULATION OF INTRACELLULAR ESTROGEN RECEPTOR SIGNALING PATHWAY | 15 | 5.22e-01 | 9.53e-01 | 0.24400 | -1.26e-01 | -1.53e-01 | -4.52e-03 | -1.42e-01 | 1.14e-02 | 3.96e-01 | 3.06e-01 | 9.76e-01 | 3.40e-01 | 9.39e-01 |
| REGULATION OF CELLULAR EXTRAVASATION | 38 | 1.64e-01 | 6.64e-01 | 0.24400 | -1.06e-01 | -1.52e-01 | -3.46e-02 | -7.59e-02 | 1.35e-01 | 2.58e-01 | 1.05e-01 | 7.12e-01 | 4.18e-01 | 1.49e-01 |
| REGULATION OF DELAYED RECTIFIER POTASSIUM CHANNEL ACTIVITY | 18 | 2.86e-01 | 8.12e-01 | 0.24400 | -1.30e-01 | -1.42e-01 | -1.46e-01 | 1.52e-02 | 3.03e-02 | 3.40e-01 | 2.96e-01 | 2.84e-01 | 9.11e-01 | 8.24e-01 |
| REGULATION OF PENTOSE PHOSPHATE SHUNT | 7 | 9.58e-01 | 1.00e+00 | 0.24400 | 1.13e-01 | 1.37e-01 | 7.30e-02 | 1.47e-01 | -3.36e-02 | 6.04e-01 | 5.30e-01 | 7.38e-01 | 5.02e-01 | 8.78e-01 |
| VENTRAL SPINAL CORD DEVELOPMENT | 45 | 1.23e-02 | 1.45e-01 | 0.24400 | 1.08e-01 | 7.14e-02 | 2.00e-01 | -3.63e-02 | -3.67e-02 | 2.09e-01 | 4.07e-01 | 2.02e-02 | 6.74e-01 | 6.70e-01 |
| TYPE B PANCREATIC CELL DIFFERENTIATION | 30 | 5.35e-02 | 3.78e-01 | 0.24400 | -5.36e-02 | -5.62e-02 | 4.60e-02 | -1.97e-01 | -1.13e-01 | 6.11e-01 | 5.94e-01 | 6.63e-01 | 6.24e-02 | 2.84e-01 |
| REGULATION OF INTEGRIN ACTIVATION | 17 | 7.79e-01 | 1.00e+00 | 0.24400 | -1.23e-01 | -1.22e-01 | -1.67e-01 | -2.86e-02 | -2.43e-02 | 3.80e-01 | 3.82e-01 | 2.32e-01 | 8.38e-01 | 8.62e-01 |
| COPII COATED VESICLE BUDDING | 42 | 1.63e-01 | 6.63e-01 | 0.24400 | 3.98e-02 | 2.33e-02 | 9.39e-02 | -3.97e-03 | 2.20e-01 | 6.56e-01 | 7.94e-01 | 2.92e-01 | 9.65e-01 | 1.35e-02 |
| MACROPHAGE PROLIFERATION | 12 | 5.45e-01 | 9.61e-01 | 0.24400 | 7.79e-02 | 1.38e-01 | -7.17e-02 | 1.55e-01 | -7.13e-02 | 6.40e-01 | 4.08e-01 | 6.67e-01 | 3.52e-01 | 6.69e-01 |
| REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 47 | 2.39e-01 | 7.63e-01 | 0.24400 | -1.36e-01 | -1.40e-01 | -6.62e-02 | -1.29e-01 | -1.47e-02 | 1.06e-01 | 9.61e-02 | 4.32e-01 | 1.26e-01 | 8.61e-01 |
| THYROID GLAND DEVELOPMENT | 31 | 5.14e-01 | 9.52e-01 | 0.24400 | 1.33e-01 | 1.11e-01 | 8.25e-02 | 1.51e-01 | -1.76e-03 | 2.00e-01 | 2.86e-01 | 4.27e-01 | 1.47e-01 | 9.87e-01 |
| CORNEA DEVELOPMENT IN CAMERA TYPE EYE | 12 | 7.26e-01 | 1.00e+00 | 0.24400 | 9.78e-02 | 8.11e-02 | 1.98e-01 | 2.49e-02 | 5.84e-02 | 5.57e-01 | 6.27e-01 | 2.35e-01 | 8.81e-01 | 7.26e-01 |
| AMELOGENESIS | 24 | 2.01e-01 | 7.18e-01 | 0.24400 | 7.29e-02 | 9.01e-02 | -3.41e-02 | 1.84e-01 | 1.05e-01 | 5.37e-01 | 4.45e-01 | 7.72e-01 | 1.19e-01 | 3.73e-01 |
| TELOMERE MAINTENANCE VIA SEMI CONSERVATIVE REPLICATION | 9 | 7.85e-01 | 1.00e+00 | 0.24400 | -6.14e-03 | -1.78e-02 | 1.02e-01 | -1.12e-01 | 1.90e-01 | 9.75e-01 | 9.26e-01 | 5.95e-01 | 5.62e-01 | 3.24e-01 |
| LYSINE METABOLIC PROCESS | 8 | 8.47e-01 | 1.00e+00 | 0.24400 | -6.44e-02 | -5.05e-02 | -3.03e-02 | -1.68e-01 | -1.53e-01 | 7.52e-01 | 8.05e-01 | 8.82e-01 | 4.10e-01 | 4.54e-01 |
| POSITIVE REGULATION OF LIPID KINASE ACTIVITY | 26 | 8.37e-01 | 1.00e+00 | 0.24400 | -1.24e-01 | -1.43e-01 | -6.30e-02 | -1.28e-01 | 5.79e-02 | 2.75e-01 | 2.08e-01 | 5.78e-01 | 2.60e-01 | 6.09e-01 |
| POSITIVE REGULATION OF COAGULATION | 30 | 3.00e-01 | 8.27e-01 | 0.24300 | 1.22e-01 | 1.33e-01 | 1.26e-01 | 1.58e-02 | -1.03e-01 | 2.49e-01 | 2.08e-01 | 2.31e-01 | 8.81e-01 | 3.28e-01 |
| ADAPTATION OF SIGNALING PATHWAY | 20 | 3.07e-01 | 8.35e-01 | 0.24300 | -7.66e-02 | -1.35e-01 | 5.20e-02 | -8.02e-02 | 1.62e-01 | 5.53e-01 | 2.97e-01 | 6.87e-01 | 5.35e-01 | 2.11e-01 |
| PHOSPHATIDYLINOSITOL DEPHOSPHORYLATION | 23 | 6.79e-01 | 1.00e+00 | 0.24300 | -9.54e-02 | -1.19e-01 | -4.42e-02 | -7.37e-02 | 1.69e-01 | 4.28e-01 | 3.23e-01 | 7.14e-01 | 5.41e-01 | 1.60e-01 |
| REGULATION OF SYNAPTIC VESICLE RECYCLING | 24 | 2.50e-01 | 7.76e-01 | 0.24300 | 9.06e-02 | 6.58e-02 | 8.07e-02 | 9.41e-02 | -1.77e-01 | 4.42e-01 | 5.77e-01 | 4.94e-01 | 4.25e-01 | 1.34e-01 |
| CELL DIFFERENTIATION IN SPINAL CORD | 49 | 1.22e-03 | 2.68e-02 | 0.24300 | 9.10e-02 | 4.69e-02 | 2.04e-01 | -6.30e-02 | -5.40e-02 | 2.70e-01 | 5.70e-01 | 1.33e-02 | 4.46e-01 | 5.13e-01 |
| LEUKOCYTE APOPTOTIC PROCESS | 118 | 6.45e-03 | 9.15e-02 | 0.24300 | -1.09e-01 | -1.26e-01 | -5.57e-03 | -1.69e-01 | 5.18e-02 | 4.11e-02 | 1.77e-02 | 9.17e-01 | 1.52e-03 | 3.31e-01 |
| REGULATION OF MEMBRANE REPOLARIZATION DURING ACTION POTENTIAL | 9 | 8.25e-01 | 1.00e+00 | 0.24300 | -1.18e-01 | -1.27e-01 | -2.13e-02 | -8.56e-02 | 1.46e-01 | 5.41e-01 | 5.09e-01 | 9.12e-01 | 6.57e-01 | 4.49e-01 |
| NEGATIVE REGULATION OF SMOOTH MUSCLE CELL DIFFERENTIATION | 19 | 3.91e-01 | 8.92e-01 | 0.24300 | -2.71e-02 | -6.39e-02 | 1.29e-01 | -1.17e-01 | 1.55e-01 | 8.38e-01 | 6.30e-01 | 3.31e-01 | 3.79e-01 | 2.42e-01 |
| AXONAL TRANSPORT OF MITOCHONDRION | 16 | 7.53e-01 | 1.00e+00 | 0.24300 | -7.86e-02 | -7.75e-02 | -4.69e-02 | -1.29e-01 | -1.67e-01 | 5.86e-01 | 5.91e-01 | 7.46e-01 | 3.72e-01 | 2.47e-01 |
| MITOTIC CELL CYCLE CHECKPOINT SIGNALING | 139 | 1.21e-03 | 2.67e-02 | 0.24300 | 1.02e-01 | 8.00e-02 | 1.85e-01 | 2.02e-02 | 8.67e-02 | 3.70e-02 | 1.04e-01 | 1.69e-04 | 6.81e-01 | 7.76e-02 |
| THIAMINE CONTAINING COMPOUND METABOLIC PROCESS | 6 | 9.86e-01 | 1.00e+00 | 0.24300 | 1.08e-01 | 8.72e-02 | 1.54e-01 | 9.38e-02 | 8.48e-02 | 6.47e-01 | 7.12e-01 | 5.14e-01 | 6.91e-01 | 7.19e-01 |
| REGULATION OF ENDODERMAL CELL DIFFERENTIATION | 7 | 9.45e-01 | 1.00e+00 | 0.24300 | -8.21e-02 | -5.59e-02 | -8.62e-02 | -1.40e-01 | -1.48e-01 | 7.07e-01 | 7.98e-01 | 6.93e-01 | 5.21e-01 | 4.97e-01 |
| HYPEROSMOTIC RESPONSE | 26 | 4.48e-01 | 9.30e-01 | 0.24300 | 9.40e-02 | 7.15e-02 | 1.92e-01 | -1.44e-03 | 8.97e-02 | 4.07e-01 | 5.28e-01 | 9.02e-02 | 9.90e-01 | 4.28e-01 |
| POSITIVE REGULATION OF NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING SIGNALING PATHWAY | 7 | 8.69e-01 | 1.00e+00 | 0.24300 | 1.13e-01 | 7.81e-02 | 1.76e-01 | 1.68e-02 | -9.25e-02 | 6.03e-01 | 7.20e-01 | 4.19e-01 | 9.38e-01 | 6.72e-01 |
| CEREBELLAR GRANULAR LAYER DEVELOPMENT | 12 | 7.45e-01 | 1.00e+00 | 0.24200 | 5.70e-02 | 5.32e-03 | 1.17e-01 | 4.07e-02 | 2.01e-01 | 7.33e-01 | 9.75e-01 | 4.85e-01 | 8.07e-01 | 2.29e-01 |
| GROWTH HORMONE SECRETION | 13 | 5.56e-01 | 9.68e-01 | 0.24200 | -4.90e-02 | -8.92e-02 | 7.85e-02 | -3.80e-02 | 2.02e-01 | 7.60e-01 | 5.78e-01 | 6.24e-01 | 8.12e-01 | 2.08e-01 |
| POSITIVE REGULATION OF BLOOD PRESSURE BY EPINEPHRINE NOREPINEPHRINE | 6 | 7.68e-01 | 1.00e+00 | 0.24200 | -8.41e-02 | -4.75e-02 | -7.96e-02 | -1.96e-01 | -6.76e-02 | 7.21e-01 | 8.40e-01 | 7.36e-01 | 4.05e-01 | 7.74e-01 |
| REGULATION OF MEMBRANE REPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 6 | 7.38e-01 | 1.00e+00 | 0.24200 | -1.26e-01 | -1.44e-01 | -4.06e-02 | -3.01e-02 | 1.40e-01 | 5.93e-01 | 5.42e-01 | 8.63e-01 | 8.98e-01 | 5.52e-01 |
| POSITIVE REGULATION OF BONE MINERALIZATION | 43 | 7.37e-02 | 4.46e-01 | 0.24200 | 2.17e-02 | 3.36e-02 | -3.06e-02 | 6.01e-02 | -2.29e-01 | 8.05e-01 | 7.03e-01 | 7.28e-01 | 4.95e-01 | 9.32e-03 |
| REGULATION OF TRANSLATIONAL ELONGATION | 12 | 7.79e-01 | 1.00e+00 | 0.24200 | 9.80e-02 | 5.30e-02 | 1.52e-01 | 3.48e-02 | 1.48e-01 | 5.57e-01 | 7.50e-01 | 3.61e-01 | 8.35e-01 | 3.76e-01 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO HYPOXIA | 11 | 5.60e-01 | 9.69e-01 | 0.24200 | -4.73e-02 | -7.40e-02 | 4.47e-02 | -1.67e-01 | 1.45e-01 | 7.86e-01 | 6.71e-01 | 7.98e-01 | 3.39e-01 | 4.04e-01 |
| POSITIVE REGULATION OF GLYCOGEN METABOLIC PROCESS | 17 | 7.39e-01 | 1.00e+00 | 0.24200 | 1.12e-01 | 1.23e-01 | 9.95e-02 | 1.25e-01 | -7.20e-02 | 4.23e-01 | 3.79e-01 | 4.78e-01 | 3.72e-01 | 6.07e-01 |
| GLUCOSE 6 PHOSPHATE METABOLIC PROCESS | 27 | 6.12e-01 | 9.90e-01 | 0.24200 | 1.10e-01 | 1.01e-01 | 5.56e-02 | 1.22e-01 | -1.35e-01 | 3.24e-01 | 3.63e-01 | 6.17e-01 | 2.72e-01 | 2.24e-01 |
| POSITIVE REGULATION OF VACUOLE ORGANIZATION | 23 | 9.06e-01 | 1.00e+00 | 0.24200 | 1.19e-01 | 1.18e-01 | 1.28e-01 | 1.08e-01 | 4.81e-02 | 3.21e-01 | 3.29e-01 | 2.87e-01 | 3.72e-01 | 6.90e-01 |
| DETECTION OF MOLECULE OF BACTERIAL ORIGIN | 13 | 7.09e-01 | 1.00e+00 | 0.24200 | 2.45e-02 | -2.96e-02 | 1.18e-01 | 1.53e-03 | 2.07e-01 | 8.78e-01 | 8.54e-01 | 4.62e-01 | 9.92e-01 | 1.95e-01 |
| NUCLEOTIDE EXCISION REPAIR | 83 | 2.97e-01 | 8.24e-01 | 0.24200 | 1.23e-01 | 1.20e-01 | 1.26e-01 | 1.14e-01 | 1.79e-03 | 5.28e-02 | 5.97e-02 | 4.74e-02 | 7.16e-02 | 9.77e-01 |
| CELLULAR RESPONSE TO INTERLEUKIN 1 | 107 | 2.07e-01 | 7.28e-01 | 0.24200 | -1.26e-01 | -1.24e-01 | -1.19e-01 | -9.59e-02 | -6.26e-02 | 2.46e-02 | 2.70e-02 | 3.38e-02 | 8.66e-02 | 2.63e-01 |
| STEROID CATABOLIC PROCESS | 24 | 6.80e-01 | 1.00e+00 | 0.24100 | -1.20e-01 | -1.31e-01 | -1.40e-01 | -8.53e-02 | 4.97e-03 | 3.09e-01 | 2.68e-01 | 2.36e-01 | 4.69e-01 | 9.66e-01 |
| SPHINGOSINE BIOSYNTHETIC PROCESS | 14 | 6.40e-01 | 1.00e+00 | 0.24100 | -4.37e-02 | -5.24e-02 | 6.17e-02 | -4.97e-02 | 2.18e-01 | 7.77e-01 | 7.34e-01 | 6.89e-01 | 7.48e-01 | 1.59e-01 |
| NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA1 PRODUCTION | 6 | 7.93e-01 | 1.00e+00 | 0.24100 | -2.02e-02 | -7.57e-03 | -9.01e-03 | -1.33e-02 | -2.40e-01 | 9.32e-01 | 9.74e-01 | 9.70e-01 | 9.55e-01 | 3.09e-01 |
| POSITIVE REGULATION OF PROTEIN DEPHOSPHORYLATION | 41 | 1.99e-01 | 7.14e-01 | 0.24100 | 3.00e-02 | -1.04e-02 | 1.24e-01 | 8.55e-03 | 2.04e-01 | 7.40e-01 | 9.08e-01 | 1.69e-01 | 9.24e-01 | 2.36e-02 |
| OLFACTORY BULB INTERNEURON DIFFERENTIATION | 12 | 2.36e-01 | 7.60e-01 | 0.24100 | -9.49e-02 | -1.39e-01 | 6.55e-02 | -1.49e-01 | -5.74e-02 | 5.69e-01 | 4.04e-01 | 6.95e-01 | 3.71e-01 | 7.31e-01 |
| HEPARAN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS | 32 | 2.78e-01 | 8.05e-01 | 0.24100 | 1.79e-03 | 3.25e-02 | -8.45e-02 | 5.75e-02 | -2.16e-01 | 9.86e-01 | 7.50e-01 | 4.08e-01 | 5.73e-01 | 3.43e-02 |
| POSITIVE REGULATION OF PLATELET AGGREGATION | 11 | 1.92e-01 | 7.02e-01 | 0.24100 | 1.59e-03 | -6.08e-03 | 1.74e-01 | -4.37e-02 | 1.61e-01 | 9.93e-01 | 9.72e-01 | 3.18e-01 | 8.02e-01 | 3.54e-01 |
| AGGRESOME ASSEMBLY | 5 | 9.43e-01 | 1.00e+00 | 0.24100 | -9.30e-02 | -1.00e-01 | -1.67e-01 | 1.33e-02 | -1.06e-01 | 7.19e-01 | 6.98e-01 | 5.17e-01 | 9.59e-01 | 6.80e-01 |
| REGULATION OF LEUKOCYTE APOPTOTIC PROCESS | 90 | 1.19e-01 | 5.76e-01 | 0.24100 | -1.18e-01 | -1.31e-01 | -3.68e-02 | -1.57e-01 | 3.22e-02 | 5.21e-02 | 3.15e-02 | 5.46e-01 | 1.01e-02 | 5.97e-01 |
| NEGATIVE REGULATION OF SMOOTH MUSCLE CELL MIGRATION | 33 | 3.37e-01 | 8.59e-01 | 0.24100 | -1.09e-01 | -1.33e-01 | -7.59e-02 | -1.51e-01 | -1.00e-02 | 2.79e-01 | 1.85e-01 | 4.50e-01 | 1.34e-01 | 9.20e-01 |
| REGULATION OF CD4 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 53 | 1.37e-01 | 6.17e-01 | 0.24100 | -1.10e-01 | -1.29e-01 | 3.42e-03 | -1.64e-01 | 5.14e-02 | 1.66e-01 | 1.04e-01 | 9.66e-01 | 3.93e-02 | 5.17e-01 |
| MALATE METABOLIC PROCESS | 9 | 4.00e-01 | 9.01e-01 | 0.24100 | -1.16e-01 | -1.58e-01 | 6.20e-03 | -1.11e-01 | -8.63e-02 | 5.47e-01 | 4.12e-01 | 9.74e-01 | 5.64e-01 | 6.54e-01 |
| ENDOSOME TO LYSOSOME TRANSPORT | 70 | 2.44e-02 | 2.34e-01 | 0.24100 | 2.23e-02 | 8.37e-03 | 1.20e-01 | -3.21e-02 | 2.05e-01 | 7.47e-01 | 9.04e-01 | 8.28e-02 | 6.43e-01 | 2.97e-03 |
| POSITIVE REGULATION OF AMYLOID BETA CLEARANCE | 8 | 7.29e-01 | 1.00e+00 | 0.24100 | -1.58e-02 | -3.55e-02 | 1.32e-02 | -5.45e-02 | 2.31e-01 | 9.38e-01 | 8.62e-01 | 9.49e-01 | 7.90e-01 | 2.57e-01 |
| POST EMBRYONIC EYE MORPHOGENESIS | 7 | 9.57e-01 | 1.00e+00 | 0.24100 | -2.50e-02 | -6.21e-03 | -1.01e-01 | -4.42e-04 | -2.17e-01 | 9.09e-01 | 9.77e-01 | 6.43e-01 | 9.98e-01 | 3.20e-01 |
| ALTERNATIVE MRNA SPLICING VIA SPLICEOSOME | 66 | 4.34e-01 | 9.21e-01 | 0.24100 | 1.21e-01 | 1.14e-01 | 1.35e-01 | 1.08e-01 | 2.43e-02 | 8.88e-02 | 1.10e-01 | 5.86e-02 | 1.28e-01 | 7.32e-01 |
| ATTACHMENT OF GPI ANCHOR TO PROTEIN | 6 | 6.95e-01 | 1.00e+00 | 0.24100 | -1.98e-02 | -6.32e-02 | 1.16e-01 | -2.00e-01 | 5.88e-03 | 9.33e-01 | 7.89e-01 | 6.22e-01 | 3.96e-01 | 9.80e-01 |
| GLUCOSAMINE CONTAINING COMPOUND CATABOLIC PROCESS | 9 | 7.35e-01 | 1.00e+00 | 0.24100 | 8.61e-02 | 1.51e-01 | -3.79e-02 | 1.23e-01 | -1.07e-01 | 6.55e-01 | 4.33e-01 | 8.44e-01 | 5.24e-01 | 5.80e-01 |
| POSITIVE REGULATION OF CELL ACTIVATION | 378 | 1.30e-07 | 1.14e-05 | 0.24100 | -1.20e-01 | -1.38e-01 | -3.10e-02 | -1.37e-01 | 6.98e-02 | 6.19e-05 | 4.24e-06 | 3.01e-01 | 4.75e-06 | 1.98e-02 |
| PROTEIN IMPORT INTO PEROXISOME MATRIX | 14 | 9.21e-01 | 1.00e+00 | 0.24100 | -1.14e-01 | -1.16e-01 | -8.83e-02 | -1.01e-01 | 1.16e-01 | 4.62e-01 | 4.51e-01 | 5.67e-01 | 5.12e-01 | 4.53e-01 |
| RESPONSE TO VITAMIN A | 15 | 5.20e-01 | 9.53e-01 | 0.24100 | 1.02e-01 | 8.55e-02 | 1.94e-01 | -3.13e-02 | -3.70e-02 | 4.93e-01 | 5.66e-01 | 1.92e-01 | 8.34e-01 | 8.04e-01 |
| BARBED END ACTIN FILAMENT CAPPING | 25 | 5.18e-01 | 9.52e-01 | 0.24100 | 1.05e-01 | 1.38e-01 | 2.96e-02 | 1.64e-01 | 4.12e-03 | 3.63e-01 | 2.33e-01 | 7.98e-01 | 1.56e-01 | 9.72e-01 |
| PROTEIN PALMITOYLATION | 28 | 6.69e-01 | 1.00e+00 | 0.24000 | 1.05e-01 | 9.94e-02 | 1.59e-01 | 5.98e-02 | 9.00e-02 | 3.36e-01 | 3.62e-01 | 1.46e-01 | 5.84e-01 | 4.10e-01 |
| DNA INTEGRATION | 8 | 1.85e-01 | 6.93e-01 | 0.24000 | 4.89e-02 | 1.23e-01 | -9.49e-03 | 8.02e-03 | 2.00e-01 | 8.11e-01 | 5.46e-01 | 9.63e-01 | 9.69e-01 | 3.27e-01 |
| POSITIVE REGULATION OF LEUKOCYTE CELL CELL ADHESION | 264 | 9.58e-05 | 3.34e-03 | 0.24000 | -1.27e-01 | -1.38e-01 | -4.90e-02 | -1.32e-01 | 5.20e-02 | 3.91e-04 | 1.09e-04 | 1.71e-01 | 2.14e-04 | 1.45e-01 |
| POSTSYNAPTIC SPECIALIZATION ASSEMBLY | 26 | 4.11e-01 | 9.08e-01 | 0.24000 | 1.00e-01 | 1.28e-01 | 8.53e-02 | 4.82e-02 | -1.47e-01 | 3.76e-01 | 2.59e-01 | 4.51e-01 | 6.71e-01 | 1.93e-01 |
| INOSITOL TRISPHOSPHATE METABOLIC PROCESS | 12 | 3.71e-01 | 8.81e-01 | 0.24000 | -7.55e-02 | -4.08e-02 | -1.32e-01 | 4.47e-02 | -1.76e-01 | 6.51e-01 | 8.07e-01 | 4.30e-01 | 7.88e-01 | 2.90e-01 |
| REGULATION OF HEXOKINASE ACTIVITY | 7 | 2.33e-01 | 7.56e-01 | 0.24000 | 1.44e-02 | 6.10e-02 | 1.05e-01 | -2.04e-01 | 3.13e-02 | 9.47e-01 | 7.80e-01 | 6.31e-01 | 3.49e-01 | 8.86e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 37 | 7.02e-01 | 1.00e+00 | 0.24000 | -1.29e-01 | -1.11e-01 | -1.36e-01 | -9.61e-02 | 2.85e-02 | 1.74e-01 | 2.42e-01 | 1.52e-01 | 3.12e-01 | 7.64e-01 |
| NEGATIVE REGULATION OF POST TRANSLATIONAL PROTEIN MODIFICATION | 86 | 1.76e-02 | 1.90e-01 | 0.24000 | 1.02e-01 | 1.00e-01 | 1.70e-01 | 3.81e-02 | 8.24e-02 | 1.03e-01 | 1.09e-01 | 6.37e-03 | 5.41e-01 | 1.86e-01 |
| PURINERGIC NUCLEOTIDE RECEPTOR SIGNALING PATHWAY | 29 | 2.18e-01 | 7.40e-01 | 0.24000 | 7.93e-02 | 6.80e-02 | 1.12e-01 | 1.34e-01 | 1.27e-01 | 4.60e-01 | 5.26e-01 | 2.95e-01 | 2.12e-01 | 2.37e-01 |
| BONE CELL DEVELOPMENT | 17 | 2.43e-01 | 7.69e-01 | 0.24000 | -1.25e-01 | -1.18e-01 | -1.41e-01 | 3.13e-02 | 8.51e-02 | 3.73e-01 | 4.00e-01 | 3.14e-01 | 8.23e-01 | 5.44e-01 |
| AUTOPHAGOSOME LYSOSOME FUSION | 9 | 7.45e-01 | 1.00e+00 | 0.24000 | -1.11e-01 | -4.55e-02 | -1.49e-01 | -1.02e-01 | -1.03e-01 | 5.65e-01 | 8.13e-01 | 4.39e-01 | 5.98e-01 | 5.93e-01 |
| IMPORT ACROSS PLASMA MEMBRANE | 202 | 1.34e-03 | 2.90e-02 | 0.24000 | 1.10e-01 | 1.30e-01 | 4.37e-02 | 1.41e-01 | -8.25e-02 | 6.97e-03 | 1.51e-03 | 2.84e-01 | 5.48e-04 | 4.33e-02 |
| SEQUESTERING OF METAL ION | 10 | 7.95e-01 | 1.00e+00 | 0.24000 | 2.39e-03 | -4.54e-02 | 6.39e-02 | 2.99e-02 | 2.25e-01 | 9.90e-01 | 8.04e-01 | 7.26e-01 | 8.70e-01 | 2.19e-01 |
| POSITIVE REGULATION OF VOLTAGE GATED CALCIUM CHANNEL ACTIVITY | 7 | 9.39e-01 | 1.00e+00 | 0.24000 | 1.22e-01 | 1.63e-01 | 6.38e-02 | 1.05e-01 | -2.73e-02 | 5.77e-01 | 4.54e-01 | 7.70e-01 | 6.29e-01 | 9.00e-01 |
| NEGATIVE REGULATION OF FAT CELL PROLIFERATION | 5 | 8.30e-01 | 1.00e+00 | 0.23900 | -9.74e-02 | -1.74e-01 | 1.57e-02 | -1.04e-01 | 8.06e-02 | 7.06e-01 | 5.01e-01 | 9.52e-01 | 6.86e-01 | 7.55e-01 |
| REGULATION OF CALCIUM ION IMPORT ACROSS PLASMA MEMBRANE | 16 | 8.23e-01 | 1.00e+00 | 0.23900 | 1.06e-01 | 1.20e-01 | 1.71e-02 | 1.02e-01 | -1.45e-01 | 4.63e-01 | 4.07e-01 | 9.06e-01 | 4.79e-01 | 3.15e-01 |
| GAMMA AMINOBUTYRIC ACID METABOLIC PROCESS | 8 | 8.73e-01 | 1.00e+00 | 0.23900 | 3.81e-02 | -4.87e-03 | 1.67e-01 | -2.18e-02 | 1.66e-01 | 8.52e-01 | 9.81e-01 | 4.14e-01 | 9.15e-01 | 4.16e-01 |
| GLYCINE BIOSYNTHETIC PROCESS | 7 | 9.08e-01 | 1.00e+00 | 0.23900 | -3.21e-05 | -2.42e-02 | 5.53e-02 | -3.67e-02 | 2.29e-01 | 1.00e+00 | 9.12e-01 | 8.00e-01 | 8.67e-01 | 2.95e-01 |
| LEUKOCYTE MEDIATED IMMUNITY | 380 | 3.73e-10 | 6.11e-08 | 0.23900 | -1.06e-01 | -1.36e-01 | 4.74e-04 | -1.43e-01 | 8.38e-02 | 3.69e-04 | 5.21e-06 | 9.87e-01 | 1.74e-06 | 5.01e-03 |
| REGULATION OF SOMATIC STEM CELL POPULATION MAINTENANCE | 12 | 1.87e-01 | 6.95e-01 | 0.23900 | 5.88e-02 | 4.23e-02 | 2.23e-01 | -3.17e-02 | 3.72e-02 | 7.24e-01 | 8.00e-01 | 1.82e-01 | 8.49e-01 | 8.23e-01 |
| CELLULAR RESPONSE TO GLUCOSE STARVATION | 49 | 3.90e-01 | 8.92e-01 | 0.23900 | 1.06e-01 | 1.06e-01 | 1.47e-01 | 6.48e-02 | 9.39e-02 | 2.00e-01 | 1.98e-01 | 7.54e-02 | 4.33e-01 | 2.55e-01 |
| RESPONSE TO OXYGEN GLUCOSE DEPRIVATION | 11 | 5.41e-01 | 9.59e-01 | 0.23900 | 1.17e-01 | 8.50e-02 | 1.85e-01 | -4.29e-02 | -8.88e-03 | 5.03e-01 | 6.25e-01 | 2.88e-01 | 8.05e-01 | 9.59e-01 |
| POSITIVE REGULATION OF TROPHOBLAST CELL MIGRATION | 7 | 9.79e-01 | 1.00e+00 | 0.23900 | 1.19e-01 | 1.25e-01 | 1.17e-01 | 6.36e-02 | -9.77e-02 | 5.85e-01 | 5.68e-01 | 5.93e-01 | 7.71e-01 | 6.54e-01 |
| CILIARY BODY MORPHOGENESIS | 5 | 6.60e-01 | 1.00e+00 | 0.23900 | 2.65e-03 | 8.88e-02 | -1.52e-01 | 1.48e-01 | -6.24e-02 | 9.92e-01 | 7.31e-01 | 5.55e-01 | 5.66e-01 | 8.09e-01 |
| TRANSPOSITION | 38 | 5.84e-01 | 9.85e-01 | 0.23900 | -1.12e-01 | -1.00e-01 | -1.56e-01 | -8.20e-02 | -5.79e-02 | 2.32e-01 | 2.84e-01 | 9.66e-02 | 3.82e-01 | 5.37e-01 |
| VESICLE TETHERING | 31 | 6.78e-01 | 1.00e+00 | 0.23900 | 1.21e-01 | 9.06e-02 | 1.59e-01 | 6.90e-02 | 6.38e-02 | 2.43e-01 | 3.83e-01 | 1.26e-01 | 5.06e-01 | 5.39e-01 |
| REGULATION OF VASOCONSTRICTION | 61 | 7.31e-02 | 4.45e-01 | 0.23900 | 6.55e-02 | 6.80e-02 | 8.80e-04 | 8.28e-02 | -2.03e-01 | 3.76e-01 | 3.58e-01 | 9.91e-01 | 2.63e-01 | 6.12e-03 |
| BONE REMODELING | 89 | 4.83e-02 | 3.58e-01 | 0.23900 | -1.28e-01 | -1.32e-01 | -5.84e-02 | -1.08e-01 | 9.01e-02 | 3.62e-02 | 3.20e-02 | 3.41e-01 | 7.91e-02 | 1.42e-01 |
| PHAGOSOME MATURATION | 28 | 6.90e-01 | 1.00e+00 | 0.23900 | -1.15e-01 | -1.36e-01 | -2.36e-02 | -1.36e-01 | 7.89e-02 | 2.92e-01 | 2.13e-01 | 8.29e-01 | 2.14e-01 | 4.70e-01 |
| REGULATION OF PINOCYTOSIS | 12 | 8.16e-01 | 1.00e+00 | 0.23900 | 1.17e-01 | 8.48e-02 | 1.86e-01 | 3.09e-02 | -1.96e-02 | 4.81e-01 | 6.11e-01 | 2.65e-01 | 8.53e-01 | 9.06e-01 |
| ATRIAL SEPTUM MORPHOGENESIS | 15 | 2.99e-01 | 8.26e-01 | 0.23900 | 4.74e-03 | -6.77e-03 | 8.76e-02 | -1.44e-01 | -1.68e-01 | 9.75e-01 | 9.64e-01 | 5.57e-01 | 3.34e-01 | 2.59e-01 |
| NEUROTRANSMITTER GATED ION CHANNEL CLUSTERING | 16 | 6.23e-01 | 9.92e-01 | 0.23800 | 2.74e-02 | 3.89e-02 | 5.82e-02 | 3.53e-02 | 2.24e-01 | 8.49e-01 | 7.87e-01 | 6.87e-01 | 8.07e-01 | 1.22e-01 |
| DORSAL VENTRAL NEURAL TUBE PATTERNING | 24 | 3.38e-01 | 8.59e-01 | 0.23800 | -5.01e-02 | -1.04e-01 | 6.98e-02 | -7.43e-02 | 1.82e-01 | 6.71e-01 | 3.78e-01 | 5.54e-01 | 5.29e-01 | 1.23e-01 |
| NERVOUS SYSTEM PROCESS | 1404 | 8.03e-23 | 8.63e-20 | 0.23800 | -1.09e-01 | -8.98e-02 | -1.58e-01 | -6.52e-02 | -8.71e-02 | 8.37e-12 | 1.69e-08 | 2.51e-23 | 4.24e-05 | 4.36e-08 |
| NEGATIVE REGULATION OF PHAGOCYTOSIS | 21 | 3.94e-02 | 3.19e-01 | 0.23800 | -7.97e-02 | -1.57e-01 | 7.93e-02 | -1.40e-01 | 5.99e-03 | 5.27e-01 | 2.14e-01 | 5.30e-01 | 2.68e-01 | 9.62e-01 |
| RNA SPLICING VIA TRANSESTERIFICATION REACTIONS | 286 | 1.64e-06 | 9.66e-05 | 0.23800 | 8.84e-02 | 6.31e-02 | 1.65e-01 | 2.50e-02 | 1.31e-01 | 1.01e-02 | 6.62e-02 | 1.55e-06 | 4.67e-01 | 1.46e-04 |
| POSITIVE REGULATION OF FAT CELL DIFFERENTIATION | 67 | 4.78e-01 | 9.40e-01 | 0.23800 | 1.31e-01 | 1.28e-01 | 1.25e-01 | 8.37e-02 | -2.70e-02 | 6.39e-02 | 7.09e-02 | 7.78e-02 | 2.36e-01 | 7.02e-01 |
| REGULATION OF MICROTUBULE POLYMERIZATION | 59 | 4.11e-01 | 9.08e-01 | 0.23800 | 1.07e-01 | 1.11e-01 | 1.07e-01 | 1.17e-01 | 8.73e-02 | 1.54e-01 | 1.39e-01 | 1.55e-01 | 1.20e-01 | 2.46e-01 |
| UMP CATABOLIC PROCESS | 5 | 9.27e-01 | 1.00e+00 | 0.23800 | -9.87e-02 | -4.40e-02 | -1.47e-01 | -4.22e-02 | -1.47e-01 | 7.02e-01 | 8.65e-01 | 5.70e-01 | 8.70e-01 | 5.70e-01 |
| MAST CELL ACTIVATION | 67 | 2.70e-02 | 2.51e-01 | 0.23800 | -1.00e-01 | -1.43e-01 | 5.49e-04 | -1.53e-01 | 5.24e-02 | 1.57e-01 | 4.25e-02 | 9.94e-01 | 3.08e-02 | 4.58e-01 |
| PROGRAMMED CELL DEATH IN RESPONSE TO REACTIVE OXYGEN SPECIES | 19 | 4.60e-01 | 9.32e-01 | 0.23800 | -1.04e-01 | -4.53e-02 | -1.89e-01 | -4.37e-02 | -7.76e-02 | 4.32e-01 | 7.32e-01 | 1.54e-01 | 7.42e-01 | 5.58e-01 |
| ENDOCRINE PANCREAS DEVELOPMENT | 46 | 9.50e-04 | 2.18e-02 | 0.23800 | -7.32e-03 | -1.72e-02 | 9.70e-02 | -1.77e-01 | -1.23e-01 | 9.32e-01 | 8.40e-01 | 2.55e-01 | 3.73e-02 | 1.48e-01 |
| LEUKOCYTE HOMEOSTASIS | 103 | 1.63e-01 | 6.64e-01 | 0.23800 | -1.25e-01 | -1.39e-01 | -7.76e-02 | -1.23e-01 | -1.73e-02 | 2.79e-02 | 1.49e-02 | 1.74e-01 | 3.08e-02 | 7.62e-01 |
| THALAMUS DEVELOPMENT | 11 | 6.59e-01 | 1.00e+00 | 0.23800 | 7.91e-02 | 8.12e-02 | 1.29e-01 | -2.30e-02 | -1.63e-01 | 6.50e-01 | 6.41e-01 | 4.60e-01 | 8.95e-01 | 3.50e-01 |
| REGULATION OF OOCYTE MATURATION | 7 | 8.83e-01 | 1.00e+00 | 0.23800 | 6.64e-02 | 4.69e-02 | 2.58e-02 | 5.79e-02 | -2.14e-01 | 7.61e-01 | 8.30e-01 | 9.06e-01 | 7.91e-01 | 3.27e-01 |
| HISTONE H4 ACETYLATION | 11 | 6.52e-01 | 1.00e+00 | 0.23800 | -9.61e-02 | -7.72e-02 | -6.58e-02 | -1.81e-02 | 1.91e-01 | 5.81e-01 | 6.58e-01 | 7.05e-01 | 9.17e-01 | 2.72e-01 |
| ADAPTIVE IMMUNE RESPONSE | 449 | 6.25e-07 | 4.48e-05 | 0.23700 | -1.18e-01 | -1.36e-01 | -4.72e-02 | -1.42e-01 | 4.00e-02 | 1.84e-05 | 7.63e-07 | 8.67e-02 | 2.56e-07 | 1.46e-01 |
| ANIMAL ORGAN REGENERATION | 60 | 4.26e-02 | 3.31e-01 | 0.23700 | 2.35e-02 | -7.07e-03 | 1.38e-01 | -5.56e-02 | 1.83e-01 | 7.53e-01 | 9.25e-01 | 6.44e-02 | 4.57e-01 | 1.40e-02 |
| B CELL DIFFERENTIATION | 144 | 5.11e-03 | 7.85e-02 | 0.23700 | -1.06e-01 | -1.35e-01 | -1.93e-02 | -1.38e-01 | 8.58e-02 | 2.81e-02 | 5.12e-03 | 6.89e-01 | 4.20e-03 | 7.55e-02 |
| RESPONSE TO SORBITOL | 6 | 8.86e-01 | 1.00e+00 | 0.23700 | 8.92e-02 | 1.43e-01 | 2.37e-02 | 1.12e-01 | -1.22e-01 | 7.05e-01 | 5.44e-01 | 9.20e-01 | 6.35e-01 | 6.06e-01 |
| MESENCHYMAL CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 6 | 8.53e-01 | 1.00e+00 | 0.23700 | 1.10e-01 | 4.85e-02 | 1.89e-01 | 7.48e-02 | 1.65e-02 | 6.40e-01 | 8.37e-01 | 4.22e-01 | 7.51e-01 | 9.44e-01 |
| POSITIVE REGULATION OF T HELPER 1 CELL DIFFERENTIATION | 6 | 6.82e-01 | 1.00e+00 | 0.23700 | 2.56e-02 | 2.57e-02 | 1.33e-01 | -1.64e-01 | -1.02e-01 | 9.13e-01 | 9.13e-01 | 5.74e-01 | 4.86e-01 | 6.66e-01 |
| RESPONSE TO ANTIBIOTIC | 36 | 7.17e-01 | 1.00e+00 | 0.23700 | 1.01e-01 | 9.48e-02 | 1.31e-01 | 7.60e-02 | 1.19e-01 | 2.93e-01 | 3.25e-01 | 1.74e-01 | 4.30e-01 | 2.18e-01 |
| REGULATION OF GENERATION OF PRECURSOR METABOLITES AND ENERGY | 132 | 1.13e-01 | 5.59e-01 | 0.23700 | 1.26e-01 | 1.21e-01 | 1.36e-01 | 8.39e-02 | -1.25e-02 | 1.27e-02 | 1.61e-02 | 6.90e-03 | 9.61e-02 | 8.04e-01 |
| PERICENTRIC HETEROCHROMATIN FORMATION | 5 | 9.52e-01 | 1.00e+00 | 0.23700 | 7.87e-02 | 9.18e-02 | 1.14e-01 | 1.45e-02 | 1.68e-01 | 7.60e-01 | 7.22e-01 | 6.59e-01 | 9.55e-01 | 5.14e-01 |
| CATECHOL CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 22 | 1.55e-01 | 6.52e-01 | 0.23700 | 1.13e-01 | 5.67e-02 | 1.87e-01 | 1.00e-02 | -7.25e-02 | 3.61e-01 | 6.45e-01 | 1.29e-01 | 9.35e-01 | 5.56e-01 |
| NEUROTRANSMITTER METABOLIC PROCESS | 25 | 8.21e-01 | 1.00e+00 | 0.23700 | 1.16e-01 | 8.93e-02 | 1.55e-01 | 6.70e-02 | 7.84e-02 | 3.17e-01 | 4.39e-01 | 1.79e-01 | 5.62e-01 | 4.97e-01 |
| SOMATIC DIVERSIFICATION OF IMMUNOGLOBULINS | 65 | 3.99e-03 | 6.49e-02 | 0.23700 | -7.22e-03 | -4.70e-02 | 1.41e-01 | -1.12e-01 | 1.46e-01 | 9.20e-01 | 5.12e-01 | 4.90e-02 | 1.20e-01 | 4.11e-02 |
| LYMPHOCYTE MEDIATED IMMUNITY | 282 | 3.94e-07 | 2.96e-05 | 0.23700 | -1.06e-01 | -1.35e-01 | -1.83e-03 | -1.44e-01 | 7.67e-02 | 2.17e-03 | 9.25e-05 | 9.58e-01 | 3.24e-05 | 2.67e-02 |
| EPIDERMIS MORPHOGENESIS | 36 | 4.26e-01 | 9.15e-01 | 0.23700 | 1.18e-01 | 9.09e-02 | 1.03e-01 | 1.53e-01 | 9.79e-03 | 2.21e-01 | 3.45e-01 | 2.87e-01 | 1.13e-01 | 9.19e-01 |
| POSITIVE REGULATION OF RUFFLE ASSEMBLY | 15 | 7.35e-01 | 1.00e+00 | 0.23700 | -1.05e-02 | 2.69e-02 | -9.02e-02 | 2.78e-02 | -2.15e-01 | 9.44e-01 | 8.57e-01 | 5.45e-01 | 8.52e-01 | 1.49e-01 |
| REGULATION OF UNSATURATED FATTY ACID BIOSYNTHETIC PROCESS | 13 | 5.08e-01 | 9.48e-01 | 0.23700 | 2.75e-02 | 6.15e-03 | 6.71e-02 | -6.30e-02 | -2.16e-01 | 8.64e-01 | 9.69e-01 | 6.76e-01 | 6.94e-01 | 1.77e-01 |
| REGULATION OF MEMBRANE DEPOLARIZATION | 45 | 7.11e-01 | 1.00e+00 | 0.23700 | 1.23e-01 | 1.26e-01 | 1.25e-01 | 9.55e-02 | 1.31e-02 | 1.55e-01 | 1.43e-01 | 1.46e-01 | 2.68e-01 | 8.79e-01 |
| POSITIVE REGULATION OF CONNECTIVE TISSUE REPLACEMENT | 12 | 8.22e-01 | 1.00e+00 | 0.23700 | 1.21e-01 | 7.90e-02 | 1.42e-01 | 7.53e-02 | 9.64e-02 | 4.69e-01 | 6.35e-01 | 3.94e-01 | 6.52e-01 | 5.63e-01 |
| GOLGI VESICLE BUDDING | 10 | 8.52e-01 | 1.00e+00 | 0.23600 | -3.38e-02 | -3.19e-02 | 3.20e-02 | -3.89e-02 | 2.26e-01 | 8.53e-01 | 8.61e-01 | 8.61e-01 | 8.31e-01 | 2.15e-01 |
| NEGATIVE REGULATION OF GLUCONEOGENESIS | 18 | 9.45e-01 | 1.00e+00 | 0.23600 | 1.20e-01 | 1.32e-01 | 8.07e-02 | 1.28e-01 | -3.08e-02 | 3.78e-01 | 3.31e-01 | 5.53e-01 | 3.46e-01 | 8.21e-01 |
| MONOAMINE TRANSPORT | 86 | 1.05e-01 | 5.37e-01 | 0.23600 | 1.26e-01 | 1.09e-01 | 1.31e-01 | 7.66e-02 | -7.34e-02 | 4.40e-02 | 8.20e-02 | 3.63e-02 | 2.19e-01 | 2.39e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CELL SURFACE | 40 | 4.10e-01 | 9.08e-01 | 0.23600 | 9.66e-02 | 9.27e-02 | 1.37e-01 | 9.22e-02 | 1.04e-01 | 2.90e-01 | 3.10e-01 | 1.35e-01 | 3.13e-01 | 2.56e-01 |
| NEGATIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 13 | 4.10e-01 | 9.08e-01 | 0.23600 | -1.05e-01 | -1.54e-01 | 4.40e-02 | -1.28e-01 | 5.15e-02 | 5.11e-01 | 3.35e-01 | 7.84e-01 | 4.25e-01 | 7.48e-01 |
| REGULATION OF SMAD PROTEIN SIGNAL TRANSDUCTION | 52 | 3.97e-01 | 8.96e-01 | 0.23600 | -1.10e-01 | -1.09e-01 | -9.39e-02 | -1.47e-01 | -3.89e-02 | 1.70e-01 | 1.73e-01 | 2.41e-01 | 6.76e-02 | 6.27e-01 |
| ERYTHROCYTE DEVELOPMENT | 37 | 4.01e-01 | 9.01e-01 | 0.23600 | 7.74e-02 | 6.40e-02 | 1.53e-01 | 3.79e-02 | 1.44e-01 | 4.15e-01 | 5.00e-01 | 1.07e-01 | 6.90e-01 | 1.30e-01 |
| GALACTOSE METABOLIC PROCESS | 8 | 6.01e-01 | 9.90e-01 | 0.23600 | 9.71e-02 | 1.43e-01 | 1.09e-01 | 7.09e-02 | -9.48e-02 | 6.34e-01 | 4.83e-01 | 5.94e-01 | 7.28e-01 | 6.42e-01 |
| POSITIVE REGULATION OF GLIOGENESIS | 68 | 1.98e-01 | 7.13e-01 | 0.23600 | 1.08e-01 | 1.02e-01 | 1.62e-01 | 5.09e-02 | 6.96e-02 | 1.22e-01 | 1.47e-01 | 2.10e-02 | 4.68e-01 | 3.21e-01 |
| RESPONSE TO COLD | 43 | 7.17e-01 | 1.00e+00 | 0.23600 | 1.14e-01 | 9.46e-02 | 1.42e-01 | 8.75e-02 | 7.67e-02 | 1.95e-01 | 2.83e-01 | 1.07e-01 | 3.21e-01 | 3.84e-01 |
| POSITIVE REGULATION OF DNA REPAIR | 124 | 4.22e-02 | 3.29e-01 | 0.23600 | 1.04e-01 | 9.07e-02 | 1.57e-01 | 5.31e-02 | 9.64e-02 | 4.63e-02 | 8.11e-02 | 2.55e-03 | 3.08e-01 | 6.37e-02 |
| PHOSPHOLIPID TRANSLOCATION | 50 | 4.61e-01 | 9.32e-01 | 0.23600 | -9.69e-02 | -8.88e-02 | -1.35e-01 | -5.52e-02 | -1.31e-01 | 2.36e-01 | 2.77e-01 | 9.92e-02 | 4.99e-01 | 1.09e-01 |
| MEMBRANE INVAGINATION | 64 | 5.96e-02 | 4.01e-01 | 0.23600 | -1.26e-01 | -1.43e-01 | -1.11e-01 | -6.27e-02 | -5.42e-02 | 8.05e-02 | 4.73e-02 | 1.26e-01 | 3.85e-01 | 4.53e-01 |
| PROTEIN LOCALIZATION TO NUCLEOPLASM | 13 | 7.77e-01 | 1.00e+00 | 0.23600 | -1.88e-02 | -4.98e-02 | 1.01e-01 | -9.09e-02 | 1.85e-01 | 9.07e-01 | 7.56e-01 | 5.28e-01 | 5.70e-01 | 2.47e-01 |
| NEGATIVE REGULATION OF EXOCYTOSIS | 32 | 6.66e-03 | 9.31e-02 | 0.23600 | 6.75e-03 | -4.58e-02 | 1.70e-01 | -1.56e-01 | -1.12e-02 | 9.47e-01 | 6.54e-01 | 9.53e-02 | 1.27e-01 | 9.12e-01 |
| OLIGOPEPTIDE TRANSMEMBRANE TRANSPORT | 9 | 8.20e-01 | 1.00e+00 | 0.23600 | -1.25e-01 | -1.36e-01 | -1.37e-01 | -1.89e-03 | 5.36e-02 | 5.15e-01 | 4.81e-01 | 4.78e-01 | 9.92e-01 | 7.81e-01 |
| PHENOL CONTAINING COMPOUND CATABOLIC PROCESS | 7 | 9.25e-01 | 1.00e+00 | 0.23600 | 1.18e-01 | 7.82e-02 | 1.13e-01 | 1.51e-01 | 9.00e-03 | 5.89e-01 | 7.20e-01 | 6.05e-01 | 4.90e-01 | 9.67e-01 |
| GLYCOSYLCERAMIDE BIOSYNTHETIC PROCESS | 8 | 7.09e-01 | 1.00e+00 | 0.23600 | -1.37e-01 | -8.78e-02 | -1.62e-01 | -3.59e-02 | -3.84e-02 | 5.02e-01 | 6.67e-01 | 4.27e-01 | 8.60e-01 | 8.51e-01 |
| NEGATIVE REGULATION OF HUMORAL IMMUNE RESPONSE MEDIATED BY CIRCULATING IMMUNOGLOBULIN | 11 | 9.25e-01 | 1.00e+00 | 0.23600 | -9.43e-02 | -8.79e-02 | -6.92e-02 | -1.16e-01 | -1.44e-01 | 5.88e-01 | 6.14e-01 | 6.91e-01 | 5.05e-01 | 4.09e-01 |
| PEPTIDYL LYSINE ACETYLATION | 64 | 1.22e-01 | 5.83e-01 | 0.23600 | 1.08e-01 | 1.16e-01 | 1.47e-01 | 4.64e-02 | 8.15e-02 | 1.37e-01 | 1.08e-01 | 4.15e-02 | 5.21e-01 | 2.60e-01 |
| MITOCHONDRIAL FISSION | 40 | 7.89e-01 | 1.00e+00 | 0.23600 | -1.26e-01 | -1.34e-01 | -1.01e-01 | -1.06e-01 | -1.31e-02 | 1.68e-01 | 1.41e-01 | 2.71e-01 | 2.46e-01 | 8.86e-01 |
| POSITIVE REGULATION OF CEREBELLAR GRANULE CELL PRECURSOR PROLIFERATION | 8 | 8.58e-01 | 1.00e+00 | 0.23600 | -7.50e-02 | -7.90e-02 | 4.41e-03 | -1.89e-01 | -8.83e-02 | 7.13e-01 | 6.99e-01 | 9.83e-01 | 3.54e-01 | 6.65e-01 |
| CYCLIC GMP AMP TRANSMEMBRANE IMPORT ACROSS PLASMA MEMBRANE | 6 | 7.67e-01 | 1.00e+00 | 0.23500 | 4.07e-02 | 5.63e-02 | 1.01e-01 | -5.44e-02 | -1.94e-01 | 8.63e-01 | 8.11e-01 | 6.69e-01 | 8.18e-01 | 4.11e-01 |
| GLOMERULAR MESANGIAL CELL PROLIFERATION | 13 | 7.77e-01 | 1.00e+00 | 0.23500 | -1.09e-01 | -6.11e-02 | -1.87e-01 | -4.21e-02 | -5.47e-02 | 4.96e-01 | 7.03e-01 | 2.43e-01 | 7.93e-01 | 7.33e-01 |
| PURINE CONTAINING COMPOUND CATABOLIC PROCESS | 57 | 2.42e-01 | 7.68e-01 | 0.23500 | -1.16e-01 | -9.90e-02 | -9.25e-02 | -1.16e-01 | -1.00e-01 | 1.28e-01 | 1.96e-01 | 2.27e-01 | 1.29e-01 | 1.92e-01 |
| REGULATION OF ASTROCYTE ACTIVATION | 8 | 5.26e-01 | 9.54e-01 | 0.23500 | -1.03e-01 | -6.60e-02 | 1.21e-02 | -2.00e-01 | 1.32e-02 | 6.13e-01 | 7.47e-01 | 9.53e-01 | 3.27e-01 | 9.48e-01 |
| BONE GROWTH | 32 | 5.27e-01 | 9.54e-01 | 0.23500 | 1.11e-01 | 1.43e-01 | 4.71e-02 | 1.40e-01 | -2.12e-02 | 2.76e-01 | 1.60e-01 | 6.45e-01 | 1.69e-01 | 8.36e-01 |
| REGULATION OF EXOSOMAL SECRETION | 19 | 7.44e-01 | 1.00e+00 | 0.23500 | 9.97e-02 | 1.12e-01 | 1.16e-01 | 5.69e-02 | 1.28e-01 | 4.52e-01 | 4.00e-01 | 3.83e-01 | 6.68e-01 | 3.35e-01 |
| CALCIUM DEPENDENT CELL CELL ADHESION VIA PLASMA MEMBRANE CELL ADHESION MOLECULES | 47 | 8.88e-02 | 4.92e-01 | 0.23500 | -9.07e-02 | -8.50e-02 | -1.31e-02 | -7.91e-02 | 1.83e-01 | 2.82e-01 | 3.14e-01 | 8.76e-01 | 3.48e-01 | 3.01e-02 |
| AMYLOID BETA CLEARANCE BY CELLULAR CATABOLIC PROCESS | 8 | 8.46e-01 | 1.00e+00 | 0.23500 | 3.54e-02 | 5.08e-02 | 1.66e-02 | 1.11e-01 | 1.97e-01 | 8.62e-01 | 8.03e-01 | 9.35e-01 | 5.88e-01 | 3.34e-01 |
| EMBRYONIC SKELETAL SYSTEM DEVELOPMENT | 126 | 8.78e-03 | 1.15e-01 | 0.23500 | 1.25e-01 | 1.08e-01 | 1.40e-01 | 5.63e-02 | -7.11e-02 | 1.51e-02 | 3.67e-02 | 6.45e-03 | 2.75e-01 | 1.68e-01 |
| CARTILAGE DEVELOPMENT INVOLVED IN ENDOCHONDRAL BONE MORPHOGENESIS | 33 | 3.23e-01 | 8.48e-01 | 0.23500 | 1.09e-01 | 1.19e-01 | 1.58e-01 | 2.48e-02 | 5.87e-02 | 2.80e-01 | 2.36e-01 | 1.15e-01 | 8.05e-01 | 5.59e-01 |
| EMBRYONIC NEUROCRANIUM MORPHOGENESIS | 8 | 7.22e-01 | 1.00e+00 | 0.23500 | 6.84e-02 | 6.36e-02 | -4.77e-02 | 2.03e-01 | 5.28e-02 | 7.38e-01 | 7.55e-01 | 8.15e-01 | 3.20e-01 | 7.96e-01 |
| NEGATIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS | 65 | 5.15e-01 | 9.52e-01 | 0.23500 | 1.17e-01 | 1.12e-01 | 1.39e-01 | 7.80e-02 | 5.94e-02 | 1.03e-01 | 1.17e-01 | 5.34e-02 | 2.77e-01 | 4.08e-01 |
| REGULATION OF SODIUM ION TRANSPORT | 80 | 3.88e-01 | 8.92e-01 | 0.23500 | 1.19e-01 | 1.22e-01 | 6.87e-02 | 1.46e-01 | -2.47e-03 | 6.53e-02 | 5.92e-02 | 2.88e-01 | 2.43e-02 | 9.70e-01 |
| REGULATION OF DNA TEMPLATED TRANSCRIPTION IN RESPONSE TO STRESS | 37 | 2.45e-01 | 7.71e-01 | 0.23500 | 1.12e-01 | 1.19e-01 | 1.67e-01 | 2.13e-02 | 5.16e-03 | 2.36e-01 | 2.12e-01 | 7.92e-02 | 8.23e-01 | 9.57e-01 |
| MYELOID CELL APOPTOTIC PROCESS | 38 | 3.09e-01 | 8.35e-01 | 0.23400 | -1.00e-01 | -1.02e-01 | -1.92e-02 | -1.85e-01 | -2.12e-03 | 2.86e-01 | 2.77e-01 | 8.38e-01 | 4.85e-02 | 9.82e-01 |
| REGULATION OF PROTON TRANSPORT | 16 | 8.27e-01 | 1.00e+00 | 0.23400 | 5.81e-02 | 4.17e-02 | 1.27e-01 | 7.95e-03 | 1.83e-01 | 6.87e-01 | 7.73e-01 | 3.80e-01 | 9.56e-01 | 2.04e-01 |
| PRESYNAPTIC ACTIVE ZONE ORGANIZATION | 8 | 8.30e-01 | 1.00e+00 | 0.23400 | -1.40e-01 | -1.32e-01 | -5.86e-02 | -1.13e-01 | 3.80e-02 | 4.92e-01 | 5.18e-01 | 7.74e-01 | 5.78e-01 | 8.53e-01 |
| MALE SEX DETERMINATION | 11 | 7.11e-01 | 1.00e+00 | 0.23400 | -8.01e-02 | -8.51e-02 | 3.01e-02 | -1.96e-01 | -4.18e-02 | 6.46e-01 | 6.25e-01 | 8.63e-01 | 2.59e-01 | 8.10e-01 |
| ZINC ION TRANSPORT | 28 | 8.26e-01 | 1.00e+00 | 0.23400 | 1.22e-01 | 1.30e-01 | 1.07e-01 | 8.37e-02 | -6.73e-02 | 2.64e-01 | 2.34e-01 | 3.26e-01 | 4.43e-01 | 5.38e-01 |
| RESPONSE TO VITAMIN E | 8 | 7.24e-01 | 1.00e+00 | 0.23400 | -9.74e-02 | -1.02e-01 | -9.83e-02 | -1.34e-02 | -1.58e-01 | 6.33e-01 | 6.17e-01 | 6.30e-01 | 9.48e-01 | 4.39e-01 |
| RESPONSE TO INTERLEUKIN 1 | 134 | 9.36e-02 | 5.05e-01 | 0.23400 | -1.25e-01 | -1.27e-01 | -1.02e-01 | -1.01e-01 | -4.78e-02 | 1.25e-02 | 1.12e-02 | 4.13e-02 | 4.27e-02 | 3.40e-01 |
| REGULATION OF HIGH VOLTAGE GATED CALCIUM CHANNEL ACTIVITY | 11 | 9.56e-01 | 1.00e+00 | 0.23400 | 9.52e-02 | 7.44e-02 | 9.94e-02 | 1.09e-01 | 1.35e-01 | 5.84e-01 | 6.69e-01 | 5.68e-01 | 5.31e-01 | 4.37e-01 |
| CLEAVAGE FURROW FORMATION | 7 | 6.42e-01 | 1.00e+00 | 0.23400 | -2.38e-02 | 5.84e-04 | 1.33e-02 | -4.90e-02 | -2.27e-01 | 9.13e-01 | 9.98e-01 | 9.51e-01 | 8.22e-01 | 2.98e-01 |
| NEGATIVE REGULATION OF FIBROBLAST PROLIFERATION | 34 | 7.58e-01 | 1.00e+00 | 0.23400 | 1.24e-01 | 1.33e-01 | 7.47e-02 | 9.95e-02 | -7.88e-02 | 2.12e-01 | 1.80e-01 | 4.51e-01 | 3.15e-01 | 4.27e-01 |
| POSITIVE REGULATION OF MACROPHAGE CHEMOTAXIS | 19 | 8.21e-01 | 1.00e+00 | 0.23400 | 1.04e-01 | 8.31e-02 | 8.33e-02 | 1.33e-01 | 1.11e-01 | 4.33e-01 | 5.31e-01 | 5.29e-01 | 3.15e-01 | 4.04e-01 |
| IMMUNE RESPONSE TO TUMOR CELL | 26 | 1.90e-01 | 6.99e-01 | 0.23300 | -1.02e-01 | -9.28e-02 | 1.94e-02 | -1.54e-01 | 1.06e-01 | 3.69e-01 | 4.13e-01 | 8.64e-01 | 1.73e-01 | 3.48e-01 |
| LATE ENDOSOME TO LYSOSOME TRANSPORT | 21 | 3.46e-01 | 8.64e-01 | 0.23300 | -3.62e-03 | 7.12e-03 | 5.03e-02 | 2.22e-02 | 2.27e-01 | 9.77e-01 | 9.55e-01 | 6.90e-01 | 8.60e-01 | 7.22e-02 |
| ANATOMICAL STRUCTURE ARRANGEMENT | 15 | 8.43e-01 | 1.00e+00 | 0.23300 | 1.22e-01 | 1.39e-01 | 7.28e-02 | 6.68e-02 | -1.02e-01 | 4.13e-01 | 3.52e-01 | 6.26e-01 | 6.54e-01 | 4.92e-01 |
| PEPTIDYL THREONINE DEPHOSPHORYLATION | 18 | 4.91e-01 | 9.45e-01 | 0.23300 | 5.15e-02 | 4.81e-02 | 1.59e-01 | -4.20e-02 | 1.50e-01 | 7.05e-01 | 7.24e-01 | 2.43e-01 | 7.58e-01 | 2.71e-01 |
| REGULATION OF NADP METABOLIC PROCESS | 9 | 8.13e-01 | 1.00e+00 | 0.23300 | 9.10e-02 | 9.05e-02 | 4.20e-02 | 1.89e-01 | -2.39e-02 | 6.36e-01 | 6.38e-01 | 8.27e-01 | 3.27e-01 | 9.01e-01 |
| NEGATIVE REGULATION OF MUSCLE CONTRACTION | 23 | 1.20e-01 | 5.78e-01 | 0.23300 | 7.13e-02 | 4.47e-02 | 1.37e-01 | 4.60e-03 | -1.69e-01 | 5.54e-01 | 7.11e-01 | 2.56e-01 | 9.70e-01 | 1.60e-01 |
| T CELL PROLIFERATION | 204 | 4.62e-03 | 7.26e-02 | 0.23300 | -1.24e-01 | -1.28e-01 | -5.84e-02 | -1.27e-01 | 5.39e-02 | 2.18e-03 | 1.66e-03 | 1.50e-01 | 1.70e-03 | 1.84e-01 |
| POSITIVE REGULATION OF CARDIAC MUSCLE CELL DIFFERENTIATION | 11 | 8.97e-01 | 1.00e+00 | 0.23300 | 3.36e-02 | 6.98e-04 | 1.20e-01 | -3.95e-03 | 1.97e-01 | 8.47e-01 | 9.97e-01 | 4.89e-01 | 9.82e-01 | 2.59e-01 |
| REGULATION OF LEUKOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELL | 38 | 6.61e-01 | 1.00e+00 | 0.23300 | -1.23e-01 | -1.14e-01 | -1.45e-01 | -6.72e-02 | 2.63e-02 | 1.91e-01 | 2.25e-01 | 1.21e-01 | 4.74e-01 | 7.79e-01 |
| REGULATION OF CELL CYCLE CHECKPOINT | 45 | 2.98e-01 | 8.25e-01 | 0.23300 | 9.08e-02 | 7.27e-02 | 1.49e-01 | 8.27e-02 | 1.08e-01 | 2.92e-01 | 3.99e-01 | 8.40e-02 | 3.37e-01 | 2.08e-01 |
| REGULATION OF DNA REPAIR | 205 | 4.46e-04 | 1.19e-02 | 0.23300 | 9.49e-02 | 7.42e-02 | 1.65e-01 | 3.38e-02 | 1.08e-01 | 1.91e-02 | 6.71e-02 | 4.88e-05 | 4.04e-01 | 7.94e-03 |
| NOTCH RECEPTOR PROCESSING | 9 | 9.77e-01 | 1.00e+00 | 0.23300 | 1.31e-01 | 1.12e-01 | 1.34e-01 | 7.99e-02 | 3.14e-04 | 4.95e-01 | 5.60e-01 | 4.85e-01 | 6.78e-01 | 9.99e-01 |
| REGULATION OF INTRACELLULAR ESTROGEN RECEPTOR SIGNALING PATHWAY | 34 | 5.40e-01 | 9.58e-01 | 0.23300 | 1.14e-01 | 9.46e-02 | 1.40e-01 | 1.12e-01 | 8.68e-03 | 2.49e-01 | 3.40e-01 | 1.57e-01 | 2.60e-01 | 9.30e-01 |
| HEMOGLOBIN METABOLIC PROCESS | 17 | 7.97e-01 | 1.00e+00 | 0.23300 | 8.28e-02 | 7.50e-02 | 1.55e-01 | 3.43e-02 | 1.28e-01 | 5.54e-01 | 5.92e-01 | 2.69e-01 | 8.07e-01 | 3.59e-01 |
| REGULATION OF T HELPER 17 TYPE IMMUNE RESPONSE | 31 | 5.81e-01 | 9.85e-01 | 0.23300 | -1.04e-01 | -1.06e-01 | -3.93e-02 | -1.72e-01 | -3.11e-02 | 3.17e-01 | 3.09e-01 | 7.05e-01 | 9.66e-02 | 7.65e-01 |
| POSITIVE REGULATION OF ASPARTIC TYPE PEPTIDASE ACTIVITY | 8 | 6.99e-01 | 1.00e+00 | 0.23300 | -9.82e-02 | -6.27e-02 | -9.64e-02 | -1.62e-01 | 7.15e-02 | 6.30e-01 | 7.59e-01 | 6.37e-01 | 4.29e-01 | 7.26e-01 |
| REGULATION OF MEIOTIC CELL CYCLE | 66 | 8.94e-02 | 4.93e-01 | 0.23300 | 1.19e-01 | 9.08e-02 | 1.66e-01 | 2.94e-02 | 5.70e-02 | 9.56e-02 | 2.02e-01 | 1.94e-02 | 6.79e-01 | 4.23e-01 |
| POSITIVE REGULATION OF T HELPER 17 TYPE IMMUNE RESPONSE | 16 | 6.14e-01 | 9.90e-01 | 0.23300 | -7.17e-02 | -5.72e-02 | -4.94e-02 | -1.67e-01 | -1.24e-01 | 6.20e-01 | 6.92e-01 | 7.32e-01 | 2.48e-01 | 3.90e-01 |
| INTERCELLULAR TRANSPORT | 10 | 9.57e-01 | 1.00e+00 | 0.23200 | 1.31e-01 | 1.39e-01 | 9.26e-02 | 8.04e-02 | -5.05e-02 | 4.72e-01 | 4.48e-01 | 6.12e-01 | 6.60e-01 | 7.82e-01 |
| CARDIOBLAST DIFFERENTIATION | 17 | 4.48e-01 | 9.30e-01 | 0.23200 | 8.93e-02 | 6.92e-02 | 1.96e-01 | -5.02e-02 | 1.46e-02 | 5.24e-01 | 6.21e-01 | 1.61e-01 | 7.20e-01 | 9.17e-01 |
| GROWTH INVOLVED IN HEART MORPHOGENESIS | 5 | 6.93e-01 | 1.00e+00 | 0.23200 | 2.21e-02 | 4.59e-02 | 1.59e-01 | -1.32e-01 | 9.29e-02 | 9.32e-01 | 8.59e-01 | 5.37e-01 | 6.09e-01 | 7.19e-01 |
| HOMEOSTASIS OF NUMBER OF CELLS WITHIN A TISSUE | 32 | 7.49e-01 | 1.00e+00 | 0.23200 | -1.13e-01 | -1.13e-01 | -6.39e-02 | -1.48e-01 | 4.87e-02 | 2.68e-01 | 2.68e-01 | 5.31e-01 | 1.47e-01 | 6.33e-01 |
| NEGATIVE REGULATION OF SYNAPSE ASSEMBLY | 8 | 6.41e-01 | 1.00e+00 | 0.23200 | 7.18e-02 | 6.22e-02 | 1.72e-01 | -1.07e-01 | -6.34e-02 | 7.25e-01 | 7.61e-01 | 4.00e-01 | 6.00e-01 | 7.56e-01 |
| NCRNA PROCESSING | 419 | 1.34e-10 | 2.30e-08 | 0.23200 | 1.05e-01 | 8.46e-02 | 1.77e-01 | 1.68e-02 | 6.53e-02 | 2.13e-04 | 2.98e-03 | 5.53e-10 | 5.54e-01 | 2.19e-02 |
| NEURONAL ACTION POTENTIAL | 32 | 6.48e-01 | 1.00e+00 | 0.23200 | -1.28e-01 | -1.46e-01 | -8.30e-02 | -9.64e-02 | 4.71e-03 | 2.11e-01 | 1.52e-01 | 4.17e-01 | 3.45e-01 | 9.63e-01 |
| DETECTION OF BIOTIC STIMULUS | 37 | 6.25e-01 | 9.93e-01 | 0.23200 | -1.08e-01 | -1.32e-01 | -4.67e-02 | -1.23e-01 | 8.60e-02 | 2.54e-01 | 1.63e-01 | 6.23e-01 | 1.97e-01 | 3.66e-01 |
| PROTEIN INSERTION INTO MEMBRANE | 73 | 2.42e-01 | 7.67e-01 | 0.23200 | 1.12e-01 | 9.85e-02 | 1.58e-01 | 4.38e-02 | 6.88e-02 | 9.71e-02 | 1.46e-01 | 1.97e-02 | 5.17e-01 | 3.10e-01 |
| POSITIVE REGULATION OF VASCULAR PERMEABILITY | 18 | 6.27e-01 | 9.94e-01 | 0.23200 | 9.92e-02 | 1.33e-01 | 6.71e-02 | 1.19e-01 | 8.74e-02 | 4.66e-01 | 3.28e-01 | 6.22e-01 | 3.83e-01 | 5.21e-01 |
| PHOTORECEPTOR CELL DEVELOPMENT | 49 | 2.62e-01 | 7.90e-01 | 0.23200 | 9.99e-02 | 1.32e-01 | 1.05e-02 | 1.01e-01 | -1.28e-01 | 2.26e-01 | 1.11e-01 | 8.99e-01 | 2.23e-01 | 1.22e-01 |
| AMINO ACID BETAINE TRANSPORT | 13 | 3.58e-01 | 8.74e-01 | 0.23200 | -3.42e-02 | -4.59e-02 | 1.01e-01 | -1.90e-01 | -6.33e-02 | 8.31e-01 | 7.74e-01 | 5.28e-01 | 2.35e-01 | 6.93e-01 |
| OSTEOCLAST DIFFERENTIATION | 103 | 1.77e-01 | 6.85e-01 | 0.23200 | -1.28e-01 | -1.31e-01 | -7.47e-02 | -1.14e-01 | 3.89e-02 | 2.52e-02 | 2.13e-02 | 1.90e-01 | 4.47e-02 | 4.95e-01 |
| RESOLUTION OF MEIOTIC RECOMBINATION INTERMEDIATES | 15 | 8.11e-01 | 1.00e+00 | 0.23200 | -1.07e-01 | -9.33e-02 | -4.97e-02 | -1.76e-01 | 6.15e-03 | 4.74e-01 | 5.31e-01 | 7.39e-01 | 2.37e-01 | 9.67e-01 |
| CELLULAR RESPONSE TO INTERFERON BETA | 26 | 7.91e-01 | 1.00e+00 | 0.23200 | -1.16e-01 | -1.30e-01 | -3.44e-02 | -1.38e-01 | 5.56e-02 | 3.05e-01 | 2.51e-01 | 7.62e-01 | 2.24e-01 | 6.24e-01 |
| NEGATIVE REGULATION OF PROTEIN UBIQUITINATION | 69 | 3.04e-02 | 2.72e-01 | 0.23200 | 1.02e-01 | 1.03e-01 | 1.72e-01 | 2.38e-02 | 4.93e-02 | 1.43e-01 | 1.41e-01 | 1.33e-02 | 7.32e-01 | 4.79e-01 |
| NEGATIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 22 | 3.92e-01 | 8.92e-01 | 0.23200 | -1.03e-01 | -1.29e-01 | 2.39e-02 | -1.60e-01 | 8.16e-03 | 4.01e-01 | 2.96e-01 | 8.46e-01 | 1.93e-01 | 9.47e-01 |
| ENDOPLASMIC RETICULUM TO CYTOSOL TRANSPORT | 27 | 3.09e-02 | 2.74e-01 | 0.23100 | 2.89e-02 | 9.15e-03 | 1.48e-01 | -1.39e-01 | -1.06e-01 | 7.95e-01 | 9.34e-01 | 1.82e-01 | 2.11e-01 | 3.38e-01 |
| EMBRYONIC EYE MORPHOGENESIS | 35 | 2.74e-01 | 8.01e-01 | 0.23100 | 1.24e-01 | 8.42e-02 | 1.60e-01 | 6.26e-02 | -3.68e-02 | 2.03e-01 | 3.89e-01 | 1.01e-01 | 5.22e-01 | 7.06e-01 |
| PENETRATION OF ZONA PELLUCIDA | 9 | 8.82e-01 | 1.00e+00 | 0.23100 | 5.66e-03 | 8.11e-03 | 7.07e-02 | -1.20e-02 | 2.20e-01 | 9.77e-01 | 9.66e-01 | 7.14e-01 | 9.50e-01 | 2.54e-01 |
| CELLULAR RESPONSE TO ETHANOL | 11 | 9.41e-01 | 1.00e+00 | 0.23100 | -1.14e-01 | -9.14e-02 | -1.13e-01 | -1.38e-01 | -1.51e-02 | 5.12e-01 | 5.99e-01 | 5.16e-01 | 4.28e-01 | 9.31e-01 |
| REGULATION OF DOPAMINERGIC NEURON DIFFERENTIATION | 12 | 7.47e-01 | 1.00e+00 | 0.23100 | 1.13e-01 | 7.77e-02 | 1.82e-01 | 6.09e-03 | -4.07e-02 | 4.99e-01 | 6.41e-01 | 2.76e-01 | 9.71e-01 | 8.07e-01 |
| ALDEHYDE CATABOLIC PROCESS | 14 | 9.51e-01 | 1.00e+00 | 0.23100 | 1.20e-01 | 1.40e-01 | 8.50e-02 | 1.10e-01 | -8.60e-03 | 4.37e-01 | 3.63e-01 | 5.82e-01 | 4.76e-01 | 9.56e-01 |
| WHITE FAT CELL DIFFERENTIATION | 17 | 7.54e-01 | 1.00e+00 | 0.23100 | 8.05e-02 | 1.21e-01 | -9.03e-03 | 9.86e-02 | -1.50e-01 | 5.66e-01 | 3.90e-01 | 9.49e-01 | 4.82e-01 | 2.83e-01 |
| TRANSLATIONAL INITIATION | 109 | 7.65e-02 | 4.53e-01 | 0.23100 | 1.20e-01 | 1.14e-01 | 1.51e-01 | 5.66e-02 | -5.71e-03 | 3.09e-02 | 3.96e-02 | 6.45e-03 | 3.07e-01 | 9.18e-01 |
| REGULATION OF DENDRITIC SPINE MAINTENANCE | 13 | 3.64e-01 | 8.78e-01 | 0.23100 | -9.30e-02 | -1.19e-01 | -1.06e-01 | 1.24e-02 | -1.38e-01 | 5.61e-01 | 4.59e-01 | 5.06e-01 | 9.38e-01 | 3.88e-01 |
| NEGATIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 34 | 3.38e-01 | 8.59e-01 | 0.23100 | -3.87e-02 | -7.15e-02 | 7.35e-02 | -8.90e-02 | 1.83e-01 | 6.96e-01 | 4.70e-01 | 4.58e-01 | 3.69e-01 | 6.51e-02 |
| POLY N ACETYLLACTOSAMINE METABOLIC PROCESS | 7 | 3.74e-01 | 8.82e-01 | 0.23100 | 3.42e-02 | -4.74e-02 | 4.47e-02 | 1.59e-01 | 1.50e-01 | 8.76e-01 | 8.28e-01 | 8.38e-01 | 4.66e-01 | 4.91e-01 |
| MYOTUBE DIFFERENTIATION INVOLVED IN SKELETAL MUSCLE REGENERATION | 8 | 8.31e-01 | 1.00e+00 | 0.23100 | 4.04e-02 | 6.67e-02 | -9.20e-02 | 1.64e-01 | -1.10e-01 | 8.43e-01 | 7.44e-01 | 6.52e-01 | 4.23e-01 | 5.92e-01 |
| PURINE NUCLEOBASE METABOLIC PROCESS | 19 | 4.80e-01 | 9.42e-01 | 0.23100 | -3.33e-02 | 2.21e-02 | -1.54e-01 | 2.58e-02 | -1.66e-01 | 8.02e-01 | 8.68e-01 | 2.46e-01 | 8.46e-01 | 2.12e-01 |
| VESICLE MEDIATED TRANSPORT BETWEEN ENDOSOMAL COMPARTMENTS | 46 | 2.27e-02 | 2.25e-01 | 0.23100 | -8.65e-02 | -1.28e-01 | -1.44e-03 | -2.67e-02 | 1.70e-01 | 3.10e-01 | 1.34e-01 | 9.87e-01 | 7.54e-01 | 4.67e-02 |
| PEPTIDYL PROLINE MODIFICATION | 33 | 6.55e-01 | 1.00e+00 | 0.23100 | 8.78e-02 | 6.30e-02 | 1.51e-01 | 4.65e-02 | 1.29e-01 | 3.83e-01 | 5.31e-01 | 1.33e-01 | 6.44e-01 | 2.00e-01 |
| MIRNA MEDIATED GENE SILENCING BY INHIBITION OF TRANSLATION | 91 | 2.20e-04 | 6.72e-03 | 0.23100 | 4.80e-02 | 6.64e-02 | -9.08e-02 | 9.24e-02 | -1.73e-01 | 4.29e-01 | 2.74e-01 | 1.35e-01 | 1.27e-01 | 4.43e-03 |
| ADIPONECTIN ACTIVATED SIGNALING PATHWAY | 7 | 9.02e-01 | 1.00e+00 | 0.23100 | 3.73e-03 | -3.72e-02 | 1.03e-01 | 1.40e-02 | 2.02e-01 | 9.86e-01 | 8.65e-01 | 6.37e-01 | 9.49e-01 | 3.54e-01 |
| HUMORAL IMMUNE RESPONSE | 238 | 3.93e-03 | 6.43e-02 | 0.23100 | -1.27e-01 | -1.20e-01 | -1.25e-01 | -7.53e-02 | 3.58e-02 | 7.11e-04 | 1.48e-03 | 8.58e-04 | 4.54e-02 | 3.41e-01 |
| RESPONSE TO HEAT | 99 | 6.31e-03 | 9.04e-02 | 0.23000 | 1.08e-01 | 1.42e-01 | 7.26e-02 | 1.10e-01 | -6.16e-02 | 6.31e-02 | 1.44e-02 | 2.12e-01 | 5.83e-02 | 2.89e-01 |
| TERTIARY ALCOHOL METABOLIC PROCESS | 22 | 5.33e-01 | 9.55e-01 | 0.23000 | 9.46e-02 | 1.22e-01 | 5.84e-02 | 1.12e-01 | -1.15e-01 | 4.43e-01 | 3.21e-01 | 6.36e-01 | 3.62e-01 | 3.52e-01 |
| ETHANOL METABOLIC PROCESS | 19 | 4.41e-01 | 9.26e-01 | 0.23000 | -1.49e-02 | -1.46e-02 | -1.20e-01 | 7.11e-02 | -1.82e-01 | 9.11e-01 | 9.12e-01 | 3.64e-01 | 5.92e-01 | 1.70e-01 |
| POSITIVE REGULATION OF ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 26 | 4.55e-01 | 9.31e-01 | 0.23000 | 2.23e-03 | -2.12e-02 | 1.10e-01 | -7.05e-02 | 1.89e-01 | 9.84e-01 | 8.52e-01 | 3.34e-01 | 5.34e-01 | 9.60e-02 |
| POSITIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 112 | 1.15e-01 | 5.65e-01 | 0.23000 | 1.16e-01 | 1.21e-01 | 1.32e-01 | 8.28e-02 | 2.33e-02 | 3.34e-02 | 2.67e-02 | 1.61e-02 | 1.30e-01 | 6.70e-01 |
| MYELOID CELL DEVELOPMENT | 80 | 9.47e-03 | 1.21e-01 | 0.23000 | -3.15e-02 | -4.97e-02 | 7.44e-02 | -4.83e-02 | 2.04e-01 | 6.26e-01 | 4.42e-01 | 2.50e-01 | 4.55e-01 | 1.61e-03 |
| ER NUCLEUS SIGNALING PATHWAY | 45 | 3.53e-01 | 8.71e-01 | 0.23000 | 8.63e-02 | 7.78e-02 | 1.49e-01 | 1.97e-02 | 1.30e-01 | 3.17e-01 | 3.67e-01 | 8.41e-02 | 8.19e-01 | 1.32e-01 |
| ENTEROENDOCRINE CELL DIFFERENTIATION | 36 | 2.02e-02 | 2.09e-01 | 0.23000 | 6.84e-02 | 6.52e-02 | 1.41e-01 | -8.80e-02 | -1.28e-01 | 4.77e-01 | 4.98e-01 | 1.43e-01 | 3.61e-01 | 1.84e-01 |
| COLLAGEN ACTIVATED SIGNALING PATHWAY | 13 | 8.47e-01 | 1.00e+00 | 0.23000 | -9.43e-02 | -1.13e-01 | -8.52e-02 | -7.94e-02 | -1.32e-01 | 5.56e-01 | 4.79e-01 | 5.95e-01 | 6.20e-01 | 4.08e-01 |
| MESODERMAL CELL FATE COMMITMENT | 17 | 1.78e-01 | 6.85e-01 | 0.23000 | 4.40e-03 | 1.69e-02 | 7.13e-02 | -7.57e-02 | -2.04e-01 | 9.75e-01 | 9.04e-01 | 6.11e-01 | 5.89e-01 | 1.45e-01 |
| GASTRIC ACID SECRETION | 13 | 6.39e-01 | 1.00e+00 | 0.23000 | -5.33e-02 | -5.70e-02 | -7.99e-02 | 4.37e-02 | 1.96e-01 | 7.39e-01 | 7.22e-01 | 6.18e-01 | 7.85e-01 | 2.21e-01 |
| MICROTUBULE CYTOSKELETON ORGANIZATION INVOLVED IN MITOSIS | 158 | 6.93e-04 | 1.68e-02 | 0.23000 | 9.62e-02 | 7.07e-02 | 1.78e-01 | 2.01e-02 | 8.04e-02 | 3.70e-02 | 1.25e-01 | 1.12e-04 | 6.63e-01 | 8.13e-02 |
| PROTEIN TRANSMEMBRANE TRANSPORT | 64 | 4.16e-02 | 3.27e-01 | 0.23000 | 3.12e-02 | 1.16e-02 | 1.19e-01 | -4.64e-02 | 1.88e-01 | 6.66e-01 | 8.72e-01 | 9.86e-02 | 5.21e-01 | 9.35e-03 |
| ATP TRANSPORT | 17 | 5.66e-01 | 9.72e-01 | 0.23000 | -6.68e-02 | -5.21e-02 | -5.89e-02 | -5.75e-03 | 2.05e-01 | 6.34e-01 | 7.10e-01 | 6.74e-01 | 9.67e-01 | 1.43e-01 |
| REGULATION OF CHROMOSOME SEGREGATION | 129 | 1.72e-02 | 1.87e-01 | 0.23000 | 1.04e-01 | 9.56e-02 | 1.61e-01 | 4.30e-02 | 7.20e-02 | 4.17e-02 | 6.06e-02 | 1.63e-03 | 3.98e-01 | 1.58e-01 |
| TRANSCRIPTION BY RNA POLYMERASE III | 59 | 9.87e-02 | 5.20e-01 | 0.23000 | 3.95e-02 | 2.40e-02 | 1.18e-01 | -2.26e-02 | 1.90e-01 | 6.00e-01 | 7.49e-01 | 1.16e-01 | 7.64e-01 | 1.16e-02 |
| MESONEPHRIC DUCT DEVELOPMENT | 8 | 8.97e-01 | 1.00e+00 | 0.23000 | 1.29e-01 | 1.05e-01 | 1.39e-01 | 3.42e-02 | -6.71e-02 | 5.27e-01 | 6.08e-01 | 4.95e-01 | 8.67e-01 | 7.42e-01 |
| ZINC ION IMPORT INTO ORGANELLE | 9 | 8.19e-01 | 1.00e+00 | 0.23000 | 1.47e-03 | 2.72e-02 | -7.73e-04 | -4.57e-02 | -2.23e-01 | 9.94e-01 | 8.88e-01 | 9.97e-01 | 8.12e-01 | 2.46e-01 |
| POSITIVE REGULATION OF BONE RESORPTION | 18 | 7.91e-01 | 1.00e+00 | 0.23000 | -1.35e-01 | -1.16e-01 | -1.12e-01 | -9.02e-02 | -1.27e-02 | 3.21e-01 | 3.92e-01 | 4.09e-01 | 5.07e-01 | 9.26e-01 |
| POSITIVE REGULATION BY SYMBIONT OF ENTRY INTO HOST | 14 | 5.19e-01 | 9.53e-01 | 0.22900 | 4.42e-02 | 6.59e-03 | 1.61e-01 | 3.50e-02 | 1.53e-01 | 7.75e-01 | 9.66e-01 | 2.97e-01 | 8.20e-01 | 3.21e-01 |
| DERMATAN SULFATE METABOLIC PROCESS | 8 | 9.66e-01 | 1.00e+00 | 0.22900 | -1.13e-01 | -1.44e-01 | -5.98e-02 | -1.25e-01 | 5.43e-03 | 5.81e-01 | 4.82e-01 | 7.70e-01 | 5.40e-01 | 9.79e-01 |
| REGULATION OF PRESYNAPTIC MEMBRANE POTENTIAL | 28 | 2.15e-01 | 7.38e-01 | 0.22900 | -4.26e-02 | -4.18e-02 | 3.63e-03 | -1.06e-01 | -1.94e-01 | 6.96e-01 | 7.02e-01 | 9.73e-01 | 3.30e-01 | 7.52e-02 |
| NOSE DEVELOPMENT | 16 | 1.89e-01 | 6.99e-01 | 0.22900 | -3.63e-02 | -1.51e-02 | 8.44e-02 | -1.68e-01 | 1.25e-01 | 8.01e-01 | 9.17e-01 | 5.59e-01 | 2.44e-01 | 3.87e-01 |
| MODULATION BY SYMBIONT OF ENTRY INTO HOST | 55 | 1.73e-01 | 6.78e-01 | 0.22900 | -1.21e-01 | -1.24e-01 | -8.34e-02 | -5.82e-02 | 1.10e-01 | 1.20e-01 | 1.12e-01 | 2.85e-01 | 4.55e-01 | 1.56e-01 |
| NEGATIVE REGULATION OF SYNAPTIC TRANSMISSION GLUTAMATERGIC | 8 | 4.65e-01 | 9.34e-01 | 0.22900 | 3.04e-02 | -2.30e-02 | 1.63e-01 | -8.60e-02 | -1.31e-01 | 8.82e-01 | 9.10e-01 | 4.26e-01 | 6.74e-01 | 5.20e-01 |
| REGULATION OF ATP BIOSYNTHETIC PROCESS | 17 | 6.67e-01 | 1.00e+00 | 0.22900 | 2.51e-02 | 8.87e-03 | 4.12e-02 | 3.46e-02 | 2.21e-01 | 8.58e-01 | 9.49e-01 | 7.69e-01 | 8.05e-01 | 1.15e-01 |
| POSITIVE REGULATION OF CD8 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 5 | 9.17e-01 | 1.00e+00 | 0.22900 | -1.13e-01 | -1.58e-01 | -8.49e-02 | -6.35e-02 | -5.92e-02 | 6.61e-01 | 5.41e-01 | 7.42e-01 | 8.06e-01 | 8.19e-01 |
| RESPONSE TO HEPARIN | 7 | 9.18e-01 | 1.00e+00 | 0.22900 | -9.22e-02 | -8.19e-02 | -9.57e-02 | -4.54e-02 | -1.61e-01 | 6.73e-01 | 7.07e-01 | 6.61e-01 | 8.35e-01 | 4.60e-01 |
| NEGATIVE REGULATION OF VIRAL PROCESS | 91 | 9.24e-02 | 5.02e-01 | 0.22900 | -1.07e-01 | -1.04e-01 | -4.08e-02 | -1.43e-01 | 8.86e-02 | 7.73e-02 | 8.52e-02 | 5.01e-01 | 1.81e-02 | 1.44e-01 |
| TRNA 5 END PROCESSING | 15 | 3.45e-01 | 8.64e-01 | 0.22900 | 8.70e-02 | 9.55e-02 | 1.74e-01 | -7.06e-02 | -2.46e-02 | 5.60e-01 | 5.22e-01 | 2.44e-01 | 6.36e-01 | 8.69e-01 |
| POSITIVE REGULATION OF ALPHA BETA T CELL ACTIVATION | 67 | 2.02e-01 | 7.20e-01 | 0.22900 | -1.06e-01 | -1.19e-01 | -2.95e-02 | -1.61e-01 | -1.19e-02 | 1.35e-01 | 9.20e-02 | 6.76e-01 | 2.23e-02 | 8.66e-01 |
| POSITIVE REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 18 | 7.08e-01 | 1.00e+00 | 0.22900 | -1.38e-02 | -5.03e-02 | 6.61e-02 | -2.10e-02 | 2.12e-01 | 9.20e-01 | 7.12e-01 | 6.27e-01 | 8.77e-01 | 1.20e-01 |
| AMINO SUGAR METABOLIC PROCESS | 40 | 4.83e-01 | 9.43e-01 | 0.22900 | 1.08e-01 | 1.09e-01 | 7.62e-02 | 1.47e-01 | -4.05e-02 | 2.39e-01 | 2.35e-01 | 4.04e-01 | 1.08e-01 | 6.58e-01 |
| SPINAL CORD MOTOR NEURON DIFFERENTIATION | 28 | 1.69e-02 | 1.85e-01 | 0.22900 | 5.84e-02 | 3.88e-03 | 1.89e-01 | -1.14e-01 | -1.58e-02 | 5.93e-01 | 9.72e-01 | 8.34e-02 | 2.97e-01 | 8.85e-01 |
| VENOUS BLOOD VESSEL DEVELOPMENT | 16 | 4.63e-01 | 9.33e-01 | 0.22900 | 7.13e-02 | 4.42e-02 | 2.01e-01 | -2.06e-02 | 6.74e-02 | 6.22e-01 | 7.59e-01 | 1.64e-01 | 8.86e-01 | 6.41e-01 |
| DNA CONFORMATION CHANGE | 88 | 1.08e-02 | 1.33e-01 | 0.22900 | 3.64e-02 | 4.20e-03 | 1.40e-01 | -3.77e-02 | 1.73e-01 | 5.55e-01 | 9.46e-01 | 2.30e-02 | 5.41e-01 | 5.01e-03 |
| D ASPARTATE IMPORT ACROSS PLASMA MEMBRANE | 5 | 9.81e-01 | 1.00e+00 | 0.22900 | 9.49e-02 | 5.39e-02 | 1.43e-01 | 9.53e-02 | 1.04e-01 | 7.13e-01 | 8.35e-01 | 5.79e-01 | 7.12e-01 | 6.87e-01 |
| TRNA 5 LEADER REMOVAL | 13 | 5.86e-01 | 9.85e-01 | 0.22900 | 9.88e-02 | 1.10e-01 | 1.54e-01 | -3.29e-02 | -7.49e-02 | 5.37e-01 | 4.92e-01 | 3.36e-01 | 8.37e-01 | 6.40e-01 |
| REGULATION OF ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN | 6 | 7.26e-01 | 1.00e+00 | 0.22900 | -3.94e-02 | -4.77e-02 | -1.72e-01 | 1.19e-01 | -6.72e-02 | 8.67e-01 | 8.40e-01 | 4.64e-01 | 6.13e-01 | 7.76e-01 |
| REGULATION OF TESTOSTERONE BIOSYNTHETIC PROCESS | 7 | 8.85e-01 | 1.00e+00 | 0.22900 | 1.64e-02 | 7.03e-02 | -1.18e-01 | 7.30e-02 | -1.67e-01 | 9.40e-01 | 7.47e-01 | 5.89e-01 | 7.38e-01 | 4.45e-01 |
| REGULATION OF NATURAL KILLER CELL DIFFERENTIATION | 12 | 9.44e-01 | 1.00e+00 | 0.22900 | -1.13e-01 | -1.33e-01 | -2.73e-02 | -1.38e-01 | 4.41e-02 | 4.99e-01 | 4.25e-01 | 8.70e-01 | 4.06e-01 | 7.91e-01 |
| CELLULAR RESPONSE TO GLUCOCORTICOID STIMULUS | 49 | 4.88e-01 | 9.44e-01 | 0.22800 | 1.21e-01 | 1.25e-01 | 1.18e-01 | 6.05e-02 | -6.63e-02 | 1.43e-01 | 1.30e-01 | 1.53e-01 | 4.64e-01 | 4.22e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 101 | 5.13e-02 | 3.71e-01 | 0.22800 | 1.04e-01 | 9.54e-02 | 1.59e-01 | 3.01e-02 | 7.88e-02 | 7.15e-02 | 9.77e-02 | 5.85e-03 | 6.01e-01 | 1.71e-01 |
| POSITIVE REGULATION OF NITRIC OXIDE METABOLIC PROCESS | 38 | 3.37e-01 | 8.59e-01 | 0.22800 | -1.26e-01 | -1.11e-01 | -6.85e-02 | -1.34e-01 | -3.87e-02 | 1.80e-01 | 2.36e-01 | 4.65e-01 | 1.54e-01 | 6.80e-01 |
| COLLAGEN ACTIVATED TYROSINE KINASE RECEPTOR SIGNALING PATHWAY | 8 | 9.24e-01 | 1.00e+00 | 0.22800 | -1.01e-01 | -1.09e-01 | -1.37e-01 | -1.76e-02 | -1.04e-01 | 6.21e-01 | 5.92e-01 | 5.01e-01 | 9.31e-01 | 6.11e-01 |
| REGULATION OF FATTY ACID METABOLIC PROCESS | 95 | 2.06e-01 | 7.27e-01 | 0.22800 | 1.19e-01 | 1.19e-01 | 1.28e-01 | 7.74e-02 | -3.92e-02 | 4.45e-02 | 4.56e-02 | 3.15e-02 | 1.92e-01 | 5.09e-01 |
| MITOTIC SPINDLE ORGANIZATION | 125 | 2.08e-03 | 3.98e-02 | 0.22800 | 9.26e-02 | 6.47e-02 | 1.82e-01 | 1.45e-02 | 7.81e-02 | 7.38e-02 | 2.11e-01 | 4.47e-04 | 7.80e-01 | 1.32e-01 |
| GLUTAMINE FAMILY AMINO ACID METABOLIC PROCESS | 75 | 8.28e-02 | 4.74e-01 | 0.22800 | 1.20e-01 | 1.38e-01 | 9.98e-02 | 5.09e-02 | -7.81e-02 | 7.25e-02 | 3.89e-02 | 1.35e-01 | 4.46e-01 | 2.42e-01 |
| MAMMARY GLAND MORPHOGENESIS | 42 | 8.12e-01 | 1.00e+00 | 0.22800 | 1.16e-01 | 1.16e-01 | 9.06e-02 | 1.30e-01 | 4.65e-03 | 1.92e-01 | 1.93e-01 | 3.09e-01 | 1.46e-01 | 9.58e-01 |
| BRONCHIOLE DEVELOPMENT | 5 | 5.58e-01 | 9.69e-01 | 0.22800 | 7.93e-03 | -5.63e-03 | -1.68e-01 | 1.54e-01 | -7.42e-03 | 9.76e-01 | 9.83e-01 | 5.16e-01 | 5.51e-01 | 9.77e-01 |
| SEPTUM PRIMUM DEVELOPMENT | 5 | 9.24e-01 | 1.00e+00 | 0.22800 | 5.45e-02 | 6.00e-02 | 4.95e-02 | -5.52e-02 | -2.00e-01 | 8.33e-01 | 8.16e-01 | 8.48e-01 | 8.31e-01 | 4.39e-01 |
| RELAXATION OF SMOOTH MUSCLE | 9 | 4.90e-01 | 9.45e-01 | 0.22800 | 3.18e-02 | -3.05e-02 | 1.96e-01 | -1.75e-02 | 1.07e-01 | 8.69e-01 | 8.74e-01 | 3.09e-01 | 9.27e-01 | 5.80e-01 |
| TOOTH ERUPTION | 5 | 9.34e-01 | 1.00e+00 | 0.22800 | 3.02e-02 | 4.58e-02 | 3.02e-03 | 1.19e-01 | 1.87e-01 | 9.07e-01 | 8.59e-01 | 9.91e-01 | 6.45e-01 | 4.70e-01 |
| PYRIMIDINE NUCLEOTIDE CATABOLIC PROCESS | 21 | 7.93e-01 | 1.00e+00 | 0.22800 | 7.68e-02 | 5.43e-02 | 1.42e-01 | 2.01e-02 | 1.50e-01 | 5.42e-01 | 6.67e-01 | 2.59e-01 | 8.74e-01 | 2.35e-01 |
| POSITIVE REGULATION OF SKELETAL MUSCLE FIBER DEVELOPMENT | 9 | 6.71e-01 | 1.00e+00 | 0.22800 | -3.00e-02 | -5.36e-02 | 1.97e-02 | -6.43e-02 | -2.09e-01 | 8.76e-01 | 7.81e-01 | 9.19e-01 | 7.38e-01 | 2.78e-01 |
| NEGATIVE REGULATION OF MACROPHAGE ACTIVATION | 18 | 3.64e-01 | 8.78e-01 | 0.22800 | -9.41e-02 | -1.22e-01 | 4.83e-02 | -1.60e-01 | 6.09e-03 | 4.90e-01 | 3.69e-01 | 7.23e-01 | 2.39e-01 | 9.64e-01 |
| NEGATIVE REGULATION OF CELL ADHESION MEDIATED BY INTEGRIN | 11 | 5.06e-01 | 9.48e-01 | 0.22800 | -1.80e-02 | -2.28e-02 | 7.25e-02 | -1.76e-01 | -1.21e-01 | 9.18e-01 | 8.96e-01 | 6.77e-01 | 3.11e-01 | 4.86e-01 |
| MRNA PROCESSING | 450 | 1.55e-08 | 1.69e-06 | 0.22800 | 9.69e-02 | 7.17e-02 | 1.62e-01 | 3.90e-02 | 9.86e-02 | 4.22e-04 | 9.09e-03 | 4.15e-09 | 1.56e-01 | 3.38e-04 |
| PROTEIN TRANSMEMBRANE IMPORT INTO INTRACELLULAR ORGANELLE | 35 | 3.77e-01 | 8.85e-01 | 0.22800 | -5.94e-02 | -7.85e-02 | 1.69e-02 | -1.04e-01 | 1.76e-01 | 5.43e-01 | 4.21e-01 | 8.63e-01 | 2.87e-01 | 7.12e-02 |
| NEGATIVE REGULATION OF CENTRIOLE REPLICATION | 7 | 9.57e-01 | 1.00e+00 | 0.22800 | -9.67e-02 | -6.31e-02 | -9.42e-02 | -1.11e-01 | -1.31e-01 | 6.58e-01 | 7.73e-01 | 6.66e-01 | 6.10e-01 | 5.47e-01 |
| NEGATIVE REGULATION OF PROTEIN TYROSINE KINASE ACTIVITY | 24 | 6.16e-01 | 9.90e-01 | 0.22800 | 8.60e-02 | 9.76e-02 | 1.04e-01 | 5.10e-02 | 1.47e-01 | 4.66e-01 | 4.08e-01 | 3.78e-01 | 6.66e-01 | 2.14e-01 |
| NUCLEAR CHROMOSOME SEGREGATION | 307 | 1.07e-05 | 4.99e-04 | 0.22800 | 9.71e-02 | 7.54e-02 | 1.62e-01 | 3.99e-02 | 9.35e-02 | 3.44e-03 | 2.30e-02 | 9.82e-07 | 2.30e-01 | 4.84e-03 |
| POSITIVE REGULATION OF CELL CELL ADHESION MEDIATED BY CADHERIN | 11 | 7.92e-01 | 1.00e+00 | 0.22700 | 1.10e-01 | 7.08e-02 | 1.51e-01 | 1.08e-01 | -1.22e-02 | 5.27e-01 | 6.84e-01 | 3.86e-01 | 5.36e-01 | 9.44e-01 |
| MITOTIC DNA INTEGRITY CHECKPOINT SIGNALING | 84 | 2.98e-02 | 2.68e-01 | 0.22700 | 1.03e-01 | 8.92e-02 | 1.72e-01 | 3.43e-03 | 5.81e-02 | 1.02e-01 | 1.58e-01 | 6.33e-03 | 9.57e-01 | 3.57e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 6 PRODUCTION | 97 | 5.16e-03 | 7.88e-02 | 0.22700 | -5.08e-02 | -8.94e-02 | 6.33e-02 | -8.39e-02 | 1.73e-01 | 3.87e-01 | 1.28e-01 | 2.81e-01 | 1.53e-01 | 3.18e-03 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 60 | 3.37e-01 | 8.59e-01 | 0.22700 | 1.14e-01 | 1.08e-01 | 1.37e-01 | 9.03e-02 | -5.72e-03 | 1.28e-01 | 1.46e-01 | 6.61e-02 | 2.26e-01 | 9.39e-01 |
| PYRIDINE CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 31 | 8.39e-01 | 1.00e+00 | 0.22700 | 1.05e-01 | 9.39e-02 | 9.71e-02 | 1.13e-01 | 9.78e-02 | 3.13e-01 | 3.66e-01 | 3.49e-01 | 2.75e-01 | 3.46e-01 |
| SPINAL CORD ASSOCIATION NEURON DIFFERENTIATION | 12 | 4.62e-01 | 9.33e-01 | 0.22700 | 6.29e-02 | 7.94e-02 | 1.27e-01 | -5.35e-02 | -1.50e-01 | 7.06e-01 | 6.34e-01 | 4.47e-01 | 7.48e-01 | 3.69e-01 |
| REGULATION OF NUCLEOTIDE BIOSYNTHETIC PROCESS | 28 | 5.71e-01 | 9.76e-01 | 0.22700 | 7.19e-02 | 6.90e-02 | 7.34e-02 | 1.22e-01 | 1.47e-01 | 5.10e-01 | 5.28e-01 | 5.02e-01 | 2.66e-01 | 1.79e-01 |
| REGULATION OF HEART MORPHOGENESIS | 10 | 7.70e-01 | 1.00e+00 | 0.22700 | -7.42e-02 | -8.12e-02 | 2.95e-02 | -1.86e-01 | -6.31e-02 | 6.85e-01 | 6.57e-01 | 8.72e-01 | 3.08e-01 | 7.30e-01 |
| BASEMENT MEMBRANE ASSEMBLY | 9 | 7.14e-01 | 1.00e+00 | 0.22700 | 3.17e-02 | 9.28e-02 | -1.06e-01 | 1.30e-01 | -1.18e-01 | 8.69e-01 | 6.30e-01 | 5.84e-01 | 5.01e-01 | 5.39e-01 |
| POSITIVE REGULATION OF ERBB SIGNALING PATHWAY | 29 | 5.14e-01 | 9.52e-01 | 0.22700 | 1.24e-01 | 1.06e-01 | 6.24e-02 | 1.44e-01 | -1.84e-02 | 2.46e-01 | 3.25e-01 | 5.61e-01 | 1.80e-01 | 8.64e-01 |
| PLASMA MEMBRANE PHOSPHOLIPID SCRAMBLING | 24 | 5.25e-01 | 9.54e-01 | 0.22700 | 1.92e-02 | 3.40e-02 | -4.71e-02 | 6.00e-02 | -2.10e-01 | 8.71e-01 | 7.73e-01 | 6.90e-01 | 6.11e-01 | 7.46e-02 |
| PROTEIN NITROSYLATION | 15 | 8.20e-01 | 1.00e+00 | 0.22700 | 8.66e-02 | 7.15e-02 | 1.04e-01 | 4.73e-02 | 1.60e-01 | 5.62e-01 | 6.32e-01 | 4.84e-01 | 7.51e-01 | 2.82e-01 |
| ESTABLISHMENT OF ENDOTHELIAL INTESTINAL BARRIER | 14 | 8.83e-01 | 1.00e+00 | 0.22700 | -1.23e-01 | -1.44e-01 | -7.96e-02 | -7.01e-02 | 6.74e-02 | 4.27e-01 | 3.52e-01 | 6.06e-01 | 6.50e-01 | 6.62e-01 |
| NUCLEAR MEMBRANE ORGANIZATION | 42 | 8.50e-02 | 4.79e-01 | 0.22700 | 1.98e-02 | 1.78e-02 | 1.16e-01 | -6.64e-02 | 1.81e-01 | 8.24e-01 | 8.42e-01 | 1.92e-01 | 4.57e-01 | 4.24e-02 |
| CHORION DEVELOPMENT | 10 | 9.53e-01 | 1.00e+00 | 0.22700 | -8.68e-02 | -9.81e-02 | -2.02e-02 | -8.20e-02 | 1.65e-01 | 6.34e-01 | 5.91e-01 | 9.12e-01 | 6.53e-01 | 3.67e-01 |
| AMINO ACID BETAINE BIOSYNTHETIC PROCESS | 5 | 6.20e-01 | 9.90e-01 | 0.22700 | -3.24e-02 | -8.48e-03 | -1.22e-01 | 1.85e-01 | 3.38e-02 | 9.00e-01 | 9.74e-01 | 6.36e-01 | 4.74e-01 | 8.96e-01 |
| DEVELOPMENT OF SECONDARY SEXUAL CHARACTERISTICS | 9 | 5.16e-01 | 9.52e-01 | 0.22700 | -9.29e-03 | -2.10e-02 | 3.22e-02 | -1.10e-02 | -2.23e-01 | 9.62e-01 | 9.13e-01 | 8.67e-01 | 9.54e-01 | 2.47e-01 |
| TRANSLATIONAL ELONGATION | 68 | 5.95e-02 | 4.01e-01 | 0.22700 | 3.34e-02 | -2.93e-03 | 1.32e-01 | -6.30e-03 | 1.81e-01 | 6.34e-01 | 9.67e-01 | 6.06e-02 | 9.28e-01 | 9.72e-03 |
| G PROTEIN COUPLED OPIOID RECEPTOR SIGNALING PATHWAY | 10 | 9.81e-01 | 1.00e+00 | 0.22700 | 1.19e-01 | 1.02e-01 | 9.62e-02 | 1.32e-01 | -3.23e-04 | 5.14e-01 | 5.75e-01 | 5.98e-01 | 4.70e-01 | 9.99e-01 |
| REGULATION OF MESENCHYMAL TO EPITHELIAL TRANSITION INVOLVED IN METANEPHROS MORPHOGENESIS | 7 | 2.43e-01 | 7.69e-01 | 0.22600 | 4.67e-03 | -1.11e-01 | 1.74e-01 | -8.62e-02 | 3.28e-02 | 9.83e-01 | 6.10e-01 | 4.25e-01 | 6.93e-01 | 8.81e-01 |
| NEGATIVE REGULATION OF STRIATED MUSCLE CONTRACTION | 9 | 5.37e-01 | 9.57e-01 | 0.22600 | -9.10e-02 | -1.21e-01 | 7.72e-02 | -1.34e-01 | 6.72e-02 | 6.37e-01 | 5.30e-01 | 6.89e-01 | 4.87e-01 | 7.27e-01 |
| NEGATIVE REGULATION OF COAGULATION | 52 | 1.01e-01 | 5.25e-01 | 0.22600 | -6.70e-02 | -6.60e-02 | -1.20e-01 | 3.76e-03 | -1.67e-01 | 4.03e-01 | 4.10e-01 | 1.35e-01 | 9.63e-01 | 3.68e-02 |
| ISG15 PROTEIN CONJUGATION | 6 | 8.49e-01 | 1.00e+00 | 0.22600 | 5.52e-03 | -5.21e-03 | 7.42e-02 | -1.11e-01 | -1.82e-01 | 9.81e-01 | 9.82e-01 | 7.53e-01 | 6.37e-01 | 4.39e-01 |
| ODONTOGENESIS | 126 | 1.55e-01 | 6.53e-01 | 0.22600 | 1.12e-01 | 1.12e-01 | 9.54e-02 | 1.29e-01 | 1.36e-02 | 2.94e-02 | 3.03e-02 | 6.43e-02 | 1.21e-02 | 7.92e-01 |
| REGULATION OF LONG TERM NEURONAL SYNAPTIC PLASTICITY | 21 | 8.56e-01 | 1.00e+00 | 0.22600 | 8.60e-02 | 6.36e-02 | 1.46e-01 | 4.62e-02 | 1.28e-01 | 4.95e-01 | 6.14e-01 | 2.48e-01 | 7.14e-01 | 3.10e-01 |
| DEOXYRIBONUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 14 | 7.89e-01 | 1.00e+00 | 0.22600 | -6.78e-02 | -8.60e-02 | 5.30e-02 | -1.31e-01 | 1.38e-01 | 6.61e-01 | 5.77e-01 | 7.31e-01 | 3.95e-01 | 3.71e-01 |
| DNA REPLICATION | 272 | 1.54e-06 | 9.23e-05 | 0.22600 | 1.03e-01 | 7.72e-02 | 1.74e-01 | 1.81e-02 | 6.27e-02 | 3.37e-03 | 2.84e-02 | 8.05e-07 | 6.08e-01 | 7.49e-02 |
| REGULATION OF STRESS GRANULE ASSEMBLY | 8 | 6.15e-01 | 9.90e-01 | 0.22600 | -2.07e-02 | -3.75e-02 | 1.46e-01 | -1.64e-01 | 3.09e-02 | 9.19e-01 | 8.54e-01 | 4.74e-01 | 4.22e-01 | 8.80e-01 |
| POSITIVE REGULATION OF GONAD DEVELOPMENT | 8 | 1.64e-01 | 6.64e-01 | 0.22600 | 6.19e-03 | -8.39e-02 | 1.83e-01 | -6.78e-02 | -7.69e-02 | 9.76e-01 | 6.81e-01 | 3.70e-01 | 7.40e-01 | 7.06e-01 |
| NEGATIVE REGULATION OF OSTEOCLAST DIFFERENTIATION | 33 | 5.82e-01 | 9.85e-01 | 0.22600 | -1.24e-01 | -1.39e-01 | -5.22e-02 | -1.08e-01 | 4.45e-02 | 2.18e-01 | 1.67e-01 | 6.04e-01 | 2.83e-01 | 6.58e-01 |
| OPSONIZATION | 16 | 8.12e-01 | 1.00e+00 | 0.22600 | -6.25e-02 | -6.51e-02 | -1.07e-01 | -5.03e-02 | -1.70e-01 | 6.65e-01 | 6.52e-01 | 4.59e-01 | 7.27e-01 | 2.39e-01 |
| POSITIVE REGULATION OF ATP METABOLIC PROCESS | 10 | 7.15e-01 | 1.00e+00 | 0.22600 | -1.01e-01 | -1.25e-01 | -1.44e-01 | -3.05e-02 | 5.94e-02 | 5.80e-01 | 4.92e-01 | 4.32e-01 | 8.67e-01 | 7.45e-01 |
| AMINOGLYCAN CATABOLIC PROCESS | 33 | 6.12e-01 | 9.90e-01 | 0.22600 | -1.21e-01 | -9.99e-02 | -1.19e-01 | -8.12e-02 | 7.51e-02 | 2.30e-01 | 3.21e-01 | 2.36e-01 | 4.19e-01 | 4.55e-01 |
| LEARNED VOCALIZATION BEHAVIOR OR VOCAL LEARNING | 10 | 9.38e-01 | 1.00e+00 | 0.22600 | 1.12e-01 | 9.23e-02 | 1.05e-01 | 1.32e-01 | -3.81e-02 | 5.41e-01 | 6.13e-01 | 5.65e-01 | 4.69e-01 | 8.35e-01 |
| SNARE COMPLEX ASSEMBLY | 22 | 4.24e-01 | 9.14e-01 | 0.22600 | -7.81e-02 | -1.14e-01 | 6.15e-02 | -1.33e-01 | 1.02e-01 | 5.26e-01 | 3.56e-01 | 6.17e-01 | 2.79e-01 | 4.07e-01 |
| POSITIVE REGULATION OF CELL CELL ADHESION MEDIATED BY INTEGRIN | 6 | 9.88e-01 | 1.00e+00 | 0.22600 | -1.28e-01 | -1.10e-01 | -1.22e-01 | -7.44e-02 | 4.37e-02 | 5.87e-01 | 6.40e-01 | 6.04e-01 | 7.52e-01 | 8.53e-01 |
| DOPAMINERGIC NEURON DIFFERENTIATION | 40 | 2.59e-03 | 4.68e-02 | 0.22600 | 5.79e-02 | 6.88e-03 | 1.89e-01 | -9.18e-02 | -5.94e-02 | 5.26e-01 | 9.40e-01 | 3.90e-02 | 3.15e-01 | 5.15e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 13 | 8.57e-01 | 1.00e+00 | 0.22600 | -8.72e-02 | -8.46e-02 | -3.14e-03 | -1.26e-01 | 1.42e-01 | 5.86e-01 | 5.97e-01 | 9.84e-01 | 4.30e-01 | 3.76e-01 |
| ERYTHROCYTE HOMEOSTASIS | 135 | 2.52e-02 | 2.38e-01 | 0.22600 | 1.03e-01 | 7.96e-02 | 1.62e-01 | 4.84e-02 | 7.37e-02 | 3.96e-02 | 1.10e-01 | 1.15e-03 | 3.31e-01 | 1.39e-01 |
| LYMPHOCYTE HOMEOSTASIS | 72 | 5.01e-01 | 9.48e-01 | 0.22600 | -1.19e-01 | -1.24e-01 | -7.15e-02 | -1.27e-01 | -1.18e-02 | 8.07e-02 | 6.83e-02 | 2.94e-01 | 6.34e-02 | 8.62e-01 |
| REGULATION OF MUSCLE ORGAN DEVELOPMENT | 23 | 7.37e-01 | 1.00e+00 | 0.22600 | 1.17e-01 | 1.07e-01 | 5.23e-02 | 1.26e-01 | -8.38e-02 | 3.29e-01 | 3.73e-01 | 6.64e-01 | 2.97e-01 | 4.87e-01 |
| AMINO SUGAR CATABOLIC PROCESS | 14 | 8.24e-01 | 1.00e+00 | 0.22600 | 9.32e-02 | 1.07e-01 | 2.87e-02 | 1.72e-01 | -2.03e-02 | 5.46e-01 | 4.88e-01 | 8.52e-01 | 2.66e-01 | 8.95e-01 |
| PML BODY ORGANIZATION | 7 | 9.87e-01 | 1.00e+00 | 0.22500 | -1.11e-01 | -1.22e-01 | -9.18e-02 | -1.07e-01 | 6.13e-02 | 6.12e-01 | 5.76e-01 | 6.74e-01 | 6.24e-01 | 7.79e-01 |
| SCHWANN CELL DIFFERENTIATION | 38 | 2.32e-01 | 7.54e-01 | 0.22500 | 9.54e-02 | 1.27e-01 | 6.95e-02 | 1.11e-01 | 9.19e-02 | 3.09e-01 | 1.75e-01 | 4.58e-01 | 2.37e-01 | 3.27e-01 |
| DENDRITIC SPINE MAINTENANCE | 22 | 7.07e-01 | 1.00e+00 | 0.22500 | -1.20e-01 | -1.31e-01 | -1.10e-01 | -6.04e-02 | -5.86e-02 | 3.28e-01 | 2.89e-01 | 3.70e-01 | 6.24e-01 | 6.34e-01 |
| CATECHOLAMINE UPTAKE INVOLVED IN SYNAPTIC TRANSMISSION | 12 | 7.02e-01 | 1.00e+00 | 0.22500 | 8.16e-02 | 2.70e-02 | 1.74e-01 | 5.79e-02 | 9.95e-02 | 6.25e-01 | 8.71e-01 | 2.98e-01 | 7.29e-01 | 5.51e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY RENIN ANGIOTENSIN | 20 | 5.07e-01 | 9.48e-01 | 0.22500 | -1.12e-01 | -1.32e-01 | 3.58e-03 | -1.44e-01 | 1.05e-02 | 3.88e-01 | 3.08e-01 | 9.78e-01 | 2.64e-01 | 9.35e-01 |
| ENDOSOME ORGANIZATION | 93 | 1.32e-02 | 1.52e-01 | 0.22500 | 4.79e-02 | 3.33e-02 | 1.40e-01 | -8.71e-03 | 1.66e-01 | 4.24e-01 | 5.79e-01 | 1.93e-02 | 8.85e-01 | 5.66e-03 |
| TROPHOBLAST GIANT CELL DIFFERENTIATION | 12 | 4.06e-01 | 9.06e-01 | 0.22500 | 9.03e-02 | 5.52e-02 | 9.68e-02 | 2.40e-02 | 1.72e-01 | 5.88e-01 | 7.41e-01 | 5.62e-01 | 8.85e-01 | 3.02e-01 |
| NEGATIVE REGULATION OF FEEDING BEHAVIOR | 6 | 8.45e-01 | 1.00e+00 | 0.22500 | 4.45e-02 | 5.43e-02 | -6.12e-02 | 1.89e-01 | -7.94e-02 | 8.50e-01 | 8.18e-01 | 7.95e-01 | 4.23e-01 | 7.36e-01 |
| ESTABLISHMENT OF SKIN BARRIER | 33 | 5.21e-03 | 7.91e-02 | 0.22500 | 1.26e-02 | 7.62e-02 | -1.17e-01 | 1.63e-01 | -6.78e-02 | 9.00e-01 | 4.48e-01 | 2.45e-01 | 1.06e-01 | 5.00e-01 |
| MULTINUCLEAR OSTEOCLAST DIFFERENTIATION | 8 | 7.98e-01 | 1.00e+00 | 0.22500 | 9.05e-02 | 9.69e-02 | 1.61e-01 | -3.16e-02 | -7.83e-02 | 6.57e-01 | 6.35e-01 | 4.30e-01 | 8.77e-01 | 7.01e-01 |
| CHROMOSOME SEPARATION | 81 | 5.54e-02 | 3.84e-01 | 0.22500 | 9.93e-02 | 8.54e-02 | 1.72e-01 | 2.93e-02 | 5.51e-02 | 1.22e-01 | 1.84e-01 | 7.44e-03 | 6.48e-01 | 3.91e-01 |
| REGULATION OF MEMBRANE DEPOLARIZATION DURING ACTION POTENTIAL | 6 | 3.67e-01 | 8.79e-01 | 0.22500 | 2.68e-02 | 1.17e-01 | -3.15e-02 | 9.94e-02 | 1.59e-01 | 9.10e-01 | 6.20e-01 | 8.94e-01 | 6.73e-01 | 4.99e-01 |
| POSITIVE REGULATION OF DEFENSE RESPONSE TO VIRUS BY HOST | 31 | 1.41e-01 | 6.26e-01 | 0.22500 | -1.14e-01 | -1.06e-01 | -1.79e-02 | -1.54e-01 | -4.69e-02 | 2.70e-01 | 3.05e-01 | 8.63e-01 | 1.39e-01 | 6.51e-01 |
| GLUTAMATERGIC NEURON DIFFERENTIATION | 15 | 8.19e-01 | 1.00e+00 | 0.22500 | 1.14e-01 | 1.48e-01 | 5.67e-02 | 7.75e-02 | -7.92e-02 | 4.44e-01 | 3.21e-01 | 7.04e-01 | 6.03e-01 | 5.95e-01 |
| REGULATION OF ORGAN GROWTH | 93 | 1.02e-02 | 1.27e-01 | 0.22500 | 7.83e-02 | 8.82e-02 | 6.82e-02 | 1.86e-02 | -1.78e-01 | 1.92e-01 | 1.42e-01 | 2.56e-01 | 7.57e-01 | 3.06e-03 |
| HAIR CELL DIFFERENTIATION | 53 | 3.34e-01 | 8.57e-01 | 0.22500 | 1.05e-01 | 1.24e-01 | 1.18e-02 | 1.26e-01 | -9.08e-02 | 1.88e-01 | 1.19e-01 | 8.82e-01 | 1.13e-01 | 2.53e-01 |
| PROTEIN LOCALIZATION TO CELL LEADING EDGE | 5 | 7.81e-01 | 1.00e+00 | 0.22500 | 1.32e-02 | 7.22e-02 | -1.37e-02 | -1.01e-01 | -1.86e-01 | 9.59e-01 | 7.80e-01 | 9.58e-01 | 6.95e-01 | 4.71e-01 |
| REGULATION OF HOMOTYPIC CELL CELL ADHESION | 34 | 3.41e-01 | 8.59e-01 | 0.22400 | -9.18e-02 | -1.24e-01 | 2.70e-02 | -1.32e-01 | 9.12e-02 | 3.54e-01 | 2.10e-01 | 7.85e-01 | 1.82e-01 | 3.58e-01 |
| RESPONSE TO CAMP | 82 | 3.08e-01 | 8.35e-01 | 0.22400 | 1.14e-01 | 1.12e-01 | 1.04e-01 | 1.05e-01 | -5.37e-02 | 7.47e-02 | 7.85e-02 | 1.03e-01 | 9.93e-02 | 4.01e-01 |
| DENTATE GYRUS DEVELOPMENT | 23 | 5.49e-01 | 9.63e-01 | 0.22400 | 1.05e-01 | 8.81e-02 | 1.77e-01 | 1.98e-03 | -8.77e-03 | 3.83e-01 | 4.65e-01 | 1.41e-01 | 9.87e-01 | 9.42e-01 |
| POSITIVE REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 14 | 9.08e-01 | 1.00e+00 | 0.22400 | -9.42e-02 | -1.13e-01 | -3.17e-02 | -7.20e-02 | 1.50e-01 | 5.42e-01 | 4.63e-01 | 8.37e-01 | 6.41e-01 | 3.31e-01 |
| PROTEIN LOCALIZATION TO PHAGOPHORE ASSEMBLY SITE | 15 | 8.11e-01 | 1.00e+00 | 0.22400 | -1.05e-01 | -7.39e-02 | -8.26e-02 | -1.47e-01 | -7.35e-02 | 4.81e-01 | 6.20e-01 | 5.80e-01 | 3.24e-01 | 6.22e-01 |
| GLIAL CELL MIGRATION | 58 | 4.19e-01 | 9.11e-01 | 0.22400 | -1.22e-01 | -1.15e-01 | -1.28e-01 | -5.89e-02 | 4.69e-02 | 1.07e-01 | 1.31e-01 | 9.07e-02 | 4.38e-01 | 5.36e-01 |
| CONSTITUTIVE HETEROCHROMATIN FORMATION | 11 | 7.94e-01 | 1.00e+00 | 0.22400 | -4.44e-02 | -6.54e-02 | 8.00e-02 | -1.47e-01 | 1.27e-01 | 7.99e-01 | 7.07e-01 | 6.46e-01 | 3.99e-01 | 4.67e-01 |
| REGULATION OF ELECTRON TRANSFER ACTIVITY | 6 | 9.76e-01 | 1.00e+00 | 0.22400 | 9.48e-02 | 1.02e-01 | 1.28e-01 | 3.35e-02 | 1.16e-01 | 6.88e-01 | 6.65e-01 | 5.88e-01 | 8.87e-01 | 6.24e-01 |
| SKELETAL MUSCLE TISSUE GROWTH | 9 | 8.51e-01 | 1.00e+00 | 0.22400 | -8.97e-03 | 1.73e-02 | -4.49e-02 | -7.70e-02 | -2.05e-01 | 9.63e-01 | 9.29e-01 | 8.16e-01 | 6.89e-01 | 2.88e-01 |
| POSITIVE REGULATION OF DOUBLE STRAND BREAK REPAIR VIA HOMOLOGOUS RECOMBINATION | 34 | 4.29e-01 | 9.17e-01 | 0.22400 | 5.65e-02 | 3.67e-02 | 1.30e-01 | -1.23e-02 | 1.69e-01 | 5.68e-01 | 7.11e-01 | 1.88e-01 | 9.01e-01 | 8.86e-02 |
| NEUROTRANSMITTER UPTAKE | 44 | 4.87e-01 | 9.43e-01 | 0.22400 | 1.07e-01 | 9.36e-02 | 1.23e-01 | 1.18e-01 | 3.11e-02 | 2.21e-01 | 2.83e-01 | 1.57e-01 | 1.76e-01 | 7.21e-01 |
| T CELL SELECTION | 52 | 4.01e-02 | 3.22e-01 | 0.22400 | -1.15e-01 | -1.29e-01 | -3.62e-04 | -1.38e-01 | 3.34e-02 | 1.50e-01 | 1.07e-01 | 9.96e-01 | 8.51e-02 | 6.77e-01 |
| T TUBULE ORGANIZATION | 6 | 9.06e-01 | 1.00e+00 | 0.22400 | -1.06e-01 | -6.53e-02 | -1.18e-01 | -6.36e-02 | 1.30e-01 | 6.54e-01 | 7.82e-01 | 6.18e-01 | 7.87e-01 | 5.82e-01 |
| CMP METABOLIC PROCESS | 8 | 6.65e-01 | 1.00e+00 | 0.22400 | -8.21e-03 | 5.27e-02 | -1.21e-01 | 1.09e-01 | -1.45e-01 | 9.68e-01 | 7.96e-01 | 5.55e-01 | 5.95e-01 | 4.78e-01 |
| CYTOLYSIS | 7 | 2.13e-01 | 7.34e-01 | 0.22400 | -7.69e-02 | -9.92e-02 | -1.08e-01 | 1.50e-01 | -5.20e-03 | 7.25e-01 | 6.49e-01 | 6.20e-01 | 4.91e-01 | 9.81e-01 |
| LEUKOCYTE CELL CELL ADHESION | 403 | 1.67e-05 | 7.30e-04 | 0.22400 | -1.17e-01 | -1.27e-01 | -5.20e-02 | -1.16e-01 | 6.38e-02 | 5.47e-05 | 1.26e-05 | 7.33e-02 | 6.03e-05 | 2.78e-02 |
| OUTFLOW TRACT SEPTUM MORPHOGENESIS | 26 | 5.75e-01 | 9.79e-01 | 0.22400 | -8.78e-02 | -1.06e-01 | -6.16e-02 | -9.88e-02 | -1.32e-01 | 4.38e-01 | 3.49e-01 | 5.87e-01 | 3.83e-01 | 2.43e-01 |
| LAMELLIPODIUM MORPHOGENESIS | 18 | 4.23e-01 | 9.13e-01 | 0.22400 | 5.98e-02 | 9.04e-02 | -9.00e-03 | 1.24e-01 | 1.51e-01 | 6.61e-01 | 5.07e-01 | 9.47e-01 | 3.61e-01 | 2.67e-01 |
| REGULATORY NCRNA MEDIATED GENE SILENCING | 610 | 1.38e-12 | 3.88e-10 | 0.22400 | -9.43e-02 | -7.66e-02 | -1.55e-01 | -6.33e-02 | -8.59e-02 | 6.87e-05 | 1.24e-03 | 6.70e-11 | 7.61e-03 | 2.90e-04 |
| REGULATION OF MITOTIC CELL CYCLE SPINDLE ASSEMBLY CHECKPOINT | 21 | 7.38e-01 | 1.00e+00 | 0.22400 | 1.02e-01 | 9.67e-02 | 1.15e-01 | 1.27e-01 | 3.09e-02 | 4.16e-01 | 4.43e-01 | 3.63e-01 | 3.15e-01 | 8.06e-01 |
| REGULATION OF SUPEROXIDE METABOLIC PROCESS | 30 | 6.77e-01 | 1.00e+00 | 0.22400 | -1.05e-01 | -1.27e-01 | -1.40e-02 | -1.31e-01 | 7.45e-02 | 3.18e-01 | 2.30e-01 | 8.95e-01 | 2.15e-01 | 4.80e-01 |
| MITOTIC G2 M TRANSITION CHECKPOINT | 50 | 1.85e-01 | 6.94e-01 | 0.22400 | 1.05e-01 | 7.09e-02 | 1.78e-01 | 1.86e-02 | 4.40e-02 | 2.00e-01 | 3.86e-01 | 2.93e-02 | 8.20e-01 | 5.90e-01 |
| REGULATION OF T HELPER CELL DIFFERENTIATION | 42 | 2.77e-01 | 8.04e-01 | 0.22400 | -9.01e-02 | -1.10e-01 | 2.48e-02 | -1.48e-01 | 8.52e-02 | 3.13e-01 | 2.18e-01 | 7.81e-01 | 9.67e-02 | 3.40e-01 |
| REGULATION OF PANCREATIC JUICE SECRETION | 7 | 9.48e-01 | 1.00e+00 | 0.22400 | 8.83e-02 | 8.72e-02 | 5.65e-02 | 1.20e-01 | -1.30e-01 | 6.86e-01 | 6.89e-01 | 7.96e-01 | 5.83e-01 | 5.50e-01 |
| CORNIFIED ENVELOPE ASSEMBLY | 6 | 9.96e-01 | 1.00e+00 | 0.22400 | -1.21e-01 | -1.33e-01 | -9.44e-02 | -9.20e-02 | 1.70e-02 | 6.07e-01 | 5.73e-01 | 6.89e-01 | 6.96e-01 | 9.43e-01 |
| SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE TRANSLOCATION | 8 | 4.49e-01 | 9.30e-01 | 0.22400 | -3.31e-02 | -1.47e-02 | 1.14e-01 | -1.89e-01 | 4.80e-03 | 8.71e-01 | 9.42e-01 | 5.77e-01 | 3.55e-01 | 9.81e-01 |
| REGULATION OF CONNECTIVE TISSUE REPLACEMENT | 15 | 7.29e-01 | 1.00e+00 | 0.22400 | -4.33e-02 | -8.73e-02 | 7.55e-02 | -8.98e-02 | 1.63e-01 | 7.72e-01 | 5.58e-01 | 6.13e-01 | 5.47e-01 | 2.73e-01 |
| NEGATIVE REGULATION OF NEURON PROJECTION REGENERATION | 14 | 7.49e-01 | 1.00e+00 | 0.22300 | 7.06e-04 | -7.29e-03 | 4.80e-02 | -3.45e-02 | 2.15e-01 | 9.96e-01 | 9.62e-01 | 7.56e-01 | 8.23e-01 | 1.63e-01 |
| NUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 18 | 8.70e-01 | 1.00e+00 | 0.22300 | -1.06e-01 | -1.20e-01 | -1.64e-02 | -1.31e-01 | 8.23e-02 | 4.36e-01 | 3.77e-01 | 9.04e-01 | 3.37e-01 | 5.46e-01 |
| CRANIOFACIAL SUTURE MORPHOGENESIS | 18 | 5.23e-01 | 9.54e-01 | 0.22300 | 1.08e-01 | 6.22e-02 | 1.84e-01 | 1.82e-02 | -1.32e-02 | 4.26e-01 | 6.48e-01 | 1.77e-01 | 8.94e-01 | 9.23e-01 |
| RESPONSE TO TOPOLOGICALLY INCORRECT PROTEIN | 155 | 6.30e-03 | 9.04e-02 | 0.22300 | 1.04e-01 | 9.49e-02 | 1.59e-01 | 3.24e-02 | 6.14e-02 | 2.59e-02 | 4.13e-02 | 6.32e-04 | 4.86e-01 | 1.87e-01 |
| POSITIVE REGULATION OF MEIOTIC CELL CYCLE | 27 | 3.07e-01 | 8.35e-01 | 0.22300 | 8.54e-02 | 4.31e-02 | 9.22e-02 | 8.64e-02 | 1.57e-01 | 4.42e-01 | 6.98e-01 | 4.07e-01 | 4.37e-01 | 1.57e-01 |
| CHEMOKINE PRODUCTION | 101 | 1.10e-01 | 5.49e-01 | 0.22300 | -1.08e-01 | -1.25e-01 | -4.67e-02 | -1.40e-01 | -2.55e-02 | 6.07e-02 | 2.98e-02 | 4.18e-01 | 1.48e-02 | 6.58e-01 |
| TELOMERE MAINTENANCE | 149 | 9.71e-04 | 2.21e-02 | 0.22300 | 4.20e-02 | 2.49e-02 | 1.27e-01 | -1.18e-02 | 1.77e-01 | 3.76e-01 | 5.99e-01 | 7.61e-03 | 8.04e-01 | 1.97e-04 |
| PROTEIN K48 LINKED DEUBIQUITINATION | 25 | 7.52e-01 | 1.00e+00 | 0.22300 | -1.01e-01 | -9.59e-02 | -5.18e-02 | -1.45e-01 | -8.09e-02 | 3.83e-01 | 4.06e-01 | 6.54e-01 | 2.08e-01 | 4.84e-01 |
| COMPLEMENT ACTIVATION | 58 | 2.18e-01 | 7.41e-01 | 0.22300 | -9.92e-02 | -8.54e-02 | -1.68e-01 | -3.07e-02 | -5.88e-02 | 1.91e-01 | 2.61e-01 | 2.69e-02 | 6.86e-01 | 4.39e-01 |
| REGULATION OF CELL FATE SPECIFICATION | 24 | 5.98e-01 | 9.89e-01 | 0.22300 | 4.01e-02 | 1.92e-02 | 1.25e-01 | -2.97e-02 | 1.77e-01 | 7.34e-01 | 8.71e-01 | 2.89e-01 | 8.01e-01 | 1.34e-01 |
| PANCREAS DEVELOPMENT | 78 | 6.49e-05 | 2.43e-03 | 0.22300 | 6.04e-02 | 4.51e-02 | 1.41e-01 | -7.83e-02 | -1.34e-01 | 3.57e-01 | 4.91e-01 | 3.11e-02 | 2.32e-01 | 4.07e-02 |
| SOMATIC DIVERSIFICATION OF IMMUNE RECEPTORS | 77 | 3.59e-03 | 6.06e-02 | 0.22300 | 1.86e-02 | -2.04e-02 | 1.54e-01 | -7.51e-02 | 1.40e-01 | 7.78e-01 | 7.57e-01 | 1.98e-02 | 2.55e-01 | 3.32e-02 |
| UTERUS DEVELOPMENT | 23 | 2.26e-01 | 7.48e-01 | 0.22300 | -6.03e-02 | -9.90e-02 | 1.54e-02 | -1.53e-01 | -1.12e-01 | 6.17e-01 | 4.11e-01 | 8.98e-01 | 2.04e-01 | 3.51e-01 |
| INTRACELLULAR TRANSPORT OF VIRUS | 10 | 8.19e-01 | 1.00e+00 | 0.22300 | -2.71e-02 | -4.07e-02 | -3.70e-02 | -7.61e-02 | -2.00e-01 | 8.82e-01 | 8.24e-01 | 8.39e-01 | 6.77e-01 | 2.73e-01 |
| PURINE NUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 10 | 9.10e-01 | 1.00e+00 | 0.22300 | -8.29e-02 | -1.15e-01 | 3.25e-02 | -1.25e-01 | 1.14e-01 | 6.50e-01 | 5.30e-01 | 8.59e-01 | 4.95e-01 | 5.33e-01 |
| INTERLEUKIN 27 MEDIATED SIGNALING PATHWAY | 7 | 6.28e-01 | 9.95e-01 | 0.22300 | -9.08e-02 | -9.65e-03 | -1.70e-01 | -9.32e-02 | -6.00e-02 | 6.77e-01 | 9.65e-01 | 4.36e-01 | 6.69e-01 | 7.83e-01 |
| POSITIVE REGULATION OF DNA BINDING | 41 | 2.29e-02 | 2.26e-01 | 0.22300 | -3.81e-02 | -4.40e-02 | 7.27e-02 | -1.76e-01 | 9.97e-02 | 6.73e-01 | 6.26e-01 | 4.20e-01 | 5.13e-02 | 2.69e-01 |
| REGULATION OF MICROTUBULE CYTOSKELETON ORGANIZATION | 155 | 2.51e-02 | 2.38e-01 | 0.22300 | 1.05e-01 | 9.94e-02 | 1.36e-01 | 8.56e-02 | 5.31e-02 | 2.42e-02 | 3.28e-02 | 3.45e-03 | 6.59e-02 | 2.54e-01 |
| INTRACELLULAR PHOSPHATE ION HOMEOSTASIS | 10 | 9.59e-01 | 1.00e+00 | 0.22200 | -8.75e-02 | -6.08e-02 | -1.47e-01 | -6.61e-02 | -1.10e-01 | 6.32e-01 | 7.39e-01 | 4.22e-01 | 7.17e-01 | 5.45e-01 |
| ENDOPLASMIC RETICULUM PLASMA MEMBRANE TETHERING | 6 | 9.86e-01 | 1.00e+00 | 0.22200 | -1.10e-01 | -9.69e-02 | -6.24e-02 | -1.39e-01 | 6.96e-02 | 6.41e-01 | 6.81e-01 | 7.91e-01 | 5.56e-01 | 7.68e-01 |
| APOPTOTIC PROCESS INVOLVED IN MORPHOGENESIS | 27 | 7.45e-01 | 1.00e+00 | 0.22200 | 1.10e-01 | 1.13e-01 | 1.38e-01 | 7.15e-02 | 1.47e-02 | 3.24e-01 | 3.07e-01 | 2.14e-01 | 5.20e-01 | 8.95e-01 |
| REGULATION OF GLUTAMATE SECRETION | 20 | 3.74e-01 | 8.83e-01 | 0.22200 | 9.85e-02 | 6.11e-02 | 1.34e-01 | 2.11e-02 | -1.32e-01 | 4.46e-01 | 6.36e-01 | 3.00e-01 | 8.70e-01 | 3.05e-01 |
| ENDOCARDIAL CELL DIFFERENTIATION | 6 | 9.50e-01 | 1.00e+00 | 0.22200 | -3.30e-02 | -3.24e-02 | -3.56e-02 | -1.01e-01 | -1.89e-01 | 8.89e-01 | 8.91e-01 | 8.80e-01 | 6.68e-01 | 4.23e-01 |
| CHROMATIN LOOPING | 11 | 4.55e-01 | 9.31e-01 | 0.22200 | 1.12e-01 | 8.00e-02 | 1.29e-01 | -2.48e-02 | -1.15e-01 | 5.19e-01 | 6.46e-01 | 4.60e-01 | 8.87e-01 | 5.10e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS EXONUCLEOLYTIC | 20 | 6.92e-01 | 1.00e+00 | 0.22200 | 5.11e-02 | 2.98e-02 | 1.49e-01 | -2.66e-03 | 1.54e-01 | 6.92e-01 | 8.18e-01 | 2.50e-01 | 9.84e-01 | 2.33e-01 |
| HYPOTHALAMUS DEVELOPMENT | 24 | 3.28e-01 | 8.53e-01 | 0.22200 | -4.79e-02 | -5.88e-02 | 8.54e-03 | -1.14e-01 | -1.74e-01 | 6.85e-01 | 6.18e-01 | 9.42e-01 | 3.32e-01 | 1.39e-01 |
| NUCLEOLUS ORGANIZATION | 16 | 6.96e-01 | 1.00e+00 | 0.22200 | 1.19e-01 | 7.75e-02 | 1.34e-01 | 9.12e-02 | -5.43e-02 | 4.10e-01 | 5.91e-01 | 3.54e-01 | 5.28e-01 | 7.07e-01 |
| MEMBRANE HYPERPOLARIZATION | 10 | 9.01e-01 | 1.00e+00 | 0.22200 | 9.52e-02 | 1.38e-01 | 2.08e-02 | 9.14e-02 | -1.11e-01 | 6.02e-01 | 4.50e-01 | 9.09e-01 | 6.17e-01 | 5.42e-01 |
| SPERMATID NUCLEUS DIFFERENTIATION | 27 | 7.94e-01 | 1.00e+00 | 0.22200 | 1.22e-01 | 1.20e-01 | 7.99e-02 | 8.92e-02 | -7.55e-02 | 2.73e-01 | 2.82e-01 | 4.72e-01 | 4.22e-01 | 4.97e-01 |
| NEGATIVE REGULATION OF ENDOCYTOSIS | 76 | 9.51e-02 | 5.09e-01 | 0.22200 | 1.13e-01 | 9.49e-02 | 1.39e-01 | 5.17e-02 | -7.47e-02 | 8.95e-02 | 1.53e-01 | 3.63e-02 | 4.36e-01 | 2.60e-01 |
| TONGUE DEVELOPMENT | 20 | 1.90e-01 | 6.99e-01 | 0.22200 | -7.98e-02 | -1.08e-01 | 8.25e-02 | -1.37e-01 | 7.40e-02 | 5.36e-01 | 4.02e-01 | 5.23e-01 | 2.87e-01 | 5.67e-01 |
| EMBRYONIC HEART TUBE DEVELOPMENT | 83 | 8.36e-02 | 4.77e-01 | 0.22200 | 1.11e-01 | 9.40e-02 | 1.61e-01 | 4.30e-02 | -1.60e-02 | 7.93e-02 | 1.39e-01 | 1.13e-02 | 4.98e-01 | 8.01e-01 |
| REGULATION OF ATP METABOLIC PROCESS | 22 | 5.33e-01 | 9.55e-01 | 0.22200 | 5.65e-02 | 3.07e-02 | 5.60e-02 | 7.63e-02 | 1.90e-01 | 6.46e-01 | 8.03e-01 | 6.49e-01 | 5.35e-01 | 1.23e-01 |
| CEREBRAL CORTEX RADIALLY ORIENTED CELL MIGRATION | 36 | 5.35e-01 | 9.56e-01 | 0.22200 | -1.00e-01 | -9.20e-02 | -1.21e-01 | -4.52e-02 | -1.19e-01 | 2.98e-01 | 3.39e-01 | 2.11e-01 | 6.39e-01 | 2.18e-01 |
| ELASTIC FIBER ASSEMBLY | 9 | 9.44e-01 | 1.00e+00 | 0.22200 | 6.17e-02 | 5.97e-02 | 1.15e-01 | 4.77e-02 | 1.62e-01 | 7.49e-01 | 7.56e-01 | 5.50e-01 | 8.04e-01 | 4.01e-01 |
| ORGAN OR TISSUE SPECIFIC IMMUNE RESPONSE | 41 | 3.34e-04 | 9.42e-03 | 0.22200 | -2.76e-03 | -9.07e-03 | 6.64e-02 | 9.32e-02 | 1.89e-01 | 9.76e-01 | 9.20e-01 | 4.62e-01 | 3.02e-01 | 3.58e-02 |
| REGULATION OF IMMUNE EFFECTOR PROCESS | 375 | 3.52e-09 | 4.82e-07 | 0.22100 | -9.42e-02 | -1.25e-01 | 7.38e-03 | -1.36e-01 | 7.80e-02 | 1.73e-03 | 3.20e-05 | 8.06e-01 | 6.43e-06 | 9.49e-03 |
| INTRACELLULAR DISTRIBUTION OF MITOCHONDRIA | 7 | 5.61e-01 | 9.70e-01 | 0.22100 | 3.41e-02 | 1.34e-03 | 2.79e-02 | 1.87e-01 | 1.11e-01 | 8.76e-01 | 9.95e-01 | 8.98e-01 | 3.93e-01 | 6.12e-01 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 34 | 4.00e-02 | 3.22e-01 | 0.22100 | -5.05e-02 | -6.22e-02 | 4.70e-02 | -2.00e-01 | 1.72e-02 | 6.10e-01 | 5.30e-01 | 6.35e-01 | 4.33e-02 | 8.63e-01 |
| POSITIVE REGULATION OF ADENYLATE CYCLASE ACTIVITY | 31 | 8.75e-01 | 1.00e+00 | 0.22100 | -1.00e-01 | -9.15e-02 | -1.11e-01 | -9.03e-02 | -1.01e-01 | 3.35e-01 | 3.78e-01 | 2.86e-01 | 3.84e-01 | 3.32e-01 |
| NOTOCHORD DEVELOPMENT | 19 | 3.32e-01 | 8.56e-01 | 0.22100 | 8.41e-02 | 8.74e-02 | 1.57e-01 | -4.91e-02 | -8.46e-02 | 5.25e-01 | 5.10e-01 | 2.36e-01 | 7.11e-01 | 5.23e-01 |
| REGULATION OF GONADOTROPIN SECRETION | 11 | 8.53e-01 | 1.00e+00 | 0.22100 | -4.67e-02 | -4.45e-02 | -6.47e-02 | -1.01e-01 | -1.74e-01 | 7.89e-01 | 7.98e-01 | 7.10e-01 | 5.60e-01 | 3.17e-01 |
| INTERMEMBRANE LIPID TRANSFER | 54 | 2.59e-01 | 7.86e-01 | 0.22100 | 1.08e-01 | 1.22e-01 | 9.27e-02 | 7.56e-02 | 8.94e-02 | 1.69e-01 | 1.20e-01 | 2.39e-01 | 3.36e-01 | 2.56e-01 |
| PITUITARY GLAND DEVELOPMENT | 40 | 5.44e-02 | 3.82e-01 | 0.22100 | 9.07e-02 | 7.08e-02 | 1.58e-01 | -4.04e-02 | -9.59e-02 | 3.21e-01 | 4.39e-01 | 8.45e-02 | 6.59e-01 | 2.94e-01 |
| REGULATION OF FIBRINOLYSIS | 18 | 6.19e-01 | 9.90e-01 | 0.22100 | 2.48e-02 | 2.78e-02 | 1.68e-02 | -3.97e-02 | -2.13e-01 | 8.56e-01 | 8.38e-01 | 9.02e-01 | 7.70e-01 | 1.17e-01 |
| ATP METABOLIC PROCESS | 124 | 9.70e-03 | 1.22e-01 | 0.22100 | 1.01e-01 | 8.30e-02 | 1.65e-01 | 1.26e-02 | 6.56e-02 | 5.28e-02 | 1.11e-01 | 1.48e-03 | 8.08e-01 | 2.07e-01 |
| GLYCOSAMINOGLYCAN CATABOLIC PROCESS | 27 | 8.16e-01 | 1.00e+00 | 0.22100 | -1.07e-01 | -1.03e-01 | -8.03e-02 | -1.04e-01 | 9.72e-02 | 3.34e-01 | 3.55e-01 | 4.70e-01 | 3.50e-01 | 3.82e-01 |
| PROTEIN RETENTION IN ER LUMEN | 8 | 7.40e-02 | 4.47e-01 | 0.22100 | 4.71e-04 | 8.35e-02 | 5.28e-02 | -1.97e-01 | -1.01e-02 | 9.98e-01 | 6.82e-01 | 7.96e-01 | 3.34e-01 | 9.61e-01 |
| REGULATION OF CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 26 | 4.61e-01 | 9.32e-01 | 0.22100 | 8.65e-02 | 1.05e-01 | 2.71e-02 | 1.57e-01 | -6.91e-02 | 4.45e-01 | 3.54e-01 | 8.11e-01 | 1.65e-01 | 5.42e-01 |
| T CELL EXTRAVASATION | 10 | 8.86e-01 | 1.00e+00 | 0.22100 | 1.03e-01 | 9.60e-02 | 1.66e-01 | 1.92e-02 | -3.27e-02 | 5.72e-01 | 5.99e-01 | 3.64e-01 | 9.16e-01 | 8.58e-01 |
| RESPONSE TO NITROSATIVE STRESS | 10 | 3.15e-01 | 8.42e-01 | 0.22100 | 3.40e-02 | 3.86e-02 | 1.65e-01 | -9.66e-02 | -9.77e-02 | 8.52e-01 | 8.33e-01 | 3.66e-01 | 5.97e-01 | 5.93e-01 |
| REGULATION OF ARTERY MORPHOGENESIS | 11 | 1.92e-02 | 2.02e-01 | 0.22100 | -1.30e-02 | -7.06e-02 | -9.20e-02 | -6.66e-02 | -1.75e-01 | 9.40e-01 | 6.85e-01 | 5.97e-01 | 7.02e-01 | 3.15e-01 |
| REGULATION OF ADAPTIVE IMMUNE RESPONSE | 201 | 6.20e-04 | 1.54e-02 | 0.22100 | -9.36e-02 | -1.18e-01 | -2.90e-03 | -1.37e-01 | 8.47e-02 | 2.21e-02 | 3.81e-03 | 9.43e-01 | 8.25e-04 | 3.84e-02 |
| LEUKOCYTE MIGRATION | 383 | 9.98e-06 | 4.75e-04 | 0.22000 | -1.17e-01 | -1.32e-01 | -6.58e-02 | -8.99e-02 | 7.15e-02 | 8.26e-05 | 9.67e-06 | 2.69e-02 | 2.52e-03 | 1.63e-02 |
| REGULATION OF BRANCHING INVOLVED IN URETERIC BUD MORPHOGENESIS | 19 | 2.78e-02 | 2.56e-01 | 0.22000 | -1.86e-03 | 2.16e-02 | 1.36e-01 | -1.67e-01 | -4.15e-02 | 9.89e-01 | 8.71e-01 | 3.06e-01 | 2.07e-01 | 7.54e-01 |
| REGULATION OF SKELETAL MUSCLE SATELLITE CELL PROLIFERATION | 12 | 5.92e-01 | 9.86e-01 | 0.22000 | -6.99e-02 | -5.53e-02 | -1.62e-02 | -1.96e-01 | -4.25e-02 | 6.75e-01 | 7.40e-01 | 9.23e-01 | 2.39e-01 | 7.99e-01 |
| NEGATIVE REGULATION OF TYPE II INTERFERON PRODUCTION | 41 | 5.77e-01 | 9.81e-01 | 0.22000 | -1.08e-01 | -1.01e-01 | -6.16e-02 | -1.02e-01 | 1.12e-01 | 2.33e-01 | 2.63e-01 | 4.95e-01 | 2.56e-01 | 2.16e-01 |
| FATTY ACID BETA OXIDATION | 74 | 3.92e-01 | 8.92e-01 | 0.22000 | 1.10e-01 | 1.27e-01 | 6.64e-02 | 1.26e-01 | -1.05e-02 | 1.02e-01 | 5.91e-02 | 3.23e-01 | 6.11e-02 | 8.76e-01 |
| AXONAL TRANSPORT | 62 | 1.79e-01 | 6.86e-01 | 0.22000 | -1.06e-01 | -1.08e-01 | -3.46e-02 | -1.47e-01 | -5.27e-02 | 1.50e-01 | 1.41e-01 | 6.37e-01 | 4.47e-02 | 4.73e-01 |
| CHROMOSOME ORGANIZATION | 606 | 2.47e-11 | 5.46e-09 | 0.22000 | 8.36e-02 | 6.00e-02 | 1.51e-01 | 3.34e-02 | 1.18e-01 | 4.40e-04 | 1.16e-02 | 1.97e-10 | 1.60e-01 | 7.05e-07 |
| REGULATION OF HORMONE BIOSYNTHETIC PROCESS | 24 | 8.38e-01 | 1.00e+00 | 0.22000 | -1.26e-01 | -1.27e-01 | -8.49e-02 | -9.21e-02 | 2.80e-02 | 2.85e-01 | 2.82e-01 | 4.72e-01 | 4.35e-01 | 8.13e-01 |
| POSITIVE REGULATION OF BEHAVIOR | 24 | 9.19e-01 | 1.00e+00 | 0.22000 | -1.18e-01 | -1.18e-01 | -9.34e-02 | -8.71e-02 | 6.49e-02 | 3.17e-01 | 3.16e-01 | 4.28e-01 | 4.60e-01 | 5.82e-01 |
| LACRIMAL GLAND DEVELOPMENT | 7 | 9.90e-01 | 1.00e+00 | 0.22000 | 1.15e-01 | 1.27e-01 | 1.12e-01 | 7.55e-02 | 2.82e-02 | 5.99e-01 | 5.59e-01 | 6.09e-01 | 7.29e-01 | 8.97e-01 |
| NEGATIVE REGULATION OF PLASMA MEMBRANE BOUNDED CELL PROJECTION ASSEMBLY | 36 | 4.26e-01 | 9.15e-01 | 0.22000 | -5.78e-02 | -2.99e-02 | -1.22e-01 | -6.26e-02 | -1.60e-01 | 5.49e-01 | 7.56e-01 | 2.07e-01 | 5.16e-01 | 9.75e-02 |
| PEPTIDYL CYSTEINE MODIFICATION | 41 | 5.13e-01 | 9.52e-01 | 0.22000 | 8.32e-02 | 8.91e-02 | 9.80e-02 | 6.87e-02 | 1.39e-01 | 3.57e-01 | 3.24e-01 | 2.78e-01 | 4.46e-01 | 1.25e-01 |
| ANTIGEN PROCESSING AND PRESENTATION | 112 | 1.99e-03 | 3.89e-02 | 0.22000 | -9.11e-02 | -1.30e-01 | 1.91e-02 | -1.13e-01 | 1.00e-01 | 9.58e-02 | 1.71e-02 | 7.27e-01 | 3.93e-02 | 6.76e-02 |
| REGULATION OF FATTY ACID BIOSYNTHETIC PROCESS | 51 | 2.91e-01 | 8.18e-01 | 0.22000 | 1.12e-01 | 9.63e-02 | 1.54e-01 | 3.50e-02 | -3.81e-02 | 1.65e-01 | 2.34e-01 | 5.66e-02 | 6.65e-01 | 6.38e-01 |
| POSITIVE REGULATION OF LONG TERM SYNAPTIC POTENTIATION | 22 | 8.65e-01 | 1.00e+00 | 0.22000 | 1.08e-01 | 1.31e-01 | 5.38e-02 | 9.56e-02 | -8.67e-02 | 3.82e-01 | 2.87e-01 | 6.62e-01 | 4.38e-01 | 4.81e-01 |
| BODY FLUID SECRETION | 87 | 3.12e-01 | 8.38e-01 | 0.22000 | 1.05e-01 | 1.03e-01 | 1.21e-01 | 9.75e-02 | 5.00e-02 | 8.91e-02 | 9.62e-02 | 5.15e-02 | 1.16e-01 | 4.20e-01 |
| MECHANOSENSORY BEHAVIOR | 14 | 8.38e-01 | 1.00e+00 | 0.22000 | 1.01e-01 | 8.84e-02 | 3.53e-02 | 1.67e-01 | -3.24e-02 | 5.11e-01 | 5.67e-01 | 8.19e-01 | 2.79e-01 | 8.34e-01 |
| REGULATION OF ANOIKIS | 24 | 9.42e-01 | 1.00e+00 | 0.22000 | 1.05e-01 | 9.45e-02 | 1.11e-01 | 9.96e-02 | 7.82e-02 | 3.71e-01 | 4.23e-01 | 3.48e-01 | 3.99e-01 | 5.07e-01 |
| DETECTION OF VISIBLE LIGHT | 46 | 3.84e-02 | 3.13e-01 | 0.22000 | -5.46e-02 | -1.66e-02 | -1.77e-01 | 7.12e-02 | -9.26e-02 | 5.21e-01 | 8.46e-01 | 3.76e-02 | 4.03e-01 | 2.77e-01 |
| NUCLEOTIDE TRANSPORT | 40 | 6.61e-01 | 1.00e+00 | 0.22000 | -1.16e-01 | -1.19e-01 | -6.57e-02 | -9.35e-02 | 8.72e-02 | 2.03e-01 | 1.93e-01 | 4.72e-01 | 3.06e-01 | 3.40e-01 |
| GASTRULATION WITH MOUTH FORMING SECOND | 26 | 6.00e-02 | 4.02e-01 | 0.22000 | 7.73e-02 | 8.19e-02 | 1.50e-01 | -9.69e-02 | -6.02e-02 | 4.95e-01 | 4.70e-01 | 1.85e-01 | 3.92e-01 | 5.95e-01 |
| NEURAL FOLD FORMATION | 7 | 9.48e-01 | 1.00e+00 | 0.22000 | -6.22e-02 | -4.76e-02 | -1.02e-01 | -7.10e-03 | -1.78e-01 | 7.76e-01 | 8.27e-01 | 6.41e-01 | 9.74e-01 | 4.15e-01 |
| SYNAPTIC VESICLE TRANSPORT | 40 | 7.61e-02 | 4.53e-01 | 0.22000 | -7.93e-02 | -1.16e-01 | 5.61e-02 | -1.57e-01 | 2.31e-02 | 3.85e-01 | 2.03e-01 | 5.39e-01 | 8.52e-02 | 8.01e-01 |
| POSITIVE REGULATION OF WOUND HEALING | 61 | 6.67e-02 | 4.21e-01 | 0.22000 | 5.20e-02 | 9.33e-02 | -2.11e-02 | 5.09e-02 | -1.84e-01 | 4.82e-01 | 2.08e-01 | 7.75e-01 | 4.92e-01 | 1.30e-02 |
| NEGATIVE REGULATION OF NEUROBLAST PROLIFERATION | 11 | 8.97e-01 | 1.00e+00 | 0.22000 | 1.07e-01 | 8.27e-02 | 1.66e-01 | 3.88e-02 | -2.68e-02 | 5.37e-01 | 6.35e-01 | 3.40e-01 | 8.24e-01 | 8.77e-01 |
| WNT SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 12 | 6.12e-01 | 9.90e-01 | 0.22000 | -1.80e-02 | -4.28e-02 | 2.63e-02 | -1.14e-01 | -1.80e-01 | 9.14e-01 | 7.97e-01 | 8.75e-01 | 4.93e-01 | 2.81e-01 |
| NEGATIVE REGULATION OF RELAXATION OF MUSCLE | 7 | 2.92e-01 | 8.20e-01 | 0.22000 | -6.53e-02 | -1.27e-01 | 1.03e-01 | -9.89e-02 | -8.69e-02 | 7.65e-01 | 5.62e-01 | 6.37e-01 | 6.51e-01 | 6.91e-01 |
| PYRIMIDINE DEOXYRIBONUCLEOTIDE METABOLIC PROCESS | 23 | 4.32e-01 | 9.19e-01 | 0.22000 | 7.45e-03 | -1.93e-02 | 1.23e-01 | -9.55e-02 | 1.53e-01 | 9.51e-01 | 8.73e-01 | 3.07e-01 | 4.28e-01 | 2.03e-01 |
| POSITIVE REGULATION OF TOOTH MINERALIZATION | 7 | 1.29e-01 | 5.97e-01 | 0.22000 | 6.98e-02 | 1.13e-01 | -1.19e-01 | 9.07e-02 | 9.01e-02 | 7.49e-01 | 6.04e-01 | 5.86e-01 | 6.78e-01 | 6.80e-01 |
| NEGATIVE REGULATION OF LIPID METABOLIC PROCESS | 108 | 3.46e-01 | 8.64e-01 | 0.22000 | 1.17e-01 | 1.11e-01 | 1.26e-01 | 7.79e-02 | 9.05e-03 | 3.58e-02 | 4.54e-02 | 2.33e-02 | 1.62e-01 | 8.71e-01 |
| MITOCHONDRIAL TRANSCRIPTION | 19 | 6.34e-01 | 9.97e-01 | 0.21900 | 9.54e-02 | 1.10e-01 | 1.13e-01 | 2.27e-02 | -1.17e-01 | 4.72e-01 | 4.05e-01 | 3.95e-01 | 8.64e-01 | 3.78e-01 |
| POSITIVE REGULATION OF EMBRYONIC DEVELOPMENT | 21 | 6.82e-01 | 1.00e+00 | 0.21900 | 1.16e-01 | 9.21e-02 | 1.51e-01 | 2.87e-02 | -5.05e-02 | 3.57e-01 | 4.65e-01 | 2.31e-01 | 8.20e-01 | 6.89e-01 |
| SEQUESTERING OF EXTRACELLULAR LIGAND FROM RECEPTOR | 11 | 2.24e-01 | 7.45e-01 | 0.21900 | -6.42e-02 | 2.30e-02 | -2.04e-01 | 4.11e-02 | 1.45e-02 | 7.12e-01 | 8.95e-01 | 2.42e-01 | 8.13e-01 | 9.33e-01 |
| DOUBLE STRAND BREAK REPAIR | 294 | 3.56e-05 | 1.44e-03 | 0.21900 | 9.04e-02 | 6.64e-02 | 1.56e-01 | 3.58e-02 | 9.98e-02 | 7.68e-03 | 5.01e-02 | 4.44e-06 | 2.91e-01 | 3.23e-03 |
| IMMUNOGLOBULIN PRODUCTION INVOLVED IN IMMUNOGLOBULIN MEDIATED IMMUNE RESPONSE | 56 | 1.62e-02 | 1.79e-01 | 0.21900 | -2.86e-03 | -4.27e-02 | 1.40e-01 | -1.06e-01 | 1.25e-01 | 9.70e-01 | 5.81e-01 | 7.09e-02 | 1.71e-01 | 1.07e-01 |
| POSITIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN INFLAMMATORY RESPONSE | 31 | 1.91e-01 | 7.00e-01 | 0.21900 | 3.63e-03 | -4.97e-02 | 6.56e-02 | 2.03e-02 | 2.02e-01 | 9.72e-01 | 6.32e-01 | 5.27e-01 | 8.45e-01 | 5.18e-02 |
| POSTSYNAPSE TO NUCLEUS SIGNALING PATHWAY | 6 | 9.65e-01 | 1.00e+00 | 0.21900 | -3.36e-02 | -3.33e-02 | 9.63e-03 | -1.91e-02 | 2.13e-01 | 8.87e-01 | 8.88e-01 | 9.67e-01 | 9.35e-01 | 3.67e-01 |
| PHOSPHATIDYLETHANOLAMINE ACYL CHAIN REMODELING | 11 | 8.58e-01 | 1.00e+00 | 0.21900 | 1.02e-01 | 1.45e-01 | 3.36e-02 | 1.24e-01 | -8.25e-03 | 5.59e-01 | 4.06e-01 | 8.47e-01 | 4.76e-01 | 9.62e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO SYNAPSE | 18 | 6.55e-01 | 1.00e+00 | 0.21900 | -6.46e-02 | -7.58e-02 | -1.02e-02 | -1.14e-02 | 1.94e-01 | 6.35e-01 | 5.77e-01 | 9.40e-01 | 9.33e-01 | 1.54e-01 |
| NEGATIVE REGULATION OF GLIAL CELL DIFFERENTIATION | 27 | 9.35e-02 | 5.04e-01 | 0.21900 | -3.70e-02 | -4.32e-02 | 9.16e-02 | -1.88e-01 | 3.20e-02 | 7.39e-01 | 6.98e-01 | 4.10e-01 | 9.15e-02 | 7.74e-01 |
| NUCLEOSIDE TRIPHOSPHATE METABOLIC PROCESS | 169 | 6.90e-03 | 9.58e-02 | 0.21900 | 1.07e-01 | 8.42e-02 | 1.59e-01 | 3.80e-02 | 5.03e-02 | 1.67e-02 | 5.88e-02 | 3.52e-04 | 3.94e-01 | 2.59e-01 |
| CELL FATE SPECIFICATION | 107 | 8.40e-07 | 5.64e-05 | 0.21900 | 6.70e-02 | 4.57e-02 | 1.82e-01 | -8.53e-02 | -3.15e-02 | 2.31e-01 | 4.14e-01 | 1.17e-03 | 1.27e-01 | 5.74e-01 |
| NEGATIVE REGULATION OF NEUROTRANSMITTER SECRETION | 6 | 8.03e-01 | 1.00e+00 | 0.21900 | 8.56e-02 | 3.63e-02 | 1.74e-01 | 1.69e-02 | -9.18e-02 | 7.17e-01 | 8.78e-01 | 4.60e-01 | 9.43e-01 | 6.97e-01 |
| MULTIVESICULAR BODY SORTING PATHWAY | 46 | 2.94e-01 | 8.22e-01 | 0.21800 | 8.32e-02 | 7.43e-02 | 1.52e-01 | 1.81e-03 | 1.10e-01 | 3.29e-01 | 3.84e-01 | 7.39e-02 | 9.83e-01 | 1.97e-01 |
| DNA INTEGRITY CHECKPOINT SIGNALING | 131 | 2.01e-03 | 3.90e-02 | 0.21800 | 1.03e-01 | 9.14e-02 | 1.67e-01 | 2.33e-03 | 3.21e-02 | 4.25e-02 | 7.08e-02 | 9.82e-04 | 9.63e-01 | 5.25e-01 |
| PERIPHERAL NERVOUS SYSTEM DEVELOPMENT | 80 | 3.29e-01 | 8.53e-01 | 0.21800 | 1.09e-01 | 1.16e-01 | 1.20e-01 | 7.93e-02 | 4.16e-02 | 9.24e-02 | 7.24e-02 | 6.38e-02 | 2.20e-01 | 5.20e-01 |
| NEGATIVE REGULATION OF KERATINOCYTE DIFFERENTIATION | 9 | 5.57e-01 | 9.68e-01 | 0.21800 | 5.99e-03 | 5.02e-02 | -1.25e-01 | 1.71e-01 | 1.98e-02 | 9.75e-01 | 7.94e-01 | 5.18e-01 | 3.74e-01 | 9.18e-01 |
| NEUROTRANSMITTER REUPTAKE | 34 | 5.34e-01 | 9.56e-01 | 0.21800 | 1.05e-01 | 9.41e-02 | 9.62e-02 | 1.24e-01 | -5.67e-02 | 2.90e-01 | 3.42e-01 | 3.32e-01 | 2.11e-01 | 5.67e-01 |
| MEMBRANE BIOGENESIS | 59 | 2.26e-01 | 7.48e-01 | 0.21800 | 6.48e-02 | 5.78e-02 | 1.20e-01 | 1.70e-02 | 1.60e-01 | 3.90e-01 | 4.43e-01 | 1.11e-01 | 8.21e-01 | 3.39e-02 |
| INTRACELLULAR MRNA LOCALIZATION | 13 | 7.90e-01 | 1.00e+00 | 0.21800 | 4.62e-02 | 4.04e-02 | 2.11e-02 | 9.19e-02 | 1.87e-01 | 7.73e-01 | 8.01e-01 | 8.95e-01 | 5.66e-01 | 2.43e-01 |
| COPPER ION TRANSPORT | 15 | 3.16e-01 | 8.44e-01 | 0.21800 | -1.12e-01 | -1.40e-01 | -5.22e-02 | -4.15e-03 | 1.13e-01 | 4.54e-01 | 3.47e-01 | 7.26e-01 | 9.78e-01 | 4.49e-01 |
| NEGATIVE REGULATION OF ERYTHROCYTE DIFFERENTIATION | 8 | 9.23e-01 | 1.00e+00 | 0.21800 | 1.32e-01 | 1.19e-01 | 7.78e-02 | 9.63e-02 | -2.73e-02 | 5.19e-01 | 5.58e-01 | 7.03e-01 | 6.37e-01 | 8.93e-01 |
| FAT SOLUBLE VITAMIN CATABOLIC PROCESS | 11 | 8.50e-01 | 1.00e+00 | 0.21800 | 1.80e-02 | 5.75e-02 | -9.98e-02 | 5.82e-02 | -1.75e-01 | 9.18e-01 | 7.41e-01 | 5.66e-01 | 7.38e-01 | 3.15e-01 |
| OXIDATIVE DEMETHYLATION | 14 | 4.49e-01 | 9.30e-01 | 0.21800 | -7.83e-02 | -8.25e-02 | -1.72e-01 | 6.01e-02 | 3.65e-02 | 6.12e-01 | 5.93e-01 | 2.64e-01 | 6.97e-01 | 8.13e-01 |
| LEUKOTRIENE METABOLIC PROCESS | 30 | 3.69e-02 | 3.06e-01 | 0.21800 | 7.63e-02 | 5.72e-02 | 1.23e-01 | 1.40e-01 | 6.21e-02 | 4.70e-01 | 5.88e-01 | 2.45e-01 | 1.84e-01 | 5.56e-01 |
| STEROID HORMONE SECRETION | 27 | 6.37e-01 | 9.98e-01 | 0.21800 | 6.06e-02 | 3.13e-02 | 1.47e-01 | 1.13e-02 | 1.45e-01 | 5.86e-01 | 7.79e-01 | 1.85e-01 | 9.19e-01 | 1.91e-01 |
| PURINE NUCLEOSIDE CATABOLIC PROCESS | 8 | 8.25e-01 | 1.00e+00 | 0.21800 | -6.87e-02 | -9.01e-02 | -1.09e-02 | -9.22e-02 | -1.62e-01 | 7.37e-01 | 6.59e-01 | 9.58e-01 | 6.51e-01 | 4.29e-01 |
| DOUBLE STRAND BREAK REPAIR VIA CLASSICAL NONHOMOLOGOUS END JOINING | 6 | 9.81e-01 | 1.00e+00 | 0.21800 | 1.04e-01 | 9.40e-02 | 1.14e-01 | 7.49e-02 | -9.61e-02 | 6.60e-01 | 6.90e-01 | 6.27e-01 | 7.51e-01 | 6.83e-01 |
| EPITHELIAL CELL PROLIFERATION INVOLVED IN LUNG MORPHOGENESIS | 10 | 8.95e-01 | 1.00e+00 | 0.21800 | 7.09e-02 | 6.29e-02 | 2.26e-02 | 9.54e-02 | -1.70e-01 | 6.98e-01 | 7.31e-01 | 9.02e-01 | 6.02e-01 | 3.51e-01 |
| OPTIC NERVE DEVELOPMENT | 20 | 8.42e-01 | 1.00e+00 | 0.21800 | 8.80e-02 | 7.89e-02 | 1.46e-01 | 4.77e-02 | 9.93e-02 | 4.96e-01 | 5.41e-01 | 2.57e-01 | 7.12e-01 | 4.42e-01 |
| HINDBRAIN RADIAL GLIA GUIDED CELL MIGRATION | 8 | 9.70e-01 | 1.00e+00 | 0.21800 | -8.38e-02 | -4.99e-02 | -1.51e-01 | -3.09e-02 | -1.19e-01 | 6.82e-01 | 8.07e-01 | 4.59e-01 | 8.80e-01 | 5.60e-01 |
| GAMMA DELTA T CELL ACTIVATION | 23 | 4.89e-01 | 9.44e-01 | 0.21800 | -9.39e-02 | -1.42e-01 | -1.42e-02 | -1.18e-01 | 6.61e-02 | 4.36e-01 | 2.37e-01 | 9.06e-01 | 3.28e-01 | 5.83e-01 |
| PROTEIN DNA COMPLEX ORGANIZATION | 796 | 1.37e-12 | 3.88e-10 | 0.21800 | 9.35e-02 | 7.18e-02 | 1.50e-01 | 4.60e-02 | 9.54e-02 | 7.14e-06 | 5.74e-04 | 6.71e-13 | 2.74e-02 | 4.64e-06 |
| INTRACELLULAR LIPID TRANSPORT | 50 | 5.23e-01 | 9.54e-01 | 0.21800 | 1.11e-01 | 1.35e-01 | 6.43e-02 | 1.12e-01 | -1.67e-02 | 1.75e-01 | 9.86e-02 | 4.31e-01 | 1.70e-01 | 8.38e-01 |
| REGULATION OF SYNAPTIC VESICLE EXOCYTOSIS | 38 | 5.24e-01 | 9.54e-01 | 0.21800 | -9.98e-02 | -9.56e-02 | -6.02e-02 | -1.19e-01 | -1.03e-01 | 2.87e-01 | 3.08e-01 | 5.20e-01 | 2.03e-01 | 2.73e-01 |
| G2 MI TRANSITION OF MEIOTIC CELL CYCLE | 7 | 9.19e-01 | 1.00e+00 | 0.21800 | 9.47e-02 | 4.69e-02 | 1.79e-01 | 4.42e-02 | 4.64e-02 | 6.64e-01 | 8.30e-01 | 4.11e-01 | 8.40e-01 | 8.32e-01 |
| NEGATIVE REGULATION OF FATTY ACID METABOLIC PROCESS | 41 | 7.83e-01 | 1.00e+00 | 0.21800 | 1.17e-01 | 1.14e-01 | 8.87e-02 | 9.34e-02 | -6.40e-02 | 1.94e-01 | 2.06e-01 | 3.26e-01 | 3.01e-01 | 4.79e-01 |
| NEGATIVE REGULATION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 13 | 8.67e-01 | 1.00e+00 | 0.21800 | -1.24e-02 | -2.11e-02 | 3.51e-02 | -1.11e-02 | 2.13e-01 | 9.38e-01 | 8.95e-01 | 8.27e-01 | 9.45e-01 | 1.83e-01 |
| RETINAL PIGMENT EPITHELIUM DEVELOPMENT | 6 | 9.06e-01 | 1.00e+00 | 0.21800 | 1.04e-01 | 1.37e-01 | 1.30e-01 | 2.84e-02 | -9.04e-03 | 6.59e-01 | 5.60e-01 | 5.81e-01 | 9.04e-01 | 9.69e-01 |
| GAMMA AMINOBUTYRIC ACID SIGNALING PATHWAY | 27 | 3.35e-01 | 8.59e-01 | 0.21800 | -6.55e-02 | -6.48e-02 | 4.41e-03 | -1.64e-01 | -1.10e-01 | 5.56e-01 | 5.60e-01 | 9.68e-01 | 1.41e-01 | 3.23e-01 |
| REGULATION OF CELLULAR KETONE METABOLIC PROCESS | 139 | 6.46e-02 | 4.13e-01 | 0.21800 | 1.14e-01 | 1.23e-01 | 1.11e-01 | 7.30e-02 | -4.31e-02 | 2.08e-02 | 1.23e-02 | 2.44e-02 | 1.37e-01 | 3.80e-01 |
| REGULATION OF CARDIAC MUSCLE CELL ACTION POTENTIAL | 28 | 1.25e-01 | 5.91e-01 | 0.21800 | 8.89e-02 | 1.47e-01 | 2.91e-02 | 1.13e-01 | -6.62e-02 | 4.16e-01 | 1.79e-01 | 7.90e-01 | 3.01e-01 | 5.44e-01 |
| NEGATIVE REGULATION OF CHROMOSOME ORGANIZATION | 89 | 1.19e-02 | 1.42e-01 | 0.21800 | 6.28e-02 | 4.28e-02 | 1.62e-01 | 5.18e-03 | 1.24e-01 | 3.06e-01 | 4.86e-01 | 8.27e-03 | 9.33e-01 | 4.34e-02 |
| REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 55 | 5.07e-01 | 9.48e-01 | 0.21800 | -9.41e-02 | -9.02e-02 | -1.13e-01 | -6.15e-02 | -1.17e-01 | 2.27e-01 | 2.47e-01 | 1.46e-01 | 4.30e-01 | 1.33e-01 |
| AMYLOID BETA CLEARANCE | 39 | 4.16e-01 | 9.11e-01 | 0.21800 | -5.44e-02 | -6.93e-02 | -3.85e-03 | -3.71e-02 | 1.95e-01 | 5.56e-01 | 4.54e-01 | 9.67e-01 | 6.89e-01 | 3.47e-02 |
| NEGATIVE REGULATION OF LYMPHOCYTE ACTIVATION | 164 | 2.83e-04 | 8.29e-03 | 0.21800 | -9.20e-02 | -1.24e-01 | 1.57e-02 | -1.22e-01 | 9.14e-02 | 4.21e-02 | 6.11e-03 | 7.29e-01 | 6.98e-03 | 4.34e-02 |
| OVARIAN FOLLICLE DEVELOPMENT | 54 | 8.96e-02 | 4.95e-01 | 0.21800 | -4.73e-02 | -3.69e-02 | -4.89e-02 | -4.96e-02 | -1.97e-01 | 5.48e-01 | 6.39e-01 | 5.35e-01 | 5.29e-01 | 1.22e-02 |
| REGULATION OF NEURON MIGRATION | 45 | 7.42e-01 | 1.00e+00 | 0.21800 | -1.10e-01 | -1.16e-01 | -1.03e-01 | -8.73e-02 | -5.75e-02 | 2.01e-01 | 1.77e-01 | 2.30e-01 | 3.11e-01 | 5.04e-01 |
| FUCOSYLATION | 17 | 8.88e-01 | 1.00e+00 | 0.21700 | 1.19e-01 | 1.18e-01 | 8.89e-02 | 9.13e-02 | 5.34e-02 | 3.94e-01 | 3.99e-01 | 5.26e-01 | 5.15e-01 | 7.03e-01 |
| PHOSPHOLIPID CATABOLIC PROCESS | 55 | 5.06e-01 | 9.48e-01 | 0.21700 | 1.10e-01 | 1.33e-01 | 6.48e-02 | 1.09e-01 | -3.86e-02 | 1.58e-01 | 8.79e-02 | 4.06e-01 | 1.64e-01 | 6.21e-01 |
| ACETYL COA BIOSYNTHETIC PROCESS FROM PYRUVATE | 9 | 5.17e-01 | 9.52e-01 | 0.21700 | 3.77e-02 | 4.32e-02 | 1.41e-01 | -1.44e-01 | -5.80e-02 | 8.45e-01 | 8.22e-01 | 4.64e-01 | 4.55e-01 | 7.63e-01 |
| ACINAR CELL DIFFERENTIATION | 5 | 8.34e-01 | 1.00e+00 | 0.21700 | 5.22e-02 | 6.63e-03 | 8.08e-02 | 2.77e-02 | -1.93e-01 | 8.40e-01 | 9.80e-01 | 7.54e-01 | 9.14e-01 | 4.55e-01 |
| CELL CYCLE CHECKPOINT SIGNALING | 188 | 1.43e-04 | 4.72e-03 | 0.21700 | 9.62e-02 | 8.01e-02 | 1.70e-01 | 7.91e-03 | 5.25e-02 | 2.29e-02 | 5.81e-02 | 6.06e-05 | 8.52e-01 | 2.14e-01 |
| REGULATION OF HELICASE ACTIVITY | 10 | 3.89e-01 | 8.92e-01 | 0.21700 | 9.27e-02 | 7.25e-02 | 1.53e-01 | -9.54e-02 | -2.80e-02 | 6.12e-01 | 6.91e-01 | 4.02e-01 | 6.01e-01 | 8.78e-01 |
| REGULATION OF PRO B CELL DIFFERENTIATION | 8 | 7.71e-01 | 1.00e+00 | 0.21700 | -5.08e-02 | -5.68e-02 | 3.93e-02 | -1.85e-01 | 7.50e-02 | 8.03e-01 | 7.81e-01 | 8.47e-01 | 3.65e-01 | 7.13e-01 |
| NOTCH SIGNALING PATHWAY | 175 | 4.07e-02 | 3.24e-01 | 0.21700 | 1.13e-01 | 1.25e-01 | 9.65e-02 | 8.58e-02 | -4.62e-02 | 9.97e-03 | 4.37e-03 | 2.76e-02 | 5.01e-02 | 2.92e-01 |
| GLANDULAR EPITHELIAL CELL DIFFERENTIATION | 72 | 2.22e-01 | 7.45e-01 | 0.21700 | 1.09e-01 | 1.13e-01 | 1.13e-01 | 5.07e-02 | -8.40e-02 | 1.09e-01 | 9.75e-02 | 9.71e-02 | 4.57e-01 | 2.18e-01 |
| REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 122 | 8.19e-02 | 4.71e-01 | 0.21700 | -1.15e-01 | -1.33e-01 | -5.15e-02 | -1.12e-01 | 3.36e-02 | 2.86e-02 | 1.12e-02 | 3.26e-01 | 3.31e-02 | 5.22e-01 |
| REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 72 | 1.66e-01 | 6.70e-01 | 0.21700 | 1.09e-01 | 1.03e-01 | 1.49e-01 | 4.32e-02 | -2.28e-02 | 1.10e-01 | 1.31e-01 | 2.87e-02 | 5.26e-01 | 7.38e-01 |
| RESPONSE TO RETINOIC ACID | 105 | 6.42e-02 | 4.13e-01 | 0.21700 | 1.10e-01 | 9.36e-02 | 1.58e-01 | 3.41e-02 | 1.67e-02 | 5.23e-02 | 9.73e-02 | 5.24e-03 | 5.46e-01 | 7.67e-01 |
| MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION | 35 | 3.39e-01 | 8.59e-01 | 0.21700 | 1.02e-01 | 1.20e-01 | 1.16e-01 | 3.61e-02 | -8.75e-02 | 2.98e-01 | 2.21e-01 | 2.35e-01 | 7.12e-01 | 3.70e-01 |
| RADIAL GLIAL CELL DIFFERENTIATION | 14 | 4.13e-01 | 9.10e-01 | 0.21700 | -4.99e-02 | -9.37e-02 | 2.59e-02 | -1.58e-01 | -1.00e-01 | 7.46e-01 | 5.44e-01 | 8.67e-01 | 3.05e-01 | 5.17e-01 |
| NUCLEAR TRANSCRIBED MRNA POLY A TAIL SHORTENING | 34 | 7.65e-01 | 1.00e+00 | 0.21700 | -1.16e-01 | -9.99e-02 | -8.71e-02 | -1.21e-01 | 3.94e-02 | 2.43e-01 | 3.14e-01 | 3.79e-01 | 2.24e-01 | 6.91e-01 |
| REGULATION OF AMYLOID FIBRIL FORMATION | 16 | 6.85e-01 | 1.00e+00 | 0.21700 | 7.37e-02 | 9.25e-02 | 3.98e-02 | -3.54e-03 | -1.77e-01 | 6.10e-01 | 5.22e-01 | 7.83e-01 | 9.80e-01 | 2.20e-01 |
| NEGATIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 110 | 8.20e-04 | 1.93e-02 | 0.21700 | 9.47e-02 | 7.64e-02 | 1.78e-01 | -1.99e-02 | 1.15e-02 | 8.60e-02 | 1.66e-01 | 1.26e-03 | 7.19e-01 | 8.35e-01 |
| TRNA CATABOLIC PROCESS | 16 | 8.14e-01 | 1.00e+00 | 0.21700 | -8.92e-02 | -9.92e-02 | -3.74e-03 | -1.71e-01 | 7.97e-04 | 5.37e-01 | 4.92e-01 | 9.79e-01 | 2.37e-01 | 9.96e-01 |
| MITOTIC SPINDLE ELONGATION | 11 | 1.67e-01 | 6.71e-01 | 0.21700 | -2.27e-03 | -2.41e-02 | 1.14e-01 | 6.75e-02 | 1.70e-01 | 9.90e-01 | 8.90e-01 | 5.13e-01 | 6.98e-01 | 3.29e-01 |
| TRIGLYCERIDE BIOSYNTHETIC PROCESS | 40 | 4.50e-01 | 9.30e-01 | 0.21700 | 9.76e-02 | 1.08e-01 | 2.24e-02 | 1.53e-01 | 4.36e-02 | 2.86e-01 | 2.37e-01 | 8.06e-01 | 9.43e-02 | 6.33e-01 |
| ENERGY DERIVATION BY OXIDATION OF ORGANIC COMPOUNDS | 305 | 2.43e-05 | 1.02e-03 | 0.21700 | 1.12e-01 | 1.05e-01 | 1.48e-01 | 3.41e-02 | 1.62e-02 | 7.43e-04 | 1.62e-03 | 8.66e-06 | 3.05e-01 | 6.28e-01 |
| NEGATIVE REGULATION OF NUCLEAR DIVISION | 63 | 4.85e-02 | 3.59e-01 | 0.21600 | 9.31e-02 | 6.63e-02 | 1.82e-01 | 4.30e-03 | 2.34e-02 | 2.01e-01 | 3.63e-01 | 1.23e-02 | 9.53e-01 | 7.48e-01 |
| POSITIVE REGULATION OF COMPLEMENT ACTIVATION | 7 | 9.24e-01 | 1.00e+00 | 0.21600 | 1.64e-02 | -2.50e-02 | 5.50e-02 | 5.09e-02 | 2.01e-01 | 9.40e-01 | 9.09e-01 | 8.01e-01 | 8.16e-01 | 3.58e-01 |
| ENAMEL MINERALIZATION | 19 | 3.33e-01 | 8.57e-01 | 0.21600 | -7.47e-02 | -5.53e-02 | -1.81e-01 | 7.23e-02 | 1.63e-02 | 5.73e-01 | 6.76e-01 | 1.72e-01 | 5.85e-01 | 9.02e-01 |
| POSITIVE REGULATION OF SECONDARY METABOLITE BIOSYNTHETIC PROCESS | 9 | 7.43e-01 | 1.00e+00 | 0.21600 | -8.09e-02 | -1.09e-01 | -4.43e-02 | 2.48e-02 | 1.61e-01 | 6.74e-01 | 5.71e-01 | 8.18e-01 | 8.97e-01 | 4.04e-01 |
| NEGATIVE REGULATION OF RECEPTOR BINDING | 12 | 6.75e-01 | 1.00e+00 | 0.21600 | 5.77e-02 | 7.83e-03 | 1.87e-01 | -2.67e-02 | 8.80e-02 | 7.29e-01 | 9.63e-01 | 2.62e-01 | 8.73e-01 | 5.97e-01 |
| MONOCARBOXYLIC ACID CATABOLIC PROCESS | 128 | 1.60e-01 | 6.59e-01 | 0.21600 | 1.07e-01 | 1.18e-01 | 7.53e-02 | 1.24e-01 | 1.15e-02 | 3.63e-02 | 2.06e-02 | 1.41e-01 | 1.53e-02 | 8.23e-01 |
| NEGATIVE REGULATION OF OXIDATIVE STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 33 | 1.09e-01 | 5.46e-01 | 0.21600 | -2.87e-02 | -2.96e-02 | 2.97e-02 | -1.49e-01 | -1.48e-01 | 7.75e-01 | 7.69e-01 | 7.68e-01 | 1.38e-01 | 1.41e-01 |
| POSITIVE REGULATION OF SKELETAL MUSCLE TISSUE DEVELOPMENT | 19 | 1.75e-01 | 6.80e-01 | 0.21600 | -3.49e-03 | -4.01e-02 | 7.19e-02 | -7.31e-02 | -1.86e-01 | 9.79e-01 | 7.62e-01 | 5.87e-01 | 5.81e-01 | 1.61e-01 |
| POSITIVE REGULATION OF CELL PROLIFERATION IN BONE MARROW | 6 | 4.50e-01 | 9.30e-01 | 0.21600 | 3.36e-02 | -8.77e-03 | -9.67e-02 | 1.87e-01 | 3.52e-02 | 8.87e-01 | 9.70e-01 | 6.82e-01 | 4.28e-01 | 8.81e-01 |
| PROTEIN K48 LINKED UBIQUITINATION | 64 | 5.10e-01 | 9.50e-01 | 0.21600 | -1.16e-01 | -1.05e-01 | -8.47e-02 | -1.18e-01 | -3.24e-02 | 1.08e-01 | 1.47e-01 | 2.41e-01 | 1.02e-01 | 6.54e-01 |
| POSITIVE REGULATION OF CAMP MEDIATED SIGNALING | 15 | 2.91e-01 | 8.18e-01 | 0.21600 | 5.46e-02 | 1.29e-01 | -8.77e-02 | 8.44e-02 | -1.10e-01 | 7.14e-01 | 3.87e-01 | 5.56e-01 | 5.71e-01 | 4.59e-01 |
| REGULATION OF APPETITE | 19 | 5.37e-01 | 9.57e-01 | 0.21600 | -9.97e-02 | -6.40e-02 | -1.74e-01 | -2.91e-02 | 3.92e-02 | 4.52e-01 | 6.29e-01 | 1.90e-01 | 8.26e-01 | 7.67e-01 |
| CONNECTIVE TISSUE REPLACEMENT | 20 | 6.99e-01 | 1.00e+00 | 0.21600 | -7.14e-02 | -9.88e-02 | 3.42e-02 | -8.53e-02 | 1.53e-01 | 5.80e-01 | 4.44e-01 | 7.91e-01 | 5.09e-01 | 2.38e-01 |
| HEPARIN METABOLIC PROCESS | 17 | 5.93e-01 | 9.86e-01 | 0.21600 | 8.06e-02 | 1.14e-01 | -5.40e-02 | 1.39e-01 | -6.93e-02 | 5.65e-01 | 4.15e-01 | 7.00e-01 | 3.21e-01 | 6.21e-01 |
| DEMETHYLATION | 51 | 4.32e-01 | 9.19e-01 | 0.21600 | -1.18e-01 | -9.59e-02 | -9.45e-02 | -1.10e-01 | 4.89e-02 | 1.46e-01 | 2.36e-01 | 2.43e-01 | 1.73e-01 | 5.45e-01 |
| PERK MEDIATED UNFOLDED PROTEIN RESPONSE | 18 | 6.53e-01 | 1.00e+00 | 0.21600 | 1.13e-01 | 1.32e-01 | 1.17e-01 | 3.01e-02 | 4.38e-02 | 4.07e-01 | 3.34e-01 | 3.91e-01 | 8.25e-01 | 7.48e-01 |
| ALPHA BETA T CELL DIFFERENTIATION | 119 | 1.98e-04 | 6.16e-03 | 0.21500 | -8.28e-02 | -1.09e-01 | 4.62e-02 | -1.53e-01 | 4.47e-02 | 1.19e-01 | 3.97e-02 | 3.84e-01 | 3.84e-03 | 3.99e-01 |
| SULFUR AMINO ACID METABOLIC PROCESS | 32 | 3.01e-01 | 8.29e-01 | 0.21500 | 4.99e-02 | 9.34e-02 | -1.82e-02 | 6.37e-02 | -1.76e-01 | 6.25e-01 | 3.61e-01 | 8.58e-01 | 5.33e-01 | 8.57e-02 |
| NEGATIVE REGULATION OF ACTIVIN RECEPTOR SIGNALING PATHWAY | 14 | 5.66e-01 | 9.72e-01 | 0.21500 | -5.84e-02 | -6.93e-04 | -1.33e-01 | 8.40e-03 | -1.58e-01 | 7.05e-01 | 9.96e-01 | 3.87e-01 | 9.57e-01 | 3.05e-01 |
| REGULATION OF MRNA 3 END PROCESSING | 12 | 7.74e-01 | 1.00e+00 | 0.21500 | -8.95e-02 | -1.41e-01 | 1.15e-02 | -1.03e-01 | 8.77e-02 | 5.91e-01 | 3.98e-01 | 9.45e-01 | 5.35e-01 | 5.99e-01 |
| CD8 POSITIVE ALPHA BETA T CELL ACTIVATION | 29 | 9.35e-01 | 1.00e+00 | 0.21500 | -1.10e-01 | -1.08e-01 | -8.82e-02 | -1.20e-01 | -1.93e-02 | 3.04e-01 | 3.15e-01 | 4.11e-01 | 2.63e-01 | 8.57e-01 |
| POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 51 | 5.83e-01 | 9.85e-01 | 0.21500 | -1.09e-01 | -1.08e-01 | -4.66e-02 | -1.27e-01 | 6.56e-02 | 1.79e-01 | 1.81e-01 | 5.65e-01 | 1.15e-01 | 4.18e-01 |
| INTERLEUKIN 33 MEDIATED SIGNALING PATHWAY | 7 | 8.72e-01 | 1.00e+00 | 0.21500 | 1.08e-01 | 1.48e-01 | 1.67e-02 | 1.07e-01 | 3.10e-02 | 6.22e-01 | 4.97e-01 | 9.39e-01 | 6.24e-01 | 8.87e-01 |
| MAMMARY GLAND EPITHELIAL CELL DIFFERENTIATION | 17 | 7.50e-01 | 1.00e+00 | 0.21500 | 1.13e-01 | 1.08e-01 | 1.38e-01 | 8.02e-03 | -5.11e-02 | 4.22e-01 | 4.39e-01 | 3.24e-01 | 9.54e-01 | 7.16e-01 |
| OTIC VESICLE MORPHOGENESIS | 10 | 8.99e-01 | 1.00e+00 | 0.21500 | -3.24e-02 | -3.28e-02 | -3.05e-02 | -6.05e-02 | -1.99e-01 | 8.59e-01 | 8.58e-01 | 8.67e-01 | 7.40e-01 | 2.77e-01 |
| POSITIVE REGULATION OF FILOPODIUM ASSEMBLY | 28 | 8.28e-01 | 1.00e+00 | 0.21500 | -1.04e-01 | -1.10e-01 | -1.20e-01 | -6.79e-02 | -6.57e-02 | 3.43e-01 | 3.12e-01 | 2.74e-01 | 5.34e-01 | 5.48e-01 |
| REGULATION OF RECEPTOR BINDING | 17 | 8.57e-01 | 1.00e+00 | 0.21500 | 9.78e-02 | 6.28e-02 | 1.61e-01 | 4.31e-02 | 6.99e-02 | 4.85e-01 | 6.54e-01 | 2.51e-01 | 7.58e-01 | 6.18e-01 |
| BEHAVIORAL RESPONSE TO COCAINE | 14 | 7.71e-01 | 1.00e+00 | 0.21500 | 7.67e-02 | 4.91e-02 | 1.03e-01 | 1.26e-01 | 1.05e-01 | 6.19e-01 | 7.50e-01 | 5.03e-01 | 4.13e-01 | 4.95e-01 |
| INORGANIC ION IMPORT ACROSS PLASMA MEMBRANE | 132 | 1.80e-02 | 1.94e-01 | 0.21500 | 8.17e-02 | 9.85e-02 | 9.89e-03 | 1.20e-01 | -1.23e-01 | 1.05e-01 | 5.06e-02 | 8.44e-01 | 1.69e-02 | 1.49e-02 |
| MATERNAL PROCESS INVOLVED IN FEMALE PREGNANCY | 54 | 2.08e-01 | 7.29e-01 | 0.21400 | 5.57e-02 | 2.93e-02 | 1.45e-01 | 1.57e-02 | 1.45e-01 | 4.79e-01 | 7.09e-01 | 6.62e-02 | 8.42e-01 | 6.60e-02 |
| NEGATIVE REGULATION OF AMYLOID FIBRIL FORMATION | 12 | 7.50e-01 | 1.00e+00 | 0.21400 | 1.13e-01 | 1.33e-01 | 7.71e-02 | 2.17e-02 | -9.53e-02 | 4.97e-01 | 4.26e-01 | 6.44e-01 | 8.96e-01 | 5.68e-01 |
| MESENCHYMAL STEM CELL MAINTENANCE INVOLVED IN NEPHRON MORPHOGENESIS | 6 | 8.06e-01 | 1.00e+00 | 0.21400 | 8.27e-02 | 3.94e-02 | 1.57e-01 | 3.92e-02 | -1.06e-01 | 7.26e-01 | 8.67e-01 | 5.05e-01 | 8.68e-01 | 6.52e-01 |
| NEGATIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 29 | 8.37e-02 | 4.77e-01 | 0.21400 | 1.13e-02 | -8.73e-03 | 1.61e-01 | -1.21e-01 | 7.14e-02 | 9.16e-01 | 9.35e-01 | 1.33e-01 | 2.60e-01 | 5.06e-01 |
| POSITIVE REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 12 | 9.45e-01 | 1.00e+00 | 0.21400 | 1.16e-01 | 1.06e-01 | 8.51e-02 | 8.01e-02 | -8.67e-02 | 4.85e-01 | 5.26e-01 | 6.10e-01 | 6.31e-01 | 6.03e-01 |
| REGULATION OF MYOBLAST PROLIFERATION | 25 | 3.99e-01 | 8.99e-01 | 0.21400 | -2.19e-02 | 1.49e-02 | -1.48e-01 | 7.02e-02 | -1.35e-01 | 8.50e-01 | 8.97e-01 | 2.00e-01 | 5.44e-01 | 2.42e-01 |
| REGULATION OF TUBE SIZE | 142 | 1.83e-03 | 3.69e-02 | 0.21400 | 4.03e-02 | 5.39e-02 | -1.38e-02 | 5.44e-02 | -1.95e-01 | 4.07e-01 | 2.67e-01 | 7.76e-01 | 2.64e-01 | 5.84e-05 |
| DEFENSE RESPONSE TO GRAM POSITIVE BACTERIUM | 112 | 1.77e-03 | 3.59e-02 | 0.21400 | -1.11e-01 | -1.25e-01 | -5.05e-02 | -5.47e-02 | 1.10e-01 | 4.15e-02 | 2.20e-02 | 3.56e-01 | 3.18e-01 | 4.39e-02 |
| REGULATION OF MYELINATION | 45 | 2.98e-01 | 8.25e-01 | 0.21400 | -5.70e-02 | -6.25e-02 | 3.73e-03 | -4.53e-02 | 1.91e-01 | 5.08e-01 | 4.68e-01 | 9.65e-01 | 5.99e-01 | 2.64e-02 |
| RESPONSE TO LEUKEMIA INHIBITORY FACTOR | 101 | 3.22e-01 | 8.47e-01 | 0.21400 | 1.15e-01 | 1.11e-01 | 1.24e-01 | 6.59e-02 | 2.37e-02 | 4.56e-02 | 5.40e-02 | 3.18e-02 | 2.52e-01 | 6.80e-01 |
| PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 221 | 2.48e-07 | 1.90e-05 | 0.21400 | -5.91e-02 | -9.64e-02 | 6.21e-02 | -1.30e-01 | 1.10e-01 | 1.30e-01 | 1.35e-02 | 1.11e-01 | 8.30e-04 | 4.88e-03 |
| EXTRAEMBRYONIC MEMBRANE DEVELOPMENT | 13 | 9.66e-01 | 1.00e+00 | 0.21400 | -1.15e-01 | -1.00e-01 | -7.99e-02 | -1.26e-01 | 6.94e-03 | 4.72e-01 | 5.32e-01 | 6.18e-01 | 4.30e-01 | 9.65e-01 |
| NEGATIVE REGULATION OF CHROMATIN ORGANIZATION | 5 | 9.86e-01 | 1.00e+00 | 0.21400 | 9.89e-02 | 8.55e-02 | 1.06e-01 | 5.88e-02 | -1.18e-01 | 7.02e-01 | 7.40e-01 | 6.81e-01 | 8.20e-01 | 6.48e-01 |
| DE NOVO CENTRIOLE ASSEMBLY | 6 | 9.49e-01 | 1.00e+00 | 0.21400 | -9.28e-02 | -9.73e-02 | 1.80e-02 | -1.64e-01 | 1.78e-02 | 6.94e-01 | 6.80e-01 | 9.39e-01 | 4.86e-01 | 9.40e-01 |
| EMBRYONIC FORELIMB MORPHOGENESIS | 33 | 1.36e-03 | 2.92e-02 | 0.21400 | 6.80e-02 | -1.14e-02 | 1.88e-01 | -3.27e-02 | -6.72e-02 | 4.99e-01 | 9.09e-01 | 6.18e-02 | 7.45e-01 | 5.04e-01 |
| REGULATION OF PROTEIN SUMOYLATION | 21 | 4.35e-01 | 9.22e-01 | 0.21400 | -1.61e-02 | -2.50e-03 | 5.16e-02 | -5.24e-02 | 2.00e-01 | 8.98e-01 | 9.84e-01 | 6.82e-01 | 6.78e-01 | 1.13e-01 |
| PROSTATE GLANDULAR ACINUS MORPHOGENESIS | 6 | 8.99e-01 | 1.00e+00 | 0.21400 | 4.60e-02 | 8.48e-02 | 3.34e-02 | -3.24e-02 | -1.85e-01 | 8.45e-01 | 7.19e-01 | 8.87e-01 | 8.91e-01 | 4.33e-01 |
| CELLULAR RESPONSE TO CADMIUM ION | 35 | 3.06e-01 | 8.35e-01 | 0.21300 | 1.12e-01 | 9.78e-02 | 1.52e-01 | -1.09e-04 | -1.58e-02 | 2.52e-01 | 3.17e-01 | 1.19e-01 | 9.99e-01 | 8.72e-01 |
| CD8 POSITIVE ALPHA BETA T CELL PROLIFERATION | 9 | 9.12e-01 | 1.00e+00 | 0.21300 | -7.67e-02 | -5.75e-02 | -3.84e-02 | -1.40e-01 | -1.23e-01 | 6.90e-01 | 7.65e-01 | 8.42e-01 | 4.66e-01 | 5.22e-01 |
| ANGIOTENSIN ACTIVATED SIGNALING PATHWAY | 18 | 6.33e-02 | 4.12e-01 | 0.21300 | 4.07e-02 | -9.26e-03 | 1.66e-01 | 6.70e-02 | 1.08e-01 | 7.65e-01 | 9.46e-01 | 2.22e-01 | 6.22e-01 | 4.29e-01 |
| CALCIUM IMPORT INTO THE MITOCHONDRION | 12 | 8.60e-01 | 1.00e+00 | 0.21300 | -1.27e-01 | -1.21e-01 | -6.84e-02 | -9.41e-02 | 3.35e-02 | 4.46e-01 | 4.67e-01 | 6.81e-01 | 5.73e-01 | 8.41e-01 |
| POSITIVE REGULATION OF TRANSLATIONAL INITIATION | 24 | 6.70e-01 | 1.00e+00 | 0.21300 | 1.03e-01 | 8.50e-02 | 5.30e-02 | 1.55e-01 | -2.81e-02 | 3.80e-01 | 4.71e-01 | 6.53e-01 | 1.90e-01 | 8.12e-01 |
| POSITIVE REGULATION OF EXCITATORY POSTSYNAPTIC POTENTIAL | 31 | 6.93e-01 | 1.00e+00 | 0.21300 | 9.07e-02 | 1.09e-01 | 4.93e-02 | 9.27e-02 | -1.19e-01 | 3.82e-01 | 2.92e-01 | 6.35e-01 | 3.72e-01 | 2.50e-01 |
| CALCIUM ION TRANSMEMBRANE TRANSPORT VIA HIGH VOLTAGE GATED CALCIUM CHANNEL | 18 | 9.65e-01 | 1.00e+00 | 0.21300 | 1.14e-01 | 1.16e-01 | 8.98e-02 | 9.77e-02 | 3.95e-02 | 4.04e-01 | 3.96e-01 | 5.09e-01 | 4.73e-01 | 7.72e-01 |
| LIGAND GATED ION CHANNEL SIGNALING PATHWAY | 31 | 8.32e-01 | 1.00e+00 | 0.21300 | -9.08e-02 | -7.93e-02 | -1.30e-01 | -5.34e-02 | -1.05e-01 | 3.81e-01 | 4.45e-01 | 2.10e-01 | 6.07e-01 | 3.11e-01 |
| NEGATIVE REGULATION OF GLUCOCORTICOID METABOLIC PROCESS | 5 | 7.92e-01 | 1.00e+00 | 0.21300 | 6.81e-02 | 8.29e-02 | 1.51e-01 | -8.91e-03 | -1.04e-01 | 7.92e-01 | 7.48e-01 | 5.58e-01 | 9.72e-01 | 6.87e-01 |
| CONVERGENT EXTENSION INVOLVED IN GASTRULATION | 9 | 8.99e-01 | 1.00e+00 | 0.21300 | 8.93e-02 | 7.01e-02 | 1.71e-01 | 3.89e-02 | 3.89e-02 | 6.43e-01 | 7.16e-01 | 3.73e-01 | 8.40e-01 | 8.40e-01 |
| REGULATION OF INOSITOL PHOSPHATE BIOSYNTHETIC PROCESS | 17 | 1.67e-01 | 6.71e-01 | 0.21300 | 2.53e-02 | 4.71e-02 | 1.15e-02 | 8.00e-02 | -1.89e-01 | 8.57e-01 | 7.37e-01 | 9.35e-01 | 5.68e-01 | 1.76e-01 |
| APOPTOTIC CELL CLEARANCE | 47 | 6.49e-01 | 1.00e+00 | 0.21300 | 1.06e-01 | 9.37e-02 | 1.19e-01 | 1.04e-01 | 1.42e-02 | 2.08e-01 | 2.67e-01 | 1.59e-01 | 2.15e-01 | 8.66e-01 |
| CELLULAR RESPONSE TO TOPOLOGICALLY INCORRECT PROTEIN | 106 | 3.30e-02 | 2.87e-01 | 0.21300 | 1.02e-01 | 9.17e-02 | 1.57e-01 | 1.48e-02 | 4.17e-02 | 6.98e-02 | 1.03e-01 | 5.36e-03 | 7.92e-01 | 4.58e-01 |
| PURINE NUCLEOSIDE TRANSMEMBRANE TRANSPORT | 5 | 3.68e-01 | 8.79e-01 | 0.21300 | -5.80e-02 | 2.96e-02 | -6.75e-02 | 3.55e-02 | 1.88e-01 | 8.22e-01 | 9.09e-01 | 7.94e-01 | 8.91e-01 | 4.68e-01 |
| LABYRINTHINE LAYER MORPHOGENESIS | 22 | 1.49e-01 | 6.37e-01 | 0.21300 | -4.29e-02 | -1.19e-02 | -5.95e-02 | 6.07e-02 | 1.90e-01 | 7.27e-01 | 9.23e-01 | 6.29e-01 | 6.22e-01 | 1.23e-01 |
| RESPONSE TO PROSTAGLANDIN | 31 | 5.83e-01 | 9.85e-01 | 0.21300 | -1.15e-01 | -8.23e-02 | -1.18e-01 | -8.75e-02 | -5.98e-02 | 2.68e-01 | 4.28e-01 | 2.54e-01 | 3.99e-01 | 5.65e-01 |
| HARD PALATE DEVELOPMENT | 8 | 7.38e-01 | 1.00e+00 | 0.21300 | -4.73e-02 | -4.90e-02 | 7.20e-02 | -1.78e-01 | -5.97e-02 | 8.17e-01 | 8.10e-01 | 7.24e-01 | 3.82e-01 | 7.70e-01 |
| RESPONSE TO CORTISOL | 6 | 8.45e-01 | 1.00e+00 | 0.21300 | -9.44e-02 | -1.53e-01 | -3.87e-02 | -9.34e-02 | -5.23e-02 | 6.89e-01 | 5.17e-01 | 8.70e-01 | 6.92e-01 | 8.25e-01 |
| FORMATION OF CYTOPLASMIC TRANSLATION INITIATION COMPLEX | 14 | 5.80e-01 | 9.83e-01 | 0.21300 | -4.05e-02 | -4.68e-02 | 4.17e-02 | -1.59e-01 | -1.20e-01 | 7.93e-01 | 7.62e-01 | 7.87e-01 | 3.03e-01 | 4.39e-01 |
| IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 315 | 5.07e-06 | 2.58e-04 | 0.21200 | -1.05e-01 | -1.33e-01 | -3.23e-02 | -1.24e-01 | 1.62e-02 | 1.40e-03 | 5.11e-05 | 3.24e-01 | 1.61e-04 | 6.20e-01 |
| RESPONSE TO TUMOR CELL | 42 | 9.01e-02 | 4.95e-01 | 0.21200 | -9.90e-02 | -9.31e-02 | 1.17e-02 | -1.51e-01 | 6.20e-02 | 2.67e-01 | 2.96e-01 | 8.96e-01 | 9.12e-02 | 4.87e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CELL PROLIFERATION | 84 | 3.84e-01 | 8.92e-01 | 0.21200 | 1.20e-01 | 1.20e-01 | 8.90e-02 | 9.08e-02 | -1.42e-02 | 5.69e-02 | 5.80e-02 | 1.58e-01 | 1.50e-01 | 8.22e-01 |
| POSITIVE REGULATION OF P38MAPK CASCADE | 31 | 7.30e-02 | 4.45e-01 | 0.21200 | -3.30e-02 | -4.90e-02 | 1.15e-01 | -1.61e-01 | 5.00e-02 | 7.51e-01 | 6.37e-01 | 2.66e-01 | 1.22e-01 | 6.30e-01 |
| REGULATION OF RRNA PROCESSING | 16 | 4.11e-01 | 9.08e-01 | 0.21200 | 4.43e-02 | 1.08e-03 | 1.66e-01 | -9.82e-02 | 7.65e-02 | 7.59e-01 | 9.94e-01 | 2.50e-01 | 4.96e-01 | 5.96e-01 |
| VIRAL RNA GENOME REPLICATION | 29 | 2.56e-01 | 7.83e-01 | 0.21200 | -4.03e-02 | -5.97e-02 | 9.27e-02 | -9.26e-02 | 1.51e-01 | 7.07e-01 | 5.78e-01 | 3.88e-01 | 3.88e-01 | 1.60e-01 |
| NEGATIVE REGULATION OF MACROPHAGE DERIVED FOAM CELL DIFFERENTIATION | 14 | 9.24e-01 | 1.00e+00 | 0.21200 | -1.19e-01 | -1.31e-01 | -6.30e-02 | -8.84e-02 | 4.53e-02 | 4.42e-01 | 3.97e-01 | 6.83e-01 | 5.67e-01 | 7.69e-01 |
| GLYCOPROTEIN CATABOLIC PROCESS | 33 | 7.50e-01 | 1.00e+00 | 0.21200 | 9.39e-02 | 7.13e-02 | 1.40e-01 | 7.22e-02 | 7.95e-02 | 3.51e-01 | 4.79e-01 | 1.64e-01 | 4.73e-01 | 4.29e-01 |
| NEGATIVE REGULATION OF ALPHA BETA T CELL PROLIFERATION | 13 | 7.46e-01 | 1.00e+00 | 0.21200 | -1.03e-01 | -8.02e-02 | -2.78e-02 | -1.40e-01 | 8.71e-02 | 5.21e-01 | 6.17e-01 | 8.62e-01 | 3.82e-01 | 5.87e-01 |
| REGULATION OF ADENYLATE CYCLASE ACTIVITY | 44 | 8.72e-01 | 1.00e+00 | 0.21200 | -1.09e-01 | -9.93e-02 | -1.09e-01 | -9.84e-02 | -4.06e-02 | 2.13e-01 | 2.54e-01 | 2.10e-01 | 2.59e-01 | 6.41e-01 |
| REGULATION OF RESPONSE TO TYPE II INTERFERON | 14 | 5.84e-01 | 9.85e-01 | 0.21200 | -5.56e-03 | -1.09e-02 | 9.49e-02 | -1.24e-01 | 1.43e-01 | 9.71e-01 | 9.43e-01 | 5.39e-01 | 4.23e-01 | 3.54e-01 |
| REGULATION OF PROTEIN TYROSINE KINASE ACTIVITY | 54 | 3.96e-01 | 8.96e-01 | 0.21200 | 9.67e-02 | 1.10e-01 | 5.07e-02 | 1.21e-01 | 7.88e-02 | 2.19e-01 | 1.64e-01 | 5.19e-01 | 1.23e-01 | 3.16e-01 |
| REGULATION OF ACROSOME REACTION | 17 | 6.59e-01 | 1.00e+00 | 0.21200 | 8.88e-02 | 7.98e-02 | -3.27e-03 | 1.72e-01 | -3.21e-02 | 5.26e-01 | 5.69e-01 | 9.81e-01 | 2.20e-01 | 8.19e-01 |
| POSITIVE REGULATION OF OSSIFICATION | 52 | 7.58e-02 | 4.52e-01 | 0.21100 | -3.17e-02 | -3.29e-02 | -5.43e-02 | -2.09e-03 | -1.99e-01 | 6.93e-01 | 6.81e-01 | 4.98e-01 | 9.79e-01 | 1.29e-02 |
| REGULATION OF AUTOPHAGY OF MITOCHONDRION IN RESPONSE TO MITOCHONDRIAL DEPOLARIZATION | 13 | 3.17e-01 | 8.45e-01 | 0.21100 | -5.26e-02 | -2.83e-02 | 5.92e-02 | -1.94e-01 | -8.42e-03 | 7.43e-01 | 8.60e-01 | 7.12e-01 | 2.26e-01 | 9.58e-01 |
| XENOPHAGY | 14 | 8.23e-01 | 1.00e+00 | 0.21100 | -9.66e-02 | -7.42e-02 | -8.00e-02 | -7.45e-02 | 1.34e-01 | 5.31e-01 | 6.31e-01 | 6.04e-01 | 6.29e-01 | 3.86e-01 |
| DELAMINATION | 7 | 5.49e-01 | 9.63e-01 | 0.21100 | 2.49e-02 | -5.75e-02 | 1.61e-01 | 2.58e-02 | 1.20e-01 | 9.09e-01 | 7.92e-01 | 4.62e-01 | 9.06e-01 | 5.84e-01 |
| DENSE CORE GRANULE LOCALIZATION | 10 | 6.03e-01 | 9.90e-01 | 0.21100 | -6.31e-02 | -4.46e-02 | -1.20e-02 | -1.96e-01 | -1.29e-02 | 7.30e-01 | 8.07e-01 | 9.48e-01 | 2.84e-01 | 9.44e-01 |
| HYDROGEN PEROXIDE METABOLIC PROCESS | 49 | 9.18e-02 | 5.01e-01 | 0.21100 | 8.60e-02 | 1.19e-01 | 7.14e-02 | 2.69e-02 | -1.31e-01 | 2.98e-01 | 1.49e-01 | 3.87e-01 | 7.44e-01 | 1.12e-01 |
| LYSOSOMAL MICROAUTOPHAGY | 13 | 9.70e-01 | 1.00e+00 | 0.21100 | -1.00e-01 | -9.07e-02 | -1.34e-01 | -7.49e-02 | -5.14e-02 | 5.31e-01 | 5.71e-01 | 4.02e-01 | 6.40e-01 | 7.48e-01 |
| B CELL LINEAGE COMMITMENT | 6 | 6.52e-01 | 1.00e+00 | 0.21100 | -2.32e-02 | -1.09e-01 | 1.24e-01 | -1.19e-01 | 4.81e-02 | 9.22e-01 | 6.43e-01 | 5.98e-01 | 6.12e-01 | 8.38e-01 |
| REGULATION OF CELLULAR RESPONSE TO HEAT | 16 | 7.07e-01 | 1.00e+00 | 0.21100 | -2.43e-02 | -1.90e-02 | 4.16e-02 | -3.02e-02 | 2.02e-01 | 8.66e-01 | 8.95e-01 | 7.73e-01 | 8.34e-01 | 1.61e-01 |
| POSITIVE REGULATION OF STEROL TRANSPORT | 38 | 5.36e-01 | 9.56e-01 | 0.21100 | 9.55e-02 | 1.18e-01 | 4.82e-02 | 1.37e-01 | 2.27e-02 | 3.08e-01 | 2.10e-01 | 6.07e-01 | 1.44e-01 | 8.09e-01 |
| PRIMITIVE HEMOPOIESIS | 8 | 8.64e-01 | 1.00e+00 | 0.21100 | 8.65e-02 | 6.67e-02 | 1.77e-01 | -7.02e-03 | -3.57e-02 | 6.72e-01 | 7.44e-01 | 3.87e-01 | 9.73e-01 | 8.61e-01 |
| REGULATION OF BONE REMODELING | 49 | 5.37e-01 | 9.57e-01 | 0.21100 | -1.14e-01 | -1.23e-01 | -4.75e-02 | -1.07e-01 | 5.22e-02 | 1.69e-01 | 1.37e-01 | 5.65e-01 | 1.94e-01 | 5.27e-01 |
| ANDROGEN RECEPTOR SIGNALING PATHWAY | 45 | 3.02e-01 | 8.30e-01 | 0.21100 | 6.13e-02 | 5.95e-02 | 1.70e-02 | 6.02e-02 | -1.82e-01 | 4.77e-01 | 4.90e-01 | 8.44e-01 | 4.84e-01 | 3.43e-02 |
| REGULATION OF ENDODEOXYRIBONUCLEASE ACTIVITY | 8 | 7.90e-01 | 1.00e+00 | 0.21100 | -5.06e-02 | -1.12e-01 | 8.25e-02 | -1.26e-01 | 8.19e-02 | 8.04e-01 | 5.83e-01 | 6.86e-01 | 5.38e-01 | 6.88e-01 |
| MITOCHONDRIAL RNA PROCESSING | 20 | 5.18e-02 | 3.73e-01 | 0.21100 | 1.95e-02 | -3.13e-03 | 1.60e-01 | -8.81e-02 | -1.04e-01 | 8.80e-01 | 9.81e-01 | 2.16e-01 | 4.95e-01 | 4.21e-01 |
| STEROL HOMEOSTASIS | 99 | 3.54e-01 | 8.72e-01 | 0.21100 | 1.10e-01 | 1.22e-01 | 5.58e-02 | 1.14e-01 | -3.85e-02 | 5.85e-02 | 3.67e-02 | 3.37e-01 | 5.02e-02 | 5.08e-01 |
| MALE MEIOSIS I | 27 | 7.96e-01 | 1.00e+00 | 0.21100 | 9.20e-02 | 7.81e-02 | 1.37e-01 | 3.00e-02 | 1.00e-01 | 4.08e-01 | 4.82e-01 | 2.17e-01 | 7.88e-01 | 3.67e-01 |
| AMINO ACID BETAINE METABOLIC PROCESS | 16 | 6.32e-01 | 9.96e-01 | 0.21100 | 5.63e-02 | 7.16e-02 | -4.07e-02 | 1.66e-01 | -8.30e-02 | 6.97e-01 | 6.20e-01 | 7.78e-01 | 2.51e-01 | 5.65e-01 |
| CAMERA TYPE EYE PHOTORECEPTOR CELL DIFFERENTIATION | 29 | 6.41e-01 | 1.00e+00 | 0.21100 | 9.13e-02 | 1.18e-01 | -3.92e-03 | 1.08e-01 | -1.03e-01 | 3.95e-01 | 2.73e-01 | 9.71e-01 | 3.15e-01 | 3.38e-01 |
| REGULATION OF LEUKOCYTE MIGRATION | 218 | 2.15e-02 | 2.17e-01 | 0.21100 | -1.17e-01 | -1.25e-01 | -8.55e-02 | -8.68e-02 | 1.49e-02 | 2.95e-03 | 1.47e-03 | 2.96e-02 | 2.72e-02 | 7.05e-01 |
| MACROPHAGE CYTOKINE PRODUCTION | 36 | 1.06e-01 | 5.39e-01 | 0.21100 | -3.46e-02 | -8.11e-02 | 1.11e-01 | -1.11e-01 | 1.10e-01 | 7.19e-01 | 4.00e-01 | 2.51e-01 | 2.49e-01 | 2.55e-01 |
| POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 113 | 1.26e-01 | 5.91e-01 | 0.21000 | 1.13e-01 | 1.15e-01 | 1.26e-01 | 5.01e-02 | 6.20e-03 | 3.80e-02 | 3.49e-02 | 2.11e-02 | 3.57e-01 | 9.09e-01 |
| REGULATION OF RECEPTOR LOCALIZATION TO SYNAPSE | 17 | 6.32e-01 | 9.96e-01 | 0.21000 | -7.54e-02 | -8.94e-02 | 1.90e-02 | -5.49e-02 | 1.65e-01 | 5.90e-01 | 5.23e-01 | 8.92e-01 | 6.95e-01 | 2.39e-01 |
| POSITIVE REGULATION OF MYOBLAST FUSION | 16 | 8.79e-01 | 1.00e+00 | 0.21000 | -9.26e-02 | -9.40e-02 | -1.42e-01 | -3.09e-02 | -7.52e-02 | 5.22e-01 | 5.15e-01 | 3.25e-01 | 8.31e-01 | 6.03e-01 |
| NEGATIVE REGULATION OF MESENCHYMAL CELL APOPTOTIC PROCESS | 10 | 5.23e-01 | 9.54e-01 | 0.21000 | 8.23e-02 | 3.65e-02 | 1.62e-01 | 5.49e-02 | -8.37e-02 | 6.52e-01 | 8.42e-01 | 3.76e-01 | 7.64e-01 | 6.47e-01 |
| DNA TEMPLATED DNA REPLICATION | 158 | 3.08e-04 | 8.82e-03 | 0.21000 | 8.91e-02 | 5.84e-02 | 1.70e-01 | -3.23e-03 | 6.41e-02 | 5.33e-02 | 2.06e-01 | 2.33e-04 | 9.44e-01 | 1.64e-01 |
| PLASMA MEMBRANE RAFT ORGANIZATION | 11 | 9.16e-01 | 1.00e+00 | 0.21000 | 3.04e-02 | 3.06e-02 | 6.00e-02 | 4.32e-02 | 1.92e-01 | 8.61e-01 | 8.61e-01 | 7.30e-01 | 8.04e-01 | 2.70e-01 |
| ADRENERGIC RECEPTOR SIGNALING PATHWAY | 32 | 5.46e-01 | 9.61e-01 | 0.21000 | 7.06e-02 | 6.87e-02 | 3.03e-02 | 7.25e-02 | -1.68e-01 | 4.90e-01 | 5.02e-01 | 7.67e-01 | 4.78e-01 | 9.93e-02 |
| SULFUR AMINO ACID TRANSPORT | 12 | 9.37e-01 | 1.00e+00 | 0.21000 | 8.94e-02 | 9.53e-02 | 3.58e-02 | 1.38e-01 | 8.28e-02 | 5.92e-01 | 5.68e-01 | 8.30e-01 | 4.09e-01 | 6.19e-01 |
| FEMALE MEIOSIS I | 13 | 3.35e-01 | 8.59e-01 | 0.21000 | 4.01e-02 | 3.74e-02 | 1.43e-01 | -1.42e-01 | 2.03e-02 | 8.02e-01 | 8.15e-01 | 3.71e-01 | 3.75e-01 | 8.99e-01 |
| PARAXIAL MESODERM MORPHOGENESIS | 10 | 7.68e-01 | 1.00e+00 | 0.21000 | 5.08e-02 | 2.42e-02 | 4.10e-02 | 3.77e-02 | -1.95e-01 | 7.81e-01 | 8.95e-01 | 8.23e-01 | 8.37e-01 | 2.87e-01 |
| NEGATIVE REGULATION OF TRANSMISSION OF NERVE IMPULSE | 6 | 9.20e-01 | 1.00e+00 | 0.21000 | -2.58e-02 | -6.48e-02 | 6.05e-02 | -1.07e-01 | 1.55e-01 | 9.13e-01 | 7.84e-01 | 7.97e-01 | 6.50e-01 | 5.10e-01 |
| REGULATION OF CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 30 | 4.43e-01 | 9.28e-01 | 0.21000 | 8.09e-03 | 2.80e-02 | -3.64e-02 | -3.60e-02 | -2.02e-01 | 9.39e-01 | 7.91e-01 | 7.30e-01 | 7.33e-01 | 5.59e-02 |
| REGULATION OF BONE DEVELOPMENT | 9 | 9.29e-01 | 1.00e+00 | 0.21000 | 1.15e-01 | 7.73e-02 | 1.21e-01 | 9.58e-02 | -3.21e-02 | 5.49e-01 | 6.88e-01 | 5.30e-01 | 6.19e-01 | 8.68e-01 |
| GLYCINE TRANSPORT | 14 | 9.98e-02 | 5.23e-01 | 0.21000 | 2.98e-03 | 5.43e-02 | 6.90e-02 | -1.55e-01 | -1.11e-01 | 9.85e-01 | 7.25e-01 | 6.55e-01 | 3.15e-01 | 4.71e-01 |
| POSITIVE REGULATION OF CELL CELL ADHESION | 311 | 8.36e-05 | 2.97e-03 | 0.21000 | -1.12e-01 | -1.22e-01 | -4.15e-02 | -1.12e-01 | 4.91e-02 | 6.91e-04 | 2.17e-04 | 2.08e-01 | 6.66e-04 | 1.37e-01 |
| SOMATIC MOTOR NEURON DIFFERENTIATION | 5 | 9.33e-01 | 1.00e+00 | 0.21000 | 2.91e-02 | -1.28e-03 | 1.68e-01 | -4.99e-02 | 1.12e-01 | 9.10e-01 | 9.96e-01 | 5.15e-01 | 8.47e-01 | 6.65e-01 |
| REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL DEDIFFERENTIATION | 5 | 9.76e-01 | 1.00e+00 | 0.21000 | 6.20e-02 | 5.13e-02 | 1.29e-01 | 5.98e-02 | 1.32e-01 | 8.10e-01 | 8.43e-01 | 6.17e-01 | 8.17e-01 | 6.10e-01 |
| DEFENSE RESPONSE TO BACTERIUM | 302 | 2.45e-04 | 7.39e-03 | 0.21000 | -1.09e-01 | -1.25e-01 | -5.25e-02 | -8.83e-02 | 7.79e-02 | 1.11e-03 | 1.93e-04 | 1.17e-01 | 8.29e-03 | 1.98e-02 |
| RRNA METHYLATION | 24 | 8.71e-02 | 4.87e-01 | 0.21000 | 4.65e-02 | 3.48e-02 | 1.68e-01 | -8.63e-02 | -7.14e-02 | 6.93e-01 | 7.68e-01 | 1.55e-01 | 4.64e-01 | 5.45e-01 |
| TRANSCRIPTION INITIATION AT RNA POLYMERASE I PROMOTER | 12 | 8.51e-01 | 1.00e+00 | 0.21000 | 7.23e-02 | 8.87e-02 | 6.88e-02 | 2.84e-02 | -1.59e-01 | 6.65e-01 | 5.95e-01 | 6.80e-01 | 8.65e-01 | 3.39e-01 |
| NEGATIVE REGULATION OF INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 32 | 4.09e-01 | 9.08e-01 | 0.21000 | -1.01e-01 | -1.28e-01 | -1.50e-02 | -1.27e-01 | -3.03e-02 | 3.22e-01 | 2.10e-01 | 8.83e-01 | 2.12e-01 | 7.67e-01 |
| REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 45 | 6.55e-01 | 1.00e+00 | 0.21000 | 1.01e-01 | 1.06e-01 | 5.06e-02 | 1.33e-01 | 4.63e-02 | 2.40e-01 | 2.18e-01 | 5.57e-01 | 1.22e-01 | 5.91e-01 |
| CARBOHYDRATE MEDIATED SIGNALING | 11 | 5.07e-01 | 9.48e-01 | 0.21000 | 2.64e-02 | 7.07e-03 | 1.29e-01 | -1.40e-01 | -8.34e-02 | 8.80e-01 | 9.68e-01 | 4.58e-01 | 4.21e-01 | 6.32e-01 |
| POSITIVE REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 90 | 2.23e-01 | 7.45e-01 | 0.21000 | 1.06e-01 | 1.09e-01 | 1.29e-01 | 6.23e-02 | 8.16e-03 | 8.12e-02 | 7.27e-02 | 3.39e-02 | 3.07e-01 | 8.93e-01 |
| NEGATIVE REGULATION OF CHEMOKINE C C MOTIF LIGAND 5 PRODUCTION | 5 | 9.29e-01 | 1.00e+00 | 0.21000 | 1.06e-02 | -1.49e-02 | 1.48e-01 | -4.58e-02 | 1.40e-01 | 9.67e-01 | 9.54e-01 | 5.66e-01 | 8.59e-01 | 5.88e-01 |
| EMBRYONIC CLEAVAGE | 8 | 7.65e-01 | 1.00e+00 | 0.21000 | 4.03e-02 | 6.00e-02 | 1.22e-01 | -5.79e-02 | 1.43e-01 | 8.44e-01 | 7.69e-01 | 5.49e-01 | 7.77e-01 | 4.85e-01 |
| POSITIVE REGULATION OF PROTEIN DEACETYLATION | 10 | 8.92e-01 | 1.00e+00 | 0.21000 | -6.51e-02 | -5.87e-02 | -1.37e-01 | 2.73e-02 | -1.29e-01 | 7.22e-01 | 7.48e-01 | 4.53e-01 | 8.81e-01 | 4.79e-01 |
| REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 53 | 7.53e-01 | 1.00e+00 | 0.20900 | 1.16e-01 | 1.15e-01 | 9.78e-02 | 8.26e-02 | -2.74e-02 | 1.44e-01 | 1.46e-01 | 2.18e-01 | 2.98e-01 | 7.30e-01 |
| ARGININE METABOLIC PROCESS | 19 | 5.95e-01 | 9.87e-01 | 0.20900 | 1.24e-01 | 1.14e-01 | 6.83e-02 | 7.96e-02 | -6.70e-02 | 3.48e-01 | 3.91e-01 | 6.06e-01 | 5.48e-01 | 6.13e-01 |
| SPINAL CORD DEVELOPMENT | 99 | 1.85e-05 | 8.05e-04 | 0.20900 | 7.14e-02 | 5.02e-02 | 1.63e-01 | -6.96e-02 | -6.92e-02 | 2.19e-01 | 3.88e-01 | 5.06e-03 | 2.31e-01 | 2.34e-01 |
| ADENYLATE CYCLASE ACTIVATING ADRENERGIC RECEPTOR SIGNALING PATHWAY | 26 | 4.82e-01 | 9.43e-01 | 0.20900 | 4.13e-02 | 3.25e-02 | -1.21e-03 | 3.06e-02 | -2.00e-01 | 7.15e-01 | 7.74e-01 | 9.91e-01 | 7.87e-01 | 7.72e-02 |
| CENTRAL NERVOUS SYSTEM MATURATION | 6 | 9.85e-01 | 1.00e+00 | 0.20900 | 9.29e-02 | 9.32e-02 | 2.98e-02 | 1.50e-01 | 5.58e-02 | 6.93e-01 | 6.93e-01 | 8.99e-01 | 5.25e-01 | 8.13e-01 |
| 7 METHYLGUANOSINE CAP HYPERMETHYLATION | 8 | 6.33e-01 | 9.96e-01 | 0.20900 | 4.95e-02 | -8.98e-04 | 1.64e-02 | 1.59e-01 | 1.26e-01 | 8.09e-01 | 9.96e-01 | 9.36e-01 | 4.37e-01 | 5.37e-01 |
| REGULATION OF SYNAPTIC TRANSMISSION GABAERGIC | 35 | 5.81e-01 | 9.85e-01 | 0.20900 | -9.09e-02 | -9.15e-02 | -3.15e-02 | -1.52e-01 | -5.60e-02 | 3.52e-01 | 3.49e-01 | 7.47e-01 | 1.21e-01 | 5.66e-01 |
| IMMUNE EFFECTOR PROCESS | 612 | 1.88e-10 | 3.15e-08 | 0.20900 | -9.81e-02 | -1.21e-01 | -1.59e-02 | -1.27e-01 | 5.44e-02 | 3.36e-05 | 3.05e-07 | 5.01e-01 | 7.22e-08 | 2.15e-02 |
| PRENYLATION | 11 | 6.24e-01 | 9.93e-01 | 0.20900 | 4.28e-02 | 4.49e-02 | -4.61e-02 | 1.77e-01 | -8.00e-02 | 8.06e-01 | 7.97e-01 | 7.91e-01 | 3.09e-01 | 6.46e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CELL SURFACE | 20 | 2.80e-01 | 8.06e-01 | 0.20900 | 1.43e-02 | 1.17e-02 | 1.06e-01 | 2.75e-02 | 1.77e-01 | 9.12e-01 | 9.28e-01 | 4.12e-01 | 8.32e-01 | 1.70e-01 |
| POSITIVE REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 12 | 4.98e-01 | 9.47e-01 | 0.20900 | 9.50e-02 | 1.42e-01 | 1.12e-01 | 8.23e-03 | -4.41e-02 | 5.69e-01 | 3.95e-01 | 5.03e-01 | 9.61e-01 | 7.91e-01 |
| CYTOPLASMIC SEQUESTERING OF NF KAPPAB | 5 | 5.51e-01 | 9.64e-01 | 0.20900 | -3.92e-02 | -5.70e-02 | 1.49e-01 | -7.25e-02 | 1.07e-01 | 8.79e-01 | 8.25e-01 | 5.65e-01 | 7.79e-01 | 6.78e-01 |
| PROTEIN LOCALIZATION TO CILIARY TRANSITION ZONE | 8 | 9.77e-01 | 1.00e+00 | 0.20900 | 9.21e-02 | 9.66e-02 | 4.73e-02 | 1.52e-01 | 2.17e-02 | 6.52e-01 | 6.36e-01 | 8.17e-01 | 4.57e-01 | 9.16e-01 |
| RESPONSE TO PAIN | 34 | 2.60e-01 | 7.89e-01 | 0.20900 | 4.37e-02 | 8.40e-02 | -7.68e-02 | 1.24e-01 | -1.16e-01 | 6.60e-01 | 3.96e-01 | 4.38e-01 | 2.12e-01 | 2.42e-01 |
| CATECHOL CONTAINING COMPOUND CATABOLIC PROCESS | 5 | 8.11e-01 | 1.00e+00 | 0.20900 | 7.66e-02 | 2.91e-02 | 2.56e-02 | 1.59e-01 | -1.04e-01 | 7.67e-01 | 9.10e-01 | 9.21e-01 | 5.38e-01 | 6.86e-01 |
| WOUND HEALING INVOLVED IN INFLAMMATORY RESPONSE | 8 | 5.09e-01 | 9.49e-01 | 0.20900 | -6.01e-02 | -9.05e-02 | 1.08e-01 | -1.39e-01 | -2.78e-02 | 7.69e-01 | 6.58e-01 | 5.97e-01 | 4.96e-01 | 8.92e-01 |
| REGULATION OF CYTOSOLIC CALCIUM ION CONCENTRATION | 57 | 4.40e-01 | 9.26e-01 | 0.20900 | 1.07e-01 | 1.15e-01 | 9.77e-02 | 5.30e-02 | -8.01e-02 | 1.62e-01 | 1.32e-01 | 2.02e-01 | 4.89e-01 | 2.96e-01 |
| NEGATIVE REGULATION OF TELOMERE MAINTENANCE | 32 | 3.33e-01 | 8.57e-01 | 0.20900 | -4.36e-02 | -6.13e-02 | 6.63e-02 | -6.47e-02 | 1.71e-01 | 6.69e-01 | 5.48e-01 | 5.16e-01 | 5.26e-01 | 9.42e-02 |
| POSITIVE REGULATION OF KERATINOCYTE DIFFERENTIATION | 19 | 6.68e-01 | 1.00e+00 | 0.20800 | 7.89e-02 | 1.02e-01 | 3.39e-02 | 1.47e-01 | 6.32e-02 | 5.51e-01 | 4.41e-01 | 7.98e-01 | 2.67e-01 | 6.33e-01 |
| REGULATION OF ACTIN FILAMENT BASED MOVEMENT | 39 | 3.42e-01 | 8.60e-01 | 0.20800 | 9.16e-02 | 1.30e-01 | 3.92e-02 | 8.57e-02 | -9.59e-02 | 3.22e-01 | 1.59e-01 | 6.72e-01 | 3.54e-01 | 3.00e-01 |
| REGULATION OF RYANODINE SENSITIVE CALCIUM RELEASE CHANNEL ACTIVITY | 23 | 7.04e-01 | 1.00e+00 | 0.20800 | -6.13e-02 | -9.48e-02 | 3.66e-02 | -9.52e-02 | 1.42e-01 | 6.11e-01 | 4.31e-01 | 7.61e-01 | 4.29e-01 | 2.38e-01 |
| GLYCOSIDE METABOLIC PROCESS | 20 | 8.32e-01 | 1.00e+00 | 0.20800 | 8.73e-02 | 9.62e-02 | 5.33e-02 | 1.04e-01 | -1.14e-01 | 4.99e-01 | 4.56e-01 | 6.80e-01 | 4.23e-01 | 3.78e-01 |
| NUCLEAR PORE ORGANIZATION | 15 | 8.89e-01 | 1.00e+00 | 0.20800 | -1.14e-01 | -1.16e-01 | -3.90e-02 | -1.22e-01 | 2.19e-02 | 4.45e-01 | 4.36e-01 | 7.94e-01 | 4.13e-01 | 8.83e-01 |
| POSITIVE REGULATION OF EPIDERMIS DEVELOPMENT | 32 | 5.22e-01 | 9.53e-01 | 0.20800 | 8.33e-02 | 1.05e-01 | -6.22e-03 | 1.56e-01 | -2.79e-02 | 4.15e-01 | 3.02e-01 | 9.51e-01 | 1.26e-01 | 7.85e-01 |
| PYRIMIDINE NUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 20 | 8.12e-01 | 1.00e+00 | 0.20800 | 2.92e-02 | 1.63e-02 | 8.72e-02 | 5.05e-03 | 1.86e-01 | 8.21e-01 | 8.99e-01 | 4.99e-01 | 9.69e-01 | 1.50e-01 |
| RESPONSE TO AMINO ACID STARVATION | 53 | 5.55e-01 | 9.67e-01 | 0.20800 | 9.42e-02 | 1.05e-01 | 7.42e-02 | 1.13e-01 | 7.16e-02 | 2.36e-01 | 1.86e-01 | 3.50e-01 | 1.55e-01 | 3.67e-01 |
| AORTIC VALVE MORPHOGENESIS | 38 | 3.08e-01 | 8.35e-01 | 0.20800 | 9.37e-02 | 5.68e-02 | 1.72e-01 | 1.05e-02 | 3.78e-02 | 3.17e-01 | 5.44e-01 | 6.58e-02 | 9.11e-01 | 6.87e-01 |
| REGULATION OF ARACHIDONIC ACID SECRETION | 7 | 9.01e-01 | 1.00e+00 | 0.20800 | -3.94e-02 | -3.37e-02 | 4.14e-03 | -1.48e-01 | -1.37e-01 | 8.57e-01 | 8.77e-01 | 9.85e-01 | 4.99e-01 | 5.30e-01 |
| BILE ACID METABOLIC PROCESS | 49 | 3.60e-01 | 8.76e-01 | 0.20800 | -1.05e-01 | -7.25e-02 | -1.56e-01 | -4.17e-02 | -2.89e-02 | 2.04e-01 | 3.80e-01 | 5.84e-02 | 6.13e-01 | 7.26e-01 |
| REGULATION OF HEPATOCYTE APOPTOTIC PROCESS | 10 | 9.28e-01 | 1.00e+00 | 0.20800 | 3.92e-02 | 4.44e-02 | 5.61e-02 | 5.23e-02 | 1.84e-01 | 8.30e-01 | 8.08e-01 | 7.59e-01 | 7.75e-01 | 3.14e-01 |
| PROGRAMMED CELL DEATH INVOLVED IN CELL DEVELOPMENT | 24 | 6.18e-01 | 9.90e-01 | 0.20800 | 2.77e-02 | 3.95e-02 | -3.17e-02 | 6.46e-02 | -1.89e-01 | 8.14e-01 | 7.38e-01 | 7.88e-01 | 5.84e-01 | 1.09e-01 |
| REGULATION OF CATECHOLAMINE METABOLIC PROCESS | 18 | 7.26e-01 | 1.00e+00 | 0.20800 | 9.55e-02 | 6.55e-02 | 1.45e-01 | 9.00e-02 | 2.66e-02 | 4.83e-01 | 6.31e-01 | 2.87e-01 | 5.09e-01 | 8.45e-01 |
| POSITIVE REGULATION OF PHOSPHATASE ACTIVITY | 27 | 5.28e-01 | 9.54e-01 | 0.20800 | -9.80e-02 | -1.40e-01 | -3.47e-02 | -1.07e-01 | 3.81e-02 | 3.78e-01 | 2.09e-01 | 7.55e-01 | 3.37e-01 | 7.32e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY NOREPINEPHRINE EPINEPHRINE | 8 | 8.74e-01 | 1.00e+00 | 0.20800 | 1.13e-02 | 3.52e-02 | -4.36e-02 | -5.11e-02 | -1.93e-01 | 9.56e-01 | 8.63e-01 | 8.31e-01 | 8.02e-01 | 3.44e-01 |
| MRNA EXPORT FROM NUCLEUS | 62 | 1.36e-01 | 6.14e-01 | 0.20800 | 8.32e-02 | 4.55e-02 | 1.34e-01 | 3.03e-02 | 1.23e-01 | 2.57e-01 | 5.36e-01 | 6.77e-02 | 6.79e-01 | 9.26e-02 |
| CELL JUNCTION MAINTENANCE | 45 | 5.00e-01 | 9.47e-01 | 0.20800 | 9.41e-02 | 9.44e-02 | 1.39e-01 | 4.37e-02 | 6.35e-02 | 2.75e-01 | 2.73e-01 | 1.06e-01 | 6.12e-01 | 4.61e-01 |
| EMBRYONIC PLACENTA MORPHOGENESIS | 27 | 2.72e-01 | 7.99e-01 | 0.20800 | 5.82e-03 | 1.59e-02 | 2.67e-02 | 6.80e-02 | 1.94e-01 | 9.58e-01 | 8.87e-01 | 8.10e-01 | 5.41e-01 | 8.17e-02 |
| CALCIUM ION REGULATED EXOCYTOSIS OF NEUROTRANSMITTER | 21 | 8.40e-01 | 1.00e+00 | 0.20700 | 9.76e-02 | 1.12e-01 | 7.82e-02 | 4.87e-02 | -1.12e-01 | 4.39e-01 | 3.75e-01 | 5.35e-01 | 6.99e-01 | 3.74e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL APOPTOTIC PROCESS | 23 | 7.31e-01 | 1.00e+00 | 0.20700 | -7.08e-02 | -4.66e-02 | -6.87e-02 | -1.12e-01 | -1.37e-01 | 5.57e-01 | 6.99e-01 | 5.69e-01 | 3.53e-01 | 2.57e-01 |
| 3 PHOSPHOADENOSINE 5 PHOSPHOSULFATE METABOLIC PROCESS | 15 | 8.60e-01 | 1.00e+00 | 0.20700 | -6.35e-02 | -6.61e-02 | -5.90e-02 | -6.53e-02 | -1.64e-01 | 6.70e-01 | 6.58e-01 | 6.93e-01 | 6.61e-01 | 2.71e-01 |
| TRNA METHYLATION | 40 | 2.20e-01 | 7.43e-01 | 0.20700 | -6.48e-02 | -8.81e-02 | 5.41e-02 | -1.53e-01 | 6.96e-02 | 4.78e-01 | 3.35e-01 | 5.54e-01 | 9.47e-02 | 4.46e-01 |
| NEGATIVE REGULATION OF SODIUM ION TRANSPORT | 17 | 5.82e-01 | 9.85e-01 | 0.20700 | 7.41e-02 | 6.04e-02 | -1.31e-02 | 1.56e-01 | -9.64e-02 | 5.97e-01 | 6.67e-01 | 9.26e-01 | 2.65e-01 | 4.91e-01 |
| IP 10 PRODUCTION | 5 | 8.60e-01 | 1.00e+00 | 0.20700 | -8.45e-02 | -3.19e-02 | -6.33e-02 | -1.71e-01 | -3.86e-02 | 7.44e-01 | 9.02e-01 | 8.06e-01 | 5.07e-01 | 8.81e-01 |
| POLYADENYLATION DEPENDENT SNORNA 3 END PROCESSING | 8 | 9.56e-01 | 1.00e+00 | 0.20700 | -1.30e-02 | -3.98e-02 | 3.64e-02 | 2.69e-04 | 2.00e-01 | 9.49e-01 | 8.45e-01 | 8.58e-01 | 9.99e-01 | 3.28e-01 |
| WATER TRANSPORT | 28 | 8.99e-01 | 1.00e+00 | 0.20700 | 1.12e-01 | 1.18e-01 | 7.14e-02 | 9.09e-02 | -5.56e-02 | 3.03e-01 | 2.81e-01 | 5.13e-01 | 4.05e-01 | 6.10e-01 |
| CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 72 | 1.28e-01 | 5.95e-01 | 0.20700 | 1.08e-01 | 1.19e-01 | 8.87e-02 | 3.67e-02 | -8.91e-02 | 1.14e-01 | 8.04e-02 | 1.93e-01 | 5.90e-01 | 1.91e-01 |
| ALANINE TRANSPORT | 16 | 5.06e-01 | 9.48e-01 | 0.20700 | 8.35e-02 | 1.21e-01 | -9.72e-03 | 3.55e-02 | -1.41e-01 | 5.63e-01 | 4.02e-01 | 9.46e-01 | 8.06e-01 | 3.28e-01 |
| POSITIVE CHEMOTAXIS | 63 | 3.66e-01 | 8.79e-01 | 0.20700 | -1.03e-01 | -1.24e-01 | -3.23e-02 | -1.25e-01 | 9.49e-03 | 1.57e-01 | 8.86e-02 | 6.57e-01 | 8.49e-02 | 8.96e-01 |
| LUNG GROWTH | 6 | 3.89e-01 | 8.92e-01 | 0.20700 | 2.61e-02 | -5.81e-02 | 1.47e-01 | -1.54e-02 | -1.30e-01 | 9.12e-01 | 8.05e-01 | 5.33e-01 | 9.48e-01 | 5.80e-01 |
| CHONDROITIN SULFATE METABOLIC PROCESS | 26 | 8.19e-01 | 1.00e+00 | 0.20700 | -7.29e-02 | -6.64e-02 | -8.65e-02 | -6.39e-02 | -1.47e-01 | 5.20e-01 | 5.58e-01 | 4.45e-01 | 5.73e-01 | 1.95e-01 |
| NEPHRON TUBULE EPITHELIAL CELL DIFFERENTIATION | 13 | 5.43e-01 | 9.60e-01 | 0.20700 | -1.02e-01 | -1.57e-01 | -2.49e-02 | -8.39e-02 | -7.16e-03 | 5.25e-01 | 3.25e-01 | 8.77e-01 | 6.01e-01 | 9.64e-01 |
| NEGATIVE REGULATION OF HORMONE BIOSYNTHETIC PROCESS | 10 | 8.79e-01 | 1.00e+00 | 0.20700 | -9.89e-02 | -9.45e-02 | -4.35e-03 | -1.19e-01 | 9.96e-02 | 5.88e-01 | 6.05e-01 | 9.81e-01 | 5.14e-01 | 5.85e-01 |
| REGULATION OF ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 64 | 6.15e-02 | 4.07e-01 | 0.20700 | -3.98e-02 | -7.40e-02 | 8.01e-02 | -1.02e-01 | 1.37e-01 | 5.81e-01 | 3.06e-01 | 2.67e-01 | 1.57e-01 | 5.73e-02 |
| GDP METABOLIC PROCESS | 9 | 7.00e-01 | 1.00e+00 | 0.20700 | 3.26e-02 | 8.52e-02 | -4.43e-02 | 1.05e-01 | -1.47e-01 | 8.66e-01 | 6.58e-01 | 8.18e-01 | 5.85e-01 | 4.46e-01 |
| DENDRITE ARBORIZATION | 10 | 9.69e-01 | 1.00e+00 | 0.20700 | -6.67e-02 | -5.94e-02 | -9.16e-02 | -4.82e-02 | -1.55e-01 | 7.15e-01 | 7.45e-01 | 6.16e-01 | 7.92e-01 | 3.95e-01 |
| RESPONSE TO TEMPERATURE STIMULUS | 165 | 1.14e-02 | 1.38e-01 | 0.20700 | 1.04e-01 | 1.23e-01 | 9.63e-02 | 8.52e-02 | -1.87e-02 | 2.07e-02 | 6.56e-03 | 3.27e-02 | 5.89e-02 | 6.78e-01 |
| ADENOSINE TO INOSINE EDITING | 7 | 9.70e-01 | 1.00e+00 | 0.20700 | -7.48e-02 | -7.60e-02 | -6.44e-02 | -2.89e-02 | 1.63e-01 | 7.32e-01 | 7.28e-01 | 7.68e-01 | 8.95e-01 | 4.56e-01 |
| NEGATIVE REGULATION OF PROTEIN DEPHOSPHORYLATION | 28 | 8.14e-01 | 1.00e+00 | 0.20700 | 8.94e-02 | 6.03e-02 | 1.24e-01 | 6.70e-02 | 1.07e-01 | 4.13e-01 | 5.81e-01 | 2.57e-01 | 5.40e-01 | 3.29e-01 |
| FIBROBLAST MIGRATION | 52 | 6.46e-01 | 1.00e+00 | 0.20700 | 1.03e-01 | 1.03e-01 | 1.00e-01 | 1.08e-01 | 1.39e-03 | 2.00e-01 | 2.00e-01 | 2.12e-01 | 1.78e-01 | 9.86e-01 |
| POSITIVE REGULATION OF FATTY ACID METABOLIC PROCESS | 38 | 2.65e-01 | 7.93e-01 | 0.20700 | 8.44e-02 | 7.20e-02 | 1.71e-01 | 7.74e-04 | 3.76e-02 | 3.68e-01 | 4.43e-01 | 6.89e-02 | 9.93e-01 | 6.88e-01 |
| POSITIVE REGULATION OF MESENCHYMAL CELL PROLIFERATION | 25 | 2.79e-01 | 8.05e-01 | 0.20700 | -3.33e-02 | -3.30e-02 | 2.39e-02 | -1.02e-01 | -1.72e-01 | 7.73e-01 | 7.75e-01 | 8.36e-01 | 3.76e-01 | 1.37e-01 |
| CLATHRIN DEPENDENT ENDOCYTOSIS | 47 | 5.52e-01 | 9.65e-01 | 0.20700 | -1.10e-01 | -9.08e-02 | -1.13e-01 | -7.90e-02 | 5.80e-02 | 1.92e-01 | 2.81e-01 | 1.80e-01 | 3.49e-01 | 4.91e-01 |
| VESICLE CARGO LOADING | 29 | 7.30e-01 | 1.00e+00 | 0.20700 | -9.45e-02 | -1.19e-01 | -2.95e-02 | -1.34e-01 | 2.48e-02 | 3.78e-01 | 2.65e-01 | 7.84e-01 | 2.11e-01 | 8.17e-01 |
| HYDROGEN PEROXIDE CATABOLIC PROCESS | 30 | 4.19e-01 | 9.11e-01 | 0.20700 | 8.39e-02 | 1.02e-01 | 9.13e-02 | 1.97e-02 | -1.29e-01 | 4.26e-01 | 3.34e-01 | 3.87e-01 | 8.52e-01 | 2.23e-01 |
| RNA SURVEILLANCE | 17 | 8.27e-01 | 1.00e+00 | 0.20600 | 7.26e-02 | 3.56e-02 | 1.35e-01 | 1.97e-02 | 1.33e-01 | 6.04e-01 | 7.99e-01 | 3.37e-01 | 8.88e-01 | 3.44e-01 |
| POSITIVE REGULATION OF MAST CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 13 | 5.52e-01 | 9.65e-01 | 0.20600 | 9.31e-02 | 2.79e-02 | 1.40e-01 | 5.23e-02 | 1.04e-01 | 5.61e-01 | 8.62e-01 | 3.81e-01 | 7.44e-01 | 5.18e-01 |
| NOTCH SIGNALING INVOLVED IN HEART DEVELOPMENT | 11 | 8.21e-01 | 1.00e+00 | 0.20600 | 1.07e-01 | 8.58e-02 | 1.47e-01 | -9.10e-03 | -4.69e-02 | 5.41e-01 | 6.22e-01 | 3.99e-01 | 9.58e-01 | 7.88e-01 |
| MICROVILLUS ASSEMBLY | 20 | 5.87e-01 | 9.85e-01 | 0.20600 | -1.10e-01 | -9.24e-02 | -1.40e-01 | -1.66e-04 | 4.66e-02 | 3.93e-01 | 4.74e-01 | 2.77e-01 | 9.99e-01 | 7.18e-01 |
| MITOCHONDRIAL RNA METABOLIC PROCESS | 51 | 1.83e-02 | 1.97e-01 | 0.20600 | 7.63e-02 | 6.43e-02 | 1.60e-01 | -2.27e-02 | -8.14e-02 | 3.46e-01 | 4.27e-01 | 4.87e-02 | 7.79e-01 | 3.15e-01 |
| AMINO ACID ACTIVATION | 43 | 2.94e-01 | 8.22e-01 | 0.20600 | -7.29e-02 | -8.37e-02 | 2.74e-02 | -1.49e-01 | 8.51e-02 | 4.08e-01 | 3.42e-01 | 7.56e-01 | 9.08e-02 | 3.35e-01 |
| NERVE DEVELOPMENT | 94 | 2.10e-01 | 7.33e-01 | 0.20600 | 1.15e-01 | 1.12e-01 | 9.13e-02 | 7.04e-02 | -5.89e-02 | 5.32e-02 | 6.14e-02 | 1.26e-01 | 2.38e-01 | 3.24e-01 |
| HISTONE MRNA METABOLIC PROCESS | 24 | 1.29e-01 | 5.97e-01 | 0.20600 | -2.07e-03 | -4.65e-02 | 1.55e-01 | -1.23e-01 | 3.50e-02 | 9.86e-01 | 6.93e-01 | 1.90e-01 | 2.95e-01 | 7.66e-01 |
| PHOSPHOLIPASE C ACTIVATING DOPAMINE RECEPTOR SIGNALING PATHWAY | 9 | 6.51e-01 | 1.00e+00 | 0.20600 | 3.86e-02 | 6.83e-02 | 8.19e-02 | -4.69e-02 | 1.66e-01 | 8.41e-01 | 7.23e-01 | 6.70e-01 | 8.08e-01 | 3.89e-01 |
| REGULATION OF THE FORCE OF HEART CONTRACTION BY CHEMICAL SIGNAL | 6 | 9.88e-01 | 1.00e+00 | 0.20600 | 8.98e-02 | 9.76e-02 | 8.80e-02 | 1.15e-01 | 6.29e-02 | 7.03e-01 | 6.79e-01 | 7.09e-01 | 6.26e-01 | 7.90e-01 |
| SYNCYTIUM FORMATION | 65 | 4.44e-01 | 9.28e-01 | 0.20600 | -1.04e-01 | -8.49e-02 | -1.44e-01 | -4.50e-02 | -4.17e-02 | 1.47e-01 | 2.36e-01 | 4.50e-02 | 5.31e-01 | 5.61e-01 |
| RESPONSE TO ALDOSTERONE | 16 | 6.54e-01 | 1.00e+00 | 0.20600 | 4.73e-02 | 6.89e-02 | 1.27e-03 | 1.20e-01 | 1.45e-01 | 7.43e-01 | 6.33e-01 | 9.93e-01 | 4.06e-01 | 3.15e-01 |
| REGULATION OF BILE ACID BIOSYNTHETIC PROCESS | 12 | 9.13e-01 | 1.00e+00 | 0.20600 | 1.10e-01 | 1.39e-01 | 6.69e-02 | 6.92e-02 | -4.22e-02 | 5.09e-01 | 4.05e-01 | 6.88e-01 | 6.78e-01 | 8.00e-01 |
| ESTABLISHMENT OF EPITHELIAL CELL APICAL BASAL POLARITY | 17 | 9.65e-01 | 1.00e+00 | 0.20600 | 1.05e-01 | 1.19e-01 | 5.11e-02 | 1.07e-01 | -5.62e-02 | 4.55e-01 | 3.94e-01 | 7.15e-01 | 4.46e-01 | 6.88e-01 |
| RESPONSE TO MINERALOCORTICOID | 33 | 7.34e-01 | 1.00e+00 | 0.20600 | 1.08e-01 | 1.28e-01 | 8.98e-02 | 7.45e-02 | -2.60e-02 | 2.84e-01 | 2.02e-01 | 3.72e-01 | 4.59e-01 | 7.96e-01 |
| RNA TEMPLATED DNA BIOSYNTHETIC PROCESS | 68 | 1.32e-01 | 6.02e-01 | 0.20600 | -3.60e-02 | -4.93e-02 | 4.62e-02 | -5.81e-02 | 1.82e-01 | 6.08e-01 | 4.82e-01 | 5.10e-01 | 4.08e-01 | 9.43e-03 |
| REGULATION OF MAST CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 28 | 1.28e-01 | 5.93e-01 | 0.20600 | -2.86e-02 | -8.28e-02 | 1.13e-01 | -1.34e-01 | 6.28e-02 | 7.93e-01 | 4.48e-01 | 2.99e-01 | 2.21e-01 | 5.65e-01 |
| AMYLOID BETA METABOLIC PROCESS | 64 | 6.07e-01 | 9.90e-01 | 0.20600 | 1.07e-01 | 9.01e-02 | 1.21e-01 | 8.96e-02 | 1.10e-02 | 1.39e-01 | 2.12e-01 | 9.47e-02 | 2.15e-01 | 8.79e-01 |
| WALKING BEHAVIOR | 35 | 6.94e-01 | 1.00e+00 | 0.20600 | -9.78e-02 | -1.11e-01 | -1.73e-02 | -1.38e-01 | 3.06e-02 | 3.17e-01 | 2.55e-01 | 8.59e-01 | 1.57e-01 | 7.54e-01 |
| RELAXATION OF CARDIAC MUSCLE | 17 | 8.40e-01 | 1.00e+00 | 0.20600 | -7.22e-02 | -5.29e-02 | -5.96e-02 | -1.02e-01 | -1.42e-01 | 6.06e-01 | 7.05e-01 | 6.71e-01 | 4.65e-01 | 3.10e-01 |
| EMBRYONIC ORGAN MORPHOGENESIS | 292 | 1.07e-05 | 4.99e-04 | 0.20600 | 1.07e-01 | 9.29e-02 | 1.41e-01 | 2.89e-02 | -3.79e-02 | 1.67e-03 | 6.30e-03 | 3.31e-05 | 3.95e-01 | 2.65e-01 |
| MOTOR NEURON AXON GUIDANCE | 23 | 4.92e-01 | 9.45e-01 | 0.20600 | -2.27e-03 | 3.60e-02 | -5.10e-02 | 1.40e-02 | -1.95e-01 | 9.85e-01 | 7.65e-01 | 6.72e-01 | 9.08e-01 | 1.05e-01 |
| REGULATION OF CELL PROLIFERATION IN BONE MARROW | 8 | 6.66e-01 | 1.00e+00 | 0.20600 | 7.21e-02 | 4.57e-02 | -3.92e-02 | 1.81e-01 | -2.78e-02 | 7.24e-01 | 8.23e-01 | 8.48e-01 | 3.76e-01 | 8.92e-01 |
| COMMON MYELOID PROGENITOR CELL PROLIFERATION | 9 | 7.56e-01 | 1.00e+00 | 0.20500 | 2.68e-02 | -9.95e-03 | 1.72e-01 | -5.14e-02 | 9.64e-02 | 8.89e-01 | 9.59e-01 | 3.73e-01 | 7.89e-01 | 6.16e-01 |
| POSITIVE REGULATION OF CELL SUBSTRATE JUNCTION ORGANIZATION | 31 | 8.37e-01 | 1.00e+00 | 0.20500 | 1.03e-01 | 1.10e-01 | 6.02e-02 | 1.15e-01 | 5.00e-02 | 3.19e-01 | 2.88e-01 | 5.62e-01 | 2.67e-01 | 6.30e-01 |
| MORPHOGENESIS OF AN ENDOTHELIUM | 17 | 8.82e-01 | 1.00e+00 | 0.20500 | 8.68e-02 | 9.18e-02 | 3.84e-02 | 5.76e-02 | -1.46e-01 | 5.36e-01 | 5.12e-01 | 7.84e-01 | 6.81e-01 | 2.96e-01 |
| INNER MITOCHONDRIAL MEMBRANE ORGANIZATION | 36 | 1.60e-01 | 6.59e-01 | 0.20500 | 9.39e-02 | 6.34e-02 | 1.69e-01 | -3.05e-02 | 5.18e-03 | 3.30e-01 | 5.10e-01 | 8.01e-02 | 7.52e-01 | 9.57e-01 |
| CANONICAL WNT SIGNALING PATHWAY INVOLVED IN REGULATION OF CELL PROLIFERATION | 6 | 6.70e-01 | 1.00e+00 | 0.20500 | 8.05e-02 | 8.66e-03 | 1.64e-01 | 9.30e-02 | 8.86e-03 | 7.33e-01 | 9.71e-01 | 4.87e-01 | 6.93e-01 | 9.70e-01 |
| MEMBRANE RAFT ORGANIZATION | 26 | 4.79e-01 | 9.42e-01 | 0.20500 | 6.44e-03 | 6.78e-03 | 1.24e-02 | 2.06e-02 | 2.04e-01 | 9.55e-01 | 9.52e-01 | 9.13e-01 | 8.56e-01 | 7.22e-02 |
| PROTEIN TRANSPORT TO VACUOLE INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS VIA THE MULTIVESICULAR BODY SORTING PATHWAY | 15 | 9.20e-01 | 1.00e+00 | 0.20500 | 1.03e-01 | 9.19e-02 | 1.49e-01 | 2.44e-02 | 2.04e-02 | 4.91e-01 | 5.38e-01 | 3.18e-01 | 8.70e-01 | 8.91e-01 |
| REGULATION OF MUSCLE HYPERTROPHY | 69 | 3.59e-01 | 8.75e-01 | 0.20500 | 1.02e-01 | 8.64e-02 | 9.76e-02 | 1.22e-01 | 4.88e-03 | 1.45e-01 | 2.14e-01 | 1.61e-01 | 8.08e-02 | 9.44e-01 |
| MEMORY | 120 | 1.49e-01 | 6.38e-01 | 0.20500 | 9.79e-02 | 1.04e-01 | 7.05e-02 | 7.87e-02 | -1.03e-01 | 6.39e-02 | 4.89e-02 | 1.82e-01 | 1.37e-01 | 5.24e-02 |
| RESPIRATORY SYSTEM DEVELOPMENT | 207 | 2.80e-02 | 2.58e-01 | 0.20500 | 1.05e-01 | 1.05e-01 | 1.12e-01 | 8.62e-02 | -1.14e-02 | 9.41e-03 | 9.38e-03 | 5.40e-03 | 3.24e-02 | 7.77e-01 |
| REGULATION OF AMYLOID BETA CLEARANCE | 20 | 7.09e-01 | 1.00e+00 | 0.20500 | 2.71e-03 | -1.03e-02 | 2.72e-02 | 8.49e-03 | 2.03e-01 | 9.83e-01 | 9.37e-01 | 8.33e-01 | 9.48e-01 | 1.17e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 8 PRODUCTION | 32 | 3.88e-01 | 8.92e-01 | 0.20500 | -6.89e-02 | -3.93e-02 | -8.59e-02 | -1.23e-01 | -1.15e-01 | 5.00e-01 | 7.00e-01 | 4.00e-01 | 2.30e-01 | 2.59e-01 |
| KERATINOCYTE MIGRATION | 20 | 5.82e-01 | 9.85e-01 | 0.20500 | -1.24e-01 | -1.19e-01 | -1.02e-01 | -4.51e-02 | 6.04e-03 | 3.36e-01 | 3.58e-01 | 4.29e-01 | 7.27e-01 | 9.63e-01 |
| POSITIVE REGULATION OF MAST CELL ACTIVATION | 18 | 1.43e-01 | 6.29e-01 | 0.20500 | 2.03e-02 | -5.92e-02 | 1.02e-01 | -2.68e-02 | 1.64e-01 | 8.81e-01 | 6.64e-01 | 4.53e-01 | 8.44e-01 | 2.28e-01 |
| NUCLEAR ENVELOPE ORGANIZATION | 52 | 3.09e-01 | 8.35e-01 | 0.20500 | 5.45e-02 | 4.96e-02 | 1.16e-01 | 9.77e-03 | 1.52e-01 | 4.97e-01 | 5.36e-01 | 1.49e-01 | 9.03e-01 | 5.78e-02 |
| HETEROPHILIC CELL CELL ADHESION VIA PLASMA MEMBRANE CELL ADHESION MOLECULES | 51 | 4.65e-01 | 9.35e-01 | 0.20500 | -1.01e-01 | -8.59e-02 | -1.50e-01 | -2.71e-02 | -3.36e-02 | 2.11e-01 | 2.88e-01 | 6.40e-02 | 7.38e-01 | 6.78e-01 |
| CELLULAR RESPONSE TO UNFOLDED PROTEIN | 88 | 7.68e-02 | 4.54e-01 | 0.20500 | 1.03e-01 | 1.03e-01 | 1.43e-01 | 1.92e-02 | 5.27e-03 | 9.50e-02 | 9.48e-02 | 2.07e-02 | 7.55e-01 | 9.32e-01 |
| INTEGRIN ACTIVATION | 26 | 7.53e-01 | 1.00e+00 | 0.20500 | -1.03e-01 | -1.26e-01 | -8.85e-02 | -6.51e-02 | 5.73e-02 | 3.61e-01 | 2.66e-01 | 4.35e-01 | 5.66e-01 | 6.13e-01 |
| CELLULAR EXTRAVASATION | 71 | 1.38e-01 | 6.20e-01 | 0.20500 | -1.08e-01 | -1.31e-01 | -4.82e-02 | -7.19e-02 | 7.57e-02 | 1.16e-01 | 5.67e-02 | 4.83e-01 | 2.95e-01 | 2.70e-01 |
| IMMUNOGLOBULIN PRODUCTION | 104 | 4.53e-05 | 1.79e-03 | 0.20500 | 1.46e-02 | -3.38e-02 | 1.50e-01 | -9.48e-02 | 9.56e-02 | 7.98e-01 | 5.51e-01 | 8.26e-03 | 9.50e-02 | 9.19e-02 |
| REGULATION OF RIG I SIGNALING PATHWAY | 20 | 7.85e-01 | 1.00e+00 | 0.20500 | -8.08e-02 | -1.00e-01 | 1.96e-02 | -1.44e-01 | 6.58e-02 | 5.31e-01 | 4.38e-01 | 8.79e-01 | 2.66e-01 | 6.11e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO VACUOLE | 63 | 4.99e-01 | 9.47e-01 | 0.20500 | -9.82e-02 | -1.07e-01 | -3.02e-02 | -1.33e-01 | 4.65e-02 | 1.78e-01 | 1.41e-01 | 6.79e-01 | 6.74e-02 | 5.23e-01 |
| REGULATION OF THYMOCYTE APOPTOTIC PROCESS | 14 | 9.50e-01 | 1.00e+00 | 0.20500 | 9.82e-02 | 9.93e-02 | 3.79e-02 | 1.43e-01 | 2.30e-02 | 5.25e-01 | 5.20e-01 | 8.06e-01 | 3.54e-01 | 8.82e-01 |
| CELL SURFACE PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 70 | 1.89e-01 | 6.97e-01 | 0.20500 | -8.67e-02 | -1.06e-01 | -2.31e-02 | -1.40e-01 | 5.51e-02 | 2.10e-01 | 1.24e-01 | 7.39e-01 | 4.34e-02 | 4.26e-01 |
| CITRATE TRANSPORT | 5 | 9.58e-01 | 1.00e+00 | 0.20500 | 2.54e-02 | 4.17e-03 | 7.06e-02 | -3.20e-02 | 1.88e-01 | 9.22e-01 | 9.87e-01 | 7.85e-01 | 9.01e-01 | 4.67e-01 |
| POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE ACTIVITY | 16 | 8.82e-01 | 1.00e+00 | 0.20500 | 7.67e-02 | 8.29e-02 | -3.04e-03 | 9.48e-02 | -1.42e-01 | 5.95e-01 | 5.66e-01 | 9.83e-01 | 5.12e-01 | 3.26e-01 |
| CELLULAR RESPONSE TO THYROID HORMONE STIMULUS | 16 | 7.11e-01 | 1.00e+00 | 0.20500 | -5.85e-02 | -9.12e-02 | 4.70e-02 | -1.49e-01 | 7.57e-02 | 6.85e-01 | 5.28e-01 | 7.45e-01 | 3.02e-01 | 6.00e-01 |
| OTIC VESICLE DEVELOPMENT | 15 | 7.38e-01 | 1.00e+00 | 0.20500 | -7.42e-02 | -9.49e-02 | 3.08e-02 | -1.61e-01 | -2.07e-02 | 6.19e-01 | 5.25e-01 | 8.36e-01 | 2.80e-01 | 8.89e-01 |
| PURINE RIBONUCLEOTIDE SALVAGE | 7 | 8.43e-01 | 1.00e+00 | 0.20500 | 1.26e-01 | 1.26e-01 | 5.29e-02 | 7.23e-02 | -4.46e-02 | 5.63e-01 | 5.64e-01 | 8.08e-01 | 7.40e-01 | 8.38e-01 |
| RETROGRADE VESICLE MEDIATED TRANSPORT GOLGI TO ENDOPLASMIC RETICULUM | 51 | 4.66e-01 | 9.35e-01 | 0.20500 | 8.14e-02 | 6.28e-02 | 1.46e-01 | 2.30e-02 | 9.69e-02 | 3.15e-01 | 4.38e-01 | 7.10e-02 | 7.76e-01 | 2.31e-01 |
| MITOPHAGY | 34 | 5.06e-01 | 9.48e-01 | 0.20500 | -1.15e-01 | -8.04e-02 | -1.19e-01 | -8.84e-02 | 1.04e-02 | 2.44e-01 | 4.17e-01 | 2.30e-01 | 3.72e-01 | 9.17e-01 |
| MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION | 129 | 8.80e-02 | 4.90e-01 | 0.20400 | 9.32e-02 | 8.68e-02 | 1.35e-01 | 5.56e-02 | 6.49e-02 | 6.76e-02 | 8.88e-02 | 7.96e-03 | 2.76e-01 | 2.03e-01 |
| NEUROBLAST DIFFERENTIATION | 8 | 6.96e-01 | 1.00e+00 | 0.20400 | 5.04e-02 | 6.71e-03 | 1.91e-01 | -1.25e-02 | 5.14e-02 | 8.05e-01 | 9.74e-01 | 3.50e-01 | 9.51e-01 | 8.01e-01 |
| GLUTAMATE CATABOLIC PROCESS | 7 | 4.97e-01 | 9.47e-01 | 0.20400 | 4.40e-02 | 8.63e-02 | 1.31e-01 | 1.21e-03 | 1.24e-01 | 8.40e-01 | 6.92e-01 | 5.49e-01 | 9.96e-01 | 5.71e-01 |
| SPINDLE ASSEMBLY | 127 | 3.39e-05 | 1.38e-03 | 0.20400 | 3.47e-02 | -1.01e-02 | 1.62e-01 | -5.53e-02 | 1.06e-01 | 4.99e-01 | 8.44e-01 | 1.66e-03 | 2.81e-01 | 3.84e-02 |
| AMMONIUM TRANSMEMBRANE TRANSPORT | 12 | 7.17e-01 | 1.00e+00 | 0.20400 | 5.61e-02 | 1.08e-01 | -2.75e-03 | 1.60e-02 | -1.64e-01 | 7.37e-01 | 5.19e-01 | 9.87e-01 | 9.23e-01 | 3.27e-01 |
| CELL CELL SIGNALING INVOLVED IN CARDIAC CONDUCTION | 32 | 5.37e-01 | 9.57e-01 | 0.20400 | 7.66e-02 | 8.51e-02 | 5.44e-02 | 7.81e-02 | -1.40e-01 | 4.53e-01 | 4.05e-01 | 5.94e-01 | 4.44e-01 | 1.71e-01 |
| CELLULAR RESPONSE TO ZINC ION | 23 | 3.82e-01 | 8.91e-01 | 0.20400 | 1.91e-02 | -1.23e-02 | 1.46e-01 | -9.67e-02 | 1.02e-01 | 8.74e-01 | 9.19e-01 | 2.25e-01 | 4.22e-01 | 3.96e-01 |
| POSTSYNAPTIC MEMBRANE ASSEMBLY | 7 | 9.54e-01 | 1.00e+00 | 0.20400 | 8.00e-02 | 9.73e-02 | 2.25e-02 | 1.54e-01 | -4.15e-02 | 7.14e-01 | 6.56e-01 | 9.18e-01 | 4.82e-01 | 8.49e-01 |
| EXTRACELLULAR VESICLE BIOGENESIS | 25 | 5.64e-01 | 9.71e-01 | 0.20400 | 2.24e-02 | 1.20e-02 | 1.15e-01 | -4.71e-02 | 1.60e-01 | 8.46e-01 | 9.17e-01 | 3.20e-01 | 6.83e-01 | 1.66e-01 |
| REGULATION OF BLOOD CIRCULATION | 247 | 7.55e-04 | 1.80e-02 | 0.20400 | 8.56e-02 | 9.09e-02 | 5.16e-02 | 8.35e-02 | -1.28e-01 | 2.05e-02 | 1.39e-02 | 1.62e-01 | 2.38e-02 | 5.24e-04 |
| POSITIVE REGULATION OF TELOMERE MAINTENANCE | 66 | 1.34e-01 | 6.08e-01 | 0.20400 | -5.29e-02 | -7.13e-02 | 4.15e-02 | -7.21e-02 | 1.64e-01 | 4.57e-01 | 3.17e-01 | 5.60e-01 | 3.11e-01 | 2.13e-02 |
| NEGATIVE REGULATION OF SMALL MOLECULE METABOLIC PROCESS | 111 | 5.08e-01 | 9.48e-01 | 0.20400 | 1.10e-01 | 1.13e-01 | 9.09e-02 | 9.27e-02 | -3.28e-03 | 4.62e-02 | 3.97e-02 | 9.81e-02 | 9.14e-02 | 9.52e-01 |
| RENAL SYSTEM PROCESS INVOLVED IN REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 22 | 3.64e-01 | 8.79e-01 | 0.20400 | -6.16e-02 | -9.05e-02 | 3.79e-02 | -2.86e-02 | 1.65e-01 | 6.17e-01 | 4.62e-01 | 7.58e-01 | 8.17e-01 | 1.79e-01 |
| RESPONSE TO MANGANESE ION | 17 | 6.95e-01 | 1.00e+00 | 0.20400 | 7.32e-02 | 9.04e-02 | 6.80e-02 | 5.67e-02 | -1.42e-01 | 6.01e-01 | 5.19e-01 | 6.27e-01 | 6.86e-01 | 3.10e-01 |
| PHOTOTRANSDUCTION | 42 | 3.78e-02 | 3.10e-01 | 0.20400 | -3.74e-02 | 6.56e-03 | -1.71e-01 | 8.48e-02 | -6.17e-02 | 6.75e-01 | 9.41e-01 | 5.55e-02 | 3.41e-01 | 4.89e-01 |
| DIACYLGLYCEROL METABOLIC PROCESS | 26 | 8.72e-01 | 1.00e+00 | 0.20400 | 8.26e-02 | 7.70e-02 | 7.73e-02 | 1.10e-01 | 1.04e-01 | 4.66e-01 | 4.97e-01 | 4.95e-01 | 3.33e-01 | 3.58e-01 |
| OXALATE TRANSPORT | 12 | 8.43e-01 | 1.00e+00 | 0.20400 | -1.08e-01 | -1.42e-01 | -7.91e-02 | -5.50e-02 | 1.61e-02 | 5.16e-01 | 3.93e-01 | 6.35e-01 | 7.41e-01 | 9.23e-01 |
| INTRACELLULAR PH REDUCTION | 51 | 1.90e-01 | 6.99e-01 | 0.20400 | -1.77e-03 | -2.93e-02 | 1.01e-01 | -3.65e-02 | 1.70e-01 | 9.83e-01 | 7.17e-01 | 2.11e-01 | 6.52e-01 | 3.53e-02 |
| PEPTIDYL LYSINE METHYLATION | 48 | 3.69e-01 | 8.80e-01 | 0.20400 | -7.53e-02 | -1.01e-01 | -4.96e-03 | -5.92e-02 | 1.49e-01 | 3.67e-01 | 2.28e-01 | 9.53e-01 | 4.78e-01 | 7.44e-02 |
| REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 24 | 4.66e-01 | 9.36e-01 | 0.20400 | 9.40e-02 | 1.12e-01 | 1.39e-01 | 1.52e-02 | 2.16e-02 | 4.25e-01 | 3.40e-01 | 2.39e-01 | 8.97e-01 | 8.55e-01 |
| CELLULAR RESPONSE TO ACIDIC PH | 16 | 6.17e-01 | 9.90e-01 | 0.20400 | 8.74e-02 | 1.29e-01 | 5.41e-02 | 1.13e-01 | 4.00e-02 | 5.45e-01 | 3.72e-01 | 7.08e-01 | 4.35e-01 | 7.82e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRIAL MEMBRANE | 37 | 2.82e-01 | 8.09e-01 | 0.20400 | 1.06e-01 | 8.95e-02 | 1.45e-01 | -3.23e-03 | -3.55e-02 | 2.65e-01 | 3.46e-01 | 1.28e-01 | 9.73e-01 | 7.09e-01 |
| ETHANOL OXIDATION | 9 | 6.51e-01 | 1.00e+00 | 0.20400 | 8.14e-03 | -8.16e-03 | -1.01e-01 | 5.60e-02 | -1.67e-01 | 9.66e-01 | 9.66e-01 | 6.00e-01 | 7.71e-01 | 3.85e-01 |
| PROTEIN QUALITY CONTROL FOR MISFOLDED OR INCOMPLETELY SYNTHESIZED PROTEINS | 29 | 4.12e-01 | 9.08e-01 | 0.20300 | 6.41e-02 | 3.68e-02 | 1.58e-01 | -4.15e-02 | 9.66e-02 | 5.50e-01 | 7.32e-01 | 1.41e-01 | 6.99e-01 | 3.68e-01 |
| RESPONSE TO INDOLE 3 METHANOL | 6 | 8.47e-01 | 1.00e+00 | 0.20300 | 5.21e-02 | 8.72e-02 | -3.95e-03 | 1.36e-01 | -1.12e-01 | 8.25e-01 | 7.11e-01 | 9.87e-01 | 5.64e-01 | 6.35e-01 |
| CARDIAC MUSCLE CELL PROLIFERATION | 57 | 3.84e-02 | 3.13e-01 | 0.20300 | 6.00e-02 | 5.25e-02 | 7.70e-02 | -3.30e-02 | -1.67e-01 | 4.33e-01 | 4.93e-01 | 3.14e-01 | 6.67e-01 | 2.88e-02 |
| REGULATION OF DNA RECOMBINATION | 128 | 1.05e-03 | 2.38e-02 | 0.20300 | 3.70e-03 | -2.00e-02 | 1.04e-01 | -7.72e-02 | 1.55e-01 | 9.42e-01 | 6.96e-01 | 4.16e-02 | 1.32e-01 | 2.40e-03 |
| RIBONUCLEOPROTEIN COMPLEX LOCALIZATION | 9 | 8.33e-01 | 1.00e+00 | 0.20300 | 4.29e-02 | 5.54e-04 | 1.02e-01 | -2.15e-02 | 1.69e-01 | 8.24e-01 | 9.98e-01 | 5.95e-01 | 9.11e-01 | 3.80e-01 |
| REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT | 55 | 7.02e-01 | 1.00e+00 | 0.20300 | 1.01e-01 | 1.08e-01 | 5.72e-02 | 1.26e-01 | 1.89e-02 | 1.96e-01 | 1.67e-01 | 4.63e-01 | 1.05e-01 | 8.08e-01 |
| POSITIVE REGULATION OF ENDOCYTOSIS | 149 | 2.34e-02 | 2.30e-01 | 0.20300 | -9.06e-02 | -1.16e-01 | -1.56e-02 | -9.86e-02 | 9.89e-02 | 5.62e-02 | 1.48e-02 | 7.42e-01 | 3.78e-02 | 3.71e-02 |
| NEGATIVE REGULATION OF FIBROBLAST MIGRATION | 10 | 9.70e-01 | 1.00e+00 | 0.20300 | -9.18e-02 | -6.46e-02 | -1.51e-01 | -3.87e-02 | -6.64e-02 | 6.15e-01 | 7.24e-01 | 4.08e-01 | 8.32e-01 | 7.16e-01 |
| INTRACELLULAR PROTEIN TRANSMEMBRANE TRANSPORT | 52 | 9.24e-02 | 5.02e-01 | 0.20300 | -1.26e-02 | -2.49e-02 | 7.84e-02 | -9.86e-02 | 1.57e-01 | 8.75e-01 | 7.56e-01 | 3.28e-01 | 2.19e-01 | 5.00e-02 |
| SOMITOGENESIS | 64 | 1.73e-01 | 6.78e-01 | 0.20300 | 8.52e-02 | 9.17e-02 | 8.32e-02 | 5.51e-02 | -1.25e-01 | 2.38e-01 | 2.05e-01 | 2.49e-01 | 4.46e-01 | 8.31e-02 |
| BROWN FAT CELL DIFFERENTIATION | 53 | 3.66e-01 | 8.79e-01 | 0.20300 | 1.01e-01 | 9.88e-02 | 1.35e-01 | 4.31e-02 | -3.40e-02 | 2.04e-01 | 2.14e-01 | 8.85e-02 | 5.87e-01 | 6.68e-01 |
| GOLGI TO PLASMA MEMBRANE PROTEIN TRANSPORT | 39 | 6.63e-01 | 1.00e+00 | 0.20300 | -8.99e-02 | -1.13e-01 | -3.46e-02 | -8.02e-02 | 1.13e-01 | 3.31e-01 | 2.23e-01 | 7.09e-01 | 3.86e-01 | 2.21e-01 |
| RESPONSE TO X RAY | 28 | 2.91e-01 | 8.18e-01 | 0.20300 | 6.50e-02 | 2.84e-02 | 1.68e-01 | -5.39e-02 | 7.10e-02 | 5.52e-01 | 7.95e-01 | 1.24e-01 | 6.21e-01 | 5.16e-01 |
| LIVER MORPHOGENESIS | 25 | 5.02e-01 | 9.48e-01 | 0.20300 | -6.57e-02 | -1.10e-01 | 4.60e-02 | -1.11e-01 | 1.01e-01 | 5.70e-01 | 3.41e-01 | 6.90e-01 | 3.36e-01 | 3.80e-01 |
| PEPTIDYL PROLINE HYDROXYLATION | 11 | 6.47e-01 | 1.00e+00 | 0.20300 | -1.60e-02 | -3.10e-02 | 1.13e-01 | -4.15e-02 | 1.60e-01 | 9.27e-01 | 8.59e-01 | 5.16e-01 | 8.11e-01 | 3.59e-01 |
| ENERGY HOMEOSTASIS | 76 | 4.50e-01 | 9.30e-01 | 0.20300 | 1.09e-01 | 1.15e-01 | 8.12e-02 | 7.18e-02 | -6.44e-02 | 9.94e-02 | 8.17e-02 | 2.21e-01 | 2.79e-01 | 3.32e-01 |
| THYROID HORMONE GENERATION | 22 | 9.28e-01 | 1.00e+00 | 0.20300 | -1.13e-01 | -9.67e-02 | -9.18e-02 | -1.03e-01 | -4.94e-04 | 3.59e-01 | 4.32e-01 | 4.56e-01 | 4.03e-01 | 9.97e-01 |
| RESPONSE TO TYPE I INTERFERON | 84 | 1.61e-01 | 6.61e-01 | 0.20300 | -9.24e-02 | -8.82e-02 | -4.58e-02 | -1.33e-01 | 7.12e-02 | 1.43e-01 | 1.62e-01 | 4.69e-01 | 3.53e-02 | 2.59e-01 |
| SNO S RNA METABOLIC PROCESS | 15 | 6.55e-01 | 1.00e+00 | 0.20300 | 4.31e-02 | -3.73e-03 | 7.88e-02 | 8.90e-02 | 1.58e-01 | 7.73e-01 | 9.80e-01 | 5.97e-01 | 5.51e-01 | 2.88e-01 |
| REGULATION OF DOUBLE STRAND BREAK REPAIR | 125 | 1.44e-01 | 6.29e-01 | 0.20300 | 8.40e-02 | 7.04e-02 | 1.29e-01 | 4.73e-02 | 1.01e-01 | 1.05e-01 | 1.74e-01 | 1.29e-02 | 3.61e-01 | 5.06e-02 |
| POSITIVE REGULATION OF KERATINOCYTE PROLIFERATION | 15 | 5.83e-01 | 9.85e-01 | 0.20300 | -2.88e-02 | 1.48e-03 | -1.53e-01 | 1.01e-01 | -8.28e-02 | 8.47e-01 | 9.92e-01 | 3.06e-01 | 5.00e-01 | 5.79e-01 |
| ESTABLISHMENT OF EPITHELIAL CELL POLARITY | 33 | 7.54e-01 | 1.00e+00 | 0.20300 | 1.06e-01 | 1.23e-01 | 3.64e-02 | 1.10e-01 | -3.53e-02 | 2.93e-01 | 2.22e-01 | 7.17e-01 | 2.73e-01 | 7.26e-01 |
| VESTIBULOCOCHLEAR NERVE MORPHOGENESIS | 7 | 9.71e-01 | 1.00e+00 | 0.20300 | -8.51e-02 | -1.10e-01 | -3.39e-02 | -1.26e-01 | -6.72e-02 | 6.96e-01 | 6.14e-01 | 8.77e-01 | 5.63e-01 | 7.58e-01 |
| POSITIVE REGULATION OF CARDIOCYTE DIFFERENTIATION | 18 | 3.70e-01 | 8.81e-01 | 0.20300 | -7.57e-02 | -1.02e-01 | 6.96e-02 | -1.21e-01 | 7.27e-02 | 5.78e-01 | 4.53e-01 | 6.09e-01 | 3.73e-01 | 5.93e-01 |
| RETINA MORPHOGENESIS IN CAMERA TYPE EYE | 63 | 3.67e-01 | 8.79e-01 | 0.20300 | -8.20e-02 | -5.49e-02 | -9.86e-02 | -9.27e-02 | -1.14e-01 | 2.60e-01 | 4.51e-01 | 1.76e-01 | 2.03e-01 | 1.18e-01 |
| NUCLEAR MIGRATION ALONG MICROTUBULE | 5 | 9.95e-01 | 1.00e+00 | 0.20200 | 1.05e-01 | 1.24e-01 | 8.24e-02 | 8.15e-02 | 3.47e-02 | 6.83e-01 | 6.32e-01 | 7.50e-01 | 7.52e-01 | 8.93e-01 |
| EATING BEHAVIOR | 37 | 5.99e-01 | 9.90e-01 | 0.20200 | 1.05e-01 | 8.47e-02 | 9.97e-02 | 7.93e-02 | -8.11e-02 | 2.70e-01 | 3.73e-01 | 2.94e-01 | 4.04e-01 | 3.93e-01 |
| NEGATIVE REGULATION OF TRANSLATIONAL INITIATION | 21 | 5.88e-01 | 9.85e-01 | 0.20200 | 9.66e-02 | 1.26e-01 | 8.20e-02 | 1.93e-02 | -9.31e-02 | 4.44e-01 | 3.19e-01 | 5.15e-01 | 8.79e-01 | 4.60e-01 |
| INTRACELLULAR ESTROGEN RECEPTOR SIGNALING PATHWAY | 53 | 7.45e-02 | 4.49e-01 | 0.20200 | 7.44e-02 | 6.33e-02 | 1.14e-01 | 1.07e-01 | 8.29e-02 | 3.49e-01 | 4.25e-01 | 1.52e-01 | 1.77e-01 | 2.97e-01 |
| POSITIVE REGULATION OF NEUROTRANSMITTER SECRETION | 17 | 7.37e-01 | 1.00e+00 | 0.20200 | 5.94e-02 | 4.97e-02 | 1.66e-02 | 8.56e-02 | -1.65e-01 | 6.71e-01 | 7.23e-01 | 9.05e-01 | 5.41e-01 | 2.39e-01 |
| MITOCHONDRIAL DNA METABOLIC PROCESS | 23 | 3.04e-01 | 8.32e-01 | 0.20200 | 8.83e-02 | 4.05e-02 | 1.74e-01 | 7.83e-03 | -3.19e-02 | 4.64e-01 | 7.36e-01 | 1.48e-01 | 9.48e-01 | 7.91e-01 |
| POSITIVE REGULATION OF CALCIUM ION IMPORT | 14 | 9.67e-01 | 1.00e+00 | 0.20200 | 9.21e-02 | 9.90e-02 | 1.00e-01 | 8.12e-02 | 7.68e-02 | 5.51e-01 | 5.21e-01 | 5.16e-01 | 5.99e-01 | 6.19e-01 |
| ETHER METABOLIC PROCESS | 26 | 3.51e-01 | 8.69e-01 | 0.20200 | -8.04e-02 | -5.58e-02 | -1.74e-01 | 2.35e-02 | 1.51e-02 | 4.78e-01 | 6.22e-01 | 1.24e-01 | 8.36e-01 | 8.94e-01 |
| RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 55 | 3.40e-01 | 8.59e-01 | 0.20200 | 1.14e-01 | 1.17e-01 | 1.08e-01 | 4.65e-02 | 1.48e-02 | 1.45e-01 | 1.33e-01 | 1.65e-01 | 5.51e-01 | 8.49e-01 |
| REGULATION OF ENDOCYTIC RECYCLING | 20 | 5.32e-01 | 9.54e-01 | 0.20200 | -1.90e-02 | -2.87e-02 | -1.79e-02 | -4.24e-03 | 1.98e-01 | 8.83e-01 | 8.24e-01 | 8.89e-01 | 9.74e-01 | 1.26e-01 |
| B CELL ACTIVATION | 263 | 7.90e-07 | 5.41e-05 | 0.20200 | -7.06e-02 | -1.05e-01 | 3.56e-02 | -1.25e-01 | 8.86e-02 | 4.87e-02 | 3.38e-03 | 3.20e-01 | 5.02e-04 | 1.34e-02 |
| POSITIVE REGULATION OF AMIDE METABOLIC PROCESS | 155 | 6.58e-02 | 4.17e-01 | 0.20200 | 1.03e-01 | 1.03e-01 | 1.07e-01 | 7.72e-02 | -4.50e-02 | 2.75e-02 | 2.70e-02 | 2.09e-02 | 9.73e-02 | 3.33e-01 |
| PHOSPHOLIPASE C ACTIVATING G PROTEIN COUPLED ACETYLCHOLINE RECEPTOR SIGNALING PATHWAY | 8 | 8.20e-01 | 1.00e+00 | 0.20200 | -6.07e-02 | -2.31e-02 | -1.84e-01 | 8.46e-03 | -5.10e-02 | 7.66e-01 | 9.10e-01 | 3.68e-01 | 9.67e-01 | 8.03e-01 |
| C4 DICARBOXYLATE TRANSPORT | 27 | 5.30e-01 | 9.54e-01 | 0.20200 | 8.96e-02 | 1.07e-01 | 7.57e-02 | 1.24e-01 | 8.67e-04 | 4.21e-01 | 3.35e-01 | 4.96e-01 | 2.65e-01 | 9.94e-01 |
| POSITIVE REGULATION OF CYTOPLASMIC TRANSLATION | 14 | 8.21e-01 | 1.00e+00 | 0.20200 | -9.24e-02 | -7.36e-02 | -3.28e-02 | -1.60e-01 | -2.26e-03 | 5.49e-01 | 6.34e-01 | 8.32e-01 | 3.00e-01 | 9.88e-01 |
| EMBRYONIC HEART TUBE MORPHOGENESIS | 70 | 1.12e-01 | 5.59e-01 | 0.20200 | 9.56e-02 | 8.28e-02 | 1.56e-01 | 1.13e-02 | -5.38e-03 | 1.67e-01 | 2.31e-01 | 2.37e-02 | 8.70e-01 | 9.38e-01 |
| POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 595 | 5.93e-06 | 2.96e-04 | 0.20100 | -1.05e-01 | -1.18e-01 | -5.03e-02 | -1.12e-01 | 2.78e-02 | 1.26e-05 | 8.96e-07 | 3.61e-02 | 3.33e-06 | 2.47e-01 |
| RESPONSE TO LEAD ION | 19 | 2.58e-01 | 7.85e-01 | 0.20100 | 6.68e-02 | 5.24e-02 | 8.48e-02 | 1.52e-01 | 5.51e-02 | 6.14e-01 | 6.92e-01 | 5.22e-01 | 2.51e-01 | 6.77e-01 |
| NEGATIVE REGULATION OF TYPE 2 IMMUNE RESPONSE | 15 | 4.31e-01 | 9.18e-01 | 0.20100 | -1.54e-02 | -2.68e-02 | 6.87e-02 | -1.47e-01 | 1.15e-01 | 9.18e-01 | 8.58e-01 | 6.45e-01 | 3.24e-01 | 4.41e-01 |
| POSITIVE REGULATION OF INFLAMMATORY RESPONSE | 149 | 2.81e-02 | 2.58e-01 | 0.20100 | -1.04e-01 | -1.26e-01 | -3.61e-02 | -1.03e-01 | 4.47e-02 | 2.87e-02 | 7.97e-03 | 4.47e-01 | 3.05e-02 | 3.46e-01 |
| ACTIN FILAMENT NETWORK FORMATION | 8 | 7.81e-01 | 1.00e+00 | 0.20100 | -7.18e-02 | -8.65e-02 | -1.58e-01 | 4.59e-02 | -2.66e-02 | 7.25e-01 | 6.72e-01 | 4.39e-01 | 8.22e-01 | 8.96e-01 |
| NEGATIVE REGULATION OF IMMUNE EFFECTOR PROCESS | 122 | 2.19e-02 | 2.21e-01 | 0.20100 | -9.00e-02 | -1.20e-01 | -2.02e-03 | -1.10e-01 | 7.64e-02 | 8.60e-02 | 2.19e-02 | 9.69e-01 | 3.61e-02 | 1.45e-01 |
| NEGATIVE REGULATION OF SIGNALING RECEPTOR ACTIVITY | 26 | 8.59e-01 | 1.00e+00 | 0.20100 | 9.41e-02 | 9.56e-02 | 1.25e-01 | 4.92e-02 | 6.55e-02 | 4.06e-01 | 3.99e-01 | 2.69e-01 | 6.64e-01 | 5.63e-01 |
| SKELETAL MUSCLE CELL DIFFERENTIATION | 71 | 2.29e-01 | 7.51e-01 | 0.20100 | 1.01e-01 | 7.95e-02 | 1.49e-01 | 4.17e-02 | -3.28e-03 | 1.41e-01 | 2.47e-01 | 3.03e-02 | 5.43e-01 | 9.62e-01 |
| POSTSYNAPTIC DENSITY ASSEMBLY | 21 | 4.67e-01 | 9.36e-01 | 0.20100 | 8.54e-02 | 1.21e-01 | 8.25e-02 | 2.40e-02 | -1.05e-01 | 4.98e-01 | 3.36e-01 | 5.13e-01 | 8.49e-01 | 4.05e-01 |
| CELLULAR LIPID CATABOLIC PROCESS | 220 | 2.70e-02 | 2.51e-01 | 0.20100 | 1.02e-01 | 1.18e-01 | 6.56e-02 | 1.09e-01 | 4.66e-04 | 9.26e-03 | 2.55e-03 | 9.35e-02 | 5.53e-03 | 9.90e-01 |
| GLOMERULUS DEVELOPMENT | 68 | 4.55e-01 | 9.31e-01 | 0.20100 | -1.06e-01 | -8.64e-02 | -1.08e-01 | -7.89e-02 | -5.94e-02 | 1.29e-01 | 2.18e-01 | 1.22e-01 | 2.61e-01 | 3.97e-01 |
| REGULATION OF NEURON PROJECTION REGENERATION | 29 | 4.66e-01 | 9.35e-01 | 0.20100 | -2.66e-02 | -2.07e-02 | -5.26e-03 | -1.30e-02 | 1.97e-01 | 8.04e-01 | 8.47e-01 | 9.61e-01 | 9.03e-01 | 6.60e-02 |
| AMYGDALA DEVELOPMENT | 5 | 9.12e-01 | 1.00e+00 | 0.20100 | -3.56e-03 | -4.26e-02 | 1.40e-01 | -1.30e-01 | 4.32e-02 | 9.89e-01 | 8.69e-01 | 5.88e-01 | 6.14e-01 | 8.67e-01 |
| PLASMA LIPOPROTEIN PARTICLE CLEARANCE | 54 | 5.92e-01 | 9.86e-01 | 0.20000 | 1.08e-01 | 1.25e-01 | 7.47e-02 | 7.73e-02 | -3.62e-02 | 1.68e-01 | 1.13e-01 | 3.43e-01 | 3.26e-01 | 6.46e-01 |
| REGULATION OF CD8 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 8 | 9.80e-01 | 1.00e+00 | 0.20000 | 7.03e-02 | 4.19e-02 | 1.34e-01 | 4.52e-02 | 1.17e-01 | 7.31e-01 | 8.37e-01 | 5.13e-01 | 8.25e-01 | 5.68e-01 |
| ANTEROGRADE AXONAL TRANSPORT | 49 | 2.29e-01 | 7.51e-01 | 0.20000 | -8.97e-02 | -9.34e-02 | 1.80e-03 | -1.53e-01 | -2.54e-03 | 2.77e-01 | 2.58e-01 | 9.83e-01 | 6.40e-02 | 9.75e-01 |
| PROSTATE GLAND MORPHOGENESIS | 27 | 1.75e-01 | 6.80e-01 | 0.20000 | 4.82e-02 | 2.02e-02 | 5.95e-02 | 4.20e-02 | -1.79e-01 | 6.65e-01 | 8.56e-01 | 5.92e-01 | 7.06e-01 | 1.07e-01 |
| RHODOPSIN MEDIATED SIGNALING PATHWAY | 12 | 5.64e-01 | 9.71e-01 | 0.20000 | 4.65e-02 | 6.91e-02 | -7.16e-02 | 1.40e-01 | 9.14e-02 | 7.80e-01 | 6.79e-01 | 6.67e-01 | 4.00e-01 | 5.84e-01 |
| MITOCHONDRIAL PROTON TRANSPORTING ATP SYNTHASE COMPLEX ASSEMBLY | 8 | 4.40e-01 | 9.26e-01 | 0.20000 | 3.04e-02 | -5.99e-02 | 1.79e-01 | -4.62e-02 | 3.98e-02 | 8.82e-01 | 7.69e-01 | 3.82e-01 | 8.21e-01 | 8.45e-01 |
| SENSORY PERCEPTION OF TEMPERATURE STIMULUS | 27 | 9.51e-01 | 1.00e+00 | 0.20000 | 1.03e-01 | 9.25e-02 | 1.14e-01 | 7.41e-02 | 4.99e-02 | 3.55e-01 | 4.06e-01 | 3.05e-01 | 5.05e-01 | 6.53e-01 |
| DOSAGE COMPENSATION | 27 | 2.77e-01 | 8.04e-01 | 0.20000 | 2.07e-02 | -1.87e-02 | 1.03e-01 | 4.99e-02 | 1.62e-01 | 8.52e-01 | 8.66e-01 | 3.56e-01 | 6.54e-01 | 1.45e-01 |
| RENAL ABSORPTION | 32 | 1.10e-01 | 5.51e-01 | 0.20000 | 2.69e-02 | 7.40e-02 | -8.31e-02 | 1.37e-01 | -9.06e-02 | 7.92e-01 | 4.69e-01 | 4.16e-01 | 1.80e-01 | 3.75e-01 |
| POSITIVE REGULATION OF SYNAPSE ASSEMBLY | 56 | 3.87e-01 | 8.92e-01 | 0.20000 | 9.16e-02 | 1.21e-01 | 2.79e-02 | 8.68e-02 | -9.38e-02 | 2.36e-01 | 1.18e-01 | 7.18e-01 | 2.61e-01 | 2.25e-01 |
| POSITIVE REGULATION OF CALCIUM ION DEPENDENT EXOCYTOSIS | 13 | 9.07e-01 | 1.00e+00 | 0.20000 | 1.16e-01 | 1.16e-01 | 1.02e-01 | 4.43e-02 | -2.54e-02 | 4.67e-01 | 4.69e-01 | 5.24e-01 | 7.82e-01 | 8.74e-01 |
| REGULATION OF RNA POLYMERASE II REGULATORY REGION SEQUENCE SPECIFIC DNA BINDING | 8 | 5.76e-01 | 9.80e-01 | 0.20000 | 3.96e-02 | 6.53e-02 | 1.29e-01 | -1.12e-01 | -7.04e-02 | 8.46e-01 | 7.49e-01 | 5.28e-01 | 5.82e-01 | 7.30e-01 |
| SNRNA TRANSPORT | 6 | 6.72e-01 | 1.00e+00 | 0.20000 | 4.35e-02 | 6.60e-02 | 2.20e-02 | -1.07e-01 | -1.48e-01 | 8.54e-01 | 7.80e-01 | 9.26e-01 | 6.51e-01 | 5.30e-01 |
| POSITIVE REGULATION OF RESPONSE TO WOUNDING | 73 | 1.21e-01 | 5.81e-01 | 0.20000 | 5.69e-02 | 9.07e-02 | -2.47e-02 | 7.16e-02 | -1.51e-01 | 4.01e-01 | 1.80e-01 | 7.15e-01 | 2.90e-01 | 2.58e-02 |
| AMINE TRANSPORT | 106 | 1.30e-01 | 5.98e-01 | 0.20000 | 9.80e-02 | 8.95e-02 | 9.15e-02 | 7.34e-02 | -9.27e-02 | 8.12e-02 | 1.11e-01 | 1.04e-01 | 1.91e-01 | 9.90e-02 |
| REGULATION OF RETROGRADE PROTEIN TRANSPORT ER TO CYTOSOL | 12 | 5.09e-01 | 9.49e-01 | 0.20000 | 6.48e-02 | 2.42e-02 | 1.64e-01 | -9.04e-02 | -5.81e-03 | 6.98e-01 | 8.85e-01 | 3.24e-01 | 5.88e-01 | 9.72e-01 |
| REGULATION OF VIRAL GENOME REPLICATION | 84 | 1.64e-02 | 1.80e-01 | 0.20000 | -7.60e-02 | -8.18e-02 | 3.36e-02 | -1.45e-01 | 7.25e-02 | 2.29e-01 | 1.95e-01 | 5.95e-01 | 2.13e-02 | 2.51e-01 |
| INDOLE CONTAINING COMPOUND METABOLIC PROCESS | 22 | 7.22e-01 | 1.00e+00 | 0.20000 | -1.53e-03 | 2.97e-02 | -8.09e-02 | 4.02e-02 | -1.76e-01 | 9.90e-01 | 8.10e-01 | 5.11e-01 | 7.44e-01 | 1.53e-01 |
| URATE METABOLIC PROCESS | 12 | 8.23e-01 | 1.00e+00 | 0.20000 | 2.77e-02 | 7.58e-02 | -7.83e-02 | 5.48e-02 | -1.56e-01 | 8.68e-01 | 6.49e-01 | 6.39e-01 | 7.42e-01 | 3.50e-01 |
| CHOLESTEROL CATABOLIC PROCESS | 9 | 8.06e-01 | 1.00e+00 | 0.20000 | -6.57e-02 | -4.65e-02 | 2.17e-02 | -1.45e-01 | 1.10e-01 | 7.33e-01 | 8.09e-01 | 9.10e-01 | 4.52e-01 | 5.69e-01 |
| LIPOPROTEIN CATABOLIC PROCESS | 15 | 6.16e-01 | 9.90e-01 | 0.20000 | 1.10e-02 | 3.76e-02 | 1.15e-02 | -8.15e-02 | -1.78e-01 | 9.41e-01 | 8.01e-01 | 9.39e-01 | 5.85e-01 | 2.33e-01 |
| NEGATIVE REGULATION OF LEUKOCYTE CELL CELL ADHESION | 146 | 1.84e-01 | 6.93e-01 | 0.20000 | -1.06e-01 | -1.12e-01 | -5.51e-02 | -1.05e-01 | 4.57e-02 | 2.70e-02 | 1.99e-02 | 2.50e-01 | 2.80e-02 | 3.40e-01 |
| ARACHIDONIC ACID SECRETION | 31 | 8.61e-01 | 1.00e+00 | 0.20000 | 1.03e-01 | 9.52e-02 | 1.01e-01 | 8.59e-02 | -5.28e-02 | 3.23e-01 | 3.59e-01 | 3.32e-01 | 4.08e-01 | 6.11e-01 |
| REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 21 | 8.11e-01 | 1.00e+00 | 0.20000 | -7.97e-02 | -7.66e-02 | -4.83e-02 | -4.91e-02 | 1.51e-01 | 5.27e-01 | 5.43e-01 | 7.01e-01 | 6.97e-01 | 2.30e-01 |
| GLYCOLYTIC PROCESS | 85 | 6.76e-01 | 1.00e+00 | 0.20000 | 1.06e-01 | 1.07e-01 | 8.99e-02 | 9.41e-02 | -1.84e-02 | 9.15e-02 | 8.95e-02 | 1.52e-01 | 1.34e-01 | 7.69e-01 |
| EYE PHOTORECEPTOR CELL DEVELOPMENT | 34 | 2.22e-01 | 7.45e-01 | 0.20000 | 5.73e-02 | 1.03e-01 | -5.31e-02 | 6.23e-02 | -1.39e-01 | 5.63e-01 | 2.97e-01 | 5.92e-01 | 5.29e-01 | 1.62e-01 |
| G PROTEIN COUPLED RECEPTOR INTERNALIZATION | 10 | 7.02e-01 | 1.00e+00 | 0.19900 | -2.38e-02 | -8.38e-02 | 9.05e-02 | -2.00e-02 | 1.54e-01 | 8.96e-01 | 6.46e-01 | 6.20e-01 | 9.13e-01 | 4.00e-01 |
| CARDIAC CONDUCTION | 94 | 2.46e-02 | 2.34e-01 | 0.19900 | 6.70e-02 | 8.65e-02 | 4.93e-02 | 4.00e-02 | -1.54e-01 | 2.61e-01 | 1.47e-01 | 4.09e-01 | 5.03e-01 | 9.79e-03 |
| POSITIVE REGULATION OF DOUBLE STRAND BREAK REPAIR | 82 | 4.85e-01 | 9.43e-01 | 0.19900 | 9.01e-02 | 8.43e-02 | 1.17e-01 | 5.99e-02 | 8.54e-02 | 1.58e-01 | 1.87e-01 | 6.74e-02 | 3.49e-01 | 1.81e-01 |
| EPIGENETIC REGULATION OF GENE EXPRESSION | 210 | 1.25e-03 | 2.73e-02 | 0.19900 | 7.17e-02 | 5.23e-02 | 1.43e-01 | 1.50e-02 | 1.06e-01 | 7.34e-02 | 1.92e-01 | 3.49e-04 | 7.07e-01 | 8.29e-03 |
| ODONTOGENESIS OF DENTIN CONTAINING TOOTH | 90 | 4.43e-01 | 9.28e-01 | 0.19900 | 9.52e-02 | 1.01e-01 | 8.20e-02 | 1.07e-01 | 4.78e-02 | 1.18e-01 | 9.82e-02 | 1.79e-01 | 7.88e-02 | 4.33e-01 |
| DNA REPAIR | 565 | 7.74e-11 | 1.46e-08 | 0.19900 | 8.33e-02 | 6.24e-02 | 1.54e-01 | 1.62e-02 | 7.06e-02 | 7.12e-04 | 1.12e-02 | 4.00e-10 | 5.10e-01 | 4.10e-03 |
| 2 OXOGLUTARATE METABOLIC PROCESS | 15 | 3.51e-01 | 8.69e-01 | 0.19900 | 4.88e-02 | 9.88e-02 | 2.95e-02 | 5.59e-02 | 1.54e-01 | 7.44e-01 | 5.08e-01 | 8.43e-01 | 7.08e-01 | 3.03e-01 |
| EMBRYONIC HINDLIMB MORPHOGENESIS | 27 | 3.50e-01 | 8.69e-01 | 0.19900 | 8.64e-02 | 4.28e-02 | 1.74e-01 | 2.64e-03 | 9.13e-03 | 4.37e-01 | 7.00e-01 | 1.17e-01 | 9.81e-01 | 9.35e-01 |
| POSITIVE REGULATION OF OLIGODENDROCYTE DIFFERENTIATION | 27 | 9.28e-01 | 1.00e+00 | 0.19900 | 1.07e-01 | 1.05e-01 | 1.12e-01 | 6.30e-02 | 2.49e-02 | 3.34e-01 | 3.46e-01 | 3.12e-01 | 5.71e-01 | 8.23e-01 |
| POSITIVE REGULATION OF MESENCHYMAL STEM CELL PROLIFERATION | 6 | 7.21e-01 | 1.00e+00 | 0.19900 | 1.02e-02 | 2.70e-02 | 1.01e-01 | -1.66e-01 | -3.28e-02 | 9.65e-01 | 9.09e-01 | 6.70e-01 | 4.81e-01 | 8.89e-01 |
| PROTEIN LOCALIZATION TO CHROMATIN | 56 | 2.92e-02 | 2.65e-01 | 0.19900 | 1.05e-01 | 5.55e-02 | 1.58e-01 | 2.49e-02 | -9.00e-05 | 1.75e-01 | 4.73e-01 | 4.08e-02 | 7.47e-01 | 9.99e-01 |
| POLYAMINE TRANSPORT | 16 | 1.75e-01 | 6.80e-01 | 0.19900 | 7.32e-02 | 7.20e-02 | 1.12e-01 | 1.24e-01 | -3.39e-02 | 6.12e-01 | 6.18e-01 | 4.36e-01 | 3.92e-01 | 8.15e-01 |
| NUCLEOBASE CONTAINING SMALL MOLECULE BIOSYNTHETIC PROCESS | 15 | 9.37e-01 | 1.00e+00 | 0.19900 | 9.79e-02 | 8.27e-02 | 6.41e-02 | 1.38e-01 | 9.01e-03 | 5.12e-01 | 5.79e-01 | 6.67e-01 | 3.56e-01 | 9.52e-01 |
| MEDIUM CHAIN FATTY ACID BIOSYNTHETIC PROCESS | 6 | 7.55e-01 | 1.00e+00 | 0.19900 | 7.55e-02 | 1.51e-01 | -6.01e-03 | 1.03e-01 | -2.02e-02 | 7.49e-01 | 5.22e-01 | 9.80e-01 | 6.62e-01 | 9.32e-01 |
| REGULATION OF FLAGELLATED SPERM MOTILITY | 18 | 8.63e-01 | 1.00e+00 | 0.19900 | -6.68e-02 | -4.47e-02 | -1.44e-01 | -2.11e-02 | -1.10e-01 | 6.24e-01 | 7.43e-01 | 2.91e-01 | 8.77e-01 | 4.20e-01 |
| REGULATION OF TISSUE REMODELING | 86 | 1.15e-01 | 5.64e-01 | 0.19900 | -1.01e-01 | -1.19e-01 | -1.65e-02 | -1.11e-01 | 5.22e-02 | 1.07e-01 | 5.62e-02 | 7.92e-01 | 7.62e-02 | 4.02e-01 |
| REGULATION OF CARDIAC MUSCLE CONTRACTION BY REGULATION OF THE RELEASE OF SEQUESTERED CALCIUM ION | 20 | 8.59e-01 | 1.00e+00 | 0.19900 | 3.67e-02 | 1.39e-02 | 9.26e-02 | 2.86e-02 | 1.69e-01 | 7.76e-01 | 9.14e-01 | 4.74e-01 | 8.25e-01 | 1.90e-01 |
| VASOCONSTRICTION | 80 | 1.13e-01 | 5.59e-01 | 0.19900 | 5.12e-03 | 2.02e-02 | -5.88e-02 | 2.51e-02 | -1.87e-01 | 9.37e-01 | 7.55e-01 | 3.64e-01 | 6.98e-01 | 3.81e-03 |
| REGULATION OF HEART CONTRACTION | 199 | 1.57e-02 | 1.75e-01 | 0.19900 | 9.21e-02 | 1.02e-01 | 6.47e-02 | 8.61e-02 | -9.48e-02 | 2.51e-02 | 1.31e-02 | 1.15e-01 | 3.62e-02 | 2.11e-02 |
| RIBONUCLEOTIDE CATABOLIC PROCESS | 48 | 5.41e-01 | 9.59e-01 | 0.19900 | -8.64e-02 | -6.47e-02 | -9.69e-02 | -7.05e-02 | -1.16e-01 | 3.00e-01 | 4.38e-01 | 2.46e-01 | 3.98e-01 | 1.64e-01 |
| FC RECEPTOR MEDIATED INHIBITORY SIGNALING PATHWAY | 5 | 8.95e-01 | 1.00e+00 | 0.19900 | 6.35e-02 | 8.34e-03 | 1.86e-01 | -1.60e-02 | 1.84e-02 | 8.06e-01 | 9.74e-01 | 4.70e-01 | 9.51e-01 | 9.43e-01 |
| REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 21 | 7.78e-01 | 1.00e+00 | 0.19900 | -1.12e-01 | -8.70e-02 | -7.51e-02 | -1.16e-01 | 1.88e-02 | 3.75e-01 | 4.90e-01 | 5.52e-01 | 3.59e-01 | 8.81e-01 |
| POSITIVE REGULATION OF JUN KINASE ACTIVITY | 31 | 4.01e-01 | 9.01e-01 | 0.19900 | 5.09e-02 | 3.16e-02 | 1.36e-01 | 3.46e-02 | 1.27e-01 | 6.24e-01 | 7.61e-01 | 1.91e-01 | 7.39e-01 | 2.20e-01 |
| SYNAPTIC VESICLE CYTOSKELETAL TRANSPORT | 18 | 5.53e-01 | 9.65e-01 | 0.19900 | -4.49e-02 | -8.25e-02 | 9.30e-02 | -1.19e-01 | 8.78e-02 | 7.42e-01 | 5.45e-01 | 4.95e-01 | 3.81e-01 | 5.19e-01 |
| NEURON REMODELING | 15 | 9.03e-01 | 1.00e+00 | 0.19800 | 8.10e-02 | 9.96e-02 | 9.66e-03 | 6.49e-02 | -1.36e-01 | 5.87e-01 | 5.04e-01 | 9.48e-01 | 6.64e-01 | 3.61e-01 |
| ACTIVATION OF INNATE IMMUNE RESPONSE | 263 | 3.13e-03 | 5.43e-02 | 0.19800 | -9.55e-02 | -1.10e-01 | -3.15e-02 | -1.30e-01 | 1.26e-02 | 7.64e-03 | 2.07e-03 | 3.79e-01 | 2.80e-04 | 7.25e-01 |
| HIPPO SIGNALING | 42 | 1.63e-01 | 6.63e-01 | 0.19800 | 3.18e-02 | 6.79e-02 | -4.26e-02 | 9.00e-02 | -1.54e-01 | 7.21e-01 | 4.46e-01 | 6.33e-01 | 3.13e-01 | 8.35e-02 |
| CDC42 PROTEIN SIGNAL TRANSDUCTION | 16 | 9.58e-01 | 1.00e+00 | 0.19800 | -1.01e-01 | -7.72e-02 | -1.33e-01 | -6.10e-02 | -3.97e-02 | 4.83e-01 | 5.93e-01 | 3.55e-01 | 6.73e-01 | 7.83e-01 |
| PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 124 | 1.72e-01 | 6.75e-01 | 0.19800 | 8.51e-02 | 6.87e-02 | 1.23e-01 | 4.58e-02 | 1.01e-01 | 1.02e-01 | 1.87e-01 | 1.83e-02 | 3.78e-01 | 5.16e-02 |
| LIPID HOMEOSTASIS | 170 | 1.86e-01 | 6.94e-01 | 0.19800 | 1.09e-01 | 1.14e-01 | 8.56e-02 | 8.37e-02 | -1.23e-02 | 1.40e-02 | 1.06e-02 | 5.42e-02 | 5.96e-02 | 7.82e-01 |
| REGULATION OF HISTONE H3 K4 METHYLATION | 11 | 3.65e-01 | 8.79e-01 | 0.19800 | -1.41e-02 | -9.32e-03 | -5.80e-02 | 1.14e-01 | -1.50e-01 | 9.36e-01 | 9.57e-01 | 7.39e-01 | 5.12e-01 | 3.88e-01 |
| NCRNA METABOLIC PROCESS | 607 | 2.04e-12 | 5.49e-10 | 0.19800 | 8.44e-02 | 6.72e-02 | 1.54e-01 | 7.69e-03 | 6.20e-02 | 3.80e-04 | 4.65e-03 | 8.64e-11 | 7.46e-01 | 9.05e-03 |
| REGULATION OF RESPONSE TO EXTRACELLULAR STIMULUS | 28 | 1.91e-01 | 7.01e-01 | 0.19800 | -8.26e-02 | -4.47e-02 | -6.64e-02 | -1.60e-01 | -2.12e-02 | 4.49e-01 | 6.82e-01 | 5.43e-01 | 1.43e-01 | 8.46e-01 |
| REGULATION OF PIGMENTATION | 17 | 8.06e-01 | 1.00e+00 | 0.19800 | -7.20e-02 | -5.20e-02 | -9.61e-02 | -1.13e-01 | -9.70e-02 | 6.07e-01 | 7.10e-01 | 4.93e-01 | 4.20e-01 | 4.89e-01 |
| ESTABLISHMENT OF MITOTIC SPINDLE LOCALIZATION | 40 | 7.27e-01 | 1.00e+00 | 0.19800 | 1.01e-01 | 1.02e-01 | 1.24e-01 | 5.76e-02 | -1.31e-03 | 2.70e-01 | 2.66e-01 | 1.73e-01 | 5.28e-01 | 9.89e-01 |
| REGULATION OF NEUROINFLAMMATORY RESPONSE | 41 | 5.46e-01 | 9.61e-01 | 0.19800 | -1.14e-01 | -1.19e-01 | -8.71e-02 | -6.62e-02 | -1.42e-02 | 2.08e-01 | 1.88e-01 | 3.34e-01 | 4.63e-01 | 8.75e-01 |
| POSITIVE REGULATION OF DNA BIOSYNTHETIC PROCESS | 68 | 1.27e-01 | 5.93e-01 | 0.19800 | -4.79e-02 | -6.59e-02 | 5.09e-02 | -1.07e-01 | 1.36e-01 | 4.94e-01 | 3.47e-01 | 4.68e-01 | 1.28e-01 | 5.18e-02 |
| ENDOTHELIN RECEPTOR SIGNALING PATHWAY | 10 | 9.11e-01 | 1.00e+00 | 0.19800 | 7.52e-03 | 5.73e-03 | 5.81e-02 | -3.33e-02 | 1.86e-01 | 9.67e-01 | 9.75e-01 | 7.50e-01 | 8.55e-01 | 3.08e-01 |
| RESPONSE TO OXYGEN LEVELS | 321 | 2.53e-03 | 4.63e-02 | 0.19800 | 1.01e-01 | 1.01e-01 | 1.20e-01 | 6.60e-02 | 8.61e-03 | 1.82e-03 | 1.85e-03 | 2.27e-04 | 4.20e-02 | 7.91e-01 |
| EPINEPHRINE TRANSPORT | 11 | 9.58e-01 | 1.00e+00 | 0.19800 | 1.02e-01 | 1.03e-01 | 1.25e-01 | 2.86e-02 | -3.95e-02 | 5.57e-01 | 5.53e-01 | 4.72e-01 | 8.70e-01 | 8.21e-01 |
| POST EMBRYONIC ANIMAL ORGAN MORPHOGENESIS | 11 | 9.61e-01 | 1.00e+00 | 0.19800 | -9.15e-02 | -6.53e-02 | -1.50e-01 | -3.92e-02 | -4.89e-02 | 5.99e-01 | 7.08e-01 | 3.88e-01 | 8.22e-01 | 7.79e-01 |
| ALCOHOL BIOSYNTHETIC PROCESS | 139 | 3.76e-02 | 3.09e-01 | 0.19800 | 8.94e-02 | 9.05e-02 | 1.10e-01 | 8.96e-02 | 5.39e-02 | 6.89e-02 | 6.54e-02 | 2.56e-02 | 6.80e-02 | 2.73e-01 |
| MOTOR BEHAVIOR | 22 | 4.84e-01 | 9.43e-01 | 0.19800 | 2.60e-02 | 3.31e-02 | 1.05e-01 | -9.70e-03 | 1.62e-01 | 8.33e-01 | 7.88e-01 | 3.96e-01 | 9.37e-01 | 1.88e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO MEMBRANE | 100 | 3.15e-01 | 8.42e-01 | 0.19800 | 9.62e-02 | 1.08e-01 | 7.95e-02 | 9.39e-02 | 5.63e-02 | 9.63e-02 | 6.30e-02 | 1.69e-01 | 1.05e-01 | 3.30e-01 |
| NEGATIVE REGULATION OF HEART RATE | 11 | 8.99e-01 | 1.00e+00 | 0.19800 | 5.06e-02 | 5.12e-02 | 4.13e-02 | 2.83e-02 | -1.77e-01 | 7.71e-01 | 7.69e-01 | 8.13e-01 | 8.71e-01 | 3.08e-01 |
| REGULATION OF CALCINEURIN MEDIATED SIGNALING | 41 | 3.54e-01 | 8.72e-01 | 0.19800 | 6.06e-02 | 9.85e-02 | -2.23e-02 | 9.56e-02 | -1.27e-01 | 5.02e-01 | 2.75e-01 | 8.05e-01 | 2.90e-01 | 1.59e-01 |
| LUNG ASSOCIATED MESENCHYME DEVELOPMENT | 8 | 9.79e-01 | 1.00e+00 | 0.19800 | 7.60e-02 | 9.06e-02 | -1.27e-02 | 1.12e-01 | -1.11e-01 | 7.10e-01 | 6.57e-01 | 9.51e-01 | 5.82e-01 | 5.87e-01 |
| METANEPHRIC EPITHELIUM DEVELOPMENT | 29 | 9.39e-01 | 1.00e+00 | 0.19800 | 1.08e-01 | 9.62e-02 | 1.11e-01 | 7.55e-02 | 8.02e-03 | 3.15e-01 | 3.70e-01 | 2.99e-01 | 4.81e-01 | 9.40e-01 |
| DETERMINATION OF ADULT LIFESPAN | 35 | 6.62e-01 | 1.00e+00 | 0.19800 | 8.71e-02 | 6.63e-02 | 1.44e-01 | 5.41e-02 | 5.81e-02 | 3.72e-01 | 4.97e-01 | 1.40e-01 | 5.79e-01 | 5.52e-01 |
| FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 81 | 2.71e-01 | 7.98e-01 | 0.19700 | 9.00e-02 | 9.09e-02 | 7.35e-02 | 7.19e-02 | -1.10e-01 | 1.61e-01 | 1.57e-01 | 2.53e-01 | 2.63e-01 | 8.77e-02 |
| PLASMA MEMBRANE TUBULATION | 19 | 6.13e-01 | 9.90e-01 | 0.19700 | 4.44e-02 | 4.06e-02 | 1.34e-01 | -5.27e-02 | 1.21e-01 | 7.38e-01 | 7.59e-01 | 3.13e-01 | 6.91e-01 | 3.61e-01 |
| MITOTIC G2 DNA DAMAGE CHECKPOINT SIGNALING | 34 | 6.13e-01 | 9.90e-01 | 0.19700 | 9.14e-02 | 7.23e-02 | 1.53e-01 | 1.06e-02 | 4.22e-02 | 3.57e-01 | 4.65e-01 | 1.22e-01 | 9.15e-01 | 6.70e-01 |
| DISTAL TUBULE DEVELOPMENT | 12 | 8.99e-01 | 1.00e+00 | 0.19700 | -1.15e-01 | -1.09e-01 | -5.22e-02 | -9.99e-02 | 3.43e-02 | 4.90e-01 | 5.14e-01 | 7.54e-01 | 5.49e-01 | 8.37e-01 |
| MAINTENANCE OF SISTER CHROMATID COHESION | 11 | 1.63e-01 | 6.63e-01 | 0.19700 | -2.55e-02 | -1.14e-01 | 7.29e-02 | -1.07e-01 | -9.20e-02 | 8.83e-01 | 5.13e-01 | 6.76e-01 | 5.38e-01 | 5.97e-01 |
| POSITIVE REGULATION OF LYMPHOCYTE ACTIVATION | 316 | 7.14e-05 | 2.62e-03 | 0.19700 | -9.63e-02 | -1.07e-01 | -1.54e-02 | -1.22e-01 | 5.52e-02 | 3.25e-03 | 1.05e-03 | 6.38e-01 | 1.97e-04 | 9.13e-02 |
| POSITIVE REGULATION OF MITOTIC CELL CYCLE SPINDLE ASSEMBLY CHECKPOINT | 12 | 6.71e-01 | 1.00e+00 | 0.19700 | -1.06e-01 | -1.06e-01 | -3.44e-04 | -1.06e-01 | 7.20e-02 | 5.25e-01 | 5.24e-01 | 9.98e-01 | 5.27e-01 | 6.66e-01 |
| VENTRICULAR CARDIAC MUSCLE CELL DEVELOPMENT | 10 | 9.00e-01 | 1.00e+00 | 0.19700 | 9.50e-02 | 6.86e-02 | 1.53e-01 | 1.09e-03 | -3.97e-02 | 6.03e-01 | 7.07e-01 | 4.01e-01 | 9.95e-01 | 8.28e-01 |
| RECOMBINATIONAL REPAIR | 169 | 7.64e-03 | 1.04e-01 | 0.19700 | 8.22e-02 | 6.15e-02 | 1.48e-01 | 1.48e-02 | 7.86e-02 | 6.53e-02 | 1.68e-01 | 8.99e-04 | 7.40e-01 | 7.77e-02 |
| PROTEIN N LINKED GLYCOSYLATION | 68 | 5.58e-01 | 9.69e-01 | 0.19700 | 1.01e-01 | 8.55e-02 | 1.32e-01 | 5.92e-02 | 1.95e-02 | 1.48e-01 | 2.23e-01 | 6.04e-02 | 3.98e-01 | 7.81e-01 |
| REGULATION OF LYMPHOID PROGENITOR CELL DIFFERENTIATION | 12 | 9.20e-01 | 1.00e+00 | 0.19700 | -8.57e-02 | -1.00e-01 | -5.07e-02 | -1.37e-01 | 3.76e-03 | 6.07e-01 | 5.48e-01 | 7.61e-01 | 4.10e-01 | 9.82e-01 |
| VITAMIN TRANSMEMBRANE TRANSPORT | 21 | 8.36e-01 | 1.00e+00 | 0.19700 | 7.03e-02 | 7.77e-02 | 9.33e-02 | 4.73e-02 | 1.30e-01 | 5.77e-01 | 5.38e-01 | 4.59e-01 | 7.07e-01 | 3.03e-01 |
| NADPH REGENERATION | 21 | 9.09e-01 | 1.00e+00 | 0.19700 | 9.53e-02 | 8.82e-02 | 7.39e-02 | 8.69e-02 | -9.42e-02 | 4.50e-01 | 4.84e-01 | 5.58e-01 | 4.91e-01 | 4.55e-01 |
| VESTIBULOCOCHLEAR NERVE DEVELOPMENT | 11 | 8.84e-01 | 1.00e+00 | 0.19700 | 9.66e-02 | 1.18e-01 | 6.19e-03 | 8.12e-02 | -9.39e-02 | 5.79e-01 | 4.98e-01 | 9.72e-01 | 6.41e-01 | 5.90e-01 |
| CHROMOSOME SEGREGATION | 409 | 1.40e-07 | 1.20e-05 | 0.19700 | 8.00e-02 | 5.61e-02 | 1.52e-01 | 1.81e-02 | 7.63e-02 | 5.51e-03 | 5.15e-02 | 1.43e-07 | 5.29e-01 | 8.09e-03 |
| FEMALE GENITALIA DEVELOPMENT | 19 | 9.32e-01 | 1.00e+00 | 0.19700 | -8.47e-02 | -9.02e-02 | -7.07e-02 | -9.03e-02 | -1.01e-01 | 5.23e-01 | 4.96e-01 | 5.94e-01 | 4.96e-01 | 4.46e-01 |
| PROTEIN LOCALIZATION TO CILIUM | 70 | 5.21e-01 | 9.53e-01 | 0.19700 | 8.23e-02 | 6.57e-02 | 1.12e-01 | 5.37e-02 | 1.10e-01 | 2.34e-01 | 3.41e-01 | 1.04e-01 | 4.37e-01 | 1.13e-01 |
| EPITHELIAL CELL MORPHOGENESIS | 29 | 5.18e-01 | 9.52e-01 | 0.19600 | 7.39e-02 | 9.50e-02 | 5.89e-03 | 1.53e-01 | 2.54e-02 | 4.91e-01 | 3.76e-01 | 9.56e-01 | 1.54e-01 | 8.13e-01 |
| POSITIVE REGULATION OF STRESS FIBER ASSEMBLY | 51 | 7.98e-01 | 1.00e+00 | 0.19600 | 1.02e-01 | 1.14e-01 | 7.46e-02 | 9.42e-02 | -2.49e-02 | 2.06e-01 | 1.58e-01 | 3.57e-01 | 2.45e-01 | 7.58e-01 |
| THROMBIN ACTIVATED RECEPTOR SIGNALING PATHWAY | 13 | 9.56e-01 | 1.00e+00 | 0.19600 | -9.46e-02 | -1.20e-01 | -4.92e-02 | -7.68e-02 | 8.38e-02 | 5.55e-01 | 4.55e-01 | 7.59e-01 | 6.31e-01 | 6.01e-01 |
| VESICLE FUSION TO PLASMA MEMBRANE | 24 | 8.70e-01 | 1.00e+00 | 0.19600 | 8.66e-02 | 9.93e-02 | 6.86e-02 | 1.06e-01 | 7.23e-02 | 4.63e-01 | 4.00e-01 | 5.61e-01 | 3.68e-01 | 5.40e-01 |
| HISTONE UBIQUITINATION | 8 | 9.59e-01 | 1.00e+00 | 0.19600 | -1.12e-01 | -1.10e-01 | -4.50e-02 | -1.09e-01 | 1.36e-03 | 5.83e-01 | 5.91e-01 | 8.26e-01 | 5.93e-01 | 9.95e-01 |
| GAMMA AMINOBUTYRIC ACID TRANSPORT | 19 | 7.53e-01 | 1.00e+00 | 0.19600 | -6.73e-02 | -2.21e-02 | -1.31e-01 | -4.37e-02 | -1.20e-01 | 6.12e-01 | 8.68e-01 | 3.21e-01 | 7.41e-01 | 3.66e-01 |
| NEGATIVE REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT | 14 | 5.55e-01 | 9.67e-01 | 0.19600 | 5.97e-02 | 4.16e-02 | -4.19e-02 | 1.39e-01 | -1.10e-01 | 6.99e-01 | 7.87e-01 | 7.86e-01 | 3.66e-01 | 4.78e-01 |
| HISTAMINE SECRETION | 12 | 5.06e-01 | 9.48e-01 | 0.19600 | 1.15e-01 | 5.39e-02 | 1.06e-01 | 1.04e-01 | -1.46e-02 | 4.92e-01 | 7.47e-01 | 5.23e-01 | 5.32e-01 | 9.30e-01 |
| POSITIVE REGULATION OF OPSONIZATION | 8 | 9.92e-01 | 1.00e+00 | 0.19600 | -9.70e-02 | -1.12e-01 | -5.99e-02 | -1.08e-01 | -3.71e-02 | 6.35e-01 | 5.85e-01 | 7.69e-01 | 5.97e-01 | 8.56e-01 |
| PURINE DEOXYRIBONUCLEOTIDE CATABOLIC PROCESS | 10 | 6.38e-01 | 9.99e-01 | 0.19600 | 3.09e-02 | -1.29e-02 | 1.73e-01 | -8.57e-02 | 1.02e-02 | 8.66e-01 | 9.44e-01 | 3.44e-01 | 6.39e-01 | 9.55e-01 |
| POSITIVE REGULATION OF TELOMERASE ACTIVITY | 33 | 5.85e-01 | 9.85e-01 | 0.19600 | -9.00e-02 | -7.52e-02 | -4.59e-02 | -1.12e-01 | 9.95e-02 | 3.71e-01 | 4.55e-01 | 6.48e-01 | 2.64e-01 | 3.23e-01 |
| OTOLITH MORPHOGENESIS | 5 | 1.60e-01 | 6.59e-01 | 0.19600 | -6.08e-02 | 8.34e-02 | -1.59e-01 | -1.76e-02 | 4.43e-02 | 8.14e-01 | 7.47e-01 | 5.37e-01 | 9.46e-01 | 8.64e-01 |
| DENDRITE EXTENSION | 35 | 8.97e-01 | 1.00e+00 | 0.19600 | -1.09e-01 | -1.08e-01 | -8.71e-02 | -8.39e-02 | -1.16e-02 | 2.66e-01 | 2.67e-01 | 3.72e-01 | 3.91e-01 | 9.05e-01 |
| MAINTENANCE OF PROTEIN LOCATION IN NUCLEUS | 23 | 8.87e-01 | 1.00e+00 | 0.19600 | 9.61e-02 | 7.68e-02 | 1.42e-01 | 3.50e-02 | 4.38e-02 | 4.25e-01 | 5.24e-01 | 2.40e-01 | 7.71e-01 | 7.16e-01 |
| OUTFLOW TRACT MORPHOGENESIS | 82 | 5.53e-03 | 8.23e-02 | 0.19600 | 8.02e-02 | 5.76e-02 | 1.43e-01 | -1.63e-03 | -9.05e-02 | 2.09e-01 | 3.67e-01 | 2.56e-02 | 9.80e-01 | 1.57e-01 |
| NEGATIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 14 | 4.97e-01 | 9.47e-01 | 0.19600 | 4.16e-02 | 3.44e-02 | 1.13e-01 | -1.06e-01 | -1.07e-01 | 7.88e-01 | 8.24e-01 | 4.66e-01 | 4.93e-01 | 4.88e-01 |
| LOW DENSITY LIPOPROTEIN PARTICLE REMODELING | 16 | 4.76e-01 | 9.40e-01 | 0.19600 | 8.45e-02 | 5.56e-02 | 8.97e-02 | 2.74e-02 | 1.39e-01 | 5.58e-01 | 7.00e-01 | 5.35e-01 | 8.50e-01 | 3.37e-01 |
| INHIBITORY POSTSYNAPTIC POTENTIAL | 16 | 6.66e-01 | 1.00e+00 | 0.19600 | 1.39e-02 | 3.07e-02 | -4.43e-02 | 8.17e-02 | -1.69e-01 | 9.24e-01 | 8.31e-01 | 7.59e-01 | 5.71e-01 | 2.43e-01 |
| EXONUCLEOLYTIC CATABOLISM OF DEADENYLATED MRNA | 13 | 6.86e-01 | 1.00e+00 | 0.19500 | 4.98e-02 | 2.89e-02 | 1.69e-01 | -6.48e-02 | 4.71e-02 | 7.56e-01 | 8.57e-01 | 2.92e-01 | 6.86e-01 | 7.69e-01 |
| REGULATION OF TRANSLATION INITIATION IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 8 | 9.75e-01 | 1.00e+00 | 0.19500 | 9.96e-02 | 9.27e-02 | 5.86e-02 | 1.05e-01 | 7.24e-02 | 6.26e-01 | 6.50e-01 | 7.74e-01 | 6.08e-01 | 7.23e-01 |
| RECEPTOR MEDIATED ENDOCYTOSIS OF VIRUS BY HOST CELL | 10 | 9.91e-01 | 1.00e+00 | 0.19500 | 1.09e-01 | 9.85e-02 | 1.10e-01 | 6.45e-02 | -1.50e-02 | 5.51e-01 | 5.90e-01 | 5.46e-01 | 7.24e-01 | 9.34e-01 |
| T HELPER 17 TYPE IMMUNE RESPONSE | 46 | 5.31e-01 | 9.54e-01 | 0.19500 | -8.32e-02 | -1.03e-01 | 2.49e-03 | -1.27e-01 | 6.56e-02 | 3.29e-01 | 2.27e-01 | 9.77e-01 | 1.35e-01 | 4.41e-01 |
| PRO B CELL DIFFERENTIATION | 12 | 4.21e-01 | 9.12e-01 | 0.19500 | 1.45e-02 | 3.97e-03 | 1.03e-01 | -1.61e-01 | -3.59e-02 | 9.31e-01 | 9.81e-01 | 5.37e-01 | 3.34e-01 | 8.29e-01 |
| CELL COMMUNICATION BY ELECTRICAL COUPLING INVOLVED IN CARDIAC CONDUCTION | 27 | 2.32e-01 | 7.54e-01 | 0.19500 | -2.35e-02 | -4.96e-02 | 4.20e-02 | -1.06e-01 | -1.49e-01 | 8.32e-01 | 6.56e-01 | 7.05e-01 | 3.42e-01 | 1.81e-01 |
| POSITIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT | 23 | 2.61e-01 | 7.89e-01 | 0.19500 | -2.08e-02 | -4.66e-02 | 1.61e-02 | -4.10e-02 | -1.83e-01 | 8.63e-01 | 6.99e-01 | 8.93e-01 | 7.34e-01 | 1.29e-01 |
| REGULATION OF POTASSIUM ION TRANSMEMBRANE TRANSPORT | 83 | 1.01e-01 | 5.25e-01 | 0.19500 | 1.24e-02 | 2.53e-02 | -5.51e-02 | 3.94e-02 | -1.81e-01 | 8.46e-01 | 6.90e-01 | 3.86e-01 | 5.35e-01 | 4.46e-03 |
| REGULATION OF LAMELLIPODIUM ORGANIZATION | 49 | 1.56e-01 | 6.53e-01 | 0.19500 | 7.12e-02 | 1.15e-01 | -3.42e-02 | 1.07e-01 | -8.49e-02 | 3.89e-01 | 1.66e-01 | 6.78e-01 | 1.96e-01 | 3.04e-01 |
| REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 32 | 8.30e-01 | 1.00e+00 | 0.19500 | 9.49e-02 | 1.17e-01 | 4.48e-02 | 9.50e-02 | -6.54e-02 | 3.53e-01 | 2.53e-01 | 6.61e-01 | 3.52e-01 | 5.22e-01 |
| INTERLEUKIN 10 PRODUCTION | 59 | 1.27e-01 | 5.93e-01 | 0.19500 | -1.12e-01 | -1.21e-01 | -5.33e-02 | -8.71e-02 | -1.99e-02 | 1.37e-01 | 1.08e-01 | 4.79e-01 | 2.47e-01 | 7.91e-01 |
| REGULATION OF TRANSLATION AT SYNAPSE | 6 | 7.83e-01 | 1.00e+00 | 0.19500 | 1.18e-02 | 8.49e-02 | -1.18e-01 | 2.14e-02 | -1.27e-01 | 9.60e-01 | 7.19e-01 | 6.16e-01 | 9.28e-01 | 5.89e-01 |
| TOLL LIKE RECEPTOR 3 SIGNALING PATHWAY | 26 | 8.26e-01 | 1.00e+00 | 0.19500 | 7.99e-02 | 7.34e-02 | 1.32e-01 | 4.06e-02 | 8.45e-02 | 4.80e-01 | 5.17e-01 | 2.46e-01 | 7.20e-01 | 4.56e-01 |
| REGULATION OF HISTONE MODIFICATION | 36 | 5.60e-01 | 9.69e-01 | 0.19500 | 8.77e-02 | 8.39e-02 | 1.06e-01 | 1.04e-01 | 3.31e-02 | 3.62e-01 | 3.84e-01 | 2.70e-01 | 2.82e-01 | 7.31e-01 |
| RESPONSE TO MAGNESIUM ION | 20 | 8.85e-01 | 1.00e+00 | 0.19500 | 9.47e-02 | 1.09e-01 | 8.74e-02 | 5.31e-02 | -8.10e-02 | 4.63e-01 | 3.99e-01 | 4.98e-01 | 6.81e-01 | 5.31e-01 |
| NEGATIVE REGULATION OF ENDOPLASMIC RETICULUM STRESS INDUCED EIF2 ALPHA PHOSPHORYLATION | 5 | 9.20e-01 | 1.00e+00 | 0.19500 | -6.93e-02 | -1.14e-01 | -5.34e-02 | -5.59e-02 | 1.19e-01 | 7.89e-01 | 6.60e-01 | 8.36e-01 | 8.28e-01 | 6.45e-01 |
| REGULATION OF T CELL ACTIVATION | 369 | 1.60e-04 | 5.12e-03 | 0.19400 | -9.95e-02 | -1.10e-01 | -3.23e-02 | -1.06e-01 | 6.01e-02 | 1.03e-03 | 3.01e-04 | 2.87e-01 | 4.58e-04 | 4.73e-02 |
| REGULATION OF HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 40 | 2.28e-01 | 7.50e-01 | 0.19400 | -8.00e-02 | -9.64e-02 | 3.16e-02 | -1.45e-01 | 1.34e-02 | 3.81e-01 | 2.92e-01 | 7.30e-01 | 1.13e-01 | 8.83e-01 |
| CHROMATIN REMODELING | 579 | 6.52e-09 | 8.04e-07 | 0.19400 | 7.07e-02 | 5.02e-02 | 1.34e-01 | 3.01e-02 | 1.06e-01 | 3.65e-03 | 3.89e-02 | 3.15e-08 | 2.15e-01 | 1.22e-05 |
| PROTEIN TARGETING TO PEROXISOME | 19 | 8.45e-01 | 1.00e+00 | 0.19400 | -5.17e-02 | -5.66e-02 | -1.35e-02 | -4.07e-02 | 1.73e-01 | 6.96e-01 | 6.69e-01 | 9.19e-01 | 7.59e-01 | 1.91e-01 |
| POSITIVE REGULATION OF CELL FATE COMMITMENT | 13 | 8.90e-01 | 1.00e+00 | 0.19400 | 5.73e-02 | 4.99e-02 | 2.68e-02 | 4.69e-02 | -1.71e-01 | 7.21e-01 | 7.55e-01 | 8.67e-01 | 7.70e-01 | 2.87e-01 |
| REGULATION OF CHROMATIN BINDING | 11 | 9.02e-01 | 1.00e+00 | 0.19400 | 7.73e-02 | 8.21e-02 | 9.72e-02 | 1.31e-02 | -1.24e-01 | 6.57e-01 | 6.37e-01 | 5.77e-01 | 9.40e-01 | 4.76e-01 |
| V D J RECOMBINATION | 19 | 4.79e-01 | 9.41e-01 | 0.19400 | 3.63e-02 | -1.42e-02 | 1.57e-01 | -1.54e-02 | 1.06e-01 | 7.84e-01 | 9.15e-01 | 2.35e-01 | 9.08e-01 | 4.24e-01 |
| ADHERENS JUNCTION MAINTENANCE | 7 | 7.55e-01 | 1.00e+00 | 0.19400 | -6.15e-02 | -7.05e-03 | -1.66e-01 | 7.65e-02 | 1.78e-02 | 7.78e-01 | 9.74e-01 | 4.46e-01 | 7.26e-01 | 9.35e-01 |
| REGULATION OF NUCLEOTIDE METABOLIC PROCESS | 45 | 3.67e-01 | 8.79e-01 | 0.19400 | 6.48e-02 | 4.83e-02 | 6.69e-02 | 1.20e-01 | 1.11e-01 | 4.52e-01 | 5.75e-01 | 4.37e-01 | 1.65e-01 | 1.97e-01 |
| REGULATION OF HEMATOPOIETIC STEM CELL DIFFERENTIATION | 17 | 5.63e-01 | 9.71e-01 | 0.19400 | -1.00e-01 | -9.01e-02 | -1.20e-02 | -1.36e-01 | -2.98e-02 | 4.73e-01 | 5.20e-01 | 9.32e-01 | 3.33e-01 | 8.31e-01 |
| S SHAPED BODY MORPHOGENESIS | 7 | 7.45e-01 | 1.00e+00 | 0.19400 | -4.80e-02 | -2.38e-02 | -5.73e-03 | -1.84e-01 | -2.96e-02 | 8.26e-01 | 9.13e-01 | 9.79e-01 | 3.99e-01 | 8.92e-01 |
| IRIS MORPHOGENESIS | 10 | 9.00e-01 | 1.00e+00 | 0.19400 | 9.14e-02 | 6.04e-02 | 1.58e-01 | 8.21e-03 | -2.65e-02 | 6.17e-01 | 7.41e-01 | 3.88e-01 | 9.64e-01 | 8.85e-01 |
| POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 19 | 8.65e-01 | 1.00e+00 | 0.19400 | 8.67e-02 | 1.06e-01 | 6.20e-02 | 8.85e-02 | 8.50e-02 | 5.13e-01 | 4.24e-01 | 6.40e-01 | 5.04e-01 | 5.21e-01 |
| HORMONE CATABOLIC PROCESS | 11 | 7.75e-01 | 1.00e+00 | 0.19400 | -4.12e-02 | -4.87e-02 | -1.12e-01 | 5.70e-02 | -1.34e-01 | 8.13e-01 | 7.80e-01 | 5.22e-01 | 7.44e-01 | 4.43e-01 |
| CD40 SIGNALING PATHWAY | 15 | 2.75e-01 | 8.02e-01 | 0.19400 | 2.31e-02 | -4.87e-02 | 1.49e-01 | -9.25e-02 | 6.30e-02 | 8.77e-01 | 7.44e-01 | 3.18e-01 | 5.35e-01 | 6.73e-01 |
| ACTIN FILAMENT BASED TRANSPORT | 21 | 9.04e-01 | 1.00e+00 | 0.19400 | -1.00e-01 | -8.17e-02 | -1.25e-01 | -6.95e-02 | 2.02e-02 | 4.26e-01 | 5.17e-01 | 3.22e-01 | 5.81e-01 | 8.72e-01 |
| HEART TRABECULA FORMATION | 15 | 9.89e-01 | 1.00e+00 | 0.19400 | -9.70e-02 | -9.72e-02 | -7.86e-02 | -1.06e-01 | -3.64e-02 | 5.15e-01 | 5.15e-01 | 5.98e-01 | 4.77e-01 | 8.07e-01 |
| VESTIBULOCOCHLEAR NERVE FORMATION | 5 | 9.50e-01 | 1.00e+00 | 0.19400 | 7.47e-02 | 4.30e-02 | 1.69e-01 | -2.38e-02 | -3.02e-02 | 7.72e-01 | 8.68e-01 | 5.12e-01 | 9.27e-01 | 9.07e-01 |
| MALE GENITALIA DEVELOPMENT | 23 | 6.98e-01 | 1.00e+00 | 0.19400 | -4.49e-02 | -4.22e-02 | -3.76e-02 | -5.88e-02 | -1.70e-01 | 7.09e-01 | 7.26e-01 | 7.55e-01 | 6.25e-01 | 1.59e-01 |
| REGULATION OF FAT CELL PROLIFERATION | 10 | 8.92e-01 | 1.00e+00 | 0.19400 | -9.37e-02 | -1.28e-01 | 2.24e-03 | -9.38e-02 | 5.92e-02 | 6.08e-01 | 4.83e-01 | 9.90e-01 | 6.08e-01 | 7.46e-01 |
| NEGATIVE REGULATION OF BMP SIGNALING PATHWAY | 67 | 2.66e-01 | 7.95e-01 | 0.19400 | -6.95e-02 | -5.20e-02 | -6.55e-02 | -1.13e-01 | -1.13e-01 | 3.25e-01 | 4.62e-01 | 3.54e-01 | 1.10e-01 | 1.08e-01 |
| REGULATION OF VENTRICULAR CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 22 | 4.41e-01 | 9.26e-01 | 0.19400 | 4.02e-02 | 6.08e-02 | -2.43e-02 | 1.22e-01 | -1.29e-01 | 7.44e-01 | 6.22e-01 | 8.43e-01 | 3.21e-01 | 2.95e-01 |
| LIPOPROTEIN BIOSYNTHETIC PROCESS | 91 | 1.54e-01 | 6.50e-01 | 0.19400 | 8.85e-02 | 7.95e-02 | 1.43e-01 | 2.44e-02 | 4.70e-02 | 1.45e-01 | 1.90e-01 | 1.82e-02 | 6.88e-01 | 4.39e-01 |
| CELLULAR DETOXIFICATION OF ALDEHYDE | 9 | 9.44e-01 | 1.00e+00 | 0.19300 | 5.25e-02 | 7.33e-02 | -4.27e-02 | 1.28e-01 | -1.05e-01 | 7.85e-01 | 7.03e-01 | 8.24e-01 | 5.06e-01 | 5.85e-01 |
| NEGATIVE REGULATION OF DOPAMINE SECRETION | 5 | 9.66e-01 | 1.00e+00 | 0.19300 | 4.30e-03 | -4.10e-03 | -3.80e-02 | 4.82e-02 | -1.83e-01 | 9.87e-01 | 9.87e-01 | 8.83e-01 | 8.52e-01 | 4.78e-01 |
| NEGATIVE REGULATION OF CAMP MEDIATED SIGNALING | 11 | 7.18e-01 | 1.00e+00 | 0.19300 | -7.14e-02 | -8.01e-02 | 5.73e-02 | -1.49e-01 | 1.64e-02 | 6.82e-01 | 6.45e-01 | 7.42e-01 | 3.91e-01 | 9.25e-01 |
| VITAMIN K METABOLIC PROCESS | 10 | 6.64e-01 | 1.00e+00 | 0.19300 | 3.82e-02 | 2.63e-02 | 1.56e-01 | 3.42e-03 | 1.05e-01 | 8.34e-01 | 8.86e-01 | 3.94e-01 | 9.85e-01 | 5.66e-01 |
| LEUKOTRIENE TRANSPORT | 7 | 6.41e-01 | 1.00e+00 | 0.19300 | -1.31e-01 | -1.00e-01 | -8.34e-02 | -5.38e-02 | 1.77e-02 | 5.48e-01 | 6.47e-01 | 7.02e-01 | 8.05e-01 | 9.35e-01 |
| MYOBLAST MIGRATION | 13 | 6.77e-01 | 1.00e+00 | 0.19300 | 4.40e-02 | 2.71e-02 | 1.15e-01 | -6.98e-02 | 1.29e-01 | 7.84e-01 | 8.66e-01 | 4.74e-01 | 6.63e-01 | 4.21e-01 |
| G PROTEIN COUPLED ACETYLCHOLINE RECEPTOR SIGNALING PATHWAY | 21 | 8.67e-01 | 1.00e+00 | 0.19300 | -1.08e-01 | -9.06e-02 | -9.67e-02 | -6.75e-02 | 5.78e-02 | 3.90e-01 | 4.72e-01 | 4.43e-01 | 5.92e-01 | 6.46e-01 |
| MUSCLE CELL CELLULAR HOMEOSTASIS | 21 | 9.31e-01 | 1.00e+00 | 0.19300 | 9.15e-02 | 1.11e-01 | 3.92e-02 | 9.04e-02 | -8.20e-02 | 4.68e-01 | 3.77e-01 | 7.56e-01 | 4.73e-01 | 5.16e-01 |
| T CELL ACTIVATION | 542 | 2.18e-07 | 1.69e-05 | 0.19300 | -9.76e-02 | -1.11e-01 | -2.51e-02 | -1.09e-01 | 5.25e-02 | 1.02e-04 | 9.05e-06 | 3.17e-01 | 1.43e-05 | 3.64e-02 |
| POSITIVE REGULATION OF CD4 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 31 | 5.99e-01 | 9.90e-01 | 0.19300 | -8.42e-02 | -8.78e-02 | 2.48e-03 | -1.48e-01 | 2.21e-02 | 4.17e-01 | 3.97e-01 | 9.81e-01 | 1.54e-01 | 8.32e-01 |
| MYELOID LEUKOCYTE DIFFERENTIATION | 227 | 7.85e-04 | 1.86e-02 | 0.19300 | -8.40e-02 | -1.07e-01 | -3.45e-03 | -8.85e-02 | 1.04e-01 | 2.92e-02 | 5.38e-03 | 9.29e-01 | 2.16e-02 | 7.09e-03 |
| LABYRINTHINE LAYER BLOOD VESSEL DEVELOPMENT | 18 | 3.14e-01 | 8.42e-01 | 0.19300 | 8.09e-02 | 4.89e-02 | 1.51e-01 | -6.58e-02 | 3.08e-02 | 5.52e-01 | 7.19e-01 | 2.66e-01 | 6.29e-01 | 8.21e-01 |
| REGULATION OF GROWTH HORMONE RECEPTOR SIGNALING PATHWAY | 6 | 9.85e-01 | 1.00e+00 | 0.19300 | -9.93e-02 | -1.15e-01 | -6.10e-02 | -8.11e-02 | -6.05e-02 | 6.74e-01 | 6.25e-01 | 7.96e-01 | 7.31e-01 | 7.97e-01 |
| NEGATIVE REGULATION OF TRANSCRIPTION BY COMPETITIVE PROMOTER BINDING | 12 | 8.19e-01 | 1.00e+00 | 0.19300 | 1.99e-02 | -1.14e-02 | 1.42e-01 | -6.01e-02 | 1.13e-01 | 9.05e-01 | 9.46e-01 | 3.95e-01 | 7.18e-01 | 4.97e-01 |
| MESENCHYME MORPHOGENESIS | 60 | 3.68e-02 | 3.06e-01 | 0.19300 | 8.05e-02 | 5.81e-02 | 1.56e-01 | -3.02e-02 | -4.51e-02 | 2.81e-01 | 4.36e-01 | 3.69e-02 | 6.85e-01 | 5.46e-01 |
| RENAL VESICLE FORMATION | 8 | 8.89e-01 | 1.00e+00 | 0.19200 | -5.16e-02 | -5.59e-02 | 3.70e-03 | -9.34e-02 | -1.50e-01 | 8.01e-01 | 7.84e-01 | 9.86e-01 | 6.47e-01 | 4.62e-01 |
| EPITHELIAL TO MESENCHYMAL TRANSITION INVOLVED IN ENDOCARDIAL CUSHION FORMATION | 18 | 8.27e-01 | 1.00e+00 | 0.19200 | 9.06e-02 | 8.52e-02 | 1.31e-01 | 4.30e-03 | 6.74e-02 | 5.06e-01 | 5.32e-01 | 3.38e-01 | 9.75e-01 | 6.20e-01 |
| CYTOSOLIC TRANSPORT | 176 | 1.02e-02 | 1.27e-01 | 0.19200 | -8.39e-02 | -1.07e-01 | -7.95e-03 | -8.88e-02 | 1.02e-01 | 5.50e-02 | 1.39e-02 | 8.56e-01 | 4.22e-02 | 1.90e-02 |
| MRNA 3 END PROCESSING | 49 | 1.84e-02 | 1.97e-01 | 0.19200 | 8.19e-02 | 2.02e-02 | 1.66e-01 | 3.39e-02 | 3.33e-02 | 3.21e-01 | 8.06e-01 | 4.43e-02 | 6.82e-01 | 6.86e-01 |
| ENDOTHELIAL CELL MORPHOGENESIS | 9 | 9.34e-01 | 1.00e+00 | 0.19200 | 3.12e-02 | 2.92e-02 | 5.34e-02 | 7.78e-02 | 1.62e-01 | 8.71e-01 | 8.79e-01 | 7.81e-01 | 6.86e-01 | 4.00e-01 |
| METANEPHRIC PART OF URETERIC BUD DEVELOPMENT | 6 | 9.77e-01 | 1.00e+00 | 0.19200 | -6.99e-02 | -5.38e-02 | -5.38e-02 | -7.97e-02 | -1.41e-01 | 7.67e-01 | 8.19e-01 | 8.20e-01 | 7.35e-01 | 5.50e-01 |
| TRANS SYNAPTIC SIGNALING BY LIPID | 7 | 9.39e-01 | 1.00e+00 | 0.19200 | -8.02e-02 | -1.01e-01 | -7.28e-02 | -8.70e-02 | 8.51e-02 | 7.13e-01 | 6.42e-01 | 7.39e-01 | 6.90e-01 | 6.97e-01 |
| RESPONSE TO GAMMA RADIATION | 50 | 3.23e-01 | 8.48e-01 | 0.19200 | 7.98e-02 | 1.03e-01 | 3.80e-02 | 3.26e-02 | -1.32e-01 | 3.29e-01 | 2.09e-01 | 6.42e-01 | 6.90e-01 | 1.07e-01 |
| NEGATIVE REGULATION OF GLYCOLYTIC PROCESS | 17 | 9.71e-01 | 1.00e+00 | 0.19200 | 9.66e-02 | 8.12e-02 | 8.32e-02 | 1.06e-01 | 5.07e-02 | 4.91e-01 | 5.62e-01 | 5.53e-01 | 4.47e-01 | 7.18e-01 |
| NEGATIVE REGULATION OF DNA BINDING | 33 | 8.05e-02 | 4.67e-01 | 0.19200 | 4.33e-02 | 1.81e-02 | 1.36e-01 | -8.66e-02 | -9.26e-02 | 6.67e-01 | 8.57e-01 | 1.77e-01 | 3.90e-01 | 3.57e-01 |
| OBSERVATIONAL LEARNING | 7 | 9.18e-01 | 1.00e+00 | 0.19200 | -3.15e-02 | -1.16e-02 | -1.39e-01 | 8.71e-02 | -9.26e-02 | 8.85e-01 | 9.57e-01 | 5.23e-01 | 6.90e-01 | 6.71e-01 |
| POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 198 | 6.09e-02 | 4.04e-01 | 0.19200 | 9.42e-02 | 9.48e-02 | 1.14e-01 | 6.54e-02 | 3.88e-02 | 2.22e-02 | 2.14e-02 | 5.57e-03 | 1.13e-01 | 3.47e-01 |
| REGULATION OF GLUTAMATE SECRETION NEUROTRANSMISSION | 5 | 9.69e-01 | 1.00e+00 | 0.19200 | 4.82e-02 | 3.76e-02 | 2.33e-02 | 7.32e-02 | -1.64e-01 | 8.52e-01 | 8.84e-01 | 9.28e-01 | 7.77e-01 | 5.24e-01 |
| REGULATION OF LONG TERM SYNAPTIC DEPRESSION | 12 | 6.67e-01 | 1.00e+00 | 0.19100 | 6.05e-02 | 9.99e-02 | 6.15e-02 | 4.89e-02 | 1.30e-01 | 7.17e-01 | 5.49e-01 | 7.12e-01 | 7.70e-01 | 4.36e-01 |
| CELLULAR RESPONSE TO TOXIC SUBSTANCE | 124 | 4.31e-01 | 9.18e-01 | 0.19100 | 1.01e-01 | 1.04e-01 | 7.01e-02 | 9.05e-02 | -4.92e-02 | 5.17e-02 | 4.47e-02 | 1.77e-01 | 8.17e-02 | 3.44e-01 |
| N TERMINAL PROTEIN AMINO ACID ACETYLATION | 15 | 6.61e-01 | 1.00e+00 | 0.19100 | 4.28e-02 | 8.63e-03 | 1.17e-01 | -5.28e-02 | 1.35e-01 | 7.74e-01 | 9.54e-01 | 4.33e-01 | 7.23e-01 | 3.64e-01 |
| REGULATION OF MEIOTIC NUCLEAR DIVISION | 33 | 3.77e-01 | 8.85e-01 | 0.19100 | -3.94e-02 | -7.78e-02 | 5.57e-02 | -1.07e-01 | 1.21e-01 | 6.95e-01 | 4.39e-01 | 5.80e-01 | 2.89e-01 | 2.30e-01 |
| ETHANOLAMINE CONTAINING COMPOUND METABOLIC PROCESS | 8 | 9.82e-01 | 1.00e+00 | 0.19100 | -7.69e-02 | -4.30e-02 | -1.28e-01 | -4.73e-02 | -1.01e-01 | 7.06e-01 | 8.33e-01 | 5.31e-01 | 8.17e-01 | 6.20e-01 |
| FEEDING BEHAVIOR | 102 | 1.90e-01 | 6.99e-01 | 0.19100 | 9.08e-02 | 9.20e-02 | 7.29e-02 | 5.36e-02 | -1.08e-01 | 1.13e-01 | 1.08e-01 | 2.03e-01 | 3.49e-01 | 5.88e-02 |
| TRNA SURVEILLANCE | 8 | 9.28e-01 | 1.00e+00 | 0.19100 | -6.57e-02 | -6.34e-02 | -4.42e-02 | -1.48e-01 | -6.64e-02 | 7.48e-01 | 7.56e-01 | 8.29e-01 | 4.69e-01 | 7.45e-01 |
| NEURAL PLATE PATTERN SPECIFICATION | 8 | 9.49e-01 | 1.00e+00 | 0.19100 | 7.31e-02 | 7.76e-02 | 6.86e-02 | 7.17e-02 | -1.24e-01 | 7.20e-01 | 7.04e-01 | 7.37e-01 | 7.25e-01 | 5.44e-01 |
| NEGATIVE REGULATION OF T CELL RECEPTOR SIGNALING PATHWAY | 24 | 5.90e-01 | 9.86e-01 | 0.19100 | 4.38e-02 | 4.93e-03 | 1.44e-01 | -2.82e-03 | 1.17e-01 | 7.10e-01 | 9.67e-01 | 2.21e-01 | 9.81e-01 | 3.19e-01 |
| ADAPTIVE IMMUNE RESPONSE BASED ON SOMATIC RECOMBINATION OF IMMUNE RECEPTORS BUILT FROM IMMUNOGLOBULIN SUPERFAMILY DOMAINS | 297 | 3.67e-06 | 1.90e-04 | 0.19100 | -6.71e-02 | -9.38e-02 | 3.16e-02 | -1.17e-01 | 9.23e-02 | 4.66e-02 | 5.40e-03 | 3.49e-01 | 5.11e-04 | 6.22e-03 |
| PEPTIDE BIOSYNTHETIC PROCESS | 806 | 9.06e-10 | 1.39e-07 | 0.19100 | 9.66e-02 | 9.27e-02 | 1.27e-01 | 3.79e-02 | 3.11e-02 | 3.08e-06 | 7.53e-06 | 7.92e-10 | 6.71e-02 | 1.34e-01 |
| STRIATED MUSCLE CELL DEVELOPMENT | 73 | 3.38e-01 | 8.59e-01 | 0.19100 | 7.82e-02 | 9.30e-02 | 7.71e-05 | 1.08e-01 | -1.01e-01 | 2.48e-01 | 1.69e-01 | 9.99e-01 | 1.12e-01 | 1.36e-01 |
| OVULATION CYCLE | 72 | 4.87e-02 | 3.59e-01 | 0.19100 | -8.76e-02 | -1.01e-01 | -8.79e-02 | -3.17e-02 | -9.94e-02 | 1.99e-01 | 1.38e-01 | 1.97e-01 | 6.42e-01 | 1.45e-01 |
| CELLULAR RESPONSE TO FOLLICLE STIMULATING HORMONE STIMULUS | 9 | 9.18e-01 | 1.00e+00 | 0.19100 | -7.52e-02 | -6.35e-02 | -1.17e-01 | 1.06e-02 | -1.14e-01 | 6.96e-01 | 7.42e-01 | 5.45e-01 | 9.56e-01 | 5.52e-01 |
| TERPENOID METABOLIC PROCESS | 96 | 3.29e-02 | 2.87e-01 | 0.19100 | 3.11e-02 | 5.58e-02 | -6.06e-02 | 9.34e-02 | -1.41e-01 | 5.99e-01 | 3.45e-01 | 3.05e-01 | 1.14e-01 | 1.66e-02 |
| POSITIVE REGULATION OF NEURON MIGRATION | 18 | 6.83e-01 | 1.00e+00 | 0.19100 | -9.06e-02 | -1.26e-01 | -8.16e-02 | -6.57e-02 | -3.88e-02 | 5.06e-01 | 3.56e-01 | 5.49e-01 | 6.30e-01 | 7.76e-01 |
| POSITIVE REGULATION OF CHONDROCYTE PROLIFERATION | 8 | 8.68e-01 | 1.00e+00 | 0.19100 | -8.86e-02 | -7.80e-02 | -1.15e-02 | -1.27e-01 | -7.87e-02 | 6.64e-01 | 7.03e-01 | 9.55e-01 | 5.34e-01 | 7.00e-01 |
| NEGATIVE REGULATION OF ORGAN GROWTH | 35 | 2.64e-01 | 7.91e-01 | 0.19100 | 6.03e-02 | 8.82e-02 | 4.78e-02 | 4.11e-02 | -1.45e-01 | 5.37e-01 | 3.66e-01 | 6.24e-01 | 6.74e-01 | 1.39e-01 |
| RESOLUTION OF RECOMBINATION INTERMEDIATES | 6 | 9.80e-01 | 1.00e+00 | 0.19100 | -4.44e-02 | -4.23e-02 | -3.40e-03 | -5.85e-02 | 1.71e-01 | 8.51e-01 | 8.58e-01 | 9.89e-01 | 8.04e-01 | 4.69e-01 |
| NUCLEOSIDE METABOLIC PROCESS | 53 | 7.35e-01 | 1.00e+00 | 0.19100 | -1.02e-01 | -9.13e-02 | -7.04e-02 | -1.10e-01 | 2.45e-02 | 1.99e-01 | 2.50e-01 | 3.75e-01 | 1.68e-01 | 7.57e-01 |
| ANATOMICAL STRUCTURE REGRESSION | 16 | 8.33e-01 | 1.00e+00 | 0.19000 | -4.83e-02 | -5.27e-02 | -1.93e-02 | -1.12e-01 | -1.35e-01 | 7.38e-01 | 7.15e-01 | 8.94e-01 | 4.37e-01 | 3.51e-01 |
| POSITIVE REGULATION OF STEM CELL PROLIFERATION | 53 | 5.51e-01 | 9.64e-01 | 0.19000 | -9.60e-02 | -1.02e-01 | -4.76e-02 | -1.09e-01 | -5.03e-02 | 2.26e-01 | 1.99e-01 | 5.49e-01 | 1.71e-01 | 5.26e-01 |
| MAMMARY GLAND ALVEOLUS DEVELOPMENT | 19 | 5.16e-01 | 9.52e-01 | 0.19000 | 4.73e-02 | 5.58e-02 | 8.70e-02 | -5.17e-02 | -1.44e-01 | 7.21e-01 | 6.74e-01 | 5.11e-01 | 6.97e-01 | 2.79e-01 |
| UNSATURATED FATTY ACID BIOSYNTHETIC PROCESS | 49 | 2.17e-01 | 7.39e-01 | 0.19000 | 6.46e-02 | 6.55e-02 | 5.48e-02 | -6.00e-03 | -1.57e-01 | 4.34e-01 | 4.28e-01 | 5.07e-01 | 9.42e-01 | 5.74e-02 |
| REGULATION OF CELLULAR PH REDUCTION | 7 | 8.21e-01 | 1.00e+00 | 0.19000 | 1.76e-02 | -4.24e-02 | 1.48e-01 | -8.77e-02 | 6.59e-02 | 9.36e-01 | 8.46e-01 | 4.97e-01 | 6.88e-01 | 7.63e-01 |
| GALACTOSE TRANSMEMBRANE TRANSPORT | 5 | 4.20e-01 | 9.11e-01 | 0.19000 | -9.95e-02 | -1.08e-01 | -8.07e-02 | 8.98e-02 | -2.09e-03 | 7.00e-01 | 6.77e-01 | 7.55e-01 | 7.28e-01 | 9.94e-01 |
| POSITIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 30 | 7.85e-01 | 1.00e+00 | 0.19000 | -1.03e-01 | -8.73e-02 | -5.89e-02 | -1.18e-01 | 2.23e-02 | 3.31e-01 | 4.08e-01 | 5.77e-01 | 2.63e-01 | 8.33e-01 |
| RESCUE OF STALLED RIBOSOME | 29 | 5.10e-01 | 9.50e-01 | 0.19000 | -1.12e-02 | -4.56e-02 | 9.91e-02 | -5.91e-02 | 1.43e-01 | 9.17e-01 | 6.71e-01 | 3.56e-01 | 5.82e-01 | 1.82e-01 |
| CENTROSOME DUPLICATION | 74 | 1.60e-01 | 6.59e-01 | 0.19000 | -7.02e-02 | -7.94e-02 | 1.53e-02 | -1.33e-01 | 8.32e-02 | 2.96e-01 | 2.38e-01 | 8.20e-01 | 4.81e-02 | 2.16e-01 |
| REGULATION OF WNT SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 9 | 8.26e-01 | 1.00e+00 | 0.19000 | 8.43e-03 | 9.73e-03 | 2.03e-02 | -9.86e-02 | -1.60e-01 | 9.65e-01 | 9.60e-01 | 9.16e-01 | 6.09e-01 | 4.05e-01 |
| CHORIO ALLANTOIC FUSION | 7 | 8.61e-01 | 1.00e+00 | 0.19000 | -2.75e-02 | -4.65e-02 | -1.31e-02 | 7.99e-02 | 1.63e-01 | 9.00e-01 | 8.31e-01 | 9.52e-01 | 7.14e-01 | 4.56e-01 |
| NUCLEOBASE TRANSPORT | 12 | 5.46e-01 | 9.61e-01 | 0.18900 | 3.48e-02 | 9.05e-02 | -8.46e-02 | 1.38e-01 | 1.51e-02 | 8.35e-01 | 5.87e-01 | 6.12e-01 | 4.07e-01 | 9.28e-01 |
| ENDOCRINE SYSTEM DEVELOPMENT | 137 | 3.45e-04 | 9.68e-03 | 0.18900 | 8.84e-02 | 7.40e-02 | 1.27e-01 | -1.59e-02 | -7.84e-02 | 7.39e-02 | 1.35e-01 | 1.02e-02 | 7.48e-01 | 1.13e-01 |
| POSITIVE REGULATION OF PODOSOME ASSEMBLY | 10 | 7.47e-01 | 1.00e+00 | 0.18900 | 3.85e-02 | 2.45e-02 | 1.38e-01 | 2.87e-02 | 1.18e-01 | 8.33e-01 | 8.93e-01 | 4.51e-01 | 8.75e-01 | 5.18e-01 |
| FAT CELL DIFFERENTIATION | 243 | 2.39e-02 | 2.33e-01 | 0.18900 | 9.96e-02 | 8.94e-02 | 1.24e-01 | 4.95e-02 | 7.56e-03 | 7.46e-03 | 1.64e-02 | 8.73e-04 | 1.84e-01 | 8.39e-01 |
| POSITIVE REGULATION OF CREB TRANSCRIPTION FACTOR ACTIVITY | 16 | 4.49e-01 | 9.30e-01 | 0.18900 | 1.70e-02 | 4.54e-02 | -8.91e-02 | 1.57e-01 | 2.98e-02 | 9.06e-01 | 7.53e-01 | 5.37e-01 | 2.78e-01 | 8.37e-01 |
| ZYMOGEN ACTIVATION | 57 | 8.27e-01 | 1.00e+00 | 0.18900 | -9.90e-02 | -8.88e-02 | -8.45e-02 | -1.03e-01 | -1.87e-02 | 1.96e-01 | 2.46e-01 | 2.70e-01 | 1.80e-01 | 8.07e-01 |
| PYRIMIDINE NUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 14 | 8.97e-01 | 1.00e+00 | 0.18900 | 4.91e-02 | 4.52e-02 | 8.39e-02 | 6.02e-03 | 1.56e-01 | 7.50e-01 | 7.70e-01 | 5.87e-01 | 9.69e-01 | 3.14e-01 |
| NUCLEAR BODY ORGANIZATION | 15 | 9.23e-01 | 1.00e+00 | 0.18900 | 8.45e-02 | 7.30e-02 | 1.36e-01 | 7.29e-03 | 6.91e-02 | 5.71e-01 | 6.25e-01 | 3.62e-01 | 9.61e-01 | 6.43e-01 |
| POSITIVE REGULATION OF DEFENSE RESPONSE | 463 | 6.15e-05 | 2.32e-03 | 0.18900 | -9.42e-02 | -1.11e-01 | -3.22e-02 | -1.11e-01 | 3.52e-02 | 5.15e-04 | 4.49e-05 | 2.35e-01 | 4.12e-05 | 1.95e-01 |
| PEPTIDYL SERINE MODIFICATION | 291 | 4.83e-03 | 7.50e-02 | 0.18900 | -9.71e-02 | -9.24e-02 | -4.82e-02 | -1.24e-01 | 1.02e-02 | 4.35e-03 | 6.67e-03 | 1.57e-01 | 2.80e-04 | 7.66e-01 |
| RETINOL METABOLIC PROCESS | 50 | 1.84e-01 | 6.93e-01 | 0.18900 | -1.08e-02 | 1.35e-02 | -1.15e-01 | 7.33e-02 | -1.30e-01 | 8.95e-01 | 8.69e-01 | 1.61e-01 | 3.70e-01 | 1.11e-01 |
| AUTOPHAGOSOME MATURATION | 60 | 1.77e-01 | 6.84e-01 | 0.18900 | 3.08e-03 | -1.09e-02 | 8.90e-02 | -5.92e-02 | 1.55e-01 | 9.67e-01 | 8.84e-01 | 2.33e-01 | 4.27e-01 | 3.73e-02 |
| HEAD MORPHOGENESIS | 35 | 8.83e-01 | 1.00e+00 | 0.18900 | -9.78e-02 | -1.09e-01 | -4.92e-02 | -1.09e-01 | -1.31e-03 | 3.16e-01 | 2.66e-01 | 6.15e-01 | 2.64e-01 | 9.89e-01 |
| INTESTINAL STEM CELL HOMEOSTASIS | 6 | 9.73e-01 | 1.00e+00 | 0.18900 | -8.60e-02 | -7.81e-02 | -1.40e-01 | 3.20e-03 | 5.13e-02 | 7.15e-01 | 7.41e-01 | 5.53e-01 | 9.89e-01 | 8.28e-01 |
| REGULATION OF SMOOTH MUSCLE CELL DIFFERENTIATION | 41 | 3.10e-01 | 8.37e-01 | 0.18900 | 6.35e-02 | 2.85e-02 | 1.58e-01 | -2.60e-03 | 7.73e-02 | 4.82e-01 | 7.52e-01 | 8.10e-02 | 9.77e-01 | 3.91e-01 |
| NEUTRAL LIPID BIOSYNTHETIC PROCESS | 46 | 6.59e-01 | 1.00e+00 | 0.18900 | 8.77e-02 | 9.32e-02 | 4.16e-02 | 1.18e-01 | 6.06e-02 | 3.03e-01 | 2.74e-01 | 6.26e-01 | 1.67e-01 | 4.77e-01 |
| AXO DENDRITIC TRANSPORT | 74 | 2.11e-01 | 7.33e-01 | 0.18900 | -8.91e-02 | -9.66e-02 | -1.54e-02 | -1.33e-01 | -2.14e-02 | 1.85e-01 | 1.51e-01 | 8.18e-01 | 4.83e-02 | 7.51e-01 |
| REGULATION OF RENAL SYSTEM PROCESS | 21 | 9.43e-01 | 1.00e+00 | 0.18900 | 9.19e-02 | 9.97e-02 | 9.23e-02 | 8.84e-02 | 2.91e-02 | 4.66e-01 | 4.29e-01 | 4.64e-01 | 4.83e-01 | 8.17e-01 |
| PROTEIN LOCALIZATION TO MICROTUBULE | 17 | 4.78e-01 | 9.40e-01 | 0.18900 | -1.48e-02 | -2.91e-02 | 1.06e-01 | -1.48e-01 | 3.46e-02 | 9.16e-01 | 8.35e-01 | 4.48e-01 | 2.89e-01 | 8.05e-01 |
| REGULATION OF PHAGOCYTOSIS | 96 | 2.62e-02 | 2.45e-01 | 0.18900 | -8.26e-02 | -1.22e-01 | -1.36e-03 | -9.32e-02 | 7.12e-02 | 1.62e-01 | 3.84e-02 | 9.82e-01 | 1.14e-01 | 2.28e-01 |
| FORELIMB MORPHOGENESIS | 39 | 2.73e-03 | 4.89e-02 | 0.18800 | 1.48e-02 | -5.56e-02 | 1.57e-01 | -8.62e-02 | -7.98e-03 | 8.73e-01 | 5.48e-01 | 8.95e-02 | 3.52e-01 | 9.31e-01 |
| NEGATIVE REGULATION OF CELLULAR SENESCENCE | 25 | 4.57e-01 | 9.32e-01 | 0.18800 | 9.73e-02 | 7.93e-02 | 1.39e-01 | -1.72e-02 | 2.79e-03 | 4.00e-01 | 4.92e-01 | 2.28e-01 | 8.82e-01 | 9.81e-01 |
| GENERATION OF PRECURSOR METABOLITES AND ENERGY | 470 | 4.37e-05 | 1.74e-03 | 0.18800 | 9.85e-02 | 8.95e-02 | 1.26e-01 | 4.12e-02 | 9.20e-03 | 2.52e-04 | 8.82e-04 | 2.74e-06 | 1.26e-01 | 7.33e-01 |
| REGULATION OF POTASSIUM ION TRANSPORT | 99 | 8.98e-02 | 4.95e-01 | 0.18800 | 3.87e-02 | 5.02e-02 | -2.59e-02 | 5.45e-02 | -1.66e-01 | 5.06e-01 | 3.88e-01 | 6.55e-01 | 3.48e-01 | 4.20e-03 |
| INTERFERON BETA PRODUCTION | 56 | 3.56e-01 | 8.74e-01 | 0.18800 | 9.12e-02 | 7.88e-02 | 1.40e-01 | 3.37e-02 | -1.47e-02 | 2.38e-01 | 3.08e-01 | 7.09e-02 | 6.63e-01 | 8.49e-01 |
| ALLANTOIN METABOLIC PROCESS | 9 | 9.45e-01 | 1.00e+00 | 0.18800 | -6.19e-02 | -5.04e-02 | -2.11e-02 | -5.78e-02 | 1.59e-01 | 7.48e-01 | 7.93e-01 | 9.13e-01 | 7.64e-01 | 4.10e-01 |
| POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 126 | 1.05e-01 | 5.37e-01 | 0.18800 | -8.87e-02 | -9.90e-02 | -1.60e-02 | -1.29e-01 | 2.76e-02 | 8.55e-02 | 5.49e-02 | 7.56e-01 | 1.25e-02 | 5.92e-01 |
| PYRIMIDINE DIMER REPAIR | 9 | 9.11e-01 | 1.00e+00 | 0.18800 | 2.07e-02 | -6.41e-03 | 1.00e-01 | -6.39e-02 | 1.44e-01 | 9.14e-01 | 9.73e-01 | 6.04e-01 | 7.40e-01 | 4.55e-01 |
| OUTER MITOCHONDRIAL MEMBRANE ORGANIZATION | 15 | 5.61e-01 | 9.70e-01 | 0.18800 | -3.01e-02 | -4.71e-02 | 6.81e-02 | -1.66e-01 | -5.49e-03 | 8.40e-01 | 7.52e-01 | 6.48e-01 | 2.67e-01 | 9.71e-01 |
| REGULATION OF JUN KINASE ACTIVITY | 44 | 5.15e-01 | 9.52e-01 | 0.18700 | 6.33e-02 | 4.88e-02 | 1.25e-01 | 4.27e-02 | 1.07e-01 | 4.68e-01 | 5.75e-01 | 1.52e-01 | 6.24e-01 | 2.21e-01 |
| EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 82 | 1.20e-01 | 5.78e-01 | 0.18700 | -8.76e-02 | -1.03e-01 | 1.32e-03 | -1.28e-01 | 1.81e-02 | 1.70e-01 | 1.06e-01 | 9.84e-01 | 4.45e-02 | 7.77e-01 |
| CHONDROCYTE PROLIFERATION | 24 | 8.01e-01 | 1.00e+00 | 0.18700 | 6.81e-02 | 9.59e-02 | 1.70e-02 | 6.03e-02 | -1.32e-01 | 5.64e-01 | 4.16e-01 | 8.85e-01 | 6.09e-01 | 2.64e-01 |
| NEGATIVE REGULATION OF GLYCOPROTEIN METABOLIC PROCESS | 26 | 7.53e-01 | 1.00e+00 | 0.18700 | 9.81e-02 | 7.69e-02 | 1.03e-01 | 5.33e-02 | -7.83e-02 | 3.87e-01 | 4.97e-01 | 3.64e-01 | 6.38e-01 | 4.89e-01 |
| ATRIAL SEPTUM DEVELOPMENT | 23 | 3.41e-01 | 8.59e-01 | 0.18700 | -1.20e-02 | -3.13e-02 | 6.06e-02 | -1.17e-01 | -1.29e-01 | 9.21e-01 | 7.95e-01 | 6.15e-01 | 3.32e-01 | 2.84e-01 |
| CELLULAR ALDEHYDE METABOLIC PROCESS | 70 | 1.53e-01 | 6.47e-01 | 0.18700 | 7.40e-02 | 8.38e-02 | 3.88e-02 | 1.38e-01 | 4.50e-02 | 2.84e-01 | 2.25e-01 | 5.74e-01 | 4.58e-02 | 5.15e-01 |
| REGULATION OF MONOCYTE DIFFERENTIATION | 20 | 9.39e-01 | 1.00e+00 | 0.18700 | 7.45e-02 | 6.78e-02 | 6.70e-02 | 8.91e-02 | 1.12e-01 | 5.64e-01 | 6.00e-01 | 6.04e-01 | 4.90e-01 | 3.86e-01 |
| NEGATIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II | 895 | 7.78e-13 | 2.55e-10 | 0.18700 | 8.95e-02 | 7.02e-02 | 1.41e-01 | 2.83e-02 | 3.99e-02 | 5.58e-06 | 3.62e-04 | 9.39e-13 | 1.51e-01 | 4.26e-02 |
| NEGATIVE REGULATION OF LEUKOCYTE PROLIFERATION | 91 | 1.98e-02 | 2.06e-01 | 0.18700 | -9.23e-02 | -1.13e-01 | 5.72e-03 | -1.13e-01 | 3.06e-02 | 1.28e-01 | 6.15e-02 | 9.25e-01 | 6.31e-02 | 6.14e-01 |
| REGULATION OF T CELL RECEPTOR SIGNALING PATHWAY | 43 | 1.84e-01 | 6.93e-01 | 0.18700 | 9.78e-03 | -2.66e-02 | 1.29e-01 | -4.84e-02 | 1.24e-01 | 9.12e-01 | 7.62e-01 | 1.45e-01 | 5.83e-01 | 1.59e-01 |
| FACE MORPHOGENESIS | 30 | 8.89e-01 | 1.00e+00 | 0.18700 | -9.91e-02 | -1.15e-01 | -5.00e-02 | -9.23e-02 | 2.97e-02 | 3.47e-01 | 2.75e-01 | 6.35e-01 | 3.82e-01 | 7.79e-01 |
| N ACETYLNEURAMINATE METABOLIC PROCESS | 11 | 9.20e-01 | 1.00e+00 | 0.18700 | 1.43e-02 | 1.62e-02 | -8.75e-03 | -2.65e-02 | -1.84e-01 | 9.35e-01 | 9.26e-01 | 9.60e-01 | 8.79e-01 | 2.91e-01 |
| REGULATION OF LIPOPROTEIN METABOLIC PROCESS | 17 | 4.71e-01 | 9.39e-01 | 0.18700 | -8.55e-03 | -4.37e-02 | 1.05e-01 | -1.40e-01 | 5.04e-02 | 9.51e-01 | 7.55e-01 | 4.54e-01 | 3.19e-01 | 7.19e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 19 | 4.29e-01 | 9.17e-01 | 0.18700 | 1.39e-02 | 7.56e-02 | -6.28e-02 | 2.37e-02 | -1.57e-01 | 9.16e-01 | 5.68e-01 | 6.35e-01 | 8.58e-01 | 2.37e-01 |
| NEGATIVE REGULATION OF ACTIN FILAMENT DEPOLYMERIZATION | 44 | 3.79e-01 | 8.87e-01 | 0.18700 | 6.30e-02 | 9.19e-02 | -2.98e-02 | 1.26e-01 | -7.60e-02 | 4.70e-01 | 2.92e-01 | 7.33e-01 | 1.48e-01 | 3.83e-01 |
| REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS NONSENSE MEDIATED DECAY | 13 | 9.58e-01 | 1.00e+00 | 0.18700 | -9.28e-02 | -8.38e-02 | -4.58e-02 | -9.57e-02 | 8.97e-02 | 5.62e-01 | 6.01e-01 | 7.75e-01 | 5.50e-01 | 5.75e-01 |
| MESODERM DEVELOPMENT | 124 | 1.44e-01 | 6.29e-01 | 0.18700 | 9.45e-02 | 9.22e-02 | 1.05e-01 | 5.58e-02 | -5.83e-02 | 6.91e-02 | 7.62e-02 | 4.40e-02 | 2.83e-01 | 2.62e-01 |
| POSITIVE REGULATION OF RESPONSE TO BIOTIC STIMULUS | 353 | 5.44e-03 | 8.18e-02 | 0.18700 | -9.46e-02 | -1.06e-01 | -4.10e-02 | -1.11e-01 | 2.97e-02 | 2.26e-03 | 6.58e-04 | 1.86e-01 | 3.49e-04 | 3.38e-01 |
| POSITIVE REGULATION OF MIRNA METABOLIC PROCESS | 60 | 1.25e-01 | 5.89e-01 | 0.18700 | 3.90e-02 | 2.51e-02 | 1.25e-01 | 1.03e-02 | 1.31e-01 | 6.02e-01 | 7.37e-01 | 9.46e-02 | 8.90e-01 | 7.99e-02 |
| PARAXIAL MESODERM FORMATION | 7 | 5.18e-01 | 9.52e-01 | 0.18700 | 2.01e-02 | -5.60e-02 | 1.30e-01 | -5.62e-02 | -1.07e-01 | 9.27e-01 | 7.97e-01 | 5.53e-01 | 7.97e-01 | 6.26e-01 |
| REGULATION OF MESENCHYMAL CELL PROLIFERATION | 32 | 3.53e-01 | 8.72e-01 | 0.18700 | 5.41e-02 | 5.71e-02 | 7.65e-02 | 3.80e-03 | -1.51e-01 | 5.96e-01 | 5.76e-01 | 4.54e-01 | 9.70e-01 | 1.40e-01 |
| COPII COATED VESICLE CARGO LOADING | 16 | 9.15e-01 | 1.00e+00 | 0.18700 | -7.03e-02 | -9.49e-02 | -2.50e-02 | -6.99e-02 | 1.24e-01 | 6.26e-01 | 5.11e-01 | 8.62e-01 | 6.28e-01 | 3.91e-01 |
| PROTEIN HOMOTETRAMERIZATION | 57 | 5.43e-01 | 9.60e-01 | 0.18700 | 9.15e-02 | 8.63e-02 | 9.38e-02 | 6.73e-02 | -7.53e-02 | 2.32e-01 | 2.60e-01 | 2.21e-01 | 3.80e-01 | 3.25e-01 |
| TORC1 SIGNALING | 96 | 9.15e-02 | 4.99e-01 | 0.18700 | 4.65e-02 | 3.82e-02 | 1.12e-01 | -2.45e-03 | 1.37e-01 | 4.31e-01 | 5.18e-01 | 5.81e-02 | 9.67e-01 | 2.08e-02 |
| CELLULAR RESPONSE TO AMYLOID BETA | 45 | 8.70e-01 | 1.00e+00 | 0.18700 | -9.29e-02 | -9.60e-02 | -6.40e-02 | -1.13e-01 | -8.99e-03 | 2.81e-01 | 2.65e-01 | 4.57e-01 | 1.90e-01 | 9.17e-01 |
| MONOSACCHARIDE BIOSYNTHETIC PROCESS | 96 | 5.97e-01 | 9.88e-01 | 0.18600 | 1.03e-01 | 1.04e-01 | 8.02e-02 | 7.88e-02 | -2.61e-02 | 8.20e-02 | 7.72e-02 | 1.75e-01 | 1.82e-01 | 6.58e-01 |
| EXTRACELLULAR EXOSOME ASSEMBLY | 7 | 9.81e-01 | 1.00e+00 | 0.18600 | -3.82e-02 | -4.72e-02 | 3.66e-02 | -6.47e-02 | 1.60e-01 | 8.61e-01 | 8.29e-01 | 8.67e-01 | 7.67e-01 | 4.64e-01 |
| RESPONSE TO FOLIC ACID | 10 | 6.37e-01 | 9.98e-01 | 0.18600 | 1.84e-03 | 6.55e-02 | -5.16e-02 | 1.84e-02 | -1.66e-01 | 9.92e-01 | 7.20e-01 | 7.77e-01 | 9.20e-01 | 3.65e-01 |
| LEUKOCYTE ACTIVATION INVOLVED IN INFLAMMATORY RESPONSE | 52 | 2.77e-02 | 2.56e-01 | 0.18600 | -8.21e-02 | -1.17e-01 | 3.67e-02 | -8.96e-02 | 7.03e-02 | 3.06e-01 | 1.45e-01 | 6.47e-01 | 2.64e-01 | 3.81e-01 |
| NEGATIVE REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE PROTEIN KINASE B SIGNAL TRANSDUCTION | 67 | 4.68e-01 | 9.36e-01 | 0.18600 | -9.89e-02 | -8.98e-02 | -4.96e-02 | -1.18e-01 | 2.33e-02 | 1.62e-01 | 2.04e-01 | 4.83e-01 | 9.54e-02 | 7.42e-01 |
| REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 186 | 8.23e-04 | 1.93e-02 | 0.18600 | -7.46e-02 | -7.99e-02 | 1.07e-02 | -1.43e-01 | 4.57e-02 | 7.94e-02 | 6.01e-02 | 8.01e-01 | 7.47e-04 | 2.82e-01 |
| GTP METABOLIC PROCESS | 24 | 6.61e-01 | 1.00e+00 | 0.18600 | 1.00e-01 | 5.86e-02 | 1.22e-01 | 7.13e-02 | 3.66e-02 | 3.96e-01 | 6.19e-01 | 3.03e-01 | 5.46e-01 | 7.56e-01 |
| THERMOCEPTION | 8 | 8.25e-01 | 1.00e+00 | 0.18600 | 8.98e-02 | 9.81e-02 | 5.54e-02 | 4.13e-02 | 1.10e-01 | 6.60e-01 | 6.31e-01 | 7.86e-01 | 8.40e-01 | 5.88e-01 |
| FATTY ACID CATABOLIC PROCESS | 104 | 3.22e-01 | 8.47e-01 | 0.18600 | 8.96e-02 | 1.01e-01 | 6.53e-02 | 1.08e-01 | 2.26e-02 | 1.14e-01 | 7.42e-02 | 2.50e-01 | 5.78e-02 | 6.91e-01 |
| FATTY ACID BETA OXIDATION USING ACYL COA OXIDASE | 12 | 8.46e-01 | 1.00e+00 | 0.18600 | 5.91e-02 | 8.54e-02 | -1.45e-02 | 1.42e-01 | -5.98e-02 | 7.23e-01 | 6.08e-01 | 9.31e-01 | 3.95e-01 | 7.20e-01 |
| DETECTION OF CELL DENSITY | 9 | 9.75e-01 | 1.00e+00 | 0.18600 | 8.21e-02 | 8.86e-02 | 8.07e-02 | 4.78e-02 | -1.06e-01 | 6.70e-01 | 6.45e-01 | 6.75e-01 | 8.04e-01 | 5.82e-01 |
| NEGATIVE REGULATION OF INFLAMMATORY RESPONSE TO WOUNDING | 9 | 8.00e-01 | 1.00e+00 | 0.18600 | -4.51e-02 | -3.71e-02 | -1.13e-01 | 3.81e-02 | 1.31e-01 | 8.15e-01 | 8.47e-01 | 5.58e-01 | 8.43e-01 | 4.98e-01 |
| MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 18 | 5.72e-01 | 9.76e-01 | 0.18600 | 6.78e-02 | 4.31e-02 | 1.61e-01 | -3.84e-02 | -2.60e-02 | 6.19e-01 | 7.52e-01 | 2.36e-01 | 7.78e-01 | 8.48e-01 |
| MACROPHAGE DIFFERENTIATION | 61 | 3.99e-02 | 3.22e-01 | 0.18600 | -3.68e-02 | -7.92e-02 | 8.65e-02 | -8.09e-02 | 1.14e-01 | 6.19e-01 | 2.85e-01 | 2.42e-01 | 2.74e-01 | 1.25e-01 |
| POSITIVE REGULATION OF REPRODUCTIVE PROCESS | 83 | 5.65e-01 | 9.71e-01 | 0.18600 | 9.77e-02 | 8.55e-02 | 8.12e-02 | 1.05e-01 | -1.27e-02 | 1.24e-01 | 1.78e-01 | 2.01e-01 | 9.92e-02 | 8.41e-01 |
| NEGATIVE REGULATION OF MRNA METABOLIC PROCESS | 90 | 4.63e-01 | 9.33e-01 | 0.18600 | 7.71e-02 | 6.92e-02 | 1.06e-01 | 6.15e-02 | 9.38e-02 | 2.06e-01 | 2.57e-01 | 8.20e-02 | 3.13e-01 | 1.24e-01 |
| POSITIVE REGULATION OF NEUROTRANSMITTER TRANSPORT | 23 | 2.83e-01 | 8.10e-01 | 0.18600 | 3.04e-02 | 1.46e-02 | -2.45e-02 | 1.16e-01 | -1.38e-01 | 8.01e-01 | 9.04e-01 | 8.39e-01 | 3.34e-01 | 2.51e-01 |
| RESPONSE TO IRON II ION | 6 | 5.89e-01 | 9.86e-01 | 0.18600 | 6.81e-02 | -2.00e-03 | 9.35e-02 | 1.22e-01 | -7.90e-02 | 7.73e-01 | 9.93e-01 | 6.92e-01 | 6.06e-01 | 7.37e-01 |
| PHOSPHATIDYLINOSITOL PHOSPHATE BIOSYNTHETIC PROCESS | 64 | 2.56e-01 | 7.83e-01 | 0.18500 | -2.91e-02 | -4.45e-02 | 4.80e-02 | -4.62e-02 | 1.65e-01 | 6.87e-01 | 5.38e-01 | 5.06e-01 | 5.23e-01 | 2.26e-02 |
| CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION | 38 | 7.73e-01 | 1.00e+00 | 0.18500 | 1.03e-01 | 9.34e-02 | 1.16e-01 | 4.17e-02 | 4.25e-03 | 2.72e-01 | 3.19e-01 | 2.18e-01 | 6.56e-01 | 9.64e-01 |
| UBIQUITIN DEPENDENT ERAD PATHWAY | 82 | 1.39e-03 | 2.95e-02 | 0.18500 | 5.74e-02 | 2.87e-02 | 1.64e-01 | -5.65e-02 | -1.54e-02 | 3.69e-01 | 6.53e-01 | 1.03e-02 | 3.77e-01 | 8.09e-01 |
| REGULATION OF CENTROMERE COMPLEX ASSEMBLY | 6 | 9.93e-01 | 1.00e+00 | 0.18500 | 8.08e-02 | 8.18e-02 | 3.43e-02 | 1.24e-01 | 6.86e-02 | 7.32e-01 | 7.29e-01 | 8.84e-01 | 6.00e-01 | 7.71e-01 |
| POSITIVE REGULATION OF CYTOKINE PRODUCTION | 483 | 8.07e-07 | 5.47e-05 | 0.18500 | -8.45e-02 | -1.04e-01 | -5.71e-03 | -1.06e-01 | 7.23e-02 | 1.47e-03 | 8.99e-05 | 8.30e-01 | 7.08e-05 | 6.47e-03 |
| DNA TEMPLATED DNA REPLICATION MAINTENANCE OF FIDELITY | 54 | 3.25e-01 | 8.49e-01 | 0.18500 | 2.72e-02 | 4.12e-03 | 1.12e-01 | -2.75e-02 | 1.42e-01 | 7.30e-01 | 9.58e-01 | 1.54e-01 | 7.27e-01 | 7.07e-02 |
| POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE ACTIVITY | 14 | 9.67e-01 | 1.00e+00 | 0.18500 | 6.75e-02 | 5.93e-02 | 9.82e-02 | 3.59e-02 | 1.24e-01 | 6.62e-01 | 7.01e-01 | 5.25e-01 | 8.16e-01 | 4.23e-01 |
| DEFINITIVE HEMOPOIESIS | 19 | 3.54e-01 | 8.72e-01 | 0.18500 | 8.78e-02 | 2.78e-02 | 1.55e-01 | 3.62e-02 | -1.90e-02 | 5.07e-01 | 8.34e-01 | 2.41e-01 | 7.85e-01 | 8.86e-01 |
| CELL COMMUNICATION BY ELECTRICAL COUPLING | 34 | 1.60e-01 | 6.59e-01 | 0.18500 | -1.76e-02 | -4.15e-02 | 4.68e-02 | -1.07e-01 | -1.36e-01 | 8.59e-01 | 6.76e-01 | 6.37e-01 | 2.79e-01 | 1.69e-01 |
| OPTIC CUP MORPHOGENESIS INVOLVED IN CAMERA TYPE EYE DEVELOPMENT | 7 | 4.67e-01 | 9.36e-01 | 0.18500 | 6.10e-02 | -2.97e-02 | 1.67e-01 | 4.01e-02 | 1.25e-03 | 7.80e-01 | 8.92e-01 | 4.43e-01 | 8.54e-01 | 9.95e-01 |
| GALACTOLIPID BIOSYNTHETIC PROCESS | 6 | 7.16e-01 | 1.00e+00 | 0.18500 | -5.91e-02 | 1.50e-04 | -1.33e-01 | 6.88e-02 | -9.10e-02 | 8.02e-01 | 9.99e-01 | 5.72e-01 | 7.70e-01 | 7.00e-01 |
| UBIQUITIN RECYCLING | 13 | 7.29e-01 | 1.00e+00 | 0.18500 | -8.97e-02 | -5.07e-02 | -8.43e-02 | -6.97e-02 | 1.08e-01 | 5.76e-01 | 7.52e-01 | 5.99e-01 | 6.63e-01 | 5.00e-01 |
| VESICLE CYTOSKELETAL TRAFFICKING | 68 | 4.46e-01 | 9.30e-01 | 0.18500 | -8.81e-02 | -8.90e-02 | -2.71e-02 | -1.33e-01 | 1.55e-02 | 2.09e-01 | 2.04e-01 | 6.99e-01 | 5.85e-02 | 8.25e-01 |
| HISTONE MRNA CATABOLIC PROCESS | 15 | 4.67e-01 | 9.36e-01 | 0.18500 | 2.56e-03 | -2.99e-02 | 1.42e-01 | -1.15e-01 | 4.79e-03 | 9.86e-01 | 8.41e-01 | 3.42e-01 | 4.41e-01 | 9.74e-01 |
| MEMBRANOUS SEPTUM MORPHOGENESIS | 8 | 9.55e-01 | 1.00e+00 | 0.18500 | -7.10e-02 | -3.88e-02 | -7.68e-02 | -1.16e-01 | -9.09e-02 | 7.28e-01 | 8.49e-01 | 7.07e-01 | 5.70e-01 | 6.56e-01 |
| FAT CELL PROLIFERATION | 14 | 9.32e-01 | 1.00e+00 | 0.18500 | -9.55e-02 | -1.02e-01 | -1.92e-02 | -1.19e-01 | 1.42e-02 | 5.36e-01 | 5.10e-01 | 9.01e-01 | 4.41e-01 | 9.27e-01 |
| REGULATION OF EXCITATORY SYNAPSE ASSEMBLY | 15 | 8.17e-01 | 1.00e+00 | 0.18500 | 8.06e-02 | 1.24e-01 | 1.60e-02 | 9.40e-02 | -5.69e-02 | 5.89e-01 | 4.07e-01 | 9.15e-01 | 5.28e-01 | 7.03e-01 |
| NEUROBLAST DIVISION | 13 | 5.62e-01 | 9.71e-01 | 0.18500 | 1.29e-02 | -4.66e-02 | 5.69e-02 | 8.38e-03 | 1.69e-01 | 9.36e-01 | 7.71e-01 | 7.22e-01 | 9.58e-01 | 2.92e-01 |
| SYNAPTIC VESICLE LOCALIZATION | 53 | 1.69e-01 | 6.74e-01 | 0.18500 | -7.52e-02 | -9.40e-02 | 1.99e-02 | -1.37e-01 | -2.24e-02 | 3.44e-01 | 2.37e-01 | 8.02e-01 | 8.50e-02 | 7.78e-01 |
| NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 58 | 4.72e-02 | 3.52e-01 | 0.18400 | -5.68e-02 | -5.18e-02 | 3.31e-02 | -1.55e-01 | 5.48e-02 | 4.55e-01 | 4.95e-01 | 6.63e-01 | 4.12e-02 | 4.71e-01 |
| UV DAMAGE EXCISION REPAIR | 12 | 8.92e-01 | 1.00e+00 | 0.18400 | 8.02e-02 | 9.77e-02 | 6.73e-02 | 9.69e-02 | -6.41e-02 | 6.30e-01 | 5.58e-01 | 6.86e-01 | 5.61e-01 | 7.01e-01 |
| DNA RECOMBINATION | 318 | 2.98e-06 | 1.62e-04 | 0.18400 | 5.92e-02 | 3.30e-02 | 1.40e-01 | -7.35e-03 | 9.81e-02 | 6.96e-02 | 3.12e-01 | 1.65e-05 | 8.22e-01 | 2.63e-03 |
| CATECHOLAMINE SECRETION | 60 | 4.11e-01 | 9.08e-01 | 0.18400 | 9.37e-02 | 8.05e-02 | 9.13e-02 | 5.02e-02 | -8.86e-02 | 2.09e-01 | 2.81e-01 | 2.21e-01 | 5.01e-01 | 2.35e-01 |
| CARDIAC ATRIUM MORPHOGENESIS | 29 | 2.42e-01 | 7.68e-01 | 0.18400 | -3.27e-02 | -5.22e-02 | 5.89e-02 | -1.38e-01 | -8.72e-02 | 7.61e-01 | 6.27e-01 | 5.83e-01 | 1.98e-01 | 4.17e-01 |
| MICROTUBULE POLYMERIZATION | 91 | 3.25e-01 | 8.49e-01 | 0.18400 | 7.81e-02 | 7.45e-02 | 1.17e-01 | 4.40e-02 | 8.18e-02 | 1.98e-01 | 2.19e-01 | 5.38e-02 | 4.68e-01 | 1.77e-01 |
| POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 52 | 4.14e-01 | 9.11e-01 | 0.18400 | 1.93e-02 | 3.64e-02 | -3.22e-02 | 2.63e-02 | -1.75e-01 | 8.09e-01 | 6.50e-01 | 6.88e-01 | 7.43e-01 | 2.92e-02 |
| CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 200 | 1.51e-01 | 6.43e-01 | 0.18400 | 9.65e-02 | 9.17e-02 | 9.14e-02 | 8.32e-02 | -3.09e-02 | 1.87e-02 | 2.54e-02 | 2.59e-02 | 4.24e-02 | 4.51e-01 |
| SYNAPTIC VESICLE MEMBRANE ORGANIZATION | 27 | 8.43e-01 | 1.00e+00 | 0.18400 | 8.56e-02 | 1.04e-01 | 5.99e-02 | 9.40e-02 | 5.82e-02 | 4.41e-01 | 3.50e-01 | 5.90e-01 | 3.98e-01 | 6.01e-01 |
| CELL CELL ADHESION MEDIATED BY INTEGRIN | 17 | 7.97e-01 | 1.00e+00 | 0.18400 | -7.25e-02 | -1.10e-01 | -3.02e-02 | -4.84e-02 | 1.16e-01 | 6.05e-01 | 4.34e-01 | 8.30e-01 | 7.30e-01 | 4.10e-01 |
| BERGMANN GLIAL CELL DIFFERENTIATION | 11 | 7.50e-01 | 1.00e+00 | 0.18400 | 1.39e-02 | -3.26e-02 | 5.97e-02 | -1.82e-02 | 1.69e-01 | 9.36e-01 | 8.51e-01 | 7.32e-01 | 9.17e-01 | 3.31e-01 |
| RESPIRATORY SYSTEM PROCESS | 37 | 6.93e-01 | 1.00e+00 | 0.18400 | 9.35e-02 | 8.81e-02 | 3.95e-02 | 9.04e-02 | -8.69e-02 | 3.25e-01 | 3.54e-01 | 6.77e-01 | 3.41e-01 | 3.60e-01 |
| NEUROMUSCULAR PROCESS | 159 | 4.00e-01 | 9.00e-01 | 0.18400 | 9.71e-02 | 1.00e-01 | 7.09e-02 | 9.25e-02 | -2.69e-02 | 3.46e-02 | 2.90e-02 | 1.23e-01 | 4.42e-02 | 5.58e-01 |
| GLYCEROPHOSPHOLIPID CATABOLIC PROCESS | 34 | 6.64e-01 | 1.00e+00 | 0.18400 | 9.31e-02 | 1.22e-01 | 3.28e-02 | 8.31e-02 | -4.70e-02 | 3.47e-01 | 2.18e-01 | 7.41e-01 | 4.01e-01 | 6.36e-01 |
| RETROGRADE TRANS SYNAPTIC SIGNALING BY LIPID | 5 | 9.96e-01 | 1.00e+00 | 0.18400 | -7.77e-02 | -6.13e-02 | -1.07e-01 | -8.67e-02 | -7.15e-02 | 7.63e-01 | 8.12e-01 | 6.80e-01 | 7.37e-01 | 7.82e-01 |
| TRIGEMINAL NERVE DEVELOPMENT | 10 | 9.44e-01 | 1.00e+00 | 0.18400 | 8.70e-02 | 7.10e-02 | 1.33e-01 | 1.54e-02 | -5.76e-02 | 6.34e-01 | 6.97e-01 | 4.68e-01 | 9.33e-01 | 7.52e-01 |
| NEUROTRANSMITTER RECEPTOR TRANSPORT TO PLASMA MEMBRANE | 16 | 9.86e-01 | 1.00e+00 | 0.18400 | 9.39e-02 | 9.10e-02 | 1.06e-01 | 7.21e-02 | 1.62e-02 | 5.15e-01 | 5.29e-01 | 4.64e-01 | 6.18e-01 | 9.10e-01 |
| OLFACTORY LOBE DEVELOPMENT | 36 | 4.03e-02 | 3.23e-01 | 0.18400 | 5.08e-02 | 1.20e-02 | 1.61e-01 | -3.93e-02 | -6.01e-02 | 5.98e-01 | 9.01e-01 | 9.51e-02 | 6.83e-01 | 5.33e-01 |
| PYRIMIDINE RIBONUCLEOTIDE METABOLIC PROCESS | 30 | 9.60e-01 | 1.00e+00 | 0.18400 | 9.88e-02 | 1.03e-01 | 6.75e-02 | 9.01e-02 | -2.72e-02 | 3.49e-01 | 3.30e-01 | 5.22e-01 | 3.93e-01 | 7.97e-01 |
| AMINO ACID TRANSMEMBRANE TRANSPORT | 93 | 1.22e-01 | 5.83e-01 | 0.18400 | 8.95e-02 | 1.13e-01 | 5.75e-02 | 4.79e-02 | -8.56e-02 | 1.36e-01 | 5.97e-02 | 3.38e-01 | 4.25e-01 | 1.54e-01 |
| RESPONSE TO LIGHT INTENSITY | 16 | 4.68e-01 | 9.36e-01 | 0.18400 | 3.80e-02 | 9.34e-02 | -7.67e-02 | 1.30e-01 | -2.55e-02 | 7.93e-01 | 5.18e-01 | 5.95e-01 | 3.67e-01 | 8.60e-01 |
| RESPONSE TO ESTRADIOL | 111 | 5.29e-02 | 3.77e-01 | 0.18400 | 9.54e-02 | 7.36e-02 | 1.34e-01 | 2.45e-02 | -2.35e-02 | 8.23e-02 | 1.80e-01 | 1.46e-02 | 6.55e-01 | 6.69e-01 |
| PLATELET DENSE GRANULE ORGANIZATION | 24 | 4.18e-01 | 9.11e-01 | 0.18300 | 3.57e-02 | 4.10e-03 | 1.38e-01 | -8.17e-02 | 8.09e-02 | 7.62e-01 | 9.72e-01 | 2.41e-01 | 4.88e-01 | 4.93e-01 |
| MONOCYTE DIFFERENTIATION | 34 | 8.29e-01 | 1.00e+00 | 0.18300 | 6.30e-02 | 4.70e-02 | 1.06e-01 | 3.30e-02 | 1.23e-01 | 5.25e-01 | 6.35e-01 | 2.86e-01 | 7.39e-01 | 2.14e-01 |
| NEGATIVE REGULATION OF DNA REPAIR | 33 | 6.63e-01 | 1.00e+00 | 0.18300 | 4.88e-02 | 2.59e-02 | 1.28e-01 | 1.48e-03 | 1.19e-01 | 6.27e-01 | 7.97e-01 | 2.02e-01 | 9.88e-01 | 2.38e-01 |
| GENITALIA MORPHOGENESIS | 11 | 8.51e-01 | 1.00e+00 | 0.18300 | -6.32e-02 | -7.40e-02 | -5.91e-02 | -2.50e-02 | -1.42e-01 | 7.17e-01 | 6.71e-01 | 7.34e-01 | 8.86e-01 | 4.16e-01 |
| PROGESTERONE BIOSYNTHETIC PROCESS | 6 | 8.38e-01 | 1.00e+00 | 0.18300 | -3.98e-03 | -4.12e-02 | 2.16e-02 | 1.03e-01 | 1.44e-01 | 9.87e-01 | 8.61e-01 | 9.27e-01 | 6.63e-01 | 5.40e-01 |
| SNO S RNA PROCESSING | 12 | 8.82e-01 | 1.00e+00 | 0.18300 | 4.57e-02 | 8.66e-03 | 6.50e-02 | 7.67e-02 | 1.46e-01 | 7.84e-01 | 9.59e-01 | 6.97e-01 | 6.45e-01 | 3.81e-01 |
| MICROTUBULE ORGANIZING CENTER LOCALIZATION | 32 | 4.25e-01 | 9.15e-01 | 0.18300 | -7.36e-02 | -6.52e-02 | -1.86e-02 | -1.15e-01 | -1.01e-01 | 4.71e-01 | 5.23e-01 | 8.55e-01 | 2.60e-01 | 3.21e-01 |
| RESPONSE TO EPIDERMAL GROWTH FACTOR | 44 | 7.00e-01 | 1.00e+00 | 0.18300 | 6.98e-02 | 5.77e-02 | 1.23e-01 | 2.76e-02 | 9.75e-02 | 4.23e-01 | 5.08e-01 | 1.59e-01 | 7.52e-01 | 2.63e-01 |
| POSITIVE REGULATION OF OSTEOBLAST DIFFERENTIATION | 71 | 1.45e-01 | 6.29e-01 | 0.18300 | -5.35e-02 | -4.36e-02 | -7.63e-02 | -1.71e-02 | -1.50e-01 | 4.36e-01 | 5.25e-01 | 2.66e-01 | 8.04e-01 | 2.83e-02 |
| RENAL SYSTEM VASCULATURE MORPHOGENESIS | 8 | 9.73e-01 | 1.00e+00 | 0.18300 | -9.32e-02 | -1.19e-01 | -8.32e-02 | -5.61e-02 | 2.38e-02 | 6.48e-01 | 5.60e-01 | 6.84e-01 | 7.84e-01 | 9.07e-01 |
| IMMUNE RESPONSE REGULATING SIGNALING PATHWAY | 461 | 7.72e-07 | 5.33e-05 | 0.18300 | -8.85e-02 | -1.13e-01 | -1.78e-02 | -1.09e-01 | 2.79e-02 | 1.12e-03 | 3.32e-05 | 5.13e-01 | 6.22e-05 | 3.05e-01 |
| HISTAMINE METABOLIC PROCESS | 6 | 9.52e-01 | 1.00e+00 | 0.18300 | -7.63e-02 | -1.26e-01 | -9.87e-04 | -6.74e-02 | 8.54e-02 | 7.46e-01 | 5.94e-01 | 9.97e-01 | 7.75e-01 | 7.17e-01 |
| ORGANELLE FISSION | 480 | 8.62e-07 | 5.69e-05 | 0.18300 | 7.75e-02 | 5.37e-02 | 1.37e-01 | 2.88e-02 | 7.05e-02 | 3.61e-03 | 4.38e-02 | 2.77e-07 | 2.80e-01 | 8.13e-03 |
| REGULATION OF TYPE I INTERFERON MEDIATED SIGNALING PATHWAY | 43 | 6.74e-01 | 1.00e+00 | 0.18300 | 9.51e-02 | 7.76e-02 | 1.28e-01 | 4.13e-02 | -1.90e-02 | 2.81e-01 | 3.79e-01 | 1.47e-01 | 6.39e-01 | 8.30e-01 |
| INDOLALKYLAMINE METABOLIC PROCESS | 11 | 9.71e-01 | 1.00e+00 | 0.18300 | -7.51e-02 | -6.17e-02 | -5.95e-02 | -9.18e-02 | -1.10e-01 | 6.66e-01 | 7.23e-01 | 7.32e-01 | 5.98e-01 | 5.29e-01 |
| DETECTION OF LIGHT STIMULUS | 61 | 3.70e-02 | 3.06e-01 | 0.18300 | -1.50e-02 | 1.78e-02 | -1.25e-01 | 9.27e-02 | -9.36e-02 | 8.39e-01 | 8.10e-01 | 9.25e-02 | 2.11e-01 | 2.06e-01 |
| RETROGRADE TRANS SYNAPTIC SIGNALING | 10 | 8.85e-01 | 1.00e+00 | 0.18300 | -5.75e-02 | -2.77e-02 | -7.92e-02 | -1.14e-01 | -1.00e-01 | 7.53e-01 | 8.79e-01 | 6.64e-01 | 5.33e-01 | 5.84e-01 |
| REGULATION OF TETRAPYRROLE METABOLIC PROCESS | 8 | 8.95e-01 | 1.00e+00 | 0.18300 | 6.41e-03 | 5.48e-02 | -5.05e-02 | -2.81e-02 | -1.64e-01 | 9.75e-01 | 7.88e-01 | 8.05e-01 | 8.90e-01 | 4.21e-01 |
| ERYTHROCYTE MATURATION | 17 | 9.12e-01 | 1.00e+00 | 0.18200 | 6.56e-02 | 7.42e-02 | 8.20e-02 | 6.73e-02 | 1.11e-01 | 6.39e-01 | 5.96e-01 | 5.58e-01 | 6.31e-01 | 4.30e-01 |
| REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 182 | 5.60e-02 | 3.85e-01 | 0.18200 | 9.04e-02 | 8.40e-02 | 1.23e-01 | 5.12e-02 | 1.64e-02 | 3.54e-02 | 5.07e-02 | 4.20e-03 | 2.34e-01 | 7.02e-01 |
| ATRIAL CARDIAC MUSCLE CELL TO AV NODE CELL COMMUNICATION | 17 | 7.53e-01 | 1.00e+00 | 0.18200 | 2.04e-02 | 3.03e-02 | -2.70e-02 | 7.04e-02 | -1.62e-01 | 8.84e-01 | 8.29e-01 | 8.47e-01 | 6.15e-01 | 2.48e-01 |
| NEUROTRANSMITTER RECEPTOR TRANSPORT ENDOSOME TO POSTSYNAPTIC MEMBRANE | 10 | 9.89e-01 | 1.00e+00 | 0.18200 | 9.97e-02 | 7.79e-02 | 9.68e-02 | 8.63e-02 | 1.99e-02 | 5.85e-01 | 6.70e-01 | 5.96e-01 | 6.37e-01 | 9.13e-01 |
| LIPID OXIDATION | 112 | 3.37e-01 | 8.59e-01 | 0.18200 | 9.07e-02 | 1.08e-01 | 5.23e-02 | 9.44e-02 | -4.23e-02 | 9.72e-02 | 4.92e-02 | 3.39e-01 | 8.45e-02 | 4.39e-01 |
| REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 41 | 8.83e-01 | 1.00e+00 | 0.18200 | 9.37e-02 | 9.66e-02 | 5.45e-02 | 8.86e-02 | -6.55e-02 | 2.99e-01 | 2.85e-01 | 5.46e-01 | 3.26e-01 | 4.68e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO ENDOPLASMIC RETICULUM | 42 | 1.72e-02 | 1.86e-01 | 0.18200 | 1.32e-02 | 2.27e-02 | 1.24e-01 | -1.16e-01 | 6.05e-02 | 8.82e-01 | 7.99e-01 | 1.65e-01 | 1.92e-01 | 4.98e-01 |
| PROGESTERONE RECEPTOR SIGNALING PATHWAY | 11 | 9.02e-01 | 1.00e+00 | 0.18200 | 7.50e-02 | 7.41e-02 | -1.24e-02 | 1.48e-01 | 2.50e-03 | 6.67e-01 | 6.71e-01 | 9.43e-01 | 3.95e-01 | 9.89e-01 |
| INNER EAR RECEPTOR CELL STEREOCILIUM ORGANIZATION | 35 | 4.25e-01 | 9.15e-01 | 0.18200 | 5.79e-02 | 9.48e-02 | 5.00e-03 | 2.74e-02 | -1.42e-01 | 5.53e-01 | 3.32e-01 | 9.59e-01 | 7.79e-01 | 1.47e-01 |
| REGULATION OF ALPHA BETA T CELL DIFFERENTIATION | 70 | 3.68e-02 | 3.06e-01 | 0.18200 | -5.49e-02 | -7.99e-02 | 6.30e-02 | -1.33e-01 | 4.64e-02 | 4.27e-01 | 2.48e-01 | 3.62e-01 | 5.45e-02 | 5.02e-01 |
| CHEMOREPULSION OF AXON | 6 | 7.96e-01 | 1.00e+00 | 0.18200 | -8.83e-02 | -1.38e-01 | -6.21e-02 | -9.69e-03 | -4.94e-02 | 7.08e-01 | 5.59e-01 | 7.92e-01 | 9.67e-01 | 8.34e-01 |
| PROTEIN AUTO ADP RIBOSYLATION | 11 | 9.38e-01 | 1.00e+00 | 0.18200 | 7.79e-02 | 6.51e-02 | 8.87e-02 | 1.15e-01 | 4.07e-02 | 6.54e-01 | 7.09e-01 | 6.10e-01 | 5.08e-01 | 8.15e-01 |
| CATECHOL CONTAINING COMPOUND METABOLIC PROCESS | 50 | 2.85e-01 | 8.12e-01 | 0.18200 | 8.95e-02 | 6.30e-02 | 1.10e-01 | 6.10e-02 | -7.27e-02 | 2.73e-01 | 4.41e-01 | 1.78e-01 | 4.55e-01 | 3.74e-01 |
| EAR MORPHOGENESIS | 124 | 1.51e-02 | 1.70e-01 | 0.18200 | 8.48e-02 | 6.37e-02 | 1.47e-01 | 1.30e-02 | -3.11e-03 | 1.03e-01 | 2.21e-01 | 4.62e-03 | 8.03e-01 | 9.52e-01 |
| STRESS GRANULE DISASSEMBLY | 5 | 8.74e-01 | 1.00e+00 | 0.18200 | 4.33e-02 | -2.07e-02 | 1.61e-01 | -6.76e-02 | 1.84e-02 | 8.67e-01 | 9.36e-01 | 5.33e-01 | 7.94e-01 | 9.43e-01 |
| ALPHA BETA T CELL ACTIVATION | 169 | 1.58e-03 | 3.29e-02 | 0.18200 | -8.13e-02 | -9.50e-02 | 1.16e-02 | -1.30e-01 | 1.88e-02 | 6.81e-02 | 3.32e-02 | 7.95e-01 | 3.47e-03 | 6.74e-01 |
| DNA DAMAGE RESPONSE | 835 | 1.84e-14 | 8.13e-12 | 0.18200 | 7.21e-02 | 5.48e-02 | 1.40e-01 | 3.86e-03 | 7.28e-02 | 3.98e-04 | 7.14e-03 | 6.36e-12 | 8.50e-01 | 3.49e-04 |
| CEREBELLAR PURKINJE CELL LAYER MORPHOGENESIS | 18 | 8.51e-01 | 1.00e+00 | 0.18200 | 4.58e-02 | 3.35e-02 | 1.26e-01 | -1.22e-02 | 1.18e-01 | 7.37e-01 | 8.06e-01 | 3.55e-01 | 9.29e-01 | 3.88e-01 |
| POSITIVE REGULATION OF GLUCOSE IMPORT | 35 | 8.06e-01 | 1.00e+00 | 0.18200 | 8.62e-02 | 1.02e-01 | 4.89e-02 | 1.03e-01 | 4.61e-02 | 3.77e-01 | 2.95e-01 | 6.17e-01 | 2.91e-01 | 6.37e-01 |
| MORPHOGENESIS OF EMBRYONIC EPITHELIUM | 150 | 6.89e-02 | 4.30e-01 | 0.18200 | 7.81e-02 | 6.69e-02 | 1.21e-01 | 5.79e-02 | 6.66e-02 | 9.88e-02 | 1.57e-01 | 1.06e-02 | 2.21e-01 | 1.59e-01 |
| FUCOSE CATABOLIC PROCESS | 9 | 9.90e-01 | 1.00e+00 | 0.18200 | -8.95e-02 | -1.10e-01 | -4.79e-02 | -7.75e-02 | 6.74e-02 | 6.42e-01 | 5.67e-01 | 8.03e-01 | 6.87e-01 | 7.26e-01 |
| N ACYLETHANOLAMINE METABOLIC PROCESS | 5 | 7.59e-01 | 1.00e+00 | 0.18100 | -5.80e-02 | 3.03e-02 | -1.18e-01 | -5.50e-02 | -1.08e-01 | 8.22e-01 | 9.07e-01 | 6.48e-01 | 8.31e-01 | 6.75e-01 |
| REGULATION OF HEPATOCYTE PROLIFERATION | 16 | 3.97e-01 | 8.96e-01 | 0.18100 | -2.61e-02 | -9.68e-02 | 6.68e-02 | -3.38e-02 | 1.31e-01 | 8.57e-01 | 5.02e-01 | 6.44e-01 | 8.15e-01 | 3.63e-01 |
| PHOSPHATIDYLGLYCEROL BIOSYNTHETIC PROCESS | 9 | 7.71e-01 | 1.00e+00 | 0.18100 | 4.29e-02 | 5.55e-02 | 6.28e-02 | -3.49e-02 | 1.51e-01 | 8.24e-01 | 7.73e-01 | 7.44e-01 | 8.56e-01 | 4.32e-01 |
| REGULATION OF TAU PROTEIN KINASE ACTIVITY | 13 | 8.26e-01 | 1.00e+00 | 0.18100 | -4.26e-02 | -6.51e-02 | -1.42e-02 | -9.71e-02 | -1.31e-01 | 7.90e-01 | 6.84e-01 | 9.29e-01 | 5.44e-01 | 4.12e-01 |
| AV NODE CELL TO BUNDLE OF HIS CELL COMMUNICATION | 14 | 8.05e-01 | 1.00e+00 | 0.18100 | 4.65e-02 | 5.71e-02 | -3.66e-02 | 1.42e-01 | -7.73e-02 | 7.63e-01 | 7.12e-01 | 8.12e-01 | 3.57e-01 | 6.16e-01 |
| PYRIDINE CONTAINING COMPOUND METABOLIC PROCESS | 83 | 4.93e-01 | 9.45e-01 | 0.18100 | 9.04e-02 | 7.65e-02 | 1.19e-01 | 6.48e-02 | 2.13e-02 | 1.55e-01 | 2.28e-01 | 6.05e-02 | 3.07e-01 | 7.38e-01 |
| HEART PROCESS | 245 | 1.20e-02 | 1.43e-01 | 0.18100 | 8.42e-02 | 9.59e-02 | 5.61e-02 | 8.52e-02 | -7.85e-02 | 2.32e-02 | 9.71e-03 | 1.30e-01 | 2.16e-02 | 3.42e-02 |
| REGULATION OF SEQUESTERING OF TRIGLYCERIDE | 15 | 9.46e-01 | 1.00e+00 | 0.18100 | -6.39e-02 | -7.06e-02 | -9.52e-03 | -8.84e-02 | 1.26e-01 | 6.69e-01 | 6.36e-01 | 9.49e-01 | 5.53e-01 | 3.98e-01 |
| MYOTUBE CELL DEVELOPMENT | 40 | 5.03e-01 | 9.48e-01 | 0.18100 | -2.48e-02 | -3.91e-03 | -5.23e-02 | -2.12e-02 | -1.70e-01 | 7.86e-01 | 9.66e-01 | 5.67e-01 | 8.17e-01 | 6.22e-02 |
| POSITIVE REGULATION OF AXON EXTENSION | 33 | 9.52e-01 | 1.00e+00 | 0.18100 | -1.00e-01 | -9.37e-02 | -9.01e-02 | -7.68e-02 | -1.84e-03 | 3.19e-01 | 3.52e-01 | 3.70e-01 | 4.45e-01 | 9.85e-01 |
| OLIGODENDROCYTE PROGENITOR PROLIFERATION | 8 | 6.14e-01 | 9.90e-01 | 0.18100 | -6.90e-02 | -1.08e-01 | -1.17e-01 | -2.48e-02 | 4.69e-02 | 7.35e-01 | 5.98e-01 | 5.67e-01 | 9.03e-01 | 8.19e-01 |
| LEARNING | 145 | 1.80e-01 | 6.87e-01 | 0.18100 | 8.78e-02 | 9.44e-02 | 6.76e-02 | 6.87e-02 | -8.29e-02 | 6.79e-02 | 4.96e-02 | 1.60e-01 | 1.53e-01 | 8.49e-02 |
| PATTERN SPECIFICATION PROCESS | 457 | 2.30e-08 | 2.25e-06 | 0.18100 | 9.12e-02 | 7.63e-02 | 1.27e-01 | 1.92e-02 | -4.58e-02 | 8.30e-04 | 5.20e-03 | 3.12e-06 | 4.81e-01 | 9.33e-02 |
| RESPONSE TO BACTERIAL LIPOPROTEIN | 10 | 7.06e-01 | 1.00e+00 | 0.18100 | -1.08e-03 | -3.92e-02 | 1.16e-01 | -1.32e-01 | -2.11e-02 | 9.95e-01 | 8.30e-01 | 5.26e-01 | 4.70e-01 | 9.08e-01 |
| REGULATION OF VENTRICULAR CARDIAC MUSCLE CELL ACTION POTENTIAL | 12 | 6.37e-01 | 9.98e-01 | 0.18100 | 4.42e-02 | 1.10e-01 | -5.57e-02 | 8.24e-02 | -9.44e-02 | 7.91e-01 | 5.11e-01 | 7.38e-01 | 6.21e-01 | 5.71e-01 |
| REGULATION OF STORE OPERATED CALCIUM CHANNEL ACTIVITY | 6 | 9.35e-01 | 1.00e+00 | 0.18100 | -7.27e-02 | -1.08e-01 | -1.99e-02 | -7.63e-02 | -9.81e-02 | 7.58e-01 | 6.47e-01 | 9.33e-01 | 7.46e-01 | 6.77e-01 |
| REGULATION OF NEUROTRANSMITTER RECEPTOR ACTIVITY | 45 | 3.78e-01 | 8.85e-01 | 0.18100 | 8.68e-02 | 1.22e-01 | 4.70e-02 | 7.88e-02 | -4.44e-02 | 3.14e-01 | 1.58e-01 | 5.86e-01 | 3.60e-01 | 6.06e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO OXIDATIVE STRESS | 61 | 3.78e-01 | 8.86e-01 | 0.18100 | -7.59e-02 | -7.42e-02 | -2.91e-02 | -1.23e-01 | -7.37e-02 | 3.05e-01 | 3.16e-01 | 6.94e-01 | 9.60e-02 | 3.20e-01 |
| NEGATIVE REGULATION OF MYOBLAST DIFFERENTIATION | 24 | 2.50e-01 | 7.75e-01 | 0.18100 | 2.20e-03 | -7.30e-03 | 1.24e-01 | -1.29e-01 | 2.70e-02 | 9.85e-01 | 9.51e-01 | 2.94e-01 | 2.75e-01 | 8.19e-01 |
| HOMOLOGOUS CHROMOSOME PAIRING AT MEIOSIS | 52 | 8.13e-01 | 1.00e+00 | 0.18100 | 9.98e-02 | 8.44e-02 | 9.46e-02 | 8.10e-02 | 5.14e-03 | 2.13e-01 | 2.92e-01 | 2.38e-01 | 3.12e-01 | 9.49e-01 |
| REGULATION OF COMPLEMENT ACTIVATION | 22 | 9.06e-01 | 1.00e+00 | 0.18100 | -9.31e-02 | -7.17e-02 | -1.29e-01 | -4.75e-02 | 4.37e-04 | 4.49e-01 | 5.60e-01 | 2.96e-01 | 6.99e-01 | 9.97e-01 |
| REGULATION OF PROTEIN IMPORT INTO NUCLEUS | 57 | 3.17e-01 | 8.44e-01 | 0.18100 | -8.26e-02 | -6.98e-02 | -4.31e-02 | -1.36e-01 | 2.47e-02 | 2.81e-01 | 3.62e-01 | 5.73e-01 | 7.60e-02 | 7.47e-01 |
| INFLAMMATORY RESPONSE TO ANTIGENIC STIMULUS | 76 | 2.56e-01 | 7.83e-01 | 0.18100 | -8.53e-02 | -1.12e-01 | -2.29e-02 | -7.39e-02 | 8.24e-02 | 1.98e-01 | 9.12e-02 | 7.30e-01 | 2.65e-01 | 2.14e-01 |
| REGULATION OF LAMELLIPODIUM ASSEMBLY | 37 | 5.02e-01 | 9.48e-01 | 0.18000 | 6.53e-02 | 9.78e-02 | -3.23e-02 | 1.03e-01 | -8.47e-02 | 4.92e-01 | 3.03e-01 | 7.34e-01 | 2.80e-01 | 3.72e-01 |
| EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 659 | 6.58e-05 | 2.45e-03 | 0.18000 | 9.52e-02 | 8.92e-02 | 1.11e-01 | 5.74e-02 | 2.00e-03 | 3.03e-05 | 9.30e-05 | 1.26e-06 | 1.19e-02 | 9.30e-01 |
| NEGATIVE REGULATION OF TYROSINE PHOSPHORYLATION OF STAT PROTEIN | 12 | 7.58e-01 | 1.00e+00 | 0.18000 | 1.57e-02 | 1.83e-02 | -5.58e-02 | -1.24e-02 | -1.69e-01 | 9.25e-01 | 9.12e-01 | 7.38e-01 | 9.41e-01 | 3.10e-01 |
| REGULATION OF HEMATOPOIETIC STEM CELL PROLIFERATION | 15 | 6.18e-01 | 9.90e-01 | 0.18000 | 4.01e-02 | 3.30e-02 | 1.07e-01 | -5.56e-02 | -1.24e-01 | 7.88e-01 | 8.25e-01 | 4.74e-01 | 7.09e-01 | 4.06e-01 |
| TRNA THREONYLCARBAMOYLADENOSINE METABOLIC PROCESS | 15 | 3.66e-01 | 8.79e-01 | 0.18000 | -7.15e-02 | -6.73e-02 | 5.97e-02 | -1.37e-01 | 2.31e-02 | 6.32e-01 | 6.52e-01 | 6.89e-01 | 3.58e-01 | 8.77e-01 |
| INNER CELL MASS CELL PROLIFERATION | 14 | 6.09e-01 | 9.90e-01 | 0.18000 | 7.86e-02 | 4.36e-02 | 1.02e-01 | -1.07e-02 | -1.18e-01 | 6.10e-01 | 7.78e-01 | 5.10e-01 | 9.45e-01 | 4.44e-01 |
| MITOTIC RECOMBINATION | 25 | 4.21e-01 | 9.12e-01 | 0.18000 | -3.33e-02 | -2.03e-02 | 3.57e-02 | -4.25e-02 | 1.67e-01 | 7.73e-01 | 8.61e-01 | 7.57e-01 | 7.13e-01 | 1.48e-01 |
| KERATINOCYTE DIFFERENTIATION | 174 | 2.08e-08 | 2.11e-06 | 0.18000 | 2.01e-02 | 4.57e-02 | -1.06e-01 | 1.37e-01 | 1.31e-03 | 6.48e-01 | 2.98e-01 | 1.61e-02 | 1.80e-03 | 9.76e-01 |
| NEGATIVE REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 38 | 5.27e-01 | 9.54e-01 | 0.18000 | -8.27e-02 | -9.26e-02 | 8.36e-03 | -1.25e-01 | 3.78e-02 | 3.78e-01 | 3.23e-01 | 9.29e-01 | 1.83e-01 | 6.87e-01 |
| REGULATION OF MAST CELL CHEMOTAXIS | 7 | 8.81e-01 | 1.00e+00 | 0.18000 | 5.14e-02 | 4.04e-02 | 1.57e-01 | -3.10e-03 | 5.91e-02 | 8.14e-01 | 8.53e-01 | 4.72e-01 | 9.89e-01 | 7.87e-01 |
| POSITIVE REGULATION OF IMMUNE RESPONSE | 700 | 2.80e-08 | 2.70e-06 | 0.18000 | -8.87e-02 | -1.08e-01 | -2.32e-02 | -1.04e-01 | 3.82e-02 | 6.25e-05 | 1.08e-06 | 2.96e-01 | 2.53e-06 | 8.51e-02 |
| ENDOPLASMIC RETICULUM TO GOLGI VESICLE MEDIATED TRANSPORT | 127 | 1.83e-02 | 1.96e-01 | 0.18000 | 6.26e-02 | 3.95e-02 | 1.31e-01 | -1.45e-02 | 9.81e-02 | 2.23e-01 | 4.42e-01 | 1.09e-02 | 7.78e-01 | 5.63e-02 |
| POSITIVE REGULATION OF INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS | 30 | 2.91e-01 | 8.18e-01 | 0.18000 | 3.49e-02 | 5.37e-02 | 5.54e-02 | -2.29e-02 | -1.57e-01 | 7.41e-01 | 6.10e-01 | 5.99e-01 | 8.28e-01 | 1.36e-01 |
| ACTIVATED T CELL PROLIFERATION | 47 | 8.88e-01 | 1.00e+00 | 0.18000 | -9.75e-02 | -8.60e-02 | -1.01e-01 | -7.29e-02 | 5.00e-04 | 2.48e-01 | 3.07e-01 | 2.32e-01 | 3.87e-01 | 9.95e-01 |
| REGULATION OF ALPHA BETA T CELL ACTIVATION | 109 | 9.63e-02 | 5.12e-01 | 0.18000 | -7.85e-02 | -8.66e-02 | -3.65e-03 | -1.36e-01 | 1.86e-02 | 1.57e-01 | 1.18e-01 | 9.48e-01 | 1.45e-02 | 7.37e-01 |
| NEGATIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 7 | 9.93e-01 | 1.00e+00 | 0.18000 | 5.19e-02 | 3.93e-02 | 7.56e-02 | 4.97e-02 | 1.41e-01 | 8.12e-01 | 8.57e-01 | 7.29e-01 | 8.20e-01 | 5.18e-01 |
| POSITIVE THYMIC T CELL SELECTION | 14 | 9.84e-01 | 1.00e+00 | 0.18000 | 8.98e-02 | 8.52e-02 | 6.99e-02 | 1.09e-01 | -1.82e-02 | 5.61e-01 | 5.81e-01 | 6.51e-01 | 4.81e-01 | 9.06e-01 |
| POSITIVE REGULATION OF ORGANELLE ASSEMBLY | 82 | 1.01e-01 | 5.26e-01 | 0.18000 | 5.94e-02 | 4.03e-02 | 1.34e-01 | 2.85e-02 | 9.20e-02 | 3.53e-01 | 5.28e-01 | 3.62e-02 | 6.56e-01 | 1.50e-01 |
| THYROID HORMONE METABOLIC PROCESS | 28 | 8.08e-01 | 1.00e+00 | 0.18000 | -7.37e-02 | -4.18e-02 | -1.08e-01 | -5.48e-02 | -1.02e-01 | 5.00e-01 | 7.02e-01 | 3.22e-01 | 6.16e-01 | 3.49e-01 |
| CARDIAC MYOFIBRIL ASSEMBLY | 19 | 8.84e-01 | 1.00e+00 | 0.18000 | -5.93e-03 | 1.40e-02 | -7.49e-02 | 2.43e-02 | -1.61e-01 | 9.64e-01 | 9.16e-01 | 5.72e-01 | 8.55e-01 | 2.25e-01 |
| NEPHRIC DUCT DEVELOPMENT | 14 | 5.63e-01 | 9.71e-01 | 0.18000 | 1.57e-02 | -1.08e-02 | 1.33e-01 | -1.18e-01 | -1.91e-02 | 9.19e-01 | 9.44e-01 | 3.90e-01 | 4.44e-01 | 9.02e-01 |
| ATRIOVENTRICULAR VALVE DEVELOPMENT | 29 | 2.48e-01 | 7.75e-01 | 0.18000 | 6.32e-02 | 2.57e-02 | 1.59e-01 | -4.64e-02 | -1.71e-02 | 5.56e-01 | 8.11e-01 | 1.39e-01 | 6.65e-01 | 8.73e-01 |
| POSITIVE REGULATION OF TYROSINE PHOSPHORYLATION OF STAT PROTEIN | 65 | 3.54e-01 | 8.73e-01 | 0.18000 | -7.88e-02 | -7.61e-02 | -2.94e-02 | -1.24e-01 | -6.33e-02 | 2.72e-01 | 2.89e-01 | 6.82e-01 | 8.35e-02 | 3.78e-01 |
| REGULATION OF ANIMAL ORGAN FORMATION | 27 | 4.05e-01 | 9.06e-01 | 0.18000 | 7.31e-02 | 4.42e-02 | 1.17e-01 | 2.01e-02 | -1.05e-01 | 5.11e-01 | 6.91e-01 | 2.94e-01 | 8.57e-01 | 3.47e-01 |
| SERINE FAMILY AMINO ACID CATABOLIC PROCESS | 14 | 6.57e-01 | 1.00e+00 | 0.18000 | -2.92e-02 | -5.85e-03 | -8.29e-02 | 6.41e-02 | 1.43e-01 | 8.50e-01 | 9.70e-01 | 5.91e-01 | 6.78e-01 | 3.55e-01 |
| REGULATION OF DNA METHYLATION DEPENDENT HETEROCHROMATIN FORMATION | 18 | 7.27e-01 | 1.00e+00 | 0.17900 | 3.85e-02 | 3.62e-02 | 5.92e-02 | -2.88e-02 | -1.58e-01 | 7.78e-01 | 7.91e-01 | 6.63e-01 | 8.33e-01 | 2.45e-01 |
| ACUTE PHASE RESPONSE | 47 | 2.34e-01 | 7.56e-01 | 0.17900 | -8.91e-02 | -9.32e-02 | -1.02e-01 | 8.07e-03 | 7.11e-02 | 2.91e-01 | 2.69e-01 | 2.25e-01 | 9.24e-01 | 3.99e-01 |
| L ARGININE TRANSMEMBRANE TRANSPORT | 14 | 4.72e-01 | 9.40e-01 | 0.17900 | -8.85e-03 | -3.11e-02 | -2.38e-02 | -8.44e-02 | -1.53e-01 | 9.54e-01 | 8.40e-01 | 8.77e-01 | 5.85e-01 | 3.21e-01 |
| REGULATION OF AUTOPHAGOSOME MATURATION | 16 | 8.36e-01 | 1.00e+00 | 0.17900 | 6.33e-02 | 3.90e-02 | 1.32e-01 | -2.58e-02 | 9.19e-02 | 6.61e-01 | 7.87e-01 | 3.60e-01 | 8.58e-01 | 5.24e-01 |
| NEGATIVE REGULATION OF ORGANELLE ASSEMBLY | 42 | 8.95e-01 | 1.00e+00 | 0.17900 | -8.90e-02 | -7.93e-02 | -8.91e-02 | -9.52e-02 | -3.00e-02 | 3.18e-01 | 3.74e-01 | 3.17e-01 | 2.86e-01 | 7.37e-01 |
| AMINE METABOLIC PROCESS | 107 | 1.83e-01 | 6.92e-01 | 0.17900 | 8.58e-02 | 7.92e-02 | 8.43e-02 | 6.04e-02 | -8.79e-02 | 1.25e-01 | 1.57e-01 | 1.32e-01 | 2.80e-01 | 1.16e-01 |
| DEOXYRIBONUCLEOSIDE DIPHOSPHATE METABOLIC PROCESS | 5 | 9.65e-01 | 1.00e+00 | 0.17900 | 4.66e-02 | 2.74e-02 | 4.60e-02 | -1.83e-02 | -1.64e-01 | 8.57e-01 | 9.16e-01 | 8.59e-01 | 9.43e-01 | 5.27e-01 |
| SPINDLE ORGANIZATION | 194 | 1.79e-04 | 5.63e-03 | 0.17900 | 6.14e-02 | 2.89e-02 | 1.49e-01 | -9.97e-03 | 7.30e-02 | 1.40e-01 | 4.88e-01 | 3.60e-04 | 8.11e-01 | 7.96e-02 |
| AMP BIOSYNTHETIC PROCESS | 12 | 9.72e-01 | 1.00e+00 | 0.17900 | -7.89e-02 | -8.97e-02 | -1.74e-02 | -1.31e-01 | 1.63e-02 | 6.36e-01 | 5.90e-01 | 9.17e-01 | 4.31e-01 | 9.22e-01 |
| MACROPHAGE CHEMOTAXIS | 41 | 8.54e-01 | 1.00e+00 | 0.17900 | -9.43e-02 | -9.46e-02 | -8.88e-02 | -5.69e-02 | 5.58e-02 | 2.96e-01 | 2.95e-01 | 3.25e-01 | 5.29e-01 | 5.37e-01 |
| EMBRYONIC ORGAN DEVELOPMENT | 446 | 8.75e-07 | 5.72e-05 | 0.17900 | 9.00e-02 | 7.11e-02 | 1.36e-01 | 2.05e-02 | 1.05e-02 | 1.11e-03 | 1.01e-02 | 9.10e-07 | 4.59e-01 | 7.04e-01 |
| CGMP MEDIATED SIGNALING | 30 | 4.86e-01 | 9.43e-01 | 0.17900 | 3.60e-02 | 5.72e-02 | -5.91e-02 | 1.25e-01 | -9.09e-02 | 7.33e-01 | 5.88e-01 | 5.75e-01 | 2.35e-01 | 3.89e-01 |
| PROTEIN EXIT FROM ENDOPLASMIC RETICULUM | 48 | 4.25e-02 | 3.31e-01 | 0.17900 | 4.63e-02 | 2.63e-02 | 1.45e-01 | -8.95e-02 | 1.15e-02 | 5.79e-01 | 7.52e-01 | 8.22e-02 | 2.84e-01 | 8.90e-01 |
| POSITIVE REGULATION OF TOLL LIKE RECEPTOR 3 SIGNALING PATHWAY | 8 | 8.94e-01 | 1.00e+00 | 0.17900 | -7.65e-02 | -4.53e-02 | -3.55e-02 | -1.04e-01 | 1.10e-01 | 7.08e-01 | 8.24e-01 | 8.62e-01 | 6.10e-01 | 5.92e-01 |
| SKELETAL SYSTEM MORPHOGENESIS | 226 | 9.13e-03 | 1.18e-01 | 0.17900 | 8.78e-02 | 8.84e-02 | 9.49e-02 | 4.93e-02 | -7.08e-02 | 2.30e-02 | 2.21e-02 | 1.40e-02 | 2.01e-01 | 6.65e-02 |
| POSITIVE REGULATION OF HIPPO SIGNALING | 10 | 8.73e-01 | 1.00e+00 | 0.17900 | 5.90e-02 | 8.88e-02 | 3.47e-03 | 1.24e-01 | -7.13e-02 | 7.47e-01 | 6.27e-01 | 9.85e-01 | 4.96e-01 | 6.96e-01 |
| FATTY ACID ALPHA OXIDATION | 8 | 8.30e-01 | 1.00e+00 | 0.17900 | 6.65e-02 | 1.10e-01 | 5.70e-02 | 7.33e-02 | 8.19e-02 | 7.45e-01 | 5.89e-01 | 7.80e-01 | 7.19e-01 | 6.88e-01 |
| ESTABLISHMENT OF RNA LOCALIZATION | 147 | 8.24e-02 | 4.72e-01 | 0.17900 | 6.63e-02 | 4.47e-02 | 1.20e-01 | 2.44e-02 | 1.02e-01 | 1.65e-01 | 3.49e-01 | 1.17e-02 | 6.09e-01 | 3.26e-02 |
| DETECTION OF STIMULUS INVOLVED IN SENSORY PERCEPTION OF PAIN | 26 | 9.35e-01 | 1.00e+00 | 0.17900 | 9.41e-02 | 8.00e-02 | 9.81e-02 | 8.00e-02 | -2.46e-02 | 4.06e-01 | 4.80e-01 | 3.86e-01 | 4.80e-01 | 8.28e-01 |
| CELLULAR MODIFIED AMINO ACID BIOSYNTHETIC PROCESS | 26 | 5.08e-01 | 9.48e-01 | 0.17900 | -9.73e-02 | -1.16e-01 | -7.96e-02 | -3.19e-02 | -3.94e-02 | 3.90e-01 | 3.05e-01 | 4.82e-01 | 7.78e-01 | 7.28e-01 |
| ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 67 | 8.42e-02 | 4.78e-01 | 0.17800 | -4.42e-02 | -6.38e-02 | 6.20e-02 | -1.29e-01 | 7.28e-02 | 5.31e-01 | 3.66e-01 | 3.80e-01 | 6.77e-02 | 3.03e-01 |
| OLIGODENDROCYTE DEVELOPMENT | 44 | 2.81e-01 | 8.08e-01 | 0.17800 | 5.92e-02 | 4.35e-02 | 1.40e-01 | -4.08e-02 | 7.19e-02 | 4.97e-01 | 6.18e-01 | 1.08e-01 | 6.40e-01 | 4.09e-01 |
| NEGATIVE REGULATION OF RECEPTOR INTERNALIZATION | 16 | 5.32e-01 | 9.54e-01 | 0.17800 | 5.93e-02 | 8.74e-02 | 7.49e-02 | -5.12e-02 | -1.11e-01 | 6.81e-01 | 5.45e-01 | 6.04e-01 | 7.23e-01 | 4.40e-01 |
| NEGATIVE REGULATION OF CELL MATURATION | 8 | 8.34e-01 | 1.00e+00 | 0.17800 | 6.67e-02 | 1.21e-01 | -4.59e-02 | 1.01e-01 | -2.43e-02 | 7.44e-01 | 5.55e-01 | 8.22e-01 | 6.22e-01 | 9.05e-01 |
| LIPID CATABOLIC PROCESS | 329 | 2.04e-02 | 2.11e-01 | 0.17800 | 8.97e-02 | 1.01e-01 | 4.76e-02 | 1.05e-01 | -1.49e-02 | 5.15e-03 | 1.67e-03 | 1.38e-01 | 1.02e-03 | 6.41e-01 |
| REGULATION OF RESPONSE TO OSMOTIC STRESS | 16 | 7.55e-01 | 1.00e+00 | 0.17800 | 2.68e-02 | -5.84e-03 | 1.33e-01 | -6.75e-02 | 9.36e-02 | 8.53e-01 | 9.68e-01 | 3.57e-01 | 6.40e-01 | 5.17e-01 |
| PURINE DEOXYRIBONUCLEOTIDE METABOLIC PROCESS | 16 | 7.77e-01 | 1.00e+00 | 0.17800 | 5.61e-02 | 5.26e-02 | 6.77e-02 | 3.64e-02 | -1.41e-01 | 6.97e-01 | 7.16e-01 | 6.39e-01 | 8.01e-01 | 3.28e-01 |
| POSITIVE REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 13 | 8.39e-01 | 1.00e+00 | 0.17800 | 9.25e-02 | 8.83e-02 | 2.42e-02 | 1.10e-01 | 5.11e-02 | 5.64e-01 | 5.81e-01 | 8.80e-01 | 4.90e-01 | 7.50e-01 |
| POSITIVE REGULATION OF VIRAL PROCESS | 62 | 4.38e-01 | 9.24e-01 | 0.17800 | 6.38e-02 | 4.85e-02 | 1.26e-01 | 2.49e-02 | 9.40e-02 | 3.85e-01 | 5.09e-01 | 8.62e-02 | 7.34e-01 | 2.00e-01 |
| STRIATED MUSCLE CELL PROLIFERATION | 80 | 3.07e-02 | 2.74e-01 | 0.17800 | 6.67e-02 | 5.82e-02 | 9.03e-02 | -2.12e-02 | -1.24e-01 | 3.03e-01 | 3.68e-01 | 1.62e-01 | 7.43e-01 | 5.59e-02 |
| CELLULAR RESPONSE TO FATTY ACID | 33 | 1.48e-01 | 6.36e-01 | 0.17800 | 3.22e-02 | 5.55e-02 | -2.23e-02 | 1.16e-01 | -1.16e-01 | 7.49e-01 | 5.81e-01 | 8.24e-01 | 2.47e-01 | 2.48e-01 |
| NEGATIVE REGULATION OF NEUROINFLAMMATORY RESPONSE | 18 | 6.63e-01 | 1.00e+00 | 0.17800 | -5.64e-02 | -3.72e-02 | 1.83e-03 | -9.50e-02 | 1.34e-01 | 6.79e-01 | 7.85e-01 | 9.89e-01 | 4.85e-01 | 3.23e-01 |
| RESPONSE TO MITOCHONDRIAL DEPOLARISATION | 19 | 6.19e-01 | 9.90e-01 | 0.17800 | -8.77e-02 | -5.90e-02 | -3.24e-02 | -1.38e-01 | 1.74e-02 | 5.08e-01 | 6.56e-01 | 8.07e-01 | 2.97e-01 | 8.96e-01 |
| POSITIVE REGULATION OF PROTEOLYSIS INVOLVED IN PROTEIN CATABOLIC PROCESS | 132 | 1.85e-01 | 6.93e-01 | 0.17800 | 8.67e-02 | 8.91e-02 | 1.09e-01 | 5.74e-02 | 3.01e-02 | 8.54e-02 | 7.71e-02 | 3.00e-02 | 2.55e-01 | 5.51e-01 |
| GLUCOSE METABOLIC PROCESS | 183 | 1.30e-01 | 5.97e-01 | 0.17800 | 9.34e-02 | 1.01e-01 | 9.41e-02 | 6.12e-02 | 3.16e-03 | 2.94e-02 | 1.81e-02 | 2.81e-02 | 1.53e-01 | 9.41e-01 |
| SECRETORY GRANULE LOCALIZATION | 13 | 3.80e-01 | 8.87e-01 | 0.17800 | -1.34e-02 | -9.73e-03 | 3.74e-02 | -1.69e-01 | -3.47e-02 | 9.33e-01 | 9.52e-01 | 8.16e-01 | 2.90e-01 | 8.29e-01 |
| LYMPHOCYTE APOPTOTIC PROCESS | 80 | 1.53e-01 | 6.49e-01 | 0.17800 | -7.67e-02 | -8.34e-02 | 7.99e-03 | -1.34e-01 | 2.92e-02 | 2.36e-01 | 1.97e-01 | 9.02e-01 | 3.89e-02 | 6.52e-01 |
| REGULATION OF ATP DEPENDENT ACTIVITY | 61 | 4.16e-01 | 9.11e-01 | 0.17800 | 7.62e-02 | 6.69e-02 | 1.30e-01 | 7.60e-03 | 6.53e-02 | 3.03e-01 | 3.66e-01 | 7.86e-02 | 9.18e-01 | 3.78e-01 |
| RESPONSE TO ORGANOPHOSPHORUS | 121 | 6.27e-02 | 4.11e-01 | 0.17800 | 8.54e-02 | 8.17e-02 | 9.74e-02 | 8.12e-02 | -3.87e-02 | 1.05e-01 | 1.21e-01 | 6.43e-02 | 1.23e-01 | 4.62e-01 |
| PLANAR CELL POLARITY PATHWAY INVOLVED IN NEURAL TUBE CLOSURE | 11 | 3.87e-01 | 8.92e-01 | 0.17800 | -2.91e-02 | -7.25e-03 | 9.73e-02 | -9.68e-02 | 1.09e-01 | 8.67e-01 | 9.67e-01 | 5.76e-01 | 5.78e-01 | 5.33e-01 |
| REGULATION OF PEPTIDYL THREONINE PHOSPHORYLATION | 43 | 6.47e-01 | 1.00e+00 | 0.17700 | -9.42e-02 | -1.05e-01 | -3.11e-02 | -8.32e-02 | 6.03e-02 | 2.85e-01 | 2.32e-01 | 7.24e-01 | 3.45e-01 | 4.94e-01 |
| POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 93 | 6.74e-01 | 1.00e+00 | 0.17700 | 9.60e-02 | 9.08e-02 | 9.69e-02 | 6.68e-02 | -1.29e-02 | 1.10e-01 | 1.30e-01 | 1.06e-01 | 2.65e-01 | 8.30e-01 |
| MONOSACCHARIDE METABOLIC PROCESS | 249 | 8.70e-02 | 4.87e-01 | 0.17700 | 9.22e-02 | 9.38e-02 | 1.00e-01 | 6.00e-02 | 2.34e-02 | 1.22e-02 | 1.08e-02 | 6.51e-03 | 1.03e-01 | 5.25e-01 |
| DEOXYRIBONUCLEOTIDE CATABOLIC PROCESS | 28 | 5.37e-01 | 9.57e-01 | 0.17700 | 3.48e-02 | 1.05e-02 | 1.36e-01 | -5.27e-02 | 9.37e-02 | 7.50e-01 | 9.23e-01 | 2.12e-01 | 6.30e-01 | 3.91e-01 |
| NEURONAL ION CHANNEL CLUSTERING | 12 | 9.31e-01 | 1.00e+00 | 0.17700 | 7.72e-02 | 8.38e-02 | 3.21e-02 | 3.24e-02 | -1.28e-01 | 6.43e-01 | 6.15e-01 | 8.47e-01 | 8.46e-01 | 4.42e-01 |
| REGULATION OF POSTSYNAPSE ORGANIZATION | 97 | 3.38e-01 | 8.59e-01 | 0.17700 | -9.68e-02 | -9.02e-02 | -7.53e-02 | -7.93e-02 | -4.47e-02 | 9.95e-02 | 1.25e-01 | 2.00e-01 | 1.77e-01 | 4.47e-01 |
| REGULATION OF INFLAMMATORY RESPONSE | 410 | 3.11e-03 | 5.41e-02 | 0.17700 | -9.20e-02 | -1.05e-01 | -5.17e-02 | -9.60e-02 | 3.85e-04 | 1.39e-03 | 2.51e-04 | 7.25e-02 | 8.49e-04 | 9.89e-01 |
| PROTEIN KINASE C SIGNALING | 35 | 7.14e-01 | 1.00e+00 | 0.17700 | 8.13e-02 | 5.58e-02 | 1.21e-01 | 7.09e-02 | 4.40e-02 | 4.05e-01 | 5.68e-01 | 2.14e-01 | 4.68e-01 | 6.53e-01 |
| POSITIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 122 | 3.82e-02 | 3.12e-01 | 0.17700 | 3.92e-02 | 3.26e-02 | 1.04e-01 | 5.68e-03 | 1.34e-01 | 4.54e-01 | 5.35e-01 | 4.71e-02 | 9.14e-01 | 1.06e-02 |
| NOREPINEPHRINE METABOLIC PROCESS | 12 | 5.38e-01 | 9.57e-01 | 0.17700 | -3.00e-02 | -7.20e-02 | -6.44e-03 | -1.01e-01 | -1.22e-01 | 8.57e-01 | 6.66e-01 | 9.69e-01 | 5.43e-01 | 4.63e-01 |
| PERICARDIUM MORPHOGENESIS | 8 | 7.71e-01 | 1.00e+00 | 0.17700 | -1.46e-02 | -5.82e-02 | -4.58e-03 | -3.71e-02 | -1.62e-01 | 9.43e-01 | 7.75e-01 | 9.82e-01 | 8.56e-01 | 4.27e-01 |
| REGULATION OF NUCLEASE ACTIVITY | 22 | 8.56e-01 | 1.00e+00 | 0.17700 | 3.22e-02 | 1.90e-02 | 9.91e-02 | -1.17e-02 | 1.41e-01 | 7.94e-01 | 8.78e-01 | 4.21e-01 | 9.24e-01 | 2.51e-01 |
| NEGATIVE REGULATION OF COLD INDUCED THERMOGENESIS | 46 | 8.90e-02 | 4.92e-01 | 0.17700 | -6.15e-02 | -8.88e-02 | 5.98e-02 | -1.26e-01 | 1.25e-02 | 4.71e-01 | 2.97e-01 | 4.83e-01 | 1.39e-01 | 8.83e-01 |
| AORTA DEVELOPMENT | 65 | 3.18e-02 | 2.80e-01 | 0.17700 | 4.54e-02 | 1.48e-02 | 1.57e-01 | -4.47e-02 | 5.03e-02 | 5.26e-01 | 8.36e-01 | 2.91e-02 | 5.33e-01 | 4.83e-01 |
| DETECTION OF MECHANICAL STIMULUS INVOLVED IN SENSORY PERCEPTION OF PAIN | 15 | 6.99e-01 | 1.00e+00 | 0.17700 | 3.95e-02 | 1.66e-02 | -3.57e-03 | 4.83e-02 | -1.65e-01 | 7.91e-01 | 9.11e-01 | 9.81e-01 | 7.46e-01 | 2.70e-01 |
| PREASSEMBLY OF GPI ANCHOR IN ER MEMBRANE | 7 | 9.40e-01 | 1.00e+00 | 0.17700 | -3.46e-02 | -8.46e-02 | 6.77e-02 | -7.23e-02 | 1.14e-01 | 8.74e-01 | 6.98e-01 | 7.56e-01 | 7.40e-01 | 6.00e-01 |
| SULFUR COMPOUND TRANSPORT | 53 | 7.26e-01 | 1.00e+00 | 0.17700 | 8.61e-02 | 8.85e-02 | 7.21e-02 | 1.04e-01 | -7.99e-03 | 2.78e-01 | 2.65e-01 | 3.64e-01 | 1.91e-01 | 9.20e-01 |
| INNER EAR AUDITORY RECEPTOR CELL DIFFERENTIATION | 45 | 4.10e-01 | 9.08e-01 | 0.17700 | 5.44e-02 | 8.62e-02 | -3.93e-02 | 7.80e-02 | -1.15e-01 | 5.28e-01 | 3.17e-01 | 6.48e-01 | 3.65e-01 | 1.82e-01 |
| PIGMENTATION | 108 | 4.41e-01 | 9.26e-01 | 0.17700 | -8.62e-02 | -9.47e-02 | -4.90e-02 | -1.11e-01 | 8.27e-03 | 1.22e-01 | 8.90e-02 | 3.79e-01 | 4.58e-02 | 8.82e-01 |
| REGULATION OF DOUBLE STRAND BREAK REPAIR VIA HOMOLOGOUS RECOMBINATION | 66 | 4.42e-01 | 9.27e-01 | 0.17700 | 7.89e-02 | 6.23e-02 | 1.32e-01 | 1.51e-02 | 5.97e-02 | 2.68e-01 | 3.82e-01 | 6.46e-02 | 8.32e-01 | 4.02e-01 |
| XENOBIOTIC EXPORT FROM CELL | 26 | 2.79e-01 | 8.05e-01 | 0.17700 | 2.30e-02 | 2.25e-02 | -6.13e-02 | 1.42e-01 | -7.82e-02 | 8.39e-01 | 8.42e-01 | 5.88e-01 | 2.09e-01 | 4.90e-01 |
| BASEMENT MEMBRANE ORGANIZATION | 36 | 5.96e-01 | 9.88e-01 | 0.17700 | -2.24e-02 | 2.23e-03 | -6.44e-02 | -3.32e-03 | -1.63e-01 | 8.16e-01 | 9.82e-01 | 5.04e-01 | 9.73e-01 | 9.09e-02 |
| TOOTH MINERALIZATION | 28 | 3.04e-01 | 8.32e-01 | 0.17600 | 1.19e-02 | 2.62e-02 | -9.83e-02 | 1.32e-01 | -5.57e-02 | 9.13e-01 | 8.10e-01 | 3.68e-01 | 2.25e-01 | 6.10e-01 |
| REGULATION OF CELL CELL ADHESION | 479 | 7.62e-05 | 2.76e-03 | 0.17600 | -9.42e-02 | -9.96e-02 | -3.96e-02 | -9.08e-02 | 4.99e-02 | 4.14e-04 | 1.88e-04 | 1.38e-01 | 6.57e-04 | 6.13e-02 |
| G0 TO G1 TRANSITION | 36 | 7.24e-01 | 1.00e+00 | 0.17600 | 8.65e-02 | 1.09e-01 | 6.34e-02 | 8.47e-02 | -2.09e-02 | 3.69e-01 | 2.56e-01 | 5.10e-01 | 3.79e-01 | 8.28e-01 |
| REGULATION OF CENTRIOLE REPLICATION | 23 | 4.18e-01 | 9.11e-01 | 0.17600 | 3.80e-03 | -2.93e-03 | 1.21e-01 | -8.72e-02 | 9.44e-02 | 9.75e-01 | 9.81e-01 | 3.17e-01 | 4.69e-01 | 4.33e-01 |
| REGULATION OF EPITHELIAL CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 14 | 3.04e-01 | 8.32e-01 | 0.17600 | 3.48e-02 | -4.56e-02 | 1.51e-01 | -8.70e-03 | 7.04e-02 | 8.22e-01 | 7.68e-01 | 3.28e-01 | 9.55e-01 | 6.48e-01 |
| GERM CELL PROLIFERATION | 10 | 5.22e-01 | 9.53e-01 | 0.17600 | 6.94e-02 | 2.94e-03 | 1.55e-01 | -4.53e-02 | -1.36e-02 | 7.04e-01 | 9.87e-01 | 3.96e-01 | 8.04e-01 | 9.41e-01 |
| PROTEIN ACYLATION | 134 | 3.47e-02 | 2.96e-01 | 0.17600 | 6.06e-02 | 5.69e-02 | 1.18e-01 | 5.49e-03 | 1.01e-01 | 2.26e-01 | 2.56e-01 | 1.84e-02 | 9.13e-01 | 4.35e-02 |
| RESPONSE TO INTERLEUKIN 6 | 41 | 2.39e-01 | 7.63e-01 | 0.17600 | -8.59e-02 | -4.43e-02 | -1.16e-01 | -8.99e-02 | -6.54e-03 | 3.41e-01 | 6.24e-01 | 1.97e-01 | 3.19e-01 | 9.42e-01 |
| PHOSPHATIDYLCHOLINE METABOLIC PROCESS | 74 | 2.07e-01 | 7.27e-01 | 0.17600 | 6.50e-02 | 8.03e-02 | 3.68e-02 | 8.92e-02 | 1.05e-01 | 3.34e-01 | 2.33e-01 | 5.85e-01 | 1.85e-01 | 1.18e-01 |
| REGULATION OF SMOOTH MUSCLE CONTRACTION | 61 | 1.07e-01 | 5.43e-01 | 0.17600 | 7.81e-02 | 6.30e-02 | 1.08e-01 | 6.43e-02 | -7.23e-02 | 2.92e-01 | 3.95e-01 | 1.46e-01 | 3.85e-01 | 3.29e-01 |
| REGULATION OF SKELETAL MUSCLE TISSUE DEVELOPMENT | 25 | 2.36e-01 | 7.59e-01 | 0.17600 | 3.47e-02 | 1.34e-03 | 9.41e-02 | -2.92e-02 | -1.42e-01 | 7.64e-01 | 9.91e-01 | 4.16e-01 | 8.00e-01 | 2.20e-01 |
| NEGATIVE REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION | 21 | 5.35e-01 | 9.56e-01 | 0.17600 | 3.27e-02 | 7.68e-02 | -6.94e-02 | 1.16e-01 | -7.57e-02 | 7.95e-01 | 5.43e-01 | 5.82e-01 | 3.57e-01 | 5.48e-01 |
| WATER SOLUBLE VITAMIN METABOLIC PROCESS | 58 | 8.00e-01 | 1.00e+00 | 0.17600 | 7.80e-02 | 6.63e-02 | 8.93e-02 | 8.04e-02 | 7.81e-02 | 3.04e-01 | 3.83e-01 | 2.40e-01 | 2.89e-01 | 3.04e-01 |
| ACTIN FILAMENT DEPOLYMERIZATION | 58 | 5.16e-01 | 9.52e-01 | 0.17600 | 7.55e-02 | 9.55e-02 | 6.58e-03 | 1.18e-01 | -4.66e-02 | 3.20e-01 | 2.09e-01 | 9.31e-01 | 1.20e-01 | 5.39e-01 |
| BEHAVIORAL RESPONSE TO ETHANOL | 10 | 9.28e-01 | 1.00e+00 | 0.17600 | -6.19e-02 | -3.46e-02 | -1.06e-01 | 2.12e-03 | -1.22e-01 | 7.35e-01 | 8.50e-01 | 5.63e-01 | 9.91e-01 | 5.05e-01 |
| REGULATION OF SKELETAL MUSCLE CELL PROLIFERATION | 15 | 3.57e-01 | 8.74e-01 | 0.17600 | 5.16e-02 | 4.82e-02 | 1.16e-01 | -1.12e-01 | -8.46e-03 | 7.29e-01 | 7.47e-01 | 4.38e-01 | 4.53e-01 | 9.55e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN | 70 | 2.03e-02 | 2.10e-01 | 0.17600 | -5.91e-02 | -1.06e-01 | 4.80e-02 | -8.02e-02 | 8.62e-02 | 3.92e-01 | 1.24e-01 | 4.87e-01 | 2.46e-01 | 2.13e-01 |
| NEGATIVE REGULATION OF STEM CELL DIFFERENTIATION | 26 | 2.44e-01 | 7.70e-01 | 0.17600 | 4.66e-02 | 4.41e-02 | 1.33e-01 | -8.57e-02 | -4.14e-02 | 6.81e-01 | 6.97e-01 | 2.39e-01 | 4.50e-01 | 7.15e-01 |
| POSITIVE REGULATION OF NERVOUS SYSTEM PROCESS | 31 | 5.44e-01 | 9.61e-01 | 0.17600 | 2.97e-02 | 4.09e-02 | 4.67e-02 | 5.28e-02 | 1.53e-01 | 7.75e-01 | 6.93e-01 | 6.53e-01 | 6.11e-01 | 1.40e-01 |
| ALPHA LINOLENIC ACID METABOLIC PROCESS | 9 | 7.93e-01 | 1.00e+00 | 0.17600 | 2.22e-02 | 1.09e-02 | 1.40e-01 | -1.02e-01 | 1.50e-02 | 9.08e-01 | 9.55e-01 | 4.66e-01 | 5.96e-01 | 9.38e-01 |
| HISTONE METHYLATION | 35 | 4.74e-01 | 9.40e-01 | 0.17600 | 1.71e-02 | -1.13e-02 | 6.19e-02 | 5.23e-02 | 1.55e-01 | 8.61e-01 | 9.08e-01 | 5.26e-01 | 5.92e-01 | 1.13e-01 |
| REGULATION OF FEAR RESPONSE | 9 | 7.33e-01 | 1.00e+00 | 0.17600 | -4.76e-02 | -2.97e-03 | -1.68e-01 | 2.37e-02 | 4.54e-04 | 8.05e-01 | 9.88e-01 | 3.84e-01 | 9.02e-01 | 9.98e-01 |
| CELLULAR RESPONSE TO ESTRADIOL STIMULUS | 37 | 7.03e-01 | 1.00e+00 | 0.17600 | 8.50e-02 | 5.53e-02 | 1.08e-01 | 5.54e-02 | 7.63e-02 | 3.71e-01 | 5.61e-01 | 2.54e-01 | 5.60e-01 | 4.22e-01 |
| PYRIMIDINE RIBONUCLEOTIDE CATABOLIC PROCESS | 8 | 8.27e-01 | 1.00e+00 | 0.17600 | 1.35e-04 | 1.75e-02 | -8.20e-02 | 1.28e-01 | -8.62e-02 | 9.99e-01 | 9.32e-01 | 6.88e-01 | 5.30e-01 | 6.73e-01 |
| NECROPTOTIC PROCESS | 45 | 5.15e-01 | 9.52e-01 | 0.17600 | -7.96e-02 | -9.32e-02 | -5.92e-02 | -1.10e-01 | 1.53e-02 | 3.56e-01 | 2.79e-01 | 4.92e-01 | 2.01e-01 | 8.59e-01 |
| SUBSTANTIA NIGRA DEVELOPMENT | 40 | 5.64e-01 | 9.71e-01 | 0.17600 | 7.33e-02 | 5.09e-02 | 1.41e-01 | -1.54e-03 | 5.42e-02 | 4.22e-01 | 5.78e-01 | 1.22e-01 | 9.87e-01 | 5.53e-01 |
| POSITIVE REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION | 62 | 8.92e-02 | 4.93e-01 | 0.17600 | 8.18e-02 | 6.38e-02 | 1.33e-01 | -2.24e-02 | -4.25e-02 | 2.65e-01 | 3.85e-01 | 6.91e-02 | 7.60e-01 | 5.63e-01 |
| CELL COMMUNICATION INVOLVED IN CARDIAC CONDUCTION | 58 | 3.29e-01 | 8.53e-01 | 0.17600 | 6.09e-02 | 6.91e-02 | 5.06e-02 | 3.98e-02 | -1.35e-01 | 4.22e-01 | 3.63e-01 | 5.05e-01 | 6.00e-01 | 7.54e-02 |
| NEGATIVE REGULATION OF GLIOGENESIS | 44 | 6.56e-02 | 4.17e-01 | 0.17600 | -1.46e-03 | -1.06e-02 | 1.05e-01 | -1.29e-01 | 5.40e-02 | 9.87e-01 | 9.03e-01 | 2.27e-01 | 1.38e-01 | 5.36e-01 |
| REGULATION OF PHOSPHATE TRANSPORT | 6 | 9.45e-01 | 1.00e+00 | 0.17500 | 1.82e-02 | 1.87e-03 | 2.47e-02 | 1.48e-02 | -1.72e-01 | 9.39e-01 | 9.94e-01 | 9.16e-01 | 9.50e-01 | 4.65e-01 |
| NEURON RECOGNITION | 45 | 6.40e-01 | 1.00e+00 | 0.17500 | -7.37e-02 | -8.26e-02 | -9.10e-02 | -4.44e-02 | -9.10e-02 | 3.92e-01 | 3.38e-01 | 2.91e-01 | 6.07e-01 | 2.91e-01 |
| AUTONOMIC NERVOUS SYSTEM DEVELOPMENT | 45 | 2.90e-01 | 8.18e-01 | 0.17500 | 8.62e-02 | 7.69e-02 | 1.06e-01 | -6.40e-03 | -7.83e-02 | 3.17e-01 | 3.72e-01 | 2.18e-01 | 9.41e-01 | 3.64e-01 |
| POSITIVE REGULATION OF VASCULAR ENDOTHELIAL CELL PROLIFERATION | 26 | 7.19e-01 | 1.00e+00 | 0.17500 | 8.52e-02 | 6.07e-02 | 7.61e-02 | 7.61e-02 | 9.09e-02 | 4.52e-01 | 5.92e-01 | 5.02e-01 | 5.02e-01 | 4.23e-01 |
| METANEPHRIC GLOMERULUS DEVELOPMENT | 16 | 7.77e-01 | 1.00e+00 | 0.17500 | 6.62e-02 | 2.63e-02 | 1.53e-01 | 6.17e-03 | 4.65e-02 | 6.46e-01 | 8.56e-01 | 2.88e-01 | 9.66e-01 | 7.48e-01 |
| REGULATION OF CELL ACTIVATION | 630 | 5.03e-09 | 6.53e-07 | 0.17500 | -7.87e-02 | -9.74e-02 | 1.81e-03 | -1.05e-01 | 6.33e-02 | 7.42e-04 | 2.97e-05 | 9.38e-01 | 6.72e-06 | 6.65e-03 |
| ENDOPLASMIC RETICULUM TUBULAR NETWORK ORGANIZATION | 20 | 9.02e-01 | 1.00e+00 | 0.17500 | -7.28e-02 | -6.12e-02 | -4.43e-02 | -1.11e-01 | -8.62e-02 | 5.73e-01 | 6.35e-01 | 7.32e-01 | 3.91e-01 | 5.04e-01 |
| FATTY ACID DERIVATIVE BIOSYNTHETIC PROCESS | 44 | 1.83e-01 | 6.93e-01 | 0.17500 | 5.31e-02 | 6.02e-02 | -1.46e-02 | 1.54e-01 | -2.10e-02 | 5.42e-01 | 4.90e-01 | 8.67e-01 | 7.78e-02 | 8.10e-01 |
| GLUTAMATE SECRETION | 28 | 4.46e-01 | 9.30e-01 | 0.17500 | 6.56e-02 | 4.21e-02 | 9.29e-02 | -3.58e-03 | -1.26e-01 | 5.48e-01 | 6.99e-01 | 3.95e-01 | 9.74e-01 | 2.47e-01 |
| NEGATIVE REGULATION OF CELL ACTIVATION | 217 | 1.12e-03 | 2.51e-02 | 0.17500 | -7.57e-02 | -9.86e-02 | 1.27e-02 | -1.12e-01 | 5.00e-02 | 5.47e-02 | 1.23e-02 | 7.47e-01 | 4.48e-03 | 2.04e-01 |
| POSITIVE REGULATION OF SEQUESTERING OF CALCIUM ION | 15 | 9.57e-01 | 1.00e+00 | 0.17500 | -8.18e-02 | -1.03e-01 | -1.10e-02 | -1.11e-01 | 3.09e-02 | 5.84e-01 | 4.91e-01 | 9.41e-01 | 4.56e-01 | 8.36e-01 |
| EXCITATORY CHEMICAL SYNAPTIC TRANSMISSION | 10 | 9.44e-01 | 1.00e+00 | 0.17500 | 1.53e-02 | 1.84e-03 | 1.03e-01 | -2.23e-02 | 1.39e-01 | 9.33e-01 | 9.92e-01 | 5.73e-01 | 9.03e-01 | 4.47e-01 |
| CELLULAR HYPEROSMOTIC RESPONSE | 19 | 9.31e-01 | 1.00e+00 | 0.17500 | 6.78e-02 | 4.28e-02 | 1.25e-01 | 2.81e-02 | 8.82e-02 | 6.09e-01 | 7.47e-01 | 3.46e-01 | 8.32e-01 | 5.06e-01 |
| SYMPATHETIC NERVOUS SYSTEM DEVELOPMENT | 22 | 2.88e-01 | 8.15e-01 | 0.17500 | -2.94e-02 | -6.92e-02 | 6.07e-02 | -1.04e-01 | -1.03e-01 | 8.11e-01 | 5.74e-01 | 6.22e-01 | 4.00e-01 | 4.05e-01 |
| CALCIUM ION IMPORT | 46 | 7.09e-01 | 1.00e+00 | 0.17500 | -7.15e-02 | -4.49e-02 | -1.16e-01 | -4.33e-02 | -9.02e-02 | 4.02e-01 | 5.99e-01 | 1.74e-01 | 6.12e-01 | 2.90e-01 |
| POSITIVE REGULATION OF ATP DEPENDENT ACTIVITY | 39 | 5.42e-01 | 9.60e-01 | 0.17500 | 8.33e-02 | 7.89e-02 | 1.24e-01 | 9.44e-03 | -4.32e-02 | 3.68e-01 | 3.94e-01 | 1.79e-01 | 9.19e-01 | 6.41e-01 |
| POSTSYNAPTIC MODULATION OF CHEMICAL SYNAPTIC TRANSMISSION | 27 | 9.65e-01 | 1.00e+00 | 0.17500 | -8.83e-02 | -8.73e-02 | -7.17e-02 | -8.56e-02 | -5.16e-02 | 4.27e-01 | 4.32e-01 | 5.19e-01 | 4.41e-01 | 6.42e-01 |
| LIPOPROTEIN METABOLIC PROCESS | 129 | 7.97e-02 | 4.64e-01 | 0.17500 | 8.68e-02 | 8.21e-02 | 1.24e-01 | 2.69e-02 | -1.41e-02 | 8.85e-02 | 1.07e-01 | 1.53e-02 | 5.98e-01 | 7.82e-01 |
| T CELL DIFFERENTIATION IN THYMUS | 84 | 5.79e-02 | 3.93e-01 | 0.17500 | -6.27e-02 | -7.64e-02 | 3.41e-02 | -8.36e-02 | 1.12e-01 | 3.20e-01 | 2.26e-01 | 5.89e-01 | 1.86e-01 | 7.56e-02 |
| TRNA THREONYLCARBAMOYLADENOSINE MODIFICATION | 5 | 9.09e-01 | 1.00e+00 | 0.17500 | -3.12e-02 | -1.41e-02 | 5.19e-02 | -1.62e-01 | -2.03e-02 | 9.04e-01 | 9.57e-01 | 8.41e-01 | 5.31e-01 | 9.37e-01 |
| REGULATION OF GOLGI TO PLASMA MEMBRANE PROTEIN TRANSPORT | 9 | 8.23e-01 | 1.00e+00 | 0.17500 | -7.46e-02 | -1.28e-01 | -9.46e-03 | -9.08e-02 | -1.12e-02 | 6.99e-01 | 5.05e-01 | 9.61e-01 | 6.37e-01 | 9.54e-01 |
| NEGATIVE REGULATION OF CARDIOCYTE DIFFERENTIATION | 13 | 6.81e-01 | 1.00e+00 | 0.17400 | -3.58e-02 | -3.37e-02 | 7.16e-03 | -1.54e-01 | -6.48e-02 | 8.23e-01 | 8.33e-01 | 9.64e-01 | 3.36e-01 | 6.86e-01 |
| REGULATION OF GLYCOGEN STARCH SYNTHASE ACTIVITY | 5 | 9.38e-01 | 1.00e+00 | 0.17400 | -4.31e-02 | -3.49e-02 | 4.80e-02 | -1.44e-01 | -6.61e-02 | 8.67e-01 | 8.92e-01 | 8.53e-01 | 5.78e-01 | 7.98e-01 |
| POSITIVE REGULATION OF CELL CYCLE CHECKPOINT | 18 | 6.35e-01 | 9.97e-01 | 0.17400 | 5.10e-02 | 5.64e-02 | 1.14e-01 | 4.08e-02 | 1.00e-01 | 7.08e-01 | 6.78e-01 | 4.04e-01 | 7.64e-01 | 4.62e-01 |
| MULTI MULTICELLULAR ORGANISM PROCESS | 203 | 1.08e-01 | 5.46e-01 | 0.17400 | 8.21e-02 | 6.57e-02 | 1.11e-01 | 6.45e-02 | 5.44e-02 | 4.38e-02 | 1.07e-01 | 6.58e-03 | 1.13e-01 | 1.81e-01 |
| GLYCOLIPID BIOSYNTHETIC PROCESS | 72 | 6.69e-01 | 1.00e+00 | 0.17400 | 9.17e-02 | 7.44e-02 | 1.12e-01 | 5.49e-02 | 2.81e-02 | 1.78e-01 | 2.75e-01 | 9.91e-02 | 4.21e-01 | 6.81e-01 |
| REGULATION OF VESICLE FUSION | 24 | 6.70e-01 | 1.00e+00 | 0.17400 | 7.83e-02 | 7.77e-02 | 1.30e-01 | -7.25e-03 | -3.49e-02 | 5.07e-01 | 5.10e-01 | 2.70e-01 | 9.51e-01 | 7.67e-01 |
| REGULATION OF NEURAL PRECURSOR CELL PROLIFERATION | 98 | 6.94e-02 | 4.32e-01 | 0.17400 | 8.84e-02 | 6.21e-02 | 1.32e-01 | 2.46e-02 | -2.51e-02 | 1.31e-01 | 2.88e-01 | 2.38e-02 | 6.74e-01 | 6.68e-01 |
| LYTIC VACUOLE ORGANIZATION | 103 | 6.80e-02 | 4.27e-01 | 0.17400 | 1.35e-02 | 8.15e-03 | 7.37e-02 | -1.73e-03 | 1.57e-01 | 8.12e-01 | 8.86e-01 | 1.96e-01 | 9.76e-01 | 5.90e-03 |
| PURKINJE MYOCYTE TO VENTRICULAR CARDIAC MUSCLE CELL COMMUNICATION | 6 | 9.95e-01 | 1.00e+00 | 0.17400 | 8.17e-02 | 7.59e-02 | 3.46e-02 | 1.23e-01 | -3.85e-02 | 7.29e-01 | 7.47e-01 | 8.83e-01 | 6.01e-01 | 8.70e-01 |
| REGULATION OF MICROTUBULE BINDING | 7 | 9.56e-01 | 1.00e+00 | 0.17400 | 3.71e-02 | 2.77e-02 | 1.30e-01 | -1.54e-02 | 1.05e-01 | 8.65e-01 | 8.99e-01 | 5.51e-01 | 9.44e-01 | 6.30e-01 |
| CELLULAR RESPONSE TO IONIZING RADIATION | 68 | 6.08e-01 | 9.90e-01 | 0.17400 | 8.59e-02 | 9.10e-02 | 7.63e-02 | 5.65e-02 | -7.52e-02 | 2.21e-01 | 1.95e-01 | 2.76e-01 | 4.20e-01 | 2.84e-01 |
| MRNA POLYADENYLATION | 24 | 8.24e-02 | 4.72e-01 | 0.17400 | 6.36e-02 | 2.43e-03 | 1.09e-01 | 2.09e-02 | -1.18e-01 | 5.89e-01 | 9.84e-01 | 3.56e-01 | 8.60e-01 | 3.16e-01 |
| AROMATIC AMINO ACID METABOLIC PROCESS | 31 | 8.35e-01 | 1.00e+00 | 0.17400 | -7.84e-02 | -5.42e-02 | -8.36e-02 | -9.40e-02 | -7.35e-02 | 4.50e-01 | 6.01e-01 | 4.21e-01 | 3.65e-01 | 4.79e-01 |
| POSITIVE REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 34 | 2.38e-01 | 7.63e-01 | 0.17400 | 2.78e-02 | 2.27e-02 | -1.13e-02 | -2.66e-02 | -1.68e-01 | 7.79e-01 | 8.19e-01 | 9.09e-01 | 7.88e-01 | 9.03e-02 |
| COPPER ION HOMEOSTASIS | 17 | 7.23e-01 | 1.00e+00 | 0.17400 | -8.13e-03 | -1.54e-02 | 7.08e-02 | -2.84e-03 | 1.58e-01 | 9.54e-01 | 9.12e-01 | 6.13e-01 | 9.84e-01 | 2.59e-01 |
| REGULATION OF PROTEIN COMPLEX STABILITY | 14 | 5.58e-01 | 9.69e-01 | 0.17400 | -9.47e-02 | -5.51e-02 | -4.13e-02 | -1.11e-01 | 6.52e-02 | 5.40e-01 | 7.21e-01 | 7.89e-01 | 4.72e-01 | 6.73e-01 |
| POSITIVE REGULATION OF STEROID METABOLIC PROCESS | 27 | 1.65e-03 | 3.40e-02 | 0.17400 | -7.50e-04 | 5.03e-02 | -1.83e-02 | 1.27e-01 | 1.06e-01 | 9.95e-01 | 6.51e-01 | 8.69e-01 | 2.54e-01 | 3.39e-01 |
| REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS | 54 | 2.43e-01 | 7.69e-01 | 0.17400 | 7.98e-02 | 9.33e-02 | 8.99e-02 | 8.40e-02 | -3.63e-03 | 3.10e-01 | 2.36e-01 | 2.53e-01 | 2.85e-01 | 9.63e-01 |
| MYOBLAST FUSION | 47 | 6.22e-01 | 9.91e-01 | 0.17400 | -7.96e-02 | -7.10e-02 | -1.29e-01 | -1.33e-02 | -4.62e-02 | 3.45e-01 | 4.00e-01 | 1.27e-01 | 8.74e-01 | 5.84e-01 |
| PROTEIN KINASE C ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 26 | 7.48e-01 | 1.00e+00 | 0.17400 | -5.45e-02 | -4.30e-02 | -1.30e-01 | 9.16e-03 | -9.13e-02 | 6.30e-01 | 7.04e-01 | 2.50e-01 | 9.36e-01 | 4.20e-01 |
| L ASPARTATE TRANSMEMBRANE TRANSPORT | 11 | 8.68e-01 | 1.00e+00 | 0.17400 | 6.52e-02 | 1.02e-01 | 9.72e-03 | 1.17e-01 | 4.34e-02 | 7.08e-01 | 5.58e-01 | 9.55e-01 | 5.03e-01 | 8.03e-01 |
| PYRUVATE METABOLIC PROCESS | 112 | 6.33e-01 | 9.96e-01 | 0.17400 | 9.04e-02 | 8.81e-02 | 8.90e-02 | 7.92e-02 | 3.46e-04 | 9.83e-02 | 1.07e-01 | 1.04e-01 | 1.48e-01 | 9.95e-01 |
| NEGATIVE REGULATION OF MONOCYTE DIFFERENTIATION | 8 | 5.32e-01 | 9.54e-01 | 0.17400 | 9.01e-02 | 6.33e-02 | 8.40e-02 | -9.13e-03 | 1.04e-01 | 6.59e-01 | 7.57e-01 | 6.81e-01 | 9.64e-01 | 6.10e-01 |
| REGULATION OF TELOMERE CAPPING | 26 | 7.74e-01 | 1.00e+00 | 0.17400 | 3.62e-02 | 3.71e-02 | 3.95e-02 | 7.47e-02 | 1.42e-01 | 7.49e-01 | 7.44e-01 | 7.27e-01 | 5.10e-01 | 2.09e-01 |
| ASYMMETRIC CELL DIVISION | 18 | 8.66e-01 | 1.00e+00 | 0.17300 | 6.81e-02 | 3.17e-02 | 1.34e-01 | 1.65e-02 | 7.91e-02 | 6.17e-01 | 8.16e-01 | 3.26e-01 | 9.04e-01 | 5.61e-01 |
| NEURAL TUBE DEVELOPMENT | 160 | 8.10e-02 | 4.68e-01 | 0.17300 | 7.88e-02 | 7.78e-02 | 1.13e-01 | 4.87e-02 | 5.18e-02 | 8.54e-02 | 8.94e-02 | 1.39e-02 | 2.88e-01 | 2.58e-01 |
| COENZYME A BIOSYNTHETIC PROCESS | 11 | 7.08e-01 | 1.00e+00 | 0.17300 | -8.33e-02 | -6.63e-02 | 1.04e-02 | -1.36e-01 | -1.32e-02 | 6.32e-01 | 7.03e-01 | 9.52e-01 | 4.36e-01 | 9.40e-01 |
| SCHWANN CELL PROLIFERATION | 9 | 9.85e-01 | 1.00e+00 | 0.17300 | -7.03e-02 | -8.13e-02 | -6.97e-03 | -1.20e-01 | 6.33e-02 | 7.15e-01 | 6.73e-01 | 9.71e-01 | 5.33e-01 | 7.42e-01 |
| RENAL VESICLE DEVELOPMENT | 18 | 4.22e-01 | 9.12e-01 | 0.17300 | -2.32e-02 | -7.04e-02 | 1.08e-01 | -1.13e-01 | 1.39e-02 | 8.64e-01 | 6.05e-01 | 4.29e-01 | 4.09e-01 | 9.19e-01 |
| NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 34 | 8.43e-01 | 1.00e+00 | 0.17300 | 7.27e-02 | 6.97e-02 | 9.85e-02 | 6.93e-02 | 7.29e-02 | 4.63e-01 | 4.82e-01 | 3.20e-01 | 4.85e-01 | 4.62e-01 |
| FATTY ACID BETA OXIDATION USING ACYL COA DEHYDROGENASE | 12 | 7.98e-01 | 1.00e+00 | 0.17300 | 1.08e-01 | 7.51e-02 | 9.26e-02 | 6.11e-02 | -1.74e-02 | 5.16e-01 | 6.53e-01 | 5.78e-01 | 7.14e-01 | 9.17e-01 |
| POSITIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 30 | 6.48e-01 | 1.00e+00 | 0.17300 | 8.17e-02 | 7.82e-02 | 1.24e-01 | -6.91e-03 | 4.03e-02 | 4.38e-01 | 4.59e-01 | 2.38e-01 | 9.48e-01 | 7.03e-01 |
| MITOCHONDRIAL CALCIUM ION HOMEOSTASIS | 24 | 7.37e-01 | 1.00e+00 | 0.17300 | -8.25e-02 | -1.06e-01 | -1.93e-02 | -9.80e-02 | -4.34e-02 | 4.84e-01 | 3.68e-01 | 8.70e-01 | 4.06e-01 | 7.13e-01 |
| PROSTATE GLANDULAR ACINUS DEVELOPMENT | 10 | 8.72e-01 | 1.00e+00 | 0.17300 | 6.93e-02 | 5.77e-02 | 1.08e-01 | 4.63e-02 | -8.90e-02 | 7.04e-01 | 7.52e-01 | 5.53e-01 | 8.00e-01 | 6.26e-01 |
| CENTRIOLE CENTRIOLE COHESION | 15 | 9.33e-01 | 1.00e+00 | 0.17300 | -4.12e-02 | -6.31e-02 | 3.28e-03 | -3.50e-02 | 1.52e-01 | 7.82e-01 | 6.72e-01 | 9.82e-01 | 8.14e-01 | 3.09e-01 |
| NK T CELL DIFFERENTIATION | 11 | 8.12e-01 | 1.00e+00 | 0.17300 | -4.72e-02 | -8.60e-02 | 4.12e-02 | -1.35e-01 | -1.54e-02 | 7.86e-01 | 6.21e-01 | 8.13e-01 | 4.37e-01 | 9.29e-01 |
| NEGATIVE REGULATION OF CELL GROWTH | 177 | 2.13e-01 | 7.34e-01 | 0.17300 | 8.21e-02 | 7.09e-02 | 1.12e-01 | 4.93e-02 | 5.69e-02 | 5.96e-02 | 1.04e-01 | 1.05e-02 | 2.58e-01 | 1.91e-01 |
| REGULATION OF CYTOCHROME C OXIDASE ACTIVITY | 5 | 9.73e-01 | 1.00e+00 | 0.17300 | -2.22e-02 | -2.33e-02 | 3.42e-02 | -9.54e-02 | 1.36e-01 | 9.31e-01 | 9.28e-01 | 8.95e-01 | 7.12e-01 | 5.98e-01 |
| RESPONSE TO UV A | 13 | 9.28e-01 | 1.00e+00 | 0.17300 | -6.15e-02 | -6.00e-02 | -1.22e-01 | 7.08e-03 | -8.72e-02 | 7.01e-01 | 7.08e-01 | 4.48e-01 | 9.65e-01 | 5.86e-01 |
| PENTOSE METABOLIC PROCESS | 11 | 8.69e-01 | 1.00e+00 | 0.17300 | 1.01e-01 | 9.11e-02 | 6.86e-02 | 3.61e-02 | -7.29e-02 | 5.63e-01 | 6.01e-01 | 6.94e-01 | 8.36e-01 | 6.75e-01 |
| NEGATIVE REGULATION OF ADENYLATE CYCLASE ACTIVATING ADRENERGIC RECEPTOR SIGNALING PATHWAY | 6 | 9.46e-01 | 1.00e+00 | 0.17300 | -9.03e-02 | -9.87e-02 | -8.82e-02 | -8.30e-03 | -6.36e-02 | 7.02e-01 | 6.76e-01 | 7.08e-01 | 9.72e-01 | 7.87e-01 |
| PEPTIDE METABOLIC PROCESS | 930 | 1.26e-09 | 1.86e-07 | 0.17200 | 8.70e-02 | 8.34e-02 | 1.17e-01 | 3.23e-02 | 2.26e-02 | 6.82e-06 | 1.61e-05 | 1.47e-09 | 9.52e-02 | 2.42e-01 |
| CELLULAR RESPONSE TO LIPOPROTEIN PARTICLE STIMULUS | 41 | 8.81e-01 | 1.00e+00 | 0.17200 | 7.96e-02 | 6.45e-02 | 9.98e-02 | 5.37e-02 | 7.99e-02 | 3.78e-01 | 4.74e-01 | 2.69e-01 | 5.51e-01 | 3.76e-01 |
| PRIMARY MIRNA PROCESSING | 18 | 7.64e-01 | 1.00e+00 | 0.17200 | -6.59e-02 | -7.81e-02 | 3.95e-02 | -1.26e-01 | 4.41e-02 | 6.28e-01 | 5.66e-01 | 7.72e-01 | 3.56e-01 | 7.46e-01 |
| PROTEIN MATURATION BY PROTEIN FOLDING | 7 | 9.10e-01 | 1.00e+00 | 0.17200 | -3.79e-02 | -5.17e-02 | 8.31e-02 | -1.35e-01 | 2.10e-02 | 8.62e-01 | 8.13e-01 | 7.03e-01 | 5.36e-01 | 9.23e-01 |
| RESPONSE TO ELECTRICAL STIMULUS | 44 | 7.89e-01 | 1.00e+00 | 0.17200 | 8.89e-02 | 7.64e-02 | 6.71e-02 | 9.80e-02 | -4.34e-02 | 3.08e-01 | 3.81e-01 | 4.41e-01 | 2.61e-01 | 6.19e-01 |
| CYTOPLASMIC TRANSLATIONAL INITIATION | 34 | 6.75e-01 | 1.00e+00 | 0.17200 | 7.66e-02 | 7.56e-02 | 9.08e-02 | 4.08e-02 | -9.07e-02 | 4.40e-01 | 4.46e-01 | 3.60e-01 | 6.81e-01 | 3.60e-01 |
| MAMMARY GLAND FORMATION | 7 | 9.83e-01 | 1.00e+00 | 0.17200 | -8.05e-02 | -9.21e-02 | -2.10e-02 | -1.04e-01 | -5.82e-02 | 7.12e-01 | 6.73e-01 | 9.23e-01 | 6.32e-01 | 7.90e-01 |
| CYTOKINE MEDIATED SIGNALING PATHWAY | 488 | 2.52e-03 | 4.63e-02 | 0.17200 | -8.60e-02 | -9.30e-02 | -5.06e-02 | -8.06e-02 | 6.75e-02 | 1.13e-03 | 4.30e-04 | 5.54e-02 | 2.30e-03 | 1.06e-02 |
| FOREBRAIN MORPHOGENESIS | 13 | 7.91e-01 | 1.00e+00 | 0.17200 | -3.37e-02 | -6.93e-02 | 8.83e-02 | -1.11e-01 | 5.96e-02 | 8.33e-01 | 6.65e-01 | 5.81e-01 | 4.87e-01 | 7.10e-01 |
| REGULATION OF NEURON APOPTOTIC PROCESS | 224 | 3.78e-03 | 6.31e-02 | 0.17200 | 8.09e-02 | 7.62e-02 | 1.27e-01 | 1.29e-02 | 3.35e-02 | 3.69e-02 | 4.93e-02 | 1.10e-03 | 7.39e-01 | 3.88e-01 |
| NEGATIVE REGULATION OF INFLAMMATORY RESPONSE | 193 | 2.57e-01 | 7.84e-01 | 0.17200 | -8.89e-02 | -9.87e-02 | -5.47e-02 | -9.39e-02 | 1.39e-02 | 3.32e-02 | 1.81e-02 | 1.90e-01 | 2.45e-02 | 7.38e-01 |
| TUBULIN DEACETYLATION | 19 | 5.28e-01 | 9.54e-01 | 0.17200 | 1.31e-02 | 1.22e-02 | 7.02e-02 | -6.82e-02 | -1.40e-01 | 9.22e-01 | 9.27e-01 | 5.97e-01 | 6.07e-01 | 2.89e-01 |
| POSITIVE REGULATION OF MITOTIC CELL CYCLE PHASE TRANSITION | 93 | 5.21e-01 | 9.53e-01 | 0.17200 | 9.34e-02 | 9.56e-02 | 9.71e-02 | 4.82e-02 | 2.83e-03 | 1.19e-01 | 1.11e-01 | 1.06e-01 | 4.22e-01 | 9.62e-01 |
| PROTEIN SUMOYLATION | 64 | 2.05e-01 | 7.26e-01 | 0.17200 | 3.06e-03 | -2.02e-02 | 8.12e-02 | -5.99e-02 | 1.38e-01 | 9.66e-01 | 7.80e-01 | 2.61e-01 | 4.08e-01 | 5.63e-02 |
| HEPATICOBILIARY SYSTEM DEVELOPMENT | 140 | 3.29e-02 | 2.87e-01 | 0.17200 | 7.23e-02 | 6.42e-02 | 1.30e-01 | 2.08e-03 | 5.75e-02 | 1.40e-01 | 1.90e-01 | 7.80e-03 | 9.66e-01 | 2.40e-01 |
| RESPONSE TO LEPTIN | 21 | 8.12e-01 | 1.00e+00 | 0.17200 | -4.06e-02 | -6.07e-02 | 4.97e-02 | -1.06e-01 | 1.03e-01 | 7.47e-01 | 6.30e-01 | 6.94e-01 | 4.01e-01 | 4.14e-01 |
| CARDIAC CONDUCTION SYSTEM DEVELOPMENT | 37 | 1.62e-01 | 6.62e-01 | 0.17200 | 5.52e-02 | 2.47e-02 | 1.49e-01 | -5.91e-02 | -1.85e-02 | 5.61e-01 | 7.95e-01 | 1.18e-01 | 5.34e-01 | 8.46e-01 |
| DOPAMINE TRANSPORT | 55 | 7.75e-01 | 1.00e+00 | 0.17200 | 9.62e-02 | 8.51e-02 | 7.26e-02 | 8.48e-02 | -2.52e-02 | 2.17e-01 | 2.75e-01 | 3.51e-01 | 2.77e-01 | 7.46e-01 |
| GOLGI TO PLASMA MEMBRANE TRANSPORT | 57 | 8.12e-01 | 1.00e+00 | 0.17200 | -9.04e-02 | -1.03e-01 | -5.55e-02 | -8.67e-02 | 1.04e-02 | 2.38e-01 | 1.77e-01 | 4.69e-01 | 2.57e-01 | 8.92e-01 |
| DORSAL VENTRAL PATTERN FORMATION | 97 | 8.87e-02 | 4.92e-01 | 0.17200 | 8.41e-02 | 6.96e-02 | 1.31e-01 | 3.80e-03 | -1.83e-02 | 1.52e-01 | 2.36e-01 | 2.55e-02 | 9.48e-01 | 7.55e-01 |
| CELL PROLIFERATION IN HINDBRAIN | 16 | 8.65e-01 | 1.00e+00 | 0.17200 | 7.35e-02 | 6.86e-02 | 1.38e-01 | 2.27e-03 | 1.87e-02 | 6.11e-01 | 6.35e-01 | 3.40e-01 | 9.87e-01 | 8.97e-01 |
| NEGATIVE REGULATION OF HEMATOPOIETIC STEM CELL DIFFERENTIATION | 5 | 9.94e-01 | 1.00e+00 | 0.17200 | 3.87e-02 | 6.27e-02 | -2.54e-02 | 6.81e-02 | -1.37e-01 | 8.81e-01 | 8.08e-01 | 9.22e-01 | 7.92e-01 | 5.96e-01 |
| GERMINAL CENTER FORMATION | 14 | 6.04e-01 | 9.90e-01 | 0.17100 | -1.17e-02 | -2.04e-02 | 9.65e-02 | -1.35e-01 | -3.46e-02 | 9.40e-01 | 8.95e-01 | 5.32e-01 | 3.80e-01 | 8.22e-01 |
| BRAIN MORPHOGENESIS | 37 | 8.86e-01 | 1.00e+00 | 0.17100 | -8.45e-02 | -9.91e-02 | -4.39e-02 | -1.03e-01 | 4.74e-05 | 3.74e-01 | 2.97e-01 | 6.44e-01 | 2.81e-01 | 1.00e+00 |
| ECTOPIC GERM CELL PROGRAMMED CELL DEATH | 17 | 7.85e-01 | 1.00e+00 | 0.17100 | 6.13e-02 | 6.20e-02 | 5.28e-02 | 8.03e-02 | -1.12e-01 | 6.62e-01 | 6.58e-01 | 7.06e-01 | 5.67e-01 | 4.24e-01 |
| REGULATION OF LYMPHOCYTE ACTIVATION | 491 | 5.60e-07 | 4.05e-05 | 0.17100 | -7.24e-02 | -9.16e-02 | 9.43e-03 | -1.01e-01 | 7.40e-02 | 5.98e-03 | 5.11e-04 | 7.20e-01 | 1.27e-04 | 5.00e-03 |
| OSMOSENSORY SIGNALING PATHWAY | 5 | 9.95e-01 | 1.00e+00 | 0.17100 | -8.50e-02 | -1.06e-01 | -5.76e-02 | -7.46e-02 | -4.48e-02 | 7.42e-01 | 6.81e-01 | 8.23e-01 | 7.73e-01 | 8.62e-01 |
| REGULATION OF EMBRYONIC DEVELOPMENT | 89 | 5.18e-02 | 3.73e-01 | 0.17100 | 7.48e-02 | 7.82e-02 | 1.09e-01 | 2.64e-03 | -7.58e-02 | 2.22e-01 | 2.02e-01 | 7.55e-02 | 9.66e-01 | 2.16e-01 |
| NEGATIVE REGULATION OF HORMONE SECRETION | 65 | 5.50e-01 | 9.64e-01 | 0.17100 | 6.61e-02 | 5.39e-02 | 1.08e-01 | 1.94e-02 | 1.00e-01 | 3.57e-01 | 4.52e-01 | 1.33e-01 | 7.86e-01 | 1.61e-01 |
| REGULATION OF TELOMERE MAINTENANCE | 98 | 7.03e-02 | 4.35e-01 | 0.17100 | -1.88e-02 | -3.38e-02 | 6.95e-02 | -6.11e-02 | 1.39e-01 | 7.47e-01 | 5.63e-01 | 2.34e-01 | 2.96e-01 | 1.76e-02 |
| BUNDLE OF HIS CELL TO PURKINJE MYOCYTE SIGNALING | 7 | 9.24e-01 | 1.00e+00 | 0.17100 | 4.14e-02 | 9.32e-02 | -4.15e-02 | 8.70e-02 | -9.80e-02 | 8.50e-01 | 6.69e-01 | 8.49e-01 | 6.90e-01 | 6.54e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF ENDOGENOUS ANTIGEN | 32 | 6.06e-01 | 9.90e-01 | 0.17100 | -5.98e-02 | -8.68e-02 | 3.64e-02 | -1.18e-01 | 5.35e-02 | 5.58e-01 | 3.96e-01 | 7.21e-01 | 2.47e-01 | 6.00e-01 |
| CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 37 | 5.30e-01 | 9.54e-01 | 0.17100 | 7.63e-02 | 9.51e-02 | 6.60e-02 | 7.98e-02 | -6.07e-02 | 4.22e-01 | 3.17e-01 | 4.87e-01 | 4.01e-01 | 5.23e-01 |
| POSITIVE REGULATION OF SYNAPTIC TRANSMISSION GABAERGIC | 15 | 7.10e-01 | 1.00e+00 | 0.17100 | -5.98e-03 | 3.05e-02 | -1.66e-02 | -7.15e-02 | -1.51e-01 | 9.68e-01 | 8.38e-01 | 9.12e-01 | 6.32e-01 | 3.10e-01 |
| PURINE NUCLEOSIDE BIOSYNTHETIC PROCESS | 10 | 8.97e-01 | 1.00e+00 | 0.17100 | 3.04e-02 | 3.99e-02 | -3.81e-03 | 7.55e-02 | -1.45e-01 | 8.68e-01 | 8.27e-01 | 9.83e-01 | 6.79e-01 | 4.27e-01 |
| CELLULAR RESPONSE TO VITAMIN D | 21 | 7.75e-01 | 1.00e+00 | 0.17100 | 6.92e-02 | 8.20e-02 | 7.58e-02 | 2.69e-02 | 1.06e-01 | 5.83e-01 | 5.15e-01 | 5.48e-01 | 8.31e-01 | 4.00e-01 |
| NEGATIVE REGULATION OF PRODUCTION OF MOLECULAR MEDIATOR OF IMMUNE RESPONSE | 45 | 4.14e-01 | 9.11e-01 | 0.17100 | 8.67e-03 | -2.06e-02 | 8.19e-02 | -4.45e-02 | 1.42e-01 | 9.20e-01 | 8.11e-01 | 3.42e-01 | 6.05e-01 | 1.00e-01 |
| REGULATION OF COLLATERAL SPROUTING | 20 | 7.37e-01 | 1.00e+00 | 0.17100 | 4.71e-02 | 1.02e-02 | 8.98e-02 | 7.36e-02 | 1.16e-01 | 7.16e-01 | 9.37e-01 | 4.87e-01 | 5.69e-01 | 3.70e-01 |
| REGULATION OF INSULIN RECEPTOR SIGNALING PATHWAY | 69 | 6.14e-01 | 9.90e-01 | 0.17100 | -7.73e-02 | -8.72e-02 | -2.32e-02 | -7.97e-02 | 9.35e-02 | 2.67e-01 | 2.11e-01 | 7.39e-01 | 2.53e-01 | 1.79e-01 |
| COENZYME A METABOLIC PROCESS | 19 | 3.00e-01 | 8.27e-01 | 0.17100 | 5.70e-02 | 6.98e-02 | 1.08e-01 | 2.57e-02 | -9.31e-02 | 6.67e-01 | 5.98e-01 | 4.13e-01 | 8.46e-01 | 4.82e-01 |
| SEMI LUNAR VALVE DEVELOPMENT | 47 | 6.87e-01 | 1.00e+00 | 0.17100 | 7.57e-02 | 5.27e-02 | 1.28e-01 | 2.81e-02 | 6.02e-02 | 3.69e-01 | 5.32e-01 | 1.30e-01 | 7.39e-01 | 4.75e-01 |
| POSITIVE REGULATION OF CHOLESTEROL EFFLUX | 27 | 6.29e-01 | 9.96e-01 | 0.17100 | 7.03e-02 | 9.59e-02 | 3.45e-02 | 1.17e-01 | 1.66e-02 | 5.27e-01 | 3.88e-01 | 7.56e-01 | 2.95e-01 | 8.81e-01 |
| REGULATION OF ALDOSTERONE METABOLIC PROCESS | 8 | 6.80e-01 | 1.00e+00 | 0.17100 | 6.28e-02 | 1.03e-01 | 1.14e-01 | 1.74e-02 | 3.89e-02 | 7.58e-01 | 6.16e-01 | 5.78e-01 | 9.32e-01 | 8.49e-01 |
| TETRAPYRROLE CATABOLIC PROCESS | 13 | 8.14e-01 | 1.00e+00 | 0.17100 | -4.35e-02 | -6.51e-02 | 7.68e-02 | -1.11e-01 | 6.87e-02 | 7.86e-01 | 6.84e-01 | 6.32e-01 | 4.87e-01 | 6.68e-01 |
| REGULATION OF MIRNA TRANSCRIPTION | 69 | 1.81e-01 | 6.88e-01 | 0.17100 | 5.32e-02 | 4.84e-02 | 1.21e-01 | 1.47e-02 | 9.52e-02 | 4.44e-01 | 4.87e-01 | 8.21e-02 | 8.33e-01 | 1.71e-01 |
| REGULATION OF TRANSLATIONAL INITIATION | 76 | 4.98e-01 | 9.47e-01 | 0.17100 | 8.36e-02 | 8.44e-02 | 1.12e-01 | 3.68e-02 | 3.12e-02 | 2.08e-01 | 2.03e-01 | 9.00e-02 | 5.79e-01 | 6.38e-01 |
| REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 50 | 2.78e-01 | 8.05e-01 | 0.17000 | 5.70e-02 | 5.81e-02 | 1.17e-01 | 3.04e-02 | 8.86e-02 | 4.85e-01 | 4.78e-01 | 1.54e-01 | 7.10e-01 | 2.78e-01 |
| NEGATIVE REGULATION OF CELL DIVISION | 17 | 5.93e-01 | 9.86e-01 | 0.17000 | 1.46e-02 | 5.87e-03 | 1.19e-01 | -1.89e-02 | 1.19e-01 | 9.17e-01 | 9.67e-01 | 3.95e-01 | 8.92e-01 | 3.95e-01 |
| NEGATIVE REGULATION OF DNA RECOMBINATION | 45 | 2.30e-01 | 7.52e-01 | 0.17000 | 3.10e-02 | 1.22e-03 | 1.28e-01 | -6.43e-02 | 8.64e-02 | 7.19e-01 | 9.89e-01 | 1.37e-01 | 4.56e-01 | 3.16e-01 |
| ACID SECRETION | 43 | 5.87e-01 | 9.85e-01 | 0.17000 | -7.03e-02 | -7.95e-02 | -6.31e-02 | -1.87e-02 | 1.16e-01 | 4.25e-01 | 3.67e-01 | 4.74e-01 | 8.32e-01 | 1.90e-01 |
| PROTEIN LOCALIZATION TO CELL CORTEX | 11 | 8.69e-01 | 1.00e+00 | 0.17000 | 7.54e-02 | 1.03e-01 | 8.54e-02 | 6.77e-02 | 2.80e-02 | 6.65e-01 | 5.54e-01 | 6.24e-01 | 6.97e-01 | 8.72e-01 |
| NEGATIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 28 | 7.63e-01 | 1.00e+00 | 0.17000 | -6.84e-02 | -7.84e-02 | 3.23e-03 | -1.35e-01 | -1.16e-03 | 5.31e-01 | 4.73e-01 | 9.76e-01 | 2.18e-01 | 9.92e-01 |
| REGULATION OF MITOTIC CENTROSOME SEPARATION | 9 | 8.94e-01 | 1.00e+00 | 0.17000 | -3.95e-02 | -6.77e-02 | 4.54e-02 | -1.40e-01 | 3.56e-02 | 8.37e-01 | 7.25e-01 | 8.14e-01 | 4.68e-01 | 8.53e-01 |
| METANEPHRIC NEPHRON DEVELOPMENT | 40 | 2.06e-01 | 7.27e-01 | 0.17000 | -3.64e-03 | -4.02e-02 | 1.13e-01 | -9.35e-02 | 7.56e-02 | 9.68e-01 | 6.60e-01 | 2.15e-01 | 3.06e-01 | 4.08e-01 |
| PROTEIN NEDDYLATION | 28 | 4.91e-01 | 9.45e-01 | 0.17000 | 6.91e-02 | 2.88e-02 | 1.51e-01 | -2.10e-03 | 2.49e-02 | 5.27e-01 | 7.92e-01 | 1.68e-01 | 9.85e-01 | 8.19e-01 |
| REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO STRESS | 32 | 2.65e-01 | 7.93e-01 | 0.17000 | 6.61e-02 | 7.59e-02 | 1.33e-01 | -2.75e-02 | -1.13e-02 | 5.18e-01 | 4.57e-01 | 1.91e-01 | 7.88e-01 | 9.12e-01 |
| REGULATION OF KERATINOCYTE DIFFERENTIATION | 40 | 4.21e-01 | 9.12e-01 | 0.17000 | 5.58e-02 | 6.88e-02 | -1.67e-03 | 1.35e-01 | 5.15e-02 | 5.42e-01 | 4.51e-01 | 9.85e-01 | 1.39e-01 | 5.73e-01 |
| HIPPOCAMPUS DEVELOPMENT | 90 | 4.24e-02 | 3.30e-01 | 0.17000 | 7.22e-02 | 6.61e-02 | 1.37e-01 | -1.78e-02 | 6.77e-03 | 2.37e-01 | 2.78e-01 | 2.44e-02 | 7.70e-01 | 9.12e-01 |
| REGULATION OF CHROMOSOME ORGANIZATION | 239 | 2.54e-03 | 4.64e-02 | 0.17000 | 5.65e-02 | 4.67e-02 | 1.18e-01 | 1.19e-02 | 9.69e-02 | 1.32e-01 | 2.13e-01 | 1.71e-03 | 7.51e-01 | 9.86e-03 |
| HISTONE MODIFICATION | 106 | 1.85e-01 | 6.93e-01 | 0.17000 | 4.82e-02 | 3.42e-02 | 1.01e-01 | 3.40e-02 | 1.18e-01 | 3.91e-01 | 5.43e-01 | 7.21e-02 | 5.45e-01 | 3.61e-02 |
| DETOXIFICATION | 153 | 3.11e-01 | 8.38e-01 | 0.16900 | 8.58e-02 | 8.54e-02 | 6.20e-02 | 7.46e-02 | -6.78e-02 | 6.69e-02 | 6.84e-02 | 1.85e-01 | 1.11e-01 | 1.48e-01 |
| POSITIVE REGULATION OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR SIGNALING PATHWAY | 9 | 9.63e-01 | 1.00e+00 | 0.16900 | 7.97e-02 | 8.16e-02 | 1.21e-01 | 1.27e-03 | -2.96e-02 | 6.79e-01 | 6.72e-01 | 5.28e-01 | 9.95e-01 | 8.78e-01 |
| NEGATIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 48 | 8.14e-01 | 1.00e+00 | 0.16900 | 6.87e-02 | 6.90e-02 | 7.00e-02 | 7.19e-02 | 9.52e-02 | 4.10e-01 | 4.08e-01 | 4.02e-01 | 3.89e-01 | 2.54e-01 |
| RECEPTOR CLUSTERING | 53 | 3.13e-01 | 8.40e-01 | 0.16900 | -6.32e-02 | -5.31e-02 | -1.52e-02 | -5.95e-02 | 1.34e-01 | 4.26e-01 | 5.04e-01 | 8.48e-01 | 4.53e-01 | 9.10e-02 |
| RESPONSE TO GONADOTROPIN | 27 | 8.42e-01 | 1.00e+00 | 0.16900 | 7.56e-02 | 6.66e-02 | 6.65e-02 | 6.20e-02 | -1.01e-01 | 4.97e-01 | 5.49e-01 | 5.50e-01 | 5.77e-01 | 3.64e-01 |
| IMP BIOSYNTHETIC PROCESS | 10 | 5.61e-01 | 9.70e-01 | 0.16900 | -3.83e-02 | -7.00e-02 | -3.88e-02 | -1.16e-01 | -8.49e-02 | 8.34e-01 | 7.02e-01 | 8.32e-01 | 5.25e-01 | 6.42e-01 |
| L SERINE CATABOLIC PROCESS | 5 | 8.62e-01 | 1.00e+00 | 0.16900 | -5.65e-02 | 1.79e-02 | -1.54e-01 | 1.24e-02 | -3.28e-02 | 8.27e-01 | 9.45e-01 | 5.50e-01 | 9.62e-01 | 8.99e-01 |
| AXIAL MESODERM DEVELOPMENT | 8 | 8.57e-01 | 1.00e+00 | 0.16900 | 7.60e-02 | 1.17e-01 | 8.33e-02 | 4.55e-02 | 8.97e-03 | 7.10e-01 | 5.67e-01 | 6.83e-01 | 8.24e-01 | 9.65e-01 |
| L ALPHA AMINO ACID TRANSMEMBRANE TRANSPORT | 65 | 6.53e-01 | 1.00e+00 | 0.16900 | 8.76e-02 | 1.05e-01 | 5.69e-02 | 6.90e-02 | -4.22e-02 | 2.22e-01 | 1.43e-01 | 4.28e-01 | 3.36e-01 | 5.56e-01 |
| RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL BY ENDOPLASMIC RETICULUM | 35 | 9.24e-01 | 1.00e+00 | 0.16900 | -9.01e-02 | -9.91e-02 | -5.75e-02 | -8.40e-02 | -1.34e-02 | 3.56e-01 | 3.10e-01 | 5.56e-01 | 3.90e-01 | 8.91e-01 |
| REGULATION OF NEURONAL SYNAPTIC PLASTICITY | 53 | 4.94e-01 | 9.47e-01 | 0.16900 | 7.13e-02 | 6.80e-02 | 1.15e-01 | 3.95e-03 | 7.39e-02 | 3.69e-01 | 3.92e-01 | 1.46e-01 | 9.60e-01 | 3.52e-01 |
| SMOOTH MUSCLE CELL DIFFERENTIATION | 72 | 2.00e-02 | 2.08e-01 | 0.16900 | 1.38e-02 | -1.78e-02 | 1.32e-01 | -7.94e-02 | 6.51e-02 | 8.39e-01 | 7.94e-01 | 5.28e-02 | 2.44e-01 | 3.39e-01 |
| NEGATIVE REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 14 | 6.71e-01 | 1.00e+00 | 0.16900 | -6.91e-03 | -2.34e-02 | 4.79e-02 | 5.40e-02 | 1.51e-01 | 9.64e-01 | 8.80e-01 | 7.57e-01 | 7.27e-01 | 3.29e-01 |
| REGULATION OF PROTEIN NEDDYLATION | 19 | 4.61e-01 | 9.32e-01 | 0.16900 | 6.01e-02 | 1.78e-02 | 1.46e-01 | -2.14e-02 | -5.28e-02 | 6.50e-01 | 8.93e-01 | 2.71e-01 | 8.72e-01 | 6.90e-01 |
| ACTIVATION OF MEIOSIS | 6 | 7.21e-01 | 1.00e+00 | 0.16900 | -4.75e-02 | -8.41e-02 | -7.95e-02 | -3.84e-02 | 1.06e-01 | 8.40e-01 | 7.21e-01 | 7.36e-01 | 8.71e-01 | 6.52e-01 |
| REGULATION OF GENE SILENCING BY REGULATORY NCRNA | 29 | 5.86e-02 | 3.96e-01 | 0.16900 | -4.92e-02 | -2.08e-02 | 4.25e-03 | -7.96e-02 | -1.39e-01 | 6.47e-01 | 8.46e-01 | 9.68e-01 | 4.58e-01 | 1.96e-01 |
| POSITIVE REGULATION OF RESPIRATORY BURST | 7 | 7.45e-01 | 1.00e+00 | 0.16800 | 2.11e-02 | -1.37e-02 | 3.13e-02 | 6.69e-02 | -1.49e-01 | 9.23e-01 | 9.50e-01 | 8.86e-01 | 7.59e-01 | 4.94e-01 |
| SARCOPLASMIC RETICULUM CALCIUM ION TRANSPORT | 40 | 8.62e-01 | 1.00e+00 | 0.16800 | -9.31e-02 | -8.14e-02 | -6.91e-02 | -8.32e-02 | 3.65e-02 | 3.08e-01 | 3.73e-01 | 4.49e-01 | 3.63e-01 | 6.90e-01 |
| RESPONSE TO DIETARY EXCESS | 34 | 8.09e-01 | 1.00e+00 | 0.16800 | 6.53e-02 | 7.89e-02 | 2.33e-02 | 4.36e-02 | -1.24e-01 | 5.10e-01 | 4.26e-01 | 8.14e-01 | 6.60e-01 | 2.11e-01 |
| XMP METABOLIC PROCESS | 7 | 7.31e-01 | 1.00e+00 | 0.16800 | -4.43e-02 | -1.09e-01 | 2.19e-02 | -9.23e-02 | -7.34e-02 | 8.39e-01 | 6.17e-01 | 9.20e-01 | 6.73e-01 | 7.37e-01 |
| RESPONSE TO AMYLOID BETA | 55 | 8.17e-01 | 1.00e+00 | 0.16800 | -7.82e-02 | -8.20e-02 | -7.47e-02 | -8.47e-02 | -5.13e-02 | 3.16e-01 | 2.93e-01 | 3.38e-01 | 2.77e-01 | 5.11e-01 |
| NEGATIVE REGULATION OF TORC1 SIGNALING | 46 | 4.10e-01 | 9.08e-01 | 0.16800 | 1.75e-02 | 1.59e-02 | 8.39e-02 | -1.48e-02 | 1.43e-01 | 8.38e-01 | 8.52e-01 | 3.25e-01 | 8.62e-01 | 9.39e-02 |
| CD8 POSITIVE ALPHA BETA T CELL DIFFERENTIATION | 15 | 9.27e-01 | 1.00e+00 | 0.16800 | -7.50e-02 | -9.61e-02 | 9.13e-04 | -1.15e-01 | -4.55e-03 | 6.15e-01 | 5.19e-01 | 9.95e-01 | 4.40e-01 | 9.76e-01 |
| REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 72 | 7.41e-01 | 1.00e+00 | 0.16800 | -8.80e-02 | -8.34e-02 | -5.91e-02 | -8.57e-02 | 5.10e-02 | 1.96e-01 | 2.21e-01 | 3.86e-01 | 2.09e-01 | 4.55e-01 |
| RIBONUCLEOSIDE MONOPHOSPHATE CATABOLIC PROCESS | 14 | 9.62e-01 | 1.00e+00 | 0.16800 | -9.70e-02 | -9.62e-02 | -5.67e-02 | -7.89e-02 | -6.25e-03 | 5.30e-01 | 5.33e-01 | 7.13e-01 | 6.09e-01 | 9.68e-01 |
| NEGATIVE REGULATION OF EXCITATORY POSTSYNAPTIC POTENTIAL | 10 | 7.64e-01 | 1.00e+00 | 0.16800 | -5.23e-02 | -7.12e-02 | -7.33e-02 | 7.12e-02 | 9.94e-02 | 7.75e-01 | 6.97e-01 | 6.88e-01 | 6.97e-01 | 5.86e-01 |
| ANTEROGRADE DENDRITIC TRANSPORT | 9 | 9.29e-01 | 1.00e+00 | 0.16800 | -5.30e-02 | -4.01e-02 | 1.43e-02 | -7.97e-02 | 1.31e-01 | 7.83e-01 | 8.35e-01 | 9.41e-01 | 6.79e-01 | 4.96e-01 |
| STRESS FIBER ASSEMBLY | 108 | 5.59e-01 | 9.69e-01 | 0.16800 | 8.34e-02 | 9.21e-02 | 5.63e-02 | 9.44e-02 | 2.45e-02 | 1.34e-01 | 9.80e-02 | 3.12e-01 | 9.02e-02 | 6.60e-01 |
| RESPONSE TO HYDROGEN PEROXIDE | 96 | 6.86e-02 | 4.29e-01 | 0.16800 | 7.92e-02 | 5.82e-02 | 1.29e-01 | 3.57e-02 | -2.52e-02 | 1.80e-01 | 3.24e-01 | 2.94e-02 | 5.45e-01 | 6.70e-01 |
| VITAMIN E METABOLIC PROCESS | 6 | 8.59e-01 | 1.00e+00 | 0.16800 | 5.08e-02 | 8.34e-02 | 1.13e-01 | -1.74e-02 | 7.46e-02 | 8.29e-01 | 7.24e-01 | 6.33e-01 | 9.41e-01 | 7.52e-01 |
| POTASSIUM ION TRANSPORT | 234 | 9.70e-03 | 1.22e-01 | 0.16700 | 5.76e-02 | 7.54e-02 | 8.43e-03 | 5.57e-02 | -1.26e-01 | 1.29e-01 | 4.68e-02 | 8.24e-01 | 1.42e-01 | 9.04e-04 |
| GLUTAMATE SECRETION NEUROTRANSMISSION | 8 | 9.43e-01 | 1.00e+00 | 0.16700 | 8.98e-04 | -6.59e-03 | 2.61e-02 | -7.39e-02 | -1.48e-01 | 9.96e-01 | 9.74e-01 | 8.98e-01 | 7.17e-01 | 4.70e-01 |
| MICROTUBULE BASED PROTEIN TRANSPORT | 14 | 8.22e-01 | 1.00e+00 | 0.16700 | -2.84e-02 | 5.77e-03 | -5.08e-02 | -8.15e-02 | -1.34e-01 | 8.54e-01 | 9.70e-01 | 7.42e-01 | 5.97e-01 | 3.86e-01 |
| MAGNESIUM ION HOMEOSTASIS | 10 | 9.30e-01 | 1.00e+00 | 0.16700 | -6.43e-02 | -2.43e-02 | -1.43e-01 | -1.10e-02 | -5.26e-02 | 7.25e-01 | 8.94e-01 | 4.35e-01 | 9.52e-01 | 7.73e-01 |
| POSITIVE REGULATION OF MORPHOGENESIS OF AN EPITHELIUM | 33 | 1.56e-01 | 6.53e-01 | 0.16700 | 1.56e-02 | 7.20e-03 | 1.33e-01 | -9.26e-02 | 3.74e-02 | 8.77e-01 | 9.43e-01 | 1.87e-01 | 3.57e-01 | 7.10e-01 |
| MRNA TRANSPORT | 113 | 2.68e-01 | 7.95e-01 | 0.16700 | 6.44e-02 | 4.55e-02 | 1.13e-01 | 2.27e-02 | 9.10e-02 | 2.37e-01 | 4.04e-01 | 3.73e-02 | 6.77e-01 | 9.47e-02 |
| SPHINGOMYELIN METABOLIC PROCESS | 20 | 2.79e-01 | 8.05e-01 | 0.16700 | -7.94e-02 | -5.11e-02 | 1.07e-02 | -1.27e-01 | 5.12e-02 | 5.39e-01 | 6.93e-01 | 9.34e-01 | 3.24e-01 | 6.92e-01 |
| CELLULAR RESPONSE TO COLD | 13 | 9.72e-01 | 1.00e+00 | 0.16700 | 8.10e-02 | 5.81e-02 | 8.03e-02 | 1.01e-01 | 3.60e-02 | 6.13e-01 | 7.17e-01 | 6.16e-01 | 5.29e-01 | 8.22e-01 |
| HINDBRAIN DEVELOPMENT | 149 | 1.02e-01 | 5.29e-01 | 0.16700 | 8.78e-02 | 7.65e-02 | 8.51e-02 | 4.80e-02 | -6.88e-02 | 6.44e-02 | 1.07e-01 | 7.31e-02 | 3.11e-01 | 1.47e-01 |
| PURINE NUCLEOTIDE TRANSPORT | 34 | 8.57e-01 | 1.00e+00 | 0.16700 | -9.42e-02 | -8.28e-02 | -7.92e-02 | -6.12e-02 | 4.53e-02 | 3.42e-01 | 4.03e-01 | 4.24e-01 | 5.37e-01 | 6.47e-01 |
| NEGATIVE REGULATION OF GLIAL CELL PROLIFERATION | 17 | 6.05e-01 | 9.90e-01 | 0.16700 | 5.94e-02 | 4.83e-02 | 1.14e-01 | -5.66e-02 | 7.56e-02 | 6.72e-01 | 7.30e-01 | 4.15e-01 | 6.86e-01 | 5.89e-01 |
| POTASSIUM ION IMPORT ACROSS PLASMA MEMBRANE | 46 | 3.69e-01 | 8.80e-01 | 0.16700 | 5.65e-02 | 8.17e-02 | 2.85e-02 | 6.10e-02 | -1.16e-01 | 5.07e-01 | 3.38e-01 | 7.38e-01 | 4.74e-01 | 1.75e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 103 | 4.52e-01 | 9.30e-01 | 0.16700 | 6.82e-02 | 6.87e-02 | 7.94e-02 | 6.73e-02 | 8.68e-02 | 2.32e-01 | 2.28e-01 | 1.64e-01 | 2.38e-01 | 1.28e-01 |
| REGULATION OF CELL CYCLE PHASE TRANSITION | 439 | 3.59e-06 | 1.89e-04 | 0.16700 | 7.02e-02 | 6.13e-02 | 1.26e-01 | 7.08e-03 | 5.56e-02 | 1.17e-02 | 2.77e-02 | 5.82e-06 | 7.99e-01 | 4.57e-02 |
| NUCLEOPHAGY | 18 | 8.59e-01 | 1.00e+00 | 0.16600 | -4.38e-02 | -3.98e-02 | -1.38e-02 | -8.98e-02 | -1.26e-01 | 7.48e-01 | 7.70e-01 | 9.19e-01 | 5.10e-01 | 3.53e-01 |
| REGULATION OF CELL SHAPE | 134 | 3.45e-01 | 8.64e-01 | 0.16600 | -9.42e-02 | -9.27e-02 | -8.15e-02 | -5.98e-02 | -4.15e-03 | 5.97e-02 | 6.40e-02 | 1.03e-01 | 2.32e-01 | 9.34e-01 |
| PEPTIDYL TYROSINE DEPHOSPHORYLATION | 30 | 7.82e-01 | 1.00e+00 | 0.16600 | -3.61e-02 | -4.39e-02 | 1.28e-02 | -5.79e-02 | 1.45e-01 | 7.32e-01 | 6.77e-01 | 9.03e-01 | 5.83e-01 | 1.70e-01 |
| RESPONSE TO 2 3 7 8 TETRACHLORODIBENZODIOXINE | 5 | 9.94e-01 | 1.00e+00 | 0.16600 | 7.54e-02 | 8.94e-02 | 5.77e-02 | 1.03e-01 | -8.88e-03 | 7.70e-01 | 7.29e-01 | 8.23e-01 | 6.90e-01 | 9.73e-01 |
| ONE CARBON METABOLIC PROCESS | 37 | 4.93e-01 | 9.46e-01 | 0.16600 | -6.83e-02 | -6.02e-02 | -1.74e-03 | -1.38e-01 | 1.72e-02 | 4.72e-01 | 5.26e-01 | 9.85e-01 | 1.46e-01 | 8.57e-01 |
| EXTRACELLULAR REGULATION OF SIGNAL TRANSDUCTION | 13 | 1.96e-01 | 7.10e-01 | 0.16600 | -2.32e-02 | 5.53e-02 | -1.29e-01 | 4.11e-02 | 7.55e-02 | 8.85e-01 | 7.30e-01 | 4.20e-01 | 7.97e-01 | 6.37e-01 |
| INOSITOL PHOSPHATE BIOSYNTHETIC PROCESS | 29 | 1.05e-01 | 5.37e-01 | 0.16600 | 3.52e-02 | 3.58e-02 | 3.12e-02 | 9.32e-02 | -1.24e-01 | 7.43e-01 | 7.39e-01 | 7.71e-01 | 3.85e-01 | 2.46e-01 |
| REGULATION OF KIDNEY DEVELOPMENT | 32 | 1.07e-01 | 5.41e-01 | 0.16600 | 1.18e-02 | 1.59e-02 | 1.05e-01 | -1.14e-01 | -5.69e-02 | 9.08e-01 | 8.76e-01 | 3.05e-01 | 2.64e-01 | 5.77e-01 |
| AROMATIC AMINO ACID TRANSPORT | 9 | 3.18e-01 | 8.45e-01 | 0.16600 | 1.13e-02 | 7.09e-02 | 5.42e-02 | -1.07e-01 | 9.00e-02 | 9.53e-01 | 7.13e-01 | 7.78e-01 | 5.78e-01 | 6.40e-01 |
| SPERM CAPACITATION | 30 | 2.43e-01 | 7.69e-01 | 0.16600 | -2.61e-02 | -2.86e-02 | -1.23e-01 | 8.47e-02 | -6.20e-02 | 8.05e-01 | 7.86e-01 | 2.44e-01 | 4.22e-01 | 5.57e-01 |
| POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 1014 | 5.18e-10 | 8.29e-08 | 0.16600 | -8.24e-02 | -1.00e-01 | -2.29e-02 | -9.29e-02 | 4.01e-02 | 8.87e-06 | 6.91e-08 | 2.17e-01 | 5.52e-07 | 3.07e-02 |
| VESICLE TARGETING | 65 | 3.17e-01 | 8.44e-01 | 0.16600 | 3.46e-02 | 2.00e-02 | 9.22e-02 | -2.17e-02 | 1.30e-01 | 6.29e-01 | 7.81e-01 | 1.99e-01 | 7.62e-01 | 6.90e-02 |
| REGULATION OF MOTOR NEURON APOPTOTIC PROCESS | 15 | 9.88e-01 | 1.00e+00 | 0.16600 | 8.52e-02 | 9.04e-02 | 9.18e-02 | 6.03e-02 | 7.88e-03 | 5.68e-01 | 5.44e-01 | 5.38e-01 | 6.86e-01 | 9.58e-01 |
| REGULATION OF GLYCOLYTIC PROCESS | 50 | 7.73e-01 | 1.00e+00 | 0.16600 | 7.59e-02 | 7.93e-02 | 5.24e-02 | 7.54e-02 | -8.41e-02 | 3.53e-01 | 3.32e-01 | 5.22e-01 | 3.56e-01 | 3.03e-01 |
| POSITIVE REGULATION OF NON CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 65 | 4.16e-01 | 9.11e-01 | 0.16600 | -7.43e-02 | -9.15e-02 | -4.09e-03 | -1.17e-01 | -2.92e-03 | 3.00e-01 | 2.02e-01 | 9.54e-01 | 1.03e-01 | 9.68e-01 |
| RNA 3 END PROCESSING | 90 | 2.86e-03 | 5.08e-02 | 0.16600 | 3.97e-02 | -1.54e-02 | 1.34e-01 | -1.60e-02 | 8.70e-02 | 5.15e-01 | 8.01e-01 | 2.82e-02 | 7.93e-01 | 1.54e-01 |
| POSITIVE REGULATION OF AMINO ACID TRANSPORT | 22 | 7.48e-01 | 1.00e+00 | 0.16600 | 7.41e-02 | 6.25e-02 | 1.24e-01 | -1.17e-02 | -5.10e-02 | 5.48e-01 | 6.12e-01 | 3.13e-01 | 9.24e-01 | 6.79e-01 |
| SPINDLE ELONGATION | 13 | 2.51e-01 | 7.77e-01 | 0.16600 | -1.17e-02 | -2.48e-02 | 1.02e-01 | 2.28e-02 | 1.26e-01 | 9.42e-01 | 8.77e-01 | 5.25e-01 | 8.87e-01 | 4.31e-01 |
| VESICLE BUDDING FROM MEMBRANE | 81 | 1.54e-01 | 6.50e-01 | 0.16600 | 1.12e-02 | 1.43e-03 | 7.18e-02 | -4.07e-02 | 1.44e-01 | 8.61e-01 | 9.82e-01 | 2.64e-01 | 5.27e-01 | 2.55e-02 |
| MEMBRANE FISSION | 42 | 5.99e-01 | 9.90e-01 | 0.16600 | 6.38e-02 | 5.79e-02 | 1.24e-01 | -1.55e-03 | 6.94e-02 | 4.74e-01 | 5.16e-01 | 1.66e-01 | 9.86e-01 | 4.37e-01 |
| SEMAPHORIN PLEXIN SIGNALING PATHWAY | 41 | 6.47e-01 | 1.00e+00 | 0.16600 | 6.96e-02 | 7.09e-02 | 1.33e-02 | 1.32e-01 | 9.94e-03 | 4.41e-01 | 4.32e-01 | 8.83e-01 | 1.44e-01 | 9.12e-01 |
| REGULATION OF CALCIUM ION TRANSPORT INTO CYTOSOL | 18 | 7.09e-01 | 1.00e+00 | 0.16600 | 7.13e-02 | 7.38e-02 | 1.05e-01 | 5.51e-02 | -5.38e-02 | 6.00e-01 | 5.88e-01 | 4.41e-01 | 6.86e-01 | 6.93e-01 |
| EQUILIBRIOCEPTION | 7 | 9.03e-01 | 1.00e+00 | 0.16600 | 2.09e-02 | 6.52e-02 | -1.05e-01 | 9.95e-02 | -4.27e-02 | 9.24e-01 | 7.65e-01 | 6.30e-01 | 6.48e-01 | 8.45e-01 |
| MULTICELLULAR ORGANISMAL LEVEL CHEMICAL HOMEOSTASIS | 73 | 1.30e-01 | 5.98e-01 | 0.16600 | -3.22e-02 | -4.87e-02 | 2.52e-02 | -1.68e-03 | 1.53e-01 | 6.35e-01 | 4.71e-01 | 7.09e-01 | 9.80e-01 | 2.38e-02 |
| EMBRYO IMPLANTATION | 58 | 4.57e-01 | 9.32e-01 | 0.16600 | 7.16e-02 | 4.28e-02 | 1.30e-01 | 2.01e-02 | 5.66e-02 | 3.46e-01 | 5.73e-01 | 8.70e-02 | 7.91e-01 | 4.56e-01 |
| EPHRIN RECEPTOR SIGNALING PATHWAY | 49 | 7.39e-01 | 1.00e+00 | 0.16600 | -7.10e-02 | -6.36e-02 | -8.97e-02 | -3.55e-02 | -9.50e-02 | 3.90e-01 | 4.41e-01 | 2.77e-01 | 6.67e-01 | 2.50e-01 |
| PROTEIN CONTAINING COMPLEX DISASSEMBLY | 241 | 3.05e-02 | 2.72e-01 | 0.16600 | 6.45e-02 | 5.71e-02 | 1.04e-01 | 3.99e-02 | 8.74e-02 | 8.44e-02 | 1.27e-01 | 5.52e-03 | 2.86e-01 | 1.95e-02 |
| HEART MORPHOGENESIS | 262 | 9.48e-03 | 1.21e-01 | 0.16600 | 8.50e-02 | 8.12e-02 | 1.07e-01 | 3.32e-02 | -3.16e-02 | 1.78e-02 | 2.36e-02 | 2.81e-03 | 3.54e-01 | 3.79e-01 |
| RESPONSE TO PH | 41 | 1.29e-01 | 5.97e-01 | 0.16600 | 7.13e-02 | 1.14e-01 | 4.80e-02 | 5.90e-02 | 6.00e-02 | 4.29e-01 | 2.08e-01 | 5.95e-01 | 5.13e-01 | 5.06e-01 |
| DIENCEPHALON DEVELOPMENT | 73 | 8.79e-03 | 1.15e-01 | 0.16500 | 1.64e-02 | -1.41e-03 | 8.36e-02 | -8.27e-02 | -1.15e-01 | 8.09e-01 | 9.83e-01 | 2.17e-01 | 2.22e-01 | 8.86e-02 |
| NEGATIVE REGULATION OF DEPHOSPHORYLATION | 35 | 8.60e-01 | 1.00e+00 | 0.16500 | 6.79e-02 | 5.21e-02 | 8.16e-02 | 5.16e-02 | 1.04e-01 | 4.87e-01 | 5.93e-01 | 4.04e-01 | 5.97e-01 | 2.89e-01 |
| POSITIVE REGULATION OF MITOTIC CELL CYCLE | 122 | 2.50e-01 | 7.76e-01 | 0.16500 | 8.86e-02 | 8.68e-02 | 1.04e-01 | 3.11e-02 | 1.11e-02 | 9.09e-02 | 9.78e-02 | 4.65e-02 | 5.53e-01 | 8.32e-01 |
| NEGATIVE REGULATION OF HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 14 | 6.74e-01 | 1.00e+00 | 0.16500 | 4.18e-02 | 1.77e-02 | 1.26e-01 | -5.23e-02 | -8.24e-02 | 7.87e-01 | 9.09e-01 | 4.16e-01 | 7.35e-01 | 5.94e-01 |
| NEGATIVE REGULATION OF RNA BIOSYNTHETIC PROCESS | 1217 | 1.01e-13 | 3.98e-11 | 0.16500 | 7.43e-02 | 5.68e-02 | 1.24e-01 | 2.19e-02 | 5.12e-02 | 1.26e-05 | 8.49e-04 | 2.70e-13 | 1.99e-01 | 2.63e-03 |
| VESICLE TRANSPORT ALONG MICROTUBULE | 45 | 4.19e-01 | 9.11e-01 | 0.16500 | -6.00e-02 | -7.51e-02 | 3.58e-02 | -1.20e-01 | 4.76e-02 | 4.86e-01 | 3.84e-01 | 6.78e-01 | 1.62e-01 | 5.81e-01 |
| GLYCOSPHINGOLIPID BIOSYNTHETIC PROCESS | 34 | 9.06e-01 | 1.00e+00 | 0.16500 | -8.17e-02 | -9.21e-02 | -5.54e-02 | -5.68e-02 | 7.60e-02 | 4.10e-01 | 3.53e-01 | 5.76e-01 | 5.67e-01 | 4.43e-01 |
| CELL CYCLE PHASE TRANSITION | 551 | 1.75e-08 | 1.85e-06 | 0.16500 | 7.02e-02 | 6.16e-02 | 1.26e-01 | -5.61e-04 | 5.00e-02 | 4.85e-03 | 1.33e-02 | 3.80e-07 | 9.82e-01 | 4.46e-02 |
| INNER EAR MORPHOGENESIS | 104 | 1.28e-01 | 5.96e-01 | 0.16500 | 7.76e-02 | 6.70e-02 | 1.28e-01 | 1.45e-02 | 2.39e-03 | 1.72e-01 | 2.38e-01 | 2.37e-02 | 7.99e-01 | 9.66e-01 |
| ANTIMICROBIAL HUMORAL IMMUNE RESPONSE MEDIATED BY ANTIMICROBIAL PEPTIDE | 79 | 1.37e-02 | 1.56e-01 | 0.16500 | -6.49e-04 | 6.04e-04 | -3.14e-02 | 9.91e-02 | 1.28e-01 | 9.92e-01 | 9.93e-01 | 6.30e-01 | 1.28e-01 | 4.93e-02 |
| METENCEPHALON DEVELOPMENT | 107 | 3.20e-01 | 8.47e-01 | 0.16500 | 9.01e-02 | 7.32e-02 | 1.07e-01 | 4.40e-02 | -1.61e-02 | 1.07e-01 | 1.91e-01 | 5.54e-02 | 4.32e-01 | 7.74e-01 |
| REGULATION OF CALCIUM ION IMPORT | 31 | 9.02e-01 | 1.00e+00 | 0.16500 | -6.13e-02 | -4.22e-02 | -1.02e-01 | -4.53e-02 | -9.53e-02 | 5.55e-01 | 6.84e-01 | 3.24e-01 | 6.63e-01 | 3.59e-01 |
| RIBOSE PHOSPHATE BIOSYNTHETIC PROCESS | 211 | 1.92e-02 | 2.02e-01 | 0.16500 | 7.90e-02 | 6.54e-02 | 1.21e-01 | 1.46e-02 | 4.16e-02 | 4.80e-02 | 1.01e-01 | 2.44e-03 | 7.14e-01 | 2.98e-01 |
| TRABECULA MORPHOGENESIS | 47 | 8.92e-01 | 1.00e+00 | 0.16500 | -8.39e-02 | -9.01e-02 | -4.42e-02 | -9.95e-02 | -9.25e-03 | 3.20e-01 | 2.85e-01 | 6.00e-01 | 2.38e-01 | 9.13e-01 |
| REGULATION OF FATTY ACID TRANSPORT | 31 | 3.45e-01 | 8.64e-01 | 0.16500 | -8.93e-02 | -9.91e-02 | -8.70e-03 | -6.40e-02 | 7.16e-02 | 3.89e-01 | 3.40e-01 | 9.33e-01 | 5.38e-01 | 4.90e-01 |
| POSITIVE REGULATION OF TYPE I INTERFERON PRODUCTION | 66 | 2.32e-01 | 7.54e-01 | 0.16500 | -4.98e-02 | -6.74e-02 | 4.54e-02 | -1.10e-01 | 7.67e-02 | 4.84e-01 | 3.43e-01 | 5.23e-01 | 1.22e-01 | 2.81e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 12 PRODUCTION | 18 | 3.24e-01 | 8.49e-01 | 0.16500 | -6.59e-02 | -1.16e-01 | 5.11e-02 | -8.16e-02 | 6.64e-03 | 6.28e-01 | 3.95e-01 | 7.08e-01 | 5.49e-01 | 9.61e-01 |
| RETINA VASCULATURE DEVELOPMENT IN CAMERA TYPE EYE | 18 | 5.23e-01 | 9.53e-01 | 0.16500 | 7.47e-02 | 3.30e-02 | 9.37e-02 | 9.59e-02 | -4.92e-02 | 5.83e-01 | 8.08e-01 | 4.91e-01 | 4.81e-01 | 7.18e-01 |
| GLUTATHIONE METABOLIC PROCESS | 52 | 6.70e-01 | 1.00e+00 | 0.16400 | 6.81e-02 | 5.02e-02 | 1.14e-01 | 4.85e-02 | 6.68e-02 | 3.95e-01 | 5.31e-01 | 1.54e-01 | 5.45e-01 | 4.04e-01 |
| POSITIVE REGULATION OF NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY | 5 | 7.17e-01 | 1.00e+00 | 0.16400 | -5.04e-03 | -7.42e-02 | 9.90e-03 | -3.63e-02 | -1.42e-01 | 9.84e-01 | 7.74e-01 | 9.69e-01 | 8.88e-01 | 5.83e-01 |
| MITOCHONDRIAL PROTEIN PROCESSING | 13 | 4.32e-01 | 9.19e-01 | 0.16400 | 1.48e-02 | -1.68e-02 | 1.14e-01 | -4.25e-02 | -1.08e-01 | 9.26e-01 | 9.16e-01 | 4.75e-01 | 7.91e-01 | 5.01e-01 |
| ADHESION OF SYMBIONT TO HOST | 12 | 8.71e-01 | 1.00e+00 | 0.16400 | 1.20e-02 | -3.46e-02 | 7.04e-02 | 2.23e-03 | 1.44e-01 | 9.43e-01 | 8.36e-01 | 6.73e-01 | 9.89e-01 | 3.88e-01 |
| ESTABLISHMENT OF PLANAR POLARITY INVOLVED IN NEURAL TUBE CLOSURE | 13 | 4.74e-01 | 9.40e-01 | 0.16400 | 1.28e-02 | 3.96e-02 | 9.48e-02 | -2.85e-02 | 1.24e-01 | 9.36e-01 | 8.05e-01 | 5.54e-01 | 8.59e-01 | 4.38e-01 |
| NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 11 | 6.72e-01 | 1.00e+00 | 0.16400 | -4.29e-02 | -6.53e-02 | 5.62e-02 | -9.47e-02 | -9.35e-02 | 8.06e-01 | 7.07e-01 | 7.47e-01 | 5.87e-01 | 5.91e-01 |
| NEGATIVE REGULATION OF CELL GROWTH INVOLVED IN CARDIAC MUSCLE CELL DEVELOPMENT | 12 | 4.08e-01 | 9.08e-01 | 0.16400 | -1.48e-02 | -1.85e-02 | 1.28e-01 | -8.86e-02 | 4.62e-02 | 9.29e-01 | 9.12e-01 | 4.42e-01 | 5.95e-01 | 7.82e-01 |
| BIOGENIC AMINE METABOLIC PROCESS | 87 | 3.04e-01 | 8.32e-01 | 0.16400 | 8.40e-02 | 6.65e-02 | 1.07e-01 | 4.75e-02 | -4.12e-02 | 1.76e-01 | 2.83e-01 | 8.33e-02 | 4.44e-01 | 5.07e-01 |
| GASTRULATION | 188 | 2.34e-02 | 2.30e-01 | 0.16400 | 8.32e-02 | 7.69e-02 | 1.11e-01 | 2.15e-02 | -3.54e-02 | 4.93e-02 | 6.91e-02 | 8.42e-03 | 6.11e-01 | 4.02e-01 |
| NEGATIVE REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 39 | 1.62e-01 | 6.62e-01 | 0.16400 | 6.85e-02 | 1.10e-01 | -3.36e-02 | 9.43e-02 | -1.24e-02 | 4.59e-01 | 2.35e-01 | 7.16e-01 | 3.08e-01 | 8.93e-01 |
| SKELETAL MUSCLE ORGAN DEVELOPMENT | 169 | 1.42e-01 | 6.27e-01 | 0.16400 | 8.46e-02 | 7.39e-02 | 9.40e-02 | 6.46e-02 | -3.63e-02 | 5.76e-02 | 9.76e-02 | 3.50e-02 | 1.47e-01 | 4.16e-01 |
| REGULATION OF SYNAPTIC VESICLE CLUSTERING | 6 | 9.60e-01 | 1.00e+00 | 0.16400 | -2.82e-02 | -1.84e-02 | 1.97e-02 | -9.69e-02 | -1.26e-01 | 9.05e-01 | 9.38e-01 | 9.34e-01 | 6.81e-01 | 5.92e-01 |
| METANEPHRIC NEPHRON MORPHOGENESIS | 24 | 6.85e-01 | 1.00e+00 | 0.16400 | -5.34e-02 | -6.30e-02 | 2.86e-02 | -1.38e-01 | -1.36e-02 | 6.51e-01 | 5.93e-01 | 8.09e-01 | 2.42e-01 | 9.08e-01 |
| REGULATION OF TELOMERASE ACTIVITY | 48 | 2.92e-01 | 8.20e-01 | 0.16400 | -2.71e-02 | -2.18e-02 | 3.16e-02 | -7.70e-02 | 1.37e-01 | 7.45e-01 | 7.94e-01 | 7.05e-01 | 3.56e-01 | 1.01e-01 |
| DORSAL VENTRAL AXIS SPECIFICATION | 12 | 6.90e-01 | 1.00e+00 | 0.16400 | 3.94e-02 | 2.65e-03 | 1.28e-01 | -5.39e-02 | -7.71e-02 | 8.13e-01 | 9.87e-01 | 4.42e-01 | 7.47e-01 | 6.44e-01 |
| REGULATION OF PROTEIN UBIQUITINATION | 180 | 7.74e-03 | 1.04e-01 | 0.16400 | 4.71e-02 | 4.19e-02 | 1.10e-01 | 5.87e-03 | 1.04e-01 | 2.75e-01 | 3.32e-01 | 1.11e-02 | 8.92e-01 | 1.63e-02 |
| CELLULAR RESPONSE TO DEXAMETHASONE STIMULUS | 24 | 8.52e-01 | 1.00e+00 | 0.16400 | -6.35e-02 | -4.82e-02 | -5.79e-02 | -1.10e-01 | -7.09e-02 | 5.90e-01 | 6.83e-01 | 6.24e-01 | 3.52e-01 | 5.48e-01 |
| REGULATION OF CELL CYCLE PROCESS | 713 | 6.97e-09 | 8.46e-07 | 0.16400 | 6.67e-02 | 5.31e-02 | 1.24e-01 | 1.38e-02 | 6.34e-02 | 2.40e-03 | 1.56e-02 | 1.81e-08 | 5.29e-01 | 3.89e-03 |
| INNATE IMMUNE RESPONSE | 912 | 1.46e-07 | 1.23e-05 | 0.16400 | -8.26e-02 | -9.49e-02 | -2.70e-02 | -8.91e-02 | 4.76e-02 | 2.32e-05 | 1.17e-06 | 1.66e-01 | 5.01e-06 | 1.48e-02 |
| CELL JUNCTION DISASSEMBLY | 27 | 6.03e-01 | 9.90e-01 | 0.16300 | 3.42e-02 | 4.86e-02 | 3.22e-03 | -2.65e-02 | -1.50e-01 | 7.58e-01 | 6.62e-01 | 9.77e-01 | 8.12e-01 | 1.77e-01 |
| NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 28 | 6.49e-01 | 1.00e+00 | 0.16300 | -9.46e-02 | -7.82e-02 | -6.51e-02 | -7.46e-02 | -4.29e-02 | 3.86e-01 | 4.74e-01 | 5.51e-01 | 4.94e-01 | 6.94e-01 |
| STRIATED MUSCLE CONTRACTION | 175 | 4.29e-02 | 3.31e-01 | 0.16300 | 7.52e-02 | 9.36e-02 | 4.07e-02 | 9.93e-02 | -2.77e-02 | 8.60e-02 | 3.26e-02 | 3.53e-01 | 2.34e-02 | 5.28e-01 |
| POSITIVE REGULATION OF ANIMAL ORGAN MORPHOGENESIS | 34 | 2.55e-01 | 7.82e-01 | 0.16300 | -2.24e-02 | -4.40e-02 | 9.93e-02 | -1.10e-01 | 4.72e-02 | 8.21e-01 | 6.57e-01 | 3.16e-01 | 2.66e-01 | 6.34e-01 |
| PEPTIDYL ARGININE MODIFICATION | 10 | 9.34e-01 | 1.00e+00 | 0.16300 | -1.10e-02 | -2.54e-02 | 9.08e-02 | -7.35e-02 | 1.11e-01 | 9.52e-01 | 8.89e-01 | 6.19e-01 | 6.87e-01 | 5.44e-01 |
| GLIAL CELL DERIVED NEUROTROPHIC FACTOR RECEPTOR SIGNALING PATHWAY | 9 | 9.83e-01 | 1.00e+00 | 0.16300 | -5.83e-02 | -4.55e-02 | -1.08e-01 | -4.84e-02 | -8.48e-02 | 7.62e-01 | 8.13e-01 | 5.75e-01 | 8.01e-01 | 6.60e-01 |
| REGULATION OF OVARIAN FOLLICLE DEVELOPMENT | 6 | 9.78e-01 | 1.00e+00 | 0.16300 | 4.57e-02 | 7.26e-02 | -3.64e-02 | 3.30e-02 | -1.30e-01 | 8.46e-01 | 7.58e-01 | 8.77e-01 | 8.89e-01 | 5.82e-01 |
| HEART VALVE MORPHOGENESIS | 60 | 3.70e-01 | 8.80e-01 | 0.16300 | 7.59e-02 | 5.31e-02 | 1.33e-01 | 1.38e-02 | 8.61e-03 | 3.10e-01 | 4.77e-01 | 7.41e-02 | 8.54e-01 | 9.08e-01 |
| NEGATIVE REGULATION OF LYASE ACTIVITY | 18 | 9.77e-01 | 1.00e+00 | 0.16300 | -8.00e-02 | -6.63e-02 | -7.33e-02 | -9.83e-02 | -2.73e-02 | 5.57e-01 | 6.26e-01 | 5.90e-01 | 4.70e-01 | 8.41e-01 |
| NEGATIVE REGULATION OF ALPHA BETA T CELL DIFFERENTIATION | 27 | 3.12e-01 | 8.38e-01 | 0.16300 | -2.70e-02 | -5.09e-02 | 9.93e-02 | -1.12e-01 | 2.80e-02 | 8.08e-01 | 6.47e-01 | 3.72e-01 | 3.13e-01 | 8.01e-01 |
| PULMONARY VALVE MORPHOGENESIS | 19 | 8.30e-01 | 1.00e+00 | 0.16300 | 6.02e-02 | 4.37e-02 | 4.02e-02 | 5.11e-02 | -1.30e-01 | 6.50e-01 | 7.42e-01 | 7.62e-01 | 7.00e-01 | 3.28e-01 |
| POSITIVE REGULATION OF AMINE TRANSPORT | 39 | 4.43e-01 | 9.28e-01 | 0.16300 | 6.56e-02 | 3.37e-02 | 1.42e-01 | -6.83e-04 | 2.89e-02 | 4.79e-01 | 7.16e-01 | 1.24e-01 | 9.94e-01 | 7.55e-01 |
| SYNAPTIC TRANSMISSION GABAERGIC | 56 | 8.04e-02 | 4.67e-01 | 0.16300 | -2.91e-02 | -2.51e-02 | 2.72e-02 | -1.31e-01 | -8.46e-02 | 7.06e-01 | 7.45e-01 | 7.25e-01 | 9.01e-02 | 2.73e-01 |
| TYROSINE PHOSPHORYLATION OF STAT PROTEIN | 81 | 2.73e-01 | 7.99e-01 | 0.16300 | -6.32e-02 | -6.46e-02 | -1.93e-02 | -1.12e-01 | -7.41e-02 | 3.25e-01 | 3.14e-01 | 7.63e-01 | 8.22e-02 | 2.49e-01 |
| POSITIVE REGULATION OF SIGNALING RECEPTOR ACTIVITY | 28 | 6.85e-01 | 1.00e+00 | 0.16300 | 3.70e-02 | 7.13e-02 | -5.59e-02 | 7.15e-02 | -1.09e-01 | 7.35e-01 | 5.14e-01 | 6.09e-01 | 5.13e-01 | 3.19e-01 |
| POSITIVE REGULATION OF TORC1 SIGNALING | 50 | 4.58e-01 | 9.32e-01 | 0.16300 | 3.58e-02 | 1.62e-02 | 1.05e-01 | -3.02e-02 | 1.14e-01 | 6.61e-01 | 8.43e-01 | 1.97e-01 | 7.12e-01 | 1.65e-01 |
| VOLUNTARY MUSCULOSKELETAL MOVEMENT | 7 | 9.25e-01 | 1.00e+00 | 0.16300 | -7.66e-02 | -8.90e-02 | -3.09e-02 | -5.47e-02 | -9.35e-02 | 7.26e-01 | 6.83e-01 | 8.87e-01 | 8.02e-01 | 6.68e-01 |
| PROTEIN LOCALIZATION TO LYSOSOME | 57 | 4.10e-01 | 9.08e-01 | 0.16300 | 3.21e-02 | 1.78e-02 | 1.06e-01 | -2.59e-02 | 1.15e-01 | 6.75e-01 | 8.16e-01 | 1.67e-01 | 7.35e-01 | 1.33e-01 |
| PREPULSE INHIBITION | 13 | 8.81e-01 | 1.00e+00 | 0.16300 | -5.87e-02 | -4.14e-02 | -9.62e-02 | 1.36e-02 | -1.09e-01 | 7.14e-01 | 7.96e-01 | 5.48e-01 | 9.32e-01 | 4.97e-01 |
| ANGIOGENESIS INVOLVED IN WOUND HEALING | 31 | 5.39e-01 | 9.58e-01 | 0.16300 | 6.57e-02 | 5.48e-02 | 1.36e-01 | -2.51e-02 | -2.65e-03 | 5.27e-01 | 5.98e-01 | 1.90e-01 | 8.09e-01 | 9.80e-01 |
| SODIUM ION TRANSMEMBRANE TRANSPORT | 169 | 8.68e-03 | 1.14e-01 | 0.16300 | 5.26e-02 | 7.15e-02 | -2.44e-02 | 1.15e-01 | -6.81e-02 | 2.38e-01 | 1.09e-01 | 5.84e-01 | 9.66e-03 | 1.27e-01 |
| ENDOPLASMIC RETICULUM CALCIUM ION HOMEOSTASIS | 25 | 5.29e-01 | 9.54e-01 | 0.16200 | 5.77e-02 | 3.40e-02 | 1.38e-01 | -5.27e-02 | 1.11e-02 | 6.18e-01 | 7.69e-01 | 2.33e-01 | 6.48e-01 | 9.24e-01 |
| NEGATIVE REGULATION OF DIGESTIVE SYSTEM PROCESS | 14 | 9.23e-01 | 1.00e+00 | 0.16200 | 4.14e-02 | 1.80e-02 | 8.40e-02 | 6.40e-02 | 1.15e-01 | 7.88e-01 | 9.07e-01 | 5.86e-01 | 6.78e-01 | 4.57e-01 |
| NEGATIVE REGULATION OF SYNAPTIC TRANSMISSION | 52 | 4.91e-01 | 9.45e-01 | 0.16200 | 6.29e-02 | 6.28e-02 | 1.10e-01 | 3.47e-02 | 7.13e-02 | 4.33e-01 | 4.34e-01 | 1.68e-01 | 6.65e-01 | 3.74e-01 |
| PROTEIN LOCALIZATION TO CYTOSKELETON | 57 | 3.00e-01 | 8.28e-01 | 0.16200 | -6.05e-02 | -6.97e-02 | 2.27e-02 | -1.31e-01 | 1.22e-02 | 4.30e-01 | 3.63e-01 | 7.67e-01 | 8.69e-02 | 8.74e-01 |
| CENTROMERE COMPLEX ASSEMBLY | 28 | 6.32e-01 | 9.96e-01 | 0.16200 | 4.59e-02 | 6.81e-03 | 1.27e-01 | -1.53e-02 | 8.86e-02 | 6.74e-01 | 9.50e-01 | 2.45e-01 | 8.89e-01 | 4.17e-01 |
| REGULATION OF CELLULAR RESPONSE TO OXIDATIVE STRESS | 22 | 2.05e-01 | 7.27e-01 | 0.16200 | -2.56e-02 | 3.80e-03 | -1.28e-01 | 4.42e-02 | 8.54e-02 | 8.36e-01 | 9.75e-01 | 2.98e-01 | 7.20e-01 | 4.88e-01 |
| POSITIVE REGULATION OF DENDRITIC SPINE MORPHOGENESIS | 15 | 7.61e-01 | 1.00e+00 | 0.16200 | -5.72e-02 | -3.24e-02 | -1.50e-02 | -7.92e-02 | 1.25e-01 | 7.01e-01 | 8.28e-01 | 9.20e-01 | 5.95e-01 | 4.03e-01 |
| TRANSCRIPTION INITIATION AT RNA POLYMERASE III PROMOTER | 8 | 9.94e-01 | 1.00e+00 | 0.16200 | 7.86e-02 | 5.35e-02 | 1.06e-01 | 6.46e-02 | 4.38e-02 | 7.00e-01 | 7.93e-01 | 6.04e-01 | 7.52e-01 | 8.30e-01 |
| AXONEMAL DYNEIN COMPLEX ASSEMBLY | 39 | 8.33e-01 | 1.00e+00 | 0.16200 | 6.90e-02 | 7.89e-02 | 4.35e-02 | 5.73e-02 | -1.01e-01 | 4.56e-01 | 3.94e-01 | 6.38e-01 | 5.36e-01 | 2.76e-01 |
| HYALURONAN CATABOLIC PROCESS | 16 | 9.40e-01 | 1.00e+00 | 0.16200 | -7.61e-02 | -6.41e-02 | -6.63e-02 | -8.92e-02 | 6.39e-02 | 5.98e-01 | 6.57e-01 | 6.46e-01 | 5.37e-01 | 6.58e-01 |
| REGULATION OF OSTEOBLAST PROLIFERATION | 30 | 7.51e-01 | 1.00e+00 | 0.16200 | 7.10e-02 | 9.05e-02 | 3.89e-02 | 1.06e-01 | -1.80e-02 | 5.01e-01 | 3.91e-01 | 7.12e-01 | 3.15e-01 | 8.64e-01 |
| NEGATIVE REGULATION OF CHONDROCYTE DIFFERENTIATION | 24 | 7.21e-01 | 1.00e+00 | 0.16200 | -8.31e-02 | -5.04e-02 | -8.12e-02 | -1.00e-01 | 1.07e-02 | 4.81e-01 | 6.69e-01 | 4.91e-01 | 3.95e-01 | 9.27e-01 |
| NEGATIVE REGULATION OF ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 32 | 3.61e-01 | 8.77e-01 | 0.16200 | -2.79e-02 | -6.64e-02 | 8.80e-02 | -9.57e-02 | 6.44e-02 | 7.85e-01 | 5.16e-01 | 3.89e-01 | 3.49e-01 | 5.28e-01 |
| PURINE NUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 20 | 8.46e-01 | 1.00e+00 | 0.16200 | 9.73e-02 | 7.64e-02 | 7.11e-02 | 7.53e-02 | -1.28e-02 | 4.51e-01 | 5.54e-01 | 5.82e-01 | 5.60e-01 | 9.21e-01 |
| MITOTIC CELL CYCLE PROCESS | 748 | 9.50e-12 | 2.31e-09 | 0.16200 | 6.27e-02 | 4.79e-02 | 1.28e-01 | -4.79e-03 | 5.90e-02 | 3.48e-03 | 2.56e-02 | 2.27e-09 | 8.23e-01 | 6.03e-03 |
| MICROTUBULE DEPOLYMERIZATION | 42 | 6.18e-01 | 9.90e-01 | 0.16200 | 7.44e-02 | 5.72e-02 | 1.26e-01 | 3.55e-02 | 1.24e-02 | 4.04e-01 | 5.22e-01 | 1.56e-01 | 6.91e-01 | 8.90e-01 |
| REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 110 | 6.32e-02 | 4.12e-01 | 0.16200 | 6.08e-02 | 3.92e-02 | 1.31e-01 | -1.56e-02 | 6.01e-02 | 2.71e-01 | 4.78e-01 | 1.78e-02 | 7.77e-01 | 2.76e-01 |
| FRUCTOSE TRANSMEMBRANE TRANSPORT | 10 | 4.35e-01 | 9.22e-01 | 0.16200 | 4.38e-02 | -2.90e-03 | 7.53e-02 | 1.35e-01 | 1.84e-02 | 8.10e-01 | 9.87e-01 | 6.80e-01 | 4.60e-01 | 9.20e-01 |
| KINETOCHORE ORGANIZATION | 20 | 2.97e-01 | 8.24e-01 | 0.16200 | -2.90e-02 | -8.52e-02 | 8.63e-02 | -1.02e-01 | -1.60e-02 | 8.22e-01 | 5.10e-01 | 5.04e-01 | 4.30e-01 | 9.02e-01 |
| TRNA PSEUDOURIDINE SYNTHESIS | 6 | 9.04e-01 | 1.00e+00 | 0.16200 | 3.30e-02 | 4.68e-02 | 1.23e-01 | -6.74e-02 | 5.56e-02 | 8.89e-01 | 8.43e-01 | 6.01e-01 | 7.75e-01 | 8.14e-01 |
| POSITIVE REGULATION OF TRANSPORTER ACTIVITY | 89 | 4.58e-01 | 9.32e-01 | 0.16200 | -7.97e-02 | -6.21e-02 | -6.75e-02 | -9.10e-02 | -5.56e-02 | 1.94e-01 | 3.12e-01 | 2.71e-01 | 1.38e-01 | 3.65e-01 |
| POSITIVE REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 10 | 7.71e-01 | 1.00e+00 | 0.16200 | 5.87e-02 | 9.91e-02 | 2.65e-02 | 1.07e-01 | -2.74e-02 | 7.48e-01 | 5.87e-01 | 8.84e-01 | 5.59e-01 | 8.81e-01 |
| HOMOCYSTEINE METABOLIC PROCESS | 13 | 7.93e-01 | 1.00e+00 | 0.16200 | -9.58e-03 | 1.69e-02 | -1.84e-02 | -4.27e-03 | -1.59e-01 | 9.52e-01 | 9.16e-01 | 9.08e-01 | 9.79e-01 | 3.20e-01 |
| NEURON INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO OXIDATIVE STRESS | 20 | 7.86e-01 | 1.00e+00 | 0.16200 | -8.76e-02 | -7.35e-02 | -2.57e-02 | -1.02e-01 | 4.39e-02 | 4.97e-01 | 5.69e-01 | 8.42e-01 | 4.30e-01 | 7.34e-01 |
| REGULATION OF NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY | 10 | 8.22e-01 | 1.00e+00 | 0.16100 | 7.27e-02 | 4.16e-02 | 1.16e-01 | -3.41e-02 | -6.62e-02 | 6.91e-01 | 8.20e-01 | 5.25e-01 | 8.52e-01 | 7.17e-01 |
| PYRIMIDINE NUCLEOSIDE TRIPHOSPHATE BIOSYNTHETIC PROCESS | 18 | 8.76e-01 | 1.00e+00 | 0.16100 | 8.32e-02 | 5.90e-02 | 1.13e-01 | 2.20e-02 | -4.85e-02 | 5.41e-01 | 6.65e-01 | 4.06e-01 | 8.72e-01 | 7.22e-01 |
| EMBRYO DEVELOPMENT | 1094 | 4.52e-09 | 5.97e-07 | 0.16100 | 8.46e-02 | 7.33e-02 | 1.09e-01 | 3.98e-02 | -5.03e-03 | 2.28e-06 | 4.17e-05 | 1.19e-09 | 2.63e-02 | 7.79e-01 |
| PURINE CONTAINING COMPOUND TRANSMEMBRANE TRANSPORT | 35 | 8.72e-01 | 1.00e+00 | 0.16100 | -9.23e-02 | -8.02e-02 | -6.65e-02 | -8.12e-02 | 2.60e-03 | 3.45e-01 | 4.11e-01 | 4.96e-01 | 4.06e-01 | 9.79e-01 |
| NEGATIVE REGULATION OF BEHAVIOR | 12 | 8.63e-01 | 1.00e+00 | 0.16100 | 2.20e-02 | -7.67e-03 | 7.35e-02 | 6.14e-02 | 1.28e-01 | 8.95e-01 | 9.63e-01 | 6.59e-01 | 7.13e-01 | 4.44e-01 |
| REGULATION OF DNA REPLICATION | 121 | 4.19e-03 | 6.71e-02 | 0.16100 | 5.66e-02 | 3.70e-02 | 1.41e-01 | -3.46e-02 | 1.48e-02 | 2.82e-01 | 4.82e-01 | 7.24e-03 | 5.11e-01 | 7.78e-01 |
| NEGATIVE REGULATION OF VASCULATURE DEVELOPMENT | 139 | 1.49e-01 | 6.36e-01 | 0.16100 | 7.77e-02 | 8.43e-02 | 3.18e-02 | 5.81e-02 | -9.19e-02 | 1.14e-01 | 8.63e-02 | 5.17e-01 | 2.37e-01 | 6.14e-02 |
| REGULATION OF NEURON PROJECTION ARBORIZATION | 14 | 4.76e-01 | 9.40e-01 | 0.16100 | 5.06e-02 | 6.34e-02 | 6.36e-02 | 8.77e-02 | -8.74e-02 | 7.43e-01 | 6.81e-01 | 6.80e-01 | 5.70e-01 | 5.71e-01 |
| CELL DIFFERENTIATION INVOLVED IN METANEPHROS DEVELOPMENT | 23 | 6.46e-01 | 1.00e+00 | 0.16100 | -2.53e-02 | -6.15e-02 | 8.14e-02 | -6.01e-02 | 1.06e-01 | 8.34e-01 | 6.09e-01 | 4.99e-01 | 6.18e-01 | 3.78e-01 |
| ACETYL COA BIOSYNTHETIC PROCESS | 16 | 7.76e-01 | 1.00e+00 | 0.16100 | 4.38e-02 | 5.19e-02 | 1.13e-01 | -3.21e-02 | 8.73e-02 | 7.61e-01 | 7.19e-01 | 4.35e-01 | 8.24e-01 | 5.46e-01 |
| NUCLEAR EXPORT | 157 | 5.27e-02 | 3.76e-01 | 0.16100 | 7.21e-02 | 6.15e-02 | 1.08e-01 | 9.90e-03 | 7.22e-02 | 1.19e-01 | 1.83e-01 | 1.96e-02 | 8.30e-01 | 1.18e-01 |
| AMIDE BIOSYNTHETIC PROCESS | 938 | 2.41e-09 | 3.42e-07 | 0.16100 | 7.84e-02 | 7.43e-02 | 1.13e-01 | 2.50e-02 | 2.99e-02 | 4.69e-05 | 1.15e-04 | 4.53e-09 | 1.94e-01 | 1.20e-01 |
| ANTERIOR POSTERIOR AXIS SPECIFICATION | 54 | 8.97e-02 | 4.95e-01 | 0.16100 | 9.36e-03 | 5.61e-03 | 5.81e-02 | -6.30e-02 | -1.36e-01 | 9.05e-01 | 9.43e-01 | 4.60e-01 | 4.24e-01 | 8.40e-02 |
| REGULATION OF FEMALE RECEPTIVITY | 7 | 9.61e-01 | 1.00e+00 | 0.16100 | 7.71e-02 | 1.11e-01 | 6.86e-02 | 5.30e-02 | -1.46e-02 | 7.24e-01 | 6.12e-01 | 7.53e-01 | 8.08e-01 | 9.47e-01 |
| REGULATION OF NUCLEOBASE CONTAINING COMPOUND TRANSPORT | 16 | 7.92e-01 | 1.00e+00 | 0.16100 | -8.42e-02 | -1.19e-01 | -4.94e-02 | -4.76e-02 | -6.02e-03 | 5.60e-01 | 4.11e-01 | 7.32e-01 | 7.42e-01 | 9.67e-01 |
| PHOSPHATE ION TRANSPORT | 28 | 8.17e-01 | 1.00e+00 | 0.16100 | 6.12e-02 | 6.33e-02 | 1.35e-02 | 1.06e-01 | -8.28e-02 | 5.75e-01 | 5.62e-01 | 9.01e-01 | 3.34e-01 | 4.48e-01 |
| FUCOSE METABOLIC PROCESS | 16 | 9.31e-01 | 1.00e+00 | 0.16100 | 3.61e-02 | 9.73e-03 | 7.45e-02 | 1.51e-02 | 1.37e-01 | 8.03e-01 | 9.46e-01 | 6.06e-01 | 9.17e-01 | 3.43e-01 |
| POSITIVE REGULATION OF CELL SIZE | 10 | 8.79e-01 | 1.00e+00 | 0.16100 | 1.70e-02 | -6.64e-03 | 1.23e-02 | -1.79e-02 | -1.58e-01 | 9.26e-01 | 9.71e-01 | 9.46e-01 | 9.22e-01 | 3.85e-01 |
| CELL FATE COMMITMENT | 279 | 7.94e-10 | 1.25e-07 | 0.16100 | 5.02e-02 | 3.26e-02 | 1.30e-01 | -5.36e-02 | -4.97e-02 | 1.49e-01 | 3.49e-01 | 1.79e-04 | 1.24e-01 | 1.53e-01 |
| CELLULAR OXIDANT DETOXIFICATION | 95 | 5.15e-01 | 9.52e-01 | 0.16100 | 8.36e-02 | 9.77e-02 | 5.41e-02 | 6.05e-02 | -5.27e-02 | 1.59e-01 | 9.99e-02 | 3.63e-01 | 3.08e-01 | 3.75e-01 |
| SPHINGOLIPID CATABOLIC PROCESS | 32 | 6.05e-01 | 9.90e-01 | 0.16100 | -1.33e-02 | -7.67e-03 | 3.83e-02 | -2.46e-02 | 1.54e-01 | 8.96e-01 | 9.40e-01 | 7.08e-01 | 8.10e-01 | 1.33e-01 |
| RNA CAPPING | 35 | 7.33e-01 | 1.00e+00 | 0.16100 | 7.38e-02 | 5.36e-02 | 1.24e-01 | 2.75e-03 | 4.62e-02 | 4.50e-01 | 5.83e-01 | 2.04e-01 | 9.78e-01 | 6.36e-01 |
| DEOXYRIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 8 | 9.72e-01 | 1.00e+00 | 0.16100 | 5.19e-02 | 4.95e-02 | -2.46e-02 | 9.79e-02 | -1.03e-01 | 7.99e-01 | 8.09e-01 | 9.04e-01 | 6.32e-01 | 6.16e-01 |
| PHAGOCYTOSIS | 230 | 6.17e-03 | 8.91e-02 | 0.16100 | -7.51e-02 | -9.83e-02 | -7.51e-03 | -7.85e-02 | 6.55e-02 | 4.97e-02 | 1.02e-02 | 8.44e-01 | 4.01e-02 | 8.68e-02 |
| POSITIVE REGULATION OF STRIATED MUSCLE CELL APOPTOTIC PROCESS | 19 | 8.60e-01 | 1.00e+00 | 0.16100 | -3.84e-02 | -6.81e-02 | 1.43e-02 | -5.97e-02 | 1.26e-01 | 7.72e-01 | 6.07e-01 | 9.14e-01 | 6.53e-01 | 3.41e-01 |
| VASODILATION | 46 | 6.38e-01 | 9.99e-01 | 0.16100 | 4.46e-02 | 4.72e-02 | 6.01e-03 | 5.32e-02 | -1.37e-01 | 6.00e-01 | 5.79e-01 | 9.44e-01 | 5.32e-01 | 1.08e-01 |
| DEFENSE RESPONSE TO OTHER ORGANISM | 1153 | 5.36e-09 | 6.82e-07 | 0.16000 | -8.12e-02 | -9.40e-02 | -3.02e-02 | -8.14e-02 | 5.26e-02 | 3.31e-06 | 7.15e-08 | 8.37e-02 | 3.09e-06 | 2.59e-03 |
| NEGATIVE REGULATION OF TELOMERE CAPPING | 8 | 8.46e-01 | 1.00e+00 | 0.16000 | 2.31e-02 | -5.61e-04 | 1.37e-01 | -9.03e-03 | 8.00e-02 | 9.10e-01 | 9.98e-01 | 5.03e-01 | 9.65e-01 | 6.95e-01 |
| PHOSPHOLIPID BIOSYNTHETIC PROCESS | 244 | 9.53e-02 | 5.10e-01 | 0.16000 | 6.67e-02 | 6.26e-02 | 8.21e-02 | 5.08e-02 | 8.96e-02 | 7.27e-02 | 9.23e-02 | 2.72e-02 | 1.71e-01 | 1.59e-02 |
| RESPONSE TO PROGESTERONE | 40 | 6.14e-01 | 9.90e-01 | 0.16000 | 6.99e-02 | 8.97e-02 | 6.01e-02 | 4.63e-02 | -8.36e-02 | 4.44e-01 | 3.26e-01 | 5.10e-01 | 6.12e-01 | 3.60e-01 |
| NEUTROPHIL HOMEOSTASIS | 20 | 5.95e-01 | 9.87e-01 | 0.16000 | -7.72e-02 | -1.12e-01 | -3.47e-02 | -5.35e-02 | -5.56e-02 | 5.50e-01 | 3.86e-01 | 7.88e-01 | 6.79e-01 | 6.67e-01 |
| REGULATION OF MAMMARY GLAND EPITHELIAL CELL PROLIFERATION | 15 | 8.92e-01 | 1.00e+00 | 0.16000 | 9.20e-02 | 1.07e-01 | 5.50e-02 | 4.05e-02 | -3.16e-02 | 5.37e-01 | 4.71e-01 | 7.12e-01 | 7.86e-01 | 8.32e-01 |
| POSITIVE REGULATION OF SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 41 | 3.70e-01 | 8.81e-01 | 0.16000 | -1.61e-02 | -3.15e-02 | -1.75e-02 | -2.34e-02 | -1.53e-01 | 8.58e-01 | 7.27e-01 | 8.46e-01 | 7.95e-01 | 8.91e-02 |
| EYE PHOTORECEPTOR CELL DIFFERENTIATION | 47 | 3.84e-01 | 8.92e-01 | 0.16000 | 3.61e-02 | 6.89e-02 | -4.04e-02 | 3.20e-02 | -1.30e-01 | 6.68e-01 | 4.14e-01 | 6.32e-01 | 7.04e-01 | 1.23e-01 |
| REGULATION OF FAT CELL DIFFERENTIATION | 140 | 3.30e-01 | 8.55e-01 | 0.16000 | 8.75e-02 | 7.98e-02 | 9.86e-02 | 4.15e-02 | -1.25e-02 | 7.39e-02 | 1.03e-01 | 4.39e-02 | 3.96e-01 | 7.99e-01 |
| PURINE NUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 40 | 9.63e-01 | 1.00e+00 | 0.16000 | 8.61e-02 | 8.52e-02 | 8.29e-02 | 6.35e-02 | 6.05e-03 | 3.46e-01 | 3.51e-01 | 3.64e-01 | 4.87e-01 | 9.47e-01 |
| NEGATIVE REGULATION OF POST TRANSCRIPTIONAL GENE SILENCING | 12 | 7.45e-02 | 4.49e-01 | 0.16000 | -4.94e-02 | -5.60e-03 | 8.31e-02 | -1.24e-01 | 2.96e-02 | 7.67e-01 | 9.73e-01 | 6.18e-01 | 4.57e-01 | 8.59e-01 |
| INSULIN METABOLIC PROCESS | 16 | 3.75e-01 | 8.83e-01 | 0.16000 | 2.98e-02 | -2.78e-02 | 1.34e-01 | -6.79e-02 | -3.57e-02 | 8.36e-01 | 8.47e-01 | 3.52e-01 | 6.38e-01 | 8.05e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II | 1193 | 5.71e-18 | 3.31e-15 | 0.16000 | 6.57e-02 | 4.77e-02 | 1.30e-01 | 3.86e-03 | 4.63e-02 | 1.31e-04 | 5.46e-03 | 4.63e-14 | 8.22e-01 | 7.02e-03 |
| GROOMING BEHAVIOR | 17 | 4.19e-01 | 9.11e-01 | 0.16000 | 2.83e-02 | 1.62e-02 | 9.21e-02 | -1.18e-01 | -4.53e-02 | 8.40e-01 | 9.08e-01 | 5.11e-01 | 4.00e-01 | 7.47e-01 |
| REGULATION OF MEMBRANE REPOLARIZATION | 36 | 3.97e-01 | 8.96e-01 | 0.16000 | 3.37e-02 | 5.42e-02 | -1.99e-02 | 9.66e-02 | -1.08e-01 | 7.26e-01 | 5.74e-01 | 8.36e-01 | 3.16e-01 | 2.62e-01 |
| NEGATIVE REGULATION OF WNT SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 7 | 9.11e-01 | 1.00e+00 | 0.16000 | -3.38e-02 | -2.84e-02 | 2.14e-02 | -1.50e-01 | -2.40e-02 | 8.77e-01 | 8.96e-01 | 9.22e-01 | 4.92e-01 | 9.12e-01 |
| POSITIVE REGULATION OF GOLGI TO PLASMA MEMBRANE PROTEIN TRANSPORT | 5 | 7.74e-01 | 1.00e+00 | 0.16000 | -3.81e-02 | -1.19e-01 | 5.42e-02 | -8.14e-02 | -1.59e-02 | 8.83e-01 | 6.44e-01 | 8.34e-01 | 7.53e-01 | 9.51e-01 |
| NEURAL TUBE PATTERNING | 39 | 5.46e-01 | 9.61e-01 | 0.16000 | 3.59e-02 | 5.47e-03 | 1.11e-01 | -2.90e-02 | 1.05e-01 | 6.98e-01 | 9.53e-01 | 2.31e-01 | 7.54e-01 | 2.57e-01 |
| EPIDERMAL CELL DIFFERENTIATION | 242 | 5.58e-07 | 4.05e-05 | 0.15900 | 3.92e-02 | 6.12e-02 | -6.71e-02 | 1.23e-01 | -2.08e-02 | 2.93e-01 | 1.01e-01 | 7.23e-02 | 9.45e-04 | 5.76e-01 |
| POSITIVE REGULATION OF CALCIUM ION TRANSPORT INTO CYTOSOL | 13 | 8.43e-01 | 1.00e+00 | 0.15900 | 9.96e-03 | 2.79e-02 | 3.58e-03 | 1.00e-02 | -1.56e-01 | 9.50e-01 | 8.62e-01 | 9.82e-01 | 9.50e-01 | 3.29e-01 |
| PROTEIN METHYLATION | 75 | 4.27e-01 | 9.16e-01 | 0.15900 | -6.15e-02 | -7.73e-02 | -1.31e-02 | -4.28e-02 | 1.17e-01 | 3.57e-01 | 2.47e-01 | 8.45e-01 | 5.21e-01 | 8.01e-02 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO HYDROGEN PEROXIDE | 9 | 9.21e-01 | 1.00e+00 | 0.15900 | -3.74e-02 | -1.54e-02 | -5.28e-02 | 1.35e-03 | 1.45e-01 | 8.46e-01 | 9.36e-01 | 7.84e-01 | 9.94e-01 | 4.52e-01 |
| COCHLEA DEVELOPMENT | 46 | 2.16e-01 | 7.38e-01 | 0.15900 | 6.96e-02 | 3.88e-02 | 1.14e-01 | 1.86e-02 | -7.55e-02 | 4.14e-01 | 6.49e-01 | 1.81e-01 | 8.27e-01 | 3.75e-01 |
| CEREBELLAR CORTEX MORPHOGENESIS | 34 | 5.27e-01 | 9.54e-01 | 0.15900 | 2.81e-02 | 2.56e-02 | 1.03e-01 | -4.44e-02 | 1.07e-01 | 7.77e-01 | 7.96e-01 | 2.99e-01 | 6.54e-01 | 2.81e-01 |
| REGULATION OF MEMBRANE LIPID DISTRIBUTION | 60 | 7.06e-01 | 1.00e+00 | 0.15900 | -5.19e-02 | -4.50e-02 | -7.43e-02 | -3.91e-02 | -1.17e-01 | 4.87e-01 | 5.47e-01 | 3.20e-01 | 6.00e-01 | 1.18e-01 |
| HINDLIMB MORPHOGENESIS | 35 | 1.97e-01 | 7.10e-01 | 0.15900 | 3.26e-02 | -8.42e-03 | 1.45e-01 | -4.22e-02 | 3.62e-02 | 7.39e-01 | 9.31e-01 | 1.36e-01 | 6.66e-01 | 7.11e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CENTROSOME | 7 | 9.88e-01 | 1.00e+00 | 0.15900 | -8.79e-02 | -8.19e-02 | -4.33e-02 | -8.87e-02 | -3.46e-02 | 6.87e-01 | 7.08e-01 | 8.43e-01 | 6.84e-01 | 8.74e-01 |
| CALCIUM INDEPENDENT CELL CELL ADHESION VIA PLASMA MEMBRANE CELL ADHESION MOLECULES | 22 | 7.19e-01 | 1.00e+00 | 0.15900 | -3.92e-02 | -1.35e-02 | -1.11e-01 | 4.68e-02 | -9.59e-02 | 7.50e-01 | 9.13e-01 | 3.69e-01 | 7.04e-01 | 4.36e-01 |
| NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 46 | 5.96e-02 | 4.01e-01 | 0.15900 | 2.65e-02 | 2.96e-02 | 1.04e-01 | -9.73e-02 | 5.83e-02 | 7.56e-01 | 7.29e-01 | 2.21e-01 | 2.53e-01 | 4.94e-01 |
| ISOPRENOID METABOLIC PROCESS | 130 | 1.71e-01 | 6.75e-01 | 0.15900 | 5.92e-02 | 8.02e-02 | 2.76e-03 | 7.29e-02 | -1.00e-01 | 2.44e-01 | 1.14e-01 | 9.57e-01 | 1.51e-01 | 4.81e-02 |
| NEGATIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 55 | 1.43e-01 | 6.29e-01 | 0.15900 | 5.42e-02 | 6.61e-02 | 8.25e-02 | -4.26e-03 | -1.06e-01 | 4.87e-01 | 3.97e-01 | 2.90e-01 | 9.56e-01 | 1.75e-01 |
| REGULATION OF AUTOPHAGY OF MITOCHONDRION | 38 | 8.64e-01 | 1.00e+00 | 0.15900 | -8.25e-02 | -7.35e-02 | -6.20e-02 | -6.59e-02 | 7.01e-02 | 3.79e-01 | 4.33e-01 | 5.09e-01 | 4.82e-01 | 4.54e-01 |
| PROTEOGLYCAN BIOSYNTHETIC PROCESS | 63 | 3.01e-01 | 8.28e-01 | 0.15900 | 2.26e-02 | 3.24e-02 | -2.91e-03 | 3.02e-02 | -1.51e-01 | 7.57e-01 | 6.56e-01 | 9.68e-01 | 6.78e-01 | 3.81e-02 |
| ESTABLISHMENT OF MITOCHONDRION LOCALIZATION | 27 | 6.90e-01 | 1.00e+00 | 0.15900 | -3.45e-02 | -4.88e-02 | -2.27e-02 | -7.67e-02 | -1.24e-01 | 7.57e-01 | 6.61e-01 | 8.39e-01 | 4.90e-01 | 2.66e-01 |
| METANEPHROS DEVELOPMENT | 91 | 1.78e-03 | 3.61e-02 | 0.15900 | 2.79e-02 | -1.57e-02 | 1.37e-01 | -6.73e-02 | 3.12e-02 | 6.46e-01 | 7.96e-01 | 2.39e-02 | 2.67e-01 | 6.07e-01 |
| NEGATIVE REGULATION OF CELL CYCLE G2 M PHASE TRANSITION | 66 | 2.10e-01 | 7.33e-01 | 0.15900 | 5.87e-02 | 2.79e-02 | 1.36e-01 | -8.29e-03 | 5.10e-02 | 4.10e-01 | 6.95e-01 | 5.68e-02 | 9.07e-01 | 4.74e-01 |
| RAP PROTEIN SIGNAL TRANSDUCTION | 12 | 9.17e-01 | 1.00e+00 | 0.15900 | -6.02e-02 | -7.63e-02 | 2.75e-02 | -1.22e-01 | -1.72e-02 | 7.18e-01 | 6.47e-01 | 8.69e-01 | 4.66e-01 | 9.18e-01 |
| COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE | 24 | 5.04e-01 | 9.48e-01 | 0.15900 | 6.58e-02 | 8.65e-02 | 1.08e-01 | -1.65e-02 | 3.89e-02 | 5.77e-01 | 4.63e-01 | 3.60e-01 | 8.89e-01 | 7.42e-01 |
| BLOOD VESSEL MATURATION | 8 | 7.83e-01 | 1.00e+00 | 0.15900 | 3.91e-02 | 8.51e-03 | 7.68e-02 | 4.60e-02 | -1.25e-01 | 8.48e-01 | 9.67e-01 | 7.07e-01 | 8.22e-01 | 5.40e-01 |
| POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA | 5 | 8.21e-01 | 1.00e+00 | 0.15900 | -1.37e-02 | 3.49e-02 | 3.47e-02 | -1.20e-01 | -9.05e-02 | 9.58e-01 | 8.92e-01 | 8.93e-01 | 6.42e-01 | 7.26e-01 |
| CEREBELLAR PURKINJE CELL LAYER FORMATION | 14 | 9.07e-01 | 1.00e+00 | 0.15900 | 1.02e-02 | -7.49e-03 | 1.02e-01 | -3.71e-02 | 1.15e-01 | 9.47e-01 | 9.61e-01 | 5.08e-01 | 8.10e-01 | 4.56e-01 |
| EPIDERMIS DEVELOPMENT | 375 | 9.27e-09 | 1.08e-06 | 0.15900 | 4.22e-02 | 6.83e-02 | -5.60e-02 | 1.16e-01 | -4.68e-02 | 1.61e-01 | 2.30e-02 | 6.24e-02 | 1.19e-04 | 1.20e-01 |
| POSITIVE REGULATION OF ACTIN FILAMENT DEPOLYMERIZATION | 13 | 9.40e-01 | 1.00e+00 | 0.15900 | 1.46e-02 | 3.74e-02 | -5.54e-02 | 1.16e-02 | -1.43e-01 | 9.27e-01 | 8.15e-01 | 7.29e-01 | 9.42e-01 | 3.73e-01 |
| NEURONAL STEM CELL POPULATION MAINTENANCE | 23 | 4.86e-01 | 9.43e-01 | 0.15900 | -2.95e-02 | -4.76e-02 | 4.19e-02 | -1.36e-01 | 4.09e-02 | 8.06e-01 | 6.93e-01 | 7.28e-01 | 2.58e-01 | 7.34e-01 |
| RHYTHMIC BEHAVIOR | 44 | 7.22e-01 | 1.00e+00 | 0.15900 | 3.76e-02 | 1.59e-02 | 9.49e-02 | 1.77e-02 | 1.19e-01 | 6.66e-01 | 8.55e-01 | 2.76e-01 | 8.39e-01 | 1.72e-01 |
| NEGATIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 42 | 8.70e-01 | 1.00e+00 | 0.15800 | -7.28e-02 | -7.73e-02 | -3.24e-02 | -9.81e-02 | 5.62e-02 | 4.14e-01 | 3.86e-01 | 7.17e-01 | 2.71e-01 | 5.28e-01 |
| NEGATIVE REGULATION OF CARTILAGE DEVELOPMENT | 31 | 5.89e-01 | 9.86e-01 | 0.15800 | -6.53e-02 | -3.20e-02 | -9.15e-02 | -9.02e-02 | -5.75e-02 | 5.29e-01 | 7.58e-01 | 3.78e-01 | 3.85e-01 | 5.80e-01 |
| VENTRICULAR SEPTUM MORPHOGENESIS | 43 | 7.34e-02 | 4.45e-01 | 0.15800 | 2.83e-03 | -2.94e-02 | 7.94e-02 | -9.89e-02 | -9.01e-02 | 9.74e-01 | 7.39e-01 | 3.68e-01 | 2.62e-01 | 3.07e-01 |
| ENDOCARDIAL CUSHION FORMATION | 31 | 7.24e-01 | 1.00e+00 | 0.15800 | -6.31e-02 | -7.61e-02 | 1.01e-02 | -1.22e-01 | -1.88e-02 | 5.43e-01 | 4.63e-01 | 9.23e-01 | 2.41e-01 | 8.56e-01 |
| POSITIVE REGULATION OF SODIUM ION TRANSMEMBRANE TRANSPORT | 16 | 8.53e-01 | 1.00e+00 | 0.15800 | 4.25e-02 | 4.11e-02 | 4.91e-02 | -2.97e-02 | -1.35e-01 | 7.69e-01 | 7.76e-01 | 7.34e-01 | 8.37e-01 | 3.49e-01 |
| NEGATIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 43 | 2.23e-01 | 7.45e-01 | 0.15800 | 2.38e-02 | 1.82e-02 | 1.21e-01 | -5.72e-02 | 7.95e-02 | 7.87e-01 | 8.36e-01 | 1.71e-01 | 5.17e-01 | 3.67e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO CELL CORTEX | 6 | 8.45e-01 | 1.00e+00 | 0.15800 | 4.91e-02 | 9.45e-02 | 2.85e-02 | 8.42e-02 | -7.59e-02 | 8.35e-01 | 6.88e-01 | 9.04e-01 | 7.21e-01 | 7.48e-01 |
| CELLULAR RESPONSE TO ALKALOID | 35 | 6.85e-01 | 1.00e+00 | 0.15800 | -3.62e-02 | -6.39e-02 | 4.75e-02 | -6.16e-02 | 1.16e-01 | 7.11e-01 | 5.13e-01 | 6.27e-01 | 5.28e-01 | 2.33e-01 |
| LYMPHOCYTE ACTIVATION | 759 | 4.38e-11 | 8.91e-09 | 0.15800 | -6.46e-02 | -8.63e-02 | 1.74e-02 | -9.65e-02 | 6.11e-02 | 2.46e-03 | 5.19e-05 | 4.14e-01 | 6.01e-06 | 4.16e-03 |
| REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 83 | 4.02e-03 | 6.52e-02 | 0.15800 | -2.20e-03 | -2.37e-02 | 9.66e-02 | -1.22e-01 | -8.64e-03 | 9.72e-01 | 7.09e-01 | 1.28e-01 | 5.39e-02 | 8.92e-01 |
| REGULATION OF HEART RATE | 99 | 4.78e-01 | 9.40e-01 | 0.15800 | 7.82e-02 | 9.20e-02 | 5.99e-02 | 7.07e-02 | -4.22e-02 | 1.79e-01 | 1.14e-01 | 3.03e-01 | 2.24e-01 | 4.68e-01 |
| INTERNAL PROTEIN AMINO ACID ACETYLATION | 53 | 4.68e-01 | 9.36e-01 | 0.15800 | 6.23e-02 | 6.51e-02 | 1.11e-01 | 9.54e-03 | 6.58e-02 | 4.33e-01 | 4.12e-01 | 1.61e-01 | 9.04e-01 | 4.07e-01 |
| REGULATION OF POST TRANSLATIONAL PROTEIN MODIFICATION | 262 | 2.00e-03 | 3.89e-02 | 0.15800 | 5.47e-02 | 4.67e-02 | 1.13e-01 | 1.51e-02 | 8.26e-02 | 1.27e-01 | 1.93e-01 | 1.68e-03 | 6.73e-01 | 2.13e-02 |
| ESTABLISHMENT OF PLANAR POLARITY OF EMBRYONIC EPITHELIUM | 16 | 7.53e-01 | 1.00e+00 | 0.15800 | 1.13e-02 | 1.29e-02 | 1.00e-01 | -4.21e-02 | 1.13e-01 | 9.38e-01 | 9.29e-01 | 4.87e-01 | 7.71e-01 | 4.34e-01 |
| MITOCHONDRION DISTRIBUTION | 16 | 8.17e-01 | 1.00e+00 | 0.15800 | 3.78e-02 | 5.32e-02 | 1.46e-02 | 1.04e-01 | 9.77e-02 | 7.93e-01 | 7.13e-01 | 9.19e-01 | 4.70e-01 | 4.99e-01 |
| RESPONSE TO AMINE | 45 | 6.74e-01 | 1.00e+00 | 0.15800 | 7.73e-02 | 6.51e-02 | 9.85e-02 | 5.27e-02 | -4.72e-02 | 3.70e-01 | 4.50e-01 | 2.53e-01 | 5.40e-01 | 5.83e-01 |
| POSITIVE T CELL SELECTION | 39 | 2.99e-01 | 8.25e-01 | 0.15800 | -8.37e-02 | -8.52e-02 | -6.79e-03 | -1.00e-01 | -2.34e-02 | 3.65e-01 | 3.57e-01 | 9.42e-01 | 2.79e-01 | 8.00e-01 |
| EMBRYONIC MORPHOGENESIS | 604 | 9.96e-07 | 6.46e-05 | 0.15800 | 8.15e-02 | 7.16e-02 | 1.10e-01 | 2.19e-02 | -2.20e-02 | 6.22e-04 | 2.63e-03 | 3.60e-06 | 3.57e-01 | 3.55e-01 |
| VACUOLAR LOCALIZATION | 82 | 1.89e-01 | 6.99e-01 | 0.15800 | 4.06e-02 | 1.65e-02 | 1.21e-01 | -1.42e-02 | 9.06e-02 | 5.25e-01 | 7.96e-01 | 5.89e-02 | 8.24e-01 | 1.56e-01 |
| THYMIC T CELL SELECTION | 23 | 3.28e-01 | 8.53e-01 | 0.15800 | -4.02e-02 | -5.56e-02 | 7.09e-02 | -4.35e-02 | 1.15e-01 | 7.38e-01 | 6.44e-01 | 5.56e-01 | 7.18e-01 | 3.39e-01 |
| PROTEIN ACETYLATION | 97 | 1.45e-01 | 6.29e-01 | 0.15800 | 4.92e-02 | 4.44e-02 | 1.09e-01 | -1.09e-02 | 9.21e-02 | 4.02e-01 | 4.49e-01 | 6.36e-02 | 8.52e-01 | 1.17e-01 |
| POSITIVE REGULATION OF DENDRITIC SPINE DEVELOPMENT | 34 | 1.99e-01 | 7.14e-01 | 0.15800 | 2.74e-02 | 4.48e-02 | 5.02e-02 | 7.10e-02 | 1.21e-01 | 7.82e-01 | 6.51e-01 | 6.13e-01 | 4.73e-01 | 2.23e-01 |
| POSITIVE REGULATION OF MUSCLE CELL APOPTOTIC PROCESS | 33 | 5.37e-01 | 9.57e-01 | 0.15800 | -7.53e-03 | -2.63e-02 | 4.31e-02 | -6.04e-02 | 1.36e-01 | 9.40e-01 | 7.94e-01 | 6.68e-01 | 5.48e-01 | 1.75e-01 |
| CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 31 | 9.73e-01 | 1.00e+00 | 0.15800 | 8.46e-02 | 9.18e-02 | 5.74e-02 | 7.48e-02 | -1.88e-02 | 4.15e-01 | 3.76e-01 | 5.80e-01 | 4.71e-01 | 8.57e-01 |
| FEMALE MEIOTIC NUCLEAR DIVISION | 38 | 1.88e-01 | 6.95e-01 | 0.15700 | 2.16e-02 | -3.01e-03 | 1.18e-01 | -9.83e-02 | 2.78e-02 | 8.18e-01 | 9.74e-01 | 2.09e-01 | 2.94e-01 | 7.67e-01 |
| ACTIVATION OF ADENYLATE CYCLASE ACTIVITY | 25 | 9.66e-01 | 1.00e+00 | 0.15700 | -7.78e-02 | -7.55e-02 | -7.81e-02 | -5.45e-02 | -6.31e-02 | 5.01e-01 | 5.14e-01 | 4.99e-01 | 6.37e-01 | 5.85e-01 |
| NEGATIVE REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 20 | 9.15e-01 | 1.00e+00 | 0.15700 | 5.68e-02 | 3.47e-02 | 1.08e-01 | 4.76e-02 | 8.07e-02 | 6.60e-01 | 7.88e-01 | 4.05e-01 | 7.13e-01 | 5.32e-01 |
| NEGATIVE REGULATION OF MOTOR NEURON APOPTOTIC PROCESS | 11 | 9.75e-01 | 1.00e+00 | 0.15700 | -5.82e-02 | -7.26e-02 | 2.32e-02 | -1.04e-01 | 6.90e-02 | 7.38e-01 | 6.77e-01 | 8.94e-01 | 5.50e-01 | 6.92e-01 |
| MICROTUBULE SEVERING | 8 | 9.32e-01 | 1.00e+00 | 0.15700 | -1.75e-02 | -2.88e-02 | 4.32e-02 | -9.18e-02 | -1.16e-01 | 9.32e-01 | 8.88e-01 | 8.32e-01 | 6.53e-01 | 5.71e-01 |
| REGULATION OF TRANSLATION IN RESPONSE TO STRESS | 19 | 7.83e-01 | 1.00e+00 | 0.15700 | 8.86e-02 | 1.13e-01 | 4.47e-02 | 4.54e-02 | -1.38e-02 | 5.04e-01 | 3.96e-01 | 7.36e-01 | 7.32e-01 | 9.17e-01 |
| DNA CATABOLIC PROCESS | 29 | 9.20e-01 | 1.00e+00 | 0.15700 | 8.15e-02 | 9.67e-02 | 5.95e-02 | 6.80e-02 | 2.46e-02 | 4.47e-01 | 3.67e-01 | 5.79e-01 | 5.26e-01 | 8.18e-01 |
| MESODERMAL CELL DIFFERENTIATION | 34 | 1.61e-01 | 6.61e-01 | 0.15700 | 1.99e-02 | 4.42e-02 | 4.26e-02 | -1.69e-02 | -1.42e-01 | 8.41e-01 | 6.56e-01 | 6.67e-01 | 8.65e-01 | 1.51e-01 |
| PEPTIDYL THREONINE MODIFICATION | 107 | 3.77e-01 | 8.85e-01 | 0.15700 | -7.35e-02 | -8.81e-02 | -1.50e-02 | -7.74e-02 | 7.31e-02 | 1.89e-01 | 1.15e-01 | 7.89e-01 | 1.67e-01 | 1.91e-01 |
| POSITIVE REGULATION OF HUMORAL IMMUNE RESPONSE | 24 | 6.77e-01 | 1.00e+00 | 0.15700 | -7.72e-02 | -9.63e-02 | -9.54e-02 | -3.07e-04 | 1.91e-02 | 5.13e-01 | 4.14e-01 | 4.18e-01 | 9.98e-01 | 8.72e-01 |
| POSITIVE REGULATION OF CELL ADHESION | 467 | 8.48e-04 | 1.98e-02 | 0.15700 | -8.58e-02 | -9.16e-02 | -3.83e-02 | -8.52e-02 | 1.55e-02 | 1.49e-03 | 6.96e-04 | 1.56e-01 | 1.60e-03 | 5.67e-01 |
| ACTIVATION OF IMMUNE RESPONSE | 502 | 8.88e-05 | 3.12e-03 | 0.15700 | -7.74e-02 | -9.66e-02 | -2.11e-02 | -9.12e-02 | 2.49e-02 | 2.99e-03 | 2.10e-04 | 4.19e-01 | 4.67e-04 | 3.39e-01 |
| POSITIVE REGULATION OF MUCUS SECRETION | 5 | 9.92e-01 | 1.00e+00 | 0.15700 | 7.27e-02 | 8.76e-02 | 1.01e-01 | 3.02e-02 | 2.54e-02 | 7.78e-01 | 7.34e-01 | 6.96e-01 | 9.07e-01 | 9.22e-01 |
| HIPPOCAMPAL NEURON APOPTOTIC PROCESS | 6 | 9.68e-01 | 1.00e+00 | 0.15700 | -6.83e-02 | -9.50e-02 | -4.83e-03 | -2.36e-02 | 1.02e-01 | 7.72e-01 | 6.87e-01 | 9.84e-01 | 9.20e-01 | 6.65e-01 |
| CEREBRAL CORTEX CELL MIGRATION | 46 | 4.47e-01 | 9.30e-01 | 0.15700 | -4.15e-02 | -3.07e-02 | -7.65e-02 | 1.14e-02 | -1.27e-01 | 6.26e-01 | 7.18e-01 | 3.69e-01 | 8.94e-01 | 1.37e-01 |
| MITOCHONDRIAL TRNA PROCESSING | 13 | 5.29e-01 | 9.54e-01 | 0.15700 | 4.10e-02 | 3.34e-02 | 1.19e-01 | -1.65e-03 | -8.72e-02 | 7.98e-01 | 8.35e-01 | 4.56e-01 | 9.92e-01 | 5.86e-01 |
| DNA TEMPLATED TRANSCRIPTION TERMINATION | 24 | 6.63e-01 | 1.00e+00 | 0.15700 | 4.93e-02 | 3.82e-02 | 1.28e-01 | 9.96e-03 | 6.46e-02 | 6.76e-01 | 7.46e-01 | 2.77e-01 | 9.33e-01 | 5.84e-01 |
| NEUROMUSCULAR SYNAPTIC TRANSMISSION | 28 | 9.76e-01 | 1.00e+00 | 0.15700 | 7.75e-02 | 6.37e-02 | 8.77e-02 | 6.72e-02 | 4.84e-02 | 4.78e-01 | 5.60e-01 | 4.22e-01 | 5.38e-01 | 6.57e-01 |
| FOREBRAIN NEURON DIFFERENTIATION | 42 | 2.10e-01 | 7.33e-01 | 0.15700 | 5.12e-02 | 3.09e-02 | 1.32e-01 | -4.88e-02 | -3.32e-02 | 5.66e-01 | 7.29e-01 | 1.38e-01 | 5.84e-01 | 7.09e-01 |
| PROTEIN LOCALIZATION TO MITOCHONDRION | 126 | 2.96e-01 | 8.24e-01 | 0.15700 | 7.21e-02 | 5.59e-02 | 1.14e-01 | 2.64e-02 | 4.96e-02 | 1.62e-01 | 2.79e-01 | 2.67e-02 | 6.09e-01 | 3.36e-01 |
| CELLULAR RESPONSE TO STEROL | 25 | 7.53e-01 | 1.00e+00 | 0.15700 | -7.12e-02 | -8.25e-02 | -8.71e-02 | 2.46e-03 | 7.12e-02 | 5.37e-01 | 4.75e-01 | 4.51e-01 | 9.83e-01 | 5.38e-01 |
| TRNA MODIFICATION | 89 | 5.29e-02 | 3.77e-01 | 0.15700 | -4.53e-02 | -5.26e-02 | 5.05e-02 | -1.10e-01 | 7.08e-02 | 4.60e-01 | 3.91e-01 | 4.10e-01 | 7.23e-02 | 2.48e-01 |
| ANTERIOR POSTERIOR AXON GUIDANCE | 7 | 9.17e-01 | 1.00e+00 | 0.15700 | -6.70e-02 | -5.90e-02 | 2.35e-02 | -1.24e-01 | -2.63e-02 | 7.59e-01 | 7.87e-01 | 9.14e-01 | 5.71e-01 | 9.04e-01 |
| POSITIVE REGULATION OF STEM CELL POPULATION MAINTENANCE | 46 | 1.85e-01 | 6.93e-01 | 0.15700 | 2.20e-02 | 1.47e-02 | 9.15e-02 | 2.93e-02 | 1.21e-01 | 7.96e-01 | 8.63e-01 | 2.83e-01 | 7.31e-01 | 1.56e-01 |
| P38MAPK CASCADE | 58 | 1.82e-01 | 6.92e-01 | 0.15700 | 5.00e-02 | 3.95e-02 | 1.33e-01 | -3.29e-02 | 4.14e-02 | 5.10e-01 | 6.03e-01 | 8.01e-02 | 6.65e-01 | 5.86e-01 |
| REGULATION OF NON CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 106 | 2.63e-01 | 7.90e-01 | 0.15700 | -7.21e-02 | -9.29e-02 | -1.54e-02 | -1.02e-01 | 8.04e-03 | 2.00e-01 | 9.84e-02 | 7.84e-01 | 7.00e-02 | 8.86e-01 |
| INTERMEDIATE FILAMENT ORGANIZATION | 72 | 1.15e-02 | 1.39e-01 | 0.15600 | -3.27e-02 | -1.86e-02 | -1.39e-01 | 5.67e-02 | -1.99e-02 | 6.32e-01 | 7.85e-01 | 4.07e-02 | 4.05e-01 | 7.70e-01 |
| REGULATION OF PROTEIN MATURATION | 68 | 4.17e-01 | 9.11e-01 | 0.15600 | -6.53e-02 | -6.32e-02 | -2.33e-02 | -1.24e-01 | -1.97e-02 | 3.52e-01 | 3.67e-01 | 7.40e-01 | 7.79e-02 | 7.79e-01 |
| PHARYNGEAL SYSTEM DEVELOPMENT | 30 | 3.76e-01 | 8.84e-01 | 0.15600 | -2.97e-02 | -5.58e-02 | 3.29e-02 | -8.72e-02 | -1.09e-01 | 7.78e-01 | 5.97e-01 | 7.55e-01 | 4.09e-01 | 3.03e-01 |
| 3 UTR MEDIATED MRNA DESTABILIZATION | 19 | 7.75e-01 | 1.00e+00 | 0.15600 | -2.33e-02 | -1.07e-02 | 2.64e-02 | -4.88e-02 | 1.44e-01 | 8.61e-01 | 9.36e-01 | 8.42e-01 | 7.13e-01 | 2.78e-01 |
| REGULATION OF VIRAL INDUCED CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 87 | 4.87e-01 | 9.43e-01 | 0.15600 | -7.07e-02 | -7.95e-02 | -7.04e-03 | -1.01e-01 | 5.28e-02 | 2.54e-01 | 2.00e-01 | 9.10e-01 | 1.03e-01 | 3.95e-01 |
| CELLULAR RESPONSE TO CHOLESTEROL | 20 | 8.66e-01 | 1.00e+00 | 0.15600 | -7.92e-02 | -6.66e-02 | -1.11e-01 | 8.58e-04 | 3.65e-02 | 5.40e-01 | 6.06e-01 | 3.89e-01 | 9.95e-01 | 7.78e-01 |
| REGULATION OF DNA BINDING | 82 | 4.21e-03 | 6.72e-02 | 0.15600 | 2.70e-02 | 2.13e-02 | 1.17e-01 | -9.65e-02 | 1.07e-02 | 6.73e-01 | 7.39e-01 | 6.61e-02 | 1.31e-01 | 8.67e-01 |
| REELIN MEDIATED SIGNALING PATHWAY | 7 | 7.82e-01 | 1.00e+00 | 0.15600 | -3.61e-02 | -5.30e-02 | 9.03e-02 | -1.02e-01 | -4.22e-02 | 8.69e-01 | 8.08e-01 | 6.79e-01 | 6.42e-01 | 8.47e-01 |
| REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 44 | 5.50e-01 | 9.64e-01 | 0.15600 | 8.62e-02 | 8.77e-02 | 9.41e-02 | 1.07e-02 | -1.67e-02 | 3.23e-01 | 3.14e-01 | 2.80e-01 | 9.03e-01 | 8.48e-01 |
| PODOSOME ASSEMBLY | 19 | 6.25e-01 | 9.93e-01 | 0.15600 | 9.66e-03 | -9.92e-03 | 1.12e-01 | -1.53e-02 | 1.07e-01 | 9.42e-01 | 9.40e-01 | 3.98e-01 | 9.08e-01 | 4.21e-01 |
| HEMATOPOIETIC STEM CELL PROLIFERATION | 33 | 2.26e-01 | 7.48e-01 | 0.15600 | 3.33e-02 | 1.61e-02 | 1.34e-01 | -6.76e-02 | -2.26e-02 | 7.41e-01 | 8.73e-01 | 1.84e-01 | 5.01e-01 | 8.22e-01 |
| DETERMINATION OF LIVER LEFT RIGHT ASYMMETRY | 5 | 9.77e-01 | 1.00e+00 | 0.15600 | 1.63e-02 | 1.18e-02 | 5.99e-02 | -7.24e-02 | -1.23e-01 | 9.50e-01 | 9.63e-01 | 8.17e-01 | 7.79e-01 | 6.34e-01 |
| REGULATION OF CENTROSOME CYCLE | 54 | 2.48e-01 | 7.75e-01 | 0.15600 | 4.64e-03 | 5.39e-03 | 7.47e-02 | -5.96e-02 | 1.23e-01 | 9.53e-01 | 9.45e-01 | 3.42e-01 | 4.49e-01 | 1.18e-01 |
| POSITIVE REGULATION OF DNA METABOLIC PROCESS | 286 | 1.49e-04 | 4.85e-03 | 0.15600 | 2.82e-02 | 1.88e-02 | 9.92e-02 | -2.65e-02 | 1.12e-01 | 4.12e-01 | 5.84e-01 | 3.88e-03 | 4.41e-01 | 1.08e-03 |
| ERBB2 ERBB4 SIGNALING PATHWAY | 5 | 8.93e-01 | 1.00e+00 | 0.15600 | 2.13e-02 | -3.13e-03 | -3.40e-02 | 1.50e-01 | -1.20e-02 | 9.34e-01 | 9.90e-01 | 8.95e-01 | 5.61e-01 | 9.63e-01 |
| ACTIVATION OF PROTEIN KINASE B ACTIVITY | 25 | 7.93e-01 | 1.00e+00 | 0.15600 | 2.71e-02 | 4.38e-02 | 1.15e-02 | -1.51e-02 | -1.46e-01 | 8.14e-01 | 7.04e-01 | 9.21e-01 | 8.96e-01 | 2.07e-01 |
| ANTIGEN PROCESSING AND PRESENTATION VIA MHC CLASS IB | 25 | 5.51e-01 | 9.64e-01 | 0.15600 | 3.13e-02 | -9.89e-03 | 1.21e-01 | -5.20e-02 | 7.67e-02 | 7.87e-01 | 9.32e-01 | 2.96e-01 | 6.53e-01 | 5.07e-01 |
| REGULATION OF DENDRITIC SPINE MORPHOGENESIS | 39 | 7.12e-01 | 1.00e+00 | 0.15600 | -7.22e-02 | -4.62e-02 | -6.85e-02 | -8.69e-02 | -6.82e-02 | 4.35e-01 | 6.17e-01 | 4.59e-01 | 3.48e-01 | 4.61e-01 |
| RESPONSE TO UV C | 14 | 8.76e-01 | 1.00e+00 | 0.15600 | 5.80e-02 | 4.40e-02 | 1.30e-01 | -3.98e-02 | 2.03e-02 | 7.07e-01 | 7.75e-01 | 3.99e-01 | 7.96e-01 | 8.96e-01 |
| REGULATION OF OXIDOREDUCTASE ACTIVITY | 77 | 7.24e-01 | 1.00e+00 | 0.15600 | 8.20e-02 | 8.83e-02 | 7.28e-02 | 5.80e-02 | 3.20e-02 | 2.13e-01 | 1.80e-01 | 2.70e-01 | 3.78e-01 | 6.27e-01 |
| REGULATION OF PROTEIN DEPHOSPHORYLATION | 75 | 2.66e-01 | 7.95e-01 | 0.15600 | 2.38e-02 | -6.66e-03 | 9.79e-02 | -9.71e-03 | 1.18e-01 | 7.21e-01 | 9.21e-01 | 1.43e-01 | 8.84e-01 | 7.72e-02 |
| MECHANORECEPTOR DIFFERENTIATION | 68 | 4.18e-01 | 9.11e-01 | 0.15600 | 5.38e-02 | 7.82e-02 | 5.02e-03 | 3.89e-02 | -1.17e-01 | 4.43e-01 | 2.65e-01 | 9.43e-01 | 5.79e-01 | 9.56e-02 |
| MAGNESIUM ION TRANSPORT | 16 | 8.57e-01 | 1.00e+00 | 0.15600 | -4.80e-02 | -6.41e-03 | -9.16e-02 | -5.25e-02 | -1.04e-01 | 7.40e-01 | 9.65e-01 | 5.26e-01 | 7.16e-01 | 4.73e-01 |
| POSITIVE REGULATION OF FOCAL ADHESION ASSEMBLY | 26 | 7.19e-01 | 1.00e+00 | 0.15600 | 5.71e-02 | 7.67e-02 | -2.19e-02 | 1.18e-01 | 2.62e-02 | 6.14e-01 | 4.98e-01 | 8.47e-01 | 2.98e-01 | 8.17e-01 |
| PHOSPHOLIPID METABOLIC PROCESS | 364 | 6.29e-02 | 4.12e-01 | 0.15500 | 7.42e-02 | 7.42e-02 | 7.87e-02 | 6.05e-02 | 5.76e-02 | 1.50e-02 | 1.51e-02 | 9.94e-03 | 4.74e-02 | 5.92e-02 |
| ANTIBACTERIAL HUMORAL RESPONSE | 60 | 5.35e-03 | 8.07e-02 | 0.15500 | -6.75e-03 | -1.24e-02 | 5.45e-02 | 4.88e-02 | 1.36e-01 | 9.28e-01 | 8.68e-01 | 4.65e-01 | 5.13e-01 | 6.77e-02 |
| INFLAMMATORY RESPONSE | 851 | 2.68e-05 | 1.12e-03 | 0.15500 | -8.08e-02 | -9.07e-02 | -5.17e-02 | -6.28e-02 | 5.26e-02 | 6.18e-05 | 7.00e-06 | 1.04e-02 | 1.86e-03 | 9.20e-03 |
| BIOLOGICAL PROCESS INVOLVED IN INTERACTION WITH SYMBIONT | 115 | 2.39e-01 | 7.63e-01 | 0.15500 | -6.97e-02 | -7.80e-02 | -1.30e-02 | -6.44e-02 | 9.41e-02 | 1.97e-01 | 1.48e-01 | 8.09e-01 | 2.33e-01 | 8.11e-02 |
| EXPORT ACROSS PLASMA MEMBRANE | 78 | 3.74e-01 | 8.83e-01 | 0.15500 | 6.55e-02 | 7.94e-02 | 2.90e-02 | 9.86e-02 | -5.43e-02 | 3.17e-01 | 2.25e-01 | 6.57e-01 | 1.32e-01 | 4.07e-01 |
| POSITIVE REGULATION OF B CELL RECEPTOR SIGNALING PATHWAY | 10 | 9.62e-01 | 1.00e+00 | 0.15500 | -6.43e-03 | -1.28e-02 | 6.57e-02 | -6.43e-02 | 1.24e-01 | 9.72e-01 | 9.44e-01 | 7.19e-01 | 7.25e-01 | 4.96e-01 |
| CERAMIDE BIOSYNTHETIC PROCESS | 68 | 2.32e-01 | 7.54e-01 | 0.15500 | -5.17e-02 | -6.85e-02 | 2.86e-02 | -5.36e-02 | 1.14e-01 | 4.61e-01 | 3.29e-01 | 6.83e-01 | 4.44e-01 | 1.04e-01 |
| PROTEIN CONTAINING COMPLEX LOCALIZATION | 178 | 4.05e-02 | 3.24e-01 | 0.15500 | 5.73e-02 | 5.61e-02 | 1.02e-01 | 1.35e-02 | 8.41e-02 | 1.87e-01 | 1.96e-01 | 1.90e-02 | 7.57e-01 | 5.30e-02 |
| REGULATION OF MITOTIC CELL CYCLE | 509 | 2.98e-06 | 1.62e-04 | 0.15500 | 5.79e-02 | 4.60e-02 | 1.17e-01 | 3.21e-03 | 7.05e-02 | 2.53e-02 | 7.59e-02 | 6.65e-06 | 9.01e-01 | 6.44e-03 |
| CYCLOOXYGENASE PATHWAY | 9 | 9.88e-01 | 1.00e+00 | 0.15500 | 9.11e-02 | 8.17e-02 | 7.71e-02 | 4.67e-02 | -2.99e-02 | 6.36e-01 | 6.71e-01 | 6.89e-01 | 8.08e-01 | 8.76e-01 |
| POSITIVE REGULATION OF MIRNA TRANSCRIPTION | 50 | 3.72e-01 | 8.82e-01 | 0.15500 | 2.62e-02 | 1.81e-02 | 1.00e-01 | -1.18e-03 | 1.14e-01 | 7.49e-01 | 8.25e-01 | 2.21e-01 | 9.88e-01 | 1.63e-01 |
| EMBRYONIC CRANIAL SKELETON MORPHOGENESIS | 44 | 5.54e-01 | 9.67e-01 | 0.15500 | 4.68e-02 | 4.11e-02 | 1.07e-01 | 2.06e-02 | 9.06e-02 | 5.91e-01 | 6.37e-01 | 2.20e-01 | 8.13e-01 | 2.98e-01 |
| PEPTIDYL GLUTAMIC ACID MODIFICATION | 26 | 9.08e-01 | 1.00e+00 | 0.15500 | 7.57e-02 | 8.93e-02 | 7.56e-02 | 6.68e-02 | 4.89e-03 | 5.04e-01 | 4.31e-01 | 5.05e-01 | 5.55e-01 | 9.66e-01 |
| STEROID HORMONE MEDIATED SIGNALING PATHWAY | 132 | 3.27e-01 | 8.53e-01 | 0.15500 | 7.80e-02 | 6.89e-02 | 7.36e-02 | 8.36e-02 | -2.60e-02 | 1.22e-01 | 1.72e-01 | 1.44e-01 | 9.73e-02 | 6.05e-01 |
| PHOSPHATIDYLCHOLINE CATABOLIC PROCESS | 16 | 8.76e-01 | 1.00e+00 | 0.15500 | -7.10e-02 | -4.92e-02 | -1.10e-01 | -3.73e-02 | 5.35e-02 | 6.23e-01 | 7.33e-01 | 4.45e-01 | 7.96e-01 | 7.11e-01 |
| NEGATIVE REGULATION OF GROWTH | 233 | 1.44e-01 | 6.29e-01 | 0.15500 | 8.01e-02 | 7.22e-02 | 1.01e-01 | 4.49e-02 | 4.47e-03 | 3.52e-02 | 5.77e-02 | 7.84e-03 | 2.38e-01 | 9.06e-01 |
| GLYCOSYL COMPOUND BIOSYNTHETIC PROCESS | 21 | 9.66e-01 | 1.00e+00 | 0.15400 | 7.58e-02 | 7.35e-02 | 3.14e-02 | 8.51e-02 | -6.70e-02 | 5.48e-01 | 5.60e-01 | 8.03e-01 | 4.99e-01 | 5.95e-01 |
| REGULATION OF PHOSPHOLIPASE C ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 6 | 9.99e-01 | 1.00e+00 | 0.15400 | -8.34e-02 | -7.53e-02 | -7.69e-02 | -6.56e-02 | -3.21e-02 | 7.23e-01 | 7.49e-01 | 7.44e-01 | 7.81e-01 | 8.92e-01 |
| INTRACELLULAR ZINC ION HOMEOSTASIS | 36 | 2.83e-01 | 8.10e-01 | 0.15400 | 4.06e-02 | 5.19e-03 | 1.35e-01 | -5.70e-02 | 2.47e-02 | 6.73e-01 | 9.57e-01 | 1.60e-01 | 5.54e-01 | 7.98e-01 |
| MAMMARY GLAND EPITHELIAL CELL PROLIFERATION | 26 | 9.26e-01 | 1.00e+00 | 0.15400 | 8.37e-02 | 7.65e-02 | 8.56e-02 | 3.44e-02 | -4.98e-02 | 4.60e-01 | 4.99e-01 | 4.50e-01 | 7.61e-01 | 6.60e-01 |
| NEGATIVE REGULATION OF CALCIUM ION TRANSPORT | 66 | 8.38e-01 | 1.00e+00 | 0.15400 | 7.53e-02 | 7.93e-02 | 7.82e-02 | 6.42e-02 | 4.05e-02 | 2.90e-01 | 2.65e-01 | 2.72e-01 | 3.67e-01 | 5.69e-01 |
| VITAMIN CATABOLIC PROCESS | 14 | 9.38e-01 | 1.00e+00 | 0.15400 | -4.74e-02 | -2.16e-02 | -1.10e-01 | -3.44e-02 | -8.80e-02 | 7.59e-01 | 8.89e-01 | 4.75e-01 | 8.24e-01 | 5.68e-01 |
| SPECIFICATION OF SYMMETRY | 136 | 1.71e-01 | 6.75e-01 | 0.15400 | 7.50e-02 | 7.94e-02 | 8.26e-02 | 3.60e-02 | -6.12e-02 | 1.31e-01 | 1.10e-01 | 9.61e-02 | 4.68e-01 | 2.18e-01 |
| GLYCEROPHOSPHOLIPID BIOSYNTHETIC PROCESS | 200 | 2.58e-01 | 7.85e-01 | 0.15400 | 7.11e-02 | 6.79e-02 | 7.03e-02 | 6.23e-02 | 7.29e-02 | 8.29e-02 | 9.78e-02 | 8.67e-02 | 1.29e-01 | 7.54e-02 |
| ACUTE INFLAMMATORY RESPONSE | 104 | 6.76e-02 | 4.25e-01 | 0.15400 | -8.32e-02 | -9.92e-02 | -6.11e-02 | -2.25e-02 | 5.25e-02 | 1.42e-01 | 8.05e-02 | 2.81e-01 | 6.91e-01 | 3.55e-01 |
| REGULATION OF CELL MATURATION | 20 | 9.49e-01 | 1.00e+00 | 0.15400 | 5.03e-02 | 5.79e-02 | 2.84e-03 | 6.81e-02 | -1.15e-01 | 6.97e-01 | 6.54e-01 | 9.82e-01 | 5.98e-01 | 3.73e-01 |
| SPHINGOMYELIN CATABOLIC PROCESS | 8 | 6.34e-01 | 9.97e-01 | 0.15400 | 3.66e-02 | 7.17e-02 | 1.13e-01 | -5.98e-02 | -3.18e-02 | 8.58e-01 | 7.26e-01 | 5.81e-01 | 7.70e-01 | 8.76e-01 |
| OLIGOSACCHARIDE BIOSYNTHETIC PROCESS | 29 | 5.86e-01 | 9.85e-01 | 0.15400 | -3.17e-02 | -5.28e-02 | -2.96e-02 | 3.12e-02 | 1.35e-01 | 7.67e-01 | 6.23e-01 | 7.83e-01 | 7.71e-01 | 2.10e-01 |
| ALCOHOL CATABOLIC PROCESS | 33 | 9.20e-01 | 1.00e+00 | 0.15400 | -7.04e-02 | -5.10e-02 | -1.05e-01 | -3.49e-02 | -6.25e-02 | 4.84e-01 | 6.12e-01 | 2.96e-01 | 7.29e-01 | 5.34e-01 |
| POSITIVE REGULATION OF NEURON PROJECTION REGENERATION | 10 | 8.83e-01 | 1.00e+00 | 0.15400 | -5.74e-02 | -3.47e-02 | -1.26e-01 | 5.64e-02 | 1.40e-02 | 7.53e-01 | 8.49e-01 | 4.91e-01 | 7.58e-01 | 9.39e-01 |
| NEGATIVE REGULATION OF MITOCHONDRION ORGANIZATION | 48 | 3.83e-01 | 8.92e-01 | 0.15400 | 3.76e-02 | 4.09e-02 | 8.88e-02 | -2.56e-02 | 1.10e-01 | 6.52e-01 | 6.24e-01 | 2.87e-01 | 7.59e-01 | 1.88e-01 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 48 | 3.08e-01 | 8.35e-01 | 0.15400 | 2.03e-02 | 3.55e-02 | -6.60e-04 | -4.20e-02 | -1.42e-01 | 8.08e-01 | 6.70e-01 | 9.94e-01 | 6.14e-01 | 8.82e-02 |
| REGULATION OF INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS | 53 | 2.28e-01 | 7.50e-01 | 0.15400 | 4.35e-02 | 6.20e-02 | 5.24e-02 | -9.07e-03 | -1.23e-01 | 5.84e-01 | 4.35e-01 | 5.09e-01 | 9.09e-01 | 1.22e-01 |
| ANTIGEN PROCESSING AND PRESENTATION OF ENDOGENOUS PEPTIDE ANTIGEN | 25 | 6.04e-01 | 9.90e-01 | 0.15400 | 2.70e-02 | -8.72e-03 | 1.24e-01 | -5.49e-02 | 6.59e-02 | 8.15e-01 | 9.40e-01 | 2.82e-01 | 6.34e-01 | 5.69e-01 |
| PROTEIN LOCALIZATION TO CELL SURFACE | 65 | 3.98e-01 | 8.97e-01 | 0.15400 | 3.52e-02 | 3.15e-02 | 7.80e-02 | 3.64e-02 | 1.18e-01 | 6.24e-01 | 6.61e-01 | 2.77e-01 | 6.12e-01 | 9.92e-02 |
| HEART GROWTH | 94 | 8.72e-02 | 4.87e-01 | 0.15400 | 5.24e-02 | 5.75e-02 | 5.67e-02 | -1.50e-02 | -1.19e-01 | 3.79e-01 | 3.36e-01 | 3.42e-01 | 8.02e-01 | 4.65e-02 |
| ENDODERM FORMATION | 57 | 1.13e-01 | 5.59e-01 | 0.15400 | 3.62e-02 | 1.34e-02 | 5.77e-02 | -1.52e-02 | -1.36e-01 | 6.36e-01 | 8.61e-01 | 4.51e-01 | 8.43e-01 | 7.52e-02 |
| RESPIRATORY BURST | 33 | 1.40e-01 | 6.24e-01 | 0.15400 | 3.92e-02 | -1.15e-02 | 1.28e-01 | -6.43e-02 | 3.67e-02 | 6.97e-01 | 9.09e-01 | 2.02e-01 | 5.22e-01 | 7.15e-01 |
| TOLL LIKE RECEPTOR SIGNALING PATHWAY | 67 | 2.20e-01 | 7.43e-01 | 0.15400 | -4.51e-02 | -6.55e-02 | 4.84e-02 | -1.11e-01 | 5.23e-02 | 5.23e-01 | 3.54e-01 | 4.93e-01 | 1.18e-01 | 4.59e-01 |
| SEX DETERMINATION | 18 | 7.49e-01 | 1.00e+00 | 0.15400 | 1.48e-03 | -5.82e-03 | 4.52e-02 | -7.75e-02 | -1.25e-01 | 9.91e-01 | 9.66e-01 | 7.40e-01 | 5.69e-01 | 3.60e-01 |
| ORGANISM EMERGENCE FROM PROTECTIVE STRUCTURE | 24 | 4.19e-01 | 9.11e-01 | 0.15400 | -3.78e-02 | -1.78e-02 | 1.70e-02 | -1.38e-01 | -4.98e-02 | 7.49e-01 | 8.80e-01 | 8.85e-01 | 2.41e-01 | 6.73e-01 |
| REGULATION OF TRIGLYCERIDE CATABOLIC PROCESS | 13 | 9.72e-01 | 1.00e+00 | 0.15400 | 3.91e-02 | 2.76e-02 | 3.91e-02 | 6.36e-02 | 1.25e-01 | 8.07e-01 | 8.63e-01 | 8.07e-01 | 6.91e-01 | 4.33e-01 |
| SPLICEOSOMAL SNRNP ASSEMBLY | 43 | 6.36e-01 | 9.98e-01 | 0.15400 | 5.09e-02 | 2.10e-02 | 7.54e-02 | 6.37e-02 | 1.04e-01 | 5.64e-01 | 8.12e-01 | 3.92e-01 | 4.70e-01 | 2.38e-01 |
| NEGATIVE REGULATION OF FATTY ACID BIOSYNTHETIC PROCESS | 25 | 7.61e-01 | 1.00e+00 | 0.15300 | 8.87e-02 | 5.95e-02 | 1.03e-01 | 3.72e-02 | 8.31e-03 | 4.43e-01 | 6.06e-01 | 3.71e-01 | 7.47e-01 | 9.43e-01 |
| CELLULAR RESPONSE TO FLUID SHEAR STRESS | 21 | 8.31e-01 | 1.00e+00 | 0.15300 | 6.42e-02 | 4.86e-02 | 1.28e-01 | 1.88e-02 | 1.75e-02 | 6.10e-01 | 7.00e-01 | 3.10e-01 | 8.82e-01 | 8.90e-01 |
| NEGATIVE REGULATION OF MYELOID CELL DIFFERENTIATION | 93 | 1.99e-01 | 7.14e-01 | 0.15300 | 7.31e-02 | 4.30e-02 | 1.21e-01 | 2.55e-02 | 3.16e-02 | 2.23e-01 | 4.73e-01 | 4.35e-02 | 6.71e-01 | 5.99e-01 |
| RESPONSE TO ISCHEMIA | 62 | 4.33e-01 | 9.20e-01 | 0.15300 | -5.72e-02 | -6.63e-02 | 2.32e-02 | -9.51e-02 | 7.91e-02 | 4.36e-01 | 3.66e-01 | 7.52e-01 | 1.95e-01 | 2.82e-01 |
| REGULATORY NCRNA PROCESSING | 84 | 6.33e-01 | 9.96e-01 | 0.15300 | -6.30e-02 | -6.58e-02 | -6.68e-02 | -5.99e-02 | -8.45e-02 | 3.19e-01 | 2.97e-01 | 2.90e-01 | 3.42e-01 | 1.81e-01 |
| PROTEIN HETEROTETRAMERIZATION | 15 | 9.74e-01 | 1.00e+00 | 0.15300 | -5.02e-02 | -5.95e-02 | 2.38e-03 | -7.16e-02 | 1.11e-01 | 7.36e-01 | 6.90e-01 | 9.87e-01 | 6.31e-01 | 4.58e-01 |
| POSTSYNAPTIC SPECIALIZATION ORGANIZATION | 41 | 3.85e-01 | 8.92e-01 | 0.15300 | 6.60e-02 | 9.68e-02 | 5.40e-02 | 1.95e-02 | -8.00e-02 | 4.64e-01 | 2.84e-01 | 5.50e-01 | 8.29e-01 | 3.75e-01 |
| ERAD PATHWAY | 108 | 2.96e-03 | 5.19e-02 | 0.15300 | 4.21e-02 | 1.54e-02 | 1.35e-01 | -5.63e-02 | 3.79e-03 | 4.50e-01 | 7.82e-01 | 1.53e-02 | 3.12e-01 | 9.46e-01 |
| FOREBRAIN GENERATION OF NEURONS | 51 | 7.49e-02 | 4.50e-01 | 0.15300 | 4.38e-02 | 1.04e-02 | 1.35e-01 | -4.87e-02 | -3.01e-02 | 5.88e-01 | 8.98e-01 | 9.64e-02 | 5.47e-01 | 7.10e-01 |
| BILE ACID BIOSYNTHETIC PROCESS | 36 | 8.01e-01 | 1.00e+00 | 0.15300 | -6.80e-02 | -4.08e-02 | -1.11e-01 | -2.45e-02 | -6.52e-02 | 4.80e-01 | 6.72e-01 | 2.50e-01 | 7.99e-01 | 4.98e-01 |
| REGULATION OF VIRAL PROCESS | 164 | 5.38e-02 | 3.79e-01 | 0.15300 | -5.14e-02 | -6.00e-02 | 1.80e-02 | -7.48e-02 | 1.06e-01 | 2.56e-01 | 1.85e-01 | 6.91e-01 | 9.82e-02 | 1.91e-02 |
| KIDNEY MESENCHYME DEVELOPMENT | 16 | 6.60e-01 | 1.00e+00 | 0.15300 | 3.81e-02 | 1.72e-02 | 1.18e-01 | -8.65e-02 | -1.37e-02 | 7.92e-01 | 9.05e-01 | 4.13e-01 | 5.49e-01 | 9.24e-01 |
| REGULATION OF POSTSYNAPTIC DENSITY ASSEMBLY | 11 | 8.93e-01 | 1.00e+00 | 0.15300 | 5.24e-02 | 9.03e-02 | 2.83e-02 | 2.30e-02 | -1.06e-01 | 7.63e-01 | 6.04e-01 | 8.71e-01 | 8.95e-01 | 5.44e-01 |
| POSITIVE REGULATION OF MYELOID CELL DIFFERENTIATION | 100 | 2.62e-01 | 7.90e-01 | 0.15300 | -7.42e-02 | -9.58e-02 | -1.14e-02 | -7.53e-02 | 5.39e-02 | 2.00e-01 | 9.78e-02 | 8.43e-01 | 1.93e-01 | 3.52e-01 |
| POSTSYNAPTIC NEUROTRANSMITTER RECEPTOR INTERNALIZATION | 23 | 8.53e-01 | 1.00e+00 | 0.15300 | -8.77e-02 | -9.19e-02 | -6.79e-02 | -2.97e-02 | 4.19e-02 | 4.66e-01 | 4.45e-01 | 5.73e-01 | 8.05e-01 | 7.28e-01 |
| REGULATION OF ACTOMYOSIN STRUCTURE ORGANIZATION | 101 | 6.59e-01 | 1.00e+00 | 0.15300 | 7.69e-02 | 8.84e-02 | 4.19e-02 | 8.85e-02 | -7.74e-03 | 1.82e-01 | 1.25e-01 | 4.67e-01 | 1.24e-01 | 8.93e-01 |
| FOREBRAIN NEURON DEVELOPMENT | 23 | 9.39e-01 | 1.00e+00 | 0.15300 | -6.36e-02 | -6.77e-02 | -5.47e-02 | -9.33e-02 | -5.52e-02 | 5.98e-01 | 5.74e-01 | 6.50e-01 | 4.38e-01 | 6.47e-01 |
| PURINE DEOXYRIBONUCLEOSIDE METABOLIC PROCESS | 5 | 9.97e-01 | 1.00e+00 | 0.15300 | 6.97e-02 | 6.43e-02 | 6.91e-02 | 2.51e-02 | -9.48e-02 | 7.87e-01 | 8.03e-01 | 7.89e-01 | 9.23e-01 | 7.14e-01 |
| CARDIAC ATRIUM DEVELOPMENT | 37 | 3.84e-01 | 8.92e-01 | 0.15300 | -3.61e-02 | -5.16e-02 | 3.64e-02 | -1.14e-01 | -7.18e-02 | 7.04e-01 | 5.87e-01 | 7.02e-01 | 2.32e-01 | 4.50e-01 |
| CYCLIC NUCLEOTIDE METABOLIC PROCESS | 40 | 9.45e-01 | 1.00e+00 | 0.15300 | -7.24e-02 | -7.17e-02 | -6.96e-02 | -6.39e-02 | -6.35e-02 | 4.28e-01 | 4.32e-01 | 4.47e-01 | 4.84e-01 | 4.87e-01 |
| PORPHYRIN CONTAINING COMPOUND METABOLIC PROCESS | 49 | 2.83e-01 | 8.10e-01 | 0.15300 | 1.57e-03 | -6.49e-04 | 8.34e-02 | -3.67e-02 | 1.23e-01 | 9.85e-01 | 9.94e-01 | 3.13e-01 | 6.57e-01 | 1.38e-01 |
| MYOBLAST PROLIFERATION | 34 | 5.51e-01 | 9.65e-01 | 0.15300 | -1.24e-02 | 2.59e-02 | -8.55e-02 | 3.58e-02 | -1.18e-01 | 9.00e-01 | 7.94e-01 | 3.88e-01 | 7.18e-01 | 2.34e-01 |
| ORGANIC HYDROXY COMPOUND CATABOLIC PROCESS | 52 | 6.85e-01 | 1.00e+00 | 0.15300 | -7.68e-02 | -6.98e-02 | -9.78e-02 | -2.01e-02 | -5.05e-02 | 3.38e-01 | 3.84e-01 | 2.22e-01 | 8.02e-01 | 5.29e-01 |
| REGULATION OF OSTEOBLAST DIFFERENTIATION | 144 | 7.33e-02 | 4.45e-01 | 0.15300 | 4.54e-02 | 4.41e-02 | 1.28e-02 | 4.84e-02 | -1.30e-01 | 3.47e-01 | 3.61e-01 | 7.91e-01 | 3.16e-01 | 7.26e-03 |
| REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY | 29 | 7.58e-01 | 1.00e+00 | 0.15300 | 5.46e-02 | 2.27e-02 | 1.20e-01 | -3.28e-03 | 7.30e-02 | 6.11e-01 | 8.32e-01 | 2.62e-01 | 9.76e-01 | 4.96e-01 |
| CGMP METABOLIC PROCESS | 16 | 9.01e-01 | 1.00e+00 | 0.15300 | -5.55e-03 | -4.63e-03 | -1.26e-02 | -7.57e-03 | -1.52e-01 | 9.69e-01 | 9.74e-01 | 9.30e-01 | 9.58e-01 | 2.93e-01 |
| POSITIVE REGULATION OF GTPASE ACTIVITY | 225 | 4.86e-02 | 3.59e-01 | 0.15300 | -8.22e-02 | -7.83e-02 | -6.15e-02 | -4.89e-02 | 6.49e-02 | 3.36e-02 | 4.29e-02 | 1.12e-01 | 2.07e-01 | 9.34e-02 |
| SYNAPTIC TRANSMISSION CHOLINERGIC | 31 | 7.20e-01 | 1.00e+00 | 0.15200 | 4.08e-02 | 5.32e-02 | 2.13e-02 | 6.41e-02 | 1.19e-01 | 6.94e-01 | 6.08e-01 | 8.38e-01 | 5.37e-01 | 2.51e-01 |
| POSTSYNAPTIC MEMBRANE ORGANIZATION | 35 | 4.75e-01 | 9.40e-01 | 0.15200 | 1.45e-02 | 2.25e-02 | 5.94e-02 | 2.04e-02 | 1.36e-01 | 8.82e-01 | 8.18e-01 | 5.43e-01 | 8.35e-01 | 1.63e-01 |
| POSITIVE REGULATION OF DOPAMINE RECEPTOR SIGNALING PATHWAY | 5 | 6.75e-01 | 1.00e+00 | 0.15200 | -5.79e-02 | -1.28e-01 | 4.48e-02 | -2.25e-02 | -2.87e-02 | 8.23e-01 | 6.19e-01 | 8.62e-01 | 9.31e-01 | 9.12e-01 |
| FREE UBIQUITIN CHAIN POLYMERIZATION | 9 | 8.75e-01 | 1.00e+00 | 0.15200 | 6.54e-02 | 1.01e-01 | 7.28e-02 | 1.82e-02 | 5.47e-02 | 7.34e-01 | 5.99e-01 | 7.05e-01 | 9.25e-01 | 7.76e-01 |
| NEURON APOPTOTIC PROCESS | 265 | 6.65e-03 | 9.31e-02 | 0.15200 | 6.85e-02 | 6.39e-02 | 1.13e-01 | 1.22e-02 | 3.97e-02 | 5.50e-02 | 7.35e-02 | 1.61e-03 | 7.33e-01 | 2.66e-01 |
| REGULATION OF COLLAGEN METABOLIC PROCESS | 41 | 6.46e-01 | 1.00e+00 | 0.15200 | -6.03e-02 | -8.30e-02 | 2.29e-02 | -8.68e-02 | 6.76e-02 | 5.04e-01 | 3.58e-01 | 7.99e-01 | 3.36e-01 | 4.54e-01 |
| SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE | 182 | 2.89e-04 | 8.40e-03 | 0.15200 | 5.09e-02 | 3.84e-02 | 1.25e-01 | -4.77e-02 | 3.55e-02 | 2.36e-01 | 3.72e-01 | 3.72e-03 | 2.67e-01 | 4.08e-01 |
| REGULATION OF CARDIAC MUSCLE CELL DIFFERENTIATION | 21 | 8.17e-01 | 1.00e+00 | 0.15200 | -3.30e-02 | -5.09e-02 | 2.70e-02 | -9.34e-02 | 9.99e-02 | 7.94e-01 | 6.86e-01 | 8.30e-01 | 4.59e-01 | 4.28e-01 |
| REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 155 | 6.71e-04 | 1.63e-02 | 0.15200 | -3.03e-02 | -3.91e-02 | 5.91e-02 | -1.23e-01 | 4.44e-02 | 5.15e-01 | 4.01e-01 | 2.04e-01 | 8.06e-03 | 3.40e-01 |
| PROTEIN CONTAINING COMPLEX ASSEMBLY | 1523 | 1.84e-15 | 9.22e-13 | 0.15200 | 6.24e-02 | 4.76e-02 | 1.14e-01 | 1.82e-02 | 5.96e-02 | 4.66e-05 | 1.90e-03 | 8.77e-14 | 2.36e-01 | 1.01e-04 |
| CELLULAR RESPONSE TO OXIDISED LOW DENSITY LIPOPROTEIN PARTICLE STIMULUS | 14 | 5.17e-01 | 9.52e-01 | 0.15200 | 3.46e-04 | -6.17e-02 | 7.12e-02 | -5.59e-02 | 1.05e-01 | 9.98e-01 | 6.89e-01 | 6.44e-01 | 7.17e-01 | 4.96e-01 |
| MITOCHONDRIAL MEMBRANE ORGANIZATION | 113 | 3.17e-02 | 2.80e-01 | 0.15200 | 6.55e-02 | 6.21e-02 | 1.20e-01 | -1.95e-02 | -4.77e-03 | 2.29e-01 | 2.54e-01 | 2.70e-02 | 7.20e-01 | 9.30e-01 |
| POSITIVE REGULATION OF MYOTUBE DIFFERENTIATION | 17 | 5.18e-01 | 9.52e-01 | 0.15200 | 2.80e-02 | 5.82e-02 | -2.20e-02 | 1.29e-01 | 4.19e-02 | 8.41e-01 | 6.78e-01 | 8.75e-01 | 3.57e-01 | 7.65e-01 |
| ASPARTATE METABOLIC PROCESS | 8 | 4.86e-01 | 9.43e-01 | 0.15200 | -3.02e-02 | 4.62e-02 | -8.60e-02 | 2.01e-02 | 1.10e-01 | 8.83e-01 | 8.21e-01 | 6.73e-01 | 9.22e-01 | 5.89e-01 |
| RNA LOCALIZATION | 183 | 4.03e-02 | 3.23e-01 | 0.15200 | 3.53e-02 | 1.72e-02 | 9.77e-02 | -6.14e-03 | 1.09e-01 | 4.11e-01 | 6.88e-01 | 2.26e-02 | 8.86e-01 | 1.09e-02 |
| REGULATION OF RECEPTOR INTERNALIZATION | 60 | 6.00e-01 | 9.90e-01 | 0.15200 | -6.96e-02 | -8.13e-02 | -1.13e-02 | -1.05e-01 | -1.99e-02 | 3.51e-01 | 2.76e-01 | 8.79e-01 | 1.59e-01 | 7.89e-01 |
| NEGATIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROCESS | 1436 | 5.54e-14 | 2.32e-11 | 0.15200 | 6.53e-02 | 4.98e-02 | 1.14e-01 | 1.80e-02 | 5.34e-02 | 3.41e-05 | 1.57e-03 | 3.78e-13 | 2.53e-01 | 6.96e-04 |
| GLOMERULAR BASEMENT MEMBRANE DEVELOPMENT | 11 | 6.98e-01 | 1.00e+00 | 0.15200 | -7.82e-03 | 2.64e-02 | -8.57e-02 | 1.19e-01 | 2.79e-02 | 9.64e-01 | 8.79e-01 | 6.23e-01 | 4.95e-01 | 8.73e-01 |
| HYPOTONIC RESPONSE | 13 | 9.62e-01 | 1.00e+00 | 0.15200 | -8.57e-02 | -8.13e-02 | -4.91e-02 | -5.38e-02 | 6.09e-02 | 5.93e-01 | 6.12e-01 | 7.59e-01 | 7.37e-01 | 7.04e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE BY HORMONE | 33 | 7.07e-01 | 1.00e+00 | 0.15200 | 4.36e-02 | 5.29e-02 | 4.23e-02 | -3.43e-03 | -1.28e-01 | 6.65e-01 | 5.99e-01 | 6.74e-01 | 9.73e-01 | 2.02e-01 |
| POSITIVE REGULATION OF GAP JUNCTION ASSEMBLY | 6 | 8.17e-01 | 1.00e+00 | 0.15100 | -1.90e-02 | -8.54e-03 | 6.32e-02 | -7.17e-02 | -1.16e-01 | 9.36e-01 | 9.71e-01 | 7.89e-01 | 7.61e-01 | 6.24e-01 |
| CELLULAR RESPONSE TO NICOTINE | 8 | 9.60e-01 | 1.00e+00 | 0.15100 | 3.48e-02 | 2.51e-03 | 1.12e-01 | 2.47e-02 | 9.29e-02 | 8.65e-01 | 9.90e-01 | 5.85e-01 | 9.04e-01 | 6.49e-01 |
| PYRIMIDINE RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 11 | 9.03e-01 | 1.00e+00 | 0.15100 | 6.40e-02 | 7.96e-02 | 6.35e-02 | 1.20e-02 | 9.10e-02 | 7.13e-01 | 6.47e-01 | 7.15e-01 | 9.45e-01 | 6.01e-01 |
| GLOMERULAR EPITHELIUM DEVELOPMENT | 24 | 5.26e-01 | 9.54e-01 | 0.15100 | -8.74e-02 | -4.58e-02 | -9.66e-02 | -5.07e-02 | -3.52e-02 | 4.58e-01 | 6.98e-01 | 4.12e-01 | 6.67e-01 | 7.65e-01 |
| GLAND DEVELOPMENT | 429 | 3.90e-03 | 6.42e-02 | 0.15100 | 7.82e-02 | 7.50e-02 | 9.36e-02 | 4.10e-02 | -2.59e-02 | 5.44e-03 | 7.68e-03 | 8.82e-04 | 1.45e-01 | 3.57e-01 |
| NEGATIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 31 | 8.04e-01 | 1.00e+00 | 0.15100 | 5.01e-02 | 5.15e-02 | 2.51e-02 | 7.47e-02 | 1.07e-01 | 6.29e-01 | 6.20e-01 | 8.09e-01 | 4.72e-01 | 3.02e-01 |
| RESPONSE TO STEROL | 35 | 7.50e-01 | 1.00e+00 | 0.15100 | -5.08e-02 | -6.76e-02 | -3.03e-02 | -1.39e-02 | 1.21e-01 | 6.03e-01 | 4.89e-01 | 7.56e-01 | 8.87e-01 | 2.17e-01 |
| HORMONE METABOLIC PROCESS | 233 | 1.00e-01 | 5.24e-01 | 0.15100 | -6.42e-02 | -5.18e-02 | -9.06e-02 | -3.23e-02 | -8.22e-02 | 9.13e-02 | 1.73e-01 | 1.72e-02 | 3.96e-01 | 3.06e-02 |
| PEROXISOME ORGANIZATION | 34 | 5.69e-01 | 9.75e-01 | 0.15100 | -2.12e-02 | -1.93e-02 | 5.22e-02 | -5.62e-02 | 1.27e-01 | 8.31e-01 | 8.45e-01 | 5.98e-01 | 5.70e-01 | 2.00e-01 |
| MAINTENANCE OF CELL POLARITY | 17 | 9.85e-01 | 1.00e+00 | 0.15100 | 7.69e-02 | 8.80e-02 | 2.73e-02 | 9.05e-02 | -1.47e-02 | 5.83e-01 | 5.30e-01 | 8.45e-01 | 5.18e-01 | 9.16e-01 |
| REGULATION OF CARDIAC MUSCLE CONTRACTION | 73 | 6.05e-01 | 9.90e-01 | 0.15100 | 7.01e-02 | 8.78e-02 | 4.15e-02 | 6.64e-02 | -6.35e-02 | 3.01e-01 | 1.94e-01 | 5.40e-01 | 3.26e-01 | 3.48e-01 |
| GLUTAMATE RECEPTOR SIGNALING PATHWAY | 47 | 6.28e-01 | 9.95e-01 | 0.15100 | -1.43e-02 | -5.99e-03 | -6.95e-02 | 2.59e-02 | -1.31e-01 | 8.65e-01 | 9.43e-01 | 4.10e-01 | 7.59e-01 | 1.21e-01 |
| REGULATION OF CDC42 PROTEIN SIGNAL TRANSDUCTION | 8 | 8.32e-01 | 1.00e+00 | 0.15100 | -2.32e-02 | 4.25e-02 | -1.06e-01 | 1.08e-02 | -9.58e-02 | 9.10e-01 | 8.35e-01 | 6.05e-01 | 9.58e-01 | 6.39e-01 |
| MICROTUBULE NUCLEATION | 43 | 5.03e-01 | 9.48e-01 | 0.15100 | 6.84e-02 | 4.95e-02 | 1.18e-01 | 1.32e-02 | -3.86e-02 | 4.38e-01 | 5.75e-01 | 1.80e-01 | 8.81e-01 | 6.62e-01 |
| NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 99 | 3.21e-01 | 8.47e-01 | 0.15100 | -4.79e-02 | -5.58e-02 | 9.40e-03 | -7.76e-02 | 1.06e-01 | 4.10e-01 | 3.37e-01 | 8.72e-01 | 1.82e-01 | 6.84e-02 |
| RESPONSE TO UV B | 21 | 5.26e-01 | 9.54e-01 | 0.15100 | 6.86e-02 | 1.18e-01 | 4.04e-03 | 5.56e-02 | -3.25e-02 | 5.86e-01 | 3.50e-01 | 9.74e-01 | 6.59e-01 | 7.97e-01 |
| REGULATION OF SMALL MOLECULE METABOLIC PROCESS | 325 | 4.15e-02 | 3.26e-01 | 0.15100 | 7.67e-02 | 8.40e-02 | 7.05e-02 | 6.37e-02 | -2.74e-02 | 1.75e-02 | 9.20e-03 | 2.88e-02 | 4.83e-02 | 3.96e-01 |
| REGULATION OF MYOBLAST DIFFERENTIATION | 72 | 2.22e-01 | 7.45e-01 | 0.15000 | 6.72e-02 | 7.53e-02 | 9.34e-02 | 1.01e-02 | -6.03e-02 | 3.24e-01 | 2.69e-01 | 1.70e-01 | 8.82e-01 | 3.77e-01 |
| DNA METABOLIC PROCESS | 986 | 1.98e-13 | 7.44e-11 | 0.15000 | 5.06e-02 | 3.30e-02 | 1.16e-01 | -8.97e-03 | 7.32e-02 | 7.10e-03 | 7.91e-02 | 5.99e-10 | 6.34e-01 | 9.98e-05 |
| GAP JUNCTION ASSEMBLY | 16 | 2.78e-01 | 8.05e-01 | 0.15000 | -4.91e-02 | -6.60e-02 | 8.19e-02 | -9.36e-02 | -2.01e-02 | 7.34e-01 | 6.47e-01 | 5.71e-01 | 5.17e-01 | 8.89e-01 |
| ONE CARBON COMPOUND TRANSPORT | 60 | 2.56e-01 | 7.83e-01 | 0.15000 | 4.40e-02 | 6.49e-02 | -3.16e-03 | 9.24e-02 | -8.90e-02 | 5.56e-01 | 3.85e-01 | 9.66e-01 | 2.16e-01 | 2.33e-01 |
| PEPTIDYL LYSINE MODIFICATION | 204 | 8.75e-03 | 1.15e-01 | 0.15000 | 3.22e-02 | 1.86e-02 | 1.00e-01 | -2.38e-02 | 1.03e-01 | 4.28e-01 | 6.47e-01 | 1.38e-02 | 5.58e-01 | 1.10e-02 |
| NEURON MATURATION | 47 | 7.01e-01 | 1.00e+00 | 0.15000 | 4.81e-02 | 5.78e-02 | 1.93e-02 | 2.04e-02 | -1.27e-01 | 5.69e-01 | 4.93e-01 | 8.19e-01 | 8.09e-01 | 1.32e-01 |
| NEGATIVE REGULATION OF AMYLOID PRECURSOR PROTEIN CATABOLIC PROCESS | 31 | 6.07e-01 | 9.90e-01 | 0.15000 | 7.40e-02 | 4.93e-02 | 9.64e-02 | 1.14e-02 | -7.25e-02 | 4.76e-01 | 6.35e-01 | 3.53e-01 | 9.12e-01 | 4.85e-01 |
| PEROXISOMAL TRANSPORT | 22 | 8.68e-01 | 1.00e+00 | 0.15000 | 1.47e-02 | 1.77e-02 | 3.11e-02 | 4.06e-02 | 1.39e-01 | 9.05e-01 | 8.86e-01 | 8.01e-01 | 7.42e-01 | 2.58e-01 |
| SYNAPTIC VESICLE CLUSTERING | 15 | 9.55e-01 | 1.00e+00 | 0.15000 | -6.41e-02 | -4.19e-02 | -6.71e-02 | -5.85e-02 | -9.37e-02 | 6.67e-01 | 7.79e-01 | 6.53e-01 | 6.95e-01 | 5.30e-01 |
| REGULATION OF DNA METABOLIC PROCESS | 506 | 1.27e-08 | 1.43e-06 | 0.15000 | 2.15e-02 | 5.79e-03 | 1.02e-01 | -4.21e-02 | 9.99e-02 | 4.07e-01 | 8.24e-01 | 9.18e-05 | 1.05e-01 | 1.18e-04 |
| NEGATIVE REGULATION OF WOUND HEALING | 72 | 4.85e-01 | 9.43e-01 | 0.15000 | -5.06e-02 | -4.77e-02 | -9.04e-02 | -5.85e-03 | -9.75e-02 | 4.58e-01 | 4.84e-01 | 1.85e-01 | 9.32e-01 | 1.52e-01 |
| CELL ACTIVATION | 1064 | 1.39e-12 | 3.88e-10 | 0.15000 | -6.82e-02 | -8.68e-02 | 3.27e-03 | -8.80e-02 | 5.08e-02 | 1.68e-04 | 1.71e-06 | 8.57e-01 | 1.23e-06 | 5.11e-03 |
| NEUROMUSCULAR PROCESS CONTROLLING POSTURE | 18 | 9.86e-01 | 1.00e+00 | 0.15000 | -6.93e-02 | -5.77e-02 | -1.02e-01 | -3.24e-02 | -5.48e-02 | 6.11e-01 | 6.72e-01 | 4.56e-01 | 8.12e-01 | 6.87e-01 |
| GLIAL CELL DEVELOPMENT | 118 | 1.89e-01 | 6.98e-01 | 0.15000 | 6.39e-02 | 6.18e-02 | 1.08e-01 | 1.09e-02 | 5.21e-02 | 2.30e-01 | 2.46e-01 | 4.18e-02 | 8.38e-01 | 3.28e-01 |
| REGULATION OF CARDIAC CONDUCTION | 26 | 7.97e-01 | 1.00e+00 | 0.15000 | 6.58e-02 | 8.89e-02 | 4.96e-02 | 1.94e-02 | -8.61e-02 | 5.61e-01 | 4.33e-01 | 6.62e-01 | 8.64e-01 | 4.47e-01 |
| CELLULAR RESPONSE TO ETHER | 6 | 6.17e-01 | 9.90e-01 | 0.15000 | -9.21e-02 | -5.43e-02 | -9.24e-02 | 2.72e-02 | -4.20e-02 | 6.96e-01 | 8.18e-01 | 6.95e-01 | 9.08e-01 | 8.59e-01 |
| RAC PROTEIN SIGNAL TRANSDUCTION | 41 | 8.96e-01 | 1.00e+00 | 0.15000 | -8.24e-02 | -8.41e-02 | -6.02e-02 | -5.09e-02 | 4.89e-02 | 3.61e-01 | 3.51e-01 | 5.05e-01 | 5.73e-01 | 5.88e-01 |
| ORGANIC ACID CATABOLIC PROCESS | 246 | 2.03e-01 | 7.22e-01 | 0.15000 | 7.76e-02 | 8.85e-02 | 5.18e-02 | 7.69e-02 | 1.82e-03 | 3.61e-02 | 1.68e-02 | 1.62e-01 | 3.77e-02 | 9.61e-01 |
| GMP METABOLIC PROCESS | 25 | 9.60e-01 | 1.00e+00 | 0.15000 | 6.55e-02 | 7.32e-02 | 1.33e-02 | 8.30e-02 | -7.57e-02 | 5.71e-01 | 5.26e-01 | 9.08e-01 | 4.73e-01 | 5.12e-01 |
| PRIMARY ALCOHOL METABOLIC PROCESS | 101 | 4.01e-02 | 3.22e-01 | 0.15000 | 3.28e-02 | 6.66e-02 | -4.07e-02 | 8.78e-02 | -8.70e-02 | 5.69e-01 | 2.47e-01 | 4.79e-01 | 1.28e-01 | 1.31e-01 |
| REGULATION OF CARDIOCYTE DIFFERENTIATION | 32 | 4.85e-01 | 9.43e-01 | 0.15000 | -3.93e-02 | -4.92e-02 | 4.84e-02 | -1.26e-01 | -1.37e-02 | 7.01e-01 | 6.30e-01 | 6.36e-01 | 2.16e-01 | 8.93e-01 |
| REGULATION OF BRANCHING INVOLVED IN PROSTATE GLAND MORPHOGENESIS | 5 | 9.60e-01 | 1.00e+00 | 0.15000 | 5.93e-03 | 7.64e-03 | 6.54e-02 | -5.96e-02 | -1.20e-01 | 9.82e-01 | 9.76e-01 | 8.00e-01 | 8.18e-01 | 6.41e-01 |
| CARDIAC MUSCLE CELL CONTRACTION | 72 | 6.82e-02 | 4.27e-01 | 0.15000 | -4.01e-03 | 3.06e-02 | -5.57e-02 | 4.16e-02 | -1.29e-01 | 9.53e-01 | 6.54e-01 | 4.13e-01 | 5.42e-01 | 5.86e-02 |
| REGULATION OF CARDIAC MUSCLE CELL ACTION POTENTIAL INVOLVED IN REGULATION OF CONTRACTION | 7 | 5.27e-01 | 9.54e-01 | 0.15000 | 4.32e-02 | 1.10e-01 | 7.22e-02 | -4.00e-02 | -4.01e-02 | 8.43e-01 | 6.14e-01 | 7.41e-01 | 8.54e-01 | 8.54e-01 |
| TENDON DEVELOPMENT | 5 | 6.73e-01 | 1.00e+00 | 0.15000 | 2.39e-02 | -9.60e-03 | 9.19e-02 | 1.11e-01 | 3.10e-02 | 9.26e-01 | 9.70e-01 | 7.22e-01 | 6.67e-01 | 9.04e-01 |
| RESPONSE TO STEROID HORMONE | 318 | 4.63e-02 | 3.48e-01 | 0.15000 | 7.62e-02 | 8.16e-02 | 7.37e-02 | 5.93e-02 | -3.12e-02 | 1.94e-02 | 1.24e-02 | 2.38e-02 | 6.89e-02 | 3.39e-01 |
| BICARBONATE TRANSPORT | 35 | 4.92e-01 | 9.45e-01 | 0.15000 | -5.65e-02 | -6.03e-02 | -5.46e-04 | -2.31e-02 | 1.23e-01 | 5.63e-01 | 5.37e-01 | 9.96e-01 | 8.13e-01 | 2.10e-01 |
| REGULATION OF DENDRITE EXTENSION | 26 | 9.85e-01 | 1.00e+00 | 0.15000 | -7.35e-02 | -6.43e-02 | -6.90e-02 | -7.72e-02 | -4.60e-02 | 5.17e-01 | 5.70e-01 | 5.43e-01 | 4.96e-01 | 6.84e-01 |
| REGULATION OF CARDIAC EPITHELIAL TO MESENCHYMAL TRANSITION | 12 | 9.20e-01 | 1.00e+00 | 0.15000 | -5.89e-02 | -6.52e-02 | 6.29e-03 | -3.67e-02 | 1.15e-01 | 7.24e-01 | 6.96e-01 | 9.70e-01 | 8.26e-01 | 4.90e-01 |
| BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR SIGNALING PATHWAY | 6 | 9.22e-01 | 1.00e+00 | 0.15000 | -4.50e-02 | -6.64e-02 | 5.07e-02 | -9.22e-02 | -6.97e-02 | 8.49e-01 | 7.78e-01 | 8.30e-01 | 6.96e-01 | 7.67e-01 |
| REGULATION OF STEROID HORMONE SECRETION | 22 | 8.95e-01 | 1.00e+00 | 0.14900 | 1.29e-02 | -3.06e-03 | 8.11e-02 | -3.64e-02 | 1.19e-01 | 9.17e-01 | 9.80e-01 | 5.10e-01 | 7.68e-01 | 3.32e-01 |
| GAP JUNCTION MEDIATED INTERCELLULAR TRANSPORT | 6 | 9.49e-01 | 1.00e+00 | 0.14900 | 6.44e-02 | 6.51e-02 | 5.20e-02 | -2.93e-02 | -1.02e-01 | 7.85e-01 | 7.82e-01 | 8.25e-01 | 9.01e-01 | 6.66e-01 |
| POSITIVE REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY | 60 | 8.05e-01 | 1.00e+00 | 0.14900 | 7.19e-02 | 8.80e-02 | 3.35e-02 | 7.84e-02 | -4.59e-02 | 3.35e-01 | 2.38e-01 | 6.53e-01 | 2.94e-01 | 5.39e-01 |
| PROTEIN TETRAMERIZATION | 88 | 5.49e-01 | 9.63e-01 | 0.14900 | 6.89e-02 | 7.17e-02 | 5.49e-02 | 6.76e-02 | -6.95e-02 | 2.64e-01 | 2.45e-01 | 3.73e-01 | 2.73e-01 | 2.60e-01 |
| MYELIN ASSEMBLY | 24 | 6.61e-01 | 1.00e+00 | 0.14900 | -6.19e-02 | -5.63e-02 | -1.17e-01 | -1.67e-02 | 3.72e-02 | 5.99e-01 | 6.33e-01 | 3.22e-01 | 8.87e-01 | 7.52e-01 |
| REGULATION OF FIBROBLAST PROLIFERATION | 87 | 4.46e-01 | 9.30e-01 | 0.14900 | 6.95e-02 | 7.56e-02 | 7.01e-02 | 4.04e-02 | -7.20e-02 | 2.62e-01 | 2.23e-01 | 2.58e-01 | 5.15e-01 | 2.46e-01 |
| RESPONSE TO TESTOSTERONE | 42 | 1.30e-01 | 5.98e-01 | 0.14900 | 8.58e-03 | -1.06e-02 | 8.76e-02 | -1.10e-01 | -4.80e-02 | 9.23e-01 | 9.05e-01 | 3.26e-01 | 2.17e-01 | 5.91e-01 |
| PROTEIN TARGETING TO MEMBRANE | 120 | 1.57e-01 | 6.54e-01 | 0.14900 | 6.73e-02 | 7.64e-02 | 9.13e-02 | 2.54e-02 | 5.41e-02 | 2.03e-01 | 1.48e-01 | 8.40e-02 | 6.30e-01 | 3.06e-01 |
| REGULATION OF PHOSPHOLIPASE ACTIVITY | 58 | 4.74e-01 | 9.40e-01 | 0.14900 | 3.93e-02 | 4.11e-02 | -8.80e-03 | 7.59e-02 | -1.15e-01 | 6.05e-01 | 5.89e-01 | 9.08e-01 | 3.17e-01 | 1.30e-01 |
| AXONOGENESIS INVOLVED IN INNERVATION | 9 | 9.45e-01 | 1.00e+00 | 0.14900 | -2.56e-03 | 9.22e-03 | -7.48e-02 | -8.02e-03 | -1.28e-01 | 9.89e-01 | 9.62e-01 | 6.98e-01 | 9.67e-01 | 5.05e-01 |
| REGULATION OF CELL CELL ADHESION MEDIATED BY INTEGRIN | 11 | 8.61e-01 | 1.00e+00 | 0.14900 | -5.41e-02 | -8.50e-02 | -1.67e-02 | 1.41e-02 | 1.08e-01 | 7.56e-01 | 6.26e-01 | 9.23e-01 | 9.36e-01 | 5.36e-01 |
| NEGATIVE REGULATION OF CELL CELL ADHESION | 198 | 1.52e-01 | 6.47e-01 | 0.14900 | -7.73e-02 | -8.16e-02 | -2.78e-02 | -8.00e-02 | 4.92e-02 | 6.09e-02 | 4.78e-02 | 5.00e-01 | 5.22e-02 | 2.32e-01 |
| PYRIMIDINE RIBONUCLEOTIDE BIOSYNTHETIC PROCESS | 22 | 8.88e-01 | 1.00e+00 | 0.14900 | 7.53e-02 | 8.04e-02 | 5.35e-02 | 2.19e-02 | -8.21e-02 | 5.41e-01 | 5.14e-01 | 6.64e-01 | 8.59e-01 | 5.05e-01 |
| REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 19 | 9.57e-01 | 1.00e+00 | 0.14900 | 6.29e-02 | 8.06e-02 | -5.03e-03 | 9.64e-02 | -4.95e-02 | 6.35e-01 | 5.43e-01 | 9.70e-01 | 4.67e-01 | 7.09e-01 |
| REGULATION OF HORMONE METABOLIC PROCESS | 39 | 6.10e-01 | 9.90e-01 | 0.14900 | -6.72e-02 | -7.20e-02 | 1.32e-02 | -1.02e-01 | 4.41e-02 | 4.68e-01 | 4.37e-01 | 8.86e-01 | 2.71e-01 | 6.33e-01 |
| NUCLEOSIDE PHOSPHATE CATABOLIC PROCESS | 83 | 3.19e-01 | 8.47e-01 | 0.14900 | -7.22e-02 | -5.75e-02 | -3.98e-02 | -9.78e-02 | -5.01e-02 | 2.55e-01 | 3.65e-01 | 5.30e-01 | 1.23e-01 | 4.30e-01 |
| CHONDROITIN SULFATE BIOSYNTHETIC PROCESS | 18 | 6.61e-01 | 1.00e+00 | 0.14900 | -2.71e-02 | -5.98e-02 | 3.59e-02 | -9.65e-02 | -8.52e-02 | 8.42e-01 | 6.60e-01 | 7.92e-01 | 4.79e-01 | 5.31e-01 |
| REGULATION OF EXTRACELLULAR MATRIX ASSEMBLY | 20 | 8.36e-01 | 1.00e+00 | 0.14900 | 5.87e-02 | 6.33e-02 | 9.85e-02 | 4.76e-02 | 5.24e-02 | 6.49e-01 | 6.24e-01 | 4.46e-01 | 7.12e-01 | 6.85e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR | 43 | 4.91e-01 | 9.45e-01 | 0.14900 | 6.98e-02 | 8.58e-02 | 9.60e-02 | 2.60e-02 | 5.41e-03 | 4.28e-01 | 3.30e-01 | 2.76e-01 | 7.68e-01 | 9.51e-01 |
| APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT | 42 | 7.63e-01 | 1.00e+00 | 0.14900 | 6.99e-02 | 7.03e-02 | 7.69e-02 | 5.68e-02 | -5.64e-02 | 4.33e-01 | 4.30e-01 | 3.88e-01 | 5.24e-01 | 5.27e-01 |
| LACTATE METABOLIC PROCESS | 18 | 9.48e-01 | 1.00e+00 | 0.14900 | -6.97e-02 | -4.98e-02 | -6.82e-02 | -6.18e-02 | -7.98e-02 | 6.09e-01 | 7.14e-01 | 6.17e-01 | 6.50e-01 | 5.58e-01 |
| DNA BIOSYNTHETIC PROCESS | 188 | 1.18e-02 | 1.42e-01 | 0.14900 | 4.07e-02 | 1.90e-02 | 1.10e-01 | -2.13e-02 | 8.71e-02 | 3.35e-01 | 6.54e-01 | 9.30e-03 | 6.14e-01 | 3.94e-02 |
| REGULATION OF MICROTUBULE BASED PROCESS | 248 | 5.78e-02 | 3.93e-01 | 0.14900 | 6.90e-02 | 6.82e-02 | 9.65e-02 | 4.28e-02 | 4.01e-02 | 6.13e-02 | 6.44e-02 | 8.88e-03 | 2.46e-01 | 2.77e-01 |
| NEGATIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION INITIATION | 7 | 9.29e-01 | 1.00e+00 | 0.14900 | 4.56e-03 | -4.25e-02 | 9.93e-02 | -7.94e-02 | 6.44e-02 | 9.83e-01 | 8.46e-01 | 6.49e-01 | 7.16e-01 | 7.68e-01 |
| ADENOSINE METABOLIC PROCESS | 10 | 4.93e-01 | 9.46e-01 | 0.14900 | -1.71e-02 | 1.06e-02 | -5.48e-02 | 1.25e-01 | 5.52e-02 | 9.25e-01 | 9.54e-01 | 7.64e-01 | 4.93e-01 | 7.63e-01 |
| DOPAMINE SECRETION | 41 | 7.54e-01 | 1.00e+00 | 0.14900 | 7.76e-02 | 6.74e-02 | 4.40e-02 | 6.46e-02 | -7.38e-02 | 3.90e-01 | 4.55e-01 | 6.26e-01 | 4.74e-01 | 4.14e-01 |
| NON MEMBRANE BOUNDED ORGANELLE ASSEMBLY | 389 | 1.56e-04 | 5.02e-03 | 0.14900 | 6.25e-02 | 4.82e-02 | 1.18e-01 | 8.18e-03 | 4.23e-02 | 3.43e-02 | 1.02e-01 | 6.01e-05 | 7.82e-01 | 1.52e-01 |
| REGULATION OF MIRNA METABOLIC PROCESS | 83 | 9.48e-02 | 5.08e-01 | 0.14900 | 4.12e-02 | 3.12e-02 | 1.15e-01 | 9.89e-03 | 7.89e-02 | 5.16e-01 | 6.23e-01 | 7.12e-02 | 8.76e-01 | 2.14e-01 |
| NEGATIVE REGULATION OF TELOMERASE ACTIVITY | 10 | 9.34e-01 | 1.00e+00 | 0.14900 | 5.43e-03 | 1.18e-02 | 5.63e-02 | -5.49e-02 | 1.26e-01 | 9.76e-01 | 9.49e-01 | 7.58e-01 | 7.64e-01 | 4.92e-01 |
| CARBOHYDRATE CATABOLIC PROCESS | 155 | 5.47e-01 | 9.61e-01 | 0.14900 | 7.60e-02 | 7.98e-02 | 7.48e-02 | 6.43e-02 | 1.50e-02 | 1.03e-01 | 8.65e-02 | 1.08e-01 | 1.67e-01 | 7.47e-01 |
| POSITIVE REGULATION OF NEUROBLAST PROLIFERATION | 37 | 3.28e-01 | 8.53e-01 | 0.14900 | 1.75e-02 | 1.90e-02 | 5.47e-02 | -7.80e-02 | -1.11e-01 | 8.54e-01 | 8.41e-01 | 5.65e-01 | 4.12e-01 | 2.42e-01 |
| INNER EAR RECEPTOR CELL DEVELOPMENT | 46 | 7.27e-01 | 1.00e+00 | 0.14900 | 5.90e-02 | 8.33e-02 | 5.96e-03 | 5.62e-02 | -9.20e-02 | 4.89e-01 | 3.28e-01 | 9.44e-01 | 5.10e-01 | 2.80e-01 |
| REGULATION OF MONOOXYGENASE ACTIVITY | 42 | 8.92e-01 | 1.00e+00 | 0.14900 | 6.64e-02 | 7.47e-02 | 4.91e-02 | 8.07e-02 | 5.62e-02 | 4.56e-01 | 4.02e-01 | 5.82e-01 | 3.65e-01 | 5.29e-01 |
| POSITIVE REGULATION OF T HELPER 17 CELL DIFFERENTIATION | 8 | 8.51e-01 | 1.00e+00 | 0.14800 | 2.91e-02 | 6.00e-02 | 1.60e-02 | -6.99e-02 | -1.12e-01 | 8.87e-01 | 7.69e-01 | 9.37e-01 | 7.32e-01 | 5.85e-01 |
| NEGATIVE REGULATION OF PLATELET AGGREGATION | 10 | 9.34e-01 | 1.00e+00 | 0.14800 | 3.59e-02 | 3.20e-02 | -3.18e-02 | 3.89e-02 | -1.31e-01 | 8.44e-01 | 8.61e-01 | 8.62e-01 | 8.32e-01 | 4.73e-01 |
| POSITIVE REGULATION OF DEPHOSPHORYLATION | 51 | 2.91e-01 | 8.18e-01 | 0.14800 | -9.86e-03 | -5.14e-02 | 6.86e-02 | -2.71e-02 | 1.18e-01 | 9.03e-01 | 5.25e-01 | 3.97e-01 | 7.38e-01 | 1.46e-01 |
| PHOTORECEPTOR CELL OUTER SEGMENT ORGANIZATION | 13 | 9.49e-01 | 1.00e+00 | 0.14800 | 6.60e-02 | 9.81e-02 | 7.73e-03 | 5.94e-02 | -6.67e-02 | 6.80e-01 | 5.40e-01 | 9.62e-01 | 7.11e-01 | 6.77e-01 |
| INSULIN SECRETION INVOLVED IN CELLULAR RESPONSE TO GLUCOSE STIMULUS | 62 | 2.45e-01 | 7.72e-01 | 0.14800 | 5.37e-02 | 7.14e-02 | 5.89e-02 | 1.34e-02 | -1.02e-01 | 4.65e-01 | 3.31e-01 | 4.23e-01 | 8.55e-01 | 1.65e-01 |
| SPECIFICATION OF ANIMAL ORGAN IDENTITY | 35 | 2.39e-01 | 7.63e-01 | 0.14800 | -1.01e-02 | -3.25e-02 | 7.58e-02 | -9.67e-02 | -7.57e-02 | 9.18e-01 | 7.39e-01 | 4.38e-01 | 3.22e-01 | 4.39e-01 |
| CELLULAR RESPONSE TO MECHANICAL STIMULUS | 69 | 2.02e-01 | 7.20e-01 | 0.14800 | -2.30e-03 | 1.47e-02 | -1.61e-03 | -3.44e-02 | -1.43e-01 | 9.74e-01 | 8.33e-01 | 9.82e-01 | 6.22e-01 | 3.94e-02 |
| POSITIVE REGULATION OF CORTICOSTEROID HORMONE SECRETION | 7 | 9.17e-01 | 1.00e+00 | 0.14800 | -1.90e-02 | 2.96e-03 | 3.69e-02 | -2.81e-02 | 1.39e-01 | 9.31e-01 | 9.89e-01 | 8.66e-01 | 8.98e-01 | 5.23e-01 |
| MAST CELL CHEMOTAXIS | 10 | 9.00e-01 | 1.00e+00 | 0.14800 | -6.11e-02 | -8.97e-02 | 4.01e-02 | -8.70e-02 | 3.09e-02 | 7.38e-01 | 6.23e-01 | 8.26e-01 | 6.34e-01 | 8.66e-01 |
| SOMITE DEVELOPMENT | 82 | 1.54e-01 | 6.50e-01 | 0.14800 | 4.92e-02 | 4.97e-02 | 6.31e-02 | 1.62e-02 | -1.13e-01 | 4.42e-01 | 4.37e-01 | 3.23e-01 | 7.99e-01 | 7.68e-02 |
| REGULATION OF COAGULATION | 73 | 4.16e-01 | 9.11e-01 | 0.14800 | -1.66e-02 | -9.96e-03 | -5.17e-02 | 6.78e-03 | -1.37e-01 | 8.06e-01 | 8.83e-01 | 4.45e-01 | 9.20e-01 | 4.28e-02 |
| AMYLOID PRECURSOR PROTEIN METABOLIC PROCESS | 93 | 6.66e-01 | 1.00e+00 | 0.14800 | 7.96e-02 | 6.52e-02 | 8.12e-02 | 6.72e-02 | -1.40e-02 | 1.85e-01 | 2.77e-01 | 1.76e-01 | 2.63e-01 | 8.16e-01 |
| MITOTIC CELL CYCLE PHASE TRANSITION | 452 | 7.39e-07 | 5.20e-05 | 0.14800 | 5.58e-02 | 4.39e-02 | 1.19e-01 | -1.61e-02 | 4.89e-02 | 4.18e-02 | 1.09e-01 | 1.42e-05 | 5.59e-01 | 7.49e-02 |
| POSITIVE REGULATION OF SODIUM ION TRANSPORT | 29 | 8.05e-01 | 1.00e+00 | 0.14800 | 7.72e-02 | 6.92e-02 | 4.46e-02 | 4.69e-02 | -8.31e-02 | 4.72e-01 | 5.19e-01 | 6.78e-01 | 6.62e-01 | 4.39e-01 |
| REGULATION OF DNA BIOSYNTHETIC PROCESS | 117 | 9.69e-02 | 5.13e-01 | 0.14800 | -9.23e-03 | -2.25e-02 | 6.67e-02 | -5.77e-02 | 1.16e-01 | 8.63e-01 | 6.74e-01 | 2.13e-01 | 2.81e-01 | 3.01e-02 |
| REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 104 | 5.80e-02 | 3.94e-01 | 0.14800 | 2.39e-02 | 7.70e-03 | 1.04e-01 | -5.42e-02 | 8.61e-02 | 6.73e-01 | 8.92e-01 | 6.64e-02 | 3.40e-01 | 1.29e-01 |
| PROTEIN N LINKED GLYCOSYLATION VIA ASPARAGINE | 23 | 2.73e-01 | 7.99e-01 | 0.14800 | -6.53e-02 | -1.19e-01 | 8.63e-03 | -3.24e-02 | 4.69e-02 | 5.88e-01 | 3.22e-01 | 9.43e-01 | 7.88e-01 | 6.97e-01 |
| ION CHANNEL MODULATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 8 | 9.85e-01 | 1.00e+00 | 0.14800 | 7.70e-03 | 1.63e-02 | -5.27e-02 | 5.73e-02 | -1.24e-01 | 9.70e-01 | 9.37e-01 | 7.96e-01 | 7.79e-01 | 5.43e-01 |
| REGULATION OF SISTER CHROMATID COHESION | 15 | 3.12e-01 | 8.38e-01 | 0.14700 | 7.86e-03 | -4.87e-02 | 3.53e-02 | -4.51e-02 | -1.26e-01 | 9.58e-01 | 7.44e-01 | 8.13e-01 | 7.62e-01 | 3.97e-01 |
| MITOTIC INTRA S DNA DAMAGE CHECKPOINT SIGNALING | 17 | 8.43e-01 | 1.00e+00 | 0.14700 | -2.11e-03 | -1.76e-02 | 9.20e-02 | -8.21e-02 | 7.82e-02 | 9.88e-01 | 9.00e-01 | 5.11e-01 | 5.58e-01 | 5.77e-01 |
| NEGATIVE REGULATION OF NUCLEASE ACTIVITY | 7 | 9.11e-01 | 1.00e+00 | 0.14700 | 5.76e-03 | -2.52e-02 | 1.26e-01 | -6.23e-02 | 3.59e-02 | 9.79e-01 | 9.08e-01 | 5.65e-01 | 7.75e-01 | 8.69e-01 |
| NEGATIVE REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY | 32 | 2.80e-01 | 8.06e-01 | 0.14700 | 1.48e-02 | 5.23e-02 | -8.70e-02 | 1.05e-01 | 1.01e-02 | 8.85e-01 | 6.09e-01 | 3.94e-01 | 3.04e-01 | 9.21e-01 |
| ALCOHOL METABOLIC PROCESS | 355 | 3.75e-03 | 6.27e-02 | 0.14700 | 6.96e-02 | 7.73e-02 | 6.64e-02 | 7.93e-02 | 1.04e-02 | 2.42e-02 | 1.23e-02 | 3.17e-02 | 1.03e-02 | 7.37e-01 |
| REGULATION OF CARDIAC MUSCLE CONTRACTION BY CALCIUM ION SIGNALING | 24 | 9.30e-01 | 1.00e+00 | 0.14700 | 3.13e-02 | 2.09e-02 | 7.84e-02 | 1.83e-02 | 1.17e-01 | 7.91e-01 | 8.59e-01 | 5.06e-01 | 8.77e-01 | 3.21e-01 |
| MRNA METABOLIC PROCESS | 743 | 1.80e-07 | 1.45e-05 | 0.14700 | 4.83e-02 | 2.88e-02 | 1.04e-01 | 7.29e-03 | 8.73e-02 | 2.50e-02 | 1.81e-01 | 1.45e-06 | 7.35e-01 | 5.03e-05 |
| DEVELOPMENTAL INDUCTION | 33 | 2.41e-01 | 7.67e-01 | 0.14700 | 3.40e-02 | 2.13e-03 | 1.34e-01 | -4.65e-02 | -1.94e-02 | 7.36e-01 | 9.83e-01 | 1.83e-01 | 6.44e-01 | 8.47e-01 |
| REGULATION OF CELL CYCLE | 1070 | 4.22e-12 | 1.10e-09 | 0.14700 | 6.27e-02 | 5.09e-02 | 1.14e-01 | 2.94e-03 | 4.55e-02 | 5.27e-04 | 4.92e-03 | 2.89e-10 | 8.71e-01 | 1.18e-02 |
| NEGATIVE REGULATION OF CYTOSOLIC CALCIUM ION CONCENTRATION | 13 | 7.52e-01 | 1.00e+00 | 0.14700 | 1.08e-02 | 2.47e-02 | -4.62e-02 | 1.26e-01 | 5.27e-02 | 9.46e-01 | 8.77e-01 | 7.73e-01 | 4.30e-01 | 7.42e-01 |
| MITOTIC CELL CYCLE | 900 | 1.12e-12 | 3.52e-10 | 0.14700 | 5.80e-02 | 4.49e-02 | 1.19e-01 | -8.33e-03 | 4.46e-02 | 3.13e-03 | 2.22e-02 | 1.39e-09 | 6.72e-01 | 2.31e-02 |
| MRNA TRANSCRIPTION | 47 | 6.91e-01 | 1.00e+00 | 0.14700 | -1.63e-02 | -3.48e-02 | 5.06e-02 | -4.10e-02 | 1.26e-01 | 8.46e-01 | 6.80e-01 | 5.49e-01 | 6.26e-01 | 1.35e-01 |
| POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 74 | 4.51e-01 | 9.30e-01 | 0.14700 | 6.67e-02 | 6.08e-02 | 6.74e-02 | 2.23e-02 | -9.15e-02 | 3.21e-01 | 3.66e-01 | 3.16e-01 | 7.40e-01 | 1.73e-01 |
| POSITIVE REGULATION OF UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 109 | 3.02e-01 | 8.30e-01 | 0.14700 | 7.17e-02 | 7.60e-02 | 9.51e-02 | 4.00e-02 | 3.74e-03 | 1.96e-01 | 1.71e-01 | 8.63e-02 | 4.70e-01 | 9.46e-01 |
| MYOBLAST DIFFERENTIATION | 109 | 2.37e-01 | 7.61e-01 | 0.14700 | 6.38e-02 | 7.16e-02 | 6.27e-02 | 2.29e-02 | -8.89e-02 | 2.50e-01 | 1.96e-01 | 2.58e-01 | 6.80e-01 | 1.09e-01 |
| LEUKOCYTE DIFFERENTIATION | 597 | 1.69e-06 | 9.75e-05 | 0.14700 | -6.50e-02 | -8.29e-02 | 5.54e-03 | -8.73e-02 | 5.29e-02 | 6.65e-03 | 5.36e-04 | 8.17e-01 | 2.67e-04 | 2.71e-02 |
| NEGATIVE REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 19 | 6.49e-01 | 1.00e+00 | 0.14700 | 5.77e-02 | 7.97e-02 | 6.59e-02 | -3.68e-02 | -7.86e-02 | 6.63e-01 | 5.48e-01 | 6.19e-01 | 7.81e-01 | 5.53e-01 |
| NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 223 | 1.21e-03 | 2.67e-02 | 0.14700 | 4.29e-02 | 4.07e-02 | 9.47e-02 | -2.41e-02 | 9.21e-02 | 2.69e-01 | 2.95e-01 | 1.48e-02 | 5.35e-01 | 1.77e-02 |
| SPLICEOSOMAL COMPLEX ASSEMBLY | 75 | 4.47e-01 | 9.30e-01 | 0.14700 | 6.00e-02 | 3.22e-02 | 1.11e-01 | 2.23e-02 | 6.41e-02 | 3.69e-01 | 6.29e-01 | 9.71e-02 | 7.39e-01 | 3.37e-01 |
| UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS VIA THE C END DEGRON RULE PATHWAY | 12 | 5.25e-01 | 9.54e-01 | 0.14700 | 3.58e-02 | -2.56e-02 | 1.24e-01 | 4.23e-02 | 4.84e-02 | 8.30e-01 | 8.78e-01 | 4.56e-01 | 8.00e-01 | 7.71e-01 |
| INTRACELLULAR GLUTAMATE HOMEOSTASIS | 5 | 9.92e-01 | 1.00e+00 | 0.14700 | -3.90e-02 | -5.75e-02 | -3.63e-02 | -5.08e-02 | -1.13e-01 | 8.80e-01 | 8.24e-01 | 8.88e-01 | 8.44e-01 | 6.61e-01 |
| MITOCHONDRION ORGANIZATION | 523 | 1.51e-07 | 1.25e-05 | 0.14700 | 4.90e-02 | 3.23e-02 | 1.17e-01 | -1.58e-02 | 6.39e-02 | 5.52e-02 | 2.06e-01 | 4.49e-06 | 5.36e-01 | 1.24e-02 |
| ADULT HEART DEVELOPMENT | 13 | 8.50e-01 | 1.00e+00 | 0.14700 | 6.50e-02 | 2.89e-02 | 1.20e-01 | -2.19e-03 | -4.44e-02 | 6.85e-01 | 8.57e-01 | 4.53e-01 | 9.89e-01 | 7.82e-01 |
| RESPONSE TO ESTROGEN | 66 | 2.89e-01 | 8.17e-01 | 0.14700 | 3.92e-02 | 4.06e-03 | 1.10e-01 | 3.07e-03 | 8.79e-02 | 5.82e-01 | 9.54e-01 | 1.21e-01 | 9.66e-01 | 2.17e-01 |
| SODIUM ION TRANSPORT | 235 | 8.60e-03 | 1.13e-01 | 0.14700 | 5.30e-02 | 6.57e-02 | -1.69e-02 | 1.05e-01 | -5.49e-02 | 1.62e-01 | 8.26e-02 | 6.55e-01 | 5.50e-03 | 1.47e-01 |
| CEREBRAL CORTEX DEVELOPMENT | 121 | 7.20e-02 | 4.41e-01 | 0.14600 | 3.54e-03 | 5.10e-03 | -7.67e-03 | -2.66e-03 | -1.46e-01 | 9.46e-01 | 9.23e-01 | 8.84e-01 | 9.60e-01 | 5.52e-03 |
| POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 17 | 9.41e-01 | 1.00e+00 | 0.14600 | 1.23e-02 | 7.11e-04 | 7.90e-02 | -3.39e-02 | 1.18e-01 | 9.30e-01 | 9.96e-01 | 5.73e-01 | 8.09e-01 | 4.01e-01 |
| NEGATIVE REGULATION OF CHOLESTEROL STORAGE | 11 | 9.45e-01 | 1.00e+00 | 0.14600 | -6.40e-02 | -6.53e-02 | -1.03e-01 | -4.85e-02 | -8.38e-03 | 7.13e-01 | 7.08e-01 | 5.54e-01 | 7.81e-01 | 9.62e-01 |
| POSITIVE REGULATION OF POST TRANSLATIONAL PROTEIN MODIFICATION | 146 | 7.77e-02 | 4.57e-01 | 0.14600 | 3.17e-02 | 2.29e-02 | 8.85e-02 | 1.06e-02 | 1.09e-01 | 5.09e-01 | 6.33e-01 | 6.50e-02 | 8.25e-01 | 2.26e-02 |
| NEGATIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 32 | 3.09e-01 | 8.35e-01 | 0.14600 | -1.80e-03 | 3.16e-03 | 4.40e-02 | -1.12e-01 | -8.26e-02 | 9.86e-01 | 9.75e-01 | 6.67e-01 | 2.72e-01 | 4.19e-01 |
| PYRIMIDINE NUCLEOBASE METABOLIC PROCESS | 20 | 9.70e-01 | 1.00e+00 | 0.14600 | 6.52e-02 | 7.69e-02 | 3.37e-02 | 8.25e-02 | -5.71e-02 | 6.14e-01 | 5.52e-01 | 7.94e-01 | 5.23e-01 | 6.58e-01 |
| NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS | 158 | 1.23e-02 | 1.45e-01 | 0.14600 | 6.14e-02 | 5.75e-02 | 1.13e-01 | -2.00e-02 | 3.33e-02 | 1.83e-01 | 2.12e-01 | 1.42e-02 | 6.65e-01 | 4.70e-01 |
| ENDODERM DEVELOPMENT | 81 | 7.81e-02 | 4.59e-01 | 0.14600 | 3.31e-02 | 1.50e-02 | 3.49e-02 | 3.08e-03 | -1.37e-01 | 6.06e-01 | 8.16e-01 | 5.87e-01 | 9.62e-01 | 3.29e-02 |
| HEMATOPOIETIC STEM CELL DIFFERENTIATION | 36 | 3.79e-01 | 8.86e-01 | 0.14600 | 6.13e-02 | 5.85e-02 | 1.05e-01 | 4.21e-02 | -3.71e-02 | 5.24e-01 | 5.44e-01 | 2.76e-01 | 6.62e-01 | 7.00e-01 |
| MODULATION BY HOST OF SYMBIONT PROCESS | 81 | 3.98e-01 | 8.98e-01 | 0.14600 | 3.71e-03 | -1.15e-02 | 4.51e-02 | 1.35e-02 | 1.38e-01 | 9.54e-01 | 8.59e-01 | 4.82e-01 | 8.34e-01 | 3.22e-02 |
| NEGATIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 71 | 2.11e-01 | 7.33e-01 | 0.14600 | -6.72e-02 | -4.86e-02 | -1.07e-01 | -4.70e-02 | 2.84e-02 | 3.28e-01 | 4.79e-01 | 1.20e-01 | 4.93e-01 | 6.79e-01 |
| POSITIVE REGULATION OF FIBROBLAST PROLIFERATION | 52 | 3.09e-01 | 8.35e-01 | 0.14600 | 5.70e-02 | 6.56e-02 | 8.53e-02 | 5.27e-03 | -8.01e-02 | 4.77e-01 | 4.13e-01 | 2.87e-01 | 9.48e-01 | 3.18e-01 |
| MODIFICATION OF POSTSYNAPTIC STRUCTURE | 21 | 5.53e-01 | 9.66e-01 | 0.14600 | 5.99e-02 | 2.68e-02 | 5.99e-02 | 8.79e-02 | -7.53e-02 | 6.35e-01 | 8.32e-01 | 6.35e-01 | 4.86e-01 | 5.50e-01 |
| EMBRYONIC PATTERN SPECIFICATION | 69 | 4.51e-01 | 9.30e-01 | 0.14600 | -5.89e-02 | -5.89e-02 | -4.63e-02 | -5.11e-02 | -9.79e-02 | 3.97e-01 | 3.98e-01 | 5.06e-01 | 4.63e-01 | 1.60e-01 |
| REGULATION OF SYSTEM PROCESS | 539 | 1.01e-02 | 1.27e-01 | 0.14600 | 7.40e-02 | 7.40e-02 | 6.41e-02 | 7.13e-02 | -3.30e-02 | 3.28e-03 | 3.30e-03 | 1.09e-02 | 4.63e-03 | 1.90e-01 |
| LIPOSACCHARIDE METABOLIC PROCESS | 106 | 4.24e-01 | 9.14e-01 | 0.14500 | 7.45e-02 | 5.55e-02 | 1.02e-01 | 2.99e-02 | 3.46e-02 | 1.85e-01 | 3.23e-01 | 6.92e-02 | 5.94e-01 | 5.38e-01 |
| REGULATION OF LIPID KINASE ACTIVITY | 38 | 8.07e-01 | 1.00e+00 | 0.14500 | -5.01e-02 | -7.34e-02 | 1.65e-02 | -7.11e-02 | 8.90e-02 | 5.93e-01 | 4.34e-01 | 8.60e-01 | 4.48e-01 | 3.43e-01 |
| NEURAL PLATE DEVELOPMENT | 8 | 8.78e-01 | 1.00e+00 | 0.14500 | -8.40e-02 | -7.47e-02 | -8.55e-02 | 8.83e-03 | -3.31e-02 | 6.81e-01 | 7.14e-01 | 6.75e-01 | 9.65e-01 | 8.71e-01 |
| RIG I SIGNALING PATHWAY | 28 | 8.45e-01 | 1.00e+00 | 0.14500 | -5.66e-02 | -5.70e-02 | 3.69e-03 | -1.11e-01 | 4.82e-02 | 6.04e-01 | 6.02e-01 | 9.73e-01 | 3.09e-01 | 6.59e-01 |
| PYRIMIDINE NUCLEOTIDE METABOLIC PROCESS | 50 | 8.26e-01 | 1.00e+00 | 0.14500 | 6.67e-02 | 5.20e-02 | 1.05e-01 | 2.02e-02 | 5.02e-02 | 4.15e-01 | 5.25e-01 | 1.99e-01 | 8.04e-01 | 5.39e-01 |
| CONVERGENT EXTENSION | 15 | 5.08e-01 | 9.48e-01 | 0.14500 | 1.46e-02 | 2.43e-02 | 1.18e-01 | -6.10e-02 | 5.04e-02 | 9.22e-01 | 8.70e-01 | 4.27e-01 | 6.82e-01 | 7.35e-01 |
| NUCLEOSIDE PHOSPHATE BIOSYNTHETIC PROCESS | 272 | 6.09e-02 | 4.04e-01 | 0.14500 | 6.83e-02 | 5.70e-02 | 1.02e-01 | 2.36e-02 | 4.64e-02 | 5.25e-02 | 1.05e-01 | 3.71e-03 | 5.02e-01 | 1.87e-01 |
| CARDIAC MUSCLE CONTRACTION | 131 | 8.55e-02 | 4.82e-01 | 0.14500 | 6.37e-02 | 8.63e-02 | 3.25e-02 | 8.33e-02 | -3.94e-02 | 2.08e-01 | 8.80e-02 | 5.20e-01 | 9.96e-02 | 4.37e-01 |
| OLIGODENDROCYTE DIFFERENTIATION | 102 | 5.78e-02 | 3.93e-01 | 0.14500 | 4.87e-02 | 4.24e-02 | 1.18e-01 | -3.02e-02 | 4.41e-02 | 3.96e-01 | 4.59e-01 | 3.87e-02 | 5.98e-01 | 4.41e-01 |
| CYTOSKELETON DEPENDENT CYTOKINESIS | 113 | 2.54e-01 | 7.82e-01 | 0.14500 | 6.38e-02 | 4.96e-02 | 1.12e-01 | 2.81e-02 | 3.36e-02 | 2.41e-01 | 3.63e-01 | 3.94e-02 | 6.05e-01 | 5.37e-01 |
| ENDOCARDIAL CUSHION DEVELOPMENT | 54 | 1.35e-01 | 6.10e-01 | 0.14500 | 4.25e-02 | 2.29e-02 | 1.25e-01 | -4.98e-02 | -2.65e-02 | 5.89e-01 | 7.71e-01 | 1.13e-01 | 5.27e-01 | 7.36e-01 |
| FORMATION OF PRIMARY GERM LAYER | 126 | 1.33e-01 | 6.06e-01 | 0.14500 | 6.79e-02 | 5.39e-02 | 7.54e-02 | 4.28e-02 | -7.73e-02 | 1.88e-01 | 2.96e-01 | 1.44e-01 | 4.06e-01 | 1.34e-01 |
| NEGATIVE REGULATION OF ANOIKIS | 18 | 9.47e-01 | 1.00e+00 | 0.14500 | 6.89e-02 | 3.87e-02 | 1.03e-01 | 4.10e-02 | 4.96e-02 | 6.13e-01 | 7.76e-01 | 4.49e-01 | 7.63e-01 | 7.15e-01 |
| REGULATION OF CARTILAGE DEVELOPMENT | 70 | 7.55e-01 | 1.00e+00 | 0.14500 | -5.52e-02 | -4.72e-02 | -5.57e-02 | -7.23e-02 | -8.60e-02 | 4.24e-01 | 4.95e-01 | 4.20e-01 | 2.95e-01 | 2.13e-01 |
| TUBE FORMATION | 149 | 2.72e-01 | 7.99e-01 | 0.14500 | 5.73e-02 | 4.89e-02 | 9.29e-02 | 4.20e-02 | 7.02e-02 | 2.27e-01 | 3.02e-01 | 5.04e-02 | 3.76e-01 | 1.39e-01 |
| NEURON PROJECTION REGENERATION | 54 | 6.32e-01 | 9.96e-01 | 0.14500 | -6.60e-02 | -5.44e-02 | -6.66e-02 | -4.27e-02 | 8.61e-02 | 4.01e-01 | 4.90e-01 | 3.97e-01 | 5.87e-01 | 2.74e-01 |
| VASCULAR TRANSPORT | 84 | 1.76e-01 | 6.81e-01 | 0.14500 | 6.37e-02 | 8.16e-02 | 6.31e-02 | 7.49e-02 | 2.55e-02 | 3.13e-01 | 1.96e-01 | 3.17e-01 | 2.36e-01 | 6.86e-01 |
| CENTRAL NERVOUS SYSTEM PROJECTION NEURON AXONOGENESIS | 29 | 7.22e-01 | 1.00e+00 | 0.14500 | 6.12e-02 | 4.26e-02 | 1.11e-01 | 5.06e-02 | 2.51e-02 | 5.68e-01 | 6.92e-01 | 3.03e-01 | 6.37e-01 | 8.15e-01 |
| INTEGRATED STRESS RESPONSE SIGNALING | 42 | 1.70e-01 | 6.74e-01 | 0.14500 | -3.83e-03 | -1.86e-02 | 1.04e-01 | -9.73e-02 | 1.54e-02 | 9.66e-01 | 8.35e-01 | 2.42e-01 | 2.75e-01 | 8.63e-01 |
| CARDIAC MUSCLE CELL ACTION POTENTIAL | 72 | 4.61e-02 | 3.48e-01 | 0.14500 | 3.61e-02 | 7.27e-02 | -1.31e-02 | 7.94e-02 | -8.88e-02 | 5.96e-01 | 2.86e-01 | 8.48e-01 | 2.44e-01 | 1.93e-01 |
| DICHOTOMOUS SUBDIVISION OF AN EPITHELIAL TERMINAL UNIT | 8 | 8.15e-01 | 1.00e+00 | 0.14500 | 4.43e-02 | 2.85e-02 | 8.56e-02 | 5.94e-02 | -8.56e-02 | 8.28e-01 | 8.89e-01 | 6.75e-01 | 7.71e-01 | 6.75e-01 |
| REGULATION OF PROSTATIC BUD FORMATION | 5 | 7.45e-01 | 1.00e+00 | 0.14500 | 1.06e-02 | -5.79e-02 | 6.06e-02 | 2.11e-02 | -1.16e-01 | 9.67e-01 | 8.23e-01 | 8.14e-01 | 9.35e-01 | 6.55e-01 |
| REGULATION OF CELLULAR RESPONSE TO HYPOXIA | 20 | 6.44e-01 | 1.00e+00 | 0.14500 | -2.30e-02 | -4.08e-02 | 4.26e-02 | -1.21e-01 | 4.67e-02 | 8.59e-01 | 7.52e-01 | 7.42e-01 | 3.48e-01 | 7.18e-01 |
| REGULATION OF CELL GROWTH | 399 | 4.92e-02 | 3.61e-01 | 0.14500 | 7.40e-02 | 6.73e-02 | 9.35e-02 | 4.00e-02 | 2.31e-02 | 1.11e-02 | 2.11e-02 | 1.34e-03 | 1.70e-01 | 4.28e-01 |
| XENOBIOTIC METABOLIC PROCESS | 123 | 2.62e-01 | 7.90e-01 | 0.14400 | -4.69e-02 | -2.68e-02 | -9.54e-02 | -6.95e-03 | -9.39e-02 | 3.69e-01 | 6.08e-01 | 6.75e-02 | 8.94e-01 | 7.22e-02 |
| NEGATIVE REGULATION OF PROTEIN SECRETION | 71 | 6.44e-01 | 1.00e+00 | 0.14400 | 7.47e-02 | 5.91e-02 | 1.05e-01 | 2.62e-02 | 2.72e-03 | 2.76e-01 | 3.89e-01 | 1.25e-01 | 7.02e-01 | 9.68e-01 |
| MITOCHONDRIAL DEPOLARIZATION | 22 | 7.29e-01 | 1.00e+00 | 0.14400 | 6.78e-02 | 3.34e-02 | 1.18e-01 | 1.53e-02 | -3.20e-02 | 5.82e-01 | 7.86e-01 | 3.39e-01 | 9.01e-01 | 7.95e-01 |
| REGULATION OF PROTEIN CATABOLIC PROCESS | 340 | 6.66e-03 | 9.31e-02 | 0.14400 | 6.45e-02 | 5.81e-02 | 1.04e-01 | 2.83e-02 | 3.99e-02 | 4.09e-02 | 6.57e-02 | 9.32e-04 | 3.70e-01 | 2.06e-01 |
| GLIAL CELL ACTIVATION | 57 | 1.08e-01 | 5.46e-01 | 0.14400 | -6.57e-02 | -8.31e-02 | 3.08e-02 | -7.84e-02 | 4.99e-02 | 3.91e-01 | 2.78e-01 | 6.87e-01 | 3.06e-01 | 5.15e-01 |
| ANIMAL ORGAN FORMATION | 66 | 3.28e-01 | 8.53e-01 | 0.14400 | 5.78e-02 | 4.80e-02 | 8.06e-02 | 5.63e-03 | -9.29e-02 | 4.17e-01 | 5.00e-01 | 2.57e-01 | 9.37e-01 | 1.92e-01 |
| RECEPTOR METABOLIC PROCESS | 71 | 4.05e-01 | 9.06e-01 | 0.14400 | -5.74e-02 | -5.32e-02 | -8.46e-03 | -5.83e-02 | 1.06e-01 | 4.03e-01 | 4.38e-01 | 9.02e-01 | 3.95e-01 | 1.23e-01 |
| INTERFERON MEDIATED SIGNALING PATHWAY | 102 | 4.12e-01 | 9.08e-01 | 0.14400 | -6.57e-02 | -6.36e-02 | -2.51e-02 | -1.06e-01 | 2.35e-02 | 2.51e-01 | 2.67e-01 | 6.62e-01 | 6.42e-02 | 6.82e-01 |
| CELLULAR RESPONSE TO BIOTIC STIMULUS | 255 | 2.36e-03 | 4.37e-02 | 0.14400 | -4.99e-02 | -6.71e-02 | 2.50e-02 | -6.16e-02 | 9.68e-02 | 1.70e-01 | 6.51e-02 | 4.91e-01 | 9.04e-02 | 7.74e-03 |
| POSITIVE REGULATION OF EXECUTION PHASE OF APOPTOSIS | 8 | 8.97e-01 | 1.00e+00 | 0.14400 | -7.13e-02 | -7.54e-02 | 6.34e-03 | -4.18e-02 | 9.06e-02 | 7.27e-01 | 7.12e-01 | 9.75e-01 | 8.38e-01 | 6.57e-01 |
| POSITIVE REGULATION OF CYCLASE ACTIVITY | 38 | 9.44e-01 | 1.00e+00 | 0.14400 | -5.85e-02 | -4.71e-02 | -8.11e-02 | -4.03e-02 | -8.31e-02 | 5.33e-01 | 6.15e-01 | 3.87e-01 | 6.67e-01 | 3.75e-01 |
| NEGATIVE REGULATION OF UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 48 | 4.96e-01 | 9.47e-01 | 0.14400 | -1.18e-03 | -1.77e-02 | 8.51e-02 | -5.21e-02 | 1.02e-01 | 9.89e-01 | 8.32e-01 | 3.08e-01 | 5.32e-01 | 2.20e-01 |
| IODIDE TRANSPORT | 9 | 9.88e-01 | 1.00e+00 | 0.14400 | 7.99e-02 | 5.31e-02 | 9.27e-02 | 5.40e-02 | -2.06e-03 | 6.78e-01 | 7.83e-01 | 6.30e-01 | 7.79e-01 | 9.91e-01 |
| TETRAPYRROLE METABOLIC PROCESS | 58 | 2.95e-01 | 8.23e-01 | 0.14400 | 2.88e-03 | -3.35e-03 | 8.13e-02 | -2.99e-02 | 1.15e-01 | 9.70e-01 | 9.65e-01 | 2.84e-01 | 6.94e-01 | 1.30e-01 |
| OOCYTE DIFFERENTIATION | 64 | 5.95e-01 | 9.87e-01 | 0.14400 | -4.59e-02 | -4.74e-02 | -2.81e-02 | -7.63e-02 | -9.87e-02 | 5.25e-01 | 5.12e-01 | 6.97e-01 | 2.91e-01 | 1.72e-01 |
| REGULATION OF ER TO GOLGI VESICLE MEDIATED TRANSPORT | 10 | 6.46e-01 | 1.00e+00 | 0.14400 | -3.36e-02 | -9.00e-02 | 2.99e-03 | -4.71e-02 | -9.61e-02 | 8.54e-01 | 6.22e-01 | 9.87e-01 | 7.96e-01 | 5.99e-01 |
| MITOCHONDRION ENDOPLASMIC RETICULUM MEMBRANE TETHERING | 7 | 9.97e-01 | 1.00e+00 | 0.14400 | -6.82e-02 | -6.98e-02 | -1.82e-02 | -7.59e-02 | 7.12e-02 | 7.55e-01 | 7.49e-01 | 9.33e-01 | 7.28e-01 | 7.44e-01 |
| BONE MORPHOGENESIS | 98 | 6.46e-02 | 4.13e-01 | 0.14400 | 6.33e-02 | 7.34e-02 | 8.97e-02 | 2.63e-02 | -5.05e-02 | 2.79e-01 | 2.09e-01 | 1.25e-01 | 6.53e-01 | 3.88e-01 |
| L SERINE METABOLIC PROCESS | 12 | 9.97e-01 | 1.00e+00 | 0.14400 | 7.53e-02 | 6.78e-02 | 6.43e-02 | 7.80e-02 | -1.34e-02 | 6.52e-01 | 6.84e-01 | 7.00e-01 | 6.40e-01 | 9.36e-01 |
| NEGATIVE REGULATION OF PROTEIN POLYMERIZATION | 75 | 7.35e-01 | 1.00e+00 | 0.14400 | 6.76e-02 | 8.31e-02 | 2.75e-02 | 7.95e-02 | -4.58e-02 | 3.12e-01 | 2.13e-01 | 6.80e-01 | 2.34e-01 | 4.93e-01 |
| REGULATION OF GOLGI ORGANIZATION | 17 | 7.12e-01 | 1.00e+00 | 0.14400 | -3.59e-02 | -5.27e-02 | -1.30e-03 | -1.22e-01 | -4.21e-02 | 7.98e-01 | 7.07e-01 | 9.93e-01 | 3.85e-01 | 7.64e-01 |
| DEFENSE RESPONSE TO SYMBIONT | 325 | 1.13e-03 | 2.53e-02 | 0.14400 | -7.16e-02 | -7.35e-02 | -8.39e-03 | -8.88e-02 | 4.64e-02 | 2.65e-02 | 2.28e-02 | 7.95e-01 | 5.90e-03 | 1.51e-01 |
| REGULATION OF PROTEIN CONTAINING COMPLEX DISASSEMBLY | 117 | 8.13e-01 | 1.00e+00 | 0.14400 | 7.42e-02 | 7.32e-02 | 6.69e-02 | 7.21e-02 | 8.32e-03 | 1.66e-01 | 1.72e-01 | 2.11e-01 | 1.78e-01 | 8.77e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE MEDIATED BY A CHEMICAL SIGNAL | 42 | 7.37e-01 | 1.00e+00 | 0.14300 | 4.58e-02 | 5.25e-02 | 3.45e-02 | 9.62e-03 | -1.20e-01 | 6.07e-01 | 5.56e-01 | 6.99e-01 | 9.14e-01 | 1.78e-01 |
| NEGATIVE REGULATION OF B CELL MEDIATED IMMUNITY | 15 | 8.51e-01 | 1.00e+00 | 0.14300 | -1.02e-02 | -3.99e-02 | 8.83e-02 | -9.06e-02 | 5.35e-02 | 9.45e-01 | 7.89e-01 | 5.54e-01 | 5.44e-01 | 7.20e-01 |
| REGULATION OF LIPID BIOSYNTHETIC PROCESS | 180 | 1.24e-01 | 5.89e-01 | 0.14300 | 7.04e-02 | 7.80e-02 | 7.27e-02 | 6.21e-02 | -1.94e-02 | 1.03e-01 | 7.11e-02 | 9.24e-02 | 1.51e-01 | 6.53e-01 |
| REGULATION OF GLIOGENESIS | 106 | 6.40e-02 | 4.13e-01 | 0.14300 | 4.72e-02 | 4.00e-02 | 1.17e-01 | -2.65e-02 | 4.80e-02 | 4.01e-01 | 4.77e-01 | 3.72e-02 | 6.38e-01 | 3.93e-01 |
| REGULATION OF LYSOSOME ORGANIZATION | 12 | 9.59e-01 | 1.00e+00 | 0.14300 | 5.06e-02 | 6.51e-02 | -3.66e-03 | 1.17e-01 | 5.13e-03 | 7.61e-01 | 6.96e-01 | 9.82e-01 | 4.83e-01 | 9.75e-01 |
| EXTRACELLULAR MATRIX DISASSEMBLY | 61 | 6.15e-01 | 9.90e-01 | 0.14300 | 5.29e-02 | 5.81e-02 | 2.02e-03 | 9.43e-02 | -7.39e-02 | 4.75e-01 | 4.33e-01 | 9.78e-01 | 2.03e-01 | 3.18e-01 |
| CARDIOLIPIN ACYL CHAIN REMODELING | 5 | 9.93e-01 | 1.00e+00 | 0.14300 | 5.49e-02 | 8.56e-02 | 1.72e-02 | 2.79e-02 | -9.53e-02 | 8.32e-01 | 7.40e-01 | 9.47e-01 | 9.14e-01 | 7.12e-01 |
| REGULATION OF G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 133 | 2.25e-01 | 7.48e-01 | 0.14300 | 5.18e-02 | 3.51e-02 | 7.91e-02 | 6.27e-02 | 7.99e-02 | 3.02e-01 | 4.84e-01 | 1.15e-01 | 2.12e-01 | 1.12e-01 |
| ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 564 | 9.28e-03 | 1.19e-01 | 0.14300 | 6.52e-02 | 5.71e-02 | 8.92e-02 | 4.22e-02 | 5.68e-02 | 8.09e-03 | 2.04e-02 | 2.92e-04 | 8.64e-02 | 2.11e-02 |
| POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY | 98 | 2.62e-01 | 7.90e-01 | 0.14300 | 6.27e-02 | 9.07e-02 | 7.56e-03 | 7.17e-02 | -5.57e-02 | 2.83e-01 | 1.21e-01 | 8.97e-01 | 2.20e-01 | 3.41e-01 |
| BRANCHING INVOLVED IN BLOOD VESSEL MORPHOGENESIS | 36 | 3.17e-01 | 8.44e-01 | 0.14300 | 2.39e-02 | -5.21e-03 | 1.27e-01 | -2.82e-02 | 5.47e-02 | 8.04e-01 | 9.57e-01 | 1.88e-01 | 7.70e-01 | 5.70e-01 |
| PRONEPHROS DEVELOPMENT | 9 | 9.19e-01 | 1.00e+00 | 0.14300 | 4.54e-02 | 1.99e-02 | 1.19e-01 | -3.21e-02 | -5.25e-02 | 8.14e-01 | 9.18e-01 | 5.36e-01 | 8.68e-01 | 7.85e-01 |
| FEMALE SEX DIFFERENTIATION | 117 | 1.73e-01 | 6.77e-01 | 0.14300 | -6.03e-02 | -6.95e-02 | -4.00e-02 | -5.74e-02 | -8.42e-02 | 2.60e-01 | 1.94e-01 | 4.54e-01 | 2.83e-01 | 1.16e-01 |
| CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 26 | 2.11e-01 | 7.33e-01 | 0.14300 | 1.93e-02 | -1.63e-02 | 8.74e-02 | -1.03e-01 | -3.90e-02 | 8.65e-01 | 8.86e-01 | 4.40e-01 | 3.63e-01 | 7.31e-01 |
| REGULATION OF DEFENSE RESPONSE TO VIRUS | 93 | 9.98e-03 | 1.25e-01 | 0.14300 | -5.16e-02 | -6.72e-02 | 5.39e-02 | -8.87e-02 | 4.92e-02 | 3.90e-01 | 2.62e-01 | 3.69e-01 | 1.39e-01 | 4.12e-01 |
| STRIATED MUSCLE CELL APOPTOTIC PROCESS | 58 | 8.15e-01 | 1.00e+00 | 0.14300 | 7.18e-02 | 6.76e-02 | 9.83e-02 | 2.71e-02 | 1.56e-02 | 3.44e-01 | 3.73e-01 | 1.95e-01 | 7.21e-01 | 8.37e-01 |
| REGULATION OF SHORT TERM NEURONAL SYNAPTIC PLASTICITY | 13 | 8.19e-01 | 1.00e+00 | 0.14300 | 5.94e-03 | 4.77e-03 | 8.26e-02 | -1.00e-01 | 5.84e-02 | 9.70e-01 | 9.76e-01 | 6.06e-01 | 5.31e-01 | 7.15e-01 |
| NUCLEAR TRANSPORT | 314 | 5.19e-03 | 7.91e-02 | 0.14300 | 5.51e-02 | 4.22e-02 | 1.00e-01 | 1.73e-03 | 7.41e-02 | 9.33e-02 | 1.99e-01 | 2.25e-03 | 9.58e-01 | 2.39e-02 |
| NADH METABOLIC PROCESS | 11 | 6.85e-01 | 1.00e+00 | 0.14300 | 1.07e-02 | -2.12e-02 | 1.05e-01 | 2.93e-02 | 8.93e-02 | 9.51e-01 | 9.03e-01 | 5.48e-01 | 8.66e-01 | 6.08e-01 |
| REGULATION OF IMMUNE RESPONSE | 875 | 1.29e-08 | 1.43e-06 | 0.14300 | -6.58e-02 | -8.56e-02 | -3.08e-03 | -8.52e-02 | 3.77e-02 | 9.51e-04 | 1.72e-05 | 8.77e-01 | 1.86e-05 | 5.84e-02 |
| TOXIN TRANSPORT | 11 | 9.64e-01 | 1.00e+00 | 0.14300 | 2.40e-02 | -1.07e-03 | 6.16e-02 | 5.10e-02 | 1.16e-01 | 8.90e-01 | 9.95e-01 | 7.23e-01 | 7.70e-01 | 5.07e-01 |
| POSITIVE REGULATION OF INTERLEUKIN 8 PRODUCTION | 61 | 1.95e-01 | 7.09e-01 | 0.14300 | -1.63e-02 | -4.08e-02 | 8.35e-02 | -8.83e-02 | 6.03e-02 | 8.26e-01 | 5.82e-01 | 2.59e-01 | 2.33e-01 | 4.16e-01 |
| GLYCEROLIPID BIOSYNTHETIC PROCESS | 236 | 2.28e-01 | 7.50e-01 | 0.14300 | 6.35e-02 | 6.26e-02 | 5.93e-02 | 6.25e-02 | 7.03e-02 | 9.26e-02 | 9.78e-02 | 1.16e-01 | 9.79e-02 | 6.28e-02 |
| REGULATION OF SYNAPTIC VESICLE MEMBRANE ORGANIZATION | 12 | 9.05e-01 | 1.00e+00 | 0.14300 | 3.94e-02 | 5.15e-02 | 7.66e-02 | 4.05e-02 | 9.27e-02 | 8.13e-01 | 7.57e-01 | 6.46e-01 | 8.08e-01 | 5.78e-01 |
| REGULATION OF MITOTIC CELL CYCLE PHASE TRANSITION | 343 | 2.02e-04 | 6.24e-03 | 0.14200 | 4.81e-02 | 3.48e-02 | 1.13e-01 | -1.12e-02 | 6.31e-02 | 1.26e-01 | 2.67e-01 | 3.41e-04 | 7.21e-01 | 4.46e-02 |
| POST EMBRYONIC DEVELOPMENT | 91 | 5.55e-01 | 9.67e-01 | 0.14200 | 6.21e-02 | 6.53e-02 | 4.87e-02 | 4.41e-02 | -8.86e-02 | 3.05e-01 | 2.82e-01 | 4.22e-01 | 4.68e-01 | 1.44e-01 |
| REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 24 | 8.94e-01 | 1.00e+00 | 0.14200 | 6.90e-02 | 8.72e-02 | 6.59e-02 | 5.89e-02 | -1.05e-02 | 5.59e-01 | 4.60e-01 | 5.76e-01 | 6.17e-01 | 9.29e-01 |
| PIGMENT CATABOLIC PROCESS | 11 | 8.54e-01 | 1.00e+00 | 0.14200 | -3.80e-02 | -6.60e-02 | 7.06e-02 | -6.05e-02 | 7.63e-02 | 8.27e-01 | 7.05e-01 | 6.85e-01 | 7.28e-01 | 6.61e-01 |
| EXTRACELLULAR MATRIX ASSEMBLY | 42 | 4.79e-01 | 9.42e-01 | 0.14200 | 6.43e-02 | 7.76e-02 | 8.35e-02 | 4.41e-02 | -3.42e-02 | 4.71e-01 | 3.84e-01 | 3.49e-01 | 6.21e-01 | 7.01e-01 |
| SELF PROTEOLYSIS | 12 | 9.58e-01 | 1.00e+00 | 0.14200 | -4.98e-02 | -6.97e-02 | 3.76e-02 | -9.57e-02 | 4.83e-02 | 7.65e-01 | 6.76e-01 | 8.21e-01 | 5.66e-01 | 7.72e-01 |
| HEMATOPOIETIC PROGENITOR CELL DIFFERENTIATION | 132 | 1.60e-01 | 6.59e-01 | 0.14200 | 6.51e-02 | 4.71e-02 | 1.15e-01 | 1.08e-02 | 2.28e-02 | 1.97e-01 | 3.50e-01 | 2.29e-02 | 8.31e-01 | 6.52e-01 |
| CELLULAR RESPONSE TO SALT | 192 | 5.49e-02 | 3.84e-01 | 0.14200 | 6.77e-02 | 5.42e-02 | 1.12e-01 | 1.38e-02 | 9.00e-03 | 1.06e-01 | 1.96e-01 | 7.70e-03 | 7.41e-01 | 8.30e-01 |
| L GLUTAMATE TRANSMEMBRANE TRANSPORT | 28 | 6.15e-01 | 9.90e-01 | 0.14200 | 2.90e-02 | 6.04e-02 | -5.18e-02 | 1.05e-01 | -4.59e-02 | 7.90e-01 | 5.80e-01 | 6.35e-01 | 3.38e-01 | 6.74e-01 |
| BRANCHED CHAIN AMINO ACID CATABOLIC PROCESS | 20 | 9.75e-01 | 1.00e+00 | 0.14200 | 7.27e-02 | 5.59e-02 | 7.64e-02 | 5.46e-02 | 5.46e-02 | 5.74e-01 | 6.65e-01 | 5.54e-01 | 6.73e-01 | 6.72e-01 |
| GLAND MORPHOGENESIS | 120 | 2.59e-01 | 7.87e-01 | 0.14200 | 6.70e-02 | 6.40e-02 | 6.41e-02 | 7.61e-02 | -4.15e-02 | 2.05e-01 | 2.26e-01 | 2.25e-01 | 1.50e-01 | 4.32e-01 |
| ISOPRENOID BIOSYNTHETIC PROCESS | 29 | 8.57e-01 | 1.00e+00 | 0.14200 | -7.05e-02 | -8.24e-02 | -4.82e-03 | -7.29e-02 | 5.54e-02 | 5.11e-01 | 4.42e-01 | 9.64e-01 | 4.97e-01 | 6.06e-01 |
| REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 37 | 5.20e-01 | 9.53e-01 | 0.14200 | 6.20e-02 | 4.44e-02 | 1.16e-01 | -3.08e-02 | 1.35e-04 | 5.14e-01 | 6.41e-01 | 2.24e-01 | 7.46e-01 | 9.99e-01 |
| REGULATION OF STEM CELL POPULATION MAINTENANCE | 71 | 1.30e-01 | 5.98e-01 | 0.14200 | 5.10e-02 | 4.55e-02 | 1.12e-01 | 2.92e-02 | 4.62e-02 | 4.58e-01 | 5.07e-01 | 1.04e-01 | 6.70e-01 | 5.01e-01 |
| TOLL SIGNALING PATHWAY | 10 | 9.91e-01 | 1.00e+00 | 0.14200 | -6.28e-02 | -5.96e-02 | -4.23e-02 | -1.03e-01 | -1.23e-02 | 7.31e-01 | 7.44e-01 | 8.17e-01 | 5.72e-01 | 9.46e-01 |
| REGULATION OF ADENYLATE CYCLASE ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 14 | 8.51e-01 | 1.00e+00 | 0.14200 | 4.91e-02 | 3.99e-02 | 5.82e-02 | 6.39e-02 | -9.27e-02 | 7.50e-01 | 7.96e-01 | 7.06e-01 | 6.79e-01 | 5.48e-01 |
| RESPONSE TO NERVE GROWTH FACTOR | 47 | 8.07e-01 | 1.00e+00 | 0.14200 | -4.45e-02 | -3.02e-02 | -6.96e-02 | -2.31e-02 | -1.09e-01 | 5.98e-01 | 7.20e-01 | 4.09e-01 | 7.84e-01 | 1.98e-01 |
| FATTY ACID ELONGATION SATURATED FATTY ACID | 7 | 9.07e-01 | 1.00e+00 | 0.14200 | 2.43e-02 | 5.46e-03 | 6.87e-02 | 8.36e-03 | -1.21e-01 | 9.11e-01 | 9.80e-01 | 7.53e-01 | 9.69e-01 | 5.79e-01 |
| REPRODUCTIVE BEHAVIOR | 42 | 4.55e-01 | 9.31e-01 | 0.14200 | 5.51e-02 | 9.19e-02 | -7.41e-03 | 8.86e-02 | -2.55e-02 | 5.36e-01 | 3.03e-01 | 9.34e-01 | 3.21e-01 | 7.74e-01 |
| PHOSPHOLIPID DEPHOSPHORYLATION | 37 | 9.13e-01 | 1.00e+00 | 0.14200 | -7.39e-02 | -8.68e-02 | -6.25e-02 | -4.54e-02 | 3.27e-02 | 4.37e-01 | 3.61e-01 | 5.10e-01 | 6.33e-01 | 7.31e-01 |
| NEGATIVE REGULATION OF CELL SUBSTRATE JUNCTION ORGANIZATION | 15 | 8.93e-01 | 1.00e+00 | 0.14100 | 4.62e-02 | 6.52e-02 | 3.10e-02 | 8.98e-02 | 6.79e-02 | 7.57e-01 | 6.62e-01 | 8.35e-01 | 5.47e-01 | 6.49e-01 |
| ORGAN INDUCTION | 22 | 5.30e-01 | 9.54e-01 | 0.14100 | 1.29e-02 | -1.29e-02 | 8.42e-02 | -6.26e-02 | -9.32e-02 | 9.16e-01 | 9.17e-01 | 4.94e-01 | 6.11e-01 | 4.49e-01 |
| DICARBOXYLIC ACID METABOLIC PROCESS | 92 | 1.78e-01 | 6.85e-01 | 0.14100 | -7.75e-02 | -5.87e-02 | -4.06e-02 | -9.42e-02 | -4.66e-03 | 1.99e-01 | 3.31e-01 | 5.01e-01 | 1.18e-01 | 9.38e-01 |
| ENDOPLASMIC RETICULUM MEMBRANE ORGANIZATION | 12 | 9.94e-01 | 1.00e+00 | 0.14100 | 7.99e-02 | 6.38e-02 | 8.07e-02 | 5.48e-02 | -1.26e-03 | 6.32e-01 | 7.02e-01 | 6.28e-01 | 7.42e-01 | 9.94e-01 |
| ADHERENS JUNCTION ASSEMBLY | 13 | 9.74e-01 | 1.00e+00 | 0.14100 | -1.53e-02 | -3.38e-02 | 5.18e-02 | -3.10e-02 | 1.22e-01 | 9.24e-01 | 8.33e-01 | 7.46e-01 | 8.46e-01 | 4.46e-01 |
| REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO OXIDATIVE STRESS | 7 | 9.43e-01 | 1.00e+00 | 0.14100 | 5.19e-02 | 6.39e-02 | 1.14e-01 | -5.61e-03 | 1.40e-02 | 8.12e-01 | 7.70e-01 | 6.02e-01 | 9.79e-01 | 9.49e-01 |
| NEURAL CREST CELL DIFFERENTIATION | 93 | 4.61e-01 | 9.32e-01 | 0.14100 | 6.60e-02 | 6.11e-02 | 6.55e-02 | 3.15e-02 | -8.09e-02 | 2.72e-01 | 3.08e-01 | 2.75e-01 | 6.00e-01 | 1.77e-01 |
| HEART VALVE DEVELOPMENT | 72 | 1.87e-01 | 6.95e-01 | 0.14100 | 4.96e-02 | 2.58e-02 | 1.26e-01 | -1.47e-02 | 2.64e-02 | 4.67e-01 | 7.05e-01 | 6.45e-02 | 8.29e-01 | 6.99e-01 |
| RESPONSE TO VIRUS | 422 | 2.55e-04 | 7.60e-03 | 0.14100 | -6.75e-02 | -7.13e-02 | -3.76e-03 | -9.20e-02 | 4.21e-02 | 1.74e-02 | 1.20e-02 | 8.95e-01 | 1.18e-03 | 1.38e-01 |
| MITOTIC CYTOKINESIS | 85 | 1.44e-01 | 6.29e-01 | 0.14100 | 5.69e-02 | 5.54e-02 | 1.15e-01 | 7.43e-04 | 1.94e-02 | 3.64e-01 | 3.78e-01 | 6.73e-02 | 9.91e-01 | 7.57e-01 |
| NEGATIVE REGULATION OF CYCLASE ACTIVITY | 15 | 9.23e-01 | 1.00e+00 | 0.14100 | -6.35e-02 | -4.57e-02 | -4.98e-02 | -9.83e-02 | 3.99e-02 | 6.70e-01 | 7.59e-01 | 7.38e-01 | 5.10e-01 | 7.89e-01 |
| RESPONSE TO PURINE CONTAINING COMPOUND | 137 | 1.55e-01 | 6.52e-01 | 0.14100 | 6.75e-02 | 6.03e-02 | 9.34e-02 | 5.32e-02 | -8.93e-03 | 1.72e-01 | 2.23e-01 | 5.91e-02 | 2.82e-01 | 8.57e-01 |
| T CELL DIFFERENTIATION | 301 | 7.54e-04 | 1.80e-02 | 0.14100 | -6.09e-02 | -7.69e-02 | 1.58e-02 | -9.27e-02 | 3.71e-02 | 6.92e-02 | 2.18e-02 | 6.37e-01 | 5.66e-03 | 2.68e-01 |
| NEGATIVE REGULATION OF SMOOTHENED SIGNALING PATHWAY | 33 | 8.20e-01 | 1.00e+00 | 0.14100 | -4.51e-02 | -7.28e-02 | 1.37e-02 | -5.97e-02 | 9.36e-02 | 6.54e-01 | 4.69e-01 | 8.92e-01 | 5.53e-01 | 3.52e-01 |
| NEGATIVE REGULATION OF DNA METABOLIC PROCESS | 135 | 4.44e-02 | 3.39e-01 | 0.14100 | 3.15e-02 | 1.72e-02 | 1.07e-01 | -3.05e-02 | 7.78e-02 | 5.27e-01 | 7.30e-01 | 3.10e-02 | 5.40e-01 | 1.19e-01 |
| DEVELOPMENT OF PRIMARY FEMALE SEXUAL CHARACTERISTICS | 102 | 2.64e-01 | 7.92e-01 | 0.14100 | -5.60e-02 | -6.36e-02 | -4.14e-02 | -5.19e-02 | -9.08e-02 | 3.28e-01 | 2.67e-01 | 4.70e-01 | 3.65e-01 | 1.13e-01 |
| IRON ION TRANSPORT | 53 | 8.43e-01 | 1.00e+00 | 0.14100 | -5.76e-02 | -6.60e-02 | -1.40e-02 | -5.94e-02 | 9.15e-02 | 4.68e-01 | 4.06e-01 | 8.60e-01 | 4.54e-01 | 2.49e-01 |
| NEGATIVE REGULATION OF AUTOPHAGOSOME ASSEMBLY | 12 | 8.26e-01 | 1.00e+00 | 0.14100 | -2.25e-02 | -3.27e-02 | -7.36e-02 | 5.57e-02 | 9.84e-02 | 8.93e-01 | 8.45e-01 | 6.59e-01 | 7.38e-01 | 5.55e-01 |
| NON MOTILE CILIUM ASSEMBLY | 63 | 5.34e-01 | 9.56e-01 | 0.14100 | -5.54e-02 | -5.77e-02 | 5.26e-03 | -1.08e-01 | 3.98e-02 | 4.47e-01 | 4.28e-01 | 9.42e-01 | 1.37e-01 | 5.85e-01 |
| GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 286 | 1.85e-01 | 6.94e-01 | 0.14100 | 6.56e-02 | 6.48e-02 | 5.90e-02 | 6.35e-02 | 6.11e-02 | 5.61e-02 | 5.95e-02 | 8.58e-02 | 6.48e-02 | 7.54e-02 |
| RRNA CATABOLIC PROCESS | 21 | 6.36e-01 | 9.98e-01 | 0.14000 | 6.02e-02 | 2.63e-02 | 1.18e-01 | -3.18e-02 | -2.13e-02 | 6.33e-01 | 8.34e-01 | 3.49e-01 | 8.01e-01 | 8.66e-01 |
| NEGATIVE REGULATION OF CHEMOKINE PRODUCTION | 29 | 5.91e-01 | 9.86e-01 | 0.14000 | -7.12e-03 | -1.12e-02 | -3.03e-02 | -5.26e-02 | -1.26e-01 | 9.47e-01 | 9.17e-01 | 7.78e-01 | 6.24e-01 | 2.40e-01 |
| PYRAMIDAL NEURON DEVELOPMENT | 9 | 9.91e-01 | 1.00e+00 | 0.14000 | -1.96e-02 | -1.07e-02 | -6.18e-02 | 1.09e-02 | -1.24e-01 | 9.19e-01 | 9.56e-01 | 7.48e-01 | 9.55e-01 | 5.21e-01 |
| STEROL TRANSPORT | 141 | 2.23e-01 | 7.45e-01 | 0.14000 | 6.61e-02 | 8.47e-02 | 3.47e-02 | 8.28e-02 | 1.02e-02 | 1.75e-01 | 8.24e-02 | 4.77e-01 | 8.96e-02 | 8.35e-01 |
| STRESS GRANULE ASSEMBLY | 29 | 7.92e-01 | 1.00e+00 | 0.14000 | -7.16e-02 | -6.91e-02 | -7.61e-03 | -9.85e-02 | 6.39e-03 | 5.04e-01 | 5.19e-01 | 9.43e-01 | 3.59e-01 | 9.52e-01 |
| POSITIVE REGULATION OF LIPID STORAGE | 27 | 9.43e-01 | 1.00e+00 | 0.14000 | 7.63e-02 | 8.91e-02 | 6.30e-02 | 4.21e-02 | -1.22e-02 | 4.92e-01 | 4.23e-01 | 5.71e-01 | 7.05e-01 | 9.13e-01 |
| POSITIVE REGULATION OF RNA METABOLIC PROCESS | 1810 | 4.38e-21 | 4.12e-18 | 0.14000 | 5.41e-02 | 3.74e-02 | 1.13e-01 | -6.97e-04 | 5.02e-02 | 1.33e-04 | 8.32e-03 | 1.26e-15 | 9.61e-01 | 3.94e-04 |
| NEGATIVE REGULATION OF RECEPTOR SIGNALING PATHWAY VIA STAT | 33 | 3.89e-01 | 8.92e-01 | 0.14000 | 3.86e-02 | 6.96e-02 | -5.79e-02 | 4.33e-02 | -8.99e-02 | 7.01e-01 | 4.89e-01 | 5.65e-01 | 6.67e-01 | 3.71e-01 |
| TRNA METABOLIC PROCESS | 190 | 4.22e-04 | 1.14e-02 | 0.14000 | 9.80e-03 | -2.11e-03 | 1.00e-01 | -6.82e-02 | 6.92e-02 | 8.16e-01 | 9.60e-01 | 1.69e-02 | 1.05e-01 | 1.00e-01 |
| PHOTORECEPTOR CELL DIFFERENTIATION | 63 | 6.18e-01 | 9.90e-01 | 0.14000 | 5.29e-02 | 7.40e-02 | 1.19e-02 | 3.88e-02 | -9.85e-02 | 4.67e-01 | 3.10e-01 | 8.70e-01 | 5.95e-01 | 1.76e-01 |
| LIPID EXPORT FROM CELL | 47 | 3.94e-01 | 8.93e-01 | 0.14000 | -2.16e-02 | -3.70e-02 | 6.25e-02 | -3.47e-02 | 1.13e-01 | 7.98e-01 | 6.61e-01 | 4.59e-01 | 6.80e-01 | 1.81e-01 |
| POTASSIUM ION HOMEOSTASIS | 34 | 7.34e-01 | 1.00e+00 | 0.14000 | 5.49e-02 | 7.19e-02 | 3.97e-02 | 2.98e-03 | -9.92e-02 | 5.80e-01 | 4.68e-01 | 6.88e-01 | 9.76e-01 | 3.17e-01 |
| POSITIVE REGULATION OF GLUTAMATE SECRETION | 11 | 8.26e-01 | 1.00e+00 | 0.14000 | 1.99e-02 | -1.42e-02 | 1.06e-01 | -7.92e-02 | -3.76e-02 | 9.09e-01 | 9.35e-01 | 5.41e-01 | 6.49e-01 | 8.29e-01 |
| NEGATIVE REGULATION OF PEPTIDASE ACTIVITY | 126 | 3.13e-01 | 8.40e-01 | 0.14000 | -6.63e-02 | -6.25e-02 | -2.08e-02 | -1.01e-01 | 2.68e-02 | 1.98e-01 | 2.26e-01 | 6.87e-01 | 5.08e-02 | 6.04e-01 |
| POSITIVE REGULATION OF AUTOPHAGOSOME ASSEMBLY | 18 | 9.19e-01 | 1.00e+00 | 0.14000 | 6.22e-02 | 4.65e-02 | 1.16e-01 | 1.09e-02 | -6.05e-03 | 6.48e-01 | 7.32e-01 | 3.95e-01 | 9.36e-01 | 9.65e-01 |
| NEGATIVE REGULATION OF BLOOD PRESSURE | 46 | 7.53e-01 | 1.00e+00 | 0.14000 | 5.98e-02 | 5.37e-02 | 1.64e-02 | 8.42e-02 | -7.59e-02 | 4.83e-01 | 5.29e-01 | 8.48e-01 | 3.23e-01 | 3.73e-01 |
| REGULATION OF PROTEIN TARGETING | 76 | 3.80e-01 | 8.87e-01 | 0.14000 | 3.87e-02 | 3.30e-02 | 8.94e-02 | 2.39e-02 | 9.18e-02 | 5.59e-01 | 6.19e-01 | 1.78e-01 | 7.19e-01 | 1.66e-01 |
| CELLULAR RESPONSE TO POTASSIUM ION | 12 | 9.64e-01 | 1.00e+00 | 0.14000 | 6.95e-02 | 7.90e-02 | 8.96e-02 | 4.30e-03 | 2.13e-02 | 6.77e-01 | 6.36e-01 | 5.91e-01 | 9.79e-01 | 8.98e-01 |
| POSTSYNAPSE ASSEMBLY | 35 | 7.43e-01 | 1.00e+00 | 0.14000 | 5.61e-02 | 6.09e-02 | 6.50e-02 | 3.36e-02 | -8.57e-02 | 5.65e-01 | 5.33e-01 | 5.06e-01 | 7.31e-01 | 3.80e-01 |
| VAGINA DEVELOPMENT | 10 | 9.01e-01 | 1.00e+00 | 0.14000 | 1.45e-02 | -6.44e-03 | 6.74e-02 | -7.12e-02 | -9.84e-02 | 9.37e-01 | 9.72e-01 | 7.12e-01 | 6.97e-01 | 5.90e-01 |
| CIRCADIAN SLEEP WAKE CYCLE | 21 | 7.92e-01 | 1.00e+00 | 0.14000 | -8.25e-03 | -3.31e-02 | 8.92e-02 | -5.37e-02 | 8.68e-02 | 9.48e-01 | 7.93e-01 | 4.79e-01 | 6.70e-01 | 4.91e-01 |
| POSITIVE REGULATION OF TYPE I INTERFERON MEDIATED SIGNALING PATHWAY | 19 | 6.68e-01 | 1.00e+00 | 0.14000 | -9.15e-03 | -5.53e-02 | 9.31e-02 | -6.08e-02 | 6.35e-02 | 9.45e-01 | 6.77e-01 | 4.82e-01 | 6.47e-01 | 6.32e-01 |
| REGULATION OF RESPIRATORY BURST | 16 | 8.36e-01 | 1.00e+00 | 0.14000 | 6.15e-02 | 3.73e-02 | 9.19e-02 | 7.64e-02 | -8.72e-03 | 6.70e-01 | 7.96e-01 | 5.24e-01 | 5.97e-01 | 9.52e-01 |
| REGULATION OF CILIUM ASSEMBLY | 93 | 2.14e-01 | 7.37e-01 | 0.14000 | -4.06e-03 | -1.79e-02 | 6.63e-02 | -2.19e-02 | 1.20e-01 | 9.46e-01 | 7.65e-01 | 2.69e-01 | 7.16e-01 | 4.62e-02 |
| TRNA PROCESSING | 128 | 6.07e-03 | 8.83e-02 | 0.14000 | 7.25e-03 | -4.60e-03 | 1.01e-01 | -7.12e-02 | 6.36e-02 | 8.87e-01 | 9.28e-01 | 4.74e-02 | 1.64e-01 | 2.14e-01 |
| ORGANONITROGEN COMPOUND BIOSYNTHETIC PROCESS | 1764 | 7.30e-12 | 1.83e-09 | 0.14000 | 6.86e-02 | 6.35e-02 | 9.78e-02 | 2.69e-02 | 2.12e-02 | 1.69e-06 | 9.19e-06 | 8.35e-12 | 6.05e-02 | 1.39e-01 |
| SUPPRESSION OF VIRAL RELEASE BY HOST | 15 | 7.74e-01 | 1.00e+00 | 0.13900 | -2.94e-02 | -5.48e-02 | 8.00e-02 | -9.38e-02 | 1.97e-02 | 8.44e-01 | 7.13e-01 | 5.91e-01 | 5.29e-01 | 8.95e-01 |
| REGULATION OF ASTROCYTE DIFFERENTIATION | 31 | 4.77e-01 | 9.40e-01 | 0.13900 | 4.55e-02 | 2.22e-02 | 1.16e-01 | -5.75e-02 | 3.34e-03 | 6.61e-01 | 8.31e-01 | 2.62e-01 | 5.79e-01 | 9.74e-01 |
| B CELL MEDIATED IMMUNITY | 130 | 2.26e-02 | 2.25e-01 | 0.13900 | -2.01e-02 | -4.99e-02 | 6.94e-02 | -7.95e-02 | 7.35e-02 | 6.92e-01 | 3.26e-01 | 1.72e-01 | 1.18e-01 | 1.48e-01 |
| CARDIAC MUSCLE CELL ACTION POTENTIAL INVOLVED IN CONTRACTION | 51 | 1.78e-01 | 6.85e-01 | 0.13900 | 5.00e-03 | 4.12e-02 | -5.68e-02 | 6.68e-02 | -1.00e-01 | 9.51e-01 | 6.11e-01 | 4.83e-01 | 4.09e-01 | 2.16e-01 |
| REGULATION OF VASCULOGENESIS | 16 | 8.87e-01 | 1.00e+00 | 0.13900 | 8.92e-04 | -4.32e-03 | 8.32e-02 | -5.04e-02 | 9.97e-02 | 9.95e-01 | 9.76e-01 | 5.65e-01 | 7.27e-01 | 4.90e-01 |
| REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY | 102 | 4.81e-01 | 9.43e-01 | 0.13900 | 6.52e-02 | 8.19e-02 | 2.45e-02 | 8.86e-02 | 4.74e-03 | 2.55e-01 | 1.53e-01 | 6.70e-01 | 1.22e-01 | 9.34e-01 |
| PROTEIN LOCALIZATION TO NUCLEAR ENVELOPE | 13 | 9.38e-01 | 1.00e+00 | 0.13900 | -9.68e-03 | -1.26e-02 | 5.27e-02 | -7.28e-02 | 1.05e-01 | 9.52e-01 | 9.37e-01 | 7.42e-01 | 6.49e-01 | 5.12e-01 |
| NEURON PROJECTION ARBORIZATION | 31 | 6.32e-01 | 9.96e-01 | 0.13900 | 5.00e-02 | 5.22e-02 | 3.72e-02 | 8.34e-02 | -7.63e-02 | 6.30e-01 | 6.15e-01 | 7.20e-01 | 4.22e-01 | 4.62e-01 |
| CELL CYCLE | 1738 | 1.22e-18 | 7.66e-16 | 0.13900 | 5.77e-02 | 4.28e-02 | 1.10e-01 | -2.74e-04 | 4.49e-02 | 6.33e-05 | 3.02e-03 | 1.89e-14 | 9.85e-01 | 1.84e-03 |
| MODIFICATION OF SYNAPTIC STRUCTURE | 27 | 6.52e-01 | 1.00e+00 | 0.13900 | 5.72e-02 | 3.20e-02 | 6.43e-02 | 5.40e-02 | -8.94e-02 | 6.07e-01 | 7.73e-01 | 5.63e-01 | 6.27e-01 | 4.21e-01 |
| DUMP METABOLIC PROCESS | 7 | 9.74e-01 | 1.00e+00 | 0.13900 | 4.08e-02 | 2.03e-02 | 4.38e-02 | 1.01e-01 | 7.14e-02 | 8.52e-01 | 9.26e-01 | 8.41e-01 | 6.43e-01 | 7.44e-01 |
| VITAMIN TRANSPORT | 52 | 7.99e-01 | 1.00e+00 | 0.13900 | 5.82e-02 | 5.44e-02 | 6.12e-02 | 8.20e-02 | 5.02e-02 | 4.68e-01 | 4.97e-01 | 4.45e-01 | 3.06e-01 | 5.31e-01 |
| SURFACTANT HOMEOSTASIS | 17 | 8.04e-01 | 1.00e+00 | 0.13900 | -6.63e-02 | -2.92e-02 | -9.76e-02 | -1.43e-02 | -6.59e-02 | 6.36e-01 | 8.35e-01 | 4.86e-01 | 9.19e-01 | 6.38e-01 |
| CELL DIVISION | 614 | 1.29e-07 | 1.14e-05 | 0.13900 | 5.87e-02 | 4.02e-02 | 1.16e-01 | 9.47e-03 | 2.78e-02 | 1.29e-02 | 8.90e-02 | 9.78e-07 | 6.88e-01 | 2.39e-01 |
| RESPONSE TO CORTICOSTEROID | 143 | 2.59e-01 | 7.86e-01 | 0.13900 | 7.05e-02 | 8.39e-02 | 6.76e-02 | 4.72e-02 | -2.18e-02 | 1.46e-01 | 8.34e-02 | 1.63e-01 | 3.30e-01 | 6.52e-01 |
| PROTEIN TARGETING TO MITOCHONDRION | 101 | 2.67e-01 | 7.95e-01 | 0.13900 | 4.24e-02 | 2.38e-02 | 1.04e-01 | -1.38e-02 | 7.67e-02 | 4.62e-01 | 6.80e-01 | 7.08e-02 | 8.10e-01 | 1.83e-01 |
| CHONDROITIN SULFATE PROTEOGLYCAN METABOLIC PROCESS | 31 | 6.66e-01 | 1.00e+00 | 0.13900 | -4.75e-02 | -5.51e-02 | -2.67e-02 | -4.02e-02 | -1.08e-01 | 6.47e-01 | 5.95e-01 | 7.97e-01 | 6.99e-01 | 2.99e-01 |
| POSITIVE REGULATION OF SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 15 | 8.29e-01 | 1.00e+00 | 0.13900 | -5.99e-03 | -1.24e-02 | 3.07e-02 | -6.90e-02 | 1.15e-01 | 9.68e-01 | 9.34e-01 | 8.37e-01 | 6.44e-01 | 4.39e-01 |
| HEART FORMATION | 33 | 5.92e-01 | 9.86e-01 | 0.13900 | -3.57e-02 | -4.61e-02 | 3.23e-02 | -1.11e-01 | -5.05e-02 | 7.22e-01 | 6.46e-01 | 7.48e-01 | 2.72e-01 | 6.15e-01 |
| IMMUNE SYSTEM DEVELOPMENT | 198 | 1.18e-03 | 2.61e-02 | 0.13900 | -1.04e-02 | -4.03e-02 | 8.02e-02 | -7.07e-02 | 7.77e-02 | 8.00e-01 | 3.29e-01 | 5.17e-02 | 8.65e-02 | 5.93e-02 |
| POSITIVE REGULATION OF MONOCYTE CHEMOTACTIC PROTEIN 1 PRODUCTION | 15 | 8.02e-01 | 1.00e+00 | 0.13900 | -3.46e-02 | -7.26e-02 | 6.10e-02 | -9.44e-02 | 9.19e-03 | 8.16e-01 | 6.27e-01 | 6.82e-01 | 5.27e-01 | 9.51e-01 |
| BENZENE CONTAINING COMPOUND METABOLIC PROCESS | 26 | 9.23e-01 | 1.00e+00 | 0.13800 | 3.69e-02 | 4.05e-02 | -4.52e-03 | 5.24e-02 | -1.16e-01 | 7.44e-01 | 7.20e-01 | 9.68e-01 | 6.44e-01 | 3.07e-01 |
| REGULATION OF CELLULAR RESPONSE TO STRESS | 629 | 1.11e-06 | 6.98e-05 | 0.13800 | 4.11e-02 | 2.97e-02 | 9.95e-02 | -5.09e-03 | 8.17e-02 | 7.82e-02 | 2.03e-01 | 2.05e-05 | 8.28e-01 | 4.66e-04 |
| REGULATION OF OLIGODENDROCYTE DIFFERENTIATION | 45 | 2.42e-01 | 7.67e-01 | 0.13800 | -3.02e-03 | -1.30e-02 | 8.04e-02 | -1.07e-01 | 3.23e-02 | 9.72e-01 | 8.80e-01 | 3.51e-01 | 2.14e-01 | 7.08e-01 |
| RESPONSE TO INTERFERON BETA | 33 | 6.94e-01 | 1.00e+00 | 0.13800 | -6.24e-02 | -5.08e-02 | -4.10e-03 | -9.86e-02 | 5.42e-02 | 5.35e-01 | 6.13e-01 | 9.67e-01 | 3.27e-01 | 5.90e-01 |
| NEGATIVE REGULATION OF CELL JUNCTION ASSEMBLY | 30 | 7.90e-01 | 1.00e+00 | 0.13800 | 3.26e-02 | 2.06e-02 | 9.51e-02 | 1.47e-02 | 9.17e-02 | 7.58e-01 | 8.45e-01 | 3.67e-01 | 8.89e-01 | 3.85e-01 |
| PROTEIN DEPOLYMERIZATION | 112 | 7.98e-01 | 1.00e+00 | 0.13800 | 7.03e-02 | 7.25e-02 | 6.25e-02 | 7.07e-02 | 6.04e-03 | 1.98e-01 | 1.85e-01 | 2.53e-01 | 1.96e-01 | 9.12e-01 |
| RESPONSE TO PROSTAGLANDIN E | 23 | 8.77e-01 | 1.00e+00 | 0.13800 | -6.96e-02 | -4.18e-02 | -6.34e-02 | -8.18e-02 | -4.25e-02 | 5.64e-01 | 7.28e-01 | 5.99e-01 | 4.97e-01 | 7.24e-01 |
| REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 58 | 5.11e-01 | 9.51e-01 | 0.13800 | -5.89e-02 | -6.39e-02 | 1.30e-02 | -1.05e-01 | 2.02e-02 | 4.38e-01 | 4.00e-01 | 8.64e-01 | 1.68e-01 | 7.90e-01 |
| POSITIVE REGULATION OF HEMOPOIESIS | 181 | 3.43e-02 | 2.95e-01 | 0.13800 | -3.95e-02 | -6.31e-02 | 3.56e-02 | -6.67e-02 | 8.85e-02 | 3.59e-01 | 1.43e-01 | 4.08e-01 | 1.22e-01 | 4.01e-02 |
| GLIAL CELL APOPTOTIC PROCESS | 15 | 9.90e-01 | 1.00e+00 | 0.13800 | -7.17e-02 | -7.86e-02 | -2.25e-02 | -8.38e-02 | 1.50e-02 | 6.31e-01 | 5.98e-01 | 8.80e-01 | 5.74e-01 | 9.20e-01 |
| POSITIVE REGULATION OF AXONOGENESIS | 72 | 7.98e-01 | 1.00e+00 | 0.13800 | -7.37e-02 | -8.29e-02 | -5.51e-02 | -4.63e-02 | 3.96e-02 | 2.79e-01 | 2.24e-01 | 4.18e-01 | 4.97e-01 | 5.62e-01 |
| TYROSINE CATABOLIC PROCESS | 6 | 9.52e-01 | 1.00e+00 | 0.13800 | 5.15e-02 | 7.41e-02 | 9.70e-02 | 1.07e-02 | 3.69e-02 | 8.27e-01 | 7.53e-01 | 6.81e-01 | 9.64e-01 | 8.76e-01 |
| DNA MODIFICATION | 99 | 3.31e-01 | 8.55e-01 | 0.13800 | -5.10e-02 | -5.74e-02 | 1.40e-02 | -9.55e-02 | 6.16e-02 | 3.81e-01 | 3.23e-01 | 8.10e-01 | 1.00e-01 | 2.89e-01 |
| SEQUESTERING OF CALCIUM ION | 138 | 2.16e-01 | 7.38e-01 | 0.13800 | -5.70e-02 | -7.64e-02 | 7.82e-03 | -7.76e-02 | 6.20e-02 | 2.48e-01 | 1.21e-01 | 8.74e-01 | 1.15e-01 | 2.09e-01 |
| CARDIAC SEPTUM MORPHOGENESIS | 72 | 3.03e-02 | 2.72e-01 | 0.13800 | 1.48e-02 | -1.08e-02 | 8.07e-02 | -6.92e-02 | -8.58e-02 | 8.28e-01 | 8.74e-01 | 2.37e-01 | 3.10e-01 | 2.08e-01 |
| WOUND HEALING SPREADING OF EPIDERMAL CELLS | 21 | 8.90e-01 | 1.00e+00 | 0.13800 | -3.65e-02 | -3.45e-02 | -9.43e-02 | 2.29e-02 | -8.39e-02 | 7.72e-01 | 7.85e-01 | 4.54e-01 | 8.56e-01 | 5.05e-01 |
| HEMATOPOIETIC OR LYMPHOID ORGAN DEVELOPMENT | 98 | 2.10e-01 | 7.33e-01 | 0.13800 | 4.64e-02 | 2.09e-02 | 1.11e-01 | -1.10e-02 | 6.37e-02 | 4.27e-01 | 7.21e-01 | 5.87e-02 | 8.51e-01 | 2.76e-01 |
| POSITIVE REGULATION OF PROTEIN UBIQUITINATION | 100 | 3.83e-01 | 8.92e-01 | 0.13800 | 3.43e-02 | 2.76e-02 | 7.97e-02 | 1.79e-02 | 1.02e-01 | 5.54e-01 | 6.34e-01 | 1.68e-01 | 7.57e-01 | 7.87e-02 |
| MODULATION OF EXCITATORY POSTSYNAPTIC POTENTIAL | 47 | 7.24e-01 | 1.00e+00 | 0.13800 | 4.30e-02 | 5.59e-02 | -1.15e-03 | 7.63e-02 | -9.04e-02 | 6.10e-01 | 5.08e-01 | 9.89e-01 | 3.65e-01 | 2.84e-01 |
| RESPONSE TO PLATELET DERIVED GROWTH FACTOR | 21 | 9.41e-01 | 1.00e+00 | 0.13800 | 5.63e-02 | 7.83e-02 | 1.59e-02 | 7.55e-02 | -6.08e-02 | 6.55e-01 | 5.34e-01 | 9.00e-01 | 5.49e-01 | 6.30e-01 |
| ENDODERMAL CELL DIFFERENTIATION | 48 | 2.77e-01 | 8.04e-01 | 0.13800 | 1.79e-02 | -3.30e-03 | 3.35e-02 | -2.23e-02 | -1.30e-01 | 8.30e-01 | 9.68e-01 | 6.88e-01 | 7.89e-01 | 1.18e-01 |
| LENS MORPHOGENESIS IN CAMERA TYPE EYE | 21 | 5.74e-01 | 9.79e-01 | 0.13800 | 3.07e-02 | 2.99e-02 | 5.34e-02 | 3.11e-02 | -1.15e-01 | 8.07e-01 | 8.12e-01 | 6.72e-01 | 8.05e-01 | 3.61e-01 |
| REGULATION OF ARP2 3 COMPLEX MEDIATED ACTIN NUCLEATION | 29 | 8.88e-01 | 1.00e+00 | 0.13800 | 5.81e-02 | 3.40e-02 | 1.08e-01 | 2.69e-02 | 4.53e-02 | 5.88e-01 | 7.51e-01 | 3.15e-01 | 8.02e-01 | 6.73e-01 |
| REGULATION OF NUCLEAR TRANSCRIBED MRNA POLY A TAIL SHORTENING | 15 | 6.67e-01 | 1.00e+00 | 0.13800 | -2.98e-02 | 1.76e-02 | -1.17e-01 | 6.21e-02 | -1.42e-02 | 8.42e-01 | 9.06e-01 | 4.33e-01 | 6.77e-01 | 9.24e-01 |
| NEUTROPHIL APOPTOTIC PROCESS | 8 | 8.39e-01 | 1.00e+00 | 0.13700 | -5.37e-02 | -1.10e-01 | 2.59e-02 | -5.37e-02 | 1.72e-02 | 7.93e-01 | 5.89e-01 | 8.99e-01 | 7.93e-01 | 9.33e-01 |
| RNA STABILIZATION | 66 | 5.88e-01 | 9.85e-01 | 0.13700 | 3.27e-02 | 1.91e-02 | 7.76e-02 | 3.15e-02 | 1.02e-01 | 6.46e-01 | 7.88e-01 | 2.76e-01 | 6.59e-01 | 1.51e-01 |
| CELL CYCLE G1 S PHASE TRANSITION | 264 | 1.31e-02 | 1.51e-01 | 0.13700 | 6.19e-02 | 6.18e-02 | 9.72e-02 | 7.15e-03 | 4.17e-02 | 8.35e-02 | 8.40e-02 | 6.52e-03 | 8.42e-01 | 2.43e-01 |
| SENSORY PERCEPTION OF LIGHT STIMULUS | 208 | 8.96e-03 | 1.16e-01 | 0.13700 | 4.23e-02 | 6.41e-02 | -3.37e-02 | 9.52e-02 | -5.24e-02 | 2.92e-01 | 1.11e-01 | 4.02e-01 | 1.79e-02 | 1.93e-01 |
| MESENCHYMAL CELL APOPTOTIC PROCESS | 15 | 4.35e-01 | 9.22e-01 | 0.13700 | 1.30e-02 | -5.16e-02 | 1.16e-01 | -5.11e-02 | 9.61e-04 | 9.31e-01 | 7.29e-01 | 4.38e-01 | 7.32e-01 | 9.95e-01 |
| REGULATION OF PROTEOLYSIS INVOLVED IN PROTEIN CATABOLIC PROCESS | 219 | 1.28e-01 | 5.95e-01 | 0.13700 | 6.40e-02 | 5.86e-02 | 9.68e-02 | 3.25e-02 | 2.92e-02 | 1.02e-01 | 1.35e-01 | 1.36e-02 | 4.07e-01 | 4.56e-01 |
| PROTEIN LOCALIZATION TO PERINUCLEAR REGION OF CYTOPLASM | 9 | 9.30e-01 | 1.00e+00 | 0.13700 | -5.78e-02 | -6.03e-02 | -5.43e-02 | 3.10e-02 | 8.90e-02 | 7.64e-01 | 7.54e-01 | 7.78e-01 | 8.72e-01 | 6.44e-01 |
| RETINAL ROD CELL DEVELOPMENT | 8 | 6.92e-01 | 1.00e+00 | 0.13700 | 4.91e-02 | 3.68e-02 | -9.37e-03 | -1.89e-02 | -1.21e-01 | 8.10e-01 | 8.57e-01 | 9.63e-01 | 9.26e-01 | 5.54e-01 |
| GERM CELL MIGRATION | 8 | 8.93e-01 | 1.00e+00 | 0.13700 | 2.57e-03 | -2.50e-02 | -1.44e-02 | -3.03e-02 | -1.31e-01 | 9.90e-01 | 9.03e-01 | 9.44e-01 | 8.82e-01 | 5.23e-01 |
| ASTROCYTE DEVELOPMENT | 42 | 4.52e-01 | 9.30e-01 | 0.13700 | 5.88e-02 | 6.88e-02 | 9.93e-02 | -7.24e-03 | -2.60e-02 | 5.10e-01 | 4.40e-01 | 2.65e-01 | 9.35e-01 | 7.71e-01 |
| BLASTOCYST DEVELOPMENT | 114 | 5.22e-01 | 9.53e-01 | 0.13700 | 7.62e-02 | 7.11e-02 | 8.31e-02 | 3.01e-02 | -1.01e-02 | 1.60e-01 | 1.90e-01 | 1.25e-01 | 5.79e-01 | 8.53e-01 |
| NEGATIVE REGULATION OF PROTEIN BINDING | 77 | 3.08e-01 | 8.35e-01 | 0.13700 | 9.56e-03 | -6.11e-03 | 8.55e-02 | -4.81e-02 | 9.49e-02 | 8.85e-01 | 9.26e-01 | 1.95e-01 | 4.65e-01 | 1.50e-01 |
| CELL CYCLE PROCESS | 1248 | 3.55e-13 | 1.21e-10 | 0.13700 | 5.30e-02 | 3.58e-02 | 1.09e-01 | 6.35e-04 | 5.29e-02 | 1.64e-03 | 3.33e-02 | 9.31e-11 | 9.70e-01 | 1.67e-03 |
| ICOSANOID BIOSYNTHETIC PROCESS | 56 | 6.80e-01 | 1.00e+00 | 0.13700 | -6.73e-02 | -8.92e-02 | -4.52e-02 | -5.26e-02 | 3.78e-02 | 3.84e-01 | 2.48e-01 | 5.59e-01 | 4.96e-01 | 6.25e-01 |
| NUCLEOBASE METABOLIC PROCESS | 38 | 6.88e-01 | 1.00e+00 | 0.13700 | 2.61e-02 | 5.82e-02 | -4.42e-02 | 5.37e-02 | -9.91e-02 | 7.81e-01 | 5.35e-01 | 6.37e-01 | 5.67e-01 | 2.91e-01 |
| ACROSOME ASSEMBLY | 27 | 5.95e-01 | 9.87e-01 | 0.13700 | 3.55e-02 | 2.87e-02 | -2.36e-02 | 2.62e-02 | -1.24e-01 | 7.49e-01 | 7.96e-01 | 8.32e-01 | 8.14e-01 | 2.65e-01 |
| LYMPHOID PROGENITOR CELL DIFFERENTIATION | 24 | 4.83e-01 | 9.43e-01 | 0.13700 | -2.25e-02 | -6.34e-02 | 5.79e-02 | -1.03e-01 | -1.15e-02 | 8.49e-01 | 5.91e-01 | 6.23e-01 | 3.81e-01 | 9.22e-01 |
| NEGATIVE REGULATION OF IMMUNE RESPONSE | 199 | 3.03e-02 | 2.72e-01 | 0.13700 | -5.95e-02 | -8.23e-02 | 5.01e-03 | -8.85e-02 | 2.20e-02 | 1.48e-01 | 4.53e-02 | 9.03e-01 | 3.13e-02 | 5.92e-01 |
| REGULATION OF PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 138 | 9.99e-02 | 5.23e-01 | 0.13600 | -4.16e-02 | -6.23e-02 | 3.40e-02 | -8.71e-02 | 6.53e-02 | 3.99e-01 | 2.06e-01 | 4.90e-01 | 7.72e-02 | 1.85e-01 |
| APOPTOTIC MITOCHONDRIAL CHANGES | 105 | 2.47e-01 | 7.75e-01 | 0.13600 | 7.03e-02 | 7.67e-02 | 8.50e-02 | 8.42e-03 | -2.17e-02 | 2.13e-01 | 1.74e-01 | 1.32e-01 | 8.81e-01 | 7.01e-01 |
| RECEPTOR RECYCLING | 46 | 6.76e-01 | 1.00e+00 | 0.13600 | -4.37e-02 | -4.20e-02 | 1.40e-02 | -7.74e-02 | 9.35e-02 | 6.08e-01 | 6.22e-01 | 8.69e-01 | 3.64e-01 | 2.72e-01 |
| RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 354 | 8.52e-05 | 3.01e-03 | 0.13600 | -3.62e-02 | -5.21e-02 | 4.08e-02 | -5.54e-02 | 9.90e-02 | 2.42e-01 | 9.23e-02 | 1.87e-01 | 7.31e-02 | 1.37e-03 |
| POSITIVE REGULATION OF VASCULOGENESIS | 12 | 8.61e-01 | 1.00e+00 | 0.13600 | -2.59e-02 | -2.11e-02 | 3.92e-02 | -1.58e-02 | 1.25e-01 | 8.76e-01 | 8.99e-01 | 8.14e-01 | 9.25e-01 | 4.53e-01 |
| REGULATION OF SIGNALING RECEPTOR ACTIVITY | 104 | 2.90e-01 | 8.18e-01 | 0.13600 | 5.32e-02 | 7.61e-02 | 1.93e-02 | 5.34e-02 | -8.19e-02 | 3.48e-01 | 1.80e-01 | 7.33e-01 | 3.47e-01 | 1.49e-01 |
| NEGATIVE REGULATION OF MITOTIC CELL CYCLE PHASE TRANSITION | 189 | 1.94e-03 | 3.81e-02 | 0.13600 | 2.31e-02 | 3.57e-03 | 1.10e-01 | -4.08e-02 | 6.48e-02 | 5.84e-01 | 9.33e-01 | 9.18e-03 | 3.33e-01 | 1.24e-01 |
| MODULATION BY HOST OF VIRAL PROCESS | 45 | 5.95e-01 | 9.87e-01 | 0.13600 | -4.05e-02 | -5.77e-02 | 4.46e-02 | -7.57e-02 | 7.61e-02 | 6.38e-01 | 5.03e-01 | 6.05e-01 | 3.79e-01 | 3.77e-01 |
| POSITIVE REGULATION OF GLUCONEOGENESIS | 21 | 3.51e-01 | 8.70e-01 | 0.13600 | 7.87e-03 | 7.15e-03 | -6.02e-02 | 4.77e-02 | 1.12e-01 | 9.50e-01 | 9.55e-01 | 6.33e-01 | 7.05e-01 | 3.76e-01 |
| ENDOCARDIAL CUSHION MORPHOGENESIS | 44 | 2.57e-01 | 7.84e-01 | 0.13600 | 1.04e-02 | -1.81e-02 | 1.07e-01 | -7.92e-02 | 1.95e-02 | 9.05e-01 | 8.35e-01 | 2.21e-01 | 3.63e-01 | 8.23e-01 |
| NEGATIVE REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 35 | 6.00e-01 | 9.90e-01 | 0.13600 | -6.64e-03 | -2.45e-02 | 8.61e-02 | -7.24e-02 | 7.19e-02 | 9.46e-01 | 8.02e-01 | 3.78e-01 | 4.59e-01 | 4.62e-01 |
| NEGATIVE REGULATION OF CELL CYCLE PROCESS | 307 | 1.09e-04 | 3.74e-03 | 0.13600 | 3.99e-02 | 2.72e-02 | 1.12e-01 | -2.48e-02 | 5.49e-02 | 2.29e-01 | 4.12e-01 | 7.54e-04 | 4.55e-01 | 9.81e-02 |
| NEGATIVE REGULATION OF TRANSPORTER ACTIVITY | 93 | 5.86e-01 | 9.85e-01 | 0.13600 | 6.66e-02 | 6.23e-02 | 3.31e-02 | 8.77e-02 | 3.68e-02 | 2.67e-01 | 2.99e-01 | 5.81e-01 | 1.44e-01 | 5.40e-01 |
| CHONDROCYTE DEVELOPMENT | 32 | 8.39e-01 | 1.00e+00 | 0.13600 | -6.60e-02 | -6.38e-02 | -6.37e-03 | -8.32e-02 | 5.53e-02 | 5.18e-01 | 5.32e-01 | 9.50e-01 | 4.15e-01 | 5.88e-01 |
| LEUKOTRIENE CATABOLIC PROCESS | 6 | 2.68e-01 | 7.95e-01 | 0.13600 | -1.15e-02 | -4.42e-02 | 9.31e-02 | 8.62e-02 | 1.61e-02 | 9.61e-01 | 8.51e-01 | 6.93e-01 | 7.15e-01 | 9.46e-01 |
| POSITIVE REGULATION OF CHROMOSOME ORGANIZATION | 104 | 1.70e-01 | 6.75e-01 | 0.13600 | 2.26e-02 | -2.63e-03 | 9.59e-02 | -1.16e-02 | 9.26e-02 | 6.90e-01 | 9.63e-01 | 9.11e-02 | 8.38e-01 | 1.03e-01 |
| REGULATION OF POSTSYNAPTIC NEUROTRANSMITTER RECEPTOR INTERNALIZATION | 15 | 9.35e-01 | 1.00e+00 | 0.13600 | -7.15e-02 | -9.14e-02 | -6.41e-02 | -2.48e-02 | -1.51e-02 | 6.32e-01 | 5.40e-01 | 6.67e-01 | 8.68e-01 | 9.19e-01 |
| CELLULAR RESPONSE TO LEUCINE STARVATION | 12 | 9.19e-01 | 1.00e+00 | 0.13600 | -4.28e-02 | -3.21e-02 | 2.27e-02 | -1.05e-01 | 6.26e-02 | 7.98e-01 | 8.47e-01 | 8.92e-01 | 5.27e-01 | 7.07e-01 |
| INTERLEUKIN 1 ALPHA PRODUCTION | 11 | 9.95e-01 | 1.00e+00 | 0.13600 | -5.05e-02 | -6.18e-02 | -3.25e-03 | -6.62e-02 | 8.73e-02 | 7.72e-01 | 7.22e-01 | 9.85e-01 | 7.04e-01 | 6.16e-01 |
| REGULATION OF OXIDATIVE STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 44 | 4.52e-01 | 9.30e-01 | 0.13600 | -5.53e-03 | -3.92e-03 | 2.71e-02 | -6.94e-02 | -1.13e-01 | 9.49e-01 | 9.64e-01 | 7.56e-01 | 4.26e-01 | 1.94e-01 |
| HUMORAL IMMUNE RESPONSE MEDIATED BY CIRCULATING IMMUNOGLOBULIN | 47 | 8.49e-01 | 1.00e+00 | 0.13600 | -5.37e-02 | -3.21e-02 | -9.39e-02 | -3.14e-02 | -6.85e-02 | 5.25e-01 | 7.04e-01 | 2.65e-01 | 7.09e-01 | 4.17e-01 |
| NEUROFILAMENT CYTOSKELETON ORGANIZATION | 10 | 9.44e-01 | 1.00e+00 | 0.13600 | 5.28e-02 | 5.25e-02 | 1.10e-01 | -8.97e-03 | -2.52e-02 | 7.73e-01 | 7.74e-01 | 5.46e-01 | 9.61e-01 | 8.90e-01 |
| HYALURONAN METABOLIC PROCESS | 33 | 6.33e-01 | 9.96e-01 | 0.13600 | -6.52e-02 | -3.93e-02 | -5.95e-02 | -5.06e-02 | 8.06e-02 | 5.17e-01 | 6.96e-01 | 5.54e-01 | 6.15e-01 | 4.23e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CELL PERIPHERY | 129 | 3.47e-01 | 8.66e-01 | 0.13500 | 5.05e-02 | 5.38e-02 | 6.49e-02 | 5.30e-02 | 7.68e-02 | 3.22e-01 | 2.92e-01 | 2.03e-01 | 2.99e-01 | 1.32e-01 |
| OLIGOSACCHARIDE METABOLIC PROCESS | 65 | 5.84e-01 | 9.85e-01 | 0.13500 | 3.04e-02 | 1.55e-02 | 4.79e-02 | 5.83e-02 | 1.07e-01 | 6.72e-01 | 8.29e-01 | 5.04e-01 | 4.16e-01 | 1.35e-01 |
| POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 167 | 1.11e-01 | 5.52e-01 | 0.13500 | -5.42e-02 | -6.12e-02 | -3.04e-03 | -1.04e-01 | 2.88e-02 | 2.26e-01 | 1.72e-01 | 9.46e-01 | 2.04e-02 | 5.20e-01 |
| RESPONSE TO EPINEPHRINE | 14 | 9.16e-01 | 1.00e+00 | 0.13500 | 2.08e-02 | 1.99e-02 | 1.71e-02 | 2.73e-02 | -1.28e-01 | 8.93e-01 | 8.98e-01 | 9.12e-01 | 8.59e-01 | 4.06e-01 |
| CRD MEDIATED MRNA STABILIZATION | 11 | 9.67e-01 | 1.00e+00 | 0.13500 | -6.77e-02 | -7.22e-02 | 3.76e-03 | -8.19e-02 | 4.22e-02 | 6.98e-01 | 6.78e-01 | 9.83e-01 | 6.38e-01 | 8.08e-01 |
| ORGAN GROWTH | 168 | 6.57e-02 | 4.17e-01 | 0.13500 | 4.54e-02 | 5.63e-02 | 3.74e-02 | 1.55e-02 | -1.07e-01 | 3.10e-01 | 2.08e-01 | 4.03e-01 | 7.29e-01 | 1.68e-02 |
| PYROPTOSIS | 36 | 8.79e-01 | 1.00e+00 | 0.13500 | -6.84e-02 | -6.72e-02 | -9.22e-02 | -1.43e-02 | 1.99e-02 | 4.77e-01 | 4.86e-01 | 3.38e-01 | 8.82e-01 | 8.36e-01 |
| MICROVILLUS ORGANIZATION | 28 | 6.20e-01 | 9.90e-01 | 0.13500 | -5.58e-02 | -3.15e-02 | -1.07e-01 | 2.94e-02 | 4.23e-02 | 6.10e-01 | 7.73e-01 | 3.25e-01 | 7.88e-01 | 6.99e-01 |
| STEROID HORMONE BIOSYNTHETIC PROCESS | 44 | 3.19e-01 | 8.47e-01 | 0.13500 | 4.63e-02 | 8.22e-02 | -9.68e-03 | 9.61e-02 | 8.09e-03 | 5.95e-01 | 3.46e-01 | 9.12e-01 | 2.70e-01 | 9.26e-01 |
| NEPHRON DEVELOPMENT | 152 | 1.96e-01 | 7.09e-01 | 0.13500 | -6.76e-02 | -6.47e-02 | -1.68e-02 | -9.47e-02 | 1.68e-02 | 1.51e-01 | 1.68e-01 | 7.21e-01 | 4.38e-02 | 7.21e-01 |
| PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 147 | 4.75e-01 | 9.40e-01 | 0.13500 | 5.46e-02 | 4.13e-02 | 8.15e-02 | 3.11e-02 | 7.73e-02 | 2.53e-01 | 3.88e-01 | 8.81e-02 | 5.16e-01 | 1.05e-01 |
| POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 26 | 9.83e-01 | 1.00e+00 | 0.13500 | 6.95e-02 | 6.13e-02 | 7.59e-02 | 6.25e-02 | -4.66e-03 | 5.40e-01 | 5.89e-01 | 5.03e-01 | 5.81e-01 | 9.67e-01 |
| REGULATION OF PH | 96 | 2.39e-01 | 7.63e-01 | 0.13500 | -2.10e-02 | -3.42e-02 | 2.72e-02 | -3.35e-03 | 1.26e-01 | 7.22e-01 | 5.62e-01 | 6.45e-01 | 9.55e-01 | 3.28e-02 |
| RENAL SYSTEM VASCULATURE DEVELOPMENT | 32 | 9.29e-01 | 1.00e+00 | 0.13500 | -4.95e-02 | -3.42e-02 | -5.37e-02 | -5.90e-02 | -9.07e-02 | 6.28e-01 | 7.38e-01 | 5.99e-01 | 5.63e-01 | 3.75e-01 |
| POSITIVE REGULATION OF VIRAL GENOME REPLICATION | 30 | 8.30e-01 | 1.00e+00 | 0.13500 | 4.27e-02 | 3.39e-02 | 1.05e-01 | -1.67e-02 | 6.22e-02 | 6.85e-01 | 7.48e-01 | 3.18e-01 | 8.74e-01 | 5.55e-01 |
| POSITIVE REGULATION OF CARTILAGE DEVELOPMENT | 31 | 7.02e-01 | 1.00e+00 | 0.13500 | -5.16e-02 | -7.17e-02 | 9.06e-03 | -8.71e-02 | -5.22e-02 | 6.19e-01 | 4.90e-01 | 9.30e-01 | 4.01e-01 | 6.15e-01 |
| PROTEIN K11 LINKED DEUBIQUITINATION | 9 | 9.96e-01 | 1.00e+00 | 0.13500 | -6.74e-02 | -7.17e-02 | -8.72e-02 | -2.45e-02 | -1.65e-02 | 7.26e-01 | 7.09e-01 | 6.50e-01 | 8.99e-01 | 9.32e-01 |
| SKIN DEVELOPMENT | 311 | 1.88e-05 | 8.15e-04 | 0.13500 | 3.68e-02 | 5.53e-02 | -4.37e-02 | 1.08e-01 | -1.70e-02 | 2.64e-01 | 9.35e-02 | 1.85e-01 | 1.11e-03 | 6.06e-01 |
| REGULATION OF EPIDERMIS DEVELOPMENT | 66 | 8.20e-01 | 1.00e+00 | 0.13500 | 6.25e-02 | 7.25e-02 | 2.08e-02 | 9.09e-02 | -1.75e-02 | 3.80e-01 | 3.09e-01 | 7.70e-01 | 2.02e-01 | 8.06e-01 |
| REGULATION OF RESPONSE TO REACTIVE OXYGEN SPECIES | 13 | 5.70e-01 | 9.76e-01 | 0.13500 | -1.36e-02 | 1.32e-02 | -8.66e-02 | 1.00e-02 | 1.01e-01 | 9.33e-01 | 9.34e-01 | 5.89e-01 | 9.50e-01 | 5.28e-01 |
| POSITIVE REGULATION OF CALCIUM MEDIATED SIGNALING | 42 | 7.78e-01 | 1.00e+00 | 0.13500 | -2.40e-02 | -2.20e-02 | -5.03e-02 | -1.73e-03 | -1.21e-01 | 7.88e-01 | 8.05e-01 | 5.73e-01 | 9.84e-01 | 1.76e-01 |
| MIRNA PROCESSING | 45 | 2.52e-01 | 7.79e-01 | 0.13500 | -5.86e-02 | -4.61e-02 | -2.51e-03 | -9.19e-02 | -6.40e-02 | 4.97e-01 | 5.92e-01 | 9.77e-01 | 2.86e-01 | 4.57e-01 |
| NUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 38 | 4.65e-01 | 9.35e-01 | 0.13500 | 7.78e-02 | 6.65e-02 | 4.69e-02 | 5.58e-02 | 4.80e-02 | 4.06e-01 | 4.78e-01 | 6.17e-01 | 5.52e-01 | 6.08e-01 |
| REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY | 58 | 2.83e-01 | 8.10e-01 | 0.13500 | 5.95e-02 | 7.53e-02 | 8.56e-02 | 2.31e-03 | -3.95e-02 | 4.34e-01 | 3.21e-01 | 2.60e-01 | 9.76e-01 | 6.03e-01 |
| RESPONSE TO TOXIC SUBSTANCE | 249 | 1.95e-01 | 7.09e-01 | 0.13400 | 6.08e-02 | 6.65e-02 | 3.25e-02 | 5.86e-02 | -7.40e-02 | 9.87e-02 | 7.09e-02 | 3.77e-01 | 1.11e-01 | 4.43e-02 |
| CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 220 | 8.07e-02 | 4.68e-01 | 0.13400 | 6.61e-02 | 5.22e-02 | 1.03e-01 | 1.58e-02 | 1.39e-02 | 9.10e-02 | 1.82e-01 | 8.75e-03 | 6.87e-01 | 7.22e-01 |
| HINDBRAIN MORPHOGENESIS | 44 | 3.36e-01 | 8.59e-01 | 0.13400 | 3.93e-02 | 4.26e-02 | 1.05e-01 | -4.78e-02 | 3.72e-02 | 6.52e-01 | 6.25e-01 | 2.29e-01 | 5.83e-01 | 6.69e-01 |
| REGULATION OF GLIAL CELL DIFFERENTIATION | 78 | 1.03e-01 | 5.32e-01 | 0.13400 | 2.90e-02 | 2.02e-02 | 1.04e-01 | -6.22e-02 | 4.50e-02 | 6.58e-01 | 7.58e-01 | 1.11e-01 | 3.42e-01 | 4.92e-01 |
| TYPE II INTERFERON MEDIATED SIGNALING PATHWAY | 26 | 6.18e-01 | 9.90e-01 | 0.13400 | -2.75e-02 | -2.39e-02 | 4.70e-02 | -1.15e-01 | 3.56e-02 | 8.09e-01 | 8.33e-01 | 6.78e-01 | 3.10e-01 | 7.53e-01 |
| PURINE NUCLEOSIDE METABOLIC PROCESS | 25 | 9.67e-01 | 1.00e+00 | 0.13400 | -5.00e-02 | -3.95e-02 | -5.55e-02 | -4.77e-02 | -9.26e-02 | 6.65e-01 | 7.32e-01 | 6.31e-01 | 6.80e-01 | 4.23e-01 |
| INTERMEDIATE FILAMENT BUNDLE ASSEMBLY | 8 | 7.78e-01 | 1.00e+00 | 0.13400 | 5.68e-02 | 1.12e-01 | 2.73e-02 | -7.97e-03 | -3.80e-02 | 7.81e-01 | 5.84e-01 | 8.93e-01 | 9.69e-01 | 8.52e-01 |
| PROTEIN DEMETHYLATION | 9 | 9.07e-01 | 1.00e+00 | 0.13400 | -3.79e-02 | -1.65e-02 | 1.60e-03 | -1.06e-01 | 7.09e-02 | 8.44e-01 | 9.32e-01 | 9.93e-01 | 5.82e-01 | 7.13e-01 |
| LONG CHAIN FATTY ACID TRANSPORT | 66 | 8.61e-01 | 1.00e+00 | 0.13400 | 6.70e-02 | 7.93e-02 | 4.44e-02 | 7.14e-02 | -1.04e-02 | 3.46e-01 | 2.65e-01 | 5.33e-01 | 3.15e-01 | 8.84e-01 |
| NEGATIVE REGULATION OF MULTICELLULAR ORGANISM GROWTH | 12 | 8.80e-01 | 1.00e+00 | 0.13400 | -6.38e-02 | -9.64e-02 | 1.52e-02 | -6.36e-02 | 1.77e-02 | 7.02e-01 | 5.63e-01 | 9.27e-01 | 7.03e-01 | 9.16e-01 |
| TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 105 | 6.21e-01 | 9.91e-01 | 0.13400 | 4.30e-02 | 3.14e-02 | 6.37e-02 | 4.28e-02 | 9.59e-02 | 4.46e-01 | 5.78e-01 | 2.59e-01 | 4.48e-01 | 8.94e-02 |
| REGULATION OF CILIUM MOVEMENT | 38 | 9.37e-01 | 1.00e+00 | 0.13400 | 7.51e-02 | 7.65e-02 | 4.56e-02 | 5.61e-02 | -3.50e-02 | 4.23e-01 | 4.15e-01 | 6.27e-01 | 5.50e-01 | 7.09e-01 |
| IMMATURE T CELL PROLIFERATION | 12 | 6.80e-01 | 1.00e+00 | 0.13400 | -7.83e-02 | -3.33e-02 | -6.75e-02 | -4.48e-02 | 6.43e-02 | 6.39e-01 | 8.42e-01 | 6.86e-01 | 7.88e-01 | 7.00e-01 |
| LYSOSOMAL TRANSPORT | 128 | 8.79e-02 | 4.90e-01 | 0.13400 | -1.20e-02 | -2.26e-02 | 6.34e-02 | -5.07e-02 | 1.03e-01 | 8.14e-01 | 6.59e-01 | 2.15e-01 | 3.22e-01 | 4.37e-02 |
| CORONARY VASCULATURE DEVELOPMENT | 48 | 7.19e-02 | 4.40e-01 | 0.13400 | -1.19e-02 | -3.35e-02 | 1.04e-01 | -7.18e-02 | 2.73e-02 | 8.87e-01 | 6.88e-01 | 2.14e-01 | 3.90e-01 | 7.44e-01 |
| CELLULAR COMPONENT ASSEMBLY INVOLVED IN MORPHOGENESIS | 128 | 1.68e-01 | 6.72e-01 | 0.13400 | 4.49e-02 | 5.66e-02 | -2.68e-02 | 6.97e-02 | -8.42e-02 | 3.81e-01 | 2.68e-01 | 6.01e-01 | 1.73e-01 | 9.99e-02 |
| CENTRIOLE ASSEMBLY | 47 | 3.52e-01 | 8.71e-01 | 0.13400 | 8.19e-03 | 1.87e-04 | 9.64e-02 | -6.33e-02 | 6.72e-02 | 9.23e-01 | 9.98e-01 | 2.53e-01 | 4.53e-01 | 4.25e-01 |
| RECEPTOR CATABOLIC PROCESS | 27 | 6.01e-01 | 9.90e-01 | 0.13400 | -1.65e-02 | 2.93e-03 | -1.25e-02 | 2.58e-02 | 1.29e-01 | 8.82e-01 | 9.79e-01 | 9.10e-01 | 8.16e-01 | 2.44e-01 |
| REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 135 | 1.71e-01 | 6.75e-01 | 0.13400 | 5.58e-02 | 4.71e-02 | 1.06e-01 | 7.51e-03 | 3.38e-02 | 2.63e-01 | 3.45e-01 | 3.27e-02 | 8.80e-01 | 4.97e-01 |
| REGULATION OF NEUROTRANSMITTER TRANSPORT | 92 | 3.03e-01 | 8.31e-01 | 0.13400 | 5.39e-02 | 5.13e-02 | 3.87e-02 | 7.46e-02 | -7.25e-02 | 3.71e-01 | 3.95e-01 | 5.21e-01 | 2.16e-01 | 2.29e-01 |
| REGULATION OF GTPASE ACTIVITY | 288 | 3.21e-02 | 2.82e-01 | 0.13400 | -7.67e-02 | -6.89e-02 | -7.42e-02 | -3.39e-02 | 2.37e-02 | 2.51e-02 | 4.42e-02 | 3.02e-02 | 3.22e-01 | 4.89e-01 |
| AXIS SPECIFICATION | 91 | 7.04e-02 | 4.35e-01 | 0.13400 | 5.02e-02 | 3.09e-02 | 1.12e-01 | -2.35e-02 | -3.57e-02 | 4.08e-01 | 6.10e-01 | 6.48e-02 | 6.99e-01 | 5.56e-01 |
| POSITIVE REGULATION OF INTEGRIN MEDIATED SIGNALING PATHWAY | 11 | 7.28e-01 | 1.00e+00 | 0.13400 | -5.59e-02 | -9.60e-02 | -6.26e-02 | 3.06e-02 | 2.55e-02 | 7.48e-01 | 5.81e-01 | 7.19e-01 | 8.61e-01 | 8.83e-01 |
| PURINE CONTAINING COMPOUND SALVAGE | 14 | 9.18e-01 | 1.00e+00 | 0.13400 | 3.78e-02 | 5.56e-02 | -6.31e-03 | -5.27e-03 | -1.15e-01 | 8.07e-01 | 7.19e-01 | 9.67e-01 | 9.73e-01 | 4.56e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 69 | 6.97e-01 | 1.00e+00 | 0.13400 | -6.51e-02 | -5.68e-02 | -3.08e-02 | -9.71e-02 | 7.91e-04 | 3.50e-01 | 4.15e-01 | 6.59e-01 | 1.63e-01 | 9.91e-01 |
| POSTSYNAPTIC DENSITY PROTEIN 95 CLUSTERING | 9 | 9.65e-01 | 1.00e+00 | 0.13400 | -1.31e-02 | 2.71e-02 | -6.59e-02 | -4.72e-03 | -1.12e-01 | 9.46e-01 | 8.88e-01 | 7.32e-01 | 9.80e-01 | 5.61e-01 |
| T CELL APOPTOTIC PROCESS | 57 | 8.39e-01 | 1.00e+00 | 0.13300 | -6.41e-02 | -6.01e-02 | -3.01e-02 | -9.11e-02 | 3.01e-02 | 4.03e-01 | 4.32e-01 | 6.95e-01 | 2.34e-01 | 6.95e-01 |
| REGULATION OF DEFENSE RESPONSE | 786 | 4.53e-05 | 1.79e-03 | 0.13300 | -6.64e-02 | -8.06e-02 | -1.89e-02 | -7.93e-02 | 1.54e-02 | 1.54e-03 | 1.22e-04 | 3.67e-01 | 1.55e-04 | 4.62e-01 |
| REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY INVOLVED IN APOPTOTIC PROCESS | 46 | 4.49e-01 | 9.30e-01 | 0.13300 | 5.65e-02 | 7.00e-02 | 8.26e-02 | -3.86e-03 | -5.33e-02 | 5.07e-01 | 4.12e-01 | 3.32e-01 | 9.64e-01 | 5.31e-01 |
| CELLULAR RESPONSE TO OSMOTIC STRESS | 51 | 6.90e-01 | 1.00e+00 | 0.13300 | -3.62e-02 | -5.64e-02 | 3.48e-02 | -5.79e-02 | 9.33e-02 | 6.55e-01 | 4.86e-01 | 6.67e-01 | 4.74e-01 | 2.49e-01 |
| REGULATION OF COLLAGEN FIBRIL ORGANIZATION | 8 | 9.61e-01 | 1.00e+00 | 0.13300 | 4.22e-02 | 6.77e-02 | 5.25e-02 | 2.61e-02 | 8.92e-02 | 8.36e-01 | 7.40e-01 | 7.97e-01 | 8.98e-01 | 6.62e-01 |
| LEUKOCYTE MIGRATION INVOLVED IN INFLAMMATORY RESPONSE | 19 | 1.24e-01 | 5.87e-01 | 0.13300 | -4.96e-02 | -1.16e-01 | -2.00e-02 | 2.73e-02 | 2.73e-02 | 7.08e-01 | 3.82e-01 | 8.80e-01 | 8.37e-01 | 8.37e-01 |
| OXALOACETATE METABOLIC PROCESS | 9 | 9.71e-01 | 1.00e+00 | 0.13300 | 4.38e-02 | 3.90e-02 | 9.82e-02 | 3.04e-02 | 6.10e-02 | 8.20e-01 | 8.39e-01 | 6.10e-01 | 8.74e-01 | 7.51e-01 |
| REGULATION OF VASCULAR PERMEABILITY | 50 | 7.08e-01 | 1.00e+00 | 0.13300 | 9.86e-03 | 4.55e-03 | 3.39e-02 | 3.13e-02 | 1.24e-01 | 9.04e-01 | 9.56e-01 | 6.78e-01 | 7.02e-01 | 1.28e-01 |
| PRESYNAPSE ORGANIZATION | 44 | 8.27e-01 | 1.00e+00 | 0.13300 | 6.78e-02 | 5.85e-02 | 7.96e-02 | 2.17e-02 | -5.38e-02 | 4.36e-01 | 5.02e-01 | 3.61e-01 | 8.04e-01 | 5.37e-01 |
| POSITIVE REGULATION OF ERYTHROCYTE DIFFERENTIATION | 31 | 9.27e-01 | 1.00e+00 | 0.13300 | 4.64e-02 | 2.63e-02 | 9.41e-02 | 1.34e-02 | 7.62e-02 | 6.55e-01 | 8.00e-01 | 3.64e-01 | 8.97e-01 | 4.63e-01 |
| ANTEROGRADE AXONAL TRANSPORT OF MITOCHONDRION | 6 | 7.35e-01 | 1.00e+00 | 0.13300 | -1.53e-02 | 4.10e-02 | 2.14e-02 | -6.29e-02 | 1.06e-01 | 9.48e-01 | 8.62e-01 | 9.28e-01 | 7.90e-01 | 6.51e-01 |
| POSITIVE REGULATION OF NEURON PROJECTION ARBORIZATION | 8 | 6.81e-01 | 1.00e+00 | 0.13300 | -6.37e-03 | 1.32e-02 | 4.59e-03 | 4.50e-02 | -1.24e-01 | 9.75e-01 | 9.48e-01 | 9.82e-01 | 8.25e-01 | 5.44e-01 |
| NEGATIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 44 | 3.16e-01 | 8.43e-01 | 0.13300 | -1.00e-02 | -2.66e-02 | 9.12e-02 | -7.28e-02 | 5.66e-02 | 9.08e-01 | 7.60e-01 | 2.95e-01 | 4.04e-01 | 5.16e-01 |
| POSITIVE REGULATION OF ALPHA BETA T CELL DIFFERENTIATION | 48 | 3.27e-01 | 8.53e-01 | 0.13300 | -2.71e-02 | -4.89e-02 | 6.57e-02 | -9.99e-02 | 1.42e-02 | 7.45e-01 | 5.58e-01 | 4.31e-01 | 2.31e-01 | 8.65e-01 |
| REGULATION OF LYASE ACTIVITY | 57 | 8.90e-01 | 1.00e+00 | 0.13300 | -7.09e-02 | -5.68e-02 | -8.19e-02 | -4.21e-02 | -2.95e-02 | 3.55e-01 | 4.58e-01 | 2.85e-01 | 5.83e-01 | 7.00e-01 |
| NITRIC OXIDE MEDIATED SIGNAL TRANSDUCTION | 28 | 4.81e-01 | 9.43e-01 | 0.13300 | -4.83e-03 | 3.52e-02 | -3.65e-02 | 1.15e-02 | -1.22e-01 | 9.65e-01 | 7.47e-01 | 7.38e-01 | 9.16e-01 | 2.64e-01 |
| PROTEIN LOCALIZATION TO CHROMOSOME | 113 | 3.89e-03 | 6.42e-02 | 0.13300 | 4.89e-03 | -3.43e-02 | 9.38e-02 | -7.68e-02 | 4.10e-02 | 9.28e-01 | 5.28e-01 | 8.50e-02 | 1.58e-01 | 4.52e-01 |
| REGULATION OF PLATELET AGGREGATION | 27 | 8.01e-01 | 1.00e+00 | 0.13300 | -5.48e-02 | -7.39e-02 | 2.69e-02 | -8.60e-02 | 3.14e-02 | 6.22e-01 | 5.06e-01 | 8.09e-01 | 4.39e-01 | 7.77e-01 |
| POSITIVE REGULATION OF LEUKOCYTE DEGRANULATION | 23 | 6.90e-01 | 1.00e+00 | 0.13200 | -2.49e-03 | -4.80e-02 | 7.18e-02 | -1.94e-02 | 9.85e-02 | 9.84e-01 | 6.90e-01 | 5.51e-01 | 8.72e-01 | 4.13e-01 |
| MESENCHYMAL CELL PROLIFERATION | 43 | 4.16e-01 | 9.11e-01 | 0.13200 | 4.24e-02 | 3.42e-02 | 8.75e-02 | -1.21e-02 | -8.23e-02 | 6.30e-01 | 6.98e-01 | 3.21e-01 | 8.91e-01 | 3.51e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO CHROMATIN | 9 | 6.74e-01 | 1.00e+00 | 0.13200 | -1.81e-02 | -9.01e-02 | 7.05e-02 | -5.41e-02 | 3.45e-02 | 9.25e-01 | 6.40e-01 | 7.14e-01 | 7.79e-01 | 8.58e-01 |
| REGULATION OF GLYCOGEN METABOLIC PROCESS | 36 | 1.98e-01 | 7.13e-01 | 0.13200 | 2.19e-02 | 2.28e-02 | 1.07e-01 | -6.29e-02 | -3.36e-02 | 8.20e-01 | 8.13e-01 | 2.67e-01 | 5.13e-01 | 7.27e-01 |
| DEFENSE RESPONSE | 1744 | 9.37e-09 | 1.08e-06 | 0.13200 | -6.97e-02 | -7.96e-02 | -3.44e-02 | -6.08e-02 | 3.81e-02 | 1.27e-06 | 3.24e-08 | 1.70e-02 | 2.45e-05 | 8.16e-03 |
| NEGATIVE REGULATION OF TRANSLATIONAL ELONGATION | 5 | 9.97e-01 | 1.00e+00 | 0.13200 | 5.25e-02 | 5.56e-02 | 9.51e-02 | 1.12e-02 | 5.00e-02 | 8.39e-01 | 8.29e-01 | 7.13e-01 | 9.65e-01 | 8.47e-01 |
| NEGATIVE REGULATION OF EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 27 | 9.73e-01 | 1.00e+00 | 0.13200 | 6.52e-02 | 7.44e-02 | 6.42e-02 | 5.32e-02 | 2.76e-02 | 5.57e-01 | 5.03e-01 | 5.64e-01 | 6.32e-01 | 8.04e-01 |
| SEGMENTATION | 99 | 1.61e-01 | 6.60e-01 | 0.13200 | 4.82e-02 | 4.24e-02 | 6.41e-02 | 2.24e-02 | -9.36e-02 | 4.07e-01 | 4.66e-01 | 2.70e-01 | 7.00e-01 | 1.08e-01 |
| VIRAL PROCESS | 414 | 1.43e-04 | 4.72e-03 | 0.13200 | -5.82e-03 | -2.08e-02 | 6.22e-02 | -3.45e-02 | 1.09e-01 | 8.39e-01 | 4.69e-01 | 2.98e-02 | 2.28e-01 | 1.35e-04 |
| REGULATION OF INNATE IMMUNE RESPONSE | 407 | 9.94e-04 | 2.26e-02 | 0.13200 | -5.68e-02 | -7.51e-02 | 4.75e-03 | -8.93e-02 | 2.50e-02 | 4.94e-02 | 9.33e-03 | 8.69e-01 | 1.99e-03 | 3.87e-01 |
| DENSE CORE GRANULE EXOCYTOSIS | 10 | 8.26e-01 | 1.00e+00 | 0.13200 | 3.03e-02 | 3.86e-02 | 8.21e-02 | -8.89e-02 | 2.05e-02 | 8.68e-01 | 8.33e-01 | 6.53e-01 | 6.26e-01 | 9.11e-01 |
| PROTEIN IMPORT INTO PEROXISOME MATRIX RECEPTOR RECYCLING | 6 | 9.96e-01 | 1.00e+00 | 0.13200 | -6.12e-02 | -4.27e-02 | -6.41e-02 | -8.61e-02 | -1.90e-02 | 7.95e-01 | 8.56e-01 | 7.86e-01 | 7.15e-01 | 9.36e-01 |
| AMIDE METABOLIC PROCESS | 1223 | 8.73e-09 | 1.04e-06 | 0.13200 | 6.36e-02 | 6.35e-02 | 9.12e-02 | 2.12e-02 | 2.46e-02 | 1.78e-04 | 1.86e-04 | 7.86e-08 | 2.13e-01 | 1.47e-01 |
| IMP METABOLIC PROCESS | 17 | 8.26e-01 | 1.00e+00 | 0.13200 | -3.73e-02 | -6.23e-02 | 1.41e-02 | -1.09e-01 | -4.49e-03 | 7.90e-01 | 6.56e-01 | 9.20e-01 | 4.35e-01 | 9.74e-01 |
| SULFATE TRANSPORT | 17 | 9.29e-01 | 1.00e+00 | 0.13200 | -7.48e-02 | -8.50e-02 | -5.96e-02 | -1.76e-02 | 2.73e-02 | 5.93e-01 | 5.44e-01 | 6.71e-01 | 9.00e-01 | 8.45e-01 |
| NEGATIVE REGULATION OF LIPOPROTEIN METABOLIC PROCESS | 5 | 8.62e-01 | 1.00e+00 | 0.13200 | -2.15e-02 | -8.28e-02 | 1.24e-02 | -3.11e-02 | -9.48e-02 | 9.34e-01 | 7.49e-01 | 9.62e-01 | 9.04e-01 | 7.13e-01 |
| IRON COORDINATION ENTITY TRANSPORT | 12 | 4.26e-01 | 9.15e-01 | 0.13200 | -4.54e-02 | 1.23e-02 | -2.64e-02 | -1.18e-01 | 2.43e-02 | 7.86e-01 | 9.41e-01 | 8.74e-01 | 4.80e-01 | 8.84e-01 |
| NEGATIVE REGULATION OF AXON EXTENSION | 43 | 6.82e-01 | 1.00e+00 | 0.13200 | 6.75e-02 | 4.41e-02 | 6.37e-02 | 7.64e-02 | -3.10e-02 | 4.44e-01 | 6.17e-01 | 4.70e-01 | 3.86e-01 | 7.25e-01 |
| THYMUS DEVELOPMENT | 49 | 5.49e-01 | 9.63e-01 | 0.13200 | 5.93e-02 | 4.52e-02 | 1.04e-01 | -1.36e-02 | -2.84e-02 | 4.72e-01 | 5.84e-01 | 2.08e-01 | 8.69e-01 | 7.31e-01 |
| PARALLEL ACTIN FILAMENT BUNDLE ASSEMBLY | 7 | 9.50e-01 | 1.00e+00 | 0.13200 | -7.80e-02 | -6.94e-02 | -2.66e-02 | -6.63e-02 | -3.67e-02 | 7.21e-01 | 7.50e-01 | 9.03e-01 | 7.61e-01 | 8.66e-01 |
| REGULATION OF PROGRAMMED NECROTIC CELL DEATH | 36 | 5.86e-01 | 9.85e-01 | 0.13200 | -5.62e-02 | -5.56e-02 | -6.66e-02 | -7.58e-02 | 3.04e-02 | 5.60e-01 | 5.64e-01 | 4.89e-01 | 4.31e-01 | 7.52e-01 |
| AMP METABOLIC PROCESS | 22 | 9.52e-01 | 1.00e+00 | 0.13200 | 7.64e-02 | 7.72e-02 | 6.75e-02 | 3.14e-02 | 1.71e-03 | 5.35e-01 | 5.31e-01 | 5.84e-01 | 7.99e-01 | 9.89e-01 |
| NEGATIVE REGULATION OF T CELL APOPTOTIC PROCESS | 24 | 9.88e-01 | 1.00e+00 | 0.13200 | -6.81e-02 | -6.47e-02 | -5.09e-02 | -5.82e-02 | 5.00e-02 | 5.64e-01 | 5.83e-01 | 6.66e-01 | 6.21e-01 | 6.72e-01 |
| SCHWANN CELL DEVELOPMENT | 30 | 6.58e-01 | 1.00e+00 | 0.13100 | 4.60e-02 | 7.16e-02 | 2.85e-02 | 7.38e-02 | 6.14e-02 | 6.63e-01 | 4.97e-01 | 7.87e-01 | 4.84e-01 | 5.60e-01 |
| CELLULAR RESPONSE TO GROWTH HORMONE STIMULUS | 25 | 4.95e-01 | 9.47e-01 | 0.13100 | -2.09e-02 | -1.69e-02 | 7.21e-02 | -6.92e-02 | 8.09e-02 | 8.57e-01 | 8.83e-01 | 5.32e-01 | 5.49e-01 | 4.84e-01 |
| INTERLEUKIN 11 MEDIATED SIGNALING PATHWAY | 6 | 9.37e-01 | 1.00e+00 | 0.13100 | 1.88e-02 | 7.65e-02 | -6.48e-02 | 4.50e-02 | -6.95e-02 | 9.36e-01 | 7.46e-01 | 7.83e-01 | 8.49e-01 | 7.68e-01 |
| REGULATION OF INTRACELLULAR STEROID HORMONE RECEPTOR SIGNALING PATHWAY | 68 | 5.31e-01 | 9.54e-01 | 0.13100 | 6.42e-02 | 4.52e-02 | 9.65e-02 | 3.86e-02 | -1.69e-02 | 3.60e-01 | 5.20e-01 | 1.69e-01 | 5.82e-01 | 8.10e-01 |
| ORGANIC HYDROXY COMPOUND BIOSYNTHETIC PROCESS | 242 | 1.34e-01 | 6.09e-01 | 0.13100 | 6.23e-02 | 6.00e-02 | 6.73e-02 | 7.08e-02 | 1.39e-02 | 9.50e-02 | 1.08e-01 | 7.15e-02 | 5.77e-02 | 7.09e-01 |
| L GLUTAMATE IMPORT | 38 | 6.77e-01 | 1.00e+00 | 0.13100 | 1.87e-02 | 4.68e-02 | -6.21e-02 | 6.89e-02 | -7.79e-02 | 8.42e-01 | 6.18e-01 | 5.08e-01 | 4.63e-01 | 4.06e-01 |
| NEGATIVE REGULATION OF HEPATOCYTE APOPTOTIC PROCESS | 7 | 9.76e-01 | 1.00e+00 | 0.13100 | -2.36e-02 | -1.30e-02 | 3.75e-02 | -7.40e-02 | 9.79e-02 | 9.14e-01 | 9.53e-01 | 8.64e-01 | 7.35e-01 | 6.54e-01 |
| EPITHELIAL TUBE FORMATION | 136 | 2.49e-01 | 7.75e-01 | 0.13100 | 4.80e-02 | 4.29e-02 | 9.13e-02 | 2.26e-02 | 6.49e-02 | 3.33e-01 | 3.88e-01 | 6.61e-02 | 6.49e-01 | 1.91e-01 |
| FRUCTOSE 1 6 BISPHOSPHATE METABOLIC PROCESS | 9 | 9.63e-01 | 1.00e+00 | 0.13100 | 2.82e-02 | -1.08e-03 | 3.05e-02 | 7.24e-02 | 1.01e-01 | 8.84e-01 | 9.96e-01 | 8.74e-01 | 7.07e-01 | 5.99e-01 |
| REGULATORY T CELL DIFFERENTIATION | 39 | 1.62e-01 | 6.61e-01 | 0.13100 | -4.96e-03 | -6.10e-02 | 8.06e-02 | -2.55e-02 | 7.93e-02 | 9.57e-01 | 5.10e-01 | 3.84e-01 | 7.83e-01 | 3.91e-01 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 184 | 9.10e-03 | 1.18e-01 | 0.13100 | 5.32e-02 | 4.31e-02 | 1.10e-01 | -1.92e-02 | -2.45e-03 | 2.13e-01 | 3.13e-01 | 1.01e-02 | 6.54e-01 | 9.54e-01 |
| SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 168 | 2.40e-02 | 2.33e-01 | 0.13100 | 2.74e-02 | 2.11e-02 | 8.98e-02 | -3.65e-02 | 8.10e-02 | 5.40e-01 | 6.37e-01 | 4.47e-02 | 4.15e-01 | 7.02e-02 |
| IN UTERO EMBRYONIC DEVELOPMENT | 383 | 1.15e-01 | 5.64e-01 | 0.13100 | 6.36e-02 | 5.60e-02 | 8.50e-02 | 3.49e-02 | 3.83e-02 | 3.26e-02 | 5.98e-02 | 4.29e-03 | 2.41e-01 | 1.98e-01 |
| RENAL SODIUM ION TRANSPORT | 15 | 9.91e-01 | 1.00e+00 | 0.13100 | -6.86e-02 | -5.42e-02 | -6.69e-02 | -6.86e-02 | 1.56e-02 | 6.46e-01 | 7.16e-01 | 6.54e-01 | 6.45e-01 | 9.17e-01 |
| REGULATION OF LONG CHAIN FATTY ACID IMPORT INTO CELL | 8 | 9.01e-01 | 1.00e+00 | 0.13100 | 5.91e-03 | 2.98e-02 | 3.65e-02 | 2.64e-02 | 1.19e-01 | 9.77e-01 | 8.84e-01 | 8.58e-01 | 8.97e-01 | 5.61e-01 |
| VENTRICULAR CARDIAC MUSCLE CELL MEMBRANE REPOLARIZATION | 27 | 5.65e-01 | 9.71e-01 | 0.13100 | 3.69e-02 | 5.80e-02 | 1.36e-02 | 7.77e-02 | -7.83e-02 | 7.40e-01 | 6.02e-01 | 9.03e-01 | 4.85e-01 | 4.81e-01 |
| MITOCHONDRIAL TRANSPORT | 181 | 4.93e-02 | 3.61e-01 | 0.13100 | 4.86e-02 | 4.34e-02 | 9.91e-02 | -1.10e-02 | 5.36e-02 | 2.59e-01 | 3.13e-01 | 2.15e-02 | 7.99e-01 | 2.14e-01 |
| REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 1087 | 1.52e-04 | 4.93e-03 | 0.13100 | -6.77e-02 | -7.68e-02 | -3.43e-02 | -7.33e-02 | 4.86e-03 | 1.63e-04 | 1.90e-05 | 5.58e-02 | 4.42e-05 | 7.86e-01 |
| ACTIVATION OF PROTEIN KINASE ACTIVITY | 86 | 4.60e-02 | 3.48e-01 | 0.13000 | -4.14e-02 | -2.97e-02 | 1.95e-02 | -1.13e-01 | -3.47e-02 | 5.07e-01 | 6.34e-01 | 7.54e-01 | 6.94e-02 | 5.78e-01 |
| POSITIVE REGULATION OF EXTRACELLULAR MATRIX ASSEMBLY | 12 | 9.06e-01 | 1.00e+00 | 0.13000 | 3.47e-02 | 5.64e-02 | 6.05e-02 | 2.11e-02 | 9.23e-02 | 8.35e-01 | 7.35e-01 | 7.16e-01 | 8.99e-01 | 5.80e-01 |
| RNA METHYLATION | 86 | 6.31e-02 | 4.12e-01 | 0.13000 | 2.25e-02 | -6.46e-03 | 1.14e-01 | -4.51e-02 | 3.88e-02 | 7.18e-01 | 9.18e-01 | 6.85e-02 | 4.69e-01 | 5.34e-01 |
| MYELOID CELL DIFFERENTIATION | 413 | 1.47e-05 | 6.57e-04 | 0.13000 | -4.64e-03 | -3.01e-02 | 7.10e-02 | -3.13e-02 | 1.00e-01 | 8.72e-01 | 2.94e-01 | 1.33e-02 | 2.75e-01 | 4.70e-04 |
| AMIDE CATABOLIC PROCESS | 20 | 5.10e-01 | 9.50e-01 | 0.13000 | 6.12e-02 | 9.57e-02 | 5.33e-02 | -2.17e-02 | -2.79e-02 | 6.36e-01 | 4.59e-01 | 6.80e-01 | 8.67e-01 | 8.29e-01 |
| CARBOHYDRATE TRANSPORT | 154 | 4.54e-01 | 9.31e-01 | 0.13000 | 6.17e-02 | 6.63e-02 | 7.36e-02 | 4.30e-02 | 3.91e-02 | 1.86e-01 | 1.55e-01 | 1.15e-01 | 3.57e-01 | 4.02e-01 |
| CHEMICAL SYNAPTIC TRANSMISSION POSTSYNAPTIC | 111 | 2.59e-01 | 7.86e-01 | 0.13000 | 5.20e-02 | 5.48e-02 | 3.47e-02 | 9.60e-02 | 2.96e-02 | 3.44e-01 | 3.19e-01 | 5.27e-01 | 8.06e-02 | 5.90e-01 |
| FEAR RESPONSE | 43 | 7.13e-01 | 1.00e+00 | 0.13000 | 2.00e-02 | 1.55e-02 | -2.22e-03 | 4.50e-03 | -1.28e-01 | 8.20e-01 | 8.60e-01 | 9.80e-01 | 9.59e-01 | 1.47e-01 |
| EPITHELIAL CELL CELL ADHESION | 15 | 9.70e-01 | 1.00e+00 | 0.13000 | 5.50e-02 | 7.35e-02 | 2.41e-02 | 8.66e-02 | 2.18e-02 | 7.12e-01 | 6.22e-01 | 8.72e-01 | 5.61e-01 | 8.84e-01 |
| POSITIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 162 | 6.28e-01 | 9.95e-01 | 0.13000 | -7.01e-02 | -6.34e-02 | -5.13e-02 | -7.28e-02 | -9.74e-03 | 1.24e-01 | 1.64e-01 | 2.60e-01 | 1.10e-01 | 8.31e-01 |
| REGULATION OF WOUND HEALING | 129 | 1.98e-01 | 7.13e-01 | 0.13000 | 1.47e-03 | 2.12e-02 | -4.76e-02 | 2.89e-02 | -1.16e-01 | 9.77e-01 | 6.77e-01 | 3.51e-01 | 5.71e-01 | 2.31e-02 |
| POSITIVE REGULATION OF MITOCHONDRIAL CALCIUM ION CONCENTRATION | 10 | 9.73e-01 | 1.00e+00 | 0.13000 | -6.96e-02 | -9.41e-02 | -4.33e-02 | -3.10e-02 | 1.96e-02 | 7.03e-01 | 6.06e-01 | 8.13e-01 | 8.65e-01 | 9.14e-01 |
| REGULATION OF CYCLASE ACTIVITY | 53 | 9.08e-01 | 1.00e+00 | 0.13000 | -7.06e-02 | -5.72e-02 | -7.73e-02 | -4.40e-02 | -2.70e-02 | 3.74e-01 | 4.72e-01 | 3.31e-01 | 5.79e-01 | 7.34e-01 |
| REGULATION OF SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 60 | 3.89e-01 | 8.92e-01 | 0.13000 | 2.45e-02 | 1.96e-02 | 1.96e-02 | 2.64e-02 | -1.22e-01 | 7.43e-01 | 7.93e-01 | 7.93e-01 | 7.24e-01 | 1.03e-01 |
| ALDITOL CATABOLIC PROCESS | 6 | 9.97e-01 | 1.00e+00 | 0.13000 | -7.04e-02 | -7.83e-02 | -2.41e-02 | -5.44e-02 | 4.74e-02 | 7.65e-01 | 7.40e-01 | 9.19e-01 | 8.17e-01 | 8.41e-01 |
| CELLULAR RESPONSE TO STRESS | 1871 | 7.05e-19 | 4.82e-16 | 0.13000 | 4.67e-02 | 3.57e-02 | 1.02e-01 | -4.54e-03 | 5.50e-02 | 8.11e-04 | 1.04e-02 | 2.95e-13 | 7.45e-01 | 8.09e-05 |
| REGULATION OF VACUOLE ORGANIZATION | 53 | 9.30e-01 | 1.00e+00 | 0.13000 | 6.73e-02 | 7.05e-02 | 7.36e-02 | 3.88e-02 | 2.00e-02 | 3.97e-01 | 3.74e-01 | 3.54e-01 | 6.25e-01 | 8.01e-01 |
| ORGANIC HYDROXY COMPOUND TRANSPORT | 302 | 2.93e-01 | 8.21e-01 | 0.13000 | 6.57e-02 | 7.07e-02 | 4.79e-02 | 6.86e-02 | -2.25e-02 | 4.97e-02 | 3.44e-02 | 1.52e-01 | 4.02e-02 | 5.01e-01 |
| FIBROBLAST PROLIFERATION | 104 | 4.35e-01 | 9.22e-01 | 0.13000 | 5.89e-02 | 6.26e-02 | 6.40e-02 | 2.90e-02 | -6.71e-02 | 3.00e-01 | 2.70e-01 | 2.59e-01 | 6.09e-01 | 2.37e-01 |
| APPENDAGE MORPHOGENESIS | 142 | 5.16e-02 | 3.72e-01 | 0.13000 | -5.47e-02 | -6.99e-02 | 2.08e-02 | -9.16e-02 | 1.15e-02 | 2.61e-01 | 1.51e-01 | 6.68e-01 | 5.96e-02 | 8.12e-01 |
| REGULATION OF CELL ADHESION | 775 | 2.78e-04 | 8.20e-03 | 0.13000 | -7.15e-02 | -7.55e-02 | -3.38e-02 | -6.60e-02 | 2.21e-02 | 7.04e-04 | 3.46e-04 | 1.09e-01 | 1.76e-03 | 2.95e-01 |
| EXTRACELLULAR TRANSPORT | 45 | 2.95e-01 | 8.22e-01 | 0.13000 | -6.62e-02 | -8.39e-02 | -6.44e-02 | 1.51e-02 | 3.18e-02 | 4.42e-01 | 3.30e-01 | 4.55e-01 | 8.61e-01 | 7.12e-01 |
| RESPONSE TO GROWTH HORMONE | 36 | 2.97e-01 | 8.24e-01 | 0.13000 | 4.68e-02 | 6.69e-02 | 6.25e-02 | 6.92e-02 | 3.78e-02 | 6.27e-01 | 4.87e-01 | 5.17e-01 | 4.72e-01 | 6.95e-01 |
| REGULATION OF CARBOHYDRATE CATABOLIC PROCESS | 61 | 6.33e-01 | 9.96e-01 | 0.13000 | 5.22e-02 | 5.04e-02 | 5.04e-02 | 4.56e-02 | -8.30e-02 | 4.80e-01 | 4.96e-01 | 4.96e-01 | 5.38e-01 | 2.62e-01 |
| REGULATION OF PROTEIN DEPOLYMERIZATION | 82 | 7.90e-01 | 1.00e+00 | 0.13000 | 6.14e-02 | 7.48e-02 | 2.78e-02 | 7.23e-02 | -3.75e-02 | 3.36e-01 | 2.42e-01 | 6.64e-01 | 2.58e-01 | 5.57e-01 |
| VACUOLE ORGANIZATION | 219 | 3.47e-02 | 2.96e-01 | 0.13000 | 1.52e-02 | 1.04e-02 | 6.50e-02 | -8.11e-03 | 1.10e-01 | 6.98e-01 | 7.91e-01 | 9.73e-02 | 8.36e-01 | 4.95e-03 |
| METANEPHROS MORPHOGENESIS | 30 | 6.33e-01 | 9.96e-01 | 0.12900 | -3.38e-02 | -5.25e-02 | 4.31e-02 | -9.83e-02 | -3.67e-02 | 7.49e-01 | 6.19e-01 | 6.83e-01 | 3.51e-01 | 7.28e-01 |
| MANNOSYLATION | 23 | 9.88e-01 | 1.00e+00 | 0.12900 | 6.45e-02 | 6.04e-02 | 8.55e-02 | 3.42e-02 | 2.16e-02 | 5.92e-01 | 6.16e-01 | 4.78e-01 | 7.77e-01 | 8.58e-01 |
| AMINO ACID TRANSPORT | 142 | 3.43e-01 | 8.62e-01 | 0.12900 | 6.20e-02 | 7.35e-02 | 4.31e-02 | 3.16e-02 | -6.81e-02 | 2.02e-01 | 1.30e-01 | 3.75e-01 | 5.15e-01 | 1.61e-01 |
| CELLULAR RESPONSE TO PURINE CONTAINING COMPOUND | 14 | 9.55e-01 | 1.00e+00 | 0.12900 | -7.20e-02 | -6.93e-02 | -3.63e-02 | -3.79e-02 | 6.33e-02 | 6.41e-01 | 6.54e-01 | 8.14e-01 | 8.06e-01 | 6.82e-01 |
| RESPONSE TO ETHANOL | 117 | 7.95e-01 | 1.00e+00 | 0.12900 | -6.41e-02 | -6.02e-02 | -4.92e-02 | -7.24e-02 | -3.67e-02 | 2.31e-01 | 2.61e-01 | 3.58e-01 | 1.76e-01 | 4.93e-01 |
| CARDIAC VENTRICLE MORPHOGENESIS | 72 | 7.66e-02 | 4.54e-01 | 0.12900 | 1.42e-02 | -1.28e-03 | 7.58e-02 | -6.96e-02 | -7.70e-02 | 8.35e-01 | 9.85e-01 | 2.66e-01 | 3.07e-01 | 2.58e-01 |
| MEMBRANE REPOLARIZATION | 52 | 3.64e-01 | 8.78e-01 | 0.12900 | 2.31e-02 | 4.57e-02 | 6.10e-03 | 2.82e-02 | -1.15e-01 | 7.73e-01 | 5.69e-01 | 9.39e-01 | 7.25e-01 | 1.51e-01 |
| POLYOL CATABOLIC PROCESS | 9 | 9.89e-01 | 1.00e+00 | 0.12900 | -9.00e-03 | -1.88e-02 | -5.44e-04 | 2.35e-02 | 1.25e-01 | 9.63e-01 | 9.22e-01 | 9.98e-01 | 9.03e-01 | 5.15e-01 |
| RESPONSE TO REDOX STATE | 14 | 9.29e-01 | 1.00e+00 | 0.12900 | 1.70e-02 | 2.60e-02 | 6.37e-02 | -4.66e-03 | 1.08e-01 | 9.12e-01 | 8.66e-01 | 6.80e-01 | 9.76e-01 | 4.84e-01 |
| NEGATIVE REGULATION OF DEVELOPMENTAL GROWTH | 108 | 3.66e-01 | 8.79e-01 | 0.12900 | 4.86e-02 | 4.91e-02 | 3.78e-02 | 4.46e-02 | -9.23e-02 | 3.83e-01 | 3.78e-01 | 4.98e-01 | 4.24e-01 | 9.74e-02 |
| POSITIVE REGULATION OF SYNAPTIC TRANSMISSION GLUTAMATERGIC | 32 | 7.19e-01 | 1.00e+00 | 0.12900 | 3.36e-02 | 5.70e-02 | 2.33e-02 | -1.79e-03 | -1.09e-01 | 7.42e-01 | 5.77e-01 | 8.19e-01 | 9.86e-01 | 2.88e-01 |
| RESPONSE TO VITAMIN D | 36 | 8.43e-01 | 1.00e+00 | 0.12900 | -2.15e-02 | -2.56e-02 | -1.63e-03 | -2.00e-02 | 1.23e-01 | 8.23e-01 | 7.91e-01 | 9.86e-01 | 8.35e-01 | 2.01e-01 |
| POLYOL BIOSYNTHETIC PROCESS | 62 | 5.00e-01 | 9.47e-01 | 0.12900 | 5.43e-02 | 4.94e-02 | 6.72e-02 | 7.81e-02 | 2.59e-02 | 4.60e-01 | 5.01e-01 | 3.60e-01 | 2.88e-01 | 7.24e-01 |
| RETINA VASCULATURE MORPHOGENESIS IN CAMERA TYPE EYE | 9 | 7.71e-01 | 1.00e+00 | 0.12900 | 2.58e-02 | -3.99e-02 | 1.07e-01 | 3.77e-03 | 5.40e-02 | 8.94e-01 | 8.36e-01 | 5.78e-01 | 9.84e-01 | 7.79e-01 |
| POSITIVE REGULATION OF CELL CYCLE PROCESS | 251 | 6.21e-02 | 4.09e-01 | 0.12900 | 5.80e-02 | 4.41e-02 | 9.87e-02 | 2.66e-02 | 3.01e-02 | 1.14e-01 | 2.29e-01 | 7.07e-03 | 4.67e-01 | 4.12e-01 |
| SPONTANEOUS NEUROTRANSMITTER SECRETION | 8 | 9.97e-01 | 1.00e+00 | 0.12900 | -6.35e-02 | -4.52e-02 | -5.79e-02 | -7.73e-02 | -3.54e-02 | 7.56e-01 | 8.25e-01 | 7.77e-01 | 7.05e-01 | 8.62e-01 |
| REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 17 | 4.29e-01 | 9.17e-01 | 0.12900 | -3.69e-03 | 3.40e-02 | 3.37e-02 | -6.67e-02 | -9.95e-02 | 9.79e-01 | 8.08e-01 | 8.10e-01 | 6.34e-01 | 4.78e-01 |
| NEGATIVE REGULATION OF CELL CYCLE | 391 | 4.40e-06 | 2.27e-04 | 0.12900 | 3.72e-02 | 2.70e-02 | 1.07e-01 | -3.16e-02 | 4.58e-02 | 2.06e-01 | 3.60e-01 | 2.83e-04 | 2.83e-01 | 1.20e-01 |
| CAMP BIOSYNTHETIC PROCESS | 10 | 8.86e-01 | 1.00e+00 | 0.12900 | -3.65e-03 | -4.53e-02 | 2.71e-02 | -1.75e-02 | 1.16e-01 | 9.84e-01 | 8.04e-01 | 8.82e-01 | 9.24e-01 | 5.24e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO MEMBRANE | 260 | 2.91e-02 | 2.65e-01 | 0.12900 | 5.15e-02 | 4.96e-02 | 9.02e-02 | 4.33e-03 | 5.81e-02 | 1.53e-01 | 1.68e-01 | 1.23e-02 | 9.04e-01 | 1.07e-01 |
| REGULATION OF GROWTH | 589 | 1.97e-03 | 3.87e-02 | 0.12900 | 6.83e-02 | 6.66e-02 | 8.12e-02 | 2.51e-02 | -1.76e-02 | 4.62e-03 | 5.77e-03 | 7.54e-04 | 2.99e-01 | 4.66e-01 |
| RESPONSE TO AMPHETAMINE | 29 | 9.27e-01 | 1.00e+00 | 0.12900 | 5.24e-02 | 5.03e-02 | 4.93e-02 | 3.09e-02 | -8.92e-02 | 6.25e-01 | 6.39e-01 | 6.46e-01 | 7.74e-01 | 4.06e-01 |
| RETROGRADE TRANSPORT ENDOSOME TO GOLGI | 95 | 4.15e-01 | 9.11e-01 | 0.12900 | -4.27e-02 | -6.56e-02 | 1.95e-02 | -6.66e-02 | 7.53e-02 | 4.72e-01 | 2.69e-01 | 7.42e-01 | 2.62e-01 | 2.05e-01 |
| DIRECT OSSIFICATION | 7 | 9.99e-01 | 1.00e+00 | 0.12900 | -4.00e-02 | -3.16e-02 | -6.23e-02 | -2.89e-02 | -9.64e-02 | 8.55e-01 | 8.85e-01 | 7.75e-01 | 8.95e-01 | 6.59e-01 |
| ADHERENS JUNCTION ORGANIZATION | 57 | 4.87e-01 | 9.43e-01 | 0.12900 | -6.33e-02 | -5.23e-02 | -7.74e-02 | 2.43e-03 | 6.22e-02 | 4.09e-01 | 4.95e-01 | 3.12e-01 | 9.75e-01 | 4.17e-01 |
| NUCLEOBASE CONTAINING COMPOUND TRANSPORT | 206 | 1.12e-01 | 5.57e-01 | 0.12900 | 3.19e-02 | 1.85e-02 | 8.01e-02 | -3.29e-03 | 9.38e-02 | 4.30e-01 | 6.47e-01 | 4.76e-02 | 9.35e-01 | 2.03e-02 |
| INTRACELLULAR IRON ION HOMEOSTASIS | 66 | 1.83e-01 | 6.93e-01 | 0.12900 | -1.05e-02 | -4.55e-02 | 7.98e-02 | -4.35e-02 | 7.82e-02 | 8.82e-01 | 5.23e-01 | 2.62e-01 | 5.41e-01 | 2.72e-01 |
| CELLULAR RESPONSE TO CAMP | 49 | 9.47e-01 | 1.00e+00 | 0.12900 | 6.58e-02 | 5.96e-02 | 5.94e-02 | 7.01e-02 | -1.47e-02 | 4.25e-01 | 4.71e-01 | 4.72e-01 | 3.96e-01 | 8.59e-01 |
| DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 70 | 7.79e-02 | 4.58e-01 | 0.12800 | -5.06e-03 | -1.11e-02 | 6.85e-02 | -1.07e-01 | 1.40e-02 | 9.42e-01 | 8.72e-01 | 3.22e-01 | 1.21e-01 | 8.39e-01 |
| NEGATIVE REGULATION OF CYTOKINE PRODUCTION | 359 | 2.52e-01 | 7.79e-01 | 0.12800 | -6.54e-02 | -6.78e-02 | -4.03e-02 | -7.37e-02 | 2.40e-02 | 3.33e-02 | 2.74e-02 | 1.90e-01 | 1.64e-02 | 4.35e-01 |
| CELLULAR RESPONSE TO HYDROGEN PEROXIDE | 65 | 1.40e-01 | 6.24e-01 | 0.12800 | 2.53e-02 | 2.10e-03 | 1.14e-01 | -5.13e-02 | 1.44e-02 | 7.25e-01 | 9.77e-01 | 1.12e-01 | 4.75e-01 | 8.41e-01 |
| POSITIVE REGULATION OF ERK1 AND ERK2 CASCADE | 220 | 2.09e-01 | 7.30e-01 | 0.12800 | -7.36e-02 | -6.61e-02 | -7.15e-02 | -3.74e-02 | 1.32e-02 | 6.01e-02 | 9.13e-02 | 6.78e-02 | 3.39e-01 | 7.35e-01 |
| NUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 71 | 8.86e-01 | 1.00e+00 | 0.12800 | 6.43e-02 | 5.71e-02 | 7.28e-02 | 3.90e-02 | 4.72e-02 | 3.49e-01 | 4.05e-01 | 2.89e-01 | 5.70e-01 | 4.92e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO MEMBRANE | 171 | 2.50e-01 | 7.76e-01 | 0.12800 | 4.17e-02 | 4.27e-02 | 6.04e-02 | 3.97e-02 | 8.75e-02 | 3.47e-01 | 3.35e-01 | 1.73e-01 | 3.71e-01 | 4.85e-02 |
| SKIN EPIDERMIS DEVELOPMENT | 125 | 2.98e-01 | 8.24e-01 | 0.12800 | 4.28e-02 | 5.32e-02 | 6.75e-03 | 6.74e-02 | -8.47e-02 | 4.08e-01 | 3.04e-01 | 8.96e-01 | 1.93e-01 | 1.02e-01 |
| NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS | 127 | 2.25e-01 | 7.48e-01 | 0.12800 | -3.74e-02 | -4.38e-02 | 2.60e-02 | -7.13e-02 | 8.57e-02 | 4.67e-01 | 3.94e-01 | 6.12e-01 | 1.65e-01 | 9.53e-02 |
| PYRIMIDINE CONTAINING COMPOUND CATABOLIC PROCESS | 42 | 6.80e-01 | 1.00e+00 | 0.12800 | -2.97e-02 | -2.78e-02 | 3.02e-02 | -6.95e-02 | 9.49e-02 | 7.39e-01 | 7.56e-01 | 7.34e-01 | 4.36e-01 | 2.87e-01 |
| CGMP BIOSYNTHETIC PROCESS | 10 | 9.91e-01 | 1.00e+00 | 0.12800 | 6.39e-02 | 4.68e-02 | 8.91e-02 | 3.77e-02 | -2.73e-02 | 7.26e-01 | 7.98e-01 | 6.26e-01 | 8.36e-01 | 8.81e-01 |
| NEPHRON MORPHOGENESIS | 77 | 1.67e-01 | 6.71e-01 | 0.12800 | -3.94e-03 | -1.77e-02 | 7.91e-02 | -8.28e-02 | 5.42e-02 | 9.52e-01 | 7.88e-01 | 2.30e-01 | 2.09e-01 | 4.11e-01 |
| FATTY ACID BIOSYNTHETIC PROCESS | 160 | 5.76e-01 | 9.80e-01 | 0.12800 | 6.93e-02 | 6.35e-02 | 5.97e-02 | 5.08e-02 | -3.74e-02 | 1.30e-01 | 1.66e-01 | 1.92e-01 | 2.67e-01 | 4.15e-01 |
| VITAMIN D METABOLIC PROCESS | 20 | 9.92e-01 | 1.00e+00 | 0.12800 | -6.13e-02 | -5.99e-02 | -3.61e-02 | -8.52e-02 | -2.13e-02 | 6.35e-01 | 6.43e-01 | 7.80e-01 | 5.10e-01 | 8.69e-01 |
| CELLULAR RESPONSE TO OXYGEN LEVELS | 160 | 4.26e-01 | 9.15e-01 | 0.12800 | 6.70e-02 | 6.91e-02 | 7.65e-02 | 2.99e-02 | -1.82e-02 | 1.43e-01 | 1.32e-01 | 9.49e-02 | 5.15e-01 | 6.91e-01 |
| NEGATIVE REGULATION OF ACTIN FILAMENT POLYMERIZATION | 61 | 7.85e-01 | 1.00e+00 | 0.12800 | 5.15e-02 | 7.06e-02 | 7.63e-03 | 6.18e-02 | -6.92e-02 | 4.87e-01 | 3.41e-01 | 9.18e-01 | 4.04e-01 | 3.50e-01 |
| CELL CELL ADHESION MEDIATED BY CADHERIN | 47 | 7.11e-01 | 1.00e+00 | 0.12800 | -7.50e-02 | -6.54e-02 | -7.39e-02 | -2.69e-02 | -1.43e-02 | 3.74e-01 | 4.38e-01 | 3.81e-01 | 7.50e-01 | 8.66e-01 |
| LONG TERM MEMORY | 36 | 8.20e-01 | 1.00e+00 | 0.12800 | 5.58e-02 | 7.81e-02 | 3.15e-02 | 2.78e-02 | -7.27e-02 | 5.62e-01 | 4.17e-01 | 7.44e-01 | 7.73e-01 | 4.51e-01 |
| REGULATION OF LIPID METABOLIC PROCESS | 329 | 3.01e-01 | 8.28e-01 | 0.12700 | 6.62e-02 | 6.91e-02 | 5.99e-02 | 5.79e-02 | -1.23e-02 | 3.89e-02 | 3.12e-02 | 6.17e-02 | 7.10e-02 | 7.01e-01 |
| SODIUM ION EXPORT ACROSS PLASMA MEMBRANE | 15 | 8.02e-01 | 1.00e+00 | 0.12700 | -2.57e-02 | -1.26e-03 | 2.66e-03 | -1.04e-01 | -6.86e-02 | 8.63e-01 | 9.93e-01 | 9.86e-01 | 4.85e-01 | 6.45e-01 |
| CELLULAR RESPONSE TO DECREASED OXYGEN LEVELS | 146 | 3.60e-01 | 8.76e-01 | 0.12700 | 6.57e-02 | 7.31e-02 | 6.76e-02 | 2.71e-02 | -3.54e-02 | 1.70e-01 | 1.27e-01 | 1.59e-01 | 5.72e-01 | 4.61e-01 |
| MACROPHAGE MIGRATION | 61 | 6.87e-01 | 1.00e+00 | 0.12700 | -6.22e-02 | -6.33e-02 | -8.97e-02 | -1.06e-02 | 1.29e-02 | 4.01e-01 | 3.93e-01 | 2.26e-01 | 8.86e-01 | 8.61e-01 |
| N TERMINAL PROTEIN AMINO ACID MODIFICATION | 27 | 9.27e-01 | 1.00e+00 | 0.12700 | 6.54e-02 | 4.05e-02 | 8.43e-02 | 3.97e-02 | 3.98e-02 | 5.56e-01 | 7.16e-01 | 4.48e-01 | 7.21e-01 | 7.20e-01 |
| REGULATION OF POSTSYNAPTIC SPECIALIZATION ASSEMBLY | 13 | 9.22e-01 | 1.00e+00 | 0.12700 | -5.22e-03 | 3.24e-02 | -4.05e-02 | -1.77e-02 | -1.15e-01 | 9.74e-01 | 8.40e-01 | 8.00e-01 | 9.12e-01 | 4.74e-01 |
| REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 45 | 7.43e-01 | 1.00e+00 | 0.12700 | 3.73e-02 | 9.78e-03 | 9.45e-02 | 6.06e-03 | 7.56e-02 | 6.65e-01 | 9.10e-01 | 2.73e-01 | 9.44e-01 | 3.80e-01 |
| POSITIVE REGULATION OF CARBOHYDRATE METABOLIC PROCESS | 80 | 4.21e-01 | 9.12e-01 | 0.12700 | 3.14e-02 | 4.86e-02 | -9.64e-03 | 6.10e-02 | -9.48e-02 | 6.27e-01 | 4.53e-01 | 8.81e-01 | 3.46e-01 | 1.43e-01 |
| REGULATION OF CELL MORPHOGENESIS | 233 | 4.13e-02 | 3.26e-01 | 0.12700 | -7.19e-02 | -5.63e-02 | -7.96e-02 | -3.08e-02 | -2.25e-02 | 5.87e-02 | 1.38e-01 | 3.63e-02 | 4.19e-01 | 5.55e-01 |
| POSITIVE REGULATION OF REGULATED SECRETORY PATHWAY | 42 | 5.29e-01 | 9.54e-01 | 0.12700 | 3.83e-04 | -3.58e-02 | 7.62e-02 | -4.74e-02 | 8.24e-02 | 9.97e-01 | 6.88e-01 | 3.93e-01 | 5.95e-01 | 3.56e-01 |
| PALLIUM DEVELOPMENT | 183 | 2.27e-02 | 2.25e-01 | 0.12700 | 4.18e-02 | 3.81e-02 | 5.80e-02 | 1.20e-03 | -9.77e-02 | 3.29e-01 | 3.74e-01 | 1.76e-01 | 9.78e-01 | 2.26e-02 |
| AMINO ACID BIOSYNTHETIC PROCESS | 74 | 2.28e-01 | 7.50e-01 | 0.12700 | 5.50e-02 | 6.33e-02 | 9.24e-02 | -1.44e-02 | -1.78e-02 | 4.13e-01 | 3.46e-01 | 1.69e-01 | 8.30e-01 | 7.91e-01 |
| REGULATION OF NEUROTRANSMITTER SECRETION | 76 | 5.22e-01 | 9.53e-01 | 0.12700 | 3.50e-02 | 4.15e-02 | 1.47e-02 | 4.11e-02 | -1.06e-01 | 5.98e-01 | 5.32e-01 | 8.24e-01 | 5.35e-01 | 1.10e-01 |
| NEGATIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 61 | 2.96e-01 | 8.24e-01 | 0.12700 | -4.48e-02 | -6.03e-02 | 4.33e-02 | -8.04e-02 | 4.57e-02 | 5.45e-01 | 4.16e-01 | 5.58e-01 | 2.77e-01 | 5.37e-01 |
| NEURAL PRECURSOR CELL PROLIFERATION | 163 | 9.98e-02 | 5.23e-01 | 0.12700 | 5.92e-02 | 3.88e-02 | 1.04e-01 | 1.08e-02 | 8.66e-03 | 1.92e-01 | 3.93e-01 | 2.16e-02 | 8.12e-01 | 8.49e-01 |
| SECONDARY PALATE DEVELOPMENT | 26 | 6.98e-01 | 1.00e+00 | 0.12700 | 3.91e-02 | 2.41e-02 | 1.05e-01 | -4.27e-02 | -3.23e-02 | 7.30e-01 | 8.32e-01 | 3.53e-01 | 7.06e-01 | 7.76e-01 |
| REGULATION OF BLOOD PRESSURE | 175 | 2.36e-01 | 7.59e-01 | 0.12700 | 5.93e-02 | 6.11e-02 | 4.84e-02 | 7.71e-02 | -2.23e-02 | 1.76e-01 | 1.63e-01 | 2.70e-01 | 7.86e-02 | 6.12e-01 |
| TROPHOBLAST CELL MIGRATION | 17 | 8.85e-01 | 1.00e+00 | 0.12700 | -5.78e-02 | -5.75e-02 | -4.87e-03 | -7.79e-02 | -5.72e-02 | 6.80e-01 | 6.82e-01 | 9.72e-01 | 5.78e-01 | 6.83e-01 |
| MESONEPHRIC TUBULE MORPHOGENESIS | 64 | 1.75e-01 | 6.81e-01 | 0.12700 | -6.41e-03 | -1.33e-02 | 7.67e-02 | -9.25e-02 | 3.66e-02 | 9.29e-01 | 8.54e-01 | 2.88e-01 | 2.01e-01 | 6.12e-01 |
| REGULATION OF NEUROBLAST PROLIFERATION | 53 | 3.38e-01 | 8.59e-01 | 0.12600 | 2.81e-02 | 1.60e-02 | 6.66e-02 | -3.00e-02 | -9.81e-02 | 7.23e-01 | 8.41e-01 | 4.02e-01 | 7.06e-01 | 2.17e-01 |
| POSITIVE REGULATION OF T HELPER CELL DIFFERENTIATION | 22 | 8.16e-01 | 1.00e+00 | 0.12600 | -2.55e-02 | -2.83e-02 | 4.53e-02 | -1.04e-01 | 4.17e-02 | 8.36e-01 | 8.19e-01 | 7.13e-01 | 4.00e-01 | 7.35e-01 |
| DICARBOXYLIC ACID CATABOLIC PROCESS | 18 | 8.90e-01 | 1.00e+00 | 0.12600 | -4.65e-02 | -3.57e-02 | 9.32e-03 | -7.00e-02 | 8.70e-02 | 7.33e-01 | 7.93e-01 | 9.45e-01 | 6.07e-01 | 5.23e-01 |
| CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 175 | 8.71e-04 | 2.02e-02 | 0.12600 | 3.57e-02 | 1.74e-02 | 1.08e-01 | -4.85e-02 | -1.93e-02 | 4.15e-01 | 6.92e-01 | 1.36e-02 | 2.69e-01 | 6.60e-01 |
| GLYCINE METABOLIC PROCESS | 15 | 9.11e-01 | 1.00e+00 | 0.12600 | -2.61e-02 | -2.71e-02 | -1.19e-02 | -5.38e-02 | 1.07e-01 | 8.61e-01 | 8.56e-01 | 9.37e-01 | 7.19e-01 | 4.72e-01 |
| ANTIMICROBIAL HUMORAL RESPONSE | 119 | 3.41e-02 | 2.94e-01 | 0.12600 | -3.52e-02 | -3.72e-02 | -2.69e-02 | 3.04e-02 | 1.08e-01 | 5.07e-01 | 4.83e-01 | 6.13e-01 | 5.67e-01 | 4.15e-02 |
| CELL ADHESION MOLECULE PRODUCTION | 18 | 3.58e-01 | 8.74e-01 | 0.12600 | 3.08e-02 | -3.23e-02 | 1.17e-01 | -1.69e-02 | -9.71e-03 | 8.21e-01 | 8.12e-01 | 3.92e-01 | 9.01e-01 | 9.43e-01 |
| CELLULAR RESPONSE TO ELECTRICAL STIMULUS | 13 | 9.58e-01 | 1.00e+00 | 0.12600 | 4.50e-02 | 7.83e-02 | -5.18e-03 | 4.82e-02 | -7.38e-02 | 7.79e-01 | 6.25e-01 | 9.74e-01 | 7.63e-01 | 6.45e-01 |
| DEOXYRIBONUCLEOSIDE METABOLIC PROCESS | 11 | 9.39e-01 | 1.00e+00 | 0.12600 | 6.58e-02 | 3.94e-02 | 3.16e-02 | 9.50e-02 | -7.16e-03 | 7.06e-01 | 8.21e-01 | 8.56e-01 | 5.85e-01 | 9.67e-01 |
| URETERIC BUD ELONGATION | 8 | 9.35e-01 | 1.00e+00 | 0.12600 | 2.44e-02 | 3.11e-02 | 9.13e-02 | -7.70e-02 | 1.09e-02 | 9.05e-01 | 8.79e-01 | 6.55e-01 | 7.06e-01 | 9.57e-01 |
| REGULATION OF MACROPHAGE CHEMOTAXIS | 28 | 8.93e-01 | 1.00e+00 | 0.12600 | -4.03e-02 | -5.63e-02 | -2.47e-02 | -6.56e-03 | 1.02e-01 | 7.12e-01 | 6.06e-01 | 8.21e-01 | 9.52e-01 | 3.48e-01 |
| HYALURONAN BIOSYNTHETIC PROCESS | 14 | 4.09e-01 | 9.08e-01 | 0.12600 | -6.40e-02 | -1.57e-02 | -3.05e-02 | -5.05e-02 | 9.00e-02 | 6.78e-01 | 9.19e-01 | 8.44e-01 | 7.44e-01 | 5.60e-01 |
| OSTEOBLAST DIFFERENTIATION | 249 | 3.55e-02 | 3.00e-01 | 0.12600 | 5.48e-02 | 4.99e-02 | 5.94e-02 | 2.03e-02 | -8.06e-02 | 1.37e-01 | 1.75e-01 | 1.07e-01 | 5.82e-01 | 2.86e-02 |
| ADIPOSE TISSUE DEVELOPMENT | 57 | 7.41e-01 | 1.00e+00 | 0.12600 | -2.46e-02 | -4.09e-02 | 2.80e-02 | -2.84e-02 | 1.10e-01 | 7.48e-01 | 5.93e-01 | 7.15e-01 | 7.10e-01 | 1.52e-01 |
| VIRAL GENOME REPLICATION | 124 | 2.41e-02 | 2.33e-01 | 0.12600 | -3.93e-02 | -4.69e-02 | 4.79e-02 | -8.96e-02 | 4.26e-02 | 4.50e-01 | 3.67e-01 | 3.57e-01 | 8.50e-02 | 4.13e-01 |
| LIMBIC SYSTEM DEVELOPMENT | 117 | 1.70e-02 | 1.85e-01 | 0.12600 | 3.70e-02 | 2.96e-02 | 1.04e-01 | -4.84e-02 | -2.02e-02 | 4.89e-01 | 5.81e-01 | 5.14e-02 | 3.66e-01 | 7.05e-01 |
| MANGANESE ION TRANSPORT | 11 | 9.13e-01 | 1.00e+00 | 0.12600 | -3.69e-02 | -2.01e-02 | -9.80e-02 | 6.51e-02 | 1.61e-02 | 8.32e-01 | 9.08e-01 | 5.74e-01 | 7.09e-01 | 9.26e-01 |
| ODONTOBLAST DIFFERENTIATION | 11 | 9.27e-01 | 1.00e+00 | 0.12600 | 7.11e-03 | -2.68e-02 | 9.30e-02 | -6.90e-02 | 4.08e-02 | 9.67e-01 | 8.78e-01 | 5.93e-01 | 6.92e-01 | 8.15e-01 |
| NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 107 | 2.17e-01 | 7.39e-01 | 0.12600 | -2.15e-02 | -4.88e-02 | 4.87e-02 | -4.89e-02 | 9.06e-02 | 7.01e-01 | 3.83e-01 | 3.85e-01 | 3.82e-01 | 1.05e-01 |
| CELL CYCLE G2 M PHASE TRANSITION | 148 | 5.23e-02 | 3.75e-01 | 0.12600 | 3.54e-02 | 2.05e-02 | 9.98e-02 | -3.49e-02 | 5.44e-02 | 4.57e-01 | 6.67e-01 | 3.61e-02 | 4.64e-01 | 2.53e-01 |
| PROTEASOMAL PROTEIN CATABOLIC PROCESS | 509 | 7.21e-05 | 2.63e-03 | 0.12600 | 4.67e-02 | 3.61e-02 | 1.00e-01 | -2.67e-03 | 4.74e-02 | 7.10e-02 | 1.63e-01 | 1.06e-04 | 9.18e-01 | 6.74e-02 |
| TETRAPYRROLE BIOSYNTHETIC PROCESS | 31 | 5.57e-01 | 9.68e-01 | 0.12600 | 2.26e-02 | 2.77e-02 | 9.09e-02 | -1.61e-02 | 7.74e-02 | 8.27e-01 | 7.90e-01 | 3.81e-01 | 8.77e-01 | 4.56e-01 |
| EMBRYONIC VISCEROCRANIUM MORPHOGENESIS | 10 | 9.50e-01 | 1.00e+00 | 0.12600 | -3.20e-02 | -3.38e-02 | -6.46e-03 | -3.44e-02 | -1.11e-01 | 8.61e-01 | 8.53e-01 | 9.72e-01 | 8.51e-01 | 5.42e-01 |
| RESPONSE TO FIBROBLAST GROWTH FACTOR | 116 | 5.54e-01 | 9.66e-01 | 0.12600 | 6.15e-02 | 5.82e-02 | 6.70e-02 | 4.34e-02 | -4.71e-02 | 2.52e-01 | 2.79e-01 | 2.12e-01 | 4.19e-01 | 3.81e-01 |
| SPINDLE LOCALIZATION | 62 | 8.02e-01 | 1.00e+00 | 0.12600 | 6.29e-02 | 6.23e-02 | 7.98e-02 | 2.56e-02 | -2.99e-02 | 3.91e-01 | 3.96e-01 | 2.77e-01 | 7.28e-01 | 6.84e-01 |
| MONONUCLEAR CELL DIFFERENTIATION | 464 | 3.33e-04 | 9.42e-03 | 0.12600 | -5.17e-02 | -6.83e-02 | 1.43e-02 | -8.02e-02 | 4.22e-02 | 5.62e-02 | 1.17e-02 | 5.98e-01 | 3.08e-03 | 1.19e-01 |
| VASCULAR ENDOTHELIAL GROWTH FACTOR PRODUCTION | 57 | 8.77e-01 | 1.00e+00 | 0.12500 | -6.26e-02 | -5.42e-02 | -7.75e-02 | -5.36e-02 | 2.55e-03 | 4.13e-01 | 4.79e-01 | 3.12e-01 | 4.84e-01 | 9.73e-01 |
| NUCLEUS ORGANIZATION | 142 | 3.94e-01 | 8.93e-01 | 0.12500 | 5.36e-02 | 4.73e-02 | 8.60e-02 | 9.77e-03 | 5.60e-02 | 2.70e-01 | 3.30e-01 | 7.69e-02 | 8.41e-01 | 2.49e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO EARLY ENDOSOME | 8 | 9.78e-01 | 1.00e+00 | 0.12500 | -7.33e-02 | -4.62e-02 | -8.51e-02 | -2.27e-02 | 2.17e-02 | 7.20e-01 | 8.21e-01 | 6.77e-01 | 9.11e-01 | 9.15e-01 |
| POSITIVE REGULATION OF REGULATORY T CELL DIFFERENTIATION | 21 | 7.04e-01 | 1.00e+00 | 0.12500 | -1.01e-02 | -3.61e-02 | 9.14e-02 | -5.59e-02 | 5.33e-02 | 9.36e-01 | 7.75e-01 | 4.68e-01 | 6.57e-01 | 6.72e-01 |
| FATTY ACID METABOLIC PROCESS | 388 | 1.43e-01 | 6.29e-01 | 0.12500 | 6.20e-02 | 6.95e-02 | 3.79e-02 | 7.43e-02 | -8.69e-03 | 3.59e-02 | 1.87e-02 | 1.99e-01 | 1.20e-02 | 7.69e-01 |
| ORGANELLE FUSION | 156 | 4.72e-02 | 3.52e-01 | 0.12500 | -3.63e-02 | -3.54e-02 | 1.89e-02 | -9.03e-02 | 6.79e-02 | 4.34e-01 | 4.45e-01 | 6.84e-01 | 5.15e-02 | 1.43e-01 |
| NEGATIVE REGULATION OF GENE EXPRESSION VIA CPG ISLAND METHYLATION | 7 | 9.87e-01 | 1.00e+00 | 0.12500 | 1.53e-02 | 2.14e-02 | 2.57e-02 | -4.76e-02 | -1.10e-01 | 9.44e-01 | 9.22e-01 | 9.06e-01 | 8.27e-01 | 6.15e-01 |
| GLYCEROLIPID METABOLIC PROCESS | 372 | 2.41e-01 | 7.67e-01 | 0.12500 | 6.29e-02 | 6.74e-02 | 4.60e-02 | 6.71e-02 | 2.38e-02 | 3.71e-02 | 2.56e-02 | 1.28e-01 | 2.63e-02 | 4.30e-01 |
| ACTOMYOSIN CONTRACTILE RING ORGANIZATION | 10 | 9.20e-01 | 1.00e+00 | 0.12500 | 2.27e-02 | 4.70e-02 | -1.68e-02 | 4.04e-02 | 1.05e-01 | 9.01e-01 | 7.97e-01 | 9.27e-01 | 8.25e-01 | 5.65e-01 |
| NEUROTRANSMITTER TRANSPORT | 198 | 3.25e-01 | 8.49e-01 | 0.12500 | 6.28e-02 | 6.46e-02 | 6.74e-02 | 4.73e-02 | -2.73e-02 | 1.28e-01 | 1.17e-01 | 1.02e-01 | 2.51e-01 | 5.07e-01 |
| VENTRICULAR CARDIAC MUSCLE CELL DIFFERENTIATION | 14 | 8.81e-01 | 1.00e+00 | 0.12500 | -7.20e-03 | -3.37e-02 | 7.93e-02 | -8.98e-02 | 1.07e-02 | 9.63e-01 | 8.27e-01 | 6.08e-01 | 5.61e-01 | 9.45e-01 |
| CELLULAR RESPONSE TO UV | 87 | 6.33e-01 | 9.96e-01 | 0.12500 | 6.96e-02 | 6.52e-02 | 7.83e-02 | 2.00e-02 | -2.22e-03 | 2.62e-01 | 2.93e-01 | 2.07e-01 | 7.47e-01 | 9.71e-01 |
| REGULATION OF BILE ACID METABOLIC PROCESS | 15 | 9.77e-01 | 1.00e+00 | 0.12500 | 4.65e-02 | 7.00e-02 | -8.38e-03 | 4.84e-02 | -7.83e-02 | 7.55e-01 | 6.39e-01 | 9.55e-01 | 7.46e-01 | 5.99e-01 |
| CHONDROITIN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS | 23 | 3.67e-01 | 8.79e-01 | 0.12500 | -2.82e-03 | -4.60e-02 | 8.99e-02 | -5.75e-02 | -4.59e-02 | 9.81e-01 | 7.03e-01 | 4.56e-01 | 6.33e-01 | 7.03e-01 |
| REGULATION OF AMIDE METABOLIC PROCESS | 570 | 2.12e-02 | 2.16e-01 | 0.12500 | 6.71e-02 | 7.05e-02 | 6.78e-02 | 3.69e-02 | -1.30e-02 | 6.18e-03 | 4.02e-03 | 5.66e-03 | 1.32e-01 | 5.96e-01 |
| NEGATIVE REGULATION OF VIRAL INDUCED CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 35 | 7.85e-01 | 1.00e+00 | 0.12500 | 2.54e-03 | -8.58e-03 | 7.18e-02 | -5.46e-02 | 8.58e-02 | 9.79e-01 | 9.30e-01 | 4.62e-01 | 5.76e-01 | 3.80e-01 |
| REGULATION OF RHODOPSIN MEDIATED SIGNALING PATHWAY | 9 | 9.13e-01 | 1.00e+00 | 0.12500 | 1.48e-02 | 2.92e-02 | -8.43e-02 | 8.56e-02 | 6.73e-03 | 9.39e-01 | 8.79e-01 | 6.61e-01 | 6.56e-01 | 9.72e-01 |
| POSITIVE REGULATION OF CELL CYCLE | 319 | 7.45e-02 | 4.49e-01 | 0.12500 | 6.16e-02 | 5.24e-02 | 8.95e-02 | 3.07e-02 | 8.32e-03 | 5.85e-02 | 1.07e-01 | 6.00e-03 | 3.45e-01 | 7.98e-01 |
| POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 140 | 4.78e-01 | 9.40e-01 | 0.12500 | -5.95e-02 | -6.21e-02 | -1.31e-02 | -8.62e-02 | 2.30e-02 | 2.24e-01 | 2.04e-01 | 7.89e-01 | 7.81e-02 | 6.39e-01 |
| NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 241 | 3.21e-03 | 5.52e-02 | 0.12500 | 2.49e-02 | 9.41e-03 | 9.85e-02 | -2.98e-02 | 6.49e-02 | 5.06e-01 | 8.01e-01 | 8.43e-03 | 4.26e-01 | 8.25e-02 |
| 7 METHYLGUANOSINE RNA CAPPING | 8 | 9.97e-01 | 1.00e+00 | 0.12500 | -6.60e-02 | -7.86e-02 | -3.21e-02 | -6.09e-02 | -1.56e-02 | 7.47e-01 | 7.00e-01 | 8.75e-01 | 7.65e-01 | 9.39e-01 |
| NEGATIVE REGULATION OF ALPHA BETA T CELL ACTIVATION | 44 | 5.85e-01 | 9.85e-01 | 0.12400 | -4.19e-02 | -4.85e-02 | 3.39e-02 | -1.00e-01 | 1.31e-02 | 6.31e-01 | 5.78e-01 | 6.97e-01 | 2.49e-01 | 8.80e-01 |
| INTERLEUKIN 8 PRODUCTION | 97 | 4.69e-01 | 9.38e-01 | 0.12400 | -5.01e-02 | -5.64e-02 | -5.10e-03 | -9.72e-02 | -1.74e-02 | 3.94e-01 | 3.37e-01 | 9.31e-01 | 9.81e-02 | 7.67e-01 |
| NEGATIVE REGULATION OF VASCULAR ASSOCIATED SMOOTH MUSCLE CELL PROLIFERATION | 34 | 7.64e-01 | 1.00e+00 | 0.12400 | -3.91e-02 | -6.61e-02 | 8.75e-03 | -7.24e-02 | 6.49e-02 | 6.93e-01 | 5.05e-01 | 9.30e-01 | 4.65e-01 | 5.12e-01 |
| ACIDIC AMINO ACID TRANSPORT | 65 | 7.45e-01 | 1.00e+00 | 0.12400 | 3.29e-02 | 4.96e-02 | -1.21e-02 | 3.61e-02 | -1.02e-01 | 6.46e-01 | 4.89e-01 | 8.66e-01 | 6.14e-01 | 1.54e-01 |
| NEGATIVE REGULATION OF PROGRAMMED CELL DEATH | 881 | 7.48e-07 | 5.21e-05 | 0.12400 | 5.45e-02 | 4.53e-02 | 9.58e-02 | 3.15e-03 | 3.47e-02 | 6.02e-03 | 2.26e-02 | 1.36e-06 | 8.74e-01 | 8.03e-02 |
| SELECTIVE AUTOPHAGY | 92 | 4.01e-01 | 9.01e-01 | 0.12400 | -6.03e-02 | -5.46e-02 | -1.34e-02 | -9.18e-02 | -1.38e-02 | 3.17e-01 | 3.65e-01 | 8.25e-01 | 1.28e-01 | 8.20e-01 |
| ACTIVATION INDUCED CELL DEATH OF T CELLS | 8 | 9.54e-01 | 1.00e+00 | 0.12400 | -6.09e-03 | 4.86e-03 | 3.67e-03 | -8.98e-02 | -8.52e-02 | 9.76e-01 | 9.81e-01 | 9.86e-01 | 6.60e-01 | 6.76e-01 |
| NEGATIVE REGULATION OF AMYLOID BETA CLEARANCE | 11 | 9.69e-01 | 1.00e+00 | 0.12400 | 1.66e-02 | 2.81e-02 | -3.12e-03 | 4.12e-02 | 1.12e-01 | 9.24e-01 | 8.72e-01 | 9.86e-01 | 8.13e-01 | 5.19e-01 |
| NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 502 | 2.54e-04 | 7.60e-03 | 0.12400 | -5.41e-02 | -7.31e-02 | 6.98e-03 | -7.49e-02 | 3.82e-02 | 3.79e-02 | 5.03e-03 | 7.89e-01 | 4.07e-03 | 1.42e-01 |
| COLUMNAR CUBOIDAL EPITHELIAL CELL DEVELOPMENT | 51 | 5.89e-01 | 9.86e-01 | 0.12400 | 1.81e-02 | 1.85e-02 | 1.17e-02 | -2.89e-02 | -1.17e-01 | 8.23e-01 | 8.19e-01 | 8.85e-01 | 7.21e-01 | 1.48e-01 |
| NEGATIVE REGULATION OF GONADOTROPIN SECRETION | 7 | 9.36e-01 | 1.00e+00 | 0.12400 | 8.10e-02 | 5.79e-02 | 6.46e-02 | 2.97e-02 | 1.97e-02 | 7.10e-01 | 7.91e-01 | 7.67e-01 | 8.92e-01 | 9.28e-01 |
| POSITIVE REGULATION OF TISSUE REMODELING | 23 | 8.69e-01 | 1.00e+00 | 0.12400 | -5.55e-02 | -8.27e-02 | 4.06e-03 | -7.35e-02 | -4.36e-03 | 6.45e-01 | 4.92e-01 | 9.73e-01 | 5.42e-01 | 9.71e-01 |
| CELLULAR RESPONSE TO PROGESTERONE STIMULUS | 7 | 9.56e-01 | 1.00e+00 | 0.12400 | 1.04e-02 | 3.91e-03 | -5.10e-02 | 8.35e-02 | 7.52e-02 | 9.62e-01 | 9.86e-01 | 8.15e-01 | 7.02e-01 | 7.31e-01 |
| ENDOTHELIAL CELL APOPTOTIC PROCESS | 67 | 5.60e-01 | 9.69e-01 | 0.12400 | -6.69e-02 | -5.52e-02 | -5.96e-02 | -4.11e-02 | -5.08e-02 | 3.44e-01 | 4.35e-01 | 3.99e-01 | 5.60e-01 | 4.72e-01 |
| CONNECTIVE TISSUE REPLACEMENT INVOLVED IN INFLAMMATORY RESPONSE WOUND HEALING | 6 | 8.11e-01 | 1.00e+00 | 0.12400 | 2.14e-02 | 1.36e-02 | 1.21e-01 | 7.00e-03 | 8.78e-03 | 9.28e-01 | 9.54e-01 | 6.09e-01 | 9.76e-01 | 9.70e-01 |
| CYTOKINE PRODUCTION | 840 | 4.62e-04 | 1.23e-02 | 0.12400 | -5.69e-02 | -6.74e-02 | -1.24e-02 | -6.63e-02 | 5.49e-02 | 5.09e-03 | 9.09e-04 | 5.43e-01 | 1.09e-03 | 6.88e-03 |
| REGULATION OF ERYTHROCYTE DIFFERENTIATION | 44 | 7.09e-01 | 1.00e+00 | 0.12400 | 2.90e-02 | 2.42e-03 | 9.24e-02 | -2.07e-02 | 7.42e-02 | 7.40e-01 | 9.78e-01 | 2.89e-01 | 8.12e-01 | 3.95e-01 |
| PURINE RIBONUCLEOSIDE CATABOLIC PROCESS | 6 | 8.99e-01 | 1.00e+00 | 0.12400 | 1.64e-02 | 5.66e-03 | 4.24e-02 | 5.00e-02 | -1.03e-01 | 9.45e-01 | 9.81e-01 | 8.57e-01 | 8.32e-01 | 6.61e-01 |
| POSITIVE REGULATION OF CHOLESTEROL STORAGE | 8 | 9.89e-01 | 1.00e+00 | 0.12400 | -1.82e-02 | -2.04e-03 | -1.73e-02 | -3.86e-02 | -1.15e-01 | 9.29e-01 | 9.92e-01 | 9.32e-01 | 8.50e-01 | 5.74e-01 |
| TELENCEPHALON DEVELOPMENT | 268 | 5.65e-03 | 8.33e-02 | 0.12400 | 5.21e-02 | 4.58e-02 | 7.57e-02 | 5.50e-03 | -6.87e-02 | 1.42e-01 | 1.97e-01 | 3.29e-02 | 8.77e-01 | 5.30e-02 |
| POSITIVE REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 16 | 9.78e-01 | 1.00e+00 | 0.12400 | 5.18e-02 | 6.39e-02 | 4.07e-02 | 4.57e-02 | -6.92e-02 | 7.20e-01 | 6.58e-01 | 7.78e-01 | 7.52e-01 | 6.32e-01 |
| PEPTIDE CATABOLIC PROCESS | 22 | 8.75e-01 | 1.00e+00 | 0.12400 | -2.13e-02 | -8.82e-04 | -2.51e-02 | -3.00e-02 | -1.15e-01 | 8.63e-01 | 9.94e-01 | 8.39e-01 | 8.08e-01 | 3.49e-01 |
| SYNAPTONEMAL COMPLEX ORGANIZATION | 25 | 8.80e-01 | 1.00e+00 | 0.12400 | 6.83e-02 | 4.61e-02 | 5.41e-02 | 6.09e-02 | -4.32e-02 | 5.55e-01 | 6.90e-01 | 6.40e-01 | 5.98e-01 | 7.09e-01 |
| NEGATIVE REGULATION OF PROTEOLYSIS INVOLVED IN PROTEIN CATABOLIC PROCESS | 59 | 3.48e-01 | 8.67e-01 | 0.12400 | -1.32e-02 | -2.32e-02 | 7.20e-02 | -6.32e-02 | 7.34e-02 | 8.61e-01 | 7.57e-01 | 3.39e-01 | 4.01e-01 | 3.30e-01 |
| NEGATIVE REGULATION OF GTPASE ACTIVITY | 21 | 8.73e-01 | 1.00e+00 | 0.12300 | 3.62e-02 | 2.43e-02 | -1.63e-03 | 7.20e-02 | -9.03e-02 | 7.74e-01 | 8.47e-01 | 9.90e-01 | 5.68e-01 | 4.74e-01 |
| NEGATIVE REGULATION OF ASTROCYTE DIFFERENTIATION | 15 | 7.07e-01 | 1.00e+00 | 0.12300 | -1.15e-02 | 2.31e-02 | -2.83e-02 | -8.41e-02 | -8.19e-02 | 9.39e-01 | 8.77e-01 | 8.50e-01 | 5.73e-01 | 5.83e-01 |
| ARTERY MORPHOGENESIS | 81 | 1.40e-01 | 6.24e-01 | 0.12300 | 2.99e-02 | 4.86e-03 | 1.06e-01 | -4.81e-02 | 2.72e-02 | 6.41e-01 | 9.40e-01 | 9.87e-02 | 4.55e-01 | 6.72e-01 |
| REGULATION OF DNA TOPOISOMERASE ATP HYDROLYZING ACTIVITY | 5 | 8.81e-01 | 1.00e+00 | 0.12300 | -7.55e-03 | -1.27e-02 | 1.05e-01 | -5.87e-02 | -2.44e-02 | 9.77e-01 | 9.61e-01 | 6.85e-01 | 8.20e-01 | 9.25e-01 |
| MONOSACCHARIDE CATABOLIC PROCESS | 49 | 9.78e-01 | 1.00e+00 | 0.12300 | 6.37e-02 | 6.55e-02 | 5.95e-02 | 5.76e-02 | 3.40e-03 | 4.40e-01 | 4.28e-01 | 4.71e-01 | 4.85e-01 | 9.67e-01 |
| RNA PROCESSING | 1257 | 4.09e-08 | 3.85e-06 | 0.12300 | 5.56e-02 | 4.85e-02 | 8.78e-02 | 9.28e-03 | 4.44e-02 | 9.04e-04 | 3.78e-03 | 1.63e-07 | 5.80e-01 | 8.03e-03 |
| REGULATION OF MACROPHAGE DIFFERENTIATION | 24 | 7.08e-01 | 1.00e+00 | 0.12300 | -3.55e-02 | -7.12e-02 | 4.72e-02 | -4.39e-02 | 6.87e-02 | 7.63e-01 | 5.46e-01 | 6.89e-01 | 7.09e-01 | 5.60e-01 |
| CELLULAR RESPONSE TO HEAT | 62 | 2.68e-01 | 7.95e-01 | 0.12300 | 5.05e-02 | 6.97e-02 | 5.87e-02 | 5.85e-02 | 3.05e-02 | 4.92e-01 | 3.43e-01 | 4.24e-01 | 4.25e-01 | 6.78e-01 |
| PROCESS UTILIZING AUTOPHAGIC MECHANISM | 552 | 1.20e-06 | 7.38e-05 | 0.12300 | 6.23e-03 | -3.38e-03 | 7.48e-02 | -3.64e-02 | 9.07e-02 | 8.02e-01 | 8.92e-01 | 2.65e-03 | 1.44e-01 | 2.65e-04 |
| REGULATION OF PEPTIDASE ACTIVITY | 299 | 8.64e-03 | 1.14e-01 | 0.12300 | -4.64e-02 | -4.92e-02 | 6.15e-03 | -9.53e-02 | 3.87e-02 | 1.67e-01 | 1.43e-01 | 8.55e-01 | 4.59e-03 | 2.50e-01 |
| FLUID TRANSPORT | 37 | 9.79e-01 | 1.00e+00 | 0.12300 | 6.69e-02 | 5.71e-02 | 6.97e-02 | 4.57e-02 | 2.25e-02 | 4.81e-01 | 5.48e-01 | 4.63e-01 | 6.31e-01 | 8.13e-01 |
| INSEMINATION | 12 | 9.84e-01 | 1.00e+00 | 0.12300 | -3.25e-03 | 9.65e-03 | -6.89e-02 | 3.75e-02 | -9.44e-02 | 9.84e-01 | 9.54e-01 | 6.79e-01 | 8.22e-01 | 5.71e-01 |
| CELLULAR KETONE METABOLIC PROCESS | 220 | 7.61e-02 | 4.53e-01 | 0.12300 | 6.02e-02 | 6.84e-02 | 7.12e-02 | 3.42e-02 | -2.50e-02 | 1.24e-01 | 8.04e-02 | 6.87e-02 | 3.82e-01 | 5.23e-01 |
| HEAT GENERATION | 17 | 9.33e-01 | 1.00e+00 | 0.12300 | 2.77e-02 | 2.35e-02 | 7.57e-02 | 2.55e-02 | 8.63e-02 | 8.43e-01 | 8.67e-01 | 5.89e-01 | 8.56e-01 | 5.38e-01 |
| POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR PRODUCTION | 29 | 6.91e-01 | 1.00e+00 | 0.12300 | 2.62e-02 | 1.88e-02 | 9.16e-02 | 1.13e-02 | 7.48e-02 | 8.07e-01 | 8.61e-01 | 3.93e-01 | 9.16e-01 | 4.86e-01 |
| GLIAL CELL PROLIFERATION | 54 | 7.33e-01 | 1.00e+00 | 0.12300 | 6.20e-02 | 7.58e-02 | 6.87e-02 | 2.63e-02 | -1.12e-02 | 4.30e-01 | 3.35e-01 | 3.82e-01 | 7.38e-01 | 8.87e-01 |
| PEPTIDYL TYROSINE DEPHOSPHORYLATION INVOLVED IN INACTIVATION OF PROTEIN KINASE ACTIVITY | 8 | 9.29e-01 | 1.00e+00 | 0.12300 | -4.04e-02 | -3.58e-02 | -1.03e-01 | -3.06e-02 | -2.49e-02 | 8.43e-01 | 8.61e-01 | 6.13e-01 | 8.81e-01 | 9.03e-01 |
| REGULATION OF TRANSLATION IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 11 | 9.84e-01 | 1.00e+00 | 0.12300 | 6.59e-02 | 7.61e-02 | 8.61e-03 | 6.51e-02 | -2.60e-02 | 7.05e-01 | 6.62e-01 | 9.61e-01 | 7.08e-01 | 8.81e-01 |
| REGULATION OF PHOSPHOLIPASE C ACTIVITY | 39 | 6.79e-01 | 1.00e+00 | 0.12300 | -5.36e-02 | -6.30e-02 | -7.20e-02 | 3.16e-03 | -5.54e-02 | 5.63e-01 | 4.96e-01 | 4.37e-01 | 9.73e-01 | 5.49e-01 |
| PROTEIN LOCALIZATION TO VACUOLE | 85 | 4.87e-01 | 9.43e-01 | 0.12300 | -1.78e-02 | -2.87e-02 | 4.47e-02 | -5.49e-02 | 9.46e-02 | 7.77e-01 | 6.48e-01 | 4.76e-01 | 3.82e-01 | 1.31e-01 |
| REGULATION OF STEROID HORMONE BIOSYNTHETIC PROCESS | 15 | 9.28e-01 | 1.00e+00 | 0.12300 | 4.95e-02 | 6.83e-02 | 3.94e-02 | 7.77e-02 | 1.97e-02 | 7.40e-01 | 6.47e-01 | 7.92e-01 | 6.02e-01 | 8.95e-01 |
| RELAXATION OF MUSCLE | 33 | 4.26e-01 | 9.15e-01 | 0.12300 | 1.21e-02 | 6.30e-03 | 7.55e-02 | -5.24e-02 | -8.02e-02 | 9.04e-01 | 9.50e-01 | 4.53e-01 | 6.03e-01 | 4.25e-01 |
| POSITIVE REGULATION OF LYASE ACTIVITY | 39 | 9.65e-01 | 1.00e+00 | 0.12300 | -5.21e-02 | -3.83e-02 | -7.90e-02 | -3.33e-02 | -5.94e-02 | 5.74e-01 | 6.79e-01 | 3.93e-01 | 7.19e-01 | 5.21e-01 |
| ASPARTATE TRANSMEMBRANE TRANSPORT | 19 | 7.72e-01 | 1.00e+00 | 0.12300 | 3.77e-02 | 5.75e-02 | 7.12e-03 | 9.82e-02 | -2.43e-02 | 7.76e-01 | 6.64e-01 | 9.57e-01 | 4.59e-01 | 8.54e-01 |
| ENDOCYTOSIS INVOLVED IN VIRAL ENTRY INTO HOST CELL | 12 | 9.91e-01 | 1.00e+00 | 0.12200 | 6.06e-02 | 7.92e-02 | 3.52e-02 | 6.00e-02 | 1.39e-02 | 7.16e-01 | 6.35e-01 | 8.33e-01 | 7.19e-01 | 9.33e-01 |
| MAMMARY GLAND EPITHELIUM DEVELOPMENT | 65 | 9.68e-01 | 1.00e+00 | 0.12200 | 6.63e-02 | 6.51e-02 | 6.22e-02 | 4.97e-02 | -1.06e-03 | 3.55e-01 | 3.64e-01 | 3.86e-01 | 4.88e-01 | 9.88e-01 |
| REGULATION OF PLASMINOGEN ACTIVATION | 18 | 7.36e-01 | 1.00e+00 | 0.12200 | -2.22e-02 | -6.19e-02 | 5.01e-02 | -9.01e-02 | 3.22e-03 | 8.70e-01 | 6.50e-01 | 7.13e-01 | 5.08e-01 | 9.81e-01 |
| BIOLOGICAL PROCESS INVOLVED IN INTERACTION WITH HOST | 206 | 9.62e-02 | 5.12e-01 | 0.12200 | 4.44e-03 | 9.92e-04 | 3.86e-02 | -1.55e-03 | 1.16e-01 | 9.13e-01 | 9.80e-01 | 3.39e-01 | 9.69e-01 | 4.11e-03 |
| ESTABLISHMENT OF ENDOTHELIAL BARRIER | 51 | 6.75e-01 | 1.00e+00 | 0.12200 | -3.57e-02 | -5.05e-02 | 3.03e-02 | -4.27e-02 | 9.16e-02 | 6.59e-01 | 5.33e-01 | 7.08e-01 | 5.98e-01 | 2.58e-01 |
| RESPONSE TO MECHANICAL STIMULUS | 209 | 1.44e-01 | 6.29e-01 | 0.12200 | 3.40e-02 | 4.32e-02 | 6.59e-03 | 3.13e-02 | -1.04e-01 | 3.97e-01 | 2.81e-01 | 8.70e-01 | 4.35e-01 | 9.26e-03 |
| REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 224 | 3.85e-01 | 8.92e-01 | 0.12200 | -6.36e-02 | -5.93e-02 | -3.50e-02 | -7.81e-02 | 1.22e-03 | 1.01e-01 | 1.26e-01 | 3.66e-01 | 4.40e-02 | 9.75e-01 |
| POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 142 | 1.86e-01 | 6.94e-01 | 0.12200 | -5.41e-02 | -6.25e-02 | 1.00e-02 | -7.21e-02 | 5.26e-02 | 2.66e-01 | 1.99e-01 | 8.37e-01 | 1.38e-01 | 2.80e-01 |
| MAINTENANCE OF PROTEIN LOCATION IN CELL | 60 | 3.71e-01 | 8.81e-01 | 0.12200 | 3.36e-02 | 2.65e-02 | 9.35e-02 | -4.74e-02 | 4.55e-02 | 6.53e-01 | 7.22e-01 | 2.11e-01 | 5.26e-01 | 5.42e-01 |
| REGULATION OF DNA METHYLATION | 20 | 6.43e-01 | 1.00e+00 | 0.12200 | 3.03e-02 | 3.17e-02 | 1.07e-01 | -1.12e-02 | 3.57e-02 | 8.14e-01 | 8.06e-01 | 4.06e-01 | 9.31e-01 | 7.82e-01 |
| CELLULAR RESPONSE TO STARVATION | 171 | 1.01e-01 | 5.25e-01 | 0.12200 | 3.65e-02 | 4.40e-02 | 5.58e-02 | 3.50e-02 | 8.51e-02 | 4.10e-01 | 3.21e-01 | 2.08e-01 | 4.30e-01 | 5.49e-02 |
| REGULATION OF HETEROCHROMATIN ORGANIZATION | 23 | 9.02e-01 | 1.00e+00 | 0.12200 | -2.89e-02 | -3.44e-02 | 2.12e-03 | -6.48e-02 | -9.28e-02 | 8.11e-01 | 7.75e-01 | 9.86e-01 | 5.90e-01 | 4.41e-01 |
| RNA MODIFICATION | 170 | 1.10e-02 | 1.35e-01 | 0.12200 | -1.34e-02 | -2.64e-02 | 7.10e-02 | -7.09e-02 | 6.24e-02 | 7.63e-01 | 5.52e-01 | 1.10e-01 | 1.11e-01 | 1.60e-01 |
| TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 42 | 3.89e-01 | 8.92e-01 | 0.12200 | -3.49e-02 | -2.81e-02 | -3.18e-02 | -4.71e-03 | -1.09e-01 | 6.95e-01 | 7.52e-01 | 7.21e-01 | 9.58e-01 | 2.23e-01 |
| POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 59 | 6.35e-01 | 9.98e-01 | 0.12200 | 3.47e-02 | 2.81e-02 | 7.86e-02 | -2.05e-02 | 7.89e-02 | 6.45e-01 | 7.09e-01 | 2.96e-01 | 7.85e-01 | 2.94e-01 |
| ARTERY DEVELOPMENT | 111 | 6.30e-02 | 4.12e-01 | 0.12200 | 4.37e-02 | 1.93e-02 | 1.09e-01 | -2.72e-02 | 1.31e-03 | 4.26e-01 | 7.25e-01 | 4.80e-02 | 6.21e-01 | 9.81e-01 |
| NEGATIVE REGULATION OF PLASMINOGEN ACTIVATION | 8 | 9.62e-01 | 1.00e+00 | 0.12200 | 1.59e-02 | -4.37e-03 | 6.75e-02 | -5.15e-02 | -8.57e-02 | 9.38e-01 | 9.83e-01 | 7.41e-01 | 8.01e-01 | 6.75e-01 |
| MIRNA CATABOLIC PROCESS | 18 | 8.26e-01 | 1.00e+00 | 0.12200 | -4.67e-02 | -4.77e-02 | 3.67e-02 | -8.14e-02 | 4.88e-02 | 7.31e-01 | 7.26e-01 | 7.88e-01 | 5.50e-01 | 7.20e-01 |
| PHAGOCYTOSIS RECOGNITION | 28 | 2.57e-01 | 7.84e-01 | 0.12200 | -4.65e-02 | -8.86e-02 | -5.34e-02 | 7.57e-04 | -4.42e-02 | 6.70e-01 | 4.17e-01 | 6.25e-01 | 9.94e-01 | 6.86e-01 |
| NCRNA EXPORT FROM NUCLEUS | 9 | 9.64e-01 | 1.00e+00 | 0.12200 | -3.64e-02 | -2.13e-02 | 4.77e-03 | -1.06e-01 | -4.20e-02 | 8.50e-01 | 9.12e-01 | 9.80e-01 | 5.82e-01 | 8.27e-01 |
| BIOLOGICAL PROCESS INVOLVED IN SYMBIOTIC INTERACTION | 310 | 1.45e-02 | 1.63e-01 | 0.12200 | -2.27e-02 | -2.81e-02 | 1.82e-02 | -2.07e-02 | 1.13e-01 | 4.91e-01 | 3.94e-01 | 5.81e-01 | 5.30e-01 | 6.37e-04 |
| SKELETAL MUSCLE CELL PROLIFERATION | 24 | 8.81e-01 | 1.00e+00 | 0.12200 | 5.43e-02 | 4.36e-02 | 9.30e-02 | -1.75e-02 | -3.09e-02 | 6.45e-01 | 7.12e-01 | 4.30e-01 | 8.82e-01 | 7.93e-01 |
| NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 28 | 8.68e-01 | 1.00e+00 | 0.12100 | -6.49e-02 | -7.03e-02 | -2.61e-02 | -5.91e-02 | -3.77e-02 | 5.52e-01 | 5.20e-01 | 8.11e-01 | 5.88e-01 | 7.30e-01 |
| NEGATIVE REGULATION OF DEFENSE RESPONSE TO VIRUS | 49 | 7.87e-01 | 1.00e+00 | 0.12100 | 4.09e-02 | 2.33e-02 | 9.61e-02 | 5.14e-03 | 5.71e-02 | 6.20e-01 | 7.78e-01 | 2.44e-01 | 9.50e-01 | 4.89e-01 |
| POSITIVE REGULATION OF TOR SIGNALING | 65 | 4.61e-01 | 9.32e-01 | 0.12100 | -1.60e-02 | -2.95e-02 | 4.04e-02 | -7.39e-02 | 8.07e-02 | 8.23e-01 | 6.81e-01 | 5.73e-01 | 3.03e-01 | 2.61e-01 |
| ECTODERM DEVELOPMENT | 21 | 5.59e-01 | 9.69e-01 | 0.12100 | 4.55e-02 | 3.99e-03 | 8.32e-02 | 7.26e-02 | 2.08e-02 | 7.18e-01 | 9.75e-01 | 5.09e-01 | 5.65e-01 | 8.69e-01 |
| REGULATION OF PROTEIN DEACETYLATION | 31 | 8.89e-01 | 1.00e+00 | 0.12100 | -3.35e-02 | -2.30e-02 | -2.37e-02 | -5.40e-02 | -9.79e-02 | 7.47e-01 | 8.25e-01 | 8.19e-01 | 6.03e-01 | 3.46e-01 |
| NEGATIVE REGULATION OF DNA BIOSYNTHETIC PROCESS | 36 | 8.70e-01 | 1.00e+00 | 0.12100 | -4.25e-02 | -4.50e-02 | 1.63e-02 | -7.18e-02 | 7.38e-02 | 6.59e-01 | 6.41e-01 | 8.65e-01 | 4.56e-01 | 4.44e-01 |
| PROSTANOID METABOLIC PROCESS | 50 | 8.12e-01 | 1.00e+00 | 0.12100 | -2.84e-02 | -2.08e-02 | -6.54e-02 | -2.79e-02 | -9.15e-02 | 7.28e-01 | 7.99e-01 | 4.23e-01 | 7.33e-01 | 2.63e-01 |
| POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 37 | 1.88e-01 | 6.95e-01 | 0.12100 | 2.41e-02 | 4.06e-02 | 9.25e-02 | -1.76e-02 | 5.98e-02 | 7.99e-01 | 6.69e-01 | 3.30e-01 | 8.53e-01 | 5.29e-01 |
| ICOSANOID TRANSPORT | 63 | 7.49e-02 | 4.50e-01 | 0.12100 | 4.63e-02 | 4.70e-02 | 8.04e-02 | 6.18e-02 | -1.49e-03 | 5.25e-01 | 5.19e-01 | 2.70e-01 | 3.96e-01 | 9.84e-01 |
| CERAMIDE METABOLIC PROCESS | 106 | 2.34e-01 | 7.56e-01 | 0.12100 | -2.48e-02 | -3.34e-02 | 3.94e-02 | -3.71e-02 | 9.99e-02 | 6.59e-01 | 5.53e-01 | 4.83e-01 | 5.09e-01 | 7.56e-02 |
| CELLULAR RESPONSE TO INSULIN LIKE GROWTH FACTOR STIMULUS | 7 | 9.92e-01 | 1.00e+00 | 0.12100 | -5.08e-02 | -5.67e-02 | -4.76e-02 | 9.34e-03 | 8.04e-02 | 8.16e-01 | 7.95e-01 | 8.27e-01 | 9.66e-01 | 7.12e-01 |
| REGULATION OF RESPONSE TO OXIDATIVE STRESS | 31 | 6.62e-01 | 1.00e+00 | 0.12100 | -4.40e-02 | -2.99e-02 | -7.55e-02 | -2.44e-02 | 7.40e-02 | 6.72e-01 | 7.73e-01 | 4.67e-01 | 8.14e-01 | 4.75e-01 |
| BONE MATURATION | 26 | 3.31e-01 | 8.56e-01 | 0.12100 | -5.11e-02 | -1.98e-03 | -5.88e-02 | -8.91e-02 | -2.45e-02 | 6.52e-01 | 9.86e-01 | 6.04e-01 | 4.32e-01 | 8.29e-01 |
| RUFFLE ASSEMBLY | 45 | 5.07e-01 | 9.48e-01 | 0.12100 | 3.83e-02 | 4.88e-02 | 6.96e-02 | 3.66e-02 | 6.76e-02 | 6.57e-01 | 5.71e-01 | 4.19e-01 | 6.71e-01 | 4.33e-01 |
| REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO HYDROGEN PEROXIDE | 6 | 9.98e-01 | 1.00e+00 | 0.12100 | 6.40e-02 | 8.20e-02 | 3.45e-02 | 4.91e-02 | -1.36e-02 | 7.86e-01 | 7.28e-01 | 8.83e-01 | 8.35e-01 | 9.54e-01 |
| ENDOLYSOSOMAL TOLL LIKE RECEPTOR SIGNALING PATHWAY | 41 | 8.77e-01 | 1.00e+00 | 0.12100 | 4.61e-02 | 2.53e-02 | 8.55e-02 | 7.19e-03 | 6.68e-02 | 6.09e-01 | 7.79e-01 | 3.43e-01 | 9.37e-01 | 4.60e-01 |
| CALCIUM ION REGULATED EXOCYTOSIS | 64 | 9.05e-01 | 1.00e+00 | 0.12100 | 6.07e-02 | 7.06e-02 | 3.43e-02 | 4.72e-02 | -5.01e-02 | 4.01e-01 | 3.28e-01 | 6.35e-01 | 5.14e-01 | 4.88e-01 |
| ANIMAL ORGAN MORPHOGENESIS | 1014 | 3.27e-05 | 1.34e-03 | 0.12100 | 6.11e-02 | 6.33e-02 | 6.67e-02 | 3.22e-02 | -3.66e-02 | 9.95e-04 | 6.44e-04 | 3.27e-04 | 8.25e-02 | 4.87e-02 |
| REGULATION OF PRESYNAPTIC CYTOSOLIC CALCIUM ION CONCENTRATION | 13 | 7.55e-01 | 1.00e+00 | 0.12100 | 2.90e-02 | 2.65e-02 | 7.39e-02 | 1.76e-02 | -8.51e-02 | 8.57e-01 | 8.69e-01 | 6.45e-01 | 9.12e-01 | 5.95e-01 |
| REGULATION OF POLYSACCHARIDE METABOLIC PROCESS | 44 | 1.13e-01 | 5.59e-01 | 0.12100 | -1.06e-02 | -3.80e-03 | 8.23e-02 | -8.52e-02 | 1.94e-02 | 9.03e-01 | 9.65e-01 | 3.45e-01 | 3.28e-01 | 8.24e-01 |
| STORE OPERATED CALCIUM ENTRY | 21 | 9.55e-01 | 1.00e+00 | 0.12000 | -4.57e-02 | -6.07e-02 | 1.99e-02 | -8.63e-02 | 2.99e-02 | 7.17e-01 | 6.30e-01 | 8.75e-01 | 4.94e-01 | 8.13e-01 |
| POST ANAL TAIL MORPHOGENESIS | 18 | 8.96e-01 | 1.00e+00 | 0.12000 | 8.66e-03 | -1.26e-02 | 7.60e-02 | 6.29e-03 | 9.18e-02 | 9.49e-01 | 9.26e-01 | 5.77e-01 | 9.63e-01 | 5.00e-01 |
| REGULATION OF STORE OPERATED CALCIUM ENTRY | 15 | 9.79e-01 | 1.00e+00 | 0.12000 | -3.14e-02 | -3.85e-02 | 3.09e-02 | -6.43e-02 | 8.31e-02 | 8.33e-01 | 7.96e-01 | 8.36e-01 | 6.66e-01 | 5.77e-01 |
| TELOMERE CAPPING | 39 | 7.95e-01 | 1.00e+00 | 0.12000 | -7.56e-03 | -1.95e-02 | 3.36e-02 | 1.09e-02 | 1.13e-01 | 9.35e-01 | 8.33e-01 | 7.17e-01 | 9.06e-01 | 2.22e-01 |
| NEGATIVE REGULATION OF DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 155 | 1.29e-01 | 5.96e-01 | 0.12000 | -5.06e-02 | -6.81e-02 | 1.57e-02 | -7.95e-02 | 2.60e-02 | 2.77e-01 | 1.43e-01 | 7.36e-01 | 8.75e-02 | 5.77e-01 |
| VENTRICULAR CARDIAC MUSCLE CELL ACTION POTENTIAL | 34 | 3.12e-01 | 8.38e-01 | 0.12000 | 2.40e-02 | 5.75e-02 | -2.52e-02 | 9.73e-02 | -2.13e-02 | 8.09e-01 | 5.62e-01 | 7.99e-01 | 3.26e-01 | 8.30e-01 |
| HOMOLOGOUS RECOMBINATION | 65 | 3.20e-01 | 8.47e-01 | 0.12000 | 1.80e-02 | 1.17e-03 | 9.91e-02 | -3.61e-02 | 5.45e-02 | 8.02e-01 | 9.87e-01 | 1.67e-01 | 6.14e-01 | 4.47e-01 |
| POSITIVE REGULATION OF MACROPHAGE MIGRATION | 26 | 8.01e-01 | 1.00e+00 | 0.12000 | 2.03e-02 | 3.33e-03 | 3.72e-03 | 7.60e-02 | 9.05e-02 | 8.58e-01 | 9.77e-01 | 9.74e-01 | 5.02e-01 | 4.24e-01 |
| ADENYLATE CYCLASE INHIBITING G PROTEIN COUPLED GLUTAMATE RECEPTOR SIGNALING PATHWAY | 9 | 9.76e-01 | 1.00e+00 | 0.12000 | -9.48e-03 | 1.90e-02 | -8.52e-02 | 1.12e-02 | -8.11e-02 | 9.61e-01 | 9.22e-01 | 6.58e-01 | 9.54e-01 | 6.74e-01 |
| POSITIVE REGULATION OF SMOOTH MUSCLE CELL MIGRATION | 45 | 8.61e-01 | 1.00e+00 | 0.12000 | 5.50e-02 | 5.52e-02 | 4.17e-02 | 1.88e-02 | -7.90e-02 | 5.24e-01 | 5.21e-01 | 6.28e-01 | 8.28e-01 | 3.59e-01 |
| PROTEOLYSIS INVOLVED IN PROTEIN CATABOLIC PROCESS | 715 | 1.11e-06 | 6.98e-05 | 0.12000 | 3.56e-02 | 2.61e-02 | 9.11e-02 | -1.00e-02 | 6.36e-02 | 1.05e-01 | 2.35e-01 | 3.31e-05 | 6.48e-01 | 3.77e-03 |
| POSITIVE REGULATION OF CALCIUM ION IMPORT ACROSS PLASMA MEMBRANE | 11 | 9.18e-01 | 1.00e+00 | 0.12000 | 2.15e-02 | -3.91e-03 | 6.68e-02 | -4.41e-02 | -8.63e-02 | 9.02e-01 | 9.82e-01 | 7.01e-01 | 8.00e-01 | 6.20e-01 |
| VASCULAR ENDOTHELIAL CELL PROLIFERATION | 49 | 4.50e-01 | 9.30e-01 | 0.12000 | -3.72e-02 | -2.54e-02 | -7.78e-02 | 1.11e-02 | 7.81e-02 | 6.52e-01 | 7.58e-01 | 3.46e-01 | 8.93e-01 | 3.44e-01 |
| REGULATION OF MORPHOGENESIS OF A BRANCHING STRUCTURE | 48 | 3.92e-01 | 8.92e-01 | 0.12000 | 1.39e-02 | 2.06e-02 | 4.08e-02 | -2.40e-02 | -1.07e-01 | 8.67e-01 | 8.05e-01 | 6.25e-01 | 7.74e-01 | 2.00e-01 |
| POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION | 81 | 5.84e-01 | 9.85e-01 | 0.11900 | 5.19e-02 | 4.52e-02 | 5.30e-02 | 4.40e-02 | -6.92e-02 | 4.19e-01 | 4.82e-01 | 4.09e-01 | 4.93e-01 | 2.82e-01 |
| NCRNA CATABOLIC PROCESS | 54 | 3.58e-01 | 8.74e-01 | 0.11900 | -1.83e-03 | -2.28e-02 | 8.68e-02 | -6.72e-02 | 4.07e-02 | 9.81e-01 | 7.72e-01 | 2.70e-01 | 3.93e-01 | 6.04e-01 |
| POSITIVE REGULATION OF CYTOSOLIC CALCIUM ION CONCENTRATION | 165 | 4.08e-01 | 9.08e-01 | 0.11900 | -6.23e-02 | -7.72e-02 | -3.25e-02 | -5.09e-02 | 2.70e-02 | 1.67e-01 | 8.70e-02 | 4.72e-01 | 2.59e-01 | 5.50e-01 |
| EPITHELIAL TUBE MORPHOGENESIS | 326 | 2.41e-02 | 2.33e-01 | 0.11900 | 5.42e-02 | 4.80e-02 | 9.10e-02 | 1.92e-02 | 1.81e-02 | 9.24e-02 | 1.36e-01 | 4.74e-03 | 5.51e-01 | 5.75e-01 |
| POSITIVE REGULATION OF HYDROLASE ACTIVITY | 484 | 1.12e-01 | 5.59e-01 | 0.11900 | -6.18e-02 | -6.44e-02 | -3.19e-02 | -6.17e-02 | 3.76e-02 | 1.98e-02 | 1.53e-02 | 2.30e-01 | 2.00e-02 | 1.56e-01 |
| REGULATION OF RESPONSE TO BIOTIC STIMULUS | 492 | 3.25e-03 | 5.56e-02 | 0.11900 | -5.24e-02 | -6.54e-02 | 2.89e-03 | -7.87e-02 | 3.14e-02 | 4.65e-02 | 1.30e-02 | 9.13e-01 | 2.79e-03 | 2.32e-01 |
| MITOCHONDRIAL GENOME MAINTENANCE | 31 | 3.08e-01 | 8.35e-01 | 0.11900 | -1.43e-02 | -6.23e-02 | 7.62e-02 | -6.53e-02 | 4.63e-03 | 8.91e-01 | 5.48e-01 | 4.63e-01 | 5.29e-01 | 9.64e-01 |
| CEREBELLAR CORTEX FORMATION | 24 | 8.90e-01 | 1.00e+00 | 0.11900 | 2.50e-02 | 2.02e-02 | 8.63e-02 | -3.45e-02 | 6.71e-02 | 8.32e-01 | 8.64e-01 | 4.64e-01 | 7.70e-01 | 5.69e-01 |
| GLIAL CELL DIFFERENTIATION | 246 | 6.70e-03 | 9.33e-02 | 0.11900 | 4.86e-02 | 4.75e-02 | 9.42e-02 | -1.57e-02 | 2.08e-02 | 1.90e-01 | 2.00e-01 | 1.09e-02 | 6.72e-01 | 5.75e-01 |
| BIOLOGICAL PROCESS INVOLVED IN INTERSPECIES INTERACTION BETWEEN ORGANISMS | 1629 | 2.08e-08 | 2.11e-06 | 0.11900 | -5.68e-02 | -6.67e-02 | -1.03e-02 | -6.32e-02 | 4.88e-02 | 1.31e-04 | 7.16e-06 | 4.87e-01 | 2.12e-05 | 1.01e-03 |
| ORGANIC ACID TRANSMEMBRANE TRANSPORT | 146 | 1.69e-01 | 6.74e-01 | 0.11900 | 5.83e-02 | 7.95e-02 | 3.76e-02 | 3.16e-02 | -4.49e-02 | 2.24e-01 | 9.74e-02 | 4.33e-01 | 5.09e-01 | 3.49e-01 |
| POSITIVE REGULATION OF DNA METHYLATION DEPENDENT HETEROCHROMATIN FORMATION | 11 | 9.99e-01 | 1.00e+00 | 0.11900 | -5.64e-02 | -5.18e-02 | -4.38e-02 | -7.30e-02 | -3.23e-02 | 7.46e-01 | 7.66e-01 | 8.02e-01 | 6.75e-01 | 8.53e-01 |
| MESODERM MORPHOGENESIS | 76 | 6.04e-01 | 9.90e-01 | 0.11900 | 5.00e-02 | 4.93e-02 | 5.68e-02 | 3.11e-02 | -7.08e-02 | 4.51e-01 | 4.57e-01 | 3.92e-01 | 6.39e-01 | 2.86e-01 |
| RESPONSE TO BACTERIUM | 668 | 3.32e-04 | 9.42e-03 | 0.11900 | -5.77e-02 | -7.01e-02 | -8.82e-03 | -5.93e-02 | 4.78e-02 | 1.09e-02 | 2.00e-03 | 6.98e-01 | 8.95e-03 | 3.50e-02 |
| RESPONSE TO OXIDATIVE STRESS | 384 | 1.75e-01 | 6.81e-01 | 0.11900 | 6.16e-02 | 6.18e-02 | 7.12e-02 | 3.80e-02 | 1.78e-03 | 3.82e-02 | 3.77e-02 | 1.66e-02 | 2.01e-01 | 9.52e-01 |
| CORTICOTROPIN SECRETION | 7 | 8.38e-01 | 1.00e+00 | 0.11900 | -1.97e-02 | -4.23e-02 | -7.30e-02 | 1.77e-02 | 7.94e-02 | 9.28e-01 | 8.46e-01 | 7.38e-01 | 9.35e-01 | 7.16e-01 |
| REGULATION OF CELL CELL ADHESION MEDIATED BY CADHERIN | 20 | 8.28e-01 | 1.00e+00 | 0.11900 | 1.14e-02 | 4.31e-03 | 9.27e-02 | -3.78e-02 | 6.29e-02 | 9.30e-01 | 9.73e-01 | 4.73e-01 | 7.70e-01 | 6.27e-01 |
| LACTATION | 37 | 7.21e-01 | 1.00e+00 | 0.11900 | 1.23e-02 | 5.84e-03 | 8.18e-02 | -2.71e-02 | 8.06e-02 | 8.97e-01 | 9.51e-01 | 3.89e-01 | 7.75e-01 | 3.96e-01 |
| REGULATION OF CELLULAR SENESCENCE | 52 | 6.10e-01 | 9.90e-01 | 0.11900 | 5.14e-02 | 2.85e-02 | 9.68e-02 | -1.13e-02 | 3.38e-02 | 5.21e-01 | 7.22e-01 | 2.27e-01 | 8.88e-01 | 6.73e-01 |
| ACTOMYOSIN STRUCTURE ORGANIZATION | 205 | 2.80e-01 | 8.06e-01 | 0.11900 | 5.50e-02 | 6.72e-02 | 6.85e-03 | 7.74e-02 | -2.30e-02 | 1.75e-01 | 9.73e-02 | 8.66e-01 | 5.60e-02 | 5.71e-01 |
| MODULATION BY HOST OF VIRAL GENOME REPLICATION | 23 | 8.85e-01 | 1.00e+00 | 0.11900 | -3.82e-02 | -5.94e-02 | 4.11e-02 | -7.35e-02 | 4.48e-02 | 7.51e-01 | 6.22e-01 | 7.33e-01 | 5.42e-01 | 7.10e-01 |
| REGULATION OF SUPRAMOLECULAR FIBER ORGANIZATION | 368 | 1.44e-01 | 6.29e-01 | 0.11900 | 5.99e-02 | 6.62e-02 | 6.08e-02 | 4.79e-02 | 9.62e-03 | 4.82e-02 | 2.91e-02 | 4.53e-02 | 1.14e-01 | 7.51e-01 |
| MAST CELL MEDIATED IMMUNITY | 55 | 5.49e-01 | 9.63e-01 | 0.11900 | -3.58e-02 | -6.35e-02 | 2.84e-02 | -7.97e-02 | 3.97e-02 | 6.46e-01 | 4.15e-01 | 7.16e-01 | 3.06e-01 | 6.10e-01 |
| RETICULOPHAGY | 18 | 8.03e-01 | 1.00e+00 | 0.11900 | 1.05e-02 | -2.17e-03 | 8.42e-02 | -7.12e-02 | -4.21e-02 | 9.39e-01 | 9.87e-01 | 5.36e-01 | 6.01e-01 | 7.57e-01 |
| COLLAGEN BIOSYNTHETIC PROCESS | 46 | 6.43e-01 | 1.00e+00 | 0.11900 | 3.49e-02 | 2.45e-02 | 1.00e-01 | -1.05e-02 | 4.59e-02 | 6.82e-01 | 7.74e-01 | 2.40e-01 | 9.02e-01 | 5.90e-01 |
| SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE | 19 | 5.41e-01 | 9.59e-01 | 0.11800 | 1.73e-02 | 3.82e-02 | 8.53e-02 | -6.48e-02 | 2.84e-02 | 8.96e-01 | 7.73e-01 | 5.20e-01 | 6.25e-01 | 8.31e-01 |
| NEGATIVE REGULATION OF STEROID HORMONE BIOSYNTHETIC PROCESS | 6 | 9.24e-01 | 1.00e+00 | 0.11800 | -3.95e-02 | -3.05e-02 | 3.56e-02 | -7.83e-02 | -6.43e-02 | 8.67e-01 | 8.97e-01 | 8.80e-01 | 7.40e-01 | 7.85e-01 |
| MEIOTIC CHROMOSOME SEGREGATION | 90 | 2.71e-01 | 7.99e-01 | 0.11800 | 5.10e-02 | 2.62e-02 | 1.02e-01 | -8.10e-03 | 1.38e-02 | 4.03e-01 | 6.68e-01 | 9.32e-02 | 8.94e-01 | 8.21e-01 |
| POSITIVE REGULATION OF GLUCOSE METABOLIC PROCESS | 44 | 8.60e-01 | 1.00e+00 | 0.11800 | 4.97e-02 | 5.82e-02 | -2.21e-04 | 8.94e-02 | 1.30e-02 | 5.68e-01 | 5.04e-01 | 9.98e-01 | 3.05e-01 | 8.81e-01 |
| INTRACELLULAR AMINO ACID HOMEOSTASIS | 8 | 8.33e-01 | 1.00e+00 | 0.11800 | -6.79e-03 | -5.97e-02 | 5.39e-02 | -6.69e-02 | -5.48e-02 | 9.73e-01 | 7.70e-01 | 7.92e-01 | 7.43e-01 | 7.88e-01 |
| SPERM DNA CONDENSATION | 17 | 8.53e-01 | 1.00e+00 | 0.11800 | -1.88e-02 | -2.11e-02 | -5.15e-02 | -4.87e-02 | -9.04e-02 | 8.93e-01 | 8.80e-01 | 7.13e-01 | 7.28e-01 | 5.19e-01 |
| REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION | 77 | 5.36e-01 | 9.57e-01 | 0.11800 | -6.75e-02 | -5.57e-02 | -7.06e-02 | -1.89e-02 | 3.10e-02 | 3.06e-01 | 3.98e-01 | 2.84e-01 | 7.74e-01 | 6.38e-01 |
| RESPONSE TO REACTIVE OXYGEN SPECIES | 196 | 5.86e-01 | 9.85e-01 | 0.11800 | 6.20e-02 | 5.73e-02 | 7.00e-02 | 4.23e-02 | -1.16e-02 | 1.35e-01 | 1.67e-01 | 9.10e-02 | 3.08e-01 | 7.80e-01 |
| COPPER ION IMPORT | 6 | 6.50e-01 | 1.00e+00 | 0.11800 | -2.09e-02 | -4.04e-02 | 3.88e-02 | 8.08e-02 | 6.18e-02 | 9.29e-01 | 8.64e-01 | 8.69e-01 | 7.32e-01 | 7.93e-01 |
| TYPE I INTERFERON PRODUCTION | 115 | 1.02e-01 | 5.29e-01 | 0.11800 | -1.02e-02 | -3.47e-02 | 7.20e-02 | -5.85e-02 | 6.28e-02 | 8.51e-01 | 5.20e-01 | 1.82e-01 | 2.78e-01 | 2.44e-01 |
| REGULATION OF METALLOPEPTIDASE ACTIVITY | 22 | 6.93e-01 | 1.00e+00 | 0.11800 | -1.42e-02 | -9.96e-04 | -8.43e-02 | -1.68e-02 | -7.90e-02 | 9.08e-01 | 9.94e-01 | 4.94e-01 | 8.92e-01 | 5.21e-01 |
| ACTIVATION OF PHOSPHOLIPASE C ACTIVITY | 27 | 9.10e-01 | 1.00e+00 | 0.11700 | -4.16e-02 | -4.08e-02 | -6.09e-02 | 1.83e-05 | -8.18e-02 | 7.08e-01 | 7.14e-01 | 5.84e-01 | 1.00e+00 | 4.62e-01 |
| PLACENTA DEVELOPMENT | 146 | 2.51e-01 | 7.77e-01 | 0.11700 | 3.85e-02 | 2.95e-02 | 8.94e-02 | -3.88e-03 | 5.84e-02 | 4.22e-01 | 5.38e-01 | 6.22e-02 | 9.36e-01 | 2.23e-01 |
| MITRAL VALVE DEVELOPMENT | 13 | 9.65e-01 | 1.00e+00 | 0.11700 | 5.53e-02 | 7.90e-02 | 3.10e-02 | 1.58e-02 | -5.69e-02 | 7.30e-01 | 6.22e-01 | 8.46e-01 | 9.21e-01 | 7.22e-01 |
| OXIDATIVE RNA DEMETHYLATION | 5 | 9.82e-01 | 1.00e+00 | 0.11700 | 7.39e-03 | -3.80e-02 | 4.61e-02 | 9.56e-03 | 1.00e-01 | 9.77e-01 | 8.83e-01 | 8.58e-01 | 9.70e-01 | 6.98e-01 |
| REGULATION OF GONAD DEVELOPMENT | 12 | 8.98e-01 | 1.00e+00 | 0.11700 | 1.32e-02 | 4.62e-03 | 3.94e-03 | 5.40e-02 | -1.03e-01 | 9.37e-01 | 9.78e-01 | 9.81e-01 | 7.46e-01 | 5.36e-01 |
| REGULATION OF ORGANELLE ASSEMBLY | 232 | 2.39e-02 | 2.33e-01 | 0.11700 | 2.58e-02 | 1.92e-02 | 8.27e-02 | -9.30e-03 | 7.61e-02 | 4.99e-01 | 6.14e-01 | 3.00e-02 | 8.07e-01 | 4.58e-02 |
| DETECTION OF MECHANICAL STIMULUS | 53 | 6.31e-01 | 9.96e-01 | 0.11700 | -3.02e-02 | -1.56e-02 | -7.65e-02 | 2.94e-02 | -7.66e-02 | 7.04e-01 | 8.44e-01 | 3.35e-01 | 7.11e-01 | 3.35e-01 |
| POSITIVE REGULATION OF CATION CHANNEL ACTIVITY | 47 | 9.24e-01 | 1.00e+00 | 0.11700 | -6.26e-02 | -6.03e-02 | -2.69e-02 | -7.39e-02 | -2.78e-03 | 4.58e-01 | 4.74e-01 | 7.50e-01 | 3.81e-01 | 9.74e-01 |
| REGULATION OF CILIUM DEPENDENT CELL MOTILITY | 27 | 9.41e-01 | 1.00e+00 | 0.11700 | 6.64e-02 | 6.77e-02 | 2.29e-02 | 6.30e-02 | -1.59e-02 | 5.51e-01 | 5.42e-01 | 8.37e-01 | 5.71e-01 | 8.86e-01 |
| INSULIN RECEPTOR SIGNALING PATHWAY | 123 | 6.90e-01 | 1.00e+00 | 0.11700 | -5.88e-02 | -5.73e-02 | -3.19e-02 | -5.20e-02 | 5.69e-02 | 2.60e-01 | 2.72e-01 | 5.42e-01 | 3.19e-01 | 2.76e-01 |
| D AMINO ACID TRANSPORT | 6 | 9.95e-01 | 1.00e+00 | 0.11700 | -5.29e-02 | -7.61e-02 | -1.95e-02 | -5.55e-02 | -4.05e-02 | 8.22e-01 | 7.47e-01 | 9.34e-01 | 8.14e-01 | 8.64e-01 |
| RIBONUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 54 | 9.17e-01 | 1.00e+00 | 0.11700 | 6.11e-02 | 6.48e-02 | 5.67e-02 | 3.71e-02 | 3.41e-02 | 4.37e-01 | 4.10e-01 | 4.71e-01 | 6.37e-01 | 6.65e-01 |
| MYOSIN FILAMENT ORGANIZATION | 6 | 8.94e-01 | 1.00e+00 | 0.11700 | -2.39e-02 | 1.56e-02 | -6.17e-02 | -4.19e-02 | 8.55e-02 | 9.19e-01 | 9.47e-01 | 7.94e-01 | 8.59e-01 | 7.17e-01 |
| KETONE BIOSYNTHETIC PROCESS | 48 | 5.30e-01 | 9.54e-01 | 0.11700 | 4.23e-02 | 5.09e-02 | 8.77e-02 | -7.22e-03 | 3.94e-02 | 6.12e-01 | 5.42e-01 | 2.93e-01 | 9.31e-01 | 6.37e-01 |
| REGULATION OF P38MAPK CASCADE | 47 | 4.36e-01 | 9.22e-01 | 0.11700 | -1.62e-02 | -2.62e-02 | 6.83e-02 | -8.49e-02 | 2.78e-02 | 8.48e-01 | 7.56e-01 | 4.18e-01 | 3.14e-01 | 7.42e-01 |
| MAINTENANCE OF PRESYNAPTIC ACTIVE ZONE STRUCTURE | 6 | 9.84e-01 | 1.00e+00 | 0.11700 | -7.41e-02 | -6.75e-02 | -5.54e-02 | -2.12e-02 | -1.93e-03 | 7.53e-01 | 7.75e-01 | 8.14e-01 | 9.28e-01 | 9.93e-01 |
| TIGHT JUNCTION ORGANIZATION | 78 | 1.09e-01 | 5.46e-01 | 0.11600 | -4.75e-02 | -2.59e-02 | -9.18e-02 | 3.85e-02 | 2.69e-02 | 4.68e-01 | 6.92e-01 | 1.61e-01 | 5.56e-01 | 6.81e-01 |
| REGULATION OF MONOATOMIC ION TRANSMEMBRANE TRANSPORT | 431 | 1.06e-01 | 5.39e-01 | 0.11600 | 5.48e-02 | 6.29e-02 | 3.15e-02 | 5.40e-02 | -5.20e-02 | 5.09e-02 | 2.52e-02 | 2.62e-01 | 5.43e-02 | 6.42e-02 |
| POSITIVE REGULATION OF GLUCOSE TRANSMEMBRANE TRANSPORT | 42 | 7.26e-01 | 1.00e+00 | 0.11600 | 5.44e-02 | 7.35e-02 | 4.04e-02 | 3.51e-02 | 4.85e-02 | 5.42e-01 | 4.10e-01 | 6.50e-01 | 6.94e-01 | 5.87e-01 |
| POSITIVE REGULATION OF INTERFERON BETA PRODUCTION | 37 | 3.60e-01 | 8.76e-01 | 0.11600 | 8.06e-03 | 3.42e-03 | 9.23e-02 | -6.99e-02 | -9.14e-03 | 9.32e-01 | 9.71e-01 | 3.31e-01 | 4.62e-01 | 9.23e-01 |
| NEGATIVE REGULATION OF BINDING | 119 | 1.08e-01 | 5.46e-01 | 0.11600 | -1.88e-02 | -3.74e-02 | 5.76e-02 | -8.14e-02 | 4.30e-02 | 7.23e-01 | 4.81e-01 | 2.78e-01 | 1.25e-01 | 4.18e-01 |
| PROTEIN STABILIZATION | 202 | 2.09e-02 | 2.15e-01 | 0.11600 | 1.32e-02 | 2.16e-03 | 8.22e-02 | -4.12e-02 | 7.01e-02 | 7.46e-01 | 9.58e-01 | 4.39e-02 | 3.13e-01 | 8.59e-02 |
| RIBOSOME ASSOCIATED UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 7 | 9.58e-01 | 1.00e+00 | 0.11600 | 1.76e-02 | 1.63e-02 | 1.01e-01 | -4.90e-02 | 1.92e-02 | 9.36e-01 | 9.41e-01 | 6.43e-01 | 8.23e-01 | 9.30e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO CELL CORTEX | 9 | 8.91e-01 | 1.00e+00 | 0.11600 | 4.46e-02 | 7.28e-02 | 6.92e-02 | 1.78e-02 | -3.40e-02 | 8.17e-01 | 7.05e-01 | 7.19e-01 | 9.26e-01 | 8.60e-01 |
| RESPONSE TO HYDROXYUREA | 11 | 9.96e-01 | 1.00e+00 | 0.11600 | 5.68e-02 | 7.14e-02 | 4.41e-02 | 5.17e-02 | 2.46e-02 | 7.44e-01 | 6.82e-01 | 8.00e-01 | 7.67e-01 | 8.88e-01 |
| REGULATION OF DENDRITIC SPINE DEVELOPMENT | 52 | 4.80e-01 | 9.42e-01 | 0.11600 | -6.72e-02 | -4.31e-02 | -5.36e-02 | -4.91e-02 | 4.32e-02 | 4.02e-01 | 5.91e-01 | 5.04e-01 | 5.40e-01 | 5.90e-01 |
| PERIPHERAL NERVOUS SYSTEM AXON REGENERATION | 8 | 9.90e-01 | 1.00e+00 | 0.11600 | -5.82e-02 | -8.26e-02 | -3.73e-02 | -4.16e-02 | -1.32e-02 | 7.76e-01 | 6.86e-01 | 8.55e-01 | 8.39e-01 | 9.49e-01 |
| CORTICAL ACTIN CYTOSKELETON ORGANIZATION | 42 | 8.96e-01 | 1.00e+00 | 0.11600 | -4.34e-02 | -4.47e-02 | -3.72e-02 | -1.98e-02 | 8.86e-02 | 6.27e-01 | 6.16e-01 | 6.76e-01 | 8.24e-01 | 3.20e-01 |
| NEGATIVE REGULATION OF KINASE ACTIVITY | 190 | 1.30e-02 | 1.51e-01 | 0.11600 | 1.68e-02 | 1.66e-02 | 6.29e-02 | -4.26e-02 | 8.47e-02 | 6.89e-01 | 6.94e-01 | 1.35e-01 | 3.11e-01 | 4.40e-02 |
| POSITIVE REGULATION OF LYMPHOCYTE DIFFERENTIATION | 124 | 2.49e-01 | 7.75e-01 | 0.11600 | -2.43e-02 | -4.32e-02 | 4.48e-02 | -6.16e-02 | 7.24e-02 | 6.41e-01 | 4.06e-01 | 3.89e-01 | 2.36e-01 | 1.64e-01 |
| PRIMARY AMINO COMPOUND METABOLIC PROCESS | 13 | 6.85e-01 | 1.00e+00 | 0.11600 | -4.93e-02 | 8.72e-03 | -9.67e-02 | -3.83e-02 | -1.32e-02 | 7.58e-01 | 9.57e-01 | 5.46e-01 | 8.11e-01 | 9.34e-01 |
| PLATELET AGGREGATION | 71 | 2.63e-01 | 7.90e-01 | 0.11600 | -2.09e-02 | -4.25e-02 | 6.60e-02 | -6.73e-02 | 4.86e-02 | 7.61e-01 | 5.36e-01 | 3.36e-01 | 3.27e-01 | 4.79e-01 |
| POSITIVE REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE PROTEIN KINASE B SIGNAL TRANSDUCTION | 168 | 6.12e-01 | 9.90e-01 | 0.11600 | -5.97e-02 | -6.13e-02 | -4.55e-02 | -5.27e-02 | -3.63e-02 | 1.82e-01 | 1.70e-01 | 3.09e-01 | 2.38e-01 | 4.17e-01 |
| EPITHELIAL CELL DEVELOPMENT | 208 | 3.73e-01 | 8.82e-01 | 0.11600 | 5.62e-02 | 5.91e-02 | 5.04e-02 | 5.36e-02 | -3.69e-02 | 1.62e-01 | 1.42e-01 | 2.10e-01 | 1.82e-01 | 3.59e-01 |
| NEGATIVE REGULATION OF RESPONSE TO WOUNDING | 94 | 6.80e-01 | 1.00e+00 | 0.11600 | -5.16e-02 | -4.95e-02 | -8.24e-02 | -1.25e-02 | -3.69e-02 | 3.87e-01 | 4.07e-01 | 1.67e-01 | 8.34e-01 | 5.36e-01 |
| REGULATION OF CELL PROLIFERATION INVOLVED IN KIDNEY DEVELOPMENT | 16 | 7.96e-01 | 1.00e+00 | 0.11600 | -4.43e-02 | -2.93e-03 | -6.65e-02 | -7.26e-02 | -4.20e-02 | 7.59e-01 | 9.84e-01 | 6.45e-01 | 6.15e-01 | 7.71e-01 |
| REGULATION OF CYTOKINESIS | 87 | 1.11e-01 | 5.51e-01 | 0.11600 | -3.19e-02 | -4.71e-02 | 3.45e-02 | -1.76e-02 | 9.31e-02 | 6.07e-01 | 4.48e-01 | 5.78e-01 | 7.76e-01 | 1.33e-01 |
| HEART DEVELOPMENT | 598 | 6.98e-03 | 9.66e-02 | 0.11600 | 5.85e-02 | 5.48e-02 | 7.53e-02 | 3.25e-02 | -1.51e-02 | 1.45e-02 | 2.19e-02 | 1.66e-03 | 1.75e-01 | 5.27e-01 |
| PROTEOGLYCAN METABOLIC PROCESS | 86 | 4.18e-01 | 9.11e-01 | 0.11600 | 1.90e-02 | 2.87e-02 | -1.02e-03 | 3.14e-02 | -1.06e-01 | 7.60e-01 | 6.45e-01 | 9.87e-01 | 6.15e-01 | 8.97e-02 |
| ALDITOL METABOLIC PROCESS | 21 | 8.08e-01 | 1.00e+00 | 0.11600 | 6.73e-03 | 7.55e-03 | -1.77e-02 | 5.69e-02 | -9.86e-02 | 9.57e-01 | 9.52e-01 | 8.88e-01 | 6.52e-01 | 4.34e-01 |
| REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 23 | 9.39e-01 | 1.00e+00 | 0.11600 | -5.38e-02 | -5.02e-02 | -1.50e-03 | -6.94e-02 | 5.59e-02 | 6.55e-01 | 6.77e-01 | 9.90e-01 | 5.64e-01 | 6.43e-01 |
| REGULATION OF PHOSPHOLIPID BIOSYNTHETIC PROCESS | 16 | 9.69e-01 | 1.00e+00 | 0.11600 | -3.05e-03 | 2.25e-02 | -6.38e-02 | 1.48e-02 | -9.24e-02 | 9.83e-01 | 8.76e-01 | 6.58e-01 | 9.19e-01 | 5.22e-01 |
| REGULATION OF CAMP MEDIATED SIGNALING | 29 | 6.91e-01 | 1.00e+00 | 0.11600 | 3.76e-02 | 7.47e-02 | 1.48e-03 | 2.81e-02 | -7.46e-02 | 7.26e-01 | 4.86e-01 | 9.89e-01 | 7.93e-01 | 4.87e-01 |
| SMOOTH MUSCLE CONTRACTION | 109 | 2.61e-01 | 7.89e-01 | 0.11500 | 5.61e-02 | 3.64e-02 | 7.71e-02 | 4.70e-02 | -2.66e-02 | 3.12e-01 | 5.11e-01 | 1.64e-01 | 3.96e-01 | 6.31e-01 |
| SULFUR COMPOUND METABOLIC PROCESS | 295 | 1.72e-01 | 6.76e-01 | 0.11500 | 5.42e-02 | 6.02e-02 | 3.64e-02 | 6.65e-02 | -3.20e-02 | 1.10e-01 | 7.54e-02 | 2.82e-01 | 4.95e-02 | 3.44e-01 |
| POSITIVE REGULATION OF CHROMATIN ORGANIZATION | 14 | 9.98e-01 | 1.00e+00 | 0.11500 | -5.58e-02 | -5.34e-02 | -3.87e-02 | -6.93e-02 | -3.22e-02 | 7.18e-01 | 7.29e-01 | 8.02e-01 | 6.53e-01 | 8.35e-01 |
| CYTOPLASMIC SEQUESTERING OF PROTEIN | 18 | 5.32e-01 | 9.54e-01 | 0.11500 | 2.32e-02 | 2.18e-02 | 1.09e-01 | -1.11e-02 | 1.71e-02 | 8.65e-01 | 8.73e-01 | 4.23e-01 | 9.35e-01 | 9.00e-01 |
| VIRAL LIFE CYCLE | 309 | 5.12e-03 | 7.85e-02 | 0.11500 | -2.08e-02 | -2.76e-02 | 4.14e-02 | -4.58e-02 | 9.10e-02 | 5.29e-01 | 4.04e-01 | 2.11e-01 | 1.66e-01 | 5.95e-03 |
| SMALL MOLECULE BIOSYNTHETIC PROCESS | 579 | 6.34e-02 | 4.12e-01 | 0.11500 | 5.92e-02 | 5.69e-02 | 6.48e-02 | 4.76e-02 | -7.20e-03 | 1.49e-02 | 1.92e-02 | 7.71e-03 | 5.00e-02 | 7.67e-01 |
| CAMP MEDIATED SIGNALING | 53 | 8.77e-01 | 1.00e+00 | 0.11500 | -5.43e-02 | -3.53e-02 | -6.25e-02 | -4.78e-02 | -5.34e-02 | 4.94e-01 | 6.57e-01 | 4.31e-01 | 5.47e-01 | 5.01e-01 |
| POSITIVE REGULATION OF CYTOSKELETON ORGANIZATION | 180 | 4.45e-01 | 9.29e-01 | 0.11500 | 5.19e-02 | 5.84e-02 | 4.65e-02 | 6.17e-02 | 3.41e-02 | 2.30e-01 | 1.76e-01 | 2.82e-01 | 1.53e-01 | 4.30e-01 |
| REGULATION OF HISTONE DEACETYLATION | 5 | 9.93e-01 | 1.00e+00 | 0.11500 | 2.28e-02 | 5.79e-03 | 1.01e-01 | -4.22e-02 | 2.68e-02 | 9.30e-01 | 9.82e-01 | 6.96e-01 | 8.70e-01 | 9.17e-01 |
| RESPONSE TO MONOSACCHARIDE | 201 | 1.16e-02 | 1.40e-01 | 0.11500 | 4.23e-02 | 4.98e-02 | 6.46e-02 | -1.10e-02 | -6.82e-02 | 3.01e-01 | 2.23e-01 | 1.14e-01 | 7.87e-01 | 9.56e-02 |
| REGULATION OF G2 MI TRANSITION OF MEIOTIC CELL CYCLE | 5 | 9.81e-01 | 1.00e+00 | 0.11500 | -1.60e-02 | -4.26e-02 | 7.42e-02 | -2.60e-02 | 7.04e-02 | 9.51e-01 | 8.69e-01 | 7.74e-01 | 9.20e-01 | 7.85e-01 |
| NEGATIVE REGULATION OF SUPRAMOLECULAR FIBER ORGANIZATION | 153 | 3.67e-01 | 8.79e-01 | 0.11500 | 5.52e-02 | 7.43e-02 | 2.00e-02 | 6.16e-02 | -2.11e-02 | 2.38e-01 | 1.13e-01 | 6.70e-01 | 1.89e-01 | 6.53e-01 |
| NEGATIVE REGULATION OF CENTROSOME DUPLICATION | 12 | 6.16e-01 | 9.90e-01 | 0.11500 | -5.05e-02 | 2.30e-03 | -3.82e-02 | -9.44e-02 | 1.65e-02 | 7.62e-01 | 9.89e-01 | 8.19e-01 | 5.71e-01 | 9.21e-01 |
| SKELETAL MUSCLE SATELLITE CELL PROLIFERATION | 17 | 7.74e-01 | 1.00e+00 | 0.11500 | -3.07e-02 | -5.04e-02 | -3.88e-02 | -6.64e-02 | -6.15e-02 | 8.27e-01 | 7.19e-01 | 7.82e-01 | 6.35e-01 | 6.61e-01 |
| MYELOID CELL HOMEOSTASIS | 166 | 1.43e-01 | 6.28e-01 | 0.11500 | 4.09e-02 | 1.85e-02 | 9.28e-02 | 1.01e-02 | 4.96e-02 | 3.63e-01 | 6.82e-01 | 3.91e-02 | 8.22e-01 | 2.71e-01 |
| VACUOLAR TRANSPORT | 163 | 8.86e-02 | 4.92e-01 | 0.11500 | -1.48e-02 | -2.02e-02 | 4.91e-02 | -5.14e-02 | 8.64e-02 | 7.45e-01 | 6.57e-01 | 2.79e-01 | 2.57e-01 | 5.70e-02 |
| NEGATIVE REGULATION OF SECRETION | 164 | 2.97e-02 | 2.68e-01 | 0.11500 | 4.57e-02 | 2.38e-02 | 1.02e-01 | -1.00e-02 | -5.42e-03 | 3.13e-01 | 6.00e-01 | 2.45e-02 | 8.25e-01 | 9.05e-01 |
| INTRACELLULAR TRANSPORT | 1513 | 9.30e-11 | 1.71e-08 | 0.11400 | 3.81e-02 | 3.06e-02 | 8.19e-02 | -5.26e-03 | 6.31e-02 | 1.31e-02 | 4.63e-02 | 9.94e-08 | 7.32e-01 | 4.04e-05 |
| CELLULAR SENESCENCE | 106 | 3.88e-01 | 8.92e-01 | 0.11400 | 2.27e-02 | 3.47e-03 | 8.00e-02 | -2.25e-02 | 7.53e-02 | 6.87e-01 | 9.51e-01 | 1.55e-01 | 6.88e-01 | 1.80e-01 |
| MEMBRANE REPOLARIZATION DURING ACTION POTENTIAL | 29 | 6.20e-01 | 9.90e-01 | 0.11400 | 4.50e-02 | 6.95e-02 | 5.00e-02 | 3.38e-02 | -5.10e-02 | 6.75e-01 | 5.17e-01 | 6.41e-01 | 7.53e-01 | 6.35e-01 |
| PIGMENT BIOSYNTHETIC PROCESS | 51 | 3.52e-01 | 8.71e-01 | 0.11400 | -4.36e-02 | -5.06e-02 | 1.71e-02 | -2.33e-02 | 8.83e-02 | 5.90e-01 | 5.32e-01 | 8.32e-01 | 7.74e-01 | 2.75e-01 |
| ACTIN MEDIATED CELL CONTRACTION | 101 | 8.47e-02 | 4.79e-01 | 0.11400 | 1.29e-02 | 3.83e-02 | -3.93e-02 | 7.08e-02 | -6.98e-02 | 8.23e-01 | 5.06e-01 | 4.95e-01 | 2.19e-01 | 2.25e-01 |
| LOW DENSITY LIPOPROTEIN PARTICLE CLEARANCE | 34 | 9.77e-01 | 1.00e+00 | 0.11400 | 6.35e-02 | 6.94e-02 | 5.18e-02 | 3.89e-02 | -1.59e-05 | 5.22e-01 | 4.84e-01 | 6.01e-01 | 6.95e-01 | 1.00e+00 |
| SPHINGOID METABOLIC PROCESS | 22 | 8.84e-01 | 1.00e+00 | 0.11400 | -6.85e-02 | -7.01e-02 | -2.79e-02 | -3.95e-02 | 3.30e-02 | 5.78e-01 | 5.69e-01 | 8.21e-01 | 7.48e-01 | 7.89e-01 |
| NEGATIVE REGULATION OF ADENYLATE CYCLASE ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 11 | 9.84e-01 | 1.00e+00 | 0.11400 | 4.80e-02 | 3.86e-02 | 3.61e-02 | 7.75e-02 | -4.37e-02 | 7.83e-01 | 8.25e-01 | 8.36e-01 | 6.56e-01 | 8.02e-01 |
| CALCINEURIN MEDIATED SIGNALING | 48 | 6.50e-01 | 1.00e+00 | 0.11400 | 3.74e-02 | 6.65e-02 | -9.63e-03 | 6.13e-02 | -5.78e-02 | 6.54e-01 | 4.26e-01 | 9.08e-01 | 4.62e-01 | 4.89e-01 |
| REGULATION OF STEM CELL DIFFERENTIATION | 78 | 7.00e-02 | 4.35e-01 | 0.11400 | -2.05e-03 | -1.35e-03 | 7.32e-02 | -8.73e-02 | -7.25e-04 | 9.75e-01 | 9.84e-01 | 2.64e-01 | 1.82e-01 | 9.91e-01 |
| NEGATIVE REGULATION OF CYTOKINE PRODUCTION INVOLVED IN INFLAMMATORY RESPONSE | 37 | 2.30e-01 | 7.52e-01 | 0.11400 | 3.35e-02 | 7.26e-02 | -5.63e-02 | 3.41e-02 | -4.76e-02 | 7.25e-01 | 4.45e-01 | 5.54e-01 | 7.20e-01 | 6.16e-01 |
| CELLULAR RESPONSE TO EXTRACELLULAR STIMULUS | 267 | 5.11e-02 | 3.70e-01 | 0.11400 | 4.01e-02 | 4.44e-02 | 6.45e-02 | 2.83e-02 | 6.67e-02 | 2.60e-01 | 2.12e-01 | 6.94e-02 | 4.27e-01 | 6.06e-02 |
| ORGANELLE MEMBRANE FUSION | 118 | 1.13e-01 | 5.59e-01 | 0.11400 | -4.84e-03 | -5.06e-03 | 4.76e-02 | -6.30e-02 | 8.18e-02 | 9.28e-01 | 9.24e-01 | 3.72e-01 | 2.37e-01 | 1.25e-01 |
| POSITIVE REGULATION OF AMYLOID BETA FORMATION | 20 | 5.59e-01 | 9.69e-01 | 0.11400 | -7.12e-02 | -7.65e-02 | -3.27e-02 | -1.79e-02 | -2.56e-02 | 5.81e-01 | 5.54e-01 | 8.00e-01 | 8.90e-01 | 8.43e-01 |
| REGULATION OF PROTEIN KINASE C SIGNALING | 18 | 9.25e-01 | 1.00e+00 | 0.11400 | 3.31e-02 | 3.32e-02 | 8.27e-02 | 1.42e-02 | 6.08e-02 | 8.08e-01 | 8.08e-01 | 5.44e-01 | 9.17e-01 | 6.55e-01 |
| CHROMOSOME ORGANIZATION INVOLVED IN MEIOTIC CELL CYCLE | 63 | 9.14e-01 | 1.00e+00 | 0.11400 | 5.37e-02 | 4.12e-02 | 8.10e-02 | 2.89e-02 | 3.03e-02 | 4.61e-01 | 5.72e-01 | 2.66e-01 | 6.91e-01 | 6.78e-01 |
| RESPONSE TO EXTRACELLULAR STIMULUS | 501 | 1.28e-02 | 1.49e-01 | 0.11400 | 5.53e-02 | 6.33e-02 | 6.30e-02 | 3.69e-02 | 2.22e-02 | 3.40e-02 | 1.53e-02 | 1.57e-02 | 1.57e-01 | 3.95e-01 |
| RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 258 | 7.38e-03 | 1.01e-01 | 0.11300 | 4.44e-02 | 3.75e-02 | 9.64e-02 | -8.61e-03 | 1.19e-02 | 2.19e-01 | 3.00e-01 | 7.68e-03 | 8.12e-01 | 7.42e-01 |
| RESPONSE TO UV | 147 | 3.97e-01 | 8.96e-01 | 0.11300 | 5.85e-02 | 5.94e-02 | 7.32e-02 | 1.18e-02 | -2.08e-02 | 2.21e-01 | 2.14e-01 | 1.26e-01 | 8.05e-01 | 6.63e-01 |
| REGULATION OF LIPID TRANSPORT | 153 | 4.26e-01 | 9.15e-01 | 0.11300 | 5.43e-02 | 5.43e-02 | 7.12e-02 | 4.32e-02 | 7.14e-03 | 2.47e-01 | 2.47e-01 | 1.29e-01 | 3.56e-01 | 8.79e-01 |
| SUPEROXIDE ANION GENERATION | 37 | 4.84e-01 | 9.43e-01 | 0.11300 | -3.49e-02 | -4.24e-02 | 3.68e-02 | -8.02e-02 | -4.54e-02 | 7.14e-01 | 6.55e-01 | 6.98e-01 | 3.98e-01 | 6.33e-01 |
| PROTEIN CATABOLIC PROCESS | 930 | 2.10e-08 | 2.11e-06 | 0.11300 | 3.47e-02 | 2.49e-02 | 8.96e-02 | -9.87e-03 | 5.38e-02 | 7.29e-02 | 1.98e-01 | 3.60e-06 | 6.10e-01 | 5.40e-03 |
| REGULATION OF KERATINOCYTE MIGRATION | 14 | 9.11e-01 | 1.00e+00 | 0.11300 | 4.17e-02 | 3.09e-02 | 7.28e-02 | 3.38e-02 | -6.08e-02 | 7.87e-01 | 8.41e-01 | 6.37e-01 | 8.27e-01 | 6.94e-01 |
| DETECTION OF ABIOTIC STIMULUS | 133 | 5.87e-02 | 3.96e-01 | 0.11300 | -3.12e-03 | 1.85e-02 | -6.65e-02 | 6.40e-02 | -6.30e-02 | 9.51e-01 | 7.13e-01 | 1.85e-01 | 2.03e-01 | 2.10e-01 |
| PRESYNAPTIC MEMBRANE ORGANIZATION | 6 | 9.88e-01 | 1.00e+00 | 0.11300 | 4.50e-02 | 5.34e-02 | 4.99e-02 | 7.39e-02 | -1.65e-04 | 8.49e-01 | 8.21e-01 | 8.32e-01 | 7.54e-01 | 9.99e-01 |
| PROTEIN LOCALIZATION TO ENDOPLASMIC RETICULUM | 68 | 7.89e-02 | 4.62e-01 | 0.11300 | 2.72e-02 | 3.85e-02 | 7.81e-02 | -6.69e-02 | -1.57e-03 | 6.98e-01 | 5.83e-01 | 2.65e-01 | 3.40e-01 | 9.82e-01 |
| REGULATION OF HUMORAL IMMUNE RESPONSE | 47 | 7.21e-01 | 1.00e+00 | 0.11300 | -1.94e-02 | -8.87e-03 | -8.23e-02 | 3.87e-02 | -6.38e-02 | 8.18e-01 | 9.16e-01 | 3.29e-01 | 6.46e-01 | 4.49e-01 |
| REGULATION OF CHOLESTEROL STORAGE | 19 | 9.90e-01 | 1.00e+00 | 0.11300 | -4.48e-02 | -3.87e-02 | -6.70e-02 | -4.43e-02 | -5.32e-02 | 7.35e-01 | 7.70e-01 | 6.13e-01 | 7.38e-01 | 6.88e-01 |
| NEGATIVE REGULATION OF CELL ADHESION | 300 | 1.06e-01 | 5.40e-01 | 0.11300 | -5.74e-02 | -6.11e-02 | -2.56e-02 | -4.13e-02 | 5.83e-02 | 8.74e-02 | 6.85e-02 | 4.46e-01 | 2.19e-01 | 8.25e-02 |
| NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 945 | 1.53e-05 | 6.77e-04 | 0.11300 | 5.74e-02 | 5.26e-02 | 7.88e-02 | 1.35e-02 | -1.80e-02 | 2.76e-03 | 6.10e-03 | 4.05e-05 | 4.82e-01 | 3.47e-01 |
| EMBRYONIC DIGIT MORPHOGENESIS | 57 | 6.16e-01 | 9.90e-01 | 0.11300 | -4.27e-02 | -6.04e-02 | 1.46e-02 | -8.14e-02 | -2.16e-02 | 5.77e-01 | 4.30e-01 | 8.49e-01 | 2.88e-01 | 7.78e-01 |
| EPITHELIAL CILIUM MOVEMENT INVOLVED IN DETERMINATION OF LEFT RIGHT ASYMMETRY | 12 | 8.39e-01 | 1.00e+00 | 0.11300 | 3.48e-02 | 1.06e-02 | 4.08e-02 | 7.67e-02 | -6.24e-02 | 8.35e-01 | 9.49e-01 | 8.07e-01 | 6.46e-01 | 7.08e-01 |
| REGULATION OF BONE MINERALIZATION | 76 | 3.75e-01 | 8.83e-01 | 0.11300 | -1.54e-02 | -2.04e-03 | -4.72e-02 | 2.75e-02 | -9.77e-02 | 8.17e-01 | 9.75e-01 | 4.77e-01 | 6.79e-01 | 1.41e-01 |
| METHYLATION | 262 | 1.88e-03 | 3.77e-02 | 0.11300 | -1.51e-02 | -3.79e-02 | 6.31e-02 | -4.73e-02 | 6.98e-02 | 6.74e-01 | 2.91e-01 | 7.87e-02 | 1.88e-01 | 5.16e-02 |
| NEGATIVE REGULATION OF ERK1 AND ERK2 CASCADE | 71 | 7.41e-01 | 1.00e+00 | 0.11300 | 4.88e-02 | 3.12e-02 | 5.52e-02 | 4.14e-02 | 6.81e-02 | 4.77e-01 | 6.50e-01 | 4.21e-01 | 5.46e-01 | 3.21e-01 |
| RESPONSE TO AUDITORY STIMULUS | 31 | 6.10e-01 | 9.90e-01 | 0.11300 | 3.27e-03 | 1.08e-02 | -8.18e-02 | 7.28e-02 | -2.50e-02 | 9.75e-01 | 9.17e-01 | 4.31e-01 | 4.83e-01 | 8.09e-01 |
| GLOMERULAR EPITHELIAL CELL DIFFERENTIATION | 21 | 8.11e-01 | 1.00e+00 | 0.11300 | -5.44e-02 | -1.98e-02 | -8.53e-02 | -7.38e-03 | -4.54e-02 | 6.66e-01 | 8.75e-01 | 4.99e-01 | 9.53e-01 | 7.19e-01 |
| NEGATIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 52 | 5.65e-01 | 9.72e-01 | 0.11300 | 3.31e-02 | 5.24e-02 | -1.49e-02 | 8.94e-02 | -2.59e-02 | 6.80e-01 | 5.13e-01 | 8.52e-01 | 2.65e-01 | 7.46e-01 |
| SYNAPTIC VESICLE RECYCLING | 76 | 6.79e-01 | 1.00e+00 | 0.11300 | 5.66e-02 | 4.17e-02 | 7.66e-02 | 2.85e-02 | -3.31e-02 | 3.94e-01 | 5.29e-01 | 2.48e-01 | 6.68e-01 | 6.17e-01 |
| MITOCHONDRIAL RNA MODIFICATION | 9 | 4.47e-01 | 9.30e-01 | 0.11300 | -3.62e-02 | -2.57e-02 | 7.46e-02 | -6.25e-02 | -3.54e-02 | 8.51e-01 | 8.94e-01 | 6.98e-01 | 7.45e-01 | 8.54e-01 |
| MUSCLE CELL PROLIFERATION | 230 | 4.49e-02 | 3.42e-01 | 0.11300 | 5.27e-02 | 4.11e-02 | 7.93e-02 | 6.06e-03 | -4.35e-02 | 1.69e-01 | 2.82e-01 | 3.82e-02 | 8.74e-01 | 2.56e-01 |
| RESPONSE TO CARBOHYDRATE | 225 | 1.46e-02 | 1.65e-01 | 0.11300 | 4.44e-02 | 4.97e-02 | 6.60e-02 | 3.29e-04 | -6.23e-02 | 2.51e-01 | 1.99e-01 | 8.79e-02 | 9.93e-01 | 1.07e-01 |
| PINOCYTOSIS | 22 | 9.62e-01 | 1.00e+00 | 0.11300 | 2.01e-02 | 1.40e-02 | 7.10e-02 | -1.18e-02 | 8.30e-02 | 8.71e-01 | 9.10e-01 | 5.64e-01 | 9.24e-01 | 5.00e-01 |
| REGULATION OF MEMBRANE POTENTIAL | 423 | 8.40e-03 | 1.11e-01 | 0.11300 | 4.19e-02 | 5.34e-02 | 2.41e-02 | 3.93e-02 | -7.70e-02 | 1.39e-01 | 5.94e-02 | 3.96e-01 | 1.65e-01 | 6.56e-03 |
| PROTEIN MATURATION | 517 | 1.46e-04 | 4.76e-03 | 0.11300 | 4.61e-02 | 3.59e-02 | 9.23e-02 | -1.18e-02 | 2.43e-02 | 7.28e-02 | 1.63e-01 | 3.26e-04 | 6.47e-01 | 3.45e-01 |
| HEXOSE PHOSPHATE TRANSPORT | 7 | 9.96e-01 | 1.00e+00 | 0.11200 | 5.62e-02 | 7.45e-02 | 3.57e-02 | 2.06e-02 | -4.75e-02 | 7.97e-01 | 7.33e-01 | 8.70e-01 | 9.25e-01 | 8.28e-01 |
| PYRIMIDINE RIBONUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 15 | 9.00e-01 | 1.00e+00 | 0.11200 | 4.16e-02 | 6.53e-02 | 4.01e-02 | 1.12e-02 | 7.02e-02 | 7.80e-01 | 6.62e-01 | 7.88e-01 | 9.40e-01 | 6.38e-01 |
| MACROPINOCYTOSIS | 10 | 9.62e-01 | 1.00e+00 | 0.11200 | 1.48e-02 | 2.42e-02 | 3.74e-02 | 4.16e-02 | 9.33e-02 | 9.35e-01 | 8.95e-01 | 8.38e-01 | 8.20e-01 | 6.10e-01 |
| RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHETIC PROCESS | 31 | 5.78e-01 | 9.82e-01 | 0.11200 | 6.18e-02 | 4.81e-02 | 5.32e-02 | 1.86e-02 | 5.75e-02 | 5.51e-01 | 6.43e-01 | 6.08e-01 | 8.58e-01 | 5.80e-01 |
| POSITIVE REGULATION OF PLASMINOGEN ACTIVATION | 8 | 9.65e-01 | 1.00e+00 | 0.11200 | -2.19e-02 | -4.95e-02 | 2.18e-02 | -7.93e-02 | 5.41e-02 | 9.14e-01 | 8.09e-01 | 9.15e-01 | 6.98e-01 | 7.91e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 5 PRODUCTION | 7 | 9.86e-01 | 1.00e+00 | 0.11200 | -1.05e-02 | -1.42e-03 | -4.40e-02 | 2.86e-02 | 9.87e-02 | 9.62e-01 | 9.95e-01 | 8.40e-01 | 8.96e-01 | 6.51e-01 |
| NEGATIVE REGULATION OF AXON EXTENSION INVOLVED IN AXON GUIDANCE | 26 | 2.81e-01 | 8.06e-01 | 0.11200 | 5.24e-02 | 6.22e-03 | 3.73e-02 | 7.58e-02 | -5.18e-02 | 6.44e-01 | 9.56e-01 | 7.42e-01 | 5.04e-01 | 6.47e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY | 310 | 7.79e-03 | 1.05e-01 | 0.11200 | 4.30e-02 | 3.47e-02 | 9.16e-02 | -1.48e-02 | 3.06e-02 | 1.93e-01 | 2.94e-01 | 5.54e-03 | 6.55e-01 | 3.55e-01 |
| MESENCHYMAL CELL MIGRATION | 61 | 9.29e-01 | 1.00e+00 | 0.11200 | 6.33e-02 | 5.46e-02 | 6.36e-02 | 3.67e-02 | -1.40e-02 | 3.92e-01 | 4.61e-01 | 3.90e-01 | 6.20e-01 | 8.50e-01 |
| REGULATION OF DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 382 | 2.58e-03 | 4.67e-02 | 0.11200 | -4.29e-02 | -5.43e-02 | 2.23e-02 | -7.35e-02 | 4.34e-02 | 1.50e-01 | 6.82e-02 | 4.54e-01 | 1.37e-02 | 1.45e-01 |
| REGULATION OF ERBB SIGNALING PATHWAY | 70 | 8.59e-01 | 1.00e+00 | 0.11200 | 6.12e-02 | 5.36e-02 | 3.77e-02 | 6.57e-02 | 1.44e-02 | 3.76e-01 | 4.38e-01 | 5.86e-01 | 3.42e-01 | 8.34e-01 |
| MACROAUTOPHAGY | 317 | 4.98e-04 | 1.29e-02 | 0.11200 | 2.71e-03 | -6.32e-03 | 7.47e-02 | -4.90e-02 | 6.73e-02 | 9.34e-01 | 8.47e-01 | 2.23e-02 | 1.34e-01 | 3.93e-02 |
| NEURON PROJECTION ORGANIZATION | 85 | 5.96e-01 | 9.88e-01 | 0.11200 | -4.12e-02 | -3.73e-02 | -4.34e-02 | -2.46e-02 | -8.35e-02 | 5.11e-01 | 5.53e-01 | 4.89e-01 | 6.95e-01 | 1.83e-01 |
| PULMONARY VALVE DEVELOPMENT | 23 | 9.71e-01 | 1.00e+00 | 0.11200 | 4.57e-02 | 3.91e-02 | 2.23e-02 | 4.65e-02 | -7.92e-02 | 7.05e-01 | 7.46e-01 | 8.53e-01 | 7.00e-01 | 5.11e-01 |
| POSITIVE REGULATION OF T CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 5 | 7.14e-01 | 1.00e+00 | 0.11200 | 9.51e-03 | 6.38e-02 | 1.88e-02 | 7.01e-02 | 5.57e-02 | 9.71e-01 | 8.05e-01 | 9.42e-01 | 7.86e-01 | 8.29e-01 |
| OOCYTE MATURATION | 33 | 9.69e-01 | 1.00e+00 | 0.11200 | -4.91e-02 | -3.75e-02 | -4.26e-02 | -6.81e-02 | -4.76e-02 | 6.25e-01 | 7.10e-01 | 6.72e-01 | 4.99e-01 | 6.36e-01 |
| MESENDODERM DEVELOPMENT | 9 | 9.92e-01 | 1.00e+00 | 0.11200 | 1.13e-02 | 1.31e-02 | 1.22e-02 | -6.03e-03 | -1.10e-01 | 9.53e-01 | 9.46e-01 | 9.49e-01 | 9.75e-01 | 5.69e-01 |
| NEGATIVE REGULATION OF CALCIUM MEDIATED SIGNALING | 21 | 9.16e-01 | 1.00e+00 | 0.11200 | 2.64e-02 | 3.42e-02 | 3.44e-02 | 4.90e-03 | -9.72e-02 | 8.34e-01 | 7.86e-01 | 7.85e-01 | 9.69e-01 | 4.41e-01 |
| POSITIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 21 | 9.37e-01 | 1.00e+00 | 0.11200 | 3.64e-02 | 4.18e-02 | -3.43e-03 | 9.06e-02 | -3.47e-02 | 7.73e-01 | 7.40e-01 | 9.78e-01 | 4.72e-01 | 7.83e-01 |
| REGULATION OF MACROAUTOPHAGY | 150 | 9.26e-02 | 5.02e-01 | 0.11200 | 2.22e-02 | 6.40e-03 | 9.04e-02 | -2.40e-02 | 5.67e-02 | 6.39e-01 | 8.92e-01 | 5.61e-02 | 6.11e-01 | 2.31e-01 |
| N TERMINAL PEPTIDYL METHIONINE ACETYLATION | 6 | 7.93e-01 | 1.00e+00 | 0.11200 | -1.45e-02 | -8.98e-02 | 5.32e-02 | -2.44e-02 | 2.78e-02 | 9.51e-01 | 7.03e-01 | 8.21e-01 | 9.17e-01 | 9.06e-01 |
| G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART PROCESS | 18 | 7.67e-01 | 1.00e+00 | 0.11200 | 1.83e-02 | 3.77e-02 | -1.96e-02 | 9.01e-02 | -4.71e-02 | 8.93e-01 | 7.82e-01 | 8.86e-01 | 5.08e-01 | 7.30e-01 |
| T CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 9 | 9.79e-01 | 1.00e+00 | 0.11200 | 4.86e-02 | 6.40e-02 | 7.01e-02 | 3.11e-02 | 1.10e-02 | 8.01e-01 | 7.40e-01 | 7.16e-01 | 8.72e-01 | 9.54e-01 |
| HEXOSE CATABOLIC PROCESS | 42 | 9.28e-01 | 1.00e+00 | 0.11200 | 5.30e-02 | 5.82e-02 | 4.99e-02 | 5.62e-02 | -2.47e-02 | 5.52e-01 | 5.14e-01 | 5.76e-01 | 5.29e-01 | 7.82e-01 |
| NEGATIVE REGULATION OF MUSCLE HYPERTROPHY | 36 | 9.36e-01 | 1.00e+00 | 0.11200 | 5.26e-02 | 5.36e-02 | 5.60e-02 | 6.01e-02 | -7.77e-03 | 5.85e-01 | 5.78e-01 | 5.61e-01 | 5.32e-01 | 9.36e-01 |
| CELLULAR COMPONENT DISASSEMBLY | 480 | 5.51e-02 | 3.84e-01 | 0.11200 | 4.85e-02 | 4.31e-02 | 7.56e-02 | 2.40e-02 | 4.41e-02 | 6.89e-02 | 1.05e-01 | 4.53e-03 | 3.68e-01 | 9.78e-02 |
| NEGATIVE REGULATION OF GENE EXPRESSION EPIGENETIC | 107 | 2.32e-01 | 7.54e-01 | 0.11200 | -1.12e-02 | -2.56e-02 | 6.09e-02 | -6.68e-02 | 5.92e-02 | 8.42e-01 | 6.47e-01 | 2.76e-01 | 2.33e-01 | 2.90e-01 |
| ACTIN FILAMENT BUNDLE ORGANIZATION | 160 | 2.59e-01 | 7.86e-01 | 0.11200 | 4.72e-02 | 6.26e-02 | 1.54e-02 | 7.69e-02 | 1.19e-02 | 3.03e-01 | 1.72e-01 | 7.37e-01 | 9.31e-02 | 7.94e-01 |
| PLASMA MEMBRANE ORGANIZATION | 161 | 4.18e-01 | 9.11e-01 | 0.11200 | 4.46e-02 | 4.80e-02 | 4.10e-02 | 6.52e-02 | 4.70e-02 | 3.28e-01 | 2.93e-01 | 3.69e-01 | 1.53e-01 | 3.04e-01 |
| THIOESTER METABOLIC PROCESS | 89 | 5.19e-01 | 9.52e-01 | 0.11200 | 4.30e-02 | 5.59e-02 | 1.17e-02 | 8.32e-02 | 2.02e-02 | 4.83e-01 | 3.62e-01 | 8.49e-01 | 1.75e-01 | 7.42e-01 |
| REGULATION OF CELL SUBSTRATE ADHESION | 213 | 4.65e-01 | 9.35e-01 | 0.11100 | -6.22e-02 | -6.73e-02 | -3.91e-02 | -5.00e-02 | 1.85e-05 | 1.18e-01 | 9.03e-02 | 3.25e-01 | 2.09e-01 | 1.00e+00 |
| POSITIVE REGULATION OF ACTIN FILAMENT POLYMERIZATION | 51 | 7.45e-01 | 1.00e+00 | 0.11100 | -4.26e-02 | -2.16e-02 | -5.12e-02 | -3.45e-02 | -7.95e-02 | 5.99e-01 | 7.89e-01 | 5.27e-01 | 6.70e-01 | 3.26e-01 |
| REGULATION OF T CELL MEDIATED IMMUNE RESPONSE TO TUMOR CELL | 8 | 9.76e-01 | 1.00e+00 | 0.11100 | -2.16e-02 | -1.72e-02 | 3.59e-02 | -2.37e-02 | 9.90e-02 | 9.16e-01 | 9.33e-01 | 8.61e-01 | 9.08e-01 | 6.28e-01 |
| REGULATION OF CYTOSKELETON ORGANIZATION | 493 | 5.57e-02 | 3.84e-01 | 0.11100 | 5.17e-02 | 5.30e-02 | 5.98e-02 | 5.03e-02 | 2.83e-02 | 4.91e-02 | 4.39e-02 | 2.29e-02 | 5.59e-02 | 2.82e-01 |
| APICAL JUNCTION ASSEMBLY | 73 | 8.47e-02 | 4.79e-01 | 0.11100 | -3.87e-02 | -8.13e-03 | -9.31e-02 | 4.50e-02 | 1.15e-02 | 5.68e-01 | 9.04e-01 | 1.69e-01 | 5.06e-01 | 8.65e-01 |
| NEGATIVE REGULATION OF PROTEIN CONTAINING COMPLEX ASSEMBLY | 140 | 4.74e-01 | 9.40e-01 | 0.11100 | 5.03e-02 | 5.35e-02 | 7.34e-02 | 2.17e-02 | 3.33e-02 | 3.04e-01 | 2.74e-01 | 1.34e-01 | 6.57e-01 | 4.96e-01 |
| ESTABLISHMENT OF ORGANELLE LOCALIZATION | 454 | 6.18e-04 | 1.53e-02 | 0.11100 | 2.15e-02 | 6.79e-03 | 7.87e-02 | -2.74e-02 | 7.00e-02 | 4.32e-01 | 8.04e-01 | 4.04e-03 | 3.16e-01 | 1.06e-02 |
| GOLGI LOCALIZATION | 14 | 9.08e-01 | 1.00e+00 | 0.11100 | -4.87e-02 | -6.97e-02 | -3.47e-02 | -1.38e-02 | -6.11e-02 | 7.53e-01 | 6.52e-01 | 8.22e-01 | 9.29e-01 | 6.92e-01 |
| REGULATION OF ISOMERASE ACTIVITY | 8 | 9.28e-01 | 1.00e+00 | 0.11100 | -6.49e-02 | -7.31e-02 | 2.51e-03 | -3.75e-02 | 3.70e-02 | 7.51e-01 | 7.20e-01 | 9.90e-01 | 8.54e-01 | 8.56e-01 |
| LIPOPROTEIN LOCALIZATION | 21 | 9.84e-01 | 1.00e+00 | 0.11100 | -4.84e-02 | -5.66e-02 | -4.37e-02 | -6.15e-02 | -3.32e-02 | 7.01e-01 | 6.54e-01 | 7.29e-01 | 6.26e-01 | 7.92e-01 |
| POSITIVE REGULATION OF NUCLEOTIDE BIOSYNTHETIC PROCESS | 13 | 8.43e-01 | 1.00e+00 | 0.11100 | -2.19e-02 | -3.78e-02 | -7.25e-02 | 5.38e-02 | 4.78e-02 | 8.91e-01 | 8.13e-01 | 6.51e-01 | 7.37e-01 | 7.66e-01 |
| PROTEIN LOCALIZATION TO GOLGI APPARATUS | 29 | 7.64e-01 | 1.00e+00 | 0.11100 | -3.52e-02 | -5.29e-02 | 4.30e-02 | -8.02e-02 | 3.17e-03 | 7.43e-01 | 6.22e-01 | 6.89e-01 | 4.55e-01 | 9.76e-01 |
| VESICLE ORGANIZATION | 351 | 1.40e-03 | 2.96e-02 | 0.11100 | 4.15e-03 | -6.06e-03 | 6.30e-02 | -5.06e-02 | 7.56e-02 | 8.94e-01 | 8.45e-01 | 4.25e-02 | 1.03e-01 | 1.49e-02 |
| BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 151 | 1.41e-01 | 6.26e-01 | 0.11100 | 4.55e-02 | 3.62e-02 | 8.93e-02 | 2.26e-02 | 2.09e-02 | 3.35e-01 | 4.43e-01 | 5.81e-02 | 6.32e-01 | 6.57e-01 |
| MEMBRANE REPOLARIZATION DURING VENTRICULAR CARDIAC MUSCLE CELL ACTION POTENTIAL | 15 | 6.60e-01 | 1.00e+00 | 0.11100 | -4.90e-02 | -2.97e-02 | -6.71e-02 | 3.79e-02 | -5.55e-02 | 7.43e-01 | 8.42e-01 | 6.53e-01 | 7.99e-01 | 7.10e-01 |
| REGULATION OF LIPASE ACTIVITY | 77 | 8.23e-01 | 1.00e+00 | 0.11100 | 4.33e-02 | 4.91e-02 | 8.57e-03 | 6.52e-02 | -6.08e-02 | 5.11e-01 | 4.57e-01 | 8.96e-01 | 3.23e-01 | 3.56e-01 |
| POSITIVE REGULATION OF PROTEIN IMPORT INTO NUCLEUS | 39 | 5.90e-01 | 9.86e-01 | 0.11100 | -1.16e-02 | -1.16e-02 | 4.32e-02 | -8.74e-02 | 5.02e-02 | 9.00e-01 | 9.00e-01 | 6.41e-01 | 3.45e-01 | 5.87e-01 |
| ASTROCYTE ACTIVATION | 25 | 5.84e-01 | 9.85e-01 | 0.11100 | 2.89e-02 | 4.48e-02 | 7.84e-02 | 6.97e-03 | 5.71e-02 | 8.02e-01 | 6.98e-01 | 4.98e-01 | 9.52e-01 | 6.21e-01 |
| T CELL HOMEOSTASIS | 44 | 6.49e-01 | 1.00e+00 | 0.11100 | -5.92e-02 | -4.43e-02 | -5.13e-02 | -1.64e-02 | 6.24e-02 | 4.97e-01 | 6.12e-01 | 5.56e-01 | 8.51e-01 | 4.74e-01 |
| POSITIVE REGULATION OF COLLAGEN METABOLIC PROCESS | 25 | 9.58e-01 | 1.00e+00 | 0.11100 | 3.59e-02 | 3.06e-02 | 8.13e-02 | 5.30e-03 | 5.81e-02 | 7.56e-01 | 7.91e-01 | 4.81e-01 | 9.63e-01 | 6.15e-01 |
| APOPTOTIC PROCESS | 1856 | 6.85e-15 | 3.22e-12 | 0.11100 | 3.54e-02 | 2.57e-02 | 8.55e-02 | -1.36e-02 | 5.33e-02 | 1.15e-02 | 6.59e-02 | 9.87e-10 | 3.32e-01 | 1.41e-04 |
| METANEPHRIC S SHAPED BODY MORPHOGENESIS | 5 | 9.99e-01 | 1.00e+00 | 0.11100 | -5.37e-02 | -3.66e-02 | -4.20e-02 | -7.67e-02 | -1.92e-02 | 8.35e-01 | 8.87e-01 | 8.71e-01 | 7.67e-01 | 9.41e-01 |
| SUBPALLIUM DEVELOPMENT | 26 | 7.98e-01 | 1.00e+00 | 0.11100 | 1.42e-02 | 4.91e-04 | 7.95e-02 | 5.95e-03 | 7.54e-02 | 9.00e-01 | 9.97e-01 | 4.83e-01 | 9.58e-01 | 5.06e-01 |
| FATTY ACID ELONGATION | 12 | 8.78e-01 | 1.00e+00 | 0.11100 | 2.68e-02 | 1.33e-02 | 4.55e-02 | 4.43e-02 | -8.54e-02 | 8.72e-01 | 9.36e-01 | 7.85e-01 | 7.90e-01 | 6.09e-01 |
| RESPONSE TO NICOTINE | 49 | 7.58e-01 | 1.00e+00 | 0.11100 | -5.78e-02 | -6.85e-02 | -2.99e-03 | -6.15e-02 | 1.96e-02 | 4.84e-01 | 4.07e-01 | 9.71e-01 | 4.56e-01 | 8.13e-01 |
| MESONEPHROS DEVELOPMENT | 99 | 1.48e-01 | 6.36e-01 | 0.11000 | 3.59e-02 | 3.46e-02 | 9.41e-02 | -2.54e-02 | 1.50e-02 | 5.37e-01 | 5.52e-01 | 1.06e-01 | 6.62e-01 | 7.97e-01 |
| ESTABLISHMENT OF BLOOD BRAIN BARRIER | 14 | 6.49e-01 | 1.00e+00 | 0.11000 | 2.80e-02 | 6.51e-03 | 5.21e-02 | 9.27e-02 | 7.97e-03 | 8.56e-01 | 9.66e-01 | 7.36e-01 | 5.48e-01 | 9.59e-01 |
| PROTEIN AUTOPROCESSING | 28 | 6.01e-01 | 9.90e-01 | 0.11000 | 2.84e-02 | 2.06e-03 | 1.03e-01 | -2.09e-02 | -1.98e-02 | 7.95e-01 | 9.85e-01 | 3.47e-01 | 8.48e-01 | 8.56e-01 |
| REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 74 | 4.66e-01 | 9.35e-01 | 0.11000 | 3.38e-02 | 5.16e-02 | -2.75e-02 | 3.20e-02 | -8.12e-02 | 6.15e-01 | 4.42e-01 | 6.83e-01 | 6.34e-01 | 2.27e-01 |
| REGULATION OF SYNAPTIC PLASTICITY | 204 | 2.47e-01 | 7.75e-01 | 0.11000 | 5.30e-02 | 5.37e-02 | 7.61e-02 | 2.60e-02 | 4.59e-03 | 1.92e-01 | 1.86e-01 | 6.09e-02 | 5.21e-01 | 9.10e-01 |
| NEURAL TUBE FORMATION | 103 | 1.99e-01 | 7.14e-01 | 0.11000 | 3.95e-02 | 4.40e-02 | 7.22e-02 | 3.46e-02 | 4.76e-02 | 4.89e-01 | 4.40e-01 | 2.05e-01 | 5.44e-01 | 4.04e-01 |
| REGULATION OF GLYCOGEN BIOSYNTHETIC PROCESS | 30 | 4.45e-01 | 9.29e-01 | 0.11000 | 2.31e-02 | 3.30e-02 | 8.17e-02 | -4.02e-02 | -4.75e-02 | 8.27e-01 | 7.55e-01 | 4.39e-01 | 7.03e-01 | 6.53e-01 |
| MUSCLE CONTRACTION | 338 | 9.87e-02 | 5.20e-01 | 0.11000 | 4.89e-02 | 5.47e-02 | 2.72e-02 | 6.60e-02 | -4.12e-02 | 1.22e-01 | 8.41e-02 | 3.89e-01 | 3.71e-02 | 1.93e-01 |
| LONG CHAIN FATTY ACYL COA METABOLIC PROCESS | 24 | 5.50e-01 | 9.64e-01 | 0.11000 | 6.43e-03 | 7.06e-03 | -2.68e-02 | 1.06e-01 | 1.36e-02 | 9.57e-01 | 9.52e-01 | 8.20e-01 | 3.70e-01 | 9.08e-01 |
| CENTRAL NERVOUS SYSTEM DEVELOPMENT | 972 | 6.06e-08 | 5.56e-06 | 0.11000 | 5.11e-02 | 4.22e-02 | 8.66e-02 | 3.08e-03 | -1.55e-02 | 6.93e-03 | 2.60e-02 | 4.72e-06 | 8.71e-01 | 4.14e-01 |
| PRODUCTION OF MOLECULAR MEDIATOR INVOLVED IN INFLAMMATORY RESPONSE | 103 | 6.20e-01 | 9.90e-01 | 0.11000 | 5.69e-02 | 4.28e-02 | 5.52e-02 | 4.36e-02 | 4.57e-02 | 3.18e-01 | 4.53e-01 | 3.33e-01 | 4.44e-01 | 4.23e-01 |
| PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 57 | 9.01e-01 | 1.00e+00 | 0.11000 | 5.08e-02 | 5.71e-02 | 5.71e-02 | 2.98e-02 | 4.61e-02 | 5.07e-01 | 4.56e-01 | 4.56e-01 | 6.97e-01 | 5.47e-01 |
| REGULATION OF GLIAL CELL PROLIFERATION | 37 | 7.73e-01 | 1.00e+00 | 0.11000 | 3.81e-02 | 3.68e-02 | 9.07e-02 | -2.01e-02 | 2.61e-02 | 6.89e-01 | 6.98e-01 | 3.40e-01 | 8.33e-01 | 7.84e-01 |
| REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 34 | 8.62e-01 | 1.00e+00 | 0.11000 | 4.59e-02 | 3.82e-02 | 4.21e-02 | 6.19e-02 | -5.41e-02 | 6.43e-01 | 7.00e-01 | 6.71e-01 | 5.32e-01 | 5.85e-01 |
| EPITHELIAL CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 45 | 6.11e-01 | 9.90e-01 | 0.11000 | -3.83e-02 | -5.01e-02 | 3.89e-02 | -7.68e-02 | 2.65e-02 | 6.57e-01 | 5.61e-01 | 6.52e-01 | 3.72e-01 | 7.59e-01 |
| CALCIUM MEDIATED SIGNALING | 203 | 6.40e-01 | 1.00e+00 | 0.11000 | -5.28e-02 | -5.68e-02 | -2.59e-02 | -5.95e-02 | 4.27e-02 | 1.94e-01 | 1.63e-01 | 5.24e-01 | 1.44e-01 | 2.94e-01 |
| GOLGI VESICLE TRANSPORT | 284 | 2.09e-02 | 2.15e-01 | 0.11000 | -6.91e-03 | -2.24e-02 | 5.26e-02 | -4.93e-02 | 7.94e-02 | 8.41e-01 | 5.16e-01 | 1.27e-01 | 1.52e-01 | 2.13e-02 |
| INTEGRIN MEDIATED SIGNALING PATHWAY | 110 | 3.45e-01 | 8.64e-01 | 0.11000 | -5.40e-02 | -7.33e-02 | -1.11e-02 | -3.76e-02 | 4.71e-02 | 3.27e-01 | 1.84e-01 | 8.40e-01 | 4.95e-01 | 3.93e-01 |
| ORGANELLE LOCALIZATION | 588 | 1.07e-04 | 3.68e-03 | 0.11000 | 2.67e-02 | 1.47e-02 | 8.05e-02 | -1.99e-02 | 6.50e-02 | 2.68e-01 | 5.42e-01 | 8.43e-04 | 4.10e-01 | 7.06e-03 |
| CELLULAR RESPONSE TO NUTRIENT | 45 | 8.06e-01 | 1.00e+00 | 0.11000 | 5.17e-02 | 5.77e-02 | 7.57e-02 | 1.91e-03 | -1.72e-02 | 5.48e-01 | 5.03e-01 | 3.80e-01 | 9.82e-01 | 8.42e-01 |
| REGULATION OF AUTOPHAGOSOME ASSEMBLY | 42 | 9.56e-01 | 1.00e+00 | 0.11000 | 5.14e-02 | 4.67e-02 | 7.84e-02 | 1.44e-02 | 2.89e-02 | 5.64e-01 | 6.00e-01 | 3.79e-01 | 8.72e-01 | 7.46e-01 |
| UNSATURATED FATTY ACID METABOLIC PROCESS | 110 | 4.52e-01 | 9.30e-01 | 0.11000 | 5.41e-03 | 2.02e-02 | -2.48e-02 | 1.91e-02 | -1.03e-01 | 9.22e-01 | 7.14e-01 | 6.53e-01 | 7.29e-01 | 6.21e-02 |
| SYNAPTIC VESICLE UNCOATING | 6 | 9.96e-01 | 1.00e+00 | 0.11000 | -3.71e-02 | -4.86e-02 | 6.55e-03 | -1.26e-02 | 8.99e-02 | 8.75e-01 | 8.37e-01 | 9.78e-01 | 9.57e-01 | 7.03e-01 |
| MAINTENANCE OF CELL NUMBER | 179 | 1.20e-02 | 1.43e-01 | 0.11000 | 3.43e-02 | 2.01e-02 | 1.00e-01 | -1.84e-02 | 8.42e-03 | 4.28e-01 | 6.42e-01 | 2.10e-02 | 6.72e-01 | 8.46e-01 |
| VESICLE LOCALIZATION | 208 | 4.28e-02 | 3.31e-01 | 0.10900 | -1.03e-02 | -1.86e-02 | 5.13e-02 | -6.15e-02 | 7.16e-02 | 7.98e-01 | 6.43e-01 | 2.02e-01 | 1.26e-01 | 7.52e-02 |
| NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 419 | 2.41e-03 | 4.45e-02 | 0.10900 | 2.63e-02 | 1.91e-02 | 7.71e-02 | -1.78e-02 | 6.83e-02 | 3.56e-01 | 5.02e-01 | 6.77e-03 | 5.33e-01 | 1.65e-02 |
| NEGATIVE REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS | 18 | 8.59e-01 | 1.00e+00 | 0.10900 | -2.64e-02 | -4.40e-02 | 4.86e-02 | -7.76e-02 | -3.09e-02 | 8.47e-01 | 7.47e-01 | 7.21e-01 | 5.69e-01 | 8.20e-01 |
| REGULATION OF NEUROGENESIS | 373 | 4.93e-02 | 3.61e-01 | 0.10900 | 5.50e-02 | 4.79e-02 | 8.00e-02 | 1.36e-02 | -6.92e-03 | 6.80e-02 | 1.12e-01 | 7.94e-03 | 6.52e-01 | 8.18e-01 |
| PHOSPHATIDYLCHOLINE ACYL CHAIN REMODELING | 14 | 9.90e-01 | 1.00e+00 | 0.10900 | 5.61e-02 | 3.58e-02 | 5.50e-02 | 6.46e-02 | 1.79e-02 | 7.16e-01 | 8.17e-01 | 7.22e-01 | 6.75e-01 | 9.08e-01 |
| POSITIVE REGULATION OF CHONDROCYTE DIFFERENTIATION | 20 | 9.11e-01 | 1.00e+00 | 0.10900 | 3.33e-02 | 3.31e-02 | 6.42e-02 | -1.26e-02 | -7.38e-02 | 7.97e-01 | 7.98e-01 | 6.19e-01 | 9.22e-01 | 5.67e-01 |
| FOAM CELL DIFFERENTIATION | 41 | 8.75e-01 | 1.00e+00 | 0.10900 | -4.81e-02 | -7.06e-02 | -9.09e-03 | -6.23e-02 | 2.59e-02 | 5.94e-01 | 4.34e-01 | 9.20e-01 | 4.90e-01 | 7.74e-01 |
| MALE MEIOTIC NUCLEAR DIVISION | 54 | 3.44e-01 | 8.62e-01 | 0.10900 | 5.85e-02 | 2.13e-02 | 8.48e-02 | 2.86e-02 | 6.14e-03 | 4.57e-01 | 7.86e-01 | 2.81e-01 | 7.16e-01 | 9.38e-01 |
| CELL GROWTH | 476 | 2.22e-01 | 7.45e-01 | 0.10900 | 5.80e-02 | 5.27e-02 | 6.77e-02 | 3.39e-02 | 6.03e-03 | 3.02e-02 | 4.86e-02 | 1.14e-02 | 2.05e-01 | 8.22e-01 |
| RESPONSE TO ZINC ION | 48 | 8.35e-01 | 1.00e+00 | 0.10900 | 4.40e-02 | 3.89e-02 | 8.75e-02 | -2.34e-03 | 2.84e-02 | 5.98e-01 | 6.41e-01 | 2.94e-01 | 9.78e-01 | 7.34e-01 |
| MITOTIC SISTER CHROMATID COHESION | 26 | 6.88e-01 | 1.00e+00 | 0.10900 | 8.28e-03 | -2.90e-02 | 8.55e-02 | -5.32e-02 | 2.92e-02 | 9.42e-01 | 7.98e-01 | 4.50e-01 | 6.39e-01 | 7.97e-01 |
| REGULATION OF TRANSMEMBRANE TRANSPORT | 561 | 9.66e-02 | 5.12e-01 | 0.10900 | 5.53e-02 | 6.18e-02 | 4.33e-02 | 4.97e-02 | -2.59e-02 | 2.51e-02 | 1.22e-02 | 7.93e-02 | 4.42e-02 | 2.93e-01 |
| RNA DESTABILIZATION | 163 | 7.41e-01 | 1.00e+00 | 0.10900 | -5.60e-02 | -5.04e-02 | -5.21e-02 | -5.84e-02 | 9.67e-03 | 2.17e-01 | 2.66e-01 | 2.51e-01 | 1.99e-01 | 8.31e-01 |
| DOPAMINE RECEPTOR SIGNALING PATHWAY | 37 | 8.10e-01 | 1.00e+00 | 0.10900 | -3.12e-02 | -4.70e-02 | 4.17e-02 | -6.14e-02 | 5.65e-02 | 7.43e-01 | 6.21e-01 | 6.60e-01 | 5.18e-01 | 5.52e-01 |
| LABYRINTHINE LAYER DEVELOPMENT | 43 | 8.76e-01 | 1.00e+00 | 0.10900 | 2.33e-03 | -1.79e-03 | 2.03e-02 | -5.00e-03 | 1.07e-01 | 9.79e-01 | 9.84e-01 | 8.18e-01 | 9.55e-01 | 2.25e-01 |
| PHOSPHATIDYLSERINE ACYL CHAIN REMODELING | 9 | 9.10e-01 | 1.00e+00 | 0.10900 | 4.01e-03 | 3.22e-02 | -8.26e-02 | 5.33e-02 | 3.41e-02 | 9.83e-01 | 8.67e-01 | 6.68e-01 | 7.82e-01 | 8.60e-01 |
| NEGATIVE REGULATION OF HEMOPOIESIS | 115 | 4.74e-01 | 9.40e-01 | 0.10900 | -4.81e-02 | -5.67e-02 | -1.61e-03 | -7.71e-02 | -2.01e-02 | 3.73e-01 | 2.93e-01 | 9.76e-01 | 1.53e-01 | 7.10e-01 |
| REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 198 | 1.31e-01 | 5.99e-01 | 0.10900 | 4.25e-02 | 4.58e-02 | 7.52e-02 | 6.45e-03 | 4.77e-02 | 3.03e-01 | 2.67e-01 | 6.80e-02 | 8.76e-01 | 2.47e-01 |
| MICROTUBULE ORGANIZING CENTER ORGANIZATION | 150 | 2.08e-01 | 7.29e-01 | 0.10900 | -2.44e-02 | -3.82e-02 | 3.87e-02 | -6.91e-02 | 5.95e-02 | 6.06e-01 | 4.19e-01 | 4.14e-01 | 1.44e-01 | 2.09e-01 |
| PHASIC SMOOTH MUSCLE CONTRACTION | 24 | 7.77e-01 | 1.00e+00 | 0.10900 | 3.40e-02 | -6.46e-03 | 8.40e-02 | 2.03e-02 | 5.65e-02 | 7.73e-01 | 9.56e-01 | 4.76e-01 | 8.63e-01 | 6.32e-01 |
| NEURAL RETINA DEVELOPMENT | 78 | 5.87e-01 | 9.85e-01 | 0.10900 | -3.14e-02 | -1.91e-02 | -1.95e-02 | -6.36e-02 | -7.79e-02 | 6.32e-01 | 7.71e-01 | 7.66e-01 | 3.31e-01 | 2.34e-01 |
| OLEFINIC COMPOUND METABOLIC PROCESS | 157 | 6.30e-02 | 4.12e-01 | 0.10900 | -3.25e-02 | -1.12e-02 | -8.03e-02 | 2.75e-02 | -5.89e-02 | 4.83e-01 | 8.08e-01 | 8.26e-02 | 5.52e-01 | 2.02e-01 |
| HEAD DEVELOPMENT | 726 | 2.04e-05 | 8.66e-04 | 0.10900 | 5.21e-02 | 4.15e-02 | 7.93e-02 | 1.15e-02 | -3.14e-02 | 1.69e-02 | 5.67e-02 | 2.71e-04 | 5.99e-01 | 1.50e-01 |
| NEGATIVE REGULATION OF PROTEIN CONTAINING COMPLEX DISASSEMBLY | 76 | 8.64e-01 | 1.00e+00 | 0.10900 | 4.94e-02 | 5.74e-02 | 1.43e-02 | 7.68e-02 | -6.69e-05 | 4.57e-01 | 3.87e-01 | 8.29e-01 | 2.47e-01 | 9.99e-01 |
| LENS DEVELOPMENT IN CAMERA TYPE EYE | 85 | 9.15e-01 | 1.00e+00 | 0.10900 | 5.11e-02 | 3.86e-02 | 6.30e-02 | 4.45e-02 | 4.23e-02 | 4.16e-01 | 5.39e-01 | 3.15e-01 | 4.79e-01 | 5.00e-01 |
| MONOATOMIC ANION HOMEOSTASIS | 20 | 7.82e-01 | 1.00e+00 | 0.10900 | -1.67e-02 | 1.38e-02 | -5.73e-02 | 3.83e-02 | -8.13e-02 | 8.97e-01 | 9.15e-01 | 6.57e-01 | 7.67e-01 | 5.29e-01 |
| ESTABLISHMENT OF SPINDLE ORIENTATION | 42 | 8.87e-01 | 1.00e+00 | 0.10900 | 4.86e-02 | 5.41e-02 | 5.57e-02 | 2.94e-02 | -5.05e-02 | 5.85e-01 | 5.44e-01 | 5.32e-01 | 7.42e-01 | 5.71e-01 |
| INOSITOL PHOSPHATE METABOLIC PROCESS | 42 | 6.06e-01 | 9.90e-01 | 0.10900 | -5.14e-02 | -4.32e-02 | -5.16e-02 | -1.01e-02 | -6.74e-02 | 5.64e-01 | 6.28e-01 | 5.63e-01 | 9.10e-01 | 4.50e-01 |
| POSITIVE REGULATION OF MITOCHONDRIAL MEMBRANE PERMEABILITY | 45 | 5.50e-01 | 9.64e-01 | 0.10900 | 4.56e-02 | 6.36e-02 | 6.44e-02 | -1.44e-03 | -3.91e-02 | 5.96e-01 | 4.60e-01 | 4.55e-01 | 9.87e-01 | 6.50e-01 |
| TRABECULA FORMATION | 26 | 9.77e-01 | 1.00e+00 | 0.10800 | -4.64e-02 | -5.56e-02 | -1.56e-02 | -7.18e-02 | -3.35e-02 | 6.82e-01 | 6.23e-01 | 8.91e-01 | 5.26e-01 | 7.68e-01 |
| REFLEX | 21 | 6.61e-01 | 1.00e+00 | 0.10800 | -6.65e-02 | -6.02e-02 | -6.01e-02 | 1.00e-02 | 2.88e-03 | 5.98e-01 | 6.33e-01 | 6.34e-01 | 9.37e-01 | 9.82e-01 |
| HOMOPHILIC CELL ADHESION VIA PLASMA MEMBRANE ADHESION MOLECULES | 164 | 6.72e-02 | 4.23e-01 | 0.10800 | -2.74e-02 | -2.93e-02 | 3.13e-02 | -4.11e-02 | 8.65e-02 | 5.45e-01 | 5.17e-01 | 4.89e-01 | 3.64e-01 | 5.59e-02 |
| TUBE DEVELOPMENT | 1121 | 3.63e-03 | 6.10e-02 | 0.10800 | 5.65e-02 | 5.32e-02 | 6.50e-02 | 3.81e-02 | -7.08e-03 | 1.41e-03 | 2.64e-03 | 2.38e-04 | 3.11e-02 | 6.89e-01 |
| DNA REPLICATION INITIATION | 35 | 6.20e-01 | 9.90e-01 | 0.10800 | 3.21e-02 | 2.95e-02 | 7.86e-02 | -5.63e-02 | -2.21e-02 | 7.42e-01 | 7.62e-01 | 4.21e-01 | 5.64e-01 | 8.21e-01 |
| REGULATION OF CYTOPLASMIC TRANSLATION | 30 | 6.42e-01 | 1.00e+00 | 0.10800 | 4.13e-02 | 7.41e-02 | 3.02e-02 | 1.05e-02 | -5.91e-02 | 6.95e-01 | 4.82e-01 | 7.74e-01 | 9.21e-01 | 5.75e-01 |
| REGULATION OF MICROTUBULE BASED MOVEMENT | 50 | 9.67e-01 | 1.00e+00 | 0.10800 | 5.88e-02 | 6.05e-02 | 5.83e-02 | 3.19e-02 | 1.29e-02 | 4.72e-01 | 4.59e-01 | 4.75e-01 | 6.96e-01 | 8.74e-01 |
| OOGENESIS | 108 | 4.06e-01 | 9.06e-01 | 0.10800 | -7.85e-05 | -3.56e-03 | -1.63e-02 | -1.43e-02 | -1.06e-01 | 9.99e-01 | 9.49e-01 | 7.69e-01 | 7.98e-01 | 5.72e-02 |
| UREA CYCLE | 10 | 9.97e-01 | 1.00e+00 | 0.10800 | -2.26e-02 | -3.42e-02 | 2.29e-02 | -4.03e-02 | 8.87e-02 | 9.02e-01 | 8.51e-01 | 9.00e-01 | 8.25e-01 | 6.27e-01 |
| L AMINO ACID TRANSPORT | 84 | 5.59e-01 | 9.69e-01 | 0.10800 | 3.80e-02 | 5.42e-02 | 4.09e-03 | 1.36e-02 | -8.42e-02 | 5.47e-01 | 3.90e-01 | 9.48e-01 | 8.30e-01 | 1.82e-01 |
| REGULATION OF PROTEIN EXIT FROM ENDOPLASMIC RETICULUM | 24 | 3.37e-01 | 8.59e-01 | 0.10800 | 4.93e-02 | 1.56e-02 | 8.22e-02 | -4.72e-02 | -8.27e-04 | 6.76e-01 | 8.95e-01 | 4.86e-01 | 6.89e-01 | 9.94e-01 |
| SEMINIFEROUS TUBULE DEVELOPMENT | 14 | 6.95e-01 | 1.00e+00 | 0.10800 | 1.12e-02 | -4.69e-02 | 8.21e-02 | -1.25e-02 | 4.93e-02 | 9.42e-01 | 7.61e-01 | 5.95e-01 | 9.36e-01 | 7.49e-01 |
| PROSTANOID BIOSYNTHETIC PROCESS | 31 | 5.34e-01 | 9.56e-01 | 0.10800 | -2.70e-02 | -3.64e-02 | -2.16e-02 | -8.81e-02 | -3.70e-02 | 7.95e-01 | 7.26e-01 | 8.35e-01 | 3.96e-01 | 7.21e-01 |
| POSITIVE REGULATION OF GLIAL CELL PROLIFERATION | 19 | 2.76e-01 | 8.04e-01 | 0.10800 | -1.75e-02 | -8.06e-03 | 8.23e-02 | -4.15e-02 | 5.28e-02 | 8.95e-01 | 9.51e-01 | 5.35e-01 | 7.54e-01 | 6.90e-01 |
| DEOXYRIBONUCLEOTIDE BIOSYNTHETIC PROCESS | 14 | 8.19e-01 | 1.00e+00 | 0.10800 | -2.82e-02 | -5.95e-02 | -2.08e-02 | -2.69e-04 | -8.30e-02 | 8.55e-01 | 7.00e-01 | 8.93e-01 | 9.99e-01 | 5.91e-01 |
| NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 118 | 6.26e-01 | 9.94e-01 | 0.10800 | -2.96e-02 | -1.56e-02 | -4.37e-02 | -3.67e-02 | -8.53e-02 | 5.79e-01 | 7.70e-01 | 4.13e-01 | 4.91e-01 | 1.10e-01 |
| REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 159 | 1.74e-01 | 6.78e-01 | 0.10800 | -1.88e-02 | -4.17e-02 | 4.25e-02 | -4.30e-02 | 7.68e-02 | 6.82e-01 | 3.64e-01 | 3.55e-01 | 3.50e-01 | 9.49e-02 |
| POSITIVE REGULATION OF PROTEIN BINDING | 59 | 3.51e-01 | 8.70e-01 | 0.10800 | -3.10e-02 | -4.72e-02 | 4.55e-02 | -7.91e-02 | -1.06e-02 | 6.80e-01 | 5.31e-01 | 5.45e-01 | 2.93e-01 | 8.88e-01 |
| POSITIVE REGULATION OF COLD INDUCED THERMOGENESIS | 100 | 3.36e-01 | 8.59e-01 | 0.10800 | 9.71e-03 | 9.97e-03 | 5.97e-02 | -3.22e-02 | 8.26e-02 | 8.67e-01 | 8.63e-01 | 3.02e-01 | 5.78e-01 | 1.53e-01 |
| AZOLE TRANSMEMBRANE TRANSPORT | 13 | 9.50e-01 | 1.00e+00 | 0.10800 | 7.12e-03 | 2.19e-02 | 3.86e-02 | -1.95e-02 | 9.59e-02 | 9.65e-01 | 8.91e-01 | 8.10e-01 | 9.03e-01 | 5.49e-01 |
| ORGANOPHOSPHATE METABOLIC PROCESS | 917 | 1.69e-02 | 1.85e-01 | 0.10800 | 5.17e-02 | 4.87e-02 | 6.60e-02 | 3.67e-02 | 2.93e-02 | 7.97e-03 | 1.24e-02 | 7.02e-04 | 5.96e-02 | 1.33e-01 |
| REGULATION OF MACROPHAGE DERIVED FOAM CELL DIFFERENTIATION | 33 | 9.76e-01 | 1.00e+00 | 0.10800 | -5.56e-02 | -6.46e-02 | -5.50e-02 | -3.46e-02 | 1.01e-02 | 5.80e-01 | 5.21e-01 | 5.85e-01 | 7.31e-01 | 9.20e-01 |
| PLACENTA BLOOD VESSEL DEVELOPMENT | 30 | 4.96e-01 | 9.47e-01 | 0.10800 | 3.56e-02 | 9.78e-03 | 8.08e-02 | -5.55e-02 | -2.47e-02 | 7.36e-01 | 9.26e-01 | 4.44e-01 | 5.99e-01 | 8.15e-01 |
| MEIOSIS I CELL CYCLE PROCESS | 133 | 3.49e-01 | 8.69e-01 | 0.10700 | 3.16e-02 | 1.18e-02 | 8.22e-02 | -8.82e-03 | 5.96e-02 | 5.30e-01 | 8.13e-01 | 1.02e-01 | 8.61e-01 | 2.35e-01 |
| POSITIVE REGULATION OF SMALL MOLECULE METABOLIC PROCESS | 141 | 3.87e-01 | 8.92e-01 | 0.10700 | 5.02e-02 | 6.15e-02 | 4.29e-02 | 5.51e-02 | -1.89e-02 | 3.04e-01 | 2.07e-01 | 3.79e-01 | 2.59e-01 | 6.98e-01 |
| NEGATIVE REGULATION OF MUSCLE CELL DIFFERENTIATION | 65 | 7.45e-01 | 1.00e+00 | 0.10700 | 2.36e-02 | 9.42e-03 | 7.47e-02 | -2.11e-02 | 6.96e-02 | 7.42e-01 | 8.96e-01 | 2.97e-01 | 7.69e-01 | 3.32e-01 |
| REGULATION OF CELL FATE COMMITMENT | 41 | 8.43e-01 | 1.00e+00 | 0.10700 | 4.91e-02 | 5.16e-02 | 7.76e-02 | -7.43e-03 | 1.94e-02 | 5.87e-01 | 5.67e-01 | 3.90e-01 | 9.34e-01 | 8.30e-01 |
| MORPHOGENESIS OF AN EPITHELIAL SHEET | 59 | 7.91e-01 | 1.00e+00 | 0.10700 | 4.30e-02 | 4.53e-02 | 1.45e-02 | 8.19e-02 | -2.57e-02 | 5.68e-01 | 5.47e-01 | 8.48e-01 | 2.76e-01 | 7.32e-01 |
| REGULATION OF MYOTUBE DIFFERENTIATION | 48 | 7.77e-01 | 1.00e+00 | 0.10700 | 3.23e-02 | 3.40e-02 | 1.37e-02 | 8.14e-02 | 4.97e-02 | 6.99e-01 | 6.83e-01 | 8.70e-01 | 3.29e-01 | 5.51e-01 |
| INTERMEDIATE FILAMENT BASED PROCESS | 94 | 7.16e-02 | 4.39e-01 | 0.10700 | 2.46e-03 | 1.34e-02 | -7.90e-02 | 7.07e-02 | -6.34e-03 | 9.67e-01 | 8.23e-01 | 1.86e-01 | 2.36e-01 | 9.15e-01 |
| QUINONE METABOLIC PROCESS | 39 | 3.22e-01 | 8.47e-01 | 0.10700 | 1.45e-02 | 8.41e-03 | 9.72e-02 | -4.17e-02 | 5.22e-04 | 8.76e-01 | 9.28e-01 | 2.94e-01 | 6.52e-01 | 9.95e-01 |
| HETEROTYPIC CELL CELL ADHESION | 61 | 7.65e-01 | 1.00e+00 | 0.10700 | -5.43e-02 | -4.79e-02 | -5.19e-02 | -1.28e-02 | 5.79e-02 | 4.63e-01 | 5.18e-01 | 4.83e-01 | 8.63e-01 | 4.34e-01 |
| REGULATION OF MULTICELLULAR ORGANISM GROWTH | 63 | 2.30e-01 | 7.52e-01 | 0.10700 | 8.39e-03 | 2.74e-03 | 8.32e-02 | -6.66e-02 | 3.28e-04 | 9.08e-01 | 9.70e-01 | 2.53e-01 | 3.60e-01 | 9.96e-01 |
| NITRIC OXIDE SYNTHASE BIOSYNTHETIC PROCESS | 20 | 9.80e-01 | 1.00e+00 | 0.10700 | -3.22e-02 | -1.80e-02 | -6.10e-02 | -3.59e-04 | -7.97e-02 | 8.03e-01 | 8.89e-01 | 6.37e-01 | 9.98e-01 | 5.37e-01 |
| TRACHEA FORMATION | 7 | 9.39e-01 | 1.00e+00 | 0.10700 | -3.24e-02 | -7.72e-02 | -1.12e-02 | 8.44e-03 | 6.51e-02 | 8.82e-01 | 7.24e-01 | 9.59e-01 | 9.69e-01 | 7.66e-01 |
| MODULATION OF INHIBITORY POSTSYNAPTIC POTENTIAL | 7 | 9.90e-01 | 1.00e+00 | 0.10700 | -2.48e-02 | -1.35e-04 | -7.76e-02 | 3.81e-02 | -5.78e-02 | 9.09e-01 | 1.00e+00 | 7.22e-01 | 8.61e-01 | 7.91e-01 |
| RESPONSE TO CYTOKINE | 906 | 3.90e-04 | 1.07e-02 | 0.10700 | -4.67e-02 | -5.42e-02 | -7.70e-05 | -6.69e-02 | 4.25e-02 | 1.70e-02 | 5.62e-03 | 9.97e-01 | 6.35e-04 | 3.01e-02 |
| NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY | 24 | 9.57e-01 | 1.00e+00 | 0.10700 | 3.62e-03 | -1.66e-02 | 5.04e-02 | -2.70e-02 | 8.86e-02 | 9.75e-01 | 8.88e-01 | 6.69e-01 | 8.19e-01 | 4.53e-01 |
| REGULATION OF CELL ADHESION MEDIATED BY INTEGRIN | 48 | 4.88e-01 | 9.44e-01 | 0.10700 | 3.23e-03 | -1.22e-02 | 4.96e-02 | -6.09e-02 | -7.11e-02 | 9.69e-01 | 8.84e-01 | 5.52e-01 | 4.65e-01 | 3.94e-01 |
| EMBRYONIC APPENDAGE MORPHOGENESIS | 119 | 4.07e-02 | 3.24e-01 | 0.10700 | -2.23e-02 | -4.34e-02 | 6.09e-02 | -7.15e-02 | 1.31e-02 | 6.75e-01 | 4.13e-01 | 2.51e-01 | 1.78e-01 | 8.05e-01 |
| VESICLE MEDIATED TRANSPORT TO THE PLASMA MEMBRANE | 145 | 8.62e-01 | 1.00e+00 | 0.10700 | -5.75e-02 | -6.23e-02 | -3.96e-02 | -5.12e-02 | 1.66e-03 | 2.32e-01 | 1.95e-01 | 4.11e-01 | 2.87e-01 | 9.73e-01 |
| GLYCOSPHINGOLIPID METABOLIC PROCESS | 62 | 7.96e-01 | 1.00e+00 | 0.10700 | -1.54e-02 | -3.51e-02 | 2.83e-02 | -2.66e-02 | 9.15e-02 | 8.34e-01 | 6.33e-01 | 7.00e-01 | 7.17e-01 | 2.13e-01 |
| ENDOCYTIC RECYCLING | 83 | 9.67e-01 | 1.00e+00 | 0.10700 | -5.75e-02 | -5.89e-02 | -5.09e-02 | -4.39e-02 | 7.34e-03 | 3.65e-01 | 3.54e-01 | 4.23e-01 | 4.89e-01 | 9.08e-01 |
| MAINTENANCE OF LOCATION IN CELL | 225 | 1.21e-01 | 5.80e-01 | 0.10600 | -3.41e-02 | -4.75e-02 | 2.50e-02 | -6.78e-02 | 5.18e-02 | 3.79e-01 | 2.20e-01 | 5.19e-01 | 7.96e-02 | 1.80e-01 |
| REGULATION OF MORPHOGENESIS OF AN EPITHELIUM | 62 | 3.92e-01 | 8.92e-01 | 0.10600 | 4.73e-03 | 5.50e-03 | 4.10e-02 | -4.89e-02 | -8.48e-02 | 9.49e-01 | 9.40e-01 | 5.77e-01 | 5.05e-01 | 2.48e-01 |
| NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 102 | 1.41e-01 | 6.25e-01 | 0.10600 | -3.08e-03 | -1.44e-02 | 7.51e-02 | -5.12e-02 | 5.32e-02 | 9.57e-01 | 8.01e-01 | 1.90e-01 | 3.71e-01 | 3.54e-01 |
| COGNITION | 304 | 3.21e-01 | 8.47e-01 | 0.10600 | 5.03e-02 | 5.40e-02 | 3.87e-02 | 4.20e-02 | -5.08e-02 | 1.31e-01 | 1.05e-01 | 2.46e-01 | 2.08e-01 | 1.28e-01 |
| TOR SIGNALING | 158 | 1.73e-01 | 6.77e-01 | 0.10600 | -2.36e-03 | -1.06e-02 | 5.47e-02 | -4.86e-02 | 7.62e-02 | 9.59e-01 | 8.17e-01 | 2.36e-01 | 2.91e-01 | 9.83e-02 |
| ENDOSOMAL VESICLE FUSION | 12 | 9.80e-01 | 1.00e+00 | 0.10600 | -4.92e-03 | -2.88e-02 | 4.98e-02 | -5.19e-02 | 7.25e-02 | 9.76e-01 | 8.63e-01 | 7.65e-01 | 7.56e-01 | 6.64e-01 |
| STEM CELL DEVELOPMENT | 87 | 7.70e-01 | 1.00e+00 | 0.10600 | 5.50e-02 | 4.63e-02 | 5.23e-02 | 3.01e-02 | -4.95e-02 | 3.75e-01 | 4.56e-01 | 3.99e-01 | 6.28e-01 | 4.25e-01 |
| MUSCLE SYSTEM PROCESS | 438 | 1.87e-01 | 6.95e-01 | 0.10600 | 5.11e-02 | 5.57e-02 | 3.17e-02 | 6.21e-02 | -2.59e-02 | 6.64e-02 | 4.57e-02 | 2.55e-01 | 2.59e-02 | 3.52e-01 |
| REGULATION OF ORGANELLE ORGANIZATION | 1151 | 1.70e-06 | 9.75e-05 | 0.10600 | 4.02e-02 | 3.46e-02 | 7.75e-02 | 1.33e-02 | 4.73e-02 | 2.14e-02 | 4.75e-02 | 9.07e-06 | 4.46e-01 | 6.74e-03 |
| REGULATION OF SPROUTING ANGIOGENESIS | 62 | 3.20e-01 | 8.47e-01 | 0.10600 | 1.33e-02 | 3.54e-02 | 1.81e-02 | -3.98e-02 | -8.89e-02 | 8.57e-01 | 6.30e-01 | 8.05e-01 | 5.88e-01 | 2.26e-01 |
| MITOCHONDRION MORPHOGENESIS | 20 | 7.59e-01 | 1.00e+00 | 0.10600 | 4.81e-02 | 4.71e-03 | 8.30e-02 | 3.99e-02 | 2.06e-02 | 7.10e-01 | 9.71e-01 | 5.21e-01 | 7.58e-01 | 8.73e-01 |
| POSITIVE REGULATION OF PROTEIN SECRETION | 142 | 3.20e-02 | 2.81e-01 | 0.10600 | 1.19e-03 | 1.31e-02 | 2.00e-02 | -3.04e-02 | -9.85e-02 | 9.81e-01 | 7.88e-01 | 6.81e-01 | 5.32e-01 | 4.27e-02 |
| REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 151 | 4.52e-01 | 9.30e-01 | 0.10600 | -5.58e-02 | -4.97e-02 | -2.11e-02 | -6.90e-02 | 2.02e-02 | 2.37e-01 | 2.92e-01 | 6.54e-01 | 1.44e-01 | 6.68e-01 |
| CARBOHYDRATE DERIVATIVE TRANSPORT | 83 | 6.77e-01 | 1.00e+00 | 0.10600 | 5.51e-02 | 6.34e-02 | 6.09e-02 | 1.49e-02 | 1.43e-02 | 3.86e-01 | 3.18e-01 | 3.38e-01 | 8.14e-01 | 8.22e-01 |
| CIRCADIAN REGULATION OF GENE EXPRESSION | 66 | 2.20e-01 | 7.44e-01 | 0.10600 | 5.32e-03 | 2.13e-02 | 4.34e-02 | -4.11e-02 | 8.44e-02 | 9.40e-01 | 7.65e-01 | 5.42e-01 | 5.63e-01 | 2.36e-01 |
| REGULATION OF LIPID STORAGE | 54 | 9.77e-01 | 1.00e+00 | 0.10600 | -4.81e-02 | -4.05e-02 | -6.15e-02 | -3.29e-02 | -4.81e-02 | 5.40e-01 | 6.07e-01 | 4.34e-01 | 6.75e-01 | 5.41e-01 |
| NEGATIVE REGULATION OF REPRODUCTIVE PROCESS | 72 | 9.35e-01 | 1.00e+00 | 0.10500 | 4.95e-02 | 5.66e-02 | 2.69e-02 | 4.24e-02 | -5.42e-02 | 4.67e-01 | 4.06e-01 | 6.93e-01 | 5.34e-01 | 4.27e-01 |
| SULFUR COMPOUND BIOSYNTHETIC PROCESS | 150 | 3.39e-01 | 8.59e-01 | 0.10500 | 3.90e-02 | 3.95e-02 | 2.19e-02 | 5.44e-02 | -6.77e-02 | 4.10e-01 | 4.04e-01 | 6.44e-01 | 2.50e-01 | 1.52e-01 |
| COPULATION | 19 | 6.95e-01 | 1.00e+00 | 0.10500 | -2.20e-02 | 2.65e-02 | -9.13e-02 | 2.45e-02 | -3.12e-02 | 8.68e-01 | 8.42e-01 | 4.91e-01 | 8.53e-01 | 8.14e-01 |
| RESPONSE TO ABIOTIC STIMULUS | 1079 | 3.91e-04 | 1.07e-02 | 0.10500 | 5.33e-02 | 5.71e-02 | 6.14e-02 | 3.40e-02 | -6.90e-03 | 3.08e-03 | 1.52e-03 | 6.60e-04 | 5.92e-02 | 7.02e-01 |
| FOREBRAIN DEVELOPMENT | 392 | 1.49e-05 | 6.66e-04 | 0.10500 | 2.98e-02 | 1.78e-02 | 7.03e-02 | -2.96e-02 | -6.36e-02 | 3.11e-01 | 5.44e-01 | 1.69e-02 | 3.15e-01 | 3.07e-02 |
| POSITIVE REGULATION OF VESICLE FUSION | 11 | 9.88e-01 | 1.00e+00 | 0.10500 | -3.87e-02 | -3.17e-02 | 3.48e-03 | -7.74e-02 | 5.06e-02 | 8.24e-01 | 8.56e-01 | 9.84e-01 | 6.57e-01 | 7.71e-01 |
| REGULATION OF ORGANIC ACID TRANSPORT | 75 | 3.21e-01 | 8.47e-01 | 0.10500 | 4.03e-02 | 4.11e-02 | 7.28e-02 | 1.10e-02 | -4.81e-02 | 5.46e-01 | 5.38e-01 | 2.75e-01 | 8.69e-01 | 4.72e-01 |
| REGULATION OF PROTEIN STABILITY | 305 | 1.32e-02 | 1.52e-01 | 0.10500 | 1.52e-02 | 3.87e-03 | 7.48e-02 | -2.60e-02 | 6.73e-02 | 6.48e-01 | 9.08e-01 | 2.47e-02 | 4.35e-01 | 4.32e-02 |
| POSITIVE REGULATION OF BINDING | 121 | 5.09e-02 | 3.69e-01 | 0.10500 | -1.47e-02 | -1.68e-02 | 5.45e-02 | -8.62e-02 | 1.17e-02 | 7.80e-01 | 7.49e-01 | 3.00e-01 | 1.01e-01 | 8.24e-01 |
| GLANDULAR EPITHELIAL CELL DEVELOPMENT | 36 | 6.32e-01 | 9.96e-01 | 0.10500 | 8.00e-03 | -2.95e-03 | 6.32e-02 | -5.73e-02 | -6.04e-02 | 9.34e-01 | 9.76e-01 | 5.11e-01 | 5.52e-01 | 5.30e-01 |
| PROTEIN DEPHOSPHORYLATION | 194 | 2.67e-01 | 7.95e-01 | 0.10500 | -2.50e-02 | -3.47e-02 | 2.34e-02 | -3.66e-02 | 8.53e-02 | 5.48e-01 | 4.04e-01 | 5.74e-01 | 3.79e-01 | 4.04e-02 |
| POSITIVE REGULATION OF GROWTH | 240 | 3.54e-01 | 8.72e-01 | 0.10500 | 5.58e-02 | 5.41e-02 | 6.02e-02 | 2.06e-02 | -3.01e-02 | 1.36e-01 | 1.48e-01 | 1.08e-01 | 5.83e-01 | 4.23e-01 |
| NEGATIVE REGULATION OF CELL DIFFERENTIATION | 686 | 8.12e-05 | 2.89e-03 | 0.10500 | 4.92e-02 | 4.04e-02 | 8.31e-02 | -1.08e-03 | -5.45e-03 | 2.79e-02 | 7.12e-02 | 2.07e-04 | 9.62e-01 | 8.08e-01 |
| INORGANIC ANION TRANSPORT | 162 | 3.10e-01 | 8.37e-01 | 0.10500 | 4.25e-02 | 5.13e-02 | 1.90e-02 | 6.79e-02 | -3.96e-02 | 3.50e-01 | 2.60e-01 | 6.76e-01 | 1.36e-01 | 3.84e-01 |
| PROTEIN LOCALIZATION TO ORGANELLE | 917 | 1.63e-08 | 1.75e-06 | 0.10500 | 1.37e-02 | -4.00e-04 | 7.37e-02 | -3.84e-02 | 6.23e-02 | 4.81e-01 | 9.84e-01 | 1.54e-04 | 4.86e-02 | 1.37e-03 |
| REGULATION OF NITRIC OXIDE METABOLIC PROCESS | 57 | 3.15e-01 | 8.42e-01 | 0.10500 | -5.88e-02 | -4.97e-02 | -7.03e-03 | -6.91e-02 | -1.43e-02 | 4.42e-01 | 5.16e-01 | 9.27e-01 | 3.67e-01 | 8.52e-01 |
| REGULATION OF LEUKOCYTE DIFFERENTIATION | 315 | 5.04e-02 | 3.67e-01 | 0.10500 | -4.23e-02 | -5.80e-02 | 1.24e-02 | -6.38e-02 | 3.97e-02 | 1.96e-01 | 7.65e-02 | 7.05e-01 | 5.14e-02 | 2.25e-01 |
| FAT SOLUBLE VITAMIN BIOSYNTHETIC PROCESS | 13 | 9.79e-01 | 1.00e+00 | 0.10500 | 2.11e-02 | 4.69e-02 | -2.13e-02 | 4.51e-02 | -7.63e-02 | 8.95e-01 | 7.70e-01 | 8.94e-01 | 7.78e-01 | 6.34e-01 |
| RESPONSE TO STARVATION | 208 | 1.37e-01 | 6.17e-01 | 0.10500 | 4.25e-02 | 5.62e-02 | 3.69e-02 | 4.86e-02 | 4.77e-02 | 2.91e-01 | 1.62e-01 | 3.59e-01 | 2.27e-01 | 2.36e-01 |
| PHOSPHATIDIC ACID METABOLIC PROCESS | 35 | 1.78e-01 | 6.85e-01 | 0.10500 | 1.24e-02 | 1.63e-02 | -7.14e-02 | 5.53e-02 | 4.84e-02 | 8.99e-01 | 8.67e-01 | 4.64e-01 | 5.71e-01 | 6.20e-01 |
| DNA METHYLATION | 47 | 7.17e-01 | 1.00e+00 | 0.10400 | -4.10e-02 | -5.04e-02 | 2.72e-02 | -6.80e-02 | 3.65e-02 | 6.27e-01 | 5.50e-01 | 7.47e-01 | 4.20e-01 | 6.65e-01 |
| STEM CELL DIFFERENTIATION | 240 | 4.60e-02 | 3.48e-01 | 0.10400 | 4.46e-02 | 4.00e-02 | 7.10e-02 | -2.91e-04 | -4.77e-02 | 2.34e-01 | 2.85e-01 | 5.82e-02 | 9.94e-01 | 2.03e-01 |
| PYRIMIDINE CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 39 | 9.47e-01 | 1.00e+00 | 0.10400 | 5.89e-02 | 4.34e-02 | 6.30e-02 | 3.68e-02 | -1.51e-02 | 5.25e-01 | 6.39e-01 | 4.96e-01 | 6.91e-01 | 8.70e-01 |
| POSITIVE REGULATION OF VOLTAGE GATED POTASSIUM CHANNEL ACTIVITY | 12 | 9.73e-01 | 1.00e+00 | 0.10400 | 3.77e-02 | 2.55e-02 | 1.99e-02 | 7.34e-02 | -5.50e-02 | 8.21e-01 | 8.79e-01 | 9.05e-01 | 6.60e-01 | 7.42e-01 |
| C21 STEROID HORMONE METABOLIC PROCESS | 36 | 7.36e-01 | 1.00e+00 | 0.10400 | -6.48e-02 | -4.87e-02 | -4.57e-02 | -3.56e-02 | 3.06e-02 | 5.01e-01 | 6.13e-01 | 6.35e-01 | 7.12e-01 | 7.51e-01 |
| POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 57 | 7.67e-01 | 1.00e+00 | 0.10400 | -6.03e-02 | -5.79e-02 | -2.13e-02 | -5.53e-02 | 1.77e-02 | 4.31e-01 | 4.49e-01 | 7.81e-01 | 4.70e-01 | 8.17e-01 |
| CYTOKINESIS | 178 | 8.80e-02 | 4.90e-01 | 0.10400 | 2.54e-02 | 9.70e-03 | 7.53e-02 | 1.77e-02 | 6.40e-02 | 5.60e-01 | 8.23e-01 | 8.32e-02 | 6.84e-01 | 1.41e-01 |
| RESPONSE TO ACIDIC PH | 28 | 1.56e-01 | 6.54e-01 | 0.10400 | 1.92e-02 | 6.52e-02 | 3.86e-02 | -1.32e-02 | 6.73e-02 | 8.61e-01 | 5.51e-01 | 7.23e-01 | 9.04e-01 | 5.38e-01 |
| POSITIVE REGULATION OF PROTEIN TARGETING TO MEMBRANE | 27 | 9.70e-01 | 1.00e+00 | 0.10400 | 3.85e-02 | 3.43e-02 | 2.09e-02 | 7.48e-02 | 4.61e-02 | 7.29e-01 | 7.58e-01 | 8.51e-01 | 5.01e-01 | 6.79e-01 |
| TRIGLYCERIDE METABOLIC PROCESS | 102 | 8.30e-01 | 1.00e+00 | 0.10400 | 4.53e-02 | 5.60e-02 | 9.49e-03 | 6.09e-02 | -4.23e-02 | 4.29e-01 | 3.28e-01 | 8.68e-01 | 2.87e-01 | 4.60e-01 |
| CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT | 54 | 5.47e-01 | 9.61e-01 | 0.10400 | -1.48e-02 | -3.21e-02 | 6.35e-02 | -5.63e-02 | 4.82e-02 | 8.51e-01 | 6.83e-01 | 4.20e-01 | 4.74e-01 | 5.40e-01 |
| CARDIAC SEPTUM DEVELOPMENT | 108 | 9.24e-02 | 5.02e-01 | 0.10400 | 2.60e-02 | 9.40e-03 | 7.43e-02 | -3.32e-02 | -5.82e-02 | 6.41e-01 | 8.66e-01 | 1.82e-01 | 5.51e-01 | 2.96e-01 |
| NEGATIVE REGULATION OF PEPTIDE SECRETION | 44 | 7.89e-01 | 1.00e+00 | 0.10400 | 2.23e-02 | 1.93e-02 | 6.83e-02 | -3.33e-02 | 6.41e-02 | 7.98e-01 | 8.25e-01 | 4.33e-01 | 7.02e-01 | 4.62e-01 |
| BONE MINERALIZATION | 116 | 2.22e-01 | 7.45e-01 | 0.10400 | -3.06e-02 | -6.68e-03 | -5.02e-02 | -1.36e-02 | -8.41e-02 | 5.69e-01 | 9.01e-01 | 3.51e-01 | 8.00e-01 | 1.18e-01 |
| MEMBRANE DOCKING | 91 | 4.21e-01 | 9.12e-01 | 0.10400 | -1.17e-02 | -2.32e-02 | 4.55e-02 | -6.76e-02 | 5.87e-02 | 8.47e-01 | 7.02e-01 | 4.53e-01 | 2.65e-01 | 3.33e-01 |
| REGULATION OF TRANSLATIONAL INITIATION IN RESPONSE TO STRESS | 14 | 9.72e-01 | 1.00e+00 | 0.10400 | 3.31e-02 | 2.26e-02 | 6.83e-02 | -2.62e-02 | 6.16e-02 | 8.30e-01 | 8.84e-01 | 6.58e-01 | 8.65e-01 | 6.90e-01 |
| PIGMENT METABOLIC PROCESS | 74 | 3.22e-01 | 8.47e-01 | 0.10400 | -3.19e-02 | -3.97e-02 | 2.72e-02 | -2.44e-02 | 8.24e-02 | 6.35e-01 | 5.55e-01 | 6.85e-01 | 7.17e-01 | 2.21e-01 |
| GROWTH | 887 | 5.21e-03 | 7.91e-02 | 0.10300 | 5.58e-02 | 5.29e-02 | 6.38e-02 | 2.28e-02 | -1.46e-02 | 4.82e-03 | 7.50e-03 | 1.27e-03 | 2.48e-01 | 4.59e-01 |
| ENDOPLASMIC RETICULUM ORGANIZATION | 96 | 5.19e-01 | 9.53e-01 | 0.10300 | -1.12e-02 | -1.89e-02 | 3.24e-02 | -7.36e-03 | 9.55e-02 | 8.50e-01 | 7.48e-01 | 5.84e-01 | 9.01e-01 | 1.06e-01 |
| POSITIVE REGULATION OF ORGANIC ACID TRANSPORT | 44 | 4.78e-01 | 9.41e-01 | 0.10300 | -4.78e-02 | -5.63e-02 | 2.11e-02 | -6.81e-02 | -1.22e-02 | 5.83e-01 | 5.18e-01 | 8.08e-01 | 4.34e-01 | 8.89e-01 |
| POSITIVE REGULATION OF CELL ADHESION MEDIATED BY INTEGRIN | 22 | 7.69e-01 | 1.00e+00 | 0.10300 | -2.25e-02 | -5.40e-02 | 5.21e-02 | -6.57e-02 | -1.51e-02 | 8.55e-01 | 6.61e-01 | 6.72e-01 | 5.94e-01 | 9.02e-01 |
| SPHINGOLIPID BIOSYNTHETIC PROCESS | 110 | 3.65e-01 | 8.79e-01 | 0.10300 | -5.78e-02 | -5.75e-02 | -1.79e-02 | -4.45e-02 | 4.15e-02 | 2.95e-01 | 2.98e-01 | 7.45e-01 | 4.20e-01 | 4.52e-01 |
| POSITIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 102 | 6.34e-02 | 4.12e-01 | 0.10300 | -6.19e-02 | -6.21e-02 | -1.25e-02 | -5.15e-02 | -1.31e-02 | 2.80e-01 | 2.78e-01 | 8.28e-01 | 3.69e-01 | 8.20e-01 |
| SPLEEN DEVELOPMENT | 38 | 4.14e-01 | 9.11e-01 | 0.10300 | 4.13e-03 | -3.53e-02 | 8.58e-02 | -3.84e-02 | 2.40e-02 | 9.65e-01 | 7.06e-01 | 3.60e-01 | 6.82e-01 | 7.98e-01 |
| RESPONSE TO ETHER | 11 | 9.70e-01 | 1.00e+00 | 0.10300 | 3.65e-02 | 4.18e-02 | 3.90e-02 | 7.38e-02 | 2.44e-02 | 8.34e-01 | 8.10e-01 | 8.23e-01 | 6.72e-01 | 8.88e-01 |
| MEIOTIC CELL CYCLE | 276 | 3.79e-03 | 6.32e-02 | 0.10300 | 3.74e-02 | 1.10e-02 | 9.04e-02 | -1.31e-02 | 2.79e-02 | 2.85e-01 | 7.54e-01 | 9.74e-03 | 7.07e-01 | 4.25e-01 |
| CYTOSOLIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 138 | 5.53e-01 | 9.66e-01 | 0.10300 | -4.23e-02 | -5.11e-02 | 7.59e-03 | -6.87e-02 | 3.83e-02 | 3.91e-01 | 3.00e-01 | 8.78e-01 | 1.64e-01 | 4.37e-01 |
| ASPARTATE FAMILY AMINO ACID CATABOLIC PROCESS | 17 | 9.21e-01 | 1.00e+00 | 0.10300 | -1.16e-02 | 1.46e-02 | -8.31e-02 | 1.12e-02 | -5.68e-02 | 9.34e-01 | 9.17e-01 | 5.53e-01 | 9.37e-01 | 6.85e-01 |
| NON CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 140 | 4.86e-01 | 9.43e-01 | 0.10300 | -4.10e-02 | -5.15e-02 | 5.06e-03 | -7.72e-02 | 1.69e-02 | 4.02e-01 | 2.93e-01 | 9.18e-01 | 1.15e-01 | 7.30e-01 |
| NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 462 | 6.78e-04 | 1.65e-02 | 0.10300 | 1.72e-02 | 1.24e-02 | 6.43e-02 | -3.11e-02 | 7.10e-02 | 5.27e-01 | 6.47e-01 | 1.79e-02 | 2.52e-01 | 8.88e-03 |
| KETONE CATABOLIC PROCESS | 14 | 3.33e-01 | 8.57e-01 | 0.10300 | -5.84e-02 | -1.78e-02 | -6.11e-02 | 2.15e-02 | -5.16e-02 | 7.05e-01 | 9.08e-01 | 6.92e-01 | 8.89e-01 | 7.38e-01 |
| POSITIVE REGULATION OF NUCLEOTIDE METABOLIC PROCESS | 18 | 8.28e-01 | 1.00e+00 | 0.10300 | -1.37e-02 | -1.86e-02 | -7.48e-02 | 6.15e-02 | 2.48e-02 | 9.20e-01 | 8.91e-01 | 5.83e-01 | 6.51e-01 | 8.56e-01 |
| POSITIVE REGULATION OF TRANSMISSION OF NERVE IMPULSE | 7 | 9.70e-01 | 1.00e+00 | 0.10300 | 2.49e-02 | 6.85e-02 | -4.11e-02 | 4.09e-02 | -4.31e-02 | 9.09e-01 | 7.54e-01 | 8.51e-01 | 8.51e-01 | 8.43e-01 |
| COBALAMIN METABOLIC PROCESS | 9 | 9.83e-01 | 1.00e+00 | 0.10300 | 9.97e-03 | -1.80e-02 | 6.94e-02 | 6.97e-03 | 7.24e-02 | 9.59e-01 | 9.25e-01 | 7.19e-01 | 9.71e-01 | 7.07e-01 |
| REGULATION OF PHOSPHOLIPID TRANSPORT | 15 | 9.68e-01 | 1.00e+00 | 0.10300 | -3.55e-02 | -5.02e-02 | -2.49e-02 | -6.65e-02 | -4.13e-02 | 8.12e-01 | 7.37e-01 | 8.68e-01 | 6.55e-01 | 7.82e-01 |
| IRON ION TRANSMEMBRANE TRANSPORT | 27 | 9.34e-01 | 1.00e+00 | 0.10300 | 3.82e-02 | 1.33e-02 | 8.10e-02 | 2.08e-02 | 4.35e-02 | 7.31e-01 | 9.05e-01 | 4.66e-01 | 8.52e-01 | 6.95e-01 |
| CELL CELL ADHESION | 922 | 7.44e-05 | 2.71e-03 | 0.10300 | -5.65e-02 | -5.82e-02 | -2.25e-02 | -4.68e-02 | 3.50e-02 | 3.59e-03 | 2.72e-03 | 2.46e-01 | 1.60e-02 | 7.13e-02 |
| INORGANIC ANION TRANSMEMBRANE TRANSPORT | 125 | 3.84e-01 | 8.92e-01 | 0.10200 | 4.17e-02 | 5.35e-02 | 1.81e-02 | 7.15e-02 | -2.15e-02 | 4.21e-01 | 3.02e-01 | 7.27e-01 | 1.67e-01 | 6.78e-01 |
| NEUTRAL LIPID METABOLIC PROCESS | 128 | 8.32e-01 | 1.00e+00 | 0.10200 | 4.70e-02 | 5.29e-02 | 2.05e-02 | 5.57e-02 | -4.44e-02 | 3.58e-01 | 3.02e-01 | 6.88e-01 | 2.76e-01 | 3.86e-01 |
| CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 284 | 6.01e-02 | 4.02e-01 | 0.10200 | -4.45e-02 | -4.40e-02 | 3.94e-03 | -6.73e-02 | 4.51e-02 | 1.97e-01 | 2.02e-01 | 9.09e-01 | 5.09e-02 | 1.91e-01 |
| REGULATION OF ACTIN NUCLEATION | 38 | 9.21e-01 | 1.00e+00 | 0.10200 | 3.62e-02 | 1.60e-02 | 8.15e-02 | 2.99e-03 | 4.78e-02 | 7.00e-01 | 8.64e-01 | 3.85e-01 | 9.75e-01 | 6.10e-01 |
| SKELETAL SYSTEM DEVELOPMENT | 509 | 2.67e-02 | 2.49e-01 | 0.10200 | 5.03e-02 | 4.86e-02 | 6.16e-02 | 2.99e-02 | -3.01e-02 | 5.18e-02 | 6.04e-02 | 1.73e-02 | 2.48e-01 | 2.46e-01 |
| NEGATIVE REGULATION OF LIPASE ACTIVITY | 16 | 9.79e-01 | 1.00e+00 | 0.10200 | -5.47e-03 | 1.46e-03 | -6.11e-02 | 1.99e-02 | -7.94e-02 | 9.70e-01 | 9.92e-01 | 6.72e-01 | 8.90e-01 | 5.82e-01 |
| PANCREATIC JUICE SECRETION | 11 | 9.97e-01 | 1.00e+00 | 0.10200 | 4.00e-02 | 4.44e-02 | -9.59e-04 | 7.59e-02 | -3.38e-02 | 8.18e-01 | 7.99e-01 | 9.96e-01 | 6.63e-01 | 8.46e-01 |
| O GLYCAN PROCESSING | 42 | 9.33e-01 | 1.00e+00 | 0.10200 | -4.47e-02 | -3.26e-02 | -6.29e-02 | -1.31e-02 | -5.72e-02 | 6.16e-01 | 7.15e-01 | 4.81e-01 | 8.84e-01 | 5.21e-01 |
| PURINE RIBONUCLEOSIDE METABOLIC PROCESS | 20 | 9.69e-01 | 1.00e+00 | 0.10200 | -1.13e-02 | 7.90e-03 | -5.83e-02 | 2.88e-02 | -7.76e-02 | 9.30e-01 | 9.51e-01 | 6.52e-01 | 8.23e-01 | 5.48e-01 |
| NEGATIVE REGULATION OF LOCOMOTION | 395 | 5.67e-01 | 9.72e-01 | 0.10200 | -5.48e-02 | -5.37e-02 | -4.95e-02 | -4.44e-02 | 9.94e-03 | 6.14e-02 | 6.68e-02 | 9.12e-02 | 1.30e-01 | 7.34e-01 |
| NEGATIVE REGULATION OF PROTEOLYSIS | 213 | 6.42e-02 | 4.13e-01 | 0.10200 | -3.78e-02 | -4.04e-02 | 1.92e-02 | -8.10e-02 | 2.00e-02 | 3.41e-01 | 3.10e-01 | 6.29e-01 | 4.16e-02 | 6.15e-01 |
| STARTLE RESPONSE | 26 | 5.89e-01 | 9.86e-01 | 0.10200 | 1.44e-02 | 5.09e-02 | -7.21e-02 | 4.05e-02 | -2.74e-02 | 8.99e-01 | 6.54e-01 | 5.24e-01 | 7.20e-01 | 8.09e-01 |
| POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 151 | 5.84e-01 | 9.85e-01 | 0.10200 | -5.47e-02 | -3.90e-02 | -6.99e-02 | -3.14e-02 | -2.36e-03 | 2.46e-01 | 4.08e-01 | 1.38e-01 | 5.06e-01 | 9.60e-01 |
| REGULATION OF PLATELET DERIVED GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 24 | 8.44e-01 | 1.00e+00 | 0.10200 | 4.51e-02 | 6.03e-02 | 5.97e-02 | -1.22e-02 | 3.14e-02 | 7.02e-01 | 6.09e-01 | 6.12e-01 | 9.17e-01 | 7.90e-01 |
| REGULATION OF PROGRAMMED CELL DEATH | 1469 | 2.26e-11 | 5.16e-09 | 0.10200 | 2.97e-02 | 1.78e-02 | 8.10e-02 | -1.98e-02 | 4.73e-02 | 5.69e-02 | 2.53e-01 | 2.04e-07 | 2.04e-01 | 2.43e-03 |
| VASCULAR PROCESS IN CIRCULATORY SYSTEM | 261 | 5.34e-02 | 3.78e-01 | 0.10200 | 3.35e-02 | 4.21e-02 | 1.43e-02 | 5.09e-02 | -6.83e-02 | 3.51e-01 | 2.42e-01 | 6.91e-01 | 1.57e-01 | 5.76e-02 |
| CELLULAR RESPONSE TO REACTIVE NITROGEN SPECIES | 16 | 9.88e-01 | 1.00e+00 | 0.10200 | 4.82e-02 | 2.99e-02 | 7.40e-02 | 3.87e-02 | 1.18e-02 | 7.39e-01 | 8.36e-01 | 6.09e-01 | 7.89e-01 | 9.35e-01 |
| XENOBIOTIC TRANSMEMBRANE TRANSPORT | 16 | 9.41e-01 | 1.00e+00 | 0.10200 | -5.24e-02 | -2.53e-02 | -4.52e-02 | -6.97e-02 | 5.05e-03 | 7.17e-01 | 8.61e-01 | 7.54e-01 | 6.29e-01 | 9.72e-01 |
| HETEROCHROMATIN ORGANIZATION | 89 | 6.13e-01 | 9.90e-01 | 0.10200 | 2.22e-02 | 1.13e-02 | 7.37e-02 | -2.21e-02 | 6.14e-02 | 7.18e-01 | 8.54e-01 | 2.29e-01 | 7.18e-01 | 3.17e-01 |
| DIGESTION | 128 | 6.32e-01 | 9.96e-01 | 0.10200 | 4.47e-02 | 5.54e-02 | 2.09e-02 | 6.02e-02 | 3.44e-02 | 3.82e-01 | 2.79e-01 | 6.83e-01 | 2.40e-01 | 5.02e-01 |
| DETECTION OF MECHANICAL STIMULUS INVOLVED IN SENSORY PERCEPTION OF SOUND | 15 | 7.80e-01 | 1.00e+00 | 0.10200 | 3.60e-02 | 4.84e-02 | 6.34e-02 | 5.15e-02 | -1.82e-03 | 8.09e-01 | 7.46e-01 | 6.71e-01 | 7.30e-01 | 9.90e-01 |
| RESPONSE TO IRON ION | 28 | 4.68e-01 | 9.36e-01 | 0.10100 | 4.78e-03 | -1.93e-02 | 8.74e-02 | -1.40e-03 | 4.76e-02 | 9.65e-01 | 8.60e-01 | 4.24e-01 | 9.90e-01 | 6.63e-01 |
| FOREBRAIN CELL MIGRATION | 64 | 5.83e-01 | 9.85e-01 | 0.10100 | 3.12e-02 | 3.56e-02 | 1.95e-02 | 5.27e-02 | -6.99e-02 | 6.66e-01 | 6.22e-01 | 7.88e-01 | 4.66e-01 | 3.34e-01 |
| RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 287 | 2.80e-02 | 2.58e-01 | 0.10100 | -4.42e-02 | -6.35e-02 | 8.53e-03 | -4.83e-02 | 4.34e-02 | 1.98e-01 | 6.41e-02 | 8.04e-01 | 1.59e-01 | 2.06e-01 |
| SMAD PROTEIN SIGNAL TRANSDUCTION | 83 | 9.58e-01 | 1.00e+00 | 0.10100 | -4.91e-02 | -4.90e-02 | -3.55e-02 | -6.11e-02 | -2.13e-02 | 4.40e-01 | 4.40e-01 | 5.76e-01 | 3.36e-01 | 7.37e-01 |
| EYE MORPHOGENESIS | 159 | 4.37e-01 | 9.22e-01 | 0.10100 | -1.69e-02 | -4.20e-03 | -3.15e-02 | -2.92e-02 | -9.01e-02 | 7.14e-01 | 9.27e-01 | 4.93e-01 | 5.25e-01 | 5.00e-02 |
| GENITALIA DEVELOPMENT | 46 | 7.47e-01 | 1.00e+00 | 0.10100 | -6.53e-03 | -1.80e-02 | 7.34e-03 | -3.35e-02 | -9.33e-02 | 9.39e-01 | 8.33e-01 | 9.31e-01 | 6.95e-01 | 2.73e-01 |
| NEGATIVE REGULATION OF G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 50 | 2.60e-01 | 7.87e-01 | 0.10100 | 8.03e-03 | -2.63e-02 | 8.50e-02 | -4.74e-03 | 4.75e-02 | 9.22e-01 | 7.48e-01 | 2.99e-01 | 9.54e-01 | 5.61e-01 |
| POSITIVE REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION | 52 | 6.95e-01 | 1.00e+00 | 0.10100 | 4.42e-02 | 4.10e-02 | 5.85e-02 | 5.19e-02 | -2.19e-02 | 5.81e-01 | 6.09e-01 | 4.65e-01 | 5.17e-01 | 7.85e-01 |
| INTRA GOLGI VESICLE MEDIATED TRANSPORT | 33 | 9.07e-01 | 1.00e+00 | 0.10100 | -5.18e-02 | -6.09e-02 | -1.49e-03 | -6.20e-02 | -4.94e-04 | 6.07e-01 | 5.45e-01 | 9.88e-01 | 5.38e-01 | 9.96e-01 |
| SIGNAL COMPLEX ASSEMBLY | 8 | 9.89e-01 | 1.00e+00 | 0.10100 | -4.61e-02 | -2.26e-02 | -8.12e-02 | 7.32e-03 | 3.09e-02 | 8.21e-01 | 9.12e-01 | 6.91e-01 | 9.71e-01 | 8.80e-01 |
| REGULATION OF LYMPHANGIOGENESIS | 6 | 7.79e-01 | 1.00e+00 | 0.10100 | -4.37e-02 | 2.84e-03 | -2.38e-02 | 9.11e-03 | 8.75e-02 | 8.53e-01 | 9.90e-01 | 9.20e-01 | 9.69e-01 | 7.11e-01 |
| NEUTRAL AMINO ACID TRANSPORT | 54 | 8.50e-01 | 1.00e+00 | 0.10100 | 5.37e-02 | 6.21e-02 | 4.25e-02 | 1.44e-02 | -3.81e-02 | 4.95e-01 | 4.30e-01 | 5.89e-01 | 8.55e-01 | 6.28e-01 |
| MOLTING CYCLE PROCESS | 93 | 6.15e-01 | 9.90e-01 | 0.10100 | 3.97e-02 | 3.25e-02 | 3.50e-02 | 3.81e-02 | -7.00e-02 | 5.08e-01 | 5.88e-01 | 5.60e-01 | 5.26e-01 | 2.43e-01 |
| DIGESTIVE SYSTEM PROCESS | 102 | 5.12e-01 | 9.51e-01 | 0.10100 | 1.95e-02 | 2.52e-02 | 6.01e-03 | 4.73e-02 | 8.30e-02 | 7.34e-01 | 6.60e-01 | 9.16e-01 | 4.09e-01 | 1.48e-01 |
| RESPONSE TO NITRIC OXIDE | 19 | 7.40e-01 | 1.00e+00 | 0.10100 | -3.74e-02 | -7.79e-02 | 2.97e-02 | -4.01e-02 | 1.48e-02 | 7.78e-01 | 5.57e-01 | 8.23e-01 | 7.62e-01 | 9.11e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS | 41 | 8.13e-01 | 1.00e+00 | 0.10100 | 6.96e-03 | 1.51e-02 | 1.70e-02 | -3.46e-02 | -9.16e-02 | 9.39e-01 | 8.68e-01 | 8.51e-01 | 7.02e-01 | 3.10e-01 |
| REGULATION OF LIPID LOCALIZATION | 183 | 4.95e-01 | 9.47e-01 | 0.10100 | 4.93e-02 | 4.98e-02 | 6.09e-02 | 3.88e-02 | -4.16e-03 | 2.50e-01 | 2.45e-01 | 1.55e-01 | 3.66e-01 | 9.23e-01 |
| SODIUM ION HOMEOSTASIS | 46 | 6.10e-01 | 9.90e-01 | 0.10100 | 3.53e-02 | 4.55e-02 | 2.88e-02 | 5.88e-02 | -5.02e-02 | 6.78e-01 | 5.94e-01 | 7.36e-01 | 4.90e-01 | 5.55e-01 |
| RETINA DEVELOPMENT IN CAMERA TYPE EYE | 156 | 2.49e-01 | 7.75e-01 | 0.10100 | 3.27e-02 | 4.15e-02 | 3.43e-02 | 3.90e-03 | -7.83e-02 | 4.81e-01 | 3.71e-01 | 4.59e-01 | 9.33e-01 | 9.15e-02 |
| REGULATION OF PHOSPHATASE ACTIVITY | 59 | 6.67e-01 | 1.00e+00 | 0.10100 | -3.70e-02 | -6.36e-02 | 1.71e-02 | -5.42e-02 | 3.83e-02 | 6.23e-01 | 3.98e-01 | 8.20e-01 | 4.71e-01 | 6.11e-01 |
| METHYLGUANOSINE CAP DECAPPING | 16 | 9.72e-01 | 1.00e+00 | 0.10100 | 4.72e-02 | 5.39e-02 | 6.93e-02 | -1.07e-02 | -7.40e-03 | 7.44e-01 | 7.09e-01 | 6.31e-01 | 9.41e-01 | 9.59e-01 |
| NEGATIVE REGULATION OF STEM CELL PROLIFERATION | 26 | 7.96e-01 | 1.00e+00 | 0.10000 | -7.90e-03 | -7.26e-05 | -5.12e-02 | -3.02e-02 | -8.05e-02 | 9.44e-01 | 9.99e-01 | 6.51e-01 | 7.90e-01 | 4.77e-01 |
| PYRIDINE NUCLEOTIDE BIOSYNTHETIC PROCESS | 28 | 9.85e-01 | 1.00e+00 | 0.10000 | 4.09e-02 | 4.74e-02 | 3.48e-02 | 4.50e-02 | 5.40e-02 | 7.08e-01 | 6.64e-01 | 7.50e-01 | 6.80e-01 | 6.21e-01 |
| ENERGY RESERVE METABOLIC PROCESS | 84 | 3.14e-01 | 8.42e-01 | 0.10000 | 6.52e-03 | 2.83e-02 | 2.75e-03 | -2.12e-02 | -9.37e-02 | 9.18e-01 | 6.54e-01 | 9.65e-01 | 7.37e-01 | 1.38e-01 |
| SINGLE STRAND BREAK REPAIR | 11 | 9.07e-01 | 1.00e+00 | 0.10000 | -1.31e-02 | -5.78e-02 | 6.14e-02 | -4.27e-02 | 3.11e-02 | 9.40e-01 | 7.40e-01 | 7.25e-01 | 8.06e-01 | 8.58e-01 |
| NEGATIVE REGULATION OF AXONOGENESIS | 60 | 8.70e-01 | 1.00e+00 | 0.10000 | 4.81e-02 | 2.92e-02 | 6.39e-02 | 4.71e-02 | 2.43e-02 | 5.19e-01 | 6.96e-01 | 3.92e-01 | 5.28e-01 | 7.44e-01 |
| LAYER FORMATION IN CEREBRAL CORTEX | 14 | 8.81e-01 | 1.00e+00 | 0.10000 | -3.99e-02 | -2.85e-02 | -7.14e-02 | 4.95e-02 | -9.67e-03 | 7.96e-01 | 8.53e-01 | 6.44e-01 | 7.48e-01 | 9.50e-01 |
| REGULATED EXOCYTOSIS | 216 | 1.37e-01 | 6.18e-01 | 0.10000 | -4.66e-02 | -5.47e-02 | 3.66e-03 | -6.96e-02 | -2.15e-03 | 2.38e-01 | 1.65e-01 | 9.26e-01 | 7.80e-02 | 9.56e-01 |
| MOLTING CYCLE | 113 | 4.16e-01 | 9.11e-01 | 0.10000 | 2.95e-02 | 2.69e-02 | 1.48e-02 | 4.47e-02 | -7.89e-02 | 5.88e-01 | 6.22e-01 | 7.86e-01 | 4.12e-01 | 1.48e-01 |
| CARDIAC VENTRICLE DEVELOPMENT | 127 | 3.76e-02 | 3.09e-01 | 0.10000 | 2.03e-02 | 1.86e-03 | 7.69e-02 | -3.77e-02 | -4.76e-02 | 6.93e-01 | 9.71e-01 | 1.34e-01 | 4.63e-01 | 3.54e-01 |
| DENDRITIC SPINE MORPHOGENESIS | 51 | 9.31e-01 | 1.00e+00 | 0.10000 | -4.42e-02 | -2.96e-02 | -4.58e-02 | -4.58e-02 | -5.47e-02 | 5.85e-01 | 7.15e-01 | 5.72e-01 | 5.71e-01 | 4.99e-01 |
| RESPONSE TO ACID CHEMICAL | 132 | 5.71e-01 | 9.76e-01 | 0.10000 | 3.77e-02 | 4.47e-02 | 4.65e-02 | 3.27e-02 | 5.78e-02 | 4.54e-01 | 3.75e-01 | 3.56e-01 | 5.16e-01 | 2.51e-01 |
| AXONAL FASCICULATION | 21 | 8.86e-01 | 1.00e+00 | 0.09990 | -4.18e-02 | -6.90e-02 | -2.77e-02 | -4.60e-03 | 5.19e-02 | 7.40e-01 | 5.84e-01 | 8.26e-01 | 9.71e-01 | 6.81e-01 |
| RESPONSE TO INORGANIC SUBSTANCE | 510 | 3.70e-02 | 3.06e-01 | 0.09990 | 4.89e-02 | 3.84e-02 | 7.46e-02 | 2.27e-02 | 6.09e-03 | 5.88e-02 | 1.38e-01 | 3.91e-03 | 3.80e-01 | 8.14e-01 |
| REGULATION OF HYDROLASE ACTIVITY | 741 | 5.56e-02 | 3.84e-01 | 0.09990 | -5.28e-02 | -5.27e-02 | -2.60e-02 | -5.47e-02 | 2.73e-02 | 1.44e-02 | 1.45e-02 | 2.28e-01 | 1.12e-02 | 2.05e-01 |
| REGULATION OF ACTIN FILAMENT BASED PROCESS | 362 | 1.54e-01 | 6.50e-01 | 0.09980 | 4.58e-02 | 5.65e-02 | 2.36e-02 | 5.86e-02 | -2.60e-02 | 1.34e-01 | 6.47e-02 | 4.41e-01 | 5.54e-02 | 3.95e-01 |
| DIOL METABOLIC PROCESS | 30 | 9.54e-01 | 1.00e+00 | 0.09980 | -1.57e-02 | -3.53e-02 | 2.76e-02 | -3.40e-02 | 8.09e-02 | 8.82e-01 | 7.38e-01 | 7.93e-01 | 7.47e-01 | 4.43e-01 |
| REGULATION OF AUTOPHAGY | 338 | 1.24e-02 | 1.46e-01 | 0.09970 | 1.48e-02 | 5.05e-03 | 6.98e-02 | -1.43e-02 | 6.79e-02 | 6.39e-01 | 8.73e-01 | 2.73e-02 | 6.50e-01 | 3.19e-02 |
| SYNAPTIC TRANSMISSION GLUTAMATERGIC | 106 | 7.45e-01 | 1.00e+00 | 0.09970 | -2.48e-02 | -2.13e-02 | -3.86e-02 | -1.62e-02 | -8.43e-02 | 6.59e-01 | 7.05e-01 | 4.92e-01 | 7.73e-01 | 1.34e-01 |
| VESICLE DOCKING | 64 | 5.41e-01 | 9.59e-01 | 0.09960 | 1.48e-02 | 4.00e-03 | 7.16e-02 | -5.26e-02 | 4.22e-02 | 8.38e-01 | 9.56e-01 | 3.22e-01 | 4.66e-01 | 5.60e-01 |
| POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 149 | 2.62e-01 | 7.90e-01 | 0.09950 | 1.65e-02 | 1.57e-02 | 5.67e-02 | -2.36e-02 | 7.49e-02 | 7.29e-01 | 7.41e-01 | 2.32e-01 | 6.19e-01 | 1.14e-01 |
| REPLACEMENT OSSIFICATION | 30 | 5.41e-01 | 9.59e-01 | 0.09950 | 1.51e-02 | 4.80e-02 | 1.60e-02 | -1.49e-02 | -8.30e-02 | 8.86e-01 | 6.49e-01 | 8.79e-01 | 8.87e-01 | 4.32e-01 |
| REGULATION OF ANATOMICAL STRUCTURE SIZE | 486 | 2.22e-02 | 2.23e-01 | 0.09930 | 3.98e-02 | 4.60e-02 | 2.93e-02 | 3.63e-02 | -6.32e-02 | 1.33e-01 | 8.21e-02 | 2.68e-01 | 1.71e-01 | 1.70e-02 |
| SMOOTHENED SIGNALING PATHWAY | 140 | 2.73e-01 | 7.99e-01 | 0.09930 | 3.65e-02 | 2.74e-02 | 8.41e-02 | -1.66e-02 | 2.07e-02 | 4.56e-01 | 5.75e-01 | 8.56e-02 | 7.34e-01 | 6.73e-01 |
| ADAPTIVE THERMOGENESIS | 165 | 1.26e-01 | 5.91e-01 | 0.09930 | -9.46e-04 | -1.06e-02 | 6.31e-02 | -4.43e-02 | 6.16e-02 | 9.83e-01 | 8.15e-01 | 1.62e-01 | 3.26e-01 | 1.72e-01 |
| EMBRYONIC PLACENTA DEVELOPMENT | 86 | 6.77e-01 | 1.00e+00 | 0.09930 | 3.96e-02 | 2.75e-02 | 7.40e-02 | -8.59e-03 | 4.44e-02 | 5.25e-01 | 6.59e-01 | 2.35e-01 | 8.91e-01 | 4.77e-01 |
| POSITIVE REGULATION OF AUTOPHAGY | 143 | 2.01e-01 | 7.18e-01 | 0.09920 | -9.33e-03 | -1.95e-02 | 5.43e-02 | -3.93e-02 | 6.99e-02 | 8.47e-01 | 6.87e-01 | 2.62e-01 | 4.17e-01 | 1.49e-01 |
| KINETOCHORE ASSEMBLY | 16 | 7.07e-01 | 1.00e+00 | 0.09920 | 3.64e-02 | -1.34e-02 | 9.04e-02 | 1.09e-02 | -7.26e-03 | 8.01e-01 | 9.26e-01 | 5.31e-01 | 9.40e-01 | 9.60e-01 |
| NEGATIVE REGULATION OF T CELL PROLIFERATION | 68 | 3.55e-01 | 8.73e-01 | 0.09920 | -5.04e-02 | -5.86e-02 | 1.27e-02 | -5.26e-02 | 3.05e-02 | 4.72e-01 | 4.03e-01 | 8.56e-01 | 4.53e-01 | 6.63e-01 |
| GLUCOSE CATABOLIC PROCESS | 25 | 9.42e-01 | 1.00e+00 | 0.09910 | 4.01e-02 | 3.14e-02 | 4.62e-02 | 4.05e-02 | -5.88e-02 | 7.28e-01 | 7.86e-01 | 6.89e-01 | 7.26e-01 | 6.11e-01 |
| TRANSITION METAL ION TRANSPORT | 93 | 6.68e-01 | 1.00e+00 | 0.09910 | -8.60e-03 | -2.10e-02 | 4.09e-02 | -2.14e-02 | 8.47e-02 | 8.86e-01 | 7.26e-01 | 4.95e-01 | 7.22e-01 | 1.58e-01 |
| MACROMOLECULE METHYLATION | 197 | 6.30e-02 | 4.12e-01 | 0.09900 | -1.66e-02 | -3.49e-02 | 5.08e-02 | -4.34e-02 | 6.21e-02 | 6.89e-01 | 3.98e-01 | 2.19e-01 | 2.94e-01 | 1.33e-01 |
| RENAL TUBULE DEVELOPMENT | 99 | 1.78e-01 | 6.85e-01 | 0.09900 | -1.45e-02 | -2.22e-02 | 5.44e-02 | -7.82e-02 | 6.16e-03 | 8.03e-01 | 7.02e-01 | 3.50e-01 | 1.79e-01 | 9.16e-01 |
| POSITIVE REGULATION OF CANONICAL NF KAPPAB SIGNAL TRANSDUCTION | 185 | 1.06e-01 | 5.39e-01 | 0.09900 | -3.71e-02 | -3.34e-02 | 9.81e-03 | -4.97e-02 | 6.89e-02 | 3.84e-01 | 4.33e-01 | 8.18e-01 | 2.44e-01 | 1.06e-01 |
| EXECUTION PHASE OF APOPTOSIS | 74 | 8.97e-01 | 1.00e+00 | 0.09890 | -5.19e-02 | -4.85e-02 | -5.01e-02 | -3.01e-02 | -3.63e-02 | 4.40e-01 | 4.70e-01 | 4.56e-01 | 6.54e-01 | 5.89e-01 |
| POSITIVE REGULATION OF CELL SUBSTRATE ADHESION | 121 | 8.89e-01 | 1.00e+00 | 0.09890 | -5.15e-02 | -5.05e-02 | -4.94e-02 | -3.54e-02 | -2.98e-02 | 3.28e-01 | 3.37e-01 | 3.48e-01 | 5.01e-01 | 5.71e-01 |
| ACTION POTENTIAL | 139 | 5.51e-02 | 3.84e-01 | 0.09890 | 2.37e-02 | 4.24e-02 | -8.66e-04 | 5.62e-02 | -6.52e-02 | 6.29e-01 | 3.88e-01 | 9.86e-01 | 2.52e-01 | 1.85e-01 |
| REGULATION OF THE FORCE OF HEART CONTRACTION | 26 | 9.29e-01 | 1.00e+00 | 0.09890 | 2.14e-02 | 4.56e-02 | -3.08e-02 | 5.66e-02 | -5.56e-02 | 8.50e-01 | 6.87e-01 | 7.86e-01 | 6.17e-01 | 6.24e-01 |
| REGULATION OF CHONDROCYTE DIFFERENTIATION | 52 | 9.41e-01 | 1.00e+00 | 0.09870 | -3.93e-02 | -3.02e-02 | -3.23e-02 | -5.35e-02 | -5.81e-02 | 6.24e-01 | 7.06e-01 | 6.87e-01 | 5.05e-01 | 4.68e-01 |
| MICROTUBULE BUNDLE FORMATION | 121 | 7.42e-01 | 1.00e+00 | 0.09860 | 4.79e-02 | 4.21e-02 | 2.45e-02 | 6.82e-02 | 2.02e-02 | 3.63e-01 | 4.24e-01 | 6.42e-01 | 1.95e-01 | 7.01e-01 |
| POSITIVE REGULATION OF PROTEIN AUTOPHOSPHORYLATION | 24 | 7.72e-01 | 1.00e+00 | 0.09860 | -5.33e-02 | -4.51e-02 | 5.26e-03 | -6.90e-02 | 7.56e-03 | 6.51e-01 | 7.02e-01 | 9.64e-01 | 5.58e-01 | 9.49e-01 |
| NAD METABOLIC PROCESS | 42 | 8.37e-01 | 1.00e+00 | 0.09860 | 2.70e-02 | 1.39e-02 | 7.36e-02 | 1.85e-02 | 5.51e-02 | 7.62e-01 | 8.77e-01 | 4.09e-01 | 8.36e-01 | 5.37e-01 |
| NEGATIVE REGULATION OF INTRACELLULAR STEROID HORMONE RECEPTOR SIGNALING PATHWAY | 36 | 6.06e-01 | 9.90e-01 | 0.09850 | -3.26e-02 | -6.31e-02 | 3.51e-02 | -5.83e-02 | -5.97e-03 | 7.35e-01 | 5.12e-01 | 7.16e-01 | 5.45e-01 | 9.51e-01 |
| MEIOTIC CELL CYCLE PROCESS | 210 | 2.24e-02 | 2.24e-01 | 0.09850 | 3.43e-02 | 5.96e-03 | 8.66e-02 | -7.38e-03 | 3.07e-02 | 3.91e-01 | 8.82e-01 | 3.05e-02 | 8.54e-01 | 4.44e-01 |
| LOCOMOTION | 1266 | 4.39e-03 | 6.96e-02 | 0.09840 | -5.46e-02 | -5.48e-02 | -3.62e-02 | -4.84e-02 | -6.64e-03 | 1.09e-03 | 1.03e-03 | 3.02e-02 | 3.79e-03 | 6.91e-01 |
| TERPENOID BIOSYNTHETIC PROCESS | 16 | 6.19e-01 | 9.90e-01 | 0.09840 | 6.06e-03 | -4.80e-03 | 9.26e-03 | 7.23e-02 | -6.56e-02 | 9.67e-01 | 9.73e-01 | 9.49e-01 | 6.17e-01 | 6.50e-01 |
| POSITIVE REGULATION OF MACROAUTOPHAGY | 71 | 5.98e-01 | 9.89e-01 | 0.09830 | 1.27e-02 | 1.30e-03 | 7.48e-02 | -2.71e-02 | 5.64e-02 | 8.53e-01 | 9.85e-01 | 2.76e-01 | 6.93e-01 | 4.12e-01 |
| SPERM FLAGELLUM ASSEMBLY | 39 | 8.55e-01 | 1.00e+00 | 0.09830 | 5.75e-03 | -8.34e-03 | 4.25e-03 | 3.92e-02 | 8.94e-02 | 9.50e-01 | 9.28e-01 | 9.63e-01 | 6.72e-01 | 3.34e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO ORGANELLE | 437 | 4.40e-04 | 1.19e-02 | 0.09830 | -8.77e-03 | -1.75e-02 | 5.16e-02 | -6.24e-02 | 5.21e-02 | 7.53e-01 | 5.31e-01 | 6.41e-02 | 2.53e-02 | 6.18e-02 |
| SMOOTH MUSCLE CELL APOPTOTIC PROCESS | 32 | 6.20e-01 | 9.90e-01 | 0.09820 | 1.36e-02 | 2.37e-02 | -4.83e-02 | 7.22e-04 | -8.11e-02 | 8.94e-01 | 8.16e-01 | 6.36e-01 | 9.94e-01 | 4.27e-01 |
| ACROSOMAL VESICLE EXOCYTOSIS | 9 | 9.65e-01 | 1.00e+00 | 0.09800 | -1.54e-02 | -4.16e-03 | -6.30e-02 | 7.33e-02 | -2.50e-03 | 9.36e-01 | 9.83e-01 | 7.43e-01 | 7.03e-01 | 9.90e-01 |
| REGULATION OF REGULATED SECRETORY PATHWAY | 117 | 8.05e-02 | 4.67e-01 | 0.09800 | 6.45e-03 | -1.98e-02 | 8.11e-02 | -4.51e-02 | 2.36e-02 | 9.04e-01 | 7.12e-01 | 1.30e-01 | 3.99e-01 | 6.59e-01 |
| POSITIVE REGULATION OF CELL GROWTH | 153 | 8.55e-01 | 1.00e+00 | 0.09790 | 4.91e-02 | 4.04e-02 | 6.35e-02 | 3.23e-02 | 2.18e-02 | 2.95e-01 | 3.88e-01 | 1.76e-01 | 4.90e-01 | 6.41e-01 |
| MUSCLE ORGAN MORPHOGENESIS | 82 | 1.77e-01 | 6.84e-01 | 0.09780 | -4.37e-03 | -2.76e-02 | 7.34e-02 | -5.79e-02 | 6.83e-03 | 9.45e-01 | 6.66e-01 | 2.51e-01 | 3.65e-01 | 9.15e-01 |
| MYOFIBROBLAST DIFFERENTIATION | 14 | 8.76e-01 | 1.00e+00 | 0.09770 | 9.20e-03 | -6.36e-03 | 9.10e-02 | -3.27e-02 | 9.44e-03 | 9.52e-01 | 9.67e-01 | 5.56e-01 | 8.32e-01 | 9.51e-01 |
| REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 140 | 1.25e-01 | 5.91e-01 | 0.09770 | -4.11e-02 | -2.73e-02 | -7.29e-03 | -8.32e-02 | 1.13e-02 | 4.01e-01 | 5.77e-01 | 8.82e-01 | 8.91e-02 | 8.18e-01 |
| AMYLOID PRECURSOR PROTEIN CATABOLIC PROCESS | 67 | 8.35e-01 | 1.00e+00 | 0.09770 | 5.18e-02 | 3.48e-02 | 6.45e-02 | 3.52e-02 | -1.58e-02 | 4.63e-01 | 6.22e-01 | 3.61e-01 | 6.18e-01 | 8.23e-01 |
| MIDBRAIN DEVELOPMENT | 86 | 1.98e-01 | 7.13e-01 | 0.09770 | 1.95e-02 | -9.64e-03 | 8.53e-02 | -3.89e-02 | 1.67e-02 | 7.54e-01 | 8.77e-01 | 1.71e-01 | 5.33e-01 | 7.89e-01 |
| NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 147 | 1.43e-01 | 6.29e-01 | 0.09770 | 3.41e-02 | 1.60e-02 | 8.80e-02 | -1.76e-02 | 8.42e-03 | 4.76e-01 | 7.37e-01 | 6.55e-02 | 7.13e-01 | 8.60e-01 |
| ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 179 | 2.84e-02 | 2.60e-01 | 0.09770 | -2.59e-02 | -5.15e-02 | 4.43e-02 | -5.84e-02 | 2.89e-02 | 5.49e-01 | 2.35e-01 | 3.06e-01 | 1.78e-01 | 5.05e-01 |
| MUSCLE STRUCTURE DEVELOPMENT | 677 | 3.18e-02 | 2.80e-01 | 0.09760 | 4.97e-02 | 4.41e-02 | 5.91e-02 | 3.66e-02 | -1.70e-02 | 2.75e-02 | 5.03e-02 | 8.74e-03 | 1.05e-01 | 4.49e-01 |
| VENTRICULAR SEPTUM DEVELOPMENT | 74 | 2.34e-01 | 7.56e-01 | 0.09760 | 1.54e-02 | -4.74e-03 | 7.19e-02 | -4.39e-02 | -4.66e-02 | 8.19e-01 | 9.44e-01 | 2.85e-01 | 5.14e-01 | 4.89e-01 |
| POSITIVE REGULATION OF CELL MATRIX ADHESION | 56 | 5.08e-01 | 9.48e-01 | 0.09750 | -2.36e-02 | -6.68e-03 | -5.77e-02 | 3.17e-02 | 6.76e-02 | 7.60e-01 | 9.31e-01 | 4.55e-01 | 6.81e-01 | 3.82e-01 |
| POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 74 | 8.80e-01 | 1.00e+00 | 0.09740 | -2.17e-02 | -1.70e-02 | -2.98e-02 | -2.79e-02 | -8.41e-02 | 7.47e-01 | 8.00e-01 | 6.57e-01 | 6.78e-01 | 2.11e-01 |
| NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 231 | 2.91e-02 | 2.65e-01 | 0.09740 | 3.50e-02 | 2.52e-02 | 8.57e-02 | -1.68e-02 | 2.59e-03 | 3.60e-01 | 5.09e-01 | 2.48e-02 | 6.61e-01 | 9.46e-01 |
| NEGATIVE REGULATION OF RESPONSE TO BIOTIC STIMULUS | 145 | 2.28e-01 | 7.50e-01 | 0.09740 | 2.26e-02 | -9.33e-04 | 7.70e-02 | -1.61e-02 | 5.27e-02 | 6.38e-01 | 9.85e-01 | 1.09e-01 | 7.38e-01 | 2.74e-01 |
| GLOMERULUS MORPHOGENESIS | 9 | 8.86e-01 | 1.00e+00 | 0.09730 | -1.13e-03 | -3.34e-02 | -2.43e-03 | 4.29e-02 | -8.07e-02 | 9.95e-01 | 8.62e-01 | 9.90e-01 | 8.24e-01 | 6.75e-01 |
| GLOMERULAR EPITHELIAL CELL DEVELOPMENT | 12 | 8.69e-01 | 1.00e+00 | 0.09730 | -1.58e-02 | 2.36e-02 | -5.57e-02 | 3.44e-02 | -6.61e-02 | 9.24e-01 | 8.88e-01 | 7.38e-01 | 8.36e-01 | 6.92e-01 |
| NEGATIVE REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 89 | 1.24e-01 | 5.87e-01 | 0.09720 | -3.77e-02 | -5.71e-03 | -7.30e-02 | -4.70e-02 | -2.15e-02 | 5.39e-01 | 9.26e-01 | 2.34e-01 | 4.44e-01 | 7.25e-01 |
| ACTIVATION OF GTPASE ACTIVITY | 96 | 3.70e-01 | 8.81e-01 | 0.09720 | -3.93e-02 | -2.70e-02 | -3.21e-02 | -8.56e-03 | 7.79e-02 | 5.06e-01 | 6.48e-01 | 5.87e-01 | 8.85e-01 | 1.87e-01 |
| ARP2 3 COMPLEX MEDIATED ACTIN NUCLEATION | 44 | 6.76e-01 | 1.00e+00 | 0.09710 | 3.78e-02 | 1.16e-02 | 8.82e-02 | -6.41e-03 | -6.33e-03 | 6.65e-01 | 8.94e-01 | 3.11e-01 | 9.41e-01 | 9.42e-01 |
| SERINE FAMILY AMINO ACID METABOLIC PROCESS | 37 | 9.70e-01 | 1.00e+00 | 0.09700 | -4.79e-02 | -4.00e-02 | -6.77e-02 | -2.93e-02 | 9.49e-03 | 6.14e-01 | 6.74e-01 | 4.76e-01 | 7.58e-01 | 9.20e-01 |
| AXON GUIDANCE | 223 | 3.62e-01 | 8.77e-01 | 0.09700 | -2.61e-02 | -2.05e-02 | -3.30e-02 | -2.47e-02 | -8.13e-02 | 5.03e-01 | 5.98e-01 | 3.96e-01 | 5.24e-01 | 3.63e-02 |
| SPERM EGG RECOGNITION | 51 | 9.44e-01 | 1.00e+00 | 0.09700 | 4.26e-02 | 5.33e-02 | 9.05e-03 | 6.82e-02 | -4.30e-03 | 5.99e-01 | 5.10e-01 | 9.11e-01 | 4.00e-01 | 9.58e-01 |
| SALIVA SECRETION | 13 | 9.85e-01 | 1.00e+00 | 0.09690 | 4.37e-02 | 2.63e-02 | 7.24e-02 | 8.71e-03 | -3.83e-02 | 7.85e-01 | 8.70e-01 | 6.51e-01 | 9.57e-01 | 8.11e-01 |
| POSITIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 61 | 8.17e-01 | 1.00e+00 | 0.09690 | -4.75e-02 | -4.48e-02 | -6.02e-02 | -4.67e-03 | -3.83e-02 | 5.21e-01 | 5.45e-01 | 4.16e-01 | 9.50e-01 | 6.05e-01 |
| NEGATIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 462 | 1.40e-01 | 6.24e-01 | 0.09670 | -4.91e-02 | -6.05e-02 | -2.76e-02 | -5.03e-02 | -1.74e-04 | 7.07e-02 | 2.59e-02 | 3.09e-01 | 6.40e-02 | 9.95e-01 |
| EXOCYTIC PROCESS | 82 | 9.18e-01 | 1.00e+00 | 0.09660 | 4.93e-02 | 3.98e-02 | 6.45e-02 | 3.42e-02 | 3.84e-04 | 4.40e-01 | 5.34e-01 | 3.13e-01 | 5.92e-01 | 9.95e-01 |
| REGULATION OF CATABOLIC PROCESS | 1028 | 8.95e-05 | 3.13e-03 | 0.09660 | 3.32e-02 | 2.67e-02 | 7.00e-02 | 7.19e-03 | 5.06e-02 | 7.14e-02 | 1.47e-01 | 1.46e-04 | 6.97e-01 | 6.08e-03 |
| SECONDARY METABOLIC PROCESS | 55 | 1.95e-01 | 7.08e-01 | 0.09650 | -3.16e-02 | -3.43e-02 | -5.86e-02 | 6.06e-02 | -5.28e-03 | 6.85e-01 | 6.60e-01 | 4.52e-01 | 4.37e-01 | 9.46e-01 |
| REGULATION OF UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 169 | 2.69e-01 | 7.96e-01 | 0.09640 | 3.21e-02 | 2.57e-02 | 7.72e-02 | -9.77e-04 | 4.05e-02 | 4.71e-01 | 5.64e-01 | 8.34e-02 | 9.83e-01 | 3.63e-01 |
| ACTIVIN RECEPTOR SIGNALING PATHWAY | 44 | 8.57e-01 | 1.00e+00 | 0.09640 | 4.52e-03 | 1.77e-02 | 7.66e-04 | -1.99e-02 | -9.25e-02 | 9.59e-01 | 8.39e-01 | 9.93e-01 | 8.20e-01 | 2.88e-01 |
| PURINE DEOXYRIBONUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 10 | 9.93e-01 | 1.00e+00 | 0.09630 | 4.16e-02 | 4.80e-02 | 5.20e-02 | 3.17e-02 | -3.90e-02 | 8.20e-01 | 7.93e-01 | 7.76e-01 | 8.62e-01 | 8.31e-01 |
| CELLULAR RESPONSE TO RADIATION | 170 | 7.78e-01 | 1.00e+00 | 0.09630 | 5.35e-02 | 5.73e-02 | 4.44e-02 | 3.26e-02 | -8.98e-03 | 2.29e-01 | 1.97e-01 | 3.18e-01 | 4.63e-01 | 8.40e-01 |
| LIPID BIOSYNTHETIC PROCESS | 707 | 4.22e-02 | 3.29e-01 | 0.09620 | 4.00e-02 | 4.02e-02 | 3.96e-02 | 5.14e-02 | 4.28e-02 | 6.98e-02 | 6.85e-02 | 7.30e-02 | 1.98e-02 | 5.23e-02 |
| NEURON MIGRATION | 167 | 2.57e-01 | 7.84e-01 | 0.09620 | -2.03e-02 | -2.27e-02 | -8.52e-04 | -5.12e-02 | -7.55e-02 | 6.51e-01 | 6.12e-01 | 9.85e-01 | 2.54e-01 | 9.22e-02 |
| ORGANELLE TRANSPORT ALONG MICROTUBULE | 84 | 3.16e-01 | 8.43e-01 | 0.09620 | -1.95e-02 | -3.03e-02 | 3.87e-02 | -7.30e-02 | -3.35e-02 | 7.57e-01 | 6.31e-01 | 5.40e-01 | 2.47e-01 | 5.96e-01 |
| ALPHA AMINO ACID CATABOLIC PROCESS | 89 | 7.70e-01 | 1.00e+00 | 0.09600 | 4.79e-02 | 6.43e-02 | 1.57e-02 | 5.01e-02 | -6.84e-03 | 4.35e-01 | 2.95e-01 | 7.98e-01 | 4.14e-01 | 9.11e-01 |
| RESPONSE TO THYROID HORMONE | 28 | 8.27e-01 | 1.00e+00 | 0.09600 | 1.68e-02 | -2.04e-03 | 7.45e-02 | -5.61e-02 | 1.56e-02 | 8.78e-01 | 9.85e-01 | 4.95e-01 | 6.07e-01 | 8.87e-01 |
| POSITIVE REGULATION OF RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL | 41 | 9.71e-01 | 1.00e+00 | 0.09600 | 3.71e-02 | 2.72e-02 | 6.81e-02 | 2.07e-02 | 4.49e-02 | 6.81e-01 | 7.63e-01 | 4.50e-01 | 8.19e-01 | 6.19e-01 |
| POSITIVE REGULATION OF MULTICELLULAR ORGANISM GROWTH | 31 | 9.13e-01 | 1.00e+00 | 0.09590 | -4.19e-02 | -3.62e-02 | 5.32e-03 | -7.36e-02 | 2.62e-02 | 6.86e-01 | 7.27e-01 | 9.59e-01 | 4.78e-01 | 8.00e-01 |
| ENDOMEMBRANE SYSTEM ORGANIZATION | 568 | 3.45e-02 | 2.96e-01 | 0.09580 | 2.66e-02 | 1.79e-02 | 5.84e-02 | 1.30e-02 | 6.76e-02 | 2.79e-01 | 4.67e-01 | 1.72e-02 | 5.97e-01 | 5.89e-03 |
| RESPONSE TO FOOD | 35 | 6.89e-01 | 1.00e+00 | 0.09570 | 2.67e-02 | 3.60e-02 | 6.27e-02 | -4.10e-02 | 3.93e-02 | 7.85e-01 | 7.12e-01 | 5.21e-01 | 6.75e-01 | 6.87e-01 |
| MEMBRANE LIPID CATABOLIC PROCESS | 38 | 7.07e-01 | 1.00e+00 | 0.09570 | 1.09e-02 | 2.35e-02 | 3.78e-02 | -3.00e-02 | 7.84e-02 | 9.07e-01 | 8.02e-01 | 6.87e-01 | 7.49e-01 | 4.03e-01 |
| NEGATIVE REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION | 39 | 9.21e-01 | 1.00e+00 | 0.09560 | -9.16e-03 | -1.43e-02 | 3.93e-02 | -4.27e-02 | 7.40e-02 | 9.21e-01 | 8.78e-01 | 6.71e-01 | 6.45e-01 | 4.24e-01 |
| GLUCOSE IMPORT | 75 | 8.46e-01 | 1.00e+00 | 0.09550 | 4.30e-02 | 4.41e-02 | 5.25e-02 | 4.75e-02 | 1.77e-02 | 5.20e-01 | 5.09e-01 | 4.32e-01 | 4.77e-01 | 7.91e-01 |
| CARDIAC CHAMBER MORPHOGENESIS | 127 | 5.32e-02 | 3.78e-01 | 0.09540 | 8.05e-03 | -7.91e-03 | 6.69e-02 | -5.32e-02 | -4.07e-02 | 8.76e-01 | 8.78e-01 | 1.93e-01 | 3.00e-01 | 4.28e-01 |
| REGULATION OF IMMUNE SYSTEM PROCESS | 1465 | 8.18e-08 | 7.42e-06 | 0.09540 | -3.96e-02 | -5.47e-02 | 9.37e-03 | -5.32e-02 | 4.02e-02 | 1.11e-02 | 4.51e-04 | 5.48e-01 | 6.53e-04 | 1.00e-02 |
| REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 445 | 7.92e-02 | 4.63e-01 | 0.09530 | 4.84e-02 | 4.57e-02 | 6.65e-02 | 1.17e-02 | -8.96e-03 | 7.98e-02 | 9.81e-02 | 1.61e-02 | 6.71e-01 | 7.46e-01 |
| POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 496 | 4.59e-02 | 3.48e-01 | 0.09520 | 3.49e-02 | 2.61e-02 | 6.76e-02 | 1.83e-02 | 4.76e-02 | 1.83e-01 | 3.19e-01 | 9.94e-03 | 4.85e-01 | 6.94e-02 |
| XENOBIOTIC CATABOLIC PROCESS | 25 | 9.62e-01 | 1.00e+00 | 0.09520 | -2.63e-02 | -3.71e-02 | 1.20e-02 | -6.60e-02 | 5.00e-02 | 8.20e-01 | 7.48e-01 | 9.17e-01 | 5.68e-01 | 6.65e-01 |
| NEGATIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 49 | 7.92e-01 | 1.00e+00 | 0.09520 | 2.07e-02 | 2.04e-02 | 5.10e-02 | -2.48e-02 | 7.07e-02 | 8.02e-01 | 8.05e-01 | 5.37e-01 | 7.64e-01 | 3.92e-01 |
| POSITIVE REGULATION OF SMOOTHENED SIGNALING PATHWAY | 36 | 9.64e-01 | 1.00e+00 | 0.09510 | 4.29e-02 | 3.06e-02 | 7.55e-02 | 1.75e-02 | 1.62e-02 | 6.56e-01 | 7.50e-01 | 4.33e-01 | 8.56e-01 | 8.67e-01 |
| REGULATION OF RECEPTOR RECYCLING | 25 | 9.58e-01 | 1.00e+00 | 0.09500 | 3.79e-02 | 4.47e-02 | 6.40e-02 | 1.55e-02 | 3.54e-02 | 7.43e-01 | 6.99e-01 | 5.79e-01 | 8.93e-01 | 7.59e-01 |
| REGULATION OF GAMMA AMINOBUTYRIC ACID SECRETION | 8 | 9.90e-01 | 1.00e+00 | 0.09500 | -4.55e-02 | -4.27e-02 | 5.85e-03 | -6.87e-02 | -1.95e-02 | 8.24e-01 | 8.34e-01 | 9.77e-01 | 7.37e-01 | 9.24e-01 |
| ORGANIC HYDROXY COMPOUND METABOLIC PROCESS | 541 | 1.19e-02 | 1.42e-01 | 0.09500 | 4.36e-02 | 4.91e-02 | 3.79e-02 | 5.70e-02 | -5.49e-03 | 8.30e-02 | 5.07e-02 | 1.31e-01 | 2.34e-02 | 8.27e-01 |
| GLUTAMATE METABOLIC PROCESS | 32 | 2.62e-01 | 7.90e-01 | 0.09500 | 6.27e-03 | 4.68e-02 | 1.75e-02 | -3.93e-02 | -7.03e-02 | 9.51e-01 | 6.47e-01 | 8.64e-01 | 7.01e-01 | 4.91e-01 |
| CIRCULATORY SYSTEM PROCESS | 577 | 1.38e-03 | 2.95e-02 | 0.09490 | 3.69e-02 | 4.54e-02 | 2.14e-02 | 5.23e-02 | -4.90e-02 | 1.30e-01 | 6.24e-02 | 3.80e-01 | 3.17e-02 | 4.43e-02 |
| POSITIVE REGULATION OF LAMELLIPODIUM ASSEMBLY | 26 | 8.58e-01 | 1.00e+00 | 0.09490 | -1.27e-03 | 2.99e-02 | -3.90e-02 | -1.61e-02 | -7.95e-02 | 9.91e-01 | 7.92e-01 | 7.31e-01 | 8.87e-01 | 4.83e-01 |
| RAB PROTEIN SIGNAL TRANSDUCTION | 16 | 9.73e-01 | 1.00e+00 | 0.09490 | -1.66e-02 | -2.36e-02 | -3.06e-02 | 2.73e-02 | 8.06e-02 | 9.09e-01 | 8.70e-01 | 8.32e-01 | 8.50e-01 | 5.77e-01 |
| NEGATIVE REGULATION OF HOMOTYPIC CELL CELL ADHESION | 12 | 9.86e-01 | 1.00e+00 | 0.09480 | 5.84e-02 | 4.49e-02 | 4.87e-02 | 2.64e-02 | -2.24e-02 | 7.26e-01 | 7.88e-01 | 7.70e-01 | 8.74e-01 | 8.93e-01 |
| RESPONSE TO ALKALOID | 90 | 8.08e-01 | 1.00e+00 | 0.09480 | 3.43e-02 | 2.61e-02 | 7.11e-02 | 9.28e-03 | 4.46e-02 | 5.73e-01 | 6.69e-01 | 2.44e-01 | 8.79e-01 | 4.64e-01 |
| POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 120 | 3.39e-01 | 8.59e-01 | 0.09470 | -1.88e-02 | -2.66e-02 | 4.32e-02 | -5.23e-02 | 5.76e-02 | 7.22e-01 | 6.14e-01 | 4.14e-01 | 3.23e-01 | 2.76e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 170 | 3.69e-01 | 8.80e-01 | 0.09470 | 2.68e-03 | 9.09e-03 | -7.14e-03 | -4.72e-03 | -9.38e-02 | 9.52e-01 | 8.38e-01 | 8.72e-01 | 9.15e-01 | 3.49e-02 |
| NEGATIVE REGULATION OF CATABOLIC PROCESS | 323 | 1.56e-01 | 6.53e-01 | 0.09460 | 2.46e-02 | 1.85e-02 | 5.95e-02 | 8.11e-03 | 6.63e-02 | 4.47e-01 | 5.68e-01 | 6.62e-02 | 8.02e-01 | 4.03e-02 |
| MITOCHONDRIAL CALCIUM ION TRANSMEMBRANE TRANSPORT | 18 | 9.68e-01 | 1.00e+00 | 0.09450 | -1.27e-02 | -1.10e-02 | 2.68e-02 | -1.15e-02 | 8.83e-02 | 9.26e-01 | 9.36e-01 | 8.44e-01 | 9.33e-01 | 5.16e-01 |
| STRIATUM DEVELOPMENT | 20 | 8.56e-01 | 1.00e+00 | 0.09450 | -2.50e-02 | -2.61e-02 | -4.26e-02 | 5.48e-02 | 5.30e-02 | 8.46e-01 | 8.40e-01 | 7.42e-01 | 6.71e-01 | 6.82e-01 |
| REGULATION OF POLYSACCHARIDE BIOSYNTHETIC PROCESS | 38 | 2.48e-01 | 7.75e-01 | 0.09450 | -1.48e-02 | 5.91e-05 | 5.85e-02 | -7.08e-02 | 1.68e-02 | 8.75e-01 | 9.99e-01 | 5.33e-01 | 4.50e-01 | 8.58e-01 |
| BASIC AMINO ACID TRANSPORT | 21 | 5.79e-01 | 9.82e-01 | 0.09450 | 4.32e-02 | 4.00e-02 | 1.99e-02 | -2.95e-02 | -6.48e-02 | 7.32e-01 | 7.51e-01 | 8.74e-01 | 8.15e-01 | 6.07e-01 |
| CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES | 149 | 5.02e-01 | 9.48e-01 | 0.09440 | 4.41e-02 | 3.05e-02 | 7.64e-02 | 3.56e-03 | 1.37e-02 | 3.53e-01 | 5.20e-01 | 1.08e-01 | 9.40e-01 | 7.72e-01 |
| ENTRY INTO HOST | 159 | 3.91e-01 | 8.92e-01 | 0.09440 | -2.95e-02 | -3.01e-02 | -7.12e-03 | -1.08e-02 | 8.34e-02 | 5.20e-01 | 5.12e-01 | 8.77e-01 | 8.14e-01 | 6.94e-02 |
| ENDOTHELIAL CELL CHEMOTAXIS | 27 | 7.95e-01 | 1.00e+00 | 0.09410 | -1.97e-02 | -5.13e-03 | 2.22e-02 | -6.48e-02 | 6.12e-02 | 8.59e-01 | 9.63e-01 | 8.42e-01 | 5.60e-01 | 5.82e-01 |
| EAR DEVELOPMENT | 218 | 2.57e-02 | 2.42e-01 | 0.09410 | 3.36e-02 | 2.19e-02 | 8.08e-02 | -1.49e-02 | -2.23e-02 | 3.92e-01 | 5.78e-01 | 3.99e-02 | 7.05e-01 | 5.70e-01 |
| AUTOPHAGY OF MITOCHONDRION | 90 | 8.00e-01 | 1.00e+00 | 0.09410 | -4.99e-02 | -4.71e-02 | -1.69e-02 | -5.14e-02 | 3.49e-02 | 4.14e-01 | 4.40e-01 | 7.82e-01 | 3.99e-01 | 5.67e-01 |
| NEGATIVE REGULATION OF SMAD PROTEIN SIGNAL TRANSDUCTION | 22 | 3.96e-02 | 3.20e-01 | 0.09410 | 3.57e-02 | 4.09e-03 | 3.57e-02 | -7.87e-02 | -9.46e-03 | 7.72e-01 | 9.74e-01 | 7.72e-01 | 5.23e-01 | 9.39e-01 |
| INTRACELLULAR PROTEIN TRANSPORT | 838 | 8.27e-06 | 4.04e-04 | 0.09410 | 2.26e-02 | 1.38e-02 | 7.04e-02 | -2.52e-02 | 5.05e-02 | 2.66e-01 | 4.97e-01 | 5.34e-04 | 2.15e-01 | 1.29e-02 |
| SPERM AXONEME ASSEMBLY | 27 | 9.14e-01 | 1.00e+00 | 0.09400 | -2.78e-02 | -3.83e-02 | -4.03e-02 | 1.01e-02 | 6.98e-02 | 8.03e-01 | 7.30e-01 | 7.17e-01 | 9.28e-01 | 5.30e-01 |
| POSITIVE REGULATION OF WNT SIGNALING PATHWAY | 138 | 6.47e-02 | 4.13e-01 | 0.09400 | -5.43e-02 | -5.50e-02 | -1.56e-02 | -4.42e-02 | -2.57e-02 | 2.70e-01 | 2.64e-01 | 7.51e-01 | 3.70e-01 | 6.03e-01 |
| RESPONSE TO IONIZING RADIATION | 136 | 6.01e-01 | 9.90e-01 | 0.09400 | 4.33e-02 | 3.72e-02 | 7.40e-02 | 6.66e-03 | 7.00e-03 | 3.83e-01 | 4.54e-01 | 1.36e-01 | 8.93e-01 | 8.88e-01 |
| REGULATION OF MONOATOMIC ION TRANSPORT | 545 | 2.62e-01 | 7.90e-01 | 0.09390 | 4.69e-02 | 5.26e-02 | 3.19e-02 | 4.32e-02 | -3.11e-02 | 6.12e-02 | 3.57e-02 | 2.02e-01 | 8.47e-02 | 2.14e-01 |
| REGULATION OF ANDROGEN RECEPTOR SIGNALING PATHWAY | 26 | 9.54e-01 | 1.00e+00 | 0.09390 | -2.63e-02 | -3.40e-02 | -6.17e-03 | -4.05e-02 | -7.27e-02 | 8.16e-01 | 7.64e-01 | 9.57e-01 | 7.21e-01 | 5.21e-01 |
| PROTEIN LOCALIZATION TO NUCLEUS | 305 | 8.27e-03 | 1.10e-01 | 0.09380 | -1.87e-03 | -1.21e-02 | 5.64e-02 | -5.85e-02 | 4.53e-02 | 9.55e-01 | 7.16e-01 | 9.03e-02 | 7.87e-02 | 1.74e-01 |
| RESPONSE TO ALCOHOL | 246 | 7.30e-01 | 1.00e+00 | 0.09380 | -5.17e-02 | -5.22e-02 | -3.19e-02 | -4.87e-02 | 3.31e-03 | 1.63e-01 | 1.58e-01 | 3.88e-01 | 1.88e-01 | 9.29e-01 |
| NERVE GROWTH FACTOR SIGNALING PATHWAY | 13 | 6.66e-01 | 1.00e+00 | 0.09370 | -1.65e-02 | -1.98e-02 | -1.14e-02 | 8.10e-02 | 3.78e-02 | 9.18e-01 | 9.01e-01 | 9.43e-01 | 6.13e-01 | 8.14e-01 |
| POSITIVE REGULATION OF MITOCHONDRIAL DEPOLARIZATION | 9 | 9.20e-01 | 1.00e+00 | 0.09370 | -1.05e-02 | -5.16e-02 | 3.92e-02 | -6.68e-02 | 2.48e-03 | 9.56e-01 | 7.89e-01 | 8.39e-01 | 7.29e-01 | 9.90e-01 |
| NEGATIVE REGULATION OF TUBULIN DEACETYLATION | 5 | 9.98e-01 | 1.00e+00 | 0.09360 | -7.99e-04 | 8.77e-03 | 1.57e-02 | -4.71e-02 | -7.89e-02 | 9.98e-01 | 9.73e-01 | 9.52e-01 | 8.55e-01 | 7.60e-01 |
| ASTROCYTE DIFFERENTIATION | 84 | 3.32e-01 | 8.57e-01 | 0.09360 | 2.22e-02 | 1.07e-02 | 7.48e-02 | -5.03e-02 | 4.92e-03 | 7.25e-01 | 8.66e-01 | 2.36e-01 | 4.25e-01 | 9.38e-01 |
| REGULATION OF PROTEIN POLYMERIZATION | 195 | 6.06e-01 | 9.90e-01 | 0.09340 | 4.57e-02 | 5.29e-02 | 4.30e-02 | 4.43e-02 | 3.00e-03 | 2.71e-01 | 2.03e-01 | 3.00e-01 | 2.86e-01 | 9.42e-01 |
| MEMBRANE PROTEIN PROTEOLYSIS | 56 | 8.19e-01 | 1.00e+00 | 0.09330 | 1.65e-02 | -7.31e-04 | 6.59e-02 | 1.86e-03 | 6.40e-02 | 8.31e-01 | 9.92e-01 | 3.93e-01 | 9.81e-01 | 4.08e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 61 | 8.93e-01 | 1.00e+00 | 0.09330 | -1.79e-02 | -3.31e-02 | 2.20e-02 | -3.33e-02 | 7.55e-02 | 8.09e-01 | 6.54e-01 | 7.66e-01 | 6.53e-01 | 3.08e-01 |
| VISUAL BEHAVIOR | 55 | 7.41e-01 | 1.00e+00 | 0.09330 | 2.84e-02 | 4.44e-02 | 1.08e-02 | 5.50e-02 | 5.27e-02 | 7.15e-01 | 5.69e-01 | 8.89e-01 | 4.80e-01 | 4.99e-01 |
| NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 90 | 2.96e-01 | 8.24e-01 | 0.09330 | -1.18e-02 | -9.33e-03 | 4.78e-02 | -5.32e-02 | 5.79e-02 | 8.47e-01 | 8.78e-01 | 4.34e-01 | 3.83e-01 | 3.42e-01 |
| NEGATIVE REGULATION OF LIPID LOCALIZATION | 66 | 9.58e-01 | 1.00e+00 | 0.09320 | 4.44e-02 | 4.23e-02 | 3.16e-02 | 3.90e-02 | -4.91e-02 | 5.33e-01 | 5.52e-01 | 6.57e-01 | 5.84e-01 | 4.91e-01 |
| VITAMIN D BIOSYNTHETIC PROCESS | 10 | 9.87e-01 | 1.00e+00 | 0.09310 | -4.27e-02 | -4.69e-02 | -5.64e-02 | 1.23e-02 | -3.64e-02 | 8.15e-01 | 7.97e-01 | 7.58e-01 | 9.46e-01 | 8.42e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 82 | 5.00e-01 | 9.47e-01 | 0.09310 | 3.03e-02 | 3.26e-02 | 6.77e-02 | -2.59e-02 | 3.79e-02 | 6.36e-01 | 6.10e-01 | 2.89e-01 | 6.85e-01 | 5.53e-01 |
| EXPLORATION BEHAVIOR | 28 | 8.06e-01 | 1.00e+00 | 0.09300 | -2.15e-02 | 1.49e-02 | -6.36e-02 | -3.07e-03 | -6.26e-02 | 8.44e-01 | 8.92e-01 | 5.60e-01 | 9.78e-01 | 5.67e-01 |
| REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 44 | 9.33e-01 | 1.00e+00 | 0.09300 | 1.53e-02 | 1.52e-02 | 4.33e-02 | 8.61e-03 | 7.90e-02 | 8.61e-01 | 8.62e-01 | 6.19e-01 | 9.21e-01 | 3.65e-01 |
| AMINO ACID CATABOLIC PROCESS | 109 | 7.14e-01 | 1.00e+00 | 0.09300 | 5.00e-02 | 6.16e-02 | 2.96e-02 | 3.72e-02 | 9.64e-03 | 3.67e-01 | 2.66e-01 | 5.94e-01 | 5.02e-01 | 8.62e-01 |
| ENDOCYTOSIS | 684 | 4.05e-03 | 6.53e-02 | 0.09290 | -3.70e-02 | -5.18e-02 | 2.33e-03 | -3.65e-02 | 5.70e-02 | 9.85e-02 | 2.10e-02 | 9.17e-01 | 1.04e-01 | 1.11e-02 |
| NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING 2 SIGNALING PATHWAY | 18 | 9.93e-01 | 1.00e+00 | 0.09280 | -3.39e-02 | -4.86e-02 | 5.09e-03 | -3.15e-02 | 6.39e-02 | 8.03e-01 | 7.21e-01 | 9.70e-01 | 8.17e-01 | 6.39e-01 |
| REGULATION OF SYNAPSE ASSEMBLY | 104 | 6.31e-01 | 9.96e-01 | 0.09280 | 4.56e-02 | 5.76e-02 | 4.67e-02 | 1.49e-02 | -2.83e-02 | 4.21e-01 | 3.10e-01 | 4.10e-01 | 7.92e-01 | 6.18e-01 |
| MACROMOLECULE CATABOLIC PROCESS | 1346 | 4.48e-09 | 5.97e-07 | 0.09280 | 1.31e-02 | 4.51e-03 | 6.48e-02 | -2.32e-02 | 6.06e-02 | 4.21e-01 | 7.81e-01 | 6.50e-05 | 1.53e-01 | 1.88e-04 |
| BODY MORPHOGENESIS | 46 | 9.51e-01 | 1.00e+00 | 0.09280 | -3.92e-02 | -3.24e-02 | -3.05e-02 | -4.24e-02 | -5.73e-02 | 6.45e-01 | 7.03e-01 | 7.20e-01 | 6.18e-01 | 5.01e-01 |
| PROTEIN POLYUBIQUITINATION | 219 | 6.53e-01 | 1.00e+00 | 0.09270 | -4.99e-02 | -5.46e-02 | -2.20e-02 | -5.10e-02 | 5.80e-03 | 2.03e-01 | 1.63e-01 | 5.74e-01 | 1.93e-01 | 8.82e-01 |
| POSITIVE REGULATION OF INSULIN SECRETION | 83 | 3.55e-01 | 8.74e-01 | 0.09270 | 2.74e-02 | 3.43e-02 | 5.50e-02 | -1.73e-02 | -5.78e-02 | 6.66e-01 | 5.89e-01 | 3.86e-01 | 7.85e-01 | 3.63e-01 |
| AROMATIC AMINO ACID FAMILY CATABOLIC PROCESS | 16 | 9.12e-01 | 1.00e+00 | 0.09260 | 1.14e-02 | 1.74e-02 | 5.90e-02 | -5.21e-02 | -4.41e-02 | 9.37e-01 | 9.04e-01 | 6.83e-01 | 7.18e-01 | 7.60e-01 |
| COLLATERAL SPROUTING | 26 | 8.44e-01 | 1.00e+00 | 0.09250 | -3.98e-02 | -6.00e-02 | -2.39e-02 | 1.08e-02 | 5.18e-02 | 7.25e-01 | 5.97e-01 | 8.33e-01 | 9.24e-01 | 6.48e-01 |
| POSITIVE REGULATION OF JNK CASCADE | 85 | 7.81e-01 | 1.00e+00 | 0.09250 | -1.96e-02 | -3.42e-02 | 2.95e-02 | -3.74e-02 | 6.87e-02 | 7.55e-01 | 5.85e-01 | 6.39e-01 | 5.51e-01 | 2.73e-01 |
| BONE TRABECULA FORMATION | 10 | 9.88e-01 | 1.00e+00 | 0.09240 | -4.77e-03 | -1.64e-02 | 2.73e-02 | -4.86e-02 | -7.18e-02 | 9.79e-01 | 9.29e-01 | 8.81e-01 | 7.90e-01 | 6.94e-01 |
| ASSOCIATIVE LEARNING | 84 | 7.41e-01 | 1.00e+00 | 0.09240 | 4.60e-02 | 5.77e-02 | 5.04e-02 | 1.93e-02 | -1.38e-02 | 4.66e-01 | 3.61e-01 | 4.24e-01 | 7.60e-01 | 8.27e-01 |
| NEGATIVE REGULATION OF RECEPTOR SIGNALING PATHWAY VIA JAK STAT | 24 | 9.71e-01 | 1.00e+00 | 0.09240 | 4.49e-02 | 2.97e-02 | 5.57e-02 | 3.12e-02 | -3.96e-02 | 7.03e-01 | 8.01e-01 | 6.37e-01 | 7.91e-01 | 7.37e-01 |
| CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 528 | 5.79e-02 | 3.93e-01 | 0.09240 | 4.51e-02 | 3.74e-02 | 6.33e-02 | 3.30e-02 | 1.35e-03 | 7.59e-02 | 1.42e-01 | 1.28e-02 | 1.94e-01 | 9.58e-01 |
| OSSIFICATION | 425 | 6.59e-02 | 4.17e-01 | 0.09220 | 3.88e-02 | 4.14e-02 | 3.93e-02 | 2.08e-02 | -5.75e-02 | 1.70e-01 | 1.43e-01 | 1.64e-01 | 4.63e-01 | 4.20e-02 |
| PHOTORECEPTOR CELL MAINTENANCE | 43 | 9.04e-01 | 1.00e+00 | 0.09200 | 3.36e-02 | 4.05e-02 | -1.86e-02 | 7.18e-02 | -1.43e-02 | 7.03e-01 | 6.46e-01 | 8.33e-01 | 4.16e-01 | 8.71e-01 |
| NEGATIVE REGULATION OF MAPK CASCADE | 164 | 4.54e-01 | 9.31e-01 | 0.09190 | -4.90e-03 | -1.59e-02 | 3.43e-02 | -3.18e-02 | 7.74e-02 | 9.14e-01 | 7.25e-01 | 4.48e-01 | 4.83e-01 | 8.72e-02 |
| REGULATION OF BINDING | 253 | 6.88e-03 | 9.57e-02 | 0.09190 | 7.22e-03 | -2.11e-03 | 6.99e-02 | -5.54e-02 | 2.11e-02 | 8.43e-01 | 9.54e-01 | 5.56e-02 | 1.29e-01 | 5.63e-01 |
| KIDNEY MORPHOGENESIS | 94 | 2.32e-01 | 7.54e-01 | 0.09190 | 8.82e-05 | -9.05e-03 | 6.75e-02 | -6.09e-02 | 1.03e-02 | 9.99e-01 | 8.79e-01 | 2.58e-01 | 3.07e-01 | 8.64e-01 |
| REGULATION OF REPRODUCTIVE PROCESS | 201 | 6.13e-01 | 9.90e-01 | 0.09190 | 4.65e-02 | 4.32e-02 | 4.59e-02 | 2.34e-02 | -4.20e-02 | 2.56e-01 | 2.91e-01 | 2.62e-01 | 5.67e-01 | 3.05e-01 |
| NUCLEOBASE CONTAINING SMALL MOLECULE METABOLIC PROCESS | 567 | 6.09e-02 | 4.04e-01 | 0.09180 | 4.52e-02 | 4.35e-02 | 6.48e-02 | 1.63e-02 | 5.90e-03 | 6.57e-02 | 7.65e-02 | 8.34e-03 | 5.06e-01 | 8.10e-01 |
| GOLGI ORGANIZATION | 141 | 5.57e-01 | 9.68e-01 | 0.09180 | -1.13e-02 | -2.72e-02 | 3.16e-02 | -2.20e-02 | 7.80e-02 | 8.16e-01 | 5.78e-01 | 5.17e-01 | 6.52e-01 | 1.10e-01 |
| REGENERATION | 181 | 3.57e-01 | 8.74e-01 | 0.09180 | 1.33e-02 | 6.88e-03 | 2.81e-02 | 7.99e-04 | 8.61e-02 | 7.58e-01 | 8.73e-01 | 5.14e-01 | 9.85e-01 | 4.57e-02 |
| CARBOHYDRATE TRANSMEMBRANE TRANSPORT | 132 | 6.28e-01 | 9.95e-01 | 0.09180 | 3.32e-02 | 3.61e-02 | 5.13e-02 | 2.82e-02 | 5.08e-02 | 5.10e-01 | 4.74e-01 | 3.09e-01 | 5.75e-01 | 3.13e-01 |
| NUCLEAR MIGRATION | 25 | 8.88e-01 | 1.00e+00 | 0.09170 | 2.02e-02 | 4.06e-02 | -1.01e-03 | 5.20e-02 | 6.03e-02 | 8.61e-01 | 7.25e-01 | 9.93e-01 | 6.53e-01 | 6.02e-01 |
| REGULATION OF CHROMATIN ORGANIZATION | 44 | 6.05e-01 | 9.90e-01 | 0.09160 | 1.23e-02 | -8.55e-03 | 8.36e-02 | -2.98e-02 | 1.71e-02 | 8.87e-01 | 9.22e-01 | 3.38e-01 | 7.32e-01 | 8.45e-01 |
| NEPHRON EPITHELIUM DEVELOPMENT | 115 | 1.89e-01 | 6.97e-01 | 0.09160 | -2.41e-02 | -2.45e-02 | 3.71e-02 | -7.46e-02 | 1.62e-02 | 6.56e-01 | 6.50e-01 | 4.92e-01 | 1.67e-01 | 7.64e-01 |
| CRANIAL SKELETAL SYSTEM DEVELOPMENT | 70 | 4.07e-01 | 9.08e-01 | 0.09160 | 3.44e-02 | 1.70e-02 | 8.14e-02 | 1.27e-02 | -1.13e-02 | 6.19e-01 | 8.06e-01 | 2.39e-01 | 8.54e-01 | 8.70e-01 |
| ADENYLATE CYCLASE INHIBITING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 79 | 7.38e-01 | 1.00e+00 | 0.09140 | 3.86e-02 | 3.03e-02 | 5.27e-02 | 5.99e-03 | -5.59e-02 | 5.53e-01 | 6.41e-01 | 4.18e-01 | 9.27e-01 | 3.90e-01 |
| RESPONSE TO METAL ION | 346 | 1.43e-01 | 6.29e-01 | 0.09140 | 4.29e-02 | 3.52e-02 | 7.10e-02 | 1.44e-02 | 4.20e-03 | 1.70e-01 | 2.61e-01 | 2.32e-02 | 6.45e-01 | 8.93e-01 |
| REGULATION OF KETONE BIOSYNTHETIC PROCESS | 21 | 7.52e-01 | 1.00e+00 | 0.09140 | 2.65e-02 | 4.86e-02 | 5.61e-02 | -2.09e-02 | -4.13e-02 | 8.33e-01 | 7.00e-01 | 6.56e-01 | 8.69e-01 | 7.43e-01 |
| SECOND MESSENGER MEDIATED SIGNALING | 298 | 6.20e-01 | 9.90e-01 | 0.09140 | -4.85e-02 | -4.21e-02 | -3.64e-02 | -5.37e-02 | -2.60e-03 | 1.50e-01 | 2.11e-01 | 2.80e-01 | 1.10e-01 | 9.38e-01 |
| ANIMAL ORGAN MATURATION | 30 | 4.15e-01 | 9.11e-01 | 0.09130 | -2.40e-02 | 1.19e-02 | -1.30e-02 | -8.29e-02 | -2.40e-02 | 8.20e-01 | 9.10e-01 | 9.02e-01 | 4.32e-01 | 8.20e-01 |
| MORPHOGENESIS OF AN EPITHELIUM | 505 | 1.22e-01 | 5.82e-01 | 0.09130 | 4.53e-02 | 4.08e-02 | 5.89e-02 | 3.37e-02 | -2.74e-03 | 8.15e-02 | 1.16e-01 | 2.34e-02 | 1.94e-01 | 9.16e-01 |
| CHOLESTEROL STORAGE | 25 | 8.65e-01 | 1.00e+00 | 0.09130 | -1.37e-02 | -2.17e-02 | 1.29e-03 | -4.78e-02 | 7.34e-02 | 9.06e-01 | 8.51e-01 | 9.91e-01 | 6.79e-01 | 5.25e-01 |
| MUSCLE CELL DEVELOPMENT | 191 | 5.04e-01 | 9.48e-01 | 0.09120 | 3.67e-02 | 4.16e-02 | 2.60e-02 | 3.71e-02 | -5.64e-02 | 3.81e-01 | 3.21e-01 | 5.36e-01 | 3.76e-01 | 1.79e-01 |
| RESPONSE TO FATTY ACID | 55 | 1.62e-01 | 6.61e-01 | 0.09120 | 1.39e-02 | 2.56e-02 | 5.87e-03 | 6.27e-02 | -5.91e-02 | 8.58e-01 | 7.42e-01 | 9.40e-01 | 4.21e-01 | 4.48e-01 |
| POSITIVE REGULATION OF FIBROBLAST MIGRATION | 15 | 5.49e-01 | 9.63e-01 | 0.09110 | 1.95e-02 | 2.05e-02 | 7.08e-02 | 4.89e-02 | 9.96e-03 | 8.96e-01 | 8.91e-01 | 6.35e-01 | 7.43e-01 | 9.47e-01 |
| RESPONSE TO DOPAMINE | 70 | 9.15e-01 | 1.00e+00 | 0.09110 | -3.44e-02 | -2.76e-02 | -3.42e-02 | -3.28e-02 | -6.41e-02 | 6.19e-01 | 6.90e-01 | 6.21e-01 | 6.35e-01 | 3.54e-01 |
| REGULATION OF OSSIFICATION | 116 | 3.72e-01 | 8.82e-01 | 0.09110 | -1.75e-02 | -1.59e-02 | -1.43e-02 | -1.17e-02 | -8.60e-02 | 7.44e-01 | 7.67e-01 | 7.90e-01 | 8.28e-01 | 1.10e-01 |
| FATTY ACYL COA BIOSYNTHETIC PROCESS | 25 | 8.06e-01 | 1.00e+00 | 0.09110 | 1.40e-02 | 7.79e-03 | -1.79e-02 | 8.22e-02 | -3.11e-02 | 9.04e-01 | 9.46e-01 | 8.77e-01 | 4.77e-01 | 7.88e-01 |
| ACROSOME REACTION | 40 | 9.31e-01 | 1.00e+00 | 0.09110 | 2.01e-02 | 1.92e-02 | -1.85e-02 | 4.11e-02 | -7.41e-02 | 8.26e-01 | 8.33e-01 | 8.40e-01 | 6.53e-01 | 4.18e-01 |
| VENTRICULAR CARDIAC MUSCLE TISSUE DEVELOPMENT | 58 | 5.59e-01 | 9.69e-01 | 0.09100 | 1.24e-02 | -2.56e-03 | 7.38e-02 | -5.18e-02 | 1.75e-03 | 8.70e-01 | 9.73e-01 | 3.31e-01 | 4.95e-01 | 9.82e-01 |
| AMYLOID FIBRIL FORMATION | 38 | 8.27e-01 | 1.00e+00 | 0.09100 | 7.88e-03 | 5.20e-05 | 6.39e-02 | -5.48e-02 | 3.36e-02 | 9.33e-01 | 1.00e+00 | 4.95e-01 | 5.59e-01 | 7.20e-01 |
| CELLULAR LIPID METABOLIC PROCESS | 972 | 5.33e-02 | 3.78e-01 | 0.09100 | 4.45e-02 | 4.87e-02 | 3.65e-02 | 4.94e-02 | 1.24e-02 | 1.88e-02 | 1.01e-02 | 5.38e-02 | 9.10e-03 | 5.13e-01 |
| VENTRICULAR SYSTEM DEVELOPMENT | 32 | 8.84e-01 | 1.00e+00 | 0.09090 | 2.56e-02 | 1.32e-02 | 4.80e-02 | -8.60e-03 | -7.11e-02 | 8.02e-01 | 8.97e-01 | 6.38e-01 | 9.33e-01 | 4.86e-01 |
| ORGANELLE DISASSEMBLY | 137 | 2.57e-01 | 7.84e-01 | 0.09080 | 1.84e-02 | 5.29e-03 | 7.67e-02 | -2.67e-02 | 3.60e-02 | 7.10e-01 | 9.15e-01 | 1.21e-01 | 5.89e-01 | 4.67e-01 |
| NEUROMUSCULAR PROCESS CONTROLLING BALANCE | 51 | 9.41e-01 | 1.00e+00 | 0.09080 | 4.59e-02 | 3.81e-02 | 5.71e-02 | 1.41e-02 | -3.51e-02 | 5.71e-01 | 6.38e-01 | 4.81e-01 | 8.61e-01 | 6.65e-01 |
| MICTURITION | 8 | 9.88e-01 | 1.00e+00 | 0.09070 | -1.31e-02 | 3.62e-03 | -6.60e-02 | 5.92e-02 | -1.39e-02 | 9.49e-01 | 9.86e-01 | 7.47e-01 | 7.72e-01 | 9.46e-01 |
| INTRACELLULAR GLUCOSE HOMEOSTASIS | 153 | 1.61e-01 | 6.59e-01 | 0.09070 | 3.24e-02 | 2.92e-02 | 6.56e-02 | -2.51e-02 | -3.73e-02 | 4.90e-01 | 5.32e-01 | 1.61e-01 | 5.92e-01 | 4.26e-01 |
| REGULATION OF SYNAPTIC VESICLE CYCLE | 12 | 9.22e-01 | 1.00e+00 | 0.09070 | -1.47e-02 | 1.56e-02 | -6.32e-02 | 5.45e-02 | 2.82e-02 | 9.30e-01 | 9.25e-01 | 7.05e-01 | 7.44e-01 | 8.65e-01 |
| SKELETAL MUSCLE TISSUE REGENERATION | 37 | 6.30e-01 | 9.96e-01 | 0.09060 | -5.08e-03 | 1.46e-02 | -8.05e-02 | 3.59e-02 | -1.45e-02 | 9.57e-01 | 8.78e-01 | 3.97e-01 | 7.05e-01 | 8.79e-01 |
| REGULATION OF PROTEIN BINDING | 140 | 2.28e-01 | 7.50e-01 | 0.09060 | 7.31e-03 | -6.39e-03 | 6.95e-02 | -3.75e-02 | 4.33e-02 | 8.81e-01 | 8.96e-01 | 1.55e-01 | 4.44e-01 | 3.76e-01 |
| POSITIVE REGULATION OF PLASMA MEMBRANE BOUNDED CELL PROJECTION ASSEMBLY | 104 | 8.90e-01 | 1.00e+00 | 0.09050 | -5.15e-02 | -4.83e-02 | -3.20e-02 | -4.29e-02 | 1.84e-02 | 3.64e-01 | 3.94e-01 | 5.73e-01 | 4.50e-01 | 7.46e-01 |
| NEGATIVE REGULATION OF PHOSPHORYLATION | 321 | 1.68e-02 | 1.84e-01 | 0.09050 | 7.43e-03 | 2.89e-03 | 5.64e-02 | -4.10e-02 | 5.71e-02 | 8.19e-01 | 9.29e-01 | 8.22e-02 | 2.06e-01 | 7.86e-02 |
| NEGATIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 47 | 9.29e-01 | 1.00e+00 | 0.09050 | 5.33e-02 | 5.19e-02 | 4.58e-02 | 1.88e-02 | -1.41e-02 | 5.27e-01 | 5.38e-01 | 5.87e-01 | 8.24e-01 | 8.68e-01 |
| TRANSPORT OF VIRUS | 21 | 9.53e-01 | 1.00e+00 | 0.09050 | 1.71e-02 | 2.58e-02 | 2.08e-02 | -3.32e-02 | -7.54e-02 | 8.92e-01 | 8.38e-01 | 8.69e-01 | 7.92e-01 | 5.50e-01 |
| REGULATION OF SYSTEMIC ARTERIAL BLOOD PRESSURE | 87 | 3.77e-01 | 8.85e-01 | 0.09040 | 3.68e-02 | 2.06e-02 | 5.82e-02 | 2.97e-02 | -4.61e-02 | 5.53e-01 | 7.40e-01 | 3.48e-01 | 6.33e-01 | 4.57e-01 |
| NEGATIVE REGULATION OF P38MAPK CASCADE | 8 | 9.61e-01 | 1.00e+00 | 0.09040 | -2.21e-02 | -3.56e-02 | -5.30e-02 | -3.42e-02 | -4.94e-02 | 9.14e-01 | 8.62e-01 | 7.95e-01 | 8.67e-01 | 8.09e-01 |
| ERROR PRONE TRANSLESION SYNTHESIS | 11 | 9.10e-01 | 1.00e+00 | 0.09040 | -3.66e-02 | -7.33e-02 | 2.05e-02 | -3.15e-02 | -6.18e-03 | 8.34e-01 | 6.74e-01 | 9.06e-01 | 8.57e-01 | 9.72e-01 |
| REGULATION OF CELL MATRIX ADHESION | 121 | 7.84e-01 | 1.00e+00 | 0.09040 | -4.83e-02 | -4.48e-02 | -4.00e-02 | -2.36e-02 | 4.07e-02 | 3.59e-01 | 3.94e-01 | 4.47e-01 | 6.53e-01 | 4.39e-01 |
| POSITIVE REGULATION OF SPROUTING ANGIOGENESIS | 28 | 4.58e-01 | 9.32e-01 | 0.09030 | -4.86e-02 | -7.49e-03 | -5.15e-02 | -3.53e-02 | 4.28e-02 | 6.56e-01 | 9.45e-01 | 6.37e-01 | 7.46e-01 | 6.95e-01 |
| ACETATE ESTER TRANSPORT | 9 | 9.09e-01 | 1.00e+00 | 0.09020 | -4.76e-02 | -3.31e-02 | -1.51e-02 | -2.98e-02 | -6.05e-02 | 8.05e-01 | 8.63e-01 | 9.38e-01 | 8.77e-01 | 7.53e-01 |
| MUSCLE ORGAN DEVELOPMENT | 342 | 5.51e-02 | 3.84e-01 | 0.09020 | 4.25e-02 | 3.14e-02 | 6.22e-02 | 1.94e-02 | -3.32e-02 | 1.77e-01 | 3.18e-01 | 4.81e-02 | 5.37e-01 | 2.92e-01 |
| GLYCOSYL COMPOUND METABOLIC PROCESS | 79 | 9.01e-01 | 1.00e+00 | 0.09010 | -4.48e-02 | -3.31e-02 | -3.76e-02 | -5.08e-02 | -3.20e-02 | 4.91e-01 | 6.11e-01 | 5.63e-01 | 4.35e-01 | 6.23e-01 |
| NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 371 | 1.98e-02 | 2.06e-01 | 0.09010 | 1.32e-02 | 8.07e-03 | 5.86e-02 | -2.92e-02 | 5.99e-02 | 6.61e-01 | 7.90e-01 | 5.26e-02 | 3.33e-01 | 4.74e-02 |
| REGULATION OF MONOATOMIC CATION TRANSMEMBRANE TRANSPORT | 299 | 7.21e-01 | 1.00e+00 | 0.09010 | 4.57e-02 | 4.82e-02 | 2.96e-02 | 4.36e-02 | -3.05e-02 | 1.74e-01 | 1.52e-01 | 3.79e-01 | 1.95e-01 | 3.65e-01 |
| POSITIVE REGULATION OF G1 S TRANSITION OF MITOTIC CELL CYCLE | 48 | 9.13e-01 | 1.00e+00 | 0.09000 | -3.55e-02 | -3.52e-02 | -4.64e-02 | -5.11e-03 | 5.84e-02 | 6.70e-01 | 6.73e-01 | 5.78e-01 | 9.51e-01 | 4.84e-01 |
| CELL ADHESION | 1467 | 3.64e-04 | 1.01e-02 | 0.08990 | -5.23e-02 | -5.11e-02 | -3.81e-02 | -3.47e-02 | 8.58e-03 | 7.92e-04 | 1.04e-03 | 1.45e-02 | 2.60e-02 | 5.82e-01 |
| POSITIVE REGULATION OF CELL DIVISION | 89 | 1.22e-02 | 1.44e-01 | 0.08990 | -5.75e-02 | -6.23e-02 | -1.24e-02 | -2.09e-02 | -1.74e-02 | 3.48e-01 | 3.10e-01 | 8.40e-01 | 7.33e-01 | 7.77e-01 |
| POLARIZED EPITHELIAL CELL DIFFERENTIATION | 25 | 9.50e-01 | 1.00e+00 | 0.08990 | 2.92e-02 | 4.82e-02 | -1.74e-02 | 6.78e-02 | 2.94e-03 | 8.01e-01 | 6.77e-01 | 8.81e-01 | 5.57e-01 | 9.80e-01 |
| POSITIVE REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 25 | 9.53e-01 | 1.00e+00 | 0.08980 | 5.43e-02 | 4.65e-02 | 4.91e-02 | 1.41e-02 | -1.84e-02 | 6.38e-01 | 6.88e-01 | 6.71e-01 | 9.03e-01 | 8.74e-01 |
| PROTEIN TARGETING | 316 | 5.36e-02 | 3.79e-01 | 0.08980 | 1.32e-02 | 1.01e-02 | 5.68e-02 | -2.05e-02 | 6.44e-02 | 6.88e-01 | 7.58e-01 | 8.26e-02 | 5.31e-01 | 4.91e-02 |
| POSITIVE REGULATION OF PROTEIN POLYMERIZATION | 89 | 4.85e-01 | 9.43e-01 | 0.08970 | 3.18e-02 | 4.78e-02 | 5.91e-03 | 6.87e-02 | 1.07e-03 | 6.04e-01 | 4.35e-01 | 9.23e-01 | 2.63e-01 | 9.86e-01 |
| FEMALE GAMETE GENERATION | 158 | 2.14e-01 | 7.37e-01 | 0.08970 | -3.74e-03 | -1.35e-02 | 3.81e-03 | -2.86e-02 | -8.38e-02 | 9.35e-01 | 7.69e-01 | 9.34e-01 | 5.35e-01 | 6.92e-02 |
| CARBOHYDRATE METABOLIC PROCESS | 541 | 1.60e-01 | 6.59e-01 | 0.08960 | 4.60e-02 | 5.18e-02 | 4.62e-02 | 3.24e-02 | -6.74e-03 | 6.73e-02 | 3.91e-02 | 6.57e-02 | 1.98e-01 | 7.89e-01 |
| PRESYNAPTIC MODULATION OF CHEMICAL SYNAPTIC TRANSMISSION | 32 | 9.07e-01 | 1.00e+00 | 0.08960 | 1.82e-02 | 1.38e-02 | 3.09e-02 | 1.23e-03 | -8.09e-02 | 8.59e-01 | 8.92e-01 | 7.62e-01 | 9.90e-01 | 4.28e-01 |
| NUCLEOTIDE SALVAGE | 17 | 8.23e-01 | 1.00e+00 | 0.08940 | -9.48e-03 | 2.14e-02 | -8.30e-02 | 6.10e-03 | -2.31e-02 | 9.46e-01 | 8.79e-01 | 5.54e-01 | 9.65e-01 | 8.69e-01 |
| POSITIVE REGULATION OF CELL MORPHOGENESIS | 31 | 7.54e-01 | 1.00e+00 | 0.08940 | -4.70e-02 | -3.85e-02 | -2.99e-02 | -3.99e-04 | 5.84e-02 | 6.51e-01 | 7.11e-01 | 7.73e-01 | 9.97e-01 | 5.73e-01 |
| POSITIVE REGULATION OF HISTONE METHYLATION | 14 | 6.07e-01 | 9.90e-01 | 0.08940 | -8.40e-03 | -8.43e-03 | -9.20e-03 | 7.56e-02 | -4.54e-02 | 9.57e-01 | 9.56e-01 | 9.52e-01 | 6.24e-01 | 7.69e-01 |
| REGULATION OF LYMPHOCYTE DIFFERENTIATION | 206 | 2.97e-01 | 8.24e-01 | 0.08920 | -2.26e-02 | -3.83e-02 | 2.70e-02 | -4.99e-02 | 5.26e-02 | 5.77e-01 | 3.43e-01 | 5.04e-01 | 2.17e-01 | 1.93e-01 |
| REGULATION OF POSITIVE CHEMOTAXIS | 25 | 9.25e-01 | 1.00e+00 | 0.08910 | 2.95e-02 | 2.52e-02 | 6.88e-02 | -1.97e-02 | -3.63e-02 | 7.99e-01 | 8.27e-01 | 5.51e-01 | 8.64e-01 | 7.54e-01 |
| CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 147 | 2.36e-01 | 7.60e-01 | 0.08910 | 2.90e-02 | 2.36e-02 | 5.51e-02 | -1.75e-02 | -5.66e-02 | 5.45e-01 | 6.21e-01 | 2.49e-01 | 7.13e-01 | 2.36e-01 |
| INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 51 | 6.47e-01 | 1.00e+00 | 0.08910 | 3.62e-02 | 5.33e-02 | 5.36e-02 | 1.43e-03 | 3.02e-02 | 6.54e-01 | 5.10e-01 | 5.08e-01 | 9.86e-01 | 7.09e-01 |
| REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 106 | 6.76e-01 | 1.00e+00 | 0.08900 | -2.76e-02 | -3.10e-02 | 1.24e-02 | -6.37e-02 | 4.47e-02 | 6.23e-01 | 5.82e-01 | 8.26e-01 | 2.57e-01 | 4.27e-01 |
| HISTONE H4 K16 ACETYLATION | 6 | 6.50e-01 | 1.00e+00 | 0.08880 | -4.99e-02 | -4.69e-02 | -3.86e-03 | 5.25e-02 | 2.06e-02 | 8.32e-01 | 8.42e-01 | 9.87e-01 | 8.24e-01 | 9.30e-01 |
| NEURON PROJECTION EXTENSION INVOLVED IN NEURON PROJECTION GUIDANCE | 36 | 5.29e-01 | 9.54e-01 | 0.08880 | -3.61e-02 | -6.49e-02 | -3.67e-02 | 2.63e-03 | -3.19e-02 | 7.08e-01 | 5.00e-01 | 7.04e-01 | 9.78e-01 | 7.40e-01 |
| NEGATIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 53 | 9.36e-01 | 1.00e+00 | 0.08870 | -4.56e-02 | -5.92e-02 | -1.31e-02 | -4.50e-02 | 9.76e-03 | 5.66e-01 | 4.56e-01 | 8.69e-01 | 5.71e-01 | 9.02e-01 |
| SMALL MOLECULE METABOLIC PROCESS | 1783 | 3.27e-04 | 9.32e-03 | 0.08860 | 4.46e-02 | 4.57e-02 | 5.52e-02 | 2.63e-02 | 5.44e-03 | 1.75e-03 | 1.34e-03 | 1.08e-04 | 6.48e-02 | 7.03e-01 |
| REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 175 | 3.73e-01 | 8.82e-01 | 0.08860 | -3.47e-02 | -3.35e-02 | -6.68e-03 | -7.33e-02 | 9.70e-03 | 4.28e-01 | 4.45e-01 | 8.79e-01 | 9.43e-02 | 8.25e-01 |
| MONOCARBOXYLIC ACID BIOSYNTHETIC PROCESS | 217 | 6.78e-01 | 1.00e+00 | 0.08850 | 4.26e-02 | 4.08e-02 | 3.14e-02 | 3.31e-02 | -4.78e-02 | 2.80e-01 | 3.01e-01 | 4.25e-01 | 4.00e-01 | 2.25e-01 |
| NEGATIVE REGULATION OF ACTIVATED T CELL PROLIFERATION | 14 | 9.10e-01 | 1.00e+00 | 0.08850 | -3.89e-02 | -8.00e-03 | -4.12e-02 | -6.02e-02 | 3.08e-02 | 8.01e-01 | 9.59e-01 | 7.90e-01 | 6.97e-01 | 8.42e-01 |
| MODIFIED AMINO ACID TRANSPORT | 47 | 9.44e-01 | 1.00e+00 | 0.08840 | -3.28e-02 | -3.06e-02 | -2.16e-02 | -6.44e-02 | -3.46e-02 | 6.97e-01 | 7.17e-01 | 7.98e-01 | 4.45e-01 | 6.81e-01 |
| REGULATION OF DEPHOSPHORYLATION | 101 | 5.17e-01 | 9.52e-01 | 0.08830 | -4.33e-03 | -2.91e-02 | 4.22e-02 | -1.99e-02 | 6.90e-02 | 9.40e-01 | 6.14e-01 | 4.64e-01 | 7.30e-01 | 2.31e-01 |
| PHOSPHOLIPID HOMEOSTASIS | 16 | 9.55e-01 | 1.00e+00 | 0.08830 | 3.11e-02 | 1.93e-02 | 3.68e-02 | 6.98e-02 | 1.51e-02 | 8.30e-01 | 8.94e-01 | 7.99e-01 | 6.29e-01 | 9.17e-01 |
| NEGATIVE REGULATION OF CYTOSKELETON ORGANIZATION | 150 | 3.70e-01 | 8.80e-01 | 0.08820 | 3.81e-02 | 5.88e-02 | 6.75e-03 | 5.06e-02 | -1.60e-02 | 4.20e-01 | 2.14e-01 | 8.87e-01 | 2.85e-01 | 7.35e-01 |
| INSULIN SECRETION | 193 | 3.26e-02 | 2.86e-01 | 0.08810 | 3.35e-02 | 4.14e-02 | 6.41e-02 | -6.35e-03 | -2.78e-02 | 4.22e-01 | 3.21e-01 | 1.25e-01 | 8.79e-01 | 5.06e-01 |
| REGULATION OF RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL | 80 | 9.00e-01 | 1.00e+00 | 0.08810 | -3.65e-02 | -4.65e-02 | 5.30e-03 | -5.07e-02 | 4.07e-02 | 5.73e-01 | 4.72e-01 | 9.35e-01 | 4.33e-01 | 5.29e-01 |
| NEUROTROPHIN SIGNALING PATHWAY | 38 | 9.19e-01 | 1.00e+00 | 0.08810 | -2.95e-02 | -4.10e-02 | 2.24e-02 | -3.56e-02 | 5.86e-02 | 7.53e-01 | 6.62e-01 | 8.12e-01 | 7.04e-01 | 5.32e-01 |
| REGULATION OF FILOPODIUM ASSEMBLY | 48 | 9.53e-01 | 1.00e+00 | 0.08800 | -2.40e-02 | -2.75e-02 | -3.53e-02 | -2.12e-02 | -6.88e-02 | 7.74e-01 | 7.42e-01 | 6.72e-01 | 8.00e-01 | 4.10e-01 |
| PROTEIN LOCALIZATION TO CELL PERIPHERY | 336 | 8.66e-02 | 4.86e-01 | 0.08790 | 3.31e-02 | 4.02e-02 | 3.12e-02 | 5.02e-02 | 3.90e-02 | 2.96e-01 | 2.05e-01 | 3.26e-01 | 1.14e-01 | 2.19e-01 |
| REGULATION OF CELL SUBSTRATE JUNCTION ORGANIZATION | 66 | 8.84e-01 | 1.00e+00 | 0.08790 | 3.70e-02 | 4.85e-02 | 1.09e-02 | 5.38e-02 | 3.16e-02 | 6.04e-01 | 4.96e-01 | 8.78e-01 | 4.50e-01 | 6.57e-01 |
| LONG CHAIN FATTY ACYL COA BIOSYNTHETIC PROCESS | 18 | 7.82e-01 | 1.00e+00 | 0.08750 | 1.09e-03 | -9.18e-03 | -2.14e-02 | 8.34e-02 | -1.23e-02 | 9.94e-01 | 9.46e-01 | 8.75e-01 | 5.40e-01 | 9.28e-01 |
| PROTEIN PROCESSING | 233 | 4.47e-01 | 9.30e-01 | 0.08750 | -4.08e-02 | -3.79e-02 | -1.20e-02 | -6.63e-02 | 3.12e-03 | 2.83e-01 | 3.18e-01 | 7.52e-01 | 8.12e-02 | 9.35e-01 |
| TRANSPORT ALONG MICROTUBULE | 164 | 1.39e-01 | 6.20e-01 | 0.08730 | 2.14e-02 | 9.26e-03 | 7.78e-02 | -2.63e-02 | 1.84e-02 | 6.36e-01 | 8.38e-01 | 8.55e-02 | 5.61e-01 | 6.85e-01 |
| CELL CELL JUNCTION ASSEMBLY | 152 | 4.99e-02 | 3.63e-01 | 0.08700 | -3.60e-02 | -1.68e-02 | -7.11e-02 | 3.02e-02 | -4.99e-03 | 4.44e-01 | 7.21e-01 | 1.30e-01 | 5.21e-01 | 9.15e-01 |
| BIOMINERAL TISSUE DEVELOPMENT | 165 | 7.06e-01 | 1.00e+00 | 0.08700 | -2.95e-02 | -1.61e-02 | -5.10e-02 | -1.61e-02 | -5.98e-02 | 5.13e-01 | 7.21e-01 | 2.58e-01 | 7.21e-01 | 1.85e-01 |
| REGULATION OF FIBROBLAST MIGRATION | 38 | 7.25e-01 | 1.00e+00 | 0.08690 | 3.27e-02 | 2.84e-02 | 4.16e-02 | 6.00e-02 | -1.85e-02 | 7.27e-01 | 7.62e-01 | 6.57e-01 | 5.22e-01 | 8.44e-01 |
| MUSCLE TISSUE DEVELOPMENT | 422 | 1.60e-01 | 6.59e-01 | 0.08690 | 4.29e-02 | 3.88e-02 | 5.51e-02 | 2.19e-02 | -2.64e-02 | 1.31e-01 | 1.72e-01 | 5.22e-02 | 4.40e-01 | 3.52e-01 |
| LINOLEIC ACID METABOLIC PROCESS | 20 | 7.93e-01 | 1.00e+00 | 0.08680 | 3.81e-03 | 6.71e-03 | -9.20e-03 | 6.02e-02 | -6.13e-02 | 9.76e-01 | 9.59e-01 | 9.43e-01 | 6.41e-01 | 6.35e-01 |
| NEGATIVE REGULATION OF COLLATERAL SPROUTING | 10 | 9.97e-01 | 1.00e+00 | 0.08670 | 3.93e-02 | 3.60e-02 | 5.13e-02 | 3.85e-02 | -2.35e-02 | 8.30e-01 | 8.44e-01 | 7.79e-01 | 8.33e-01 | 8.97e-01 |
| SMALL MOLECULE CATABOLIC PROCESS | 366 | 2.76e-01 | 8.03e-01 | 0.08650 | 4.21e-02 | 5.46e-02 | 2.06e-02 | 4.55e-02 | -1.51e-02 | 1.67e-01 | 7.27e-02 | 4.98e-01 | 1.35e-01 | 6.20e-01 |
| NEGATIVE REGULATION OF LYMPHOCYTE DIFFERENTIATION | 59 | 9.61e-01 | 1.00e+00 | 0.08650 | -3.98e-02 | -5.10e-02 | -4.25e-03 | -5.12e-02 | 2.56e-02 | 5.97e-01 | 4.98e-01 | 9.55e-01 | 4.97e-01 | 7.33e-01 |
| POSITIVE REGULATION OF PROTEIN CONTAINING COMPLEX DISASSEMBLY | 36 | 9.76e-01 | 1.00e+00 | 0.08640 | 4.30e-02 | 3.56e-02 | 4.82e-02 | 1.90e-02 | 4.08e-02 | 6.55e-01 | 7.12e-01 | 6.16e-01 | 8.44e-01 | 6.72e-01 |
| APOPTOTIC SIGNALING PATHWAY | 600 | 2.72e-04 | 8.07e-03 | 0.08640 | 1.36e-02 | 6.09e-03 | 6.50e-02 | -3.30e-02 | 4.39e-02 | 5.69e-01 | 7.99e-01 | 6.53e-03 | 1.68e-01 | 6.59e-02 |
| NUCLEUS LOCALIZATION | 33 | 8.66e-01 | 1.00e+00 | 0.08630 | 1.83e-02 | 3.60e-02 | -8.25e-03 | 5.64e-02 | 5.07e-02 | 8.55e-01 | 7.20e-01 | 9.35e-01 | 5.75e-01 | 6.14e-01 |
| POSITIVE REGULATION OF DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 231 | 1.10e-01 | 5.51e-01 | 0.08630 | -3.28e-02 | -3.96e-02 | 2.13e-02 | -5.02e-02 | 4.27e-02 | 3.90e-01 | 3.00e-01 | 5.77e-01 | 1.88e-01 | 2.64e-01 |
| REGULATION OF ACTION POTENTIAL | 55 | 3.12e-01 | 8.38e-01 | 0.08620 | 3.20e-02 | 6.18e-02 | 2.48e-02 | 4.02e-02 | 1.87e-02 | 6.81e-01 | 4.28e-01 | 7.51e-01 | 6.06e-01 | 8.11e-01 |
| REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 95 | 8.22e-01 | 1.00e+00 | 0.08610 | -1.58e-02 | -8.63e-03 | -3.67e-02 | 2.00e-03 | -7.57e-02 | 7.90e-01 | 8.84e-01 | 5.36e-01 | 9.73e-01 | 2.02e-01 |
| HEMOPOIESIS | 914 | 2.17e-07 | 1.69e-05 | 0.08610 | -1.30e-02 | -3.14e-02 | 4.82e-02 | -4.30e-02 | 4.56e-02 | 5.06e-01 | 1.07e-01 | 1.34e-02 | 2.74e-02 | 1.95e-02 |
| CARBOHYDRATE DERIVATIVE BIOSYNTHETIC PROCESS | 614 | 7.74e-02 | 4.56e-01 | 0.08600 | 4.35e-02 | 3.64e-02 | 6.26e-02 | 1.58e-02 | -1.66e-03 | 6.55e-02 | 1.23e-01 | 8.05e-03 | 5.04e-01 | 9.44e-01 |
| RESPONSE TO RADIATION | 410 | 5.02e-01 | 9.48e-01 | 0.08590 | 4.35e-02 | 4.65e-02 | 4.13e-02 | 4.03e-02 | -2.46e-03 | 1.31e-01 | 1.06e-01 | 1.51e-01 | 1.61e-01 | 9.32e-01 |
| MULTICELLULAR ORGANISMAL RESPONSE TO STRESS | 89 | 8.33e-01 | 1.00e+00 | 0.08570 | -1.91e-02 | -8.51e-03 | -4.21e-02 | 1.57e-03 | -7.16e-02 | 7.55e-01 | 8.90e-01 | 4.93e-01 | 9.80e-01 | 2.43e-01 |
| BRANCHING MORPHOGENESIS OF A NERVE | 10 | 6.20e-01 | 9.90e-01 | 0.08570 | -4.05e-02 | -6.55e-02 | 2.09e-02 | 1.38e-02 | -2.79e-02 | 8.24e-01 | 7.20e-01 | 9.09e-01 | 9.40e-01 | 8.78e-01 |
| REGULATION OF PLASMA MEMBRANE ORGANIZATION | 16 | 9.64e-01 | 1.00e+00 | 0.08570 | -2.09e-02 | -2.13e-02 | -4.19e-02 | -3.55e-03 | 6.84e-02 | 8.85e-01 | 8.83e-01 | 7.72e-01 | 9.80e-01 | 6.36e-01 |
| NEGATIVE REGULATION OF TOR SIGNALING | 72 | 8.27e-01 | 1.00e+00 | 0.08560 | -1.06e-02 | -1.38e-02 | 3.22e-02 | -3.00e-02 | 7.13e-02 | 8.76e-01 | 8.39e-01 | 6.37e-01 | 6.59e-01 | 2.95e-01 |
| CALCIUM ION HOMEOSTASIS | 320 | 3.25e-01 | 8.49e-01 | 0.08550 | -4.53e-02 | -5.08e-02 | -1.28e-02 | -4.99e-02 | 5.29e-03 | 1.64e-01 | 1.18e-01 | 6.93e-01 | 1.25e-01 | 8.71e-01 |
| DEPHOSPHORYLATION | 288 | 1.96e-01 | 7.10e-01 | 0.08550 | -1.01e-02 | -2.19e-02 | 3.54e-02 | -2.69e-02 | 6.90e-02 | 7.68e-01 | 5.22e-01 | 3.01e-01 | 4.33e-01 | 4.40e-02 |
| PROTON TRANSMEMBRANE TRANSPORT | 141 | 6.65e-01 | 1.00e+00 | 0.08550 | 2.65e-02 | 1.38e-02 | 6.43e-02 | 4.77e-03 | 4.76e-02 | 5.87e-01 | 7.78e-01 | 1.88e-01 | 9.22e-01 | 3.29e-01 |
| POSITIVE REGULATION OF LAMELLIPODIUM ORGANIZATION | 34 | 7.37e-01 | 1.00e+00 | 0.08540 | 1.08e-02 | 4.58e-02 | -4.20e-02 | 1.67e-02 | -5.51e-02 | 9.13e-01 | 6.44e-01 | 6.72e-01 | 8.66e-01 | 5.78e-01 |
| TRANSLESION SYNTHESIS | 25 | 8.28e-01 | 1.00e+00 | 0.08540 | 4.59e-02 | 1.38e-02 | 6.65e-02 | 1.79e-02 | -1.55e-02 | 6.91e-01 | 9.05e-01 | 5.65e-01 | 8.77e-01 | 8.93e-01 |
| REGULATION OF POSTSYNAPTIC MEMBRANE POTENTIAL | 141 | 7.87e-01 | 1.00e+00 | 0.08520 | 3.83e-02 | 4.34e-02 | 2.19e-02 | 5.37e-02 | -2.34e-02 | 4.33e-01 | 3.74e-01 | 6.54e-01 | 2.71e-01 | 6.32e-01 |
| BONE TRABECULA MORPHOGENESIS | 13 | 1.00e+00 | 1.00e+00 | 0.08520 | 4.53e-02 | 4.07e-02 | 4.38e-02 | 3.98e-02 | -6.48e-03 | 7.77e-01 | 7.99e-01 | 7.85e-01 | 8.04e-01 | 9.68e-01 |
| REGULATION OF MYELOID CELL DIFFERENTIATION | 206 | 3.67e-02 | 3.05e-01 | 0.08520 | -1.57e-02 | -4.07e-02 | 4.72e-02 | -4.17e-02 | 3.72e-02 | 6.98e-01 | 3.13e-01 | 2.43e-01 | 3.02e-01 | 3.57e-01 |
| PROTEIN DEACETYLATION | 51 | 5.39e-01 | 9.57e-01 | 0.08510 | 1.35e-02 | 1.59e-02 | 6.96e-02 | -4.42e-02 | 3.32e-03 | 8.68e-01 | 8.45e-01 | 3.90e-01 | 5.85e-01 | 9.67e-01 |
| REGULATION OF EPITHELIAL CELL MIGRATION | 282 | 2.05e-01 | 7.26e-01 | 0.08500 | -1.78e-02 | -8.17e-04 | -3.74e-02 | -2.05e-02 | -7.14e-02 | 6.06e-01 | 9.81e-01 | 2.80e-01 | 5.54e-01 | 3.92e-02 |
| NUCLEIC ACID PHOSPHODIESTER BOND HYDROLYSIS | 24 | 9.77e-01 | 1.00e+00 | 0.08500 | 4.09e-02 | 5.82e-02 | 2.97e-02 | 2.96e-02 | -2.04e-02 | 7.29e-01 | 6.22e-01 | 8.01e-01 | 8.02e-01 | 8.63e-01 |
| RESPONSE TO LIGHT STIMULUS | 302 | 5.92e-01 | 9.86e-01 | 0.08500 | 4.18e-02 | 4.92e-02 | 2.78e-02 | 4.63e-02 | -1.21e-02 | 2.12e-01 | 1.41e-01 | 4.06e-01 | 1.67e-01 | 7.17e-01 |
| CELL MIGRATION IN HINDBRAIN | 16 | 9.82e-01 | 1.00e+00 | 0.08500 | 8.62e-03 | 1.55e-02 | 2.75e-02 | -1.79e-02 | 7.63e-02 | 9.52e-01 | 9.15e-01 | 8.49e-01 | 9.01e-01 | 5.97e-01 |
| CELLULAR RESPONSE TO OXIDATIVE STRESS | 248 | 3.50e-02 | 2.98e-01 | 0.08490 | 2.22e-02 | 1.51e-02 | 7.14e-02 | -3.53e-02 | 1.21e-02 | 5.47e-01 | 6.83e-01 | 5.28e-02 | 3.38e-01 | 7.42e-01 |
| METANEPHRIC NEPHRON EPITHELIUM DEVELOPMENT | 25 | 9.68e-01 | 1.00e+00 | 0.08490 | 3.60e-02 | 2.95e-02 | 5.37e-02 | -1.09e-02 | -4.52e-02 | 7.55e-01 | 7.99e-01 | 6.42e-01 | 9.25e-01 | 6.96e-01 |
| ADULT LOCOMOTORY BEHAVIOR | 80 | 5.27e-01 | 9.54e-01 | 0.08490 | -9.35e-03 | -7.27e-03 | 3.99e-02 | -5.74e-02 | 4.66e-02 | 8.85e-01 | 9.11e-01 | 5.37e-01 | 3.75e-01 | 4.71e-01 |
| REGULATION OF TRANSFERASE ACTIVITY | 673 | 4.61e-04 | 1.23e-02 | 0.08490 | 2.17e-02 | 1.48e-02 | 6.45e-02 | -2.49e-02 | 4.16e-02 | 3.37e-01 | 5.12e-01 | 4.32e-03 | 2.70e-01 | 6.58e-02 |
| STEROID BIOSYNTHETIC PROCESS | 177 | 7.97e-02 | 4.64e-01 | 0.08470 | 2.78e-02 | 4.24e-02 | 9.54e-03 | 6.56e-02 | 1.47e-02 | 5.24e-01 | 3.31e-01 | 8.27e-01 | 1.32e-01 | 7.36e-01 |
| SCF DEPENDENT PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 47 | 9.07e-01 | 1.00e+00 | 0.08470 | 1.22e-02 | 1.26e-02 | 4.28e-02 | 7.67e-03 | 7.05e-02 | 8.85e-01 | 8.82e-01 | 6.12e-01 | 9.28e-01 | 4.03e-01 |
| MEMBRANE REPOLARIZATION DURING CARDIAC MUSCLE CELL ACTION POTENTIAL | 23 | 7.03e-01 | 1.00e+00 | 0.08470 | 1.53e-02 | 4.06e-02 | 1.09e-02 | 3.25e-02 | -6.41e-02 | 8.99e-01 | 7.36e-01 | 9.28e-01 | 7.87e-01 | 5.94e-01 |
| PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 278 | 1.84e-01 | 6.93e-01 | 0.08440 | 3.27e-02 | 4.12e-02 | 1.89e-02 | 5.79e-02 | 2.55e-02 | 3.48e-01 | 2.37e-01 | 5.87e-01 | 9.66e-02 | 4.65e-01 |
| NEURON CELLULAR HOMEOSTASIS | 59 | 2.31e-01 | 7.53e-01 | 0.08440 | -3.62e-02 | -3.42e-02 | 2.95e-02 | -6.08e-02 | -9.15e-03 | 6.31e-01 | 6.49e-01 | 6.95e-01 | 4.19e-01 | 9.03e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 91 | 1.09e-01 | 5.47e-01 | 0.08440 | -4.51e-03 | 8.87e-03 | 3.87e-02 | -7.33e-02 | 1.23e-02 | 9.41e-01 | 8.84e-01 | 5.23e-01 | 2.27e-01 | 8.40e-01 |
| ASPARTATE FAMILY AMINO ACID METABOLIC PROCESS | 47 | 8.24e-01 | 1.00e+00 | 0.08440 | -7.73e-03 | 1.61e-02 | -3.66e-02 | -2.07e-02 | -7.10e-02 | 9.27e-01 | 8.49e-01 | 6.65e-01 | 8.06e-01 | 4.00e-01 |
| CYTOKINE PRODUCTION INVOLVED IN INFLAMMATORY RESPONSE | 77 | 6.57e-01 | 1.00e+00 | 0.08440 | 3.78e-02 | 3.45e-02 | 1.56e-02 | 3.96e-02 | 5.19e-02 | 5.66e-01 | 6.01e-01 | 8.13e-01 | 5.48e-01 | 4.31e-01 |
| NEGATIVE REGULATION OF DEFENSE RESPONSE | 308 | 1.77e-01 | 6.84e-01 | 0.08430 | -3.68e-02 | -5.32e-02 | 1.24e-03 | -5.01e-02 | 2.06e-02 | 2.67e-01 | 1.08e-01 | 9.70e-01 | 1.31e-01 | 5.34e-01 |
| SPERM MITOCHONDRIAL SHEATH ASSEMBLY | 6 | 9.96e-01 | 1.00e+00 | 0.08430 | 9.17e-03 | 1.57e-02 | -2.39e-02 | 7.30e-02 | 2.98e-02 | 9.69e-01 | 9.47e-01 | 9.19e-01 | 7.57e-01 | 9.00e-01 |
| ENDOPLASMIC RETICULUM LOCALIZATION | 10 | 9.73e-01 | 1.00e+00 | 0.08420 | 2.68e-02 | 4.76e-02 | 1.11e-02 | 6.31e-02 | 2.65e-03 | 8.84e-01 | 7.94e-01 | 9.51e-01 | 7.30e-01 | 9.88e-01 |
| MIRNA MEDIATED GENE SILENCING BY MRNA DESTABILIZATION | 62 | 4.11e-01 | 9.08e-01 | 0.08410 | -2.80e-02 | -2.53e-02 | -7.24e-02 | -4.03e-03 | 2.01e-02 | 7.03e-01 | 7.31e-01 | 3.24e-01 | 9.56e-01 | 7.84e-01 |
| VESICLE DOCKING INVOLVED IN EXOCYTOSIS | 42 | 7.97e-01 | 1.00e+00 | 0.08400 | 3.32e-02 | 2.82e-02 | 6.76e-02 | 1.59e-02 | -1.83e-02 | 7.09e-01 | 7.52e-01 | 4.48e-01 | 8.58e-01 | 8.38e-01 |
| NEGATIVE REGULATION OF WNT SIGNALING PATHWAY | 167 | 2.39e-01 | 7.63e-01 | 0.08400 | 2.71e-02 | 2.36e-02 | 7.14e-02 | -1.41e-02 | 2.16e-02 | 5.46e-01 | 5.98e-01 | 1.11e-01 | 7.53e-01 | 6.30e-01 |
| IMPORT INTO NUCLEUS | 163 | 2.41e-01 | 7.66e-01 | 0.08400 | 6.40e-04 | -5.95e-03 | 4.94e-02 | -5.04e-02 | 4.51e-02 | 9.89e-01 | 8.96e-01 | 2.77e-01 | 2.67e-01 | 3.20e-01 |
| MESENCHYME DEVELOPMENT | 311 | 2.85e-02 | 2.61e-01 | 0.08400 | 3.26e-02 | 2.88e-02 | 6.73e-02 | -1.47e-02 | -2.04e-02 | 3.23e-01 | 3.83e-01 | 4.12e-02 | 6.56e-01 | 5.35e-01 |
| REGULATION OF TRANSLATIONAL INITIATION BY EIF2 ALPHA PHOSPHORYLATION | 10 | 9.77e-01 | 1.00e+00 | 0.08400 | 2.38e-02 | 3.04e-02 | 2.95e-02 | -2.05e-02 | 6.53e-02 | 8.96e-01 | 8.68e-01 | 8.72e-01 | 9.11e-01 | 7.21e-01 |
| REGULATION OF TRANSPORTER ACTIVITY | 253 | 7.45e-01 | 1.00e+00 | 0.08390 | 4.50e-02 | 5.11e-02 | 3.25e-02 | 3.65e-02 | 3.09e-03 | 2.18e-01 | 1.61e-01 | 3.73e-01 | 3.18e-01 | 9.32e-01 |
| PHENOL CONTAINING COMPOUND BIOSYNTHETIC PROCESS | 46 | 4.45e-01 | 9.29e-01 | 0.08380 | -2.93e-02 | -6.08e-02 | 1.58e-02 | -3.53e-02 | -3.13e-02 | 7.31e-01 | 4.76e-01 | 8.53e-01 | 6.79e-01 | 7.14e-01 |
| POSITIVE REGULATION OF CELLULAR SENESCENCE | 17 | 9.44e-01 | 1.00e+00 | 0.08380 | 8.18e-03 | -2.60e-03 | -3.52e-02 | 3.40e-02 | -6.74e-02 | 9.53e-01 | 9.85e-01 | 8.02e-01 | 8.08e-01 | 6.30e-01 |
| RESPONSE TO SALT | 352 | 1.82e-01 | 6.89e-01 | 0.08380 | 3.97e-02 | 3.18e-02 | 6.17e-02 | 2.48e-02 | -3.90e-04 | 2.00e-01 | 3.05e-01 | 4.67e-02 | 4.23e-01 | 9.90e-01 |
| CARDIAC CHAMBER DEVELOPMENT | 168 | 6.58e-02 | 4.17e-01 | 0.08360 | 1.80e-02 | 5.94e-03 | 6.48e-02 | -3.13e-02 | -3.83e-02 | 6.87e-01 | 8.94e-01 | 1.48e-01 | 4.85e-01 | 3.92e-01 |
| REGULATION OF RNA EXPORT FROM NUCLEUS | 13 | 8.21e-01 | 1.00e+00 | 0.08350 | -2.20e-02 | -6.52e-02 | 2.79e-02 | 5.88e-03 | 3.78e-02 | 8.91e-01 | 6.84e-01 | 8.62e-01 | 9.71e-01 | 8.14e-01 |
| SERINE FAMILY AMINO ACID BIOSYNTHETIC PROCESS | 19 | 9.94e-01 | 1.00e+00 | 0.08350 | 2.00e-02 | 2.98e-03 | 5.06e-02 | 6.88e-03 | 6.28e-02 | 8.80e-01 | 9.82e-01 | 7.02e-01 | 9.59e-01 | 6.35e-01 |
| NEUROBLAST PROLIFERATION | 80 | 6.70e-01 | 1.00e+00 | 0.08340 | 3.33e-02 | 2.23e-02 | 6.62e-02 | -9.43e-03 | -2.97e-02 | 6.07e-01 | 7.30e-01 | 3.06e-01 | 8.84e-01 | 6.46e-01 |
| CENTRAL NERVOUS SYSTEM NEURON AXONOGENESIS | 39 | 4.99e-01 | 9.47e-01 | 0.08340 | -1.87e-02 | -3.64e-02 | 5.78e-02 | -3.58e-02 | 2.55e-02 | 8.40e-01 | 6.94e-01 | 5.32e-01 | 6.99e-01 | 7.83e-01 |
| NEGATIVE REGULATION OF MACROPHAGE MIGRATION | 14 | 6.94e-01 | 1.00e+00 | 0.08340 | -1.27e-02 | -4.49e-02 | -3.96e-02 | -1.73e-02 | -5.39e-02 | 9.34e-01 | 7.71e-01 | 7.97e-01 | 9.11e-01 | 7.27e-01 |
| REGULATION OF BMP SIGNALING PATHWAY | 115 | 3.98e-01 | 8.97e-01 | 0.08340 | 2.06e-02 | 1.95e-02 | 4.24e-02 | -2.97e-02 | -5.89e-02 | 7.03e-01 | 7.18e-01 | 4.32e-01 | 5.82e-01 | 2.75e-01 |
| RESPONSE TO FORSKOLIN | 14 | 9.96e-01 | 1.00e+00 | 0.08330 | 3.98e-02 | 2.39e-02 | 5.60e-02 | 3.93e-02 | 1.04e-02 | 7.97e-01 | 8.77e-01 | 7.17e-01 | 7.99e-01 | 9.46e-01 |
| REGULATION OF LIPOPROTEIN LIPASE ACTIVITY | 16 | 9.84e-01 | 1.00e+00 | 0.08330 | -7.50e-03 | 8.86e-03 | -8.58e-03 | -2.77e-02 | -7.73e-02 | 9.59e-01 | 9.51e-01 | 9.53e-01 | 8.48e-01 | 5.93e-01 |
| KIDNEY EPITHELIUM DEVELOPMENT | 145 | 1.05e-01 | 5.39e-01 | 0.08330 | -1.46e-02 | -1.35e-02 | 4.45e-02 | -5.88e-02 | 3.32e-02 | 7.62e-01 | 7.79e-01 | 3.55e-01 | 2.21e-01 | 4.90e-01 |
| MULTICELLULAR ORGANISM GROWTH | 144 | 2.62e-01 | 7.90e-01 | 0.08320 | 3.30e-02 | 3.69e-02 | 6.26e-02 | -1.39e-02 | -1.92e-02 | 4.95e-01 | 4.45e-01 | 1.95e-01 | 7.73e-01 | 6.90e-01 |
| MAINTENANCE OF LOCATION | 335 | 2.22e-01 | 7.45e-01 | 0.08310 | -2.96e-02 | -3.69e-02 | 1.34e-02 | -5.04e-02 | 4.42e-02 | 3.51e-01 | 2.46e-01 | 6.73e-01 | 1.13e-01 | 1.65e-01 |
| AMINOGLYCAN METABOLIC PROCESS | 118 | 9.29e-01 | 1.00e+00 | 0.08310 | -4.52e-02 | -3.82e-02 | -5.38e-02 | -2.22e-02 | -2.72e-03 | 3.96e-01 | 4.73e-01 | 3.12e-01 | 6.77e-01 | 9.59e-01 |
| REGULATION OF POSTSYNAPTIC DENSITY ORGANIZATION | 14 | 9.75e-01 | 1.00e+00 | 0.08300 | -4.68e-02 | -1.97e-02 | -5.32e-02 | -3.75e-02 | -8.69e-03 | 7.62e-01 | 8.98e-01 | 7.30e-01 | 8.08e-01 | 9.55e-01 |
| SISTER CHROMATID COHESION | 53 | 6.96e-01 | 1.00e+00 | 0.08300 | -2.10e-02 | -4.86e-02 | 2.68e-02 | -5.06e-02 | 2.83e-02 | 7.91e-01 | 5.40e-01 | 7.36e-01 | 5.24e-01 | 7.21e-01 |
| NEGATIVE REGULATION OF CATION CHANNEL ACTIVITY | 46 | 9.47e-01 | 1.00e+00 | 0.08300 | 3.52e-02 | 3.60e-02 | 9.00e-03 | 5.17e-02 | 4.00e-02 | 6.80e-01 | 6.73e-01 | 9.16e-01 | 5.44e-01 | 6.39e-01 |
| POSITIVE REGULATION OF MRNA METABOLIC PROCESS | 190 | 7.47e-01 | 1.00e+00 | 0.08290 | -3.48e-02 | -4.06e-02 | -5.77e-03 | -5.23e-02 | 3.54e-02 | 4.08e-01 | 3.34e-01 | 8.91e-01 | 2.14e-01 | 4.00e-01 |
| VITAMIN METABOLIC PROCESS | 107 | 9.75e-01 | 1.00e+00 | 0.08280 | 4.16e-02 | 3.98e-02 | 4.78e-02 | 3.21e-02 | 1.49e-02 | 4.57e-01 | 4.77e-01 | 3.93e-01 | 5.66e-01 | 7.89e-01 |
| CORTICAL CYTOSKELETON ORGANIZATION | 50 | 9.86e-01 | 1.00e+00 | 0.08280 | -4.04e-02 | -4.38e-02 | -3.06e-02 | -2.36e-02 | 4.25e-02 | 6.21e-01 | 5.92e-01 | 7.08e-01 | 7.73e-01 | 6.03e-01 |
| POSITIVE REGULATION OF PROTEIN LOCALIZATION | 458 | 2.22e-03 | 4.18e-02 | 0.08280 | 3.55e-02 | 4.45e-02 | 5.79e-02 | 1.02e-02 | 1.25e-02 | 1.92e-01 | 1.03e-01 | 3.37e-02 | 7.08e-01 | 6.46e-01 |
| NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 692 | 4.39e-02 | 3.36e-01 | 0.08270 | 3.34e-02 | 3.04e-02 | 5.88e-02 | 9.94e-03 | 3.53e-02 | 1.34e-01 | 1.72e-01 | 8.35e-03 | 6.56e-01 | 1.13e-01 |
| POSITIVE REGULATION OF CATALYTIC ACTIVITY | 900 | 4.30e-02 | 3.32e-01 | 0.08270 | -3.89e-02 | -4.19e-02 | -8.17e-03 | -4.86e-02 | 3.38e-02 | 4.77e-02 | 3.30e-02 | 6.78e-01 | 1.34e-02 | 8.52e-02 |
| POSITIVE REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 15 | 9.15e-01 | 1.00e+00 | 0.08260 | 2.94e-02 | 5.49e-02 | 3.16e-02 | 2.15e-02 | -3.85e-02 | 8.44e-01 | 7.13e-01 | 8.32e-01 | 8.85e-01 | 7.96e-01 |
| REGULATION OF DEVELOPMENTAL GROWTH | 311 | 6.46e-02 | 4.13e-01 | 0.08250 | 1.80e-02 | 2.15e-02 | 2.58e-02 | -1.69e-02 | -7.12e-02 | 5.86e-01 | 5.14e-01 | 4.33e-01 | 6.09e-01 | 3.08e-02 |
| REGULATION OF METAL ION TRANSPORT | 381 | 7.88e-01 | 1.00e+00 | 0.08250 | 4.39e-02 | 4.58e-02 | 3.26e-02 | 4.05e-02 | -8.62e-03 | 1.41e-01 | 1.24e-01 | 2.75e-01 | 1.74e-01 | 7.73e-01 |
| SMOOTH MUSCLE CELL PROLIFERATION | 160 | 4.59e-01 | 9.32e-01 | 0.08240 | 3.67e-02 | 2.45e-02 | 6.85e-02 | 1.22e-02 | -3.18e-04 | 4.23e-01 | 5.92e-01 | 1.35e-01 | 7.90e-01 | 9.94e-01 |
| NEGATIVE REGULATION OF MOLECULAR FUNCTION | 754 | 4.82e-04 | 1.26e-02 | 0.08240 | 8.60e-03 | -2.57e-03 | 5.52e-02 | -3.09e-02 | 5.20e-02 | 6.88e-01 | 9.04e-01 | 9.88e-03 | 1.49e-01 | 1.50e-02 |
| CARBOHYDRATE HOMEOSTASIS | 248 | 1.10e-01 | 5.51e-01 | 0.08220 | 3.30e-02 | 2.92e-02 | 6.76e-02 | -9.87e-03 | -1.22e-02 | 3.70e-01 | 4.28e-01 | 6.69e-02 | 7.89e-01 | 7.41e-01 |
| RESPONSE TO INSULIN | 262 | 1.06e-01 | 5.39e-01 | 0.08220 | 9.68e-03 | 4.60e-03 | 5.48e-02 | -3.42e-02 | 4.96e-02 | 7.87e-01 | 8.98e-01 | 1.27e-01 | 3.40e-01 | 1.67e-01 |
| POSITIVE REGULATION OF MEMBRANE DEPOLARIZATION | 11 | 9.65e-01 | 1.00e+00 | 0.08210 | -2.25e-02 | -5.53e-02 | 1.32e-02 | -4.75e-02 | 2.73e-02 | 8.97e-01 | 7.51e-01 | 9.40e-01 | 7.85e-01 | 8.75e-01 |
| LIPID STORAGE | 93 | 9.13e-01 | 1.00e+00 | 0.08210 | -3.24e-02 | -3.25e-02 | -7.42e-03 | -3.75e-02 | 5.63e-02 | 5.90e-01 | 5.88e-01 | 9.02e-01 | 5.32e-01 | 3.48e-01 |
| REGULATION OF CELL DIFFERENTIATION | 1558 | 1.68e-04 | 5.31e-03 | 0.08200 | 4.10e-02 | 3.74e-02 | 5.64e-02 | 1.44e-02 | -1.59e-02 | 6.90e-03 | 1.37e-02 | 2.01e-04 | 3.42e-01 | 2.94e-01 |
| PHENOL CONTAINING COMPOUND METABOLIC PROCESS | 105 | 4.75e-01 | 9.40e-01 | 0.08190 | -8.72e-03 | -1.42e-02 | -1.12e-02 | 3.97e-03 | -7.93e-02 | 8.77e-01 | 8.02e-01 | 8.42e-01 | 9.44e-01 | 1.60e-01 |
| PROTEIN EXPORT FROM NUCLEUS | 59 | 7.28e-01 | 1.00e+00 | 0.08190 | -2.77e-02 | -1.81e-02 | -7.18e-03 | -6.29e-02 | 4.00e-02 | 7.13e-01 | 8.10e-01 | 9.24e-01 | 4.03e-01 | 5.95e-01 |
| RESPONSE TO GRAVITY | 9 | 8.18e-01 | 1.00e+00 | 0.08190 | -4.87e-02 | -2.24e-02 | -2.36e-02 | -1.72e-02 | -5.46e-02 | 8.00e-01 | 9.08e-01 | 9.02e-01 | 9.29e-01 | 7.77e-01 |
| TERMINAL BUTTON ORGANIZATION | 6 | 9.98e-01 | 1.00e+00 | 0.08190 | 1.50e-02 | 1.30e-02 | -1.99e-02 | 6.91e-02 | 3.38e-02 | 9.49e-01 | 9.56e-01 | 9.33e-01 | 7.70e-01 | 8.86e-01 |
| REGULATION OF ENDOPLASMIC RETICULUM STRESS INDUCED INTRINSIC APOPTOTIC SIGNALING PATHWAY | 32 | 3.53e-01 | 8.72e-01 | 0.08180 | -2.96e-03 | 8.95e-03 | 6.46e-02 | -4.79e-02 | -1.17e-02 | 9.77e-01 | 9.30e-01 | 5.27e-01 | 6.39e-01 | 9.09e-01 |
| DEOXYRIBONUCLEOTIDE METABOLIC PROCESS | 42 | 7.93e-01 | 1.00e+00 | 0.08180 | 1.85e-03 | -1.65e-02 | 6.45e-02 | -4.50e-02 | 1.53e-02 | 9.83e-01 | 8.53e-01 | 4.70e-01 | 6.14e-01 | 8.64e-01 |
| POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 189 | 3.66e-01 | 8.79e-01 | 0.08160 | 7.05e-03 | 7.04e-03 | 4.20e-02 | -1.56e-02 | 6.75e-02 | 8.67e-01 | 8.67e-01 | 3.19e-01 | 7.12e-01 | 1.09e-01 |
| ENDOSOMAL TRANSPORT | 242 | 4.61e-01 | 9.32e-01 | 0.08150 | 3.30e-03 | -5.47e-03 | 3.73e-02 | -1.16e-02 | 7.12e-02 | 9.30e-01 | 8.83e-01 | 3.18e-01 | 7.57e-01 | 5.63e-02 |
| ACTIN FILAMENT BASED MOVEMENT | 128 | 1.66e-01 | 6.70e-01 | 0.08140 | -5.02e-04 | 2.11e-02 | -4.35e-02 | 5.06e-02 | -4.15e-02 | 9.92e-01 | 6.80e-01 | 3.95e-01 | 3.23e-01 | 4.17e-01 |
| EPITHELIAL STRUCTURE MAINTENANCE | 33 | 8.53e-01 | 1.00e+00 | 0.08130 | -3.20e-02 | -1.23e-02 | -2.88e-02 | -2.13e-02 | 6.45e-02 | 7.51e-01 | 9.03e-01 | 7.75e-01 | 8.32e-01 | 5.21e-01 |
| POSITIVE REGULATION OF CATABOLIC PROCESS | 575 | 4.02e-02 | 3.23e-01 | 0.08130 | 2.90e-02 | 2.65e-02 | 5.87e-02 | 4.99e-03 | 4.00e-02 | 2.34e-01 | 2.78e-01 | 1.61e-02 | 8.38e-01 | 1.01e-01 |
| ORGANONITROGEN COMPOUND CATABOLIC PROCESS | 1269 | 1.14e-06 | 7.12e-05 | 0.08120 | 2.38e-02 | 2.01e-02 | 6.37e-02 | -1.08e-02 | 3.80e-02 | 1.53e-01 | 2.28e-01 | 1.36e-04 | 5.17e-01 | 2.27e-02 |
| REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 109 | 3.73e-01 | 8.82e-01 | 0.08120 | -3.21e-02 | -3.05e-02 | 1.86e-02 | -4.93e-02 | 4.30e-02 | 5.63e-01 | 5.82e-01 | 7.37e-01 | 3.74e-01 | 4.38e-01 |
| POSITIVE REGULATION OF PROGRAMMED CELL DEATH | 546 | 1.69e-03 | 3.47e-02 | 0.08110 | -1.98e-03 | -1.77e-02 | 5.28e-02 | -3.91e-02 | 4.41e-02 | 9.37e-01 | 4.79e-01 | 3.49e-02 | 1.18e-01 | 7.79e-02 |
| POSITIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS | 85 | 1.84e-02 | 1.97e-01 | 0.08110 | 2.45e-02 | 3.81e-02 | 4.57e-02 | 4.76e-02 | -1.26e-02 | 6.96e-01 | 5.44e-01 | 4.66e-01 | 4.48e-01 | 8.41e-01 |
| POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 157 | 4.41e-01 | 9.26e-01 | 0.08100 | 1.71e-02 | 1.88e-02 | 1.79e-02 | -1.70e-02 | -7.28e-02 | 7.12e-01 | 6.84e-01 | 6.99e-01 | 7.13e-01 | 1.15e-01 |
| GLIOGENESIS | 329 | 4.34e-02 | 3.34e-01 | 0.08090 | 3.32e-02 | 3.61e-02 | 6.29e-02 | -9.40e-03 | 9.81e-03 | 3.01e-01 | 2.61e-01 | 4.99e-02 | 7.69e-01 | 7.60e-01 |
| REGULATION OF RAC PROTEIN SIGNAL TRANSDUCTION | 19 | 9.93e-01 | 1.00e+00 | 0.08080 | -2.01e-02 | -3.44e-02 | 2.02e-02 | -4.61e-02 | 4.91e-02 | 8.79e-01 | 7.95e-01 | 8.79e-01 | 7.28e-01 | 7.11e-01 |
| ARACHIDONIC ACID METABOLIC PROCESS | 56 | 6.85e-01 | 1.00e+00 | 0.08080 | -5.29e-03 | 8.17e-03 | -3.63e-02 | 4.16e-02 | -5.82e-02 | 9.45e-01 | 9.16e-01 | 6.39e-01 | 5.90e-01 | 4.51e-01 |
| LONG CHAIN FATTY ACID METABOLIC PROCESS | 104 | 3.66e-01 | 8.79e-01 | 0.08070 | 8.03e-03 | 1.88e-02 | -3.74e-02 | 6.85e-02 | -2.49e-03 | 8.87e-01 | 7.41e-01 | 5.10e-01 | 2.27e-01 | 9.65e-01 |
| TUBE MORPHOGENESIS | 915 | 4.72e-02 | 3.52e-01 | 0.08070 | 4.11e-02 | 4.08e-02 | 4.95e-02 | 2.26e-02 | -1.40e-02 | 3.50e-02 | 3.65e-02 | 1.10e-02 | 2.45e-01 | 4.73e-01 |
| REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 115 | 6.39e-01 | 9.99e-01 | 0.08070 | -2.65e-02 | -3.25e-02 | 8.37e-03 | -6.84e-02 | -2.43e-03 | 6.24e-01 | 5.47e-01 | 8.77e-01 | 2.05e-01 | 9.64e-01 |
| REGULATION OF CLATHRIN DEPENDENT ENDOCYTOSIS | 18 | 8.97e-01 | 1.00e+00 | 0.08070 | -3.06e-02 | -7.08e-03 | -4.13e-02 | -6.01e-02 | 1.41e-02 | 8.22e-01 | 9.59e-01 | 7.61e-01 | 6.59e-01 | 9.17e-01 |
| NEGATIVE REGULATION OF FAT CELL DIFFERENTIATION | 60 | 8.08e-01 | 1.00e+00 | 0.08060 | 2.81e-02 | 5.72e-03 | 6.91e-02 | -4.52e-03 | 2.96e-02 | 7.07e-01 | 9.39e-01 | 3.55e-01 | 9.52e-01 | 6.91e-01 |
| MACROMOLECULE DEACYLATION | 63 | 3.20e-01 | 8.47e-01 | 0.08050 | 4.92e-03 | 1.35e-02 | 5.27e-02 | -4.91e-02 | -3.29e-02 | 9.46e-01 | 8.52e-01 | 4.70e-01 | 5.01e-01 | 6.51e-01 |
| CHLORIDE TRANSPORT | 116 | 5.24e-01 | 9.54e-01 | 0.08050 | 2.89e-02 | 3.87e-02 | 1.65e-02 | 4.61e-02 | -4.17e-02 | 5.90e-01 | 4.71e-01 | 7.58e-01 | 3.91e-01 | 4.37e-01 |
| CELLULAR RESPONSE TO CHEMICAL STRESS | 307 | 2.47e-02 | 2.34e-01 | 0.08040 | 1.71e-02 | 8.72e-03 | 6.78e-02 | -3.25e-02 | 2.11e-02 | 6.06e-01 | 7.93e-01 | 4.09e-02 | 3.28e-01 | 5.26e-01 |
| CENTRAL NERVOUS SYSTEM NEURON DEVELOPMENT | 85 | 5.68e-01 | 9.73e-01 | 0.08040 | 2.60e-02 | 1.93e-02 | 5.84e-02 | -1.02e-02 | -4.36e-02 | 6.78e-01 | 7.59e-01 | 3.52e-01 | 8.70e-01 | 4.87e-01 |
| SPROUTING ANGIOGENESIS | 183 | 6.61e-01 | 1.00e+00 | 0.08040 | 3.26e-02 | 4.37e-02 | 1.20e-02 | 2.14e-02 | -5.37e-02 | 4.47e-01 | 3.07e-01 | 7.79e-01 | 6.18e-01 | 2.10e-01 |
| HOMOTYPIC CELL CELL ADHESION | 93 | 5.91e-01 | 9.86e-01 | 0.08040 | -3.08e-02 | -4.09e-02 | 2.41e-02 | -5.15e-02 | 2.47e-02 | 6.08e-01 | 4.95e-01 | 6.88e-01 | 3.91e-01 | 6.80e-01 |
| NEGATIVE REGULATION OF INNATE IMMUNE RESPONSE | 89 | 2.86e-01 | 8.12e-01 | 0.08040 | 1.35e-02 | -1.41e-02 | 7.27e-02 | -2.55e-02 | 1.20e-02 | 8.26e-01 | 8.18e-01 | 2.36e-01 | 6.77e-01 | 8.44e-01 |
| NEGATIVE REGULATION OF RNA CATABOLIC PROCESS | 78 | 7.92e-01 | 1.00e+00 | 0.08030 | 1.01e-02 | 7.60e-03 | 3.83e-02 | 1.51e-02 | 6.78e-02 | 8.77e-01 | 9.08e-01 | 5.59e-01 | 8.18e-01 | 3.01e-01 |
| CARBOHYDRATE PHOSPHORYLATION | 22 | 9.91e-01 | 1.00e+00 | 0.08020 | 3.20e-02 | 4.01e-02 | 3.11e-02 | 7.28e-03 | -5.28e-02 | 7.95e-01 | 7.45e-01 | 8.01e-01 | 9.53e-01 | 6.68e-01 |
| MONOATOMIC CATION TRANSMEMBRANE TRANSPORT | 814 | 6.47e-02 | 4.13e-01 | 0.08010 | 3.61e-02 | 4.29e-02 | 1.95e-02 | 4.36e-02 | -3.16e-02 | 7.96e-02 | 3.74e-02 | 3.45e-01 | 3.46e-02 | 1.26e-01 |
| NEGATIVE REGULATION OF TYPE I INTERFERON PRODUCTION | 44 | 5.28e-01 | 9.54e-01 | 0.08000 | 7.36e-03 | -2.50e-02 | 7.04e-02 | -9.67e-03 | 2.60e-02 | 9.33e-01 | 7.74e-01 | 4.19e-01 | 9.12e-01 | 7.66e-01 |
| LAMELLIPODIUM ORGANIZATION | 86 | 4.61e-01 | 9.32e-01 | 0.08000 | 1.26e-02 | 2.88e-02 | -3.97e-02 | 5.86e-02 | 2.00e-02 | 8.39e-01 | 6.44e-01 | 5.25e-01 | 3.47e-01 | 7.49e-01 |
| RNA CATABOLIC PROCESS | 349 | 1.59e-01 | 6.59e-01 | 0.07990 | -1.05e-02 | -1.89e-02 | 3.25e-02 | -3.58e-02 | 5.99e-02 | 7.37e-01 | 5.43e-01 | 2.97e-01 | 2.50e-01 | 5.46e-02 |
| POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 67 | 5.46e-01 | 9.61e-01 | 0.07990 | -2.21e-02 | -2.64e-02 | 3.86e-02 | -5.99e-02 | 1.08e-02 | 7.54e-01 | 7.09e-01 | 5.85e-01 | 3.96e-01 | 8.78e-01 |
| RESPONSE TO FUNGICIDE | 7 | 9.91e-01 | 1.00e+00 | 0.07990 | -2.73e-02 | -3.16e-02 | 1.18e-02 | -3.72e-02 | -5.58e-02 | 9.00e-01 | 8.85e-01 | 9.57e-01 | 8.65e-01 | 7.98e-01 |
| POSITIVE REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION | 29 | 8.32e-01 | 1.00e+00 | 0.07990 | -2.77e-02 | -3.73e-02 | -3.61e-02 | 2.07e-02 | -4.99e-02 | 7.96e-01 | 7.28e-01 | 7.36e-01 | 8.47e-01 | 6.42e-01 |
| UDP GLUCOSE METABOLIC PROCESS | 6 | 9.60e-01 | 1.00e+00 | 0.07990 | -8.75e-03 | -5.29e-02 | 5.56e-02 | -4.91e-03 | 1.97e-02 | 9.70e-01 | 8.22e-01 | 8.14e-01 | 9.83e-01 | 9.33e-01 |
| CYCLIC NUCLEOTIDE BIOSYNTHETIC PROCESS | 20 | 9.49e-01 | 1.00e+00 | 0.07980 | 3.01e-02 | 7.28e-04 | 5.81e-02 | 1.01e-02 | 4.45e-02 | 8.15e-01 | 9.96e-01 | 6.53e-01 | 9.38e-01 | 7.30e-01 |
| ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 1213 | 5.69e-02 | 3.90e-01 | 0.07980 | 4.09e-02 | 4.05e-02 | 3.92e-02 | 3.15e-02 | -2.32e-02 | 1.65e-02 | 1.76e-02 | 2.16e-02 | 6.49e-02 | 1.74e-01 |
| NEUROINFLAMMATORY RESPONSE | 82 | 4.84e-01 | 9.43e-01 | 0.07980 | -4.77e-02 | -5.12e-02 | -7.72e-03 | -3.69e-02 | 7.00e-03 | 4.55e-01 | 4.23e-01 | 9.04e-01 | 5.63e-01 | 9.13e-01 |
| PHOSPHOLIPASE C ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 103 | 6.85e-01 | 1.00e+00 | 0.07980 | -2.41e-02 | -2.83e-02 | -5.15e-02 | 1.62e-03 | -4.82e-02 | 6.72e-01 | 6.19e-01 | 3.66e-01 | 9.77e-01 | 3.98e-01 |
| TEMPERATURE HOMEOSTASIS | 181 | 2.22e-01 | 7.45e-01 | 0.07970 | -1.81e-02 | -2.34e-02 | 3.56e-02 | -4.35e-02 | 4.81e-02 | 6.74e-01 | 5.87e-01 | 4.09e-01 | 3.13e-01 | 2.64e-01 |
| ENDOTHELIAL CELL DEVELOPMENT | 65 | 7.47e-01 | 1.00e+00 | 0.07960 | -6.35e-03 | -1.65e-02 | 4.54e-02 | -1.75e-02 | 6.04e-02 | 9.29e-01 | 8.19e-01 | 5.26e-01 | 8.07e-01 | 3.99e-01 |
| REGULATION OF JNK CASCADE | 130 | 8.04e-01 | 1.00e+00 | 0.07950 | -2.87e-02 | -4.02e-02 | 8.16e-03 | -3.58e-02 | 5.03e-02 | 5.72e-01 | 4.29e-01 | 8.72e-01 | 4.80e-01 | 3.22e-01 |
| EXCITATORY SYNAPSE ASSEMBLY | 32 | 7.35e-01 | 1.00e+00 | 0.07940 | 1.32e-02 | 4.88e-02 | -2.10e-02 | 1.74e-02 | -5.48e-02 | 8.97e-01 | 6.33e-01 | 8.37e-01 | 8.64e-01 | 5.92e-01 |
| CEREBELLAR GRANULAR LAYER MORPHOGENESIS | 8 | 9.99e-01 | 1.00e+00 | 0.07940 | -3.49e-02 | -3.47e-02 | -3.44e-02 | -5.19e-02 | -2.79e-03 | 8.64e-01 | 8.65e-01 | 8.66e-01 | 7.99e-01 | 9.89e-01 |
| RESPONSE TO XENOBIOTIC STIMULUS | 424 | 1.58e-01 | 6.58e-01 | 0.07940 | 3.80e-02 | 3.63e-02 | 4.86e-02 | 3.35e-02 | -8.24e-03 | 1.80e-01 | 1.99e-01 | 8.64e-02 | 2.37e-01 | 7.71e-01 |
| REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 76 | 9.70e-01 | 1.00e+00 | 0.07930 | 3.77e-02 | 4.29e-02 | 2.30e-02 | 4.26e-02 | 2.62e-02 | 5.70e-01 | 5.18e-01 | 7.29e-01 | 5.21e-01 | 6.93e-01 |
| MORPHOGENESIS OF A BRANCHING STRUCTURE | 195 | 4.48e-02 | 3.42e-01 | 0.07930 | 2.80e-02 | 2.14e-02 | 6.99e-02 | 1.21e-02 | 3.81e-03 | 5.00e-01 | 6.06e-01 | 9.24e-02 | 7.72e-01 | 9.27e-01 |
| POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 272 | 5.63e-01 | 9.71e-01 | 0.07920 | 4.06e-02 | 4.18e-02 | 5.05e-02 | 1.41e-02 | -1.13e-02 | 2.49e-01 | 2.36e-01 | 1.52e-01 | 6.89e-01 | 7.48e-01 |
| INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 63 | 1.60e-01 | 6.59e-01 | 0.07900 | 1.05e-02 | 3.22e-02 | 4.56e-02 | -4.04e-02 | -3.71e-02 | 8.85e-01 | 6.59e-01 | 5.31e-01 | 5.79e-01 | 6.10e-01 |
| INFLAMMATORY RESPONSE TO WOUNDING | 27 | 9.08e-01 | 1.00e+00 | 0.07880 | -1.56e-02 | -3.65e-02 | 4.13e-02 | -2.02e-02 | 5.02e-02 | 8.89e-01 | 7.43e-01 | 7.10e-01 | 8.56e-01 | 6.51e-01 |
| POSITIVE REGULATION OF MONOATOMIC ION TRANSMEMBRANE TRANSPORT | 149 | 6.54e-01 | 1.00e+00 | 0.07870 | 2.95e-03 | 9.33e-03 | -4.93e-03 | -5.87e-03 | -7.77e-02 | 9.50e-01 | 8.44e-01 | 9.17e-01 | 9.02e-01 | 1.01e-01 |
| RESPONSE TO OSMOTIC STRESS | 79 | 7.65e-01 | 1.00e+00 | 0.07870 | -8.07e-03 | -1.99e-02 | 4.48e-02 | -3.30e-02 | 5.13e-02 | 9.01e-01 | 7.60e-01 | 4.92e-01 | 6.12e-01 | 4.30e-01 |
| APPENDAGE DEVELOPMENT | 177 | 8.21e-02 | 4.71e-01 | 0.07860 | 3.86e-03 | -6.96e-03 | 6.45e-02 | -4.19e-02 | 1.39e-02 | 9.29e-01 | 8.73e-01 | 1.39e-01 | 3.36e-01 | 7.50e-01 |
| RESPIRATORY GASEOUS EXCHANGE BY RESPIRATORY SYSTEM | 70 | 5.17e-01 | 9.52e-01 | 0.07850 | 3.33e-02 | 5.39e-03 | 4.58e-02 | 4.55e-02 | 2.92e-02 | 6.30e-01 | 9.38e-01 | 5.07e-01 | 5.10e-01 | 6.73e-01 |
| MEMBRANE FUSION | 174 | 5.65e-01 | 9.71e-01 | 0.07840 | -4.12e-03 | -1.30e-02 | 3.11e-02 | -3.12e-02 | 6.34e-02 | 9.25e-01 | 7.68e-01 | 4.79e-01 | 4.77e-01 | 1.49e-01 |
| CELL DIFFERENTIATION IN HINDBRAIN | 21 | 9.55e-01 | 1.00e+00 | 0.07830 | 1.31e-02 | 3.62e-03 | 4.93e-02 | -2.78e-02 | -5.23e-02 | 9.17e-01 | 9.77e-01 | 6.96e-01 | 8.26e-01 | 6.78e-01 |
| NEGATIVE REGULATION OF ENDOTHELIAL CELL APOPTOTIC PROCESS | 37 | 4.98e-01 | 9.47e-01 | 0.07820 | -4.23e-02 | -4.49e-02 | -2.52e-02 | 3.53e-03 | -4.07e-02 | 6.56e-01 | 6.36e-01 | 7.91e-01 | 9.70e-01 | 6.68e-01 |
| RECEPTOR LOCALIZATION TO SYNAPSE | 57 | 5.00e-01 | 9.47e-01 | 0.07820 | -1.67e-02 | -3.31e-03 | 2.52e-02 | -3.86e-02 | 6.08e-02 | 8.28e-01 | 9.66e-01 | 7.42e-01 | 6.15e-01 | 4.27e-01 |
| POSITIVE REGULATION OF PHOSPHOLIPASE ACTIVITY | 48 | 7.28e-01 | 1.00e+00 | 0.07820 | -7.40e-03 | -1.21e-02 | -3.28e-02 | 4.23e-02 | -5.52e-02 | 9.29e-01 | 8.85e-01 | 6.94e-01 | 6.12e-01 | 5.08e-01 |
| POSITIVE REGULATION OF HORMONE SECRETION | 139 | 3.73e-01 | 8.82e-01 | 0.07820 | 7.59e-03 | 1.06e-02 | 2.28e-02 | -1.97e-02 | -7.10e-02 | 8.77e-01 | 8.29e-01 | 6.42e-01 | 6.89e-01 | 1.49e-01 |
| RESPONSE TO TUMOR NECROSIS FACTOR | 248 | 2.76e-01 | 8.03e-01 | 0.07810 | -3.36e-02 | -4.17e-02 | -2.94e-03 | -1.92e-02 | 5.35e-02 | 3.63e-01 | 2.58e-01 | 9.36e-01 | 6.03e-01 | 1.47e-01 |
| REGULATION OF GLYCOPROTEIN METABOLIC PROCESS | 58 | 8.48e-01 | 1.00e+00 | 0.07810 | 2.95e-02 | 2.43e-02 | 5.71e-02 | -1.09e-02 | -3.54e-02 | 6.98e-01 | 7.49e-01 | 4.52e-01 | 8.86e-01 | 6.41e-01 |
| REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 215 | 2.06e-01 | 7.27e-01 | 0.07810 | -1.30e-03 | -4.21e-03 | 3.89e-02 | -4.34e-02 | 5.18e-02 | 9.74e-01 | 9.15e-01 | 3.25e-01 | 2.73e-01 | 1.91e-01 |
| REGULATION OF CD8 POSITIVE ALPHA BETA T CELL ACTIVATION | 21 | 9.81e-01 | 1.00e+00 | 0.07800 | 1.30e-02 | 3.14e-02 | -1.73e-02 | -1.35e-03 | -6.81e-02 | 9.18e-01 | 8.03e-01 | 8.91e-01 | 9.91e-01 | 5.89e-01 |
| PYRIMIDINE CONTAINING COMPOUND METABOLIC PROCESS | 85 | 9.38e-01 | 1.00e+00 | 0.07800 | 3.24e-02 | 2.70e-02 | 5.82e-02 | 6.95e-03 | 2.97e-02 | 6.06e-01 | 6.67e-01 | 3.54e-01 | 9.12e-01 | 6.36e-01 |
| REGULATION OF CATION CHANNEL ACTIVITY | 115 | 9.66e-01 | 1.00e+00 | 0.07800 | 3.88e-02 | 3.88e-02 | 2.21e-02 | 5.01e-02 | -8.44e-03 | 4.73e-01 | 4.72e-01 | 6.82e-01 | 3.53e-01 | 8.76e-01 |
| REGULATION OF T CELL APOPTOTIC PROCESS | 39 | 9.82e-01 | 1.00e+00 | 0.07780 | -2.52e-02 | -2.35e-02 | -8.71e-03 | -2.80e-02 | 6.33e-02 | 7.85e-01 | 8.00e-01 | 9.25e-01 | 7.62e-01 | 4.94e-01 |
| THIOESTER BIOSYNTHETIC PROCESS | 43 | 8.89e-01 | 1.00e+00 | 0.07770 | 3.26e-02 | 3.62e-02 | 4.46e-02 | 2.98e-02 | -2.81e-02 | 7.11e-01 | 6.82e-01 | 6.13e-01 | 7.35e-01 | 7.50e-01 |
| REGULATION OF SMOOTHENED SIGNALING PATHWAY | 84 | 8.56e-01 | 1.00e+00 | 0.07770 | -2.77e-02 | -4.17e-02 | 1.41e-02 | -5.21e-02 | 2.47e-02 | 6.61e-01 | 5.09e-01 | 8.23e-01 | 4.09e-01 | 6.95e-01 |
| SKELETAL MUSCLE ACETYLCHOLINE GATED CHANNEL CLUSTERING | 10 | 4.97e-01 | 9.47e-01 | 0.07760 | -1.35e-02 | 1.67e-02 | 6.52e-02 | -3.18e-02 | 1.73e-02 | 9.41e-01 | 9.27e-01 | 7.21e-01 | 8.62e-01 | 9.24e-01 |
| NADP METABOLIC PROCESS | 41 | 9.05e-01 | 1.00e+00 | 0.07760 | 3.31e-02 | 2.26e-02 | 4.11e-02 | 4.00e-02 | -3.37e-02 | 7.14e-01 | 8.02e-01 | 6.49e-01 | 6.57e-01 | 7.09e-01 |
| REGULATION OF APOPTOTIC SIGNALING PATHWAY | 381 | 6.12e-03 | 8.87e-02 | 0.07760 | -6.15e-03 | -1.40e-02 | 4.98e-02 | -5.18e-02 | 2.50e-02 | 8.37e-01 | 6.39e-01 | 9.51e-02 | 8.23e-02 | 4.02e-01 |
| AMIDE TRANSPORT | 344 | 6.40e-02 | 4.13e-01 | 0.07760 | 2.52e-02 | 3.62e-02 | 2.35e-02 | 1.11e-02 | -5.83e-02 | 4.21e-01 | 2.49e-01 | 4.54e-01 | 7.24e-01 | 6.31e-02 |
| PROTEIN POLYMERIZATION | 272 | 4.33e-01 | 9.19e-01 | 0.07740 | 3.70e-02 | 4.12e-02 | 4.86e-02 | 2.31e-02 | 5.16e-03 | 2.93e-01 | 2.42e-01 | 1.68e-01 | 5.11e-01 | 8.84e-01 |
| DETECTION OF MECHANICAL STIMULUS INVOLVED IN SENSORY PERCEPTION | 35 | 8.50e-01 | 1.00e+00 | 0.07740 | -3.72e-03 | -8.60e-03 | -2.83e-03 | 1.51e-02 | -7.52e-02 | 9.70e-01 | 9.30e-01 | 9.77e-01 | 8.77e-01 | 4.41e-01 |
| REGULATION OF CIRCADIAN RHYTHM | 110 | 8.32e-01 | 1.00e+00 | 0.07710 | 3.04e-02 | 3.06e-02 | 5.36e-02 | 1.44e-02 | 3.17e-02 | 5.81e-01 | 5.80e-01 | 3.32e-01 | 7.95e-01 | 5.66e-01 |
| ANTIVIRAL INNATE IMMUNE RESPONSE | 48 | 3.63e-01 | 8.78e-01 | 0.07710 | -2.52e-03 | 1.86e-02 | 3.56e-02 | -5.37e-02 | 3.79e-02 | 9.76e-01 | 8.23e-01 | 6.69e-01 | 5.20e-01 | 6.50e-01 |
| LOCOMOTORY EXPLORATION BEHAVIOR | 14 | 9.53e-01 | 1.00e+00 | 0.07700 | -2.01e-02 | 1.22e-02 | -6.85e-02 | 2.30e-02 | -1.20e-02 | 8.96e-01 | 9.37e-01 | 6.57e-01 | 8.81e-01 | 9.38e-01 |
| PURINE NUCLEOBASE BIOSYNTHETIC PROCESS | 9 | 9.91e-01 | 1.00e+00 | 0.07700 | -1.84e-02 | -2.11e-02 | 1.73e-03 | -6.89e-02 | 1.99e-02 | 9.24e-01 | 9.13e-01 | 9.93e-01 | 7.21e-01 | 9.18e-01 |
| POSITIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 32 | 9.84e-01 | 1.00e+00 | 0.07700 | 1.33e-02 | -2.59e-03 | 4.08e-02 | 1.16e-02 | 6.27e-02 | 8.96e-01 | 9.80e-01 | 6.89e-01 | 9.10e-01 | 5.39e-01 |
| VASCULAR ASSOCIATED SMOOTH MUSCLE CELL MIGRATION | 44 | 4.85e-01 | 9.43e-01 | 0.07680 | -2.06e-02 | -2.38e-02 | -3.86e-02 | -5.42e-02 | -2.20e-02 | 8.13e-01 | 7.85e-01 | 6.58e-01 | 5.34e-01 | 8.01e-01 |
| LOCOMOTORY BEHAVIOR | 198 | 7.41e-01 | 1.00e+00 | 0.07670 | 3.57e-02 | 3.43e-02 | 5.26e-02 | 7.96e-03 | 2.46e-02 | 3.86e-01 | 4.06e-01 | 2.02e-01 | 8.47e-01 | 5.50e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 107 | 7.19e-01 | 1.00e+00 | 0.07670 | 3.23e-02 | 2.66e-02 | 3.20e-02 | 2.07e-03 | -5.57e-02 | 5.63e-01 | 6.35e-01 | 5.67e-01 | 9.71e-01 | 3.20e-01 |
| PROTEIN LOCALIZATION TO POSTSYNAPSE | 40 | 9.03e-01 | 1.00e+00 | 0.07660 | 1.57e-02 | 2.52e-02 | 3.70e-02 | 3.78e-03 | 6.01e-02 | 8.64e-01 | 7.83e-01 | 6.86e-01 | 9.67e-01 | 5.11e-01 |
| PROTEIN HETEROOLIGOMERIZATION | 28 | 9.70e-01 | 1.00e+00 | 0.07660 | -4.14e-02 | -3.20e-02 | -5.27e-02 | 1.95e-03 | 1.86e-02 | 7.05e-01 | 7.69e-01 | 6.29e-01 | 9.86e-01 | 8.65e-01 |
| POSITIVE REGULATION OF LOCOMOTION | 589 | 4.64e-02 | 3.49e-01 | 0.07640 | -3.59e-02 | -3.76e-02 | -1.62e-02 | -4.01e-02 | -3.56e-02 | 1.37e-01 | 1.18e-01 | 5.01e-01 | 9.60e-02 | 1.40e-01 |
| POSITIVE REGULATION OF RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 34 | 9.32e-01 | 1.00e+00 | 0.07640 | 2.03e-02 | 9.00e-03 | 2.12e-02 | 5.62e-02 | 4.17e-02 | 8.38e-01 | 9.28e-01 | 8.31e-01 | 5.71e-01 | 6.74e-01 |
| POSITIVE REGULATION OF PROTEIN DEPOLYMERIZATION | 19 | 9.07e-01 | 1.00e+00 | 0.07630 | 3.21e-02 | 4.78e-02 | 3.13e-02 | -2.84e-02 | -2.67e-02 | 8.09e-01 | 7.18e-01 | 8.13e-01 | 8.30e-01 | 8.40e-01 |
| REGULATION OF GLUCOSE TRANSMEMBRANE TRANSPORT | 76 | 7.23e-01 | 1.00e+00 | 0.07620 | -2.40e-02 | -1.60e-02 | 7.39e-03 | -5.08e-02 | 4.83e-02 | 7.17e-01 | 8.10e-01 | 9.11e-01 | 4.44e-01 | 4.66e-01 |
| FOCAL ADHESION ASSEMBLY | 83 | 6.64e-01 | 1.00e+00 | 0.07620 | 1.08e-02 | 1.52e-02 | -1.81e-02 | 5.97e-02 | 3.95e-02 | 8.64e-01 | 8.11e-01 | 7.75e-01 | 3.47e-01 | 5.33e-01 |
| NEGATIVE REGULATION OF PROTEIN LOCALIZATION | 208 | 3.75e-01 | 8.83e-01 | 0.07610 | -4.53e-03 | -2.04e-02 | 3.73e-02 | -3.26e-02 | 5.38e-02 | 9.10e-01 | 6.12e-01 | 3.54e-01 | 4.17e-01 | 1.81e-01 |
| REGULATION OF CELLULAR CATABOLIC PROCESS | 686 | 1.06e-02 | 1.31e-01 | 0.07600 | 1.42e-02 | 9.03e-03 | 5.16e-02 | -8.95e-03 | 5.24e-02 | 5.25e-01 | 6.87e-01 | 2.11e-02 | 6.89e-01 | 1.93e-02 |
| ERK1 AND ERK2 CASCADE | 335 | 2.34e-01 | 7.56e-01 | 0.07600 | -3.70e-02 | -4.02e-02 | -7.40e-03 | -2.87e-02 | 4.36e-02 | 2.45e-01 | 2.06e-01 | 8.16e-01 | 3.66e-01 | 1.70e-01 |
| BILE ACID SECRETION | 12 | 9.95e-01 | 1.00e+00 | 0.07560 | -5.47e-03 | -3.51e-03 | -4.23e-02 | 3.78e-02 | -4.96e-02 | 9.74e-01 | 9.83e-01 | 8.00e-01 | 8.20e-01 | 7.66e-01 |
| REACTIVE NITROGEN SPECIES METABOLIC PROCESS | 76 | 6.13e-01 | 9.90e-01 | 0.07540 | -4.03e-02 | -3.62e-02 | -5.20e-03 | -4.79e-02 | -2.05e-02 | 5.43e-01 | 5.85e-01 | 9.38e-01 | 4.70e-01 | 7.58e-01 |
| CALCIUM ION TRANSPORT INTO CYTOSOL | 28 | 8.42e-01 | 1.00e+00 | 0.07540 | -4.18e-02 | -3.74e-02 | 1.94e-03 | -4.78e-02 | -1.56e-02 | 7.02e-01 | 7.32e-01 | 9.86e-01 | 6.61e-01 | 8.87e-01 |
| RETINOIC ACID RECEPTOR SIGNALING PATHWAY | 32 | 9.18e-01 | 1.00e+00 | 0.07530 | -1.30e-02 | -8.23e-03 | 1.80e-02 | -5.39e-02 | -4.70e-02 | 8.99e-01 | 9.36e-01 | 8.60e-01 | 5.98e-01 | 6.45e-01 |
| RECEPTOR INTERNALIZATION | 123 | 4.52e-01 | 9.30e-01 | 0.07530 | -1.45e-02 | -2.68e-02 | 4.11e-02 | -3.71e-02 | 4.10e-02 | 7.81e-01 | 6.08e-01 | 4.31e-01 | 4.78e-01 | 4.33e-01 |
| NEGATIVE REGULATION OF HYDROLASE ACTIVITY | 204 | 7.26e-01 | 1.00e+00 | 0.07530 | -3.04e-02 | -3.43e-02 | 2.49e-03 | -4.63e-02 | 3.77e-02 | 4.54e-01 | 3.98e-01 | 9.51e-01 | 2.55e-01 | 3.54e-01 |
| ENDOSOME TO PLASMA MEMBRANE PROTEIN TRANSPORT | 15 | 9.78e-01 | 1.00e+00 | 0.07520 | 2.01e-02 | 4.13e-03 | 4.74e-02 | -2.56e-02 | 4.83e-02 | 8.93e-01 | 9.78e-01 | 7.50e-01 | 8.63e-01 | 7.46e-01 |
| REGULATION OF INTRACELLULAR TRANSPORT | 321 | 4.05e-01 | 9.06e-01 | 0.07510 | 2.24e-02 | 1.82e-02 | 4.99e-02 | -1.59e-03 | 4.81e-02 | 4.89e-01 | 5.75e-01 | 1.24e-01 | 9.61e-01 | 1.38e-01 |
| REGULATION OF GLUCOSE METABOLIC PROCESS | 99 | 8.66e-01 | 1.00e+00 | 0.07510 | 3.74e-02 | 5.12e-02 | 2.07e-02 | 3.26e-02 | -1.14e-02 | 5.20e-01 | 3.78e-01 | 7.22e-01 | 5.75e-01 | 8.45e-01 |
| TISSUE REMODELING | 179 | 1.84e-01 | 6.93e-01 | 0.07510 | -4.07e-02 | -4.66e-02 | 2.71e-03 | -4.03e-02 | 1.33e-02 | 3.47e-01 | 2.82e-01 | 9.50e-01 | 3.52e-01 | 7.59e-01 |
| REGULATION OF MAP KINASE ACTIVITY | 140 | 5.71e-01 | 9.76e-01 | 0.07510 | 1.14e-03 | -7.02e-03 | 4.61e-02 | -1.72e-02 | 5.63e-02 | 9.81e-01 | 8.86e-01 | 3.47e-01 | 7.26e-01 | 2.50e-01 |
| NEGATIVE REGULATION OF CARBOHYDRATE METABOLIC PROCESS | 54 | 8.42e-01 | 1.00e+00 | 0.07500 | 1.79e-02 | 2.17e-02 | 5.33e-02 | -2.08e-02 | 3.95e-02 | 8.20e-01 | 7.83e-01 | 4.98e-01 | 7.91e-01 | 6.15e-01 |
| REGULATION OF MRNA METABOLIC PROCESS | 339 | 2.70e-01 | 7.97e-01 | 0.07500 | 8.71e-03 | 3.09e-06 | 4.28e-02 | -1.75e-02 | 5.84e-02 | 7.83e-01 | 1.00e+00 | 1.76e-01 | 5.80e-01 | 6.46e-02 |
| REGULATION OF SYNAPTIC TRANSMISSION GLUTAMATERGIC | 75 | 8.42e-01 | 1.00e+00 | 0.07490 | 1.24e-02 | 1.13e-02 | 1.78e-02 | -3.55e-03 | -7.08e-02 | 8.53e-01 | 8.65e-01 | 7.90e-01 | 9.58e-01 | 2.89e-01 |
| NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 558 | 3.98e-03 | 6.49e-02 | 0.07490 | -1.68e-02 | -2.28e-02 | 3.23e-02 | -5.49e-02 | 2.75e-02 | 4.98e-01 | 3.56e-01 | 1.92e-01 | 2.66e-02 | 2.67e-01 |
| POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 126 | 6.96e-01 | 1.00e+00 | 0.07480 | 8.03e-03 | 8.50e-03 | 1.06e-02 | -1.37e-02 | -7.18e-02 | 8.76e-01 | 8.69e-01 | 8.37e-01 | 7.90e-01 | 1.64e-01 |
| PLATELET ACTIVATION | 128 | 2.23e-01 | 7.45e-01 | 0.07470 | -1.30e-02 | -2.71e-02 | 4.89e-02 | -3.86e-02 | 2.81e-02 | 7.99e-01 | 5.96e-01 | 3.39e-01 | 4.51e-01 | 5.83e-01 |
| MAINTENANCE OF PROTEIN LOCATION | 85 | 5.20e-01 | 9.53e-01 | 0.07470 | 1.69e-02 | 2.22e-02 | 5.51e-02 | -3.22e-02 | 2.68e-02 | 7.87e-01 | 7.23e-01 | 3.80e-01 | 6.08e-01 | 6.69e-01 |
| NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 193 | 6.44e-01 | 1.00e+00 | 0.07460 | 1.75e-02 | 1.98e-02 | 2.78e-02 | 2.08e-02 | 6.05e-02 | 6.75e-01 | 6.36e-01 | 5.05e-01 | 6.18e-01 | 1.47e-01 |
| REGULATION OF ENDOTHELIAL CELL MIGRATION | 220 | 5.25e-01 | 9.54e-01 | 0.07450 | -1.25e-02 | 1.35e-03 | -3.13e-02 | -1.73e-02 | -6.42e-02 | 7.49e-01 | 9.73e-01 | 4.24e-01 | 6.58e-01 | 1.01e-01 |
| CELL CELL RECOGNITION | 72 | 9.56e-01 | 1.00e+00 | 0.07450 | 3.33e-02 | 4.24e-02 | 1.59e-02 | 4.44e-02 | 2.03e-02 | 6.25e-01 | 5.34e-01 | 8.16e-01 | 5.15e-01 | 7.66e-01 |
| NEUROTRANSMITTER RECEPTOR INTERNALIZATION | 30 | 9.25e-01 | 1.00e+00 | 0.07450 | -1.37e-02 | -7.27e-03 | 2.30e-02 | -2.32e-02 | 6.51e-02 | 8.96e-01 | 9.45e-01 | 8.27e-01 | 8.26e-01 | 5.37e-01 |
| CYCLIC NUCLEOTIDE MEDIATED SIGNALING | 80 | 7.88e-01 | 1.00e+00 | 0.07440 | -2.11e-02 | 2.63e-04 | -5.27e-02 | -5.55e-04 | -4.81e-02 | 7.44e-01 | 9.97e-01 | 4.15e-01 | 9.93e-01 | 4.57e-01 |
| RENAL SYSTEM PROCESS | 117 | 7.93e-02 | 4.63e-01 | 0.07430 | 2.20e-03 | 2.83e-03 | 1.59e-02 | 4.82e-02 | 5.42e-02 | 9.67e-01 | 9.58e-01 | 7.67e-01 | 3.67e-01 | 3.12e-01 |
| REGULATION OF TRIGLYCERIDE METABOLIC PROCESS | 43 | 8.56e-01 | 1.00e+00 | 0.07430 | 2.19e-02 | 4.20e-02 | -1.27e-02 | 4.99e-02 | 2.50e-02 | 8.04e-01 | 6.34e-01 | 8.86e-01 | 5.71e-01 | 7.76e-01 |
| GLUCAN BIOSYNTHETIC PROCESS | 44 | 4.60e-01 | 9.32e-01 | 0.07410 | 9.83e-03 | 2.86e-02 | 4.38e-02 | -3.74e-02 | -3.55e-02 | 9.10e-01 | 7.43e-01 | 6.16e-01 | 6.68e-01 | 6.83e-01 |
| PROTEIN COMPLEX OLIGOMERIZATION | 249 | 1.29e-01 | 5.96e-01 | 0.07390 | 2.67e-02 | 2.71e-02 | 3.69e-02 | 2.10e-02 | -4.71e-02 | 4.69e-01 | 4.61e-01 | 3.16e-01 | 5.69e-01 | 2.01e-01 |
| REGULATION OF RESPONSE TO WOUNDING | 166 | 5.30e-01 | 9.54e-01 | 0.07380 | -2.12e-03 | 1.36e-02 | -4.36e-02 | 2.69e-02 | -5.12e-02 | 9.62e-01 | 7.63e-01 | 3.32e-01 | 5.49e-01 | 2.55e-01 |
| LOCALIZATION WITHIN MEMBRANE | 657 | 8.09e-02 | 4.68e-01 | 0.07370 | 2.90e-02 | 3.05e-02 | 4.50e-02 | 2.04e-02 | 3.50e-02 | 2.05e-01 | 1.83e-01 | 4.91e-02 | 3.73e-01 | 1.26e-01 |
| TISSUE MORPHOGENESIS | 620 | 8.87e-02 | 4.92e-01 | 0.07370 | 3.53e-02 | 3.05e-02 | 5.25e-02 | 2.22e-02 | -2.35e-03 | 1.34e-01 | 1.95e-01 | 2.55e-02 | 3.45e-01 | 9.20e-01 |
| POLYSACCHARIDE METABOLIC PROCESS | 96 | 2.12e-01 | 7.34e-01 | 0.07370 | 1.26e-02 | 4.13e-02 | -5.45e-04 | 2.39e-03 | -5.97e-02 | 8.31e-01 | 4.85e-01 | 9.93e-01 | 9.68e-01 | 3.12e-01 |
| NEGATIVE REGULATION OF GENE EXPRESSION | 1479 | 3.46e-02 | 2.96e-01 | 0.07360 | -3.65e-02 | -3.21e-02 | -2.78e-02 | -4.73e-02 | -7.06e-03 | 1.86e-02 | 3.90e-02 | 7.32e-02 | 2.34e-03 | 6.50e-01 |
| INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 31 | 8.69e-01 | 1.00e+00 | 0.07350 | 1.36e-02 | 3.68e-02 | -2.22e-02 | -8.33e-03 | -5.74e-02 | 8.96e-01 | 7.23e-01 | 8.30e-01 | 9.36e-01 | 5.80e-01 |
| PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION | 778 | 1.99e-02 | 2.07e-01 | 0.07340 | 2.04e-02 | 1.12e-02 | 5.50e-02 | -2.68e-03 | 4.27e-02 | 3.33e-01 | 5.96e-01 | 9.09e-03 | 8.99e-01 | 4.26e-02 |
| HOMEOSTASIS OF NUMBER OF CELLS | 299 | 2.39e-01 | 7.63e-01 | 0.07340 | -2.05e-02 | -3.38e-02 | 2.37e-02 | -3.57e-02 | 4.47e-02 | 5.41e-01 | 3.15e-01 | 4.81e-01 | 2.89e-01 | 1.84e-01 |
| NEGATIVE REGULATION OF PROGRAMMED NECROTIC CELL DEATH | 21 | 8.06e-01 | 1.00e+00 | 0.07340 | 4.66e-03 | 5.36e-03 | -2.60e-02 | -3.44e-02 | -5.89e-02 | 9.71e-01 | 9.66e-01 | 8.36e-01 | 7.85e-01 | 6.40e-01 |
| NEGATIVE REGULATION OF ION TRANSMEMBRANE TRANSPORTER ACTIVITY | 69 | 8.44e-01 | 1.00e+00 | 0.07340 | 2.89e-02 | 2.77e-02 | -8.02e-03 | 6.00e-02 | 1.09e-02 | 6.78e-01 | 6.91e-01 | 9.08e-01 | 3.89e-01 | 8.76e-01 |
| MATING BEHAVIOR | 36 | 5.16e-01 | 9.52e-01 | 0.07330 | 1.51e-02 | 5.60e-02 | -2.94e-02 | 3.21e-02 | -1.10e-02 | 8.75e-01 | 5.61e-01 | 7.60e-01 | 7.39e-01 | 9.09e-01 |
| CARDIAC MUSCLE TISSUE MORPHOGENESIS | 61 | 7.42e-01 | 1.00e+00 | 0.07330 | -4.71e-03 | -1.69e-02 | 3.28e-02 | -4.90e-02 | -3.99e-02 | 9.49e-01 | 8.19e-01 | 6.58e-01 | 5.08e-01 | 5.90e-01 |
| ORGANIC ACID BIOSYNTHETIC PROCESS | 321 | 5.72e-01 | 9.76e-01 | 0.07320 | 3.51e-02 | 3.32e-02 | 3.67e-02 | 2.46e-02 | -3.28e-02 | 2.80e-01 | 3.07e-01 | 2.59e-01 | 4.49e-01 | 3.12e-01 |
| RESPONSE TO PEPTIDE | 502 | 4.09e-02 | 3.25e-01 | 0.07320 | 2.82e-02 | 2.07e-02 | 6.26e-02 | -5.51e-04 | 1.44e-02 | 2.80e-01 | 4.27e-01 | 1.62e-02 | 9.83e-01 | 5.81e-01 |
| POLYADENYLATION DEPENDENT RNA CATABOLIC PROCESS | 8 | 9.99e-01 | 1.00e+00 | 0.07310 | 1.33e-02 | 1.40e-02 | 3.09e-02 | -1.21e-02 | 6.22e-02 | 9.48e-01 | 9.45e-01 | 8.80e-01 | 9.53e-01 | 7.61e-01 |
| REGULATION OF MONOATOMIC ANION TRANSPORT | 16 | 9.70e-01 | 1.00e+00 | 0.07310 | 8.35e-03 | 1.46e-02 | -3.60e-02 | 4.49e-04 | -6.14e-02 | 9.54e-01 | 9.20e-01 | 8.03e-01 | 9.98e-01 | 6.71e-01 |
| FATTY ACID TRANSPORT | 115 | 7.44e-01 | 1.00e+00 | 0.07310 | 3.33e-02 | 3.29e-02 | 4.41e-02 | 3.34e-02 | -9.38e-03 | 5.37e-01 | 5.42e-01 | 4.14e-01 | 5.36e-01 | 8.62e-01 |
| REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 32 | 9.34e-01 | 1.00e+00 | 0.07310 | -1.15e-02 | -8.87e-03 | 1.38e-02 | -5.16e-02 | 4.77e-02 | 9.10e-01 | 9.31e-01 | 8.93e-01 | 6.13e-01 | 6.41e-01 |
| REGULATION OF PROTEIN TARGETING TO MEMBRANE | 32 | 9.75e-01 | 1.00e+00 | 0.07300 | 7.17e-03 | -8.96e-04 | 1.97e-02 | 3.07e-02 | 6.28e-02 | 9.44e-01 | 9.93e-01 | 8.47e-01 | 7.64e-01 | 5.39e-01 |
| POSITIVE REGULATION OF GENE EXPRESSION | 1130 | 3.48e-06 | 1.84e-04 | 0.07290 | -1.18e-02 | -2.37e-02 | 3.91e-02 | -4.69e-02 | 2.99e-02 | 5.02e-01 | 1.79e-01 | 2.65e-02 | 7.83e-03 | 9.03e-02 |
| RECEPTOR MEDIATED ENDOCYTOSIS | 254 | 6.11e-01 | 9.90e-01 | 0.07280 | -3.06e-02 | -4.14e-02 | 2.08e-03 | -4.48e-02 | 2.55e-02 | 4.01e-01 | 2.56e-01 | 9.55e-01 | 2.19e-01 | 4.84e-01 |
| PROTEIN MODIFICATION BY SMALL PROTEIN REMOVAL | 107 | 6.21e-01 | 9.90e-01 | 0.07280 | -8.76e-03 | -1.51e-02 | 1.64e-02 | -4.58e-02 | -5.12e-02 | 8.76e-01 | 7.88e-01 | 7.69e-01 | 4.13e-01 | 3.60e-01 |
| CELLULAR RESPONSE TO LIPID | 592 | 7.55e-02 | 4.51e-01 | 0.07270 | 2.79e-02 | 1.50e-02 | 5.73e-02 | 1.03e-02 | 3.00e-02 | 2.46e-01 | 5.34e-01 | 1.73e-02 | 6.69e-01 | 2.13e-01 |
| MAINTENANCE OF GASTROINTESTINAL EPITHELIUM | 23 | 8.24e-01 | 1.00e+00 | 0.07260 | 2.06e-02 | 5.15e-02 | 3.05e-03 | 2.41e-02 | 4.01e-02 | 8.64e-01 | 6.69e-01 | 9.80e-01 | 8.41e-01 | 7.39e-01 |
| NEGATIVE REGULATION OF TRANSMEMBRANE TRANSPORT | 138 | 9.41e-01 | 1.00e+00 | 0.07240 | 3.22e-02 | 3.18e-02 | 3.21e-02 | 4.00e-02 | 2.39e-02 | 5.14e-01 | 5.19e-01 | 5.15e-01 | 4.17e-01 | 6.28e-01 |
| ARF PROTEIN SIGNAL TRANSDUCTION | 21 | 9.95e-01 | 1.00e+00 | 0.07240 | -2.09e-02 | -1.84e-02 | -5.16e-02 | 9.43e-03 | -4.14e-02 | 8.68e-01 | 8.84e-01 | 6.82e-01 | 9.40e-01 | 7.43e-01 |
| RIBOSE PHOSPHATE METABOLIC PROCESS | 361 | 4.68e-01 | 9.36e-01 | 0.07240 | 3.53e-02 | 3.18e-02 | 5.38e-02 | 8.14e-03 | 5.43e-03 | 2.49e-01 | 3.00e-01 | 7.93e-02 | 7.90e-01 | 8.59e-01 |
| POSITIVE REGULATION OF MAPK CASCADE | 467 | 3.40e-01 | 8.59e-01 | 0.07220 | -4.17e-02 | -4.16e-02 | -2.43e-02 | -3.40e-02 | 2.85e-04 | 1.23e-01 | 1.23e-01 | 3.68e-01 | 2.08e-01 | 9.92e-01 |
| THYMOCYTE APOPTOTIC PROCESS | 20 | 9.98e-01 | 1.00e+00 | 0.07210 | -3.20e-02 | -3.10e-02 | -2.59e-02 | -3.55e-02 | 3.58e-02 | 8.04e-01 | 8.11e-01 | 8.41e-01 | 7.83e-01 | 7.81e-01 |
| LAMELLIPODIUM ASSEMBLY | 67 | 7.15e-01 | 1.00e+00 | 0.07210 | -1.33e-02 | -7.41e-04 | -6.11e-02 | 3.55e-02 | 4.64e-03 | 8.50e-01 | 9.92e-01 | 3.87e-01 | 6.15e-01 | 9.48e-01 |
| PEPTIDYL AMINO ACID MODIFICATION | 893 | 2.77e-03 | 4.95e-02 | 0.07200 | -1.76e-02 | -2.24e-02 | 2.34e-02 | -4.04e-02 | 4.69e-02 | 3.71e-01 | 2.55e-01 | 2.35e-01 | 4.06e-02 | 1.74e-02 |
| XENOBIOTIC TRANSPORT | 59 | 4.77e-01 | 9.40e-01 | 0.07200 | 7.10e-03 | 2.35e-02 | -1.57e-02 | 5.38e-02 | -3.79e-02 | 9.25e-01 | 7.54e-01 | 8.35e-01 | 4.74e-01 | 6.15e-01 |
| ICOSANOID METABOLIC PROCESS | 118 | 5.78e-01 | 9.82e-01 | 0.07200 | -6.76e-03 | 3.27e-03 | -3.24e-02 | 2.73e-02 | -5.78e-02 | 8.99e-01 | 9.51e-01 | 5.43e-01 | 6.09e-01 | 2.78e-01 |
| CELLULAR RESPONSE TO LIGHT STIMULUS | 114 | 8.12e-01 | 1.00e+00 | 0.07190 | 4.18e-02 | 4.66e-02 | 2.53e-02 | 2.45e-02 | 3.60e-03 | 4.41e-01 | 3.90e-01 | 6.40e-01 | 6.51e-01 | 9.47e-01 |
| TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 225 | 7.87e-02 | 4.62e-01 | 0.07190 | -9.79e-03 | -3.04e-02 | 4.16e-02 | -1.83e-02 | 4.57e-02 | 8.00e-01 | 4.33e-01 | 2.83e-01 | 6.37e-01 | 2.38e-01 |
| NEGATIVE REGULATION OF ORGANELLE ORGANIZATION | 337 | 9.12e-02 | 4.98e-01 | 0.07180 | 1.83e-02 | 2.09e-02 | 4.98e-02 | -8.84e-03 | 4.27e-02 | 5.63e-01 | 5.10e-01 | 1.16e-01 | 7.80e-01 | 1.78e-01 |
| REGULATION OF LOCOMOTION | 1082 | 6.99e-02 | 4.35e-01 | 0.07180 | -3.69e-02 | -3.29e-02 | -2.86e-02 | -3.49e-02 | -2.60e-02 | 4.05e-02 | 6.73e-02 | 1.12e-01 | 5.23e-02 | 1.49e-01 |
| MESENCHYMAL CELL DIFFERENTIATION | 256 | 1.93e-01 | 7.04e-01 | 0.07170 | 2.78e-02 | 1.77e-02 | 6.32e-02 | -6.33e-03 | -4.73e-03 | 4.44e-01 | 6.25e-01 | 8.14e-02 | 8.62e-01 | 8.96e-01 |
| POSITIVE REGULATION OF LIPID METABOLIC PROCESS | 139 | 1.16e-01 | 5.66e-01 | 0.07170 | 1.89e-02 | 2.15e-02 | 4.96e-02 | 2.53e-02 | 3.51e-02 | 7.01e-01 | 6.61e-01 | 3.13e-01 | 6.07e-01 | 4.75e-01 |
| HETEROCYCLE CATABOLIC PROCESS | 518 | 3.49e-02 | 2.96e-01 | 0.07170 | -2.40e-02 | -2.56e-02 | 1.67e-02 | -4.83e-02 | 3.60e-02 | 3.49e-01 | 3.18e-01 | 5.14e-01 | 5.97e-02 | 1.61e-01 |
| OUTER DYNEIN ARM ASSEMBLY | 23 | 9.79e-01 | 1.00e+00 | 0.07170 | -3.01e-02 | -2.39e-02 | -2.70e-02 | -1.40e-02 | -5.23e-02 | 8.03e-01 | 8.43e-01 | 8.23e-01 | 9.08e-01 | 6.64e-01 |
| POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 335 | 6.02e-01 | 9.90e-01 | 0.07150 | -4.02e-02 | -3.39e-02 | -4.52e-02 | -1.73e-02 | 3.20e-03 | 2.06e-01 | 2.86e-01 | 1.55e-01 | 5.86e-01 | 9.20e-01 |
| GERM CELL DEVELOPMENT | 345 | 1.07e-01 | 5.42e-01 | 0.07150 | -1.79e-02 | -2.23e-02 | -4.30e-02 | -4.34e-04 | -4.93e-02 | 5.67e-01 | 4.76e-01 | 1.70e-01 | 9.89e-01 | 1.15e-01 |
| ESTABLISHMENT OF PROTEIN LOCALIZATION | 1622 | 4.13e-07 | 3.08e-05 | 0.07130 | 1.69e-02 | 9.47e-03 | 5.77e-02 | -1.81e-02 | 3.24e-02 | 2.58e-01 | 5.25e-01 | 1.06e-04 | 2.25e-01 | 2.94e-02 |
| REGULATION OF PROTEIN SECRETION | 261 | 2.15e-02 | 2.17e-01 | 0.07120 | -1.18e-02 | -5.11e-03 | 1.73e-02 | -4.25e-02 | -5.30e-02 | 7.43e-01 | 8.87e-01 | 6.30e-01 | 2.37e-01 | 1.41e-01 |
| REGULATION OF RESPONSE TO STRESS | 1437 | 1.15e-05 | 5.28e-04 | 0.07120 | -1.75e-02 | -2.90e-02 | 2.77e-02 | -4.30e-02 | 3.62e-02 | 2.68e-01 | 6.58e-02 | 7.89e-02 | 6.33e-03 | 2.16e-02 |
| HORMONE TRANSPORT | 311 | 5.15e-02 | 3.72e-01 | 0.07110 | 2.81e-02 | 3.31e-02 | 4.72e-02 | 5.74e-03 | -3.02e-02 | 3.94e-01 | 3.16e-01 | 1.52e-01 | 8.62e-01 | 3.60e-01 |
| ERBB SIGNALING PATHWAY | 123 | 6.37e-01 | 9.98e-01 | 0.07110 | -2.32e-02 | -7.01e-03 | -6.22e-02 | 1.16e-02 | -2.17e-02 | 6.57e-01 | 8.93e-01 | 2.34e-01 | 8.24e-01 | 6.78e-01 |
| MRNA CATABOLIC PROCESS | 295 | 4.62e-01 | 9.33e-01 | 0.07090 | -6.25e-03 | -1.21e-02 | 2.47e-02 | -2.33e-02 | 6.08e-02 | 8.53e-01 | 7.21e-01 | 4.65e-01 | 4.91e-01 | 7.26e-02 |
| POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 1310 | 2.83e-04 | 8.29e-03 | 0.07090 | 3.17e-02 | 3.07e-02 | 4.56e-02 | 6.19e-03 | -3.11e-02 | 5.42e-02 | 6.17e-02 | 5.60e-03 | 7.07e-01 | 5.82e-02 |
| POSITIVE REGULATION OF PROTEIN KINASE ACTIVITY | 274 | 5.19e-01 | 9.53e-01 | 0.07090 | -3.23e-02 | -3.23e-02 | -1.01e-03 | -5.16e-02 | 1.67e-02 | 3.58e-01 | 3.58e-01 | 9.77e-01 | 1.41e-01 | 6.34e-01 |
| REGULATION OF EXOCYTOSIS | 178 | 4.57e-01 | 9.32e-01 | 0.07090 | 2.91e-02 | 2.17e-02 | 5.77e-02 | -7.69e-03 | -1.77e-02 | 5.03e-01 | 6.18e-01 | 1.84e-01 | 8.59e-01 | 6.84e-01 |
| REGULATION OF CARBOHYDRATE METABOLIC PROCESS | 181 | 3.66e-01 | 8.79e-01 | 0.07080 | 2.75e-02 | 3.97e-02 | 2.70e-02 | 1.59e-02 | -4.12e-02 | 5.24e-01 | 3.57e-01 | 5.31e-01 | 7.12e-01 | 3.39e-01 |
| ADENYLATE CYCLASE ACTIVATING DOPAMINE RECEPTOR SIGNALING PATHWAY | 9 | 9.84e-01 | 1.00e+00 | 0.07070 | 2.98e-02 | 5.52e-02 | 1.92e-02 | 7.64e-03 | 2.51e-02 | 8.77e-01 | 7.74e-01 | 9.21e-01 | 9.68e-01 | 8.96e-01 |
| ENDOCHONDRAL BONE MORPHOGENESIS | 59 | 2.52e-01 | 7.78e-01 | 0.07050 | 1.70e-02 | 3.96e-02 | 4.70e-02 | -2.67e-02 | -1.38e-02 | 8.21e-01 | 5.99e-01 | 5.32e-01 | 7.23e-01 | 8.55e-01 |
| CARBOHYDRATE BIOSYNTHETIC PROCESS | 206 | 8.39e-01 | 1.00e+00 | 0.07030 | 3.58e-02 | 4.22e-02 | 3.14e-02 | 2.38e-02 | -1.82e-02 | 3.75e-01 | 2.97e-01 | 4.38e-01 | 5.57e-01 | 6.53e-01 |
| REGULATION OF VASCULATURE DEVELOPMENT | 337 | 2.43e-01 | 7.69e-01 | 0.07020 | 2.63e-02 | 2.87e-02 | 3.20e-02 | -2.18e-03 | -4.88e-02 | 4.07e-01 | 3.65e-01 | 3.12e-01 | 9.45e-01 | 1.24e-01 |
| NEGATIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 134 | 2.82e-01 | 8.09e-01 | 0.07010 | 3.56e-04 | -5.32e-03 | 5.31e-02 | -4.51e-02 | 6.19e-03 | 9.94e-01 | 9.15e-01 | 2.88e-01 | 3.68e-01 | 9.02e-01 |
| RESPONSE TO PEPTIDE HORMONE | 415 | 7.56e-02 | 4.52e-01 | 0.07000 | 2.60e-02 | 1.99e-02 | 6.02e-02 | 8.73e-04 | 1.44e-02 | 3.63e-01 | 4.87e-01 | 3.53e-02 | 9.76e-01 | 6.14e-01 |
| POSITIVE REGULATION OF CELL DIFFERENTIATION | 854 | 1.91e-03 | 3.78e-02 | 0.07000 | 3.02e-02 | 2.61e-02 | 5.34e-02 | 1.71e-03 | -2.14e-02 | 1.34e-01 | 1.96e-01 | 8.00e-03 | 9.32e-01 | 2.88e-01 |
| POSTSYNAPSE ORGANIZATION | 179 | 5.53e-01 | 9.65e-01 | 0.07000 | -4.00e-02 | -3.47e-02 | -1.57e-02 | -4.30e-02 | -1.39e-03 | 3.56e-01 | 4.24e-01 | 7.17e-01 | 3.21e-01 | 9.74e-01 |
| MAPK CASCADE | 746 | 4.01e-02 | 3.22e-01 | 0.06990 | -3.34e-02 | -3.77e-02 | 3.37e-04 | -3.95e-02 | 2.81e-02 | 1.20e-01 | 7.94e-02 | 9.88e-01 | 6.65e-02 | 1.92e-01 |
| MONOCARBOXYLIC ACID METABOLIC PROCESS | 612 | 4.66e-01 | 9.35e-01 | 0.06990 | 3.33e-02 | 3.87e-02 | 1.68e-02 | 4.01e-02 | -1.96e-02 | 1.59e-01 | 1.02e-01 | 4.78e-01 | 9.04e-02 | 4.08e-01 |
| MITOCHONDRION LOCALIZATION | 46 | 9.15e-01 | 1.00e+00 | 0.06980 | 3.80e-03 | 3.52e-03 | 2.37e-02 | -2.84e-02 | -5.90e-02 | 9.64e-01 | 9.67e-01 | 7.81e-01 | 7.39e-01 | 4.89e-01 |
| MONOATOMIC ION HOMEOSTASIS | 581 | 2.09e-02 | 2.15e-01 | 0.06970 | -3.33e-02 | -4.09e-02 | 5.47e-03 | -3.69e-02 | 2.62e-02 | 1.70e-01 | 9.23e-02 | 8.22e-01 | 1.28e-01 | 2.80e-01 |
| ALPHA AMINO ACID METABOLIC PROCESS | 197 | 1.68e-01 | 6.71e-01 | 0.06970 | 3.02e-02 | 4.63e-02 | 1.62e-02 | -2.71e-03 | -3.92e-02 | 4.65e-01 | 2.63e-01 | 6.96e-01 | 9.48e-01 | 3.43e-01 |
| REGULATION OF STEROID METABOLIC PROCESS | 101 | 6.89e-01 | 1.00e+00 | 0.06960 | 2.94e-02 | 4.29e-02 | 2.07e-02 | 3.84e-02 | -1.55e-02 | 6.10e-01 | 4.56e-01 | 7.19e-01 | 5.04e-01 | 7.88e-01 |
| DNA METHYLATION DEPENDENT HETEROCHROMATIN FORMATION | 28 | 9.76e-01 | 1.00e+00 | 0.06960 | 2.78e-02 | 2.98e-02 | 4.35e-02 | -1.62e-02 | -3.21e-02 | 7.99e-01 | 7.85e-01 | 6.91e-01 | 8.82e-01 | 7.69e-01 |
| POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 983 | 7.04e-02 | 4.35e-01 | 0.06950 | -3.86e-02 | -3.53e-02 | -2.22e-02 | -3.96e-02 | -6.00e-03 | 4.02e-02 | 6.09e-02 | 2.39e-01 | 3.55e-02 | 7.50e-01 |
| SENSORY ORGAN MORPHOGENESIS | 272 | 1.17e-01 | 5.69e-01 | 0.06910 | 1.50e-02 | 1.50e-02 | 3.64e-02 | -2.24e-02 | -5.00e-02 | 6.70e-01 | 6.70e-01 | 3.01e-01 | 5.24e-01 | 1.56e-01 |
| RNA DECAPPING | 19 | 9.97e-01 | 1.00e+00 | 0.06910 | 2.89e-02 | 1.76e-02 | 5.79e-02 | 3.35e-03 | 1.67e-02 | 8.28e-01 | 8.94e-01 | 6.62e-01 | 9.80e-01 | 9.00e-01 |
| CIRCULATORY SYSTEM DEVELOPMENT | 1175 | 5.55e-02 | 3.84e-01 | 0.06910 | 3.49e-02 | 3.36e-02 | 4.13e-02 | 2.08e-02 | -1.70e-02 | 4.40e-02 | 5.20e-02 | 1.70e-02 | 2.30e-01 | 3.27e-01 |
| NEGATIVE REGULATION OF BLOOD CIRCULATION | 24 | 7.99e-01 | 1.00e+00 | 0.06900 | 2.19e-02 | 3.24e-02 | 5.34e-02 | 1.29e-02 | -1.50e-02 | 8.53e-01 | 7.84e-01 | 6.51e-01 | 9.13e-01 | 8.99e-01 |
| CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 89 | 6.33e-01 | 9.96e-01 | 0.06890 | 1.77e-02 | 3.05e-02 | -2.78e-02 | 1.62e-02 | -4.96e-02 | 7.72e-01 | 6.19e-01 | 6.50e-01 | 7.92e-01 | 4.19e-01 |
| CIRCADIAN RHYTHM | 196 | 5.39e-01 | 9.58e-01 | 0.06880 | -1.64e-02 | -1.91e-02 | 2.18e-02 | -3.30e-02 | 5.04e-02 | 6.93e-01 | 6.44e-01 | 5.99e-01 | 4.26e-01 | 2.24e-01 |
| CELL SUBSTRATE JUNCTION ORGANIZATION | 100 | 8.33e-01 | 1.00e+00 | 0.06870 | 2.29e-02 | 3.08e-02 | -6.45e-03 | 5.46e-02 | 1.50e-02 | 6.92e-01 | 5.95e-01 | 9.11e-01 | 3.45e-01 | 7.95e-01 |
| REGULATION OF ACTIN FILAMENT ORGANIZATION | 259 | 6.51e-01 | 1.00e+00 | 0.06870 | 3.36e-02 | 4.26e-02 | 2.68e-02 | 3.25e-02 | -2.84e-04 | 3.52e-01 | 2.38e-01 | 4.58e-01 | 3.67e-01 | 9.94e-01 |
| REGULATION OF RELEASE OF SEQUESTERED CALCIUM ION INTO CYTOSOL BY SARCOPLASMIC RETICULUM | 29 | 9.93e-01 | 1.00e+00 | 0.06860 | -3.97e-02 | -4.25e-02 | -2.53e-02 | -1.91e-02 | 1.77e-02 | 7.11e-01 | 6.92e-01 | 8.14e-01 | 8.59e-01 | 8.69e-01 |
| DEOXYRIBONUCLEOSIDE MONOPHOSPHATE METABOLIC PROCESS | 23 | 9.96e-01 | 1.00e+00 | 0.06850 | -2.75e-02 | -3.27e-02 | 9.46e-03 | -3.86e-02 | 3.59e-02 | 8.20e-01 | 7.86e-01 | 9.37e-01 | 7.48e-01 | 7.65e-01 |
| NEGATIVE REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 12 | 9.03e-01 | 1.00e+00 | 0.06850 | -1.28e-02 | 1.04e-02 | 3.13e-02 | -5.20e-02 | 2.72e-02 | 9.39e-01 | 9.50e-01 | 8.51e-01 | 7.55e-01 | 8.70e-01 |
| NEUROTRANSMITTER RECEPTOR LOCALIZATION TO POSTSYNAPTIC SPECIALIZATION MEMBRANE | 22 | 8.97e-01 | 1.00e+00 | 0.06840 | -4.81e-03 | 1.47e-02 | 1.49e-02 | -1.45e-02 | 6.33e-02 | 9.69e-01 | 9.05e-01 | 9.04e-01 | 9.06e-01 | 6.07e-01 |
| REGULATION OF ENDOCRINE PROCESS | 39 | 8.60e-01 | 1.00e+00 | 0.06830 | -2.09e-02 | -3.25e-02 | -7.83e-03 | -5.56e-02 | 3.77e-03 | 8.21e-01 | 7.25e-01 | 9.33e-01 | 5.48e-01 | 9.68e-01 |
| NEGATIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 128 | 6.57e-01 | 1.00e+00 | 0.06810 | 2.06e-02 | 3.93e-03 | 5.47e-02 | -1.27e-02 | 3.23e-02 | 6.87e-01 | 9.39e-01 | 2.85e-01 | 8.04e-01 | 5.28e-01 |
| NEUROTRANSMITTER SECRETION | 138 | 7.29e-01 | 1.00e+00 | 0.06800 | 2.67e-02 | 3.31e-02 | 3.06e-02 | 8.56e-03 | -4.25e-02 | 5.88e-01 | 5.02e-01 | 5.34e-01 | 8.62e-01 | 3.89e-01 |
| REGULATION OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR SIGNALING PATHWAY | 15 | 9.84e-01 | 1.00e+00 | 0.06790 | 1.36e-02 | 1.42e-02 | 4.48e-02 | -4.33e-02 | 1.84e-02 | 9.28e-01 | 9.24e-01 | 7.64e-01 | 7.72e-01 | 9.02e-01 |
| MUSCLE CELL APOPTOTIC PROCESS | 91 | 9.10e-01 | 1.00e+00 | 0.06780 | 3.24e-02 | 3.22e-02 | 4.76e-02 | -1.28e-03 | 1.57e-02 | 5.93e-01 | 5.96e-01 | 4.32e-01 | 9.83e-01 | 7.96e-01 |
| NEGATIVE REGULATION OF TRANSPORT | 452 | 2.24e-01 | 7.46e-01 | 0.06780 | 3.21e-02 | 2.43e-02 | 5.40e-02 | 5.96e-03 | -4.52e-03 | 2.41e-01 | 3.76e-01 | 4.89e-02 | 8.28e-01 | 8.69e-01 |
| REPRODUCTIVE SYSTEM DEVELOPMENT | 289 | 3.04e-02 | 2.72e-01 | 0.06770 | 2.09e-02 | 5.97e-03 | 3.85e-02 | 9.57e-03 | -5.04e-02 | 5.42e-01 | 8.61e-01 | 2.61e-01 | 7.80e-01 | 1.40e-01 |
| NEGATIVE REGULATION OF PROTEIN SUMOYLATION | 8 | 9.89e-01 | 1.00e+00 | 0.06770 | -4.10e-02 | -1.87e-02 | -2.46e-02 | -4.24e-02 | -1.23e-02 | 8.41e-01 | 9.27e-01 | 9.04e-01 | 8.36e-01 | 9.52e-01 |
| RESPONSE TO LIPID | 893 | 1.34e-03 | 2.90e-02 | 0.06760 | 2.11e-02 | 1.08e-02 | 5.92e-02 | -7.79e-03 | 2.11e-02 | 2.84e-01 | 5.82e-01 | 2.69e-03 | 6.93e-01 | 2.86e-01 |
| ESTABLISHMENT OR MAINTENANCE OF BIPOLAR CELL POLARITY | 55 | 9.70e-01 | 1.00e+00 | 0.06760 | 2.61e-02 | 2.49e-02 | 6.32e-03 | 5.50e-02 | 1.40e-02 | 7.37e-01 | 7.49e-01 | 9.35e-01 | 4.80e-01 | 8.58e-01 |
| CELL DIFFERENTIATION INVOLVED IN EMBRYONIC PLACENTA DEVELOPMENT | 24 | 7.97e-01 | 1.00e+00 | 0.06750 | 1.09e-02 | 2.54e-03 | -7.86e-05 | -1.05e-02 | 6.58e-02 | 9.26e-01 | 9.83e-01 | 9.99e-01 | 9.29e-01 | 5.77e-01 |
| NEGATIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 12 | 9.96e-01 | 1.00e+00 | 0.06750 | 1.84e-03 | 1.59e-03 | 4.31e-02 | -2.46e-02 | 4.57e-02 | 9.91e-01 | 9.92e-01 | 7.96e-01 | 8.83e-01 | 7.84e-01 |
| REGULATION OF TOLL LIKE RECEPTOR 3 SIGNALING PATHWAY | 12 | 9.74e-01 | 1.00e+00 | 0.06750 | 1.98e-02 | 4.12e-02 | 3.12e-02 | -9.13e-04 | 3.86e-02 | 9.05e-01 | 8.05e-01 | 8.52e-01 | 9.96e-01 | 8.17e-01 |
| RESPONSE TO CATECHOLAMINE | 86 | 8.84e-01 | 1.00e+00 | 0.06740 | -1.87e-02 | -1.77e-02 | -1.43e-02 | -1.73e-02 | -5.81e-02 | 7.65e-01 | 7.76e-01 | 8.19e-01 | 7.82e-01 | 3.52e-01 |
| TISSUE HOMEOSTASIS | 264 | 5.94e-01 | 9.87e-01 | 0.06730 | -3.88e-02 | -3.65e-02 | -1.83e-02 | -3.41e-02 | 1.38e-02 | 2.78e-01 | 3.07e-01 | 6.09e-01 | 3.40e-01 | 7.00e-01 |
| CAMERA TYPE EYE MORPHOGENESIS | 130 | 7.57e-01 | 1.00e+00 | 0.06730 | 2.05e-02 | 3.08e-02 | 1.49e-02 | 3.68e-03 | -5.41e-02 | 6.86e-01 | 5.45e-01 | 7.70e-01 | 9.42e-01 | 2.87e-01 |
| REGULATION OF MUSCLE CELL DIFFERENTIATION | 155 | 7.69e-01 | 1.00e+00 | 0.06720 | 3.13e-02 | 2.07e-02 | 5.41e-02 | 1.33e-02 | 2.12e-03 | 5.01e-01 | 6.56e-01 | 2.45e-01 | 7.75e-01 | 9.64e-01 |
| POSTREPLICATION REPAIR | 33 | 9.64e-01 | 1.00e+00 | 0.06710 | 7.52e-03 | -1.40e-02 | 4.21e-02 | -8.58e-03 | 4.90e-02 | 9.40e-01 | 8.89e-01 | 6.75e-01 | 9.32e-01 | 6.26e-01 |
| POSITIVE REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 28 | 7.97e-01 | 1.00e+00 | 0.06710 | -1.90e-02 | -1.57e-02 | 3.94e-02 | -4.59e-02 | 1.54e-02 | 8.62e-01 | 8.86e-01 | 7.18e-01 | 6.75e-01 | 8.88e-01 |
| BLOOD VESSEL MORPHOGENESIS | 679 | 3.05e-01 | 8.33e-01 | 0.06680 | 3.35e-02 | 3.34e-02 | 3.76e-02 | 1.86e-02 | -2.16e-02 | 1.36e-01 | 1.38e-01 | 9.46e-02 | 4.08e-01 | 3.36e-01 |
| POSITIVE REGULATION OF MOLECULAR FUNCTION | 1221 | 4.81e-03 | 7.48e-02 | 0.06680 | -2.59e-02 | -2.90e-02 | 7.93e-03 | -4.40e-02 | 3.08e-02 | 1.27e-01 | 8.85e-02 | 6.41e-01 | 9.60e-03 | 7.04e-02 |
| REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 1424 | 3.05e-04 | 8.78e-03 | 0.06670 | 3.02e-02 | 2.94e-02 | 4.58e-02 | 2.29e-03 | -2.39e-02 | 5.58e-02 | 6.33e-02 | 3.76e-03 | 8.85e-01 | 1.30e-01 |
| MIRNA METABOLIC PROCESS | 101 | 2.97e-01 | 8.24e-01 | 0.06670 | -8.27e-03 | -5.65e-03 | 4.26e-02 | -2.97e-02 | 4.06e-02 | 8.86e-01 | 9.22e-01 | 4.59e-01 | 6.06e-01 | 4.81e-01 |
| POST TRANSLATIONAL PROTEIN MODIFICATION | 1000 | 3.92e-03 | 6.42e-02 | 0.06670 | 1.15e-02 | 2.27e-03 | 4.84e-02 | -9.79e-03 | 4.32e-02 | 5.37e-01 | 9.03e-01 | 9.54e-03 | 6.00e-01 | 2.08e-02 |
| PROTEIN LOCALIZATION TO SYNAPSE | 73 | 6.56e-01 | 1.00e+00 | 0.06660 | 2.87e-02 | 4.60e-02 | 3.06e-02 | 2.33e-02 | -2.96e-03 | 6.71e-01 | 4.96e-01 | 6.51e-01 | 7.30e-01 | 9.65e-01 |
| CELLULAR RESPONSE TO EXTERNAL STIMULUS | 329 | 9.10e-02 | 4.98e-01 | 0.06660 | 2.44e-02 | 3.05e-02 | 4.71e-02 | 7.17e-03 | 2.51e-02 | 4.46e-01 | 3.41e-01 | 1.42e-01 | 8.23e-01 | 4.34e-01 |
| RESPONSE TO ANGIOTENSIN | 35 | 4.16e-02 | 3.27e-01 | 0.06650 | -2.73e-02 | -4.36e-02 | 3.28e-02 | 2.57e-02 | -6.04e-03 | 7.80e-01 | 6.56e-01 | 7.37e-01 | 7.92e-01 | 9.51e-01 |
| ORGANELLE ASSEMBLY | 961 | 8.15e-04 | 1.92e-02 | 0.06640 | 1.67e-02 | 8.55e-03 | 5.60e-02 | -1.43e-02 | 2.69e-02 | 3.79e-01 | 6.53e-01 | 3.29e-03 | 4.54e-01 | 1.57e-01 |
| EPIBOLY | 37 | 9.71e-01 | 1.00e+00 | 0.06640 | 1.08e-02 | 1.58e-02 | -2.97e-02 | 4.75e-02 | -3.00e-02 | 9.09e-01 | 8.68e-01 | 7.55e-01 | 6.17e-01 | 7.52e-01 |
| EXOCRINE PANCREAS DEVELOPMENT | 7 | 9.31e-01 | 1.00e+00 | 0.06630 | 1.69e-02 | 6.01e-02 | 1.73e-02 | -4.33e-03 | -1.39e-02 | 9.38e-01 | 7.83e-01 | 9.37e-01 | 9.84e-01 | 9.49e-01 |
| REGULATION OF HETEROTYPIC CELL CELL ADHESION | 24 | 7.64e-01 | 1.00e+00 | 0.06630 | -1.66e-02 | -2.16e-02 | 1.84e-02 | 2.32e-02 | 5.27e-02 | 8.88e-01 | 8.55e-01 | 8.76e-01 | 8.44e-01 | 6.55e-01 |
| CHONDROCYTE DIFFERENTIATION | 113 | 7.11e-01 | 1.00e+00 | 0.06630 | -3.30e-02 | -4.04e-02 | 5.73e-03 | -3.69e-02 | 1.67e-02 | 5.44e-01 | 4.58e-01 | 9.16e-01 | 4.99e-01 | 7.59e-01 |
| REGULATION OF CATALYTIC ACTIVITY | 1430 | 2.91e-04 | 8.41e-03 | 0.06610 | -1.67e-02 | -2.12e-02 | 2.04e-02 | -4.07e-02 | 3.96e-02 | 2.90e-01 | 1.79e-01 | 1.96e-01 | 9.84e-03 | 1.21e-02 |
| MEMBRANE LIPID BIOSYNTHETIC PROCESS | 148 | 5.86e-01 | 9.85e-01 | 0.06610 | 2.06e-02 | 1.48e-02 | 5.43e-02 | 6.76e-03 | 2.71e-02 | 6.66e-01 | 7.56e-01 | 2.54e-01 | 8.87e-01 | 5.70e-01 |
| RESPONSE TO MUSCLE STRETCH | 24 | 9.99e-01 | 1.00e+00 | 0.06610 | -3.46e-02 | -2.80e-02 | -4.70e-02 | -1.34e-02 | -1.43e-03 | 7.69e-01 | 8.12e-01 | 6.90e-01 | 9.10e-01 | 9.90e-01 |
| DICARBOXYLIC ACID TRANSPORT | 98 | 8.96e-01 | 1.00e+00 | 0.06610 | 2.74e-02 | 3.31e-02 | 2.53e-02 | 2.40e-02 | -3.61e-02 | 6.40e-01 | 5.71e-01 | 6.65e-01 | 6.82e-01 | 5.37e-01 |
| ORGANIC ACID TRANSPORT | 341 | 4.72e-01 | 9.40e-01 | 0.06600 | 2.42e-02 | 3.22e-02 | 1.36e-02 | 2.05e-02 | -4.61e-02 | 4.42e-01 | 3.07e-01 | 6.66e-01 | 5.16e-01 | 1.43e-01 |
| STEM CELL PROLIFERATION | 120 | 4.87e-01 | 9.43e-01 | 0.06600 | 1.30e-02 | 8.29e-03 | 4.76e-02 | -2.92e-02 | -3.16e-02 | 8.06e-01 | 8.75e-01 | 3.68e-01 | 5.81e-01 | 5.50e-01 |
| REGULATION OF HEMOPOIESIS | 406 | 1.85e-02 | 1.97e-01 | 0.06600 | -2.29e-03 | -2.02e-02 | 4.74e-02 | -3.11e-02 | 2.69e-02 | 9.37e-01 | 4.84e-01 | 1.01e-01 | 2.82e-01 | 3.52e-01 |
| EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 221 | 2.07e-01 | 7.27e-01 | 0.06590 | -9.72e-03 | -1.07e-02 | 3.55e-02 | -4.03e-02 | 3.54e-02 | 8.03e-01 | 7.84e-01 | 3.63e-01 | 3.02e-01 | 3.64e-01 |
| EPITHELIAL TO MESENCHYMAL TRANSITION | 176 | 2.68e-01 | 7.95e-01 | 0.06590 | -1.00e-03 | -9.33e-03 | 5.03e-02 | -3.43e-02 | 2.35e-02 | 9.82e-01 | 8.31e-01 | 2.49e-01 | 4.33e-01 | 5.91e-01 |
| REGULATION OF PROTEOLYSIS | 588 | 5.67e-03 | 8.35e-02 | 0.06590 | -5.43e-03 | -9.42e-03 | 3.65e-02 | -4.69e-02 | 2.64e-02 | 8.22e-01 | 6.96e-01 | 1.30e-01 | 5.21e-02 | 2.74e-01 |
| ENDOCRINE PROCESS | 87 | 8.09e-01 | 1.00e+00 | 0.06590 | -5.59e-03 | -8.44e-03 | 1.48e-02 | -3.60e-02 | -5.22e-02 | 9.28e-01 | 8.92e-01 | 8.12e-01 | 5.61e-01 | 4.00e-01 |
| CELLULAR RESPONSE TO XENOBIOTIC STIMULUS | 189 | 5.17e-01 | 9.52e-01 | 0.06580 | -8.27e-03 | -2.96e-03 | -2.28e-02 | 1.22e-02 | -5.99e-02 | 8.45e-01 | 9.44e-01 | 5.88e-01 | 7.73e-01 | 1.56e-01 |
| OLEFINIC COMPOUND BIOSYNTHETIC PROCESS | 28 | 9.42e-01 | 1.00e+00 | 0.06580 | -6.10e-03 | 1.72e-02 | -3.67e-02 | 2.06e-02 | -4.72e-02 | 9.55e-01 | 8.75e-01 | 7.37e-01 | 8.51e-01 | 6.65e-01 |
| NEGATIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 44 | 8.60e-01 | 1.00e+00 | 0.06580 | -2.54e-02 | -2.73e-02 | 2.44e-03 | -3.02e-02 | -4.49e-02 | 7.71e-01 | 7.54e-01 | 9.78e-01 | 7.29e-01 | 6.06e-01 |
| CELL CELL JUNCTION ORGANIZATION | 208 | 2.07e-02 | 2.13e-01 | 0.06560 | -8.42e-03 | 9.90e-03 | -4.07e-02 | 4.89e-02 | 9.68e-03 | 8.34e-01 | 8.05e-01 | 3.11e-01 | 2.25e-01 | 8.10e-01 |
| AUTOPHAGOSOME ORGANIZATION | 115 | 8.05e-01 | 1.00e+00 | 0.06560 | -1.69e-02 | -2.02e-02 | 2.21e-02 | -3.87e-02 | 4.03e-02 | 7.54e-01 | 7.09e-01 | 6.82e-01 | 4.73e-01 | 4.55e-01 |
| REGULATION OF PROTEIN MODIFICATION PROCESS | 1251 | 2.70e-05 | 1.12e-03 | 0.06560 | 1.26e-02 | 6.38e-03 | 5.30e-02 | -1.97e-02 | 3.01e-02 | 4.53e-01 | 7.04e-01 | 1.60e-03 | 2.41e-01 | 7.35e-02 |
| POSITIVE REGULATION OF NEUROGENESIS | 228 | 5.99e-01 | 9.90e-01 | 0.06560 | 2.83e-02 | 2.37e-02 | 5.39e-02 | 1.03e-04 | 6.31e-03 | 4.62e-01 | 5.38e-01 | 1.61e-01 | 9.98e-01 | 8.70e-01 |
| REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 144 | 7.53e-01 | 1.00e+00 | 0.06560 | 2.45e-02 | 3.63e-02 | -1.26e-03 | 1.39e-02 | -4.68e-02 | 6.12e-01 | 4.52e-01 | 9.79e-01 | 7.74e-01 | 3.32e-01 |
| REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 278 | 8.10e-02 | 4.68e-01 | 0.06560 | 4.50e-03 | -6.20e-03 | 4.98e-02 | -4.20e-02 | 1.98e-03 | 8.97e-01 | 8.59e-01 | 1.53e-01 | 2.28e-01 | 9.55e-01 |
| REGULATION OF CELLULAR COMPONENT SIZE | 350 | 4.46e-01 | 9.30e-01 | 0.06560 | 3.18e-02 | 3.72e-02 | 3.75e-02 | 2.22e-02 | -2.26e-03 | 3.07e-01 | 2.32e-01 | 2.28e-01 | 4.76e-01 | 9.42e-01 |
| CYTOSKELETON DEPENDENT INTRACELLULAR TRANSPORT | 201 | 1.83e-01 | 6.93e-01 | 0.06550 | 1.01e-03 | -6.72e-03 | 5.00e-02 | -4.12e-02 | 6.86e-03 | 9.80e-01 | 8.70e-01 | 2.21e-01 | 3.14e-01 | 8.67e-01 |
| PROTEIN LOCALIZATION TO EXTRACELLULAR REGION | 364 | 3.45e-03 | 5.83e-02 | 0.06550 | 1.74e-02 | 2.60e-02 | 4.26e-02 | -1.61e-02 | -3.52e-02 | 5.68e-01 | 3.95e-01 | 1.63e-01 | 5.99e-01 | 2.48e-01 |
| ESTROUS CYCLE | 16 | 9.99e-01 | 1.00e+00 | 0.06550 | 2.88e-02 | 3.19e-02 | 2.48e-02 | 2.39e-02 | -3.54e-02 | 8.42e-01 | 8.25e-01 | 8.64e-01 | 8.68e-01 | 8.06e-01 |
| DNA SYNTHESIS INVOLVED IN DNA REPAIR | 39 | 7.51e-01 | 1.00e+00 | 0.06550 | 1.18e-02 | -1.85e-02 | 5.73e-02 | -2.22e-02 | 5.14e-03 | 8.99e-01 | 8.42e-01 | 5.36e-01 | 8.10e-01 | 9.56e-01 |
| PROTEIN HOMOOLIGOMERIZATION | 188 | 5.75e-01 | 9.79e-01 | 0.06540 | 2.85e-02 | 2.77e-02 | 3.77e-02 | 2.38e-02 | -2.67e-02 | 5.01e-01 | 5.12e-01 | 3.73e-01 | 5.73e-01 | 5.28e-01 |
| GENOMIC IMPRINTING | 18 | 9.87e-01 | 1.00e+00 | 0.06540 | 1.98e-02 | 1.83e-02 | -1.21e-02 | 4.56e-02 | 3.64e-02 | 8.85e-01 | 8.93e-01 | 9.29e-01 | 7.38e-01 | 7.89e-01 |
| TRANSEPITHELIAL TRANSPORT | 34 | 8.89e-01 | 1.00e+00 | 0.06530 | -2.65e-02 | -4.27e-02 | 5.43e-03 | -2.63e-02 | -3.18e-02 | 7.89e-01 | 6.66e-01 | 9.56e-01 | 7.91e-01 | 7.48e-01 |
| CELL RECOGNITION | 153 | 5.71e-01 | 9.76e-01 | 0.06520 | -2.62e-02 | -3.61e-02 | -3.53e-02 | -6.55e-03 | -3.12e-02 | 5.76e-01 | 4.40e-01 | 4.52e-01 | 8.89e-01 | 5.05e-01 |
| CELLULAR RESPONSE TO ACID CHEMICAL | 86 | 9.00e-01 | 1.00e+00 | 0.06520 | 3.28e-03 | 2.81e-03 | 3.13e-02 | -7.05e-03 | 5.66e-02 | 9.58e-01 | 9.64e-01 | 6.16e-01 | 9.10e-01 | 3.64e-01 |
| ORGANIC CYCLIC COMPOUND CATABOLIC PROCESS | 560 | 8.17e-02 | 4.71e-01 | 0.06510 | -2.26e-02 | -2.39e-02 | 1.27e-02 | -4.24e-02 | 3.46e-02 | 3.60e-01 | 3.33e-01 | 6.07e-01 | 8.64e-02 | 1.61e-01 |
| RESPONSE TO HORMONE | 841 | 1.31e-02 | 1.51e-01 | 0.06510 | 2.99e-02 | 2.96e-02 | 4.53e-02 | 1.64e-02 | -1.20e-02 | 1.41e-01 | 1.44e-01 | 2.57e-02 | 4.20e-01 | 5.53e-01 |
| VESICLE MEDIATED TRANSPORT | 1468 | 5.57e-04 | 1.41e-02 | 0.06500 | -6.76e-03 | -1.59e-02 | 2.82e-02 | -1.69e-02 | 5.34e-02 | 6.65e-01 | 3.07e-01 | 7.10e-02 | 2.78e-01 | 6.15e-04 |
| MONOATOMIC CATION TRANSPORT | 997 | 1.99e-01 | 7.14e-01 | 0.06490 | 3.08e-02 | 3.53e-02 | 1.85e-02 | 3.88e-02 | -1.30e-02 | 9.95e-02 | 5.88e-02 | 3.22e-01 | 3.82e-02 | 4.88e-01 |
| DENDRITE MORPHOGENESIS | 129 | 6.93e-01 | 1.00e+00 | 0.06490 | -2.37e-02 | -2.17e-02 | -1.95e-02 | -1.33e-02 | -5.12e-02 | 6.42e-01 | 6.71e-01 | 7.02e-01 | 7.94e-01 | 3.16e-01 |
| REGULATION OF ENDOCYTOSIS | 284 | 1.64e-01 | 6.64e-01 | 0.06480 | -1.21e-02 | -2.91e-02 | 3.32e-02 | -3.78e-02 | 2.60e-02 | 7.25e-01 | 3.99e-01 | 3.35e-01 | 2.73e-01 | 4.50e-01 |
| REGULATION OF T CELL DIFFERENTIATION IN THYMUS | 26 | 9.10e-01 | 1.00e+00 | 0.06470 | 3.18e-02 | 5.46e-02 | 1.16e-02 | 6.86e-03 | -4.91e-03 | 7.79e-01 | 6.30e-01 | 9.19e-01 | 9.52e-01 | 9.65e-01 |
| REGULATION OF ANIMAL ORGAN MORPHOGENESIS | 121 | 2.58e-01 | 7.86e-01 | 0.06470 | -1.62e-02 | -1.35e-02 | 3.43e-02 | -4.44e-02 | 2.42e-02 | 7.58e-01 | 7.97e-01 | 5.15e-01 | 3.99e-01 | 6.46e-01 |
| REGULATION OF BODY FLUID LEVELS | 351 | 7.52e-02 | 4.50e-01 | 0.06460 | 3.74e-03 | -5.41e-03 | 4.09e-02 | 2.39e-03 | 4.95e-02 | 9.04e-01 | 8.62e-01 | 1.88e-01 | 9.39e-01 | 1.11e-01 |
| SIGNAL RELEASE | 467 | 4.30e-02 | 3.32e-01 | 0.06440 | 2.35e-02 | 2.76e-02 | 3.47e-02 | 6.88e-03 | -3.97e-02 | 3.83e-01 | 3.06e-01 | 1.99e-01 | 7.99e-01 | 1.42e-01 |
| VENTRICULAR CARDIAC MUSCLE TISSUE MORPHOGENESIS | 47 | 9.14e-01 | 1.00e+00 | 0.06430 | -7.74e-03 | -1.65e-02 | 2.71e-02 | -4.92e-02 | -2.55e-02 | 9.27e-01 | 8.45e-01 | 7.48e-01 | 5.60e-01 | 7.62e-01 |
| SENSORY SYSTEM DEVELOPMENT | 394 | 4.22e-01 | 9.12e-01 | 0.06430 | 3.03e-02 | 3.56e-02 | 3.16e-02 | 2.09e-02 | -2.26e-02 | 3.01e-01 | 2.25e-01 | 2.82e-01 | 4.76e-01 | 4.41e-01 |
| REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 185 | 6.09e-01 | 9.90e-01 | 0.06430 | -1.47e-02 | -2.18e-02 | 2.61e-02 | -3.23e-02 | 4.15e-02 | 7.30e-01 | 6.09e-01 | 5.41e-01 | 4.49e-01 | 3.31e-01 |
| REGULATION OF CALCIUM MEDIATED SIGNALING | 81 | 8.50e-01 | 1.00e+00 | 0.06430 | 6.62e-03 | 1.14e-02 | 3.05e-03 | 1.03e-02 | -6.20e-02 | 9.18e-01 | 8.59e-01 | 9.62e-01 | 8.73e-01 | 3.35e-01 |
| ICOSANOID SECRETION | 46 | 2.40e-01 | 7.64e-01 | 0.06430 | 8.49e-03 | -6.17e-03 | 5.58e-02 | 2.99e-02 | 2.37e-03 | 9.21e-01 | 9.42e-01 | 5.12e-01 | 7.25e-01 | 9.78e-01 |
| REGULATION OF MACROPHAGE MIGRATION | 45 | 6.63e-01 | 1.00e+00 | 0.06420 | -7.49e-03 | -2.26e-02 | -3.60e-02 | 3.51e-02 | 3.21e-02 | 9.31e-01 | 7.93e-01 | 6.76e-01 | 6.83e-01 | 7.10e-01 |
| ACTIN NUCLEATION | 55 | 8.29e-01 | 1.00e+00 | 0.06420 | -9.60e-03 | -2.49e-02 | 2.65e-02 | -4.07e-02 | -3.24e-02 | 9.02e-01 | 7.49e-01 | 7.34e-01 | 6.01e-01 | 6.78e-01 |
| MONOCARBOXYLIC ACID TRANSPORT | 174 | 6.11e-01 | 9.90e-01 | 0.06400 | 7.79e-03 | 1.44e-02 | -6.68e-03 | 2.20e-02 | -5.75e-02 | 8.59e-01 | 7.44e-01 | 8.79e-01 | 6.16e-01 | 1.91e-01 |
| STRIATED MUSCLE TISSUE DEVELOPMENT | 260 | 7.86e-01 | 1.00e+00 | 0.06400 | 3.19e-02 | 3.01e-02 | 3.54e-02 | 1.32e-02 | -2.74e-02 | 3.75e-01 | 4.04e-01 | 3.26e-01 | 7.14e-01 | 4.47e-01 |
| NONRIBOSOMAL PEPTIDE BIOSYNTHETIC PROCESS | 17 | 7.21e-01 | 1.00e+00 | 0.06400 | -3.59e-02 | -1.57e-02 | -4.21e-03 | -3.70e-03 | 5.03e-02 | 7.98e-01 | 9.11e-01 | 9.76e-01 | 9.79e-01 | 7.20e-01 |
| REGULATION OF NERVOUS SYSTEM PROCESS | 114 | 8.92e-01 | 1.00e+00 | 0.06400 | -3.01e-02 | -2.86e-02 | -1.90e-02 | -1.21e-02 | 4.31e-02 | 5.78e-01 | 5.98e-01 | 7.25e-01 | 8.23e-01 | 4.26e-01 |
| NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 170 | 4.82e-01 | 9.43e-01 | 0.06390 | -1.64e-02 | -2.77e-02 | 1.28e-02 | -5.16e-02 | 1.52e-02 | 7.13e-01 | 5.33e-01 | 7.74e-01 | 2.46e-01 | 7.32e-01 |
| REGULATION OF PHOSPHATIDYLCHOLINE METABOLIC PROCESS | 10 | 8.05e-01 | 1.00e+00 | 0.06390 | -1.43e-02 | 1.47e-02 | 5.32e-03 | 2.67e-02 | 5.41e-02 | 9.38e-01 | 9.36e-01 | 9.77e-01 | 8.84e-01 | 7.67e-01 |
| SENSORY ORGAN DEVELOPMENT | 578 | 1.12e-02 | 1.36e-01 | 0.06380 | 2.51e-02 | 2.58e-02 | 4.68e-02 | 2.33e-04 | -2.42e-02 | 3.03e-01 | 2.88e-01 | 5.45e-02 | 9.92e-01 | 3.21e-01 |
| POSITIVE REGULATION OF TRANSMEMBRANE TRANSPORT | 204 | 6.89e-01 | 1.00e+00 | 0.06370 | 2.15e-02 | 3.20e-02 | 9.87e-03 | 1.29e-02 | -4.81e-02 | 5.97e-01 | 4.31e-01 | 8.08e-01 | 7.50e-01 | 2.36e-01 |
| REGULATION OF STEM CELL PROLIFERATION | 91 | 8.20e-01 | 1.00e+00 | 0.06370 | -3.43e-03 | -6.02e-03 | 1.47e-02 | -3.30e-02 | -5.20e-02 | 9.55e-01 | 9.21e-01 | 8.09e-01 | 5.87e-01 | 3.91e-01 |
| GLUCAN METABOLIC PROCESS | 73 | 5.39e-01 | 9.58e-01 | 0.06360 | -2.36e-03 | 1.66e-02 | 7.12e-03 | -2.99e-02 | -5.31e-02 | 9.72e-01 | 8.06e-01 | 9.16e-01 | 6.58e-01 | 4.33e-01 |
| CELL PROLIFERATION IN FOREBRAIN | 26 | 9.75e-01 | 1.00e+00 | 0.06350 | 4.15e-03 | -1.71e-02 | 4.09e-02 | -1.16e-03 | 4.53e-02 | 9.71e-01 | 8.80e-01 | 7.18e-01 | 9.92e-01 | 6.89e-01 |
| POSITIVE REGULATION OF LIPASE ACTIVITY | 59 | 9.48e-01 | 1.00e+00 | 0.06350 | 1.73e-02 | 2.35e-02 | -4.57e-03 | 4.32e-02 | -3.59e-02 | 8.18e-01 | 7.55e-01 | 9.52e-01 | 5.66e-01 | 6.33e-01 |
| DEVELOPMENTAL MATURATION | 318 | 5.28e-01 | 9.54e-01 | 0.06340 | 2.73e-02 | 2.67e-02 | 3.07e-02 | 4.42e-03 | -4.01e-02 | 4.03e-01 | 4.14e-01 | 3.47e-01 | 8.92e-01 | 2.19e-01 |
| POSITIVE REGULATION OF MONOATOMIC ION TRANSPORT | 202 | 8.57e-01 | 1.00e+00 | 0.06340 | 2.22e-02 | 2.34e-02 | 6.49e-03 | 2.30e-02 | -4.91e-02 | 5.87e-01 | 5.66e-01 | 8.74e-01 | 5.73e-01 | 2.29e-01 |
| EPITHELIAL CELL APOPTOTIC PROCESS | 143 | 7.53e-01 | 1.00e+00 | 0.06340 | 2.30e-02 | 2.17e-02 | 4.92e-02 | 6.49e-03 | 2.37e-02 | 6.36e-01 | 6.55e-01 | 3.10e-01 | 8.93e-01 | 6.25e-01 |
| COLLAGEN METABOLIC PROCESS | 103 | 9.39e-01 | 1.00e+00 | 0.06340 | 2.54e-02 | 2.36e-02 | 4.43e-02 | 1.58e-02 | 2.44e-02 | 6.56e-01 | 6.79e-01 | 4.37e-01 | 7.82e-01 | 6.68e-01 |
| REGULATION OF CELLULAR LOCALIZATION | 946 | 2.89e-03 | 5.12e-02 | 0.06320 | 1.95e-02 | 1.85e-02 | 4.92e-02 | -3.71e-03 | 2.89e-02 | 3.10e-01 | 3.34e-01 | 1.03e-02 | 8.47e-01 | 1.31e-01 |
| MOTOR NEURON APOPTOTIC PROCESS | 21 | 9.95e-01 | 1.00e+00 | 0.06310 | 2.09e-02 | 1.79e-02 | 5.13e-02 | -1.55e-03 | 2.42e-02 | 8.68e-01 | 8.87e-01 | 6.84e-01 | 9.90e-01 | 8.48e-01 |
| RESPONSE TO ENDOGENOUS STIMULUS | 1700 | 2.01e-05 | 8.58e-04 | 0.06310 | 2.75e-02 | 2.54e-02 | 5.00e-02 | 5.02e-03 | -6.73e-03 | 5.89e-02 | 8.08e-02 | 5.95e-04 | 7.31e-01 | 6.44e-01 |
| NEGATIVE REGULATION OF CELL DEVELOPMENT | 275 | 7.02e-02 | 4.35e-01 | 0.06300 | -2.14e-03 | -1.03e-02 | 4.38e-02 | -4.33e-02 | -8.35e-03 | 9.51e-01 | 7.68e-01 | 2.11e-01 | 2.17e-01 | 8.12e-01 |
| NON CANONICAL WNT SIGNALING PATHWAY | 66 | 9.46e-01 | 1.00e+00 | 0.06290 | 2.42e-02 | 2.87e-02 | 3.80e-02 | 1.85e-02 | 2.76e-02 | 7.34e-01 | 6.87e-01 | 5.93e-01 | 7.95e-01 | 6.98e-01 |
| PROTEIN K63 LINKED UBIQUITINATION | 56 | 9.70e-01 | 1.00e+00 | 0.06290 | 1.11e-02 | -5.14e-05 | 4.57e-02 | -1.22e-02 | 3.99e-02 | 8.86e-01 | 9.99e-01 | 5.54e-01 | 8.74e-01 | 6.05e-01 |
| SMOOTH MUSCLE CELL MIGRATION | 86 | 5.44e-01 | 9.61e-01 | 0.06290 | 1.80e-02 | 1.09e-02 | 1.89e-02 | -2.48e-02 | -5.04e-02 | 7.73e-01 | 8.61e-01 | 7.62e-01 | 6.91e-01 | 4.19e-01 |
| MUCOPOLYSACCHARIDE METABOLIC PROCESS | 89 | 9.93e-01 | 1.00e+00 | 0.06280 | -3.21e-02 | -2.81e-02 | -3.75e-02 | -2.65e-02 | -3.95e-03 | 6.01e-01 | 6.47e-01 | 5.41e-01 | 6.66e-01 | 9.49e-01 |
| REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 1718 | 1.80e-04 | 5.63e-03 | 0.06280 | -2.91e-02 | -3.12e-02 | 3.62e-03 | -4.00e-02 | 2.26e-02 | 4.48e-02 | 3.11e-02 | 8.03e-01 | 5.83e-03 | 1.19e-01 |
| EPITHELIAL CELL DIFFERENTIATION | 722 | 4.29e-01 | 9.17e-01 | 0.06260 | 2.96e-02 | 3.38e-02 | 6.55e-03 | 3.58e-02 | -2.40e-02 | 1.75e-01 | 1.22e-01 | 7.64e-01 | 1.02e-01 | 2.72e-01 |
| ANATOMICAL STRUCTURE MATURATION | 253 | 6.70e-01 | 1.00e+00 | 0.06260 | 9.84e-03 | 1.22e-02 | -1.97e-04 | -5.96e-04 | -6.06e-02 | 7.88e-01 | 7.39e-01 | 9.96e-01 | 9.87e-01 | 9.71e-02 |
| REGULATION OF TRIGLYCERIDE BIOSYNTHETIC PROCESS | 21 | 9.93e-01 | 1.00e+00 | 0.06250 | 1.61e-02 | 2.46e-02 | -8.27e-03 | 4.16e-02 | 3.53e-02 | 8.99e-01 | 8.46e-01 | 9.48e-01 | 7.42e-01 | 7.80e-01 |
| REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 139 | 1.68e-01 | 6.72e-01 | 0.06240 | -1.44e-02 | -2.77e-02 | 3.99e-02 | -3.62e-02 | -3.31e-03 | 7.69e-01 | 5.73e-01 | 4.16e-01 | 4.61e-01 | 9.46e-01 |
| REGULATION OF BEHAVIOR | 73 | 8.19e-01 | 1.00e+00 | 0.06230 | -1.13e-03 | -8.26e-03 | 2.61e-02 | 1.32e-02 | 5.44e-02 | 9.87e-01 | 9.03e-01 | 7.00e-01 | 8.45e-01 | 4.22e-01 |
| PROTEIN O LINKED GLYCOSYLATION | 96 | 4.86e-01 | 9.43e-01 | 0.06230 | -9.42e-03 | 1.01e-02 | -4.77e-02 | 3.59e-02 | 1.16e-02 | 8.73e-01 | 8.64e-01 | 4.20e-01 | 5.44e-01 | 8.44e-01 |
| POSITIVE REGULATION OF PEPTIDE SECRETION | 110 | 6.66e-01 | 1.00e+00 | 0.06230 | 1.74e-02 | 2.59e-02 | 2.40e-02 | 3.06e-03 | -4.82e-02 | 7.53e-01 | 6.38e-01 | 6.63e-01 | 9.56e-01 | 3.83e-01 |
| T CELL RECEPTOR SIGNALING PATHWAY | 133 | 2.74e-01 | 8.01e-01 | 0.06220 | 1.79e-02 | 8.32e-05 | 5.84e-02 | -2.07e-03 | -1.16e-02 | 7.21e-01 | 9.99e-01 | 2.45e-01 | 9.67e-01 | 8.17e-01 |
| CELL PROJECTION ASSEMBLY | 589 | 2.58e-01 | 7.85e-01 | 0.06210 | -3.10e-02 | -2.95e-02 | -1.37e-02 | -2.38e-02 | 3.58e-02 | 1.99e-01 | 2.21e-01 | 5.71e-01 | 3.25e-01 | 1.38e-01 |
| REGULATION OF CELL DEVELOPMENT | 815 | 4.51e-03 | 7.11e-02 | 0.06210 | 2.38e-02 | 1.48e-02 | 5.48e-02 | -7.42e-03 | -2.75e-03 | 2.48e-01 | 4.72e-01 | 7.82e-03 | 7.19e-01 | 8.94e-01 |
| EPITHELIUM DEVELOPMENT | 1206 | 2.44e-01 | 7.69e-01 | 0.06200 | 3.01e-02 | 3.27e-02 | 2.10e-02 | 3.12e-02 | -2.14e-02 | 7.86e-02 | 5.56e-02 | 2.20e-01 | 6.77e-02 | 2.11e-01 |
| BINDING OF SPERM TO ZONA PELLUCIDA | 38 | 9.91e-01 | 1.00e+00 | 0.06200 | -2.51e-02 | -1.31e-02 | -2.91e-02 | -2.77e-02 | -3.78e-02 | 7.89e-01 | 8.89e-01 | 7.56e-01 | 7.68e-01 | 6.87e-01 |
| POST EMBRYONIC ANIMAL ORGAN DEVELOPMENT | 18 | 9.06e-01 | 1.00e+00 | 0.06200 | 7.76e-03 | 3.72e-02 | -9.99e-03 | 1.54e-02 | 4.54e-02 | 9.55e-01 | 7.85e-01 | 9.42e-01 | 9.10e-01 | 7.39e-01 |
| NEGATIVE REGULATION OF OSTEOBLAST PROLIFERATION | 15 | 9.64e-01 | 1.00e+00 | 0.06190 | 1.80e-02 | 4.27e-02 | -8.29e-04 | 4.10e-02 | -1.59e-04 | 9.04e-01 | 7.75e-01 | 9.96e-01 | 7.83e-01 | 9.99e-01 |
| POLYSACCHARIDE CATABOLIC PROCESS | 21 | 8.17e-01 | 1.00e+00 | 0.06180 | -6.44e-04 | 1.24e-02 | 3.54e-02 | -2.26e-02 | -4.36e-02 | 9.96e-01 | 9.22e-01 | 7.79e-01 | 8.58e-01 | 7.29e-01 |
| CARDIAC MUSCLE CELL DIFFERENTIATION | 129 | 5.38e-01 | 9.57e-01 | 0.06180 | -2.15e-02 | -1.93e-02 | 1.27e-02 | -4.88e-02 | -2.09e-02 | 6.73e-01 | 7.05e-01 | 8.04e-01 | 3.38e-01 | 6.82e-01 |
| NEGATIVE REGULATION OF CELL SUBSTRATE ADHESION | 61 | 8.38e-01 | 1.00e+00 | 0.06160 | -2.60e-02 | -3.20e-02 | -8.73e-03 | 5.72e-03 | 4.46e-02 | 7.26e-01 | 6.66e-01 | 9.06e-01 | 9.38e-01 | 5.47e-01 |
| CELLULAR MODIFIED AMINO ACID METABOLIC PROCESS | 122 | 8.12e-01 | 1.00e+00 | 0.06150 | -1.93e-02 | -3.09e-03 | -4.66e-02 | 9.59e-04 | -3.50e-02 | 7.13e-01 | 9.53e-01 | 3.74e-01 | 9.85e-01 | 5.05e-01 |
| PURINE CONTAINING COMPOUND METABOLIC PROCESS | 460 | 4.95e-01 | 9.47e-01 | 0.06140 | 3.03e-02 | 2.99e-02 | 3.97e-02 | 1.47e-02 | -1.30e-02 | 2.66e-01 | 2.71e-01 | 1.44e-01 | 5.90e-01 | 6.32e-01 |
| REGULATION OF MRNA EXPORT FROM NUCLEUS | 7 | 8.70e-01 | 1.00e+00 | 0.06140 | 5.19e-04 | -5.01e-02 | -3.19e-03 | 2.40e-02 | -2.59e-02 | 9.98e-01 | 8.18e-01 | 9.88e-01 | 9.12e-01 | 9.05e-01 |
| HOMOLOGOUS CHROMOSOME SEGREGATION | 64 | 9.13e-01 | 1.00e+00 | 0.06130 | 3.19e-02 | 1.55e-02 | 4.57e-02 | 1.74e-02 | -1.09e-02 | 6.59e-01 | 8.30e-01 | 5.27e-01 | 8.10e-01 | 8.81e-01 |
| MONOATOMIC ION TRANSMEMBRANE TRANSPORT | 975 | 2.89e-02 | 2.63e-01 | 0.06130 | 2.31e-02 | 3.12e-02 | 7.88e-03 | 3.39e-02 | -3.23e-02 | 2.22e-01 | 9.92e-02 | 6.77e-01 | 7.30e-02 | 8.73e-02 |
| REGULATION OF KINASE ACTIVITY | 565 | 1.82e-02 | 1.96e-01 | 0.06130 | 1.18e-03 | -3.37e-03 | 3.94e-02 | -3.86e-02 | 2.65e-02 | 9.62e-01 | 8.91e-01 | 1.10e-01 | 1.17e-01 | 2.81e-01 |
| INORGANIC ION HOMEOSTASIS | 515 | 5.62e-02 | 3.86e-01 | 0.06100 | -3.07e-02 | -3.66e-02 | 3.64e-03 | -3.75e-02 | 3.59e-03 | 2.33e-01 | 1.55e-01 | 8.88e-01 | 1.45e-01 | 8.89e-01 |
| CELLULAR RESPONSE TO CALCIUM ION | 84 | 6.31e-01 | 9.96e-01 | 0.06090 | -4.66e-04 | -1.46e-02 | 3.28e-02 | -4.91e-02 | -3.28e-03 | 9.94e-01 | 8.17e-01 | 6.04e-01 | 4.36e-01 | 9.59e-01 |
| FIBROBLAST APOPTOTIC PROCESS | 25 | 9.61e-01 | 1.00e+00 | 0.06080 | 2.40e-02 | 2.06e-02 | 2.68e-02 | -7.30e-03 | 4.38e-02 | 8.35e-01 | 8.59e-01 | 8.17e-01 | 9.50e-01 | 7.04e-01 |
| REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 167 | 9.89e-01 | 1.00e+00 | 0.06050 | 3.15e-02 | 3.10e-02 | 3.18e-02 | 2.52e-02 | 7.75e-03 | 4.83e-01 | 4.89e-01 | 4.78e-01 | 5.73e-01 | 8.63e-01 |
| CELLULAR RESPONSE TO ABIOTIC STIMULUS | 318 | 6.31e-01 | 9.96e-01 | 0.06050 | 3.02e-02 | 3.37e-02 | 3.71e-02 | 9.51e-03 | -1.19e-02 | 3.55e-01 | 3.02e-01 | 2.55e-01 | 7.71e-01 | 7.16e-01 |
| RESPONSE TO CALCIUM ION | 140 | 8.13e-01 | 1.00e+00 | 0.06040 | -2.34e-02 | -3.36e-02 | -7.43e-03 | -3.71e-02 | -2.32e-02 | 6.33e-01 | 4.92e-01 | 8.79e-01 | 4.49e-01 | 6.36e-01 |
| REGULATION OF FEEDING BEHAVIOR | 27 | 9.93e-01 | 1.00e+00 | 0.06030 | 1.94e-02 | 1.64e-02 | 2.97e-02 | 3.29e-02 | 3.20e-02 | 8.61e-01 | 8.82e-01 | 7.89e-01 | 7.67e-01 | 7.74e-01 |
| NEURON PROJECTION EXTENSION | 168 | 6.72e-01 | 1.00e+00 | 0.06020 | 7.69e-03 | 2.67e-03 | -2.41e-03 | 1.34e-02 | -5.81e-02 | 8.63e-01 | 9.52e-01 | 9.57e-01 | 7.64e-01 | 1.94e-01 |
| LIPID METABOLIC PROCESS | 1354 | 7.47e-02 | 4.49e-01 | 0.06010 | 2.73e-02 | 3.05e-02 | 1.87e-02 | 3.91e-02 | 7.31e-03 | 9.21e-02 | 5.93e-02 | 2.49e-01 | 1.57e-02 | 6.51e-01 |
| LIPID MODIFICATION | 185 | 7.72e-01 | 1.00e+00 | 0.06000 | 2.28e-02 | 3.04e-02 | 2.68e-04 | 4.64e-02 | 4.37e-04 | 5.93e-01 | 4.75e-01 | 9.95e-01 | 2.76e-01 | 9.92e-01 |
| POST TRANSCRIPTIONAL REGULATION OF GENE EXPRESSION | 971 | 7.44e-03 | 1.02e-01 | 0.06000 | -1.48e-02 | -3.39e-03 | -3.88e-02 | -1.66e-02 | -3.98e-02 | 4.36e-01 | 8.58e-01 | 4.08e-02 | 3.80e-01 | 3.55e-02 |
| MEMBRANE ORGANIZATION | 777 | 6.08e-02 | 4.04e-01 | 0.05990 | 8.88e-03 | 4.47e-03 | 3.89e-02 | -1.40e-02 | 4.22e-02 | 6.74e-01 | 8.32e-01 | 6.49e-02 | 5.06e-01 | 4.52e-02 |
| PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR SIGNALING PATHWAY | 23 | 9.94e-01 | 1.00e+00 | 0.05990 | -1.85e-02 | -1.35e-02 | -1.16e-02 | -1.84e-03 | 5.41e-02 | 8.78e-01 | 9.11e-01 | 9.24e-01 | 9.88e-01 | 6.54e-01 |
| PYRIMIDINE NUCLEOTIDE BIOSYNTHETIC PROCESS | 29 | 9.66e-01 | 1.00e+00 | 0.05990 | 3.05e-02 | 1.36e-02 | 4.39e-02 | 2.26e-03 | -2.31e-02 | 7.76e-01 | 8.99e-01 | 6.82e-01 | 9.83e-01 | 8.29e-01 |
| CARDIOCYTE DIFFERENTIATION | 163 | 3.39e-01 | 8.59e-01 | 0.05980 | 1.82e-02 | 2.17e-02 | 4.14e-02 | -5.90e-03 | -3.20e-02 | 6.88e-01 | 6.33e-01 | 3.61e-01 | 8.97e-01 | 4.81e-01 |
| POSITIVE REGULATION OF RECEPTOR RECYCLING | 14 | 9.96e-01 | 1.00e+00 | 0.05980 | -2.65e-02 | -3.28e-02 | 1.38e-02 | -3.29e-02 | 2.30e-02 | 8.64e-01 | 8.32e-01 | 9.29e-01 | 8.31e-01 | 8.82e-01 |
| QUATERNARY AMMONIUM GROUP TRANSPORT | 29 | 6.96e-01 | 1.00e+00 | 0.05980 | -2.05e-03 | 1.12e-02 | 4.21e-02 | -3.47e-02 | -2.15e-02 | 9.85e-01 | 9.17e-01 | 6.95e-01 | 7.46e-01 | 8.41e-01 |
| SEX DIFFERENTIATION | 266 | 2.40e-02 | 2.33e-01 | 0.05970 | 1.88e-02 | -1.12e-03 | 5.07e-02 | 3.14e-03 | -2.52e-02 | 5.98e-01 | 9.75e-01 | 1.54e-01 | 9.30e-01 | 4.80e-01 |
| CELLULAR RESPONSE TO PEPTIDE | 367 | 2.01e-01 | 7.17e-01 | 0.05970 | 7.78e-03 | -3.26e-04 | 4.56e-02 | -1.05e-02 | 3.62e-02 | 7.98e-01 | 9.91e-01 | 1.33e-01 | 7.30e-01 | 2.34e-01 |
| POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 182 | 2.24e-01 | 7.45e-01 | 0.05960 | 1.66e-02 | 1.55e-02 | 5.23e-02 | -1.26e-02 | -1.22e-02 | 7.00e-01 | 7.18e-01 | 2.24e-01 | 7.70e-01 | 7.77e-01 |
| MUSCLE HYPERTROPHY | 103 | 9.93e-01 | 1.00e+00 | 0.05940 | 2.95e-02 | 2.61e-02 | 2.38e-02 | 3.45e-02 | 1.47e-02 | 6.05e-01 | 6.47e-01 | 6.77e-01 | 5.45e-01 | 7.96e-01 |
| REGULATION OF RUFFLE ASSEMBLY | 32 | 6.63e-01 | 1.00e+00 | 0.05940 | 9.91e-03 | 1.36e-02 | 2.75e-02 | 3.11e-02 | -3.90e-02 | 9.23e-01 | 8.94e-01 | 7.88e-01 | 7.61e-01 | 7.03e-01 |
| NEGATIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 72 | 3.90e-01 | 8.92e-01 | 0.05930 | 1.49e-02 | 3.25e-02 | -2.66e-02 | 1.93e-02 | 3.41e-02 | 8.27e-01 | 6.34e-01 | 6.97e-01 | 7.77e-01 | 6.16e-01 |
| RESPONSE TO POTASSIUM ION | 17 | 9.94e-01 | 1.00e+00 | 0.05930 | 2.56e-02 | 3.92e-02 | 3.88e-03 | 5.87e-03 | -3.57e-02 | 8.55e-01 | 7.80e-01 | 9.78e-01 | 9.67e-01 | 7.99e-01 |
| SYNAPSE ASSEMBLY | 185 | 1.16e-01 | 5.66e-01 | 0.05910 | 8.69e-03 | 2.06e-02 | 3.03e-02 | -3.00e-02 | -3.43e-02 | 8.39e-01 | 6.29e-01 | 4.77e-01 | 4.81e-01 | 4.21e-01 |
| REGULATION OF MEMBRANE PERMEABILITY | 72 | 4.72e-01 | 9.40e-01 | 0.05910 | 1.16e-02 | 3.64e-02 | 8.90e-03 | -1.06e-02 | -4.29e-02 | 8.65e-01 | 5.93e-01 | 8.96e-01 | 8.77e-01 | 5.29e-01 |
| HEMOSTASIS | 220 | 3.39e-01 | 8.59e-01 | 0.05900 | -2.59e-02 | -3.34e-02 | 1.06e-02 | -3.88e-02 | -8.64e-03 | 5.07e-01 | 3.94e-01 | 7.87e-01 | 3.21e-01 | 8.25e-01 |
| NEGATIVE REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 24 | 7.22e-01 | 1.00e+00 | 0.05880 | 1.34e-02 | 4.29e-02 | -1.87e-02 | -5.32e-03 | 3.25e-02 | 9.10e-01 | 7.16e-01 | 8.74e-01 | 9.64e-01 | 7.83e-01 |
| CELLULAR CATABOLIC PROCESS | 1537 | 2.11e-05 | 8.92e-04 | 0.05880 | 1.17e-02 | 1.35e-02 | 3.97e-02 | -1.02e-02 | 3.82e-02 | 4.44e-01 | 3.77e-01 | 9.34e-03 | 5.04e-01 | 1.23e-02 |
| POSITIVE REGULATION OF SECRETION | 305 | 2.87e-02 | 2.62e-01 | 0.05880 | -1.40e-03 | -5.11e-03 | 3.56e-02 | -3.12e-02 | -3.45e-02 | 9.67e-01 | 8.78e-01 | 2.85e-01 | 3.49e-01 | 3.00e-01 |
| SPERMATID DIFFERENTIATION | 202 | 1.91e-01 | 7.01e-01 | 0.05870 | -7.47e-03 | -1.04e-02 | -4.62e-02 | 2.72e-02 | -2.00e-02 | 8.55e-01 | 7.98e-01 | 2.57e-01 | 5.05e-01 | 6.24e-01 |
| POSITIVE REGULATION OF MONOOXYGENASE ACTIVITY | 26 | 9.94e-01 | 1.00e+00 | 0.05860 | -1.83e-02 | -2.95e-02 | 1.93e-02 | -3.46e-02 | 2.56e-02 | 8.72e-01 | 7.94e-01 | 8.65e-01 | 7.60e-01 | 8.21e-01 |
| CELLULAR RESPONSE TO PROSTAGLANDIN E STIMULUS | 15 | 8.66e-01 | 1.00e+00 | 0.05860 | -3.31e-03 | 3.62e-02 | -2.04e-02 | -2.67e-02 | -3.13e-02 | 9.82e-01 | 8.08e-01 | 8.91e-01 | 8.58e-01 | 8.34e-01 |
| SUBSTRATE ADHESION DEPENDENT CELL SPREADING | 99 | 4.84e-01 | 9.43e-01 | 0.05850 | 1.92e-02 | 1.09e-03 | 3.16e-02 | 1.85e-02 | -4.13e-02 | 7.41e-01 | 9.85e-01 | 5.86e-01 | 7.50e-01 | 4.77e-01 |
| BEHAVIOR | 629 | 3.54e-01 | 8.72e-01 | 0.05850 | 2.90e-02 | 3.07e-02 | 3.66e-02 | 1.22e-02 | -1.19e-02 | 2.14e-01 | 1.89e-01 | 1.17e-01 | 6.00e-01 | 6.09e-01 |
| MICROTUBULE BASED TRANSPORT | 204 | 2.09e-01 | 7.30e-01 | 0.05850 | 6.50e-04 | -1.46e-02 | 4.87e-02 | -2.14e-02 | 1.94e-02 | 9.87e-01 | 7.20e-01 | 2.31e-01 | 5.98e-01 | 6.32e-01 |
| POSITIVE REGULATION OF PROTEOLYSIS | 340 | 1.40e-01 | 6.24e-01 | 0.05840 | 9.52e-03 | 9.85e-03 | 4.12e-02 | -2.84e-02 | 2.69e-02 | 7.63e-01 | 7.55e-01 | 1.92e-01 | 3.69e-01 | 3.94e-01 |
| POLYOL METABOLIC PROCESS | 103 | 6.89e-01 | 1.00e+00 | 0.05840 | 2.00e-02 | 1.69e-02 | 1.57e-02 | 4.96e-02 | -3.26e-03 | 7.26e-01 | 7.67e-01 | 7.83e-01 | 3.84e-01 | 9.54e-01 |
| ENDOTHELIUM DEVELOPMENT | 143 | 4.72e-01 | 9.40e-01 | 0.05830 | 1.27e-02 | 1.24e-02 | 4.99e-02 | -2.39e-02 | 4.04e-03 | 7.93e-01 | 7.99e-01 | 3.03e-01 | 6.22e-01 | 9.34e-01 |
| LIPID LOCALIZATION | 496 | 3.21e-01 | 8.47e-01 | 0.05820 | 2.00e-02 | 2.53e-02 | 6.32e-03 | 3.10e-02 | -3.67e-02 | 4.46e-01 | 3.34e-01 | 8.10e-01 | 2.37e-01 | 1.62e-01 |
| POSITIVE REGULATION OF CELL DEVELOPMENT | 426 | 7.69e-02 | 4.55e-01 | 0.05820 | -6.53e-03 | -1.64e-02 | 3.75e-02 | -3.14e-02 | 2.61e-02 | 8.17e-01 | 5.62e-01 | 1.84e-01 | 2.66e-01 | 3.56e-01 |
| VASCULATURE DEVELOPMENT | 794 | 1.69e-01 | 6.74e-01 | 0.05810 | 2.66e-02 | 2.48e-02 | 3.22e-02 | 1.47e-02 | -2.82e-02 | 2.02e-01 | 2.36e-01 | 1.23e-01 | 4.81e-01 | 1.76e-01 |
| RESPONSE TO NITROGEN COMPOUND | 1083 | 2.87e-04 | 8.38e-03 | 0.05800 | 1.43e-02 | 7.53e-03 | 5.15e-02 | -1.22e-02 | 1.73e-02 | 4.27e-01 | 6.76e-01 | 4.16e-03 | 4.96e-01 | 3.35e-01 |
| REGULATION OF MRNA CATABOLIC PROCESS | 240 | 7.23e-01 | 1.00e+00 | 0.05800 | -2.28e-02 | -1.98e-02 | -6.43e-03 | -3.69e-02 | 3.23e-02 | 5.43e-01 | 5.97e-01 | 8.64e-01 | 3.25e-01 | 3.88e-01 |
| KERATAN SULFATE METABOLIC PROCESS | 18 | 9.27e-01 | 1.00e+00 | 0.05790 | -4.06e-03 | -3.63e-02 | 2.20e-02 | 1.02e-02 | 3.79e-02 | 9.76e-01 | 7.90e-01 | 8.72e-01 | 9.40e-01 | 7.81e-01 |
| RESPONSE TO BMP | 170 | 6.07e-01 | 9.90e-01 | 0.05780 | 1.58e-02 | 1.48e-02 | 3.32e-02 | -1.34e-02 | -3.99e-02 | 7.23e-01 | 7.39e-01 | 4.56e-01 | 7.63e-01 | 3.69e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 71 | 8.84e-01 | 1.00e+00 | 0.05780 | -1.15e-03 | 1.15e-02 | -2.48e-03 | -1.28e-02 | -5.51e-02 | 9.87e-01 | 8.67e-01 | 9.71e-01 | 8.52e-01 | 4.22e-01 |
| MICROTUBULE CYTOSKELETON ORGANIZATION | 628 | 7.26e-02 | 4.43e-01 | 0.05770 | 1.69e-02 | 7.67e-03 | 4.99e-02 | -8.63e-03 | 2.07e-02 | 4.69e-01 | 7.43e-01 | 3.28e-02 | 7.12e-01 | 3.76e-01 |
| REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 249 | 7.95e-02 | 4.64e-01 | 0.05760 | -1.99e-02 | -2.57e-02 | 2.37e-02 | -3.95e-02 | -1.20e-02 | 5.89e-01 | 4.85e-01 | 5.20e-01 | 2.83e-01 | 7.44e-01 |
| CARBOHYDRATE DERIVATIVE CATABOLIC PROCESS | 170 | 6.11e-01 | 9.90e-01 | 0.05760 | -2.39e-02 | -2.33e-02 | 1.06e-02 | -3.65e-02 | 2.76e-02 | 5.91e-01 | 6.01e-01 | 8.12e-01 | 4.12e-01 | 5.34e-01 |
| FAT SOLUBLE VITAMIN METABOLIC PROCESS | 45 | 9.72e-01 | 1.00e+00 | 0.05760 | -1.07e-03 | 1.04e-02 | -4.85e-03 | -1.84e-02 | -5.33e-02 | 9.90e-01 | 9.04e-01 | 9.55e-01 | 8.31e-01 | 5.36e-01 |
| NEUROGENESIS | 1648 | 1.11e-03 | 2.49e-02 | 0.05760 | 2.63e-02 | 2.52e-02 | 4.21e-02 | 6.17e-04 | -1.48e-02 | 7.53e-02 | 8.83e-02 | 4.39e-03 | 9.67e-01 | 3.15e-01 |
| SECRETORY GRANULE ORGANIZATION | 63 | 4.87e-01 | 9.43e-01 | 0.05760 | 8.07e-03 | -1.43e-02 | 3.51e-02 | -4.13e-02 | -1.06e-02 | 9.12e-01 | 8.44e-01 | 6.30e-01 | 5.71e-01 | 8.84e-01 |
| CELLULAR METABOLIC COMPOUND SALVAGE | 29 | 9.79e-01 | 1.00e+00 | 0.05760 | -8.67e-03 | 6.37e-03 | -1.76e-02 | -3.02e-02 | -4.44e-02 | 9.36e-01 | 9.53e-01 | 8.70e-01 | 7.78e-01 | 6.79e-01 |
| MOTILE CILIUM ASSEMBLY | 64 | 9.92e-01 | 1.00e+00 | 0.05720 | -2.59e-02 | -3.42e-02 | -3.88e-03 | -2.80e-02 | 2.53e-02 | 7.20e-01 | 6.36e-01 | 9.57e-01 | 6.99e-01 | 7.26e-01 |
| CELLULAR RESPONSE TO VITAMIN | 28 | 9.87e-01 | 1.00e+00 | 0.05720 | -2.17e-02 | -6.81e-03 | -2.22e-02 | -3.64e-02 | -3.07e-02 | 8.43e-01 | 9.50e-01 | 8.39e-01 | 7.39e-01 | 7.79e-01 |
| POSITIVE REGULATION OF ACTIVATED T CELL PROLIFERATION | 26 | 9.56e-01 | 1.00e+00 | 0.05720 | -2.07e-02 | -2.90e-02 | -2.53e-02 | 2.71e-02 | 2.50e-02 | 8.55e-01 | 7.98e-01 | 8.23e-01 | 8.11e-01 | 8.25e-01 |
| RESPONSE TO KETONE | 198 | 4.36e-01 | 9.22e-01 | 0.05690 | -5.89e-03 | -3.54e-03 | 1.54e-02 | -3.56e-02 | -4.11e-02 | 8.86e-01 | 9.32e-01 | 7.09e-01 | 3.88e-01 | 3.18e-01 |
| CELL MOTILITY | 1721 | 6.18e-02 | 4.07e-01 | 0.05690 | -3.13e-02 | -3.03e-02 | -2.04e-02 | -2.82e-02 | -1.17e-02 | 3.10e-02 | 3.67e-02 | 1.58e-01 | 5.19e-02 | 4.20e-01 |
| RENAL SYSTEM DEVELOPMENT | 316 | 3.43e-02 | 2.95e-01 | 0.05690 | -8.65e-03 | -1.16e-02 | 3.46e-02 | -4.11e-02 | -1.19e-02 | 7.91e-01 | 7.22e-01 | 2.90e-01 | 2.09e-01 | 7.16e-01 |
| ACTIVATION OF PROTEIN KINASE C ACTIVITY | 5 | 9.99e-01 | 1.00e+00 | 0.05690 | -1.21e-02 | -6.11e-03 | 1.30e-02 | -5.30e-02 | 8.95e-03 | 9.63e-01 | 9.81e-01 | 9.60e-01 | 8.38e-01 | 9.72e-01 |
| BONE DEVELOPMENT | 204 | 1.71e-01 | 6.75e-01 | 0.05690 | 1.80e-02 | 3.20e-02 | 1.04e-02 | 3.26e-02 | -2.66e-02 | 6.57e-01 | 4.30e-01 | 7.97e-01 | 4.22e-01 | 5.12e-01 |
| MAINTENANCE OF BLOOD BRAIN BARRIER | 36 | 8.24e-01 | 1.00e+00 | 0.05670 | -1.30e-02 | -1.69e-02 | 2.88e-02 | -2.92e-02 | -3.28e-02 | 8.92e-01 | 8.61e-01 | 7.65e-01 | 7.62e-01 | 7.34e-01 |
| TRANSMISSION OF NERVE IMPULSE | 68 | 8.82e-01 | 1.00e+00 | 0.05670 | -1.23e-02 | -1.68e-02 | 5.45e-03 | -1.99e-02 | -4.85e-02 | 8.61e-01 | 8.11e-01 | 9.38e-01 | 7.77e-01 | 4.89e-01 |
| MALE SEX DIFFERENTIATION | 163 | 3.13e-01 | 8.40e-01 | 0.05660 | 1.48e-02 | -6.20e-04 | 2.79e-02 | 6.69e-03 | -4.65e-02 | 7.45e-01 | 9.89e-01 | 5.38e-01 | 8.83e-01 | 3.06e-01 |
| POLYSACCHARIDE BIOSYNTHETIC PROCESS | 64 | 3.42e-01 | 8.60e-01 | 0.05650 | 1.12e-02 | 3.95e-02 | 1.42e-02 | -1.35e-02 | -3.35e-02 | 8.77e-01 | 5.85e-01 | 8.44e-01 | 8.52e-01 | 6.43e-01 |
| CELLULAR RESPONSE TO INSULIN STIMULUS | 203 | 7.51e-01 | 1.00e+00 | 0.05640 | -1.41e-02 | -1.59e-02 | 1.58e-02 | -2.90e-02 | 4.05e-02 | 7.29e-01 | 6.96e-01 | 6.97e-01 | 4.77e-01 | 3.20e-01 |
| PEPTIDE TRANSPORT | 254 | 1.50e-01 | 6.39e-01 | 0.05640 | 1.52e-02 | 2.54e-02 | 2.31e-02 | 2.62e-03 | -4.20e-02 | 6.76e-01 | 4.86e-01 | 5.27e-01 | 9.43e-01 | 2.49e-01 |
| CELLULAR RESPONSE TO NITROGEN COMPOUND | 662 | 2.19e-02 | 2.21e-01 | 0.05630 | 1.46e-02 | 9.03e-03 | 4.82e-02 | -3.37e-03 | 2.32e-02 | 5.22e-01 | 6.92e-01 | 3.44e-02 | 8.82e-01 | 3.08e-01 |
| POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 1247 | 5.84e-04 | 1.46e-02 | 0.05610 | 1.64e-02 | 1.48e-02 | 4.64e-02 | -7.90e-03 | 2.12e-02 | 3.29e-01 | 3.80e-01 | 5.83e-03 | 6.39e-01 | 2.08e-01 |
| CANONICAL WNT SIGNALING PATHWAY | 302 | 3.84e-02 | 3.13e-01 | 0.05610 | -1.64e-02 | -2.19e-02 | 3.03e-02 | -3.85e-02 | 1.44e-03 | 6.24e-01 | 5.12e-01 | 3.66e-01 | 2.50e-01 | 9.66e-01 |
| CARDIAC CELL DEVELOPMENT | 92 | 8.57e-01 | 1.00e+00 | 0.05610 | 2.18e-02 | 2.58e-02 | 2.83e-02 | 1.83e-02 | -2.95e-02 | 7.18e-01 | 6.69e-01 | 6.39e-01 | 7.62e-01 | 6.25e-01 |
| ESTABLISHMENT OF CELL POLARITY | 153 | 9.17e-01 | 1.00e+00 | 0.05600 | -2.34e-02 | -1.44e-02 | -2.73e-02 | -1.97e-02 | -3.53e-02 | 6.18e-01 | 7.58e-01 | 5.60e-01 | 6.73e-01 | 4.51e-01 |
| REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 277 | 3.08e-01 | 8.35e-01 | 0.05600 | -3.05e-02 | -2.25e-02 | -4.09e-02 | 4.36e-03 | -9.02e-04 | 3.82e-01 | 5.20e-01 | 2.41e-01 | 9.01e-01 | 9.79e-01 |
| REGULATION OF AMYLOID PRECURSOR PROTEIN CATABOLIC PROCESS | 54 | 9.15e-01 | 1.00e+00 | 0.05590 | 2.26e-02 | 7.99e-03 | 4.14e-02 | 7.03e-03 | -2.80e-02 | 7.74e-01 | 9.19e-01 | 5.98e-01 | 9.29e-01 | 7.22e-01 |
| REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 515 | 2.30e-02 | 2.26e-01 | 0.05570 | -1.09e-02 | -1.18e-02 | 2.69e-02 | -4.57e-02 | 5.35e-03 | 6.73e-01 | 6.48e-01 | 2.96e-01 | 7.57e-02 | 8.36e-01 |
| NEGATIVE REGULATION OF MONOATOMIC ION TRANSPORT | 125 | 9.63e-01 | 1.00e+00 | 0.05570 | 1.66e-02 | 2.38e-02 | -2.45e-03 | 1.79e-02 | -4.39e-02 | 7.48e-01 | 6.46e-01 | 9.62e-01 | 7.30e-01 | 3.96e-01 |
| GLOMERULAR MESANGIUM DEVELOPMENT | 18 | 8.83e-01 | 1.00e+00 | 0.05540 | -2.69e-02 | -2.63e-03 | -5.64e-04 | -4.74e-02 | -9.99e-03 | 8.43e-01 | 9.85e-01 | 9.97e-01 | 7.28e-01 | 9.41e-01 |
| RUFFLE ORGANIZATION | 57 | 4.63e-01 | 9.33e-01 | 0.05540 | 1.09e-03 | 1.30e-02 | 3.72e-02 | -4.65e-03 | 3.87e-02 | 9.89e-01 | 8.65e-01 | 6.27e-01 | 9.52e-01 | 6.14e-01 |
| AXON EXTENSION | 111 | 8.61e-01 | 1.00e+00 | 0.05540 | 1.99e-02 | 1.59e-02 | 1.19e-02 | 3.59e-02 | -3.14e-02 | 7.17e-01 | 7.73e-01 | 8.29e-01 | 5.14e-01 | 5.67e-01 |
| RETINA HOMEOSTASIS | 75 | 7.88e-01 | 1.00e+00 | 0.05530 | -7.07e-03 | 7.24e-03 | -5.08e-02 | 1.48e-02 | -1.29e-02 | 9.16e-01 | 9.14e-01 | 4.47e-01 | 8.25e-01 | 8.47e-01 |
| CELL MATURATION | 191 | 8.73e-01 | 1.00e+00 | 0.05530 | 1.03e-02 | 1.14e-02 | -4.88e-04 | 4.72e-03 | -5.29e-02 | 8.06e-01 | 7.86e-01 | 9.91e-01 | 9.10e-01 | 2.07e-01 |
| NUCLEOSIDE BISPHOSPHATE BIOSYNTHETIC PROCESS | 54 | 7.26e-01 | 1.00e+00 | 0.05530 | 1.72e-02 | 2.04e-02 | 4.71e-02 | 6.99e-03 | -8.69e-03 | 8.27e-01 | 7.96e-01 | 5.49e-01 | 9.29e-01 | 9.12e-01 |
| AMINO ACID METABOLIC PROCESS | 278 | 2.69e-01 | 7.96e-01 | 0.05530 | 2.38e-02 | 2.89e-02 | 3.48e-02 | -1.45e-02 | -1.52e-02 | 4.94e-01 | 4.06e-01 | 3.18e-01 | 6.77e-01 | 6.62e-01 |
| REGULATION OF PROTEIN CONTAINING COMPLEX ASSEMBLY | 403 | 1.33e-01 | 6.05e-01 | 0.05520 | 1.01e-02 | 8.96e-03 | 4.37e-02 | -1.71e-02 | 2.57e-02 | 7.28e-01 | 7.58e-01 | 1.32e-01 | 5.57e-01 | 3.76e-01 |
| REGULATION OF CELLULAR COMPONENT BIOGENESIS | 956 | 4.78e-03 | 7.45e-02 | 0.05520 | 1.09e-02 | 1.15e-02 | 3.90e-02 | -7.22e-03 | 3.50e-02 | 5.69e-01 | 5.48e-01 | 4.13e-02 | 7.05e-01 | 6.66e-02 |
| REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 218 | 2.48e-01 | 7.75e-01 | 0.05520 | 1.17e-02 | 6.42e-03 | 3.44e-02 | -4.48e-03 | -4.07e-02 | 7.65e-01 | 8.70e-01 | 3.81e-01 | 9.09e-01 | 3.00e-01 |
| NEGATIVE REGULATION OF ERBB SIGNALING PATHWAY | 32 | 9.96e-01 | 1.00e+00 | 0.05520 | 2.72e-02 | 3.26e-02 | 2.72e-02 | 1.04e-02 | 1.98e-02 | 7.90e-01 | 7.50e-01 | 7.90e-01 | 9.19e-01 | 8.46e-01 |
| MEMBRANE LIPID METABOLIC PROCESS | 208 | 8.11e-01 | 1.00e+00 | 0.05510 | 2.57e-02 | 2.38e-02 | 4.10e-02 | 7.97e-03 | -8.47e-03 | 5.23e-01 | 5.54e-01 | 3.08e-01 | 8.43e-01 | 8.33e-01 |
| REGULATION OF HISTONE METHYLATION | 16 | 6.94e-01 | 1.00e+00 | 0.05510 | -1.92e-02 | -1.56e-02 | -6.19e-03 | 4.49e-02 | -1.91e-02 | 8.94e-01 | 9.14e-01 | 9.66e-01 | 7.56e-01 | 8.95e-01 |
| POSITIVE REGULATION OF MACROPHAGE DERIVED FOAM CELL DIFFERENTIATION | 19 | 9.28e-01 | 1.00e+00 | 0.05480 | -9.01e-03 | -1.58e-02 | -4.90e-02 | 5.09e-03 | -1.58e-02 | 9.46e-01 | 9.05e-01 | 7.12e-01 | 9.69e-01 | 9.05e-01 |
| EXPORT FROM CELL | 870 | 3.65e-03 | 6.11e-02 | 0.05480 | 2.15e-02 | 2.10e-02 | 4.03e-02 | 5.46e-03 | -2.11e-02 | 2.81e-01 | 2.94e-01 | 4.36e-02 | 7.85e-01 | 2.90e-01 |
| APOPTOTIC DNA FRAGMENTATION | 19 | 9.94e-01 | 1.00e+00 | 0.05470 | -2.18e-02 | -1.98e-02 | -4.40e-02 | -1.40e-02 | 8.25e-04 | 8.69e-01 | 8.81e-01 | 7.40e-01 | 9.16e-01 | 9.95e-01 |
| HORMONE BIOSYNTHETIC PROCESS | 65 | 5.70e-01 | 9.76e-01 | 0.05460 | -7.89e-03 | 1.50e-02 | -3.69e-02 | 3.55e-02 | 8.34e-03 | 9.12e-01 | 8.34e-01 | 6.07e-01 | 6.21e-01 | 9.07e-01 |
| REGULATION OF SECRETION | 603 | 5.99e-03 | 8.74e-02 | 0.05450 | 1.47e-02 | 1.15e-02 | 4.30e-02 | -1.16e-02 | -2.53e-02 | 5.37e-01 | 6.28e-01 | 7.14e-02 | 6.27e-01 | 2.89e-01 |
| MUSCLE CELL MIGRATION | 100 | 4.77e-01 | 9.40e-01 | 0.05450 | 2.31e-02 | 1.61e-02 | 3.13e-02 | -2.57e-02 | -2.31e-02 | 6.90e-01 | 7.81e-01 | 5.88e-01 | 6.56e-01 | 6.89e-01 |
| REGULATION OF INSULIN SECRETION | 161 | 1.73e-01 | 6.77e-01 | 0.05450 | 8.37e-03 | 1.54e-02 | 4.08e-02 | -2.48e-02 | -1.96e-02 | 8.55e-01 | 7.36e-01 | 3.72e-01 | 5.87e-01 | 6.68e-01 |
| TISSUE REGENERATION | 73 | 4.53e-01 | 9.31e-01 | 0.05410 | 1.42e-02 | 1.66e-02 | -3.71e-02 | 3.29e-02 | -4.17e-04 | 8.34e-01 | 8.06e-01 | 5.84e-01 | 6.27e-01 | 9.95e-01 |
| POSTSYNAPTIC SIGNAL TRANSDUCTION | 38 | 8.39e-01 | 1.00e+00 | 0.05410 | -1.92e-02 | -3.13e-03 | -1.36e-03 | -1.45e-02 | 4.83e-02 | 8.38e-01 | 9.73e-01 | 9.88e-01 | 8.77e-01 | 6.06e-01 |
| PROGRAMMED NECROTIC CELL DEATH | 56 | 9.19e-01 | 1.00e+00 | 0.05390 | -2.06e-02 | -2.69e-02 | -2.21e-02 | -3.55e-02 | -3.21e-03 | 7.89e-01 | 7.27e-01 | 7.75e-01 | 6.46e-01 | 9.67e-01 |
| TISSUE MIGRATION | 364 | 3.03e-01 | 8.32e-01 | 0.05390 | -8.65e-03 | 5.69e-03 | -2.02e-02 | -1.35e-02 | -4.70e-02 | 7.77e-01 | 8.52e-01 | 5.08e-01 | 6.58e-01 | 1.23e-01 |
| REGULATION OF CELL JUNCTION ASSEMBLY | 199 | 6.49e-01 | 1.00e+00 | 0.05390 | 2.19e-02 | 3.03e-02 | 2.79e-02 | 1.71e-02 | 2.08e-02 | 5.94e-01 | 4.61e-01 | 4.97e-01 | 6.78e-01 | 6.13e-01 |
| RIGHTING REFLEX | 8 | 8.51e-01 | 1.00e+00 | 0.05380 | -2.58e-02 | -2.64e-02 | 3.47e-02 | -3.62e-03 | -1.79e-02 | 9.00e-01 | 8.97e-01 | 8.65e-01 | 9.86e-01 | 9.30e-01 |
| SPONTANEOUS SYNAPTIC TRANSMISSION | 14 | 9.87e-01 | 1.00e+00 | 0.05370 | 1.31e-02 | 3.00e-02 | 1.81e-02 | -2.34e-02 | -3.06e-02 | 9.32e-01 | 8.46e-01 | 9.07e-01 | 8.79e-01 | 8.43e-01 |
| GAMETE GENERATION | 724 | 3.47e-02 | 2.96e-01 | 0.05370 | -1.44e-02 | -2.34e-02 | -1.27e-02 | -1.75e-02 | -4.07e-02 | 5.09e-01 | 2.84e-01 | 5.60e-01 | 4.22e-01 | 6.19e-02 |
| ENDOCRINE HORMONE SECRETION | 56 | 9.68e-01 | 1.00e+00 | 0.05360 | -2.02e-02 | -3.29e-02 | 1.13e-02 | -3.47e-02 | 7.00e-03 | 7.94e-01 | 6.70e-01 | 8.83e-01 | 6.53e-01 | 9.28e-01 |
| NUCLEOSIDE BISPHOSPHATE METABOLIC PROCESS | 116 | 6.22e-01 | 9.91e-01 | 0.05360 | 1.42e-02 | 2.59e-02 | -1.52e-03 | 4.14e-02 | -1.67e-02 | 7.92e-01 | 6.30e-01 | 9.77e-01 | 4.41e-01 | 7.57e-01 |
| REGULATION OF CELL DIVISION | 177 | 9.59e-02 | 5.12e-01 | 0.05320 | 9.37e-03 | 4.03e-03 | 5.20e-02 | -3.77e-03 | 3.06e-03 | 8.30e-01 | 9.26e-01 | 2.33e-01 | 9.31e-01 | 9.44e-01 |
| NEGATIVE REGULATION OF JNK CASCADE | 37 | 9.72e-01 | 1.00e+00 | 0.05310 | 2.50e-02 | 2.73e-02 | 3.10e-02 | -7.99e-03 | 2.07e-02 | 7.92e-01 | 7.74e-01 | 7.45e-01 | 9.33e-01 | 8.28e-01 |
| NEGATIVE REGULATION OF AUTOPHAGY | 86 | 8.40e-01 | 1.00e+00 | 0.05300 | 6.27e-03 | 1.71e-02 | 7.76e-03 | 1.15e-02 | 4.78e-02 | 9.20e-01 | 7.84e-01 | 9.01e-01 | 8.54e-01 | 4.44e-01 |
| AMINOGLYCAN BIOSYNTHETIC PROCESS | 73 | 9.81e-01 | 1.00e+00 | 0.05300 | -1.63e-02 | -1.32e-02 | -2.01e-02 | -8.38e-03 | -4.35e-02 | 8.10e-01 | 8.45e-01 | 7.67e-01 | 9.01e-01 | 5.21e-01 |
| REGULATION OF GLUCONEOGENESIS | 51 | 9.68e-01 | 1.00e+00 | 0.05290 | 2.89e-02 | 3.37e-02 | 2.25e-03 | 2.20e-02 | -1.85e-02 | 7.21e-01 | 6.77e-01 | 9.78e-01 | 7.86e-01 | 8.20e-01 |
| PROTEOLYSIS | 1554 | 5.83e-04 | 1.46e-02 | 0.05290 | 1.73e-02 | 1.69e-02 | 4.24e-02 | -9.03e-03 | 1.83e-02 | 2.55e-01 | 2.65e-01 | 5.26e-03 | 5.52e-01 | 2.28e-01 |
| NEGATIVE REGULATION OF CELL MATRIX ADHESION | 37 | 9.67e-01 | 1.00e+00 | 0.05280 | -2.34e-02 | -2.63e-02 | 7.80e-03 | -1.69e-02 | 3.47e-02 | 8.06e-01 | 7.82e-01 | 9.35e-01 | 8.59e-01 | 7.15e-01 |
| REGULATION OF CARBOHYDRATE BIOSYNTHETIC PROCESS | 102 | 7.23e-01 | 1.00e+00 | 0.05280 | 1.38e-02 | 2.41e-02 | 2.18e-02 | -3.07e-03 | -3.90e-02 | 8.09e-01 | 6.74e-01 | 7.03e-01 | 9.57e-01 | 4.96e-01 |
| SUPEROXIDE METABOLIC PROCESS | 66 | 8.97e-01 | 1.00e+00 | 0.05260 | 1.42e-03 | -3.02e-03 | 3.36e-02 | -3.65e-02 | -1.73e-02 | 9.84e-01 | 9.66e-01 | 6.37e-01 | 6.08e-01 | 8.08e-01 |
| LOCOMOTOR RHYTHM | 15 | 9.89e-01 | 1.00e+00 | 0.05260 | -1.51e-02 | -3.76e-02 | 2.07e-03 | -1.05e-02 | 3.19e-02 | 9.19e-01 | 8.01e-01 | 9.89e-01 | 9.44e-01 | 8.31e-01 |
| PROTEIN DESTABILIZATION | 46 | 9.33e-01 | 1.00e+00 | 0.05250 | -2.91e-02 | -2.11e-02 | -7.25e-03 | -3.46e-02 | -1.47e-02 | 7.33e-01 | 8.04e-01 | 9.32e-01 | 6.85e-01 | 8.63e-01 |
| BRANCHED CHAIN AMINO ACID METABOLIC PROCESS | 26 | 9.73e-01 | 1.00e+00 | 0.05250 | 3.28e-02 | 2.24e-02 | 2.28e-02 | 1.89e-02 | 1.72e-02 | 7.72e-01 | 8.43e-01 | 8.40e-01 | 8.67e-01 | 8.80e-01 |
| PYRAMIDAL NEURON DIFFERENTIATION | 12 | 9.98e-01 | 1.00e+00 | 0.05230 | 1.17e-02 | 9.43e-03 | 3.64e-02 | -3.08e-02 | -1.56e-02 | 9.44e-01 | 9.55e-01 | 8.27e-01 | 8.54e-01 | 9.25e-01 |
| POSITIVE REGULATION OF EXOCYTOSIS | 74 | 9.84e-01 | 1.00e+00 | 0.05230 | 2.70e-02 | 2.06e-02 | 2.42e-02 | 1.77e-02 | -2.61e-02 | 6.87e-01 | 7.59e-01 | 7.19e-01 | 7.92e-01 | 6.97e-01 |
| AMELOBLAST DIFFERENTIATION | 5 | 9.80e-01 | 1.00e+00 | 0.05230 | -1.13e-02 | -1.77e-02 | 2.01e-02 | 2.14e-02 | -3.78e-02 | 9.65e-01 | 9.45e-01 | 9.38e-01 | 9.34e-01 | 8.84e-01 |
| REGULATION OF HORMONE SECRETION | 248 | 2.54e-01 | 7.82e-01 | 0.05230 | 1.25e-02 | 1.38e-02 | 3.54e-02 | -1.26e-02 | -3.12e-02 | 7.35e-01 | 7.08e-01 | 3.37e-01 | 7.32e-01 | 3.97e-01 |
| MONOATOMIC ION TRANSPORT | 1196 | 1.15e-01 | 5.64e-01 | 0.05220 | 2.24e-02 | 2.80e-02 | 1.11e-02 | 3.09e-02 | -1.90e-02 | 1.92e-01 | 1.03e-01 | 5.20e-01 | 7.16e-02 | 2.67e-01 |
| REGULATION OF CALCIUM ION TRANSPORT | 241 | 9.30e-01 | 1.00e+00 | 0.05220 | 2.13e-02 | 2.17e-02 | 3.08e-02 | 1.23e-02 | 2.65e-02 | 5.68e-01 | 5.62e-01 | 4.10e-01 | 7.41e-01 | 4.79e-01 |
| NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 954 | 4.83e-04 | 1.26e-02 | 0.05220 | -3.52e-03 | -2.44e-03 | 2.94e-02 | -4.00e-02 | 1.55e-02 | 8.54e-01 | 8.99e-01 | 1.23e-01 | 3.65e-02 | 4.17e-01 |
| REGULATION OF PHOSPHORYLATION | 1011 | 2.35e-03 | 4.36e-02 | 0.05220 | 2.25e-03 | -2.25e-03 | 3.80e-02 | -2.98e-02 | 1.94e-02 | 9.04e-01 | 9.03e-01 | 4.07e-02 | 1.09e-01 | 2.97e-01 |
| POSITIVE REGULATION OF GLYCOPROTEIN METABOLIC PROCESS | 26 | 9.18e-01 | 1.00e+00 | 0.05200 | -3.11e-03 | 1.52e-02 | 1.28e-02 | -3.85e-02 | -2.85e-02 | 9.78e-01 | 8.94e-01 | 9.10e-01 | 7.34e-01 | 8.01e-01 |
| MONOATOMIC ANION TRANSPORT | 161 | 4.44e-01 | 9.28e-01 | 0.05200 | -1.16e-02 | 1.21e-03 | -2.59e-02 | 1.41e-02 | -4.11e-02 | 8.00e-01 | 9.79e-01 | 5.70e-01 | 7.57e-01 | 3.68e-01 |
| POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 101 | 8.89e-01 | 1.00e+00 | 0.05170 | 1.68e-02 | 9.14e-03 | 4.71e-02 | -5.84e-03 | 7.48e-03 | 7.71e-01 | 8.74e-01 | 4.14e-01 | 9.19e-01 | 8.97e-01 |
| CILIUM MOVEMENT | 194 | 3.28e-01 | 8.53e-01 | 0.05160 | 1.51e-02 | 2.16e-03 | 3.66e-03 | 4.50e-02 | 1.99e-02 | 7.18e-01 | 9.59e-01 | 9.30e-01 | 2.80e-01 | 6.33e-01 |
| MULTICELLULAR ORGANISMAL LEVEL HOMEOSTASIS | 781 | 7.03e-02 | 4.35e-01 | 0.05160 | -1.02e-02 | -1.60e-02 | 2.04e-02 | -1.60e-02 | 4.04e-02 | 6.28e-01 | 4.47e-01 | 3.31e-01 | 4.48e-01 | 5.45e-02 |
| DEVELOPMENTAL GROWTH | 633 | 2.95e-01 | 8.22e-01 | 0.05160 | 2.02e-02 | 2.05e-02 | 2.29e-02 | 8.03e-06 | -3.62e-02 | 3.86e-01 | 3.78e-01 | 3.25e-01 | 1.00e+00 | 1.20e-01 |
| GENERATION OF NEURONS | 1421 | 2.91e-03 | 5.14e-02 | 0.05150 | 2.10e-02 | 1.86e-02 | 3.76e-02 | -5.89e-03 | -2.05e-02 | 1.84e-01 | 2.41e-01 | 1.75e-02 | 7.10e-01 | 1.96e-01 |
| MICROTUBULE BASED PROCESS | 901 | 1.86e-02 | 1.97e-01 | 0.05130 | 1.54e-02 | 5.47e-03 | 4.63e-02 | -6.83e-03 | 1.34e-02 | 4.32e-01 | 7.81e-01 | 1.84e-02 | 7.28e-01 | 4.95e-01 |
| DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS | 217 | 5.98e-02 | 4.01e-01 | 0.05130 | 4.29e-03 | -1.38e-02 | 3.33e-02 | -5.23e-03 | -3.58e-02 | 9.13e-01 | 7.26e-01 | 3.97e-01 | 8.94e-01 | 3.63e-01 |
| NEGATIVE REGULATION OF SIGNALING | 1399 | 4.80e-04 | 1.26e-02 | 0.05120 | 9.23e-03 | 5.10e-03 | 4.21e-02 | -1.82e-02 | 2.03e-02 | 5.63e-01 | 7.49e-01 | 8.32e-03 | 2.55e-01 | 2.04e-01 |
| ADULT BEHAVIOR | 141 | 7.80e-01 | 1.00e+00 | 0.05110 | 7.33e-03 | 9.02e-03 | 3.43e-02 | -1.68e-02 | 3.20e-02 | 8.81e-01 | 8.53e-01 | 4.82e-01 | 7.31e-01 | 5.12e-01 |
| RAS PROTEIN SIGNAL TRANSDUCTION | 319 | 4.48e-01 | 9.30e-01 | 0.05090 | -1.30e-03 | -4.14e-03 | 7.62e-03 | 1.80e-02 | 4.68e-02 | 9.68e-01 | 8.99e-01 | 8.15e-01 | 5.80e-01 | 1.51e-01 |
| CELLULAR COMPONENT MAINTENANCE | 72 | 7.05e-01 | 1.00e+00 | 0.05080 | 1.09e-02 | 8.37e-03 | 4.82e-02 | -7.62e-03 | -3.86e-03 | 8.73e-01 | 9.02e-01 | 4.80e-01 | 9.11e-01 | 9.55e-01 |
| CELL PROLIFERATION INVOLVED IN KIDNEY DEVELOPMENT | 22 | 9.99e-01 | 1.00e+00 | 0.05080 | 8.66e-03 | 2.44e-03 | 3.35e-02 | -1.31e-02 | 3.47e-02 | 9.44e-01 | 9.84e-01 | 7.85e-01 | 9.15e-01 | 7.78e-01 |
| CELL CELL ADHESION VIA PLASMA MEMBRANE ADHESION MOLECULES | 269 | 2.53e-01 | 7.80e-01 | 0.05070 | -1.32e-02 | -1.05e-02 | 1.40e-02 | -1.27e-02 | 4.40e-02 | 7.09e-01 | 7.68e-01 | 6.93e-01 | 7.19e-01 | 2.15e-01 |
| REGULATION OF ESTABLISHMENT OF PLANAR POLARITY | 51 | 9.34e-01 | 1.00e+00 | 0.05070 | -2.22e-02 | -1.04e-02 | -1.85e-02 | -7.39e-03 | 3.97e-02 | 7.84e-01 | 8.98e-01 | 8.19e-01 | 9.27e-01 | 6.24e-01 |
| POSITIVE REGULATION OF MEMBRANE PERMEABILITY | 49 | 5.74e-01 | 9.79e-01 | 0.05070 | -8.99e-03 | 5.04e-03 | 2.76e-02 | -3.78e-02 | -1.65e-02 | 9.13e-01 | 9.51e-01 | 7.38e-01 | 6.47e-01 | 8.42e-01 |
| CELLULAR HOMEOSTASIS | 782 | 2.31e-03 | 4.30e-02 | 0.05050 | 2.62e-06 | -4.33e-03 | 3.95e-02 | -2.24e-02 | 2.16e-02 | 1.00e+00 | 8.37e-01 | 6.00e-02 | 2.87e-01 | 3.04e-01 |
| REGULATION OF VESICLE MEDIATED TRANSPORT | 507 | 1.80e-01 | 6.87e-01 | 0.05050 | 3.81e-03 | -7.48e-03 | 3.81e-02 | -1.94e-02 | 2.54e-02 | 8.83e-01 | 7.73e-01 | 1.42e-01 | 4.55e-01 | 3.27e-01 |
| CONNECTIVE TISSUE DEVELOPMENT | 278 | 7.15e-01 | 1.00e+00 | 0.05030 | -2.25e-02 | -2.36e-02 | 3.48e-03 | -3.80e-02 | 3.51e-03 | 5.19e-01 | 4.97e-01 | 9.20e-01 | 2.76e-01 | 9.20e-01 |
| SECRETION | 926 | 4.70e-03 | 7.37e-02 | 0.05030 | 2.01e-02 | 1.91e-02 | 4.04e-02 | 7.12e-03 | -8.93e-03 | 2.99e-01 | 3.25e-01 | 3.73e-02 | 7.13e-01 | 6.45e-01 |
| CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM | 451 | 9.39e-02 | 5.05e-01 | 0.05030 | -1.08e-02 | -1.86e-02 | -2.67e-02 | 5.77e-03 | -3.63e-02 | 6.93e-01 | 4.99e-01 | 3.30e-01 | 8.34e-01 | 1.87e-01 |
| ESTABLISHMENT OF TISSUE POLARITY | 67 | 9.41e-01 | 1.00e+00 | 0.05010 | -2.34e-02 | -1.56e-02 | -6.98e-03 | -3.57e-02 | -1.98e-02 | 7.40e-01 | 8.25e-01 | 9.21e-01 | 6.13e-01 | 7.79e-01 |
| NEGATIVE REGULATION OF EPITHELIAL CELL MIGRATION | 108 | 2.01e-01 | 7.17e-01 | 0.05010 | 3.93e-03 | 2.85e-02 | -3.85e-02 | -1.35e-03 | -1.41e-02 | 9.44e-01 | 6.09e-01 | 4.90e-01 | 9.81e-01 | 8.00e-01 |
| NEGATIVE REGULATION OF AMIDE METABOLIC PROCESS | 329 | 2.27e-01 | 7.48e-01 | 0.05000 | 7.06e-03 | 1.89e-02 | -8.48e-03 | -1.30e-02 | -4.31e-02 | 8.26e-01 | 5.56e-01 | 7.91e-01 | 6.86e-01 | 1.79e-01 |
| ADENYLATE CYCLASE MODULATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 240 | 8.39e-01 | 1.00e+00 | 0.05000 | 1.09e-02 | 1.89e-02 | -4.58e-03 | 1.63e-02 | -4.16e-02 | 7.71e-01 | 6.15e-01 | 9.03e-01 | 6.63e-01 | 2.67e-01 |
| NEGATIVE REGULATION OF ANDROGEN RECEPTOR SIGNALING PATHWAY | 15 | 8.65e-01 | 1.00e+00 | 0.04990 | 9.52e-03 | -3.13e-02 | 3.10e-02 | 1.76e-02 | 1.22e-02 | 9.49e-01 | 8.34e-01 | 8.35e-01 | 9.06e-01 | 9.35e-01 |
| CELL ADHESION MEDIATED BY INTEGRIN | 86 | 8.61e-01 | 1.00e+00 | 0.04990 | 8.35e-04 | -4.65e-03 | 2.26e-02 | -1.96e-02 | -3.97e-02 | 9.89e-01 | 9.41e-01 | 7.17e-01 | 7.54e-01 | 5.24e-01 |
| REGULATION OF HORMONE LEVELS | 522 | 9.14e-02 | 4.99e-01 | 0.04990 | 3.13e-03 | 1.13e-02 | 1.04e-03 | 2.69e-03 | -4.84e-02 | 9.03e-01 | 6.57e-01 | 9.68e-01 | 9.16e-01 | 5.83e-02 |
| NEGATIVE REGULATION OF CELL PROJECTION ORGANIZATION | 180 | 9.34e-01 | 1.00e+00 | 0.04990 | 1.95e-02 | 1.92e-02 | 5.85e-03 | 1.53e-02 | -3.83e-02 | 6.51e-01 | 6.57e-01 | 8.92e-01 | 7.24e-01 | 3.75e-01 |
| RESPONSE TO OXYGEN CONTAINING COMPOUND | 1742 | 2.33e-04 | 7.06e-03 | 0.04990 | 1.71e-02 | 1.12e-02 | 4.43e-02 | -3.97e-04 | 1.00e-02 | 2.34e-01 | 4.38e-01 | 2.08e-03 | 9.78e-01 | 4.87e-01 |
| PROTEIN PHOSPHORYLATION | 1275 | 5.49e-03 | 8.20e-02 | 0.04960 | -1.37e-02 | -1.69e-02 | 1.89e-02 | -3.40e-02 | 2.17e-02 | 4.10e-01 | 3.09e-01 | 2.56e-01 | 4.11e-02 | 1.92e-01 |
| STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 228 | 6.67e-01 | 1.00e+00 | 0.04940 | 1.31e-02 | 6.58e-03 | 4.19e-02 | -1.14e-03 | 2.17e-02 | 7.33e-01 | 8.64e-01 | 2.75e-01 | 9.76e-01 | 5.73e-01 |
| POSITIVE REGULATION OF PROTEIN EXPORT FROM NUCLEUS | 17 | 9.88e-01 | 1.00e+00 | 0.04940 | -1.47e-02 | -1.15e-02 | -4.20e-02 | -4.52e-03 | 1.74e-02 | 9.17e-01 | 9.35e-01 | 7.64e-01 | 9.74e-01 | 9.01e-01 |
| GLYCOPROTEIN BIOSYNTHETIC PROCESS | 291 | 6.98e-01 | 1.00e+00 | 0.04930 | 2.02e-02 | 1.88e-02 | 1.99e-02 | 2.34e-02 | -2.71e-02 | 5.54e-01 | 5.82e-01 | 5.58e-01 | 4.93e-01 | 4.27e-01 |
| CILIUM ORGANIZATION | 410 | 5.84e-01 | 9.85e-01 | 0.04910 | -3.90e-03 | -8.42e-03 | 2.25e-02 | -1.48e-02 | 4.00e-02 | 8.92e-01 | 7.70e-01 | 4.34e-01 | 6.06e-01 | 1.65e-01 |
| CARBOHYDRATE DERIVATIVE METABOLIC PROCESS | 983 | 2.18e-01 | 7.40e-01 | 0.04900 | 2.33e-02 | 1.95e-02 | 3.81e-02 | 4.25e-03 | -2.35e-03 | 2.16e-01 | 3.00e-01 | 4.31e-02 | 8.21e-01 | 9.01e-01 |
| CELLULAR COMPONENT MORPHOGENESIS | 753 | 3.32e-01 | 8.56e-01 | 0.04890 | 3.53e-03 | 6.16e-03 | -3.63e-03 | 1.12e-03 | -4.82e-02 | 8.69e-01 | 7.74e-01 | 8.65e-01 | 9.58e-01 | 2.44e-02 |
| POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 312 | 6.86e-02 | 4.29e-01 | 0.04860 | 1.87e-03 | 5.30e-03 | 3.64e-02 | -3.16e-02 | -1.82e-03 | 9.55e-01 | 8.72e-01 | 2.69e-01 | 3.36e-01 | 9.56e-01 |
| POSITIVE REGULATION OF LIPID TRANSPORT | 86 | 5.29e-01 | 9.54e-01 | 0.04850 | -3.01e-02 | -2.91e-02 | -9.78e-04 | -1.22e-02 | 2.10e-02 | 6.29e-01 | 6.40e-01 | 9.87e-01 | 8.45e-01 | 7.36e-01 |
| NEGATIVE REGULATION OF MONOATOMIC ION TRANSMEMBRANE TRANSPORT | 95 | 9.79e-01 | 1.00e+00 | 0.04840 | 2.08e-02 | 2.16e-02 | -1.98e-03 | 3.75e-02 | -5.63e-03 | 7.26e-01 | 7.16e-01 | 9.73e-01 | 5.28e-01 | 9.24e-01 |
| ENDOTHELIAL CELL MIGRATION | 270 | 6.90e-01 | 1.00e+00 | 0.04830 | 5.77e-04 | 1.13e-02 | -1.28e-02 | -7.89e-03 | -4.46e-02 | 9.87e-01 | 7.50e-01 | 7.18e-01 | 8.24e-01 | 2.08e-01 |
| REGULATION OF STEROID BIOSYNTHETIC PROCESS | 79 | 7.45e-01 | 1.00e+00 | 0.04770 | 1.30e-02 | 2.66e-02 | 3.84e-03 | 3.18e-02 | -1.94e-02 | 8.42e-01 | 6.83e-01 | 9.53e-01 | 6.25e-01 | 7.66e-01 |
| TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 392 | 2.04e-01 | 7.24e-01 | 0.04770 | -3.59e-03 | -1.56e-02 | 3.33e-02 | -2.66e-02 | 1.39e-02 | 9.03e-01 | 5.96e-01 | 2.57e-01 | 3.65e-01 | 6.36e-01 |
| POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 62 | 9.67e-01 | 1.00e+00 | 0.04760 | 1.16e-02 | 1.33e-02 | 2.28e-02 | -6.80e-03 | -3.73e-02 | 8.75e-01 | 8.57e-01 | 7.56e-01 | 9.26e-01 | 6.11e-01 |
| RESPONSE TO DEXAMETHASONE | 38 | 9.19e-01 | 1.00e+00 | 0.04760 | -2.16e-03 | 9.06e-03 | 1.94e-02 | -3.54e-02 | -2.34e-02 | 9.82e-01 | 9.23e-01 | 8.36e-01 | 7.06e-01 | 8.03e-01 |
| FILOPODIUM ASSEMBLY | 66 | 9.97e-01 | 1.00e+00 | 0.04750 | -2.37e-02 | -2.22e-02 | -3.26e-02 | -5.97e-03 | -1.02e-02 | 7.40e-01 | 7.55e-01 | 6.47e-01 | 9.33e-01 | 8.86e-01 |
| RHO PROTEIN SIGNAL TRANSDUCTION | 128 | 6.20e-01 | 9.90e-01 | 0.04740 | -1.93e-02 | -1.97e-02 | -2.38e-02 | 2.14e-02 | 2.16e-02 | 7.07e-01 | 7.00e-01 | 6.42e-01 | 6.76e-01 | 6.73e-01 |
| CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 543 | 2.65e-01 | 7.94e-01 | 0.04730 | 3.21e-03 | 3.78e-03 | 8.40e-03 | -7.10e-03 | -4.58e-02 | 8.98e-01 | 8.80e-01 | 7.38e-01 | 7.77e-01 | 6.82e-02 |
| POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 1620 | 4.96e-05 | 1.89e-03 | 0.04730 | -1.01e-02 | -1.53e-02 | 2.65e-02 | -3.06e-02 | 1.61e-02 | 4.98e-01 | 3.05e-01 | 7.54e-02 | 3.99e-02 | 2.80e-01 |
| ORGANOPHOSPHATE CATABOLIC PROCESS | 142 | 4.34e-01 | 9.21e-01 | 0.04720 | 1.18e-02 | 2.88e-02 | 9.71e-03 | 3.81e-03 | -3.40e-02 | 8.09e-01 | 5.53e-01 | 8.42e-01 | 9.38e-01 | 4.85e-01 |
| CELLULAR RESPONSE TO PEPTIDE HORMONE STIMULUS | 302 | 2.64e-01 | 7.91e-01 | 0.04710 | 3.26e-03 | -2.08e-03 | 3.78e-02 | -7.86e-03 | 2.67e-02 | 9.22e-01 | 9.50e-01 | 2.59e-01 | 8.14e-01 | 4.24e-01 |
| MYOTUBE DIFFERENTIATION | 127 | 7.86e-01 | 1.00e+00 | 0.04700 | -2.49e-03 | 7.83e-03 | -3.02e-02 | 3.18e-02 | -1.49e-02 | 9.61e-01 | 8.79e-01 | 5.57e-01 | 5.36e-01 | 7.72e-01 |
| REGULATION OF TRANS SYNAPTIC SIGNALING | 469 | 2.30e-01 | 7.52e-01 | 0.04700 | 1.99e-02 | 2.19e-02 | 3.35e-02 | 9.33e-03 | -1.11e-02 | 4.61e-01 | 4.16e-01 | 2.14e-01 | 7.29e-01 | 6.81e-01 |
| REGULATION OF PHOSPHORUS METABOLIC PROCESS | 1136 | 6.25e-03 | 9.00e-02 | 0.04700 | 6.57e-03 | 1.79e-03 | 3.85e-02 | -1.90e-02 | 1.78e-02 | 7.09e-01 | 9.19e-01 | 2.87e-02 | 2.79e-01 | 3.11e-01 |
| NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 94 | 8.16e-01 | 1.00e+00 | 0.04700 | -2.24e-02 | -1.21e-02 | -1.87e-02 | -1.39e-02 | -3.19e-02 | 7.07e-01 | 8.40e-01 | 7.54e-01 | 8.16e-01 | 5.94e-01 |
| ORGANIC ACID METABOLIC PROCESS | 937 | 5.77e-01 | 9.81e-01 | 0.04690 | 2.28e-02 | 2.45e-02 | 2.08e-02 | 1.46e-02 | -2.09e-02 | 2.37e-01 | 2.04e-01 | 2.80e-01 | 4.48e-01 | 2.77e-01 |
| CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 1249 | 1.90e-03 | 3.78e-02 | 0.04690 | 9.46e-03 | 1.61e-03 | 4.19e-02 | -1.07e-02 | 1.54e-02 | 5.74e-01 | 9.24e-01 | 1.27e-02 | 5.26e-01 | 3.61e-01 |
| TRANSMEMBRANE TRANSPORT | 1481 | 5.97e-02 | 4.01e-01 | 0.04690 | 2.21e-02 | 2.93e-02 | 1.61e-02 | 2.31e-02 | -7.47e-03 | 1.55e-01 | 5.88e-02 | 3.01e-01 | 1.37e-01 | 6.30e-01 |
| REGULATION OF EPITHELIAL CELL PROLIFERATION | 395 | 8.93e-01 | 1.00e+00 | 0.04670 | 2.02e-02 | 2.27e-02 | 1.04e-02 | 1.51e-02 | -3.04e-02 | 4.90e-01 | 4.40e-01 | 7.22e-01 | 6.07e-01 | 3.00e-01 |
| REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 169 | 4.73e-01 | 9.40e-01 | 0.04650 | 9.65e-03 | 1.24e-02 | 3.07e-02 | -9.12e-03 | -2.99e-02 | 8.29e-01 | 7.81e-01 | 4.91e-01 | 8.38e-01 | 5.02e-01 |
| REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY | 234 | 6.61e-01 | 1.00e+00 | 0.04650 | -4.00e-03 | 1.50e-03 | -1.33e-03 | -8.87e-03 | -4.55e-02 | 9.16e-01 | 9.68e-01 | 9.72e-01 | 8.15e-01 | 2.31e-01 |
| NEGATIVE REGULATION OF EPIDERMIS DEVELOPMENT | 14 | 9.80e-01 | 1.00e+00 | 0.04640 | -6.75e-03 | 2.17e-02 | -3.17e-02 | -3.16e-03 | -2.49e-02 | 9.65e-01 | 8.88e-01 | 8.37e-01 | 9.84e-01 | 8.72e-01 |
| RESPONSE TO GROWTH FACTOR | 730 | 1.27e-02 | 1.48e-01 | 0.04640 | 1.19e-02 | 7.37e-03 | 3.86e-02 | -1.16e-02 | -1.82e-02 | 5.83e-01 | 7.34e-01 | 7.60e-02 | 5.94e-01 | 4.01e-01 |
| REGULATION OF TRANSPORT | 1711 | 2.43e-02 | 2.34e-01 | 0.04590 | 1.95e-02 | 1.85e-02 | 3.63e-02 | 2.72e-03 | 7.56e-03 | 1.79e-01 | 2.03e-01 | 1.24e-02 | 8.51e-01 | 6.03e-01 |
| SENSORY PERCEPTION OF PAIN | 76 | 9.08e-01 | 1.00e+00 | 0.04570 | 6.09e-04 | 4.53e-03 | 2.77e-02 | -2.02e-02 | 2.98e-02 | 9.93e-01 | 9.46e-01 | 6.76e-01 | 7.60e-01 | 6.53e-01 |
| POSITIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 382 | 4.08e-01 | 9.08e-01 | 0.04560 | -4.94e-03 | -8.54e-03 | 2.70e-02 | -2.51e-02 | 2.50e-02 | 8.68e-01 | 7.74e-01 | 3.65e-01 | 3.99e-01 | 4.01e-01 |
| POSITIVE REGULATION OF SIGNALING | 1731 | 6.25e-03 | 9.00e-02 | 0.04560 | -2.35e-02 | -2.32e-02 | -2.30e-03 | -3.11e-02 | -4.02e-03 | 1.04e-01 | 1.08e-01 | 8.74e-01 | 3.14e-02 | 7.81e-01 |
| INTRACELLULAR RECEPTOR SIGNALING PATHWAY | 338 | 2.55e-01 | 7.83e-01 | 0.04550 | 8.02e-03 | -9.05e-04 | 4.19e-02 | -7.96e-03 | 1.39e-02 | 8.00e-01 | 9.77e-01 | 1.86e-01 | 8.01e-01 | 6.61e-01 |
| CELL CELL SIGNALING BY WNT | 441 | 4.60e-02 | 3.48e-01 | 0.04550 | 1.23e-02 | 1.26e-02 | 4.14e-02 | -7.11e-03 | -1.16e-03 | 6.58e-01 | 6.50e-01 | 1.36e-01 | 7.98e-01 | 9.67e-01 |
| REGULATION OF CELL SIZE | 176 | 8.71e-01 | 1.00e+00 | 0.04520 | 1.93e-02 | 2.51e-02 | 1.54e-02 | 2.83e-02 | -5.69e-04 | 6.59e-01 | 5.65e-01 | 7.24e-01 | 5.18e-01 | 9.90e-01 |
| ORGANIC ANION TRANSPORT | 429 | 6.21e-01 | 9.90e-01 | 0.04510 | 1.76e-02 | 2.59e-02 | 8.35e-03 | 1.85e-02 | -2.54e-02 | 5.31e-01 | 3.58e-01 | 7.67e-01 | 5.10e-01 | 3.67e-01 |
| POSITIVE REGULATION OF PROTEIN MATURATION | 27 | 8.27e-01 | 1.00e+00 | 0.04510 | -3.58e-03 | 1.07e-02 | -2.81e-02 | -3.34e-02 | -2.24e-03 | 9.74e-01 | 9.23e-01 | 8.01e-01 | 7.64e-01 | 9.84e-01 |
| PEPTIDYL TYROSINE MODIFICATION | 271 | 8.91e-01 | 1.00e+00 | 0.04500 | -2.35e-02 | -2.37e-02 | -4.58e-03 | -2.84e-02 | 9.01e-03 | 5.05e-01 | 5.02e-01 | 8.97e-01 | 4.20e-01 | 7.99e-01 |
| DUMP CATABOLIC PROCESS | 6 | 9.99e-01 | 1.00e+00 | 0.04490 | -1.98e-02 | -1.13e-02 | -3.11e-02 | 2.25e-02 | -5.34e-03 | 9.33e-01 | 9.62e-01 | 8.95e-01 | 9.24e-01 | 9.82e-01 |
| POSITIVE REGULATION OF PROTEIN CONTAINING COMPLEX ASSEMBLY | 192 | 7.64e-01 | 1.00e+00 | 0.04480 | -2.33e-02 | -2.00e-02 | -2.99e-03 | -3.14e-02 | -8.21e-03 | 5.78e-01 | 6.32e-01 | 9.43e-01 | 4.53e-01 | 8.45e-01 |
| CELLULAR RESPONSE TO KETONE | 97 | 8.95e-01 | 1.00e+00 | 0.04460 | -7.11e-03 | -1.73e-02 | 1.75e-02 | -3.55e-02 | -8.60e-03 | 9.04e-01 | 7.68e-01 | 7.66e-01 | 5.45e-01 | 8.84e-01 |
| REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 341 | 3.68e-01 | 8.79e-01 | 0.04460 | 1.32e-02 | 5.74e-03 | 3.80e-02 | -1.17e-02 | -1.42e-02 | 6.75e-01 | 8.55e-01 | 2.28e-01 | 7.10e-01 | 6.53e-01 |
| POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 134 | 8.68e-01 | 1.00e+00 | 0.04450 | 1.08e-02 | 7.59e-03 | 2.36e-02 | -4.09e-03 | -3.51e-02 | 8.30e-01 | 8.79e-01 | 6.37e-01 | 9.35e-01 | 4.82e-01 |
| POSITIVE REGULATION OF OXIDOREDUCTASE ACTIVITY | 44 | 9.96e-01 | 1.00e+00 | 0.04450 | 1.71e-02 | 1.49e-02 | 3.68e-02 | -4.31e-03 | 9.66e-03 | 8.45e-01 | 8.65e-01 | 6.73e-01 | 9.61e-01 | 9.12e-01 |
| REGULATION OF DENDRITE DEVELOPMENT | 91 | 8.72e-01 | 1.00e+00 | 0.04440 | 1.15e-02 | 9.85e-03 | 1.38e-02 | 2.16e-02 | -3.30e-02 | 8.50e-01 | 8.71e-01 | 8.20e-01 | 7.21e-01 | 5.87e-01 |
| POSITIVE REGULATION OF CALCIUM ION TRANSMEMBRANE TRANSPORT | 82 | 9.47e-01 | 1.00e+00 | 0.04440 | 1.66e-02 | 1.39e-02 | 3.83e-02 | -5.42e-04 | -6.11e-03 | 7.95e-01 | 8.28e-01 | 5.49e-01 | 9.93e-01 | 9.24e-01 |
| AXON DEVELOPMENT | 481 | 4.60e-01 | 9.32e-01 | 0.04440 | -9.99e-03 | -1.02e-02 | 2.24e-03 | -2.53e-02 | -3.35e-02 | 7.07e-01 | 7.01e-01 | 9.33e-01 | 3.42e-01 | 2.08e-01 |
| CILIUM OR FLAGELLUM DEPENDENT CELL MOTILITY | 155 | 6.50e-01 | 1.00e+00 | 0.04420 | 1.91e-02 | 7.87e-03 | 5.17e-03 | 3.84e-02 | 4.58e-03 | 6.81e-01 | 8.66e-01 | 9.12e-01 | 4.09e-01 | 9.22e-01 |
| POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 210 | 6.46e-01 | 1.00e+00 | 0.04410 | 1.37e-02 | 5.50e-03 | 3.04e-02 | -2.42e-03 | -2.83e-02 | 7.33e-01 | 8.91e-01 | 4.48e-01 | 9.52e-01 | 4.79e-01 |
| CYTOPLASMIC MICROTUBULE ORGANIZATION | 59 | 9.43e-01 | 1.00e+00 | 0.04360 | 1.21e-02 | 1.62e-02 | 2.50e-02 | 4.92e-04 | -2.94e-02 | 8.73e-01 | 8.29e-01 | 7.40e-01 | 9.95e-01 | 6.96e-01 |
| CALCIUM ION TRANSPORT | 427 | 8.13e-01 | 1.00e+00 | 0.04360 | 1.90e-02 | 2.34e-02 | 1.30e-02 | 2.69e-02 | 9.69e-03 | 5.00e-01 | 4.07e-01 | 6.44e-01 | 3.40e-01 | 7.31e-01 |
| SPHINGOLIPID METABOLIC PROCESS | 162 | 8.50e-01 | 1.00e+00 | 0.04350 | -2.55e-02 | -2.49e-02 | -5.56e-03 | -2.24e-02 | 9.34e-03 | 5.75e-01 | 5.84e-01 | 9.03e-01 | 6.23e-01 | 8.37e-01 |
| HORMONE MEDIATED SIGNALING PATHWAY | 185 | 2.11e-01 | 7.33e-01 | 0.04340 | 1.02e-02 | 1.90e-03 | 1.45e-02 | 3.86e-02 | -8.94e-03 | 8.11e-01 | 9.64e-01 | 7.34e-01 | 3.65e-01 | 8.34e-01 |
| REGULATION OF EXTRACELLULAR MATRIX ORGANIZATION | 61 | 7.73e-01 | 1.00e+00 | 0.04340 | 1.37e-02 | 2.11e-02 | 2.55e-02 | 2.03e-02 | -1.39e-02 | 8.54e-01 | 7.76e-01 | 7.31e-01 | 7.84e-01 | 8.52e-01 |
| DEVELOPMENTAL CELL GROWTH | 226 | 8.40e-01 | 1.00e+00 | 0.04340 | -1.34e-02 | -1.57e-02 | -1.20e-02 | -7.47e-03 | -3.54e-02 | 7.29e-01 | 6.84e-01 | 7.56e-01 | 8.47e-01 | 3.59e-01 |
| POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 778 | 5.84e-02 | 3.95e-01 | 0.04310 | -3.56e-03 | -6.26e-03 | 2.68e-02 | -1.73e-02 | 2.81e-02 | 8.66e-01 | 7.66e-01 | 2.03e-01 | 4.12e-01 | 1.82e-01 |
| SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 462 | 2.70e-01 | 7.97e-01 | 0.04310 | -1.86e-02 | -2.06e-02 | -1.03e-02 | 3.86e-03 | 3.10e-02 | 4.93e-01 | 4.47e-01 | 7.05e-01 | 8.87e-01 | 2.53e-01 |
| EXTERNAL ENCAPSULATING STRUCTURE ORGANIZATION | 312 | 4.56e-01 | 9.31e-01 | 0.04310 | 2.00e-03 | 6.13e-03 | -2.92e-03 | 1.30e-02 | -4.04e-02 | 9.52e-01 | 8.52e-01 | 9.29e-01 | 6.92e-01 | 2.19e-01 |
| TYROSINE METABOLIC PROCESS | 17 | 9.98e-01 | 1.00e+00 | 0.04290 | -3.46e-03 | 1.20e-02 | -3.39e-02 | 1.21e-02 | -1.95e-02 | 9.80e-01 | 9.31e-01 | 8.09e-01 | 9.31e-01 | 8.89e-01 |
| REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 286 | 4.54e-01 | 9.31e-01 | 0.04290 | 3.49e-03 | -7.43e-03 | 3.24e-02 | -2.65e-02 | 4.07e-03 | 9.19e-01 | 8.29e-01 | 3.45e-01 | 4.41e-01 | 9.06e-01 |
| CELL MORPHOGENESIS | 914 | 3.37e-01 | 8.59e-01 | 0.04280 | -2.04e-02 | -1.94e-02 | -1.35e-02 | -1.80e-02 | -2.31e-02 | 2.96e-01 | 3.20e-01 | 4.87e-01 | 3.56e-01 | 2.37e-01 |
| REGULATION OF LONG TERM SYNAPTIC POTENTIATION | 46 | 8.56e-01 | 1.00e+00 | 0.04250 | -2.85e-02 | -1.14e-02 | -2.87e-02 | -6.17e-03 | -7.35e-04 | 7.38e-01 | 8.93e-01 | 7.36e-01 | 9.42e-01 | 9.93e-01 |
| NEGATIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 133 | 9.79e-01 | 1.00e+00 | 0.04240 | 2.14e-02 | 1.59e-02 | 2.45e-02 | 1.37e-02 | -1.75e-02 | 6.70e-01 | 7.51e-01 | 6.26e-01 | 7.85e-01 | 7.28e-01 |
| PHYSIOLOGICAL CARDIAC MUSCLE HYPERTROPHY | 29 | 9.46e-01 | 1.00e+00 | 0.04230 | 6.86e-03 | 9.74e-03 | 3.98e-02 | -7.88e-03 | 2.10e-03 | 9.49e-01 | 9.28e-01 | 7.11e-01 | 9.41e-01 | 9.84e-01 |
| PHOSPHOLIPID TRANSPORT | 101 | 9.41e-01 | 1.00e+00 | 0.04230 | 9.39e-03 | 1.65e-02 | -1.72e-02 | 9.54e-03 | -3.23e-02 | 8.70e-01 | 7.75e-01 | 7.65e-01 | 8.68e-01 | 5.75e-01 |
| POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 16 | 9.97e-01 | 1.00e+00 | 0.04220 | -5.69e-03 | -1.77e-02 | 6.67e-03 | -2.22e-02 | -3.00e-02 | 9.69e-01 | 9.02e-01 | 9.63e-01 | 8.78e-01 | 8.35e-01 |
| STRIATED MUSCLE CELL DIFFERENTIATION | 298 | 7.33e-01 | 1.00e+00 | 0.04220 | -1.07e-02 | -5.17e-03 | -1.61e-02 | -1.67e-03 | -3.72e-02 | 7.50e-01 | 8.78e-01 | 6.33e-01 | 9.60e-01 | 2.70e-01 |
| EPITHELIAL CELL PROLIFERATION | 468 | 7.97e-01 | 1.00e+00 | 0.04210 | 1.29e-02 | 1.32e-02 | 6.08e-03 | 1.18e-02 | -3.54e-02 | 6.31e-01 | 6.23e-01 | 8.22e-01 | 6.62e-01 | 1.90e-01 |
| REGULATION OF RAS PROTEIN SIGNAL TRANSDUCTION | 172 | 7.10e-01 | 1.00e+00 | 0.04200 | -3.49e-04 | 4.45e-03 | -1.13e-03 | 2.23e-02 | 3.53e-02 | 9.94e-01 | 9.20e-01 | 9.80e-01 | 6.14e-01 | 4.24e-01 |
| MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 45 | 9.86e-01 | 1.00e+00 | 0.04200 | -1.87e-02 | -2.55e-02 | 1.01e-02 | -2.32e-02 | 1.09e-02 | 8.28e-01 | 7.67e-01 | 9.06e-01 | 7.88e-01 | 8.99e-01 |
| RESPONSE TO ORGANIC CYCLIC COMPOUND | 876 | 9.98e-02 | 5.23e-01 | 0.04190 | 1.66e-02 | 1.48e-02 | 3.53e-02 | 4.10e-04 | -3.75e-03 | 4.06e-01 | 4.57e-01 | 7.61e-02 | 9.84e-01 | 8.50e-01 |
| REGULATION OF WNT SIGNALING PATHWAY | 325 | 6.03e-02 | 4.03e-01 | 0.04180 | -5.72e-04 | -3.45e-03 | 3.36e-02 | -1.91e-02 | -1.56e-02 | 9.86e-01 | 9.15e-01 | 2.98e-01 | 5.55e-01 | 6.29e-01 |
| ENDOTHELIAL CELL PROLIFERATION | 197 | 9.05e-01 | 1.00e+00 | 0.04170 | -1.65e-02 | -1.02e-02 | -3.19e-02 | -1.37e-02 | -1.26e-02 | 6.90e-01 | 8.04e-01 | 4.40e-01 | 7.40e-01 | 7.60e-01 |
| PHOSPHATIDYLINOSITOL 3 KINASE PROTEIN KINASE B SIGNAL TRANSDUCTION | 285 | 8.62e-01 | 1.00e+00 | 0.04170 | -2.23e-02 | -1.98e-02 | -7.29e-03 | -2.81e-02 | -3.53e-03 | 5.17e-01 | 5.66e-01 | 8.32e-01 | 4.14e-01 | 9.18e-01 |
| AMEBOIDAL TYPE CELL MIGRATION | 478 | 5.30e-01 | 9.54e-01 | 0.04170 | 1.47e-02 | 2.36e-02 | 7.72e-03 | 6.87e-03 | -2.93e-02 | 5.81e-01 | 3.77e-01 | 7.72e-01 | 7.97e-01 | 2.73e-01 |
| POSITIVE REGULATION OF PHOSPHORYLATION | 636 | 1.94e-01 | 7.05e-01 | 0.04140 | -1.54e-02 | -1.63e-02 | 1.21e-02 | -3.14e-02 | 8.91e-03 | 5.09e-01 | 4.83e-01 | 6.03e-01 | 1.77e-01 | 7.01e-01 |
| POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 401 | 4.61e-01 | 9.32e-01 | 0.04130 | -2.49e-04 | -1.48e-03 | 2.61e-02 | -2.43e-02 | 2.08e-02 | 9.93e-01 | 9.59e-01 | 3.69e-01 | 4.04e-01 | 4.75e-01 |
| DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 231 | 7.85e-01 | 1.00e+00 | 0.04120 | 1.59e-02 | 1.08e-02 | 2.06e-02 | 1.55e-02 | -2.58e-02 | 6.78e-01 | 7.77e-01 | 5.90e-01 | 6.84e-01 | 5.00e-01 |
| SYNAPTIC VESICLE EXOCYTOSIS | 91 | 8.40e-01 | 1.00e+00 | 0.04100 | 9.51e-03 | 1.31e-02 | 2.43e-02 | -4.60e-04 | -2.88e-02 | 8.75e-01 | 8.29e-01 | 6.89e-01 | 9.94e-01 | 6.35e-01 |
| CARTILAGE DEVELOPMENT | 199 | 8.94e-01 | 1.00e+00 | 0.04080 | -1.67e-02 | -1.62e-02 | 1.56e-03 | -3.11e-02 | -1.24e-02 | 6.84e-01 | 6.94e-01 | 9.70e-01 | 4.50e-01 | 7.63e-01 |
| INTRACELLULAR SODIUM ION HOMEOSTASIS | 22 | 7.48e-01 | 1.00e+00 | 0.04070 | 4.47e-03 | 3.97e-02 | -8.45e-04 | 6.88e-03 | 3.47e-03 | 9.71e-01 | 7.47e-01 | 9.95e-01 | 9.55e-01 | 9.78e-01 |
| HOMEOSTATIC PROCESS | 1660 | 2.13e-03 | 4.05e-02 | 0.04040 | 6.87e-03 | 2.83e-03 | 3.36e-02 | -5.92e-03 | 2.03e-02 | 6.41e-01 | 8.48e-01 | 2.24e-02 | 6.88e-01 | 1.68e-01 |
| SUPRAMOLECULAR FIBER ORGANIZATION | 811 | 6.95e-01 | 1.00e+00 | 0.04020 | 1.68e-02 | 1.94e-02 | 1.89e-02 | 1.43e-02 | 1.99e-02 | 4.15e-01 | 3.47e-01 | 3.61e-01 | 4.88e-01 | 3.35e-01 |
| REGULATION OF AXONOGENESIS | 145 | 8.93e-01 | 1.00e+00 | 0.03990 | -2.18e-02 | -2.64e-02 | -1.95e-02 | 1.03e-03 | 6.14e-03 | 6.51e-01 | 5.84e-01 | 6.85e-01 | 9.83e-01 | 8.98e-01 |
| REGULATION OF GLUCOSE IMPORT | 58 | 9.93e-01 | 1.00e+00 | 0.03970 | 1.31e-02 | 1.78e-02 | 1.51e-02 | 1.78e-02 | 2.32e-02 | 8.63e-01 | 8.15e-01 | 8.43e-01 | 8.14e-01 | 7.59e-01 |
| REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS | 113 | 7.03e-01 | 1.00e+00 | 0.03960 | 1.29e-02 | 1.39e-02 | 2.95e-02 | 1.25e-02 | -1.35e-02 | 8.13e-01 | 7.99e-01 | 5.88e-01 | 8.18e-01 | 8.04e-01 |
| POSITIVE REGULATION OF TRANSPORT | 859 | 5.84e-02 | 3.95e-01 | 0.03920 | -6.93e-03 | -1.10e-02 | 2.37e-02 | -2.48e-02 | 1.39e-02 | 7.30e-01 | 5.83e-01 | 2.38e-01 | 2.17e-01 | 4.90e-01 |
| CALCIUM ION TRANSMEMBRANE TRANSPORT | 338 | 8.55e-01 | 1.00e+00 | 0.03920 | 1.64e-02 | 2.32e-02 | 3.18e-03 | 2.68e-02 | -5.93e-04 | 6.05e-01 | 4.64e-01 | 9.20e-01 | 3.96e-01 | 9.85e-01 |
| POSITIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 60 | 1.00e+00 | 1.00e+00 | 0.03920 | -2.04e-02 | -1.85e-02 | -1.53e-02 | -2.17e-02 | 8.45e-03 | 7.84e-01 | 8.04e-01 | 8.38e-01 | 7.71e-01 | 9.10e-01 |
| MICROTUBULE BASED MOVEMENT | 401 | 3.12e-01 | 8.38e-01 | 0.03900 | 1.18e-02 | -1.92e-03 | 3.58e-02 | 1.10e-03 | 9.97e-03 | 6.86e-01 | 9.47e-01 | 2.18e-01 | 9.70e-01 | 7.32e-01 |
| BLOOD VESSEL ENDOTHELIAL CELL PROLIFERATION INVOLVED IN SPROUTING ANGIOGENESIS | 51 | 9.92e-01 | 1.00e+00 | 0.03900 | -1.67e-02 | -1.84e-02 | -2.57e-02 | -1.55e-02 | -1.31e-03 | 8.37e-01 | 8.20e-01 | 7.50e-01 | 8.49e-01 | 9.87e-01 |
| REGULATION OF ACTIN FILAMENT LENGTH | 149 | 8.96e-01 | 1.00e+00 | 0.03900 | -3.66e-03 | 5.92e-03 | -5.82e-03 | -1.20e-02 | -3.60e-02 | 9.39e-01 | 9.01e-01 | 9.02e-01 | 8.01e-01 | 4.49e-01 |
| POSITIVE REGULATION OF KINASE ACTIVITY | 328 | 7.54e-01 | 1.00e+00 | 0.03870 | -1.77e-02 | -1.56e-02 | 1.93e-03 | -2.98e-02 | 7.02e-03 | 5.82e-01 | 6.27e-01 | 9.52e-01 | 3.54e-01 | 8.27e-01 |
| RESPONSE TO NUTRIENT | 147 | 6.69e-01 | 1.00e+00 | 0.03860 | 1.43e-02 | 2.36e-02 | 2.08e-02 | 1.58e-02 | 6.71e-03 | 7.65e-01 | 6.22e-01 | 6.63e-01 | 7.41e-01 | 8.88e-01 |
| PHOSPHORYLATION | 1528 | 6.42e-03 | 9.13e-02 | 0.03840 | -1.81e-03 | -5.21e-03 | 2.67e-02 | -1.97e-02 | 1.85e-02 | 9.06e-01 | 7.33e-01 | 8.09e-02 | 1.98e-01 | 2.27e-01 |
| GLYCOPROTEIN METABOLIC PROCESS | 358 | 7.51e-01 | 1.00e+00 | 0.03830 | 1.57e-02 | 1.44e-02 | 1.97e-02 | 1.50e-02 | -2.00e-02 | 6.10e-01 | 6.40e-01 | 5.23e-01 | 6.25e-01 | 5.16e-01 |
| LONG TERM SYNAPTIC POTENTIATION | 102 | 8.64e-01 | 1.00e+00 | 0.03830 | -1.89e-02 | -1.33e-02 | 7.80e-04 | -2.79e-02 | -1.23e-02 | 7.42e-01 | 8.17e-01 | 9.89e-01 | 6.26e-01 | 8.30e-01 |
| SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 65 | 9.65e-01 | 1.00e+00 | 0.03790 | -9.13e-03 | -3.76e-03 | 1.13e-02 | -2.22e-02 | 2.68e-02 | 8.99e-01 | 9.58e-01 | 8.75e-01 | 7.57e-01 | 7.09e-01 |
| GLYCOSYLATION | 215 | 8.42e-01 | 1.00e+00 | 0.03790 | 4.47e-03 | -6.86e-04 | 2.90e-02 | -4.32e-03 | 2.35e-02 | 9.10e-01 | 9.86e-01 | 4.63e-01 | 9.13e-01 | 5.53e-01 |
| CELL MATRIX ADHESION | 232 | 5.15e-01 | 9.52e-01 | 0.03750 | -6.53e-03 | -6.88e-03 | -2.09e-02 | 2.95e-02 | 2.97e-03 | 8.64e-01 | 8.57e-01 | 5.84e-01 | 4.38e-01 | 9.38e-01 |
| NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 1192 | 2.67e-02 | 2.49e-01 | 0.03750 | -1.08e-02 | -1.60e-02 | 1.74e-02 | -2.66e-02 | 4.71e-03 | 5.30e-01 | 3.52e-01 | 3.12e-01 | 1.21e-01 | 7.84e-01 |
| NEGATIVE REGULATION OF CELL POPULATION PROLIFERATION | 904 | 1.18e-01 | 5.72e-01 | 0.03740 | 1.46e-02 | 1.60e-02 | 2.95e-02 | -1.69e-03 | -7.77e-03 | 4.56e-01 | 4.14e-01 | 1.33e-01 | 9.31e-01 | 6.92e-01 |
| POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 1069 | 1.97e-01 | 7.11e-01 | 0.03730 | -1.03e-02 | -1.43e-02 | 1.35e-02 | -1.75e-02 | 2.44e-02 | 5.71e-01 | 4.30e-01 | 4.56e-01 | 3.34e-01 | 1.77e-01 |
| NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 1676 | 1.12e-02 | 1.37e-01 | 0.03730 | -4.65e-03 | -1.02e-02 | 2.32e-02 | -2.23e-02 | 1.51e-02 | 7.51e-01 | 4.88e-01 | 1.14e-01 | 1.28e-01 | 3.03e-01 |
| POSITIVE REGULATION OF CALCIUM ION TRANSPORT | 113 | 9.76e-01 | 1.00e+00 | 0.03700 | 9.49e-03 | 7.40e-03 | 2.52e-02 | 7.70e-03 | 2.31e-02 | 8.62e-01 | 8.92e-01 | 6.44e-01 | 8.88e-01 | 6.71e-01 |
| EXOCYTOSIS | 331 | 6.43e-01 | 1.00e+00 | 0.03690 | -1.11e-02 | -1.30e-02 | 3.94e-03 | -1.95e-02 | -2.60e-02 | 7.28e-01 | 6.85e-01 | 9.02e-01 | 5.41e-01 | 4.17e-01 |
| REGULATION OF POSTSYNAPTIC MEMBRANE NEUROTRANSMITTER RECEPTOR LEVELS | 81 | 6.99e-01 | 1.00e+00 | 0.03690 | -1.06e-02 | -3.85e-03 | 1.17e-02 | -1.82e-03 | 3.31e-02 | 8.69e-01 | 9.52e-01 | 8.56e-01 | 9.77e-01 | 6.07e-01 |
| REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION | 94 | 8.99e-01 | 1.00e+00 | 0.03660 | -2.15e-03 | -8.89e-03 | 2.91e-02 | -1.08e-02 | 1.71e-02 | 9.71e-01 | 8.82e-01 | 6.26e-01 | 8.57e-01 | 7.75e-01 |
| RHYTHMIC PROCESS | 287 | 4.50e-01 | 9.30e-01 | 0.03650 | -1.04e-02 | -1.76e-02 | 2.02e-02 | -1.55e-02 | 1.63e-02 | 7.61e-01 | 6.08e-01 | 5.56e-01 | 6.52e-01 | 6.34e-01 |
| NEUROMUSCULAR JUNCTION DEVELOPMENT | 50 | 7.96e-01 | 1.00e+00 | 0.03620 | -2.38e-02 | -2.27e-02 | 4.72e-03 | -9.46e-03 | 1.09e-02 | 7.71e-01 | 7.81e-01 | 9.54e-01 | 9.08e-01 | 8.94e-01 |
| CELL PART MORPHOGENESIS | 644 | 4.50e-01 | 9.30e-01 | 0.03600 | -1.08e-03 | -7.85e-04 | 3.54e-03 | -7.08e-03 | -3.51e-02 | 9.63e-01 | 9.73e-01 | 8.78e-01 | 7.59e-01 | 1.28e-01 |
| POSITIVE REGULATION OF SYNAPTIC TRANSMISSION | 166 | 5.47e-01 | 9.61e-01 | 0.03590 | 8.27e-03 | 1.13e-02 | 2.54e-02 | 1.01e-03 | -2.11e-02 | 8.54e-01 | 8.01e-01 | 5.72e-01 | 9.82e-01 | 6.40e-01 |
| VESICLE MEDIATED TRANSPORT IN SYNAPSE | 208 | 6.07e-01 | 9.90e-01 | 0.03580 | 2.17e-04 | 1.99e-03 | 1.30e-02 | -6.23e-03 | -3.27e-02 | 9.96e-01 | 9.60e-01 | 7.46e-01 | 8.77e-01 | 4.16e-01 |
| PROTEIN AUTOPHOSPHORYLATION | 189 | 7.55e-01 | 1.00e+00 | 0.03550 | -9.93e-03 | -1.34e-02 | 1.89e-02 | -1.80e-02 | 1.73e-02 | 8.14e-01 | 7.50e-01 | 6.54e-01 | 6.69e-01 | 6.82e-01 |
| CELLULAR RESPONSE TO HORMONE STIMULUS | 589 | 2.89e-01 | 8.17e-01 | 0.03520 | 1.39e-02 | 1.26e-02 | 2.75e-02 | 9.25e-03 | -6.27e-03 | 5.63e-01 | 6.01e-01 | 2.53e-01 | 7.01e-01 | 7.95e-01 |
| ENSHEATHMENT OF NEURONS | 143 | 8.88e-01 | 1.00e+00 | 0.03500 | -8.44e-04 | 1.29e-03 | 2.17e-02 | -2.14e-02 | 1.72e-02 | 9.86e-01 | 9.79e-01 | 6.55e-01 | 6.59e-01 | 7.23e-01 |
| REPRODUCTION | 1419 | 3.35e-02 | 2.91e-01 | 0.03460 | 1.62e-02 | 7.12e-03 | 2.42e-02 | 9.93e-03 | -1.42e-02 | 3.08e-01 | 6.53e-01 | 1.26e-01 | 5.31e-01 | 3.71e-01 |
| SPERM MOTILITY | 127 | 9.00e-01 | 1.00e+00 | 0.03460 | 6.60e-03 | 3.38e-03 | -1.40e-02 | 3.06e-02 | -2.93e-03 | 8.98e-01 | 9.48e-01 | 7.85e-01 | 5.52e-01 | 9.54e-01 |
| POSTSYNAPTIC CYTOSKELETON ORGANIZATION | 17 | 1.00e+00 | 1.00e+00 | 0.03460 | 2.03e-02 | 2.05e-02 | 1.79e-02 | 7.48e-04 | -6.39e-03 | 8.85e-01 | 8.84e-01 | 8.98e-01 | 9.96e-01 | 9.64e-01 |
| REGULATION OF DENDRITE MORPHOGENESIS | 57 | 7.66e-01 | 1.00e+00 | 0.03440 | -1.11e-02 | -2.00e-02 | 2.04e-02 | 3.24e-03 | 1.54e-02 | 8.85e-01 | 7.94e-01 | 7.90e-01 | 9.66e-01 | 8.40e-01 |
| PROTEIN LOCALIZATION TO CELL JUNCTION | 102 | 5.92e-01 | 9.86e-01 | 0.03440 | -1.29e-02 | 5.65e-03 | -1.84e-02 | 1.19e-03 | 2.53e-02 | 8.22e-01 | 9.21e-01 | 7.48e-01 | 9.83e-01 | 6.58e-01 |
| FERTILIZATION | 194 | 6.97e-01 | 1.00e+00 | 0.03440 | -1.14e-02 | -1.82e-02 | -2.42e-02 | 7.35e-03 | 8.87e-03 | 7.85e-01 | 6.62e-01 | 5.60e-01 | 8.60e-01 | 8.31e-01 |
| FACULTATIVE HETEROCHROMATIN FORMATION | 40 | 9.96e-01 | 1.00e+00 | 0.03430 | 1.67e-03 | -6.01e-03 | 2.79e-02 | -1.42e-02 | 1.26e-02 | 9.85e-01 | 9.48e-01 | 7.60e-01 | 8.76e-01 | 8.90e-01 |
| CELLULAR RESPONSE TO ALCOHOL | 99 | 8.79e-01 | 1.00e+00 | 0.03430 | -1.41e-02 | -1.98e-02 | -9.23e-03 | 1.31e-02 | 1.82e-02 | 8.09e-01 | 7.34e-01 | 8.74e-01 | 8.22e-01 | 7.55e-01 |
| REGULATION OF NEURON PROJECTION DEVELOPMENT | 431 | 8.40e-01 | 1.00e+00 | 0.03430 | -1.60e-02 | -1.45e-02 | -1.52e-02 | -7.85e-03 | -2.04e-02 | 5.70e-01 | 6.05e-01 | 5.89e-01 | 7.80e-01 | 4.67e-01 |
| CELL SUBSTRATE ADHESION | 344 | 4.01e-01 | 9.01e-01 | 0.03420 | -1.86e-02 | -2.21e-02 | -1.59e-02 | 4.08e-03 | -8.13e-03 | 5.53e-01 | 4.81e-01 | 6.12e-01 | 8.96e-01 | 7.96e-01 |
| JNK CASCADE | 157 | 7.90e-01 | 1.00e+00 | 0.03410 | -5.29e-03 | -1.87e-02 | 1.92e-02 | -5.19e-03 | 1.98e-02 | 9.09e-01 | 6.86e-01 | 6.79e-01 | 9.11e-01 | 6.68e-01 |
| REGULATION OF MITOCHONDRION ORGANIZATION | 147 | 8.79e-01 | 1.00e+00 | 0.03390 | -9.84e-03 | -5.81e-03 | 1.02e-02 | -2.99e-02 | 4.29e-03 | 8.37e-01 | 9.03e-01 | 8.31e-01 | 5.31e-01 | 9.28e-01 |
| REGULATION OF CELL PROJECTION ASSEMBLY | 220 | 6.41e-01 | 1.00e+00 | 0.03370 | -1.48e-02 | -1.10e-02 | 2.59e-04 | -6.07e-03 | 2.75e-02 | 7.05e-01 | 7.78e-01 | 9.95e-01 | 8.77e-01 | 4.82e-01 |
| REGULATION OF PEPTIDE TRANSPORT | 195 | 3.31e-01 | 8.56e-01 | 0.03370 | -2.98e-03 | 2.68e-03 | 2.15e-02 | -1.95e-02 | -1.67e-02 | 9.43e-01 | 9.48e-01 | 6.05e-01 | 6.39e-01 | 6.88e-01 |
| SYNAPTIC SIGNALING | 747 | 1.07e-01 | 5.44e-01 | 0.03350 | 1.32e-02 | 2.01e-02 | 2.13e-02 | 1.42e-03 | -9.26e-03 | 5.38e-01 | 3.50e-01 | 3.21e-01 | 9.47e-01 | 6.66e-01 |
| CHEMICAL HOMEOSTASIS | 996 | 5.56e-02 | 3.84e-01 | 0.03340 | 7.37e-03 | 3.42e-03 | 3.13e-02 | -5.87e-03 | 6.04e-03 | 6.94e-01 | 8.55e-01 | 9.49e-02 | 7.54e-01 | 7.47e-01 |
| RESPONSE TO VITAMIN | 82 | 6.97e-01 | 1.00e+00 | 0.03310 | 7.92e-03 | 1.87e-02 | 1.78e-02 | 9.70e-03 | -1.64e-02 | 9.01e-01 | 7.69e-01 | 7.81e-01 | 8.79e-01 | 7.97e-01 |
| NEGATIVE REGULATION OF INTRACELLULAR TRANSPORT | 58 | 9.99e-01 | 1.00e+00 | 0.03310 | -8.80e-03 | -4.39e-03 | -1.42e-02 | -1.59e-02 | -2.32e-02 | 9.08e-01 | 9.54e-01 | 8.51e-01 | 8.34e-01 | 7.60e-01 |
| NEGATIVE REGULATION OF INTERLEUKIN 10 PRODUCTION | 20 | 9.81e-01 | 1.00e+00 | 0.03300 | -1.45e-02 | -1.61e-02 | -3.41e-03 | 7.00e-03 | -2.37e-02 | 9.11e-01 | 9.01e-01 | 9.79e-01 | 9.57e-01 | 8.54e-01 |
| IMPORT INTO CELL | 900 | 1.88e-01 | 6.97e-01 | 0.03260 | 1.59e-03 | -5.11e-03 | 1.75e-02 | 7.50e-03 | 2.59e-02 | 9.35e-01 | 7.95e-01 | 3.74e-01 | 7.03e-01 | 1.87e-01 |
| MALE GAMETE GENERATION | 571 | 1.08e-01 | 5.46e-01 | 0.03260 | 2.65e-04 | -1.01e-02 | -2.58e-03 | 3.05e-03 | -3.07e-02 | 9.91e-01 | 6.81e-01 | 9.16e-01 | 9.01e-01 | 2.09e-01 |
| POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 698 | 2.85e-01 | 8.12e-01 | 0.03250 | -1.33e-02 | -1.49e-02 | 1.01e-02 | -2.25e-02 | 7.21e-03 | 5.51e-01 | 5.02e-01 | 6.49e-01 | 3.11e-01 | 7.46e-01 |
| ACTIN FILAMENT ORGANIZATION | 443 | 8.79e-01 | 1.00e+00 | 0.03240 | 1.11e-02 | 1.44e-02 | 1.30e-02 | 1.19e-02 | 2.02e-02 | 6.88e-01 | 6.03e-01 | 6.38e-01 | 6.66e-01 | 4.66e-01 |
| REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 889 | 7.36e-02 | 4.46e-01 | 0.03180 | -4.74e-05 | 1.03e-03 | 1.22e-02 | -9.17e-03 | -2.79e-02 | 9.98e-01 | 9.58e-01 | 5.38e-01 | 6.43e-01 | 1.57e-01 |
| TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 617 | 5.14e-01 | 9.52e-01 | 0.03180 | 7.30e-03 | 1.04e-02 | 6.99e-03 | 8.15e-03 | -2.71e-02 | 7.57e-01 | 6.59e-01 | 7.67e-01 | 7.29e-01 | 2.50e-01 |
| AXONEME ASSEMBLY | 92 | 9.30e-01 | 1.00e+00 | 0.03170 | 1.51e-02 | 6.62e-03 | 1.65e-03 | 2.63e-02 | 6.46e-03 | 8.03e-01 | 9.13e-01 | 9.78e-01 | 6.63e-01 | 9.15e-01 |
| FACE DEVELOPMENT | 49 | 9.88e-01 | 1.00e+00 | 0.03160 | -1.16e-02 | -2.45e-02 | 1.02e-03 | -1.38e-02 | 8.59e-03 | 8.88e-01 | 7.66e-01 | 9.90e-01 | 8.68e-01 | 9.17e-01 |
| MAMMARY GLAND DEVELOPMENT | 126 | 9.00e-01 | 1.00e+00 | 0.03150 | 5.46e-03 | -2.12e-04 | 2.67e-02 | -8.06e-03 | -1.35e-02 | 9.16e-01 | 9.97e-01 | 6.05e-01 | 8.76e-01 | 7.94e-01 |
| POSITIVE REGULATION OF AMYLOID PRECURSOR PROTEIN CATABOLIC PROCESS | 25 | 9.03e-01 | 1.00e+00 | 0.03150 | -1.87e-02 | -2.29e-02 | 6.86e-03 | 4.65e-03 | -6.68e-03 | 8.71e-01 | 8.43e-01 | 9.53e-01 | 9.68e-01 | 9.54e-01 |
| DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 918 | 9.32e-02 | 5.03e-01 | 0.03110 | -6.67e-03 | -1.54e-02 | 6.53e-05 | -8.36e-03 | -2.48e-02 | 7.32e-01 | 4.29e-01 | 9.97e-01 | 6.67e-01 | 2.03e-01 |
| RESPONSE TO ACETYLCHOLINE | 36 | 9.50e-01 | 1.00e+00 | 0.03080 | 1.11e-03 | 2.08e-02 | -1.56e-02 | 1.51e-02 | 6.34e-03 | 9.91e-01 | 8.29e-01 | 8.71e-01 | 8.75e-01 | 9.47e-01 |
| POSITIVE REGULATION OF MAP KINASE ACTIVITY | 86 | 8.49e-01 | 1.00e+00 | 0.03080 | -8.03e-04 | 2.59e-03 | 6.31e-03 | 7.56e-03 | -2.90e-02 | 9.90e-01 | 9.67e-01 | 9.19e-01 | 9.04e-01 | 6.42e-01 |
| REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 57 | 9.96e-01 | 1.00e+00 | 0.03050 | 1.62e-02 | 9.53e-03 | 2.30e-02 | 5.19e-04 | 7.04e-03 | 8.32e-01 | 9.01e-01 | 7.64e-01 | 9.95e-01 | 9.27e-01 |
| COLLAGEN CATABOLIC PROCESS | 44 | 9.91e-01 | 1.00e+00 | 0.03040 | -6.51e-03 | 1.08e-03 | -1.70e-02 | 1.63e-02 | 1.80e-02 | 9.40e-01 | 9.90e-01 | 8.45e-01 | 8.51e-01 | 8.36e-01 |
| BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 170 | 9.18e-01 | 1.00e+00 | 0.03020 | 1.10e-02 | 1.79e-02 | 1.08e-04 | -2.11e-03 | -2.16e-02 | 8.04e-01 | 6.88e-01 | 9.98e-01 | 9.62e-01 | 6.28e-01 |
| CELL CELL SIGNALING | 1630 | 3.76e-05 | 1.51e-03 | 0.02990 | 4.48e-03 | 1.23e-02 | 1.42e-02 | -4.48e-03 | -2.24e-02 | 7.63e-01 | 4.08e-01 | 3.38e-01 | 7.63e-01 | 1.32e-01 |
| NEURON DEVELOPMENT | 1091 | 3.74e-01 | 8.82e-01 | 0.02950 | 4.73e-03 | 6.74e-03 | 8.82e-03 | -5.28e-03 | -2.64e-02 | 7.92e-01 | 7.07e-01 | 6.23e-01 | 7.68e-01 | 1.41e-01 |
| SHORT CHAIN FATTY ACID METABOLIC PROCESS | 16 | 1.00e+00 | 1.00e+00 | 0.02940 | -2.64e-03 | -3.74e-03 | 7.18e-03 | -1.77e-02 | -2.19e-02 | 9.85e-01 | 9.79e-01 | 9.60e-01 | 9.03e-01 | 8.80e-01 |
| RESPONSE TO AXON INJURY | 79 | 1.00e+00 | 1.00e+00 | 0.02930 | -1.33e-02 | -1.40e-02 | -1.05e-02 | -6.37e-03 | 1.84e-02 | 8.39e-01 | 8.29e-01 | 8.72e-01 | 9.22e-01 | 7.78e-01 |
| SINGLE FERTILIZATION | 158 | 9.34e-01 | 1.00e+00 | 0.02900 | -7.56e-03 | -7.05e-03 | -2.24e-02 | 6.68e-03 | 1.38e-02 | 8.70e-01 | 8.78e-01 | 6.28e-01 | 8.85e-01 | 7.65e-01 |
| POSITIVE REGULATION OF CELL POPULATION PROLIFERATION | 1217 | 7.66e-02 | 4.54e-01 | 0.02890 | 5.80e-03 | 3.63e-03 | 2.64e-02 | -9.63e-03 | 1.24e-03 | 7.33e-01 | 8.31e-01 | 1.21e-01 | 5.72e-01 | 9.42e-01 |
| ADENYLATE CYCLASE ACTIVATING G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 152 | 9.59e-01 | 1.00e+00 | 0.02840 | -4.90e-04 | 3.89e-03 | -3.53e-03 | 5.24e-03 | -2.74e-02 | 9.92e-01 | 9.34e-01 | 9.40e-01 | 9.11e-01 | 5.59e-01 |
| SEXUAL REPRODUCTION | 989 | 2.53e-02 | 2.39e-01 | 0.02820 | -4.10e-03 | -1.57e-02 | 6.66e-03 | -1.23e-02 | -1.83e-02 | 8.27e-01 | 4.04e-01 | 7.23e-01 | 5.12e-01 | 3.30e-01 |
| ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY | 223 | 9.96e-01 | 1.00e+00 | 0.02760 | -1.58e-02 | -1.59e-02 | -1.17e-02 | -1.07e-02 | -3.31e-03 | 6.84e-01 | 6.83e-01 | 7.64e-01 | 7.83e-01 | 9.32e-01 |
| STEROID METABOLIC PROCESS | 315 | 3.08e-01 | 8.35e-01 | 0.02690 | -1.09e-02 | -3.40e-03 | -1.62e-02 | 1.61e-02 | 8.32e-03 | 7.39e-01 | 9.17e-01 | 6.21e-01 | 6.24e-01 | 8.00e-01 |
| NEGATIVE REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS | 65 | 6.87e-01 | 1.00e+00 | 0.02670 | -8.97e-03 | -1.31e-02 | 1.67e-02 | 9.37e-03 | 9.76e-03 | 9.00e-01 | 8.55e-01 | 8.16e-01 | 8.96e-01 | 8.92e-01 |
| ORGANOPHOSPHATE ESTER TRANSPORT | 147 | 9.85e-01 | 1.00e+00 | 0.02660 | -1.14e-02 | -4.95e-03 | -2.29e-02 | -5.55e-03 | -8.32e-04 | 8.11e-01 | 9.17e-01 | 6.32e-01 | 9.07e-01 | 9.86e-01 |
| REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 48 | 7.04e-01 | 1.00e+00 | 0.02650 | -4.55e-03 | 2.07e-02 | -1.02e-02 | 2.61e-03 | -1.19e-02 | 9.56e-01 | 8.04e-01 | 9.03e-01 | 9.75e-01 | 8.87e-01 |
| DENDRITIC SPINE DEVELOPMENT | 86 | 6.94e-01 | 1.00e+00 | 0.02640 | -2.01e-02 | -7.80e-03 | -1.06e-02 | -5.45e-03 | 9.49e-03 | 7.48e-01 | 9.01e-01 | 8.66e-01 | 9.30e-01 | 8.79e-01 |
| CELL JUNCTION ASSEMBLY | 423 | 6.26e-02 | 4.11e-01 | 0.02540 | -7.14e-03 | 8.48e-03 | -1.74e-02 | 1.04e-02 | -1.05e-02 | 8.01e-01 | 7.65e-01 | 5.40e-01 | 7.13e-01 | 7.11e-01 |
| REGULATION OF AXON EXTENSION | 85 | 9.64e-01 | 1.00e+00 | 0.02480 | 4.88e-03 | -2.32e-03 | 2.11e-02 | 7.85e-04 | -1.20e-02 | 9.38e-01 | 9.70e-01 | 7.37e-01 | 9.90e-01 | 8.49e-01 |
| MUSCLE CELL DIFFERENTIATION | 407 | 8.09e-01 | 1.00e+00 | 0.02450 | 9.15e-03 | 6.53e-03 | 1.80e-02 | 6.70e-03 | -1.03e-02 | 7.51e-01 | 8.21e-01 | 5.33e-01 | 8.17e-01 | 7.21e-01 |
| ACTIN FILAMENT BASED PROCESS | 774 | 3.02e-01 | 8.30e-01 | 0.02380 | 3.27e-03 | 1.04e-02 | -7.03e-03 | 1.95e-02 | -4.26e-03 | 8.77e-01 | 6.22e-01 | 7.39e-01 | 3.55e-01 | 8.40e-01 |
| PROSTAGLANDIN TRANSPORT | 28 | 6.01e-01 | 9.90e-01 | 0.02370 | -1.71e-02 | 1.02e-02 | -3.92e-03 | 5.94e-04 | 1.23e-02 | 8.76e-01 | 9.25e-01 | 9.71e-01 | 9.96e-01 | 9.10e-01 |
| WOUND HEALING | 407 | 2.06e-01 | 7.27e-01 | 0.02350 | -1.29e-02 | -4.09e-03 | -1.50e-02 | 5.50e-03 | -1.06e-02 | 6.56e-01 | 8.87e-01 | 6.04e-01 | 8.49e-01 | 7.14e-01 |
| SYNAPSE ORGANIZATION | 449 | 4.50e-01 | 9.30e-01 | 0.02290 | 2.08e-03 | 4.95e-03 | 1.52e-02 | -7.17e-03 | -1.46e-02 | 9.40e-01 | 8.57e-01 | 5.80e-01 | 7.94e-01 | 5.96e-01 |
| CALCIUM ION TRANSMEMBRANE IMPORT INTO CYTOSOL | 198 | 9.47e-01 | 1.00e+00 | 0.02230 | -1.05e-02 | -1.57e-02 | 3.93e-03 | -1.08e-02 | -3.21e-03 | 7.99e-01 | 7.03e-01 | 9.24e-01 | 7.94e-01 | 9.38e-01 |
| MULTICELLULAR ORGANISM REPRODUCTION | 876 | 1.61e-01 | 6.59e-01 | 0.02110 | 3.85e-04 | -8.21e-03 | 3.99e-03 | 3.11e-03 | -1.88e-02 | 9.85e-01 | 6.80e-01 | 8.41e-01 | 8.76e-01 | 3.45e-01 |
| COLLAGEN FIBRIL ORGANIZATION | 63 | 9.74e-01 | 1.00e+00 | 0.02110 | -2.10e-03 | 5.57e-03 | 6.21e-04 | 1.17e-03 | -2.02e-02 | 9.77e-01 | 9.39e-01 | 9.93e-01 | 9.87e-01 | 7.82e-01 |
| POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 480 | 4.68e-01 | 9.36e-01 | 0.02090 | 7.38e-03 | 1.47e-02 | 1.25e-02 | 2.28e-03 | -2.39e-03 | 7.82e-01 | 5.81e-01 | 6.39e-01 | 9.32e-01 | 9.29e-01 |
| REGULATION OF NUCLEAR TRANSCRIBED MRNA CATABOLIC PROCESS DEADENYLATION DEPENDENT DECAY | 26 | 9.12e-01 | 1.00e+00 | 0.02080 | -1.31e-02 | 8.16e-04 | 8.42e-03 | -1.01e-02 | 9.27e-03 | 9.08e-01 | 9.94e-01 | 9.41e-01 | 9.29e-01 | 9.35e-01 |
| PROTEIN AUTOUBIQUITINATION | 67 | 7.27e-01 | 1.00e+00 | 0.02070 | -6.80e-03 | 6.30e-03 | -4.89e-03 | 1.62e-02 | 7.40e-03 | 9.23e-01 | 9.29e-01 | 9.45e-01 | 8.19e-01 | 9.17e-01 |
| ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 979 | 2.72e-01 | 7.99e-01 | 0.02060 | 1.62e-03 | -6.76e-04 | 1.27e-02 | -2.74e-03 | -1.59e-02 | 9.32e-01 | 9.71e-01 | 5.00e-01 | 8.85e-01 | 3.99e-01 |
| DENDRITE DEVELOPMENT | 219 | 6.64e-01 | 1.00e+00 | 0.02060 | -7.86e-03 | -7.30e-03 | -2.46e-03 | 5.96e-03 | -1.64e-02 | 8.41e-01 | 8.52e-01 | 9.50e-01 | 8.79e-01 | 6.77e-01 |
| CYTOSKELETON ORGANIZATION | 1446 | 7.41e-01 | 1.00e+00 | 0.02020 | 2.36e-03 | 1.78e-03 | 7.70e-03 | 6.12e-03 | 1.74e-02 | 8.80e-01 | 9.10e-01 | 6.24e-01 | 6.97e-01 | 2.68e-01 |
| CELL JUNCTION ORGANIZATION | 716 | 4.20e-02 | 3.28e-01 | 0.01990 | 7.28e-05 | 1.04e-02 | -5.21e-03 | 1.50e-02 | -6.10e-03 | 9.97e-01 | 6.36e-01 | 8.12e-01 | 4.94e-01 | 7.81e-01 |
| REGULATION OF CELL PROJECTION ORGANIZATION | 661 | 5.84e-01 | 9.85e-01 | 0.01920 | -1.08e-02 | -8.27e-03 | -9.47e-03 | 3.66e-05 | -9.77e-03 | 6.36e-01 | 7.17e-01 | 6.78e-01 | 9.99e-01 | 6.68e-01 |
| NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 161 | 7.18e-01 | 1.00e+00 | 0.01830 | 2.42e-03 | 3.86e-03 | -1.64e-02 | -2.86e-03 | -6.18e-03 | 9.58e-01 | 9.33e-01 | 7.20e-01 | 9.50e-01 | 8.92e-01 |
| NEUROPEPTIDE SIGNALING PATHWAY | 102 | 9.67e-01 | 1.00e+00 | 0.01830 | 1.27e-03 | 6.87e-03 | -1.31e-02 | -4.91e-03 | -9.37e-03 | 9.82e-01 | 9.05e-01 | 8.19e-01 | 9.32e-01 | 8.70e-01 |
| MORPHOGENESIS OF A POLARIZED EPITHELIUM | 89 | 9.74e-01 | 1.00e+00 | 0.01720 | 4.51e-03 | 1.51e-02 | -9.60e-04 | 5.79e-03 | -3.51e-03 | 9.41e-01 | 8.05e-01 | 9.88e-01 | 9.25e-01 | 9.54e-01 |
| RESPONSE TO WOUNDING | 538 | 4.20e-01 | 9.11e-01 | 0.01710 | 2.06e-03 | 5.86e-03 | 5.13e-03 | 1.32e-02 | 7.24e-03 | 9.35e-01 | 8.16e-01 | 8.39e-01 | 6.00e-01 | 7.74e-01 |
| POSITIVE REGULATION OF LIPID LOCALIZATION | 111 | 6.09e-01 | 9.90e-01 | 0.01670 | -2.46e-03 | 2.51e-03 | 1.57e-02 | 4.20e-03 | 1.49e-03 | 9.64e-01 | 9.64e-01 | 7.76e-01 | 9.39e-01 | 9.78e-01 |
| REGULATION OF EXTENT OF CELL GROWTH | 101 | 9.58e-01 | 1.00e+00 | 0.01620 | -2.63e-03 | -9.59e-03 | 1.28e-02 | 6.49e-04 | -1.19e-03 | 9.64e-01 | 8.68e-01 | 8.25e-01 | 9.91e-01 | 9.84e-01 |
| SENSORY PERCEPTION OF MECHANICAL STIMULUS | 179 | 9.86e-01 | 1.00e+00 | 0.01520 | 3.48e-03 | 7.77e-03 | 4.60e-04 | 1.17e-02 | 4.51e-03 | 9.36e-01 | 8.58e-01 | 9.92e-01 | 7.87e-01 | 9.17e-01 |
| CELL PROJECTION ORGANIZATION | 1547 | 3.82e-01 | 8.92e-01 | 0.01490 | -5.71e-03 | -4.90e-03 | 6.39e-03 | -9.86e-03 | 5.23e-03 | 7.08e-01 | 7.47e-01 | 6.75e-01 | 5.17e-01 | 7.31e-01 |
| ACTIN POLYMERIZATION OR DEPOLYMERIZATION | 186 | 9.77e-01 | 1.00e+00 | 0.00998 | -4.66e-03 | -5.39e-04 | 1.85e-03 | -7.52e-03 | -4.19e-03 | 9.13e-01 | 9.90e-01 | 9.65e-01 | 8.60e-01 | 9.22e-01 |
Detailed Gene set reports
REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS INVOLVED IN CHOLESTEROL TRANSPORT
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.037 |
| p.adjustMANOVA | 0.306 |
| s.dist | 1.43 |
| s.ADOS | 0.767 |
| s.diagnosis | 0.783 |
| s.iIQ | 0.603 |
| s.iLang | 0.654 |
| s.motor | -0.211 |
| p.ADOS | 0.00114 |
| p.diagnosis | 0.000892 |
| p.iIQ | 0.0105 |
| p.iLang | 0.00555 |
| p.motor | 0.37 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| MIR27B | 16063 | 16022 |
| MIR17 | 14492 | 14992 |
| LDLRAP1 | 13854 | 13542 |
| PCSK9 | 13352 | 12934 |
| ANXA2 | 13175 | 12050 |
| ABCA2 | 11134 | 11691 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ABCA2 | 11691 | 11134 | 10060 | 12667 | 5925 |
| ANXA2 | 12050 | 13175 | 5053 | 16386 | 5001 |
| LDLRAP1 | 13542 | 13854 | 11628 | 12358 | 3461 |
| MIR17 | 14992 | 14492 | 13481 | 12181 | -3938 |
| MIR27B | 16022 | 16063 | 10251 | 17483 | -9087 |
| PCSK9 | 12934 | 13352 | 9030 | 11343 | -7144 |
POSITIVE REGULATION OF NATURAL KILLER CELL CHEMOTAXIS
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.0924 |
| p.adjustMANOVA | 0.502 |
| s.dist | 1.39 |
| s.ADOS | -0.725 |
| s.diagnosis | -0.762 |
| s.iIQ | -0.582 |
| s.iLang | -0.702 |
| s.motor | -0.00696 |
| p.ADOS | 0.005 |
| p.diagnosis | 0.00317 |
| p.iIQ | 0.0241 |
| p.iLang | 0.00659 |
| p.motor | 0.979 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| XCL1 | -6053 | -5963 |
| CCL4 | -4603 | -5032 |
| CCL3 | -3603 | -2350 |
| CCL7 | -2145 | -2632 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CCL3 | -2350 | -3603 | 154 | -2597 | -1787 |
| CCL4 | -5032 | -4603 | -6882 | -3403 | 5000 |
| CCL5 | 566 | -1271 | 3890 | 1981 | 11737 |
| CCL7 | -2632 | -2145 | -5829 | 1644 | 1008 |
| XCL1 | -5963 | -6053 | -7784 | -4429 | -9398 |
POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION OF STAT PROTEIN
| metric | value |
|---|---|
| setSize | 17 |
| pMANOVA | 8.57e-07 |
| p.adjustMANOVA | 5.69e-05 |
| s.dist | 1.38 |
| s.ADOS | -0.714 |
| s.diagnosis | -0.664 |
| s.iIQ | -0.716 |
| s.iLang | -0.661 |
| s.motor | -0.0046 |
| p.ADOS | 3.45e-07 |
| p.diagnosis | 2.11e-06 |
| p.iIQ | 3.13e-07 |
| p.iLang | 2.38e-06 |
| p.motor | 0.974 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | ADOS |
|---|---|---|
| IFNA6 | -7934 | -6140 |
| IFNA16 | -7806 | -6116 |
| IFNA1 | -7836 | -5836 |
| IFNA21 | -7559 | -5944 |
| IFNA14 | -7617 | -5883 |
| IFNA2 | -7320 | -5995 |
| IFNE | -7066 | -6111 |
| IFNB1 | -7328 | -5877 |
| IFNG | -6769 | -4996 |
| IFNA13 | -7358 | -4456 |
| IFNA5 | -6358 | -4932 |
| IFNA7 | -4957 | -3857 |
| IFNK | -7006 | -1714 |
| IFNA8 | -3219 | -2440 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| IFNA1 | -5836 | -5850 | -7836 | -3369 | -209 |
| IFNA13 | -4456 | -4231 | -7358 | 1091 | -9347 |
| IFNA14 | -5883 | -5951 | -7617 | -4437 | -3769 |
| IFNA16 | -6116 | -6077 | -7806 | -4686 | -8163 |
| IFNA2 | -5995 | -6120 | -7320 | -4521 | 11931 |
| IFNA21 | -5944 | -5772 | -7559 | -4378 | 12315 |
| IFNA5 | -4932 | -4984 | -6358 | -3775 | -8153 |
| IFNA6 | -6140 | -6173 | -7934 | -4609 | 12318 |
| IFNA7 | -3857 | -726 | -4957 | -4230 | -8996 |
| IFNA8 | -2440 | 390 | -3219 | -2356 | 5183 |
| IFNB1 | -5877 | -5995 | -7328 | -4158 | 10875 |
| IFNE | -6111 | -6170 | -7066 | -4648 | 12519 |
| IFNG | -4996 | -4941 | -6769 | -3029 | -8084 |
| IFNK | -1714 | 1525 | -7006 | 13903 | 5008 |
| IFNW1 | 131 | 3494 | -6574 | 2279 | -9521 |
| LIF | 8907 | 5582 | 11666 | 5737 | 5241 |
| RET | 11027 | 10486 | 9772 | 9828 | 3602 |
T FOLLICULAR HELPER CELL DIFFERENTIATION
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.00785 |
| p.adjustMANOVA | 0.105 |
| s.dist | 1.38 |
| s.ADOS | -0.673 |
| s.diagnosis | -0.697 |
| s.iIQ | -0.534 |
| s.iLang | -0.719 |
| s.motor | -0.395 |
| p.ADOS | 0.00204 |
| p.diagnosis | 0.00141 |
| p.iIQ | 0.0143 |
| p.iLang | 0.000978 |
| p.motor | 0.07 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | diagnosis |
|---|---|---|
| GPR183 | -3860 | -5677 |
| RC3H1 | -2940 | -5597 |
| IL6 | -3955 | -4090 |
| IL21 | -3437 | -4536 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ASCL2 | 4678 | 3257 | 5603 | 1319 | -6676 |
| FOXP1 | -1020 | -1430 | -2089 | 1407 | 1600 |
| GPR183 | -5648 | -5677 | -7075 | -3860 | 5239 |
| IL21 | -5034 | -4536 | -7228 | -3437 | -8047 |
| IL6 | -3409 | -4090 | 2075 | -3955 | 724 |
| RC3H1 | -5545 | -5597 | -7568 | -2940 | -8272 |
| RC3H2 | -1559 | -1587 | -3011 | 547 | -5676 |
POSITIVE REGULATION OF FC RECEPTOR MEDIATED STIMULATORY SIGNALING PATHWAY
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.104 |
| p.adjustMANOVA | 0.536 |
| s.dist | 1.36 |
| s.ADOS | -0.702 |
| s.diagnosis | -0.725 |
| s.iIQ | -0.611 |
| s.iLang | -0.67 |
| s.motor | -0.0416 |
| p.ADOS | 0.00654 |
| p.diagnosis | 0.00498 |
| p.iIQ | 0.018 |
| p.iLang | 0.00947 |
| p.motor | 0.872 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| PTPRC | -5248 | -4705 |
| LYN | -4223 | -3716 |
| PTPRJ | -3248 | -2718 |
| CD226 | -2042 | -2099 |
| APPL2 | -868 | -910 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| APPL2 | -910 | -868 | -2972 | 968 | -4803 |
| CD226 | -2099 | -2042 | -5344 | 1654 | -5760 |
| LYN | -3716 | -4223 | -3656 | -2727 | 647 |
| PTPRC | -4705 | -5248 | -4565 | -2680 | 9883 |
| PTPRJ | -2718 | -3248 | -1521 | -2261 | 4663 |
FATTY ACYL COA CATABOLIC PROCESS
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.104 |
| p.adjustMANOVA | 0.536 |
| s.dist | 1.29 |
| s.ADOS | 0.661 |
| s.diagnosis | 0.637 |
| s.iIQ | 0.641 |
| s.iLang | 0.646 |
| s.motor | 0.0693 |
| p.ADOS | 0.0105 |
| p.diagnosis | 0.0136 |
| p.iIQ | 0.013 |
| p.iLang | 0.0123 |
| p.motor | 0.788 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | iLang |
|---|---|---|
| NUDT19 | 15378 | 15948 |
| NUDT8 | 14998 | 13794 |
| NUDT7 | 11713 | 13726 |
| FITM2 | 12011 | 13242 |
| ACOT7 | 7663 | 11573 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ACOT7 | 7663 | 8180 | 3768 | 11573 | 1119 |
| FITM2 | 12011 | 12312 | 10071 | 13242 | 7637 |
| NUDT19 | 15378 | 15105 | 11728 | 15948 | -7358 |
| NUDT7 | 11713 | 9759 | 12413 | 13726 | 8455 |
| NUDT8 | 14998 | 14898 | 13719 | 13794 | 955 |
MEDIUM CHAIN FATTY ACYL COA METABOLIC PROCESS
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.068 |
| p.adjustMANOVA | 0.427 |
| s.dist | 1.26 |
| s.ADOS | 0.663 |
| s.diagnosis | 0.617 |
| s.iIQ | 0.496 |
| s.iLang | 0.716 |
| s.motor | -0.0129 |
| p.ADOS | 0.00492 |
| p.diagnosis | 0.00883 |
| p.iIQ | 0.0353 |
| p.iLang | 0.00238 |
| p.motor | 0.956 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | ADOS |
|---|---|---|
| NUDT19 | 15948 | 15378 |
| ACSM2A | 17199 | 13587 |
| NUDT8 | 13794 | 14998 |
| NUDT7 | 13726 | 11713 |
| HSD17B4 | 14349 | 10928 |
| ACOT7 | 11573 | 7663 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ACOT7 | 7663 | 8180 | 3768 | 11573 | 1119 |
| ACSM2A | 13587 | 11802 | 6796 | 17199 | 9744 |
| HSD17B4 | 10928 | 11237 | 3914 | 14349 | -5438 |
| NUDT19 | 15378 | 15105 | 11728 | 15948 | -7358 |
| NUDT7 | 11713 | 9759 | 12413 | 13726 | 8455 |
| NUDT8 | 14998 | 14898 | 13719 | 13794 | 955 |
NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.124 |
| p.adjustMANOVA | 0.587 |
| s.dist | 1.25 |
| s.ADOS | -0.641 |
| s.diagnosis | -0.681 |
| s.iIQ | -0.457 |
| s.iLang | -0.639 |
| s.motor | 0.265 |
| p.ADOS | 0.013 |
| p.diagnosis | 0.0084 |
| p.iIQ | 0.0766 |
| p.iLang | 0.0134 |
| p.motor | 0.304 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| MIR29B1 | -5711 | -5839 |
| IL4 | -4566 | -4175 |
| PPARG | -4529 | -3978 |
| DLX1 | -2447 | -590 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CFLAR | 3818 | 4109 | 534 | 6477 | 6501 |
| DLX1 | -590 | -2447 | 6992 | -2192 | 10137 |
| IL4 | -4175 | -4566 | -5895 | -134 | 8390 |
| MIR29B1 | -5839 | -5711 | -7765 | -4502 | -9525 |
| PPARG | -3978 | -4529 | -3357 | -2955 | 6220 |
REGULATION OF NATURAL KILLER CELL CHEMOTAXIS
| metric | value |
|---|---|
| setSize | 8 |
| pMANOVA | 0.0526 |
| p.adjustMANOVA | 0.376 |
| s.dist | 1.25 |
| s.ADOS | -0.646 |
| s.diagnosis | -0.633 |
| s.iIQ | -0.597 |
| s.iLang | -0.591 |
| s.motor | -0.172 |
| p.ADOS | 0.00156 |
| p.diagnosis | 0.00194 |
| p.iIQ | 0.00347 |
| p.iLang | 0.00377 |
| p.motor | 0.398 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | diagnosis |
|---|---|---|
| XCL1 | -5963 | -6053 |
| KLRK1 | -5404 | -5626 |
| KLRC4-KLRK1 | -4663 | -4990 |
| CCL4 | -5032 | -4603 |
| CCL3 | -2350 | -3603 |
| CCL7 | -2632 | -2145 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CCL2 | 7880 | 11543 | 2220 | 9973 | -2645 |
| CCL3 | -2350 | -3603 | 154 | -2597 | -1787 |
| CCL4 | -5032 | -4603 | -6882 | -3403 | 5000 |
| CCL5 | 566 | -1271 | 3890 | 1981 | 11737 |
| CCL7 | -2632 | -2145 | -5829 | 1644 | 1008 |
| KLRC4-KLRK1 | -4663 | -4990 | -6692 | -346 | -5331 |
| KLRK1 | -5404 | -5626 | -6673 | -3888 | -2838 |
| XCL1 | -5963 | -6053 | -7784 | -4429 | -9398 |
EMBRYONIC PROCESS INVOLVED IN FEMALE PREGNANCY
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.129 |
| p.adjustMANOVA | 0.597 |
| s.dist | 1.21 |
| s.ADOS | 0.646 |
| s.diagnosis | 0.639 |
| s.iIQ | 0.603 |
| s.iLang | 0.506 |
| s.motor | 0.171 |
| p.ADOS | 0.00611 |
| p.diagnosis | 0.0067 |
| p.iIQ | 0.0105 |
| p.iLang | 0.0319 |
| p.motor | 0.469 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | diagnosis |
|---|---|---|
| CITED2 | 14876 | 13779 |
| NODAL | 13611 | 14322 |
| TLE6 | 13430 | 14162 |
| JUNB | 14609 | 12750 |
| SP3 | 12715 | 12351 |
| EMP2 | 3923 | 5075 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CITED2 | 14876 | 13779 | 12306 | 15963 | -2468 |
| EMP2 | 3923 | 5075 | 414 | 10135 | 6604 |
| JUNB | 14609 | 12750 | 13862 | 10273 | 11524 |
| NODAL | 13611 | 14322 | 9712 | 13064 | -4771 |
| SP3 | 12715 | 12351 | 12159 | 9852 | 7432 |
| TLE6 | 13430 | 14162 | 11033 | 13253 | 1424 |
POSITIVE REGULATION OF PHOSPHOLIPID TRANSLOCATION
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.185 |
| p.adjustMANOVA | 0.694 |
| s.dist | 1.2 |
| s.ADOS | -0.591 |
| s.diagnosis | -0.587 |
| s.iIQ | -0.613 |
| s.iLang | -0.504 |
| s.motor | -0.325 |
| p.ADOS | 0.0221 |
| p.diagnosis | 0.0231 |
| p.iIQ | 0.0176 |
| p.iLang | 0.0509 |
| p.motor | 0.208 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | ADOS |
|---|---|---|
| FASLG | -7372 | -4795 |
| ATP8A1 | -6785 | -4648 |
| ABCB4 | -5439 | -3438 |
| ATP8A2 | -3604 | -312 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ABCB4 | -3438 | -3118 | -5439 | -488 | 2543 |
| ATP8A1 | -4648 | -4556 | -6785 | -1046 | -4407 |
| ATP8A2 | -312 | 443 | -3604 | 3168 | -3472 |
| FASLG | -4795 | -4342 | -7372 | -863 | -8908 |
| TMEM30A | 5232 | 3669 | 5027 | 3423 | 3100 |
HEAT ACCLIMATION
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.283 |
| p.adjustMANOVA | 0.81 |
| s.dist | 1.19 |
| s.ADOS | 0.617 |
| s.diagnosis | 0.593 |
| s.iIQ | 0.585 |
| s.iLang | 0.561 |
| s.motor | 0.176 |
| p.ADOS | 0.0168 |
| p.diagnosis | 0.0216 |
| p.iIQ | 0.0235 |
| p.iLang | 0.0297 |
| p.motor | 0.496 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | diagnosis |
|---|---|---|
| HSPA1B | 15672 | 15441 |
| HSPA6 | 14201 | 14696 |
| HSBP1 | 13474 | 13425 |
| HSPA1A | 13672 | 12600 |
| HSBP1L1 | 2326 | 1642 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| HSBP1 | 13474 | 13425 | 10773 | 14694 | 7276 |
| HSBP1L1 | 2326 | 1642 | 2612 | 1717 | 3167 |
| HSPA1A | 13672 | 12600 | 13258 | 14318 | 10656 |
| HSPA1B | 15672 | 15441 | 14063 | 16669 | -519 |
| HSPA6 | 14201 | 14696 | 7857 | 16139 | -3830 |
POSITIVE REGULATION OF RAC PROTEIN SIGNAL TRANSDUCTION
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.243 |
| p.adjustMANOVA | 0.769 |
| s.dist | 1.19 |
| s.ADOS | -0.604 |
| s.diagnosis | -0.59 |
| s.iIQ | -0.507 |
| s.iLang | -0.634 |
| s.motor | -0.207 |
| p.ADOS | 0.0194 |
| p.diagnosis | 0.0223 |
| p.iIQ | 0.0494 |
| p.iLang | 0.0141 |
| p.motor | 0.423 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | ADOS |
|---|---|---|
| PIK3CB | -3757 | -5516 |
| PIK3CG | -3113 | -4635 |
| ALS2 | -734 | -1966 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ALS2 | -1966 | -2299 | 532 | -734 | 7553 |
| AUTS2 | -1845 | -1494 | -4350 | 2868 | 135 |
| KRAS | 5307 | 6342 | 4463 | 1712 | -3339 |
| PIK3CB | -5516 | -5468 | -7583 | -3757 | -7250 |
| PIK3CG | -4635 | -5191 | -5347 | -3113 | -1669 |
NEGATIVE REGULATION OF VASOCONSTRICTION
| metric | value |
|---|---|
| setSize | 8 |
| pMANOVA | 0.0531 |
| p.adjustMANOVA | 0.377 |
| s.dist | 1.19 |
| s.ADOS | -0.614 |
| s.diagnosis | -0.631 |
| s.iIQ | -0.56 |
| s.iLang | -0.538 |
| s.motor | -0.163 |
| p.ADOS | 0.00263 |
| p.diagnosis | 0.00199 |
| p.iIQ | 0.00607 |
| p.iLang | 0.00835 |
| p.motor | 0.424 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| MTNR1B | -4945 | -5017 |
| ARHGAP42 | -3688 | -3846 |
| DOCK4 | -3568 | -3482 |
| ADM | -3218 | -2444 |
| DOCK5 | -2657 | -2625 |
| BMPR2 | -2177 | -2870 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ADM | -2444 | -3218 | -371 | -890 | 10443 |
| ARHGAP42 | -3846 | -3688 | -6548 | -326 | -8585 |
| BMPR2 | -2870 | -2177 | -5153 | -104 | -620 |
| DOCK4 | -3482 | -3568 | -5147 | -1753 | -471 |
| DOCK5 | -2625 | -2657 | -2964 | -1573 | -1357 |
| LEP | -569 | 479 | -3725 | 1571 | -6406 |
| MMP2 | 6073 | 3159 | 6725 | 7568 | 1757 |
| MTNR1B | -5017 | -4945 | -7165 | -843 | 1809 |
SERINE PHOSPHORYLATION OF STAT PROTEIN
| metric | value |
|---|---|
| setSize | 21 |
| pMANOVA | 7.82e-06 |
| p.adjustMANOVA | 0.000384 |
| s.dist | 1.18 |
| s.ADOS | -0.608 |
| s.diagnosis | -0.579 |
| s.iIQ | -0.59 |
| s.iLang | -0.588 |
| s.motor | -0.0433 |
| p.ADOS | 1.41e-06 |
| p.diagnosis | 4.4e-06 |
| p.iIQ | 2.9e-06 |
| p.iLang | 3.1e-06 |
| p.motor | 0.731 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | iIQ |
|---|---|---|
| IFNA6 | -6140 | -7934 |
| IFNA16 | -6116 | -7806 |
| IFNA1 | -5836 | -7836 |
| IFNA21 | -5944 | -7559 |
| IFNA14 | -5883 | -7617 |
| IFNA2 | -5995 | -7320 |
| IFNE | -6111 | -7066 |
| IFNB1 | -5877 | -7328 |
| IFNG | -4996 | -6769 |
| IFNA13 | -4456 | -7358 |
| IFNA5 | -4932 | -6358 |
| NLK | -4267 | -4754 |
| IFNA7 | -3857 | -4957 |
| IFNK | -1714 | -7006 |
| IFNA8 | -2440 | -3219 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| GADD45A | -1919 | -1609 | 970 | -3455 | -4396 |
| GGNBP2 | 5667 | 2674 | 3091 | 7193 | 854 |
| IFNA1 | -5836 | -5850 | -7836 | -3369 | -209 |
| IFNA13 | -4456 | -4231 | -7358 | 1091 | -9347 |
| IFNA14 | -5883 | -5951 | -7617 | -4437 | -3769 |
| IFNA16 | -6116 | -6077 | -7806 | -4686 | -8163 |
| IFNA2 | -5995 | -6120 | -7320 | -4521 | 11931 |
| IFNA21 | -5944 | -5772 | -7559 | -4378 | 12315 |
| IFNA5 | -4932 | -4984 | -6358 | -3775 | -8153 |
| IFNA6 | -6140 | -6173 | -7934 | -4609 | 12318 |
| IFNA7 | -3857 | -726 | -4957 | -4230 | -8996 |
| IFNA8 | -2440 | 390 | -3219 | -2356 | 5183 |
| IFNB1 | -5877 | -5995 | -7328 | -4158 | 10875 |
| IFNE | -6111 | -6170 | -7066 | -4648 | 12519 |
| IFNG | -4996 | -4941 | -6769 | -3029 | -8084 |
| IFNK | -1714 | 1525 | -7006 | 13903 | 5008 |
| IFNW1 | 131 | 3494 | -6574 | 2279 | -9521 |
| LIF | 8907 | 5582 | 11666 | 5737 | 5241 |
| NLK | -4267 | -4658 | -4754 | -2428 | 6367 |
| PWP1 | 13514 | 13850 | 11271 | 12172 | -6519 |
| RET | 11027 | 10486 | 9772 | 9828 | 3602 |
NEGATIVE REGULATION OF SEQUESTERING OF TRIGLYCERIDE
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0931 |
| p.adjustMANOVA | 0.503 |
| s.dist | 1.18 |
| s.ADOS | -0.607 |
| s.diagnosis | -0.637 |
| s.iIQ | -0.456 |
| s.iLang | -0.58 |
| s.motor | 0.276 |
| p.ADOS | 0.00999 |
| p.diagnosis | 0.00687 |
| p.iIQ | 0.0533 |
| p.iLang | 0.0138 |
| p.motor | 0.243 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| OSBPL8 | -4273 | -4464 |
| PPARG | -4529 | -3978 |
| TREM2 | -4365 | -4104 |
| ABHD5 | -2122 | -1769 |
| PPARA | -1304 | -810 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ABHD5 | -1769 | -2122 | -2692 | 2094 | 1478 |
| OSBPL8 | -4464 | -4273 | -6094 | -2203 | 3191 |
| PNPLA2 | 4497 | 3722 | 7198 | 3011 | 9223 |
| PPARA | -810 | -1304 | -148 | 1573 | 9106 |
| PPARG | -3978 | -4529 | -3357 | -2955 | 6220 |
| TREM2 | -4104 | -4365 | -6177 | -1577 | -2466 |
REGULATION OF MYELOID DENDRITIC CELL ACTIVATION
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.024 |
| p.adjustMANOVA | 0.233 |
| s.dist | 1.18 |
| s.ADOS | -0.578 |
| s.diagnosis | -0.685 |
| s.iIQ | -0.161 |
| s.iLang | -0.612 |
| s.motor | 0.423 |
| p.ADOS | 0.0253 |
| p.diagnosis | 0.00795 |
| p.iIQ | 0.534 |
| p.iLang | 0.0179 |
| p.motor | 0.101 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | iLang |
|---|---|---|
| IL10 | -4564 | -3539 |
| TSPAN32 | -4013 | -2537 |
| HAVCR2 | -4259 | -2293 |
| CD2 | -4886 | -234 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CD2 | -4216 | -4886 | -5162 | -234 | 9842 |
| CLEC4D | 4691 | 4314 | 694 | 6812 | -8836 |
| HAVCR2 | -3380 | -4259 | -1074 | -2293 | 8180 |
| IL10 | -3537 | -4564 | 2545 | -3539 | 9624 |
| TSPAN32 | -774 | -4013 | 10039 | -2537 | 11706 |
INTERLEUKIN 5 MEDIATED SIGNALING PATHWAY
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.127 |
| p.adjustMANOVA | 0.593 |
| s.dist | 1.17 |
| s.ADOS | -0.609 |
| s.diagnosis | -0.637 |
| s.iIQ | -0.399 |
| s.iLang | -0.66 |
| s.motor | -0.0469 |
| p.ADOS | 0.00976 |
| p.diagnosis | 0.00686 |
| p.iIQ | 0.0908 |
| p.iLang | 0.00508 |
| p.motor | 0.842 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | diagnosis |
|---|---|---|
| IL5 | -4384 | -5449 |
| STAT5A | -2984 | -4491 |
| LYN | -2727 | -4223 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CSF2RB | 3199 | 1350 | 6464 | 892 | 6673 |
| IL5 | -5719 | -5449 | -7493 | -4384 | -5758 |
| IL5RA | -2401 | -1047 | -5764 | 2047 | -3535 |
| JAK2 | 969 | 980 | -788 | 1740 | -3302 |
| LYN | -3716 | -4223 | -3656 | -2727 | 647 |
| STAT5A | -3086 | -4491 | 3771 | -2984 | 10474 |
LOBAR BRONCHUS EPITHELIUM DEVELOPMENT
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.0197 |
| p.adjustMANOVA | 0.206 |
| s.dist | 1.16 |
| s.ADOS | 0.614 |
| s.diagnosis | 0.631 |
| s.iIQ | 0.254 |
| s.iLang | 0.579 |
| s.motor | -0.421 |
| p.ADOS | 0.0174 |
| p.diagnosis | 0.0145 |
| p.iIQ | 0.325 |
| p.iLang | 0.0249 |
| p.motor | 0.103 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| HOXA5 | 15733 | 15031 |
| SPDEF | 15318 | 14901 |
| ADAMTSL2 | 14542 | 14611 |
| AGR2 | 15118 | 13841 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ADAMTSL2 | 14611 | 14542 | 12070 | 15066 | -3697 |
| AGR2 | 13841 | 15118 | 3515 | 16758 | 2051 |
| HOXA5 | 15031 | 15733 | 2357 | 17202 | -8109 |
| IL13 | 787 | -793 | 4754 | -1143 | -389 |
| SPDEF | 14901 | 15318 | 7441 | 16659 | -6369 |
LOBAR BRONCHUS DEVELOPMENT
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0251 |
| p.adjustMANOVA | 0.238 |
| s.dist | 1.16 |
| s.ADOS | 0.63 |
| s.diagnosis | 0.622 |
| s.iIQ | 0.329 |
| s.iLang | 0.621 |
| s.motor | -0.245 |
| p.ADOS | 0.00752 |
| p.diagnosis | 0.00828 |
| p.iIQ | 0.163 |
| p.iLang | 0.00839 |
| p.motor | 0.298 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | diagnosis |
|---|---|---|
| HOXA5 | 15031 | 15733 |
| SPDEF | 14901 | 15318 |
| ADAMTSL2 | 14611 | 14542 |
| AGR2 | 13841 | 15118 |
| WNT7B | 12902 | 11409 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ADAMTSL2 | 14611 | 14542 | 12070 | 15066 | -3697 |
| AGR2 | 13841 | 15118 | 3515 | 16758 | 2051 |
| HOXA5 | 15031 | 15733 | 2357 | 17202 | -8109 |
| IL13 | 787 | -793 | 4754 | -1143 | -389 |
| SPDEF | 14901 | 15318 | 7441 | 16659 | -6369 |
| WNT7B | 12902 | 11409 | 11034 | 15717 | 8446 |
FOREBRAIN NEURON FATE COMMITMENT
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.0144 |
| p.adjustMANOVA | 0.163 |
| s.dist | 1.16 |
| s.ADOS | 0.61 |
| s.diagnosis | 0.584 |
| s.iIQ | 0.629 |
| s.iLang | 0.367 |
| s.motor | -0.303 |
| p.ADOS | 0.00519 |
| p.diagnosis | 0.00742 |
| p.iIQ | 0.00393 |
| p.iLang | 0.0924 |
| p.motor | 0.165 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | ADOS |
|---|---|---|
| ASCL1 | 13285 | 14997 |
| FEZF2 | 12838 | 13351 |
| BCL11B | 10339 | 14395 |
| NKX2-1 | 10797 | 13682 |
| GATA2 | 9649 | 12656 |
| TBR1 | 7978 | 6646 |
| PAX6 | 6570 | 6794 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ASCL1 | 14997 | 15106 | 13285 | 12430 | -6562 |
| BCL11B | 14395 | 13922 | 10339 | 16734 | -418 |
| FEZF2 | 13351 | 13718 | 12838 | 7901 | 303 |
| GATA2 | 12656 | 11680 | 9649 | 14348 | -5068 |
| NKX2-1 | 13682 | 13179 | 10797 | 15227 | 1311 |
| PAX6 | 6794 | 6246 | 6570 | 5465 | 819 |
| TBR1 | 6646 | 6390 | 7978 | 1720 | -4296 |
POSITIVE REGULATION OF PLATELET ACTIVATION
| metric | value |
|---|---|
| setSize | 9 |
| pMANOVA | 0.00385 |
| p.adjustMANOVA | 0.0639 |
| s.dist | 1.15 |
| s.ADOS | -0.585 |
| s.diagnosis | -0.652 |
| s.iIQ | -0.236 |
| s.iLang | -0.695 |
| s.motor | 0.156 |
| p.ADOS | 0.00237 |
| p.diagnosis | 0.000707 |
| p.iIQ | 0.22 |
| p.iLang | 0.000305 |
| p.motor | 0.418 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | diagnosis |
|---|---|---|
| GP5 | -3864 | -5321 |
| PLEK | -3816 | -4955 |
| GP1BA | -2862 | -3717 |
| PLA2G4A | -1978 | -3107 |
| TLR4 | -2062 | -2699 |
| GP9 | -656 | -2901 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| GP1BA | -1777 | -3717 | 6284 | -2862 | 11861 |
| GP1BB | 5023 | 4103 | 11439 | -241 | 10968 |
| GP5 | -4974 | -5321 | -4727 | -3864 | 3825 |
| GP9 | 185 | -2901 | 7648 | -656 | 11322 |
| JAK2 | 969 | 980 | -788 | 1740 | -3302 |
| PLA2G4A | -3642 | -3107 | -4841 | -1978 | -4008 |
| PLEK | -4362 | -4955 | -3803 | -3816 | -7485 |
| SELP | -3733 | -3147 | -6308 | 2151 | 10457 |
| TLR4 | -1396 | -2699 | 208 | -2062 | -5495 |
RECEPTOR MEDIATED ENDOCYTOSIS INVOLVED IN CHOLESTEROL TRANSPORT
| metric | value |
|---|---|
| setSize | 8 |
| pMANOVA | 0.0647 |
| p.adjustMANOVA | 0.413 |
| s.dist | 1.15 |
| s.ADOS | 0.611 |
| s.diagnosis | 0.633 |
| s.iIQ | 0.45 |
| s.iLang | 0.561 |
| s.motor | -0.193 |
| p.ADOS | 0.00274 |
| p.diagnosis | 0.00192 |
| p.iIQ | 0.0276 |
| p.iLang | 0.00599 |
| p.motor | 0.345 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| MIR27B | 16063 | 16022 |
| MIR17 | 14492 | 14992 |
| LDLRAP1 | 13854 | 13542 |
| PCSK9 | 13352 | 12934 |
| LDLR | 13185 | 12593 |
| ANXA2 | 13175 | 12050 |
| ABCA2 | 11134 | 11691 |
| LRP6 | 825 | 613 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ABCA2 | 11691 | 11134 | 10060 | 12667 | 5925 |
| ANXA2 | 12050 | 13175 | 5053 | 16386 | 5001 |
| LDLR | 12593 | 13185 | 9069 | 13716 | 3176 |
| LDLRAP1 | 13542 | 13854 | 11628 | 12358 | 3461 |
| LRP6 | 613 | 825 | -2915 | 5498 | -3467 |
| MIR17 | 14992 | 14492 | 13481 | 12181 | -3938 |
| MIR27B | 16022 | 16063 | 10251 | 17483 | -9087 |
| PCSK9 | 12934 | 13352 | 9030 | 11343 | -7144 |
POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS IN THE VACUOLE
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.216 |
| p.adjustMANOVA | 0.738 |
| s.dist | 1.15 |
| s.ADOS | 0.576 |
| s.diagnosis | 0.583 |
| s.iIQ | 0.579 |
| s.iLang | 0.515 |
| s.motor | 0.226 |
| p.ADOS | 0.0257 |
| p.diagnosis | 0.024 |
| p.iIQ | 0.025 |
| p.iLang | 0.0463 |
| p.motor | 0.38 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | iIQ |
|---|---|---|
| MARCHF2 | 15010 | 13440 |
| LRP1 | 14735 | 11803 |
| LDLR | 13185 | 9069 |
| LRP2 | 7512 | 8288 |
| CD81 | 6786 | 5631 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CD81 | 6086 | 6786 | 5631 | 6346 | 4998 |
| LDLR | 12593 | 13185 | 9069 | 13716 | 3176 |
| LRP1 | 14619 | 14735 | 11803 | 15584 | 5288 |
| LRP2 | 8194 | 7512 | 8288 | 8412 | 4786 |
| MARCHF2 | 15562 | 15010 | 13440 | 16881 | 1315 |
NATURAL KILLER CELL CHEMOTAXIS
| metric | value |
|---|---|
| setSize | 10 |
| pMANOVA | 0.0333 |
| p.adjustMANOVA | 0.289 |
| s.dist | 1.15 |
| s.ADOS | -0.593 |
| s.diagnosis | -0.595 |
| s.iIQ | -0.54 |
| s.iLang | -0.545 |
| s.motor | -0.161 |
| p.ADOS | 0.00117 |
| p.diagnosis | 0.00111 |
| p.iIQ | 0.00309 |
| p.iLang | 0.00285 |
| p.motor | 0.377 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| XCL1 | -6053 | -5963 |
| KLRK1 | -5626 | -5404 |
| PIK3CG | -5191 | -4635 |
| KLRC4-KLRK1 | -4990 | -4663 |
| CCL4 | -4603 | -5032 |
| CCL3 | -3603 | -2350 |
| CCL7 | -2145 | -2632 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CCL2 | 7880 | 11543 | 2220 | 9973 | -2645 |
| CCL3 | -2350 | -3603 | 154 | -2597 | -1787 |
| CCL4 | -5032 | -4603 | -6882 | -3403 | 5000 |
| CCL5 | 566 | -1271 | 3890 | 1981 | 11737 |
| CCL7 | -2632 | -2145 | -5829 | 1644 | 1008 |
| KLRC4-KLRK1 | -4663 | -4990 | -6692 | -346 | -5331 |
| KLRK1 | -5404 | -5626 | -6673 | -3888 | -2838 |
| PIK3CD | 6158 | 5150 | 4730 | 8051 | 1840 |
| PIK3CG | -4635 | -5191 | -5347 | -3113 | -1669 |
| XCL1 | -5963 | -6053 | -7784 | -4429 | -9398 |
REGULATION OF CHRONIC INFLAMMATORY RESPONSE
| metric | value |
|---|---|
| setSize | 9 |
| pMANOVA | 0.00773 |
| p.adjustMANOVA | 0.104 |
| s.dist | 1.15 |
| s.ADOS | -0.578 |
| s.diagnosis | -0.62 |
| s.iIQ | -0.381 |
| s.iLang | -0.494 |
| s.motor | 0.459 |
| p.ADOS | 0.00267 |
| p.diagnosis | 0.00127 |
| p.iIQ | 0.0479 |
| p.iLang | 0.0103 |
| p.motor | 0.017 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| IDO1 | -4643 | -4266 |
| IL4 | -4566 | -4175 |
| IL10 | -4564 | -3537 |
| TNFAIP3 | -2411 | -2070 |
| CYP19A1 | -2053 | -2403 |
| ADORA2B | -955 | -1397 |
| LTA | -421 | -1144 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ADORA2B | -1397 | -955 | -3006 | 3741 | 7036 |
| CCL5 | 566 | -1271 | 3890 | 1981 | 11737 |
| CYP19A1 | -2403 | -2053 | -4272 | -596 | 159 |
| IDO1 | -4266 | -4643 | -3503 | -2923 | 10077 |
| IL10 | -3537 | -4564 | 2545 | -3539 | 9624 |
| IL4 | -4175 | -4566 | -5895 | -134 | 8390 |
| LTA | -1144 | -421 | -3129 | 2668 | 1955 |
| TNF | 5418 | 3304 | 4845 | 9905 | 7058 |
| TNFAIP3 | -2070 | -2411 | -881 | -2500 | 2531 |
PH REDUCTION
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.196 |
| p.adjustMANOVA | 0.71 |
| s.dist | 1.14 |
| s.ADOS | 0.587 |
| s.diagnosis | 0.572 |
| s.iIQ | 0.577 |
| s.iLang | 0.525 |
| s.motor | 0.12 |
| p.ADOS | 0.0128 |
| p.diagnosis | 0.0152 |
| p.iIQ | 0.0144 |
| p.iLang | 0.0258 |
| p.motor | 0.612 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | iIQ |
|---|---|---|
| SLC4A3 | 15647 | 13836 |
| TCIRG1 | 14470 | 11611 |
| ATP4A | 13709 | 11420 |
| ATP6V1B1 | 12788 | 10438 |
| CCKBR | 10230 | 11018 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ATP4A | 13709 | 13374 | 11420 | 13485 | 2906 |
| ATP4B | 2319 | 2926 | -604 | 4676 | 1143 |
| ATP6V1B1 | 12788 | 12926 | 10438 | 12205 | -2479 |
| CCKBR | 10230 | 8741 | 11018 | 11363 | 11288 |
| SLC4A3 | 15647 | 15321 | 13836 | 16760 | 1023 |
| TCIRG1 | 14470 | 14679 | 11611 | 15355 | 2453 |
ZYMOGEN INHIBITION
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.00403 |
| p.adjustMANOVA | 0.0652 |
| s.dist | 1.12 |
| s.ADOS | -0.504 |
| s.diagnosis | -0.519 |
| s.iIQ | -0.146 |
| s.iLang | -0.592 |
| s.motor | 0.599 |
| p.ADOS | 0.021 |
| p.diagnosis | 0.0175 |
| p.iIQ | 0.503 |
| p.iLang | 0.00671 |
| p.motor | 0.00604 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | motor | iLang |
|---|---|---|
| CST7 | 10608 | -3522 |
| CARD8 | 8302 | -3329 |
| CARD16 | 11701 | -1330 |
| CARD18 | 1088 | -2232 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| BCL2L12 | 1187 | 1366 | 4185 | 201 | 8009 |
| CARD16 | -4507 | -3291 | -3886 | -1330 | 11701 |
| CARD18 | -5387 | -4494 | -7691 | -2232 | 1088 |
| CARD8 | -4506 | -5020 | -3842 | -3329 | 8302 |
| CAST | -191 | -537 | 1758 | 2118 | 7436 |
| CST7 | -2592 | -4176 | 7216 | -3522 | 10608 |
| NOL3 | 11674 | 10390 | 13229 | 7142 | 9303 |
CEREBRAL CORTEX GABAERGIC INTERNEURON DEVELOPMENT
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.136 |
| p.adjustMANOVA | 0.617 |
| s.dist | 1.11 |
| s.ADOS | 0.582 |
| s.diagnosis | 0.584 |
| s.iIQ | 0.484 |
| s.iLang | 0.471 |
| s.motor | -0.292 |
| p.ADOS | 0.0135 |
| p.diagnosis | 0.0132 |
| p.iIQ | 0.0401 |
| p.iLang | 0.0458 |
| p.motor | 0.215 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| RAC3 | 15533 | 15339 |
| CNTN2 | 14010 | 14005 |
| FEZF2 | 13718 | 13351 |
| DRD1 | 10627 | 11927 |
| LHX6 | 12049 | 10217 |
| DRD2 | 2818 | 4044 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CNTN2 | 14005 | 14010 | 10000 | 15835 | -1102 |
| DRD1 | 11927 | 10627 | 10579 | 12995 | 3773 |
| DRD2 | 4044 | 2818 | 3964 | 5048 | 370 |
| FEZF2 | 13351 | 13718 | 12838 | 7901 | 303 |
| LHX6 | 10217 | 12049 | 3788 | 13481 | -5162 |
| RAC3 | 15339 | 15533 | 10350 | 14938 | -9387 |
LEUCINE IMPORT ACROSS PLASMA MEMBRANE
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.17 |
| p.adjustMANOVA | 0.675 |
| s.dist | 1.1 |
| s.ADOS | 0.533 |
| s.diagnosis | 0.561 |
| s.iIQ | 0.467 |
| s.iLang | 0.511 |
| s.motor | 0.365 |
| p.ADOS | 0.0392 |
| p.diagnosis | 0.0297 |
| p.iIQ | 0.0705 |
| p.iLang | 0.0476 |
| p.motor | 0.157 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| SLC7A8 | 14111 | 13313 |
| SLC3A2 | 12952 | 13194 |
| SLC7A5 | 13881 | 11120 |
| SLC43A1 | 10470 | 10891 |
| SLC43A2 | 4623 | 6116 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| SLC3A2 | 13194 | 12952 | 12699 | 11192 | 7197 |
| SLC43A1 | 10891 | 10470 | 8677 | 12388 | 2607 |
| SLC43A2 | 6116 | 4623 | 5780 | 8459 | 4893 |
| SLC7A5 | 11120 | 13881 | 7271 | 12457 | 8778 |
| SLC7A8 | 13313 | 14111 | 7575 | 16268 | 3823 |
LEUKOTRIENE D4 BIOSYNTHETIC PROCESS
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0122 |
| p.adjustMANOVA | 0.144 |
| s.dist | 1.1 |
| s.ADOS | 0.453 |
| s.diagnosis | 0.475 |
| s.iIQ | 0.38 |
| s.iLang | 0.642 |
| s.motor | 0.475 |
| p.ADOS | 0.0547 |
| p.diagnosis | 0.044 |
| p.iIQ | 0.107 |
| p.iLang | 0.00649 |
| p.motor | 0.0439 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | diagnosis |
|---|---|---|
| GGTLC1 | 17405 | 15654 |
| GGTA1 | 14638 | 13498 |
| GGT1 | 13268 | 10067 |
| GGT6 | 13815 | 7937 |
| GGT5 | 13685 | 7796 |
| GGT7 | 8799 | 6503 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| GGT1 | 9264 | 10067 | 5563 | 13268 | 5155 |
| GGT5 | 10691 | 7796 | 11426 | 13685 | 11998 |
| GGT6 | 4488 | 7937 | -4340 | 13815 | -7777 |
| GGT7 | 5958 | 6503 | 5634 | 8799 | 7575 |
| GGTA1 | 14060 | 13498 | 13037 | 14638 | 11477 |
| GGTLC1 | 15769 | 15654 | 13240 | 17405 | 11655 |
SUBSTRATE DEPENDENT CELL MIGRATION CELL EXTENSION
| metric | value |
|---|---|
| setSize | 8 |
| pMANOVA | 0.052 |
| p.adjustMANOVA | 0.373 |
| s.dist | 1.1 |
| s.ADOS | -0.532 |
| s.diagnosis | -0.545 |
| s.iIQ | -0.479 |
| s.iLang | -0.532 |
| s.motor | -0.34 |
| p.ADOS | 0.00914 |
| p.diagnosis | 0.00762 |
| p.iIQ | 0.0191 |
| p.iLang | 0.00921 |
| p.motor | 0.0963 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| P2RY12 | -5714 | -5371 |
| NRP1 | -4252 | -4204 |
| SHTN1 | -3064 | -3495 |
| CD2AP | -2556 | -2475 |
| NCK1 | -459 | -1611 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CD2AP | -2475 | -2556 | -4623 | -440 | -4969 |
| CTTN | 3623 | 1965 | 4578 | 4063 | 3710 |
| NCK1 | -1611 | -459 | -4560 | 616 | -6531 |
| NRP1 | -4204 | -4252 | -5525 | -2257 | 744 |
| NTN1 | 117 | 639 | -1315 | 2026 | -925 |
| P2RY12 | -5371 | -5714 | -5858 | -4153 | -2841 |
| SDCBP | 5939 | 4520 | 6375 | 3459 | -6965 |
| SHTN1 | -3495 | -3064 | -6145 | 942 | -1364 |
PROTEIN RETENTION IN GOLGI APPARATUS
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.368 |
| p.adjustMANOVA | 0.879 |
| s.dist | 1.09 |
| s.ADOS | -0.58 |
| s.diagnosis | -0.592 |
| s.iIQ | -0.501 |
| s.iLang | -0.505 |
| s.motor | -0.0359 |
| p.ADOS | 0.0248 |
| p.diagnosis | 0.0218 |
| p.iIQ | 0.0524 |
| p.iLang | 0.0507 |
| p.motor | 0.89 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| VPS13C | -4580 | -4529 |
| GOLPH3 | -4504 | -3782 |
| SORL1 | -2554 | -1446 |
| VPS13A | -249 | -15 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| GOLPH3 | -3782 | -4504 | -3766 | -1997 | 8881 |
| SORL1 | -1446 | -2554 | -1486 | 816 | 3097 |
| VPS13A | -15 | -249 | 1181 | 155 | 785 |
| VPS13C | -4529 | -4580 | -5630 | -3121 | -5720 |
| VPS13D | 2454 | 3667 | -2225 | 8311 | -2094 |
RRNA PSEUDOURIDINE SYNTHESIS
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.0138 |
| p.adjustMANOVA | 0.157 |
| s.dist | 1.09 |
| s.ADOS | 0.429 |
| s.diagnosis | 0.306 |
| s.iIQ | 0.652 |
| s.iLang | 0.276 |
| s.motor | 0.635 |
| p.ADOS | 0.0495 |
| p.diagnosis | 0.161 |
| p.iIQ | 0.00281 |
| p.iLang | 0.206 |
| p.motor | 0.00364 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | motor |
|---|---|---|
| RPUSD2 | 13174 | 11937 |
| NHP2 | 12150 | 8957 |
| RPUSD1 | 10063 | 10284 |
| NOP10 | 8833 | 11471 |
| NAF1 | 8306 | 9934 |
| GAR1 | 10570 | 6486 |
| TSR3 | 10116 | 141 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| GAR1 | 9878 | 7987 | 10570 | 8681 | 6486 |
| NAF1 | 6845 | 4930 | 8306 | 7738 | 9934 |
| NHP2 | 15108 | 15230 | 12150 | 16846 | 8957 |
| NOP10 | 3316 | 2508 | 8833 | 1060 | 11471 |
| RPUSD1 | 10542 | 8447 | 10063 | 13603 | 10284 |
| RPUSD2 | 14117 | 12302 | 13174 | 15732 | 11937 |
| TSR3 | 8581 | 7142 | 10116 | 3051 | 141 |
MICROGLIAL CELL MEDIATED CYTOTOXICITY
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.0763 |
| p.adjustMANOVA | 0.453 |
| s.dist | 1.08 |
| s.ADOS | -0.558 |
| s.diagnosis | -0.647 |
| s.iIQ | -0.227 |
| s.iLang | -0.534 |
| s.motor | 0.325 |
| p.ADOS | 0.0308 |
| p.diagnosis | 0.0122 |
| p.iIQ | 0.38 |
| p.iLang | 0.0386 |
| p.motor | 0.208 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| STAP1 | -5914 | -5667 |
| TYROBP | -4759 | -2665 |
| ITGAM | -1172 | -1955 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CX3CR1 | 2150 | 1168 | -202 | 8843 | 9318 |
| ITGAM | -1955 | -1172 | -4973 | 2307 | -1550 |
| SPI1 | 2047 | -617 | 8690 | -1117 | 9803 |
| STAP1 | -5667 | -5914 | -6854 | -4257 | -2476 |
| TYROBP | -2665 | -4759 | 6699 | -3257 | 9978 |
T HELPER 2 CELL CYTOKINE PRODUCTION
| metric | value |
|---|---|
| setSize | 13 |
| pMANOVA | 0.00112 |
| p.adjustMANOVA | 0.0251 |
| s.dist | 1.08 |
| s.ADOS | -0.529 |
| s.diagnosis | -0.589 |
| s.iIQ | -0.304 |
| s.iLang | -0.591 |
| s.motor | 0.304 |
| p.ADOS | 0.000947 |
| p.diagnosis | 0.000235 |
| p.iIQ | 0.0573 |
| p.iLang | 0.000224 |
| p.motor | 0.0577 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | diagnosis |
|---|---|---|
| IFNA2 | -4521 | -6120 |
| XCL1 | -4429 | -6053 |
| IFNB1 | -4158 | -5995 |
| IL6 | -3955 | -4090 |
| ARG1 | -3094 | -4438 |
| DENND1B | -1823 | -3119 |
| IL4 | -134 | -4566 |
| GATA3 | -109 | -485 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ARG1 | -4394 | -4438 | -5273 | -3094 | 3996 |
| CD81 | 6086 | 6786 | 5631 | 6346 | 4998 |
| DENND1B | -3308 | -3119 | -3950 | -1823 | 4059 |
| GATA3 | 1458 | -485 | 7290 | -109 | 11402 |
| IFNA2 | -5995 | -6120 | -7320 | -4521 | 11931 |
| IFNB1 | -5877 | -5995 | -7328 | -4158 | 10875 |
| IL4 | -4175 | -4566 | -5895 | -134 | 8390 |
| IL6 | -3409 | -4090 | 2075 | -3955 | 724 |
| NLRP3 | 2918 | 1221 | 5051 | 3674 | 7833 |
| PRKCZ | 6900 | 6392 | 5067 | 8149 | 342 |
| RSAD2 | 1707 | -2528 | 6214 | 1428 | 3514 |
| TBX21 | 2310 | 2117 | 3699 | 972 | 3402 |
| XCL1 | -5963 | -6053 | -7784 | -4429 | -9398 |
REGULATION OF PHOSPHOLIPID TRANSLOCATION
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.211 |
| p.adjustMANOVA | 0.733 |
| s.dist | 1.07 |
| s.ADOS | -0.541 |
| s.diagnosis | -0.558 |
| s.iIQ | -0.468 |
| s.iLang | -0.528 |
| s.motor | -0.228 |
| p.ADOS | 0.0218 |
| p.diagnosis | 0.0179 |
| p.iIQ | 0.0469 |
| p.iLang | 0.025 |
| p.motor | 0.334 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| ATP8A1 | -4556 | -4648 |
| FASLG | -4342 | -4795 |
| ABCB4 | -3118 | -3438 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ABCB4 | -3438 | -3118 | -5439 | -488 | 2543 |
| ATP8A1 | -4648 | -4556 | -6785 | -1046 | -4407 |
| ATP8A2 | -312 | 443 | -3604 | 3168 | -3472 |
| FASLG | -4795 | -4342 | -7372 | -863 | -8908 |
| PRKCD | 1784 | 334 | 6043 | -782 | 4248 |
| TMEM30A | 5232 | 3669 | 5027 | 3423 | 3100 |
REGULATION OF NODAL SIGNALING PATHWAY INVOLVED IN DETERMINATION OF LEFT RIGHT ASYMMETRY
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.16 |
| p.adjustMANOVA | 0.659 |
| s.dist | 1.05 |
| s.ADOS | 0.557 |
| s.diagnosis | 0.639 |
| s.iIQ | 0.393 |
| s.iLang | 0.453 |
| s.motor | -0.174 |
| p.ADOS | 0.0311 |
| p.diagnosis | 0.0133 |
| p.iIQ | 0.128 |
| p.iLang | 0.0796 |
| p.motor | 0.501 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| DAND5 | 14493 | 14264 |
| NODAL | 14322 | 13611 |
| SMAD2 | 12429 | 12494 |
| SHH | 9805 | 11773 |
| CER1 | 9335 | 3835 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CER1 | 3835 | 9335 | -2084 | 3572 | -4908 |
| DAND5 | 14264 | 14493 | 10642 | 16747 | 7635 |
| NODAL | 13611 | 14322 | 9712 | 13064 | -4771 |
| SHH | 11773 | 9805 | 11077 | 10996 | -797 |
| SMAD2 | 12494 | 12429 | 8551 | 13111 | 118 |
NEGATIVE REGULATION OF TOLL LIKE RECEPTOR 2 SIGNALING PATHWAY
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.192 |
| p.adjustMANOVA | 0.703 |
| s.dist | 1.05 |
| s.ADOS | -0.557 |
| s.diagnosis | -0.586 |
| s.iIQ | -0.423 |
| s.iLang | -0.511 |
| s.motor | -0.00566 |
| p.ADOS | 0.0107 |
| p.diagnosis | 0.0072 |
| p.iIQ | 0.0528 |
| p.iLang | 0.0193 |
| p.motor | 0.979 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| TREM2 | -4365 | -4104 |
| LYN | -4223 | -3716 |
| MFHAS1 | -2804 | -2729 |
| TNFAIP3 | -2411 | -2070 |
| ACOD1 | -1874 | -2137 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ACOD1 | -2137 | -1874 | -6351 | 1154 | -9637 |
| LYN | -3716 | -4223 | -3656 | -2727 | 647 |
| MFHAS1 | -2729 | -2804 | -4996 | 1622 | 590 |
| NOD2 | 5369 | 5610 | 2536 | 10053 | 6014 |
| TLR6 | 880 | -991 | 8940 | -651 | 11606 |
| TNFAIP3 | -2070 | -2411 | -881 | -2500 | 2531 |
| TREM2 | -4104 | -4365 | -6177 | -1577 | -2466 |
PROTEIN POLYUFMYLATION
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.187 |
| p.adjustMANOVA | 0.695 |
| s.dist | 1.05 |
| s.ADOS | 0.55 |
| s.diagnosis | 0.497 |
| s.iIQ | 0.609 |
| s.iLang | 0.402 |
| s.motor | -0.107 |
| p.ADOS | 0.0333 |
| p.diagnosis | 0.0545 |
| p.iIQ | 0.0184 |
| p.iLang | 0.119 |
| p.motor | 0.679 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | ADOS |
|---|---|---|
| UFM1 | 13956 | 15402 |
| UFL1 | 13701 | 15128 |
| UFC1 | 11884 | 14840 |
| DDRGK1 | 9872 | 10468 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| DDRGK1 | 10468 | 10357 | 9872 | 8865 | 1644 |
| UBA5 | -261 | -643 | 465 | -802 | 6 |
| UFC1 | 14840 | 13274 | 11884 | 16158 | -4870 |
| UFL1 | 15128 | 14338 | 13701 | 15500 | -4772 |
| UFM1 | 15402 | 15101 | 13956 | 14959 | 8977 |
CD4 POSITIVE ALPHA BETA T CELL CYTOKINE PRODUCTION
| metric | value |
|---|---|
| setSize | 19 |
| pMANOVA | 5.06e-05 |
| p.adjustMANOVA | 0.00192 |
| s.dist | 1.04 |
| s.ADOS | -0.51 |
| s.diagnosis | -0.573 |
| s.iIQ | -0.26 |
| s.iLang | -0.583 |
| s.motor | 0.284 |
| p.ADOS | 0.000119 |
| p.diagnosis | 1.54e-05 |
| p.iIQ | 0.0499 |
| p.iLang | 1.07e-05 |
| p.motor | 0.0323 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | diagnosis |
|---|---|---|
| IFNA2 | -4521 | -6120 |
| XCL1 | -4429 | -6053 |
| IFNB1 | -4158 | -5995 |
| IL6 | -3955 | -4090 |
| ARG1 | -3094 | -4438 |
| DENND1B | -1823 | -3119 |
| SLAMF1 | -1482 | -2920 |
| IL18 | -735 | -3978 |
| IL18R1 | -1034 | -2580 |
| IL1B | -1592 | -1091 |
| IL4 | -134 | -4566 |
| GATA3 | -109 | -485 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ARG1 | -4394 | -4438 | -5273 | -3094 | 3996 |
| ARID5A | 5685 | 5788 | 6032 | 3961 | 5268 |
| CD81 | 6086 | 6786 | 5631 | 6346 | 4998 |
| DENND1B | -3308 | -3119 | -3950 | -1823 | 4059 |
| GATA3 | 1458 | -485 | 7290 | -109 | 11402 |
| IFNA2 | -5995 | -6120 | -7320 | -4521 | 11931 |
| IFNB1 | -5877 | -5995 | -7328 | -4158 | 10875 |
| IL18 | -3784 | -3978 | -5279 | -735 | 5804 |
| IL18R1 | -2843 | -2580 | -5070 | -1034 | -7954 |
| IL1B | 382 | -1091 | 7632 | -1592 | 11562 |
| IL1R1 | -1865 | -1361 | -4158 | 1765 | 2971 |
| IL4 | -4175 | -4566 | -5895 | -134 | 8390 |
| IL6 | -3409 | -4090 | 2075 | -3955 | 724 |
| NLRP3 | 2918 | 1221 | 5051 | 3674 | 7833 |
| PRKCZ | 6900 | 6392 | 5067 | 8149 | 342 |
| RSAD2 | 1707 | -2528 | 6214 | 1428 | 3514 |
| SLAMF1 | 1188 | -2920 | 9131 | -1482 | 6677 |
| TBX21 | 2310 | 2117 | 3699 | 972 | 3402 |
| XCL1 | -5963 | -6053 | -7784 | -4429 | -9398 |
NEGATIVE REGULATION OF MONOCYTE CHEMOTACTIC PROTEIN 1 PRODUCTION
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 0.0907 |
| p.adjustMANOVA | 0.498 |
| s.dist | 1.04 |
| s.ADOS | -0.428 |
| s.diagnosis | -0.409 |
| s.iIQ | -0.507 |
| s.iLang | -0.415 |
| s.motor | -0.542 |
| p.ADOS | 0.0692 |
| p.diagnosis | 0.0828 |
| p.iIQ | 0.0315 |
| p.iLang | 0.0781 |
| p.motor | 0.0214 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | motor | iIQ |
|---|---|---|
| NR1H4 | -8423 | -5073 |
| ERBIN | -6861 | -5904 |
| APOD | -3128 | -6738 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| APOD | -4460 | -4005 | -6738 | -2389 | -3128 |
| C1QTNF3 | -4821 | -5045 | -5765 | -3886 | 849 |
| ERBIN | -4144 | -4339 | -5904 | -1509 | -6861 |
| GSTP1 | 11717 | 11957 | 3611 | 15494 | -8330 |
| NR1H4 | -2087 | -1594 | -5073 | -305 | -8423 |
| SOCS5 | 5125 | 5412 | 5159 | 3559 | -2024 |
REGULATION OF CALCIUM ION EXPORT ACROSS PLASMA MEMBRANE
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.168 |
| p.adjustMANOVA | 0.671 |
| s.dist | 1.03 |
| s.ADOS | 0.438 |
| s.diagnosis | 0.394 |
| s.iIQ | 0.602 |
| s.iLang | 0.296 |
| s.motor | 0.524 |
| p.ADOS | 0.0901 |
| p.diagnosis | 0.128 |
| p.iIQ | 0.0198 |
| p.iLang | 0.252 |
| p.motor | 0.0426 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | motor |
|---|---|---|
| MIR1-1 | 13519 | 9533 |
| CALM1 | 9835 | 10767 |
| CALM3 | 9908 | 6145 |
| YWHAE | 7939 | 5796 |
| CALM2 | 8291 | 3872 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| CALM1 | 8279 | 7164 | 9835 | 9962 | 10767 |
| CALM2 | 7549 | 5320 | 8291 | 6293 | 3872 |
| CALM3 | 8982 | 9274 | 9908 | 6758 | 6145 |
| MIR1-1 | 15846 | 15670 | 13519 | 17409 | 9533 |
| YWHAE | 8690 | 9259 | 7939 | 8312 | 5796 |
POSITIVE REGULATION OF CARDIAC MUSCLE ADAPTATION
| metric | value |
|---|---|
| setSize | 9 |
| pMANOVA | 0.0767 |
| p.adjustMANOVA | 0.454 |
| s.dist | 1.03 |
| s.ADOS | 0.564 |
| s.diagnosis | 0.556 |
| s.iIQ | 0.396 |
| s.iLang | 0.532 |
| s.motor | -0.0509 |
| p.ADOS | 0.0034 |
| p.diagnosis | 0.00385 |
| p.iIQ | 0.0397 |
| p.iLang | 0.00572 |
| p.motor | 0.791 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | ADOS | diagnosis |
|---|---|---|
| MIR199A1 | 15751 | 15820 |
| MIR214 | 15244 | 15683 |
| MIR17 | 14992 | 14492 |
| MIR34B | 14490 | 14050 |
| MIR208A | 14326 | 13976 |
| MIR34C | 14205 | 13774 |
| MIR20A | 13541 | 13299 |
| PPP3CA | 3377 | 3605 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| MIR17 | 14992 | 14492 | 13481 | 12181 | -3938 |
| MIR199A1 | 15751 | 15820 | 13535 | 16343 | -5283 |
| MIR208A | 14326 | 13976 | 12837 | 14912 | 10355 |
| MIR20A | 13541 | 13299 | 9012 | 15020 | -1628 |
| MIR214 | 15244 | 15683 | -303 | 17515 | -8461 |
| MIR34B | 14490 | 14050 | 13347 | 14112 | 10804 |
| MIR34C | 14205 | 13774 | 13138 | 14135 | 8953 |
| PPP3CA | 3377 | 3605 | -66 | 9052 | 1081 |
| TRPC3 | -4465 | -4356 | -6532 | -1860 | -4485 |
DISRUPTION OF PLASMA MEMBRANE INTEGRITY IN ANOTHER ORGANISM
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 1.24e-15 |
| p.adjustMANOVA | 6.65e-13 |
| s.dist | 1.03 |
| s.ADOS | -0.508 |
| s.diagnosis | -0.489 |
| s.iIQ | -0.255 |
| s.iLang | 0.106 |
| s.motor | 0.697 |
| p.ADOS | 0.0311 |
| p.diagnosis | 0.0379 |
| p.iIQ | 0.279 |
| p.iLang | 0.654 |
| p.motor | 0.00312 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | motor | ADOS |
|---|---|---|
| DEFA4 | 11941 | -4311 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| DEFA1 | 813 | 2199 | 810 | 12293 | 12497 |
| DEFA1B | 813 | 2199 | 810 | 12293 | 12497 |
| DEFA3 | 813 | 2199 | 810 | 12293 | 12497 |
| DEFA4 | -4311 | -5275 | 6030 | -4205 | 11941 |
| DEFA5 | -3259 | -3355 | -6375 | 4538 | -5494 |
| DEFA6 | 1122 | -959 | 51 | 8587 | 10974 |
ISOCITRATE METABOLIC PROCESS
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.329 |
| p.adjustMANOVA | 0.853 |
| s.dist | 1.03 |
| s.ADOS | 0.488 |
| s.diagnosis | 0.429 |
| s.iIQ | 0.55 |
| s.iLang | 0.426 |
| s.motor | 0.389 |
| p.ADOS | 0.0588 |
| p.diagnosis | 0.0968 |
| p.iIQ | 0.0331 |
| p.iLang | 0.0992 |
| p.motor | 0.132 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iIQ | ADOS |
|---|---|---|
| IDH1 | 12237 | 12961 |
| ACO2 | 10664 | 14085 |
| IDH3B | 11568 | 12676 |
| IDH3A | 10852 | 8047 |
| IDH2 | 1305 | 4384 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ACO2 | 14085 | 14683 | 10664 | 15721 | 8167 |
| IDH1 | 12961 | 11476 | 12237 | 12190 | 4761 |
| IDH2 | 4384 | 5357 | 1305 | 7239 | -936 |
| IDH3A | 8047 | 6651 | 10852 | 6304 | 8324 |
| IDH3B | 12676 | 10485 | 11568 | 14536 | 8276 |
ISOLEUCINE TRANSPORT
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.249 |
| p.adjustMANOVA | 0.775 |
| s.dist | 1.03 |
| s.ADOS | 0.506 |
| s.diagnosis | 0.529 |
| s.iIQ | 0.512 |
| s.iLang | 0.41 |
| s.motor | 0.298 |
| p.ADOS | 0.0502 |
| p.diagnosis | 0.0407 |
| p.iIQ | 0.0472 |
| p.iLang | 0.113 |
| p.motor | 0.248 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | iIQ |
|---|---|---|
| SLC3A2 | 12952 | 12699 |
| SLC6A20 | 12281 | 10095 |
| SLC7A5 | 13881 | 7271 |
| SLC43A1 | 10470 | 8677 |
| SLC43A2 | 4623 | 5780 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| SLC3A2 | 13194 | 12952 | 12699 | 11192 | 7197 |
| SLC43A1 | 10891 | 10470 | 8677 | 12388 | 2607 |
| SLC43A2 | 6116 | 4623 | 5780 | 8459 | 4893 |
| SLC6A20 | 11818 | 12281 | 10095 | 10591 | 81 |
| SLC7A5 | 11120 | 13881 | 7271 | 12457 | 8778 |
MYELOID DENDRITIC CELL CHEMOTAXIS
| metric | value |
|---|---|
| setSize | 5 |
| pMANOVA | 0.00189 |
| p.adjustMANOVA | 0.0378 |
| s.dist | 1.03 |
| s.ADOS | -0.448 |
| s.diagnosis | -0.438 |
| s.iIQ | 0.0327 |
| s.iLang | -0.677 |
| s.motor | 0.449 |
| p.ADOS | 0.0829 |
| p.diagnosis | 0.0899 |
| p.iIQ | 0.899 |
| p.iLang | 0.00876 |
| p.motor | 0.0824 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | motor |
|---|---|---|
| CCL19 | -2427 | 7729 |
| SPI1 | -1117 | 9803 |
| CCR7 | -831 | 11634 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ARHGEF5 | 720 | 4193 | 4955 | 211 | 12091 |
| CCL19 | -1219 | -1349 | 2564 | -2427 | 7729 |
| CCL21 | -3830 | -2466 | -7140 | -1265 | -9323 |
| CCR7 | 2303 | 612 | 8737 | -831 | 11634 |
| SPI1 | 2047 | -617 | 8690 | -1117 | 9803 |
MAST CELL PROLIFERATION
| metric | value |
|---|---|
| setSize | 7 |
| pMANOVA | 0.209 |
| p.adjustMANOVA | 0.73 |
| s.dist | 1.03 |
| s.ADOS | -0.549 |
| s.diagnosis | -0.564 |
| s.iIQ | -0.377 |
| s.iLang | -0.537 |
| s.motor | 0.0334 |
| p.ADOS | 0.0119 |
| p.diagnosis | 0.0097 |
| p.iIQ | 0.0842 |
| p.iLang | 0.0138 |
| p.motor | 0.879 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | diagnosis | ADOS |
|---|---|---|
| NF1 | -4752 | -4661 |
| LYN | -4223 | -3716 |
| KITLG | -3559 | -3797 |
| RAC2 | -3999 | -2708 |
| ENPP3 | -2784 | -3862 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| ENPP3 | -3862 | -2784 | -6844 | 1027 | -6591 |
| KIT | 539 | -1259 | 1135 | 3960 | 7429 |
| KITLG | -3797 | -3559 | -5274 | -2184 | -1026 |
| LYN | -3716 | -4223 | -3656 | -2727 | 647 |
| NF1 | -4661 | -4752 | -5712 | -3095 | 621 |
| RAC2 | -2708 | -3999 | 3774 | -2735 | 10960 |
| STAT6 | 10376 | 11235 | 9566 | 9035 | 288 |
REGULATION OF PHENOTYPIC SWITCHING
| metric | value |
|---|---|
| setSize | 6 |
| pMANOVA | 1.79e-08 |
| p.adjustMANOVA | 1.88e-06 |
| s.dist | 1.02 |
| s.ADOS | -0.467 |
| s.diagnosis | -0.518 |
| s.iIQ | 0.175 |
| s.iLang | -0.556 |
| s.motor | 0.464 |
| p.ADOS | 0.0476 |
| p.diagnosis | 0.028 |
| p.iIQ | 0.459 |
| p.iLang | 0.0184 |
| p.motor | 0.0491 |
Warning: Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
Removed 396 rows containing missing values (`geom_tile()`).
| Gene | iLang | diagnosis |
|---|---|---|
| MIR199B | -4303 | -5131 |
| MIR145 | -4363 | -4798 |
| MIR143 | -2750 | -3830 |
| FGF9 | -1452 | -465 |
Click HERE to show all gene set members
| ADOS | diagnosis | iIQ | iLang | motor | |
|---|---|---|---|---|---|
| DNMT1 | 4982 | 5672 | 1775 | 8348 | 360 |
| FGF9 | -353 | -465 | 1378 | -1452 | -3207 |
| MIR143 | -1977 | -3830 | 6414 | -2750 | 11910 |
| MIR145 | -3418 | -4798 | 10533 | -4363 | 10338 |
| MIR199B | -4134 | -5131 | 7548 | -4303 | 11400 |
| MYOCD | 3650 | 3656 | 3199 | 6091 | 8536 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.3.2 (2023-10-31)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## time zone: Australia/Melbourne
## tzcode source: system (glibc)
##
## attached base packages:
## [1] stats4 parallel stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.3.3
## [2] GGally_2.2.0
## [3] ggplot2_3.4.4
## [4] reshape2_1.4.4
## [5] beeswarm_0.4.0
## [6] gtools_3.9.5
## [7] tibble_3.2.1
## [8] dplyr_1.1.4
## [9] echarts4r_0.4.5
## [10] gplots_3.1.3
## [11] HGNChelper_0.8.1
## [12] eulerr_7.0.0
## [13] kableExtra_1.3.4
## [14] data.table_1.14.10
## [15] IlluminaHumanMethylationEPICanno.ilm10b4.hg19_0.6.0
## [16] minfi_1.48.0
## [17] bumphunter_1.44.0
## [18] locfit_1.5-9.8
## [19] iterators_1.0.14
## [20] foreach_1.5.2
## [21] Biostrings_2.70.1
## [22] XVector_0.42.0
## [23] SummarizedExperiment_1.32.0
## [24] Biobase_2.62.0
## [25] MatrixGenerics_1.14.0
## [26] matrixStats_1.2.0
## [27] GenomicRanges_1.54.1
## [28] GenomeInfoDb_1.38.5
## [29] IRanges_2.36.0
## [30] S4Vectors_0.40.2
## [31] BiocGenerics_0.48.1
## [32] mitch_1.15.2
## [33] limma_3.58.1
##
## loaded via a namespace (and not attached):
## [1] splines_4.3.2 later_1.3.2
## [3] BiocIO_1.12.0 bitops_1.0-7
## [5] filelock_1.0.3 preprocessCore_1.64.0
## [7] XML_3.99-0.16 lifecycle_1.0.4
## [9] lattice_0.22-5 MASS_7.3-60
## [11] base64_2.0.1 scrime_1.3.5
## [13] magrittr_2.0.3 sass_0.4.8
## [15] rmarkdown_2.25 jquerylib_0.1.4
## [17] yaml_2.3.8 httpuv_1.6.13
## [19] doRNG_1.8.6 askpass_1.2.0
## [21] DBI_1.2.0 RColorBrewer_1.1-3
## [23] abind_1.4-5 zlibbioc_1.48.0
## [25] quadprog_1.5-8 rvest_1.0.3
## [27] purrr_1.0.2 RCurl_1.98-1.14
## [29] rappdirs_0.3.3 GenomeInfoDbData_1.2.11
## [31] genefilter_1.84.0 annotate_1.80.0
## [33] svglite_2.1.3 DelayedMatrixStats_1.24.0
## [35] codetools_0.2-19 DelayedArray_0.28.0
## [37] xml2_1.3.6 tidyselect_1.2.0
## [39] farver_2.1.1 beanplot_1.3.1
## [41] BiocFileCache_2.10.1 illuminaio_0.44.0
## [43] webshot_0.5.5 jsonlite_1.8.8
## [45] GenomicAlignments_1.38.1 multtest_2.58.0
## [47] ellipsis_0.3.2 survival_3.5-7
## [49] systemfonts_1.0.5 tools_4.3.2
## [51] progress_1.2.3 Rcpp_1.0.12
## [53] glue_1.7.0 gridExtra_2.3
## [55] SparseArray_1.2.3 xfun_0.41
## [57] HDF5Array_1.30.0 withr_2.5.2
## [59] fastmap_1.1.1 rhdf5filters_1.14.1
## [61] fansi_1.0.6 openssl_2.1.1
## [63] caTools_1.18.2 digest_0.6.33
## [65] R6_2.5.1 mime_0.12
## [67] colorspace_2.1-0 biomaRt_2.58.0
## [69] RSQLite_2.3.4 utf8_1.2.4
## [71] tidyr_1.3.0 generics_0.1.3
## [73] rtracklayer_1.62.0 prettyunits_1.2.0
## [75] httr_1.4.7 htmlwidgets_1.6.4
## [77] S4Arrays_1.2.0 ggstats_0.5.1
## [79] pkgconfig_2.0.3 gtable_0.3.4
## [81] blob_1.2.4 siggenes_1.76.0
## [83] htmltools_0.5.7 scales_1.3.0
## [85] png_0.1-8 knitr_1.45
## [87] rstudioapi_0.15.0 tzdb_0.4.0
## [89] rjson_0.2.21 nlme_3.1-164
## [91] curl_5.2.0 cachem_1.0.8
## [93] rhdf5_2.46.1 stringr_1.5.1
## [95] KernSmooth_2.23-22 AnnotationDbi_1.64.1
## [97] restfulr_0.0.15 GEOquery_2.70.0
## [99] pillar_1.9.0 grid_4.3.2
## [101] reshape_0.8.9 vctrs_0.6.5
## [103] promises_1.2.1 dbplyr_2.4.0
## [105] xtable_1.8-4 evaluate_0.23
## [107] readr_2.1.5 GenomicFeatures_1.54.1
## [109] cli_3.6.2 compiler_4.3.2
## [111] Rsamtools_2.18.0 rlang_1.1.3
## [113] crayon_1.5.2 rngtools_1.5.2
## [115] labeling_0.4.3 nor1mix_1.3-2
## [117] mclust_6.0.1 plyr_1.8.9
## [119] stringi_1.8.3 viridisLite_0.4.2
## [121] BiocParallel_1.36.0 munsell_0.5.0
## [123] Matrix_1.6-4 hms_1.1.3
## [125] sparseMatrixStats_1.14.0 bit64_4.0.5
## [127] Rhdf5lib_1.24.1 KEGGREST_1.42.0
## [129] statmod_1.5.0 shiny_1.8.0
## [131] highr_0.10 memoise_2.0.1
## [133] bslib_0.6.1 bit_4.0.5END of report